PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Sui, Y; Yang, Z; Xiong, S; Zhang, L; Blanchard, KL; Peiper, SC; Dynan, WS; Tuan, D; Ko, L				Sui, Y.; Yang, Z.; Xiong, S.; Zhang, L.; Blanchard, K. L.; Peiper, S. C.; Dynan, W. S.; Tuan, D.; Ko, L.			Gene amplification and associated loss of 5 ' regulatory sequences of CoAA in human cancers	ONCOGENE			English	Article						gene amplification; CoAA oncogene; transcriptional coactivator	BINDING PROTEIN; CHROMOSOMAL TRANSLOCATIONS; RECEPTOR COREGULATORS; SYNOVIAL SARCOMA; DNA METHYLATION; FRAGILE SITES; COACTIVATOR; EXPRESSION; IDENTIFICATION; TRANSCRIPTION	CoAA is an RRM-containing transcriptional coactivator that stimulates transcriptional activation and regulates alternative splicing. We show that the CoAA gene is amplified at the chromosome 11q13 locus in a subset of primary human cancers including non-small cell lung carcinoma, squamous cell skin carcinoma and lymphoma. Analysis of 42 primary tumors suggests that CoAA amplifies independently from the CCND1 locus. Detailed mapping of three CoAA amplicons reveals that the amplified CoAA gene is consistently located at the 50 boundaries of the amplicons. The CoAA coding and basal promoter sequences are retained within the amplicons but upstream silencing sequences are lost. CoAA protein is overexpressed in tumors containing the amplified CoAA gene. RNA dot blot analysis of 100 cases of primary tumors suggests elevated CoAA mRNA expression. CoAA positively regulates its own basal promoter in transfection assays. Thus, gene amplification, loss of silencing sequence and positive feedback regulation may lead to drastic upregulation of CoAA protein. CoAA has transforming activities when tested in soft agar assays, and CoAA is homologous to oncoproteins EWS and TLS, which regulate alternative splicing. These data imply that CoAA may share a similar oncogenic mechanism with oncogene EWS and that CoAA deregulation may alter the alternative splicing of target genes.	Med Coll Georgia, Dept Pathol, IMMAG, Augusta, GA 30912 USA; Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Lilly Res Labs, Indianapolis, IN USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; Eli Lilly	Ko, L (corresponding author), Med Coll Georgia, Dept Pathol, IMMAG, 1120 15th St,CB2803, Augusta, GA 30912 USA.	lko@mcg.edu		Dynan, William/0000-0002-4045-5662; Ko, Lan/0000-0002-0089-9090	NATIONAL CANCER INSTITUTE [R01CA098239] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073453] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA098239-03, R01 CA098239] Funding Source: Medline; NHLBI NIH HHS [R01 HL089519, R01 HL073453] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antonson P, 2003, MOL CELL BIOL, V23, P1260, DOI 10.1128/MCB.23.4.1260-1268.2003; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Auboeuf D, 2005, MOL CELL BIOL, V25, P5307, DOI 10.1128/MCB.25.13.5307-5316.2005; Auboeuf D, 2004, MOL CELL BIOL, V24, P442, DOI 10.1128/MCB.24.1.442-453.2004; Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; Buttel I, 2004, ANN NY ACAD SCI, V1028, P14, DOI 10.1196/annals.1322.002; Bystritskiy AA, 2004, CRIT REV EUKAR GENE, V14, P65, DOI 10.1615/CritRevEukaryotGeneExpr.v14.40; Caiafa P, 2005, J CELL BIOCHEM, V94, P257, DOI 10.1002/jcb.20325; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; Fox AH, 2002, CURR BIOL, V12, P13, DOI 10.1016/S0960-9822(01)00632-7; Gibbons R, 2005, GENOME, V48, P160, DOI 10.1139/G04-085; Grandinetti KB, 2006, ONCOGENE, V25, P706, DOI 10.1038/sj.onc.1209095; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Guan XY, 1996, CANCER RES, V56, P3446; Iwasaki T, 2001, J BIOL CHEM, V276, P33375, DOI 10.1074/jbc.M101517200; Jasinska A, 2004, FEBS LETT, V567, P136, DOI 10.1016/j.febslet.2004.03.109; Kalnina Z, 2005, GENE CHROMOSOME CANC, V42, P342, DOI 10.1002/gcc.20156; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim J, 1999, PHYSIOL GENOMICS, V1, P127, DOI 10.1152/physiolgenomics.1999.1.3.127; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Koreth J, 1999, J PATHOL, V187, P28, DOI 10.1002/(SICI)1096-9896(199901)187:1<28::AID-PATH166>3.0.CO;2-R; Kuang SQ, 2002, J BIOL CHEM, V277, P45356, DOI 10.1074/jbc.C200509200; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; Lee JW, 2005, STEM CELLS, V23, P738, DOI 10.1634/stemcells.2004-0375; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Penalva LOF, 2003, MICROBIOL MOL BIOL R, V67, P343, DOI 10.1128/MMBR.67.3.343-359.2003; Rabbitts TH, 1999, J PATHOL, V187, P39; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Schmid CW, 1998, NUCLEIC ACIDS RES, V26, P4541, DOI 10.1093/nar/26.20.4541; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; Sorensen PHB, 1996, SEMIN CANCER BIOL, V7, P3, DOI 10.1006/scbi.1996.0002; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252; Zainabadi K, 2005, GENOMICS, V85, P704, DOI 10.1016/j.ygeno.2005.02.014; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	40	19	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					822	835		10.1038/sj.onc.1209847	http://dx.doi.org/10.1038/sj.onc.1209847			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16878147	Green Accepted			2022-12-25	WOS:000244063800004
J	Mallakin, A; Taneja, P; Matise, LA; Willingham, MC; Inoue, K				Mallakin, A.; Taneja, P.; Matise, L. A.; Willingham, M. C.; Inoue, K.			Expression of Dmp1 in specific differentiated, nonproliferating cells and its regulation by E2Fs	ONCOGENE			English	Article						Dmp1; Ki67; Arf; E2F; cell cycle; immunohistochemistry	ARF TUMOR-SUPPRESSOR; D-TYPE CYCLINS; TRANSCRIPTION FACTOR DMP1; CELLULAR PROLIFERATION; GENE-EXPRESSION; MYB PROMOTER; IN-VIVO; FAMILY; COMPLEXES; ARREST	Dmp1 is a Myb-like transcription factor that transmits oncogenic Ras-Raf signaling to the Arf-p53 pathway and induces cell cycle arrest. Immunohistochemical staining was performed to identify the pattern of Dmp1 expression in normal murine tissues compared with the proliferation marker, Ki67. In thymus, the nuclei of mature T lymphocytes in the medulla were strongly positive for Dmp1, whereas Ki67 was detected only in the cortex. In intestine, Dmp1 was detected in the nuclei of super. cial layers of the villi, whereas Ki67- positive cells were con. ned to the lower one- third of the crypt. Double staining for Dmp1 and Ki67 revealed that these two proteins were expressed in mutually exclusive fashion in nearly all the tissues examined. Subsets of E2Fs were speci. cally bound to the Dmp1 promoter upon mitogenic signaling and E2Fs 1- 4 inhibited the Dmp1 promoter in a reporter assay. The Dmp1 promoter was repressed when the cells entered the S to G2/ M phase of the cell cycle when both Dmp1 and Arf expressions were downregulated. The Dmp1 mRNA was not downregulated by serum in E2F- DB(+) cells, suggesting that the Dmp1 promoter repression is E2F- dependent. This explains why the Dmp1 and Ki67- positive cells are stained in mutually exclusive fashion in normal tissues.	Wake Forest Univ Hlth Sci, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Univ Hlth Sci, Dept Pathol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University School of Medicine; Wake Forest University; Wake Forest University School of Medicine	Inoue, K (corresponding author), Wake Forest Univ Hlth Sci, Dept Canc Biol, 2102 Gray Bldg,Med Ctr Blvd, Winston Salem, NC 27157 USA.	kinoue@wfubmc.edu			NATIONAL CANCER INSTITUTE [R01CA106314, R01CA106312, P30CA012197] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106314-03, CA12197-31, R01 CA106314-02, R01 CA106314, P30 CA012197, R01 CA106314-01, 5R01CA106312-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Barrett KL, 2001, J HISTOCHEM CYTOCHEM, V49, P821, DOI 10.1177/002215540104900703; Bentley HA, 2005, CLIN BIOCHEM, V38, P183, DOI 10.1016/j.clinbiochem.2004.10.009; Bertwistle D, 2004, HYBRIDOMA HYBRIDOM, V23, P293, DOI 10.1089/hyb.2004.23.293; Campanero MR, 1999, MOL CELL BIOL, V19, P8442; Catchpole S, 2002, J BIOL CHEM, V277, P39015, DOI 10.1074/jbc.M202960200; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DeGregori J, 2002, BBA-REV CANCER, V1602, P131, DOI 10.1016/S0304-419X(02)00051-3; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Hirai H, 1996, MOL CELL BIOL, V16, P6457; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Inoue K, 2001, GENE DEV, V15, P2934, DOI 10.1101/gad.929901; Inoue K, 2000, GENE DEV, V14, P1797; INOUE K, 1994, BLOOD, V84, P2672, DOI 10.1182/blood.V84.8.2672.bloodjournal8482672; Inoue K, 1998, J BIOL CHEM, V273, P29188, DOI 10.1074/jbc.273.44.29188; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Joaquin M, 2003, CELL MOL LIFE SCI, V60, P2389, DOI 10.1007/s00018-003-3037-4; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KINDBLOM LG, 1995, VIRCHOWS ARCH, V427, P19; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; LOPEZ F, 1991, CYTOMETRY, V12, P42, DOI 10.1002/cyto.990120107; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Lu Z, 2006, ONCOGENE, V25, P230, DOI 10.1038/sj.onc.1209025; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Quon KC, 2001, GENE DEV, V15, P2917, DOI 10.1101/gad.949001; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sala A, 1999, J CELL PHYSIOL, V179, P245; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sreeramaneni R, 2005, MOL CELL BIOL, V25, P220, DOI 10.1128/MCB.25.1.220-232.2005; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	41	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2006	25	59					7703	7713		10.1038/sj.onc.1209750	http://dx.doi.org/10.1038/sj.onc.1209750			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16878159	Green Accepted			2022-12-25	WOS:000242830800005
J	Chang, CF; Chou, HT; Lin, YJ; Lee, SJ; Chuang, JL; Chuang, DT; Huang, TH				Chang, Chi-Fon; Chou, Hui-Ting; Lin, Yi-Jan; Lee, Shin-Jye; Chuang, Jacinta L.; Chuang, David T.; Huang, Tai-huang			Structure of the subunit binding domain and dynamics of the di-domain region from the core of human branched chain alpha-ketoacid dehydrogenase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BEARING DOMAIN; DIHYDROLIPOYL ACETYLTRANSFERASE COMPONENT; MULTIENZYME COMPLEX; ESCHERICHIA-COLI; LIPOIC ACID; BACILLUS-STEAROTHERMOPHILUS; 3-DIMENSIONAL STRUCTURE; CHEMICAL-SHIFT; BACKBONE DYNAMICS; PYRUVATE	The homo-24-meric dihydrolipoyl transacylase (E2) scaffold of the human branched-chain alpha-ketoacid dehydrogenase complex (BCKDC) contains the lipoyl-bearing domain (hbLBD), the subunit-binding domain (hbSBD) and the inner core domain that are linked to carry out E2 functions in substrate channeling and recognition. In this study, we employed NMR techniques to determine the structure of hbSBD and dynamics of several truncated constructs from the E2 component of the human BCKDC, including hbLBD ( residues 1-84), hbSBD ( residues 111-149), and a di-domain (hbDD) (residues 1-166) comprising hbLBD, hbSBD and the interdomain linker. The solution structure of hbSBD consists of two nearly parallel helices separated by a long loop, similar to the structures of the SBD isolated from other species, but it lacks the short 310 helix. The NMR results show that the structures of hbLBD and hbSBD in isolated forms are not altered by the presence of the interdomain linker in hbDD. The linker region is not entirely exposed to solvent, where amide resonances associated with similar to 50% of the residues are observable. However, the tethering of these two domains in hbDD significantly retards the overall rotational correlation times of hbLBD and hbSBD, changing from 5.54 ns and 5.73 ns in isolated forms to 8.37 ns and 8.85 ns in the linked hbDD, respectively. We conclude that the presence of the interdomain linker restricts the motional freedom of the hbSBD more significantly than hbLBD, and that the linker region likely exists as a soft rod rather than a flexible string in solution.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75216 USA; Natl Taiwan Normal Univ, Dept Phys, Taipei 106, Taiwan	Academia Sinica - Taiwan; Academia Sinica - Taiwan; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Taiwan Normal University	Huang, TH (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.	bmthh@ibms.sinica.edu.tw		Chang, Chi-Fon/0000-0002-2961-0748	NIDDK NIH HHS [DK-26578] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; Bracken C, 1999, J MOL BIOL, V285, P2133, DOI 10.1006/jmbi.1998.2429; Brautigam CA, 2006, STRUCTURE, V14, P611, DOI 10.1016/j.str.2006.01.001; Chang CF, 2002, J BIOL CHEM, V277, P15865, DOI 10.1074/jbc.M110952200; Chauhan HJ, 2000, EUR J BIOCHEM, V267, P7158, DOI 10.1046/j.1432-1327.2000.01820.x; Chuang D.T., 2001, METABOLIC MOL BASES, P1971; CHUANG DT, 2001, ENCY MOL MED, V1, P393; Chuang JL, 2002, J BIOL CHEM, V277, P36905, DOI 10.1074/jbc.C200430200; Ciszak EM, 2006, J BIOL CHEM, V281, P648, DOI 10.1074/jbc.M507850200; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DARDEL F, 1993, J MOL BIOL, V229, P1037, DOI 10.1006/jmbi.1993.1103; FARROW NA, 1995, J BIOMOL NMR, V6, P153, DOI 10.1007/BF00211779; Frank RAW, 2005, STRUCTURE, V13, P1119, DOI 10.1016/j.str.2005.04.021; GREEN JDF, 1992, J BIOL CHEM, V267, P23484; GREEN JDF, 1995, J MOL BIOL, V248, P328, DOI 10.1006/jmbi.1995.0225; Gu YQ, 2003, P NATL ACAD SCI USA, V100, P7015, DOI 10.1073/pnas.0732060100; Harris RA, 1997, ADV ENZYME REGUL, V37, P271, DOI 10.1016/S0065-2571(96)00009-X; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; HIYAMA Y, 1988, J AM CHEM SOC, V110, P2378, DOI 10.1021/ja00216a006; Huang YT, 2001, J MOL BIOL, V307, P1075, DOI 10.1006/jmbi.2001.4539; ISHIMA R, 1995, J MAGN RESON SER B, V108, P73, DOI 10.1006/jmrb.1995.1104; KALIA YN, 1993, J MOL BIOL, V230, P323, DOI 10.1006/jmbi.1993.1145; KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kouza M, 2005, BIOPHYS J, V89, P3353, DOI 10.1529/biophysj.105.065151; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lefevre JF, 1996, BIOCHEMISTRY-US, V35, P2674, DOI 10.1021/bi9526802; Lessard IAD, 1996, BIOCHEMISTRY-US, V35, P16863, DOI 10.1021/bi961683r; Mande SS, 1996, STRUCTURE, V4, P277, DOI 10.1016/S0969-2126(96)00032-9; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; Milne JLS, 2002, EMBO J, V21, P5587, DOI 10.1093/emboj/cdf574; Milne JLS, 2006, J BIOL CHEM, V281, P4364, DOI 10.1074/jbc.M504363200; Naik MT, 2004, PROTEIN SCI, V13, P2483, DOI 10.1110/ps.04783104; Naik MT, 2002, FEBS LETT, V530, P133, DOI 10.1016/S0014-5793(02)03444-0; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; RADFORD SE, 1989, J BIOL CHEM, V264, P767; Reed LJ, 2001, J BIOL CHEM, V276, P38329, DOI 10.1074/jbc.R100026200; REED LJ, 1985, CURR TOP CELL REGUL, V27, P41; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; Ricaud PM, 1996, J MOL BIOL, V264, P179, DOI 10.1006/jmbi.1996.0632; ROBIEN MA, 1992, BIOCHEMISTRY-US, V31, P3463, DOI 10.1021/bi00128a021; RUSSELL GC, 1991, BIOCHIM BIOPHYS ACTA, V1076, P225, DOI 10.1016/0167-4838(91)90271-Z; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Zhou ZH, 2001, P NATL ACAD SCI USA, V98, P14802, DOI 10.1073/pnas.011597698	46	12	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28345	28353		10.1074/jbc.M605005200	http://dx.doi.org/10.1074/jbc.M605005200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16861235	hybrid			2022-12-25	WOS:000240534400072
J	Myerburg, MM; Butterworth, MB; McKenna, EE; Peters, KW; Frizzell, RA; Kleyman, TR; Pilewski, JM				Myerburg, Mike M.; Butterworth, Michael B.; McKenna, Erin E.; Peters, Kathryn W.; Frizzell, Raymond A.; Kleyman, Thomas R.; Pilewski, Joseph M.			Airway surface liquid volume regulates ENaC by altering the serine protease-protease inhibitor balance - A mechanism for sodium hyperabsorption in cystic fibrosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; FACTOR ACTIVATOR INHIBITOR; RESPIRATORY EPITHELIA; POTENTIAL DIFFERENCE; PERICILIARY LIQUID; ION-TRANSPORT; EXPRESSION; IDENTIFICATION; STIMULATION; ALDOSTERONE	Efficient clearance of mucus and inhaled pathogens from the lung is dependent on an optimal airway surface liquid (ASL) volume, which is maintained by the regulated transport of sodium and chloride across the airway epithelium. Accumulating evidence suggests that impaired mucus clearance in cystic fibrosis (CF) airways is a result of ASL depletion caused by excessive Na+ absorption through the epithelial sodium channel ( ENaC). However, the cellular mechanisms that result in increased ENa Cactivity in CF airways are not completely understood. Recently, proteases were shown to modulate the activity of ENaC, but the relevance of this mechanism to the physiologic regulation of ASL volume is unknown. Using primary human airway epithelial cells, we demonstrate that: (i) protease inhibitors are present in the ASL and prevent the activation of near-silent ENaC, (ii) when the ASL volume is increased, endogenous protease inhibitors become diluted, allowing for proteolytic activation of near-silent channels, and (iii) in CF, the normally present near-silent pool of ENaC is constitutively active and the alpha subunit undergoes increased proteolytic processing. These findings indicate that the ASL volume modulates the activity of ENaC by modification of the serine protease-protease inhibitor balance and that alterations in this balance contribute to excessive Na+ absorption in cystic fibrosis.	Univ Pittsburgh, Med Ctr, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Renal Electrolyte Div, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Pilewski, JM (corresponding author), Univ Pittsburgh, Med Ctr, Div Pulm Allergy & Crit Care Med, 628 NW Montefiore Univ Hosp,3459 5th Ave, Pittsburgh, PA 15213 USA.	pilewskijm@upmc.edu	Pilewski, Joseph/AAF-5149-2021		NHLBI NIH HHS [K08 HL087932, T32 HL007653] Funding Source: Medline; NIDDK NIH HHS [DK72506, DK56490, DK065161, DK54814] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL087932, T32HL007653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054814, P50DK056490, P30DK072506, R01DK065161, R56DK065161] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adebamiro A, 2005, J GEN PHYSIOL, V126, P339, DOI 10.1085/jgp.200509285; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; Bridges RJ, 2001, AM J PHYSIOL-LUNG C, V281, pL16, DOI 10.1152/ajplung.2001.281.1.L16; Butterworth MB, 2005, AM J PHYSIOL-RENAL, V289, pF969, DOI 10.1152/ajprenal.00390.2003; Butterworth MB, 2005, J GEN PHYSIOL, V125, P81, DOI 10.1085/jgp.2004.09124; Caldwell RA, 2005, AM J PHYSIOL-LUNG C, V288, pL813, DOI 10.1152/ajplung.00435.2004; Caldwell RA, 2004, AM J PHYSIOL-CELL PH, V286, pC190, DOI 10.1152/ajpcell.00342.2003; Carattino MD, 2006, J BIOL CHEM, V281, P18901, DOI 10.1074/jbc.M604109200; Chraibi A, 1998, J GEN PHYSIOL, V111, P127, DOI 10.1085/jgp.111.1.127; de la Rosa DA, 2002, J GEN PHYSIOL, V119, P427, DOI 10.1085/jgp.20028559; Devor DC, 2000, AM J PHYSIOL-CELL PH, V279, pC461, DOI 10.1152/ajpcell.2000.279.2.C461; Devor DC, 1999, AM J PHYSIOL-CELL PH, V276, pC827, DOI 10.1152/ajpcell.1999.276.4.C827; Donaldson SH, 2002, J BIOL CHEM, V277, P8338, DOI 10.1074/jbc.M105044200; Ergonul Z, 2006, AM J PHYSIOL-RENAL, V291, pF683, DOI 10.1152/ajprenal.00422.2005; Fajac I, 1998, EUR RESPIR J, V12, P1295, DOI 10.1183/09031936.98.12061295; Fajac I, 2004, THORAX, V59, P971, DOI 10.1136/thx.2003.020933; Fan B, 2005, J BIOL CHEM, V280, P34513, DOI 10.1074/jbc.M502119200; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Jayaraman S, 2001, P NATL ACAD SCI USA, V98, P8119, DOI 10.1073/pnas.131087598; JIANG CW, 1993, SCIENCE, V262, P424, DOI 10.1126/science.8211164; Joo NS, 2006, J BIOL CHEM, V281, P7392, DOI 10.1074/jbc.M512766200; Joo NS, 2004, J BIOL CHEM, V279, P38854, DOI 10.1074/jbc.M407077200; Joo NS, 2002, J BIOL CHEM, V277, P50710, DOI 10.1074/jbc.M208826200; Kawaguchi T, 1997, J BIOL CHEM, V272, P27558, DOI 10.1074/jbc.272.44.27558; Knight KK, 2006, P NATL ACAD SCI USA, V103, P2805, DOI 10.1073/pnas.0511184103; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Liang XB, 2006, J BIOL CHEM, V281, P16323, DOI 10.1074/jbc.M601360200; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; Marlor CW, 1997, J BIOL CHEM, V272, P12202, DOI 10.1074/jbc.272.18.12202; Matsui H, 1998, J CLIN INVEST, V102, P1125, DOI 10.1172/JCI2687; Matsui H, 2000, J CLIN INVEST, V105, P1419, DOI 10.1172/JCI4546; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; Michlig S, 2005, J BIOL CHEM, V280, P38264, DOI 10.1074/jbc.M506308200; Morimoto T, 2006, AM J PHYSIOL-RENAL, V291, pF663, DOI 10.1152/ajprenal.00514.2005; Planes C, 2005, AM J PHYSIOL-LUNG C, V288, pL1099, DOI 10.1152/ajplung.00332.2004; Planes C, 2002, J BIOL CHEM, V277, P47318, DOI 10.1074/jbc.M209158200; Satlin LM, 2001, AM J PHYSIOL-RENAL, V280, pF1010, DOI 10.1152/ajprenal.2001.280.6.F1010; Sheng S, 2006, AM J PHYSIOL-RENAL, V290, pF1488, DOI 10.1152/ajprenal.00439.2005; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Tarran R, 2006, J GEN PHYSIOL, V127, P591, DOI 10.1085/jgp.200509468; Tarran R, 2005, J BIOL CHEM, V280, P35751, DOI 10.1074/jbc.M505832200; Tarran R, 2001, J GEN PHYSIOL, V118, P223, DOI 10.1085/jgp.118.2.223; Tong ZY, 2004, AM J PHYSIOL-LUNG C, V287, pL928, DOI 10.1152/ajplung.00160.2004; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; Wang H, 2006, J BIOL CHEM, V281, P14129, DOI 10.1074/jbc.M512511200	49	92	95	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27942	27949		10.1074/jbc.M606449200	http://dx.doi.org/10.1074/jbc.M606449200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16873367	hybrid			2022-12-25	WOS:000240534400030
J	Schultz, A; Nottrott, S; Hartmuth, K; Luhrmann, R				Schultz, Annemarie; Nottrott, Stephanie; Hartmuth, Klaus; Luehrmann, Reinhard			RNA structural requirements for the association of the spliceosomal hPrp31 protein with the U4 and U4atac small nuclear ribonucleoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT RETINITIS-PIGMENTOSA; U6; SNRNA; YEAST; LOCALIZATION; EXISTENCE; INTERACT; U4/U6.U5; COMPLEX; GENE	The kink-turn, a stem I-internal loop-stem II structure of the 5' stem-loop of U4 and U4atac small nuclear (sn) RNAs bound by 15.5K protein is required for binding of human Prp31 protein (hPrp31) during U4 and U4atac snRNP assembly. In box C/D snoRNPs a similar kink-turn with bound 15.5K protein is required for selective binding of proteins NOP56 and NOP58. Here we analyzed RNA structural requirements for association of hPrp31 with U4 snRNP in vitro by hydroxyl radical footprinting. hPrp31 induced protection of the terminal penta-loop, as well as of stems I and II flanking the kink-turn. Similar protection was found with U4/U6 snRNA duplex prebound with 15.5K protein. A detailed mutational analysis of the U4 snRNA elements by electrophoretic mobility shift analysis revealed that stem I could not be shortened, although it tolerated sequence alterations. However, introduction of a third Watson-Crick base pair into stem II significantly reduced hPrp31 binding. While stem I of U4atac snRNA showed relaxed binding requirements, its stem II requirements were likewise restricted to two base pairs. In contrast, as shown previously, stem II of the kink-turn motif in box C/D snoRNAs is comprised of three base pairs, and NOP56 and NOP58 require a G-C pair at the central position. This indicates that hPrp31 binding specificity is achieved by the recognition of the two base pair long stem II of the U4 and U4atac snRNAs and suggests how discrimination is achieved by RNA structural elements during assembly of U4/U6 and U4atac/U6atac snRNPs and box C/D snoRNPs.	Max Planck Inst Biophys Chem, Dept Cellular Biochem, D-37077 Gottingen, Germany	Max Planck Society	Luhrmann, R (corresponding author), Max Planck Inst Biophys Chem, Dept Cellular Biochem, Fassberg 11, D-37077 Gottingen, Germany.	reinhard.luehrmann@mpi-bpc.mpg.de						BRINGMANN P, 1984, EMBO J, V3, P1357, DOI 10.1002/j.1460-2075.1984.tb01977.x; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; Brow DA, 2002, ANNU REV GENET, V36, P333, DOI 10.1146/annurev.genet.36.043002.091635; Burge CB, 1999, RNA WORLD, P525; Gautier T, 1997, MOL CELL BIOL, V17, P7088, DOI 10.1128/MCB.17.12.7088; HASHIMOTO C, 1984, NUCLEIC ACIDS RES, V12, P3283, DOI 10.1093/nar/12.7.3283; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; Klein DJ, 2001, EMBO J, V20, P4214, DOI 10.1093/emboj/20.15.4214; Kuhn-Holsken E, 2005, RNA, V11, P1915, DOI 10.1261/rna.2176605; Lescoute A, 2006, RNA, V12, P83, DOI 10.1261/rna.2208106; Makarov EM, 2002, SCIENCE, V298, P2205, DOI 10.1126/science.1077783; Makarova OV, 2002, EMBO J, V21, P1148, DOI 10.1093/emboj/21.5.1148; Mougin A, 2002, J MOL BIOL, V317, P631, DOI 10.1006/jmbi.2002.5451; MYSLINSKI E, 1991, BIOCHIMIE, V73, P17, DOI 10.1016/0300-9084(91)90069-D; Nilsen TW, 2003, BIOESSAYS, V25, P1147, DOI 10.1002/bies.10394; Nilsen TW, 1998, COLD SPRING HARBOR M, P279; Nottrott S, 1999, EMBO J, V18, P6119, DOI 10.1093/emboj/18.21.6119; Nottrott S, 2002, EMBO J, V21, P5527, DOI 10.1093/emboj/cdf544; RINKE J, 1985, J MOL BIOL, V185, P721, DOI 10.1016/0022-2836(85)90057-9; Schaffert N, 2004, EMBO J, V23, P3000, DOI 10.1038/sj.emboj.7600296; Schneider C, 2002, MOL CELL BIOL, V22, P3219, DOI 10.1128/MCB.22.10.3219-3229.2002; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Vidovic I, 2000, MOL CELL, V6, P1331, DOI 10.1016/S1097-2765(00)00131-3; Vithana EN, 2001, MOL CELL, V8, P375, DOI 10.1016/S1097-2765(01)00305-7; Watkins NJ, 2000, CELL, V103, P457, DOI 10.1016/S0092-8674(00)00137-9; Watkins NJ, 2002, MOL CELL BIOL, V22, P8342, DOI 10.1128/MCB.22.23.8342-8352.2002; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8	27	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28278	28286		10.1074/jbc.M603350200	http://dx.doi.org/10.1074/jbc.M603350200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16857676	hybrid, Green Published			2022-12-25	WOS:000240534400065
J	Bachelet, I; Munitz, A; Mankutad, D; Levi-Schaffer, F				Bachelet, Ido; Munitz, Ariel; Mankutad, David; Levi-Schaffer, Francesca			Mast cell costimulation by CD226/CD112 (DNAM-1/Nectin-2) - A novel interface in the allergic process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL-BLOOD EOSINOPHILS; FC-EPSILON-RI; RECEPTOR IRP60 CD300A; DNAM-1 CD226; T-CELLS; POLIOVIRUS RECEPTOR; ADHESION MOLECULE; HISTAMINE-RELEASE; NECTIN-2 CD112; PVR CD155	Mast cells have critical effector functions in various immune reactions. In allergic inflammation, mast cells interact with tissue-infiltrating eosinophils, forming a regulatory unit in the late and chronic phases of the allergic process. However, the pathways and molecules within this unit are still largely undefined. Here, we show that human mast cells and eosinophils express DNAX accessory molecule 1 (DNAM-1, CD226) and its ligand Nectin-2 (CD112). CD226 synergizes with Fc epsilon RI on mast cells, and its engagement augments degranulation through a pathway involving Fyn, linker of activation of T-cells, phospholipase C gamma 2, and CD18. This pathway is subject to negative interference by inhibitory receptors and is completely inhibited by linking IgE with IRp60 (CD300a) using a bispecific antibody. Moreover, blocking CD112 expressed on eosinophils using neutralizing antibodies normalized the hyperactivity resulting from IgE-dependent activation of mast cells co-cultured with eosinophils. Our findings demonstrate a novel interface between these two effector cells, implicating relevance for in vivo allergic states. Moreover, costimulatory responses might be a critical component in allergic reactions and may therefore become novel targets for anti-allergic therapy.	Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmacol, IL-91905 Jerusalem, Israel; Hadassah Univ Hosp, Dept Obstet & Gynecol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Levi-Schaffer, F (corresponding author), Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmacol, IL-91905 Jerusalem, Israel.	fls@cc.huji.ac.il		Levi-Schaffer, Francesca/0000-0003-0620-2810				Astier A, 2000, J IMMUNOL, V164, P6091, DOI 10.4049/jimmunol.164.12.6091; Bachelet I, 2005, J IMMUNOL, V175, P7989, DOI 10.4049/jimmunol.175.12.7989; Bachelet I, 2006, J ALLERGY CLIN IMMUN, V117, P1314, DOI 10.1016/j.jaci.2006.04.031; Bottino C, 2003, J EXP MED, V198, P557, DOI 10.1084/jem.20030788; Bryceson YT, 2006, BLOOD, V107, P159, DOI 10.1182/blood-2005-04-1351; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Hartman ML, 2001, BLOOD, V97, P1086, DOI 10.1182/blood.V97.4.1086; Hundley TR, 2004, BLOOD, V104, P2410, DOI 10.1182/blood-2004-02-0631; Inamura N, 1998, J IMMUNOL, V160, P4026; Kallinich T, 2005, CLIN EXP ALLERGY, V35, P1521, DOI 10.1111/j.1365-2222.2005.02369.x; Kashiwakura J, 2004, J IMMUNOL, V173, P5247, DOI 10.4049/jimmunol.173.8.5247; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Lappalainen H, 2004, ARTERIOSCL THROM VAS, V24, P1880, DOI 10.1161/01.ATV.0000140820.51174.8d; Leyton L, 1999, MOL IMMUNOL, V36, P755, DOI 10.1016/S0161-5890(99)00086-3; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Malaviya R, 1999, P NATL ACAD SCI USA, V96, P8110, DOI 10.1073/pnas.96.14.8110; Masson D, 2001, GUT, V49, P236, DOI 10.1136/gut.49.2.236; Munitz A, 2006, BLOOD, V107, P1996, DOI 10.1182/blood-2005-07-2926; Munitz A, 2005, J IMMUNOL, V174, P110, DOI 10.4049/jimmunol.174.1.110; Nishimoto H, 2005, BLOOD, V106, P4241, DOI 10.1182/blood-2005-04-1358; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; Oskeritzian C, 1996, CELL IMMUNOL, V167, P205, DOI 10.1006/cimm.1996.0028; Pende D, 2006, BLOOD, V107, P2030, DOI 10.1182/blood-2005-07-2696; Secor VH, 2000, J EXP MED, V191, P813, DOI 10.1084/jem.191.5.813; Shibuya A, 1996, IMMUNITY, V4, P573, DOI 10.1016/S1074-7613(00)70060-4; Shibuya K, 1999, IMMUNITY, V11, P615, DOI 10.1016/S1074-7613(00)80136-3; Shibuya K, 2003, J EXP MED, V198, P1829, DOI 10.1084/jem.20030958; Shin JS, 2001, FEMS MICROBIOL LETT, V197, P131, DOI 10.1016/S0378-1097(01)00108-2; Shin JS, 2000, SCIENCE, V289, P785, DOI 10.1126/science.289.5480.785; Shirakawa J, 2005, INT IMMUNOL, V17, P217, DOI 10.1093/intimm/dxh199; Tahara-Hanaoka S, 2006, BLOOD, V107, P1491, DOI 10.1182/blood-2005-04-1684; Tahara-Hanaoka S, 2004, INT IMMUNOL, V16, P533, DOI 10.1093/intimm/dxh059; Tashiro M, 1997, J IMMUNOL, V158, P2382; Temkin V, 2002, J IMMUNOL, V169, P2662, DOI 10.4049/jimmunol.169.5.2662; Toda M, 2004, J BIOL CHEM, V279, P48443, DOI 10.1074/jbc.M408725200; Tomasec P, 2005, NAT IMMUNOL, V6, P181, DOI 10.1038/ni1156; ZHEUTLIN LM, 1984, J IMMUNOL, V133, P2180	37	58	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27190	27196		10.1074/jbc.M602359200	http://dx.doi.org/10.1074/jbc.M602359200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16831868	hybrid			2022-12-25	WOS:000240397700046
J	Chandor, A; Berteau, O; Douki, T; Gasparutto, D; Sanakis, Y; Ollagnier-De-Choudens, S; Atta, M; Fontecave, M				Chandor, Alexia; Berteau, Olivier; Douki, Thierry; Gasparutto, Didier; Sanakis, Yannis; Ollagnier-de-Choudens, Sandrine; Atta, Mohamed; Fontecave, Marc			Dinucleotide spore photoproduct, a minimal substrate of the DNA repair spore photoproduct lyase enzyme from Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAEROBIC RIBONUCLEOTIDE REDUCTASE; III OXIDASE HEMN; S-ADENOSYLMETHIONINE; RADICAL MECHANISMS; ACTIVATING ENZYME; BIOTIN SYNTHASE; IRON; SULFUR; ACID; PROTEINS	The overwhelming majority of DNA photoproducts in UV-irradiated spores is a unique thymine dimer called spore photoproduct (SP, 5-thymine-5,6-dihydrothymine). This lesion is repaired by the spore photoproduct lyase (SP lyase) enzyme that directly reverts SP to two unmodified thymines. The SP lyase is an S-adenosylmethionine-dependent iron-sulfur protein that belongs to the radical S-adenosylmethionine superfamily. In this study, by using a well characterized preparation of the SP lyase enzyme from Bacillus subtilis, we show that SP in the form of a dinucleoside monophosphate (spore photoproduct of thymidilyl-(3 '-5 ')-thymidine) is efficiently repaired, allowing a kinetic characterization of the enzyme. The preparation of this new substrate is described, and its identity is confirmed by mass spectrometry and comparison with authentic spore photoproduct. The fact that the spore photoproduct of thymidilyl-(3 '-5 ')-thymidine dimer is repaired by SP lyase may indicate that the SP lesion does not absolutely need to be contained within a single or double-stranded DNA for recognition and repaired by the SP lyase enzyme.	Univ Grenoble 1, CNRS, Commissariat Energie Atom, UMR 5047,DRDC CB,Lab Chim & Biochim,Ctr Redox Bio, F-38054 Grenoble 09, France; Univ Grenoble 1, Serv Chim Inorgan & Biol, Commissariat Energie Atom, Dept Rech Fondamentale Mat Condensee,UMR E3, F-38054 Grenoble 09, France; NCSR Demokritos, Inst Mat Sci, Athens 15310, Greece	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); National Centre of Scientific Research "Demokritos"	Fontecave, M (corresponding author), Univ Grenoble 1, CNRS, Commissariat Energie Atom, UMR 5047,DRDC CB,Lab Chim & Biochim,Ctr Redox Bio, 17 Rue Martyrs, F-38054 Grenoble 09, France.	marc.fontecave@cea.fr	Chandor-Proust, Alexia/C-1109-2013; Thierry, Douki/H-2108-2018; Berteau, Olivier/AAF-9080-2019	Chandor-Proust, Alexia/0000-0002-4827-3281; Thierry, Douki/0000-0002-5022-071X; Berteau, Olivier/0000-0002-3434-5168				BEAUCAGE SL, 1992, TETRAHEDRON, V48, P2223, DOI 10.1016/S0040-4020(01)88752-4; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cheek J, 2002, J AM CHEM SOC, V124, P2860, DOI 10.1021/ja017784g; Cheek J, 2001, J BIOL INORG CHEM, V6, P209, DOI 10.1007/s007750100210; DONNELLAN JE, 1965, SCIENCE, V149, P308, DOI 10.1126/science.149.3681.308; Douki T, 2005, PHOTOCH PHOTOBIO SCI, V4, P591, DOI 10.1039/b503771a; Douki T, 2005, PHOTOCHEM PHOTOBIOL, V81, P163, DOI 10.1562/2004-08-18-RA-278.1; Douki T, 2003, PHOTOCH PHOTOBIO SCI, V2, P433, DOI 10.1039/b300173c; Douki T, 2001, BIOCHEMISTRY-US, V40, P2495, DOI 10.1021/bi0022543; Douki T, 2000, J PHOTOCH PHOTOBIO B, V54, P145, DOI 10.1016/S1011-1344(00)00009-9; Fajardo-Cavazos P, 2005, CURR MICROBIOL, V51, P331, DOI 10.1007/s00284-005-0052-8; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; Fontecave M, 2001, CURR OPIN CHEM BIOL, V5, P506, DOI 10.1016/S1367-5931(00)00237-4; Frey PA, 2001, ADV PROTEIN CHEM, V58, P1; Friedel MG, 2006, CHEM COMMUN, P445, DOI 10.1039/b514103f; Krebs C, 2002, J AM CHEM SOC, V124, P912, DOI 10.1021/ja017562i; Layer G, 2005, J BIOL CHEM, V280, P29038, DOI 10.1074/jbc.M501275200; Layer G, 2002, J BIOL CHEM, V277, P34136, DOI 10.1074/jbc.M205247200; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Mees A, 2004, SCIENCE, V306, P1789, DOI 10.1126/science.1101598; Mehl RA, 1999, ORG LETT, V1, P1065, DOI 10.1021/ol9908676; Mulliez E, 1999, J BIOL INORG CHEM, V4, P614, DOI 10.1007/s007750050385; NICHOLSON WL, 1991, P NATL ACAD SCI USA, V88, P8288, DOI 10.1073/pnas.88.19.8288; Ollagnier S, 1999, J AM CHEM SOC, V121, P6344, DOI 10.1021/ja990073m; Ollagnier-de Choudens S, 2000, BIOCHEMISTRY-US, V39, P4165, DOI 10.1021/bi992090u; Ollagnier-de Choudens S, 2002, J BIOL CHEM, V277, P13449, DOI 10.1074/jbc.M111324200; Pierrel F, 2003, J BIOL CHEM, V278, P29515, DOI 10.1074/jbc.M301518200; Ravanat JL, 2001, J PHOTOCH PHOTOBIO B, V63, P88, DOI 10.1016/S1011-1344(01)00206-8; Rebeil R, 2001, P NATL ACAD SCI USA, V98, P9038, DOI 10.1073/pnas.161278998; Rebeil R, 1998, J BACTERIOL, V180, P4879, DOI 10.1128/JB.180.18.4879-4885.1998; SETLOW B, 1987, P NATL ACAD SCI USA, V84, P421, DOI 10.1073/pnas.84.2.421; SETLOW P, 1995, ANNU REV MICROBIOL, V49, P29, DOI 10.1146/annurev.mi.49.100195.000333; Slieman TA, 2000, J BACTERIOL, V182, P6412, DOI 10.1128/JB.182.22.6412-6417.2000; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Tamarit J, 1999, J BIOL CHEM, V274, P31291, DOI 10.1074/jbc.274.44.31291; VARGHESE AJ, 1970, BIOCHEM BIOPH RES CO, V38, P484, DOI 10.1016/0006-291X(70)90739-4	37	48	49	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26922	26931		10.1074/jbc.M602297200	http://dx.doi.org/10.1074/jbc.M602297200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16829676	hybrid			2022-12-25	WOS:000240397700019
J	Huang, Y; Qiao, F; Abagyan, R; Hazard, S; Tomlinson, S				Huang, Yuxiang; Qiao, Fei; Abagyan, Ruben; Hazard, Starr; Tomlinson, Stephen			Defining the CD59-C9 binding interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEIN CD59; COMPLEMENT INHIBITORS; CANCER-IMMUNOTHERAPY; ACTIVE-SITE; C9; THERAPEUTICS; INJURY; C5B-9; C8; MOLECULE	CD59 is a membrane glycoprotein that regulates formation of the cytolytic membrane attack complex(MAC or C5b-9) on host cell membranes. It functions by binding to C8 (alpha chain) and C9 after their structural rearrangement during MAC assembly. Previous studies indicated that the CD59 binding site in C9 was located within a 25-residue disulfide-bonded loop, and in C8 alpha was located within a 51-residue sequence that overlaps the CD59 binding region of C9. By peptide screens and the use of peptides in binding assays, functional assays, and computer modeling and docking studies, we have identified a 6-residue sequence of human C9, spanning residues 365-371, as the primary CD59 recognition domain involved in CD59-mediated regulation of MAC formation. The data also indicate that both C8 alpha and C9 bind to a similar or overlapping site on CD59. Furthermore, data from CD59-peptide docking models are consistent with the C9 binding site on CD59 located at a hydrophobic pocket, putatively identified previously by CD59 mutational and modeling studies.	Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29403 USA; Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29403 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Medical University of South Carolina; Medical University of South Carolina; Scripps Research Institute	Tomlinson, S (corresponding author), Med Univ S Carolina, Dept Microbiol & Immunol, 173 Ashley Ave, Charleston, SC 29403 USA.	tomlinss@musc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047386] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 47386] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; Arumugam TV, 2004, SHOCK, V21, P401, DOI 10.1097/00024382-200405000-00002; Bodian DL, 1997, J EXP MED, V185, P507, DOI 10.1084/jem.185.3.507; Cavasotto CN, 2004, J MOL BIOL, V337, P209, DOI 10.1016/j.jmb.2004.01.003; CHANG CP, 1994, J BIOL CHEM, V269, P26424; DECKERT M, 1992, EUR J IMMUNOL, V22, P2943, DOI 10.1002/eji.1830221128; Fishelson Z, 2003, MOL IMMUNOL, V40, P109, DOI 10.1016/S0161-5890(03)00112-3; Fonsatti E, 2000, Clin Ter, V151, P187; Fraser DA, 2003, J BIOL CHEM, V278, P48921, DOI 10.1074/jbc.M302598200; Gelderman KA, 2004, TRENDS IMMUNOL, V25, P158, DOI 10.1016/j.it.2004.01.008; Ghiran I, 2003, J BIOL CHEM, V278, P21024, DOI 10.1074/jbc.M302306200; Giddings KS, 2004, NAT STRUCT MOL BIOL, V11, P1173, DOI 10.1038/nsmb862; He C, 2005, J IMMUNOL, V174, P5750, DOI 10.4049/jimmunol.174.9.5750; Huang YX, 2005, J BIOL CHEM, V280, P34073, DOI 10.1074/jbc.M504922200; HUESLER T, 1996, BIOCHEMISTRY-US, V35, P3263; HUESLER T, 1995, J BIOL CHEM, V270, P3483, DOI 10.1074/JBC.270.8.3483; LAMBRIS JD, 2000, THERAPEUTIC INTERVEN; LOCKERT DH, 1995, J BIOL CHEM, V270, P19723, DOI 10.1074/jbc.270.34.19723; Marcenaro E, 2003, EUR J IMMUNOL, V33, P3367, DOI 10.1002/eji.200324425; MERI S, 1990, IMMUNOLOGY, V71, P1; Morgan BP, 2003, MOL IMMUNOL, V40, P159, DOI 10.1016/S0161-5890(03)00111-1; NINOMIYA H, 1992, J BIOL CHEM, V267, P13675; Quigg RJ, 2002, TRENDS MOL MED, V8, P430, DOI 10.1016/S1471-4914(02)02386-9; ROLLINS SA, 1991, J IMMUNOL, V146, P2345; Sahu A, 2000, IMMUNOPHARMACOLOGY, V49, P133, DOI 10.1016/S0162-3109(00)80299-4; TOMLINSON S, 1994, J IMMUNOL, V152, P1927; Yu JH, 1997, J EXP MED, V185, P745, DOI 10.1084/jem.185.4.745	27	70	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27398	27404		10.1074/jbc.M603690200	http://dx.doi.org/10.1074/jbc.M603690200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16844690	hybrid			2022-12-25	WOS:000240397700066
J	Bullesbach, EE; Schwabe, C				Bullesbach, Erika E.; Schwabe, Christian			The mode of interaction of the relaxin-like factor (RLF) with the leucine-rich repeat G protein-activated receptor 8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-LIKE PEPTIDE; RECEPTOR-BINDING SITE; SOLID-PHASE SYNTHESIS; TESTICULAR CANCER; INSL3 GENE; CRYPTORCHIDISM; CHAIN; LGR8; DETERMINANTS; CONFORMATION	The relaxin-like factor (RLF, also named INSL3) is a critical component in the chain of events that lead to the normal positioning of the gonads in the male fetus. RLF and relaxin share features of the secondary structure to the extent that relaxin cross-reacts with the LGR8, the RLF receptor. Although both hormones interact with their receptors essentially via the B chain, the sharply defined binding cassette of relaxin is not present in RLF. Structure and function analysis of RLF derivatives with single amino acid replacements revealed that the most important binding residues are tryptophan B27, followed by arginine B16 and valine B19. Single alanine replacements for each individual position resulted in a relative receptor affinity of 4.0% (B16), 6.1% (B19), and 0.5% (B27). Tryptophan B27 is located on an extended structure, and arginine B16 and valine B19 are positioned on the exposed surface of the B chain helix. The 3 residues could be brought together to form a contiguous binding area if the C-terminal end of the B chain were free to fold back against the central portion of the B chain helix. Such a movement depends critically on the flexibility of the C-terminal end, which is controlled by positions B23-25. In as much as these major binding residues seem hardly sufficient to explain the strong binding of RLF to LGR8 we searched for and found an extended region where little contributions by individual residues added up to a strong receptor affinity. This mode of interaction could drive the binding energy sufficiently high to account for the picomolar binding constant of RLF and its receptor.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Schwabe, C (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	schwabec@musc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD040406] Funding Source: NIH RePORTER; NICHD NIH HHS [1-R01-HD40406] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adham IM, 2000, MOL CELL ENDOCRINOL, V160, P11, DOI 10.1016/S0303-7207(99)00188-4; ADHAM IM, 1993, J BIOL CHEM, V268, P26668; Adler A J, 1973, Methods Enzymol, V27, P675; Bogatcheva NV, 2003, MOL ENDOCRINOL, V17, P2639, DOI 10.1210/me.2003-0096; BULLESBACH EE, 1992, J BIOL CHEM, V267, P22957; Bullesbach EE, 2000, J BIOL CHEM, V275, P35276, DOI 10.1074/jbc.M005728200; BULLESBACH EE, 1991, J BIOL CHEM, V266, P10754; Bullesbach EE, 2005, J BIOL CHEM, V280, P14051, DOI 10.1074/jbc.M500030200; Bullesbach EE, 2005, J BIOL CHEM, V280, P14586, DOI 10.1074/jbc.M414443200; Bullesbach EE, 2004, BIOCHEMISTRY-US, V43, P8021, DOI 10.1021/bi049601j; Bullesbach EE, 1999, J BIOL CHEM, V274, P22354, DOI 10.1074/jbc.274.32.22354; Bullesbach EE, 2002, BIOCHEMISTRY-US, V41, P274, DOI 10.1021/bi0117302; Bullesbach EE, 1999, BIOCHEMISTRY-US, V38, P3073, DOI 10.1021/bi982687u; BULLESBACH EE, 1995, J BIOL CHEM, V270, P16011, DOI 10.1074/jbc.270.27.16011; BULLESBACH EE, 1994, J BIOL CHEM, V269, P13124; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; Dawson NF, 1999, J PEPT RES, V53, P542, DOI 10.1034/j.1399-3011.1999.00060.x; Drapeau G R, 1977, Methods Enzymol, V47, P189; EIGENBROT C, 1991, J MOL BIOL, V221, P15, DOI 10.1016/0022-2836(91)90796-9; Halls ML, 2005, J PHARMACOL EXP THER, V313, P677, DOI 10.1124/jpet.104.080655; HUA QX, 1992, BIOCHEMISTRY-US, V31, P11940, DOI 10.1021/bi00162a037; Huyghe E, 2003, J UROLOGY, V170, P5, DOI 10.1097/01.ju.0000053866.68623.da; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; Kumagai J, 2002, J BIOL CHEM, V277, P31283, DOI 10.1074/jbc.C200398200; Lim HN, 2001, EUR J ENDOCRINOL, V144, P129, DOI 10.1530/eje.0.1440129; MARUYAMA K, 1992, J PROTEIN CHEM, V11, P1, DOI 10.1007/BF01025086; MIRMIRA RG, 1989, J BIOL CHEM, V264, P6349; Moller H, 1996, CANCER CAUSE CONTROL, V7, P264, DOI 10.1007/BF00051302; Nef S, 1999, NAT GENET, V22, P295, DOI 10.1038/10364; Rosengren KJ, 2006, J BIOL CHEM, V281, P5845, DOI 10.1074/jbc.M511210200; Smith KJ, 2001, J PEPT SCI, V7, P495, DOI 10.1002/psc.344; STEINER AL, 1979, METHOD HORM RADIOIMM, P3; WANG SS, 1973, J AM CHEM SOC, V95, P1328, DOI 10.1021/ja00785a602; Zimmermann S, 1999, MOL ENDOCRINOL, V13, P681, DOI 10.1210/me.13.5.681	35	27	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26136	26143		10.1074/jbc.M601414200	http://dx.doi.org/10.1074/jbc.M601414200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16844694	hybrid			2022-12-25	WOS:000240249500029
J	Kareta, MS; Botello, ZM; Ennis, JJ; Chou, C; Chedin, F				Kareta, Michael S.; Botello, Zaida M.; Ennis, Joshua J.; Chou, Christina; Chedin, Frederic			Reconstitution and mechanism of the stimulation of de novo methylation by human DNMT3L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLTRANSFERASES DNMT3A; ADENOSYL-L-METHIONINE; ENZYMATIC-PROPERTIES; N-METHYLTRANSFERASE; CATALYTIC-ACTIVITY; BINDING; PROTEIN; FAMILY; EXPRESSION; GENE	The DNMT3-like protein, DNMT3L, is required for germ line DNA methylation, although it is inactive as a DNA methyltransferase per se. Previous studies have shown that DNMT3L physically associates with the active de novo DNA methyltransferases, DNMT3A and DNMT3B, and stimulates their catalytic activities in a cell culture system. However, the mechanism by which DNMT3L stimulates de novo methylation remains unclear. Here, we have purified the full-length human DNMT3A2 and DNMT3L proteins and determined unique conditions that allow for the proper reconstitution of the stimulation of DNMT3A2 de novo methyltransferase activity by DNMT3L. These conditions include the use of buffers resembling physiological conditions and the preincubation of the two proteins. Under these conditions, maximal stimulation is reached at equimolar amounts of DNMT3L and DNMT3A2 proteins, and the catalytic efficiency of DNMT3A2 is increased up to 20-fold. Biochemical analysis revealed that whereas DNMT3L on its own does not significantly bind to the methyl group donor, S-adenosyl-L-methionine (SAM), it strongly increases the binding of SAM to DNMT3A2. DNA binding, on the contrary, was not appreciably improved. Analysis of DNA methyltransferase complexes in solution using size exclusion chromatography revealed that DNMT3A2 forms large structures of heterogeneous sizes, whereas DNMT3L appears as a monomer. Binding of DNMT3L to DNMT3A2 promotes a dramatic reorganization of DNMT3A2 subunits and leads to the formation of specific complexes with enhanced DNA methyltransferase activity and increased SAM binding.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Davis, Ctr Genet & Dev, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Chedin, F (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, 1 Shields Ave, Davis, CA 95616 USA.	flchedin@ucdavis.edu		Kareta, Michael/0000-0002-6980-9065; Chedin, Frederic/0000-0002-1306-5335				Aapola U, 2000, GENOMICS, V65, P293, DOI 10.1006/geno.2000.6168; Aoki A, 2001, NUCLEIC ACIDS RES, V29, P3506, DOI 10.1093/nar/29.17.3506; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848; Bourc'his D, 2004, NATURE, V431, P96, DOI 10.1038/nature02886; CABRERO C, 1988, HEPATOLOGY, V8, P1530, DOI 10.1002/hep.1840080610; CAREY J, 1991, METHOD ENZYMOL, V208, P103; Chedin F, 2002, P NATL ACAD SCI USA, V99, P16916, DOI 10.1073/pnas.262443999; Chen ZX, 2005, J CELL BIOCHEM, V95, P902, DOI 10.1002/jcb.20447; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; DUERRE JA, 1989, BIOCHIM BIOPHYS ACTA, V985, P211, DOI 10.1016/0005-2736(89)90366-0; FAUMAN EB, 1999, S ADENOSYLMETHIONINE, P1, DOI DOI 10.1142/9789812813077_0001; FRANCIS DM, 1980, BIOCHEM J, V187, P819, DOI 10.1042/bj1870819; Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721; Gowher H, 2005, J BIOL CHEM, V280, P13341, DOI 10.1074/jbc.M413412200; Hata K, 2002, DEVELOPMENT, V129, P1983; Hata K, 2006, MOL REPROD DEV, V73, P116, DOI 10.1002/mrd.20387; Jair KW, 2006, CANCER RES, V66, P682, DOI 10.1158/0008-5472.CAN-05-1980; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaneda M, 2004, NATURE, V429, P900, DOI 10.1038/nature02633; La Salle S, 2004, DEV BIOL, V268, P403, DOI 10.1016/j.ydbio.2003.12.031; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; LOTTA T, 1995, BIOCHEMISTRY-US, V34, P4202, DOI 10.1021/bi00013a008; Lucifero D, 2004, HUM MOL GENET, V13, P839, DOI 10.1093/hmg/ddh104; Luka Z, 2003, BIOCHEM BIOPH RES CO, V312, P1067, DOI 10.1016/j.bbrc.2003.11.037; Margot JB, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-7; MARTIN RL, 1989, J BIOL CHEM, V264, P11768; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Reik W, 2005, NAT REV GENET, V6, P403, DOI 10.1038/nrg1602; REITZ RC, 1989, J BIOL CHEM, V264, P8097; Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655; Romani AMP, 2000, FRONT BIOSCI, V5, pD720, DOI 10.2741/Romani; Sakai Y, 2004, GENE EXPR PATTERNS, V5, P231, DOI 10.1016/j.modgep.2004.07.011; Suetake I, 2004, J BIOL CHEM, V279, P27816, DOI 10.1074/jbc.M400181200; Suetake I, 2003, J BIOCHEM, V133, P737, DOI 10.1093/jb/mvg095; Taoka S, 1999, BIOCHEMISTRY-US, V38, P13155, DOI 10.1021/bi990865t; Touyz RM, 2004, FRONT BIOSCI-LANDMRK, V9, P1278, DOI 10.2741/1316; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Waterland RA, 2006, HUM MOL GENET, V15, P705, DOI 10.1093/hmg/ddi484; Webster KE, 2005, P NATL ACAD SCI USA, V102, P4068, DOI 10.1073/pnas.0500702102; Wilson JR, 2002, CELL, V111, P105, DOI 10.1016/S0092-8674(02)00964-9; Wu Q, 2005, J MED CHEM, V48, P7243, DOI 10.1021/jm050568o; Yokochi T, 2004, BIOORG CHEM, V32, P234, DOI 10.1016/j.bioorg.2004.04.005; Yokochi T, 2002, J BIOL CHEM, V277, P11735, DOI 10.1074/jbc.M106590200	49	131	135	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25893	25902		10.1074/jbc.M603140200	http://dx.doi.org/10.1074/jbc.M603140200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829525	hybrid			2022-12-25	WOS:000240249500004
J	Narvaez, AJ; Voevodskaya, N; Thelander, L; Graeslund, A				Narvaez, Ana J.; Voevodskaya, Nina; Thelander, Lars; Graeslund, Astrid			The involvement of Arg(265) of mouse ribonucleotide reductase R2 protein in proton transfer and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADICAL TRANSFER PATHWAY; SITE-DIRECTED MUTAGENESIS; COUPLED ELECTRON-TRANSFER; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; SUBUNIT INTERACTION; BACTERIORHODOPSIN; MECHANISM; PHOTOCYCLE; ARGININE	Ribonucleotide reductase class I enzymes consist of two nonidentical subunits, R1 and R2, the latter containing a diiron carboxylate center and a stable tyrosyl radical (Tyr(.)), both essential for catalysis. Catalysis is known to involve highly conserved amino acid residues covering a range of similar to 35 angstrom and a concerted mechanism involving long range electron transfer, probably coupled to proton transfer. A number of residues involved in electron transfer in both the R1 and R2 proteins have been identified, but no direct model has been presented regarding the proton transfer side of the process. Arg(265) is conserved in all known sequences of class Ia R2. In this study we have used site-directed mutagenesis to gain insight into the role of this residue, which lies close to the catalytically essential Asp(266) and Trp(103). Mutants to Arg(265) included replacement by Ala, Glu, Gln, and Tyr. All mutants of Arg(265) were found to have no or low catalytic activity with the exception of Arg(265) to Glu, which shows similar to 40% of the activity of native R2. We also found that the Arg mutants were capable of stable tyrosyl radical generation, with similar kinetics of radical formation and R1 binding as native R2. Our results, supported by molecular modeling, strongly suggest that Arg(265) is involved in the proton- coupled electron transfer pathway and may act as a proton mediator during catalysis.	Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden	Stockholm University; Umea University	Graeslund, A (corresponding author), Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden.	astrid@dbb.su.se						Andersson K. K., 1995, ADV INORG CHEM, V43, P359; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; CHANG CH, 1979, CANCER RES, V39, P5081; Chang CJ, 2004, BBA-BIOENERGETICS, V1655, P13, DOI 10.1016/j.bbabio.2003.08.010; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; Doherty MK, 2000, BIOCHEMISTRY-US, V39, P10695, DOI 10.1021/bi000871l; Ehrenberg A, 2001, BIOSYSTEMS, V62, P9, DOI 10.1016/S0303-2647(01)00133-2; Ekberg M, 1996, J BIOL CHEM, V271, P20655, DOI 10.1074/jbc.271.34.20655; Ekberg M, 1998, J BIOL CHEM, V273, P21003, DOI 10.1074/jbc.273.33.21003; Eklund H, 2001, PROG BIOPHYS MOL BIO, V77, P177, DOI 10.1016/S0079-6107(01)00014-1; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ENGSTROM Y, 1979, BIOCHEMISTRY-US, V18, P2941, DOI 10.1021/bi00581a004; Graslund A, 1996, ANNU REV BIOPH BIOM, V25, P259; Hogbom M, 2003, P NATL ACAD SCI USA, V100, P3209, DOI 10.1073/pnas.0536684100; Ingemarson R, 1996, BIOCHEMISTRY-US, V35, P8603, DOI 10.1021/bi960184n; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Kauppi B, 1996, J MOL BIOL, V262, P706, DOI 10.1006/jmbi.1996.0546; Kolberg M, 2004, BBA-PROTEINS PROTEOM, V1699, P1, DOI 10.1016/j.bbapap.2004.02.007; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MATZKE EA, 1992, J BIOL CHEM, V267, P19095; Meredith D, 2004, J BIOL CHEM, V279, P15795, DOI 10.1074/jbc.M313922200; Mowat CG, 2001, BIOCHEMISTRY-US, V40, P12292, DOI 10.1021/bi011360h; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; Petkova AT, 1999, BIOCHEMISTRY-US, V38, P1562, DOI 10.1021/bi981968z; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; Rova U, 1999, J BIOL CHEM, V274, P23746, DOI 10.1074/jbc.274.34.23746; ROVA U, 1995, BIOCHEMISTRY-US, V34, P4267, DOI 10.1021/bi00013a016; Schmidt PP, 1998, J BIOL CHEM, V273, P21463, DOI 10.1074/jbc.273.34.21463; Sjoberg B. M., 1995, NUCLEIC ACIDS MOL BI, V9, P192; Sjoberg BM, 1997, STRUCT BOND, V88, P139; SJOBERG BM, 1994, STRUCTURE, V2, P793, DOI 10.1016/S0969-2126(94)00080-8; Strand KR, 2004, J BIOL CHEM, V279, P46794, DOI 10.1074/jbc.M407346200; Strand KR, 2002, J BIOL CHEM, V277, P34229, DOI 10.1074/jbc.M203358200; Stubbe J, 2003, CHEM REV, V103, P2167, DOI 10.1021/cr020421u; Stubbe J, 1998, P NATL ACAD SCI USA, V95, P2723, DOI 10.1073/pnas.95.6.2723; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; SUBRAMANIAM S, 1990, P NATL ACAD SCI USA, V87, P1013, DOI 10.1073/pnas.87.3.1013; Tanimoto T, 2004, BIOCHEMISTRY-US, V43, P9439, DOI 10.1021/bi049368p; THELANDER L, 1993, MET IONS BIOL SYST, V30, P109; THORGEIRSSON TE, 1991, BIOCHEMISTRY-US, V30, P9133, DOI 10.1021/bi00102a003; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; Uppsten M, 2006, J MOL BIOL, V359, P365, DOI 10.1016/j.jmb.2006.03.035; Xiao YW, 2004, BIOCHEMISTRY-US, V43, P12809, DOI 10.1021/bi049238g; Yun D, 2002, BIOCHEMISTRY-US, V41, P981, DOI 10.1021/bi011797p	47	9	10	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26022	26028		10.1074/jbc.M604598200	http://dx.doi.org/10.1074/jbc.M604598200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829694	hybrid			2022-12-25	WOS:000240249500017
J	Robertson, AS; Belorgey, D; Gubb, D; Dafforn, TR; Lomas, DA				Robertson, Andrew S.; Belorgey, Didier; Gubb, David; Dafforn, Timothy R.; Lomas, David A.			Inhibitory activity of the Drosophila melanogaster serpin necrotic is dependent on lysine residues in the D-helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; HEPARIN ACTIVATION; ANTITHROMBIN; BINDING; MECHANISM; PROTEINASE; PROTEASE; COMPLEX; TOLL	Necrotic is a member of the serine protease inhibitor or serpin superfamily. It is a potent inhibitor of elastase and chymotrypsin type proteases and is responsible for regulating the anti-fungal response in Drosophila melanogaster. Necrotic contains three basic lysine residues within the D-helix that are homologous to those found in the heparin-binding domain of antithrombin and heparin co-factor II. We show here that substitution of all three lysine residues for glutamines caused cellular necrosis and premature death in Drosophila in keeping with a loss of function phenotype. The lysine to glutamine substitutions had no effect on the overall structure of recombinant Necrotic protein but abolished the formation of stable complexes with target proteases. Individual substitutions with either glutamine or alanine demonstrated that lysine 68 was the most critical residue for inhibitory activity. Despite the homology to other serpins, Necrotic did not bind, nor was it activated by sulfated glycans. These data demonstrate a critical role for basic residues within the D-helix (and lysine 68 in particular) in the inhibitory mechanism of the serpin Necrotic.	Univ Cambridge, Dept Med, Inst Med Res, Cambridge CB2 2XY, England; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England; Univ Birmingham, Birmingham B15 2TT, W Midlands, England; CIC bioGUNE, Derio 48160, Spain	University of Cambridge; University of Cambridge; University of Birmingham; CIC bioGUNE	Lomas, DA (corresponding author), Univ Cambridge, Dept Med, Inst Med Res, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	dal16@cam.ac.uk	Gubb, David/F-9793-2011; Dafforn, Tim/A-9072-2015	Dafforn, Tim/0000-0003-2257-6679	MRC [G0500306, G8225539] Funding Source: UKRI; Medical Research Council [G8225539, G0500306] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		ANDREASEN PA, 1994, FEBS LETT, V338, P239, DOI 10.1016/0014-5793(94)80276-9; Belzar KJ, 2002, J BIOL CHEM, V277, P8551, DOI 10.1074/jbc.M110807200; BIETH JG, 1995, METHOD ENZYMOL, V248, P59; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; GETTINS PGW, 1996, SERPINS STRUCTURE FU, P65; Green C, 2000, GENETICS, V156, P1117; Green C, 2003, DEVELOPMENT, V130, P1473, DOI 10.1242/dev.00350; Huntington JA, 2003, J THROMB HAEMOST, V1, P1535, DOI 10.1046/j.1538-7836.2003.00305.x; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Johnson DJD, 2003, BIOCHEMISTRY-US, V42, P8712, DOI 10.1021/bi034524y; Levashina EA, 1999, SCIENCE, V285, P1917, DOI 10.1126/science.285.5435.1917; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Meagher JL, 2000, J BIOL CHEM, V275, P2698, DOI 10.1074/jbc.275.4.2698; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; O'Keeffe D, 2004, J BIOL CHEM, V279, P50267, DOI 10.1074/jbc.M408774200; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1981, J BIOL CHEM, V256, P1073; Onda M, 2005, J BIOL CHEM, V280, P13735, DOI 10.1074/jbc.M413282200; Robertson AS, 2003, J BIOL CHEM, V278, P6175, DOI 10.1074/jbc.M209277200; RUBIN H, 1990, J BIOL CHEM, V265, P1199; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Strickland DK, 2003, J THROMB HAEMOST, V1, P1663, DOI 10.1046/j.1538-7836.2003.00330.x; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652	27	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26437	26443		10.1074/jbc.M606085200	http://dx.doi.org/10.1074/jbc.M606085200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16835244	hybrid			2022-12-25	WOS:000240249500061
J	Thomas, JT; Prakash, D; Weih, K; Moos, M				Thomas, J. Terrig; Prakash, David; Weih, Karis; Moos, Malcolm, Jr.			CDMP1/GDF5 has specific processing requirements that restrict its action to joint surfaces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-SITU HYBRIDIZATION; BONE MORPHOGENETIC PROTEINS; EARLY XENOPUS DEVELOPMENT; TGF-BETA-SUPERFAMILY; BRACHYDACTYLY TYPE-C; PROHORMONE CONVERTASES; EMBRYONIC-DEVELOPMENT; CARTILAGE FORMATION; SPEMANN ORGANIZER; PRO-PROTEIN	CDMP1/GDF5 has not demonstrated biological activity in Xenopus embryos when overexpressed by mRNA injection. We provide biological and biochemical evidence that to become active, the protein requires cleavage by two distinct proteolytic enzymes. We demonstrate a specific overlap in the expression patterns of CDMP1/GDF5 with the proteases required to release the mature peptide at the location of the future articular surface but not in the future joint space. Taken together, these observations provide a plausible mechanism for local action of CDMP1/GDF5 consistent with requirements imposed by current models of pattern formation in the developing limb.	US FDA, Div Cellular & Gene Therapies, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA)	Thomas, JT (corresponding author), US FDA, Div Cellular & Gene Therapies, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA.	john.thomas@fda.hhs.gov; malcolm.moos@fda.hhs.gov	Moos, Malcolm C/F-3673-2011	Moos, Malcolm C/0000-0002-9575-9938				Baur ST, 2000, DEVELOPMENT, V127, P605; Beck S, 2002, NAT CELL BIOL, V4, P981, DOI 10.1038/ncb890; Birsoy B, 2005, DEVELOPMENT, V132, P591, DOI 10.1242/dev.01599; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Butler K, 2001, METHODS, V23, P303, DOI 10.1006/meth.2000.1142; Chang CB, 1999, DEVELOPMENT, V126, P3347; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Constam DB, 1996, J CELL BIOL, V134, P181, DOI 10.1083/jcb.134.1.181; Constam DB, 2000, GENE DEV, V14, P1146; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; Cui YZ, 2001, GENE DEV, V15, P2797; Dale L, 1999, BIOESSAYS, V21, P751, DOI 10.1002/(SICI)1521-1878(199909)21:9<751::AID-BIES6>3.0.CO;2-I; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dionne MS, 2001, MOL CELL BIOL, V21, P636, DOI 10.1128/MCB.21.2.636-643.2001; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; Duprez D, 1996, MECH DEVELOP, V57, P145, DOI 10.1016/0925-4773(96)00540-0; EVANS JP, 1991, METHOD CELL BIOL, V36, P117; Everman DB, 2002, AM J MED GENET, V112, P291, DOI 10.1002/ajmg.10777; Faiyaz-Ul-Haque M, 2002, CLIN GENET, V61, P454, DOI 10.1034/j.1399-0004.2002.610610.x; Francis-West PH, 1999, DEVELOPMENT, V126, P1305; Goutel C, 2000, MECH DEVELOP, V99, P15, DOI 10.1016/S0925-4773(00)00470-6; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; Gurdon J. B., 1967, METHODS DEV BIOL, P75; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; Irvine KD, 2001, ANNU REV CELL DEV BI, V17, P189, DOI 10.1146/annurev.cellbio.17.1.189; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KAY BL, 1991, METHOD CELL BIOL, V36, P657; KELLER R, 1991, METHOD CELL BIOL, V36, P61; Moos M, 1995, DEVELOPMENT, V121, P4293; Nelsen S, 2005, DEV DYNAM, V233, P1038, DOI 10.1002/dvdy.20378; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Pacifici Maurizio, 2005, Birth Defects Research, V75, P237, DOI 10.1002/bdrc.20050; Pathi S, 1999, DEV BIOL, V209, P239, DOI 10.1006/dbio.1998.9181; Polinkovsky A, 1997, NAT GENET, V17, P18, DOI 10.1038/ng0997-18; Seemann P, 2005, J CLIN INVEST, V115, P2373, DOI 10.1172/JCI25118; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Settle SH, 2003, DEV BIOL, V254, P116, DOI 10.1016/S0012-1606(02)00022-2; Sive Hazel L., 2000, EARLY DEV XENOPUS LA; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; TANNAHILL D, 1989, DEVELOPMENT, V106, P775; Thomas JT, 1997, NAT GENET, V17, P58, DOI 10.1038/ng0997-58; Thomas JT, 1996, NAT GENET, V12, P315, DOI 10.1038/ng0396-315; Tozer Samuel, 2005, Birth Defects Research, V75, P226, DOI 10.1002/bdrc.20049; Tsumaki N, 2002, J BONE MINER RES, V17, P898, DOI 10.1359/jbmr.2002.17.5.898; Wolfman NM, 1997, J CLIN INVEST, V100, P321, DOI 10.1172/JCI119537; Yi SE, 2000, DEVELOPMENT, V127, P621; Zaidi AU, 2000, J HISTOCHEM CYTOCHEM, V48, P1369, DOI 10.1177/002215540004801007	48	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26725	26733		10.1074/jbc.M603851200	http://dx.doi.org/10.1074/jbc.M603851200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829522	hybrid			2022-12-25	WOS:000240249500090
J	Zhao, H; Waite, JH				Zhao, Hua; Waite, J. Herbert			Linking adhesive and structural proteins in the attachment plaque of Mytilus californianus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-A2 ELECTROPHORETIC VARIANTS; PHRAGMATOPOMA-CALIFORNICA; CROSS-LINKING; DOPA; EDULIS; QUINOPROTEINS; CEMENT; FAMILY; BYSSUS	The byssal attachment of California mussels Mytilus californianus provides secure adhesion in the presence of moisture, a feat that still eludes most synthetic polymers. Matrix-assisted laser desorption ionization mass spectrometry was used to probe the footprints of byssal attachment plaques on glass cover slips for adhesive proteins. Besides the abundant mcfp-3 protein family (Zhao, H., Robertson, N. B., Jewhurst, S. A., and Waite, J. H. (2006) J. Biol. Chem. 281, 11090 - 11096), two new proteins, mcfp-5 and mcfp-6, with masses of 8.9 kDa and 11.6 kDa, respectively, were identified in footprints, partially characterized and completely sequenced from a cDNA library. mcfp-5 resembles mcfp-3 in its basic pI and abundant 3,4-dihydroxyphenyl-L-alanine (Dopa; 30 mol %), but is distinct in two respects: it is more homogeneous in primary sequence and is polyphosphorylated. mcfp-6 is basic and contains a small amount of Dopa (< 5 mol %). In contrast to mcfp-3 and - 5, tyrosine prevails at 20 mol %, and cysteine is present at 11 mol %, one-third of which remains thiolate. Given the oxidative instability of Dopa and cysteine at pH 8.2 (seawater), we tested the hypothesis that thiols serve to scavenge dopaquinones by adduct formation. Plaque footprints were hydrolyzed and screened for cysteine dopaquinone adducts using phenylboronate affinity chromatography. 5-S-Cysteinyldopa was detected at nearly 1 mol %. The results suggest that mcfp-6 may provide a cohesive link between the surface-coupling Dopa-rich proteins and the bulk of the plaque proteins.	Univ Calif Santa Barbara, Inst Marine Sci, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Inst Marine Sci, Dept Chem & Biochem, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Waite, JH (corresponding author), Univ Calif Santa Barbara, Inst Marine Sci, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	waite@lifesci.ucsb.edu			NIDCR NIH HHS [DE015415] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015415] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Burzio LA, 2000, BIOCHEMISTRY-US, V39, P11147, DOI 10.1021/bi0002434; Dalsin JL, 2005, LANGMUIR, V21, P640, DOI 10.1021/la048626g; DURKIN JP, 1981, TOXICON, V19, P535, DOI 10.1016/0041-0101(81)90012-X; Hiraoka M, 2005, J LIPID RES, V46, P2441, DOI 10.1194/jlr.M500248-JLR200; INOUE K, 1995, J BIOL CHEM, V270, P6698, DOI 10.1074/jbc.270.12.6698; ISRAELACHVILI JN, 1985, INTERMOLECULAR SURFA, P12; Lee BP, 2006, MACROMOLECULES, V39, P1740, DOI 10.1021/ma0518959; McDowell LM, 1999, J BIOL CHEM, V274, P20293, DOI 10.1074/jbc.274.29.20293; Ohkawa K, 2004, BIOFOULING, V20, P101, DOI 10.1080/08927010410001681246; PAPOV VV, 1995, J BIOL CHEM, V270, P20183, DOI 10.1074/jbc.270.34.20183; PAZ MA, 1991, J BIOL CHEM, V266, P689; RZEPECKI LM, 1992, BIOL BULL, V183, P123, DOI 10.2307/1542413; SHIER WT, 1978, ANAL BIOCHEM, V87, P604, DOI 10.1016/0003-2697(78)90711-X; STERNSON AW, 1973, J ELECTROANAL CHEM, V46, P313, DOI 10.1016/S0022-0728(73)80139-1; Stewart RJ, 2004, J EXP BIOL, V207, P4727, DOI 10.1242/jeb.01330; Thompson JB, 2001, NATURE, V414, P773, DOI 10.1038/414773a; TSE DCS, 1976, J MED CHEM, V19, P37, DOI 10.1021/jm00223a008; Waite JH, 2005, J ADHESION, V81, P297, DOI 10.1080/00218460590944602; WAITE JH, 1995, METHOD ENZYMOL, V258, P1; Waite JH, 2002, INTEGR COMP BIOL, V42, P1172, DOI 10.1093/icb/42.6.1172; Waite JH, 2001, BIOCHEMISTRY-US, V40, P2887, DOI 10.1021/bi002718x; WAITE JH, 1984, METHOD ENZYMOL, V107, P397; WALKER P, 1987, SURF COAT, V1, P189; Yu ME, 1999, J AM CHEM SOC, V121, P5825, DOI 10.1021/ja990469y; Zhang JG, 1997, BIOCHEMISTRY-US, V36, P2380, DOI 10.1021/bi962164r; Zhao H, 2006, J BIOL CHEM, V281, P11090, DOI 10.1074/jbc.M510792200; Zhao H, 2005, J BIOL CHEM, V280, P42938, DOI 10.1074/jbc.M508457200; Zhao H, 2005, BIOCHEMISTRY-US, V44, P15915, DOI 10.1021/bi051530g	28	210	227	5	98	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26150	26158		10.1074/jbc.M604357200	http://dx.doi.org/10.1074/jbc.M604357200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16844688	hybrid			2022-12-25	WOS:000240249500031
J	Li, J; Uchida, T; Todo, T; Kitagawa, T				Li, Jiang; Uchida, Takeshi; Todo, Takeshi; Kitagawa, Teizo			Similarities and differences between cyclobutane pyrimidine dimer photolyase and (6-4) photolyase as revealed by resonance Raman spectroscopy - Electron transfer from the FAD cofactor to ultraviolet-damaged DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVIN ADENINE-DINUCLEOTIDE; ENZYME-SUBSTRATE COMPLEX; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MOLECULAR-DYNAMICS; THYMINE DIMER; HETERO ATOMS; BINDING; REPAIR; SPECTRA	The cyclobutane pyrimidine dimer (CPD) and (6-4) photoproduct, two major types of DNA damage caused by UV light, are repaired under illumination with near UV-visible light by CPD and (6-4) photolyases, respectively. To understand the mechanism of DNA repair, we examined the resonance Raman spectra of complexes between damaged DNA and the neutral semiquinoid and oxidized forms of (6-4) and CPD photolyases. The marker band for a neutral semiquinoid flavin and band I of the oxidized flavin, which are derived from the vibrations of the benzene ring of FAD, were shifted to lower frequencies upon binding of damaged DNA by CPD photolyase but not by ( 6-4) photolyase, indicating that CPD interacts with the benzene ring of FAD directly but that the (6-4) photoproduct does not. Bands II and VII of the oxidized flavin and the 1398/1391 cm(-1) bands of the neutral semiquinoid flavin, which may reflect the bending of U-shaped FAD, were altered upon substrate binding, suggesting that CPD and the (6-4) photoproduct interact with the adenine ring of FAD. When substrate was bound, there was an upshifted 1528 cm(-1) band of the neutral semiquinoid flavin in CPD photolyase, indicating a weakened hydrogen bond at N(5)-H of FAD, and band X seemed to be downshifted in (6-4) photolyase, indicating a weakened hydrogen bond at N(3)-H of FAD. These Raman spectra led us to conclude that the two photolyases have different electron transfer mechanisms as well as different hydrogen bonding environments, which account for the higher redox potential of CPD photolyase.	Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan; Grad Univ Adv Studies, Sch Adv Sci, Dept Photosci, Kanagawa 2400193, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Kyoto 6068501, Japan	National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Graduate University for Advanced Studies - Japan; Kyoto University	Kitagawa, T (corresponding author), Toyota Phys & Chem Res Inst, Aichi 4801192, Japan.	teizo@ims.ac.jp	Uchida, Takeshi/A-6455-2017	Uchida, Takeshi/0000-0001-9270-8329				ABE M, 1987, SPECTROCHIM ACTA A, V43, P1027, DOI 10.1016/0584-8539(87)80175-7; Antony J, 2000, J AM CHEM SOC, V122, P1057, DOI 10.1021/ja993784t; BENECKY M, 1979, BIOCHEMISTRY-US, V18, P3471, DOI 10.1021/bi00583a006; BOWMAN WD, 1981, BIOCHEMISTRY-US, V20, P3313, DOI 10.1021/bi00514a051; Christine KS, 2002, J BIOL CHEM, V277, P38339, DOI 10.1074/jbc.M206531200; Cichon MK, 2002, ANGEW CHEM INT EDIT, V41, P767, DOI 10.1002/1521-3773(20020301)41:5<767::AID-ANIE767>3.0.CO;2-B; FRANKLIN WA, 1982, J BIOL CHEM, V257, P13535; Gindt YM, 2005, J AM CHEM SOC, V127, P10472, DOI 10.1021/ja051441r; Hahn J, 1998, J MOL MODEL, V4, P73, DOI 10.1007/s008940050133; Hahn J, 1999, J PHYS CHEM B, V103, P2001, DOI 10.1021/jp984197h; Hitomi K, 2001, J BIOL CHEM, V276, P10103, DOI 10.1074/jbc.M008828200; Hitomi K, 1997, J BIOL CHEM, V272, P32591, DOI 10.1074/jbc.272.51.32591; ISRAELACHVILI J, 1982, NATURE, V300, P341, DOI 10.1038/300341a0; JORNS MS, 1985, BIOCHEMISTRY-US, V24, P1856, DOI 10.1021/bi00329a008; JORNS MS, 1990, BIOCHEMISTRY-US, V29, P552, DOI 10.1021/bi00454a032; Kao YT, 2005, P NATL ACAD SCI USA, V102, P16128, DOI 10.1073/pnas.0506586102; Kay CWM, 1999, BIOCHEMISTRY-US, V38, P16740, DOI 10.1021/bi991442u; KIM ST, 1994, J BIOL CHEM, V269, P8535; Komori H, 2001, P NATL ACAD SCI USA, V98, P13560, DOI 10.1073/pnas.241371398; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LIVELY CR, 1990, J PHYS CHEM-US, V94, P3980, DOI 10.1021/j100373a021; Ludwig ML, 1997, BIOCHEMISTRY-US, V36, P1259, DOI 10.1021/bi962180o; MacFarlane AW, 2003, BIOCHEMISTRY-US, V42, P8558, DOI 10.1021/bi034015w; MacFarlane AW, 2001, BIOCHEMISTRY-US, V40, P15203, DOI 10.1021/bi0114224; MCFARLAND JT, 1987, BIOL APPL RAMAN SPEC, V2; Mees A, 2004, SCIENCE, V306, P1789, DOI 10.1126/science.1101598; Miura R, 2001, CHEM REC, V1, P183, DOI 10.1002/tcr.1007; MORRIS MD, 1986, ADV SPECTROSCOPY, V13; MULLER F, 1983, J RAMAN SPECTROSC, V14, P106, DOI 10.1002/jrs.1250140211; Murgida DH, 2001, J RAMAN SPECTROSC, V32, P551, DOI 10.1002/jrs.719; NISHIMOTO K, 1984, BIOCHIM BIOPHYS ACTA, V802, P321, DOI 10.1016/0304-4165(84)90178-8; NISHIMOTO K, 1986, J BIOCHEM-TOKYO, V100, P1647, DOI 10.1093/oxfordjournals.jbchem.a121873; NISHINA Y, 1983, J BIOCHEM-TOKYO, V94, P1979, DOI 10.1093/oxfordjournals.jbchem.a134552; NISHINA Y, 1980, J BIOCHEM-TOKYO, V88, P411, DOI 10.1093/oxfordjournals.jbchem.a132987; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; SANCAR GB, 1987, J BIOL CHEM, V262, P492; Sanders DB, 1999, J AM CHEM SOC, V121, P5127, DOI 10.1021/ja982660y; Schelvis JPM, 2003, J PHYS CHEM B, V107, P12352, DOI 10.1021/jp034209l; SCHMIDT J, 1983, BIOCHEMISTRY-US, V22, P76, DOI 10.1021/bi00270a011; SUGIYAMA T, 1985, BIOCHEMISTRY-US, V24, P3012, DOI 10.1021/bi00333a031; Tamada T, 1997, NAT STRUCT BIOL, V4, P887, DOI 10.1038/nsb1197-887; Todo T, 1999, MUTAT RES-DNA REPAIR, V434, P89, DOI 10.1016/S0921-8777(99)00013-0; Todo T, 1997, NUCLEIC ACIDS RES, V25, P764, DOI 10.1093/nar/25.4.764; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; TODO T, 1993, NATURE, V361, P371, DOI 10.1038/361371a0; WANG BY, 1989, BIOCHEMISTRY-US, V28, P1148, DOI 10.1021/bi00429a032; Weber S, 2005, BBA-BIOENERGETICS, V1707, P1, DOI 10.1016/j.bbabio.2004.02.010; Weber S, 2001, BIOPHYS J, V81, P1195, DOI 10.1016/S0006-3495(01)75777-3; Weber S, 2001, J AM CHEM SOC, V123, P3790, DOI 10.1021/ja003426m; YAGI K, 1987, CHEM SCRIPTA, V27A, P27; YAGI K, 1980, BIOCHEMISTRY-US, V19, P1553, DOI 10.1021/bi00549a003; Zhao XD, 1997, J BIOL CHEM, V272, P32580, DOI 10.1074/jbc.272.51.32580; Zheng YG, 1999, BIOCHEMISTRY-US, V38, P16727, DOI 10.1021/bi9918893; Zheng YJ, 1996, J AM CHEM SOC, V118, P9402, DOI 10.1021/ja9608151	56	34	35	3	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25551	25559		10.1074/jbc.M604483200	http://dx.doi.org/10.1074/jbc.M604483200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16816385	hybrid			2022-12-25	WOS:000240031300058
J	Punga, T; Bengoechea-Alonso, MT; Ericsson, J				Punga, Tanel; Bengoechea-Alonso, Maria T.; Ericsson, Johan			Phosphorylation and ubiquitination of the transcription factor sterol regulatory element-binding protein-1 in response to DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SREBP FAMILY; DEPENDENT DEGRADATION; PROTEASOME PATHWAY; GENE-EXPRESSION; IN-VIVO; ACTIVATION; COACTIVATOR; CHOLESTEROL; RECRUITMENT; PROTEOLYSIS	Members of the sterol regulatory element-binding protein (SREBP) family of transcription factors control cholesterol and lipid metabolism and play critical roles during adipocyte differentiation. The transcription factor SREBP1 is degraded by the ubiquitin-proteasome system following phosphorylation of Thr(426) and Ser(430) in its phosphodegron. We now demonstrate that the glycogen synthase kinase (GSK)-3 beta-dependent phosphorylation of these residues in SREBP1 is enhanced in response to specific DNA binding. DNA binding enhances the direct interaction between the C-terminal domain of SREBP1 and GSK-3 beta. Accordingly, we demonstrate that GSK-3 beta is recruited to the promoters of SREBP target genes in vivo. As a result of the phosphorylation of Thr(426) and Ser(430), the ubiquitin ligase Fbw7 is recruited to SREBP molecules associated with target promoters. Using a reconstituted ubiquitination system, we demonstrate that Fbw7-mediated ubiquitination of SREBP1 is dependent on its DNA binding activity. Thus, DNA binding could provide a mechanistic link between the phosphorylation, ubiquitination, and degradation of active transcription factors.	Univ Uppsala, Ludwig Inst Canc Res, Biomed Ctr, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research; Uppsala University	Ericsson, J (corresponding author), Univ Uppsala, Ludwig Inst Canc Res, Biomed Ctr, Box 595,Husargatan 3, S-75124 Uppsala, Sweden.	johan.ericsson@licr.uu.se	Ericsson, Johan/AAA-6664-2020; Punga, Tanel/K-9844-2019	Ericsson, Johan/0000-0003-1186-6574; Punga, Tanel/0000-0002-0561-367X				Bengoechea-Alonso MT, 2005, P NATL ACAD SCI USA, V102, P11681, DOI 10.1073/pnas.0501494102; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Espenshade PJ, 2006, J CELL SCI, V119, P973, DOI 10.1242/jcs02866; Giandomenico V, 2003, MOL CELL BIOL, V23, P2587, DOI 10.1128/MCB.23.7.2587-2599.2003; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Hirano Y, 2003, J BIOL CHEM, V278, P16809, DOI 10.1074/jbc.M212448200; Hirano Y, 2001, J BIOL CHEM, V276, P36431, DOI 10.1074/jbc.M105200200; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Kotzka J, 2004, J BIOL CHEM, V279, P22404, DOI 10.1074/jbc.M401198200; Lee DY, 2005, CELL, V123, P423, DOI 10.1016/j.cell.2005.08.015; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; Lipford JR, 2005, NATURE, V438, P113, DOI 10.1038/nature04098; Minella AC, 2005, CELL CYCLE, V4, P1356, DOI 10.4161/cc.4.10.2058; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Morris MC, 2003, NATURE, V423, P1009, DOI 10.1038/nature01720; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Rawson RB, 2003, NAT REV MOL CELL BIO, V4, P631, DOI 10.1038/nrm1174; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Sundqvist A, 2003, P NATL ACAD SCI USA, V100, P13833, DOI 10.1073/pnas.2335135100; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101	30	92	99	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25278	25286		10.1074/jbc.M604983200	http://dx.doi.org/10.1074/jbc.M604983200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16825193	hybrid			2022-12-25	WOS:000240031300029
J	Nakayama, H; Wilkin, BJ; Bodi, I; Molkentin, JD				Nakayama, Hiroyuki; Wilkin, Benjamin J.; Bodi, Ilona; Molkentin, Jeffery D.			Calcineurin-dependent cardiomyopathy is activated by TRPC in the adult mouse heart	FASEB JOURNAL			English	Article						signaling; calcium; store-operated; NFAT	CAPACITATIVE CALCIUM-ENTRY; NUCLEAR TRANSLOCATION; CARDIAC-HYPERTROPHY; SKELETAL-MUSCLE; CELLS; CHANNELS; NFAT; CARDIOMYOCYTES; INHIBITION; EXPRESSION	The manner in which Ca2+-sensitive signaling proteins are activated in contracting cardiomyocytes is an intriguing theoretical problem given that the cytoplasm is continually bathed with systolic Ca2+ concentrations that should maximally activate most Ca2+-sensitive signaling kinases and phosphatases. Store-operated Ca2+ entry, partially attributed to transient receptor potential (TRP) proteins, can mediate activation of the Ca2+-sensitive phosphatase calcineurin in nonexcitable cells. Here we investigated the gain-of-function phenotype associated with TRPC3 expression in the mouse heart using transgenesis to examine the potential role of store-operated Ca2+ entry in regulating cardiac calcineurin activation and ensuing hypertrophy/ myopathy. Adult myocytes isolated from TRPC3 transgenic mice showed abundant store-operated Ca2+ entry that was inhibited with SKF96365 but not verapamil or KB-R7943. Associated with this induction in store-operated Ca2+ entry, TRPC3 transgenic mice showed increased calcineurin-nuclear factor of activated T cells (NFAT) activation in vivo, cardiomyopathy, and increased hypertrophy after neuroendocrine agonist or pressure overload stimulation. The cardiomyopathic phenotype and increased hypertrophy after pressure overload stimulation were blocked by targeted disruption of the calcineurin A beta gene. Thus, enhanced store-operated Ca2+ entry in the heart can regulate calcineurin-NFAT signaling in vivo, which could secondarily the hypertrophic response and cardiomyopathy.	Univ Cincinnati, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati Childrens Hosp,Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Dept Surg, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Molkentin, JD (corresponding author), Univ Cincinnati, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati Childrens Hosp,Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.molkentin@cchmc.org	Tuluc, Petronel/C-2527-2011	Molkentin, Jeffery/0000-0002-3558-6529	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL069779, P50HL077101, R01HL062927, R01HL081104, R01HL060562] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NHLBI NIH HHS [P01 HL069779-06A10003, P01 HL069779, R01 HL060562, P50 HL077101, R01 HL081104, R01 HL062927-10A1, R01 HL062927, R01 HL060562-11, R01 HL081104-04, P50 HL077101-050004] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bikah G, 2000, NAT IMMUNOL, V1, P402, DOI 10.1038/80841; Brochet DXP, 2005, P NATL ACAD SCI USA, V102, P3099, DOI 10.1073/pnas.0500059102; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P4586, DOI 10.1073/pnas.072647999; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Cohen RA, 1999, CIRC RES, V84, P210, DOI 10.1161/01.RES.84.2.210; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Eisner DA, 2000, CIRC RES, V87, P1087, DOI 10.1161/01.RES.87.12.1087; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; Freichel M, 1999, CELL PHYSIOL BIOCHEM, V9, P270, DOI 10.1159/000016321; Garcia RL, 1997, BIOCHEM BIOPH RES CO, V239, P279, DOI 10.1006/bbrc.1997.7458; Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959-437X(00)00225-2; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; HUANG J, 2006, AM J PHYSL      0118; Hunton DL, 2004, AM J PHYSIOL-HEART C, V286, pH1124, DOI 10.1152/ajpheart.00162.2003; Hunton DL, 2002, J BIOL CHEM, V277, P14266, DOI 10.1074/jbc.M107167200; Kaiser RA, 2004, J BIOL CHEM, V279, P15524, DOI 10.1074/jbc.M313717200; Kiriazis H, 2002, CARDIOVASC RES, V53, P372, DOI 10.1016/S0008-6363(01)00487-4; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Liu YW, 2005, J CELL BIOL, V168, P887, DOI 10.1083/jcb.200408128; Liu YW, 2001, J CELL BIOL, V155, P27, DOI 10.1083/jcb.200103020; Mignen O, 2003, J BIOL CHEM, V278, P40088, DOI 10.1074/jbc.M306365200; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MONTELL C, 1985, SCIENCE, V230, P1040, DOI 10.1126/science.3933112; Ohki G, 2000, J BIOL CHEM, V275, P39055, DOI 10.1074/jbc.M003606200; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Rosenberg P, 2004, P NATL ACAD SCI USA, V101, P9387, DOI 10.1073/pnas.0308179101; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Uehara A, 2002, CELL CALCIUM, V31, P89, DOI 10.1054/ceca.2001.0257; Wilkins BJ, 2004, CIRC RES, V94, P110, DOI 10.1161/01.RES.0000109415.17511.18; Wu X, 2006, J CLIN INVEST, V116, P675, DOI 10.1172/JCI27374	34	217	234	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1660	1670		10.1096/fj.05-5560com	http://dx.doi.org/10.1096/fj.05-5560com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16873889	Green Accepted			2022-12-25	WOS:000240266600011
J	Baluchamy, S; Sankar, N; Navaraj, A; Moran, E; Thimmapaya, B				Baluchamy, S.; Sankar, N.; Navaraj, A.; Moran, E.; Thimmapaya, B.			Relationship between E1A binding to cellular proteins, c-myc activation and S-phase induction	ONCOGENE			English	Article						E1A; p300; c-myc repression; cell cycle	ACETYLTRANSFERASE COMPLEX; G(1) EXIT; P300; TRANSFORMATION; ACETYLATION; EXPRESSION; DEPLETION; PRB	We recently showed that p300/CREB-binding protein (CBP) plays an important role in maintaining cells in G0/G1 phase by keeping c-myc in a repressed state. Consistent with this, adenovirus E1A oncoprotein induces c-myc in a p300-dependent manner, and the c-myc induction is linked to S-phase induction. The induction of S phase by E1A is dependent on its binding to and inactivating several host proteins including p300/CBP. To determine whether there is a correlation between the host proteins binding to the N-terminal region of E1A, activation of c-myc and induction of S phase, we assayed the c-myc and S-phase induction in quiescent human cells by infecting them with Ad N-terminal E1A mutants with mutations that specifically affect binding to different chromatin-associated proteins including pRb, p300, p400 and p300/CBP-associated factor (PCAF). We show that the mutants that failed to bind to p300 or pRb were severely defective for c-myc and S-phase induction. The induction of c-myc and S phase was only moderately affected when E1A failed to bind to p400. Furthermore, analysis of the E1A mutants that fail to bind to p300, and both p300 and PCAF suggests that PCAF may also play a role in c-myc repression, and that the two chromatin-associated proteins may repress c-myc independently. In summary, these results suggest that c-myc deregulation by E1A through its interaction with these chromatin-associated proteins is an important step in the E1A-mediated cell cycle deregulation and possibly in cell transformation.	Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; Temple Univ, Sch Med, Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA	Northwestern University; Feinberg School of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Thimmapaya, B (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, 303 E Chicago Ave,Olson 8452, Chicago, IL 60611 USA.	b-thimmapaya@northwestern.edu	Natesan, Sankar/C-9866-2015		NCI NIH HHS [CA74403, R01 CA074403] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074403] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baluchamy S, 2003, P NATL ACAD SCI USA, V100, P9524, DOI 10.1073/pnas.1633700100; BARBEAU D, 1994, ONCOGENE, V9, P359; Buchmann AM, 1998, MOL CELL BIOL, V18, P4565, DOI 10.1128/MCB.18.8.4565; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Goodman RH, 2000, GENE DEV, V14, P1553; GRISCH SM, 2002, NAT REV MOL CELL BIO, V6, P441; Harbour JW, 2001, ARCH OPHTHALMOL-CHIC, V119, P1699; Kolli S, 2001, P NATL ACAD SCI USA, V98, P4646, DOI 10.1073/pnas.081141998; Lang SE, 2003, ONCOGENE, V22, P2836, DOI 10.1038/sj.onc.1206376; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; Nees M, 2000, CANCER RES, V60, P4289; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Rajabi HN, 2005, J BIOL CHEM, V280, P361, DOI 10.1074/jbc.M408633200; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Santoso BY, 2006, NAT STRUCT MOL BIOL, V13, P131, DOI 10.1038/nsmb1048; SOULE HD, 1990, CANCER RES, V50, P6075; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; WANG HGH, 1995, J VIROL, V69, P7917, DOI 10.1128/JVI.69.12.7917-7924.1995; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993	24	16	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					781	787		10.1038/sj.onc.1209825	http://dx.doi.org/10.1038/sj.onc.1209825			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16862175				2022-12-25	WOS:000243902200015
J	Oakes, SR; Robertson, FG; Kench, JG; Gardiner-Garden, M; Wand, MP; Green, JE; Ormandy, CJ				Oakes, S. R.; Robertson, F. G.; Kench, J. G.; Gardiner-Garden, M.; Wand, M. P.; Green, J. E.; Ormandy, C. J.			Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions	ONCOGENE			English	Article						prolactin receptor; mouse; mammary; carcinogenesis; C3(1)/SV40T	TRANSGENIC MOUSE MODEL; BREAST-CANCER; GLAND DEVELOPMENT; GROWTH-HORMONE; EXPRESSION; MICE; RISK; PROSTATE; PRL; BROMOCRIPTINE	Top quartile serum prolactin levels confer a twofold increase in the relative risk of developing breast cancer. Prolactin exerts this effect at an ill defined point in the carcinogenic process, via mechanisms involving direct action via prolactin receptors within mammary epithelium and/or indirect action through regulation of other hormones such as estrogen and progesterone. We have addressed these questions by examining mammary carcinogenesis in transplants of mouse mammary epithelium expressing the SV40T oncogene, with or without the prolactin receptor, using host animals with a normal endocrine system. In prolactin receptor knockout transplants the area of neoplasia was significantly smaller (7 versus 17%; P < 0.001 at 22 weeks and 7 versus 14%; P=0.009 at 32 weeks). Low-grade neoplastic lesions displayed reduced BrdU incorporation rate (11.3 versus 17% P=0.003) but no change in apoptosis rate. Tumor latency increased (289 days versus 236 days, P < 0.001). Tumor frequency, growth rate, morphology, cell proliferation and apoptosis were not altered. Thus, prolactin acts directly on the mammary epithelial cells to increase cell proliferation in preinvasive lesions, resulting in more neoplasia and acceleration of the transition to invasive carcinoma. Targeting of mammary prolactin signaling thus provides a strategy to prevent the early progression of neoplasia to invasive carcinoma.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; Inst Clin Pathol & Med Res, Dept Tissue Pathol, Westmead, NSW, Australia; Univ New S Wales, Sch Math, Dept Stat, Sydney, NSW, Australia; Lab Cell Regulat & Carcinogenesis, Transgen Oncogenesis Grp, Bethesda, MD USA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney	Ormandy, CJ (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	c.ormandy@garvan.org.au	Ormandy, Chris/G-4165-2014; Wand, Matt P/F-9413-2012	Wand, Matt P/0000-0003-2555-896X; Oakes, Samantha/0000-0003-1838-2310; Ormandy, Christopher/0000-0002-2504-7919; Kench, James Geoffrey/0000-0001-8687-4988	NATIONAL CANCER INSTITUTE [ZIABC005740, Z01BC005740] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATTIA MAM, 1966, CANCER RES, V26, P1787; Binart N, 2000, ENDOCRINOLOGY, V141, P2691, DOI 10.1210/en.141.7.2691; BONNETERRE J, 1988, EUR J CANCER CLIN ON, V24, P1851, DOI 10.1016/0277-5379(88)90097-1; BONNETERRE J, 1987, CANCER RES, V47, P4724; BRADBURY JM, 1995, DEV BIOL, V170, P553, DOI 10.1006/dbio.1995.1236; Brisken C, 1999, DEV BIOL, V210, P96, DOI 10.1006/dbio.1999.9271; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Chen WY, 1999, CLIN CANCER RES, V5, P3583; Clement-Lacroix P, 1999, ENDOCRINOLOGY, V140, P96, DOI 10.1210/en.140.1.96; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Das R, 1997, J MAMMARY GLAND BIOL, V2, P29, DOI 10.1023/A:1026369412612; DEOME KB, 1959, CANCER RES, V19, P515; Freemark M, 2001, ENDOCRINOLOGY, V142, P532, DOI 10.1210/en.142.2.532; GINSBURG E, 1995, CANCER RES, V55, P2591; Goffin V, 2005, ENDOCR REV, V26, P400, DOI 10.1210/er.2004-0016; Goffin V, 1996, J BIOL CHEM, V271, P16573, DOI 10.1074/jbc.271.28.16573; Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280; Gutzman JH, 2004, J STEROID BIOCHEM, V88, P69, DOI 10.1016/j.jsbmb.2003.10.008; Hankinson SE, 1998, JNCI-J NATL CANCER I, V90, P1292, DOI 10.1093/jnci/90.17.1292; Hankinson SE, 1999, J NATL CANCER I, V91, P629, DOI 10.1093/jnci/91.7.629; Horseman ND, 1997, EMBO J, V16, P6926, DOI 10.1093/emboj/16.23.6926; Hutchinson JN, 2000, ONCOGENE, V19, P6130, DOI 10.1038/sj.onc.1203970; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Ling C, 2000, ENDOCRINOLOGY, V141, P3564, DOI 10.1210/en.141.10.3564; Llovera M, 2000, ONCOGENE, V19, P4695, DOI 10.1038/sj.onc.1203846; MANNI A, 1989, BREAST CANCER RES TR, V14, P289, DOI 10.1007/BF01806300; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; MERSHON J, 1995, ENDOCRINOLOGY, V136, P3619, DOI 10.1210/en.136.8.3619; Missmer SA, 2004, JNCI-J NATL CANCER I, V96, P1856, DOI 10.1093/jnci/djh336; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Naylor MJ, 2003, ENDOCRINE, V20, P111, DOI 10.1385/ENDO:20:1-2:111; Naylor MJ, 2002, DEV DYNAM, V225, P100, DOI 10.1002/dvdy.10133; Ormandy CJ, 1997, J MAMMARY GLAND BIOL, V2, P355, DOI 10.1023/A:1026395229025; Ormandy CJ, 1997, J CLIN ENDOCR METAB, V82, P3692, DOI 10.1210/jc.82.11.3692; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; PEYRAT JP, 1984, EUR J CANCER CLIN ON, V20, P1363, DOI 10.1016/0277-5379(84)90054-3; PINHEIRO J, 2005, R PACKAGE VERSION, V3, P1; Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555; Robertson FG, 2003, ENDOCRINOLOGY, V144, P3196, DOI 10.1210/en.2003-0068; Rose-Hellekant TA, 2003, ONCOGENE, V22, P4664, DOI 10.1038/sj.onc.1206619; Schroeder MD, 2003, ENDOCRINOLOGY, V144, P5300, DOI 10.1210/en.2003-0826; Schroeder MD, 2002, MOL ENDOCRINOL, V16, P45, DOI 10.1210/me.16.1.45; Shibata MA, 1998, TOXICOL PATHOL, V26, P177, DOI 10.1177/019262339802600121; Touraine P, 1998, J CLIN ENDOCR METAB, V83, P667, DOI 10.1210/jc.83.2.667; Tworoger SS, 2004, CANCER RES, V64, P6814, DOI 10.1158/0008-5472.CAN-04-1870; Vomachka AJ, 2000, ONCOGENE, V19, P1077, DOI 10.1038/sj.onc.1203348; Vonderhaar BK, 1999, ENDOCR-RELAT CANCER, V6, P389, DOI 10.1677/erc.0.0060389; WELSCH CW, 1975, BRIT J CANCER, V32, P427, DOI 10.1038/bjc.1975.243; WELSCH CW, 1977, CANCER RES, V37, P951; Wennbo H, 2000, ONCOGENE, V19, P1072, DOI 10.1038/sj.onc.1203349; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820	52	68	70	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					543	553		10.1038/sj.onc.1209838	http://dx.doi.org/10.1038/sj.onc.1209838			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16862169				2022-12-25	WOS:000243731600007
J	Roos, WP; Batista, LFZ; Naumann, SC; Wick, W; Weller, M; Menck, CFM; Kaina, B				Roos, W. P.; Batista, L. F. Z.; Naumann, S. C.; Wick, W.; Weller, M.; Menck, C. F. M.; Kaina, B.			Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O-6-methylguanine	ONCOGENE			English	Article						apoptosis; DNA damage; DNA repair; MGMT; glioblastoma; Fas; p53	HUMAN O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; ALKYLATING-AGENTS; MISMATCH REPAIR; METHYLTRANSFERASE MGMT; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; CLINICAL-RESPONSE; TRANSGENIC MICE; RNA-POLYMERASE; BRAIN-TUMORS; DAMAGE	Methylating drugs such as temozolomide (TMZ) are widely used in the treatment of brain tumours (malignant gliomas). The mechanism of TMZ-induced glioma cell death is unknown. Here, we show that malignant glioma cells undergo apoptosis following treatment with the methylating agents N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) and TMZ. Cell death determined by colony formation and apoptosis following methylation is greatly stimulated by p53. Transfection experiments with O-6-methylguanine-DNA methyltransferase (MGMT) and depletion of MGMT by O-6-benzylguanine showed that, in gliomas, the apoptotic signal originates from O6-methylguanine (O(6)MeG) and that repair of O6MeG by MGMT prevents apoptosis. We further demonstrate that O(6)MeG-triggered apoptosis requires Fas/CD95/Apo-1 receptor activation in p53 non-mutated glioma cells, whereas in p53 mutated gliomas the same DNA lesion triggers the mitochondrial apoptotic pathway. This occurs less effectively via Bcl-2 degradation and caspase-9, -2, -7 and -3 activation. O(6)MeG-triggered apoptosis in gliomas is a late response (occurring > 120 h after treatment) that requires extensive cell proliferation. Stimulation of cell cycle progression by the Pasteurella multocida toxin promoted apoptosis whereas serum starvation attenuated it. O(6)MeG-induced apoptosis in glioma cells was preceded by the formation of DNA double-strand breaks (DSBs), as measured by gamma H2AX formation. Glioma cells mutated in DNA-PKcs, which is involved in non-homologous endjoining, were more sensitive to TMZ-induced apoptosis, supporting the involvement of DSBs as a downstream apoptosis triggering lesion. Overall, the data demonstrate that cell death induced by TMZ in gliomas is due to apoptosis and that determinants of sensitivity of gliomas to TMZ are MGMT, p53, proliferation rate and DSB repair.	Johannes Gutenberg Univ Mainz, Dept Toxicol, D-55131 Mainz, Germany; Univ Sao Paulo, Dept Microbiol, Inst Biomed Sci, Sao Paulo, Brazil; Univ Tubingen, Sch Med, Hertie Inst Clin Brain Res, Dept Gen Neurol, Tubingen, Germany	Johannes Gutenberg University of Mainz; Universidade de Sao Paulo; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Kaina, B (corresponding author), Johannes Gutenberg Univ Mainz, Dept Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.	kaina@uni-mainz.de	Menck, Carlos FM/G-6321-2011; Kaina, Bernd/AAE-4692-2020; Roos, Wynand/B-4846-2008; Wick, Wolfgang/AAA-2545-2020	Menck, Carlos FM/0000-0003-1941-0694; Roos, Wynand/0000-0002-0474-7414; Wick, Wolfgang/0000-0002-6171-634X; Weller, Michael/0000-0002-1748-174X				ALLALUNISTURNER MJ, 1995, RADIAT RES, V144, P288, DOI 10.2307/3578948; Anda T, 2003, NEUROL RES, V25, P241, DOI 10.1179/016164103101201445; Balajee AS, 1997, P NATL ACAD SCI USA, V94, P4306, DOI 10.1073/pnas.94.9.4306; Becker K, 2003, CARCINOGENESIS, V24, P541, DOI 10.1093/carcin/24.3.541; Becker K, 1996, CANCER RES, V56, P3244; BERANEK DT, 1990, MUTAT RES, V231, P11, DOI 10.1016/0027-5107(90)90173-2; Bobola MS, 2001, CLIN CANCER RES, V7, P613; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN JM, 1992, CARCINOGENESIS, V13, P1503; Chen ZP, 1999, CAN J NEUROL SCI, V26, P104; Debiak M, 2004, DNA REPAIR, V3, P359, DOI 10.1016/j.dnarep.2003.11.013; DOLAN ME, 1990, P NATL ACAD SCI USA, V87, P5368, DOI 10.1073/pnas.87.14.5368; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; Dunkern T, 2003, MUTAT RES-REV MUTAT, V544, P167, DOI 10.1016/j.mrrev.2003.06.005; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; Esteller M, 2001, CANCER RES, V61, P3225; Gerson SL, 2004, NAT REV CANCER, V4, P296, DOI 10.1038/nrc1319; Gunther W, 2003, BRIT J CANCER, V88, P463, DOI 10.1038/sj.bjc.6600711; Hammond LA, 2004, CLIN CANCER RES, V10, P1645, DOI 10.1158/1078-0432.CCR-03-0174; Hampson R, 1997, J BIOL CHEM, V272, P28596, DOI 10.1074/jbc.272.45.28596; Hegi ME, 2004, CLIN CANCER RES, V10, P1871, DOI 10.1158/1078-0432.CCR-03-0384; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hermisson M, 2006, J NEUROCHEM, V96, P766, DOI 10.1111/j.1471-4159.2005.03583.x; Hickman MJ, 2004, MOL CELL, V14, P105, DOI 10.1016/S1097-2765(04)00162-5; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Hirose Y, 2001, CANCER RES, V61, P5843; KAINA B, 1991, CARCINOGENESIS, V12, P1857; Kaina B, 1997, MUTAT RES-FUND MOL M, V381, P227, DOI 10.1016/S0027-5107(97)00187-5; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Komarova EA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P41; Lindahl T, 2000, MUTAT RES-REV MUTAT, V462, P129, DOI 10.1016/S1383-5742(00)00024-7; Lips J, 2001, CARCINOGENESIS, V22, P579, DOI 10.1093/carcin/22.4.579; Ljungman M, 1996, ONCOGENE, V13, P823; Margison GP, 2002, BIOESSAYS, V24, P255, DOI 10.1002/bies.10063; Meikrantz W, 1998, CARCINOGENESIS, V19, P369, DOI 10.1093/carcin/19.2.369; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; O'Connell MJ, 2005, J CELL SCI, V118, P1, DOI 10.1242/jcs.01626; Ochs K, 2000, CANCER RES, V60, P5815; Orth JHC, 2003, BIOCHEMISTRY-US, V42, P4971, DOI 10.1021/bi0272959; Paz MF, 2004, CLIN CANCER RES, V10, P4933, DOI 10.1158/1078-0432.CCR-04-0392; Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X; PEGG AE, 1993, BIOCHEMISTRY-US, V32, P11998, DOI 10.1021/bi00096a009; Pepponi R, 2003, J PHARMACOL EXP THER, V304, P661, DOI 10.1124/jpet.102.043950; Pohl U, 1999, CELL PHYSIOL BIOCHEM, V9, P29, DOI 10.1159/000016300; Preuss I, 1996, INT J CANCER, V65, P506, DOI 10.1002/(SICI)1097-0215(19960208)65:4<506::AID-IJC19>3.0.CO;2-7; PREUSS I, 1995, INT J CANCER, V61, P321, DOI 10.1002/ijc.2910610308; RENART J, 1979, P NATL ACAD SCI USA, V76, P3116, DOI 10.1073/pnas.76.7.3116; Roos W, 2004, ONCOGENE, V23, P359, DOI 10.1038/sj.onc.1207080; Roos WP, 2000, INT J RADIAT BIOL, V76, P1493, DOI 10.1080/09553000050176252; SCUDIERO DA, 1984, CANCER RES, V44, P2467; Silber JR, 1999, CLIN CANCER RES, V5, P807; SKLAR R, 1981, NATURE, V289, P417, DOI 10.1038/289417a0; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Tominaga Y, 1997, CARCINOGENESIS, V18, P889, DOI 10.1093/carcin/18.5.889; TSARYK R, 2005, IN PRESS CANC LETT; Wischhusen J, 2003, ONCOGENE, V22, P8233, DOI 10.1038/sj.onc.1207198	60	391	410	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					186	197		10.1038/sj.onc.1209785	http://dx.doi.org/10.1038/sj.onc.1209785			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819506				2022-12-25	WOS:000243398300003
J	Graeff, R; Liu, Q; Kriksunov, IA; Hao, Q; Lee, HC				Graeff, Richard; Liu, Qun; Kriksunov, Irina A.; Hao, Quan; Lee, Hon Cheung			Acidic residues at the active sites of CD38 and ADP-ribosyl cyclase determine nicotinic acid adenine dinucleotide phosphate (NAADP) synthesis and hydrolysis activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-ACINAR; CA2+; ACTIVATION; MOLECULE; SURFACE; LOCALIZATION; GLYCOPROTEIN; EXPRESSION; PROTEIN; ENZYME	Nicotinic acid adenine dinucleotide phosphate (NAADP) is a novel metabolite of NADP that has now been established as a Ca2+ messenger in many cellular systems. Its synthesis is catalyzed by multifunctional enzymes, CD38 and ADP-ribosyl cyclase (cyclase). The degradation pathway for NAADP is unknown and no enzyme that can specifically hydrolyze it has yet been identified. Here we show that CD38 can, in fact, hydrolyze NAADP to ADP-ribose 2'-phosphate. This activity was low at neutrality but greatly increased at acidic pH. This novel pH dependence suggests that the hydrolysis is determined by acidic residues at the active site. X-ray crystallography of the complex of CD38 with one of its substrates, NMN, showed that the nicotinamide moiety was in close contact with Glu146 at 3.27 angstrom and Asp(155) at 2.52 angstrom. Changing Glu(146) to uncharged Gly and Ala, and Asp(155) to Gln and Asn, by site-directed mutagenesis indeed eliminated the strong pH dependence. Changing Asp(155) to Glu, in contrast, preserved the dependence. The specificity of the two acidic residues was further demonstrated by changing the adjacent Asp(147) to Val, which had minimal effect on the pH dependence. Crystallography confirmed that Asp(147) was situated and directed away from the bound substrate. Synthesis of NAADP catalyzed by CD38 is known to have strong preference for acidic pH, suggesting that Glu(146) and Asp(155) are also critical determinants. This was shown to be case by mutagensis. Likewise, using similar approaches, Glu(98) of the cyclase, which is equivalent to Glu(146) in CD38, was found to be responsible for controlling the pH dependence of NAADP synthesis by the cyclase. Based on these findings, a catalytic model is proposed.	Cornell Univ, MacCHESS, Cornell High Energy Synchrotron Source, Ithaca, NY 14853 USA; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Univ Hong Kong, Dept Physiol, Hong Kong, Hong Kong, Peoples R China	Cornell University; University of Minnesota System; University of Minnesota Twin Cities; University of Hong Kong	Hao, Q (corresponding author), Cornell Univ, MacCHESS, Cornell High Energy Synchrotron Source, Ithaca, NY 14853 USA.	qh22@cornell.edu; leehc@tc.umn.edu	Lee, Hon Cheung/C-4329-2009; Liu, Qun/A-8757-2011; Hao, Quan/C-4304-2009; Graeff, Richard Milton/B-3425-2011	Liu, Qun/0000-0002-1179-290X; Hao, Quan/0000-0002-9642-0514	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061568] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01646] Funding Source: Medline; NIGMS NIH HHS [GM061568] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; Adebanjo OA, 1999, NAT CELL BIOL, V1, P409, DOI 10.1038/15640; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Basile G, 2005, P NATL ACAD SCI USA, V102, P14509, DOI 10.1073/pnas.0503691102; Beck A, 2006, FASEB J, V20, P962, DOI 10.1096/fj.05-5538fje; Berridge G, 2002, BIOCHEM J, V365, P295, DOI 10.1042/BJ20020180; Billington RA, 2002, J PHYSIOL-LONDON, V544, P107, DOI 10.1113/jphysiol.2002.030098; Churchill GC, 2003, CURR BIOL, V13, P125, DOI 10.1016/S0960-9822(03)00002-2; Churchill GC, 2002, CELL, V111, P703, DOI 10.1016/S0092-8674(02)01082-6; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Fernandez JE, 1998, J BIOL REG HOMEOS AG, V12, P81; Ferrero E, 1999, J LEUKOCYTE BIOL, V65, P151, DOI 10.1002/jlb.65.2.151; Gasser A, 2006, J BIOL CHEM, V281, P2489, DOI 10.1074/jbc.M506525200; Gasser A, 2006, J BIOL CHEM, V281, P16906, DOI 10.1074/jbc.M601347200; Graeff R, 2002, BIOCHEM J, V367, P163, DOI 10.1042/BJ20020644; Graeff R, 2001, J BIOL CHEM, V276, P12169, DOI 10.1074/jbc.M011299200; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JACKSON DG, 1990, J IMMUNOL, V144, P2811; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Khoo KM, 1999, BRAIN RES, V821, P17, DOI 10.1016/S0006-8993(98)01347-X; Kinnear NP, 2004, J BIOL CHEM, V279, P54319, DOI 10.1074/jbc.M406132200; KOGUMA T, 1994, BBA-MOL CELL RES, V1223, P160, DOI 10.1016/0167-4889(94)90087-6; Kolisek M, 2005, MOL CELL, V18, P61, DOI 10.1016/j.molcel.2005.02.033; Lee HC, 2000, CHEM IMMUNOL, V75, P39; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; Lee HC, 2003, CURR BIOL, V13, pR186, DOI 10.1016/S0960-9822(03)00120-9; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; LEE HC, 1993, BIOCHEM BIOPH RES CO, V191, P639, DOI 10.1006/bbrc.1993.1265; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; Lee HC, 1997, J BIOL CHEM, V272, P4172, DOI 10.1074/jbc.272.7.4172; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; Lee HC, 2005, J BIOL CHEM, V280, P33693, DOI 10.1074/jbc.R500012200; LEE HC, 2002, CYCLIC ADP RIBOSE NA; Liu Q, 2005, STRUCTURE, V13, P1331, DOI 10.1016/j.str.2005.05.012; MALAVASI F, 1992, INT J CLIN LAB RES, V22, P73, DOI 10.1007/BF02591400; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; Munshi C, 2000, J BIOL CHEM, V275, P21566, DOI 10.1074/jbc.M909365199; Munshi C, 1999, J BIOL CHEM, V274, P30770, DOI 10.1074/jbc.274.43.30770; Munshi CB, 1997, METHOD ENZYMOL, V280, P318; Munshi CB, 2002, J BIOL CHEM, V277, P49453, DOI 10.1074/jbc.M209313200; MUNSHI CB, 2002, CYCLIC ADP RIBOSE NA, P81; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Prasad GS, 1996, PROTEINS, V24, P138, DOI 10.1002/(SICI)1097-0134(199601)24:1<138::AID-PROT10>3.3.CO;2-K; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; Togashi K, 2006, EMBO J, V25, P1804, DOI 10.1038/sj.emboj.7601083; Yalcintepe L, 2005, EXP CELL RES, V303, P14, DOI 10.1016/j.yexcr.2004.09.010; Yamada M, 1997, BRAIN RES, V756, P52, DOI 10.1016/S0006-8993(97)00117-0; Yamamoto-Katayama S, 2002, J MOL BIOL, V316, P711, DOI 10.1006/jmbi.2001.5386; Yamasaki M, 2005, CURR BIOL, V15, P874, DOI 10.1016/j.cub.2005.04.033; Yamasaki M, 2004, J BIOL CHEM, V279, P7234, DOI 10.1074/jbc.M311088200	51	61	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28951	28957		10.1074/jbc.M604370200	http://dx.doi.org/10.1074/jbc.M604370200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16861223	hybrid			2022-12-25	WOS:000240680500049
J	Preston, RJS; Ajzner, E; Razzari, C; Karageorgi, S; Dua, S; Dahlback, B; Lane, DA				Preston, Roger J. S.; Ajzner, Eva; Razzari, Cristina; Karageorgi, Stalo; Dua, Sonia; Dahlback, Bjorn; Lane, David A.			Multifunctional specificity of the protein C/activated protein C Gla domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-THROMBOMODULIN COMPLEX; CARBOXYGLUTAMIC ACID DOMAIN; K-DEPENDENT PROTEINS; COFACTOR ACTIVITY; ANTICOAGULANT ACTIVITY; PHOSPHOLIPID-BINDING; ACTIVATED RECEPTOR-1; MEMBRANE-BINDING; SENSITIVE REGION; SITE	Activated protein C (APC) has potent anticoagulant and antiinflammatory properties that are mediated in part by its interactions with its cofactor protein S and the endothelial cell protein C receptor (EPCR). The protein C/APC Gla domain is implicated in both interactions. We sought to identify how the protein C Gla domain enables specific protein-protein interactions in addition to its conserved role in phospholipid binding. The human prothrombin Gla domain, which cannot bind EPCR or support protein S cofactor activity, has 22/45 residues that are not shared with the human protein C Gla domain. We hypothesized that the unique protein C/APC Gla domain residues were responsible for mediating the specific interactions. To assess this, we generated 13 recombinant protein C/APC variants incorporating the prothrombin residue substitutions. Despite anticoagulant activity similar to wild-type APC in the absence of protein S, APC variants APC(PT33 -39) (N33S/V34S/D35T/D36A/L38D/A39V) and APC(PT36/38/39) (D36A/L38D/A39V) were not stimulated by protein S, whereas APC(PT35/36) (D35T/D36A) exhibited reduced protein S sensitivity. Moreover, PC(PT8/10) (L8V/H10K) displayed negligible EPCR affinity, despite normal binding to anionic phospholipid vesicles and factor Va proteolysis in the presence and absence of protein S. A single residue variant, PC(PT8), also failed to bind EPCR. Factor VIIa, which also possesses Leu-8, bound soluble EPCR with similar affinity to wild-type protein C, collectively confirming Leu-8 as the critical residue for EPCR recognition. These results reveal the specific Gla domain residues responsible for mediating protein C/APC molecular recognition with both its cofactor and receptor and further illustrate the multifunctional potential of Gla domains.	Univ London Imperial Coll Sci Technol & Med, Dept Haematol, Div Investigat Sci, London W12 0NN, England; Lund Univ, Univ Hosp, Dept Lab Med, Div Clin Chem, S-20502 Malmo, Sweden; Mangiagalli & Regina Elena Fdn, Inst Ricovero & Cura Carattere Sci Nat Pubbl Magg, Dept Med & Med Specialties, I-20122 Milan, Italy; Univ Milan, I-20122 Milan, Italy	Imperial College London; Lund University; Skane University Hospital; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Preston, RJS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Haematol, Div Investigat Sci, Hammersmith Hosp Campus, London W12 0NN, England.	roger.preston@imperial.ac.uk		Preston, Roger/0000-0003-0108-4077; Dahlback, Bjorn/0000-0003-1546-0328				Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Castellino FJ, 1997, METHOD ENZYMOL, V282, P369; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; CHRISTIANSEN WT, 1994, BIOCHEMISTRY-US, V33, P14993, DOI 10.1021/bi00254a007; CHRISTIANSEN WT, 1995, BIOCHEMISTRY-US, V34, P10376, DOI 10.1021/bi00033a008; Dahlback B, 2003, J THROMB HAEMOST, V1, P1525, DOI 10.1046/j.1538-7836.2003.00299.x; DAHLBACK B, 1990, J BIOL CHEM, V265, P8127; Esmon CT, 1999, HAEMATOLOGICA, V84, P363; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FOSTER D, 1984, P NATL ACAD SCI-BIOL, V81, P4766, DOI 10.1073/pnas.81.15.4766; FUKUDOME K, 1995, J BIOL CHEM, V270, P5571, DOI 10.1074/jbc.270.10.5571; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; Giri TK, 1999, THROMB HAEMOSTASIS, V82, P1627, DOI 10.1055/s-0037-1614890; Giri TK, 1998, THROMB HAEMOSTASIS, V80, P798; Hackeng TM, 2000, BIOCHEM J, V349, P757, DOI 10.1042/bj3490757; He XH, 1998, J BIOL CHEM, V273, P27449, DOI 10.1074/jbc.273.42.27449; He XH, 1999, J BIOL CHEM, V274, P4970, DOI 10.1074/jbc.274.8.4970; HEMKER HC, 1995, THROMB HAEMOSTASIS, V74, P134; Huang MD, 2003, NAT STRUCT BIOL, V10, P751, DOI 10.1038/nsb971; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Knobe KE, 1999, PROTEINS, V35, P218, DOI 10.1002/(SICI)1097-0134(19990501)35:2<218::AID-PROT8>3.0.CO;2-2; McDonald JF, 1997, BIOCHEMISTRY-US, V36, P5120, DOI 10.1021/bi9626160; Mille-Baker B, 2003, BLOOD, V101, P1416, DOI 10.1182/blood-2002-08-2353; Mosnier LO, 2003, BIOCHEM J, V373, P65, DOI 10.1042/BJ20030341; Oganesyan V, 2002, J BIOL CHEM, V277, P24851, DOI 10.1074/jbc.C200163200; Perera L, 2000, BIOPHYS J, V79, P2925, DOI 10.1016/S0006-3495(00)76530-1; Preston RJS, 2005, FEBS J, V272, P97, DOI 10.1111/j.1432-1033.2004.04401.x; Regan LM, 1997, J BIOL CHEM, V272, P26279, DOI 10.1074/jbc.272.42.26279; REITSMA PH, 1995, THROMB HAEMOSTASIS, V73, P876; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Saller F, 2005, BLOOD, V105, P122, DOI 10.1182/blood-2004-06-2176; SELIGSOHN U, 1984, NEW ENGL J MED, V310, P559, DOI 10.1056/NEJM198403013100904; Sere KM, 2004, BLOOD, V104, P3624, DOI 10.1182/blood-2004-03-1146; Smirnov MD, 1998, J BIOL CHEM, V273, P9031, DOI 10.1074/jbc.273.15.9031; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; Stenberg Y, 1998, EUR J BIOCHEM, V251, P558, DOI 10.1046/j.1432-1327.1998.2510558.x; Sun YH, 2003, BLOOD, V101, P2277, DOI 10.1182/blood-2002-06-1691; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; Villoutreix BO, 2001, J COMPUT AID MOL DES, V15, P13, DOI 10.1023/A:1011158717139; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1984, SEMIN THROMB HEMOST, V10, P131, DOI 10.1055/s-2007-1004415; Yegneswaran S, 1997, J BIOL CHEM, V272, P25013, DOI 10.1074/jbc.272.40.25013	43	97	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28850	28857		10.1074/jbc.M604966200	http://dx.doi.org/10.1074/jbc.M604966200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16867987	hybrid, Green Published			2022-12-25	WOS:000240680500039
J	Majka, J; Binz, SK; Wold, MS; Burgers, PMJ				Majka, Jerzy; Binz, Sara K.; Wold, Marc S.; Burgers, Peter M. J.			Replication protein a directs loading of the DNA damage checkpoint clamp to 5 '-DNA junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; CELL NUCLEAR ANTIGEN; FACTOR-C; SACCHAROMYCES-CEREVISIAE; IN-VITRO; TRANSLESION SYNTHESIS; EXCISION-REPAIR; ATP UTILIZATION; BINDING DOMAIN; COMPLEX	The heterotrimeric checkpoint clamp comprises the Saccharomyces cerevisiae Rad17, Mec3, and Ddc1 subunits (Rad17/3/1, the 9-1-1 complex in humans). This DNA damage response factor is loaded onto DNA by the Rad24-RFC (replication factor C-like complex with Rad24) clamp loader and ATP. Although Rad24-RFC alone does not bind to naked partial double-stranded DNA, coating of the single strand with single-stranded DNA-binding protein RPA (replication protein A) causes binding of Rad24-RFC via interactions with RPA. However, RPA-mediated binding is abrogated when the DNA is coated with RPA containing a rpa1-K45E (rfa1-t11) mutation. These properties allowed us to determine the role of RPA in clamp-loading specificity. The Rad17/3/1 clamp is loaded with comparable efficiency onto naked primer/template DNA with either a 3'-junction or a 5'-junction. Remarkably, when the DNA was coated with RPA, loading of Rad17/3/1 at 3'-junctions was completely inhibited, thereby providing specificity to loading at 5'-junctions. However, Rad17/3/1 loaded at 5'-junctions can slide across double-stranded DNA to nearby 3'-junctions and thereby affect the activity of proteins that act at 3'-termini. These studies show a unique specificity of the checkpoint loader for 5'-junctions of RPA-coated DNA. The implications of this specificity for checkpoint function are discussed.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Univ Iowa, Carvel Coll Med, Dept Biochem, Iowa City, IA 52242 USA	Washington University (WUSTL); University of Iowa	Burgers, PMJ (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, 660 S Euclid Ave, St Louis, MO 63110 USA.	burgers@biochem.wustl.edu	Wold, Marc/F-5806-2010; Burgers, Peter M/AAW-6621-2021	Wold, Marc/0000-0002-4580-1624	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044721, R01GM032431] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44721, GM32431, R01 GM032431] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen BL, 1998, NUCLEIC ACIDS RES, V26, P3877, DOI 10.1093/nar/26.17.3877; Bae KH, 2003, NUCLEIC ACIDS RES, V31, P3006, DOI 10.1093/nar/gkg422; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkareva E, 2002, EMBO J, V21, P1855, DOI 10.1093/emboj/21.7.1855; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; Bylund GO, 2005, MOL CELL BIOL, V25, P5445, DOI 10.1128/MCB.25.13.5445-5455.2005; Clerici M, 2004, MOL CELL BIOL, V24, P10126, DOI 10.1128/MCB.24.23.10126-10144.2004; Ellison V, 2003, PLOS BIOL, V1, P231, DOI 10.1371/journal.pbio.0000033; FORTUNE JM, 2006, IN PRESS NUCL ACIDS; Garg P, 2005, J BIOL CHEM, V280, P23446, DOI 10.1074/jbc.C500173200; Giannattasio M, 2004, EMBO J, V23, P429, DOI 10.1038/sj.emboj.7600051; Gomes XV, 2001, J BIOL CHEM, V276, P34768, DOI 10.1074/jbc.M011631200; Gomes XV, 2000, J BIOL CHEM, V275, P14541, DOI 10.1074/jbc.275.19.14541; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Kai M, 2003, MUTAT RES-FUND MOL M, V532, P59, DOI 10.1016/j.mrfmmm.2003.08.010; Kai M, 2003, GENE DEV, V17, P64, DOI 10.1101/gad.1043203; Kantake N, 2003, J BIOL CHEM, V278, P23410, DOI 10.1074/jbc.M302995200; Kim HS, 2001, MOL CELL BIOL, V21, P3725, DOI 10.1128/MCB.21.11.3725-3737.2001; Kobayashi M, 2006, J BIOL CHEM, V281, P4308, DOI 10.1074/jbc.M511090200; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Longhese MP, 2003, MUTAT RES-FUND MOL M, V532, P41, DOI 10.1016/j.mrfmmm.2003.08.009; Majka J, 2003, P NATL ACAD SCI USA, V100, P2249, DOI 10.1073/pnas.0437148100; Majka J, 2004, J BIOL CHEM, V279, P20921, DOI 10.1074/jbc.M400898200; Majka J, 2004, PROG NUCLEIC ACID RE, V78, P227, DOI 10.1016/S0079-6603(04)78006-X; Matsumoto Y, 2001, PROG NUCLEIC ACID RE, V68, P129; Paulovich AG, 1998, GENETICS, V150, P75; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Rouse J, 2002, MOL CELL, V9, P857, DOI 10.1016/S1097-2765(02)00507-5; Sabbioneda S, 2005, J BIOL CHEM, V280, P38657, DOI 10.1074/jbc.M507638200; Schmidt SLG, 2001, J BIOL CHEM, V276, P34784, DOI 10.1074/jbc.M011633200; Sibenaller ZA, 1998, BIOCHEMISTRY-US, V37, P12496, DOI 10.1021/bi981110+; Soustelle C, 2002, GENETICS, V161, P535; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; Toueille M, 2004, NUCLEIC ACIDS RES, V32, P3316, DOI 10.1093/nar/gkh652; Umezu K, 1998, GENETICS, V148, P989; Wang WS, 2004, P NATL ACAD SCI USA, V101, P16762, DOI 10.1073/pnas.0407686101; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189; Zou L, 2003, P NATL ACAD SCI USA, V100, P13827, DOI 10.1073/pnas.2336100100; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	43	150	152	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27855	27861		10.1074/jbc.M605176200	http://dx.doi.org/10.1074/jbc.M605176200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16864589	hybrid			2022-12-25	WOS:000240534400021
J	Rofougaran, R; Vodnala, M; Hofer, A				Rofougaran, Reza; Vodnala, Munender; Hofer, Anders			Enzymatically active mammalian ribonucleotide reductase exists primarily as an alpha(6)beta(2) octamer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLOSTERIC REGULATION; DIPHOSPHATE REDUCTASE; SUBUNIT INTERACTION; CALF THYMUS; DNA-DAMAGE; PROTEIN R1; ELECTROPHORETIC MOBILITY; COMPREHENSIVE MODEL; RECOMBINANT MOUSE; PURIFICATION	Ribonucleotide reductase synthesizes deoxyribonucleotides, which are essential building blocks for DNA synthesis. The mammalian ribonucleotide reductase is described as an alpha(2)beta(2) complex consisting of R1 (alpha) and R2 (beta) proteins. ATP stimulates and dATP inhibits enzyme activity by binding to an allosteric site called the activity site on the R1 protein. Despite the opposite effects by ATP and dATP on enzyme activity, both nucleotides induce formation of R1 oligomers. By using a new technique termed Gas-phase Electrophoretic-Mobility Macromolecule Analysis (GEMMA), we have found that the ATP/dATP-induced R1 oligomers have a defined size (hexamers) and can interact with the R2 dimer to form an enzymatically active protein complex (alpha(6)beta(2)). The newly discovered alpha(6)beta(2) complex can either be in an active or an inhibited state depending on whether ATP or dATP is bound. Our results suggest that this protein complex is the major form of ribonucleotide reductase at physiological levels of R1-R2 protein and nucleotides.	Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden	Umea University	Hofer, A (corresponding author), Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden.	anders.hofer@medchem.umu.se		Hofer, Anders/0000-0003-2890-2957; Vodnala, Munender/0000-0002-6219-6243				Bacher G, 2001, J MASS SPECTROM, V36, P1038, DOI 10.1002/jms.208; Birgander PL, 2005, J BIOL CHEM, V280, P14997, DOI 10.1074/jbc.M500565200; BROWN NC, 1969, J MOL BIOL, V46, P25, DOI 10.1016/0022-2836(69)90055-2; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8; DAVIS R, 1994, J BIOL CHEM, V269, P23171; ENGSTROM Y, 1979, BIOCHEMISTRY-US, V18, P2941, DOI 10.1021/bi00581a004; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; ERIKSSON S, 1979, BIOCHEMISTRY-US, V18, P2948, DOI 10.1021/bi00581a005; ERIKSSON S, 1981, J BIOL CHEM, V256, P193; Hakansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200; Hofer A, 1998, J BIOL CHEM, V273, P34098, DOI 10.1074/jbc.273.51.34098; Ingemarson R, 1996, BIOCHEMISTRY-US, V35, P8603, DOI 10.1021/bi960184n; Kashlan OB, 2003, BIOCHEMISTRY-US, V42, P1696, DOI 10.1021/bi020634d; Kashlan OB, 2002, BIOCHEMISTRY-US, V41, P462, DOI 10.1021/bi011653a; Kaufman SL, 1996, ANAL CHEM, V68, P1895, DOI 10.1021/ac951128f; Kaufman SL, 2000, ANAL CHIM ACTA, V406, P3, DOI 10.1016/S0003-2670(99)00597-8; LYCKSELL PO, 1994, BIOCHEMISTRY-US, V33, P2838, DOI 10.1021/bi00176a013; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; Nordlund N, 2006, ANNU REV BIOCHEM, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443; Reichard P, 2000, J BIOL CHEM, V275, P33021, DOI 10.1074/jbc.M005337200; Sobott F, 2002, CURR OPIN STRUC BIOL, V12, P729, DOI 10.1016/S0959-440X(02)00400-1; THELANDER L, 1980, J BIOL CHEM, V255, P7426; THELANDER L, 1973, J BIOL CHEM, V248, P4591; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361	25	79	81	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27705	27711		10.1074/jbc.M605573200	http://dx.doi.org/10.1074/jbc.M605573200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16861739	hybrid			2022-12-25	WOS:000240534400006
J	Rosengren, KJ; Zhang, S; Lin, F; Daly, NL; Scott, DJ; Hughes, RA; Bathgate, RAD; Craik, DJ; Wade, JD				Rosengren, K. Johan; Zhang, Suode; Lin, Feng; Daly, Norelle L.; Scott, Daniel J.; Hughes, Richard A.; Bathgate, Ross A. D.; Craik, David J.; Wade, John D.			Solution structure and characterization of the LGR8 receptor binding surface of insulin-like peptide 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELAXIN-LIKE FACTOR; IN-VITRO; INSL3; FIELD; ACTIVATION; PROTEIN; CHAIN	Insulin-like peptide 3 (INSL3), a member of the relaxin peptide family, is produced in testicular Leydig cells and ovarian thecal cells. Gene knock-out experiments have identified a key biological role in initiating testes descent during fetal development. Additionally, INSL3 has an important function in mediating male and female germ cell function. These actions are elicited via its recently identified receptor, LGR8, a member of the leucine-rich repeat-containing G-protein- coupled receptor family. To identify the structural features that are responsible for the interaction of INSL3 with its receptor, its solution structure was determined by NMR spectroscopy together with in vitro assays of a series of B-chain alanine-substituted analogs. Synthetic human INSL3 was found to adopt a characteristic relaxin/ insulin-like fold in solution but is a highly dynamic molecule. The four termini of this two-chain peptide are disordered, and additional conformational exchange is evident in the molecular core. Alanine-substituted analogs were used to identify the key residues of INSL3 that are responsible for the interaction with the ectodomain of LGR8. These include Arg(B16) and Val(B19), with His(B12) and Arg(B20) playing a secondary role, as evident from the synergistic effect on the activity in double and triple mutants involving these residues. Together, these amino acids combine with the previously identified critical residue, Trp(B27), to form the receptor binding surface. The current results provide clear direction for the design of novel specific agonists and antagonists of this receptor.	Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Parkville, Vic 3010, Australia; Univ Melbourne, Dept Pharmacol, Parkville, Vic 3010, Australia; Univ Kalmar, Dept Chem & Biomed Sci, SE-39281 Kalmar, Sweden; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia	Florey Institute of Neuroscience & Mental Health; University of Melbourne; University of Melbourne; Linnaeus University; University of Kalmar; University of Queensland	Wade, JD (corresponding author), Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Parkville, Vic 3010, Australia.	j.wade@hfi.unimelb.edu.au	Bathgate, Ross/ABE-6471-2020; Rosengren, K. Johan/P-4450-2016; Craik, David/B-1695-2010; Daly, Norelle L/D-4302-2013; Scott, Daniel J/B-9880-2017	Bathgate, Ross/0000-0001-6301-861X; Rosengren, K. Johan/0000-0002-5007-8434; Craik, David/0000-0003-0007-6796; Daly, Norelle L/0000-0002-4697-6602; Scott, Daniel J/0000-0001-6332-2793; Wade, John/0000-0002-1352-6568				Adham IM, 2002, MOL ENDOCRINOL, V16, P244, DOI 10.1210/me.16.2.244; ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; Bathgate RAD, 2006, BIOCHEMISTRY-US, V45, P1043, DOI 10.1021/bi052233e; BATHGATE RAD, 2005, PHARMACOL REV, V58, P7; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bullesbach EE, 2005, J BIOL CHEM, V280, P14051, DOI 10.1074/jbc.M500030200; Bullesbach EE, 2005, J BIOL CHEM, V280, P14586, DOI 10.1074/jbc.M414443200; Bullesbach EE, 2004, BIOCHEMISTRY-US, V43, P8021, DOI 10.1021/bi049601j; Bullesbach EE, 1999, BIOCHEMISTRY-US, V38, P3073, DOI 10.1021/bi982687u; BULLESBACH EE, 1995, J BIOL CHEM, V270, P16011, DOI 10.1074/jbc.270.27.16011; BURKHARDT E, 1994, GENOMICS, V20, P13, DOI 10.1006/geno.1994.1121; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; Del Borgo MP, 2006, J BIOL CHEM, V281, P13068, DOI 10.1074/jbc.M600472200; EIGENBROT C, 1991, J MOL BIOL, V221, P15, DOI 10.1016/0022-2836(91)90796-9; FU P, 2004, J PEPT RES, V63, P1; Ivell R, 2003, MOL HUM REPROD, V9, P175, DOI 10.1093/molehr/gag025; Kawamura K, 2004, P NATL ACAD SCI USA, V101, P7323, DOI 10.1073/pnas.0307061101; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kumagai J, 2002, J BIOL CHEM, V277, P31283, DOI 10.1074/jbc.C200398200; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; Muda M, 2005, MOL HUM REPROD, V11, P591, DOI 10.1093/molehr/gah205; Nef S, 2000, GENE DEV, V14, P3075, DOI 10.1101/gad.843800; Nef S, 1999, NAT GENET, V22, P295, DOI 10.1038/10364; Olsen HB, 1998, J MOL BIOL, V284, P477, DOI 10.1006/jmbi.1998.2175; Rosengren KJ, 2006, J BIOL CHEM, V281, P5845, DOI 10.1074/jbc.M511210200; Smith KJ, 2001, J PEPT SCI, V7, P495, DOI 10.1002/psc.344; Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q; Zimmermann S, 1999, MOL ENDOCRINOL, V13, P681, DOI 10.1210/me.13.5.681	28	61	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28287	28295		10.1074/jbc.M603829200	http://dx.doi.org/10.1074/jbc.M603829200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16867980	hybrid			2022-12-25	WOS:000240534400066
J	Arvisais, EW; Romanelli, A; Hou, XY; Davis, JS				Arvisais, Edward W.; Romanelli, Angela; Hou, Xiaoying; Davis, John S.			AKT-independent phosphorylation of TSC2 and activation of mTOR and ribosomal protein S6 kinase signaling by prostaglandin F2 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TRANSLATION; TUBEROUS-SCLEROSIS; MAMMALIAN TARGET; TUMOR-SUPPRESSOR; CORPUS-LUTEUM; CELL-GROWTH; FACTOR-I; RECEPTOR; PATHWAY; INSULIN	Prostaglandin F2 alpha (PGF2 alpha) is an important mediator of corpus luteum (CL) regression, although the cellular signaling events that mediate this process have not been clearly identified. It is established that PGF2 alpha binds to a G-protein-coupled receptor (GPCR) to stimulate protein kinase C (PKC) and Raf-MEK-Erk signaling in luteal cells. The present experiments were performed to determine whether PGF2 alpha stimulates the mammalian target of rapamycin (mTOR)/ribosomal protein S6 kinase 1 (S6K1) signaling pathway in steroidogenic luteal cells. We demonstrate that PGF2 alpha treatment results in a time- and concentration-dependent stimulation of the phosphorylation and activation of S6K1. The stimulation of S6K1 in response to PGF2 alpha treatment was abolished by the mTOR inhibitor rapamycin. Treatment with PGF2 alpha did not increase AKT phosphorylation but increased the phosphorylation of Erk and the tumor suppressor protein tuberous sclerosis complex 2 (TSC2), an upstream regulator of mTOR. The effects of PGF2 alpha were mimicked by the PKC activator PMA and inhibited by U0126, a MEK1 inhibitor. The activation of mTOR/S6K1 and putative down stream processes involving the translational apparatus (i.e. 4EBP1 phosphorylation, release of 4EBP1 binding in m(7)G cap binding assays, and the phosphorylation and synthesis of S6) were completely sensitive to treatment with rapamycin, implicating mTOR in the actions of PGF2 alpha. Taken together, our data suggest that GPCR activation in response to PGF2 alpha stimulates the mTOR pathway which increases the translational machinery in luteal cells. The translation of proteins under the control of mTOR may have implications for luteal development and regression and offer new strategies for therapeutic intervention in PGF2 alpha-target tissues.	Univ Nebraska, Med Ctr, Olson Ctr Womens Hlth, Dept Obstet & Gynecol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Olson Ctr Womens Hlth, Dept Pharmacol, Omaha, NE 68198 USA; Serono Res Inst, Rockland, MA 02370 USA; Dept Vet Affairs Med Ctr, Omaha, NE 68105 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System	Davis, JS (corresponding author), 983255 Nebraska Med Ctr, Omaha, NE 68189 USA.	jsdavis@unmc.edu	Davis, John S/C-3234-2014	Davis, John/0000-0003-3468-4079	NICHD NIH HHS [R01HD38813] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038813] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams JW, 1996, J BIOL CHEM, V271, P1179, DOI 10.1074/jbc.271.2.1179; Alam H, 2004, J BIOL CHEM, V279, P19431, DOI 10.1074/jbc.M401235200; Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Carlson CJ, 2004, BIOCHEM BIOPH RES CO, V316, P533, DOI 10.1016/j.bbrc.2004.02.082; CHAKRAVORTY A, 1993, ENDOCRINOLOGY, V133, P1331, DOI 10.1210/en.133.3.1331; Chen DB, 1998, ENDOCRINOLOGY, V139, P3876, DOI 10.1210/en.139.9.3876; Chen DB, 2001, ENDOCRINOLOGY, V142, P887, DOI 10.1210/en.142.2.887; Crespo JL, 2002, MICROBIOL MOL BIOL R, V66, P579, DOI 10.1128/MMBR.66.4.579-591.2002; DAVIS JS, 1987, P NATL ACAD SCI USA, V84, P3728, DOI 10.1073/pnas.84.11.3728; Davis JS, 2002, FRONT BIOSCI-LANDMRK, V7, pD1949, DOI 10.2741/davis1; Diaz FJ, 2002, MOL CELL ENDOCRINOL, V191, P65, DOI 10.1016/S0303-7207(02)00056-4; Findlay GM, 2005, CURR OPIN GENET DEV, V15, P69, DOI 10.1016/j.gde.2004.11.002; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Fujino H, 2002, J BIOL CHEM, V277, P48786, DOI 10.1074/jbc.M209393200; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; Gual P, 2003, DIABETOLOGIA, V46, P1532, DOI 10.1007/s00125-003-1223-4; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Hakeda Y, 1997, ENDOCRINOLOGY, V138, P1821, DOI 10.1210/en.138.5.1821; HANSEL W, 1991, J REPROD FERTIL, P77; Hartley D, 2002, J CELL BIOCHEM, V85, P304, DOI 10.1002/jcb.10135; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Ishii Y, 2001, BIOCHEM BIOPH RES CO, V285, P1, DOI 10.1006/bbrc.2001.5106; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; Kwiatkowski DJ, 2005, HUM MOL GENET, V14, pR251, DOI 10.1093/hmg/ddi260; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; Martin KA, 2002, ADV CANCER RES, V86, P1, DOI 10.1016/S0065-230X(02)86001-8; Masuda-Robens J, 2001, METHOD ENZYMOL, V333, P45; MCCRACKEN JA, 1970, J CLIN ENDOCR METAB, V30, P544, DOI 10.1210/jcem-30-4-544; McCracken JA, 1999, PHYSIOL REV, V79, P263, DOI 10.1152/physrev.1999.79.2.263; MEYER GT, 1980, ANAT REC, V197, P369, DOI 10.1002/ar.1091970311; Meyuhas O, 2000, COLD SPRING HARBOR M, V39, P671; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Naegele S, 2004, J BIOL CHEM, V279, P46023, DOI 10.1074/jbc.M404945200; Niswender GD, 2000, PHYSIOL REV, V80, P1, DOI 10.1152/physrev.2000.80.1.1; Olson DM, 2003, PLACENTA, V24, pS47, DOI 10.1053/plac.2002.0938; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; PHARRISS BB, 1969, P SOC EXP BIOL MED, V130, P92; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Richards JS, 2002, MOL ENDOCRINOL, V16, P580, DOI 10.1210/me.16.3.580; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; SAKAMOTO K, 1994, J BIOL CHEM, V269, P3881; Sakamoto K, 2002, DNA SEQUENCE, V13, P307, DOI 10.1080/1042517021000011645; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Shao JY, 2004, CANCER RES, V64, P229, DOI 10.1158/0008-5472.CAN-03-1859; Sharif NA, 2003, J OCUL PHARMACOL TH, V19, P501, DOI 10.1089/108076803322660422; Shea-Eaton W, 2002, MOL CELL ENDOCRINOL, V188, P161, DOI 10.1016/S0303-7207(01)00715-8; Skurk C, 2005, CIRC RES, V96, P308, DOI 10.1161/01.RES.0000156273.30274.f7; Stocco DM, 2005, MOL ENDOCRINOL, V19, P2647, DOI 10.1210/me.2004-0532; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; Tang XW, 2003, BIOCHEM J, V374, P137, DOI 10.1042/BJ20021910; Tee AR, 2005, SEMIN CELL DEV BIOL, V16, P29, DOI 10.1016/j.semcdb.2004.11.005; Wang LJ, 2002, CIRC RES, V91, P821, DOI 10.1161/01.RES.0000041029.97988.E9; Westfall SD, 2000, ENDOCRINE, V12, P315, DOI 10.1385/ENDO:12:3:315; Yan Y, 2005, ONCOGENE, V24, P3285, DOI 10.1038/sj.onc.1208492	64	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26904	26913		10.1074/jbc.M605371200	http://dx.doi.org/10.1074/jbc.M605371200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16816403	hybrid			2022-12-25	WOS:000240397700017
J	DeLucia, AM; Chaudhuri, S; Potapova, O; Grindley, NDF; Joyce, CM				DeLucia, Angela M.; Chaudhuri, Santanov; Potapova, Olga; Grindley, Nigel D. F.; Joyce, Catherine M.			The properties of steric gate mutants reveal different constraints within the active sites of Y-family and A-family DNA polymerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED-FIT MECHANISM; I KLENOW FRAGMENT; NUCLEOTIDE INCORPORATION; SULFOLOBUS-SOLFATARICUS; REVERSE-TRANSCRIPTASE; CRYSTAL-STRUCTURES; STRUCTURAL BASIS; DINB HOMOLOG; FIDELITY; COMPLEX	Y-family (lesion-bypass) DNA polymerases show the same overall structural features seen in other members of the polymerase superfamily, yet their active sites are more open, with fewer contacts to the DNA and nucleotide substrates. This raises the question of whether analogous active-site side chains play equivalent roles in the bypass polymerases and their classical DNA polymerase counterparts. In Klenow fragment, an A-family DNA polymerase, the steric gate side chain (Glu(710)) not only prevents ribonucleotide incorporation but also plays an important role in discrimination against purine-pyrimidine mispairs. In this work we show that the steric gate (Phe(12)) of the Y-family polymerase Dbh plays a very minor role in fidelity, despite its analogous role in sugar selection. Using ribonucleotide discrimination to report on the positioning of a mispaired dNTP, we found that the pyrimidine of a Pu-dPyTP nascent mispair occupies a similar position to that of a correctly paired dNTP in the Dbh active site, whereas in Klenow fragment the mispaired dNTP sits higher in the active site pocket. If purine-pyrimidine mispairs adopt the expected wobble geometry, the difference between the two polymerases can be attributed to the binding of the templating base, with the looser binding site of Dbh permitting a variety of template conformations with only minimal adjustment at the incoming dNTP. In Klenow fragment the templating base is more rigidly held, so that changes in base pair geometry would affect the dNTP position, allowing the Glu(710) side chain to serve as a sensor of nascent mispairs.	Yale Univ, Dept Mol Biophys & Biochem, Bass Ctr Mol & Struct Biol, New Haven, CT 06520 USA	Yale University	Joyce, CM (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, Bass Ctr Mol & Struct Biol, 266 Whitney Ave,POB 208114, New Haven, CT 06520 USA.	catherine.joyce@yale.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028550] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-28550] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Astatke M, 1998, P NATL ACAD SCI USA, V95, P3402, DOI 10.1073/pnas.95.7.3402; Bonnin A, 1999, J MOL BIOL, V290, P241, DOI 10.1006/jmbi.1999.2900; Cases-Gonzalez CE, 2000, J BIOL CHEM, V275, P19759, DOI 10.1074/jbc.M910361199; Cramer J, 2005, J BIOL CHEM, V280, P40552, DOI 10.1074/jbc.M504481200; DeLucia AM, 2003, NUCLEIC ACIDS RES, V31, P4129, DOI 10.1093/nar/gkg417; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2106, DOI 10.1021/bi0357457; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; Gardner AF, 1999, NUCLEIC ACIDS RES, V27, P2545, DOI 10.1093/nar/27.12.2545; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; HUNTER WN, 1987, J BIOL CHEM, V262, P9962; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; Johnson SJ, 2003, P NATL ACAD SCI USA, V100, P3895, DOI 10.1073/pnas.0630532100; Joyce CM, 1995, METHOD ENZYMOL, V262, P3; Joyce CM, 2004, BIOCHEMISTRY-US, V43, P14317, DOI 10.1021/bi048422z; Kobayashi S, 2002, J BIOL CHEM, V277, P34198, DOI 10.1074/jbc.M204826200; Kokoska RJ, 2002, J BIOL CHEM, V277, P19633, DOI 10.1074/jbc.M202021200; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Li Y, 2001, PROTEIN SCI, V10, P1225, DOI 10.1110/ps.250101; Ling H, 2004, MOL CELL, V13, P751, DOI 10.1016/S1097-2765(04)00101-7; Minnick DT, 2002, P NATL ACAD SCI USA, V99, P1194, DOI 10.1073/pnas.032457899; Nair DT, 2004, NATURE, V430, P377, DOI 10.1038/nature02692; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Potapova O, 2002, J BIOL CHEM, V277, P28157, DOI 10.1074/jbc.M202607200; Purohit V, 2003, BIOCHEMISTRY-US, V42, P10200, DOI 10.1021/bi0341206; Rothwell PJ, 2005, MOL CELL, V19, P345, DOI 10.1016/j.molcel.2005.06.032; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Silvian LF, 2001, NAT STRUCT BIOL, V8, P984, DOI 10.1038/nsb1101-984; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Uijon SN, 2004, STRUCTURE, V12, P1395, DOI 10.1016/j.str.2004.05.011; Vaisman A, 2005, EMBO J, V24, P2957, DOI 10.1038/sj.emboj.7600786; Washington MT, 2001, CELL, V107, P917, DOI 10.1016/S0092-8674(01)00613-4; Yang GW, 2002, BIOCHEMISTRY-US, V41, P10256, DOI 10.1021/bi0202171; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0	36	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27286	27291		10.1074/jbc.M604393200	http://dx.doi.org/10.1074/jbc.M604393200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16831866	hybrid			2022-12-25	WOS:000240397700055
J	Khanna, H; Akimoto, M; Siffroi-Fernandez, S; Friedman, JS; Hicks, D; Swaroop, A				Khanna, Hemant; Akimoto, Masayuki; Siffroi-Fernandez, Sandrine; Friedman, James S.; Hicks, David; Swaroop, Anand			Retinoic acid regulates the expression of photoreceptor transcription factor NRL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RETINOBLASTOMA CELLS; THYROID-HORMONE RECEPTOR; DEVELOPING MOUSE RETINA; GENE-EXPRESSION; ROD PHOTORECEPTORS; LEUCINE-ZIPPER; CONE PHOTORECEPTORS; PROMOTER ACTIVITY; RHODOPSIN GENE; HOMEOBOX GENE	NRL (neural retina leucine zipper) is a key basic motif-leucine zipper (bZIP) transcription factor, which orchestrates rod photoreceptor differentiation by activating the expression of rod-specific genes. The deletion of Nrl in mice results in functional cones that are derived from rod precursors. However, signaling pathways modulating the expression or activity of NRL have not been elucidated. Here, we show that retinoic acid ( RA), a diffusible factor implicated in rod development, activates the expression of NRL in serum-deprived Y79 human retinoblastoma cells and in primary cultures of rat and porcine photoreceptors. The effect of RA is mimicked by TTNPB, a RA receptor agonist, and requires new protein synthesis. DNaseI footprinting and electrophoretic mobility shift assays ( EMSA) using bovine retinal nuclear extract demonstrate that RA response elements (RAREs) identified within the Nrl promoter bind to RA receptors. Furthermore, in transiently transfected Y79 and HEK293 cells the activity of Nrl-promoter driving a luciferase reporter gene is induced by RA, and this activation is mediated by RAREs. Our data suggest that signaling by RA via RA receptors regulates the expression of NRL, providing a framework for delineating early steps in photoreceptor cell fate determination.	Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48105 USA; Kyoto Univ Hosp, Translat Res Ctr, Sakyo Ku, Kyoto 6068507, Japan; CNRS, UMR 7518, Lab Neurobiol Rhythms, Ctr Neurochim, F-67084 Strasbourg, France	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Kyoto University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Swaroop, A (corresponding author), Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, 1000 Wall St, Ann Arbor, MI 48105 USA.	swaroop@umich.edu	Akimoto, Masayuki/AAP-3676-2020	Swaroop, Anand/0000-0002-1975-1141; Akimoto, Masayuki/0000-0002-5899-2925	NATIONAL EYE INSTITUTE [R01EY011115] Funding Source: NIH RePORTER; NEI NIH HHS [F31 EY007003, P30 EY007003, EY011115, R01 EY011115, R01 EY011115-10, EY007003] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Akhmedov NB, 2000, P NATL ACAD SCI USA, V97, P5551, DOI 10.1073/pnas.97.10.5551; Akimoto M, 2006, P NATL ACAD SCI USA, V103, P3890, DOI 10.1073/pnas.0508214103; ALTSHULER D, 1993, DEVELOPMENT, V119, P1317; Bessant DAR, 1999, NAT GENET, V21, P355, DOI 10.1038/7678; Boatright JH, 2002, VISION RES, V42, P933, DOI 10.1016/S0042-6989(02)00037-8; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Cayouette M, 2003, NEURON, V40, P897, DOI 10.1016/S0896-6273(03)00756-6; Chau KY, 2000, J BIOL CHEM, V275, P37264, DOI 10.1074/jbc.M002763200; Chen JC, 2005, J NEUROSCI, V25, P118, DOI 10.1523/JNEUROSCI.3571-04.2005; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; Chen Y, 2003, MOL VIS, V9, P345; Cheng H, 2004, HUM MOL GENET, V13, P1563, DOI 10.1093/hmg/ddh173; Coolen M, 2005, DEV GENES EVOL, V215, P327, DOI 10.1007/s00427-005-0476-y; CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402; DELEEUW AM, 1990, J NEUROCYTOL, V19, P253, DOI 10.1007/BF01217303; DIPOLO A, 1995, P NATL ACAD SCI USA, V92, P4016, DOI 10.1073/pnas.92.9.4016; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Forrest D, 2002, CURR OPIN NEUROBIOL, V12, P49, DOI 10.1016/S0959-4388(02)00289-1; Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591; Grondona JM, 1996, DEVELOPMENT, V122, P2173; Haider NB, 2000, NAT GENET, V24, P127, DOI 10.1038/72777; Haider NB, 2001, HUM MOL GENET, V10, P1619, DOI 10.1093/hmg/10.16.1619; Harris VK, 2001, ONCOGENE, V20, P1730, DOI 10.1038/sj.onc.1204249; HICKS D, 1992, J NEUROSCI, V12, P2022; Hyatt GA, 1996, P NATL ACAD SCI USA, V93, P13298, DOI 10.1073/pnas.93.23.13298; Janssen JJM, 1999, CURR EYE RES, V19, P338, DOI 10.1076/ceyr.19.4.338.5307; KALTER H, 1959, PHYSIOL REV, V39, P69, DOI 10.1152/physrev.1959.39.1.69; Kastner P, 1997, DEVELOPMENT, V124, P313; KELLEY MW, 1994, DEVELOPMENT, V120, P2091; KIM T, 1996, SCIENCE, V273, P1719; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; Lahiri DK, 2000, BRAIN RES PROTOC, V5, P257, DOI 10.1016/S1385-299X(00)00021-0; Lerner LE, 2002, J BIOL CHEM, V277, P25877, DOI 10.1074/jbc.M201407200; Lerner LE, 2001, J BIOL CHEM, V276, P34999, DOI 10.1074/jbc.M103301200; Levine EM, 2000, CELL MOL LIFE SCI, V57, P224, DOI 10.1007/PL00000686; Li AM, 2003, INVEST OPHTH VIS SCI, V44, P996, DOI 10.1167/iovs.02-0434; Li AM, 2002, INVEST OPHTH VIS SCI, V43, P1375; Livesey FJ, 2001, NAT REV NEUROSCI, V2, P109, DOI 10.1038/35053522; Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774; Mitton KP, 2000, J BIOL CHEM, V275, P29794, DOI 10.1074/jbc.M003658200; Mitton KP, 2003, HUM MOL GENET, V12, P365, DOI 10.1093/hmg/ddg035; Mori M, 2001, INVEST OPHTH VIS SCI, V42, P1312; Ng L, 2001, NAT GENET, V27, P94, DOI 10.1038/83829; Nishida A, 2003, NAT NEUROSCI, V6, P1255, DOI 10.1038/nn1155; Nishiguchi KM, 2004, P NATL ACAD SCI USA, V101, P17819, DOI 10.1073/pnas.0408183101; Peng GH, 2005, HUM MOL GENET, V14, P747, DOI 10.1093/hmg/ddi070; Pittler SJ, 2004, J BIOL CHEM, V279, P19800, DOI 10.1074/jbc.M401864200; Rattner A, 1999, ANNU REV GENET, V33, P89, DOI 10.1146/annurev.genet.33.1.89; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; Roberts MR, 2006, P NATL ACAD SCI USA, V103, P6218, DOI 10.1073/pnas.0509981103; Roberts MR, 2005, INVEST OPHTH VIS SCI, V46, P2897, DOI 10.1167/iovs.05-0093; SANDALTZOPOULOS R, 1994, NUCLEIC ACIDS RES, V22, P1511, DOI 10.1093/nar/22.8.1511; Swain PK, 2001, J BIOL CHEM, V276, P36824, DOI 10.1074/jbc.M105855200; Swain PK, 1997, NEURON, V19, P1329, DOI 10.1016/S0896-6273(00)80423-7; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Swaroop A, 1999, HUM MOL GENET, V8, P299, DOI 10.1093/hmg/8.2.299; Tan E, 2001, INVEST OPHTH VIS SCI, V42, P589; Traverso V, 2003, INVEST OPHTH VIS SCI, V44, P4550, DOI 10.1167/iovs.03-0460; Vazquez D, 1979, MOL BIOL BIOCH BIOPH, V30, P1, DOI 10.1007/978-3-642-81309-2; Whitaker SL, 2004, J BIOL CHEM, V279, P49010, DOI 10.1074/jbc.M406080200; Williams DS, 2002, VISION RES, V42, P455, DOI 10.1016/S0042-6989(01)00228-0; Young TL, 2004, NEURON, V41, P867, DOI 10.1016/S0896-6273(04)00141-2; Zhang JK, 2004, NAT GENET, V36, P351, DOI 10.1038/ng1318	63	49	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27327	27334		10.1074/jbc.M605500200	http://dx.doi.org/10.1074/jbc.M605500200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16854989	Green Accepted, hybrid			2022-12-25	WOS:000240397700059
J	Risinger, GM; Hunt, TS; Updike, DL; Bullen, EC; Howard, EW				Risinger, George M., Jr.; Hunt, Tamara S.; Updike, Dawn L.; Bullen, Elizabeth C.; Howard, Eric W.			Matrix metalloproteinase-2 expression by vascular smooth muscle cells is mediated by both stimulatory and inhibitory signals in response to growth factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FACTOR-I; GENE-EXPRESSION; FACTOR RECEPTOR; FACTOR-BB; IGF-I; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; TARGETED OVEREXPRESSION; ENDOTHELIAL-CELLS	In response to growth factors, vascular smooth muscle cells (VSMCs) undergo a phenotypic modulation from a contractile, non-proliferative state to an activated, migratory state. This transition is characterized by changes in their gene expression profile, particularly by a significant down-regulation of contractile proteins. Platelet-derived growth factor (PDGF)-BB has long been known to initiate VSMC de-differentiation and mitogenesis. Insulin-like growth factor (IGF)-I, on the other hand, has differing effects depending on the model studied. Here, we report that both IGF-I and PDGF-BB stimulated VSMC de-differentiation of rat heart-derived SMCs in culture, although only PDGF-BB was capable of inducing proliferation. Although both PDGF-BB and IGF-I stimulation resulted in decreased smooth muscle alpha-actin expression and increased matrix metalloproteinase (MMP)-2 expression, the response to IGF-I was significantly more rapid. The increased MMP-2 expression in response to both growth factors was due to increased transcription rates and was dependent on the action of phosphatidylinositol 3-kinase (PI3K) and its downstream effector, Akt. Both PDGF-BB and IGF-I activated PI3K/ Akt to similar degrees; however, only PDGF-BB concomitantly stimulated an inhibitory signaling pathway that antagonized the effects of Akt but did not alter the extent or duration of Akt activation. Together, these findings suggest that changes in MMP-2 expression are part of the program of VSMC phenotypic modulation and that both PDGF-BB and IGF-I, despite their different abilities to induce proliferation in this model, are capable of inducing VSMC activation.	Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Howard, EW (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, BMSB 566,940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	eric-howard@ouhsc.edu			NHLBI NIH HHS [HL-62268] Funding Source: Medline; NIGMS NIH HHS [GM-63638] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063638] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNQVIST HJ, 1995, METABOLISM, V44, P58, DOI 10.1016/0026-0495(95)90222-8; Auge N, 2004, CIRCULATION, V110, P571, DOI 10.1161/01.CIR.0000136995.83451.1D; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; BANSKOTA NK, 1989, MOL ENDOCRINOL, V3, P1183, DOI 10.1210/mend-3-8-1183; Bayes-Genis A, 2000, CIRC RES, V86, P125, DOI 10.1161/01.RES.86.2.125; Bendeck MP, 1996, CIRC RES, V78, P38, DOI 10.1161/01.RES.78.1.38; BENDECK MP, 1994, CIRC RES, V75, P539, DOI 10.1161/01.RES.75.3.539; Berk BC, 2001, PHYSIOL REV, V81, P999, DOI 10.1152/physrev.2001.81.3.999; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; Bottles KD, 1999, BBA-GEN SUBJECTS, V1428, P147, DOI 10.1016/S0304-4165(99)00059-8; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Cheng L, 1998, CIRCULATION, V98, P2195, DOI 10.1161/01.CIR.98.20.2195; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Dandre F, 2004, AM J PHYSIOL-HEART C, V286, pH2042, DOI 10.1152/ajpheart.00625.2003; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Goodall S, 2002, EUR J VASC ENDOVASC, V24, P72, DOI 10.1053/ejvs.2002.1675; Hayashi K, 2004, J BIOL CHEM, V279, P40807, DOI 10.1074/jbc.M405100200; Hayashi K, 1998, J BIOL CHEM, V273, P28860, DOI 10.1074/jbc.273.44.28860; Hayashi K, 1999, J CELL BIOL, V145, P727, DOI 10.1083/jcb.145.4.727; HultgardhNilsson A, 1997, CARDIOVASC RES, V34, P418, DOI 10.1016/S0008-6363(97)00030-8; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; Jenkins GM, 1998, CIRCULATION, V97, P82, DOI 10.1161/01.CIR.97.1.82; Johnson C, 2004, ARTERIOSCL THROM VAS, V24, P54, DOI 10.1161/01.ATV.0000100402.69997.C3; Johnson S, 1999, AM J PHYSIOL-LUNG C, V277, pL1109, DOI 10.1152/ajplung.1999.277.6.L1109; Kaplan-Albuquerque N, 2003, J BIOL CHEM, V278, P39830, DOI 10.1074/jbc.M305991200; Kenagy RD, 1997, CIRCULATION, V96, P3555; KHORSANDI MJ, 1992, J CLIN INVEST, V90, P1926, DOI 10.1172/JCI116070; Koul D, 2001, ONCOGENE, V20, P6669, DOI 10.1038/sj.onc.1204799; Kuemmerle JF, 2003, AM J PHYSIOL-GASTR L, V284, pG411, DOI 10.1152/ajpgi.00310.2002; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; Kuzuya M, 2003, CIRCULATION, V108, P1375, DOI 10.1161/01.CIR.0000086463.15540.3C; LEMIRE JM, 1994, AM J PATHOL, V144, P1068; Li Hongyan, 2002, Journal of Cardiovascular Pharmacology and Therapeutics, V7, P227, DOI 10.1177/107424840200700405; Liao JH, 2003, J BIOL CHEM, V278, P31871, DOI 10.1074/jbc.M301931200; Longo GM, 2002, J CLIN INVEST, V110, P625, DOI 10.1172/JCI200215334; MA X, 1998, AM J PHYSIOL, V274, P1206; Martinez A, 2004, BIOCHEM J, V383, P413, DOI 10.1042/BJ20040920; Newby AC, 2005, PHYSIOL REV, V85, P1, DOI 10.1152/physrev.00048.2003; Newby AC, 1999, CARDIOVASC RES, V41, P345, DOI 10.1016/S0008-6363(98)00286-7; Newby AC, 1996, CURR OPIN CARDIOL, V11, P574, DOI 10.1097/00001573-199611000-00004; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; OWENS GK, 1995, PHYSIOL REV, V75, P487; Park BK, 2001, CANCER RES, V61, P7647; PAULY RR, 1994, CIRC RES, V75, P41, DOI 10.1161/01.RES.75.1.41; PHELPS ED, 2005, AM J PHYSIOL, V290, pC352; Rao RS, 1997, CARDIOVASC RES, V36, P118, DOI 10.1016/S0008-6363(97)00156-9; Reusch HP, 2001, J BIOL CHEM, V276, P33630, DOI 10.1074/jbc.M105322200; Saga H, 1999, EXP CELL RES, V247, P279, DOI 10.1006/excr.1998.4339; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Shah PK, 2001, CIRCULATION, V104, P1878, DOI 10.1161/circ.104.16.1878; Sorby M, 1996, J BIOL CHEM, V271, P10963; Tack I, 2002, DIABETES, V51, P182, DOI 10.2337/diabetes.51.1.182; Thyberg J, 1998, HISTOL HISTOPATHOL, V13, P871, DOI 10.14670/HH-13.871; Thyberg J, 1996, INT REV CYTOL, V169, P183, DOI 10.1016/S0074-7696(08)61987-7; Uzui H, 2000, ATHEROSCLEROSIS, V149, P51, DOI 10.1016/S0021-9150(99)00295-6; Vinals F, 1999, MOL CELL BIOL, V19, P2763; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Wen JK, 2002, LIFE SCI, V70, P799, DOI 10.1016/S0024-3205(01)01446-1; Zempo N, 1996, ARTERIOSCL THROM VAS, V16, P28, DOI 10.1161/01.ATV.16.1.28; Zhang DL, 2004, J BIOL CHEM, V279, P19683, DOI 10.1074/jbc.M313145200; Zhao GS, 2001, ENDOCRINOLOGY, V142, P623, DOI 10.1210/en.142.2.623; Zhu BH, 2001, ENDOCRINOLOGY, V142, P3598, DOI 10.1210/en.142.8.3598	62	54	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25915	25925		10.1074/jbc.M513513200	http://dx.doi.org/10.1074/jbc.M513513200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16854986	hybrid			2022-12-25	WOS:000240249500006
J	Goyal, P; Pandey, D; Siess, W				Goyal, Pankaj; Pandey, Dharmendra; Siess, Wolfgang			Phosphorylation-dependent regulation of unique nuclear and nucleolar localization signals of LIM kinase 2 in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; COFILIN PHOSPHORYLATION; ACTIN; IDENTIFICATION; ACTIVATION; IMPORT; EXPORT; TRANSLOCATION; RECOGNITION; INHIBITION	LIM kinases (LIMKs) regulate actin dynamics through cofilin phosphorylation and also have a function in the nucleus. Recently we have shown that LIMK2 shuttles between cytoplasm and nucleus in endothelial cells and that nuclear import is inhibited by protein kinase C-mediated phosphorylation of Ser-283. Here we aimed to identify the structural features of LIMK2 responsible for nuclear import. We found that the kinase domain of LIMK2 is localized exclusively in the nucleus and, in contrast to the kinase domain of LIMK1, it accumulated in the nucleolus. Through site-directed mutagenesis, we identified the basic amino acid-rich motif KKRTLRKNDRKKR ( amino acids 491-503) as the functional nuclear and nucleolar localization signal of LIMK2. After fusing this motif to enhanced green fluorescent protein, the fusion protein localized exclusively in the nucleus and nucleolus. Mutagenesis studies showed that phosphorylation of Thr-494, a putative protein kinase C phosphorylation site identified within the nuclear localization signal, inhibits nuclear import of the enhanced green fluorescent protein-PDZ kinase domain of LIMK2. After inhibiting nuclear export with leptomycin B, phosphorylation of either Ser-283 or Thr-494 reduced the nuclear import of LIMK2. Phosphorylation of both Ser-283 and Thr-494 sites inhibited nuclear import completely. Our findings identify a unique basic amino acid-rich motif ( amino acids 491-503) in LIMK2 which is not present in LIMK1 that serves to target the protein not only to the nucleus but also to the nucleolus. Phosphorylation of Thr-494 within this motif negatively regulates nuclear import of LIMK2.	Univ Munich, Inst Prevent Cardiovasc Dis, D-80336 Munich, Germany	University of Munich	Goyal, P (corresponding author), Univ Munich, Klinikum Innenstadt, Inst Prophykaxe & Epidemiol Kreislaufkrankheiten, Pettenkoferstr 9, D-80336 Munich, Germany.	pankaj.goyal@med.uni-muenchen.de	Pandey, Dharmendra/O-9158-2017; Siess, Wolfgang/A-6430-2009; Goyal, Pankaj/C-3567-2012	Pandey, Dharmendra/0000-0002-3172-5923; Siess, Wolfgang/0000-0003-0698-6416; Pandey, Dharmendra/0000-0003-4871-964X				Amano T, 2002, J BIOL CHEM, V277, P22093, DOI 10.1074/jbc.M201444200; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; Catez F, 2002, MOL CELL BIOL, V22, P1126, DOI 10.1128/MCB.22.4.1126-1139.2002; de Lanerolle P, 2005, NAT STRUCT MOL BIOL, V12, P742, DOI 10.1038/nsmb983; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; Dundr M, 2002, MOL CELL, V9, P5, DOI 10.1016/S1097-2765(02)00433-1; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Gerbi SA, 2003, CURR OPIN CELL BIOL, V15, P318, DOI 10.1016/S0955-0674(03)00049-8; Gettemans J, 2005, TRAFFIC, V6, P847, DOI 10.1111/j.1600-0854.2005.00326.x; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Goyal P, 2005, J BIOL CHEM, V280, P27569, DOI 10.1074/jbc.M504448200; Guo YX, 2003, VIROLOGY, V306, P225, DOI 10.1016/S0042-6822(02)00081-8; Heist EK, 1998, J BIOL CHEM, V273, P19763, DOI 10.1074/jbc.273.31.19763; Horke S, 2004, J BIOL CHEM, V279, P26563, DOI 10.1074/jbc.M401017200; Hulo N, 2004, NUCLEIC ACIDS RES, V32, pD134, DOI 10.1093/nar/gkh044; JACKSON D, 1994, SCIENCE, V266, P1581, DOI 10.1126/science.7527157; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Kubota S, 1999, ONCOGENE, V18, P1503, DOI 10.1038/sj.onc.1202429; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; Leung AKL, 2003, BIOCHEM J, V376, P553, DOI 10.1042/BJ20031169; MIZUNO K, 1994, ONCOGENE, V9, P1605; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Pederson T, 2005, MOL BIOL CELL, V16, P5055, DOI 10.1091/mbc.E05-07-0656; Roovers K, 2003, DEV CELL, V5, P273, DOI 10.1016/S1534-5807(03)00206-5; Rowland RRR, 2003, VIRUS RES, V95, P23, DOI 10.1016/S0168-1702(03)00161-8; Russo G, 1997, J BIOL CHEM, V272, P5229, DOI 10.1074/jbc.272.8.5229; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; SLICE LW, 1992, BIOCHEMISTRY-US, V31, P12062, DOI 10.1021/bi00163a014; Sumi T, 2002, BIOCHEM BIOPH RES CO, V290, P1315, DOI 10.1006/bbrc.2002.6346; Takahashi H, 2002, DEV BIOL, V241, P259, DOI 10.1006/dbio.2001.0512; Taniguchi E, 2002, J BIOL CHEM, V277, P48884, DOI 10.1074/jbc.M206307200; Timmers ACJ, 1999, FEBS LETT, V452, P335, DOI 10.1016/S0014-5793(99)00669-9; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yang N, 1999, BIOCHEM J, V338, P793, DOI 10.1042/0264-6021:3380793; Yang N, 1998, EXP CELL RES, V241, P242, DOI 10.1006/excr.1998.4053	42	28	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25223	25230		10.1074/jbc.M603399200	http://dx.doi.org/10.1074/jbc.M603399200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16820362	hybrid			2022-12-25	WOS:000240031300023
J	Momcilovic, M; Hong, SP; Carlson, M				Momcilovic, Milica; Hong, Seung-Pyo; Carlson, Marian			Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA SIGNAL-TRANSDUCTION; FATTY-ACID OXIDATION; KAPPA-B; SACCHAROMYCES-CEREVISIAE; GLUCOSE REPRESSION; UPSTREAM KINASES; FOOD-INTAKE; LKB1; TAB1; PATHWAYS	The Snf1/AMP-activated protein kinase (AMPK) family is important for metabolic regulation and is highly conserved from yeast to mammals. The upstream kinases are also functionally conserved, and the AMPK kinases LKB1 and Ca2+/calmodulindependent protein kinase kinase activate Snf1 in mutant yeast cells lacking the native Snf1-activating kinases, Sak1, Tos3, and Elm1. Here, we exploited the yeast genetic system to identify members of the mammalian AMPK kinase family by their function as Snf1-activating kinases. A mouse embryo cDNA library in a yeast expression vector was used to transform sak1 Delta tos3 Delta elm1 Delta yeast cells. Selection for a Snf(+) growth phenotype yielded cDNA plasmids expressing LKB1, Ca2+/calmodulin-dependent protein kinase kinase, and transforming growth factor-beta-activated kinase (TAK1), a member of the mitogen-activated protein kinase kinase kinase family. We present genetic and biochemical evidence that TAK1 activates Snf1 protein kinase in vivo and in vitro. We further show that recombinant TAK1, fused to the activation domain of its binding partner TAB1, phosphorylates Thr-172 in the activation loop of the AMPK catalytic domain. Finally, expression of TAK1 and TAB1 in HeLa cells or treatment of cells with cytokines stimulated phosphorylation of Thr-172 of AMPK. These findings indicate that TAK1 is a functional member of the Snf1/AMPK kinase family and support TAK1 as a candidate for an authentic AMPK kinase in mammalian cells.	Columbia Univ, Dept Genet & Dev & Microbiol, New York, NY 10032 USA; Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Columbia University; Columbia University	Carlson, M (corresponding author), Columbia Univ, Dept Genet & Dev & Microbiol, 701 W 168th St,HSC922, New York, NY 10032 USA.	mbc1@columbia.edu	Hong, Raymond/R-6915-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK070653] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK070653, R21 DK070653] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersson U, 2004, J BIOL CHEM, V279, P12005, DOI 10.1074/jbc.C300557200; BLACKETER MJ, 1993, MOL CELL BIOL, V13, P5567, DOI 10.1128/MCB.13.9.5567; Bouquin N, 2000, J CELL SCI, V113, P1435; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; Cheung PCF, 2004, BIOCHEM J, V378, P27, DOI 10.1042/BJ20031794; Crute BE, 1998, J BIOL CHEM, V273, P35347, DOI 10.1074/jbc.273.52.35347; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hedbacker K, 2004, MOL CELL BIOL, V24, P8255, DOI 10.1128/MCB.24.18.8255-8263.2004; Hedbacker K, 2004, MOL CELL BIOL, V24, P1836, DOI 10.1128/MCB.24.5.1836-1843.2004; Hong SP, 2005, J BIOL CHEM, V280, P21804, DOI 10.1074/jbc.M501887200; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Lee J, 2000, J LEUKOCYTE BIOL, V68, P909; Li J, 2005, CIRC RES, V97, P872, DOI 10.1161/01.RES.0000187458.77026.10; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nath N, 2003, MOL CELL BIOL, V23, P3909, DOI 10.1128/MCB.23.11.3909-3917.2003; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Sakurai H, 2002, BIOCHEM BIOPH RES CO, V297, P1277, DOI 10.1016/S0006-291X(02)02379-3; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Sakurai H, 2000, FEBS LETT, V474, P141, DOI 10.1016/S0014-5793(00)01588-X; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Song WJ, 1998, EMBO J, V17, P5757, DOI 10.1093/emboj/17.19.5757; Sreenivasan A, 2003, MOL CELL BIOL, V23, P6327, DOI 10.1128/MCB.23.17.6327-6337.2003; Sreenivasan A, 1999, MOL CELL BIOL, V19, P7983; Sutherland CM, 2003, CURR BIOL, V13, P1299, DOI 10.1016/S0960-9822(03)00459-7; Suzuki A, 2005, J BIOL CHEM, V280, P31557, DOI 10.1074/jbc.M503714200; Suzuki A, 2004, BIOCHEM BIOPH RES CO, V324, P986, DOI 10.1016/j.bbrc.2004.09.145; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; WOODS A, 1994, J BIOL CHEM, V269, P19509; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788	57	367	383	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25336	25343		10.1074/jbc.M604399200	http://dx.doi.org/10.1074/jbc.M604399200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16835226	hybrid			2022-12-25	WOS:000240031300035
J	Tanaka, M; Okudaira, S; Kishi, Y; Ohkawa, R; Iseki, S; Ota, M; Noji, S; Yatomi, Y; Aoki, J; Arai, H				Tanaka, Masayuki; Okudaira, Shinichi; Kishi, Yasuhiro; Ohkawa, Ryunosuke; Iseki, Sachiko; Ota, Masato; Noji, Sumihare; Yatomi, Yutaka; Aoki, Junken; Arai, Hiroyuki			Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; LYSOPHOSPHOLIPASE-D; CELL MOTILITY; IDENTIFICATION; EXPRESSION; SPHINGOSINE-1-PHOSPHATE; METASTASIS; CARCINOMA; MIGRATION; MOTOGEN	Autotaxin (ATX) is a cancer-associated motogen that has multiple biological activities in vitro through the production of bioactive small lipids, lysophosphatidic acid (LPA). ATX and LPA are abundantly present in circulating blood. However, their roles in circulation remain to be solved. To uncover the physiological role of ATX we analyzed ATX knock-out mice. In ATX-null embryos, early blood vessels appeared to form properly, but they failed to develop into mature vessels. As a result ATX-null mice are lethal around embryonic day 10.5. The phenotype is much more severe than those of LPA receptor knock-out mice reported so far. In cultured allantois explants, neither ATX nor LPA was angiogenic. However, both of them helped to maintain preformed vessels by preventing disassembly of the vessels that was not antagonized by Ki16425, an LPA receptor antagonist. In serum from heterozygous mice both lysophospholipase D activity and LPA level were about half of those from wild-type mice, showing that ATX is responsible for the bulk of LPA production in serum. The present study revealed a previously unassigned role of ATX in stabilizing vessels through novel LPA signaling pathways.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Univ Hosp, Dept Clin Lab, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Med & Dent Univ, Dept Dev Biol, Grad Sch Dent, Bunkyo Ku, Tokyo 1138549, Japan; Univ Tokushima, Fac Engn, Dept Biol Sci & Technol, Tokushima 7708506, Japan; Japan Sci & Technol Corp, PRESTO, Kawaguchi, Saitama 3320012, Japan	University of Tokyo; University of Tokyo; Tokyo Medical & Dental University (TMDU); Tokushima University; Japan Science & Technology Agency (JST)	Aoki, J (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	jaoki@mol.f.u-tokyo.ac.jp	Noji, Sumihare/E-3047-2010; Ohkawa, Ryunosuke/C-5402-2017	Ohkawa, Ryunosuke/0000-0002-8584-133X; Aoki, Junken/0000-0001-9435-1896; Yatomi, Yutaka/0000-0003-1719-4297				Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Aoki J, 2004, SEMIN CELL DEV BIOL, V15, P477, DOI 10.1016/j.semcdb.2004.05.001; Aoki J, 2002, J BIOL CHEM, V277, P48737, DOI 10.1074/jbc.M206812200; Argraves WS, 2002, DEV DYNAM, V225, P298, DOI 10.1002/dvdy.10162; Baumforth KRN, 2005, BLOOD, V106, P2138, DOI 10.1182/blood-2005-02-0471; Clair T, 2003, CANCER RES, V63, P5446; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; Euer N, 2002, ANTICANCER RES, V22, P733; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; Iseki S, 1997, DEVELOPMENT, V124, P3375; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Kehlen A, 2004, INT J CANCER, V109, P833, DOI 10.1002/ijc.20022; Kharel Y, 2005, J BIOL CHEM, V280, P36865, DOI 10.1074/jbc.M506293200; Kishi Y, 2006, J BIOL CHEM, V281, P17492, DOI 10.1074/jbc.M601803200; Kishimoto T, 2003, CLIN CHIM ACTA, V333, P59, DOI 10.1016/S0009-8981(03)00165-7; Kono M, 2004, J BIOL CHEM, V279, P29367, DOI 10.1074/jbc.M403937200; Kotarsky K, 2006, J PHARMACOL EXP THER, V318, P619, DOI 10.1124/jpet.105.098848; Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Mizugishi K, 2005, MOL CELL BIOL, V25, P11113, DOI 10.1128/MCB.25.24.11113-11121.2005; Nam SW, 2000, ONCOGENE, V19, P241, DOI 10.1038/sj.onc.1203263; Nam SW, 2001, CANCER RES, V61, P6938; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994; Ruwisch L, 2001, N-S ARCH PHARMACOL, V363, P358, DOI 10.1007/s002100000365; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Stassar MJJG, 2001, BRIT J CANCER, V85, P1372, DOI 10.1054/bjoc.2001.2074; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Takuwa Y, 2002, BBA-MOL CELL BIOL L, V1582, P112, DOI 10.1016/S1388-1981(02)00145-2; Tanaka M, 2004, FEBS LETT, V571, P197, DOI 10.1016/j.febslet.2004.06.083; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Yang SY, 2002, CLIN EXP METASTAS, V19, P603, DOI 10.1023/A:1020950420196; Yang Y, 1999, AM J RESP CELL MOL, V21, P216, DOI 10.1165/ajrcmb.21.2.3667; YATOMI Y, 1995, ANAL BIOCHEM, V230, P315, DOI 10.1006/abio.1995.1480; Ye XQ, 2005, NATURE, V435, P104, DOI 10.1038/nature03505; Zhang GX, 1999, CHINESE MED J-PEKING, V112, P330; Zhao Z, 1999, Zhonghua Gan Zang Bing Za Zhi, V7, P140	40	365	377	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25822	25830		10.1074/jbc.M605142200	http://dx.doi.org/10.1074/jbc.M605142200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16829511	hybrid			2022-12-25	WOS:000240031300084
J	Nemchinov, LG; Paape, MJ; Sohn, EJ; Bannerman, DD; Zarlenga, DS; Hammond, RW				Nemchinov, Lev G.; Paape, Max J.; Sohn, Eun J.; Bannerman, Douglas D.; Zarlenga, Dante S.; Hammond, Rosemarie W.			Bovine CD14 receptor produced in plants reduces severity of intramammary bacterial infection	FASEB JOURNAL			English	Article						potato virus X; plant-derived therapeutic; coliform mastitis; apoptosis; LPS	ESCHERICHIA-COLI; LIPOPOLYSACCHARIDE; ENDOTOXIN; COWS; EXPRESSION; PROTEINS; MASTITIS; VACCINES; MICE	CD14 is a high-affinity receptor protein for the complex of bacterial LPS (LPS) and LPS binding protein in animals. Binding of the soluble form of CD14 (sCD14) to LPS, found in the outer membrane of Escherichia coli and other Gram-negative bacteria, enhances host innate immune responses, reduces the severity of mastitis, and facilitates clearance and neutralization of LPS, thus protecting against an excessive immune response to LPS and development of endotoxic shock. A truncated form of sCD14, carrying a histidine residue affinity tag for purification, was incorporated into Potato virus X for transient expression in Nicotiana benthamiana plants. Western blots probed with CD14-specific antibodies demonstrated that crude plant extracts and affinity-purified samples contained immunoreactive sCD14. Biological activity of plant-derived recombinant bovine sCD14 (PrbosCD14) was demonstrated in vitro by LPS-induced apoptosis and interleukin (IL) -8 production in bovine endothelial cells, and in vivo by enhancement of LPS-induced neutrophil recruitment. Finally, in PrbosCD14-infused glands subsequently infected with E. coli, lower numbers of viable bacteria were recovered and there was an absence of clinical symptoms, demonstrating prophylactic efficacy of PrbosCD14. This is the first report of a functionally active animal receptor protein made in plants and the prophylactic use of a plant-derived protein to reduce the severity of bacterial infections in animals.	USDA ARS, Mol Plant Pathol Lab, Beltsville, MD 20705 USA; USDA ARS, Beltsville Agr Res Ctr, Beltsville, MD 20705 USA; Bovine Funct Genom Lab, Beltsville, MD USA	United States Department of Agriculture (USDA); United States Department of Agriculture (USDA)	Hammond, RW (corresponding author), USDA ARS, Mol Plant Pathol Lab, Rm 214 ,Bldg 004 BARC W, Beltsville, MD 20705 USA.	hammondr@ba.ars.usda.gov						BANKS KL, 1985, AM J VET RES, V46, P1568; Bannerman DD, 2004, CLIN DIAGN LAB IMMUN, V11, P463, DOI 10.1128/CDLI.11.3.463-472.2004; Bannerman DD, 2003, J DAIRY SCI, V86, P3128, DOI 10.3168/jds.S0022-0302(03)73914-9; Bannerman DD, 2003, AM J PHYSIOL-LUNG C, V284, pL899, DOI 10.1152/ajplung.00338.2002; Bannerman DD, 2002, J BIOL CHEM, V277, P8048, DOI 10.1074/jbc.M111249200; Bannerman DD, 1998, J BIOL CHEM, V273, P35371, DOI 10.1074/jbc.273.52.35371; BRAMLEY AJ, 1976, J DAIRY SCI, V79, P3094; CHAPMAN S, 1992, PLANT J, V2, P549; Lee JW, 2003, VET RES, V34, P307, DOI 10.1051/vetres:2003006; Lee JW, 2003, INFECT IMMUN, V71, P4034, DOI 10.1128/IAI.71.7.4034-4039.2003; LOPPNOW H, 1995, INFECT IMMUN, V63, P1020, DOI 10.1128/IAI.63.3.1020-1026.1995; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; Ma JKC, 2000, NAT BIOTECHNOL, V18, P1141, DOI 10.1038/81113; Ma JKC, 2003, NAT REV GENET, V4, P794, DOI 10.1038/nrg1177; MILLER RH, 1986, J DAIRY SCI, V69, P1942, DOI 10.3168/jds.S0022-0302(86)80621-X; NACIONAL MASTITIS COUNCIL, 1996, CURRENT CONCEPTS BOV, V4; Paape MJ, 1996, AM J VET RES, V57, P477; Pugin J, 1995, Prog Clin Biol Res, V392, P369; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Shuster DE, 1996, AM J VET RES, V57, P1569; Sohn EJ, 2004, VET RES, V35, P597, DOI 10.1051/vetres:2004035; Streatfield SJ, 2003, INT J PARASITOL, V33, P479, DOI 10.1016/S0020-7519(03)00052-3; Wall RJ, 2005, NAT BIOTECHNOL, V23, P445, DOI 10.1038/nbt1078; Wang Y, 2002, VET IMMUNOL IMMUNOP, V86, P115, DOI 10.1016/S0165-2427(02)00021-1; WANG Y, 1997, J CELL BIOL MED BI S, V8, pA85	25	12	13	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2006	20	9					1345	1351		10.1096/fj.05-5295com	http://dx.doi.org/10.1096/fj.05-5295com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816109				2022-12-25	WOS:000240266000011
J	Wuerzberger-Davis, SM; Nakamura, Y; Seufzer, BJ; Miyamoto, S				Wuerzberger-Davis, S. M.; Nakamura, Y.; Seufzer, B. J.; Miyamoto, S.			NF-kappa B activation by combinations of NEMO SUMOylation and ATM activation stresses in the absence of DNA damage	ONCOGENE			English	Article						NEMO; SUMOylation; ATM; H2O2	DOUBLE-STRAND BREAKS; FIELD GEL-ELECTROPHORESIS; PROTEIN-TYROSINE KINASE; HAMSTER OVARY CELLS; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; TOPOISOMERASE-I; CLEAVABLE COMPLEXES; SIGNALING PATHWAY; GENOTOXIC STRESS	The inactive transcription factor NF-kappa B is localized in the cytoplasm and rapidly responds to a variety of extracellular factors and intracellular stress conditions to initiate multiple cellular responses. While the knowledge regarding NF-kappa B signaling pathways initiated by extracellular ligands is rapidly expanding, the mechanisms of activation by intracellular stress conditions are not well understood. We recently described a critical role for a small ubiquitin-like modifier (SUMO) modi. cation of NF-kappa B essential modulator (NEMO), the regulatory subunit of the I kappa B kinase, in response to certain genotoxic stress conditions. One important unanswered question is whether the role of this modi. cation is limited to the genotoxic agents or some other signaling pathways also employ SUMOylation of NEMO to regulate NF-kappa B activation. Here, we report that a variety of other stress conditions, including oxidative stress, ethanol exposure, heat shock and electric shock, also induce NEMO SUMOylation, thus demonstrating that DNA damage per se is not necessary for this NEMO modi. cation to occur. Moreover, combinations of certain SUMO stress and ATM (ataxia telangiectasia mutated) activation conditions lead to NF-kappa B activation without inducing DNA damage. Our study helps to conceptualize how individual or a combination of different stress conditions may funnel into this previously unappreciated signal transduction mechanism to regulate the activity of the ubiquitous NF-kappa B transcription factor.	Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Univ Wisconsin, Canc Biol Program, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Miyamoto, S (corresponding author), Univ Wisconsin, Dept Pharmacol, 3795 Med Sci Ctr,1300 Univ Ave, Madison, WI 53706 USA.	smiyamot@wisc.edu			NCI NIH HHS [R01-CA77474, R01-CA81065] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081065, R01CA077474] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGER DD, 1991, RADIAT RES, V128, P150, DOI 10.2307/3578132; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banath JP, 2003, CANCER RES, V63, P4347; Barzilai A, 2002, DNA REPAIR, V1, P3, DOI 10.1016/S1568-7864(01)00007-6; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gloire G, 2006, ONCOGENE, V25, P5485, DOI 10.1038/sj.onc.1209542; Habraken Y, 2001, BIOCHEM PHARMACOL, V62, P603, DOI 10.1016/S0006-2952(01)00709-2; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hiraoka W, 1998, J CLIN INVEST, V102, P1961, DOI 10.1172/JCI3437; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501; Huang TT, 2002, MOL CELL BIOL, V22, P5813, DOI 10.1128/MCB.22.16.5813-5825.2002; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Hur GM, 2003, GENE DEV, V17, P873, DOI 10.1101/gad.1062403; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Jasin M, 1996, TRENDS GENET, V12, P224, DOI 10.1016/0168-9525(96)10019-6; Kamata H, 2002, FEBS LETT, V519, P231, DOI 10.1016/S0014-5793(02)02712-6; Karin M, 2001, BIOFACTORS, V15, P87, DOI 10.1002/biof.5520150207; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kim SH, 2000, NUMER HEAT TR A-APPL, V38, P1, DOI 10.1080/10407780050134947; KINASHI Y, 1995, RADIAT RES, V141, P153, DOI 10.2307/3579042; Kretz-Remy C, 2001, J BIOL CHEM, V276, P43723, DOI 10.1074/jbc.M010821200; Kurepa J, 2003, J BIOL CHEM, V278, P6862, DOI 10.1074/jbc.M209694200; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee SJ, 1998, ONCOGENE, V17, P1821, DOI 10.1038/sj.onc.1202088; Leight ER, 2001, MOL CELL BIOL, V21, P4149, DOI 10.1128/MCB.21.13.4149-4161.2001; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Michalke M, 2000, FEBS LETT, V465, P64, DOI 10.1016/S0014-5793(99)01719-6; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; O'Connor S, 2004, MOL CELL BIOL, V24, P4895, DOI 10.1128/MCB.24.11.4895-4908.2004; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; Piret B, 1999, ONCOGENE, V18, P2261, DOI 10.1038/sj.onc.1202541; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sarkaria JN, 1998, CANCER RES, V58, P4375; Sauer H, 1999, J CELL BIOCHEM, V75, P710, DOI 10.1002/(SICI)1097-4644(19991215)75:4<710::AID-JCB16>3.0.CO;2-Z; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shi YL, 2004, P NATL ACAD SCI USA, V101, P5898, DOI 10.1073/pnas.0307718101; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Siebenlist U, 2005, NAT REV IMMUNOL, V5, P435, DOI 10.1038/nri1629; Sigala JLD, 2004, SCIENCE, V304, P1963, DOI 10.1126/science.1098387; Storz P, 2005, FRONT BIOSCI-LANDMRK, V10, P1881, DOI 10.2741/1667; Strumberg D, 2000, MOL CELL BIOL, V20, P3977, DOI 10.1128/MCB.20.11.3977-3987.2000; Szabo G, 2001, ALCOHOL CLIN EXP RES, V25, P1188; Tabary O, 2003, AM J PATHOL, V162, P293, DOI 10.1016/S0002-9440(10)63820-5; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Ward RJ, 1996, FEBS LETT, V389, P119, DOI 10.1016/0014-5793(96)00545-5; Wu JX, 1997, NUCLEIC ACIDS RES, V25, P4181, DOI 10.1093/nar/25.21.4181; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Wuerzberger-Davis SM, 2005, MOL CANCER RES, V3, P345, DOI 10.1158/1541-7786.MCR-05-0028; Yao Z, 2001, BONE, V28, P167, DOI 10.1016/S8756-3282(00)00425-7; Zhou WD, 2004, J BIOL CHEM, V279, P32262, DOI 10.1074/jbc.M404173200	67	60	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					641	651		10.1038/sj.onc.1209815	http://dx.doi.org/10.1038/sj.onc.1209815			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16862178				2022-12-25	WOS:000243902200002
J	Braun, S; Mauch, C; Boukamp, P; Werner, S				Braun, S.; Mauch, C.; Boukamp, P.; Werner, S.			Novel roles of NM23 proteins in skin homeostasis, repair and disease	ONCOGENE			English	Article						skin; keratinocyte; NM23; wound healing; epidermis; differentiation	KERATINOCYTE GROWTH-FACTOR; NUCLEOSIDE DIPHOSPHATE KINASE; GENE-EXPRESSION; TGF-ALPHA; EPIDERMIS; ORGANIZATION; DIFFERENTIATION; STROMELYSIN-2; NEUROBLASTOMA; PROLIFERATION	Keratinocyte growth factor (KGF) is an important regulator of epidermal homeostasis and repair. Therefore, the identification of KGF target genes in keratinocytes should contribute to our understanding of the molecular mechanisms underlying these processes. In a search for KGF-regulated genes, we identified the gene encoding the nucleoside diphosphate kinase NM23-H1. Apart from a housekeeping function, NM23 proteins are involved in the regulation of many cellular processes as well as in tumor metastasis, but their functions in epidermal homeostasis and repair are largely unknown. Here, we show a high expression of NM23-H1 and NM23-H2 in the KGF-responsive keratinocytes of the hyperprotiferative epidermis of mouse skin wounds and of patients suffering from the skin disease psoriasis. To determine if this overexpression is functionally important, we generated HaCaT keratinocyte cell lines overexpressing NM23-Hl and/or-H2. Whereas the enhanced levels of NM23 did not affect cell proliferation in monoculture, NM23-H2 and double transfectants but not NM23-Hl transfectants formed a strongly hyperthickened epithelium in three-dimensional organotypic cultures. The abnormal epithelial morphology resulted from enhanced proliferation, reduced apoptosis and alterations in the differentiation pattern. These findings suggest that epidermal homeostasis depends on a tight regulation of the levels of NM23 isoforms.	ETH, Inst Cell Biol, CH-8093 Zurich, Switzerland; Univ Cologne, Dept Dermatol & Venerol, Cologne, Germany; German Canc Res Ctr, Dept Genet Skin Carcinogenesis, D-6900 Heidelberg, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Cologne; Helmholtz Association; German Cancer Research Center (DKFZ)	Werner, S (corresponding author), ETH, Inst Cell Biol, Schafmattstr 18, CH-8093 Zurich, Switzerland.	Sabine.werner@cell.biol.ethz.ch		Werner, Sabine/0000-0001-7397-8710				Beer HD, 2002, J BIOL CHEM, V277, P20740, DOI 10.1074/jbc.M111233200; BERNARD BA, 1988, J INVEST DERMATOL, V90, P801, DOI 10.1111/1523-1747.ep12462014; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; Chang CL, 1996, ONCOGENE, V12, P659; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Finch PW, 1997, AM J PATHOL, V151, P1619; Finch PW, 2004, ADV CANCER RES, V91, P69, DOI 10.1016/S0065-230X(04)91003-2; Fournier HN, 2003, J BIOENERG BIOMEMBR, V35, P81, DOI 10.1023/A:1023450008347; Frank S, 1997, ONCOGENE, V14, P915, DOI 10.1038/sj.onc.1200905; Gassmann MG, 1999, ONCOGENE, V18, P6667, DOI 10.1038/sj.onc.1203120; Gassmann MG, 2000, EXP CELL RES, V258, P23, DOI 10.1006/excr.2000.4904; GILLES AM, 1991, J BIOL CHEM, V266, P8784; Gromov P, 2003, MOL CELL PROTEOMICS, V2, P70, DOI 10.1074/mcp.M200051-MCP200; GROTENDORST GR, 1989, J CELL PHYSIOL, V139, P617, DOI 10.1002/jcp.1041390323; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; IGAWA M, 1994, CANCER RES, V54, P1313; KADUNCE DP, 1995, DERMATOL CLIN, V13, P723, DOI 10.1016/S0733-8635(18)30037-8; Kanitakis J, 1997, J CUTAN PATHOL, V24, P151, DOI 10.1111/j.1600-0560.1997.tb01569.x; KEIM D, 1992, J CLIN INVEST, V89, P919, DOI 10.1172/JCI115672; Keller UAD, 2006, MOL CELL BIOL, V26, P3773, DOI 10.1128/MCB.26.10.3773-3784.2006; Kimura N, 2000, J BIOENERG BIOMEMBR, V32, P309, DOI 10.1023/A:1005549315846; KING LE, 1990, J INVEST DERMATOL, V95, pS10, DOI 10.1111/1523-1747.ep12505661; Krampert M, 2004, MOL BIOL CELL, V15, P5242, DOI 10.1091/mbc.E04-02-0109; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; LAKSO M, 1992, CELL GROWTH DIFFER, V3, P873; Madlener M, 1996, BIOCHEM J, V320, P659, DOI 10.1042/bj3200659; Narayanan R, 2003, J BIOENERG BIOMEMBR, V35, P49, DOI 10.1023/A:1023441806530; Ornitz DM, 2001, GENOME BIOL, V2; Postel EH, 2003, J BIOENERG BIOMEMBR, V35, P31, DOI 10.1023/A:1023485505621; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; Sato Y, 2000, PATHOL INT, V50, P200, DOI 10.1046/j.1440-1827.2000.01030.x; Schoop VM, 1999, J INVEST DERMATOL, V112, P343, DOI 10.1046/j.1523-1747.1999.00524.x; SCHULTZ G, 1991, J CELL BIOCHEM, V45, P346, DOI 10.1002/jcb.240450407; STAHL JA, 1991, CANCER RES, V51, P445; Stark Hans-Jurgen, 2004, Biol Proced Online, V6, P55, DOI 10.1251/bpo72; STEEG PS, 1993, BREAST CANCER RES TR, V25, P175, DOI 10.1007/BF00662142; STEEG PS, 1989, INVAS METAST, V9, P351; Wei SJ, 2004, J BIOL CHEM, V279, P5993, DOI 10.1074/jbc.M310820200; WEINSTEIN GD, 1985, J INVEST DERMATOL, V85, P579, DOI 10.1111/1523-1747.ep12283594; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; Werner S, 1998, CYTOKINE GROWTH F R, V9, P153, DOI 10.1016/S1359-6101(98)00010-0; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	49	19	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					532	542		10.1038/sj.onc.1209822	http://dx.doi.org/10.1038/sj.onc.1209822			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16862176				2022-12-25	WOS:000243731600006
J	Laiho, P; Kokko, A; Vanharanta, S; Salovaara, R; Sammalkorpi, H; Jarvinen, H; Mecklin, JP; Karttunen, TJ; Tuppurainen, K; Davalos, V; Schwartz, S; Arango, D; Makinen, MJ; Aaltonen, LA				Laiho, P.; Kokko, A.; Vanharanta, S.; Salovaara, R.; Sammalkorpi, H.; Jarvinen, H.; Mecklin, J-P; Karttunen, T. J.; Tuppurainen, K.; Davalos, V.; Schwartz, S., Jr.; Arango, D.; Makinen, M. J.; Aaltonen, L. A.			Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis	ONCOGENE			English	Article						molecular classification; microarray; serrated colorectal cancer; EPHB2	CPG ISLAND METHYLATION; CELL NEVUS SYNDROME; MICROSATELLITE INSTABILITY; GENE-EXPRESSION; HYPERPLASTIC POLYPOSIS; HUMAN HOMOLOG; ADENOMAS; NEOPLASIA; PATHWAYS; HEDGEHOG	Serrated colorectal carcinomas (CRCs) are morphologically different from conventional CRCs and have been proposed to follow a distinct pathway of CRC formation. Despite studies of single molecular events in this tumor type, the diagnosis of serrated CRC relies on morphology and the putative unique biological character of these tumors has not been established. Here we show that the gene expression pro. ling of 37 CRCs separated serrated and conventional CRCs into two distinct branches in unsupervised hierarchical clustering (P-value 7.8 x 10(-7)), and revealed 201 differentially expressed genes representing potential biomarkers for serrated CRC. Immunohistochemistry was utilized to verify the key findings in the 37 CRCs examined by express ion profiling, and a separate validation set of 37 serrated and 86 conventional CRCs was examined to evaluate the candidate biomarkers in an extended sample material. Ephrin receptor B2, hypoxia-inducible factor 1-alpha and patched appeared as proteins important for genesis of serrated CRC. This study establishes serrated CRCs as a biologically distinct subclass of CRC and represents a step forward in the molecular classification of these cancers. The study also provides a platform to understand the molecular basis of serrated CRC and in long term may contribute to the development of specific treatment options for this tumor type.	Univ Helsinki, Dept Med Genet, Biomedicum Helsinki, FIN-00014 Helsinki, Finland; Univ Helsinki, Mol & Canc Biol Res Program, Biomedicum Helsinki, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Surg 2, FIN-00014 Helsinki, Finland; Jyvaskyla Cent Hosp, Dept Surg, Jyvaskyla, Finland; Univ Oulu, Dept Pathol, Oulu, Finland; Hosp Gen Valle Hebron, Res Inst, CIBBIM, Mol Biol & Biochem Res Ctr, Barcelona, Spain	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Central Finland Central Hospital; University of Oulu; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR)	Aaltonen, LA (corresponding author), Univ Helsinki, Dept Med Genet, Biomedicum Helsinki, Room B520A,POB 63, FIN-00014 Helsinki, Finland.	lauri.aaltonen@helsinki.fi	Mecklin, Jukka-Pekka/AAC-9650-2019; Arango, Diego/M-5667-2016; Mecklin, Jukka-Pekka/AAB-5378-2020; Schwartz, Simo/H-7776-2012; Arango, Diego/AFW-0125-2022; Aaltonen, Lauri/A-5375-2010; Davalos, Veronica/AAR-8547-2020; Davalos, Veronica/S-1668-2016	Arango, Diego/0000-0003-2953-3284; Mecklin, Jukka-Pekka/0000-0003-4895-2249; Arango, Diego/0000-0003-2953-3284; Aaltonen, Lauri/0000-0001-6839-4286; Davalos, Veronica/0000-0003-4077-5137; Schwartz, Simo/0000-0001-8297-7971; Karttunen, Tuomo/0000-0002-8843-7957; Stefanius, Karoliina/0000-0002-9456-1954				Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; Alazzouzi H, 2005, CANCER RES, V65, P10170, DOI 10.1158/0008-5472.CAN-05-2580; Arango D, 2005, GASTROENTEROLOGY, V129, P874, DOI 10.1053/j.gastro.2005.06.066; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Chan AOO, 2002, AM J PATHOL, V160, P529, DOI 10.1016/S0002-9440(10)64872-9; Goldstein NS, 2006, AM J CLIN PATHOL, V125, P146, DOI 10.1309/87BD0C6UCGUG126J; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hawkins NJ, 2001, J NATL CANCER I, V93, P1307, DOI 10.1093/jnci/93.17.1307; Hawkins NJ, 2002, PATHOLOGY, V34, P548, DOI 10.1080/0031302021000035965; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Higuchi T, 2004, J CLIN PATHOL, V57, P682, DOI 10.1136/jcp.2003.015230; Hoffman EP, 2004, NAT REV GENET, V5, P229, DOI 10.1038/nrg1297; Huusko P, 2004, NAT GENET, V36, P979, DOI 10.1038/ng1408; Iino H, 1999, J CLIN PATHOL, V52, P5, DOI 10.1136/jcp.52.1.5; Jass JR, 2002, GASTROENTEROLOGY, V123, P862, DOI 10.1053/gast.2002.35392; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lazarus R, 2005, AM J CLIN PATHOL, V123, P349, DOI 10.1309/VBAGV3BR96N2EQTR; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; LONGACRE TA, 1990, AM J SURG PATHOL, V14, P524, DOI 10.1097/00000478-199006000-00003; Makinen MJ, 2001, J PATHOL, V193, P286, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH800>3.0.CO;2-2; Mullor JL, 2002, TRENDS CELL BIOL, V12, P562, DOI 10.1016/S0962-8924(02)02405-4; Narita T, 2000, DEVELOPMENT, V127, P981; Oldak M, 2001, INT J MOL MED, V8, P445; Pages G, 2005, CARDIOVASC RES, V65, P564, DOI 10.1016/j.cardiores.2004.09.032; Park SJ, 2003, AM J PATHOL, V162, P815, DOI 10.1016/S0002-9440(10)63878-3; PRESTRIDGE DS, 1995, J MOL BIOL, V249, P923, DOI 10.1006/jmbi.1995.0349; Rashid A, 2000, GASTROENTEROLOGY, V119, P323, DOI 10.1053/gast.2000.9361; Salovaara R, 2000, J CLIN ONCOL, V18, P2193, DOI 10.1200/JCO.2000.18.11.2193; Sawyer EJ, 2002, GUT, V51, P200, DOI 10.1136/gut.51.2.200; SCHWARTZ RA, 1978, NEW ENGL J MED, V299, P49; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tateyama H, 2002, AM J SURG PATHOL, V26, P249, DOI 10.1097/00000478-200202000-00013; Tuppurainen K, 2005, J PATHOL, V207, P285, DOI 10.1002/path.1850; Yashiro M, 2005, CANCER EPIDEM BIOMAR, V14, P2253, DOI 10.1158/1055-9965.EPI-04-0790; Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r28; Zhong H, 1999, CANCER RES, V59, P5830	45	115	119	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					312	320		10.1038/sj.onc.1209778	http://dx.doi.org/10.1038/sj.onc.1209778			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819509				2022-12-25	WOS:000243398300016
J	Singh, P; Wu, H; Clark, C; Owlia, A				Singh, P.; Wu, H.; Clark, C.; Owlia, A.			Annexin II binds progastrin and gastrin-like peptides, and mediates growth factor effects of autocrine and exogenous gastrins on colon cancer and intestinal epithelial cells	ONCOGENE			English	Article						Mr of gastrin-binding proteins; SELDI-TOFMS; antisense and sense Annexin II RNA	GLYCINE-EXTENDED GASTRIN; C-OXIDASE VB; TRANSGENIC MICE; CALPACTIN-I; TENASCIN-C; ENHANCED EXPRESSION; SIGNALING PATHWAYS; PANCREATIC CANCERS; INSULIN-RECEPTOR; GENE-EXPRESSION	We and others have reported the presence of novel progastrin (PG)/gastrin receptors on normal and cancerous intestinal cells. We had earlier reported the presence of 33 - 36 kDa gastrin-binding proteins on cellular membranes of colon cancer cells. The goal of the current study was to identify the protein(s) in the 33 - 36 kDa band, and analyse its functional significance. A carbodiimide crosslinker was used for crosslinking radio-labeled gastrins to membrane proteins from gastrin/PG responsive cell lines. Native membrane proteins, crosslinked to the ligand, were solubulized and enriched by > 1000-fold, and analysed by surface-enhanced laser desorption/ionization-time of light-mass spectrometry. The peptide masses were researched against the NCBInr database using the ProFound search engine. Annexin II (ANX II) was identified, and confirmed by matrix-assisted laser desorption/ionization-time of flight-mass spectrometry. As HCT-116 cells express autocrine PG, the in situ association of PG with ANX II was demonstrated in pulldown assays. Direct binding of PG with ANX II was confirmed in an in vitro binding assay. In order to confirm a functional importance of these observations, sense and anti-sense (AS) ANX II RNA-expressing clones of intestinal epithelial (IEC-18) and human colon cancer (HCT-116) cell lines were generated. AS clones demonstrated a significant loss in the growth response to exogenous (IEC-18) and autocrine (HCT-116) PG. We have thus discovered that membrane-associated ANX II binds PG/gastrins, and partially mediates growth factor effects of the peptides.	Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; Ciphergen Biosyst Inc, Fremont, CA USA	University of Texas System; University of Texas Medical Branch Galveston	Singh, P (corresponding author), Univ Texas, Med Branch, Dept Neurosci & Cell Biol, 10-104 Med Res Bldg,Route 1043, Galveston, TX 77555 USA.	posingh@utmb.edu			NATIONAL CANCER INSTITUTE [R01CA097959, R01CA072992] Funding Source: NIH RePORTER; NCI NIH HHS [CA72992, CA097959, R01 CA097959] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aly A, 2001, INT J CANCER, V94, P307, DOI 10.1002/ijc.1483; Baldwin GS, 2001, J BIOL CHEM, V276, P7791, DOI 10.1074/jbc.M009985200; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; BRAMBILLA R, 1991, BIOCHEM J, V278, P447, DOI 10.1042/bj2780447; Brown D, 2003, ENDOCRINOLOGY, V144, P201, DOI 10.1210/en.2002-220501; Chakladar A, 2005, BIOCHEM BIOPH RES CO, V336, P190, DOI 10.1016/j.bbrc.2005.08.061; Chiang YP, 1999, MOL CELL BIOCHEM, V199, P139, DOI 10.1023/A:1006942128672; CHIANG YP, 1993, CANCER RES, V53, P6017; CHICONE L, 1989, BIOCHEM BIOPH RES CO, V164, P512, DOI 10.1016/0006-291X(89)91749-X; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; Cobb S, 2004, CANCER-AM CANCER SOC, V100, P1311, DOI 10.1002/cncr.20094; Das S, 2005, J PROTEOME RES, V4, P920, DOI 10.1021/pr050023i; Dockray GJ, 1996, PHYSIOL REV, V76, P767, DOI 10.1152/physrev.1996.76.3.767; Emoto K, 2001, CANCER, V92, P1419, DOI 10.1002/1097-0142(20010915)92:6<1419::AID-CNCR1465>3.0.CO;2-J; Ferrand A, 2005, CANCER RES, V65, P2770, DOI 10.1158/0008-5472.CAN-04-0978; FROHLICH M, 1990, MOL CELL BIOL, V10, P3216, DOI 10.1128/MCB.10.6.3216; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GINSBERG BH, 1978, BIOCHIM BIOPHYS ACTA, V542, P88, DOI 10.1016/0304-4165(78)90235-0; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; GOULD RJ, 1981, BIOCHEMISTRY-US, V20, P6776, DOI 10.1021/bi00527a006; Hajjar KA, 2000, ANN NY ACAD SCI, V902, P265; Hollande F, 1997, GASTROENTEROLOGY, V113, P1576, DOI 10.1053/gast.1997.v113.pm9352860; Hollande F, 2001, J BIOL CHEM, V276, P40402, DOI 10.1074/jbc.M105090200; KEUTZER JC, 1990, EXP CELL RES, V188, P153, DOI 10.1016/0014-4827(90)90291-H; Koh TJ, 1999, J CLIN INVEST, V103, P1119, DOI 10.1172/JCI4910; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; Kucharczak J, 2001, ONCOGENE, V20, P7021, DOI 10.1038/sj.onc.1204882; Lambert O, 2004, J BIOL CHEM, V279, P10872, DOI 10.1074/jbc.M313657200; Laumonnier Y, 2006, BLOOD, V107, P3342, DOI 10.1182/blood-2005-07-2840; Lei S, 2004, J BIOL CHEM, V279, P42492, DOI 10.1074/jbc.M404025200; Mettouchi A, 1997, MOL CELL BIOL, V17, P3202, DOI 10.1128/MCB.17.6.3202; NALDINI L, 1990, BIOCHEMISTRY-US, V29, P5153, DOI 10.1021/bi00473a022; NARAYAN S, 1992, MOL CELL BIOCHEM, V112, P163; Ottewell PD, 2005, AM J PHYSIOL-GASTR L, V288, pG541, DOI 10.1152/ajpgi.00268.2004; OYAMA F, 1991, CANCER RES, V51, P4876; OZAKI T, 1993, ONCOGENE, V8, P1707; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Rengifo-Cam W, 2005, GASTROENTEROLOGY, V128, pA485; Rengifo-Cam W, 2004, CURR PHARM DESIGN, V10, P2345, DOI 10.2174/1381612043383999; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; Siddheshwar RK, 2001, GUT, V48, P47, DOI 10.1136/gut.48.1.47; SINGH P, 1994, AM J PHYSIOL, V267, pG235, DOI 10.1152/ajpgi.1994.267.2.G235; SINGH P, 1987, CANCER RES, V47, P5000; Singh P, 2000, GASTROENTEROLOGY, V119, P162, DOI 10.1053/gast.2000.8527; Singh P, 1996, CANCER RES, V56, P4111; SINGH P, 1995, J BIOL CHEM, V270, P8429, DOI 10.1074/jbc.270.15.8429; Singh P, 2000, AM J PHYSIOL-GASTR L, V278, pG390, DOI 10.1152/ajpgi.2000.278.3.G390; Singh P, 2003, AM J PHYSIOL-GASTR L, V284, pG328, DOI 10.1152/ajpgi.00351.2002; SINGH P, 1994, CANCER RES, V54, P6563; SINGH P, 1994, AM J PHYSIOL, V267, P608; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; Tanaka T, 2004, ONCOGENE, V23, P3980, DOI 10.1038/sj.onc.1207555; VISHWANATHA JK, 1993, CARCINOGENESIS, V14, P2575, DOI 10.1093/carcin/14.12.2575; VISHWANATHA JK, 1993, J CELL SCI, V105, P533; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; Wang TC, 1996, J CLIN INVEST, V98, P1918, DOI 10.1172/JCI118993; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691; Wu H, 2000, J BIOL CHEM, V275, P32491, DOI 10.1074/jbc.M002458200; Wu H, 2003, AM J PHYSIOL-GASTR L, V285, pG1097, DOI 10.1152/ajpgi.00216.2003; ZHANG QX, 1994, BBA-GENE STRUCT EXPR, V1219, P567, DOI 10.1016/0167-4781(94)90091-4	61	63	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					425	440		10.1038/sj.onc.1209798	http://dx.doi.org/10.1038/sj.onc.1209798			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832341				2022-12-25	WOS:000243544000011
J	Elble, RC; Walia, V; Cheng, HC; Connon, CJ; Mundhenk, L; Gruber, AD; Pauli, BU				Elble, Randolph C.; Walia, Vijay; Cheng, Hung-chi; Connon, Che J.; Mundhenk, Lars; Gruber, Achim D.; Pauli, Bendicht U.			The putative chloride channel hCLCA2 has a single C-terminal transmembrane segment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEINS; BREAST-CANCER; FUNCTIONAL-CHARACTERIZATION; STRUCTURE PREDICTION; MOLECULAR-CLONING; BETA(4) INTEGRIN; FAMILY; CELLS; GENE; LUNG	Calcium-activated chloride channel (CLCA) proteins were first described as a family of plasma membrane Cl- channels that could be activated by calcium. Genetic and electrophysiological studies have supported this view. The human CLCA2 protein is expressed as a 943-amino-acid precursor whose N-terminal signal sequence is removed followed by internal cleavage near amino acid position 680. Earlier investigations of transmembrane geometry suggested five membrane passes. However, analysis by the more recently derived simple modular architecture research tool algorithm predicts that a C-terminal 22-amino-acid hydrophobic segment comprises the only transmembrane pass. To resolve this question, we raised an antibody against hCLCA2 and investigated the synthesis, localization, maturation, and topology of the protein. Cell surface biotinylation and endoglycosidase H analysis revealed a 128-kDa precursor confined to the endoplasmic reticulum and a maturely glycosylated 141-kDa precursor at the cell surface by 48 h post-transfection. By 72 h, 109-kDa N-terminal and 35-kDa C-terminal cleavage products were detected at the cell surface but not in the endoplasmic reticulum. Surprisingly, however, the 109-kDa product was spontaneously shed into the medium or removed by acid washes, whereas the precursor and 35-kDa product were retained by the membrane. Two other CLCA family members, bCLCA2 and hCLCA1, also demonstrated preferential release of the N-terminal product. Transfer of the hCLCA2 C-terminal hydrophobic segment to a secreted form of green fluorescent protein was sufficient to target that protein to the plasma membrane. Together, these data indicate that hCLCA2 is mostly extracellular with only a single transmembrane segment followed by a short cytoplasmic tail and is itself unlikely to form a channel.	So Illinois Univ, Sch Med, Dept Pharmacol, Springfield, IL 62794 USA; So Illinois Univ, Sch Med, Inst Canc, Springfield, IL 62794 USA; Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, Tainan 70101, Taiwan; Cardiff Univ, Sch Optometry & Vis Sci, Cardiff CF23 9BD, S Glam, Wales; Free Univ Berlin, Dept Vet Pathol, D-14163 Berlin, Germany; Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA	Southern Illinois University System; Southern Illinois University; Southern Illinois University System; Southern Illinois University; National Cheng Kung University; Cardiff University; Free University of Berlin; Cornell University	Elble, RC (corresponding author), So Illinois Univ, Sch Med, Dept Pharmacol, Springfield, IL 62794 USA.	relble2@siumed.edu	Gruber, Achim D./ABA-4514-2021; Connon, Che/B-3128-2012; Walia, Vijay/F-1647-2013	Connon, Che/0000-0001-8264-6531; 				Abdel-Ghany M, 2003, J BIOL CHEM, V278, P49406, DOI 10.1074/jbc.M309086200; Abdel-Ghany M, 2002, J BIOL CHEM, V277, P34391, DOI 10.1074/jbc.M205307200; Abdel-Ghany M, 2001, J BIOL CHEM, V276, P25438, DOI 10.1074/jbc.M100478200; Agnel M, 1999, FEBS LETT, V455, P295, DOI 10.1016/S0014-5793(99)00891-1; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Bachelder RE, 1999, J BIOL CHEM, V274, P20733, DOI 10.1074/jbc.274.29.20733; Beckley JR, 2004, J BIOL CHEM, V279, P41634, DOI 10.1074/jbc.M408334200; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Connon CJ, 2004, J HISTOCHEM CYTOCHEM, V52, P415, DOI 10.1177/002215540405200313; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Cunningham SA, 1995, J BIOL CHEM, V270, P31016, DOI 10.1074/jbc.270.52.31016; Elble RC, 1997, J BIOL CHEM, V272, P27853, DOI 10.1074/jbc.272.44.27853; Elble RC, 2002, J BIOL CHEM, V277, P18586, DOI 10.1074/jbc.M200829200; Elble RC, 2001, J BIOL CHEM, V276, P40510, DOI 10.1074/jbc.M104821200; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Evans SR, 2004, J BIOL CHEM, V279, P41792, DOI 10.1074/jbc.M408354200; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gandhi R, 1998, J BIOL CHEM, V273, P32096, DOI 10.1074/jbc.273.48.32096; Gibson A, 2005, J BIOL CHEM, V280, P27205, DOI 10.1074/jbc.M504654200; Grignani F, 1998, CANCER RES, V58, P14; Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261; Gruber AD, 1999, CANCER RES, V59, P5488; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; Gruber AD, 1999, BBA-GENE STRUCT EXPR, V1444, P418, DOI 10.1016/S0167-4781(99)00008-1; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Kamada F, 2004, GENES IMMUN, V5, P540, DOI 10.1038/sj.gene.6364124; Komiya T, 1999, BIOCHEM BIOPH RES CO, V255, P347, DOI 10.1006/bbrc.1999.0168; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Loewen ME, 2005, PHYSIOL REV, V85, P1061, DOI 10.1152/physrev.00016.2004; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Pawlowski K, 2006, PROTEINS, V63, P424, DOI 10.1002/prot.20887; Ritzka M, 2004, HUM GENET, V115, P483, DOI 10.1007/s00439-004-1190-y; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; Yamazaki J, 2005, BBA-BIOMEMBRANES, V1715, P132, DOI 10.1016/j.bbamem.2005.08.001	39	30	32	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29448	29454		10.1074/jbc.M605919200	http://dx.doi.org/10.1074/jbc.M605919200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16873362	hybrid			2022-12-25	WOS:000240896300007
J	Wu, CC; Gardarin, A; Martel, A; Mintz, E; Guillain, F; Catty, P				Wu, Chen-Chou; Gardarin, Aurelie; Martel, Anne; Mintz, Elisabeth; Guillain, Florent; Catty, Patrice			The cadmium transport sites of CadA, the Cd2+-ATPase from Listeria monocytogenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; METAL-BINDING DOMAIN; MEMBRANE H+-ATPASE; SARCOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; DISEASE MUTATION; STRUCTURAL BASIS; CA2+-ATPASE; MECHANISM; CA2+	CadA, the Cd2(+)- ATPase from Listeria monocytogenes, belongs to the Zn2(+)/ Cd2(+)/ Pb2(+)- ATPase bacterial subfamily of P-1B-ATPases that ensure detoxification of the bacteria. Whereas it is the major determinant of Listeria resistance to Cd2+, CadA expressed in Saccharomyces cerevisiae severely decreases yeast tolerance to Cd2+ ( Wu, C. C., Bal, N., Perard, J., Lowe, J., Boscheron, C., Mintz, E., and Catty, P. ( 2004) Biochem. Biophys. Res. Commun. 324, 1034 - 1040). This phenotype, which reflects in vivo Cd2+- transport activity, was used to select from 33 point mutations, shared out among the eight transmembrane ( TM) segments of CadA, those that affect the activity of the protein. Six mutations affecting CadA were found: M149A in TM3; E164A in TM4; C354A, P355A, and C356A in TM6; and D692A in TM8. Functional studies of the six mutants produced in Sf9 cells revealed that Cys(354) and Cys(356) in TM6 as well as Asp(692) in TM8 and Met149 in TM3 could participate at the Cd2+- binding site( s). In the canonical Cys- Pro- Cys motif of P-1B- ATPases, the two cysteines act at distinct steps in the transport mechanism, Cys(354) being directly involved in Cd2+ binding, while Cys356 seems to be required for Cd2+ occlusion. This confirms an earlier observation that the two equivalent Cys of Ccc2, the yeast Cu+- ATPase, also act at different steps. In TM4, Glu(164), which is conserved among P1B- ATPases, may be required for Cd2+ release. Finally, analysis of the role of Cd2+ in the phosphorylation from ATP and from Pi of the mutants suggests that two Cd2+ ions are involved in the reaction cycle of CadA.	Univ Grenoble 1, CEA CNRS, UMR 5090,Commissariat Energie Atom,Direct Sci Viv, Lab Biophys Mol & Cellulaire,Dept Reponse & Dynam, F-38054 Grenoble 9, France	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Catty, P (corresponding author), Univ Grenoble 1, CEA CNRS, UMR 5090,Commissariat Energie Atom,Direct Sci Viv, Lab Biophys Mol & Cellulaire,Dept Reponse & Dynam, 17 Rue Martyrs, F-38054 Grenoble 9, France.	patrice.catty@cea.fr		Martel, Anne/0000-0002-1232-8519				ADEBAYO AO, 1995, J BIOL CHEM, V270, P27812, DOI 10.1074/jbc.270.46.27812; ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; Andersen JP, 1998, ACTA PHYSIOL SCAND, V163, P45; Arguello JM, 2003, J MEMBRANE BIOL, V195, P93, DOI 10.1007/s00232-003-2048-2; Bal N, 2001, FEBS LETT, V506, P249, DOI 10.1016/S0014-5793(01)02927-1; Bal N, 2003, BIOCHEM J, V369, P681, DOI 10.1042/BJ20021416; Banci L, 2006, J MOL BIOL, V356, P638, DOI 10.1016/j.jmb.2005.11.055; Banci L, 2002, J MOL BIOL, V323, P883, DOI 10.1016/S0022-2836(02)01007-0; Bissig KD, 2001, BIOCHEM J, V357, P217, DOI 10.1042/0264-6021:3570217; Buch-Pedersen MJ, 2000, J BIOL CHEM, V275, P39167, DOI 10.1074/jbc.M007537200; Bukrinsky JT, 2001, FEBS LETT, V494, P6, DOI 10.1016/S0014-5793(01)02301-8; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; Dutta SJ, 2006, BIOCHEMISTRY-US, V45, P5923, DOI 10.1021/bi0523456; Fan B, 2002, J BIOL CHEM, V277, P46987, DOI 10.1074/jbc.M208490200; Forbes JR, 1998, AM J HUM GENET, V63, P1663, DOI 10.1086/302163; GUIMARAESMOTTA H, 1980, ARCH BIOCHEM BIOPHYS, V203, P395, DOI 10.1016/0003-9861(80)90192-7; Haas R, 1999, Hum Mutat, V14, P88, DOI 10.1002/(SICI)1098-1004(1999)14:1<88::AID-HUMU15>3.0.CO;2-H; Henkel G, 2004, CHEM REV, V104, P801, DOI 10.1021/cr020620d; Inesi G, 2004, J BIOL CHEM, V279, P31629, DOI 10.1074/jbc.M403211200; Kuhlbrandt W, 2004, NAT REV MOL CELL BIO, V5, P282, DOI 10.1038/nrm1354; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; KUO CL, 1983, MOL CELL BIOL, V3, P1730, DOI 10.1128/MCB.3.10.1730; La Fontaine S, 1998, J BIOL CHEM, V273, P31375; La Fontaine S, 2001, HUM MOL GENET, V10, P361, DOI 10.1093/hmg/10.4.361; Liu JB, 2006, BIOCHEMISTRY-US, V45, P763, DOI 10.1021/bi051836n; Lowe J, 2004, J BIOL CHEM, V279, P25986, DOI 10.1074/jbc.M308736200; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Mandal AK, 2004, J BIOL CHEM, V279, P54802, DOI 10.1074/jbc.M410854200; Mandal AK, 2003, BIOCHEMISTRY-US, V42, P11040, DOI 10.1021/bi034806y; Melchers K, 1996, J BIOL CHEM, V271, P446, DOI 10.1074/jbc.271.1.446; Miras R, 2001, PROTEIN EXPRES PURIF, V22, P299, DOI 10.1006/prep.2001.1436; Moller JV, 2005, CURR OPIN STRUC BIOL, V15, P387, DOI 10.1016/j.sbi.2005.06.005; Myari A, 2004, J INORG BIOCHEM, V98, P1483, DOI 10.1016/j.jinorgbio.2004.05.013; Nies DH, 2003, FEMS MICROBIOL REV, V27, P313, DOI 10.1016/S0168-6445(03)00048-2; PEARSON RG, 1963, J AM CHEM SOC, V85, P3533, DOI 10.1021/ja00905a001; SIKORSKI RS, 1989, GENETICS, V122, P19; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Tumer Z, 1999, ADV EXP MED BIOL, V448, P83; Voskoboinik I, 2001, BIOCHEM BIOPH RES CO, V281, P966, DOI 10.1006/bbrc.2001.4445; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WEBER K, 1969, J BIOL CHEM, V244, P4406; Wu CC, 2004, BIOCHEM BIOPH RES CO, V324, P1034, DOI 10.1016/j.bbrc.2004.09.160; WU CC, 2006, BIOCHIMIE PARIS, DOI DOI 10.1016/J.BIOCHI.2006.06.013; Yoshimizu T, 1998, BIOSCI BIOTECH BIOCH, V62, P1258, DOI 10.1271/bbb.62.1258	48	17	18	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29533	29541		10.1074/jbc.M604658200	http://dx.doi.org/10.1074/jbc.M604658200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16835223	hybrid			2022-12-25	WOS:000240896300015
J	Cabrita, MA; Jaggi, F; Widjaja, SP; Christofori, G				Cabrita, Miguel A.; Jaeggi, Fabienne; Widjaja, Sandra P.; Christofori, Gerhard			A functional interaction between Sprouty proteins and Caveolin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; ERK ACTIVATION; CELL-GROWTH; MAP KINASE; IN-VIVO; TRANSLOCATION DOMAIN; SIGNALING PATHWAYS; DOWN-REGULATION; FGF; ANTAGONIST	Growth factor-mediated signal transduction cascades can be regulated spatio-temporally by signaling modulators, such as Sprouty proteins. The four mammalian Sprouty family members are palmitoylated phosphoproteins that can attenuate or potentiate numerous growth factor-induced signaling pathways. Previously, we have shown that Sprouty-1 and Sprouty-2 associate with Caveolin-1, the major structural protein of caveolae. Like Sprouty, Caveolin-1 inhibits growth factor-induced mitogen-activated protein kinase activation. Here, we demonstrate that all four mammalian Sprouty family members physically interact with Caveolin-1. The C terminus of Caveolin-1 is the major Sprouty-binding site, whereas Sprouty binds Caveolin-1 via its conserved C-terminal domain. A single point mutation in this domain results in loss of Caveolin-1 interaction. Moreover, we demonstrate that the various Sprouty isoforms differ dramatically in their cooperation with Caveolin-1-mediated inhibition of mitogen-activated protein kinase activation and that such cooperation is also highly dependent on the type of growth factor investigated and on cell density. Together, the data suggest that the Sprouty/Caveolin-1 interaction modulates signaling in a growth factor- and Sprouty isoform-specific manner.	Univ Basel, Ctr Biomed, Dept Clin Biol Sci, Inst Biochem & Genet, CH-4058 Basel, Switzerland	University of Basel	Christofori, G (corresponding author), Univ Basel, Ctr Biomed, Dept Clin Biol Sci, Inst Biochem & Genet, Mattenstr 28, CH-4058 Basel, Switzerland.	gerhard.christofori@unibas.ch						Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Basson MA, 2005, DEV CELL, V8, P229, DOI 10.1016/j.devcel.2004.12.004; Cabrita MA, 2003, THROMB HAEMOSTASIS, V90, P586, DOI 10.1160/TH03-04-0217; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chambers D, 2000, MECH DEVELOP, V91, P361, DOI 10.1016/S0925-4773(99)00288-9; Christofori G, 2003, NAT CELL BIOL, V5, P377, DOI 10.1038/ncb0503-377; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; de Alvaro C, 2005, MOL BIOL CELL, V16, P4454, DOI 10.1091/mbc.E05-05-0419; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Fielding CJ, 2001, ADV DRUG DELIVER REV, V49, P251, DOI 10.1016/S0169-409X(01)00140-5; Fong CW, 2003, J BIOL CHEM, V278, P33456, DOI 10.1074/jbc.M301317200; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0; Furthauer M, 2001, DEVELOPMENT, V128, P2175; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Glienke J, 2000, MECH DEVELOP, V96, P91, DOI 10.1016/S0925-4773(00)00378-6; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Gross I, 2003, J BIOL CHEM, V278, P41420, DOI 10.1074/jbc.M306425200; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Guy GR, 2003, J CELL SCI, V116, P3061, DOI 10.1242/jcs.00652; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Haglund K, 2005, EMBO REP, V6, P635, DOI 10.1038/sj.embor.7400453; Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400; King JAJ, 2005, BIOCHEM J, V388, P445, DOI 10.1042/BJ20041284; Kramer S, 1999, DEVELOPMENT, V126, P2515; Lee CC, 2004, ONCOGENE, V23, P5193, DOI 10.1038/sj.onc.1207646; Lee SH, 2001, J BIOL CHEM, V276, P4128, DOI 10.1074/jbc.M006922200; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Leeksma OC, 2002, EUR J BIOCHEM, V269, P2546, DOI 10.1046/j.1432-1033.2002.02921.x; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Lim J, 2002, MOL CELL BIOL, V22, P7953, DOI 10.1128/MCB.22.22.7953-7966.2002; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Mailleux AA, 2001, MECH DEVELOP, V102, P81, DOI 10.1016/S0925-4773(01)00286-6; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Mason JM, 2004, MOL BIOL CELL, V15, P2176, DOI 10.1091/mbc.E03-07-0503; Mason JM, 2006, TRENDS CELL BIOL, V16, P45, DOI 10.1016/j.tcb.2005.11.004; Michou AI, 1999, J VIROL, V73, P1399, DOI 10.1128/JVI.73.2.1399-1410.1999; Minowada G, 1999, DEVELOPMENT, V126, P4465; Nonami A, 2005, GENES CELLS, V10, P887, DOI 10.1111/j.1365-2443.2005.00886.x; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Orlichenko L, 2006, J BIOL CHEM, V281, P4570, DOI 10.1074/jbc.M512088200; Ozaki K, 2005, J CELL SCI, V118, P5861, DOI 10.1242/jcs.02711; Poppleton HM, 2004, BIOCHEM BIOPH RES CO, V323, P98, DOI 10.1016/j.bbrc.2004.08.070; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Razani B, 2001, J BIOL CHEM, V276, P38121; Razani B, 2001, AM J PHYSIOL-CELL PH, V281, pC1241, DOI 10.1152/ajpcell.2001.281.4.C1241; Reich A, 1999, DEVELOPMENT, V126, P4139; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Rubin C, 2005, J BIOL CHEM, V280, P9735, DOI 10.1074/jbc.M408308200; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; Sasaki A, 2003, CELL CYCLE, V2, P281, DOI 10.4161/cc.2.4.418; Schlessinger J, 2004, SCIENCE, V306, P1506, DOI 10.1126/science.1105396; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shim K, 2005, DEV CELL, V8, P553, DOI 10.1016/j.devcel.2005.02.009; Taketomi T, 2005, NAT NEUROSCI, V8, P855, DOI 10.1038/nn1485; Tefft D, 2002, AM J PHYSIOL-LUNG C, V283, pL700, DOI 10.1152/ajplung.00372.2001; Volonte D, 1999, FEBS LETT, V445, P431, DOI 10.1016/S0014-5793(99)00164-7; Williams TM, 2005, J BIOL CHEM, V280, P25134, DOI 10.1074/jbc.M501186200; Williams TM, 2005, AM J PHYSIOL-CELL PH, V288, pC494, DOI 10.1152/ajpcell.00458.2004; Williams TM, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-214; Williams TM, 2004, J BIOL CHEM, V279, P51630, DOI 10.1074/jbc.M409214200; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Wong ESM, 2001, J BIOL CHEM, V276, P5866, DOI 10.1074/jbc.M006945200; Wu XL, 2005, P NATL ACAD SCI USA, V102, P14058, DOI 10.1073/pnas.0506714102; Yao Q, 2005, J MOL BIOL, V348, P491, DOI 10.1016/j.jmb.2005.02.003; Yigzaw Y, 2001, J BIOL CHEM, V276, P22742, DOI 10.1074/jbc.M100123200; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200; Zhang CX, 2005, ARTERIOSCL THROM VAS, V25, P533, DOI 10.1161/01.ATV.0000155461.50450.5a; Zhao YY, 2002, P NATL ACAD SCI USA, V99, P11375, DOI 10.1073/pnas.172360799	80	19	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29201	29212		10.1074/jbc.M603921200	http://dx.doi.org/10.1074/jbc.M603921200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16877379	hybrid			2022-12-25	WOS:000240680500075
J	Hung, SH; Zhang, W; Pixley, RA; Jameson, BA; Huang, YC; Colman, RF; Colman, RW				Hung, Su-Hwi; Zhang, Wei; Pixley, Robin A.; Jameson, Bradford A.; Huang, Yu Chu; Colman, Roberta F.; Colman, Robert W.			New insights from the structure-function analysis of the catalytic region of human platelet phosphodiesterase 3A - A role for the unique 44-amino acid insert	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; INHIBITED CAMP-PHOSPHODIESTERASE; SUBTILIS ADENYLOSUCCINATE LYASE; SITE-DIRECTED MUTAGENESIS; SERPIN-PROTEASE COMPLEX; CRYSTAL-STRUCTURE; 8-<(4-BROMO-2,3-DIOXOBUTYL)THIO>ADENOSINE 3',5'-CYCLIC-MONOPHOSPHATE; ACTIVE-SITE; INACTIVATION; EXPRESSION	Human phosphodiesterase 3A (PDE3A) degrades cAMP, the major inhibitor of platelet function, thus potentiating platelet function. Of the 11 human PDEs, only PDE3A and 3B have 44-amino acid inserts in the catalytic domain. Their function is not clear. Incubating Sp-adenosine-3', 5'-cyclic-S-(4-bromo-2,3-dioxobutyl) monophosphorothioate (Sp-cAMPS-BDB) with PDE3A irreversibly inactivates the enzyme. High pressure liquid chromatography ( HPLC) analysis of a tryptic digest yielded an octapeptide within the insert of PDE3A ((K)(TYNVTDDK813)-Y-806), suggesting that a substrate-binding site exists within the insert. Because Sp-cAMPS-BDB reacts with nucleophilic residues, mutants Y807A, D811A, and D812A were produced. Sp-cAMPS-BDB inactivates D811A and D812A but not Y807A. A docking model showed that Tyr(807) is 3.3 angstroms from the reactive carbon, whereas Asp(811) and Asp(812) are > 15 angstroms away from Sp-cAMPS-BDB. Y807A has an altered K-m but no change in k(cat). Activity of wild type but not Y807A is inhibited by an anti-insert antibody. These data suggest that Tyr(807) is modified by Sp-cAMPS-BDB and involved in substrate binding. Because the homologous amino acid in PDE3B is Cys(792), we prepared the mutant Y807C and found that its K-m and k(cat) were similar to the wild type. Moreover, Sp-cAMPS-BDB irreversibly inactivates Y807C with similar kinetics to wild type, suggesting that the tyrosine may, like the cysteine, serve as a H donor. Kinetic analyses of nine additional insert mutants reveal that H782A, T810A, Y814A, and C816S exhibit an altered k(cat) but not K-m, indicating that catalysis is modulated. We document a new functional role for the insert in which substrate binding may produce a conformational change. This change would allow the substrate to bind to Tyr(807) and other amino acids in the insert to interact with residues important for catalysis in the active site cleft.	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; Drexel Univ, Coll Med, Dept Biochem, Philadelphia, PA 19104 USA; Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Drexel University; University of Delaware	Colman, RW (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St, Philadelphia, PA 19140 USA.	colmanr@temple.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL064943] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-64943] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALDWIN ET, 1993, P NATL ACAD SCI USA, V90, P6796, DOI 10.1073/pnas.90.14.6796; Beebe HG, 1999, ARCH INTERN MED, V159, P2041, DOI 10.1001/archinte.159.17.2041; BOTT R, 1982, BIOCHEMISTRY-US, V21, P6956, DOI 10.1021/bi00269a052; Cheung PP, 1998, ARCH BIOCHEM BIOPHYS, V360, P99, DOI 10.1006/abbi.1998.0915; Cheung PP, 1996, BLOOD, V88, P1321, DOI 10.1182/blood.V88.4.1321.bloodjournal8841321; GRANT PG, 1990, BIOCHEMISTRY-US, V29, P887, DOI 10.1021/bi00456a006; GRANT PG, 1984, BIOCHEMISTRY-US, V23, P1801, DOI 10.1021/bi00303a034; Gum PA, 2003, J AM COLL CARDIOL, V41, P961, DOI 10.1016/S0735-1097(02)03014-0; Huai Q, 2004, P NATL ACAD SCI USA, V101, P9624, DOI 10.1073/pnas.0401120101; Huai Q, 2004, J BIOL CHEM, V279, P13095, DOI 10.1074/jbc.M311556200; Hung SH, 2002, BIOCHEMISTRY-US, V41, P2962, DOI 10.1021/bi0119823; Hung SH, 2002, BIOORG CHEM, V30, P16, DOI 10.1006/bioo.2001.1226; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; JAMES MNG, 1982, P NATL ACAD SCI-BIOL, V79, P6137, DOI 10.1073/pnas.79.20.6137; Jarvis B, 2000, DRUGS, V60, P347, DOI 10.2165/00003495-200060020-00012; Lee ME, 2002, FEBS LETT, V530, P53, DOI 10.1016/S0014-5793(02)03396-3; Lee TT, 1998, BIOCHEMISTRY-US, V37, P8481, DOI 10.1021/bi9805339; Lee TT, 1997, J BIOL CHEM, V272, P458; Levy JH, 2002, ANN THORAC SURG, V73, P325, DOI 10.1016/S0003-4975(01)02719-9; Matetzky S, 2004, CIRCULATION, V109, P3171, DOI 10.1161/01.CIR.0000130846.46168.03; MEIJER A, 1993, CIRCULATION, V87, P1524, DOI 10.1161/01.CIR.87.5.1524; Movsesian MA, 2003, J CARD FAIL, V9, P475, DOI 10.1016/S1071-9164(03)00135-0; Mseeh F, 2000, THROMB RES, V98, P395, DOI 10.1016/S0049-3848(00)00195-X; Omburo GA, 1997, BLOOD, V89, P1019, DOI 10.1182/blood.V89.3.1019; Scapin G, 2004, BIOCHEMISTRY-US, V43, P6091, DOI 10.1021/bi049868i; Tang KM, 1997, BIOCHEM J, V323, P217; Varnerin JP, 2004, PROTEIN EXPRES PURIF, V35, P225, DOI 10.1016/j.pep.2004.01.009; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822; Ye S, 2001, NAT STRUCT BIOL, V8, P979, DOI 10.1038/nsb1101-979; Zhang KYJ, 2004, MOL CELL, V15, P279, DOI 10.1016/j.molcel.2004.07.005; Zhang W, 2000, BLOOD, V95, P3380, DOI 10.1182/blood.V95.11.3380.011k25_3380_3386; Zhang W, 2001, PROTEIN SCI, V10, P1481, DOI 10.1110/ps.6601	32	9	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29236	29244		10.1074/jbc.M606558200	http://dx.doi.org/10.1074/jbc.M606558200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16873361	hybrid			2022-12-25	WOS:000240680500079
J	Pawlak, J; Mackessy, SP; Fry, BG; Bhatia, M; Mourier, G; Fruchart-Gaillard, C; Servent, D; Menez, R; Stura, E; Menez, A; Kini, RM				Pawlak, Joanna; Mackessy, Stephen P.; Fry, Bryan G.; Bhatia, Madhav; Mourier, Gilles; Fruchart-Gaillard, Carole; Servent, Denis; Menez, Renee; Stura, Enrico; Menez, Andre; Kini, R. Manjunatha			Denmotoxin, a three-finger toxin from the colubrid snake Boiga dendrophila (mangrove catsnake) with bird-specific activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; SITE-DIRECTED MUTAGENESIS; ALPHA-NEUROTOXINS; TREE SNAKE; BUNGARUS-CANDIDUS; BINDING-SITE; VENOM; COMPLEX; IDENTIFICATION; SECRETION	Boiga dendrophila (mangrove catsnake) is a colubrid snake that lives in Southeast Asian lowland rainforests and mangrove swamps and that preys primarily on birds. We have isolated, purified, and sequenced a novel toxin from its venom, which we named denmotoxin. It is a monomeric polypeptide of 77 amino acid residues with five disulfide bridges. In organ bath experiments, it displayed potent postsynaptic neuromuscular activity and irreversibly inhibited indirectly stimulated twitches in chick biventer cervicis nerve-muscle preparations. In contrast, it induced much smaller and readily reversible inhibition of electrically induced twitches in mouse hemidiaphragm nerve-muscle preparations. More precisely, the chick muscle alpha(1)beta gamma delta-nicotinic acetylcholine receptor was 100-fold more susceptible compared with the mouse receptor. These data indicate that denmotoxin has a bird-specific postsynaptic activity. We chemically synthesized denmotoxin, crystallized it, and solved its crystal structure at 1.9 angstrom by the molecular replacement method. The toxin structure adopts a non-conventional three-finger fold with an additional (fifth) disulfide bond in the first loop and seven additional residues at its N terminus, which is blocked by a pyroglutamic acid residue. This is the first crystal structure of a three-finger toxin from colubrid snake venom and the first fully characterized bird-specific toxin. Denmotoxin illustrates the relationship between toxin specificity and the primary prey type that constitutes the snake's diet.	Natl Univ Singapore, Fac Sci, Dept Biol Sci, Prot Sci Lab, Singapore 117543, Singapore; Natl Univ Singapore, Fac Sci, Dept Pharmacol, Singapore 117543, Singapore; Univ No Colorado, Sch Biol Sci, Greeley, CO 80639 USA; State Atom Energy Commiss, Dept Ingn Etudes Prot, F-91191 Gif Sur Yvette, France; Virginia Commonwealth Univ, Coll Med, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA	National University of Singapore; National University of Singapore; University of Northern Colorado; CEA; Virginia Commonwealth University	Kini, RM (corresponding author), Natl Univ Singapore, Fac Sci, Dept Biol Sci, Prot Sci Lab, Sci Dr 4, Singapore 117543, Singapore.	dbskinim@nus.edu.sg	Mackessy, Stephen/GPT-0793-2022; Stura, Enrico A./A-2793-2010; Kini, Manjunatha/H-8029-2012; Fruchart Gaillard, Carole/GWV-2801-2022	Stura, Enrico A./0000-0001-6718-2118; Fruchart Gaillard, Carole/0000-0002-3149-4774; Mackessy, Stephen/0000-0003-4515-2545; Servent, Denis/0000-0002-0774-1691; Kini, Manjunatha/0000-0002-6100-3251				Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; Antil S, 1999, J BIOL CHEM, V274, P34851, DOI 10.1074/jbc.274.49.34851; Banerjee Y, 2005, J BIOL CHEM, V280, P42601, DOI 10.1074/jbc.M508987200; BARCHAN D, 1992, P NATL ACAD SCI USA, V89, P7717, DOI 10.1073/pnas.89.16.7717; Bourne Y, 2005, EMBO J, V24, P1512, DOI 10.1038/sj.emboj.7600620; BRAZIL VITAL, 1926, MEM INST BUTANTAN, V3, P301; Broaders M, 1999, J NAT TOXINS, V8, P155; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bulbring E, 1997, BRIT J PHARMACOL, V120, P3; BURDEN SJ, 1975, P NATL ACAD SCI USA, V72, P3245, DOI 10.1073/pnas.72.8.3245; CHANG C. C., 1963, ARCH INTERNATL PHARMACODYN THER, V144, P241; Chang CC, 1999, J BIOMED SCI, V6, P368, DOI 10.1159/000025412; DEWEILLE JR, 1991, P NATL ACAD SCI USA, V88, P2437, DOI 10.1073/pnas.88.6.2437; DUFTON MJ, 1988, PHARMACOL THERAPEUT, V36, P1, DOI 10.1016/0163-7258(88)90111-8; Endo T., 1991, P165; ENDO T, 1987, PHARMACOL THERAPEUT, V34, P403, DOI 10.1016/0163-7258(87)90002-7; FIORDALISI JJ, 1994, BIOCHEMISTRY-US, V33, P12962, DOI 10.1021/bi00248a004; Fruchart-Gaillard C, 2002, P NATL ACAD SCI USA, V99, P3216, DOI 10.1073/pnas.042699899; Fry BG, 2003, J MOL EVOL, V57, P446, DOI 10.1007/s00239-003-2497-3; Fry BG, 2003, RAPID COMMUN MASS SP, V17, P2047, DOI 10.1002/rcm.1148; GILSBORG BL, 1960, BR J PHARM CHEMOTHER, V15, P410; Grutter T, 2001, TRENDS BIOCHEM SCI, V26, P459, DOI 10.1016/S0968-0004(01)01921-1; HARVEY AL, 1978, TOXICON, V16, P219, DOI 10.1016/0041-0101(78)90082-X; Hill RE, 2000, TOXICON, V38, P1663, DOI 10.1016/S0041-0101(00)00091-X; Hill RE, 1997, TOXICON, V35, P671, DOI 10.1016/S0041-0101(96)00174-2; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; Kini RM, 2002, CLIN EXP PHARMACOL P, V29, P815, DOI 10.1046/j.1440-1681.2002.03725.x; Krajewski JL, 2001, MOL PHARMACOL, V60, P725; Kumar TKS, 1997, J BIOMOL STRUCT DYN, V15, P431, DOI 10.1080/07391102.1997.10508957; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEVINSON SR, 1976, TOXICON, V14, P307, DOI 10.1016/0041-0101(76)90027-1; Lewis RJ, 2003, NAT REV DRUG DISCOV, V2, P790, DOI 10.1038/nrd1197; Lumsden N. G., 2004, Autonomic & Autacoid Pharmacology, V24, P107, DOI 10.1111/j.1474-8673.2004.00322.x; Lumsden NG, 2005, TOXICON, V45, P329, DOI 10.1016/j.toxicon.2004.11.003; Lumsden NG, 2004, TOXICON, V43, P819, DOI 10.1016/j.toxicon.2004.03.012; Mackessy SP, 2006, TOXICON, V47, P537, DOI 10.1016/j.toxicon.2006.01.007; Mackessy SP, 2002, J TOXICOL-TOXIN REV, V21, P43, DOI 10.1081/TXR-120004741; Malany S, 2000, BIOCHEMISTRY-US, V39, P15388, DOI 10.1021/bi001825o; MARTINS N, 1917, COLLECT TRAB I BUTAN, V1, P427; MCDOWELL RS, 1992, BIOCHEMISTRY-US, V31, P4766, DOI 10.1021/bi00135a004; MENEZ A, 1980, BIOCHEMISTRY-US, V19, P4166, DOI 10.1021/bi00559a005; Mourier G, 2000, PROTEIN ENG, V13, P217, DOI 10.1093/protein/13.3.217; Mourier G, 2003, MOL PHARMACOL, V63, P26, DOI 10.1124/mol.63.1.26; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NEUMANN D, 1989, P NATL ACAD SCI USA, V86, P7255, DOI 10.1073/pnas.86.18.7255; Nirthanan S, 2003, TOXICON, V41, P397, DOI 10.1016/S0041-0101(02)00388-4; Nirthanan S, 2002, J BIOL CHEM, V277, P17811, DOI 10.1074/jbc.M111152200; Ohno M, 1998, PROG NUCLEIC ACID RE, V59, P307; Osaka H, 2000, J BIOL CHEM, V275, P5478, DOI 10.1074/jbc.275.8.5478; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PILLET L, 1993, J BIOL CHEM, V268, P909; Potter LT, 2001, LIFE SCI, V68, P2541, DOI 10.1016/S0024-3205(01)01050-5; PradoFranceschi J, 1996, TOXICON, V34, P459, DOI 10.1016/0041-0101(95)00146-8; Ricciardi A, 2000, J BIOL CHEM, V275, P18302, DOI 10.1074/jbc.275.24.18302; SERVENT D, 2001, HDB NEUROTOXICOLOGY, P385; Smith CG, 2003, FASEB J, V17, P788, DOI 10.1096/fj.03-0093life; Takacs Z, 2001, MOL BIOL EVOL, V18, P1800, DOI 10.1093/oxfordjournals.molbev.a003967; Teixeira-Clerc F, 2002, J BIOL CHEM, V277, P25741, DOI 10.1074/jbc.M200534200; Torres AM, 2001, BIOCHEM J, V360, P539, DOI 10.1042/0264-6021:3600539; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; Tsetlin V, 1999, EUR J BIOCHEM, V264, P281, DOI 10.1046/j.1432-1327.1999.00623.x; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vidal N, 2005, CR BIOL, V328, P1000, DOI 10.1016/j.crvi.2005.10.001; Vidal N, 2002, CR BIOL, V325, P987, DOI 10.1016/S1631-0691(02)01509-3; WANG SS, 1973, J AM CHEM SOC, V95, P1328, DOI 10.1021/ja00785a602; WEINSTEIN SA, 1991, TOXICON, V29, P401, DOI 10.1016/0041-0101(91)90014-I; Williams Janice A., 1993, Biochemical Society Transactions, V21, p73S; Wu PL, 2006, J BIOL CHEM, V281, P7937, DOI 10.1074/jbc.M513035200; Yasuda Osamu, 1994, Artery, V21, P287	70	154	159	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29030	29041		10.1074/jbc.M605850200	http://dx.doi.org/10.1074/jbc.M605850200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16864572	hybrid			2022-12-25	WOS:000240680500058
J	Dehm, SM; Tindall, DJ				Dehm, Scott M.; Tindall, Donald J.			Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COOH-TERMINAL INTERACTION; BINDING DOMAIN; NUCLEAR RECEPTORS; EXPRESSION; REGIONS; ANTIGEN; TRANSACTIVATION; TRANSCRIPTION; COACTIVATORS; INTERDOMAIN	Androgen ablation inhibits androgen receptor (AR) activity and is as an effective treatment for advanced prostate cancer (PCa). Invariably, PCa relapses in a form resistant to further hormonal manipulations. Although this stage of the disease is androgen-refractory, or androgen depletion-independent (ADI), most tumors remain AR-dependent through aberrant mechanisms of AR activation. We employed the LNCaP/C4-2 model of PCa progression to study AR activity in androgen-dependent and ADI PCa cells. In this report, we show that the AR is transcriptionally inactive in androgen-dependent LNCaP cells in the absence of androgens. However, in ADI C4-2 cells, the AR displays a high level of constitutive, androgen-independent transcriptional activity. To study the mechanisms of ligand dependent and ligand-independent AR activation in these AR-expressing cells, we generated a reporter system based on swapping the DNA binding domain of the AR with the DNA binding domain of the yeast Gal4 transcription factor. In androgen-dependent PCa cells, the well characterized C-terminal AR activation function-2 (AF-2) domain was critical for strong, ligand-dependent activity. Conversely, in ADI PCa cells, constitutive, ligand-independent AR activity was AF-2-independent but instead dependent on N-terminal AR domains. Importantly, the ligand- and AF-2-independent mode of AR activation observed in ADI PCa cells was completely resistant to the antiandrogen, bicalutamide. Our data thus demonstrate that the AR can inappropriately activate transcription in ADI PCa cells via mechanisms that are resistant to castration and AR antagonism, the two modes of androgen ablation used to treat advanced PCa.	Mayo Clin & Mayo Fdn, Coll Med, Dept Urol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Tindall, DJ (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Dept Urol Res, 200 1st St SW, Rochester, MN 55905 USA.	tindall.donald@mayo.edu			NCI NIH HHS [CA91956] Funding Source: Medline; NIDDK NIH HHS [DK60920] Funding Source: Medline; PHS HHS [D65236] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA091956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060920] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agoulnik IU, 2005, CANCER RES, V65, P7959, DOI 10.1158/0008-5472.CAN-04-3541; Alen P, 1999, MOL CELL BIOL, V19, P6085; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Bohl CE, 2004, J MED CHEM, V47, P3765, DOI 10.1021/jm0499007; Callewaert L, 2006, CANCER RES, V66, P543, DOI 10.1158/0008-5472.CAN-05-2389; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Christiaens V, 2002, J BIOL CHEM, V277, P49230, DOI 10.1074/jbc.M209322200; Culig Z, 2004, J STEROID BIOCHEM, V92, P265, DOI 10.1016/j.jsbmb.2004.10.003; Debes JD, 2005, CANCER RES, V65, P5965, DOI 10.1158/0008-5472.CAN-04-2837; Eder IE, 2000, CANCER GENE THER, V7, P997, DOI 10.1038/sj.cgt.7700202; Estebanez-Perpina E, 2005, J BIOL CHEM, V280, P8060, DOI 10.1074/jbc.M407046200; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Gao WQ, 2004, ENDOCRINOLOGY, V145, P5420, DOI 10.1210/en.2004-0627; Gregory CW, 2001, CANCER RES, V61, P4315; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Haag P, 2005, J STEROID BIOCHEM, V96, P251, DOI 10.1016/j.jsbmb.2005.04.029; He B, 2002, J BIOL CHEM, V277, P25631, DOI 10.1074/jbc.M202809200; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 2004, MOL CELL, V16, P425, DOI 10.1016/j.molcel.2004.09.036; He B, 2002, J BIOL CHEM, V277, P10226, DOI 10.1074/jbc.M111975200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; He B, 2001, J BIOL CHEM, V276, P42293, DOI 10.1074/jbc.M107492200; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Huang WB, 1999, J BIOL CHEM, V274, P25756, DOI 10.1074/jbc.274.36.25756; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; Lamb DJ, 2001, VITAM HORM, V62, P199, DOI 10.1016/S0083-6729(01)62005-3; Liao XB, 2005, MOL CANCER THER, V4, P505, DOI 10.1158/1535-7163.MCT-04-0313; Litvinov IV, 2003, J CLIN ENDOCR METAB, V88, P2972, DOI 10.1210/jc.2002-022038; Marhefka CA, 2004, J MED CHEM, V47, P993, DOI 10.1021/jm030336u; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; Metzger E, 2003, EMBO J, V22, P270, DOI 10.1093/emboj/cdg023; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Roy-Burman P, 2005, CANCER BIOL THER, V4, P4, DOI 10.4161/cbt.4.1.1563; Scherr D, 2003, UROLOGY, V61, P14, DOI 10.1016/S0090-4295(02)02395-6; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Slagsvold T, 2000, MOL ENDOCRINOL, V14, P1603, DOI 10.1210/me.14.10.1603; Warnmark A, 2003, MOL ENDOCRINOL, V17, P1901, DOI 10.1210/me.2002-0384; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; Yeung F, 2000, J BIOL CHEM, V275, P40846, DOI 10.1074/jbc.M002755200; Yin DH, 2003, J PHARMACOL EXP THER, V304, P1334, DOI 10.1124/jpet.102.040840; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; Zhu P, 2006, CELL, V124, P615, DOI 10.1016/j.cell.2005.12.032	47	79	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27882	27893		10.1074/jbc.M605002200	http://dx.doi.org/10.1074/jbc.M605002200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16870607	hybrid			2022-12-25	WOS:000240534400024
J	Denny, PW; Shams-Eldin, H; Price, HP; Smith, DF; Schwarz, RT				Denny, Paul W.; Shams-Eldin, Hosam; Price, Helen. P.; Smith, Deborah F.; Schwarz, Ralph T.			The protozoan inositol phosphorylceramide synthase - A novel drug target that defines a new class of sphingolipid synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; LIPID RAFTS; SCHIZOSACCHAROMYCES-POMBE; LEISHMANIA-MEXICANA; TRYPANOSOMA-CRUZI; ANCHORING MUTANT; AUR1 GENE; BIOSYNTHESIS; SPHINGOMYELIN; PHOSPHATIDYLINOSITOL	Sphingolipids are ubiquitous and essential components of eukaryotic membranes, particularly the plasma membrane. The biosynthetic pathway for the formation of these lipid species is conserved up to the formation of sphinganine. However, a divergence is apparent in the synthesis of complex sphingolipids. In animal cells, ceramide is a substrate for sphingomyelin (SM) production via the enzyme SM synthase. In contrast, fungi utilize phytoceramide in the synthesis of inositol phosphorylceramide (IPC) catalyzed by IPC synthase. Because of the absence of a mammalian equivalent, this essential enzyme represents an attractive target for anti-fungal compounds. In common with the fungi, the kinetoplastid protozoa (and higher plants) synthesize IPC rather than SM. However, orthologues of the gene believed to encode the fungal IPC synthase (AUR1) are not readily identified in the complete genome data bases of these species. By utilizing bioinformatic and functional genetic approaches, we have isolated a functional orthologue of AUR1 in the kinetoplastids, causative agents of a range of important human diseases. Expression of this gene in a mammalian cell line led to the synthesis of an IPC-like species, strongly indicating that IPC synthase activity is reconstituted. Furthermore, the gene product can be specifically inhibited by an anti-fungal-targeting IPC synthase. We propose that the kinetoplastid AUR1 functional orthologue encodes an enzyme that defines a new class of protozoan sphingolipid synthase. The identification and characterization of the protozoan IPC synthase, an enzyme with no mammalian equivalent, will raise the possibility of developing anti-protozoal drugs with minimal toxic side affects.	Univ Durham, Wolfson Res Inst, Ctr Infect Dis, Stockton On Tees TS17 6BH, England; Univ Marburg, Med Ctr Hyg & Med Microbiol, Inst Virol, D-35043 Marburg, Germany; Univ York, Dept Biol, Immunol & Infect Unit, York YO10 5YW, N Yorkshire, England; Univ Sci & Tech Lille Flandres Artois, UMR 8576 CNRS, Unite Glycobiol Struct & Fonctionnelle, Inst Federatif Rech 118, F-59655 Villeneuve Dascq, France	Durham University; Philipps University Marburg; University of York - UK; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Denny, PW (corresponding author), Univ Durham, Wolfson Res Inst, Ctr Infect Dis, Queens Campus, Stockton On Tees TS17 6BH, England.	p.w.denny@durham.ac.uk	Denny, Paul/B-8431-2013; Filho, Fernando C/Q-8021-2018	Denny, Paul/0000-0002-5051-1613; Price, Helen/0000-0003-1537-4390	BBSRC [BB/D52396X/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/D52396X/1] Funding Source: Medline; Wellcome Trust [077503] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; Bromley PE, 2003, ARCH BIOCHEM BIOPHYS, V417, P219, DOI 10.1016/S0003-9861(03)00339-4; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Croft SL, 2005, TRENDS PARASITOL, V21, P508, DOI 10.1016/j.pt.2005.08.026; Denny PW, 2004, MOL MICROBIOL, V53, P725, DOI 10.1111/j.1365-2958.2004.04208.x; Denny PW, 2004, MOL MICROBIOL, V52, P313, DOI 10.1111/j.1365-2958.2003.03975.x; Denny PW, 2001, FEBS LETT, V491, P148, DOI 10.1016/S0014-5793(01)02172-X; Dickson RC, 1997, J BIOL CHEM, V272, P29620, DOI 10.1074/jbc.272.47.29620; Dickson RC, 1999, BBA-GEN SUBJECTS, V1426, P347, DOI 10.1016/S0304-4165(98)00135-4; Figueiredo JM, 2005, BIOCHEM J, V387, P519, DOI 10.1042/BJ20041842; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; Futerman AH, 2005, TRENDS CELL BIOL, V15, P312, DOI 10.1016/j.tcb.2005.04.006; Georgopapadakou NH, 2000, EXPERT OPIN INV DRUG, V9, P1787, DOI 10.1517/13543784.9.8.1787; Ghosh S, 2002, INFECT IMMUN, V70, P6828, DOI 10.1128/IAI.70.12.6828-6838.2002; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hashida-Okado T, 1998, CURR GENET, V33, P38, DOI 10.1007/s002940050306; HashidaOkado T, 1996, MOL GEN GENET, V251, P236; HEIDLER SA, 1995, ANTIMICROB AGENTS CH, V39, P2765, DOI 10.1128/AAC.39.12.2765; Heidler SA, 2000, BBA-MOL BASIS DIS, V1500, P147, DOI 10.1016/S0925-4439(99)00097-6; Huitema K, 2004, EMBO J, V23, P33, DOI 10.1038/sj.emboj.7600034; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KANESHIRO ES, 1986, J LIPID RES, V27, P1294; LESTER RL, 1993, ADV LIPID RES, V26, P253; Levine TP, 2000, MOL BIOL CELL, V11, P2267, DOI 10.1091/mbc.11.7.2267; Liebisch G, 2004, BBA-MOL CELL BIOL L, V1686, P108, DOI 10.1016/j.bbalip.2004.09.003; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; Luberto C, 2003, J BIOL CHEM, V278, P32733, DOI 10.1074/jbc.M300932200; Luberto C, 2001, GENE DEV, V15, P201, DOI 10.1101/gad.856001; Magee T, 2002, BIOL RES, V35, P127, DOI 10.4067/S0716-97602002000200003; Nagiec MM, 2003, BIOCHEM BIOPH RES CO, V307, P369, DOI 10.1016/S0006-291X(03)01164-1; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; Neuwald AF, 1997, PROTEIN SCI, V6, P1764, DOI 10.1002/pro.5560060817; Nyame AK, 2004, ARCH BIOCHEM BIOPHYS, V426, P182, DOI 10.1016/j.abb.2004.04.004; Pierce SK, 2002, NAT REV IMMUNOL, V2, P96, DOI 10.1038/nri726; Ralton JE, 1998, J BIOL CHEM, V273, P4245, DOI 10.1074/jbc.273.7.4245; Rost B, 1996, METHOD ENZYMOL, V266, P525; Salto ML, 2003, EUKARYOT CELL, V2, P756, DOI 10.1128/EC.2.4.756-768.2003; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; Segui B, 2002, BIOCHEM J, V366, P23, DOI 10.1042/BJ20020317; Shams-Eldin H, 2002, MOL BIOCHEM PARASIT, V120, P73, DOI 10.1016/S0166-6851(01)00434-0; Shams-Eldin H, 2001, YEAST, V18, P33, DOI 10.1002/1097-0061(200101)18:1<33::AID-YEA648>3.0.CO;2-Z; SINGH BN, 1988, BIOCHEM BIOPH RES CO, V157, P1239, DOI 10.1016/S0006-291X(88)81007-6; Sperling P, 2003, BBA-MOL CELL BIOL L, V1632, P1, DOI 10.1016/S1388-1981(03)00033-7; Zhang K, 2005, MOL MICROBIOL, V55, P1566, DOI 10.1111/j.1365-2958.2005.04493.x; Zufferey R, 2003, J BIOL CHEM, V278, P44708, DOI 10.1074/jbc.M308063200	46	69	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28200	28209		10.1074/jbc.M600796200	http://dx.doi.org/10.1074/jbc.M600796200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16861742	Green Accepted, hybrid			2022-12-25	WOS:000240534400058
J	Drouet, J; Frit, P; Delteil, C; de Villartay, JP; Salles, B; Calsou, P				Drouet, Jerome; Frit, Philippe; Delteil, Christine; de Villartay, Jean-Pierre; Salles, Bernard; Calsou, Patrick			Interplay between Ku, artemis, and the DNA-dependent protein kinase catalytic subunit at DNA ends	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; SEVERE COMBINED IMMUNODEFICIENCY; V(D)J RECOMBINATION; LIGASE-IV; POLY(ADP-RIBOSE) POLYMERASE-1; GENOMIC INSTABILITY; SKIN FIBROBLASTS; REGULATES DNA; CELL-LINE; DAMAGE	Repair of DNA double strand breaks (DSB) by the nonhomologous end-joining pathway in mammals requires at least seven proteins involved in a simplified two-step process: (i) recognition and synapsis of the DNA ends dependent on the DNA-dependent protein kinase (DNA-PK) formed by the Ku70/Ku80 heterodimer and the catalytic subunit DNA-PKcs in association with Artemis; (ii) ligation dependent on the DNA ligase IV (.) XRCC4 (.) Cernunnos-XLF complex. The Artemis protein exhibits exonuclease and endonuclease activities that are believed to be involved in the processing of a subclass of DSB. Here, we have analyzed the interactions of Artemis and nonhomologous end-joining pathway proteins both in a context of human nuclear cell extracts and in cells. DSB-inducing agents specifically elicit the mobilization of Artemis to damaged chromatin together with DNA-PK and XRCC4/ligase IV proteins. DNA-PKcs is necessary for the loading of Artemis on damaged DNA and is the main kinase that phosphorylates Artemis in cells damaged with highly efficient DSB producers. Under kinase-preventive conditions, both in vitro and in cells, Ku-mediated assembly of DNA-PK on DNA ends is responsible for a dissociation of the DNA-PKcs (.) Artemis complex. Conversely, DNA-PKcs kinase activity prevents Artemis dissociation from the DNA-PK (.) DNA complex. Altogether, our data allow us to propose a model in which a DNA-PKcs-mediated phosphorylation is necessary both to activate Artemis endonuclease activity and to maintain its association with the DNA end site. This tight functional coupling between the activation of both DNA-PKcs and Artemis may avoid improper processing of DNA.	CNRS, UMR 5089, Inst Pharmacol & Biol Struct, F-31077 Toulouse 4, France; INSERM, Hop Necker Enfants Malad, U768, Unite Dev Normal & Pathol Syst Immunitaire, F-75015 Paris, France; Univ Paris Descartes, Fac Med Rene Descartes, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Salles, B (corresponding author), CNRS, UMR 5089, Inst Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse 4, France.	bernard.salles@ipbs.fr	de Villartay, jean pierre/H-9353-2017; calsou, patrick/AAB-5123-2020; salles, bernard/B-8531-2008	de Villartay, jean pierre/0000-0001-5987-0463; Calsou, Patrick/0000-0001-7951-9806				Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Audebert M, 2004, J BIOL CHEM, V279, P55117, DOI 10.1074/jbc.M404524200; Boskovic J, 2003, EMBO J, V22, P5875, DOI 10.1093/emboj/cdg555; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Calsou P, 2003, J MOL BIOL, V326, P93, DOI 10.1016/S0022-2836(02)01328-1; Calsou P, 1999, J BIOL CHEM, V274, P7848, DOI 10.1074/jbc.274.12.7848; CAVAZZANACALVO M, 1993, J CLIN INVEST, V91, P1214, DOI 10.1172/JCI116282; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chen L, 2005, CANCER SCI, V96, P134, DOI 10.1111/j.1349-7006.2005.00019.x; Collis SJ, 2005, ONCOGENE, V24, P949, DOI 10.1038/sj.onc.1208332; Cui XP, 2005, MOL CELL BIOL, V25, P10842, DOI 10.1128/MCB.25.24.10842-10852.2005; Dai Y, 2003, P NATL ACAD SCI USA, V100, P2462, DOI 10.1073/pnas.0437964100; de Villartay JP, 2003, CURR OPIN IMMUNOL, V15, P592, DOI 10.1016/S0952-7915(03)00101-8; Dip R, 2005, FASEB J, V19, P704, DOI 10.1096/fj.04-3041rev; Downs JA, 2004, NAT REV MOL CELL BIO, V5, P367, DOI 10.1038/nrm1367; Drouet J, 2005, J BIOL CHEM, V280, P7060, DOI 10.1074/jbc.M410746200; Elmroth K, 2003, DNA REPAIR, V2, P363, DOI 10.1016/S1568-7864(02)00235-5; Evans PM, 2006, HUM MOL GENET, V15, P1303, DOI 10.1093/hmg/ddl050; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Gell D, 1999, NUCLEIC ACIDS RES, V27, P3494, DOI 10.1093/nar/27.17.3494; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Gupta S, 2005, NUCLEIC ACIDS RES, V33, P6972, DOI 10.1093/nar/gki990; Hammarsten O, 2000, J BIOL CHEM, V275, P1541, DOI 10.1074/jbc.275.3.1541; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; Harris R, 2004, J MOL BIOL, V335, P573, DOI 10.1016/j.jmb.2003.10.047; Hoppe BS, 2000, RADIAT RES, V153, P125, DOI 10.1667/0033-7587(2000)153[0125:COTRMC]2.0.CO;2; Jin SF, 1997, J BIOL CHEM, V272, P24763, DOI 10.1074/jbc.272.40.24763; Kim CH, 2002, J PHARMACOL EXP THER, V303, P753, DOI 10.1124/jpet.102.038505; Lees-Miller SP, 2003, BIOCHIMIE, V85, P1161, DOI 10.1016/j.biochi.2003.10.011; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; Llorca O, 2004, MICRON, V35, P625, DOI 10.1016/j.micron.2004.05.004; Ma YM, 2004, MOL CELL, V16, P701, DOI 10.1016/j.molcel.2004.11.017; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Ma YM, 2005, J BIOL CHEM, V280, P33839, DOI 10.1074/jbc.M507113200; Marangoni E, 2000, NUCLEIC ACIDS RES, V28, P4778, DOI 10.1093/nar/28.23.4778; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Moshous D, 2000, HUM MOL GENET, V9, P583, DOI 10.1093/hmg/9.4.583; Moshous D, 2003, J CLIN INVEST, V111, P381, DOI 10.1172/JCI200316774; Nicolas N, 1996, EUR J IMMUNOL, V26, P1118, DOI 10.1002/eji.1830260524; Nicolas N, 1998, J EXP MED, V188, P627, DOI 10.1084/jem.188.4.627; O'Driscoll M, 2006, NAT REV GENET, V7, P45, DOI 10.1038/nrg1746; ONO M, 1994, NUCLEIC ACIDS RES, V22, P3918, DOI 10.1093/nar/22.19.3918; Pannicke U, 2004, EMBO J, V23, P1987, DOI 10.1038/sj.emboj.7600206; Poinsignon C, 2004, EUR J IMMUNOL, V34, P3146, DOI 10.1002/eji.200425455; Poinsignon C, 2004, J EXP MED, V199, P315, DOI 10.1084/jem.20031142; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; Reddy YVR, 2004, J BIOL CHEM, V279, P39408, DOI 10.1074/jbc.M406432200; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Rivera-Calzada A, 2005, STRUCTURE, V13, P243, DOI 10.1016/j.str.2004.12.006; Rooney S, 2004, IMMUNOL REV, V200, P115, DOI 10.1111/j.0105-2896.2004.00165.x; Rooney S, 2004, P NATL ACAD SCI USA, V101, P2410, DOI 10.1073/pnas.0308757101; Rooney S, 2003, J EXP MED, V197, P553, DOI 10.1084/jem.20021891; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; SHILOH Y, 1983, CARCINOGENESIS, V4, P917, DOI 10.1093/carcin/4.7.917; Singleton BK, 1999, MOL CELL BIOL, V19, P3267; Veuger SJ, 2003, CANCER RES, V63, P6008; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang HC, 2005, CANCER RES, V65, P4020, DOI 10.1158/0008-5472.CAN-04-3055; Wang JH, 2005, DNA REPAIR, V4, P556, DOI 10.1016/j.dnarep.2005.02.001; Weterings E, 2004, DNA REPAIR, V3, P1425, DOI 10.1016/j.dnarep.2004.06.003; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Zhang XS, 2004, MOL CELL BIOL, V24, P9207, DOI 10.1128/MCB.24.20.9207-9220.2004; Zhang ZM, 2004, STRUCTURE, V12, P495, DOI 10.1016/j.str.2004.02.007	67	61	65	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27784	27793		10.1074/jbc.M603047200	http://dx.doi.org/10.1074/jbc.M603047200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16857680	hybrid			2022-12-25	WOS:000240534400014
J	Partridge, JD; Scott, C; Tang, Y; Poole, RK; Green, J				Partridge, Jonathan D.; Scott, Colin; Tang, Yue; Poole, Robert K.; Green, Jeffrey			Escherichia coli transcriptome dynamics during the transition from anaerobic to aerobic conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACONITASE-B; POSTTRANSCRIPTIONAL REGULATION; 2-COMPONENT SYSTEM; FUMARASE FUMA; FNR; GENES; OXYGEN; SUPEROXIDE; EXPRESSION; REGULON	Escherichia coli is a metabolically versatile bacterium that is able to grow in the presence and absence of oxygen. Several previous transcript-profiling experiments have compared separate anaerobic and aerobic cultures. Here the process of adaptation was investigated by determining changes in transcript profiles when anaerobic steady-state cultures were perturbed by the introduction of air. Within 5 min of culture aeration the abundances of transcripts associated with anaerobic metabolism were decreased, whereas transcripts associated with aerobic metabolism were increased. In addition to the rapid switch to aerobic central metabolism, transcript profiling, supported by experiments with relevant mutants, revealed transient changes suggesting that the peroxide stress response, methionine biosynthesis, and degradation of putrescine play important roles during the adaptation to aerobic conditions.	Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Green, J (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England.	jeff.green@sheffield.ac.uk	Partridge, Jonathan/GSD-6795-2022; Scott, Colin/A-4682-2009; Tang, Yue/C-7094-2011	Scott, Colin/0000-0001-6110-6982; Partridge, Jonathan/0000-0003-2536-5404	Biotechnology and Biological Sciences Research Council [BBS/B/01472] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Alexeeva S, 2000, J BACTERIOL, V182, P4934, DOI 10.1128/JB.182.17.4934-4940.2000; Barras F, 2005, ADV MICROB PHYSIOL, V50, P41, DOI 10.1016/S0065-2911(05)50002-X; BENOFSKY C, 1973, ANAL BIOCHEM, V53, P452; Bock A., 1996, ESCHERICHIA COLI SAL, V2, P262; BONGAERTS J, 1995, MOL MICROBIOL, V16, P521, DOI 10.1111/j.1365-2958.1995.tb02416.x; Butland G, 2005, NATURE, V433, P531, DOI 10.1038/nature03239; Chattopadhyay MK, 2003, P NATL ACAD SCI USA, V100, P2261, DOI 10.1073/pnas.2627990100; CLARK DP, 1989, FEMS MICROBIOL LETT, V63, P223, DOI 10.1111/j.1574-6968.1989.tb03398.x; Constantinidou C, 2006, J BIOL CHEM, V281, P4802, DOI 10.1074/jbc.M512312200; COTTER PA, 1992, FEMS MICROBIOL LETT, V91, P31; Covert MW, 2004, NATURE, V429, P92, DOI 10.1038/nature02456; Cunningham L, 1998, MICROBIOL-SGM, V144, P2113, DOI 10.1099/00221287-144-8-2113; DORMAN CJ, 1988, J BACTERIOL, V170, P2816, DOI 10.1128/jb.170.6.2816-2826.1988; Evans C. G. T., 1970, METHODS MICROBIOLOGY, V2, DOI [10.1016/S0580-9517(08)70227-7, DOI 10.1016/S0580-9517(08)70227-7]; Flatley J, 2005, J BIOL CHEM, V280, P10065, DOI 10.1074/jbc.M410393200; Gennis R. B., 1996, ESCHERICHIA COLI SAL, P217; Georgellis D, 1999, J BIOL CHEM, V274, P35950, DOI 10.1074/jbc.274.50.35950; Georgellis D, 2001, SCIENCE, V292, P2314, DOI 10.1126/science.1059361; Giel JL, 2006, MOL MICROBIOL, V60, P1058, DOI 10.1111/j.1365-2958.2006.05160.x; Gimenez R, 2003, J BACTERIOL, V185, P6448, DOI 10.1128/JB.185.21.6448-6455.2003; GONZALEZFLECHA B, 1995, J BIOL CHEM, V270, P13681, DOI 10.1074/jbc.270.23.13681; Gort AS, 1999, MOL MICROBIOL, V32, P179, DOI 10.1046/j.1365-2958.1999.01343.x; Govantes F, 2000, MOL MICROBIOL, V38, P1061, DOI 10.1046/j.1365-2958.2000.02215.x; Green J, 2004, NAT REV MICROBIOL, V2, P954, DOI 10.1038/nrmicro1022; GREENE RC, 1996, ESCHERICHIA COLI SAL, P542; GRUER MJ, 1994, MICROBIOL-SGM, V140, P2531, DOI 10.1099/00221287-140-10-2531; Guest John R., 1996, P317; Hondorp ER, 2004, PLOS BIOL, V2, P1738, DOI 10.1371/journal.pbio.0020336; Hoskisson PA, 2005, MICROBIOL-SGM, V151, P3153, DOI 10.1099/mic.0.27924-0; IMLAY JA, 1995, J BIOL CHEM, V270, P19767; Imlay JA, 2002, ADV MICROB PHYSIOL, V46, P111, DOI 10.1016/S0065-2911(02)46003-1; Jordan PA, 1999, BIOCHEM J, V344, P739, DOI 10.1042/0264-6021:3440739; Jung IL, 2003, BIOCHEM BIOPH RES CO, V301, P915, DOI 10.1016/S0006-291X(03)00064-0; Jung IL, 2003, CELL BIOL TOXICOL, V19, P29, DOI 10.1023/A:1022065614490; Kang YS, 2005, J BACTERIOL, V187, P1135, DOI 10.1128/JB.187.3.1135-1160.2005; Karimova G, 1998, P NATL ACAD SCI USA, V95, P5752, DOI 10.1073/pnas.95.10.5752; Kurihara S, 2005, J BIOL CHEM, V280, P4602, DOI 10.1074/jbc.M411114200; LANG E, 1972, FRESEN Z ANAL CHEM, V260, P8, DOI 10.1007/BF00437519; Leichert LI, 2004, PLOS BIOL, V2, P1723, DOI 10.1371/journal.pbio.0020333; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; Lynch A. Simon, 1996, P361; Martin RG, 1999, MOL MICROBIOL, V34, P431, DOI 10.1046/j.1365-2958.1999.01599.x; Miller JH., 1972, EXPT MOL GENETICS; MUNRO GF, 1972, J BIOL CHEM, V247, P1272; PARK SJ, 1995, J BACTERIOL, V177, P6255, DOI 10.1128/jb.177.21.6255-6262.1995; Park SJ, 1997, J BACTERIOL, V179, P4138, DOI 10.1128/jb.179.13.4138-4142.1997; Perrenoud A, 2005, J BACTERIOL, V187, P3171, DOI 10.1128/JB.187.9.3171-3179.2005; Pomposiello PJ, 2001, J BACTERIOL, V183, P3890, DOI 10.1128/JB.183.13.3890-3902.2001; Rozen S, 2000, Methods Mol Biol, V132, P365; Salmon K, 2003, J BIOL CHEM, V278, P29837, DOI 10.1074/jbc.M213060200; Sambrook J, 2001, MOL CLONING LAB MANU; Seaver LC, 2004, J BIOL CHEM, V279, P48742, DOI 10.1074/jbc.M408754200; Storz G, 2000, BACTERIAL STRESS RESPONSES, P47; Sutton VR, 2004, J BACTERIOL, V186, P8018, DOI 10.1128/JB.186.23.8018-8025.2004; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; Tang Y, 1999, MICROBIOL-SGM, V145, P3069, DOI 10.1099/00221287-145-11-3069; Tang Y, 2005, MOL MICROBIOL, V56, P1149, DOI 10.1111/j.1365-2958.2005.04610.x; Tang Y, 2004, MOL MICROBIOL, V51, P1817, DOI 10.1111/j.1365-2958.2003.03954.x; Tao K, 1999, FEBS LETT, V457, P90, DOI 10.1016/S0014-5793(99)01013-3; Tkachenko A G, 2001, Mikrobiologiia, V70, P487; Travers A, 2005, NAT REV MICROBIOL, V3, P157, DOI 10.1038/nrmicro1088; Tseng CP, 2001, J BACTERIOL, V183, P461, DOI 10.1128/JB.183.2.461-467.2001; Varghese S, 2003, J BACTERIOL, V185, P221, DOI 10.1128/JB.185.1.221-230.2003; Williams CH, 2002, NAT STRUCT BIOL, V9, P447, DOI 10.1038/nsb801; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; Zheng M, 1999, J BACTERIOL, V181, P4639, DOI 10.1128/JB.181.15.4639-4643.1999; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	67	85	86	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27806	27815		10.1074/jbc.M603450200	http://dx.doi.org/10.1074/jbc.M603450200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16857675	hybrid			2022-12-25	WOS:000240534400016
J	Asano, S; Park, JE; Yu, LR; Zhou, M; Sakchaisri, K; Park, CJ; Kang, YH; Thorner, J; Veenstra, TD; Lee, KS				Asano, Satoshi; Park, Jung-Eun; Yu, Li-Rong; Zhou, Ming; Sakchaisri, Krisada; Park, Chong J.; Kang, Young H.; Thorner, Jeremy; Veenstra, Timothy D.; Lee, Kyung S.			Direct phosphorylation and activation of a Nim1-related kinase Gin4 by Elm1 in budding yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREVISIAE CELL-CYCLE; MITOTIC SIGNALING NETWORK; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; GENE-PRODUCT; SEPTIN FUNCTION; EVENTS; MORPHOGENESIS; LOCALIZATION; ORGANIZATION	In budding yeast, Gin4, a Nim1-related kinase, plays an important role in proper organization of the septin ring at the mother-bud neck, a filamentous structure that is critical for diverse cellular processes including mitotic entry and cytokinesis. How Gin4 kinase activity is regulated is not known. Here we showed that a neck-associated Ser/Thr kinase Elm1, which is important for septin assembly, is critical for proper modification of Gin4 and its physiological substrate Shs1. In vitro studies with purified recombinant proteins demonstrated that Elm1 directly phosphorylates and activates Gin4, which in turn phosphorylates Shs1. Consistent with these observations, acute inhibition of Elm1 activity abolished mitotic Gin4 phosphorylation and Gin4-dependent Shs1 modification in vivo. In addition, a gin4 mutant lacking the Elm1-dependent phosphorylation sites exhibited an impaired localization to the bud-neck and, as a result, induced a significant growth defect with an elongated bud morphology. Thus, Elm1 regulates the septin assembly-dependent cellular events by directly phosphorylating and activating the Gin4-dependent pathway(s).	NCI, NIH, Lab Metab, Canc Res Ctr, Bethesda, MD 20892 USA; NCI, Lab Proteom & Analyt Technol, NIH, Ft Detrick, MD 21702 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California Berkeley	Lee, KS (corresponding author), NCI, NIH, Lab Metab, Canc Res Ctr, 9000 Rockville Pike,Bldg 37,Rm 3118, Bethesda, MD 20892 USA.	kyunglee@mail.nih.gov	THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X; Yu, Li-Rong/0000-0001-6084-991X	Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [GM21841] Funding Source: Medline; DIVISION OF BASIC SCIENCES - NCI [Z01BC010521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021841, R01GM021841] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; Altman R, 1997, J CELL BIOL, V138, P119, DOI 10.1083/jcb.138.1.119; Asano S, 2005, EMBO J, V24, P2194, DOI 10.1038/sj.emboj.7600683; Barral Y, 1999, GENE DEV, V13, P176, DOI 10.1101/gad.13.2.176; Bishop AC, 1998, CURR BIOL, V8, P257, DOI 10.1016/S0960-9822(98)70198-8; Bouquin N, 2000, J CELL SCI, V113, P1435; BYERS B, 1976, J CELL BIOL, V69, P717, DOI 10.1083/jcb.69.3.717; Carroll CW, 1998, J CELL BIOL, V143, P709, DOI 10.1083/jcb.143.3.709; Cid VJ, 2001, MOL BIOL CELL, V12, P1645, DOI 10.1091/mbc.12.6.1645; Edgington NP, 1999, MOL CELL BIOL, V19, P1369; FORD SK, 1991, DEV GENET, V12, P281, DOI 10.1002/dvg.1020120405; Frazier JA, 1998, J CELL BIOL, V143, P737, DOI 10.1083/jcb.143.3.737; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAARER BK, 1987, MOL CELL BIOL, V7, P3678, DOI 10.1128/MCB.7.10.3678; Hanrahan J, 2003, MOL CELL, V12, P663, DOI 10.1016/j.molcel.2003.08.006; Iwase M, 2004, CELL STRUCT FUNCT, V29, P1, DOI 10.1247/csf.29.1; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; KIM HB, 1991, J CELL BIOL, V112, P535, DOI 10.1083/jcb.112.4.535; Koehler CM, 1997, FEBS LETT, V408, P109, DOI 10.1016/S0014-5793(97)00401-8; Longtine MS, 2000, MOL CELL BIOL, V20, P4049, DOI 10.1128/MCB.20.11.4049-4061.2000; Longtine MS, 2003, TRENDS CELL BIOL, V13, P403, DOI 10.1016/S0962-8924(03)00151-X; Longtine MS, 1998, J CELL BIOL, V143, P719, DOI 10.1083/jcb.143.3.719; Mino A, 1998, BIOCHEM BIOPH RES CO, V251, P732, DOI 10.1006/bbrc.1998.9541; Mortensen EM, 2002, MOL BIOL CELL, V13, P2091, DOI 10.1091/mbc.01-10-0500; Okuzaki D, 2001, FEBS LETT, V489, P197, DOI 10.1016/S0014-5793(01)02104-4; Sakchaisri K, 2004, P NATL ACAD SCI USA, V101, P4124, DOI 10.1073/pnas.0400641101; Sherman F, 1986, LAB COURSE MANUAL ME; Shulewitz MJ, 1999, MOL CELL BIOL, V19, P7123; Sreenivasan A, 2003, MOL CELL BIOL, V23, P6327, DOI 10.1128/MCB.23.17.6327-6337.2003; Sreenivasan A, 1999, MOL CELL BIOL, V19, P7983; Sung H, 2005, FEMS YEAST RES, V5, P943, DOI 10.1016/j.femsyr.2005.03.008; Theesfeld CL, 2003, MOL BIOL CELL, V14, P3280, DOI 10.1091/mbc.e03-03-0154; Tjandra H, 1998, CURR BIOL, V8, P991, DOI 10.1016/S0960-9822(07)00419-8; Versele M, 2005, TRENDS CELL BIOL, V15, P414, DOI 10.1016/j.tcb.2005.06.007; Versele M, 2004, MOL BIOL CELL, V15, P4568, DOI 10.1091/mbc.E04-04-0330	35	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27090	27098		10.1074/jbc.M601483200	http://dx.doi.org/10.1074/jbc.M601483200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16861226	Green Published, hybrid			2022-12-25	WOS:000240397700036
J	Shin, JH; Kelman, Z				Shin, Jae-Ho; Kelman, Zvi			The replicative helicases of bacteria, archaea, and eukarya can unwind RNA-DNA hybrid substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II HOLOENZYME; R-LOOP FORMATION; TRANSCRIPTIONAL ACTIVATION; ESCHERICHIA-COLI; MCM PROTEINS; IFN-GAMMA; DUPLEX; INITIATION; COMPLEX; BINDING	Replicative helicases are hexameric enzymes that unwind DNA during chromosomal replication. They use energy from nucleoside triphosphate hydrolysis to translocate along one strand of the duplex DNA and displace the complementary strand. Here, the ability of a replicative helicase from each of the three domains, bacteria, archaea, and eukarya, to unwind RNA-containing substrate was determined. It is shown that all three helicases can unwind DNA-RNA hybrids while translocating along the single-stranded DNA. No unwinding could be observed when the helicases were provided with a single-stranded RNA overhang. Using DNA, RNA, and DNA-RNA chimeric oligonucleotides it was found that whereas the enzymes can bind both DNA and RNA, they could translocate only along DNA and only DNA stimulates the ATPase activity of the enzymes. Recent observations suggest that helicases may interact with enzymes participating in RNA metabolism and that RNA-DNA hybrids may be present on the chromosomes. Thus, the results presented here may suggest a new role for the replicative helicases during chromosomal replication or in other cellular processes.	Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA	University System of Maryland; University of Maryland Baltimore	Kelman, Z (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	kelman@umbi.umd.edu						Bayne EH, 2005, TRENDS GENET, V21, P370, DOI 10.1016/j.tig.2005.05.007; Bernstein E, 2005, GENE DEV, V19, P1635, DOI 10.1101/gad.1324305; Broccoli S, 2004, MOL MICROBIOL, V52, P1769, DOI 10.1111/j.1365-2958.2004.04092.x; Chen YJ, 2005, J MOL BIOL, V346, P389, DOI 10.1016/j.jmb.2004.11.076; Corey DR, 2005, TRENDS BIOCHEM SCI, V30, P655, DOI 10.1016/j.tibs.2005.09.007; DaFonseca CJ, 2001, P NATL ACAD SCI USA, V98, P3034, DOI 10.1073/pnas.061487598; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; GRABCZYK E, 1995, J BIOL CHEM, V270, P1791, DOI 10.1074/jbc.270.4.1791; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Holland L, 2002, EUR J BIOCHEM, V269, P5192, DOI 10.1046/j.1432-1033.2002.03224.x; Huertas P, 2003, MOL CELL, V12, P711, DOI 10.1016/j.molcel.2003.08.010; Kaplan DL, 2000, J MOL BIOL, V301, P285, DOI 10.1006/jmbi.2000.3965; Kaplan DL, 2003, J BIOL CHEM, V278, P49171, DOI 10.1074/jbc.M308074200; Kelman LM, 2003, MOL MICROBIOL, V48, P605, DOI 10.1046/j.1365-2958.2003.03369.x; Kelman Z, 2005, CURR OPIN MICROBIOL, V8, P669, DOI 10.1016/j.mib.2005.10.001; Kornberg A., 1992, DNA REPLICATION; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Lei M, 2001, J CELL SCI, V114, P1447; Li XL, 2005, CELL, V122, P365, DOI 10.1016/j.cell.2005.06.008; Masse E, 1997, J BIOL CHEM, V272, P12816, DOI 10.1074/jbc.272.19.12816; MCENTEE K, 1980, P NATL ACAD SCI-BIOL, V77, P857, DOI 10.1073/pnas.77.2.857; Morag E, 1996, BIOCHEM J, V316, P193, DOI 10.1042/bj3160193; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; REABAN ME, 1994, J BIOL CHEM, V269, P21850; ROBERTS RW, 1992, SCIENCE, V258, P1463, DOI 10.1126/science.1279808; Santamaria D, 1998, J BIOL CHEM, V273, P33386, DOI 10.1074/jbc.273.50.33386; Shin JH, 2003, J BIOL CHEM, V278, P49053, DOI 10.1074/jbc.M308599200; Snyder M, 2005, P NATL ACAD SCI USA, V102, P14539, DOI 10.1073/pnas.0507479102; Yankulov K, 1999, MOL CELL BIOL, V19, P6154; You ZY, 2003, EMBO J, V22, P6148, DOI 10.1093/emboj/cdg576; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963	33	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26914	26921		10.1074/jbc.M605518200	http://dx.doi.org/10.1074/jbc.M605518200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16829518	hybrid			2022-12-25	WOS:000240397700018
J	Tolia, A; Chavez-Gutierrez, L; De Strooper, B				Tolia, Alexandra; Chavez-Gutierrez, Lucia; De Strooper, Bart			Contribution of presenilin transmembrane domains 6 and 7 to a water-containing cavity in the gamma-secretase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTAGENESIS; DISULFIDE CROSS-LINKING; AMYLOID PRECURSOR PROTEIN; ACTIVE-SITE; ALZHEIMERS-DISEASE; P-GLYCOPROTEIN; INTRAMEMBRANE PROTEOLYSIS; HIPPOCAMPAL-NEURONS; TRICHODERMA-REESEI; BINDING SITE	Secretase is a multiprotein complex responsible for the intramembranous cleavage of the amyloid precursor protein and other type I transmembrane proteins. Mutations in Presenilin, the catalytic core of this complex, cause Alzheimer disease. Little is known about the structure of the protein and even less about the catalytic mechanism, which involves proteolytic cleavage in the hydrophobic environment of the cell membrane. It is basically unclear how water, needed to perform hydrolysis, is provided to this reaction. Presenilin transmembrane domains 6 and 7 seem critical in this regard, as each bears a critical aspartate contributing to catalytic activity. Current models imply that both aspartyl groups should closely oppose each other and have access to water. This is, however, still to be experimentally verified. Here, we have performed cysteine-scanning mutagenesis of both domains and have demonstrated that several of the introduced residues are exposed to water, providing experimental evidence for the existence of a water-filled cavity in the catalytic core of Presenilin. In addition, we have demonstrated that the two aspartates reside within this cavity and are opposed to each other in the native complex. We have also identified the conserved tyrosine 389 as a critical partner in the catalytic mechanism. Several additional amino acid substitutions affect differentially the processing of gamma-secretase substrates, implying that they contribute to enzyme specificity. Our data suggest the possibility that more selective gamma-secretase inhibitors could be designed.	VIB4, Ctr Human Genet, Neuronal Cell Biol & Gene Transfer Lab, B-3000 Louvain, Belgium; Katholieke Univ Leuven, B-3000 Louvain, Belgium	KU Leuven	De Strooper, B (corresponding author), VIB4, Ctr Human Genet, Neuronal Cell Biol & Gene Transfer Lab, Herestr 49, B-3000 Louvain, Belgium.	Bart.destrooper@med.kuleuven.be	Chávez-Gutiérrez, Lucía/E-2657-2017; de+Strooper, Bart/Z-1638-2019; De Strooper, Bart/F-6507-2012	De Strooper, Bart/0000-0001-5455-5819				Annaert W, 2002, ANNU REV CELL DEV BI, V18, P25, DOI 10.1146/annurev.cellbio.18.020402.142302; Annaert WG, 2001, NEURON, V32, P579, DOI 10.1016/S0896-6273(01)00512-8; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; CAMPION D, 1995, HUM MOL GENET, V4, P2373, DOI 10.1093/hmg/4.12.2373; Coates L, 2001, BIOCHEMISTRY-US, V40, P13149, DOI 10.1021/bi010626h; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; Digby HR, 2005, J NEUROCHEM, V95, P1746, DOI 10.1111/j.1471-4159.2005.03494.x; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Eilers M, 2000, P NATL ACAD SCI USA, V97, P5796, DOI 10.1073/pnas.97.11.5796; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Esselens C, 2004, J CELL BIOL, V166, P1041, DOI 10.1083/jcb.200406060; Feramisco JD, 2004, J BIOL CHEM, V279, P8487, DOI 10.1074/jbc.M312623200; Huang W, 2005, BIOCHEMISTRY-US, V44, P2419, DOI 10.1021/bi048808+; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimura-Someya T, 2000, J BIOL CHEM, V275, P18692, DOI 10.1074/jbc.M000354200; Koivula A, 2002, J AM CHEM SOC, V124, P10015, DOI 10.1021/ja012659q; Koivula A, 1996, PROTEIN ENG, V9, P691, DOI 10.1093/protein/9.8.691; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Kornilova AY, 2006, BIOCHEMISTRY-US, V45, P7598, DOI 10.1021/bi060107k; Kornilova AY, 2005, P NATL ACAD SCI USA, V102, P3230, DOI 10.1073/pnas.0407640102; Kuwabara N, 2004, J BIOL CHEM, V279, P40567, DOI 10.1074/jbc.M401132200; Laudon H, 2005, J BIOL CHEM, V280, P35352, DOI 10.1074/jbc.M507217200; Lazarov VK, 2006, P NATL ACAD SCI USA, V103, P6889, DOI 10.1073/pnas.0602321103; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; Loo TW, 2004, J BIOL CHEM, V279, P7692, DOI 10.1074/jbc.M311825200; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; Maltese WA, 2001, J BIOL CHEM, V276, P20267, DOI 10.1074/jbc.M007238200; Martoglio B, 2003, HUM MOL GENET, V12, pR201, DOI 10.1093/hmg/ddg303; Michiels F, 2002, NAT BIOTECHNOL, V20, P1154, DOI 10.1038/nbt746; Mueckler M, 2005, J BIOL CHEM, V280, P39562, DOI 10.1074/jbc.M509050200; Nyabi O, 2003, J BIOL CHEM, V278, P43430, DOI 10.1074/jbc.M306957200; Oh YS, 2005, AM J PHYSIOL-CELL PH, V289, pC576, DOI 10.1152/ajpcell.00636.2004; Ostermann N, 2004, J MOL BIOL, V342, P889, DOI 10.1016/j.jmb.2004.07.073; Ponting CP, 2002, HUM MOL GENET, V11, P1037, DOI 10.1093/hmg/11.9.1037; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; Slotboom DJ, 2001, J BIOL CHEM, V276, P10775, DOI 10.1074/jbc.M011064200; Spasic D, 2006, J BIOL CHEM, V281, P26569, DOI 10.1074/jbc.M600592200; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tamura N, 2003, CURR OPIN CHEM BIOL, V7, P570, DOI 10.1016/j.cbpa.2003.08.014; Tedde A, 2003, ARCH NEUROL-CHICAGO, V60, P1541, DOI 10.1001/archneur.60.11.1541; Urban S, 2002, CURR OPIN GENET DEV, V12, P512, DOI 10.1016/S0959-437X(02)00334-9; Vullo A, 2004, BIOINFORMATICS, V20, P653, DOI 10.1093/bioinformatics/btg463; Ward SDC, 2002, J BIOL CHEM, V277, P2247, DOI 10.1074/jbc.M107647200; WASCO W, 1995, NAT MED, V1, P848, DOI 10.1038/nm0995-848a; Wiltfang J, 2001, J BIOL CHEM, V276, P42645, DOI 10.1074/jbc.M102790200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yuan H, 1999, J NEUROSCI METH, V88, P45, DOI 10.1016/S0165-0270(99)00011-4	56	110	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27633	27642		10.1074/jbc.M604997200	http://dx.doi.org/10.1074/jbc.M604997200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16844686	hybrid, Green Published			2022-12-25	WOS:000240397700088
J	Halbedel, S; Busse, J; Schmidl, SR; Stulke, J				Halbedel, Sven; Busse, Julia; Schmidl, Sebastian R.; Stuelke, Joerg			Regulatory protein phosphorylation in Mycoplasma pneumoniae - A PP2C-type phosphatase serves to dephosphorylate HPR(Ser-P)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSION; BACILLUS-SUBTILIS; HPR KINASE/PHOSPHORYLASE; KINASE; CCPA; PHOSPHOENOLPYRUVATE; MUTAGENESIS; TN4001; ENZYME; ROLES	Among the few regulatory events in the minimal bacterium Mycoplasma pneumoniae is the phosphorylation of the HPr phosphocarrier protein of the phosphotransferase system. In the presence of glycerol, HPr is phosphorylated in an ATP-dependent manner by the HPr kinase/phosphorylase. The role of the latter enzyme was studied by constructing a M. pneumoniae hprK mutant defective in HPr kinase/phosphorylase. This mutant strain no longer exhibited HPr kinase activity but, surprisingly, still had phosphatase activity toward serine-phosphorylated HPr (HPr(Ser-P)). An inspection of the genome sequence revealed the presence of a gene (prpC) encoding a presumptive protein serine/threonine phosphatase of the PP2C family. The phosphatase PrpC was purified and its biochemical activity in HPr(Ser-P) dephosphorylation demonstrated. Moreover, a prpC mutant strain was isolated and found to be impaired in HPr(Ser-P) dephosphorylation. Homologues of PrpC are present in many bacteria possessing HPr(Ser-P), suggesting that PrpC may play an important role in adjusting the cellular HPr phosphorylation state and thus controlling the diverse regulatory functions exerted by the different forms of HPr.	Univ Gottingen, Inst Microbiol & Genet, Dept Gen Microbiol, D-37077 Gottingen, Germany	University of Gottingen	Stulke, J (corresponding author), Univ Gottingen, Inst Microbiol & Genet, Dept Gen Microbiol, Grisebachstr 8, D-37077 Gottingen, Germany.	jstuelk@gwdg.de	Stülke, Jörg/AAD-1600-2021	Stulke, Jorg/0000-0001-5881-5390; Halbedel, Sven/0000-0002-5575-8973				Adler E, 1997, MOL MICROBIOL, V23, P57, DOI 10.1046/j.1365-2958.1997.1801552.x; Allen GS, 2003, J MOL BIOL, V326, P1203, DOI 10.1016/S0022-2836(02)01378-5; Bi WL, 1998, ANAL BIOCHEM, V256, P137, DOI 10.1006/abio.1997.2516; Darbon E, 2002, MOL MICROBIOL, V43, P1039, DOI 10.1046/j.1365-2958.2002.02800.x; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; DEUTSCHER J, 1995, MOL MICROBIOL, V15, P1049, DOI 10.1111/j.1365-2958.1995.tb02280.x; Dybvig K, 2000, J BACTERIOL, V182, P4343, DOI 10.1128/JB.182.15.4343-4347.2000; Gaidenko TA, 2002, J BACTERIOL, V184, P6109, DOI 10.1128/JB.184.22.6109-6114.2002; Glass JI, 2006, P NATL ACAD SCI USA, V103, P425, DOI 10.1073/pnas.0510013103; Halbedel S, 2005, FEMS MICROBIOL LETT, V247, P193, DOI 10.1016/j.femsle.2005.05.004; Halbedel S, 2004, J BACTERIOL, V186, P7936, DOI 10.1128/JB.186.23.7936-7943.2004; HEDREYDA CT, 1993, PLASMID, V30, P170, DOI 10.1006/plas.1993.1047; Herro R, 2005, J MOL MICROB BIOTECH, V9, P224, DOI 10.1159/000089650; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; Hutchison CA, 1999, SCIENCE, V286, P2165, DOI 10.1126/science.286.5447.2165; Irmler A, 2001, P NATL ACAD SCI USA, V98, P12978, DOI 10.1073/pnas.231254998; Ludwig H, 2002, MOL MICROBIOL, V45, P543, DOI 10.1046/j.1365-2958.2002.03034.x; Maniatis T., 1989, MOL CLONING LAB MAN; MASON PW, 1981, J BIOL CHEM, V256, P1861; Merzbacher M, 2004, EUR J BIOCHEM, V271, P367, DOI 10.1046/j.1432-1033.2003.03935.x; Mijakovic I, 2002, P NATL ACAD SCI USA, V99, P13442, DOI 10.1073/pnas.212410399; Monedero V, 2001, EMBO J, V20, P3928, DOI 10.1093/emboj/20.15.3928; Nessler S, 2003, J BACTERIOL, V185, P4003, DOI 10.1128/JB.185.14.4003-4010.2003; Obuchowski M, 2000, J BACTERIOL, V182, P5634, DOI 10.1128/JB.182.19.5634-5638.2000; Obuchowski Michal, 2005, Postepy Biochem, V51, P95; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Reizer J, 1998, MOL MICROBIOL, V27, P1157, DOI 10.1046/j.1365-2958.1998.00747.x; Schirmer F, 1997, J BACTERIOL, V179, P1329, DOI 10.1128/jb.179.4.1329-1336.1997; Schumacher MA, 2004, CELL, V118, P731, DOI 10.1016/j.cell.2004.08.027; Shi L, 2004, FRONT BIOSCI-LANDMRK, V9, P1382, DOI 10.2741/1318; Steinhauer K, 2002, MICROBIOL-SGM, V148, P3277, DOI 10.1099/00221287-148-10-3277; Stulke J, 1998, MOL MICROBIOL, V28, P865, DOI 10.1046/j.1365-2958.1998.00839.x; STULKE J, 2004, TOPICS CURR GENET, V9, P179; Weiner J, 2003, NUCLEIC ACIDS RES, V31, P6306, DOI 10.1093/nar/gkg841; Zimmerman CU, 2005, FEMS MICROBIOL LETT, V253, P315, DOI 10.1016/j.femsle.2005.09.054	35	36	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26253	26259		10.1074/jbc.M605010200	http://dx.doi.org/10.1074/jbc.M605010200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16857667	hybrid			2022-12-25	WOS:000240249500042
J	Sauna, ZE; Nandigama, K; Ambudkar, SV				Sauna, Zuben E.; Nandigama, Krishnamachary; Ambudkar, Suresh V.			Exploiting reaction intermediates of the ATPase reaction to elucidate the mechanism of transport by P-glycoprotein (ABCB1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN MOTOR DOMAIN; ENZYMATIC TRANSITION-STATES; POWER STROKE STATE; MULTIDRUG-RESISTANCE; CATALYTIC CYCLE; GLUTAMATE RESIDUES; CRYSTAL-STRUCTURE; BERYLLIUM FLUORIDE; ANALOG DESIGN; HYDROLYSIS	The transport cycle of ABC transporters in general and P-glycoprotein in particular has been extensively studied, but the molecular mechanism remains controversial. We identify stable reaction intermediates in the progression of the P-glycoprotein-mediated ATPase reaction equivalent to the enzyme-substrate (E.S, P-glycoprotein.ATP) and enzyme-product (E.P, P.glycoprotein.ADP.P-i) reaction intermediates. These have been characterized using the photoaffinity analog 8-azido-[alpha-P-32] ATP as well as under equilibrium conditions using [alpha-P-32] ATP, in which a cross-linking step is not involved. Similar results were obtained when 8-azido[alpha-32P] ATP or [alpha-32P] ATP was used. The reaction intermediates were characterized basedontheir kinetic properties and the nature (triphosphate/diphosphate) of the trapped nucleotide. Using this defined framework and the Walker B E556Q/ E1201Q mutant that traps nucleotide in the absence of vanadate or beryllium fluoride, the high to low affinity switch in the transport substrate binding site can be attributed to the formation of the E.S reaction intermediate of the ATPase reaction. Importantly, the posthydrolysis E.P state continues to have low affinity for substrate, suggesting that conformational changes that form the E.S complex are coupled to the conformational change at the transport substrate site to do mechanical work. Thus, the formation of E.S reaction intermediate duringasingleturnoverofthecatalyticcycleappearstoprovidethe initial power stroke for movement of drug substrate from inner leaflet to outer leaflet of lipid bilayer. This novel approach applies transition state theory to elucidate the mechanism of P-glycoprotein and other ABC transporters and has wider applications in testing cause-effect hypotheses in coupled systems.	NCI, Cell Biol Lab, Ctr Canc Res, NIH,DHHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ambudkar, SV (corresponding author), NCI, Cell Biol Lab, Ctr Canc Res, NIH,DHHS, Bethesda, MD 20892 USA.	ambudkar@helix.nih.gov	Ambudkar, Suresh V/L-1317-2016; Sauna, Zuben E./AAA-7149-2019		Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC010030, Z01BC010030] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Shawi MK, 2003, J BIOL CHEM, V278, P52629, DOI 10.1074/jbc.M308175200; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; Ambudkar SV, 1998, METHOD ENZYMOL, V292, P492; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Chen C, 2006, J BIOL CHEM, V281, P13777, DOI 10.1074/jbc.M513369200; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5.1225-1233.2002; Davies DR, 2004, FEBS LETT, V577, P315, DOI 10.1016/j.febslet.2004.10.022; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; FERSHT A, 1999, STRUCTURE MECH PROTE, P38; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GOODNO CC, 1982, P NATL ACAD SCI-BIOL, V79, P21, DOI 10.1073/pnas.79.1.21; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; Gottesman MM, 2001, J BIOENERG BIOMEMBR, V33, P453, DOI 10.1023/A:1012866803188; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; Gourinath S, 2003, STRUCTURE, V11, P1621, DOI 10.1016/j.str.2003.10.013; Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199; Higgins CF, 2004, NAT STRUCT MOL BIOL, V11, P918, DOI 10.1038/nsmb836; Highsmith S, 2000, BIOCHEMISTRY-US, V39, P12330, DOI 10.1021/bi001146d; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; Jones PM, 2004, CELL MOL LIFE SCI, V61, P682, DOI 10.1007/s00018-003-3336-9; Kagawa R, 2004, EMBO J, V23, P2734, DOI 10.1038/sj.emboj.7600293; Kerr KM, 2001, J BIOL CHEM, V276, P8657, DOI 10.1074/jbc.M010044200; Kozak L, 2002, J BIOL CHEM, V277, P33580, DOI 10.1074/jbc.M205415200; Martin C, 2000, BIOCHEMISTRY-US, V39, P11901, DOI 10.1021/bi000559b; Oloo EO, 2004, J BIOL CHEM, V279, P45013, DOI 10.1074/jbc.M405084200; Qu Q, 2003, BIOCHEMISTRY-US, V42, P1345, DOI 10.1021/bi0267745; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; Ramachandra M, 1996, MOL BIOL CELL, V7, P1485, DOI 10.1091/mbc.7.10.1485; Rayment I, 1996, J BIOL CHEM, V271, P15850, DOI 10.1074/jbc.271.27.15850; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Sauna ZE, 2001, J BIOENERG BIOMEMBR, V33, P481, DOI 10.1023/A:1012875105006; Sauna ZE, 2001, J BIOL CHEM, V276, P33301, DOI 10.1074/jbc.C100369200; Sauna ZE, 2001, J BIOL CHEM, V276, P21199, DOI 10.1074/jbc.M100886200; Sauna ZE, 2001, J BIOL CHEM, V276, P11653, DOI 10.1074/jbc.M011294200; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Schowen RL, 2003, P NATL ACAD SCI USA, V100, P11931, DOI 10.1073/pnas.2235806100; Schramm VL, 1998, ANNU REV BIOCHEM, V67, P693, DOI 10.1146/annurev.biochem.67.1.693; Schramm VL, 2005, ARCH BIOCHEM BIOPHYS, V433, P13, DOI 10.1016/j.abb.2004.08.035; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; Shih WM, 2000, CELL, V102, P683, DOI 10.1016/S0092-8674(00)00090-8; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Tombline G, 2005, BIOCHEMISTRY-US, V44, P12879, DOI 10.1021/bi0509797; Tombline G, 2004, J BIOL CHEM, V279, P31212, DOI 10.1074/jbc.M404689200; Tombline G, 2004, J BIOL CHEM, V279, P46518, DOI 10.1074/jbc.M408052200; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; van der Does C, 2006, J BIOL CHEM, V281, P5694, DOI 10.1074/jbc.M511730200; WATTERSON JG, 1975, EUR J BIOCHEM, V56, P79, DOI 10.1111/j.1432-1033.1975.tb02209.x; YOUNT RG, 1992, PHILOS T ROY SOC B, V336, P55, DOI 10.1098/rstb.1992.0044	59	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26501	26511		10.1074/jbc.M601917200	http://dx.doi.org/10.1074/jbc.M601917200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16844693	hybrid			2022-12-25	WOS:000240249500068
J	Rouzaud, F; Costin, GE; Yamaguchi, Y; Valencia, JC; Berens, WF; Chen, KG; Hoashi, T; Bohm, M; Abdel-Malek, ZA; Hearing, VJ				Rouzaud, Francois; Costin, Gertrude-E.; Yamaguchi, Yuji; Valencia, Julio C.; Berens, Werner F.; Chen, Kevin G.; Hoashi, Toshihiko; Boehm, Markus; Abdel-Malek, Zalfa A.; Hearing, Vincent J.			Regulation of constitutive and UVR-induced skin pigmentation by melanocortin 1 receptor isoforms	FASEB JOURNAL			English	Article						splice variant; melanocyte; UVR	PROTEIN-COUPLED RECEPTORS; HUMAN MELANOCYTES; CYTOPLASMIC TAIL; MSH RECEPTOR; DNA-DAMAGE; EXPRESSION; VARIANTS; GENE; MC1R; PALMITOYLATION	Melanin synthesized by epidermal melanocytes protects the skin against UVR-induced DNA damage and skin cancer. Exposure to UVR increases the synthesis of the photoprotective eumelanin on activation of MC1R, a melanoma susceptibility gene. We studied the expression of MC1R under UVR and alpha-MSH stimulation in skin of different ethnic origins and in melanocytes of various pigmentary levels. This study identifies and characterizes a novel MC1R isoform (MC1R350) generated by alternative splicing of the classically known MC1R (MC1R317). We demonstrate that the melanin content of melanocytes shows a significant positive correlation with MC1R317 levels but correlates inversely with the amount of MC1R350, suggesting that this latter isoform could act as a negative regulator of melanin synthesis. We confirmed that hypothesis by showing that while MC1R317 signaling significantly increases the expression of MITF and tyrosinase, two key factors in the melanin synthesis pathway, MC1R350 dramatically hampers their expression. In the skin, we show that UVR does not increase MC1R350 expression but does significantly increase MC1R317. Taken together, our results strongly suggest that MC1R350 acts as a negative regulator of skin pigmentation and demonstrate for the first time that MC1R isoform-specific expression is closely related to skin pigmentation and photoprotection.	Univ Florida, Dept Med Chem, Gainesville, FL 32610 USA; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Munster, Dept Dermatol, D-4400 Munster, Germany; Univ Munster, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, D-4400 Munster, Germany; Univ Cincinnati, Coll Med, Dept Dermatol, Cincinnati, OH USA	State University System of Florida; University of Florida; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Munster; University of Munster; University System of Ohio; University of Cincinnati	Rouzaud, F (corresponding author), Univ Florida, Dept Med Chem, Rm P5-26,1600 SW Archer Rd, Gainesville, FL 32610 USA.	frouzaud@ufl.edu	Yamaguchi, Yuji/B-9312-2008; Yamaguchi, Yuji/X-6681-2019; Chen, Kevin G/D-6769-2011; Chen, Kevin/GYU-8963-2022	Chen, Kevin G/0000-0003-2983-6330; Yamaguchi, Yuji/0000-0003-4338-2662	DIVISION OF BASIC SCIENCES - NCI [Z01BC009100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009110] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 NS999999] Funding Source: Medline; NIEHS NIH HHS [R01 ES009110] Funding Source: Medline	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bohm M, 1999, EXP DERMATOL, V8, P453, DOI 10.1111/j.1600-0625.1999.tb00303.x; Bohm M, 1999, ANN NY ACAD SCI, V885, P372; Bonilla C, 2005, HUM GENET, V116, P402, DOI 10.1007/s00439-004-1251-2; Box NF, 2001, J INVEST DERMATOL, V116, P224, DOI 10.1046/j.1523-1747.2001.01224.x; Box NF, 1997, HUM MOL GENET, V6, P1891, DOI 10.1093/hmg/6.11.1891; Chakraborty AK, 1999, ANN NY ACAD SCI, V885, P100; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; DONATIEN PD, 1992, ARCH DERMATOL RES, V284, P424, DOI 10.1007/BF00372074; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; Everts RE, 2000, ANIM GENET, V31, P194, DOI 10.1046/j.1365-2052.2000.00639.x; Frandberg PA, 1998, BIOCHEM BIOPH RES CO, V245, P490, DOI 10.1006/bbrc.1998.8459; HALDER RM, 1995, CANCER, V75, P667, DOI 10.1002/1097-0142(19950115)75:2+<667::AID-CNCR2820751409>3.0.CO;2-I; HARRISON GA, 1973, J INVEST DERMATOL, V60, P418, DOI 10.1111/1523-1747.ep12702616; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Im SB, 1998, CANCER RES, V58, P47; Imoto K, 2002, J INVEST DERMATOL, V119, P1177, DOI 10.1046/j.1523-1747.2002.19514.x; Irani BG, 2004, CURR PHARM DESIGN, V10, P3443, DOI 10.2174/1381612043382891; JIMENEZ M, 1989, J BIOL CHEM, V264, P3397; Jimenez-Cervantes C, 2001, FEBS LETT, V508, P44, DOI 10.1016/S0014-5793(01)03025-3; Jimenez-Cervantes C, 2001, J INVEST DERMATOL, V117, P156, DOI 10.1046/j.0022-202x.2001.01393.x; John PR, 2002, HUM MUTAT, V19, DOI 10.1002/humu.9030; KAWATE N, 1994, J BIOL CHEM, V269, P30651; KLUNGLAND H, 1995, MAMM GENOME, V6, P636, DOI 10.1007/BF00352371; KRICKER A, 1994, CANCER CAUSE CONTROL, V5, P367, DOI 10.1007/BF01804988; Little C., 1957, INHERITANCE COAT COL; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; Mandrika I, 2005, BIOCHEM BIOPH RES CO, V326, P349, DOI 10.1016/j.bbrc.2004.11.036; Milligan G, 2004, MOL PHARMACOL, V66, P1, DOI 10.1124/mol.104.000497.; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Newton JM, 2000, MAMM GENOME, V11, P24, DOI 10.1007/s003350010005; PAWELEK JM, 1992, PIGM CELL RES, V5, P348, DOI 10.1111/j.1600-0749.1992.tb00561.x; PRESTON DS, 1992, NEW ENGL J MED, V327, P1649, DOI 10.1056/NEJM199212033272307; Rana BK, 1999, GENETICS, V151, P1547; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; Rouzaud F, 2000, GENET SEL EVOL, V32, P511, DOI 10.1051/gse:2000102; Rouzaud F, 2005, MUTAT RES-FUND MOL M, V571, P133, DOI 10.1016/j.mrfmmm.2004.09.014; Rouzaud F, 2003, FASEB J, V17, P2154, DOI 10.1096/fj.03-0206fje; Salahpour A, 2000, TRENDS ENDOCRIN MET, V11, P163, DOI 10.1016/S1043-2760(00)00260-5; Sanchez-Laorden BL, 2006, J INVEST DERMATOL, V126, P172, DOI 10.1038/sj.jid.5700036; Schioth HB, 1999, BIOCHEM BIOPH RES CO, V260, P488, DOI 10.1006/bbrc.1999.0935; Schulein R, 1996, BIOCHEM J, V313, P611, DOI 10.1042/bj3130611; Scott MC, 2002, J CELL SCI, V115, P2349; Scott MC, 2002, PIGM CELL RES, V15, P433, DOI 10.1034/j.1600-0749.2002.02051.x; Searle A.G., 1968, COMP GENETICS COAT C; SIEGRIST W, 1986, ANAL BIOCHEM, V159, P191, DOI 10.1016/0003-2697(86)90327-1; SILVERS WK, 1955, J EXP ZOOL, V130, P199, DOI 10.1002/jez.1401300203; SILVERS WK (ED), 1979, COAT COLORS MICE MOD; Smith R, 1998, J INVEST DERMATOL, V111, P119, DOI 10.1046/j.1523-1747.1998.00252.x; Sturm RA, 2001, GENE, V277, P49, DOI 10.1016/S0378-1119(01)00694-1; Suzuki I, 1996, ENDOCRINOLOGY, V137, P1627, DOI 10.1210/en.137.5.1627; Tadokoro T, 2005, J INVEST DERMATOL, V124, P1326, DOI 10.1111/j.0022-202X.2005.23760.x; Tadokoro T, 2003, FASEB J, V17, P1177, DOI 10.1096/fj.02-0865fje; Tan CP, 1999, FEBS LETT, V451, P137, DOI 10.1016/S0014-5793(99)00525-6; Tanaka K, 1998, ENDOCRINOLOGY, V139, P803, DOI 10.1210/en.139.2.803; VALVERDE P, 1995, NAT GENET, V11, P328, DOI 10.1038/ng1195-328; Wilson S, 1998, BRIT J PHARMACOL, V125, P1387, DOI 10.1038/sj.bjp.0702238	58	35	38	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1927	+		10.1096/fj.06-5922fje	http://dx.doi.org/10.1096/fj.06-5922fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16877522				2022-12-25	WOS:000240267000033
J	Bon, M; McGowan, SJ; Cook, PR				Bon, Michael; McGowan, Simon J.; Cook, Peter R.			Many expressed genes in bacteria and yeast are transcribed only once per cell cycle	FASEB JOURNAL			English	Article						database; nascent RNA; transcription rate; transcriptomics	RNA-POLYMERASE-II; ESCHERICHIA-COLI; VISUALIZATION; UNITS; STRAND	The steady-state levels of all mature transcripts expressed in bacteria and yeast have been cataloged, but we do not yet know the numbers of nascent transcripts and so RNA polymerases engaged on all genes. Such catalogs are presented here. As mRNA levels depend on the balance between synthesis and degradation, we use published data to calculate the numbers of engaged polymerases required to maintain these levels in the face of the known rate of degradation. Most genes, including essential ones, prove not to be transcribed most of the time, and many produce only one message per cell cycle. Some cells even fail to produce an essential message during a cycle, and so must depend on their mother's messages and/or proteins for survival. We speculate that evolution sets the rate of message production so low to conserve energy, minimize transcription-induced mutation, and permit regulation over the widest range.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Cook, PR (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	peter.cook@path.ox.ac.uk		Cook, Peter/0000-0002-6639-188X; McGowan, Simon/0000-0001-9720-1914				Beletskii A, 1996, P NATL ACAD SCI USA, V93, P13919, DOI 10.1073/pnas.93.24.13919; Bernstein JA, 2002, P NATL ACAD SCI USA, V99, P9697, DOI 10.1073/pnas.112318199; BEYER AL, 1981, J MOL BIOL, V147, P269, DOI 10.1016/0022-2836(81)90441-1; Bremer H, 1996, ESCHERICHIA COLI SAL; CONDON C, 1995, J BACTERIOL, V177, P4152, DOI 10.1128/jb.177.14.4152-4156.1995; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; FAKAN S, 1986, J CELL BIOL, V103, P1153, DOI 10.1083/jcb.103.4.1153; Femino A, 1998, SCIENCE, V280, P585, DOI 10.1126/science.280.5363.585; FRENCH SL, 1989, J BACTERIOL, V171, P4207, DOI 10.1128/JB.171.8.4207-4216.1989; Gerdes SY, 2003, J BACTERIOL, V185, P5673, DOI 10.1128/JB.185.19.5673-5684.2003; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Hsu LM, 2002, BBA-GENE STRUCT EXPR, V1577, P191, DOI 10.1016/S0167-4781(02)00452-9; Jackson DA, 2000, FASEB J, V14, P242, DOI 10.1096/fasebj.14.2.242; Jackson DA, 1998, MOL BIOL CELL, V9, P1523, DOI 10.1091/mbc.9.6.1523; Kimura H, 2002, J CELL BIOL, V159, P777, DOI 10.1083/jcb.200206019; LAIRD CD, 1976, CHROMOSOMA, V58, P193, DOI 10.1007/BF00701359; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; MCKNIGHT SL, 1979, CELL, V17, P551; OBRIEN T, 1991, MOL CELL BIOL, V11, P5285, DOI 10.1128/MCB.11.10.5285; OSHEIM YN, 1985, CELL, V43, P143, DOI 10.1016/0092-8674(85)90019-4; Rosenfeld N, 2005, SCIENCE, V307, P1962, DOI 10.1126/science.1106914; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; WOLGEMUTH DJ, 1981, J MOL BIOL, V147, P247, DOI 10.1016/0022-2836(81)90440-X	27	34	35	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1721	+		10.1096/fj.06-6087fje	http://dx.doi.org/10.1096/fj.06-6087fje			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16818468				2022-12-25	WOS:000240266600027
J	Bourette, RP; Grasset, MF; Mouchiroud, G				Bourette, R. P.; Grasset, M-F; Mouchiroud, G.			E2a/Pbx1 oncogene inhibits terminal differentiation but not myeloid potential of pro-T cells	ONCOGENE			English	Article						leukemia; hematopoiesis; differentiation	STIMULATING FACTOR-RECEPTOR; HEMATOPOIETIC PROGENITORS; ACUTE LEUKEMIAS; TRANSCRIPTION FACTORS; INTERACTING PROTEIN; LINEAGE COMMITMENT; MARROW CULTURES; FDC-P1 CELLS; IN-VITRO; GENE	E2a/Pbx1 is a fusion oncoprotein resulting from the t(1; 19) translocation found in human pre-B acute lymphocytic leukemia and in a small number of acute T-lymphoid and myeloid leukemias. It was previously suggested that E2a/Pbx1 could cooperate with normal or oncogenic signaling pathways to immortalize myeloid and lymphoid progenitor cells. To address this question, we introduced the receptor of the macrophage-colony-stimulating factor (M-CSF-R) in pro-T cells immortalized by a conditional, estradiol-dependent, E2a/Pbx1-protein, and continuously proliferating in response to stem cell factor and interleukin-7. We asked whether M-CSF-R would be functional in an early T progenitor cell and influence the fate of E2a/Pbx1-immortalized cells. E2a-Pbx1 immortalized pro-T cells could proliferate and shifted from lymphoid to myeloid lineage after signaling through exogenously expressed M-CSF-R, irrespective of the presence of estradiol. However, terminal macrophage differentiation of the cells was obtained only when estradiol was withdrawn from cultures. This demonstrated that M-CSF-R is functional for proliferation and differentiation signaling in a T-lymphoid progenitor cell, which, in addition, unveiled myeloid potential of pro-T progenitors. Moreover, the block of differentiation induced by the E2a/Pbx1 oncogene could be modulated by hematopoietic cytokines such as M-CSF, suggesting plasticity of leukemic progenitor cells. Finally, additional experiments suggested that PU.1 and eight twenty-one transcriptional regulators might be implicated in the mechanisms of oncogenesis by E2a/Pbx1.	CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS)	Bourette, RP (corresponding author), CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, 16 Rue Dubois, F-69622 Villeurbanne, France.	bourette@biomserv.univ-lyon1.fr	Bourette, Roland/ABB-3343-2020; Mouchiroud, Guy/K-1153-2018	Bourette, Roland/0000-0003-2074-4878				ARNAUD S, 2002, BMC IMMUNOL, V3, P15; Bakri Y, 2005, BLOOD, V105, P2707, DOI 10.1182/blood-2004-04-1448; Balciunaite G, 2005, BLOOD, V105, P1930, DOI 10.1182/blood-2004-08-3087; Beutler B, 2003, J LEUKOCYTE BIOL, V74, P479, DOI 10.1189/jlb.0203082; BORZILLO GV, 1989, MOL CELL BIOL, V9, P3973, DOI 10.1128/MCB.9.9.3973; Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; Bourgin C, 2000, FEBS LETT, V480, P113, DOI 10.1016/S0014-5793(00)01906-2; Calabi F, 2001, MOL CELL BIOL, V21, P5658, DOI 10.1128/MCB.21.16.5658-5666.2001; Carnicer MJ, 2004, LEUKEMIA RES, V28, P19, DOI 10.1016/S0145-2126(03)00125-5; CARROLL AJ, 1984, BLOOD, V63, P721; Chen D, 2001, EXP HEMATOL, V29, P971, DOI 10.1016/S0301-472X(01)00670-1; CHENG GY, 1986, J EXP MED, V163, P414, DOI 10.1084/jem.163.2.414; Chevallier N, 2004, BLOOD, V103, P1454, DOI 10.1182/blood-2003-06-2081; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; Dakic A, 2005, J EXP MED, V201, P1487, DOI 10.1084/jem.20050075; Davis JN, 2003, GENE, V303, P1, DOI 10.1016/S0378-1119(02)01172-1; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; Du Y, 2002, EXP HEMATOL, V30, P649, DOI 10.1016/S0301-472X(02)00817-2; Duval D, 2000, FASEB J, V14, P1577, DOI 10.1096/fj.14.11.1577; Erickson PF, 1996, BLOOD, V88, P1813; Follows GA, 2005, ONCOGENE, V24, P3643, DOI 10.1038/sj.onc.1208655; Fukuyama T, 2001, ONCOGENE, V20, P6225, DOI 10.1038/sj.onc.1204794; Gilliland D Gary, 2004, Hematology Am Soc Hematol Educ Program, P80; Gosse SG, 2005, CELL SIGNAL, V17, P1352, DOI 10.1016/j.cellsig.2005.02.002; HOFFBRAND AV, 1988, BLOOD REV, V2, P9, DOI 10.1016/0268-960X(88)90003-3; Ibanez V, 2004, CANCER RES, V64, P4547, DOI 10.1158/0008-5472.CAN-03-3689; Iwasaki-Arai J, 2003, J EXP MED, V197, P1311, DOI 10.1084/jem.20021843; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1994, ONCOGENE, V9, P3159; Katsura Y, 2002, NAT REV IMMUNOL, V2, P127, DOI 10.1038/nri721; Kelly LM, 2000, EMBO J, V19, P1987, DOI 10.1093/emboj/19.9.1987; King AG, 2002, P NATL ACAD SCI USA, V99, P4508, DOI 10.1073/pnas.072087899; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kondo M, 2000, NATURE, V407, P383, DOI 10.1038/35030112; Krause DS, 2002, ONCOGENE, V21, P3262, DOI 10.1038/sj.onc.1205316; Lacaud G, 2002, BLOOD, V100, P458, DOI 10.1182/blood-2001-12-0321; Lee CK, 2001, J IMMUNOL, V166, P5964, DOI 10.4049/jimmunol.166.10.5964; Lindberg SR, 2005, EXP HEMATOL, V33, P189, DOI 10.1016/j.exphem.2004.10.011; Lodie TA, 1997, J IMMUNOL, V158, P1848; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Mancini A, 2004, ONCOGENE, V23, P6581, DOI 10.1038/sj.onc.1207841; Matsuoka T, 2003, MOL CELL BIOL, V23, P6049, DOI 10.1128/MCB.23.17.6049-6062.2003; Metcalf D, 1998, BLOOD, V92, P345, DOI 10.1182/blood.V92.2.345b.Con2_345_347; Nutt SL, 2005, J EXP MED, V201, P221, DOI 10.1084/jem.20041535; Pawlak G, 2000, EXP HEMATOL, V28, P1164, DOI 10.1016/S0301-472X(00)00522-1; Rochford JJ, 2004, MOL CELL BIOL, V24, P9863, DOI 10.1128/MCB.24.22.9863-9872.2004; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; Sasmono RT, 2003, BLOOD, V101, P1155, DOI 10.1182/blood-2002-02-0569; Scheijen B, 2002, ONCOGENE, V21, P3314, DOI 10.1038/sj.onc.1205317; STANLEY ER, 1994, STEM CELLS, V12, P15; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; Sykes DB, 2004, MOL CELL BIOL, V24, P1256, DOI 10.1128/MCB.24.3.1256-1269.2004; Sykes DB, 2003, LEUKEMIA LYMPHOMA, V44, P1187, DOI 10.1080/1042819031000090273; Sykes DB, 2001, BLOOD, V98, P2308, DOI 10.1182/blood.V98.8.2308; Tagoh H, 2002, GENE DEV, V16, P1721, DOI 10.1101/gad.222002; Tamura T, 1999, ONCOGENE, V18, P6488, DOI 10.1038/sj.onc.1203062; TORRES H, 1990, LEUKEMIA, V4, P673; TROUSSARD X, 1995, BRIT J HAEMATOL, V89, P516, DOI 10.1111/j.1365-2141.1995.tb08357.x; Zheng R, 2004, LEUKEMIA RES, V28, P121, DOI 10.1016/S0145-2126(03)00184-X; Zheng R, 2004, BLOOD, V103, P267, DOI 10.1182/blood-2003-06-1969; Zhu J, 2002, ONCOGENE, V21, P3295, DOI 10.1038/sj.onc.1205318	63	15	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	2					234	247		10.1038/sj.onc.1209777	http://dx.doi.org/10.1038/sj.onc.1209777			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819510				2022-12-25	WOS:000243398300007
J	Lallemand, C; Blanchard, B; Palmieri, M; Lebon, P; May, E; Tovey, MG				Lallemand, C.; Blanchard, B.; Palmieri, M.; Lebon, P.; May, E.; Tovey, M. G.			Single-stranded RNA viruses inactivate the transcriptional activity of p53 but induce NOXA-dependent apoptosis via post-translational modifications of IRF-1, IRF-3 and CREB	ONCOGENE			English	Article						NOXA; p53; IRF-1; IRF-3; virus	INDEPENDENT PHOSPHOLIPASE A(2); OXIDE SYNTHASE EXPRESSION; REGULATORY FACTOR-I; GENE-EXPRESSION; ANTIVIRAL RESPONSE; BH3-ONLY PROTEINS; FACTOR DRAF1; INTERFERON; CELLS; ACTIVATION	To characterize the mechanisms underlying apoptosis induced by viral infection, transcriptional activation of genes encoding members of the 'BH3-only' family of proteins was analysed during the course of virus infection. Among these genes, only NOXA is transcriptionally activated by vesicular stomatitis virus (VSV), sendai virus (SV), measles virus, herpes simplex virus, or dsRNA and required for efficient apoptosis of cells. Transcriptional activation of NOXA by VSV or SV is independent of p53, but requires the presence of interferon regulatory factor 1 (IRF-1), IRF-3 and cAMP-responsive element binding protein (CREB). Binding to and transactivation of the NOXA promoter by each of these transcription factors is governed by post-translational modi. cation involving different pathways for each factor. Thus, SV infection activates IRF-3and CREB by phosphorylation triggered by Toll like receptor 3 signalling, and a pathway involving calcium-independent phopholipase A2, respectively. In addition transactivation induced by IRF-1 during viral infection correlates with a 10 kDa increase in its molecular weight, suggesting a covalent linkage with a previously unknown regulatory polypeptide.	Inst Andre Lwoff, Lab Viral Oncol, UPR 9045, CNRS, F-94801 Villejuif, France; Univ Verona, Sez Chim Biol, Dipartimento Sci Morfol Biomed, I-37100 Verona, Italy; Univ Paris 05, Hop Cochin, Virol Lab, Paris, France	Centre National de la Recherche Scientifique (CNRS); University of Verona; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Lallemand, C (corresponding author), Inst Andre Lwoff, Lab Viral Oncol, UPR 9045, CNRS, 7 Rue Guy Moquet, F-94801 Villejuif, France.	lalleman@vjf.cnrs.fr		lallemand, christophe/0000-0001-5965-2482; Tovey, Michael/0000-0002-3058-0494				Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189; Bouker KB, 2004, CANCER RES, V64, P4030, DOI 10.1158/0008-5472.CAN-03-3602; Castelli JC, 1997, J EXP MED, V186, P967, DOI 10.1084/jem.186.6.967; Chow WA, 2000, J IMMUNOL, V164, P3512, DOI 10.4049/jimmunol.164.7.3512; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Geiss G, 2001, J BIOL CHEM, V276, P30178, DOI 10.1074/jbc.C100137200; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; Licata JM, 2003, INT REV IMMUNOL, V22, P451, DOI 10.1080/08830180305217; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lyles DS, 2000, MICROBIOL MOL BIOL R, V64, P709, DOI 10.1128/MMBR.64.4.709-724.2000; Maggi LB, 2002, J BIOL CHEM, V277, P38449, DOI 10.1074/jbc.M206247200; Marques JT, 2005, J VIROL, V79, P11105, DOI 10.1128/JVI.79.17.11105-11114.2005; Martinson BD, 2003, J LIPID RES, V44, P1686, DOI 10.1194/jlr.M300018-JLR200; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Miro-Mur F, 2003, ONCOGENE, V22, P5451, DOI 10.1038/sj.onc.1206538; Moehler M, 2001, CANCER GENE THER, V8, P158, DOI 10.1038/sj.cgt.7700288; Moran JM, 2005, J BIOL CHEM, V280, P28162, DOI 10.1074/jbc.M500013200; Moro A, 2000, BIOCHEM BIOPH RES CO, V269, P31, DOI 10.1006/bbrc.2000.2256; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Nakagawa K, 2000, EUR J BIOCHEM, V267, P1680, DOI 10.1046/j.1432-1327.2000.01163.x; Nakagawa K, 2002, FEBS LETT, V530, P204, DOI 10.1016/S0014-5793(02)03486-5; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Ruiz-Ruiz C, 2004, J BIOL CHEM, V279, P19712, DOI 10.1074/jbc.M313023200; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Sun YP, 2005, J BIOL CHEM, V280, P15561, DOI 10.1074/jbc.m412630200; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; Tanaka N, 1998, GENES CELLS, V3, P29, DOI 10.1046/j.1365-2443.1998.00164.x; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Weaver BK, 2001, FASEB J, V15, P501, DOI 10.1096/fj.00-0222com; Williams SD, 2001, AM J PHYSIOL-HEART C, V281, pH168, DOI 10.1152/ajpheart.2001.281.1.H168; Xie RL, 2001, J BIOL CHEM, V276, P18624, DOI 10.1074/jbc.M010391200; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yoneyama Mitsutoshi, 2004, Uirusu, V54, P161, DOI 10.2222/jsv.54.161	41	45	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					328	338		10.1038/sj.onc.1209795	http://dx.doi.org/10.1038/sj.onc.1209795			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832344				2022-12-25	WOS:000243544000002
J	Hajjar, E; Perahia, D; Debat, H; Nespoulous, C; Robert, CH				Hajjar, Eric; Perahia, David; Debat, Helene; Nespoulous, Claude; Robert, Charles H.			Odorant binding and conformational dynamics in the odorant-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPLICIT SOLVENT MODELS; MOLECULAR-DYNAMICS; BETA-LACTOGLOBULIN; FREE-ENERGY; COMPUTER-SIMULATIONS; OLFACTORY RECEPTOR; MEAN FORCE; LIGAND; THERMODYNAMICS; TRANSTHYRETIN	In mammals, the olfactory epithelium secretes odorantbinding proteins ( OBPs), which are lipocalins found freely dissolved in the mucus layer protecting the olfactory neurons. OBPs may act as passive transporters of predominantly hydrophobic odorant molecules across the aqueous mucus layer, or they may play a more active role in which the olfactory neuronal receptor recognizes the OBP- ligand complex. To better understand the molecular events accompanying the initial steps in the olfaction process, we have performed molecular dynamics studies of rat and pig OBPs with the odorant molecule thymol. These calculations provide an atomic level description of conformational changes and pathway intermediates that remain difficult to study directly. A series of eight independent molecular dynamics trajectories of rat OBP permitted the observation of a consensus pathway for ligand unbinding and the calculation of the potential of mean force ( PMF) along this path. Titration microcalorimetry confirmed the specific binding of thymol to this protein with a strong hydrophobic component. In both rat and pig OBPs we observed lipocalin strand pair opening in the presence of ligand, consistent with potential roles of these proteins in olfactive receptor recognition.	Univ Paris 11, CNRS, MIP, UMR8619 Modelisat & Ingn Prot, F-91405 Orsay, France; French Natl Inst Agr Res, NOPA, BOG, F-78352 Jouy En Josas, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Robert, CH (corresponding author), Univ Paris 11, CNRS, MIP, UMR8619 Modelisat & Ingn Prot, Bat 430, F-91405 Orsay, France.		Perahia, David/A-4277-2016	Perahia, David/0000-0001-7480-3349; Robert, Charles/0000-0003-0337-1504; DEBAT, Helene/0000-0003-0020-2748				Beck DAC, 2005, BIOCHEMISTRY-US, V44, P609, DOI 10.1021/bi0486381; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Blanchet MA, 1996, NAT STRUCT BIOL, V3, P934, DOI 10.1038/nsb1196-934; Briand L, 2000, EUR J BIOCHEM, V267, P3079, DOI 10.1046/j.1432-1033.2000.01340.x; BROOKS BR, 1983, J COMPUT CHEM, V93, P2487; Chau PL, 2001, CHEM PHYS LETT, V334, P343, DOI 10.1016/S0009-2614(00)01427-5; Chorny I, 2005, J PHYS CHEM B, V109, P24056, DOI 10.1021/jp055043m; Feig M, 2004, CURR OPIN STRUC BIOL, V14, P217, DOI 10.1016/j.sbi.2004.03.009; Ferrara P, 2002, PROTEINS, V46, P24, DOI 10.1002/prot.10001; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P46, DOI 10.1016/S0167-4838(00)00147-3; Forge V, 2000, J MOL BIOL, V296, P1039, DOI 10.1006/jmbi.1999.3515; Garemyr R, 1999, PROTEINS, V37, P417, DOI 10.1002/(SICI)1097-0134(19991115)37:3<417::AID-PROT9>3.0.CO;2-U; Gilson MK, 1997, BIOPHYS J, V72, P1047, DOI 10.1016/S0006-3495(97)78756-3; Goleblowski J, 2006, J MOL STRUC-THEOCHEM, V763, P165, DOI 10.1016/j.theochem.2006.01.013; Grubmuller H., 1996, SOLVATE 1 0; Hamada D, 1996, NAT STRUCT BIOL, V3, P868, DOI 10.1038/nsb1096-868; JORGENSEN WL, 1990, J AM CHEM SOC, V112, P4768, DOI 10.1021/ja00168a022; Korndorfer IP, 2003, J MOL BIOL, V330, P385, DOI 10.1016/S0022-2836(03)00573-4; Kosztin I, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2166379; KUMAR S, 1992, J COMPUT CHEM, V13, P1011, DOI 10.1002/jcc.540130812; Kuwata K, 2001, J MOL BIOL, V305, P1073, DOI 10.1006/jmbi.2000.4350; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lazar J, 2002, BIOCHEMISTRY-US, V41, P11786, DOI 10.1021/bi0256734; Lazaridis T, 1999, PROTEINS, V35, P133, DOI 10.1002/(SICI)1097-0134(19990501)35:2<133::AID-PROT1>3.0.CO;2-N; Lobel D, 2001, CHEM SENSES, V26, P673, DOI 10.1093/chemse/26.6.673; Lobel D, 1998, EUR J BIOCHEM, V254, P318, DOI 10.1046/j.1432-1327.1998.2540318.x; Matarazzo V, 2002, CHEM SENSES, V27, P691, DOI 10.1093/chemse/27.8.691; Monaco HL, 2000, BBA-PROTEIN STRUCT M, V1482, P65, DOI 10.1016/S0167-4838(00)00140-0; MONACO HL, 1995, SCIENCE, V268, P1039, DOI 10.1126/science.7754382; Nespoulous C, 2004, CHEM SENSES, V29, P189, DOI 10.1093/chemse/bjh017; Norberg J, 2003, Q REV BIOPHYS, V36, P257, DOI 10.1017/S0033583503003895; Paci E, 2005, FEBS J, V272, P4826, DOI 10.1111/j.1742-4658.2005.04898.x; Pelosi P, 1996, J NEUROBIOL, V30, P3; Ponder JW, 2003, ADV PROTEIN CHEM, V66, P27; Pophof B, 2002, NATURWISSENSCHAFTEN, V89, P515, DOI 10.1007/s00114-002-0364-5; Qin BY, 1998, BIOCHEMISTRY-US, V37, P14014, DOI 10.1021/bi981016t; Ramoni R, 2002, BIOCHEM J, V365, P739, DOI 10.1042/BJ20011631; Resat H, 1997, BIOPHYS J, V72, P522, DOI 10.1016/S0006-3495(97)78692-2; ROBERT CH, 1988, BIOCHEMISTRY-US, V27, P6829, DOI 10.1021/bi00418a027; ROUX B, 1995, COMPUT PHYS COMMUN, V91, P275, DOI 10.1016/0010-4655(95)00053-I; Roux B, 1999, BIOPHYS CHEM, V78, P1, DOI 10.1016/S0301-4622(98)00226-9; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Spinelli S, 1998, BIOCHEMISTRY-US, V37, P7913, DOI 10.1021/bi980179e; Swanson JMJ, 2004, BIOPHYS J, V86, P67, DOI 10.1016/S0006-3495(04)74084-9; Tegoni M, 2004, TRENDS BIOCHEM SCI, V29, P257, DOI 10.1016/j.tibs.2004.03.003; Tegoni M, 1996, NAT STRUCT BIOL, V3, P863, DOI 10.1038/nsb1096-863; Vincent F, 2000, J MOL BIOL, V300, P127, DOI 10.1006/jmbi.2000.3820; Woo HJ, 2005, P NATL ACAD SCI USA, V102, P6825, DOI 10.1073/pnas.0409005102; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4	50	41	41	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29929	29937		10.1074/jbc.M604869200	http://dx.doi.org/10.1074/jbc.M604869200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16849331	hybrid, Green Published			2022-12-25	WOS:000240896300054
J	Maia, LF; Soares, MR; Valente, AP; Almeida, FCL; Oliveira, AC; Gomes, AMO; Freitas, MS; Schneemann, A; Johnson, JE; Silva, JL				Maia, Lenize F.; Soares, Marcia R.; Valente, Ana P.; Almeida, Fabio C. L.; Oliveira, Andrea C.; Gomes, Andre M. O.; Freitas, Monica S.; Schneemann, Anette; Johnson, John E.; Silva, Jerson L.			Structure of a membrane-binding domain from a non-enveloped animal virus - Insights into the mechanism of membrane permeability and cellular entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSION PEPTIDE; FUNCTIONAL IMPLICATIONS; PORE FORMATION; HEMAGGLUTININ; SPECTROSCOPY; PROGRAM; MODELS; HELIX	The gamma 1-peptide is a 21-residue lipid-binding domain from the non-enveloped Flock House virus (FHV). Unlike enveloped viruses, the entry of non-enveloped viruses into cells is believed to occur without membrane fusion. In this study, we performed NMR experiments to establish the solution structure of a membrane-binding peptide from a small non-enveloped icosahedral virus. The three-dimensional structure of the FHV gamma(1)-domain was determined at pH 6.5 and 4.0 in a hydrophobic environment. The secondary and tertiary structures were evaluated in the context of the capacity of the peptide for permeabilizing membrane vesicles of different lipid composition, as measured by fluorescence assays. At both pH values, the peptide has a kinked structure, similar to the fusion domain from the enveloped viruses. The secondary structure was similar in three different hydrophobic environments as follows: water/trifluoroethanol, SDS, and membrane vesicles of different compositions. The ability of the peptide to induce vesicle leakage was highly dependent on the membrane composition. Although the gamma-peptide shares some structural properties to fusion domains of enveloped viruses, it did not induce membrane fusion. Our results suggest that small protein components such as the gamma-peptide in nodaviruses (such as FHV) and VP4 in picornaviruses have a crucial role in conducting nucleic acids through cellular membranes and that their structures resemble the fusion domains of membrane proteins from enveloped viruses.	Univ Fed Rio de Janeiro, Programa Biol Estrutrural, Inst Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Ctr Nacl Ressonancia Magnet Nucl Jiri Jonas, BR-21941590 Rio De Janeiro, Brazil; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Scripps Research Institute	Silva, JL (corresponding author), Univ Fed Rio de Janeiro, Programa Biol Estrutrural, Inst Bioquim Med, BR-21941590 Rio De Janeiro, Brazil.	jerson@bioqmed.ufrj.br	SILVA, JERSON Lima/GRF-1442-2022; de Freitas, Mônica Santos/E-8540-2015; Valente, Ana Paula/J-3010-2017; Silva, Jerson/J-8984-2014; Almeida, Fabio/O-4989-2018; Maia, Lenize F./N-9420-2013; Gomes, Andre M.O./C-4009-2014; Oliveira, Andrea C/O-6695-2018; Johnson, Johnson/HDL-9124-2022	SILVA, JERSON Lima/0000-0001-9523-9441; de Freitas, Mônica Santos/0000-0003-3105-7918; Valente, Ana Paula/0000-0001-7219-1123; Silva, Jerson/0000-0001-9523-9441; Almeida, Fabio/0000-0001-6046-7006; Maia, Lenize F./0000-0002-7433-4156; Gomes, Andre M.O./0000-0003-1052-8004; Soares, Marcia/0000-0001-9272-9488				AUE WP, 1976, J CHEM PHYS, V64, P4226, DOI 10.1063/1.431994; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bong DT, 1999, CHEM BIOL, V6, P473, DOI 10.1016/S1074-5521(99)80065-9; Chang DK, 1997, J VIROL, V71, P6593, DOI 10.1128/JVI.71.9.6593-6602.1997; CHENG RH, 1994, STRUCTURE, V2, P271; Corcoran JA, 2004, J BIOL CHEM, V279, P51386, DOI 10.1074/jbc.M406990200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; Epand RM, 2003, BBA-BIOMEMBRANES, V1614, P116, DOI 10.1016/S0005-2736(03)00169-X; FISHER AJ, 1993, NATURE, V361, P176, DOI 10.1038/361176a0; FRICKS CE, 1990, J VIROL, V64, P1934, DOI 10.1128/JVI.64.5.1934-1945.1990; Glaser RW, 1999, BIOCHEMISTRY-US, V38, P2560, DOI 10.1021/bi982130e; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; Harrison Stephen C., 1996, P59; Hinz A, 2005, EUR BIOPHYS J BIOPHY, V34, P285, DOI 10.1007/s00249-004-0450-z; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Hsu CH, 2002, J BIOL CHEM, V277, P22725, DOI 10.1074/jbc.M200089200; Huang CY, 2002, P NATL ACAD SCI USA, V99, P2788, DOI 10.1073/pnas.052700099; Janshoff A, 1999, BIOCHEMISTRY-US, V38, P5328, DOI 10.1021/bi982976i; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Johnson JE, 1996, P NATL ACAD SCI USA, V93, P27, DOI 10.1073/pnas.93.1.27; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lai AL, 2006, J BIOL CHEM, V281, P5760, DOI 10.1074/jbc.M512280200; LEAR JD, 1988, SCIENCE, V240, P1177, DOI 10.1126/science.2453923; Li YM, 2005, P NATL ACAD SCI USA, V102, P7529, DOI 10.1073/pnas.0408749102; Marheineke K, 1998, FEBS LETT, V441, P49, DOI 10.1016/S0014-5793(98)01523-3; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MILLHAUSER GL, 1995, BIOCHEMISTRY-US, V34, P3873, DOI 10.1021/bi00012a001; Nicol F, 2000, BIOPHYS J, V78, P818, DOI 10.1016/S0006-3495(00)76639-2; Nieva JL, 2003, BBA-BIOMEMBRANES, V1614, P104, DOI 10.1016/S0005-2736(03)00168-8; Oliveira AC, 2000, J BIOL CHEM, V275, P16037, DOI 10.1074/jbc.M910145199; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Rex S, 1996, BIOPHYS CHEM, V58, P75, DOI 10.1016/0301-4622(95)00087-9; Rohl CA, 1996, PROTEIN SCI, V5, P1687, DOI 10.1002/pro.5560050822; Rossmann MG, 2000, VIROLOGY, V269, P239, DOI 10.1006/viro.2000.0258; Schievano E, 2004, BIOCHEMISTRY-US, V43, P9343, DOI 10.1021/bi0496438; Schneemann A, 1998, J VIROL, V72, P8738, DOI 10.1128/JVI.72.11.8738-8746.1998; SCHNEEMANN A, 1992, J VIROL, V66, P6728, DOI 10.1128/JVI.66.11.6728-6734.1992; Schneemann A, 1998, ADV VIRUS RES, V50, P381, DOI 10.1016/S0065-3527(08)60812-X; Schwarcz WD, 2004, CELL MOL BIOL, V50, P419; Shmulevitz M, 2004, J VIROL, V78, P2808, DOI 10.1128/JVI.78.6.2808-2818.2004; Smith AE, 2004, SCIENCE, V304, P237, DOI 10.1126/science.1094823; Tihova M, 2001, J MOL BIOL, V314, P985, DOI 10.1006/jmbi.2000.5238; Wang LT, 2005, PROTEIN SCI, V14, P1661, DOI 10.1110/ps.051390405; WUTHRICK K, 1986, PROTEINS NUCL ACIDS	47	25	25	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29278	29286		10.1074/jbc.M604689200	http://dx.doi.org/10.1074/jbc.M604689200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16861222	hybrid			2022-12-25	WOS:000240680500083
J	Muller, HK; Wiborg, O; Haase, J				Muller, Heidi Kaastrup; Wiborg, Ove; Haase, Jana			Subcellular redistribution of the serotonin transporter by secretory carrier membrane protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER MEMBRANE-PROTEINS; BIOGENIC-AMINE TRANSPORTERS; CELL-SURFACE; SYNTAXIN 1A; KINASE-C; NEUROTRANSMITTER TRANSPORTERS; NOREPINEPHRINE TRANSPORTER; GABA TRANSPORTERS; SCAMP1 FUNCTION; TRAFFICKING	The serotonin transporter (SERT) belongs to the SLC6 family of sodium- and chloride-dependent neurotransmitter transporters responsible for uptake of amino acids and biogenic amines from extracellular spaces. Their activities and subcellular distributions are regulated by various cellular mechanisms, including interactions with other proteins. Using the yeast two-hybrid approach we screened a human brain cDNA library and identified secretory carrier membrane protein 2 (SCAMP2) as a novel SERT-interacting protein. GST-pulldown assays confirmed the physical interaction between SCAMP2 and the N-terminal domain of SERT. In addition, SERT was found to form a complex with SCAMP2 as demonstrated by co-immunoprecipitation from a heterologous expression system and from rat brain homogenate. Co-expression of SERT and SCAMP2 in mammalian cells results in the subcellular redistribution of SERT with a decrease in cell surface SERT and a concomitant reduction in 5-HT uptake activity. Using confocal microscopy we show that in neuronal cells endogenous SERT co-localizes with SCAMP2 in discrete structures also containing the lipid raft marker flotillin-1 and the SNARE protein syntaxin 1A. In contrast, SERT immunoreactivity is clearly segregated from transferrin receptor-containing endosomes. A single amino acid mutation, cysteine-201 to alanine, within the conserved cytoplasmic E peptide of SCAMP2, abolished SCAMP2-mediated down-regulation of SERT, although this mutation had no effect on the physical interaction between SERT and SCAMP2. Taken together, our results suggest that SCAMP2 plays an important role in the regulation of the subcellular distribution of SERT.	Univ Coll Dublin, Sch Biomol & Biomed Sci, Conway Inst, Dublin 4, Ireland; Univ Dublin Trinity Coll, Dublin 2, Ireland; Arhus Psychiat Univ Hosp, Ctr Basic Psychiat Res, DK-8240 Risskov, Denmark	University College Dublin; Trinity College Dublin; Aarhus University	Haase, J (corresponding author), Univ Coll Dublin, Sch Biomol & Biomed Sci, Conway Inst, Dublin 4, Ireland.	jana.haase@ucd.ie	Haase, Jana/C-1210-2008	Haase, Jana/0000-0002-5949-8355; Kaastrup Muller, Heidi/0000-0002-9842-8114				Bauman AL, 2000, J NEUROSCI, V20, P7571; Beckman ML, 1998, J NEUROSCI, V18, P6103; Blakely RD, 2000, CURR OPIN NEUROBIOL, V10, P328, DOI 10.1016/S0959-4388(00)00088-X; BRAND SH, 1991, J BIOL CHEM, V266, P18949; BRAND SH, 1993, EMBO J, V12, P3753, DOI 10.1002/j.1460-2075.1993.tb06053.x; Castle A, 2005, J CELL SCI, V118, P3769, DOI 10.1242/jcs.02503; Chen NH, 2004, PFLUG ARCH EUR J PHY, V447, P519, DOI 10.1007/s00424-003-1064-5; Deken SL, 2000, NAT NEUROSCI, V3, P998, DOI 10.1038/79939; Deken SL, 2003, J NEUROSCI, V23, P1563; Eaton M, 1996, EXP NEUROL, V140, P105, DOI 10.1006/exnr.1996.0121; Fernandez-Chacon R, 2000, J BIOL CHEM, V275, P12752, DOI 10.1074/jbc.275.17.12752; Fernandez-Chacon R, 1999, J BIOL CHEM, V274, P32551, DOI 10.1074/jbc.274.46.32551; Gagescu R, 2000, MOL BIOL CELL, V11, P2775, DOI 10.1091/mbc.11.8.2775; Geerlings A, 2001, J BIOL CHEM, V276, P17584, DOI 10.1074/jbc.M010602200; Glebov OO, 2006, NAT CELL BIOL, V8, P46, DOI 10.1038/ncb1342; Guo ZH, 2002, J BIOL CHEM, V277, P35357, DOI 10.1074/jbc.M202259200; Haase J, 2001, BIOCHEM SOC T, V29, P722, DOI 10.1042/BST0290722; Haass NK, 1996, J CELL BIOL, V134, P731, DOI 10.1083/jcb.134.3.731; Hubbard C, 2000, MOL BIOL CELL, V11, P2933, DOI 10.1091/mbc.11.9.2933; Iversen L, 2000, MOL PSYCHIATR, V5, P357, DOI 10.1038/sj.mp.4000728; Jayanthi LD, 2004, J BIOL CHEM, V279, P19315, DOI 10.1074/jbc.M311172200; Jess U, 2002, BIOCHEM BIOPH RES CO, V294, P272, DOI 10.1016/S0006-291X(02)00460-6; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; Liu LX, 2005, MOL BIOL CELL, V16, P4463, DOI 10.1091/mbc.E05-03-0231; Liu LX, 2002, MOL BIOL CELL, V13, P4266, DOI 10.1091/mbc.E02-03-0136; Magnani F, 2004, J BIOL CHEM, V279, P38770, DOI 10.1074/jbc.M400831200; Mortensen OV, 1999, MOL BRAIN RES, V68, P141, DOI 10.1016/S0169-328X(99)00083-2; Murphy DL, 2004, MOL INTERV, V4, P109, DOI 10.1124/mi.4.2.8; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; Quick MW, 2003, NEURON, V40, P537, DOI 10.1016/S0896-6273(03)00605-6; Robinson MB, 2002, J NEUROCHEM, V80, P1, DOI 10.1046/j.0022-3042.2001.00698.x; RUDNICK G, 1991, MOL PHARMACOL, V40, P421; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; Schloss P, 1998, J PSYCHOPHARMACOL, V12, P115, DOI 10.1177/026988119801200201; Singleton DR, 1997, J CELL SCI, V110, P2099; Sung U, 2003, J NEUROSCI, V23, P1697; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Zhu CB, 2004, MOL PHARMACOL, V65, P1462, DOI 10.1124/mol.65.6.1462	39	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28901	28909		10.1074/jbc.M602848200	http://dx.doi.org/10.1074/jbc.M602848200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16870614	hybrid			2022-12-25	WOS:000240680500044
J	Tan, AHM; Wong, SC; Lam, KP				Tan, Andy Hee-Meng; Wong, Siew-Cheng; Lam, Kong-Peng			Regulation of mouse inducible costimulator (ICOS) expression by Fyn-NFATc2 and ERK signaling in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULE ICOS; CUTTING EDGE; TRANSCRIPTIONAL REGULATION; CO-STIMULATION; CD28; DIFFERENTIATION; ACTIVATION; CD4(+); KINASE; NFAT	The inducible costimulator (ICOS), a member of the CD28 family of costimulatory molecules, is rapidly induced upon T cell activation. Although the critical role of ICOS in costimulating T cell responses is well documented, little is known of the intracellular signaling pathways and mechanisms that regulate ICOS expression. Here, we report that Fyn, NFAT, and ERK signaling influence ICOS expression as various chemical inhibitors, such as PP2 that targets Src kinases, U0126 that targets MEK1/2, and cyclosporin A or FK506 that targets calcineurin and thereby affects NFAT, attenuate T cell receptor-mediated ICOS induction. Moreover, ectopic expression of NFATc2 or a constitutively active MEK2 amplifies ICOS transcription and transactivates a 288-bp core region of the icos promoter in luciferase reporter assays. We also identify a site on the icos promoter that is sensitive to ERK signaling and further show that NFATc2 can bind the icos promoter in vivo and that this binding is diminished when Fyn signaling is ablated. The normal activation of ERK but reduced nuclear translocation of NFATc2 in Fyn(-/-) CD4(+) T cells further suggest that Fyn and NFATc2 act in a common axis, separate from that involving ERK, to drive ICOS transcription. Taken together, our findings indicate that Fyn-calcineurin-NFATc2 and MEK2-ERK1/2 are two independent signaling pathways that cooperate to control T cell receptor-mediated ICOS induction.	Singapore Inst Immunol, Lab Immune Regulat, Singapore 138673, Singapore		Lam, KP (corresponding author), Singapore Inst Immunol, Lab Immune Regulat, 61 Biopolis Dr, Singapore 138673, Singapore.	mcblamkp@imcb.a-star.edu.sg	Lam, Kong-Peng/G-5374-2012	Lam, Kong-Peng/0000-0002-1316-4333				Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Akiba H, 2005, J IMMUNOL, V175, P2340, DOI 10.4049/jimmunol.175.4.2340; Arimura Y, 2002, INT IMMUNOL, V14, P555, DOI 10.1093/intimm/dxf022; Beier KC, 2000, EUR J IMMUNOL, V30, P3707, DOI 10.1002/1521-4141(200012)30:12<3707::AID-IMMU3707>3.0.CO;2-Q; Burr JS, 2001, J IMMUNOL, V166, P5331, DOI 10.4049/jimmunol.166.9.5331; Cannons JL, 2004, IMMUNITY, V21, P693, DOI 10.1016/j.immuni.2004.09.012; Casolaro V, 2000, J BIOL CHEM, V275, P36605, DOI 10.1074/jbc.M007086200; Chambers CA, 2001, TRENDS IMMUNOL, V22, P217, DOI 10.1016/S1471-4906(01)01868-3; CIVIL A, 1995, RES IMMUNOL, V146, P158, DOI 10.1016/0923-2494(96)80250-1; Coyle AJ, 2000, IMMUNITY, V13, P95, DOI 10.1016/S1074-7613(00)00011-X; Coyle AJ, 2004, SPRINGER SEMIN IMMUN, V25, P349, DOI 10.1007/s00281-003-0154-y; Dong C, 2001, J IMMUNOL, V166, P3659, DOI 10.4049/jimmunol.166.6.3659; Dong C, 2001, NATURE, V409, P97, DOI 10.1038/35051100; FALTYNEK CR, 1995, BIOCHEMISTRY-US, V34, P12404, DOI 10.1021/bi00038a038; Frauwirth KA, 2002, J CLIN INVEST, V109, P295, DOI 10.1172/JCI200214941; FRUMAN DA, 1995, MOL CELL BIOL, V15, P3857; Gonzalo JA, 2001, NAT IMMUNOL, V2, P597, DOI 10.1038/89739; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; Harada H, 2003, J CLIN INVEST, V112, P234, DOI 10.1172/JCI200317008; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Hutloff A, 1999, NATURE, V397, P263, DOI 10.1038/16717; Ling V, 2001, GENOMICS, V78, P155, DOI 10.1006/geno.2001.6655; London CA, 2000, J IMMUNOL, V164, P265, DOI 10.4049/jimmunol.164.1.265; Loots GG, 2005, NUCLEIC ACIDS RES, V33, pW56, DOI 10.1093/nar/gki355; LUCAS PJ, 1995, J IMMUNOL, V154, P5757; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; McAdam AJ, 2000, J IMMUNOL, V165, P5035, DOI 10.4049/jimmunol.165.9.5035; McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107; Nurieva RI, 2003, IMMUNITY, V18, P801, DOI 10.1016/S1074-7613(03)00144-4; Ozkaynak E, 2001, NAT IMMUNOL, V2, P591, DOI 10.1038/89731; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rottman JB, 2001, NAT IMMUNOL, V2, P605, DOI 10.1038/89750; Rudd CE, 2003, NAT REV IMMUNOL, V3, P544, DOI 10.1038/nri1131; Sarafova S, 1999, J BIOL CHEM, V274, P16126, DOI 10.1074/jbc.274.23.16126; Schweitzer AN, 1997, J IMMUNOL, V158, P2713; Shilling RA, 2005, J IMMUNOL, V175, P2061, DOI 10.4049/jimmunol.175.4.2061; STEIN PH, 1994, MOL CELL BIOL, V14, P3392, DOI 10.1128/MCB.14.5.3392; Suh WK, 2004, J IMMUNOL, V172, P5917, DOI 10.4049/jimmunol.172.10.5917; Swallow MM, 1999, IMMUNITY, V11, P423, DOI 10.1016/S1074-7613(00)80117-X; Tafuri A, 2001, NATURE, V409, P105, DOI 10.1038/35051113; Warnatz K, 2006, BLOOD, V107, P3045, DOI 10.1182/blood-2005-07-2955; Wassink L, 2004, J IMMUNOL, V173, P1779, DOI 10.4049/jimmunol.173.3.1779; Whitmire JK, 2000, CURR OPIN IMMUNOL, V12, P448, DOI 10.1016/S0952-7915(00)00119-9; Yoshinaga SK, 1999, NATURE, V402, P827, DOI 10.1038/45582; Zheng Y, 2005, J IMMUNOL, V174, P3117, DOI 10.4049/jimmunol.174.5.3117	49	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28666	28678		10.1074/jbc.M604081200	http://dx.doi.org/10.1074/jbc.M604081200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16880206	hybrid			2022-12-25	WOS:000240680500020
J	Aas, FE; Egge-Jacobsen, W; Winther-Larsen, HC; Lovold, C; Hitchen, PG; Dell, A; Koomey, M				Aas, Finn Erik; Egge-Jacobsen, Wolfgang; Winther-Larsen, Hanne C.; Lovold, Cecilia; Hitchen, Paul G.; Dell, Anne; Koomey, Michael			Neisseria gonorrhoeae type IV pili undergo multisite, hierarchical modifications with phosphoethanolamine and phosphocholine requiring an enzyme structurally related to lipopolysaccharide phosphoethanolamine transferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEMATODE-SECRETED PRODUCT; HAEMOPHILUS-INFLUENZAE; STREPTOCOCCUS-PNEUMONIAE; FLAGELLIN GLYCOSYLATION; NATURAL TRANSFORMATION; PROTEIN GLYCOSYLATION; SALMONELLA-ENTERICA; MENINGOCOCCAL PILIN; MASS-SPECTROMETRY; INNER-CORE	The zwitterionic phospho-forms phosphoethanolamine and phosphocholine are recognized as influential and important substituents of pathogen cell surfaces. PilE, the major pilin subunit protein of the type IV pilus (Tfp) colonization factor of Neisseria gonorrhoeae undergoes unique, post-translational modifications with these moieties. These phospho-form modifications have been shown to be O-linked alternately to a specific, conserved serine residue of PilE. However, the enzymes and precursors involved in their addition are unknown, and the full spectrum of PilE post-translational modifications has yet to be defined. Here, an intact protein-based mass spectrometric approach was integrated with bioinformatics and reverse genetics to address these matters. Specifically we show that a protein limited in its distribution to pathogenic Neisseria species and structurally related to enzymes implicated in phosphoethanolamine modification of lipopolysaccharide is necessary for PilE covalent modification with phosphoethanolamine and phosphocholine. These findings strongly suggest that protein phospho-form modification is mechanistically similar to processes underlying analogous modifications of prokaryotic saccharolipid glycans. We also show that PilE undergoes multisite and hierarchical phospho-form modifications and that the stoichiometries of site occupancy can be influenced by PilE primary structure and the abundance of the pilin-like protein PilV. Together, these findings have important implications for the structure and antigenicity of PilE.	Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway; Univ Oslo, Ctr Mol Biol & Neurosci, N-0316 Oslo, Norway; Univ Oslo, Biotechnol Ctr Oslo, N-0317 Oslo, Norway; Univ London Imperial Coll Sci Technol & Med, Fac Nat Sci, Div Mol Biosci, London SW7 2AZ, England	University of Oslo; University of Oslo; University of Oslo; Imperial College London	Koomey, M (corresponding author), Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway.	johnk@imbv.uio.no		Koomey, Michael/0000-0001-5844-2344				Arora SK, 2005, INFECT IMMUN, V73, P4395, DOI 10.1128/IAI.73.7.4395-4398.2005; Benz I, 2001, MOL MICROBIOL, V40, P1403, DOI 10.1046/j.1365-2958.2001.02487.x; BOSLEGO JW, 1991, VACCINE, V9, P154, DOI 10.1016/0264-410X(91)90147-X; BRILES DE, 1992, INFECT IMMUN, V60, P1957, DOI 10.1128/IAI.60.5.1957-1962.1992; CLOSE TJ, 1982, GENE, V20, P305, DOI 10.1016/0378-1119(82)90048-8; Cox AD, 2003, J BACTERIOL, V185, P3270, DOI 10.1128/JB.185.11.3270-3277.2003; Craig L, 2004, NAT REV MICROBIOL, V2, P363, DOI 10.1038/nrmicro885; Cundell DR, 1996, ADV EXP MED BIOL, V416, P89; Deehan MR, 1998, J IMMUNOL, V160, P2692; Drake SL, 1995, MOL MICROBIOL, V18, P975, DOI 10.1111/j.1365-2958.1995.18050975.x; FREITAG NE, 1995, MOL MICROBIOL, V16, P575, DOI 10.1111/j.1365-2958.1995.tb02420.x; Grass S, 2003, MOL MICROBIOL, V48, P737, DOI 10.1046/j.1365-2958.2003.03450.x; Harnett MM, 1998, PARASITE IMMUNOL, V20, P551, DOI 10.1046/j.1365-3024.1998.00181.x; Hegge FT, 2004, P NATL ACAD SCI USA, V101, P10798, DOI 10.1073/pnas.0402397101; Hendrixson DR, 2004, MOL MICROBIOL, V52, P471, DOI 10.1111/j.1365-2958.2004.03988.x; KOOMEY JM, 1987, J BACTERIOL, V169, P790, DOI 10.1128/jb.169.2.790-795.1987; Lee H, 2004, J BACTERIOL, V186, P4124, DOI 10.1128/JB.186.13.4124-4133.2004; Mackinnon FG, 2002, MOL MICROBIOL, V43, P931, DOI 10.1046/j.1365-2958.2002.02754.x; PARGE HE, 1995, NATURE, V378, P32, DOI 10.1038/378032a0; Rahman MM, 2000, MICROBIOL-UK, V146, P1901, DOI 10.1099/00221287-146-8-1901; Reynolds CM, 2005, J BIOL CHEM, V280, P21202, DOI 10.1074/jbc.M500964200; Schirm M, 2005, ANAL CHEM, V77, P7774, DOI 10.1021/ac051316y; Schirm M, 2003, MOL MICROBIOL, V48, P1579, DOI 10.1046/j.1365-2958.2003.03527.x; Schmidt KA, 2001, SEX TRANSM DIS, V28, P555, DOI 10.1097/00007435-200110000-00001; Serino L, 2000, MOL MICROBIOL, V35, P1550, DOI 10.1046/j.1365-2958.2000.01825.x; Serino L, 2002, MOL MICROBIOL, V43, P437, DOI 10.1046/j.1365-2958.2002.02755.x; Snyder LAS, 2001, J BACTERIOL, V183, P1233, DOI 10.1128/JB.183.4.1233-1241.2001; Stimson E, 1996, BIOCHEM J, V316, P29, DOI 10.1042/bj3160029; STIMSON E, 1995, MOL MICROBIOL, V17, P1201, DOI 10.1111/j.1365-2958.1995.mmi_17061201.x; SUD IJ, 1975, J BACTERIOL, V124, P713, DOI 10.1128/JB.124.2.713-717.1975; Swords WE, 2001, CELL MICROBIOL, V3, P525, DOI 10.1046/j.1462-5822.2001.00132.x; Szymanski CM, 2005, NAT REV MICROBIOL, V3, P225, DOI 10.1038/nrmicro1100; Szymanski CM, 2002, INFECT IMMUN, V70, P2242, DOI 10.1128/IAI.70.4.2242-2244.2002; Tamayo R, 2005, J BACTERIOL, V187, P3391, DOI 10.1128/JB.187.10.3391-3399.2005; TONJUM T, 1995, MOL MICROBIOL, V16, P451, DOI 10.1111/j.1365-2958.1995.tb02410.x; Warren MJ, 2003, INFECT IMMUN, V71, P6892, DOI 10.1128/IAI.71.12.6892-6898.2003; Weiser JN, 1998, J EXP MED, V187, P631, DOI 10.1084/jem.187.4.631; Weiser JN, 1998, INFECT IMMUN, V66, P4263; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Winther-Larsen HC, 2001, P NATL ACAD SCI USA, V98, P15276, DOI 10.1073/pnas.261574998; Wolfgang M, 1999, MOL MICROBIOL, V31, P1345, DOI 10.1046/j.1365-2958.1999.01269.x; Wolfgang M, 2000, EMBO J, V19, P6408, DOI 10.1093/emboj/19.23.6408; Wolfgang M, 1998, MOL MICROBIOL, V29, P321, DOI 10.1046/j.1365-2958.1998.00935.x; Wright JC, 2004, J BACTERIOL, V186, P6970, DOI 10.1128/JB.186.20.6970-6982.2004; ZHANG QY, 1992, P NATL ACAD SCI USA, V89, P5366, DOI 10.1073/pnas.89.12.5366	45	53	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27712	27723		10.1074/jbc.M604324200	http://dx.doi.org/10.1074/jbc.M604324200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16825186	hybrid			2022-12-25	WOS:000240534400007
J	Yang, ST; Jeong, JH; Brown, AL; Lee, CH; Pandolfi, PP; Chung, JH; Kim, MK				Yang, Shutong; Jeong, Jae-Hoon; Brown, Alexandra L.; Lee, Chang-Hun; Pandolfi, Pier Paolo; Chung, Jay H.; Kim, Myung K.			Promyelocytic leukemia activates Chk2 by mediating Chk2 autophosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE RESPONSE; PML NUCLEAR-BODIES; RETINOIC ACID; RAR-ALPHA; TUMOR-SUPPRESSOR; HISTONE H2AX; CHECKPOINT; PROTEIN; PHOSPHORYLATION; APOPTOSIS	Chk2 is a kinase critical for DNA damage- induced apoptosis and is considered a tumor suppressor. Chk2 is essential for p53 transcriptional and apoptotic activities. Although mutations of p53 are present in more than half of all tumors, mutations of Chk2 in cancers are rare, suggesting that Chk2 may be inactivated by unknown alternative mechanisms. Here we elucidate one such alternative mechanism regulated by PML (promyelocytic leukemia) that is involved in acute promyelocytic leukemia (APL). Although p53 inactivating mutations are extremely rare in APL, t(15; 17) chromosomal translocation which fuses retinoic acid receptor (RAR alpha) to PML is almost always present in APL, while the other PML allele is intact. We demonstrate that PML interacts with Chk2 and activates Chk2 by mediating its autophosphorylation step, an essential step for Chk2 activity that occurs after phosphorylation by the upstream kinase ATM (ataxia telangiectasia- mutated). PML/ RAR alpha in APL suppresses Chk2 by dominantly inhibiting the autophosphorylation step, but inactivation of PML/ RAR alpha with alltrans retinoic acid (ATRA) restores Chk2 autophosphorylation and activity. Thus, by fusing PML with RAR alpha, the APL cells appear to have achieved functional suppression of Chk2 compromising the Chk2- p53 apoptotic pathway.	NHLBI, Lab Biochem Genet, NIH, Bethesda, MD 20892 USA; Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Chung, JH (corresponding author), NHLBI, Lab Biochem Genet, NIH, 10 Ctr Dr,Bldg 10,Rm 7D14, Bethesda, MD 20892 USA.	ChungJ@nhlbi.nih.gov; KimM@nhlbi.nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002243, Z01HL002243] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bernardi R, 2003, ONCOGENE, V22, P9048, DOI 10.1038/sj.onc.1207106; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; BOND JA, 1994, ONCOGENE, V9, P1885; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Kogan SC, 2000, BLOOD, V95, P1541, DOI 10.1182/blood.V95.5.1541.005k28_1541_1550; Kwok C, 2006, CANCER CELL, V9, P95, DOI 10.1016/j.ccr.2006.01.005; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lombard DB, 2000, CANCER RES, V60, P2331; LONGO L, 1993, LEUKEMIA LYMPHOMA, V11, P405, DOI 10.3109/10428199309067933; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Pandolfi PP, 2001, ONCOGENE, V20, P5726, DOI 10.1038/sj.onc.1204600; Pandolfi PP, 2001, HUM MOL GENET, V10, P769, DOI 10.1093/hmg/10.7.769; Rego EM, 2006, ONCOGENE, V25, P1974, DOI 10.1038/sj.onc.1209216; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Sternsdorf T, 2006, CANCER CELL, V9, P81, DOI 10.1016/j.ccr.2005.12.030; Takahashi Y, 2004, ONCOGENE, V23, P2819, DOI 10.1038/sj.onc.1207533; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Xu ZX, 2005, MOL CELL, V17, P721, DOI 10.1016/j.molcel.2005.02.014; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869	46	41	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26645	26654		10.1074/jbc.M604391200	http://dx.doi.org/10.1074/jbc.M604391200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16835227	hybrid			2022-12-25	WOS:000240249500082
J	Carrotta, R; Di Carlo, M; Manno, M; Montana, G; Picone, P; Romancino, D; San Biagio, PL				Carrotta, R.; Di Carlo, M.; Manno, M.; Montana, G.; Picone, P.; Romancino, D.; San Biagio, P. L.			Toxicity of recombinant beta-amyloid prefibrillar oligomers on the morphogenesis of the sea urchin Paracentrotus lividus	FASEB JOURNAL			English	Article						A beta 42; light scattering; toxicity	LONG-TERM POTENTIATION; ALZHEIMERS-DISEASE; COMMON MECHANISM; PROTEIN; AGGREGATION; PEPTIDE; FIBRILLOGENESIS; NEUROTOXICITY; PATHOGENESIS; HYPOTHESIS	A distinctive feature of Alzheimer's disease is the deposition of amyloid beta-protein (A beta) in senile or diffuse plaques. The 42 residue beta-peptide (A beta 42) is the predominant form found in plaques. In the present work we report a high-yield expression and purification method of production of a recombinant A beta 42. The purified recombinant peptide shows characteristics similar to the synthetic human peptide. Different size aggregates, either small oligomers or larger aggregates, were obtained upon dissolving the recombinant A beta 42 peptide under different conditions at pH 7.2 or pH 3, respectively. We report a new toxicity assay on the morphogenic development of the sea urchin Paracentrotus lividus and study the toxicity of the two kinds of aggregates. Despite the difference between the ionic strength of human extracellular fluid (0.154 mol/l) and artificial sea water (0.48 mol/l), toxicity data collected in this system have an intrinsic relevance. The different ionic strength, in fact, could change the kinetics of oligomer formation, but the effect of morphogenic development reported here is related to the final oligomer sizes. Results of the toxicity assay of A beta 42 on sea urchin development also show a dose-dependent effect. After only 4 h of embryo development, one can note morphological defects in the cell membrane. Retardation of the embryo's development, along with cellular disorders visible inside the blastocoele, can be observed after 1 day of development. Cellular degeneration in two different pathological phenotypes the occluded blastulae and the occluded prism - is present after 48 h of development. Results show that a greater effect on cell death is induced by the small oligomers stabilized under physiological conditions than at acid pH. In this case only occluded blastulae are found after 48 h of development.	CNR, IBF, UO Palermo, I-90146 Palermo, Italy; CNR, Ist Biomed & Immunol Mol, I-90146 Palermo, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomedicina e di Immunologia Molecolare "Alberto Monroy" (IBIM-CNR)	San Biagio, PL (corresponding author), CNR, IBF, UO Palermo, Via Ugo La Malfa,153, I-90146 Palermo, Italy.	pierluigi.sanbiagio@pa.ibf.cnr.it	Manno, Mauro/F-1385-2010; Romancino, Daniele/C-3031-2015; Picone, Pasquale/AAX-3158-2020	Manno, Mauro/0000-0001-9843-0428; Romancino, Daniele/0000-0003-2041-0122; Carrotta, Rita/0000-0003-4628-2819; Picone, Pasquale/0000-0001-7127-2183; Di Carlo, Marta/0000-0002-7934-1275; SAN BIAGIO, PIER LUIGI/0000-0002-4622-7361; Montana, Giovanna/0000-0003-3368-4114				BERNE B. J., 1976, DYNAMIC LIGHT SCATTE; Bitan G, 2004, ACCOUNTS CHEM RES, V37, P357, DOI 10.1021/ar000214l; Bitan G, 2005, AMYLOID, V12, P88, DOI 10.1080/13506120500106958; Bondos SE, 2003, ANAL BIOCHEM, V316, P223, DOI 10.1016/S0003-2697(03)00059-9; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; BURDICK D, 1992, J BIOL CHEM, V267, P546; Carrotta R, 2005, J BIOL CHEM, V280, P30001, DOI 10.1074/jbc.M500052200; Carter J., 2001, Current Molecular Medicine (Hilversum), V1, P733, DOI 10.2174/1566524013363177; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Crescenzi O, 2002, EUR J BIOCHEM, V269, P5642, DOI 10.1046/j.1432-1033.2002.03271.x; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; DiCarlo M, 1996, BIOCHEM BIOPH RES CO, V229, P511; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Fezoui Y, 2000, AMYLOID, V7, P166, DOI 10.3109/13506120009146831; Fezoui Y, 2002, J BIOL CHEM, V277, P36948, DOI 10.1074/jbc.M204168200; Giudice G., 1973, DEV BIOL SEA URCHIN; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hoshi M, 2003, P NATL ACAD SCI USA, V100, P6370, DOI 10.1073/pnas.1237107100; Huang THJ, 2000, J BIOL CHEM, V275, P36436, DOI 10.1074/jbc.M005698200; Huglin M. B., 1972, LIGHT SCATTERING POL; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kammerer RA, 2004, P NATL ACAD SCI USA, V101, P4435, DOI 10.1073/pnas.0306786101; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kienlen-Campard P, 2002, J BIOL CHEM, V277, P15666, DOI 10.1074/jbc.M200887200; LaFerla FM, 2002, NAT REV NEUROSCI, V3, P862, DOI 10.1038/nrn960; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; Marchesi VT, 2005, P NATL ACAD SCI USA, V102, P9093, DOI 10.1073/pnas.0503181102; Matsubara K, 2003, PROTEIN EXPRES PURIF, V30, P55, DOI 10.1016/S1046-5928(03)00069-X; Nakajima Y, 2004, EVOL DEV, V6, P95, DOI 10.1111/j.1525-142X.2004.04011.x; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; Romancino DP, 2001, DEV BIOL, V234, P107, DOI 10.1006/dbio.2001.0233; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; SHEN CL, 1994, BIOPHYS J, V67, P1238, DOI 10.1016/S0006-3495(94)80593-4; STEPANEK P, 1993, DYNAMIC LIGHT SCATTE; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang HW, 2002, BRAIN RES, V924, P133, DOI 10.1016/S0006-8993(01)03058-X; Wilquet V, 2004, CURR OPIN NEUROBIOL, V14, P582, DOI 10.1016/j.conb.2004.08.001	41	40	41	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1916	+		10.1096/fj.06-5716fje	http://dx.doi.org/10.1096/fj.06-5716fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16818470				2022-12-25	WOS:000240267000029
J	Fernandez, MM; Guan, RJ; Swaminathan, CP; Malchiodi, EL; Mariuzza, RA				Fernandez, Marisa M.; Guan, Rongjin; Swaminathan, Chittoor P.; Malchiodi, Emilio L.; Mariuzza, Roy A.			Crystal structure of staphylococcal enterotoxin I (SEI) in complex with a human major histocompatibility complex class II molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIC-SHOCK-SYNDROME; RECEPTOR BETA-CHAIN; T-CELL-ACTIVATION; 3-DIMENSIONAL STRUCTURE; HIGH-AFFINITY; BINDING SITE; SUPERANTIGENS; PEPTIDE; ZINC; TCR	Superantigens are bacterial or viral proteins that elicit massive T cell activation through simultaneous binding to major histocompatibility complex (MHC) class II and T cell receptors. This activation results in uncontrolled release of inflammatory cytokines, causing toxic shock. A remarkable property of superantigens, which distinguishes them from T cell receptors, is their ability to interact with multiple MHC class II alleles independently of MHC-bound peptide. Previous crystallographic studies have shown that staphylococcal and streptococcal superantigens belonging to the zinc family bind to a high affinity site on the class II beta-chain. However, the basis for promiscuous MHC recognition by zinc-dependent superantigens is not obvious, because the beta-chain is polymorphic and the MHC-bound peptide forms part of the binding interface. To understand how zinc-dependent superantigens recognize MHC, we determined the crystal structure, at 2.0 A resolution, of staphylococcal enterotoxin I bound to the human class II molecule HLA-DR1 bearing a peptide from influenza hemagglutinin. Interactions between the superantigen and DR1 beta-chain are mediated by a zinc ion, and 22% of the buried surface of peptide(.)MHC is contributed by the peptide. Comparison of the staphylococcal enterotoxin I(.)peptide(.)DR1 structure with ones determined previously revealed that zinc-dependent superantigens achieve promiscuous binding to MHC by targeting conservatively substituted residues of the polymorphic beta-chain. Additionally, these superantigens circumvent peptide specificity by engaging MHC-bound peptides at their conformationally conserved N-terminal regions while minimizing sequence-specific interactions with peptide residues to enhance cross-reactivity.	Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Struct Biol Lab, Rockville, MD 20850 USA; Univ Buenos Aires, Fac Farm & Bioquim, Catedra Inmunol, Lab Inmunol Estructural,Consejo Nacl Invest Cient, RA-1113 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Farm & Bioquim, Inst Estudios Inmunidad Humoral, Lab Inmunol Estructural,Consejo Nacl Invest Cient, RA-1113 Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Mariuzza, RA (corresponding author), Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Struct Biol Lab, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	mariuzza@carb.nist.gov		Fernandez, Marisa/0000-0002-7480-5907; Malchiodi, Emilio/0000-0001-7501-3330	NIAID NIH HHS [R01 AI036900, R37 AI036900, R37 AI036900-12] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI036900, R01AI036900] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banks MC, 2003, J INFECT DIS, V187, P77, DOI 10.1086/345874; BOHACH GA, 1990, CRIT REV MICROBIOL, V17, P251, DOI 10.3109/10408419009105728; Cho SW, 2005, STRUCTURE, V13, P1775, DOI 10.1016/j.str.2005.08.015; Davis IW, 2004, NUCLEIC ACIDS RES, V32, pW615, DOI 10.1093/nar/gkh398; Dinges MM, 2000, CLIN MICROBIOL REV, V13, P16, DOI 10.1128/CMR.13.1.16-34.2000; Fernandez MM, 2006, MOL IMMUNOL, V43, P927, DOI 10.1016/j.molimm.2005.06.029; Fields BA, 1996, NATURE, V384, P188, DOI 10.1038/384188a0; Frayser M, 1999, PROTEIN EXPRES PURIF, V15, P105, DOI 10.1006/prep.1998.0987; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; Hemmer B, 2000, J IMMUNOL, V164, P861, DOI 10.4049/jimmunol.164.2.861; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; Jarraud S, 2001, J IMMUNOL, V166, P669, DOI 10.4049/jimmunol.166.1.669; Kieke MC, 2001, J MOL BIOL, V307, P1305, DOI 10.1006/jmbi.2001.4560; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; Kotb M, 1998, CURR OPIN MICROBIOL, V1, P56, DOI 10.1016/S1369-5274(98)80143-4; Langley R, 2005, J IMMUNOL, V174, P2926, DOI 10.4049/jimmunol.174.5.2926; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Li HM, 1999, ANNU REV IMMUNOL, V17, P435, DOI 10.1146/annurev.immunol.17.1.435; Li HM, 1998, IMMUNITY, V9, P807, DOI 10.1016/S1074-7613(00)80646-9; Li PL, 1997, J EXP MED, V186, P375, DOI 10.1084/jem.186.3.375; Li YL, 2005, EMBO J, V24, P2968, DOI 10.1038/sj.emboj.7600771; Li YL, 2001, IMMUNITY, V14, P93, DOI 10.1016/S1074-7613(01)00092-9; McCormick JK, 2000, GRAM-POSITIVE PATHOGENS, P43; McCormick JK, 2001, ANNU REV MICROBIOL, V55, P77, DOI 10.1146/annurev.micro.55.1.77; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nicholson MJ, 2005, IMMUNITY, V23, P351, DOI 10.1016/j.immuni.2005.09.009; Omoe K, 2002, J CLIN MICROBIOL, V40, P857, DOI 10.1128/JCM.40.3.857-862.2002; Papageorgiou AC, 1998, J MOL BIOL, V277, P61, DOI 10.1006/jmbi.1997.1577; Papageorgiou AC, 2004, J BIOL CHEM, V279, P1297, DOI 10.1074/jbc.M307333200; Petersson K, 2001, EMBO J, V20, P3306, DOI 10.1093/emboj/20.13.3306; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Proft T, 2003, CLIN EXP IMMUNOL, V133, P299, DOI 10.1046/j.1365-2249.2003.02203.x; Roussel A, 1997, NAT STRUCT BIOL, V4, P635, DOI 10.1038/nsb0897-635; Rudolph MG, 2006, ANNU REV IMMUNOL, V24, P419, DOI 10.1146/annurev.immunol.23.021704.115658; SCHAD EM, 1995, EMBO J, V14, P3292, DOI 10.1002/j.1460-2075.1995.tb07336.x; SCHERER MT, 1993, ANNU REV CELL BIOL, V9, P101, DOI 10.1146/annurev.cb.09.110193.000533; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Sundberg E, 1999, NAT STRUCT BIOL, V6, P123; Sundberg EJ, 2002, CURR OPIN IMMUNOL, V14, P36, DOI 10.1016/S0952-7915(01)00296-5; Sundberg EJ, 2003, STRUCTURE, V11, P1151, DOI 10.1016/S0969-2126(03)00187-4; Sundberg EJ, 2002, STRUCTURE, V10, P687, DOI 10.1016/S0969-2126(02)00759-1; Sundstrom M, 1996, J BIOL CHEM, V271, P32212, DOI 10.1074/jbc.271.50.32212; WALKER PA, 1994, BIO-TECHNOL, V12, P601, DOI 10.1038/nbt0694-601; Zavala-Ruiz Z, 2003, J BIOL CHEM, V278, P44904, DOI 10.1074/jbc.M307652200	48	37	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25356	25364		10.1074/jbc.M603969200	http://dx.doi.org/10.1074/jbc.M603969200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16829512	Green Accepted, hybrid			2022-12-25	WOS:000240031300037
J	Hur, GM; Kim, YS; Won, M; Choksi, S; Liu, ZG				Hur, Gang Min; Kim, You-Sun; Won, Minho; Choksi, Swati; Liu, Zheng-Gang			The death domain kinase RIP has an important role in DNA damage-induced, p53-independent cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; RECEPTOR-INTERACTING PROTEIN; JNK ACTIVATION; P53; NECROSIS; STRESS; RESISTANCE; APOPTOSIS; RESPONSES; PATHWAY	Tumor suppressor p53 plays a critical role in cellular responses, such as cell cycle arrest and apoptosis following DNA damage. DNA damage-induced cell death can be mediated by a p53-dependent or p53-independent pathway. Although p53-mediated apoptosis has been well documented, little is known about the signaling components of p53-independent cell death. Here we report that the death domain kinase, RIP (receptor-interacting protein), is important for DNA damage-induced, p53-independent cell death. DNA damage induces cell death in both wild-type and p53(-/-) mouse embryonic fibroblast cells. We found that RIP-/- mouse embryonic fibroblast cells, which have a mutant form of the p53 protein, are resistant to DNA damage-induced cell death. The reconstitution of RIP protein expression in RIP-/- cells restored the sensitivity of cells to DNA damage-induced cell death. We also found that RIP mediates this process through activating mitogen-activated protein kinase, JNK1. Furthermore, knocking down the expression of RIP blocked DNA damage-induced cell death in the human colon cancer cell line, p53 null HCT 116. Taken together, our study demonstrates that RIP is one of the critical components involved in mediating DNA damage-induced, p53-independent cell death.	NCI, Cell & Canc Biol Branch, NIH, Canc Res Ctr, Bethesda, MD 20892 USA; Chungnam Natl Univ, Dept Pharmacol, Coll Med, Taejon, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Chungnam National University	Liu, ZG (corresponding author), NCI, Cell & Canc Biol Branch, NIH, Canc Res Ctr, 37 Convent Dr,Rm 1066A, Bethesda, MD 20892 USA.	zgliu@helix.nih.gov	Hur, Gang-min/ABF-9263-2021	Hur, Gang-min/0000-0003-4870-6574; Won, Minho/0000-0002-5873-5216	NATIONAL CANCER INSTITUTE [Z01SC010376, ZIASC010376] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; Branch P, 2000, ONCOGENE, V19, P3138, DOI 10.1038/sj.onc.1203668; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Devin A, 2003, EMBO REP, V4, P623, DOI 10.1038/sj.embor.embor854; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hur GM, 2003, GENE DEV, V17, P873, DOI 10.1101/gad.1062403; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532; Petak Istvan, 2001, Pathology and Oncology Research, V7, P95; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Shen HM, 2004, MOL CELL BIOL, V24, P5914, DOI 10.1128/MCB.24.13.5914-5922.2004; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Waring P, 1999, IMMUNOL CELL BIOL, V77, P312, DOI 10.1046/j.1440-1711.1999.00837.x; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904; Zunino F, 1997, PHARMACOL THERAPEUT, V76, P177, DOI 10.1016/S0163-7258(97)00086-7	27	21	22	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25011	25017		10.1074/jbc.M605577200	http://dx.doi.org/10.1074/jbc.M605577200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16825191	hybrid			2022-12-25	WOS:000240031300003
J	Pan, YL; Zhao, LN; Liang, J; Liu, J; Shi, YQ; Liu, N; Zhang, GY; Jin, HF; Gao, J; Xie, HH; Wang, J; Liu, ZG; Fan, DM				Pan, Yanglin; Zhao, Lina; Liang, Jie; Liu, Jie; Shi, Yongquan; Liu, Na; Zhang, Guoyun; Jin, Haifeng; Gao, Juan; Xie, Huahong; Wang, Jun; Liu, Zhiguo; Fan, Daiming			Cellular prion protein promotes invasion and metastasis of gastric cancer	FASEB JOURNAL			English	Article						PrPc; extracellular matrix	TRUNCATED PRP; HUMAN NEURONS; EXPRESSION; STROMELYSIN-3; TUMOR; ADHESION; CELLS; DEATH; LINE; OVEREXPRESSION	Cellular prion protein (PrPc) is a glycosylphosphatidylinositol (GPI) - anchored membrane protein that is highly conserved in mammalian species. PrPc has the characteristics of adhesive molecules and is thought to play a role in cell adhesion and membrane signaling. Here we investigated the possible role of PrPc in the process of invasiveness and metastasis in gastric cancers. PrPc was found to be highly expressed in metastatic gastric cancers compared to nonmetastatic ones by immunohistochemical staining. PrPc significantly promoted the adhesive, invasive, and in vivo metastatic abilities of gastric cancer cell lines SGC7901 and MKN45. PrPc also increased promoter activity and the expression of MMP11 by activating phosphorylated ErK1/2 in gastric cancer cells. MEK inhibitor PD98059 and MMP11 antibody (Ab) significantly inhibited in vitro invasive and in vivo metastatic abilities induced by PrPc. N-terminal fragment (amino acid 24 - 90) was suggested to be an indispensable region for signal transduction and invasion-promoting function of PrPc. Taken together, the present work revealed a novel function of PrPc that the existence of N-terminal region of PrPc could promote the invasive and metastatic abilities of gastric cancer cells at least partially through activation of MEK/ERK pathway and consequent transactivation of MMP11. - Pan, Y., Zhao, L., Liang, J., Liu, J., Shi, Y., Liu, N., Zhang, G., Jin, H., Gao, J., Xie, H., Wang, J., Liu, Z., Fan, D. Cellular prion protein promotes invasion and metastasis of gastric cancer.	Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, Xian 710032, Shaanxi Provi, Peoples R China; Fourth Mil Med Univ, Xijing Hosp, Inst Digest Dis, Xian 710032, Shaanxi Provi, Peoples R China	Air Force Military Medical University; Air Force Military Medical University	Fan, DM (corresponding author), Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, 17 Changle Western Rd, Xian 710032, Shaanxi Provi, Peoples R China.	fandaim@fmmu.edu.cn	Shi, Yongquan/AAE-3954-2020; liu, na/W-7939-2019; Zhao, Lina/GVR-7716-2022; gao, juan/GXV-1381-2022	liu, zhiguo/0000-0002-8485-7356				Andarawewa KL, 2003, CANCER RES, V63, P5844; Boulay A, 2001, CANCER RES, V61, P2189; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; Brown DR, 1998, EUR J CELL BIOL, V75, P29, DOI 10.1016/S0171-9335(98)80043-5; Brown DR, 2002, J NEUROSCI RES, V67, P211, DOI 10.1002/jnr.10118; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Delany AM, 2001, ENDOCRINOLOGY, V142, P1561, DOI 10.1210/en.142.4.1561; Delebecq TJ, 2000, CLIN CANCER RES, V6, P1086; Deng H, 2005, BIOCHEM BIOPH RES CO, V326, P274, DOI 10.1016/j.bbrc.2004.11.027; Diarra-Mehrpour M, 2004, CANCER RES, V64, P719, DOI 10.1158/0008-5472.CAN-03-1735; Du JP, 2005, INT J CANCER, V113, P213, DOI 10.1002/ijc.20570; Flechsig E, 2004, CURR MOL MED, V4, P337, DOI 10.2174/1566524043360645; Flechsig E, 2003, EMBO J, V22, P3095, DOI 10.1093/emboj/cdg285; Gabus C, 2001, J BIOL CHEM, V276, P19301, DOI 10.1074/jbc.M009754200; Graner E, 2000, MOL BRAIN RES, V76, P85, DOI 10.1016/S0169-328X(99)00334-4; Hundt C, 2003, BIOL CHEM, V384, P791, DOI 10.1515/BC.2003.088; Hynes RO, 2003, CELL, V113, P821, DOI 10.1016/S0092-8674(03)00468-9; Khasigov PZ, 2003, BIOCHEMISTRY-MOSCOW+, V68, P711, DOI 10.1023/A:1025051214001; Kim BH, 2004, MOL BRAIN RES, V124, P40, DOI 10.1016/j.molbrainres.2004.02.005; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; Li RL, 2001, CELL IMMUNOL, V207, P49, DOI 10.1006/cimm.2000.1751; Liu N, 2004, CLIN CANCER RES, V10, P6239, DOI 10.1158/1078-0432.CCR-04-0242; Lysek DA, 2004, BIOCHEMISTRY-US, V43, P10393, DOI 10.1021/bi0494828; Mange A, 2002, FEBS LETT, V514, P159, DOI 10.1016/S0014-5793(02)02338-4; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Nakopoulou L, 2002, MODERN PATHOL, V15, P1154, DOI 10.1097/01.MP.0000037317.84782.CD; Nunziante M, 2003, J BIOL CHEM, V278, P3726, DOI 10.1074/jbc.M206313200; Pammer J, 2000, VIRCHOWS ARCH, V436, P466, DOI 10.1007/s004280050474; Pammer J, 1998, AM J PATHOL, V153, P1353, DOI 10.1016/S0002-9440(10)65720-3; Pan T, 2002, BIOCHEM J, V368, P81, DOI 10.1042/BJ20020773; Pan YL, 2004, BIOCHEM BIOPH RES CO, V315, P686, DOI 10.1016/j.bbrc.2004.01.108; Perret AG, 2002, CANCER-AM CANCER SOC, V94, P765, DOI 10.1002/cncr.10270; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; Roucou X, 2005, CELL DEATH DIFFER, V12, P783, DOI 10.1038/sj.cdd.4401629; Roucou X, 2003, J BIOL CHEM, V278, P40877, DOI 10.1074/jbc.M306177200; Satoh J, 2000, AM J PATHOL, V157, P59, DOI 10.1016/S0002-9440(10)64517-8; Schmitt-Ulms G, 2001, J MOL BIOL, V314, P1209, DOI 10.1006/jmbi.2000.5183; SCNEIDER B, 2003, P NALT ACAD SCI US, P13326; Selvey S, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-40; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Skoglund J, 2004, ONCOLOGY-BASEL, V67, P67, DOI 10.1159/000080288; Thamilselvan V, 2004, GASTROENTEROLOGY, V126, P8, DOI 10.1053/j.gastro.2003.10.078; Vassallo N, 2003, J NEUROCHEM, V86, P538, DOI 10.1046/j.1471-4159.2003.01882.x; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Walmsley AR, 2003, J BIOL CHEM, V278, P37241, DOI 10.1074/jbc.M302036200; WANG F, 2005, CANC LETT, V11; Wopfner F, 1999, J MOL BIOL, V289, P1163, DOI 10.1006/jmbi.1999.2831; Zhang CC, 2006, P NATL ACAD SCI USA, V103, P2184, DOI 10.1073/pnas.0510577103	49	92	101	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1886	+		10.1096/fj.06-6138fje	http://dx.doi.org/10.1096/fj.06-6138fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16877520				2022-12-25	WOS:000240267000019
J	Brenneis, C; Maier, TJ; Schmidt, R; Hofacker, A; Zulauf, L; Jakobsson, PJ; Scholich, K; Geisslinger, G				Brenneis, Christian; Maier, Thorsten J.; Schmidt, Ronald; Hofacker, Annette; Zulauf, Lars; Jakobsson, Per-Johan; Scholich, Klaus; Geisslinger, Gerd			Inhibition of prostaglandin E-2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition	FASEB JOURNAL			English	Article						PGE2; cyclooxygenase; TNF alpha	E SYNTHASE; PROINFLAMMATORY CYTOKINES; MECHANICAL ALLODYNIA; MACROPHAGES; EXPRESSION; PROTEIN; PAIN; INFLAMMATION	Prostaglandin E-2 (PGE(2)) produced by cyclooxygenase-2 (COX-2) and microsomal prostaglandin E-2 synthase-1 (mPGES-1) plays an important role in the pathophysiology of inflammation, pain, and fever. We investigated the actions of TNF alpha toward stimulation of PGE2 synthesis in primary spinal cord neurons. TNF alpha induced COX-2 and mPGES-1 expression in neurons, followed by formation of PGE(2), which was blocked by a selective COX-2 inhibitor. Surprisingly, the "selective COX-1" inhibitor SC-560 completely inhibited TNF alpha-induced PGE(2) synthesis in neurons at nanomolar concentrations. Moreover, SC-560 inhibited PGE(2) and thromboxane A(2) synthesis in human monocytes and platelets with IC50 of 1.8 nM and 2.5 nM, respectively. SC-560 treatment neither altered TNF alpha-induced COX-2 or mPGES-1 expression nor did the addition of the calcium ionophore A23187 or arachidonic acid reverse the inhibition by SC-560. Moreover, no influence of SC-560 on PGE(2) synthase activities or PGE(2) transport was seen. Most importantly, SC-560 blocked TNF alpha-induced PGE(2) synthesis in COX-1-deficient spinal cord neurons, demonstrating a COX-1-independent inhibition of PGE(2) synthesis. Although SC-560 inhibited LPS-induced PGE(2) synthesis in neurons and RAW264.7 macrophages in whole cell assays, no inhibition was observed in lysates of the same cells. Taken together our data demonstrate that SC-560 acts at least in some cell types as an unselective COX inhibitor despite its selectivity toward COX-1 under cell-free conditions.	Univ Frankfurt Klinikum, Pharmazentrum Frankfurt, ZAFES, D-60590 Frankfurt, Germany; Karolinska Hosp, S-10401 Stockholm, Sweden	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Karolinska Institutet; Karolinska University Hospital	Geisslinger, G (corresponding author), Univ Frankfurt Klinikum, Pharmazentrum Frankfurt, ZAFES, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	geisslinger@em.uni-frankfurt.de	Jakobsson, Per-Johan/ABC-5594-2021					DeLeo JA, 2000, NEUROREPORT, V11, P599, DOI 10.1097/00001756-200002280-00033; Demasi M, 2000, INFLAMM RES, V49, P737, DOI 10.1007/s000110050655; Ehnert C, 2004, J NEUROCHEM, V88, P948, DOI 10.1046/j.1471-4159.2003.02229.x; Fournier T, 1997, J BIOL CHEM, V272, P31065, DOI 10.1074/jbc.272.49.31065; Garavito RM, 2002, PROSTAG OTH LIPID M, V68-9, P129; Gierse JK, 2005, J PHARMACOL EXP THER, V312, P1206, DOI 10.1124/jpet.104.076877; Graham Garry G, 2005, Am J Ther, V12, P46, DOI 10.1097/00045391-200501000-00008; Hinz B, 2000, BIOCHEM BIOPH RES CO, V272, P744, DOI 10.1006/bbrc.2000.2859; Ivanov AI, 2004, FRONT BIOSCI-LANDMRK, V9, P1977, DOI 10.2741/1383; Kojima F, 2004, ARTHRITIS RES THER, V6, pR355, DOI 10.1186/ar1195; Kojima F, 2003, ARTHRITIS RHEUM, V48, P2819, DOI 10.1002/art.11261; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Loll PJ, 1996, BIOCHEMISTRY-US, V35, P7330, DOI 10.1021/bi952776w; Murakami M, 2002, PROSTAG OTH LIPID M, V68-9, P383, DOI 10.1016/S0090-6980(02)00043-6; Palomer A, 2002, J MED CHEM, V45, P1402, DOI 10.1021/jm010458r; Reid G, 2003, P NATL ACAD SCI USA, V100, P9244, DOI 10.1073/pnas.1033060100; Riendeau D, 2001, J PHARMACOL EXP THER, V296, P558; Rouzer CA, 2004, J BIOL CHEM, V279, P34256, DOI 10.1074/jbc.M402594200; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; Schafers M, 2003, J NEUROSCI, V23, P2517; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Tanioka T, 2003, BIOCHEM BIOPH RES CO, V303, P1018, DOI 10.1016/S0006-291X(03)00470-4; Thoren S, 2000, EUR J BIOCHEM, V267, P6428, DOI 10.1046/j.1432-1327.2000.01735.x; Trebino CE, 2005, J BIOL CHEM, V280, P16579, DOI 10.1074/jbc.M412075200; Trebino CE, 2003, P NATL ACAD SCI USA, V100, P9044, DOI 10.1073/pnas.1332766100; Vanegas HN, 2001, PROG NEUROBIOL, V64, P327, DOI 10.1016/S0301-0082(00)00063-0; Walker MC, 2001, BIOCHEM J, V357, P709, DOI 10.1042/0264-6021:3570709; Warner TD, 2006, FASEB J, V20, P542, DOI 10.1096/fj.05-4434fje; Watkins LR, 2003, ADV EXP MED BIOL, V521, P1	29	66	68	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2006	20	9					1352	1360		10.1096/fj.05-5346com	http://dx.doi.org/10.1096/fj.05-5346com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816110				2022-12-25	WOS:000240266000012
J	Kuo, AH; Stoica, GE; Riegel, AT; Wellstein, A				Kuo, A. H.; Stoica, G. E.; Riegel, A. T.; Wellstein, A.			Recruitment of insulin receptor substrate-1 and activation of NF-kappa B essential for midkine growth signaling through anaplastic lymphoma kinase	ONCOGENE			English	Article						ALK; MK; IRS-1; NF-kappa B; autocrine	IGF-I RECEPTOR; LEUKOCYTE TYROSINE KINASE; FUNCTIONAL-ANALYSIS; ALK KINASE; ATIC-ALK; GENE; PLEIOTROPHIN; EXPRESSION; TRANSFORMATION; TRANSCRIPTION	Anaplastic lymphoma kinase (ALK) is a transmembrane receptor tyrosine kinase in the insulin receptor superfamily. We recently demonstrated that the growth factors pleiotrophin (PTN) and midkine (MK) are ligands for ALK and that upon ALK activation, insulin receptor substrate-1 (IRS-1) and other substrates are phosphorylated. Here, the role of IRS-1 in ligand-mediated ALK signaling is investigated in interleukin-3 (IL-3)-dependent 32D murine myeloid cells. These cells do not express ALK and IRS family members, and do not respond to exogenously added PTN or MK. We show that expression of ALK plus IRS-1 renders these cells independent of IL-3 owing to the activation of ALK by endogenous MK. Mutational analysis reveals that this transformed phenotype of 32D cells requires kinase-active ALK as well as the interaction of ALK with IRS-1. Furthermore, 32D/IRS-1/ALK cells display an enhanced activation of mitogen-activated protein kinase and PI3-kinase pathways, and a selective transcriptional activation of nuclear factor (NF)-kappa B. Small interfering RNA-mediated knockdown of the endogenous MK or p65/NF-kappa B revealed that both these are rate limiting for the transformed phenotype induced by ALK plus IRS-1. We conclude that the recruitment of IRS-1 to activated ALK and the activation of NF-kappa B are essential for the autocrine growth and survival signaling of MK.	Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20007 USA	Georgetown University	Wellstein, A (corresponding author), Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Res Bldg E311,3970 Reservoir Rd, Washington, DC 20007 USA.	wellstea@georgetown.edu			NATIONAL CANCER INSTITUTE [R01CA101811] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR014567] Funding Source: NIH RePORTER; NCI NIH HHS [CA101811] Funding Source: Medline; NCRR NIH HHS [C06 RR14567] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Ballinger MD, 1999, NAT BIOTECHNOL, V17, P1199, DOI 10.1038/70746; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Baserga R, 2000, GROWTH HORM IGF RES, V10, pS43, DOI 10.1016/S1096-6374(00)90021-2; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; Bowden ET, 2002, J BIOL CHEM, V277, P35862, DOI 10.1074/jbc.M203963200; Burks DJ, 2001, DIABETES, V50, pS140, DOI 10.2337/diabetes.50.2007.S140; Chang Q, 2002, CANCER RES, V62, P6035; Colleoni GWB, 2000, AM J PATHOL, V156, P781, DOI 10.1016/S0002-9440(10)64945-0; Cristofanelli B, 2000, ONCOGENE, V19, P3245, DOI 10.1038/sj.onc.1203664; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; Delsol G, 1997, BLOOD, V89, P1483, DOI 10.1182/blood.V89.5.1483.1483_1483_1490; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; Dirks WG, 2002, INT J CANCER, V100, P49, DOI 10.1002/ijc.10435; Englund C, 2003, NATURE, V425, P512, DOI 10.1038/nature01950; FANG WJ, 1992, J BIOL CHEM, V267, P25889; Feng SH, 1999, MOL CELL BIOL, V19, P7995; Freeman M, 2003, NATURE, V425, P468, DOI 10.1038/425468a; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; Hernandez L, 1999, BLOOD, V94, P3265; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; Lawrence B, 2000, AM J PATHOL, V157, P377, DOI 10.1016/S0002-9440(10)64550-6; Lee HH, 2003, NATURE, V425, P507, DOI 10.1038/nature01916; Li XQ, 2004, HUM PATHOL, V35, P711, DOI 10.1016/j.humpath.2003.12.004; Lu KV, 2005, J BIOL CHEM, V280, P26953, DOI 10.1074/jbc.M502614200; Ma ZG, 2000, BLOOD, V95, P2144, DOI 10.1182/blood.V95.6.2144; Maheshwari G, 2001, J CELL BIOL, V155, P1123, DOI 10.1083/jcb.200109060; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mirkin BL, 2005, ONCOGENE, V24, P4965, DOI 10.1038/sj.onc.1208671; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; Osajima-Hakomori Y, 2005, AM J PATHOL, V167, P213, DOI 10.1016/S0002-9440(10)62966-5; Ozes ON, 1999, NATURE, V401, P82; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Pulford K, 2004, J CELL PHYSIOL, V199, P330, DOI 10.1002/jcp.10472; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887; Romano MF, 1999, BLOOD, V94, P4060, DOI 10.1182/blood.V94.12.4060.424k23_4060_4066; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Scharf JG, 2003, HORM METAB RES, V35, P685; Schulte AM, 1997, TUMOUR ANGIOGENESIS, P273; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; Singh AB, 2005, CELL SIGNAL, V17, P1183, DOI 10.1016/j.cellsig.2005.03.026; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Surmacz E, 2004, J EXP CLIN CANC RES, V23, P385; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Trinei M, 2000, CANCER RES, V60, P793; Ueno H, 1996, J BIOL CHEM, V271, P27707, DOI 10.1074/jbc.271.44.27707; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; White MF, 1998, RECENT PROG HORM RES, V53, P119; Zamorano J, 2001, INT IMMUNOL, V13, P1479, DOI 10.1093/intimm/13.12.1479; Zhang N, 1999, Curr Opin Hematol, V6, P44, DOI 10.1097/00062752-199901000-00008; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	69	42	46	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					859	869		10.1038/sj.onc.1209840	http://dx.doi.org/10.1038/sj.onc.1209840			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16878150				2022-12-25	WOS:000244063800007
J	Wu, Y; McRoberts, K; Berr, SS; Frierson, HF; Conaway, M; Theodorescu, D				Wu, Y.; McRoberts, K.; Berr, S. S.; Frierson, H. F., Jr.; Conaway, M.; Theodorescu, D.			Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia	ONCOGENE			English	Article						neoplasm metastasis; endothelial growth factors; bladder neoplasms; gene expression profiling; xenograft model antitumor assays	HUMAN BLADDER-CANCER; ENDOTHELIN AXIS; PROSTATE-CANCER; CELLS; PROGRESSION; EXPRESSION; INVASION; GENE; IDENTIFICATION; RECEPTORS	Most deaths from urinary bladder cancer are owing to metastatic disease. A reduction in Rho GDP Dissociation Inhibitor 2 (RhoGDI2) protein has been associated with increased risk of metastasis in patients with locally advanced bladder cancer, whereas in animal models, RhoGDI2 reconstitution in cells without expression results in lung metastasis suppression. Recently, we noted an inverse correlation between tumor RhoGDI2 and Neuromedin U (NMU) expression, suggesting that NMU might be a target of the lung metastasis suppressor effect of RhoGDI2. Here we evaluated whether NMU is regulated by RhoGDI2 and is functionally important in tumor progression. We used small interfering RNA knockdown of endogenous RhoGDI2 in poorly tumorigenic and non-metastatic human bladder cancer T24 cells and observed increased NMU RNA expression. Although NMU overexpression did not increase the monolayer growth of T24 or related T24T poorly metastatic human bladder cancer cells, it did augment anchorage-independent growth for the latter. Overexpression of NMU in T24 and T24T cells significantly promoted tumor formation of both cell lines in nude mice, but did not alter the growth rate of established tumors. Furthermore, NMU-overexpressing xenografts were associated with lower animal body weight than control tumors, indicating a possible role of NMU in cancer cachexia. NMU overexpression in T24T cells significantly enhanced their lung metastatic ability. Bioluminescent in vivo imaging revealed that lung metastases in T24T grew faster than the same tumors in the subcutaneous microenvironment. In conclusion, NMU is a RhoGDI2-regulated gene that appears important for tumorigenicity, lung metastasis and cancer cachexia, and thus a promising therapeutic target in cancer.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Dept Radiol, Charlottesville, VA USA; Univ Virginia, Dept Pathol, Charlottesville, VA USA; Univ Virginia, Dept Hlth Evaluat Sci, Charlottesville, VA USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia	Theodorescu, D (corresponding author), Univ Virginia, Dept Mol Physiol & Biol Phys, Box 800422, Charlottesville, VA 22908 USA.	dt9d@virginia.edu			NATIONAL CANCER INSTITUTE [R01CA075115, R29CA075115] Funding Source: NIH RePORTER; NCI NIH HHS [CA075115] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHAI E, 2002, NAT REV CANCER, V2, P133; Alevizos I, 2001, ONCOGENE, V20, P6196, DOI 10.1038/sj.onc.1204685; Brighton PJ, 2004, PHARMACOL REV, V56, P231, DOI 10.1124/pr.56.2.3; Cameron MD, 2000, CANCER RES, V60, P2541; Cao CQ, 2003, PAIN, V104, P609, DOI 10.1016/S0304-3959(03)00118-0; Chan ISF, 1999, BIOMETRICS, V55, P1202, DOI 10.1111/j.0006-341X.1999.01202.x; Chung LWK, 2005, J UROLOGY, V173, P10, DOI 10.1097/01.ju.0000141582.15218.10; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Euer NI, 2005, ONCOL REP, V13, P375; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; Gildea JJ, 2002, CANCER RES, V62, P6418; Gildea JJ, 2000, GENE CHROMOSOME CANC, V27, P252, DOI 10.1002/(SICI)1098-2264(200003)27:3<252::AID-GCC5>3.0.CO;2-9; Hanada R, 2004, NAT MED, V10, P1067, DOI 10.1038/nm1106; Harding MA, 2002, CANCER RES, V62, P6981; Howard AD, 2000, NATURE, V406, P70, DOI 10.1038/35017610; Ida T, 2005, ENDOCRINOLOGY, V146, P4217, DOI 10.1210/en.2005-0107; Im JH, 2004, CANCER RES, V64, P8613, DOI 10.1158/0008-5472.CAN-04-2078; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jenkins DE, 2003, CLIN EXP METASTAS, V20, P745, DOI 10.1023/B:CLIN.0000006817.25962.87; Johnson EN, 2004, J IMMUNOL, V173, P7230, DOI 10.4049/jimmunol.173.12.7230; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Kamai T, 2003, BJU INT, V91, P234, DOI 10.1046/j.1464-410X.2003.03063.x; Kowalski TJ, 2005, J ENDOCRINOL, V185, P151, DOI 10.1677/joe.1.05948; Martignoni Marcus E, 2003, Mol Cancer, V2, P36, DOI 10.1186/1476-4598-2-36; Moriyama M, 2006, BIOCHEM BIOPH RES CO, V341, P1149, DOI 10.1016/j.bbrc.2006.01.075; Moriyama M, 2005, J EXP MED, V202, P217, DOI 10.1084/jem.20050248; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Oxford G, 2003, J UROLOGY, V170, P1987, DOI 10.1097/01.ju.0000088670.02905.78; Robinson Victoria L, 2004, Cancer Treat Res, V118, P1; Seraj MJ, 2001, CLIN EXP METASTAS, V18, P519, DOI 10.1023/A:1011819621859; Shetzline SE, 2004, BLOOD, V104, P1833, DOI 10.1182/blood-2003-10-3577; Shousha S, 2006, NEUROSCI LETT, V391, P87, DOI 10.1016/j.neulet.2005.08.033; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; STRASSMANN G, 1995, CYTOKINES MOL THER, V1, P107; Theodorescu D, 2004, CLIN CANCER RES, V10, P3800, DOI 10.1158/1078-0432.CCR-03-0653; Tisdale MJ, 2005, PHYSIOLOGY, V20, P340, DOI 10.1152/physiol.00019.2005; Titus B, 2005, CANCER RES, V65, P7320, DOI 10.1158/0008-5472.CAN-05-1403; Welch DR, 2004, BREAST CANCER RES, V6, P61, DOI 10.1186/bcr736; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5; Yu XH, 2003, NEUROSCIENCE, V120, P467, DOI 10.1016/S0306-4522(03)00300-2; Zheng XX, 2005, BIOORG MED CHEM LETT, V15, P4531, DOI 10.1016/j.bmcl.2005.07.003; Zhou XW, 2004, RADIAT RES, V162, P287, DOI 10.1667/RR3220	42	46	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					765	773		10.1038/sj.onc.1209835	http://dx.doi.org/10.1038/sj.onc.1209835			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16878152				2022-12-25	WOS:000243902200013
J	Inoue, Y; Itoh, Y; Abe, K; Okamoto, T; Daitoku, H; Fukamizu, A; Onozaki, K; Hayashi, H				Inoue, Y.; Itoh, Y.; Abe, K.; Okamoto, T.; Daitoku, H.; Fukamizu, A.; Onozaki, K.; Hayashi, H.			Smad3 is acetylated by p300/CBP to regulate its transactivation activity	ONCOGENE			English	Article						acetylation; CBP; p300; Smad2; Smad3; TGF-beta	GROWTH-FACTOR-BETA; TRANSCRIPTIONAL COACTIVATOR P/CAF; TGF-BETA; DNA-BINDING; RECEPTOR; PHOSPHORYLATION; ACTIVATION; IDENTIFICATION; SUPERFAMILY; ANTAGONIST	Smad proteins are crucial for the intracellular signaling of transforming growth factor-P (TGF-beta). Upon their receptor-induced activation, Smad proteins are phosphorylated and translocated to the nucleus to activate the transcription of a select set of target genes. Here, we show that the co-activator p300/CBP bound and acetylated Smad3 as well as Smad2 in vivo, and that the acetylation was stimulated by TGF-beta. A major acetylation site of Smad3 by p300/CBP is Lys-378 in the MH2 domain (Smad3C) known to be critical for the regulation of transcriptional activity. Replacement of Lys-378 with Arg decreased the transcriptional activity of GAL4-Smad3C in a luciferase assay. Moreover, p300/CBP potentiated the transcriptional activity of GAL4-Smad3C, but not the acetylation-resistant GAL4-Smad3C(K378R) mutant. These results suggest that acetylation of Smad3 by p300/CBP regulates positively its transcriptional activity.	Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Mol Hlth Sci, Mizuho Ku, Nagoya, Aichi 4678603, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Mol & Cellular Biol, Mizuho Ku, Nagoya, Aichi 4678603, Japan; Univ Tsukuba, Inst Appl Biochem, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 305, Japan	Nagoya City University; Nagoya City University; University of Tsukuba	Hayashi, H (corresponding author), Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Mol Hlth Sci, Mizuho Ku, 3-1 Tanabe Dori, Nagoya, Aichi 4678603, Japan.	hhayashi@phar.nagoya-cu.ac.jp	fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Callahan JF, 2002, J MED CHEM, V45, P999, DOI 10.1021/jm010493y; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Enari M, 2006, GENE DEV, V20, P1087, DOI 10.1101/gad.1381906; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hasan S, 2002, J MOL MED, V80, P463, DOI 10.1007/s00109-002-0341-7; Hattori T, 2003, ONCOGENE, V22, P1273, DOI 10.1038/sj.onc.1206204; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Huse M, 2001, MOL CELL, V8, P671, DOI 10.1016/S1097-2765(01)00332-X; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Inoue Y, 2004, J INTERF CYTOK RES, V24, P43, DOI 10.1089/107999004772719909; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kawabata H, 2002, J BIOL CHEM, V277, P8099, DOI 10.1074/jbc.M108250200; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102; Miyazono K, 2000, J CELL SCI, V113, P1101; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Takahashi N, 2002, EUR J BIOCHEM, V269, P4559, DOI 10.1046/j.1432-1033.2002.03157.x; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521	34	106	115	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2007	26	4					500	508		10.1038/sj.onc.1209826	http://dx.doi.org/10.1038/sj.onc.1209826			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16862174				2022-12-25	WOS:000243731600003
J	Yang, G; Xu, Y; Chen, X; Hu, G				Yang, G.; Xu, Y.; Chen, X.; Hu, G.			IFITM1 plays an essential role in the antiproliferative action of interferon-gamma	ONCOGENE			English	Article						control of cell cycle progression; IFITM1; interferon-gamma; p53; extracellular signal-regulated kinase	SIGNAL-TRANSDUCTION PATHWAYS; BREAST-CANCER PROGRESSION; CYCLIN-DEPENDENT KINASE; MYC MESSENGER-RNA; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; DOWN-REGULATION; CELL-GROWTH; C-MYC; DIFFERENTIAL RESPONSE	Interferon-gamma (IFN-gamma) is a pleiotropic cytokine involved in antiproliferative and anti-virus responses, immune surveillance and tumor suppression. These biological responses to IFN-gamma are mainly mediated by the regulation of gene expression. It has been reported that growth-inhibitory role of IFN-gamma is dependent on activation of signal transducers and activators of transcription 1 (STAT1); however, the molecular basis downstream of STAT1 remains unclear. Here, we report that an IFN-gamma-induced gene, interferon-induced transmembrane protein 1 (IFITM1), plays a key role in the antiproliferative action of IFN-gamma. Overexpression of IFITM1 negatively regulated cell growth, whereas suppression of IFITM1 blocked the antiproliferative effect of IFN-gamma, accelerated the cell growth rate and conferred tumorigenicity to a nonmalignant hepatocyte in nude mice. Further, IFITM1 could inhibit the activity of extracellular signal-regulated kinase, enhance the transcriptional activity of p53 and stabilize the p53 protein by inhibiting p53 phosphorylation on Thr55. Suppression of p53 reduced the growth-inhibitory capacity of both IFITM1 and IFN-gamma. Therefore, these findings indicated that the antiproliferative action of IFN-gamma requires the induction of IFITM1, and provided a crosstalk between two well-known signaling mediators, STAT1 and p53, both of which play critical roles in tumor suppression.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Hu, G (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China.	hgxgene@sunm.shcnc.ac.cn						Abba MC, 2004, BREAST CANCER RES, V6, pR499, DOI 10.1186/bcr899; ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P591, DOI 10.1093/nar/19.3.591; Akyerli CB, 2005, LEUKEMIA RES, V29, P283, DOI 10.1016/j.leukres.2004.07.007; Alber D, 1996, J INTERF CYTOK RES, V16, P375, DOI 10.1089/jir.1996.16.375; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Buard A, 1998, CANCER RES, V58, P840; Catchpoole D, 1997, J MED GENET, V34, P353, DOI 10.1136/jmg.34.5.353; CHEN YX, 1984, J IMMUNOL, V133, P2496; Cheng M, 1999, J BIOL CHEM, V274, P6553, DOI 10.1074/jbc.274.10.6553; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEBLANDRE GA, 1995, J BIOL CHEM, V270, P23860, DOI 10.1074/jbc.270.40.23860; DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVANS SS, 1990, BLOOD, V76, P2583; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; Galbiati F, 2001, MOL BIOL CELL, V12, P2229, DOI 10.1091/mbc.12.8.2229; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Halaschek-Wiener J, 2004, CELL SIGNAL, V16, P1319, DOI 10.1016/j.cellsig.2004.04.003; Huang HT, 2000, CANCER RES, V60, P6868; Huang RM, 2002, FASEB J, V16, DOI 10.1096/fj.01-0687com; Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Karnik P, 1998, HUM MOL GENET, V7, P895, DOI 10.1093/hmg/7.5.895; KELLY JM, 1985, EUR J BIOCHEM, V153, P367, DOI 10.1111/j.1432-1033.1985.tb09312.x; Kominsky SL, 2000, CANCER RES, V60, P3904; Li HH, 2004, MOL CELL, V13, P867, DOI 10.1016/S1097-2765(04)00123-6; LIU MK, 1994, INFECT IMMUN, V62, P2722, DOI 10.1128/IAI.62.7.2722-2731.1994; Lu KH, 1997, CANCER RES, V57, P387; MAIER JAM, 1995, BIOCHEM BIOPH RES CO, V214, P582, DOI 10.1006/bbrc.1995.2325; Mandal M, 1998, ONCOGENE, V16, P217, DOI 10.1038/sj.onc.1201529; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; MATSUMOTO AK, 1993, J EXP MED, V178, P1407, DOI 10.1084/jem.178.4.1407; Matsushita K, 2006, CANCER SCI, V97, P57, DOI 10.1111/j.1349-7006.2006.00137.x; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NEGRINI M, 1995, CANCER RES, V55, P3003; Nguyen DT, 2004, MOL BIOL CELL, V15, P4248, DOI 10.1091/mbc.E03-11-0851; Notari M, 2006, BLOOD, V107, P2507, DOI 10.1182/blood-2005-09-3732; OBriant KC, 1997, GENE CHROMOSOME CANC, V18, P111, DOI 10.1002/(SICI)1098-2264(199702)18:2<111::AID-GCC5>3.0.CO;2-5; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Rodig S, 1998, EUR CYTOKINE NETW, V9, P49; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Sakatsume M, 1998, J BIOL CHEM, V273, P3021, DOI 10.1074/jbc.273.5.3021; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schlegel A, 2001, J BIOL CHEM, V276, P4398, DOI 10.1074/jbc.M005448200; SELIGER B, 1991, J VIROL, V65, P6307, DOI 10.1128/JVI.65.11.6307-6311.1991; Stancato LF, 1998, J BIOL CHEM, V273, P18701, DOI 10.1074/jbc.273.30.18701; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; Tran YK, 1996, CANCER RES, V56, P2916; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yeh PY, 2004, ONCOGENE, V23, P3580, DOI 10.1038/sj.onc.1207426; Yeh PY, 2001, BIOCHEM BIOPH RES CO, V284, P880, DOI 10.1006/bbrc.2001.5043; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	60	101	107	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					594	603		10.1038/sj.onc.1209807	http://dx.doi.org/10.1038/sj.onc.1209807			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16847454				2022-12-25	WOS:000243731600011
J	Martin, PM; Aeder, SE; Chrestensen, CA; Sturgill, TW; Hussaini, IM				Martin, P. M.; Aeder, S. E.; Chrestensen, C. A.; Sturgill, T. W.; Hussaini, I. M.			Phorbol 12-myristate 13-acetate and serum synergize to promote rapamycin-insensitive cell proliferation via protein kinase C-eta	ONCOGENE			English	Article						PKC; PKC-eta; p70S6K; glioblastoma; rapamycin	BREAST-CANCER CELLS; MESSENGER-RNA TRANSLATION; SIGNAL-TRANSDUCTION; GLIOBLASTOMA CELLS; MAMMALIAN TARGET; IN-VIVO; ACTIVATION; PHOSPHORYLATION; PATHWAY; MTOR	Previously, we have shown that PKC-eta (protein kinase Ceta) positively regulates glioblastoma proliferation and confers resistance to irradiation-induced apoptosis. In this study, we investigated the efficacy of rapamycin in inhibiting cell proliferation in two glioblastoma cell lines U-251MG (PKC-eta expressing) and U-1242MG (PKC-eta deficient) following PKC-eta activation. In U-251MG cells, rapamycin (10 nM) treatment was less effective as an antiproliferative agent when cells were concurrently stimulated with 10% serum and phorbol 12-myristate 13-acetate (PMA, 100 nM), a potent activator of PKC isozymes. Rapamycin-insensitive growth was owing to PKC-eta, as U-1242MG and U-251MG cells infected with a kinase-dead form of PKC-eta (U-251kr) were susceptible to rapamycin-induced inhibition of cell proliferation. Furthermore, U-251MG cells transfected with PKC-eta antisense oligonucleotides were sensitive to rapamycin. PKC-eta-expressing cells stimulated with PMA maintained p70S6K phosphorylation on Thr389 and phosphorylation of rpS6 (ser235/36), suggesting p70S6K kinase activity was still intact. Inhibition of p70S6K expression with small interfering RNA oligonucleotides inhibited cell proliferation greater than 50% in the presence of a combination of PMA and serum. Additionally, p70S6K co-precipitated with PKC-eta, suggesting a physical interaction between PKC-eta and p70S6K regulates the observed phosphorylation. Taken together, these data demonstrate that rapamycin-insensitive glioblastoma proliferation involves PKC-eta signaling.	Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22903 USA; Univ Virginia, Dept Neurosci, Charlottesville, VA 22903 USA	University of Virginia; University of Virginia; University of Virginia	Martin, PM (corresponding author), Fisk Univ, Dept Biol, Nashville, TN 37208 USA.	pmartin@fisk.edu			NATIONAL CANCER INSTITUTE [R01CA090851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062890] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA90851] Funding Source: Medline; NIGMS NIH HHS [GM62890] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aeder SE, 2004, ONCOGENE, V23, P9062, DOI 10.1038/sj.onc.1208093; Aspeslet LJ, 2000, CLIN THER, V22, pB86, DOI 10.1016/S0149-2918(00)89025-6; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Choe G, 2003, CANCER RES, V63, P2742; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Dilling MB, 2002, J BIOL CHEM, V277, P13907, DOI 10.1074/jbc.M110782200; Dutcher Janice P, 2004, Curr Oncol Rep, V6, P111, DOI 10.1007/s11912-004-0022-5; Eshleman JS, 2002, CANCER RES, V62, P7291; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Feldkamp MM, 1997, J NEURO-ONCOL, V35, P223, DOI 10.1023/A:1005800114912; Galanis E, 2005, J CLIN ONCOL, V23, P5294, DOI 10.1200/JCO.2005.23.622; Geoerger B, 2001, CANCER RES, V61, P1527; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Huang S, 2001, DRUG RESIST UPDATE, V4, P378, DOI 10.1054/drup.2002.0227; Hussaini IA, 2002, NEURO-ONCOLOGY, V4, P9, DOI 10.1093/neuonc/4.1.9; Hussaini IM, 2000, J BIOL CHEM, V275, P22348, DOI 10.1074/jbc.M003203200; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Jiffar T, 2004, LEUKEMIA, V18, P505, DOI 10.1038/sj.leu.2403275; Lang D, 1995, NEUROSCI LETT, V201, P199, DOI 10.1016/0304-3940(95)12178-1; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; Levy EI, 2004, J NEUROSURG, V100, P688, DOI 10.3171/jns.2004.100.4.0688; Maasho K, 2004, J IMMUNOL METHODS, V284, P133, DOI 10.1016/j.jim.2003.10.010; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Mischel PS, 2003, BRAIN PATHOL, V13, P52; Mischel PS, 2003, CANCER BIOL THER, V2, P242, DOI 10.4161/cbt.2.3.369; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Newton Herbert B, 2004, Expert Rev Anticancer Ther, V4, P105, DOI 10.1586/14737140.4.1.105; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Noh WC, 2004, CLIN CANCER RES, V10, P1013, DOI 10.1158/1078-0432.CCR-03-0043; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Rodriguez Alfredo E, 2003, J Invasive Cardiol, V15, P515; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schlegel J, 2002, ANN NY ACAD SCI, V973, P224, DOI 10.1111/j.1749-6632.2002.tb04638.x; Schlegel J, 2002, ANTICANCER RES, V22, P2837; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schondorf T, 2004, ANTI-CANCER DRUG, V15, P265, DOI 10.1097/01.cad.0000119457.84063.cb; Steck PA, 1999, GENE CHROMOSOME CANC, V24, P135, DOI 10.1002/(SICI)1098-2264(199902)24:2<135::AID-GCC6>3.0.CO;2-A; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Thomas CY, 2003, INT J CANCER, V104, P19, DOI 10.1002/ijc.10880; Xu G, 2004, INT J ONCOL, V24, P893; Yu K, 2001, ENDOCR-RELAT CANCER, V8, P249, DOI 10.1677/erc.0.0080249	51	11	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					407	414		10.1038/sj.onc.1209791	http://dx.doi.org/10.1038/sj.onc.1209791			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832347				2022-12-25	WOS:000243544000009
J	Walker, SR; Nelson, EA; Frank, DA				Walker, S. R.; Nelson, E. A.; Frank, D. A.			STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas	ONCOGENE			English	Article						STAT5; BCL6; transcription; chromatin	B-CELL LYMPHOMA; AFFECTING BAND 3Q27; CHRONIC MYELOGENOUS LEUKEMIA; CONSTITUTIVE ACTIVATION; SIGNAL TRANSDUCER; GENE-EXPRESSION; SELF-RENEWAL; DIFFERENTIATION; TRANSLOCATIONS; IDENTIFICATION	Deregulated expression of BCL6 is a pathogenic event in many lymphomas. BCL6 blocks cellular differentiation by repressing transcription of its target genes, and this may promote tumorigenesis. Conversely, the transcription factor signal transducers and activators of transcription (STAT) 5 promotes differentiation in many systems. STAT5 upregulates a number of genes repressed by BCL6, raising the possibility that STAT5 and BCL6 have opposing roles in transcriptional regulation. Therefore, we sought to determine the effects of STAT5 activation on BCL6 expression and function. We found that activation of STAT5 downregulates BCL6 expression in B-lymphoma cells and other hematopoietic cell lines. We identified two potential STAT-binding regions in the first exon and first intron of BCL6 that fell within regions of high interspecies homology, suggesting conservation of regulatory function. STAT5 can bind inducibly and regulate transcription at one of these regions, identifying BCL6 as a STAT5 target gene. Additionally, STAT5-mediated downregulation of BCL6 results in loss of BCL6 repression of its target genes, confirming that STAT5 is a negative regulator of BCL6 function. The STAT5 responsive region of the BCL6 gene is mutated frequently in B-cell lymphomas, suggesting that loss of the repressive effects of STAT5 on BCL6 might contribute to the pathogenesis of these cancers.	Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Frank, DA (corresponding author), Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, 44 Binney St,M522B, Boston, MA 02115 USA.	david_frank@dfci.harvard.edu						Alvarez JV, 2005, CANCER RES, V65, P5054, DOI 10.1158/0008-5472.CAN-04-4281; BajalicaLagercrantz S, 1997, LEUKEMIA, V11, P594, DOI 10.1038/sj.leu.2400577; Baron BW, 2004, P NATL ACAD SCI USA, V101, P14198, DOI 10.1073/pnas.0406138101; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; Battle TE, 2003, BLOOD, V102, P3016, DOI 10.1182/blood-2002-09-2972; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brudno M, 2004, GENOME RES, V14, P685, DOI 10.1101/gr.2067704; Buitenhuis M, 2003, BLOOD, V101, P134, DOI 10.1182/blood-2002-03-0740; Cattoretti G, 2005, CANCER CELL, V7, P445, DOI 10.1016/j.ccr.2005.03.037; Chaganti SR, 1998, GENE CHROMOSOME CANC, V23, P323, DOI 10.1002/(SICI)1098-2264(199812)23:4<323::AID-GCC7>3.3.CO;2-V; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; Cui Y, 2004, MOL CELL BIOL, V24, P8037, DOI 10.1128/MCB.24.18.8037-8047.2004; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; de Mattos SF, 2004, MOL CELL BIOL, V24, P10058, DOI 10.1128/MCB.24.22.10058-10071.2004; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Frank DA, 1999, MOL MED, V5, P432; FRANK DA, 1995, P NATL ACAD SCI USA, V92, P7779, DOI 10.1073/pnas.92.17.7779; Fujita N, 2004, CELL, V119, P75, DOI 10.1016/j.cell.2004.09.014; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; HAPP B, 1993, J STEROID BIOCHEM, V47, P21, DOI 10.1016/0960-0760(93)90053-Y; Hardison RC, 1997, GENOME RES, V7, P959, DOI 10.1101/gr.7.10.959; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Ichinohasama R, 1998, CANCER GENET CYTOGEN, V104, P19, DOI 10.1016/S0165-4608(97)00412-3; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kikuchi M, 2000, ONCOGENE, V19, P4941, DOI 10.1038/sj.onc.1203864; Leong PL, 2002, ONCOGENE, V21, P2846, DOI 10.1038/sj.onc.1205385; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Logarajah S, 2003, ONCOGENE, V22, P5572, DOI 10.1038/sj.onc.1206689; Lossos IS, 2003, LEUKEMIA, V17, P1390, DOI 10.1038/sj.leu.2402997; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Melzner I, 2005, BLOOD, V105, P2535, DOI 10.1182/blood-2004-09-3701; Messika EJ, 1998, J EXP MED, V188, P515, DOI 10.1084/jem.188.3.515; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; Moriggl R, 2005, CANCER CELL, V7, P87, DOI 10.1016/j.ccr.2004.12.010; Nakajima H, 2001, EMBO J, V20, P6836, DOI 10.1093/emboj/20.23.6836; Nelson EA, 2004, J BIOL CHEM, V279, P54724, DOI 10.1074/jbc.M408464200; Niu HF, 2003, J EXP MED, V198, P211, DOI 10.1084/jem.20021395; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; OHASHI K, 1995, BIOCHEM BIOPH RES CO, V214, P461, DOI 10.1006/bbrc.1995.2309; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Otaki JM, 2005, NEUROSCI RES, V53, P189, DOI 10.1016/j.neures.2005.06.018; Pasqualucci L, 2003, BLOOD, V101, P2914, DOI 10.1182/blood-2002-11-3387; Rascle A, 2003, MOL CELL BIOL, V23, P4162, DOI 10.1128/MCB.23.12.4162-4173.2003; Robertson MJ, 1996, EXP HEMATOL, V24, P406; Scheeren FA, 2005, NAT IMMUNOL, V6, P303, DOI 10.1038/ni1172; Schuringa JJ, 2004, J EXP MED, V200, P623, DOI 10.1084/jem.20041024; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Shuai K, 1996, ONCOGENE, V13, P247; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Xi SC, 2003, CANCER RES, V63, P6763; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BHH, 1993, CANCER RES, V53, P2732; Zhou G, 2005, EXP MOL PATHOL, V78, P25, DOI 10.1016/j.yexmp.2004.08.008	62	91	91	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	2					224	233		10.1038/sj.onc.1209775	http://dx.doi.org/10.1038/sj.onc.1209775			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819511				2022-12-25	WOS:000243398300006
J	Wang, X; Zhao, J				Wang, X.; Zhao, J.			KLF8 transcription factor participates in oncogenic transformation	ONCOGENE			English	Article						KLF8; transformation; v-Src	FOCAL ADHESION KINASE; TUMOR-SUPPRESSOR GENE; CELL-CYCLE; COLORECTAL-CANCER; PROSTATE-CANCER; OVARIAN-CANCER; HUMAN BREAST; FAK; PROGRESSION; EXPRESSION	Kruppel-like factor 8 (KLF8) is a member of the family of KLF transcription factors. Several KLF members have been shown to play a role in oncogenesis. We have previously demonstrated that KLF8 mediates cell cycle progression downstream of focal adhesion kinase (FAK) by upregulating cyclin D1. FAK plays a critical role in transformation and tumorigenesis and is aberrantly upregulated in many types of human cancer. Little is known about the function of KLF8 in these regards. Here we provide evidence suggesting a novel role of KLF8 in oncogenic transformation. We show that KLF8 expression is elevated in several types of human cancer cells and primary tumor tissues. Induced expression of ectopic KLF8 causes serum-independent growth and morphological transformation in NIH3T3 cells and enhances anchorage-independent growth of v-Src-transformed cells. In contrast, expression of a dominant-negative mutant of KLF8 dramatically suppresses the transformed phenotypes induced by v-Src. In addition, the KLF8-enhanced transformation in the v-Src cells was prevented by ablating cyclin D1 expression. Overall, these results indicate that KLF8 is required for v-Src-induced transformation and may play a role in tumor progression of human cancer.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College	Zhao, J (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, 47 New Scotland Ave,Mail Code 165,MS338, Albany, NY 12208 USA.	zhaojh@mail.amc.edu						Benlimame N, 2005, J CELL BIOL, V171, P505, DOI 10.1083/jcb.200504124; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Cance WG, 2000, CLIN CANCER RES, V6, P2417; Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Dong JT, 2001, CANCER METAST REV, V20, P173, DOI 10.1023/A:1015575125780; Ellenrieder V, 2004, GASTROENTEROLOGY, V127, P607, DOI 10.1053/j.gastro.2004.05.018; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Ghaleb AM, 2005, CELL RES, V15, P92, DOI 10.1038/sj.cr.7290271; Grisaru-Granovsky S, 2005, INT J CANCER, V113, P372, DOI 10.1002/ijc.20607; Kimmelman AC, 2004, ONCOGENE, V23, P5077, DOI 10.1038/sj.onc.1207662; Leslie K, 2006, CANCER RES, V66, P2544, DOI 10.1158/0008-5472.CAN-05-2203; Lim KH, 2004, MOL CELL, V15, P491, DOI 10.1016/j.molcel.2004.08.014; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; McLean GW, 2004, GENE DEV, V18, P2998, DOI 10.1101/gad.316304; Nandan MO, 2004, ONCOGENE, V23, P3404, DOI 10.1038/sj.onc.1207397; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Sood AK, 2004, AM J PATHOL, V165, P1087, DOI 10.1016/S0002-9440(10)63370-6; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; van Nimwegen MJ, 2005, CANCER RES, V65, P4698, DOI 10.1158/0008-5472.CAN-04-4126; van Vliet J, 2000, NUCLEIC ACIDS RES, V28, P1955; Wei HJ, 2006, J BIOL CHEM, V281, P16664, DOI 10.1074/jbc.M513135200; Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066; Zhao JH, 2000, J CELL SCI, V113, P3063; Zhao JH, 2003, MOL CELL, V11, P1503, DOI 10.1016/S1097-2765(03)00179-5; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	32	88	102	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					456	461		10.1038/sj.onc.1209796	http://dx.doi.org/10.1038/sj.onc.1209796			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832343				2022-12-25	WOS:000243544000014
J	Tremouilhac, P; Strandberg, E; Wadhwani, P; Ulrich, AS				Tremouilhac, Pierre; Strandberg, Erik; Wadhwani, Parvesh; Ulrich, Anne S.			Synergistic transmembrane alignment of the antimicrobial heterodimer PGLa/magainin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-STATE NMR; MAGNETIC-RESONANCE-SPECTROSCOPY; LIPID-BILAYERS; PEPTIDE PGLA; ESCHERICHIA-COLI; XENOPUS-LAEVIS; MAGAININ 2; F-19 NMR; MEMBRANES; ORIENTATION	The antimicrobial activity of amphipathic alpha-helical peptides is usually attributed to the formation of pores in bacterial membranes, but direct structural information about such a membrane-bound state is sparse. Solid state H-2-NMR has previously shown that the antimicrobial peptide PGLa undergoes a concentration-dependent realignment from a surface-bound S-state to a tilted T-state. The corresponding change in helix tilt angle from 98 to 125 was interpreted as the formation of PGLa/magainin hetero-dimers residing on the bilayer surface. Under no conditions so far, has an upright membrane-inserted I-state been observed in which a transmembrane helix alignment would be expected. Here, we have demonstrated that PGLa is able to assume such an I-state in a 1: 1 mixture with magainin 2 at a peptide-to-lipid ratio as low as 1: 100 in dimyristoylphosphatidylcholine/dimyristoylphosphatidylglycerol model membranes. This H-2-NMR analysis is based on seven orientational constraints from Ala-3,3,3-d(3) substituted in a non-perturbing manner for four native Ala residues as well as two Ile and one Gly. The observed helix tilt of 158 is rationalized by the formation of heterodimers. This structurally synergistic effect between the two related peptides from the skin of Xenopus laevis correlates very well with their known functional synergistic mode of action. To our knowledge, this example of PGLa is the first case where an alpha-helical antimicrobial peptide is directly shown to assume a transmembrane state that is compatible with the postulated toroidal wormhole pore structure.	Univ Karlsruhe, Inst Organ Chem, D-76131 Karlsruhe, Germany; Forschungszentrum Karlsruhe, Inst Biol Interfaces, D-76344 Eggenstein Leopoldshafen, Germany	Helmholtz Association; Karlsruhe Institute of Technology; Helmholtz Association; Karlsruhe Institute of Technology	Ulrich, AS (corresponding author), Univ Karlsruhe, Inst Organ Chem, Fritz Haber Weg 6, D-76131 Karlsruhe, Germany.	anne.ulrich@ibg.fzk.de	Ulrich, Anne S/H-5519-2013	Ulrich, Anne S/0000-0001-5571-9483; Tremouilhac, Pierre/0000-0002-0487-3947; Wadhwani, Parvesh/0000-0002-7290-5154; Strandberg, Erik/0000-0002-2401-7478				Afonin S, 2004, MAGN RESON CHEM, V42, P195, DOI 10.1002/mrc.1340; Bechinger B, 1998, BIOPHYS J, V74, P981, DOI 10.1016/S0006-3495(98)74021-4; BECHINGER B, 1993, PROTEIN SCI, V2, P2077, DOI 10.1002/pro.5560021208; DEWAAL A, 1991, FEBS LETT, V293, P219, DOI 10.1016/0014-5793(91)81191-A; Glaser RW, 2005, BIOPHYS J, V88, P3392, DOI 10.1529/biophysj.104.056424; Glaser RW, 2004, J MAGN RESON, V168, P153, DOI 10.1016/j.jmr.2004.02.008; Glaser RW, 2003, J MAGN RESON, V164, P104, DOI 10.1016/S1090-7807(03)00207-6; GOMES AV, 1993, BIOCHEMISTRY-US, V32, P5365, DOI 10.1021/bi00071a011; Hallock KJ, 2003, BIOPHYS J, V84, P3052, DOI 10.1016/S0006-3495(03)70031-9; Hancock REW, 1999, ANTIMICROB AGENTS CH, V43, P1317, DOI 10.1128/AAC.43.6.1317; Hara T, 2001, BIOCHEMISTRY-US, V40, P12395, DOI 10.1021/bi011413v; HOFFMANN W, 1983, EMBO J, V2, P711, DOI 10.1002/j.1460-2075.1983.tb01489.x; Huang HW, 2000, BIOCHEMISTRY-US, V39, P8347, DOI 10.1021/bi000946l; JURETIC D, 1990, STUD BIOPHYS, V138, P79; Lee DK, 1999, J PHYS CHEM B, V103, P8383, DOI 10.1021/jp9914929; Ludtke SJ, 1996, BIOCHEMISTRY-US, V35, P13723, DOI 10.1021/bi9620621; Marassi FM, 1999, APPL MAGN RESON, V17, P433, DOI 10.1007/BF03162176; Massiot D, 2002, MAGN RESON CHEM, V40, P70, DOI 10.1002/mrc.984; Matsuzaki K, 1998, BBA-REV BIOMEMBRANES, V1376, P391, DOI 10.1016/S0304-4157(98)00014-8; Matsuzaki K, 1999, FEBS LETT, V449, P221, DOI 10.1016/S0014-5793(99)00443-3; Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P15144, DOI 10.1021/bi9811617; MATSUZAKI K, 1991, BIOCHIM BIOPHYS ACTA, V1063, P162, DOI 10.1016/0005-2736(91)90366-G; Nagle JF, 2000, BBA-REV BIOMEMBRANES, V1469, P159, DOI 10.1016/S0304-4157(00)00016-2; Opella SJ, 2004, CHEM REV, V104, P3587, DOI 10.1021/cr0304121; RICHTER K, 1985, PEPTIDES, V6, P17, DOI 10.1016/0196-9781(85)90345-6; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; SORAVIA E, 1988, FEBS LETT, V228, P337, DOI 10.1016/0014-5793(88)80027-9; Strandberg E, 2006, BIOPHYS J, V90, P1676, DOI 10.1529/biophysj.105.073858; Strandberg E, 2004, CONCEPT MAGN RESON A, V23A, P89, DOI 10.1002/cmr.a.20024; Strandberg E, 2004, BIOPHYS J, V86, P3709, DOI 10.1529/biophysj.103.035402; TREMOUILHAC P, 2006, IN PRESS BIOCH BIOPH; Ulrich A. S., 2006, NMR SPECTROSCOPY BIO, P215; Ulrich AS, 2005, PROG NUCL MAG RES SP, V46, P1, DOI 10.1016/j.pnmrs.2004.11.001; ULRICH AS, 1992, BIOCHEMISTRY-US, V31, P10390, DOI 10.1021/bi00157a029; van der Wel PCA, 2002, BIOPHYS J, V83, P1479, DOI 10.1016/S0006-3495(02)73918-0; van 't Hof W, 2001, BIOL CHEM, V382, P597, DOI 10.1515/BC.2001.072; WESTERHOFF HV, 1995, EUR J BIOCHEM, V228, P257; Wieprecht T, 2000, BIOCHEMISTRY-US, V39, P442, DOI 10.1021/bi992146k; WILLIAMS RW, 1990, BIOCHEMISTRY-US, V29, P4490, DOI 10.1021/bi00470a031; Yang L, 2000, BIOPHYS J, V79, P2002, DOI 10.1016/S0006-3495(00)76448-4; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	42	89	90	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32089	32094		10.1074/jbc.M604759200	http://dx.doi.org/10.1074/jbc.M604759200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16877761	hybrid			2022-12-25	WOS:000241414500006
J	Moulis, C; Joucla, G; Harrison, D; Fabre, E; Potocki-Veronese, G; Monsan, P; Remaud-Simeon, M				Moulis, Claire; Joucla, Gilles; Harrison, David; Fabre, Emeline; Potocki-Veronese, Gabrielle; Monsan, Pierre; Remaud-Simeon, Magali			Understanding the polymerization mechanism of glycoside-hydrolase family 70 glucansucrases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESENTEROIDES NRRL B-512F; NEISSERIA-POLYSACCHAREA AMYLOSUCRASE; ALPHA-AMYLASE FAMILY; AMINO-ACID-RESIDUES; LEUCONOSTOC-MESENTEROIDES; MOLECULAR CHARACTERIZATION; OLIGOSACCHARIDE SYNTHESIS; STREPTOCOCCUS-SOBRINUS; DEXTRANSUCRASE ACTION; SEQUENCE-ANALYSIS	Glucan formation catalyzed by two GH-family 70 enzymes, Leuconostoc mesenteroides NRRL B-512F dextransucrase and L. mesenteroides NRRL B-1355 alternansucrase, was investigated by combining biochemical and kinetic characterization of the recombinant enzymes and their respective products. Using HPAEC analysis, we showed that two molecules act as initiator of polymerization: sucrose itself and glucose produced by hydrolysis, the latter being preferred when produced in sufficient amounts. Then, elongation occurs by transfer of the glucosyl residue coming from sucrose to the non-reducing end of initially formed products. Dextransucrase preferentially produces an isomaltooligosaccharide series, whose concentration is always low because of the high ability of these products to be elongated and form high molecular weight dextran. Compared with dextransucrase, alternansucrase has a broader specificity. It produces a myriad of oligosaccharides with various alpha-1,3 and/or alpha-1,6 links in early reaction stages. Only some of them are further elongated. Overall alternan polymer is smaller in size than dextran. In dextransucrase, the A repeats often found in C-terminal domain of GH-family 70 were found to play a major role in efficient dextran elongation. Their truncation result in an enzyme much less efficient to catalyze high molecular weight polymer formation. It is thus proposed that, in dextransucrase, the A repeats define anchoring zones for the growing chains, favoring their elongation. Based on these results, a semi-processive mechanism involving only one active site and an elongation by the non-reducing end is proposed for the GH-family 70 glucansucrases.	CNRS, UMR 5504, Lab Biotechnol Bioproc, UMR 792,INRA,INSA, F-31077 Toulouse 4, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); INRAE; Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Institut National des Sciences Appliquees de Toulouse	Remaud-Simeon, M (corresponding author), CNRS, UMR 5504, Lab Biotechnol Bioproc, UMR 792,INRA,INSA, 135 Ave Rangueil, F-31077 Toulouse 4, France.	remaud@insa-toulouse.fr	Veronese, Gabrielle/GTF-3473-2022	MOULIS, Claire/0000-0002-1937-9052; Joucla, Gilles/0000-0003-4192-9628				Albenne C, 2004, J BIOL CHEM, V279, P726, DOI 10.1074/jbc.M309891200; Arguello-Morales MA, 2000, FEMS MICROBIOL LETT, V182, P81, DOI 10.1016/S0378-1097(99)00572-8; BARIK S, 1995, MOL BIOTECHNOL, V3, P1, DOI 10.1007/BF02821329; Bozonnet S, 2002, J BACTERIOL, V184, P5753, DOI 10.1128/JB.184.20.5753-5761.2002; CHEETHAM NH, 1991, CARBOHYD POLYM, V16, P349; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; De Montalk GP, 1999, J BACTERIOL, V181, P375; Devulpalle KS, 1997, PROTEIN SCI, V6, P2489; DITSON SL, 1984, CARBOHYD RES, V126, P170, DOI 10.1016/0008-6215(84)85135-6; EBERT KH, 1968, ADV ENZYMOL RAMB, V30, P179; Funane K, 1998, BIOSCI BIOTECH BIOCH, V62, P123, DOI 10.1271/bbb.62.123; Funane K, 2005, FEBS LETT, V579, P4739, DOI 10.1016/j.febslet.2005.07.050; Jensen MH, 2004, BIOCHEMISTRY-US, V43, P3104, DOI 10.1021/bi0357762; Joucla G, 2006, FEBS LETT, V580, P763, DOI 10.1016/j.febslet.2006.01.001; KATO C, 1992, BIOCHEM BIOPH RES CO, V189, P1184, DOI 10.1016/0006-291X(92)92329-V; KOBAYASHI M, 1986, AGR BIOL CHEM TOKYO, V50, P2585, DOI 10.1080/00021369.1986.10867780; KOEPSELL HJ, 1953, J BIOL CHEM, V200, P793; Kralj S, 2002, APPL ENVIRON MICROB, V68, P4283, DOI 10.1128/AEM.68.9.4283-4291.2002; Kralj S, 2004, MICROBIOL-SGM, V150, P3681, DOI 10.1099/mic.0.27321-0; Kralj S, 2005, BIOCHEMISTRY-US, V44, P9206, DOI 10.1021/bi050447q; MACGREGOR EA, 1996, FEBS LETT, V378, P266; MILLER AW, 1986, ANAL BIOCHEM, V156, P357, DOI 10.1016/0003-2697(86)90266-6; Monchois V, 1997, APPL MICROBIOL BIOT, V48, P465, DOI 10.1007/s002530051081; Monchois V, 1998, APPL ENVIRON MICROB, V64, P1644; Monchois V, 1999, FEMS MICROBIOL REV, V23, P131, DOI 10.1016/S0168-6445(98)00041-2; Monsan P, 2001, INT DAIRY J, V11, P675, DOI 10.1016/S0958-6946(01)00113-3; MOOSER G, 1989, BIOCHEMISTRY-US, V28, P443, DOI 10.1021/bi00428a006; MOOSER G, 1991, J BIOL CHEM, V266, P8916; MOOSER G, 1992, ENZYMES, V20, P188; Moulis C, 2006, FEMS MICROBIOL LETT, V261, P203, DOI 10.1111/j.1574-6968.2006.00347.x; Pizzut-Serin S, 2005, FEBS LETT, V579, P1405, DOI 10.1016/j.febslet.2004.12.097; Remaud-Simeon M, 2000, J MOL CATAL B-ENZYM, V10, P117, DOI 10.1016/S1381-1177(00)00119-3; Richard GT, 2003, CARBOHYD RES, V338, P855, DOI 10.1016/S0008-6215(03)00070-3; ROBYT JF, 1974, ARCH BIOCHEM BIOPHYS, V165, P634, DOI 10.1016/0003-9861(74)90291-4; Robyt JF, 1995, ADV CARBOHYD CHEM BI, V51, P133, DOI 10.1016/S0065-2318(08)60193-6; ROBYT JF, 1983, CARBOHYD RES, V113, P301, DOI 10.1016/0008-6215(83)88245-7; ROBYT JF, 1978, CARBOHYD RES, V61, P433, DOI 10.1016/S0008-6215(00)84503-6; Sarcabal P, 2000, FEBS LETT, V474, P33, DOI 10.1016/S0014-5793(00)01567-2; Skov LK, 2002, J BIOL CHEM, V277, P47741, DOI 10.1074/jbc.M207860200; Skov LK, 2001, J BIOL CHEM, V276, P25273, DOI 10.1074/jbc.M010998200; STODOLA FH, 1952, J AM CHEM SOC, V74, P3202, DOI 10.1021/ja01132a540; SU DL, 1994, ARCH BIOCHEM BIOPHYS, V308, P471, DOI 10.1006/abbi.1994.1067; SUMNER JAMES B., 1935, JOUR BIOL CHEM, V108, P51; TSUCHIYA HM, 1953, J AM CHEM SOC, V75, P757, DOI 10.1021/ja01099a521; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235	47	114	121	1	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31254	31267		10.1074/jbc.M604850200	http://dx.doi.org/10.1074/jbc.M604850200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16864576				2022-12-25	WOS:000241235300010
J	Djavaheri-Mergny, M; Amelotti, M; Mathieu, J; Besancon, F; Bauvy, C; Souquere, S; Pierron, G; Codogno, P				Djavaheri-Mergny, Mojgan; Amelotti, Manuela; Mathieu, Julie; Besancon, Francoise; Bauvy, Chantal; Souquere, Sylvie; Pierron, Gerard; Codogno, Patrice			NF-kappa B activation represses tumor necrosis factor-alpha-induced autophagy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; OXIDATIVE STRESS; UP-REGULATION; CANCER; INDUCTION; SURVIVAL; LIFE; INHIBITION	Activation of NF-kappa B and autophagy are two processes involved in the regulation of cell death, but the possible crosstalk between these two signaling pathways is largely unknown. Here, we show that NF-kappa B activation mediates repression of autophagy in tumor necrosis factor-alpha (TNF alpha)-treated Ewing sarcoma cells. This repression is associated with an NF-kappa B-dependent activation of the autophagy inhibitor mTOR. In contrast, in cells lacking NF-kappa B activation, TNF alpha treatment up-regulates the expression of the autophagy-promoting protein Beclin 1 and subsequently induces the accumulation of autophagic vacuoles. Both of these responses are dependent on reactive oxygen species (ROS) production and can be mimicked in NF-kappa B-competent cells by the addition of H2O2. Small interfering RNA-mediated knockdown of beclin 1 and atg7 expression, two autophagy-related genes, reduced TNF alpha- and reactive oxygen species-induced apoptosis in cells lacking NF-kappa B activation and in NF-kappa B-competent cells, respectively. These findings demonstrate that autophagy may amplify apoptosis when associated with a death signaling pathway. They are also evidence that inhibition of autophagy is a novel mechanism of the antiapoptotic function of NF-kappa B activation. We suggest that stimulation of autophagy may be a potential way bypassing the resistance of cancer cells to anti-cancer agents that activate NF-kappa B.	Univ Paris Sud, Fac Pharm, INSERM, U756, F-92296 Chatenay Malabry, France; San Paolo Med Sch, Biochem & Mol Biol Lab, I-20142 Milan, Italy; Hop St Louis, INSERM, U685, Ctr Hayem, F-75475 Paris 10, France; CNRS, UPR 1983, Inst Andre Lwoff, Lab Replicat ADN & Ultrastruct Noyau, F-94801 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)	Djavaheri-Mergny, M (corresponding author), Univ Paris Sud, Fac Pharm, INSERM, U756, 5 Rue Jean Baptiste Clement, F-92296 Chatenay Malabry, France.	mojgan.mergny@cep.u-psud.fr	Djavaheri-Mergny, Mojgan/N-6315-2017; Codogno, Patrice/G-1384-2013; Djavaheri-Mergny, Mojgan/L-3890-2019	Djavaheri-Mergny, Mojgan/0000-0003-4893-6505; Codogno, Patrice/0000-0002-5492-3180; Djavaheri-Mergny, Mojgan/0000-0003-4893-6505				Alva AS, 2004, CELL DEATH DIFFER, V11, P1046, DOI 10.1038/sj.cdd.4401445; Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Brouard S, 2002, J BIOL CHEM, V277, P17950, DOI 10.1074/jbc.M108317200; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Djavaheri-Mergny M, 2004, FEBS LETT, V578, P111, DOI 10.1016/j.febslet.2004.10.082; Gomez-Santos C, 2003, J NEUROSCI RES, V73, P341, DOI 10.1002/jnr.10663; Iwanaga M, 1998, FREE RADICAL BIO MED, V24, P1256, DOI 10.1016/S0891-5849(97)00443-7; Jaattela M, 2004, ONCOGENE, V23, P2746, DOI 10.1038/sj.onc.1207513; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Jia L, 1997, BRIT J HAEMATOL, V98, P673, DOI 10.1046/j.1365-2141.1997.2623081.x; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Lavieu G, 2006, J BIOL CHEM, V281, P8518, DOI 10.1074/jbc.M506182200; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Martin DN, 2004, DEVELOPMENT, V131, P275, DOI 10.1242/dev.00933; Mathieu J, 2005, ONCOGENE, V24, P7145, DOI 10.1038/sj.onc.1208889; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Ollinger K, 1997, J BIOL CHEM, V272, P23707, DOI 10.1074/jbc.272.38.23707; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pattingre S, 2004, METHOD ENZYMOL, V390, P17; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200; Saeki K, 2000, CELL DEATH DIFFER, V7, P1263, DOI 10.1038/sj.cdd.4400759; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; Tomas-Zapico C, 2005, FASEB J, V19, P2066, DOI 10.1096/fj.04-3595fje; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Xu Y, 2006, J BIOL CHEM, V281, P19179, DOI 10.1074/jbc.M513377200; Xue L, 2001, CURR BIOL, V11, P361, DOI 10.1016/S0960-9822(01)00100-2; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Zheng L, 2006, NEUROSCI LETT, V394, P184, DOI 10.1016/j.neulet.2005.10.035; Zhou A, 2003, ONCOGENE, V22, P2054, DOI 10.1038/sj.onc.1206262	61	380	410	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30373	30382		10.1074/jbc.M602097200	http://dx.doi.org/10.1074/jbc.M602097200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16857678	Green Published, hybrid			2022-12-25	WOS:000241075900011
J	Goda, E; Kamiyama, S; Uno, T; Yoshida, H; Ueyama, M; Kinoshita-Toyoda, A; Toyoda, H; Ueda, R; Nishihara, S				Goda, Emi; Kamiyama, Shin; Uno, Takaaki; Yoshida, Hideki; Ueyama, Morio; Kinoshita-Toyoda, Akiko; Toyoda, Hidenao; Ueda, Ryu; Nishihara, Shoko			Identification and characterization of a novel Drosophila 3 '-phosphoadenosine 5 '-phosphosulfate transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; NUCLEOTIDE-SUGAR TRANSPORTER; MOLECULAR-CLONING; TOUT-VELU; FRINGE CONNECTION; SALIVARY-GLAND; GENE; MELANOGASTER; EXPRESSION; GLYCOSAMINOGLYCANS	Sulfation of macromolecules requires the translocation of a high energy form of nucleotide sulfate, i.e. 3'-phosphoadenosine 5'-phosphosulfate ( PAPS), from the cytosol into the Golgi apparatus. In this study, we identified a novel Drosophila PAPS transporter gene dPAPST2 by conducting data base searches and screening the PAPS transport activity among the putative nucleotide sugar transporter genes in Drosophila. The amino acid sequence of dPAPST2 showed 50.5 and 21.5% homology to the human PAPST2 and SLALOM, respectively. The heterologous expression of dPAPST2 in yeast revealed that the dPAPST2 protein is a PAPS transporter with an apparent K-m value of 2.3 mu M. The RNA interference of dPAPST2 in cell line and flies showed that the dPAPST2 gene is essential for the sulfation of cellular proteins and the viability of the fly. In RNA interference flies, an analysis of the genetic interaction between dPAPST2 and genes that contribute to glycosaminoglycan synthesis suggested that dPAPST2 is involved in the glycosaminoglycan synthesis and the subsequent signaling. The dPAPST2 and sll genes showed a similar ubiquitous distribution. These results indicate that dPAPST2 may be involved in Hedgehog and Decapentaplegic signaling by controlling the sulfation of heparan sulfate.	Soka Univ, Cell Biol Lab, Dept Bioinformat, Hachioji, Tokyo 1928577, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Chiba Univ, Fac Pharmaceut Sci, Dept Analyt Chem, Chiba 2638522, Japan; Natl Inst Genet, Invertebrate Genet Lab, Shizuoka 4418540, Japan	Soka University; Japan Science & Technology Agency (JST); Chiba University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Nishihara, S (corresponding author), Soka Univ, Cell Biol Lab, Dept Bioinformat, 1-236 Tangi Cho, Hachioji, Tokyo 1928577, Japan.	shoko@t.soka.ac.jp		Ueyama, Morio/0000-0002-2950-7361; Nishihara, Shoko/0000-0002-1668-2603				Baeg GH, 2001, DEVELOPMENT, V128, P87; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Brook WJ, 1996, ANNU REV CELL DEV BI, V12, P161, DOI 10.1146/annurev.cellbio.12.1.161; DENNIS RD, 1991, CELL TISSUE RES, V265, P589, DOI 10.1007/BF00340883; Fu WM, 2003, DEVELOPMENT, V130, P5229, DOI 10.1242/dev.00764; Goto S, 2001, NAT CELL BIOL, V3, P816, DOI 10.1038/ncb0901-816; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; Ichimiya T, 2004, J BIOL CHEM, V279, P42638, DOI 10.1074/jbc.M404900200; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jullien D, 1997, MECH DEVELOP, V68, P179, DOI 10.1016/S0925-4773(97)00136-6; Kamimura K, 2001, J BIOL CHEM, V276, P17014, DOI 10.1074/jbc.M011354200; Kamimura K, 2004, J CELL BIOL, V166, P1069, DOI 10.1083/jcb.200403077; Kamiyama S, 2006, J BIOL CHEM, V281, P10945, DOI 10.1074/jbc.M508991200; Kamiyama S, 2004, TRENDS GLYCOSCI GLYC, V16, P109, DOI 10.4052/tigg.16.109; Kamiyama S, 2003, J BIOL CHEM, V278, P25958, DOI 10.1074/jbc.M302439200; Kurima K, 1998, P NATL ACAD SCI USA, V95, P8681, DOI 10.1073/pnas.95.15.8681; LI H, 1995, J BIOL CHEM, V270, P29453, DOI 10.1074/jbc.270.49.29453; Lin XH, 2004, DEVELOPMENT, V131, P6009, DOI 10.1242/dev.01522; Lin XH, 2000, MATRIX BIOL, V19, P303, DOI 10.1016/S0945-053X(00)00073-1; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lin XH, 1999, DEVELOPMENT, V126, P3715; Luders F, 2003, EMBO J, V22, P3635, DOI 10.1093/emboj/cdg345; Muraoka M, 2001, FEBS LETT, V495, P87, DOI 10.1016/S0014-5793(01)02358-4; Nakamura Y, 2002, J BIOL CHEM, V277, P46280, DOI 10.1074/jbc.M203873200; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Selleck SB, 2004, TRENDS GLYCOSCI GLYC, V16, P95, DOI 10.4052/tigg.16.95; Selva EM, 2001, NAT CELL BIOL, V3, P809, DOI 10.1038/ncb0901-809; Sen J, 1998, CELL, V95, P471, DOI 10.1016/S0092-8674(00)81615-3; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Suda T, 2004, J BIOL CHEM, V279, P26469, DOI 10.1074/jbc.M311353200; Tabata T, 2004, DEVELOPMENT, V131, P703, DOI 10.1242/dev.01043; Takei Y, 2004, DEVELOPMENT, V131, P73, DOI 10.1242/dev.00913; Takemae H, 2003, J BIOL CHEM, V278, P15571, DOI 10.1074/jbc.M301123200; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Tiralongo J, 2006, GLYCOBIOLOGY, V16, P73, DOI 10.1093/glycob/cwj029; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Wilson IBH, 2002, J BIOL CHEM, V277, P21207, DOI 10.1074/jbc.M201634200; Zhu XJ, 2005, DEVELOPMENT, V132, P3813, DOI 10.1242/dev.01962	40	18	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28508	28517		10.1074/jbc.M605045200	http://dx.doi.org/10.1074/jbc.M605045200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16873373	hybrid			2022-12-25	WOS:000240680500004
J	Guffanti, E; Percudani, R; Harismendy, O; Soutourina, J; Werner, M; Iacovella, MG; Negri, R; Dieci, G				Guffanti, Elisa; Percudani, Riccardo; Harismendy, Olivier; Soutourina, Julie; Werner, Michel; Iacovella, Maria Giuseppina; Negri, Rodolfo; Dieci, Giorgio			Nucleosome depletion activates poised RNA polymerase III at unconventional transcription sites in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST GENOME; HEAT-SHOCK; GENE; PROMOTER; EXPRESSION; UPSTREAM; U6; RETROTRANSPOSON; REINITIATION; ORGANIZATION	RNA polymerase (pol) III, assisted by the transcription factors TFIIIC and TFIIIB, transcribes small untranslated RNAs, such as tRNAs. In addition to known pol III-transcribed genes, the Saccharomyces cerevisiae genome contains loci (ZOD1, ETC1-8) associated to incomplete pol III transcription complexes (Moqtaderi, Z., and Struhl, K. (2004) Mol. Cell. Biol. 24, 4118-4127). We show that a short segment of the ZOD1 locus, containing box A and box B promoter elements and a termination signal between them, directs the pol III-dependent production of a small RNA both in vitro and in vivo. In yeast cells, the levels of both ZOD1- and ETC5-specific transcripts were dramatically enhanced upon nucleosome depletion. Remarkably, transcription factor and pol III occupancy at the corresponding loci did not change significantly upon derepression, thus suggesting that chromatin opening activates poised pol III to transcription. Comparative genomic analysis revealed that the ZOD1 promoter is the only surviving portion of a tDNA(Ile) ancestor, whose transcription capacity has been preserved throughout evolution independently from the encoded RNA product. Similarly, another TFIIIC/TFIIIB-associated locus, close to the YGR033c open reading frame, was found to be the strictly conserved remnant of an ancient tDNA(Arg). The maintenance, by eukaryotic genomes, of chromatin-repressed, non-coding transcription units has implications for both genome expression and organization.	Univ Parma, Dipartimento Biochim & Biol Mol, I-43100 Parma, Italy; CEA Saclay, Commiss Energie Atom, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France; Univ Roma La Sapienza, Dipartimento Biol Cellulare, Ist Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomembrane e Bioenergetica (IBBE-CNR); University of Parma; CEA; UDICE-French Research Universities; Universite Paris Saclay; Fondazione Cenci Bolognetti; Sapienza University Rome	Dieci, G (corresponding author), Univ Parma, Dipartimento Biochim & Biol Mol, Parco Area Sci 23-A, I-43100 Parma, Italy.	giorgio.dieci@unipr.it	Soutourina, Julie/F-8305-2014; Werner, Michel/B-7316-2009; Dieci, Giorgio/B-3434-2012; percudani, riccardo/B-4872-2011; Harismendy, Olivier/AAM-2072-2021	Soutourina, Julie/0000-0001-5218-2350; Werner, Michel/0000-0002-2965-5858; Dieci, Giorgio/0000-0002-8792-3961; percudani, riccardo/0000-0001-8452-1062; Harismendy, Olivier/0000-0002-8098-9888; Iacovella, Maria Giuseppina/0000-0003-4564-9519				Allen TA, 2004, NAT STRUCT MOL BIOL, V11, P816, DOI 10.1038/nsmb813; Andrau JC, 1999, J MOL BIOL, V288, P511, DOI 10.1006/jmbi.1999.2724; Bachman N, 2005, GENE DEV, V19, P955, DOI 10.1101/gad.1299105; Bolton EC, 2003, GENOME RES, V13, P254, DOI 10.1101/gr.612203; Braglia P, 2005, J BIOL CHEM, V280, P19551, DOI 10.1074/jbc.M412238200; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; BURNOL AF, 1993, NATURE, V362, P475, DOI 10.1038/362475a0; CHALKER DL, 1992, GENE DEV, V6, P117, DOI 10.1101/gad.6.1.117; Conesa C, 2005, MOL CELL BIOL, V25, P8631, DOI 10.1128/MCB.25.19.8631-8642.2005; Devine SE, 1996, GENE DEV, V10, P620, DOI 10.1101/gad.10.5.620; Dieci G, 2000, J MOL BIOL, V299, P601, DOI 10.1006/jmbi.2000.3783; Dieci G, 2003, TRENDS BIOCHEM SCI, V28, P202, DOI 10.1016/S0968-0004(03)00054-9; Dieci G, 2002, J BIOL CHEM, V277, P6903, DOI 10.1074/jbc.M105036200; Donze D, 2001, EMBO J, V20, P520, DOI 10.1093/emboj/20.3.520; Ferrari R, 2004, P NATL ACAD SCI USA, V101, P13442, DOI 10.1073/pnas.0403851101; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; Harismendy O, 2003, EMBO J, V22, P4738, DOI 10.1093/emboj/cdg466; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Huet J, 1996, METHOD ENZYMOL, V273, P249; HULL MW, 1994, MOL CELL BIOL, V14, P1266, DOI 10.1128/MCB.14.2.1266; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Kuras Laurent, 2004, Methods Mol Biol, V284, P147; Kurtzman CP, 2003, FEMS YEAST RES, V3, P417, DOI 10.1016/S1567-1356(03)00012-6; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6986, DOI 10.1073/pnas.88.16.6986; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MARSOLIER MC, 1995, GENE DEV, V9, P410, DOI 10.1101/gad.9.4.410; Martens JA, 2004, NATURE, V429, P571, DOI 10.1038/nature02538; Moqtaderi Z, 2004, MOL CELL BIOL, V24, P4118, DOI 10.1128/MCB.24.10.4118-4127.2004; Noma KI, 2006, CELL, V125, P859, DOI 10.1016/j.cell.2006.04.028; Olivas WM, 1997, NUCLEIC ACIDS RES, V25, P4619, DOI 10.1093/nar/25.22.4619; Radonjic M, 2005, MOL CELL, V18, P171, DOI 10.1016/j.molcel.2005.03.010; Roberts DN, 2003, P NATL ACAD SCI USA, V100, P14695, DOI 10.1073/pnas.2435566100; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Simms TA, 2004, NUCLEIC ACIDS RES, V32, P5206, DOI 10.1093/nar/gkh858; WHITE RJ, 2002, RNA POLYM 3 TRANSCRI; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567	39	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29155	29164		10.1074/jbc.M600387200	http://dx.doi.org/10.1074/jbc.M600387200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16816405	hybrid			2022-12-25	WOS:000240680500070
J	Unno, H; Uchida, T; Sugawara, H; Kurisu, G; Sugiyama, T; Yamaya, T; Sakakibara, H; Hase, T; Kusunoki, M				Unno, Hideaki; Uchida, Tatsuya; Sugawara, Hajime; Kurisu, Genji; Sugiyama, Tatsuo; Yamaya, Tomoyuki; Sakakibara, Hitoshi; Hase, Toshiharu; Kusunoki, Masami			Atomic structure of plant glutamine synthetase - A key enzyme for plant productivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; METHIONINE SULFOXIMINE; ALPHA-POLYPEPTIDE; PROGRAM; INHIBITION; MICROSCOPY; EVOLUTION; MOLSCRIPT; ROOTS; GENES	Plants provide nourishment for animals and other heterotrophs as the sole primary producer in the food chain. Glutamine synthetase (GS), one of the essential enzymes for plant autotrophy catalyzes the incorporation of ammonia into glutamate to generate glutamine with concomitant hydrolysis of ATP, and plays a crucial role in the assimilation and re-assimilation of ammonia derived from a wide variety of metabolic processes during plant growth and development. Elucidation of the atomic structure of higher plant GS is important to understand its detailed reaction mechanism and to obtain further insight into plant productivity and agronomical utility. Here we report the first crystal structures of maize (Zea mays L.) GS. The structure reveals a unique decameric structure that differs significantly from the bacterial GS structure. Higher plants have several isoenzymes of GS differing in heat stability and catalytic properties for efficient responses to variation in the environment and nutrition. A key residue responsible for the heat stability was found to be Ile-161 in GS1a. The three structures in complex with substrate analogues, including phosphinothricin, a widely used herbicide, lead us to propose a mechanism for the transfer of phosphate from ATP to glutamate and to interpret the inhibitory action of phosphinothricin as a guide for the development of new potential herbicides.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; RIKEN, Ctr Plasma Sci, Yokohama, Kanagawa 2300045, Japan	Osaka University; RIKEN	Kusunoki, M (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kusunoki@protein.osaka-u.ac.jp	KURISU, GENJI/AAD-7109-2022; Hase, Toshiharu/H-9271-2013; KURISU, GENJI/ABA-5960-2020; Sakakibara, Hitoshi/A-6040-2010; Hideaki, UNNO/ABG-9471-2020	KURISU, GENJI/0000-0002-5354-0807; KURISU, GENJI/0000-0002-5354-0807; Sakakibara, Hitoshi/0000-0001-5449-6492; Hideaki, UNNO/0000-0001-5917-269X				Allen KN, 2004, TRENDS BIOCHEM SCI, V29, P495, DOI 10.1016/j.tibs.2004.07.008; ALMASSY RJ, 1986, NATURE, V323, P304, DOI 10.1038/323304a0; Buchanan B.B., 2000, BIOCH MOL BIOL PLANT; Clemente MT, 1999, PLANT MOL BIOL, V40, P835, DOI 10.1023/A:1006257323624; Clemente MT, 1999, EUR J BIOCHEM, V264, P453, DOI 10.1046/j.1432-1327.1999.00636.x; CULLIMORE JV, 1980, PLANTA, V150, P392, DOI 10.1007/BF00390175; Eisenberg D, 2000, BBA-PROTEIN STRUCT M, V1477, P122, DOI 10.1016/S0167-4838(99)00270-8; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; HASCHEMEYER RH, 1968, T NEW YORK ACAD SCI, V30, P875, DOI 10.1111/j.2164-0947.1968.tb02531.x; Ishiyama K, 2004, J BIOL CHEM, V279, P16598, DOI 10.1074/jbc.M313710200; Ishiyama K, 2004, PLANT CELL PHYSIOL, V45, P1640, DOI 10.1093/pcp/pch190; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawabata T, 2003, NUCLEIC ACIDS RES, V31, P3367, DOI 10.1093/nar/gkg581; Krajewski WW, 2005, P NATL ACAD SCI USA, V102, P10499, DOI 10.1073/pnas.0502248102; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMADA Y, 1993, P NATL ACAD SCI USA, V90, P3009, DOI 10.1073/pnas.90.7.3009; LOGUSCH EW, 1989, BIOCHEMISTRY-US, V28, P3043, DOI 10.1021/bi00433a046; Meister A., 1980, GLUTAMINE METABOLISM, P1; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RHEE SG, 1989, ADV ENZYMOL RAMB, V62, P37; RONZIO RA, 1969, BIOCHEMISTRY-US, V8, P1066, DOI 10.1021/bi00831a038; SAKAKIBARA H, 1992, PLANT CELL PHYSIOL, V33, P49; Sakakibara H, 1996, J BIOL CHEM, V271, P29561, DOI 10.1074/jbc.271.47.29561; SHAPIRO BM, 1968, BIOCHEMISTRY-US, V7, P2153, DOI 10.1021/bi00846a018; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; TSUPRUN VL, 1980, BIOCHIM BIOPHYS ACTA, V626, P1, DOI 10.1016/0005-2795(80)90190-7	31	112	120	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29287	29296		10.1074/jbc.M601497200	http://dx.doi.org/10.1074/jbc.M601497200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16829528	hybrid			2022-12-25	WOS:000240680500084
J	Belfield, JL; Whittaker, C; Cader, MZ; Chawla, S				Belfield, Johanna L.; Whittaker, Chris; Cader, M. Zaeem; Chawla, Sangeeta			Differential effects of Ca2+ and cAMP on transcription mediated by MEF2D and cAMP-response element-binding protein in hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE NEURONS; MYOCYTE-ENHANCER FACTOR-2; LONG-TERM POTENTIATION; GENE-EXPRESSION; CALCIUM-CHANNELS; CELLULAR-LOCALIZATION; SYNAPTIC PLASTICITY; CORTICAL-NEURONS; NERVOUS-SYSTEM; CROSS-TALK	In neurons, the second messengers Ca2+ and cAMP are mediators of transcriptional responses that are important for the development and function of the nervous system. The pro-survival neuronal transcription factors cAMP-response elementbinding protein (CREB) and myocyte enhancer factor-2 (MEF2) both stimulate gene expression in response to activity-dependent increases in the concentration of intracellular Ca2+ ions. CREB is also activated by increases in intracellular cAMP. Here we have investigated whether the MEF2 family member MEF2D, similar to CREB, is also activated by cAMP in hippocampal neurons. We have shown that, unlike CREB, MEF2D is not activated by agents that increase intracellular cAMP. Moreover, increases in cAMP inhibit Ca2+-activated MEF2D-mediated gene expression. We have also shown that cAMP inhibits Ca2+-induced nuclear export of the MEF2 co-repressor HDAC5 and prevents Ca2+-stimulated nuclear import of the MEF2 co-activator NFAT3/c4. Our results suggest that cAMP interferes with MEF2D-mediated gene expression at multiple levels by antagonizing the derepression of MEF2D by HDAC5 and by inhibiting recruitment of the co-activator NFAT.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	University of Cambridge	Chawla, S (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Ct Rd, Cambridge CB2 1PD, England.	sc10008@cam.ac.uk		Cader, Mohammed Zaeem/0000-0002-4121-748X	Biotechnology and Biological Sciences Research Council [JF20603] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; Benedito AB, 2005, J BIOL CHEM, V280, P2818, DOI 10.1074/jbc.M408741200; Blaeser F, 2000, J BIOL CHEM, V275, P197, DOI 10.1074/jbc.275.1.197; Chawla S, 2003, J NEUROCHEM, V85, P151, DOI 10.1046/j.1471-4159.2003.01648.x; Chow CW, 2000, MOL CELL BIOL, V20, P702, DOI 10.1128/MCB.20.2.702-712.2000; Cooper DMF, 2003, BIOCHEM SOC T, V31, P912; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Ferguson GD, 2004, PHYSIOLOGY, V19, P271, DOI 10.1152/physiol.00010.2004; Flavell SW, 2006, SCIENCE, V311, P1008, DOI 10.1126/science.1122511; Fukuchi M, 2005, J PHARMACOL SCI, V98, P212, DOI 10.1254/jphs.FMJ05001X4; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Hansen TVO, 2004, J NEUROCHEM, V89, P15, DOI 10.1046/j.1471-4159.2003.02252.x; Hanson MG, 1998, J NEUROSCI, V18, P7361; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; HELL JW, 1995, EMBO J, V14, P3036, DOI 10.1002/j.1460-2075.1995.tb07306.x; IKESHIMA H, 1995, NEUROSCI LETT, V200, P117, DOI 10.1016/0304-3940(95)12092-I; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Li MT, 2001, J NEUROSCI, V21, P6544, DOI 10.1523/JNEUROSCI.21-17-06544.2001; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Lin SL, 2003, J NEUROCHEM, V87, P1076, DOI 10.1046/j.1471-4159.2003.02076.x; Lin X, 1996, MOL BRAIN RES, V42, P307, DOI 10.1016/S0169-328X(96)00135-0; Linseman DA, 2003, J BIOL CHEM, V278, P41472, DOI 10.1074/jbc.M307245200; Liu LD, 2003, P NATL ACAD SCI USA, V100, P8532, DOI 10.1073/pnas.1332804100; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Mao ZX, 1999, J BIOL CHEM, V274, P31102, DOI 10.1074/jbc.274.43.31102; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Matsuo R, 1998, NEUROSCI LETT, V244, P173, DOI 10.1016/S0304-3940(98)00159-1; Mckenzie GJ, 2005, J NEUROCHEM, V93, P171, DOI 10.1111/j.1471-4159.2005.03010.x; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Nguyen PV, 2003, PROG NEUROBIOL, V71, P401, DOI 10.1016/j.pneurobio.2003.12.003; Poser S, 2003, J NEUROSCI, V23, P4420; Ramanan N, 2005, NAT NEUROSCI, V8, P759, DOI 10.1038/nn1462; Rogue PJ, 1998, P NATL ACAD SCI USA, V95, P9178, DOI 10.1073/pnas.95.16.9178; Schroeter S, 2000, J COMP NEUROL, V420, P211; Shalizi A, 2006, SCIENCE, V311, P1012, DOI 10.1126/science.1122513; Shalizi A, 2003, J NEUROSCI, V23, P7326; Sheridan CM, 2002, J BIOL CHEM, V277, P48664, DOI 10.1074/jbc.M207029200; Soulsby MD, 2005, BIOCHEM J, V392, P493, DOI 10.1042/BJ20051325; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; Wang XM, 2005, J BIOL CHEM, V280, P16705, DOI 10.1074/jbc.M501819200; Wayman GA, 1997, J BIOL CHEM, V272, P16073, DOI 10.1074/jbc.272.26.16073; Wu XY, 2001, J BIOL CHEM, V276, P24177, DOI 10.1074/jbc.M100412200; Yang TTC, 2002, MOL CELL BIOL, V22, P3892, DOI 10.1128/MCB.22.11.3892-3904.2002; YOSHIDA A, 1992, J NEUROSCI, V12, P1094; Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323; Zhao M, 1999, MOL CELL BIOL, V19, P21; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697	53	53	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27724	27732		10.1074/jbc.M601485200	http://dx.doi.org/10.1074/jbc.M601485200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16870618	hybrid			2022-12-25	WOS:000240534400008
J	Dash, C; Fisher, TS; Prasad, VR; Le Grice, SFJ				Dash, Chandravanu; Fisher, Timothy S.; Prasad, Vinayaka R.; Le Grice, Stuart F. J.			Examining interactions of HIV-1 reverse transcriptase with single-stranded template nucleotides by nucleoside analog interference	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PRIMER GRIP REGION; SUBUNIT-SELECTIVE MUTAGENESIS; DIFFERENT SEQUENCE CONTEXTS; POLYMERASE ACTIVE-SITE; T7 DNA-POLYMERASE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; TRANSLESION SYNTHESIS; FINGERS SUBDOMAIN	Crystallographic studies have implicated several residues of the p66 fingers subdomain of human immunodeficiency virus type-1 reverse transcriptase in contacting the single-stranded template overhang immediately ahead of the DNA polymerase catalytic center. This interaction presumably assists in inducing the appropriate geometry on the template base for efficient and accurate incorporation of the incoming dNTP. To investigate this, we introduced nucleoside analogs either individually or in tandem into the DNA template ahead of the catalytic center and investigated whether they induce pausing of the replication machinery before serving as the template base. Analogs included abasic tetrahydrofuran linkages, neutralizing methylphosphonate linkages, and conformationally locked nucleosides. In addition, several Phe-61 mutants were included in our analysis, based on previous data indicating that altering this residue affects both strand displacement synthesis and the fidelity of DNA synthesis. We demonstrate here that altering the topology of the template strand two nucleotides ahead of the catalytic center can interrupt DNA synthesis. Mutating Phe-61 to either Ala or Leu accentuates this defect, whereas replacement with an aromatic residue (Trp) allows the mutant enzyme to bypass the template analogs with relative ease.	NCI, Frederick Canc Res & Dev Ctr, Resistance Mechanisms Lab, HIV Drug Resistance Program,NIH, Frederick, MD 21702 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Yeshiva University; Albert Einstein College of Medicine	Le Grice, SFJ (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Resistance Mechanisms Lab, HIV Drug Resistance Program,NIH, Frederick, MD 21702 USA.	slegrice@ncifcrf.gov	Fisher, Timothy S/D-8517-2011; Prasad, Vinayaka R./A-1029-2011	Fisher, Timothy S/0000-0002-8909-313X; Prasad, Vinayaka/0000-0002-9461-0189; Dash, Chandravanu/0000-0003-4466-8355	Intramural NIH HHS Funding Source: Medline; NIAID NIH HHS [R37 AI030861] Funding Source: Medline; NIDA NIH HHS [K99 DA024558, R00 DA024558] Funding Source: Medline; DIVISION OF BASIC SCIENCES - NCI [Z01BC010492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030861] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R00DA024558] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Allawi HT, 2003, J MOL BIOL, V328, P537, DOI 10.1016/S0022-2836(03)00351-6; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; Bibillo A, 2005, J BIOL CHEM, V280, P30282, DOI 10.1074/jbc.M502457200; BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; Boyer PL, 2002, J VIROL, V76, P3248, DOI 10.1128/JVI.76.7.3248-3256.2002; CAI H, 1993, J BIOL CHEM, V268, P23567; Cannistraro VJ, 2004, J BIOL CHEM, V279, P18288, DOI 10.1074/jbc.M400282200; Chary P, 1997, J BIOL CHEM, V272, P5805, DOI 10.1074/jbc.272.9.5805; Dash C, 2006, J BIOL CHEM, V281, P2773, DOI 10.1074/jbc.M510369200; Dash C, 2004, J BIOL CHEM, V279, P37095, DOI 10.1074/jbc.M403306200; DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X; Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208; Fisher TS, 2003, J MOL BIOL, V325, P443, DOI 10.1016/S0022-2836(02)01225-1; Fisher TS, 2002, J BIOL CHEM, V277, P22345, DOI 10.1074/jbc.M200282200; Furge LL, 1998, BIOCHEMISTRY-US, V37, P3567, DOI 10.1021/bi9722094; Gao R, 2004, BIOCHEMISTRY-US, V43, P6167, DOI 10.1021/bi040005z; Ghosh M, 1997, BIOCHEMISTRY-US, V36, P5758, DOI 10.1021/bi963045e; Ghosh M, 1996, BIOCHEMISTRY-US, V35, P8553, DOI 10.1021/bi952773j; Goldschmidt V, 2002, J BIOL CHEM, V277, P43233, DOI 10.1074/jbc.M205295200; GOODMAN MF, 1994, ANN NY ACAD SCI, V726, P132, DOI 10.1111/j.1749-6632.1994.tb52804.x; Gutierrez-Rivas M, 2001, NUCLEIC ACIDS RES, V29, P4963, DOI 10.1093/nar/29.24.4963; Hoehn ST, 2001, NUCLEIC ACIDS RES, V29, P3413, DOI 10.1093/nar/29.16.3413; Hsiou Y, 1996, STRUCTURE, V4, P853, DOI 10.1016/S0969-2126(96)00091-3; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Huang XW, 2003, BIOCHEMISTRY-US, V42, P2456, DOI 10.1021/bi026912q; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KEW Y, 1994, J BIOL CHEM, V269, P15331; Klarmann GJ, 2000, J BIOL CHEM, V275, P359, DOI 10.1074/jbc.275.1.359; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Lanchy JM, 1998, J BIOL CHEM, V273, P24425, DOI 10.1074/jbc.273.38.24425; Lanchy JM, 2000, J BIOL CHEM, V275, P12306, DOI 10.1074/jbc.275.16.12306; LATHAM GJ, 1994, J BIOL CHEM, V269, P28527; Latham GJ, 2000, J BIOL CHEM, V275, P15025, DOI 10.1074/jbc.M000279200; LeGrice SFJ, 1995, METHOD ENZYMOL, V262, P130, DOI 10.1016/0076-6879(95)62015-X; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; Lener D, 2003, J BIOL CHEM, V278, P26526, DOI 10.1074/jbc.M302374200; Lhomme J, 1999, BIOPOLYMERS, V52, P65, DOI 10.1002/1097-0282(1999)52:2<65::AID-BIP1>3.0.CO;2-U; Ling H, 2004, MOL CELL, V13, P751, DOI 10.1016/S1097-2765(04)00101-7; Malins DC, 2000, P NATL ACAD SCI USA, V97, P12442, DOI 10.1073/pnas.230438797; Mbisa JL, 2005, J VIROL, V79, P419, DOI 10.1128/JVI.79.1.419-427.2005; Palaniappan C, 1997, J BIOL CHEM, V272, P11157, DOI 10.1074/jbc.272.17.11157; Peletskaya EN, 2001, J VIROL, V75, P9435, DOI 10.1128/JVI.75.19.9435-9445.2001; Petersen M, 2000, J MOL RECOGNIT, V13, P44, DOI 10.1002/(SICI)1099-1352(200001/02)13:1<44::AID-JMR486>3.0.CO;2-6; Powell MD, 1999, J BIOL CHEM, V274, P19885, DOI 10.1074/jbc.274.28.19885; PRASAD VR, 1991, P NATL ACAD SCI USA, V88, P11363, DOI 10.1073/pnas.88.24.11363; Rausch JW, 2003, P NATL ACAD SCI USA, V100, P11279, DOI 10.1073/pnas.1932546100; Rigourd M, 2000, J BIOL CHEM, V275, P26944; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; Wisniewski M, 1999, J BIOL CHEM, V274, P28175, DOI 10.1074/jbc.274.40.28175; Wohrl BM, 1997, J BIOL CHEM, V272, P17581, DOI 10.1074/jbc.272.28.17581; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343; Yi-Brunozzi HY, 2005, J BIOL CHEM, V280, P20154, DOI 10.1074/jbc.M411228200; Yu Q, 1998, J VIROL, V72, P7676, DOI 10.1128/JVI.72.9.7676-7680.1998; Zhang WH, 2002, P NATL ACAD SCI USA, V99, P10090, DOI 10.1073/pnas.152186199; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	56	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27873	27881		10.1074/jbc.M603970200	http://dx.doi.org/10.1074/jbc.M603970200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16867979	hybrid			2022-12-25	WOS:000240534400023
J	Isaacs, AM; Senn, DB; Yuan, ML; Shine, JP; Yankner, BA				Isaacs, Adrian M.; Senn, David B.; Yuan, Menglan; Shine, James P.; Yankner, Bruce A.			Acceleration of amyloid beta-peptide aggregation by physiological concentrations of calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMER A-BETA; IN-VIVO; PROTEIN FIBRILLOGENESIS; CELL-DEATH; CONGO RED; NEURONS; DISEASE; BRAIN; CALBINDIN-D-28K; NEUROTOXICITY	Alzheimer disease is characterized by the accumulation of aggregated amyloid beta-peptide (A beta) in the brain. The physiological mechanisms and factors that predispose to A beta aggregation and deposition are not well understood. In this report, we show that calcium can predispose to A beta aggregation and fibril formation. Calcium increased the aggregation of early forming protofibrillar structures and markedly increased conversion of protofibrils to mature amyloid fibrils. This occurred at levels 20-fold below the calcium concentration in the extracellular space of the brain, the site at which amyloid plaque deposition occurs. In the absence of calcium, protofibrils can remain stable in vitro for several days. Using this approach, we directly compared the neurotoxicity of protofibrils and mature amyloid fibrils and demonstrate that both species are inherently toxic to neurons in culture. Thus, calcium may be an important predisposing factor for A beta aggregation and toxicity. The high extracellular concentration of calcium in the brain, together with impaired intraneuronal calcium regulation in the aging brain and Alzheimer disease, may play an important role in the onset of amyloid-related pathology.	Harvard Univ, Sch Med, Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Yankner, BA (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 77 Ave Louis Pasteur,MRB-858C, Boston, MA 02115 USA.	bruce_yankner@hms.harvard.edu	Senn, David B/E-7813-2010	Senn, David/0000-0002-4869-3550	NIA NIH HHS [R01 AG017573, AG17573] Funding Source: Medline; NINDS NIH HHS [NS030352, R01 NS030352] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017573] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Biere AL, 1996, J BIOL CHEM, V271, P32916, DOI 10.1074/jbc.271.51.32916; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Bu J, 2003, EXP NEUROL, V182, P220, DOI 10.1016/S0014-4886(03)00094-3; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; Dineley KT, 2001, J NEUROSCI, V21, P4125, DOI 10.1523/JNEUROSCI.21-12-04125.2001; Fahandejsaadi A, 2004, NEUROREPORT, V15, P443, DOI 10.1097/00001756-200403010-00012; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hayashi H, 2004, J NEUROSCI, V24, P4894, DOI 10.1523/JNEUROSCI.0861-04.2004; Huang XD, 2004, J BIOL INORG CHEM, V9, P954, DOI 10.1007/s00775-004-0602-8; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; Klunk WE, 1999, ANAL BIOCHEM, V266, P66, DOI 10.1006/abio.1998.2933; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; MARK RJ, 1995, J NEUROSCI, V15, P6239; McGowan E, 2005, NEURON, V47, P191, DOI 10.1016/j.neuron.2005.06.030; Naiki H, 1996, LAB INVEST, V74, P374; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tariot PN, 2004, JAMA-J AM MED ASSOC, V291, P317, DOI 10.1001/jama.291.3.317; VILLA A, 1994, EUR J NEUROSCI, V6, P1491, DOI 10.1111/j.1460-9568.1994.tb01010.x; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wogulis M, 2005, J NEUROSCI, V25, P1071, DOI 10.1523/JNEUROSCI.2381-04.2005; Wu CK, 2003, NEUROSCIENCE, V120, P249, DOI 10.1016/S0306-4522(03)00248-3; Yoo AS, 2000, NEURON, V27, P561, DOI 10.1016/S0896-6273(00)00066-0	33	118	125	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27916	27923		10.1074/jbc.M602061200	http://dx.doi.org/10.1074/jbc.M602061200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16870617	hybrid, Green Accepted			2022-12-25	WOS:000240534400027
J	Kim, SH; Pytlos, MJ; Rosche, WA; Sinden, RR				Kim, Seung-Hwan; Pytlos, Malgorzata J.; Rosche, William A.; Sinden, Richard R.			(CAG)center dot(CTG) repeats associated with neurodegenerative diseases are stable in the Escherichia coli chromosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY TYPE-1; TRIPLET REPEATS; DNA-REPLICATION; TRINUCLEOTIDE REPEATS; CTG REPEATS; LAGGING STRANDS; IN-VIVO; INSTABILITY; EXPANSION; DELETION	(CAG)(n)(.)(CTG)(n) expansion is associated with many neurodegenerative diseases. Repeat instability has been extensively studied in bacterial plasmids, where repeats undergo deletion at high rates. We report an assay for (CAG)(n)(.)(CTG)(n) deletion from the chloramphenicol acetyltransferase gene integrated into the Escherichia coli chromosome. In strain AB1157, deletion rates for 25 - 60 (CAG)(.)( CTG) repeats integrated in the chromosome ranged from 6.88 x 10(-9) to 1.33 x 10(-10), or similar to 6,300 to 660,000-fold lower than in plasmid pBR325. In contrast to the situation in plasmids, deletions occur at a higher rate when (CTG)(43), rather than (CAG)(43), comprised the leading template strand, and complete rather than partial deletions were the predominant mutation observed. Repeats were also stable on long term growth following multiple passages through exponential and stationary phase. Mutations in priA and recG increased or decreased deletion rates, but repeats were still greatly stabilized in the chromosome. The remarkable stability of (CAG)(n)(.)(CTG)(n) repeats in the E. coli chromosome may result from the differences in the mechanisms for replication or the probability for recombination afforded by a high plasmid copy number. The integration of (CAG)(n)(.)(CTG) n repeats into the chromosome provides a model system in which the inherent stability of these repeats reflects that in the human genome more closely.	Texas A&M Univ Syst, Hlth Sci Ctr, Ctr Genome Res, Lab DNA Struct & Mutagenesis,Inst Biosci & Techno, Houston, TX 77030 USA; Univ Tulsa, Dept Biol Sci, Tulsa, OK 74104 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; University of Tulsa	Sinden, RR (corresponding author), Florida Inst Technol, Dept Biol Sci, Lab DNA Struct & Mutagenesis, 150 W Univ Blvd, Melbourne, FL 32901 USA.	Rsinden@fit.edu	Sinden, Richard/AAE-3086-2019	Kim, Seung-Hwan/0000-0002-9397-3324	NIEHS NIH HHS [ES05508] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BACKMAN K, 1978, COLD SPRING HARB SYM, V43, P69; Bhattacharyya S, 2002, GENETICS, V162, P579; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Boyd D, 2000, J BACTERIOL, V182, P842, DOI 10.1128/JB.182.3.842-847.2000; Callahan JL, 2003, MOL CELL BIOL, V23, P7849, DOI 10.1128/MCB.23.21.7849-7860.2003; Cleary JD, 2003, CYTOGENET GENOME RES, V100, P25, DOI 10.1159/000072837; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; Fijalkowska IJ, 1998, P NATL ACAD SCI USA, V95, P10020, DOI 10.1073/pnas.95.17.10020; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; Gawel D, 2002, MUTAT RES-FUND MOL M, V501, P129, DOI 10.1016/S0027-5107(02)00020-9; Gomes-Pereira M, 2004, NUCLEIC ACIDS RES, V32, P2865, DOI 10.1093/nar/gkh612; Gorbunova V, 2003, MOL CELL BIOL, V23, P4485, DOI 10.1128/MCB.23.13.4485-4493.2003; Gregg AV, 2002, MOL CELL, V9, P241, DOI 10.1016/S1097-2765(02)00455-0; Hashem VI, 2004, NUCLEIC ACIDS RES, V32, P6334, DOI 10.1093/nar/gkh976; Hashem VI, 2004, MUTAT RES-FUND MOL M, V554, P95, DOI 10.1016/j.mrfmmm.2004.03.012; Hashem VI, 2002, MUTAT RES-FUND MOL M, V502, P25, DOI 10.1016/S0027-5107(02)00026-X; Hashem VI, 2002, MUTAT RES-FUND MOL M, V508, P107, DOI 10.1016/S0027-5107(02)00190-2; Jakupciak JP, 1999, J BIOL CHEM, V274, P23468, DOI 10.1074/jbc.274.33.23468; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; Kennedy L, 2003, HUM MOL GENET, V12, P3359, DOI 10.1093/hmg/ddg352; Kornberg A., 1992, DNA REPLICATION; Krasilnikova MM, 2004, MOL CELL BIOL, V24, P2286, DOI 10.1128/MCB.24.6.2286-2295.2004; Maliszewska-Tkaczyk M, 2000, P NATL ACAD SCI USA, V97, P12678, DOI 10.1073/pnas.220424697; Martorell L, 2004, NEUROLOGY, V62, P269, DOI 10.1212/WNL.62.2.269; Napierala M, 2002, J BIOL CHEM, V277, P34087, DOI 10.1074/jbc.M202128200; Oussatcheva EA, 2001, J BIOL CHEM, V276, P30878, DOI 10.1074/jbc.M104697200; Pearson CE, 2002, NUCLEIC ACIDS RES, V30, P4534, DOI 10.1093/nar/gkf572; Pearson CE, 1996, BIOCHEMISTRY-US, V35, P5041, DOI 10.1021/bi9601013; Pelletier R, 2003, MOL CELL BIOL, V23, P1349, DOI 10.1128/MCB.23.4.1349-1357.2003; Pineiro E, 2003, NUCLEIC ACIDS RES, V31, P6733, DOI 10.1093/nar/gkg898; Rosche WA, 1996, J BACTERIOL, V178, P5042, DOI 10.1128/jb.178.16.5042-5044.1996; ROSCHE WA, 1995, J BACTERIOL, V177, P4385, DOI 10.1128/jb.177.15.4385-4391.1995; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Saveson CJ, 1997, GENETICS, V146, P457; Sinden RR, 1999, AM J HUM GENET, V64, P346, DOI 10.1086/302271; VILETTE D, 1995, MOL MICROBIOL, V17, P493, DOI 10.1111/j.1365-2958.1995.mmi_17030493.x; WOHRLE D, 1993, NAT GENET, V4, P140, DOI 10.1038/ng0693-140; WONG LJC, 1995, AM J HUM GENET, V56, P114; Yang Z, 2003, AM J HUM GENET, V73, P1092, DOI 10.1086/379523; Zar J.H., 1999, BIOSTAT ANAL, V4th	41	5	6	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27950	27955		10.1074/jbc.M601129200	http://dx.doi.org/10.1074/jbc.M601129200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16873366	hybrid			2022-12-25	WOS:000240534400031
J	Chen, E; Kwon, YT; Lim, MS; Dube, ID; Hough, MR				Chen, E.; Kwon, Y. T.; Lim, M. S.; Dube, I. D.; Hough, M. R.			Loss of Ubr1 promotes aneuploidy and accelerates B-cell lymphomagenesis in TLX1/HOX11-transgenic mice	ONCOGENE			English	Article						HOX11; homeobox; B cell lymphoma; aneuploidy; chromosome missegregation	END RULE PATHWAY; LINEAGE LYMPHOMAS; UBIQUITIN LIGASES; HOMEOBOX GENE; HOX11; DEGRADATION; INTERACTS; COMPONENT; ONCOGENE; SUBUNIT	The TLX1/HOX11 homeobox gene was originally identified at the recurrent t(10;14)(q24;q11) translocation breakpoint, a chromosomal abnormality observed in 5-7% of T-cell acute lymphoblastic leukemias (T-ALLs). Proviral insertional mutagenesis studies performed on transgenic mice ectopically expressing TLX1/HOX11 in B lymphocytes (IgH mu-HOX11(Tg) mice) revealed the Ubr1 gene locus as a frequent site of proviral insertion, concomitant with accelerated development of diffuse large B-cell lymphoma. Insertion into this genomic region was confirmed by Southern blotting and by the ability to generate a polymerase chain reaction (PCR) amplicon across the viral-genome junction. Western immunoblot and semiquantitative reverse transcriptase-PCR analysis revealed downregulated expression of the Ubr1 gene product subsequent to viral integration. Loss or reduced levels of Ubr1 expression was associated with 5/14 spontaneous B-cell lymphomas in IgH mu-HOX11(Tg) mice and one of nine primary human T-ALLs. To gain mechanistic insight into the cooperativity between TLX1/HOX11 and Ubr1, IgH(mu)-HOX11(Tg)/Ubr1(+/-) mice were generated. IgH mu-HOX11(Tg)/Ubr1(+/-) mice exhibited a modest but statistically significant acceleration of disease onset relative to IgH mu-HOX11(Tg)/Ubr1(+/-) mice. Moreover, micronucleus assays to detect for chromosome missegregation were conducted and revealed increased presence of micronuclei in IgH mu-HOX11(Tg)/Ubr1(-/-) primary B lymphocyte cultures, and in both TLX1/HOX11-overexpressing T cell lines and fibroblast cultures following transfection with short interfering RNAs (siRNAs) targeting Ubr1. Karyotyping of primary B lymphocyte cultures revealed increased incidences of hypodiploid karyotypes. Finally, mitotic figures analysed from Ubr1 siRNA-transfected fibroblast cultures revealed no defects in chromosome congression to the metaphase plate, but increased incidences of atypical anaphase figures, including the development of anaphase bridges and lagging chromosomes. Based on these findings, we identify a synergistic role between TLX1/HOX11 overexpression and Ubr1 inactivation in promoting chromosome missegregation, permitting the accrual of additional chromosome losses and cytogenic abnormalities en route to malignancy.	Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Mol & Cellular Biol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Pharm, Ctr Pharmacogenet, Pittsburgh, PA 15260 USA; Univ Utah, Dept Pathol, Salt Lake City, UT USA; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Utah System of Higher Education; University of Utah; University of Toronto	Hough, MR (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Mol & Cellular Biol, 2075 Bayview Ave,Room S232, Toronto, ON M4N 3M5, Canada.	margaret.hough@sw.ca	Hough, Margaret/AAA-1026-2019	Hough, Margaret/0000-0001-8539-6398; Lim, Megan/0000-0002-0415-2867; Chen, Edwin/0000-0003-0742-9734	NIGMS NIH HHS [GM69482] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069482] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen E, 2006, ONCOGENE, V25, P2575, DOI 10.1038/sj.onc.1209285; DEGROOT RJ, 1991, P NATL ACAD SCI USA, V88, P8967, DOI 10.1073/pnas.88.20.8967; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; DUBE ID, 1986, BLOOD, V67, P1181; DUBE ID, 1991, BLOOD, V78, P2996; Hamilton MH, 2003, P NATL ACAD SCI USA, V100, P5081, DOI 10.1073/pnas.0831228100; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HAWLEY RG, 1994, ONCOGENE, V9, P1; Hawley RG, 1997, CANCER RES, V57, P337; Hough MR, 1998, P NATL ACAD SCI USA, V95, P13853, DOI 10.1073/pnas.95.23.13853; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Keller G, 1998, BLOOD, V92, P877, DOI 10.1182/blood.V92.3.877.415k11_877_887; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KLINKEN SP, 1988, J IMMUNOL, V140, P1123; Kwon YT, 1998, P NATL ACAD SCI USA, V95, P7898, DOI 10.1073/pnas.95.14.7898; Kwon YT, 2003, MOL CELL BIOL, V23, P8255, DOI 10.1128/MCB.23.22.8255-8271.2003; Kwon YT, 2002, SCIENCE, V297, P96, DOI 10.1126/science.1069531; Kwon YT, 2001, MOL CELL BIOL, V21, P8007, DOI 10.1128/MCB.21.23.8007-8021.2001; Lawson TG, 1999, J BIOL CHEM, V274, P9871, DOI 10.1074/jbc.274.14.9871; Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246; Mulder LCF, 2000, J BIOL CHEM, V275, P29749, DOI 10.1074/jbc.M004670200; Rao H, 2001, NATURE, V410, P955, DOI 10.1038/35073627; Riz I, 2005, ONCOGENE, V24, P5561, DOI 10.1038/sj.onc.1208727; Tasaki T, 2005, MOL CELL BIOL, V25, P7120, DOI 10.1128/MCB.25.16.7120-7136.2005; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Yin JH, 2004, HUM MOL GENET, V13, P2421, DOI 10.1093/hmg/ddh269; Yoshida S, 2002, PLANT J, V32, P129, DOI 10.1046/j.1365-313X.2002.01407.x	27	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5752	5763		10.1038/sj.onc.1209573	http://dx.doi.org/10.1038/sj.onc.1209573			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16862188				2022-12-25	WOS:000240765800006
J	Downes, BP; Saracco, SA; Lee, SS; Crowell, DN; Vierstra, RD				Downes, Brian P.; Saracco, Scott A.; Lee, Sang Sook; Crowell, Dring N.; Vierstra, Richard D.			MUBs, a family of ubiquitin-fold proteins that are plasma membrane-anchored by prenylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; GREEN FLUORESCENT PROTEIN; CRYSTAL-STRUCTURE; ABSCISIC-ACID; ARABIDOPSIS; ISOPRENYLATION; PALMITOYLATION; IDENTIFICATION; SYSTEM; PLANTS	Ubiquitin (Ub)-fold proteins are rapidly emerging as an important class of eukaryotic modifiers, which often exert their influence by post-translational addition to other intracellular proteins. Despite assuming a common beta-grasp three-dimensional structure, their functions are highly diverse because of distinct surface features and targets and include tagging proteins for selective breakdown, nuclear import, autophagic recycling, vesicular trafficking, polarized morphogenesis, and the stress response. Here we describe a novel family of Membrane-anchored Ub-fold (MUB) proteins that are present in animals, filamentous fungi, and plants. Extending from the C terminus of the Ub-fold is typically a cysteine-containing CAAX (where A indicates aliphatic amino acid) sequence that can direct the attachment of either a 15-carbon farnesyl or a 20-carbon geranylgeranyl moiety in vitro. Modified forms of several MUBs were detected in transgenic Arabidopsis thaliana, suggesting that these MUBs are prenylated in vivo. Both cell fractionation and confocal microscopic analyses of Arabidopsis plants expressing GFP-MUB fusions showed that the modified forms are membrane-anchored with a significant enrichment on the plasma membrane. This plasma membrane location was blocked in vivo in prenyltransferase mutants and by mevinolin, which inhibits the synthesis of prenyl groups. In addition to the five MUBs with CAAX boxes, Arabidopsis has one MUB variant with a cysteine-rich C terminus distinct from the CAAX box that is also membrane-anchored, possibly through the attachment of a long chain acyl group. Although the physiological role(s) of MUBs remain unknown, the discovery of these prenylated forms further expands the diversity and potential functions of Ub-fold proteins in eukaryotic biology.	Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN 46202 USA	University of Wisconsin System; University of Wisconsin Madison; Indiana University System; Indiana University-Purdue University Indianapolis	Vierstra, RD (corresponding author), Univ Wisconsin, Dept Genet, 425 Henry Mall, Madison, WI 53706 USA.	vierstra@wisc.edu			NIGMS NIH HHS [5-F32-GM065736-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM065736] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; Andersen KM, 2005, ESSAYS BIOCHEM, V41, P49, DOI 10.1042/EB0410049; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Blanc G, 2003, GENOME RES, V13, P137, DOI 10.1101/gr.751803; Bracha K, 2002, J BIOL CHEM, V277, P29856, DOI 10.1074/jbc.M202916200; BRIGGS MS, 1992, P NATL ACAD SCI USA, V89, P2017, DOI 10.1073/pnas.89.6.2017; Cadinanos J, 2003, J BIOL CHEM, V278, P42091, DOI 10.1074/jbc.M306700200; Chadwick BP, 1999, GENE, V233, P189, DOI 10.1016/S0378-1119(99)00138-9; Cort JR, 2002, PROTEINS, V48, P733, DOI 10.1002/prot.10197; Crowell DN, 1998, PLANT PHYSIOL, V118, P115, DOI 10.1104/pp.118.1.115; Crowell DN, 2000, PROG LIPID RES, V39, P393, DOI 10.1016/S0163-7827(00)00010-2; Cutler S, 1996, SCIENCE, V273, P1239, DOI 10.1126/science.273.5279.1239; Cutler SR, 2000, P NATL ACAD SCI USA, V97, P3718, DOI 10.1073/pnas.97.7.3718; Davis SJ, 1998, PLANT MOL BIOL, V36, P521, DOI 10.1023/A:1005991617182; DESCHENES RJ, 1987, MOL CELL BIOL, V7, P2344, DOI 10.1128/MCB.7.7.2344; Dietrich A, 2003, BIOCHEM J, V376, P449, DOI 10.1042/BJ20030578; Dittmar GAG, 2002, SCIENCE, V295, P2442, DOI 10.1126/science.1069989; Downes B, 2005, BIOCHEM SOC T, V33, P393, DOI 10.1042/BST0330393; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Galichet A, 2003, CURR OPIN PLANT BIOL, V6, P530, DOI 10.1016/j.pbi.2003.09.005; Gonzalo S, 1998, MOL BIOL CELL, V9, P585, DOI 10.1091/mbc.9.3.585; GUARINO LA, 1995, CELL, V80, P301, DOI 10.1016/0092-8674(95)90413-1; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; Hemmerlin A, 2000, PLANT PHYSIOL, V123, P1257, DOI 10.1104/pp.123.4.1257; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Johnson CD, 2005, PLANT PHYSIOL, V139, P722, DOI 10.1104/pp.105.065045; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Komatsu M, 2004, EMBO J, V23, P1977, DOI 10.1038/sj.emboj.7600205; Kouno T, 2005, J BIOL CHEM, V280, P24610, DOI 10.1074/jbc.M413565200; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; KUZNETSOV SA, 1987, FEBS LETT, V212, P145, DOI 10.1016/0014-5793(87)81574-0; Lake MW, 2001, NATURE, V414, P325, DOI 10.1038/35104586; Larsen CN, 2002, J PROTEOME RES, V1, P411, DOI 10.1021/pr025522n; Lavy M, 2002, PLANT CELL, V14, P2431, DOI 10.1105/tpc.005561; Lee MH, 2002, PLANT PHYSIOL, V129, P1507, DOI 10.1104/pp.003624; Lee YJ, 2001, PLANT CELL, V13, P2175, DOI 10.1105/tpc.13.10.2175; LINDER ME, 2000, PROTEIN LIPIDATION, P215; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; McNally T, 2003, PROTEIN SCI, V12, P1562, DOI 10.1110/ps.0382803; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Paz Y, 2000, J BIOL CHEM, V275, P25445, DOI 10.1074/jbc.C000307200; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Randall SK, 1999, CRIT REV BIOCHEM MOL, V34, P325, DOI 10.1080/10409239991209336; RANDALL SK, 1993, PLANT CELL, V5, P433, DOI 10.1105/tpc.5.4.433; Rao-Naik C, 1998, J BIOL CHEM, V273, P34976, DOI 10.1074/jbc.273.52.34976; Roskoski R, 2003, BIOCHEM BIOPH RES CO, V303, P1, DOI 10.1016/S0006-291X(03)00323-1; Running MP, 2004, P NATL ACAD SCI USA, V101, P7815, DOI 10.1073/pnas.0402385101; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; Singh S, 2005, PROTEIN SCI, V14, P2095, DOI 10.1110/ps.051577605; Smalle J, 2004, ANNU REV PLANT BIOL, V55, P555, DOI 10.1146/annurev.arplant.55.031903.141801; Smalle J, 2002, PLANT CELL, V14, P17, DOI 10.1105/tpc.010381; Smotrys JE, 2004, ANNU REV BIOCHEM, V73, P559, DOI 10.1146/annurev.biochem.73.011303.073954; Suzuki NN, 2005, AUTOPHAGY, V1, P119, DOI 10.4161/auto.1.2.1859; Umebayashi K, 2003, CELL STRUCT FUNCT, V28, P443, DOI 10.1247/csf.28.443; Valdez-Taubas J, 2005, EMBO J, V24, P2524, DOI 10.1038/sj.emboj.7600724; VIJAYKUMAR S, 1987, J BIOL CHEM, V262, P6396; Vinarov DA, 2004, NAT METHODS, V1, P149, DOI 10.1038/NMETH716; Wang CY, 2001, NAT STRUCT BIOL, V8, P47; Webb JH, 1999, FEBS LETT, V444, P136, DOI 10.1016/S0014-5793(99)00025-3; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yalovsky S, 2000, PLANT CELL, V12, P1257, DOI 10.1105/tpc.12.8.1257; Yoshimoto K, 2004, PLANT CELL, V16, P2967, DOI 10.1105/tpc.104.025395; ZHU JK, 1993, P NATL ACAD SCI USA, V90, P8557, DOI 10.1073/pnas.90.18.8557; Ziegelhoffer EC, 2000, P NATL ACAD SCI USA, V97, P7633, DOI 10.1073/pnas.130189397; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	71	40	56	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27145	27157		10.1074/jbc.M602283200	http://dx.doi.org/10.1074/jbc.M602283200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16831869	hybrid			2022-12-25	WOS:000240397700042
J	Ernst, R; Koch, J; Horn, C; Tampe, R; Schmitt, L				Ernst, Robert; Koch, Joachim; Horn, Carsten; Tampe, Robert; Schmitt, Lutz			Engineering ATPase activity in the isolated ABC cassette of human TAP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAIN; RETRACTED ARTICLE. SEE; ESCHERICHIA-COLI; CATALYTIC CYCLE; GASTRIC H+,K+-ATPASE; CARBOXYLATE RESIDUES; MUTATIONAL ANALYSIS; HISTIDINE PERMEASE; DISTINCT FUNCTIONS; PROTEIN SECRETION	The human transporter associated with antigen processing ( TAP) translocates antigenic peptides from the cytosol into the endoplasmic reticulum lumen. The functional unit of TAP is a heterodimer composed of the TAP1 and TAP2 subunits, both of which are members of the ABC-transporter family. ABC-transporters are ATP-dependent pumps, channels, or receptors that are composed of four modules: two nucleotide-binding domains (NBDs) and two transmembrane domains (TMDs). Although the TMDs are rather divergent in sequence, the NBDs are conserved with respect to structure and function. Interestingly, the NBD of TAP1 contains mutations at amino acid positions that have been proposed to be essential for catalytic activity. Instead of a glutamate, proposed to act as a general base, TAP1 contains an aspartate and a glutamine instead of the conserved histidine, which has been suggested to act as the linchpin. We used this degeneration to evaluate the individual contribution of these two amino acids to the ATPase activity of the engineered TAP1-NBD mutants. Based on our results a catalytic hierarchy of these two fundamental amino acids in ATP hydrolysis of the mutated TAP1 motor domain was deduced.	Univ Dusseldorf, Inst Biochem, D-40225 Dusseldorf, Germany; Goethe Univ Frankfurt, Inst Biochem, Bioctr, D-60439 Frankfurt, Germany	Heinrich Heine University Dusseldorf; Goethe University Frankfurt	Schmitt, L (corresponding author), Univ Dusseldorf, Inst Biochem, Univ Str 1, D-40225 Dusseldorf, Germany.	lutz.schmitt@uni-duesseldorf.de	Ernst, Robert/AAW-2967-2020; Tampé, Robert/H-2953-2015; Ernst, Robert/H-9513-2013	Ernst, Robert/0000-0002-0283-3490; Tampé, Robert/0000-0002-0403-2160; 				Alberts P, 2001, CURR BIOL, V11, P242, DOI 10.1016/S0960-9822(01)00073-2; Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; Arora S, 2001, P NATL ACAD SCI USA, V98, P7241, DOI 10.1073/pnas.131132198; BLIGHT MA, 1994, TRENDS BIOTECHNOL, V12, P450, DOI 10.1016/0167-7799(94)90020-5; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Chen M, 2003, J BIOL CHEM, V278, P29686, DOI 10.1074/jbc.M302757200; Chen M, 2004, J BIOL CHEM, V279, P46073, DOI 10.1074/jbc.M404042200; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Daumke O, 2001, EUR J BIOCHEM, V268, P4776, DOI 10.1046/j.1432-1327.2001.02406.x; Davidson AL, 1997, J BACTERIOL, V179, P5458, DOI 10.1128/jb.179.17.5458-5464.1997; DELEPELAIRE P, 1994, J BIOL CHEM, V269, P27952; FALLER LD, 1990, BIOCHEMISTRY-US, V29, P3179, DOI 10.1021/bi00465a004; FALLER LD, 1989, BIOCHEMISTRY-US, V28, P6771, DOI 10.1021/bi00442a034; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; Gadsby DC, 2006, NATURE, V440, P477, DOI 10.1038/nature04712; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; Geourjon C, 2001, TRENDS BIOCHEM SCI, V26, P539, DOI 10.1016/S0968-0004(01)01907-7; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holland IB, 2005, MOL MEMBR BIOL, V22, P29, DOI 10.1080/09687860500042013; Horn C, 2003, J MOL BIOL, V334, P403, DOI 10.1016/j.jmb.2003.09.079; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Hou YX, 2002, J BIOL CHEM, V277, P5110, DOI 10.1074/jbc.M107133200; Janas E, 2003, J BIOL CHEM, V278, P26862, DOI 10.1074/jbc.M301227200; Jones PM, 2004, CELL MOL LIFE SCI, V61, P682, DOI 10.1007/s00018-003-3336-9; Karttunen JT, 2001, P NATL ACAD SCI USA, V98, P7431, DOI 10.1073/pnas.121180198; Lapinski PE, 2001, J BIOL CHEM, V276, P7526, DOI 10.1074/jbc.M009448200; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Lubelski J, 2006, BIOCHEMISTRY-US, V45, P648, DOI 10.1021/bi051276s; Mildvan AS, 2004, BIOCHEMISTRY-US, V43, P14517, DOI 10.1021/bi048052e; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Nikaido K, 1999, J BIOL CHEM, V274, P26727, DOI 10.1074/jbc.274.38.26727; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; Orelle C, 2003, J BIOL CHEM, V278, P47002, DOI 10.1074/jbc.M308268200; Oswald C, 2006, N-S ARCH PHARMACOL, V372, P385, DOI 10.1007/s00210-005-0031-4; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Payen LF, 2003, J BIOL CHEM, V278, P38537, DOI 10.1074/jbc.M305786200; Ramaen O, 2003, BIOCHEM J, V376, P749, DOI 10.1042/BJ20030998; Ramaen O, 2006, J MOL BIOL, V359, P940, DOI 10.1016/j.jmb.2006.04.005; Reyes CL, 2005, SCIENCE, V308, P1028, DOI 10.1126/science.1107733; Sauna ZE, 2001, J BIOENERG BIOMEMBR, V33, P481, DOI 10.1023/A:1012875105006; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; Saveanu L, 2001, J BIOL CHEM, V276, P22107, DOI 10.1074/jbc.M011221200; Schmitt L, 2002, CURR OPIN STRUC BIOL, V12, P754, DOI 10.1016/S0959-440X(02)00399-8; Schmitt L, 2000, CHEMBIOCHEM, V1, P17; Schneider E, 1998, FEMS MICROBIOL REV, V22, P1; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Tombline G, 2004, J BIOL CHEM, V279, P46518, DOI 10.1074/jbc.M408052200; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P14138, DOI 10.1021/bi001128w; van der Does C, 2006, J BIOL CHEM, V281, P5694, DOI 10.1074/jbc.M511730200; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; Verdon G, 2003, J MOL BIOL, V334, P255, DOI 10.1016/j.jmb.2003.08.065; Vergani P, 2005, NATURE, V433, P876, DOI 10.1038/nature03313; Yang J, 1997, P NATL ACAD SCI USA, V94, P1568, DOI 10.1073/pnas.94.4.1568; Ye JQ, 2004, BBA-BIOENERGETICS, V1659, P1, DOI 10.1016/j.bbabio.2004.06.003; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369; Zaitseva J, 2005, BIOCHEMISTRY-US, V44, P9680, DOI 10.1021/bi0506122; Zaitseva J, 2005, EMBO J, V24, P1901, DOI 10.1038/sj.emboj.7600657; Zaitseva J, 1996, PROTEIN SCI, V5, P1100	63	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27471	27480		10.1074/jbc.M601131200	http://dx.doi.org/10.1074/jbc.M601131200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16864587	hybrid			2022-12-25	WOS:000240397700074
J	Khasawneh, FT; Huang, JS; Turek, JW; Le Breton, GC				Khasawneh, Fadi T.; Huang, Jin-Sheng; Turek, Joseph W.; Le Breton, Guy C.			Differential mapping of the amino acids mediating agonist and antagonist coordination with the human thromboxane A(2) receptor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2ND EXTRACELLULAR LOOP; MUSCARINIC ACETYLCHOLINE-RECEPTORS; SITE-DIRECTED MUTAGENESIS; LIGAND-BINDING; 13-AZAPROSTANOIC ACID; PROSTAGLANDIN; RESIDUES; ACTIVATION; EXPRESSION; BIOSYNTHESIS	Despite the well documented involvement of thromboxane A(2) receptor (TPR) signaling in the pathogenesis of thrombotic diseases, there are currently no rationally designed antagonists available for clinical use. To a large extent, this derives from a lack of knowledge regarding the topography of the TPR ligand binding pocket. On this basis, the purpose of the current study was to identify the specific amino acid residues in the TPR protein that regulate ligand coordination and binding. The sites selected for mutation reside within or in close proximity to a region we previously defined as a TPR ligand binding region (i.e. the C terminus of the second extracellular loop and the leading edge of the fifth transmembrane domain). Mutation of these residues caused varying effects on the TPR-ligand coordination process. Specifically, the D193A, D193Q, and D193R mutants lost SQ29,548 (antagonist) binding and exhibited a dramatically reduced calcium response, which could not be restored by elevated U46619 (agonist) doses. The F184Y mutant lost SQ29,548 binding and exhibited a reduced calcium response (which could be restored by elevated U46619); and the T186A and S191T mutants lost SQ29,548 binding and retained a normal U46619-induced calcium response. Furthermore, these last three mutants also revealed a divergence in the binding of two structurally different antagonists, SQ29,548 and BM13.505. Two separate mutants that exhibited SQ29,548 binding yielded either a normal (F196Y) or reduced (S201T) U46619 response. Finally, mutation of other residues directly adjacent to those described above (e. g. E190A and F200A) produced no detectable effects on either SQ29,548 binding or the U46619-induced response. In summary, these results identify key amino acids (in particular Asp(193)) involved in TPR ligand coordination. These findings also demonstrate that TPR-specific ligands interact with different residues in the ligand-binding pocket.	Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Le Breton, GC (corresponding author), Univ Illinois, Dept Pharmacol, 835 S Wolcott Ave,M-C 868, Chicago, IL 60612 USA.	gcl@uic.edu		Turek, Joseph/0000-0002-4006-7555	NHLBI NIH HHS [HL23540-23] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alla SA, 1996, J BIOL CHEM, V271, P1748, DOI 10.1074/jbc.271.3.1748; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ARMSTRONG RA, 1993, BRIT J PHARMACOL, V110, P548, DOI 10.1111/j.1476-5381.1993.tb13845.x; Audoly L, 1997, J BIOL CHEM, V272, P13475, DOI 10.1074/jbc.272.21.13475; Betz SF, 2006, J MED CHEM, V49, P637, DOI 10.1021/jm0506928; Brandoli C, 1998, J NEUROSCI, V18, P7953; Chiang N, 1996, ARCH BIOCHEM BIOPHYS, V334, P9, DOI 10.1006/abbi.1996.0423; CLARKE RJ, 1991, NEW ENGL J MED, V325, P1137, DOI 10.1056/NEJM199110173251605; Cotte N, 2000, EUR J BIOCHEM, V267, P4253, DOI 10.1046/j.1432-1033.2000.01472.x; DAngelo DD, 1996, J BIOL CHEM, V271, P6233, DOI 10.1074/jbc.271.11.6233; Dorn GW, 1997, J BIOL CHEM, V272, P12399, DOI 10.1074/jbc.272.19.12399; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; FITZGERALD GA, 1987, FASEB J, V46, P154; FRASER CM, 1989, MOL PHARMACOL, V36, P840; FUNK CD, 1993, MOL PHARMACOL, V44, P934; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; HALUSHKA PV, 1989, ANNU REV PHARMACOL, V29, P213; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hoffmann C, 1999, J BIOL CHEM, V274, P14639, DOI 10.1074/jbc.274.21.14639; Hoffmann SH, 2000, MOL ENDOCRINOL, V14, P1099, DOI 10.1210/me.14.7.1099; Huang JS, 2006, CELL SIGNAL, V18, P564, DOI 10.1016/j.cellsig.2005.06.011; HUNG SC, 1983, BIOCHIM BIOPHYS ACTA, V728, P171, DOI 10.1016/0005-2736(83)90468-6; JIN B, 1994, J CHEM INF COMP SCI, V34, P1014, DOI 10.1021/ci00020a041; KIM SO, 1992, BIOCHEM PHARMACOL, V43, P313; Komiotis D, 1996, BIOCHEM PHARMACOL, V52, P763, DOI 10.1016/0006-2952(96)00359-0; LEBRETON GC, 1979, P NATL ACAD SCI USA, V76, P4097; Liapakis G, 2000, J BIOL CHEM, V275, P37779, DOI 10.1074/jbc.M002092200; Lin X, 2005, J NEUROCHEM, V93, P257, DOI 10.1111/j.1471-4159.2004.02969.x; NARUMIYA S, 1993, J LIPID MEDIATOR, V6, P155; OATES JA, 1988, NEW ENGL J MED, V319, P689, DOI 10.1056/NEJM198809153191106; OGLETREE ML, 1987, FED PROC, V46, P133; Okuma Minoru, 1996, Polish Journal of Pharmacology, V48, P77; OLAH ME, 1994, J BIOL CHEM, V269, P24692; PAGE KM, 1995, EUR J PHARM-MOLEC PH, V289, P429, DOI 10.1016/0922-4106(95)90151-5; PATRONO C, 1990, STROKE, V21, P130; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; Shi L, 2004, P NATL ACAD SCI USA, V101, P440, DOI 10.1073/pnas.2237265100; So SP, 2003, J BIOL CHEM, V278, P10922, DOI 10.1074/jbc.M209337200; Stillman BA, 1998, EUR J PHARMACOL, V357, P73, DOI 10.1016/S0014-2999(98)00522-6; SVENSSON J, 1977, PROSTAGLANDINS, V14, P425, DOI 10.1016/0090-6980(77)90258-1; SVENSSON J, 1976, ACTA PHYSIOL SCAND, V98, P285, DOI 10.1111/j.1748-1716.1976.tb10313.x; Taylor DM, 2003, EUR J MED CHEM, V38, P1015, DOI 10.1016/j.ejmech.2003.07.003; Tiruppathi C, 2000, P NATL ACAD SCI USA, V97, P7440, DOI 10.1073/pnas.97.13.7440; TOWNSENDNICHOLSON A, 1994, J BIOL CHEM, V269, P2373; Turek JW, 2002, J BIOL CHEM, V277, P16791, DOI 10.1074/jbc.M105872200; USHIKUBI F, 1993, J EXP MED, V178, P1825, DOI 10.1084/jem.178.5.1825; YAMAMOTO Y, 1993, J MED CHEM, V36, P820, DOI 10.1021/jm00059a005	47	22	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26951	26965		10.1074/jbc.M507469200	http://dx.doi.org/10.1074/jbc.M507469200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16837469	hybrid			2022-12-25	WOS:000240397700022
J	Rosenberg, E; Litus, I; Schwarzfuchs, N; Sinay, R; Schlesinger, P; Golenser, J; Baumeister, S; Lingelbach, K; Pollack, Y				Rosenberg, Elli; Litus, Ilena; Schwarzfuchs, Nurit; Sinay, Rosa; Schlesinger, Pnina; Golenser, Jacob; Baumeister, Stefan; Lingelbach, Klaus; Pollack, Yaakov			pfmdr2 confers heavy metal resistance to Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; TRANSPORT; MALARIA; GENE; TOXICITY	Heavy metals are required by all organisms for normal function, but high levels of heavy metals are toxic. Therefore, homeostasis of these metals is crucial. In the human malaria-causing agent Plasmodium falciparum, the mechanisms of heavy metal transport have yet to be characterized. We have developed a P. falciparum line resistant to heavy metals from a wild-type line sensitive to heavy metals. A molecular and biochemical analysis of the involvement of the P. falciparum multidrug resistance 2 (pfmdr2) gene, an ABC-type transporter, in heavy metal homeostasis was studied. Using a novel uptake assay applied on these two strains, it was demonstrated that, when exposed to heavy metals, the sensitive line accumulates metal, whereas no accumulation was observed in the resistant line. The accumulation occurs within the parasite itself and not in the cytoplasm of the red blood cell. This difference in the accumulation pattern is not a result of amplification of the pfmdr2 gene or of a change in the expression pattern of the gene in the two lines. Sequencing of the gene from both lines revealed a major difference; a stop codon is found in the sensitive line upstream of the normal termination, resulting in a truncated protein that lacks 188 amino acids that contain a portion of the essential cytoplasmatic transporter domain, thereby rendering it inactive. In contrast, the resistant line harbors a full-length, active protein. These findings strongly suggest that the PFMDR2 protein acts as an efflux pump of heavy metals.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Immunol & Microbiol, IL-84105 Beer Sheva, Israel; Hebrew Univ Jerusalem, Dept Parasitol, IL-91120 Jerusalem, Israel; Univ Marburg, Dept Biol Zool, D-35032 Marburg, Germany	Ben Gurion University; Hebrew University of Jerusalem; Philipps University Marburg	Pollack, Y (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Immunol & Microbiol, POB 653, IL-84105 Beer Sheva, Israel.	polak@bgu.ac.il		Baumeister, Stefan/0000-0002-7784-3474				Agranoff DD, 1998, MOL MICROBIOL, V28, P403, DOI 10.1046/j.1365-2958.1998.00790.x; Ansorge I, 1996, BIOCHEM J, V315, P307, DOI 10.1042/bj3150307; BENTING J, 1994, BIOCHEM J, V300, P821, DOI 10.1042/bj3000821; Broeks A, 1996, EMBO J, V15, P6132, DOI 10.1002/j.1460-2075.1996.tb01001.x; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a; Hall JL, 2002, J EXP BOT, V53, P1, DOI 10.1093/jexbot/53.366.1; HUNT NH, 1990, BLOOD CELLS, V16, P499; Jin YH, 2003, NAT GENET, V34, P326, DOI 10.1038/ng1172; Jones PM, 2004, CELL MOL LIFE SCI, V61, P682, DOI 10.1007/s00018-003-3336-9; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a; ORTIZ DF, 1992, EMBO J, V11, P3491, DOI 10.1002/j.1460-2075.1992.tb05431.x; ORTIZ DF, 1995, J BIOL CHEM, V270, P4721, DOI 10.1074/jbc.270.9.4721; PAPADOPOULOU B, 1994, J BIOL CHEM, V269, P11980; Peel SA, 2001, DRUG RESIST UPDATE, V4, P66, DOI 10.1054/drup.2001.0183; POLLACK Y, 1990, PARASITOL RES, V76, P570, DOI 10.1007/BF00932563; POLLACK Y, 1982, NUCLEIC ACIDS RES, V10, P539, DOI 10.1093/nar/10.2.539; Rosen BP, 2002, COMP BIOCHEM PHYS A, V133, P689, DOI 10.1016/S1095-6433(02)00201-5; Rubio JP, 1996, PARASITOL TODAY, V12, P135, DOI 10.1016/0169-4758(96)10003-X; RUBIO JP, 1994, EXP PARASITOL, V79, P137, DOI 10.1006/expr.1994.1073; Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a; Silver S, 1996, ANNU REV MICROBIOL, V50, P753, DOI 10.1146/annurev.micro.50.1.753; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Valko M, 2005, CURR MED CHEM, V12, P1161, DOI 10.2174/0929867053764635; WILSON CM, 1989, SCIENCE, V244, P1184, DOI 10.1126/science.2658061; ZALIS MG, 1993, MOL BIOCHEM PARASIT, V62, P83, DOI 10.1016/0166-6851(93)90180-6	32	28	28	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27039	27045		10.1074/jbc.M601686200	http://dx.doi.org/10.1074/jbc.M601686200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16849328	hybrid			2022-12-25	WOS:000240397700030
J	Johnson, D; Bennett, ES				Johnson, Daniel; Bennett, Eric S.			Isoform-specific effects of the beta(2) subunit on voltage-gated sodium channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHERITED CARDIAC-ARRHYTHMIA; LONG-QT SYNDROME; SIALIC-ACID; CONGENITAL DISORDERS; BETA-2 SUBUNIT; NA+ CHANNEL; HUMAN BRAIN; GLYCOSYLATION DEFECTS; AUXILIARY SUBUNIT; SKELETAL-MUSCLE	Voltage-gated sodium channels (Na-v) are complex glycoproteins comprised of an alpha subunit and often one to several beta subunits. We have shown that sialic acid residues linked to Na-v alpha and beta(1) subunits alter channel gating. To determine whether beta(2)-linked sialic acids similarly impact Na-v gating, we co-expressed beta(2) with Na(v)1.5 or Na(v)1.2 in Pro5 (complete sialylation) and in Lec2 (essentially no sialylation) cells. beta(2) sialic acids caused a significant hyperpolarizing shift in Na(v)1.5 voltage-dependent gating, thus describing for the first time an effect of beta(2) on Na(v)1.5 gating. In contrast, beta(2) caused a sialic acid-independent depolarizing shift in Na(v)1.2 gating. A deglycosylated mutant, beta(2-Delta N), had no effect on Na(v)1.5 gating, indicating further the impact of beta(2) N-linked sialic acids on Na(v)1.5 gating. Conversely, beta(2-Delta N) modulated Na(v)1.2 gating virtually identically to beta(2), confirming that beta(2) N-linked sugars have no impact on Na(v)1.2 gating. Thus, beta(2) modulates Na-v gating through multiple mechanisms possibly determined by the associated alpha subunit. beta(1) and beta(2) were expressed together with Na(v)1.5 or Na(v)1.2 in Pro5 and Lec2 cells. Together beta(1) and beta(2) produced a significantly larger sialic acid-dependent hyperpolarizing shift in Nav1.5 gating. Under fully sialylating conditions, the Na(v)1.2(.)beta(.)(1)beta(2) complex behaved like Na(v)1.2 alone. When sialylation was reduced, only the sialic acid-independent depolarizing effects of beta(2) on Na(v)1.2 gating were apparent. Thus, the varied effects of beta(1) and beta(2) on Na(v)1.5 and Na(v)1.2 gating are apparently synergistic and highlight the complex manner, through subunit-and sugar-dependent mechanisms, by which Na-v activity is modulated.	Univ S Florida, Dept Mol Pharmacol & Physiol, Coll Med, Tampa, FL 33612 USA; Univ S Florida, Programs Cardiovasc Sci & Neurosci, Coll Med, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Bennett, ES (corresponding author), Univ S Florida, Dept Mol Pharmacol & Physiol, Coll Med, MDC 8, Tampa, FL 33612 USA.	esbennet@hsc.usf.edu			NIAMS NIH HHS [R-01AR45169] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045169] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abriel H, 2001, CIRC RES, V88, P740, DOI 10.1161/hh0701.089668; Barresi R, 2004, NAT MED, V10, P696, DOI 10.1038/nm1059; Bennett E, 1997, J GEN PHYSIOL, V109, P327, DOI 10.1085/jgp.109.3.327; Bennett ES, 2002, J PHYSIOL-LONDON, V538, P675, DOI 10.1113/jphysiol.2001.013285; BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683a0; Blackburn-Munro G, 1999, NEUROSCIENCE, V90, P153, DOI 10.1016/S0306-4522(98)00415-1; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Chen CL, 2002, P NATL ACAD SCI USA, V99, P17072, DOI 10.1073/pnas.212638099; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DOBYNS WB, 1989, AM J MED GENET, V32, P195, DOI 10.1002/ajmg.1320320213; Donahue LM, 2000, BRAIN RES, V887, P335, DOI 10.1016/S0006-8993(00)03033-X; Dubowitz T, 2000, ANN NEUROL, V47, P143, DOI 10.1002/1531-8249(200002)47:2<143::AID-ANA2>3.0.CO;2-Y; Eubanks J, 1997, NEUROREPORT, V8, P2775, DOI 10.1097/00001756-199708180-00025; Fozzard HA, 1996, PHYSIOL REV, V76, P887, DOI 10.1152/physrev.1996.76.3.887; Gastaldi M, 1998, NEUROSCI LETT, V249, P53, DOI 10.1016/S0304-3940(98)00394-2; Goldin AL, 2001, ANNU REV PHYSIOL, V63, P871, DOI 10.1146/annurev.physiol.63.1.871; Isom LL, 2001, NEUROSCIENTIST, V7, P42, DOI 10.1177/107385840100700108; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; Jaeken J, 2004, CURR OPIN PEDIATR, V16, P434, DOI 10.1097/01.mop.0000133636.56790.4a; Jaeken J, 2003, J INHERIT METAB DIS, V26, P99, DOI 10.1023/A:1024431131208; Johnson D, 2004, J BIOL CHEM, V279, P44303, DOI 10.1074/jbc.M408900200; Maier SKG, 2004, CIRCULATION, V109, P1421, DOI 10.1161/01.CIR.0000121421.61896.24; Malhotra JD, 2001, CIRCULATION, V103, P1303; Marban E, 1998, J PHYSIOL-LONDON, V508, P647, DOI 10.1111/j.1469-7793.1998.647bp.x; Marquardt T, 2003, EUR J PEDIATR, V162, P359, DOI 10.1007/s00431-002-1136-0; Martinez-Duncker I, 2005, BLOOD, V105, P2671, DOI 10.1182/blood-2004-09-3509; Meadows LS, 2002, NEUROSCIENCE, V114, P745, DOI 10.1016/S0306-4522(02)00242-7; MESSNER DJ, 1985, J BIOL CHEM, V260, P597; MILLER JA, 1983, BIOCHEMISTRY-US, V22, P462, DOI 10.1021/bi00271a032; Morgan K, 2000, P NATL ACAD SCI USA, V97, P2308, DOI 10.1073/pnas.030362197; Qu Y, 2001, MOL CELL NEUROSCI, V18, P570, DOI 10.1006/mcne.2001.1039; RECIOPINTO E, 1990, NEURON, V5, P675, DOI 10.1016/0896-6273(90)90221-Z; ROBERTS RH, 1987, J BIOL CHEM, V262, P2298; Schaller KL, 2003, CEREBELLUM, V2, P2, DOI 10.1080/14734220309424; SCHMIDT JW, 1987, J BIOL CHEM, V262, P13713; Spampanato J, 2003, NEUROSCIENCE, V116, P37, DOI 10.1016/S0306-4522(02)00698-X; Splawski I, 2002, SCIENCE, V297, P1333, DOI 10.1126/science.1073569; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; STANLEY P, 1985, MOL CELL BIOL, V5, P923, DOI 10.1128/MCB.5.5.923; Stocker PJ, 2006, J GEN PHYSIOL, V127, P253, DOI 10.1085/jgp.200509423; Tyrrell L, 2001, J NEUROSCI, V21, P9629, DOI 10.1523/JNEUROSCI.21-24-09629.2001; Vijayaragavan K, 2004, BIOCHEM BIOPH RES CO, V319, P531, DOI 10.1016/j.bbrc.2004.05.026; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; WOLLNER DA, 1987, J BIOL CHEM, V262, P14709; Yu FH, 2003, J NEUROSCI, V23, P7577; Zhang Y, 1999, J MEMBRANE BIOL, V171, P195, DOI 10.1007/s002329900571	47	54	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25875	25881		10.1074/jbc.M605060200	http://dx.doi.org/10.1074/jbc.M605060200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16847056	hybrid			2022-12-25	WOS:000240249500002
J	Nelson, EA; Walker, SR; Li, W; Liu, XS; Frank, DA				Nelson, Erik A.; Walker, Sarah R.; Li, Wei; Liu, X. Shirley; Frank, David A.			Identification of human STAT5-dependent gene regulatory elements based on interspecies homology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE; BINDING-SITES; SIGNAL TRANSDUCER; STAT PROTEINS; ONCOSTATIN M; PROMOTER; INTERLEUKIN-2; ACTIVATION; EXPRESSION; CELLS	STAT5 is a transcription factor essential for hematopoietic physiology. STAT5 functions to transduce signals from cytokines to the nucleus where it regulates gene expression. Although several important transcriptional targets of STAT5 are known, most remain unidentified. To identify novel STAT5 targets, we searched chromosomes 21 and 22 for clusters of STAT5 binding sites contained within regions of interspecies homology. We identified four such regions, including one with tandem STAT5 binding sites in the first intron of the NCAM2 gene. Unlike known STAT5 binding sites, this site is found within a very large intron and resides similar to 200 kb from the first coding exon of NCAM2. We demonstrate that this region confers STAT5-dependent transcriptional activity. We show that STAT5 binds in vivo to the NCAM2 intron in the NKL natural killer cell line and that this binding is induced by cytokines that activate STAT5. Neither STAT1 nor STAT3 bind to this region, despite sharing a consensus binding sequence with STAT5. Activation of STAT4 and STAT5 causes the accumulation of both of these STATs to the NCAM2 regulatory region. Therefore, using an informatics based approach to identify STAT5 targets, we have identified NCAM2 as both a STAT4- and STAT5-regulated gene, and we show that its expression is regulated by cytokines essential for natural killer cell survival and differentiation. This strategy may be an effective way to identify functional binding regions for transcription factors with known cognate binding sites anywhere in the genome.	Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biostat & Computat Biol, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Harvard Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard T.H. Chan School of Public Health	Frank, DA (corresponding author), Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	david_frank@dfci.harvard.edu	Li, Wei/A-8544-2009	Li, Wei/0000-0001-9931-5990	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004069] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01 HG004069, R01 HG004069-01] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Becknell B, 2005, ADV IMMUNOL, V86, P209, DOI 10.1016/S0065-2776(04)86006-1; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bream JH, 2004, J BIOL CHEM, V279, P41249, DOI 10.1074/jbc.M401168200; Brudno M, 2004, GENOME RES, V14, P685, DOI 10.1101/gr.2067704; Bulyk ML, 2004, GENOME BIOL, V5; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Cho SS, 1996, J IMMUNOL, V157, P4781; Chughtai N, 2002, J BIOL CHEM, V277, P31107, DOI 10.1074/jbc.M200156200; Crnic I, 2004, CANCER RES, V64, P8630, DOI 10.1158/0008-5472.CAN-04-2523; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Fehniger TA, 1999, J IMMUNOL, V162, P4511; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; FRANK DA, 1995, P NATL ACAD SCI USA, V92, P7779, DOI 10.1073/pnas.92.17.7779; Frank David A, 2003, Cancer Treat Res, V115, P267; Grimley PM, 1999, CYTOKINE GROWTH F R, V10, P131, DOI 10.1016/S1359-6101(99)00011-8; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; John S, 1999, MOL CELL BIOL, V19, P1910; Kaiser U, 1996, LEUKEMIA LYMPHOMA, V20, P389, DOI 10.3109/10428199609052420; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; LeBaron MJ, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-6; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Ma YS, 1999, NUCLEIC ACIDS RES, V27, P4649, DOI 10.1093/nar/27.23.4649; Martone R, 2003, P NATL ACAD SCI USA, V100, P12247, DOI 10.1073/pnas.2135255100; Meyer WKH, 1997, J BIOL CHEM, V272, P31821, DOI 10.1074/jbc.272.50.31821; Nelson EA, 2004, J BIOL CHEM, V279, P54724, DOI 10.1074/jbc.M408464200; NITTA T, 1989, J EXP MED, V170, P1757, DOI 10.1084/jem.170.5.1757; Nobrega MA, 2003, SCIENCE, V302, P413, DOI 10.1126/science.1088328; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Perl AK, 1999, NAT MED, V5, P286, DOI 10.1038/6502; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Rascle A, 2003, NUCLEIC ACIDS RES, V31, P6882, DOI 10.1093/nar/gkg907; Robertson MJ, 1996, EXP HEMATOL, V24, P406; Sternberg DW, 2004, J CLIN ONCOL, V22, P361, DOI 10.1200/JCO.2004.10.124; Takasaki S, 2000, CELL BIOL INT, V24, P101, DOI 10.1006/cbir.1999.0457; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Ureta-Vidal A, 2003, NAT REV GENET, V4, P251, DOI 10.1038/nrg1043; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Walmod PS, 2004, NEUROCHEM RES, V29, P2015, DOI 10.1007/s11064-004-6875-z; Wang Y, 2005, J BIOL CHEM, V280, P10955, DOI 10.1074/jbc.M412808200; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; Yu CR, 1996, J IMMUNOL, V157, P126; Zhang XK, 2001, J BIOL CHEM, V276, P33576, DOI 10.1074/jbc.M104978200	45	18	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26216	26224		10.1074/jbc.M605001200	http://dx.doi.org/10.1074/jbc.M605001200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16840779	Green Accepted, hybrid			2022-12-25	WOS:000240249500038
J	Okano, K; Schnaper, HW; Bomsztyk, K; Hayashida, T				Okano, Kazuhiro; Schnaper, H. William; Bomsztyk, Karol; Hayashida, Tomoko			RACK1 binds to Smad3 to modulate transforming growth factor-beta 1-stimulated alpha 2(I) collagen transcription in renal tubular epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-REGULATED KINASE; TGF-BETA; SCAFFOLD PROTEIN; MESANGIAL CELLS; I EXPRESSION; MAP KINASE; RECEPTOR; TGF-BETA-1; ACTIVATION	Although it is clear that transforming growth factor-beta 1 (TGF-beta 1) is critical for renal fibrogenesis, the complexity of the involved mechanisms is increasingly apparent. TGF-beta 1 stimulates phosphorylation of Smad2/3 and activates other signaling molecules as well. The molecular link between these other kinases and Smads is not known. We sought new binding partners for Smad3 in renal cells and identified receptor for activated protein kinase C1 (RACK1) as a novel binding partner of Smad3. The linker region of Smad3 and the tryptophan-aspartic acid repeat 6 and 7 of RACK1 are sufficient for the association. RACK1 also interacts with Smad3 in the human kidney epithelial cell line, HKC. Silencing RACK1 increases transcriptional activity of TGF-beta 1-responsive promoter sequences of the Smad binding element (SBE), p3TP-Lux, and alpha 2(I) collagen. Conversely, overexpressed RACK1 negatively modulates alpha 2(I) collagen transcriptional activity in TGF-beta 1-stimulated cells. RACK1 did not affect phosphorylation of Smad3 at the C terminus or in the linker region. However, RACK1 reduced direct binding of Smad3 to the SBE motif. Mutating a RACK1 tyrosine at residue 246, but not at 228, decreased the inhibitory effect of RACK1 on both alpha 2(I) collagen promoter activity and Smad binding to SBE induced by TGF-beta 1. These results suggest that RACK1 modulates transcription of alpha 2(I) collagen by TGF-beta 1 through interference with Smad3 binding to the gene promoter.	Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA; Univ Washington, Seattle, WA 98109 USA	Northwestern University; Feinberg School of Medicine; University of Washington; University of Washington Seattle	Schnaper, HW (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pediat, 303 E Chicago Ave,Ward 12-120, Chicago, IL 60611 USA.	schnaper@northwestern.edu		Hayashida, Tomoko/0000-0002-4160-7859	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK049362, R01DK045978, R01DK049362, R37DK045978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045134] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45978, R01 DK049362, DK49362] Funding Source: Medline; NIGMS NIH HHS [GM45134] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Attisano L, 1996, MOL CELL BIOL, V16, P1066; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; Bottinger EP, 2002, J AM SOC NEPHROL, V13, P2600, DOI 10.1097/01.ASN.0000033611.79556.AE; Ceci M, 2003, NATURE, V426, P579, DOI 10.1038/nature02160; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2002, ONCOGENE, V21, P7619, DOI 10.1038/sj.onc.1206002; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Deng WG, 2003, ANAL BIOCHEM, V323, P12, DOI 10.1016/j.ab.2003.08.007; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Ghosh AK, 2004, J BIOL CHEM, V279, P47455, DOI 10.1074/jbc.M403477200; HANSCH GM, 1995, J CELL PHYSIOL, V163, P451, DOI 10.1002/jcp.1041630304; Hayashida T, 1999, KIDNEY INT, V56, P1710, DOI 10.1046/j.1523-1755.1999.00733.x; Hayashida T, 2004, J AM SOC NEPHROL, V15, P2032, DOI 10.1097/01.ASN.0000133198.74973.60; Hayashida T, 2003, FASEB J, V17, P1576, DOI 10.1096/fj.03-0037fje; Isono M, 2000, J AM SOC NEPHROL, V11, P2222, DOI 10.1681/ASN.V11122222; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; MCKAY NG, 1993, EXP MOL PATHOL, V59, P211, DOI 10.1006/exmp.1993.1040; Miyajima A, 2000, KIDNEY INT, V58, P2301, DOI 10.1046/j.1523-1755.2000.00414.x; Nilsson J, 2004, EMBO REP, V5, P1137, DOI 10.1038/sj.embor.7400291; Patterson RL, 2004, P NATL ACAD SCI USA, V101, P2328, DOI 10.1073/pnas.0308567100; Poncelet AC, 1999, KIDNEY INT, V56, P1354, DOI 10.1046/j.1523-1755.1999.00680.x; Poncelet AC, 1998, AM J PHYSIOL-RENAL, V275, pF458; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; Racusen LC, 1997, J LAB CLIN MED, V129, P318, DOI 10.1016/S0022-2143(97)90180-3; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Runyan CE, 2004, J BIOL CHEM, V279, P2632, DOI 10.1074/jbc.M310412200; Runyan CE, 2003, AM J PHYSIOL-RENAL, V285, pF413, DOI 10.1152/ajprenal.00082.2003; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; Sasaki A, 2001, J BIOL CHEM, V276, P17871, DOI 10.1074/jbc.M008422200; Schnaper HW, 2003, AM J PHYSIOL-RENAL, V284, pF243, DOI 10.1152/ajprenal.00300.2002; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yang JW, 2003, J AM SOC NEPHROL, V14, P3167, DOI 10.1097/01.ASN.0000099373.33259.B2; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	38	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26196	26204		10.1074/jbc.M606710200	http://dx.doi.org/10.1074/jbc.M606710200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16849317	hybrid			2022-12-25	WOS:000240249500036
J	Peng, XH; Karna, P; Cao, ZH; Jiang, BH; Zhou, MX; Yang, L				Peng, Xiang-Hong; Karna, Prasanthi; Cao, Zehong; Jiang, Bing-Hua; Zhou, Muxiang; Yang, Lily			Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1 alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; EGF RECEPTOR; EPITHELIAL-CELLS; STRUCTURAL BASIS; FAMILY; INHIBITION; COEXPRESSION; ACTIVATION; TARGET	Although increasing evidence supports a link between epidermal growth factor receptor (EGFR) signaling and resistance to apoptosis, the mechanism by which the EGFR signaling pathway inhibits apoptosis is not well understood. In this study, we found that epidermal growth factor (EGF) stimulation increased the level of expression of the inhibitor of apoptosis protein survivin in breast cancer cells but not in normal mammary epithelial cells. We further demonstrated that activation of survivin gene expression is mediated by oxygen-independent hypoxia-inducible factor (HIF)-1 alpha up-regulation in EGF-treated cancer cells. EGFR signaling activated the phosphoinositide 3-kinase/AKT pathway, subsequently increasing the level of HIF-1 alpha under normoxic conditions. HIF-1 alpha then activated survivin gene transcription through direct binding to the survivin promoter. Furthermore, we found that overexpression of HIF-1 alpha small interfering RNA blocks EGF-induced survivin gene up-regulation and increases apoptosis induced by the chemotherapy drug docetaxel. However, transfection of a plasmid expressing HIF-1 alpha gene activates survivin gene expression and reduces the apoptotic response. Our results demonstrate a novel pathway for EGFR signaling-mediated apoptosis resistance in human cancer cells. Although the role of HIF-1 alpha in regulating cell survival under hypoxic conditions has been studied extensively, our results show that normoxic breast cancer cells utilize cross-talk between EGFR signals and HIF-1 alpha to up-regulate the anti-apoptotic survivin gene, providing a strong rationale for the targeting of HIF-1 alpha as a therapeutic approach for both hypoxic and normoxic tumor cells. Understanding key molecular events in EGFR signaling-induced apoptosis resistance should provide new information for the development of novel therapeutic agents targeting EGFR, HIF-1 alpha, and/or survivin.	Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA; W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA	Emory University; Emory University; Emory University; West Virginia University	Yang, L (corresponding author), Emory Univ, Sch Med, Dept Surg, Rm C-4088,1365 C Clifton Rd NE, Atlanta, GA 30322 USA.	Lyang02@emory.edu		Jiang, Bing-Hua/0000-0003-4526-2031	NATIONAL CANCER INSTITUTE [R29CA080017, R01CA095643] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA095643-01A1, R29 CA080017-04, R29 CA080017-05, R29 CA080017, R01 CA095643-03, R01 CA095643-02, R01 CA095643-04, R29 CA080017-03, R01 CA95643, R01 CA095643, R29CA80017] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abd El-Rehim DM, 2004, BRIT J CANCER, V91, P1532, DOI 10.1038/sj.bjc.6602184; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Asanuma H, 2005, CANCER RES, V65, P11018, DOI 10.1158/0008-5472.CAN-05-0491; Baselga J, 2002, ANN ONCOL, V13, P8, DOI 10.1093/annonc/mdf092; Bucci B, 1997, ANTICANCER RES, V17, P769; Buchholz TA, 2005, CANCER, V104, P676, DOI 10.1002/cncr.21217; Camirand A, 2005, BREAST CANCER RES, V7, pR570, DOI 10.1186/bcr1028; CHRYSOGELOS SA, 1994, BREAST CANCER RES TR, V29, P29, DOI 10.1007/BF00666179; Danielsen AJ, 2002, GROWTH FACTORS, V20, P1, DOI 10.1080/08977190290022185; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200; Fry MJ, 2001, BREAST CANCER RES, V3, P304, DOI 10.1186/bcr312; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; HARRIS AL, 1994, BREAST CANCER RES TR, V29, P1, DOI 10.1007/BF00666176; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Ling X, 2004, J BIOL CHEM, V279, P15196, DOI 10.1074/jbc.M310947200; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Navolanic PM, 2003, INT J ONCOL, V22, P237; Normanno N, 2005, FRONT BIOSCI-LANDMRK, V10, P2611, DOI 10.2741/1725; Peng XH, 2005, CANCER RES, V65, P1909, DOI 10.1158/0008-5472.CAN-04-3196; Phillips RJ, 2005, J BIOL CHEM, V280, P22473, DOI 10.1074/jbc.M500963200; Post DE, 2001, GENE THER, V8, P1801, DOI 10.1038/sj.gt.3301605; Qiu LH, 2005, INT J ONCOL, V27, P823; Rae JM, 2004, BREAST CANCER RES TR, V87, P87, DOI 10.1023/B:BREA.0000041585.26734.f9; Reis JS, 2005, BREAST CANCER RES, V7, pR1028, DOI 10.1186/bcr1341; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Semenza GL, 2000, ADV EXP MED BIOL, V475, P123; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Tamm I, 1998, CANCER RES, V58, P5315; Tanaka K, 2000, CLIN CANCER RES, V6, P127; Wang Q, 2005, EXP MOL PATHOL, V79, P100, DOI 10.1016/j.yexmp.2005.05.002; Yang L, 2003, CANCER RES, V63, P6815; Yang L, 2004, GENE THER, V11, P1215, DOI 10.1038/sj.gt.3302280; Zhong H, 2000, CANCER RES, V60, P1541	40	244	268	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25903	25914		10.1074/jbc.M603414200	http://dx.doi.org/10.1074/jbc.M603414200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16847054	Green Accepted, hybrid			2022-12-25	WOS:000240249500005
J	Sanderson-Smith, ML; Walker, MJ; Ranson, M				Sanderson-Smith, Martina L.; Walker, Mark J.; Ranson, Marie			The maintenance of high affinity plasminogen binding by group A streptococcal plasminogen-binding M-like protein is mediated by arginine and histidine residues within the a1 and a2 repeat domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL SURFACE PROTEIN; KRINGLE-2 DOMAIN; PAM; INFECTION; POLYPEPTIDES; ACTIVATORS; PYOGENES; IMPETIGO; SEQUENCE; REGION	Subversion of the plasminogen activation system is implicated in the virulence of group A streptococci (GAS). GAS displays receptors for the human zymogen plasminogen on the cell surface, one of which is the plasminogen- binding group A streptococcal M- like protein (PAM). The plasminogen binding domain of PAM is highly variable, and this variation has been linked to host selective immune pressure. Site- directed mutagenesis of full- length PAM protein from an invasive GAS isolate was undertaken to assess the contribution of residues in the a1 and a2 repeat domains to plasminogen binding function. Mutagenesis to alanine of key plasminogen binding lysine residues in the a1 and a2 repeats (Lys(98) and Lys(111)) did not abrogate plasminogen binding by PAM nor did additional mutagenesis of Arg(101) and His(102) and Glu(104), which have previously been implicated in plasminogen binding. Plasminogen binding was only abolished with the additional mutagenesis of Arg(114) and His(115) to alanine. Furthermore, mutagenesis of both arginine (Arg(101) and Arg(114)) and histidine (His(102) and His(115)) residues abolished interaction with plasminogen despite the presence of Lys(98) and Lys(111) in the binding repeats. This study shows for the first time that residues Arg(101), Arg(114), His(102), and His(115) in both the a1 and a2 repeat domains of PAM can mediate high affinity plasminogen binding. These data suggest that highly conserved arginine and histidine residues may compensate for variation elsewhere in the a1 and a2 plasminogen binding repeats, and may explain the maintenance of high affinity plasminogen binding by naturally occurring variants of PAM.	Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia	University of Wollongong	Ranson, M (corresponding author), Univ Wollongong, Sch Biol Sci, Northfields Ave, Wollongong, NSW 2522, Australia.	mranson@uow.edu.au	Ranson, Marie/A-6324-2008; Walker, Mark J./F-6940-2011; Ranson, Marie/GRO-5792-2022; Sanderson-Smith, Martina L/H-9614-2013; Sanderson-Smith, Martina/O-9387-2019; Ranson, Marie/AAC-4468-2019	Ranson, Marie/0000-0002-5570-9645; Ranson, Marie/0000-0002-5570-9645; Sanderson-Smith, Martina L/0000-0002-6366-4993; Ranson, Marie/0000-0002-5570-9645; Walker, Mark/0000-0001-7423-2769				Andronicos NM, 1997, BBA-PROTEIN STRUCT M, V1337, P27, DOI 10.1016/S0167-4838(96)00146-X; [Anonymous], 1982, PHYS BIOCH APPL BIOC; BERGE A, 1993, J BIOL CHEM, V268, P25417; Bessen DE, 1996, J INFECT DIS, V173, P896, DOI 10.1093/infdis/173.4.896; Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X; Carapetis JR, 1999, EPIDEMIOL INFECT, V122, P59, DOI 10.1017/S0950268898001952; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; GRADDIS TJ, 1993, BIOCHEMISTRY-US, V32, P12664, DOI 10.1021/bi00210a015; KHANDKE KM, 1988, J BIOL CHEM, V263, P5075; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lahteenmaki K, 2001, FEMS MICROBIOL REV, V25, P531, DOI 10.1111/j.1574-6976.2001.tb00590.x; Marti DN, 1997, BIOCHEMISTRY-US, V36, P11591, DOI 10.1021/bi971316v; McKay FC, 2004, INFECT IMMUN, V72, P364, DOI 10.1128/IAI.72.1.364-370.2004; PHILLIPS GN, 1981, P NATL ACAD SCI-BIOL, V78, P4689, DOI 10.1073/pnas.78.8.4689; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; Rios-Steiner JL, 2001, J MOL BIOL, V308, P705, DOI 10.1006/jmbi.2001.4646; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanderson-Smith M, 2006, J BIOL CHEM, V281, P3217, DOI 10.1074/jbc.M508758200; SANDERSONSMITH ML, 2004, CURR TRENDS MICROBIO, V1, P75; Schenone MM, 2000, J PEPT RES, V56, P438, DOI 10.1034/j.1399-3011.2000.00810.x; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sun HM, 2004, SCIENCE, V305, P1283, DOI 10.1126/science.1101245; Svensson MD, 1999, INFECT IMMUN, V67, P3915, DOI 10.1128/IAI.67.8.3915-3920.1999; Svensson MD, 2002, MICROBIOL-SGM, V148, P3933, DOI 10.1099/00221287-148-12-3933; Walker MJ, 2005, TRENDS MICROBIOL, V13, P308, DOI 10.1016/j.tim.2005.05.006; WISTEDT AC, 1995, MOL MICROBIOL, V18, P569, DOI 10.1111/j.1365-2958.1995.mmi_18030569.x; Wistedt AC, 1998, J BIOL CHEM, V273, P24420, DOI 10.1074/jbc.273.38.24420	29	36	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25965	25971		10.1074/jbc.M603846200	http://dx.doi.org/10.1074/jbc.M603846200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16822869	Green Submitted, hybrid			2022-12-25	WOS:000240249500011
J	Seidler, DG; Goldoni, S; Agnew, C; Cardi, C; Thakur, ML; Owens, RT; McQuillan, DJ; Iozzo, RV				Seidler, Daniela G.; Goldoni, Silvia; Agnew, Christopher; Cardi, Christopher; Thakur, Mathew L.; Owens, Rick T.; McQuillan, David J.; Iozzo, Renato V.			Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH PROTEOGLYCANS; CHICK-EMBRYO FIBROBLASTS; DOWN-REGULATION; EGF RECEPTOR; CELL-GROWTH; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; UP-REGULATION; SUPPRESSION; INDUCTION	Decorin is not only a regulator of matrix assembly but also a key signaling molecule that modulates the activity of tyrosine kinase receptors such as the epidermal growth factor receptor (EGFR). Decorin evokes protracted internalization of the EGFR via a caveolar-mediated endocytosis, which leads to EGFR degradation and attenuation of its signaling pathway. In this study, we tested if systemic delivery of decorin protein core would affect the biology of an orthotopic squamous carcinoma xenograft. After tumor engraftment, the animals were given intraperitoneal injections of either vehicle or decorin protein core (2.5-10 mg kg(-1)) every 2 days for 18-38 days. This regimen caused a significant and dose-dependent inhibition of the tumor xenograft growth, with a concurrent decrease in mitotic index and a significant increase in apoptosis. Positron emission tomography showed that the metabolic activity of the tumor xenografts was significantly reduced by decorin treatment. Decorin protein core specifically targeted the tumor cells enriched in EGFR and caused a significant downregulation of EGFR and attenuation of its activity. In vitro studies showed that the uptake of decorin by the A431 cells was rapid and caused a protracted down-regulation of the EGFR to levels similar to those observed in the tumor xenografts. Furthermore, decorin induced apoptosis via activation of caspase-3. This could represent an additional mechanism whereby decorin might influence cell growth and survival.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Radiat, Radiopharmaceut Res Ctr, Philadelphia, PA 19107 USA; LifeCell Corp, Branchburg, NJ 08876 USA; Thomas Jefferson Univ, Cellular Biol & Signaling Program, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Rm 249 JAH, Philadelphia, PA 19107 USA.	iozzo@mail.jci.tju.edu	Iozzo, Renato/AAS-1980-2020	Thakur, Mathew/0000-0003-2409-039X; Iozzo, Renato/0000-0002-5908-5112	NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA39481, R01 CA47282] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Biglari A, 2004, CANCER GENE THER, V11, P721, DOI 10.1038/sj.cgt.7700783; Bix G, 2004, J CELL BIOL, V166, P97, DOI 10.1083/jcb.200401150; Cao L, 2000, J CELL BIOCHEM, V77, P569, DOI 10.1002/(SICI)1097-4644(20000615)77:4<569::AID-JCB5>3.0.CO;2-K; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Carraway KL, 2001, CURR OPIN CELL BIOL, V13, P125, DOI 10.1016/S0955-0674(00)00188-5; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Davies CD, 2001, MICROVASC RES, V62, P26, DOI 10.1006/mvre.2001.2311; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; Dharmawardana PG, 2006, ANTI-CANCER DRUG, V17, P13, DOI 10.1097/01.cad.0000185180.72604.ac; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; Goldoni S, 2004, J BIOL CHEM, V279, P6606, DOI 10.1074/jbc.M310342200; Grant DS, 2002, ONCOGENE, V21, P4765, DOI 10.1038/sj.onc.1205595; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; He YY, 2006, ONCOGENE, V25, P1521, DOI 10.1038/sj.onc.1209184; Iozzo RV, 1999, PROG NUCLEIC ACID RE, V62, P19; Iozzo RV, 1999, P NATL ACAD SCI USA, V96, P3092, DOI 10.1073/pnas.96.6.3092; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jiang XN, 2004, J HISTOCHEM CYTOCHEM, V52, P1575, DOI 10.1369/jhc.4A6353.2004; KAWAMOTO T, 1984, J BIOL CHEM, V259, P7761; Kolettas E, 1998, EUR J BIOCHEM, V254, P266, DOI 10.1046/j.1432-1327.1998.2540266.x; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; McDoniels-Silvers AL, 2002, CLIN CANCER RES, V8, P1127; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Miyasaka Y, 2001, BRIT J CANCER, V85, P228, DOI 10.1054/bjoc.2001.1901; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Nash MA, 2002, CLIN CANCER RES, V8, P1754; Nash MA, 1999, CANCER RES, V59, P6192; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; Parsons-Wingerter P, 2005, AM J PATHOL, V167, P193, DOI 10.1016/S0002-9440(10)62965-3; Perez S, 2001, ONCOGENE, V20, P1135, DOI 10.1038/sj.onc.1204200; Petit AMV, 1997, AM J PATHOL, V151, P1523; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Reed CC, 2005, ONCOGENE, V24, P1104, DOI 10.1038/sj.onc.1208329; Reed CC, 2002, ONCOGENE, V21, P3688, DOI 10.1038/sj.onc.1205470; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Schonherr E, 2001, J BIOL CHEM, V276, P40687, DOI 10.1074/jbc.M105426200; Seidler DG, 2005, BIOCHEM BIOPH RES CO, V332, P1162, DOI 10.1016/j.bbrc.2005.04.175; Shridhar V, 2001, CANCER RES, V61, P5895; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tikhomirov O, 2004, J BIOL CHEM, V279, P12988, DOI 10.1074/jbc.M311655200; Tralhao JG, 2003, FASEB J, V17, P464, DOI 10.1096/fj.02-0534fje; Troup S, 2003, CLIN CANCER RES, V9, P207; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; Xaus J, 2001, BLOOD, V98, P2124, DOI 10.1182/blood.V98.7.2124; Zhu JX, 2005, J BIOL CHEM, V280, P32468, DOI 10.1074/jbc.M503833200	60	145	149	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26408	26418		10.1074/jbc.M602853200	http://dx.doi.org/10.1074/jbc.M602853200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16835231	hybrid			2022-12-25	WOS:000240249500058
J	Yu, X; Egner, PA; Wakabayashi, J; Wakabayashi, N; Yamamoto, M; Kensler, TW				Yu, Xiang; Egner, Patricia A.; Wakabayashi, Junko; Wakabayashi, Nobunao; Yamamoto, Masayuki; Kensler, Thomas W.			Nrf2-mediated induction of cytoprotective enzymes by 15-deoxy-Delta(12,14)-prostaglandin J(2) is attenuated by alkenal/one oxidoreductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; TRANSCRIPTION FACTOR NRF2; SQUAMOUS CARCINOMA-CELLS; PPAR-GAMMA; CYCLOPENTENONE PROSTAGLANDINS; GENE-EXPRESSION; PROTEIN; KEAP1; UBIQUITINATION; INDUCERS	NADPH-dependent alkenal/one oxidoreductase (Aor) was discovered to be highly inducible in rat liver following treatment with the cancer chemopreventive agent 3H-1,2-dithiole-3-thione. Aor was further characterized as an Nrf2-regulated antioxidative enzyme that reduces carbon-carbon double bonds in a variety of alpha, beta-unsaturated aldehydes and ketones. 15-Deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)) is a reactive membrane lipid metabolite that activates multiple pathways, including Nrf2-mediated induction of cytoprotective enzymes. Physiologically, it is postulated that 15d-PGJ(2) alkylates key regulatory proteins via the electrophilic carbon centers found in two alpha,beta-unsaturated ketone moieties. This current study addresses the metabolism of 15d-PGJ(2) by rat Aor (rAor) and subsequent deactivation of the Nrf2 signaling pathway by both rat and human AOR. We demonstrate that induction of NADPH-dependent quinone oxidoreductase activity by 15d-PGJ(2) is markedly attenuated in mouse embryonic fibroblasts that overexpress rAor. Luciferase reporter assay and quantitative real-time PCR confirmed these findings. Concentrations required for doubling the NADPH-dependent quinone oxidoreductase response are increased from 1.8 mu m in wild-type to > 10 mu m in rat Aor transgenic fibroblasts. 15d-PGJ(2) is metabolized by recombinant rAor with a K-m of 9.6 mu m and k(cat) of 18.5 min(-1). The major product is 12,13-dihydro-15-deoxy-Delta(12,14)-prostaglandin J(2) (dihydro-15d-PGJ(2)). The reduction of C=C by Aor yielding dihydro-15d-PGJ(2) abolishes the inducibility in an antioxidant response element-driven luciferase assay. Collectively, these results demonstrate that 15d-PGJ(2) can be catabolized by Aor, thereby attenuating subsequent Nrf2 signaling and possibly inflammatory and apoptotic processes also influenced by 15d-PGJ(2).	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Div Toxicol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Pharmacol & Mol Sci, John Hopkins Sch Med, Baltimore, MD 21205 USA; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Tsukuba; University of Tsukuba	Kensler, TW (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Div Toxicol, 615 N Wolfe St, Baltimore, MD 21205 USA.	tkensler@jhsph.edu	Yamamoto, Masayuki/A-4873-2010; Kensler, Thomas W/D-8686-2014	Yamamoto, Masayuki/0000-0002-9073-9436; Kensler, Thomas W/0000-0002-6676-261X	NCI NIH HHS [CA39416] Funding Source: Medline; NIEHS NIH HHS [ES06052, ES03819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039416] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819, P01ES006052] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Camp HS, 2000, DIABETES, V49, P539, DOI 10.2337/diabetes.49.4.539; Dick RA, 2001, J BIOL CHEM, V276, P40803, DOI 10.1074/jbc.M105487200; Dick RA, 2004, J BIOL CHEM, V279, P17269, DOI 10.1074/jbc.M400427200; Dinkova-Kostova AT, 2001, P NATL ACAD SCI USA, V98, P3404, DOI 10.1073/pnas.051632198; Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367; Fahey JW, 2004, METHOD ENZYMOL, V382, P243; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Hong F, 2005, J BIOL CHEM, V280, P31768, DOI 10.1074/jbc.M503346200; Hori T, 2004, J BIOL CHEM, V279, P22615, DOI 10.1074/jbc.M312655200; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Ishii T, 2004, CIRC RES, V94, P609, DOI 10.1161/01.RES.0000119171.44657.45; Itoh K, 2004, MOL CELL BIOL, V24, P36, DOI 10.1128/MCB.24.1.36-45.2004; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; Katoh Y, 2005, ARCH BIOCHEM BIOPHYS, V433, P342, DOI 10.1016/j.abb.2004.10.012; Kensler TW, 1998, CANCER EPIDEM BIOMAR, V7, P127; Kim EH, 2004, ANN NY ACAD SCI, V1030, P493, DOI 10.1196/annals.1329.061; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Knight LP, 1999, CARCINOGENESIS, V20, P1215, DOI 10.1093/carcin/20.7.1215; Kobayashi A, 2006, MOL CELL BIOL, V26, P221, DOI 10.1128/MCB.26.1.221-229.2006; Kobayashi M, 2005, ANTIOXID REDOX SIGN, V7, P385, DOI 10.1089/ars.2005.7.385; Kondo M, 2002, P NATL ACAD SCI USA, V99, P7367, DOI 10.1073/pnas.112212599; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Levonen AL, 2004, BIOCHEM J, V378, P373, DOI 10.1042/BJ20031049; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; Moos PJ, 2003, J BIOL CHEM, V278, P745, DOI 10.1074/jbc.M211134200; Mullally JE, 2001, J BIOL CHEM, V276, P30366, DOI 10.1074/jbc.M102198200; Oliva JL, 2003, P NATL ACAD SCI USA, V100, P4772, DOI 10.1073/pnas.0735842100; Paumi CM, 2003, BIOCHEMISTRY-US, V42, P5429, DOI 10.1021/bi027347u; Perez-Sala D, 2003, J BIOL CHEM, V278, P51251, DOI 10.1074/jbc.M309409200; Primiano T, 1996, CARCINOGENESIS, V17, P2297, DOI 10.1093/carcin/17.11.2297; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Sanchez-Gomez FJ, 2004, MOL PHARMACOL, V66, P1349, DOI 10.1124/mol.104.002824; Sawyer N, 2002, BRIT J PHARMACOL, V137, P1163, DOI 10.1038/sj.bjp.0704973; Shibata T, 2002, J BIOL CHEM, V277, P10459, DOI 10.1074/jbc.M110314200; Siavash H, 2004, BRIT J CANCER, V91, P1074, DOI 10.1038/sj.bjc.6602055; Siavash H, 2004, CANCER LETT, V211, P97, DOI 10.1016/j.canlet.2004.02.003; Soares AF, 2005, BIOCHEM BIOPH RES CO, V337, P521, DOI 10.1016/j.bbrc.2005.09.085; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Yang XY, 2000, J BIOL CHEM, V275, P4541, DOI 10.1074/jbc.275.7.4541; Yates MS, 2006, CANCER RES, V66, P2488, DOI 10.1158/0008-5472.CAN-05-3823; YOKOMIZO T, 1993, J BIOL CHEM, V268, P18128; Yu X, 2005, MUTAT RES-FUND MOL M, V591, P93, DOI 10.1016/j.mrfmmm.2005.04.017; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004	51	23	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26245	26252		10.1074/jbc.M604620200	http://dx.doi.org/10.1074/jbc.M604620200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16857669	hybrid			2022-12-25	WOS:000240249500041
J	Arad, S; Konnikov, N; Goukassian, DA; Gilchrest, BA				Arad, Simin; Konnikov, Nellie; Goukassian, David A.; Gilchrest, Barbara A.			T-oligos augment UV-induced protective responses in human skin	FASEB JOURNAL			English	Article						NER; oligonucleotides; melanin content; CPD	DNA-REPAIR CAPACITY; TRANSCRIPTION-COUPLED REPAIR; P53 MUTATIONS; 6-4 PHOTOPRODUCTS; HUMAN MELANOCYTES; CELL CARCINOMA; DAMAGE; MELANOGENESIS; CANCER; GENE	We have shown that DNA oligonucleotides substantially homologous to the telomere 3-prime overhang sequence (T-oligos) increase DNA repair capacity (DRC) in cultured human cells and decrease UV-induced mutation rate and photocarcinogenesis in mouse skin. To investigate the protective effects of T-oligos in intact human skin, paired skin explants obtained from adult donors were treated with T-oligos or diluent alone for 24 h, then UVB-or sham-irradiated, and processed after 6, 24, 48, 72, and 96 h for histological analysis. After UV irradiation apoptotic epidermal cells were comparable in diluent-and T-oligo-treated skin. Proliferating (Ki67+) cells were sparse in sham-irradiated skin and for 24 h after UV in both diluent-and T-oligo-treated specimens. However, compared to diluent controls, at 48 and 72 h T-oligos significantly inhibited UV-induced rebound hyperproliferation. Maximum and comparable cyclobutane pyrimidine dimers (CPDs) were detected immediately after UV irradiation in diluent- and T-oligo-treated skin, but CPDs were strikingly reduced in T-oligo-vs. diluent-treated skin at 24, 48, and 72 h. Total and activated p53 protein was increased in T-oligo-vs. diluent-pretreated skin at the time of irradiation, and up to 3-fold increases persisted for 24 h post-UV. Over 5 days, UV irradiation and T-oligo comparably increased expression of melanogenic proteins and each increased epidermal melanin content 3-to 5-fold, with distinct nuclear capping in many keratinocytes. In combination, these findings predict that T-oligo treatment will increase melanogenesis, prolong epidermal arrest, and increase DNA repair rate after UV irradiation, thus decreasing the severity of acute and chronic photodamage in human skin. Moreover, the data document an inducible SOS-like response consisting of increased melanogenesis and increased DNA repair capacity in human skin following UV-induced damage that is also produced by T-oligos in the absence of initial damage.	Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA	Boston University	Goukassian, DA (corresponding author), Boston Univ, Sch Med, Dept Dermatol, 609 Albany St, Boston, MA 02118 USA.	dgoukass@bu.edu; bgilchre@bu.edu		Goukassian, David/0000-0001-5270-5270	NCI NIH HHS [R0I CA 10515-02] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baba T, 1996, J DERMATOL SCI, V12, P18, DOI 10.1016/0923-1811(95)00452-1; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bhawan J, 1999, AM J DERMATOPATH, V21, P225, DOI 10.1097/00000372-199906000-00003; BOHR VA, 1995, MUTAT RES-DNAGING G, V338, P25, DOI 10.1016/0921-8734(95)00008-T; Botchkareva NV, 2001, FASEB J, V15, P645, DOI 10.1096/fj.00-0368com; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Bykov VJ, 2000, J INVEST DERMATOL, V114, P40, DOI 10.1046/j.1523-1747.2000.00821.x; CARR AH, 1995, TRENDS CELL BIOL, P32; CLEAVER JE, 1994, CELL, V76, P1, DOI 10.1016/0092-8674(94)90165-1; Coultas L, 2000, APOPTOSIS, V5, P491, DOI 10.1023/A:1009617727938; Cruz PD, 2000, J INVEST DERMATOL, V114, P253, DOI 10.1046/j.1523-1747.2000.00866.x; Drouin R, 1997, PHOTOCHEM PHOTOBIOL, V66, P719, DOI 10.1111/j.1751-1097.1997.tb03213.x; Einspahr JG, 2003, RECENT RESULTS CANC, V163, P151; Eller MS, 2003, FASEB J, V17, P152, DOI 10.1096/fj.02-0197com; Eller MS, 2002, EXP CELL RES, V276, P185, DOI 10.1006/excr.2002.5531; ELLER MS, 1994, NATURE, V372, P413, DOI 10.1038/372413a0; Eller MS, 1996, P NATL ACAD SCI USA, V93, P1087, DOI 10.1073/pnas.93.3.1087; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; FITZPATRICK TB, 2003, FITZPATRICKS DERMATO, P819; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Francis MA, 1999, CARCINOGENESIS, V20, P19, DOI 10.1093/carcin/20.1.19; FREEDBERG IM, 1999, FITZPATRICKS DERMATO, P1555; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gilchrest BA, 1999, J INVEST DERM SYMP P, V4, P35, DOI 10.1038/sj.jidsp.5640178; Gilchrest BA, 1996, PHOTOCHEM PHOTOBIOL, V63, P1, DOI 10.1111/j.1751-1097.1996.tb02988.x; Gilchrest BA, 1997, FASEB J, V11, P322, DOI 10.1096/fasebj.11.5.9141498; Goukassian D, 2000, FASEB J, V14, P1325, DOI 10.1096/fj.14.10.1325; Goukassian DA, 2004, P NATL ACAD SCI USA, V101, P3933, DOI 10.1073/pnas.0306389101; Goukassian DA, 2002, FASEB J, V16, P754, DOI 10.1096/fj.01-0829fje; Grossman D, 1997, ARCH DERMATOL, V133, P1263, DOI 10.1001/archderm.133.10.1263; Hadshiew IM, 2001, J DERMATOL SCI, V25, P127, DOI 10.1016/S0923-1811(00)00125-0; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Khlgatian MK, 2002, J INVEST DERMATOL, V118, P126, DOI 10.1046/j.0022-202x.2001.01667.x; LANE DP, 1992, NATURE, V358, P16; Li GZ, 2003, P NATL ACAD SCI USA, V100, P527, DOI 10.1073/pnas.0235444100; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MARWAHA V, 2005, J BIOL CHEM; Moriwaki SI, 1996, MUTAT RES-DNA REPAIR, V364, P117, DOI 10.1016/0921-8777(96)00029-8; Nylander K, 2000, J PATHOL, V190, P39, DOI 10.1002/(SICI)1096-9896(200001)190:1<39::AID-PATH492>3.0.CO;2-V; OLSEN WM, 1990, J INVEST DERMATOL, V94, P101, DOI 10.1111/1523-1747.ep12873961; PATRICK MH, 1977, PHOTOCHEM PHOTOBIOL, V25, P357, DOI 10.1111/j.1751-1097.1977.tb07355.x; Pedeux R, 1998, J INVEST DERMATOL, V111, P472, DOI 10.1046/j.1523-1747.1998.00324.x; Perkins JL, 2005, J CLIN ONCOL, V23, P3733, DOI 10.1200/JCO.2005.06.237; Petrocelli T, 1996, ONCOGENE, V12, P1387; Puri N, 2004, FASEB J, V18, P1373, DOI 10.1096/fj.04-1774com; Radman M, 1975, Basic Life Sci, V5A, P355; RADMAN M, 1970, J MOL BIOL, V49, P203, DOI 10.1016/0022-2836(70)90386-4; Reuven NB, 1998, MOL CELL, V2, P191, DOI 10.1016/S1097-2765(00)80129-X; SAGE E, 1993, PHOTOCHEM PHOTOBIOL, V57, P163, DOI 10.1111/j.1751-1097.1993.tb02273.x; Smit NPM, 2001, PHOTOCHEM PHOTOBIOL, V74, P424, DOI 10.1562/0031-8655(2001)074<0424:MOPAIO>2.0.CO;2; Spatz A, 2001, CANCER RES, V61, P2480; Tadokoro T, 2005, J INVEST DERMATOL, V124, P1326, DOI 10.1111/j.0022-202X.2005.23760.x; WALKER SL, 2003, DERMATOLOGY GEN MED, P1275; WEI QY, 1995, J INVEST DERMATOL, V104, P933, DOI 10.1111/1523-1747.ep12606207; WEI Z, 1993, P NATL ACAD SCI USA, V90, P1614; WERNINGHAUS K, 1991, PHOTODERMATOL PHOTO, V8, P236; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Young AR, 1996, J INVEST DERMATOL, V106, P1307, DOI 10.1111/1523-1747.ep12349031; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	60	47	49	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1895	+		10.1096/fj.06-5964fje	http://dx.doi.org/10.1096/fj.06-5964fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16877521				2022-12-25	WOS:000240267000022
J	Cai, BB; Chang, SH; Becker, EBE; Bonni, A; Xia, ZG				Cai, Beibei; Chang, Sandra H.; Becker, Esther B. E.; Bonni, Azad; Xia, Zhengui			p38 MAP kinase mediates apoptosis through phosphorylation of Bim(EL) at Ser-65	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; RAT CEREBELLAR NEURONS; C-JUN; CORTICAL-NEURONS; BH3-ONLY PROTEIN; GENE-EXPRESSION; CELL-DEATH; HEME OXYGENASE-1; BCL-2 FAMILY	The stress-activated c-Jun N-terminal protein kinase (JNK) and p38 mitogen-activated protein ( MAP) kinase ( p38) regulate apoptosis induced by several forms of cellular insults. Potential targets for these kinases include members of the Bcl-2 family proteins, which mediate apoptosis generated through the mitochondria-initiated, intrinsic cell death pathway. Indeed, the activities of several Bcl-2 family proteins, both pro-and antiapoptotic, are controlled by JNK phosphorylation. For example, the pro-apoptotic activity of Bim(EL), a member of the Bcl-2 family, is stimulated by JNK phosphorylation at Ser-65. In contrast, there is no reported evidence that p38-induced apoptosis is due to direct phosphorylation of Bcl-2 family proteins. Here we report evidence that sodium arsenite-induced apoptosis in PC12 cells may be due to direct phosphorylation of BimEL at Ser-65 by p38. This conclusion is supported by data showing that ectopic expression of a wild type, but not a non-phosphorylatable S65A mutant of BimEL, potentiates sodium arsenite-induced apoptosis and by experiments showing direct phosphorylation of BimEL at Ser-65 by p38 in vitro. Furthermore, sodium arsenite induced BimEL phosphorylation at Ser-65, which was blocked by p38 inhibition. This study provides the first example whereby p38 induces apoptosis by phosphorylating a member of the Bcl-2 family and illustrates that phosphorylation of BimEL on Ser-65 may be a common regulatory point for cell death induced by both JNK and p38 pathways.	Univ Washington, Dept Environm & Occupat Hlth Sci, Toxicol Program, Box 357234, Seattle, WA 98195 USA; Univ Washington, Grad Program Neurobiol & Behav, Seattle, WA 98195 USA; Harvard Univ, Sch Med, Dept Pathol, Program Biol & Biomed Sci, Boston, MA 02115 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Harvard University; Harvard Medical School	Xia, ZG (corresponding author), Univ Washington, Dept Environm & Occupat Hlth Sci, Toxicol Program, Box 357234, Seattle, WA 98195 USA.	zxia@u.washington.edu		Becker, Esther B E/0000-0002-5238-4902	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007032, R01ES012215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044069] Funding Source: NIH RePORTER; NIEHS NIH HHS [T32 ES007032, ES 012215] Funding Source: Medline; NINDS NIH HHS [NS421021, NS44069] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amato SF, 1998, CANCER RES, V58, P241; Bantounas I, 2005, J NEUROSCI RES, V79, P661, DOI 10.1002/jnr.20389; Basu A, 2003, FEBS LETT, V538, P41, DOI 10.1016/S0014-5793(03)00131-5; Becker EBE, 2004, J NEUROSCI, V24, P8762, DOI 10.1523/JNEUROSCI.2953-04.2004; Bernstam L, 2000, J TOXICOL ENV HEAL B, V3, P293, DOI 10.1080/109374000436355; Bhakar AL, 2003, J NEUROSCI, V23, P11373; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Caughlan A, 2004, TOXICOL SCI, V78, P125, DOI 10.1093/toxsci/kfh038; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Figueroa-Masot XA, 2001, J NEUROSCI, V21, P4657, DOI 10.1523/JNEUROSCI.21-13-04657.2001; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Grethe S, 2006, CELL SIGNAL, V18, P531, DOI 10.1016/j.cellsig.2005.05.023; Grethe S, 2004, EXP CELL RES, V298, P632, DOI 10.1016/j.yexcr.2004.05.007; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Harada H, 2004, P NATL ACAD SCI USA, V101, P15313, DOI 10.1073/pnas.0406837101; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; KUNIMOTO M, 1994, BIOCHEM BIOPH RES CO, V204, P310, DOI 10.1006/bbrc.1994.2461; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Lee PC, 2005, TOXICOL SCI, V85, P541, DOI 10.1093/toxsci/kfi101; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Ley R, 2005, J BIOL CHEM, V280, P17657, DOI 10.1074/jbc.M412342200; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Ley R, 2004, J BIOL CHEM, V279, P8837, DOI 10.1074/jbc.M311578200; Li SP, 2003, CANCER RES, V63, P3473; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Miralem T, 2005, J BIOL CHEM, V280, P17084, DOI 10.1074/jbc.M413121200; Namgung U, 2000, J NEUROSCI, V20, P6442, DOI 10.1523/JNEUROSCI.20-17-06442.2000; Namgung U, 2001, TOXICOL APPL PHARM, V174, P130, DOI 10.1006/taap.2001.9200; Newhouse K, 2004, TOXICOL SCI, V79, P137, DOI 10.1093/toxsci/kfh089; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oberto A, 1996, J PHARMACOL EXP THER, V279, P435; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199; SARAFIAN TA, 1994, TOXICOL LETT, V74, P149, DOI 10.1016/0378-4274(94)90093-0; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; She QB, 2002, J BIOL CHEM, V277, P24039, DOI 10.1074/jbc.M109907200; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wong HK, 2005, MOL CELL BIOL, V25, P8732, DOI 10.1128/MCB.25.19.8732-8747.2005; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	65	164	168	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25215	25222		10.1074/jbc.M512627200	http://dx.doi.org/10.1074/jbc.M512627200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16818494	hybrid			2022-12-25	WOS:000240031300022
J	Moffatt, JD; Lever, R; Page, CP				Moffatt, James D.; Lever, Rebecca; Page, Clive P.			Activation of corticotropin-releasing factor receptor-2 causes bronchorelaxation and inhibits pulmonary inflammation in mice	FASEB JOURNAL			English	Article						urocortin; airway; neutrophil; smooth muscle; epithelium	MOUSE ISOLATED TRACHEA; EPITHELIUM; PEPTIDE; RELAXATION; LIGANDS; HYPERREACTIVITY; UROCORTIN-2; ENDOTOXIN; AIRWAYS; FAMILY	Urocortins are members of the corticotropin-releasing factor (CRF) family of peptides that bind to two receptors, CRF1 and CRF2. While CRF1 is a high-affinity receptor for CRF, urocortin III binds with much greater affinity to CRF2. In the present study we investigated the effect of CRF2 receptor activation with urocortin III on airway smooth muscle tone in vitro and in an acute model of airway inflammation in mice. Urocortin III caused relaxation of methacholine-precontracted mouse tracheal segments. CRF caused similar relaxation, but with reduced potency compared to urocortin III, consistent with the CRF2 receptor subtype. Relaxation induced by urocortin III was concentration-dependently inhibited by the CRF2 antagonist, astressin 2B, with an IC50 in the nanomolar range. These relaxations were potentiated by inhibition of phosphodiesterases but unaffected by inhibition of cyclooxygenase and NO or by removal of the epithelium. Finally, the number of neutrophils retrieved by bronchoalveolar lavage after administration of bacterial LPS (LPS) was reduced by prior intraperitoneal (i. p.) injection of urocortin III. This effect was also suppressed by astressin 2B, implicating CRF2 receptors. Therefore, CRF2 agonists appear to have both bronchorelaxant and anti-inflammatory activities and might represent an interesting therapeutic approach to the treatment of inflammatory lung diseases.-Moffatt, J. D., Lever, R., Page, C. P. Activation of corticotropinreleasing factor receptor-2 (CRF2) causes bronchorelaxation and inhibits pulmonary inflammation in mice.	Kings Coll London, Sackler Inst Pulm Pharmacol, London SE1 1UL, England; Univ London, Sch Pharm, London WC1N 1AX, England	University of London; King's College London; University of London; University College London; University of London School of Pharmacy	Moffatt, JD (corresponding author), Kings Coll London, Sackler Inst Pulm Pharmacol, 5th Floor,Hodgkin Bldg,Guys Campus, London SE1 1UL, England.	james.moffatt@kcl.ac.uk		Page, Clive Peter/0000-0002-9358-3799				AGNELLO D, 1998, AM J PHYSIOL, V275, pF757; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Dautzenberg FM, 2002, TRENDS PHARMACOL SCI, V23, P71, DOI 10.1016/S0165-6147(02)01946-6; Deleuze V, 2004, AM J PHYSIOL-LUNG C, V286, pL98, DOI 10.1152/ajplung.00053.2003; deMoraes VLG, 1996, BRIT J PHARMACOL, V117, P1792; Hauger RL, 2003, PHARMACOL REV, V55, P21, DOI 10.1124/pr.55.1.3; Hsu SY, 2001, NAT MED, V7, P605, DOI 10.1038/87936; Kao J, 1999, AM J PHYSIOL-LUNG C, V277, pL264, DOI 10.1152/ajplung.1999.277.2.L264; KNOWLES MR, 1995, AM J RESP CRIT CARE, V151, pS65, DOI 10.1164/ajrccm/151.3_Pt_2.S65; Kornerup KN, 2005, BRIT J PHARMACOL, V144, P1011, DOI 10.1038/sj.bjp.0706133; la Fleur SE, 2005, P NATL ACAD SCI USA, V102, P7647, DOI 10.1073/pnas.0408531102; Lan RS, 2001, BRIT J PHARMACOL, V132, P93, DOI 10.1038/sj.bjp.0703776; Lefort J, 2001, AM J RESP CELL MOL, V24, P345, DOI 10.1165/ajrcmb.24.3.4289; Lefort J, 1998, J IMMUNOL, V161, P474; Lewis K, 2001, P NATL ACAD SCI USA, V98, P7570, DOI 10.1073/pnas.121165198; Moffatt JD, 2004, BRIT J PHARMACOL, V141, P1159, DOI 10.1038/sj.bjp.0705720; Moffatt JD, 2002, AM J RESP CELL MOL, V26, P680, DOI 10.1165/ajrcmb.26.6.4693; Porcher C, 2005, AM J PHYSIOL-GASTR L, V288, pG1091, DOI 10.1152/ajpgi.00302.2004; Rivier J, 2002, J MED CHEM, V45, P4737, DOI 10.1021/jm0202122; Sashinami H, 2005, ENDOCRINOLOGY, V146, P5003, DOI 10.1210/en.2005-0439; Schlemper V, 2005, BRIT J PHARMACOL, V145, P740, DOI 10.1038/sj.bjp.0706222; Schwarz UR, 2001, BIOCHEM PHARMACOL, V62, P1153, DOI 10.1016/S0006-2952(01)00760-2; Suda T, 2004, PEPTIDES, V25, P1689, DOI 10.1016/j.peptides.2004.03.027; Wiley KE, 2004, BRIT J PHARMACOL, V143, P508, DOI 10.1038/sj.bjp.0705985	24	21	21	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2006	20	11					1877	+		10.1096/fj.05-5315fje	http://dx.doi.org/10.1096/fj.05-5315fje			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16855006				2022-12-25	WOS:000240267000016
J	Vazquez, G; Bird, GSJ; Mori, Y; Putney, JW				Vazquez, Guillermo; Bird, Gary St. J.; Mori, Yasuo; Putney, James W., Jr.			Native TRPC7 channel activation by an inositol trisphosphate receptor-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DT40 B-LYMPHOCYTES; TRANSIENT RECEPTOR; 1,4,5-TRISPHOSPHATE RECEPTORS; CATION CHANNELS; PROTEIN; CELLS; ENTRY; EXPRESSION	In DT40 B lymphocytes, Canonical Transient Receptor Potential 7 (TRPC7) functions as a diacylglycerol-activated non-selective cation channel. However, previous work indicated that the non-store-operated Ca2+ entry in this cell type depends upon inositol trisphosphate receptors ( IP3R). With the cell-attached configuration oleyl-acetyl-glycerol (OAG) induced single channel activity ( 75 pS) that was not observed in TRPC7(-/-) cells but was rescued by expression of TRPC7 under conditions expected to produce relatively low levels of expression ((LowT7)TRPC7(-/-)). A DT40 cell line lacking IP3R (IP3R-/- cells) showed no OAG-induced single channel activity, but this activity was rescued by transient expression of an IP3R ((IP3R-/-)-I-IP3R). Single channel properties in (LowT7)TRPC7(-/-) or (IP3R-/-)-I-IP3R DT40 cells were indistinguishable from one another and from wildtype cells. Thus, TRPC7 forms, or is part of, the channel underlying endogenous diacylglycerol-activated currents in DT40 B lymphocytes, and this activity of native TRPC7 requires IP3R. However, with conditions expected to produce greater expression levels, TRPC7 functioned independently of the presence of IP3R. This finding may serve to resolve previously conflicting reports from expression studies of TRPC channels.	NIEHS, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; Kyoto Univ, Grad Sch Engn, Dept Synthet Chem & Biol Chem, Mol Biol Lab, Kyoto 6158510, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Kyoto University	Vazquez, G (corresponding author), NIEHS, NIH, Dept Hlth & Human Serv, POB 12233, Res Triangle Pk, NC 27709 USA.	vazquez1@niehs.nih.gov	Putney, James W/F-7247-2019; Bird, Gary/AAI-8186-2021	Putney, James W/0000-0002-3379-4789; Bird, Gary/0000-0003-1389-8748	Intramural NIH HHS [Z99 ES999999] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090087] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; COLQUHOUN D, 1995, SINGLE CHANNELL RECO; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Lemonnier L, 2006, FASEB J, V20, P503, DOI 10.1096/fj.05-4714fje; Lievremont JP, 2005, J BIOL CHEM, V280, P35346, DOI 10.1074/jbc.M507606200; Lievremont JP, 2004, AM J PHYSIOL-CELL PH, V287, pC1709, DOI 10.1152/ajpcell.00350.2004; Mery L, 2001, FEBS LETT, V487, P377, DOI 10.1016/S0014-5793(00)02362-0; Morita T, 2004, BIOCHEM J, V382, P793, DOI 10.1042/BJ20031970; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Putney JW, 2004, TRENDS CELL BIOL, V14, P282, DOI 10.1016/j.tcb.2004.04.002; Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431; Riccio A, 2002, J BIOL CHEM, V277, P12302, DOI 10.1074/jbc.M112313200; Shi J, 2004, J PHYSIOL-LONDON, V561, P415, DOI 10.1113/jphysiol.2004.075051; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Trebak M, 2005, MOL PHARMACOL, V67, P558, DOI 10.1124/mol.104.007252; Trebak M, 2003, CELL CALCIUM, V33, P451, DOI 10.1016/S0143-4160(03)00056-3; Trebak M, 2003, J BIOL CHEM, V278, P16244, DOI 10.1074/jbc.M300544200; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; van Rossum DB, 2004, P NATL ACAD SCI USA, V101, P2323, DOI 10.1073/pnas.0308565100; Vazquez G, 2004, BBA-MOL CELL RES, V1742, P21, DOI 10.1016/j.bbamcr.2004.08.015; Vazquez G, 2003, J BIOL CHEM, V278, P21649, DOI 10.1074/jbc.M302162200; Vazquez G, 2002, EMBO J, V21, P4531, DOI 10.1093/emboj/cdf467	26	36	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25250	25258		10.1074/jbc.M604994200	http://dx.doi.org/10.1074/jbc.M604994200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16822861	Green Accepted, hybrid			2022-12-25	WOS:000240031300026
J	Wang, D; Portis, AR				Wang, Dafu; Portis, Archie R., Jr.			Increased sensitivity of oxidized large isoform of ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco) activase to ADP inhibition is due to an interaction between its carboxyl extension and nucleotide-binding pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NADP-MALATE-DEHYDROGENASE; COVALENT CROSS-LINKING; OXYGENASE ACTIVASE; INTRINSIC FLUORESCENCE; COMPLEX-FORMATION; CONTACT SITES; ATP; ARABIDOPSIS; SPINACH	In Arabidopsis, oxidation of the large (46-kDa) isoform activase to form a disulfide bond in the C-terminal extension (C-extension) significantly increases its ADP sensitivity for both ATP hydrolysis and ribulose-1,5-bisphosphate carboxylase/oxygenase ( Rubisco) activation, thereby decreasing both activities at physiological ratios of ADP/ATP. In this study, we demonstrate that the C-extension of the oxidized large activase isoform can be cross-linked with regions containing residues that contribute to the nucleotide-binding pocket, with a higher efficiency in the presence of ADP or the absence of nucleotides than with ATP. Coupled with measurements demonstrating a redox-dependent protease sensitivity of the C-extension and a lower ATP or adenosine 5'-O-(thiotriphosphate) (ATP gamma S) affinity of the oxidized large isoform than either the reduced form or the smaller isoform, the results suggest that the C-extension plays an inhibitory role in ATP hydrolysis, regulated by redox changes. In contrast, the ADP affinities of the small isoform and the reduced or oxidized large isoform were similar, which indicates that the C-extension selectively interferes with the proper binding of ATP, possibly by interfering with the coordination of the gamma-phosphate. Furthermore, replacement of conserved, negatively charged residues (Asp(390), Glu(394), and Asp(401)) in the C-extension with alanine significantly reduced the sensitivities of the mutants to ADP inhibition, which suggests the involvement of electrostatic interactions between them and positively charged residues in or near the nucleotide-binding pocket. These studies provide new insights into the mechanism of redox regulation of activase by the C-extension in the large isoform.	Univ Illinois, Dept Plant Biol, Urbana, IL 61801 USA; USDA ARS, Photosynth Res Unit, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; United States Department of Agriculture (USDA)	Portis, AR (corresponding author), Univ Illinois, Dept Plant Biol, Urbana, IL 61801 USA.	arportis@uiuc.edu	Wang, Dafu/D-5417-2009					Cai K, 2001, P NATL ACAD SCI USA, V98, P4877, DOI 10.1073/pnas.051632898; Itoh Y, 2001, P NATL ACAD SCI USA, V98, P4883, DOI 10.1073/pnas.051632998; Johansson K, 1999, BIOCHEMISTRY-US, V38, P4319, DOI 10.1021/bi982876c; Kallis RP, 2000, PLANT PHYSIOL, V123, P1077, DOI 10.1104/pp.123.3.1077; Keil B., 1992, SPECIFICITY PROTEOLY, P335, DOI DOI 10.1007/978-3-642-48380-6; Li CH, 2005, J BIOL CHEM, V280, P24864, DOI 10.1074/jbc.M503547200; Lilley RM, 1997, PLANT PHYSIOL, V114, P605, DOI 10.1104/pp.114.2.605; Neuwald AF, 1999, GENOME RES, V9, P27; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Pioszak AA, 2000, BIOCHEMISTRY-US, V39, P13450, DOI 10.1021/bi000795m; Portis AR, 2003, PHOTOSYNTH RES, V75, P11, DOI 10.1023/A:1022458108678; ROBINSON SP, 1989, ARCH BIOCHEM BIOPHYS, V268, P93, DOI 10.1016/0003-9861(89)90568-7; Ruelland E, 1998, J BIOL CHEM, V273, P33482, DOI 10.1074/jbc.273.50.33482; RUNDLE SJ, 1991, J BIOL CHEM, V266, P4677; SALVUCCI ME, 1992, ARCH BIOCHEM BIOPHYS, V298, P688, DOI 10.1016/0003-9861(92)90467-B; Salvucci ME, 2004, FEBS LETT, V560, P205, DOI 10.1016/S0014-5793(04)00111-5; Salvucci ME, 2003, PLANTA, V216, P736, DOI 10.1007/s00425-002-0923-1; SALVUCCI ME, 1994, ARCH BIOCHEM BIOPHYS, V314, P178, DOI 10.1006/abbi.1994.1427; Schurmann P, 2000, ANNU REV PLANT PHYS, V51, P371, DOI 10.1146/annurev.arplant.51.1.371; Schuster G.B., 1992, ADV PHOTOCHEM, P69, DOI DOI 10.1002/9780470133484.CH2; SHEN JB, 1991, J BIOL CHEM, V266, P8963; SHEN JB, 1992, PLANT PHYSIOL, V99, P1201, DOI 10.1104/pp.99.3.1201; To KY, 1999, PLANTA, V209, P66, DOI 10.1007/s004250050607; van de Loo FJ, 1998, BIOCHEMISTRY-US, V37, P4621, DOI 10.1021/bi972566e; vandeLoo FJ, 1996, BIOCHEMISTRY-US, V35, P8143, DOI 10.1021/bi9604901; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang DF, 2006, PHOTOSYNTH RES, V88, P185, DOI 10.1007/s11120-006-9051-2; WANG ZY, 1991, BIOCHIM BIOPHYS ACTA, V1079, P263, DOI 10.1016/0167-4838(91)90067-A; WANG ZY, 1992, PLANT PHYSIOL, V99, P1348, DOI 10.1104/pp.99.4.1348; WANG ZY, 1993, BIOCHIM BIOPHYS ACTA, V1202, P47, DOI 10.1016/0167-4838(93)90061-U; WERNEKE JM, 1989, PLANT CELL, V1, P815, DOI 10.1105/tpc.1.8.815; Zhang N, 1999, P NATL ACAD SCI USA, V96, P9438, DOI 10.1073/pnas.96.16.9438; Zhang N, 2002, P NATL ACAD SCI USA, V99, P3330, DOI 10.1073/pnas.042529999; Zhang N, 2001, PHOTOSYNTH RES, V68, P29, DOI 10.1023/A:1011845506196; Zhang ZL, 2000, J BIOCHEM-TOKYO, V128, P383, DOI 10.1093/oxfordjournals.jbchem.a022765	35	27	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25241	25249		10.1074/jbc.M604756200	http://dx.doi.org/10.1074/jbc.M604756200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16822862	hybrid			2022-12-25	WOS:000240031300025
J	Wang, Y; Levy, DE				Wang, Yaming; Levy, David E.			C-elegans STAT: evolution of a regulatory switch	FASEB JOURNAL			English	Article						transcription factors; domain accretion; nuclear accumulation; DNA binding factor; nematodes; tyrosine phosphorylation; SH2 domain	DNA-BINDING DOMAIN; TYROSINE PHOSPHORYLATION; NUCLEAR TRANSLOCATION; DICTYOSTELIUM STAT; PROTEIN; GENE; TRANSCRIPTION; SEQUENCE; KINASES; GROWTH	STAT transcription factors have been implicated in many biological processes, particularly host immune defense and development. Here we characterize a STAT orthologue from the nematode, C. elegans. We show that this protein, termed STA-1, is structurally and functionally related to other vertebrate and invertebrate STAT proteins, recognizing a cis DNA element conserved through phylogeny. Unexpectedly, STA-1 lacks the conserved amino-terminal oligomerization domain found in vertebrate and other invertebrate STAT proteins, a feature also lacking in orthologues from a distantly related nematode species and from the slime mold, Dictyostelium discoideum. This absence suggests that a primordial STAT protein lacked this domain, which was accreted later in evolution to provide further regulatory control of STAT signaling. Derivation of null mutants demonstrated that STA-1 is not required for nematode viability, despite its widespread expression in multiple tissues of the worm. However, mutant STA-1 proteins that lack functional coiled-coil and DNA binding domains could still be activated and accumulated in the nucleus, suggesting that DNA binding is not a necessary prerequisite for nuclear retention of activated STAT proteins. Our results shed new light on the evolution and function of the STAT signaling pathway and on the structural requirements for STAT activation.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, NYU Canc Inst, New York, NY 10016 USA	New York University; New York University; New York University	Levy, DE (corresponding author), NYU, Sch Med, Dept Pathol, 550 1St Ave,MSB548, New York, NY 10016 USA.	del243@med.nyu.edu	Levy, David/AAG-6202-2019; Levy, David/GPS-4945-2022	Levy, David/0000-0002-7320-7788; 	NIAID NIH HHS [AI28900] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028900] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adler K, 1996, FEBS LETT, V395, P286, DOI 10.1016/0014-5793(96)01053-8; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BACH EA, 2003, SIGNAL TRANSDUCERS A, P87; Barillas-Mury C, 1999, EMBO J, V18, P959, DOI 10.1093/emboj/18.4.959; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; Bluyssen HAR, 1997, J BIOL CHEM, V272, P4600, DOI 10.1074/jbc.272.7.4600; BRENNER S, 1974, GENETICS, V77, P71; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; da Graca LS, 2004, DEVELOPMENT, V131, P435, DOI 10.1242/dev.00922; Darnell JE, 1997, P NATL ACAD SCI USA, V94, P11767, DOI 10.1073/pnas.94.22.11767; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dearolf CR, 1999, CELL MOL LIFE SCI, V55, P1578, DOI 10.1007/s000180050397; Edgley M, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf051; Fields S, 1999, P NATL ACAD SCI USA, V96, P8825, DOI 10.1073/pnas.96.16.8825; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Fukuzawa M, 2001, MOL CELL, V7, P779, DOI 10.1016/S1097-2765(01)00222-2; Henriksen MA, 2002, GENE DEV, V16, P2379, DOI 10.1101/gad.1020702; Herrington J, 1999, J BIOL CHEM, V274, P5138, DOI 10.1074/jbc.274.8.5138; Hombria JCG, 2002, CURR BIOL, V12, pR569, DOI 10.1016/S0960-9822(02)01057-6; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Levy DE, 1999, CELL MOL LIFE SCI, V55, P1559, DOI 10.1007/s000180050395; Levy DE, 1998, METHODS, V15, P167, DOI 10.1006/meth.1998.0621; Lin CC, 2004, J BIOL CHEM, V279, P3308, DOI 10.1074/jbc.M309749200; Lodige I, 2005, J BIOL CHEM, V280, P43087, DOI 10.1074/jbc.M509180200; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; Meyer T, 2004, EUR J BIOCHEM, V271, P4606, DOI 10.1111/j.1432-1033.2004.04423.x; Meyer T, 2003, GENE DEV, V17, P1992, DOI 10.1101/gad.268003; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Oates AC, 1999, DEV DYNAM, V215, P352, DOI 10.1002/(SICI)1097-0177(199908)215:4<352::AID-AJA7>3.0.CO;2-J; Ortmann RA, 2000, ARTHRITIS RES, V2, P16, DOI 10.1186/ar66; Ota N, 2004, NAT IMMUNOL, V5, P208, DOI 10.1038/ni1032; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Plasterk RHA, 1995, METHOD CELL BIOL, V48, P59; Plowman GD, 1999, P NATL ACAD SCI USA, V96, P13603, DOI 10.1073/pnas.96.24.13603; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Schindler C, 2000, ADV PHARMACOL, V47, P113; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Stein LD, 2003, PLOS BIOL, V1, P166, DOI 10.1371/journal.pbio.0000045; Strehlow I, 1998, J BIOL CHEM, V273, P28049, DOI 10.1074/jbc.273.43.28049; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Wang YM, 2006, CURR BIOL, V16, P89, DOI 10.1016/j.cub.2005.11.061; Williams JG, 1999, TRENDS BIOCHEM SCI, V24, P333, DOI 10.1016/S0968-0004(99)01443-7; Williams JG, 2000, CURR OPIN GENET DEV, V10, P503, DOI 10.1016/S0959-437X(00)00119-2; WILLIAMS JG, 2003, SIGNAL TRANSDUCERS A, P105; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Zeidler MP, 2000, ONCOGENE, V19, P2598, DOI 10.1038/sj.onc.1203482; Zhang Y, 2002, NATURE, V418, P331, DOI 10.1038/nature00891; Zhukovskaya NV, 2004, DEVELOPMENT, V131, P447, DOI 10.1242/dev.00927	58	23	23	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1641	1652		10.1096/fj.06-6051com	http://dx.doi.org/10.1096/fj.06-6051com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16873887				2022-12-25	WOS:000240266600009
J	Sun, XL; Tong, YG; Qing, H; Chen, CH; Song, WH				Sun, Xiulian; Tong, Yigang; Qing, Hong; Chen, Chia-Hsiung; Song, Weihong			Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome	FASEB JOURNAL			English	Article						amyloid beta; Alzheimer's disease pathogenesis	AMYLOID PRECURSOR PROTEIN; BETA-SECRETASE ACTIVITY; CLEAVING ENZYME; ASPARTYL PROTEASE; TRANSCRIPTIONAL REGULATION; EXPRESSION; SITE; GENERATION; CLEAVAGE; FAMILY	Almost all Down syndrome (DS) patients develop characteristic Alzheimer's disease (AD) neuropathology, including neuritic plaques and neurofibrillary tangles, after middle age. The mechanism underlying AD neuropathology in DS has been unknown. A beta is the central component of neuritic plaques and is generated from APP by cleavage by the beta- and gamma-secretases. Here we show that beta-secretase activity is markedly elevated in DS. The ratio of mature to immature forms of BACE1 is altered in DS. DS has significantly higher levels of mature BACE1 proteins in Golgi than normal controls. Time-lapse live image analysis showed that BACE1 proteins were predominantly immobile in Golgi in DS cells, while they underwent normal trafficking in controls. Thus, overproduction of A beta in DS is caused by abnormal BACE1 protein trafficking and maturation. Our results provide a novel molecular mechanism by which AD develops in DS and support the therapeutic potential of inhibiting BACE1 in AD and DS.	Univ British Columbia, Dept Psychiat, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Grad Program Neurosci, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Song, WH (corresponding author), Univ British Columbia, Dept Psychiat, Brain Res Ctr, 2255 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	weihong@interchange.ubc.ca	Song, Weihong/O-7623-2017	Song, Weihong/0000-0001-9928-889X; Tong, Yigang/0000-0002-8503-8045				Acquati F, 2000, FEBS LETT, V468, P59, DOI 10.1016/S0014-5793(00)01192-3; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Busciglio J, 2002, NEURON, V33, P677, DOI 10.1016/S0896-6273(02)00604-9; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Charlwood J, 2001, J BIOL CHEM, V276, P16739, DOI 10.1074/jbc.M009361200; Christensen MA, 2004, MOL CELL BIOL, V24, P865, DOI 10.1128/MCB.24.2.865-874.2004; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Cruts M, 2001, NEUROSCI LETT, V313, P105, DOI 10.1016/S0304-3940(01)02234-0; Down J.L., 1866, OBSERVATION ETHNIC C, DOI DOI 10.1038/HDY.1966.69; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Fukumoto H, 2004, AM J PATHOL, V164, P719, DOI 10.1016/S0002-9440(10)63159-8; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Huse JT, 2003, J BIOL CHEM, V278, P17141, DOI 10.1074/jbc.M213303200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; JACOBS PA, 1959, LANCET, V1, P710; Kao SC, 2004, J BIOL CHEM, V279, P1942, DOI 10.1074/jbc.M309219200; KITAZUME S, 2004, GLYCOCONJ J, V20, P59; Lammich S, 2004, EMBO REP, V5, P620, DOI 10.1038/sj.embor.7400166; LEJEUNE J., 1959, BULL ACAD NATL MED [PARIS], V143, P256; Li QM, 2004, J BIOL CHEM, V279, P10542, DOI 10.1074/jbc.M310001200; Li Y, 2006, FASEB J, V20, P285, DOI 10.1096/fj.05-4986com; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Mutton D, 1996, J MED GENET, V33, P387, DOI 10.1136/jmg.33.5.387; Nicolaou M, 2001, NEUROGENETICS, V3, P203; Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9; Pastorino L, 2004, MOL CELL NEUROSCI, V25, P642, DOI 10.1016/j.mcn.2003.12.013; PODLISNY MB, 1987, SCIENCE, V238, P669, DOI 10.1126/science.2960019; Qing H, 2004, FASEB J, V18, P1571, DOI 10.1096/fj.04-1994fje; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Rogers GW, 2004, P NATL ACAD SCI USA, V101, P2794, DOI 10.1073/pnas.0308576101; Russo C, 2000, NATURE, V405, P531, DOI 10.1038/35014735; Schmechel A, 2004, J BIOL CHEM, V279, P39710, DOI 10.1074/jbc.M402785200; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Solans A, 2000, CYTOGENET CELL GENET, V89, P177, DOI 10.1159/000015608; Sun XL, 2006, FASEB J, V20, P1369, DOI 10.1096/FJ.05-5632COM; Sun XL, 2005, FASEB J, V19, P739, DOI 10.1096/fj.04-3426com; Tonelli DD, 2004, NUCLEIC ACIDS RES, V32, P1808, DOI 10.1093/nar/gkh348; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; von Arnim CAF, 2005, J BIOL CHEM, V280, P17777, DOI 10.1074/jbc.M414248200; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Westmeyer GG, 2004, J BIOL CHEM, V279, P53205, DOI 10.1074/jbc.M410378200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; ZHOU W, 2006, IN PRESS MOL CELL BI, V26	57	51	59	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2006	20	9					1361	1368		10.1096/fj.05-5628com	http://dx.doi.org/10.1096/fj.05-5628com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816111				2022-12-25	WOS:000240266000013
J	Motamed-Khorasani, A; Jurisica, I; Letarte, M; Shaw, PA; Parkes, RK; Zhang, X; Evangelou, A; Rosen, B; Murphy, KJ; Brown, TJ				Motamed-Khorasani, A.; Jurisica, I.; Letarte, M.; Shaw, P. A.; Parkes, R. K.; Zhang, X.; Evangelou, A.; Rosen, B.; Murphy, K. J.; Brown, T. J.			Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression	ONCOGENE			English	Article						ovarian cancer; androgen; BRCA1; BRCA2; BACH2; acetylcholinesterase	PROTEIN-INTERACTION NETWORK; MESSENGER-RNA EXPRESSION; SIGNALING PATHWAY; CONSTITUTIVE ACTIVATION; PROGESTERONE-RECEPTORS; SURFACE EPITHELIUM; BREAST; TUMORS; CARCINOMA; BETA	Epidemiological studies have implicated androgens in the etiology and progression of epithelial ovarian cancer. We previously reported that some androgen responses were dysregulated in malignant ovarian epithelial cells relative to control, non-malignant ovarian surface epithelial (OSE) cells. Moreover, dysregulated androgen responses were observed in OSE cells derived from patients with germline BRCA-1 or -2 mutations (OSEb), which account for the majority of familial ovarian cancer predisposition, and such altered responses may be involved in ovarian carcinogenesis or progression. In the present study, gene expression pro. ling using cDNA microarrays identified 17 genes differentially expressed in response to continuous androgen exposure in OSEb cells and ovarian cancer cells as compared to OSE cells derived from control patients. A subset of these differentially affected genes was selected and verified by quantitative real-time reverse transcription -polymerase chain reaction. Six of the gene products mapped to the OPHID protein -protein interaction database, and five were networked within two interacting partners. Basic leucine zipper transcription factor 2 (BACH2) and acetylcholinesterase (ACHE), which were upregulated by androgen in OSEb cells relative to OSE cells, were further investigated using an ovarian cancer tissue microarray from a separate set of 149 clinical samples. Both cytoplasmic ACHE and BACH2 immunostaining were significantly increased in ovarian cancer relative to benign cases. High levels of cytoplasmic ACHE staining correlated with decreased survival, whereas nuclear BACH2 staining correlated with decreased time to disease recurrence. The finding that products of genes differentially responsive to androgen in OSEb cells may predict survival and disease progression supports a role for altered androgen effects in ovarian cancer. In addition to BACH2 and ACHE, this study highlights a set of potentially functionally related genes for further investigation in ovarian cancer.	Mt Sinai Hosp, Dept Obstet & Gynecol, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5G 1X8, Canada; Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Div Signaling Biol, Toronto, ON, Canada; Univ Toronto, Dept Comp Sci, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Canc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Obstet & Gynecol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Div Pathol,Ontario Canc Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst,Div Gynecol Oncol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Brown, TJ (corresponding author), Mt Sinai Hosp, Dept Obstet & Gynecol, Samuel Lunenfeld Res Inst, Room 876,600 Univ Ave, Toronto, ON M5G 1X5, Canada.	brown@mshri.on.ca	Brown, Theodore J./E-2192-2013	Brown, Theodore J./0000-0002-3074-4516				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; AUERSPERG N, 1994, LAB INVEST, V71, P510; Auersperg N, 1997, J CELL PHYSIOL, V173, P261, DOI 10.1002/(SICI)1097-4652(199711)173:2<261::AID-JCP32>3.0.CO;2-G; Barrios-Rodiles M, 2005, SCIENCE, V307, P1621, DOI 10.1126/science.1105776; Beheshti B, 2003, NEOPLASIA, V5, P53, DOI 10.1016/S1476-5586(03)80017-9; Brown KR, 2005, BIOINFORMATICS, V21, P2076, DOI 10.1093/bioinformatics/bti273; Buchholz TA, 2002, INT J CANCER, V97, P557, DOI 10.1002/ijc.10109; Camp RL, 2000, LAB INVEST, V80, P1943, DOI 10.1038/labinvest.3780204; Cardillo MR, 1998, J EXP CLIN CANC RES, V17, P231; CHADHA S, 1993, HUM PATHOL, V24, P90, DOI 10.1016/0046-8177(93)90067-Q; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P717; Deng CX, 2000, BIOESSAYS, V22, P728; EASTON DF, 1995, AM J HUM GENET, V56, P265; Edmondson R, 2002, BRIT J CANCER, V86, P879, DOI 10.1038/sj.bjc.6600154; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Evangelou A, 2003, CANCER RES, V63, P2416; Evangelou A, 2000, CANCER RES, V60, P929; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Foss DL, 1998, ANIM BIOTECHNOL, V9, P67, DOI 10.1080/10495399809525893; GRAY RJ, 1992, J AM STAT ASSOC, V87, P942, DOI 10.2307/2290630; Hage JJ, 2000, GYNECOL ONCOL, V76, P413, DOI 10.1006/gyno.1999.5720; HELZLSOUER KJ, 1995, JAMA-J AM MED ASSOC, V274, P1926, DOI 10.1001/jama.274.24.1926; Hirashima Y, 2003, J BIOL CHEM, V278, P26793, DOI 10.1074/jbc.M212187200; HIRTE HW, 1992, GYNECOL ONCOL, V44, P223, DOI 10.1016/0090-8258(92)90046-L; Hu W, 2000, ANTICANCER RES, V20, P729; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Imaoka S, 2001, CANCER LETT, V166, P119, DOI 10.1016/S0304-3835(00)00572-3; Isern J, 2003, BIOCHEM BIOPH RES CO, V307, P139, DOI 10.1016/S0006-291X(03)01081-7; Johnson G, 2000, INT J DEV NEUROSCI, V18, P781, DOI 10.1016/S0736-5748(00)00049-6; Johnson G, 2000, APPL BIOCHEM BIOTECH, V83, P131, DOI 10.1385/ABAB:83:1-3:131; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kanehisa M, 2002, NUCLEIC ACIDS RES, V30, P42, DOI 10.1093/nar/30.1.42; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Kobayashi A, 2000, MOL CELL BIOL, V20, P1733, DOI 10.1128/MCB.20.5.1733-1746.2000; Kohonen T., 2001, SELF ORG MAPS, P501; KRUK PA, 1994, EXP CELL RES, V215, P97, DOI 10.1006/excr.1994.1320; KUHNEL R, 1987, J STEROID BIOCHEM, V26, P393, DOI 10.1016/0022-4731(87)90106-3; KUHNEL R, 1988, ANTICANCER RES, V8, P281; Lau KM, 1999, P NATL ACAD SCI USA, V96, P5722, DOI 10.1073/pnas.96.10.5722; Li AJ, 2005, CANCER EPIDEM BIOMAR, V14, P2919, DOI 10.1158/1055-9965.EPI-05-0540; Li AJ, 2003, CLIN CANCER RES, V9, P3667; LINSLEY PS, 1986, CANCER RES, V46, P6380; Lu J, 2002, ACTA BIOCH BIOPH SIN, V34, P95; Lutz LB, 2003, MOL ENDOCRINOL, V17, P1106, DOI 10.1210/me.2003-0032; Marks A, 1999, BRIT J CANCER, V80, P569, DOI 10.1038/sj.bjc.6690393; Modugno F, 2001, ANN EPIDEMIOL, V11, P568, DOI 10.1016/S1047-2797(01)00213-7; Muto A, 2002, J BIOL CHEM, V277, P20724, DOI 10.1074/jbc.M112003200; Nishimoto A, 2005, CANCER RES, V65, P6701, DOI 10.1158/0008-5472.CAN-05-0130; OTASEK D, 2006, SIAM C DAT MIN 22 AP, P1; Park JJ, 2000, CANCER RES, V60, P5946; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Rask K, 2003, BRIT J CANCER, V89, P1298, DOI 10.1038/sj.bjc.6601265; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Risch HA, 1998, JNCI-J NATL CANCER I, V90, P1774, DOI 10.1093/jnci/90.23.1774; Robertson DM, 2004, ENDOCR-RELAT CANCER, V11, P35, DOI 10.1677/erc.0.0110035; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Schildkraut JM, 1996, OBSTET GYNECOL, V88, P554, DOI 10.1016/0029-7844(96)00226-8; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully RE, 1995, J CELL BIOCHEM, P208; Shaw PA, 2001, GYNECOL ONCOL, V80, P132, DOI 10.1006/gyno.2000.6068; Shin S, 2003, P NATL ACAD SCI USA, V100, P7201, DOI 10.1073/pnas.1132020100; Steinmetz R, 2004, MOL ENDOCRINOL, V18, P2570, DOI 10.1210/me.2004-0082; Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029; SULTAN M, 2002, BIOINFORMATICS, V18, P111; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vidal CJ, 2005, CHEM-BIOL INTERACT, V157, P227, DOI 10.1016/j.cbi.2005.10.035; Windmill KF, 1997, MUTAT RES-FUND MOL M, V376, P153, DOI 10.1016/S0027-5107(97)00038-9; Yang LV, 2001, MECH DEVELOP, V104, P105, DOI 10.1016/S0925-4773(01)00376-8; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897; ZAKUT H, 1990, J CLIN INVEST, V86, P900, DOI 10.1172/JCI114791	73	31	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					198	214		10.1038/sj.onc.1209773	http://dx.doi.org/10.1038/sj.onc.1209773			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16832351				2022-12-25	WOS:000243398300004
J	Zhang, YW; Staal, B; Su, Y; Swiatek, P; Zhao, P; Cao, B; Resau, J; Sigler, R; Bronson, R; Vande Woude, GF				Zhang, Y-W; Staal, B.; Su, Y.; Swiatek, P.; Zhao, P.; Cao, B.; Resau, J.; Sigler, R.; Bronson, R.; Vande Woude, G. F.			Evidence that MIG-6 is a tumor-suppressor gene	ONCOGENE			English	Article						MIG-6; mutation; lung carcinogenesis; signal transduction; EGF; HGF/SF	CELL LUNG-CANCER; EGF RECEPTOR; ENDOGENOUS INHIBITOR; ALLELIC LOSS; C-MET; EXPRESSION; MUTATIONS; GROWTH; ACTIVATION; P73	Mitogen-inducible gene 6 (MIG-6) is located in human chromosome 1p36, a locus frequently associated with human lung cancer. MIG-6 is a negative regulator of epidermal growth factor (EGF) signaling, and we show that Mig-6 - like EGF - is induced by hepatocyte growth factor/scatter factor (HGF/SF) in human lung cancer cell lines. Frequently, the receptors for both factors, EGFR and Met, are expressed in same lung cancer cell line, and MIG-6 is induced by both factors in a mitogen-activated protein kinase-dependent fashion. However, not all tumor lines express MIG-6 in response to either EGF or HGF/SF. In these cases, we. nd missense and nonsense mutations in the MIG-6 coding region, as well as evidence for MIG-6 transcriptional silencing. Moreover, germline disruption of Mig-6 in mice leads to the development of animals with epithelial hyperplasia, adenoma, and adenocarcinoma in organs like the lung, gallbladder, and bile duct. These data suggests that MIG-6 is a tumor-suppressor gene and is therefore a candidate gene for the frequent 1p36 genetic alterations found in lung cancer.	Andel Res Inst, Mol Oncol Lab, Grand Rapids, MI 49503 USA; Andel Res Inst, Lab Germline Modificat, Grand Rapids, MI 49503 USA; Andel Res Inst, Lab Antibody Technol, Grand Rapids, MI 49503 USA; Andel Res Inst, Lab Analyt Cellular & Mol Microscopy, Grand Rapids, MI 49503 USA; Div Pfizer, Esper Therapeut, Ann Arbor, MI USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Pfizer; Harvard University; Harvard Medical School	Zhang, YW (corresponding author), Andel Res Inst, Mol Oncol Lab, 333 Bostwick NE, Grand Rapids, MI 49503 USA.	yu-wen.zhang@vai.org; george.vandewoude@vai.org						Amatschek S, 2004, CANCER RES, V64, P844, DOI 10.1158/0008-5472.CAN-03-2361; Anastasi S, 2005, ONCOGENE, V24, P4540, DOI 10.1038/sj.onc.1208658; Anastasi S, 2003, ONCOGENE, V22, P4221, DOI 10.1038/sj.onc.1206516; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Ferby I, 2006, NAT MED, V12, P568, DOI 10.1038/nm1401; Fiorentino L, 2000, MOL CELL BIOL, V20, P7735, DOI 10.1128/MCB.20.20.7735-7750.2000; Fujii T, 2002, CANCER RES, V62, P3340; Girard L, 2000, CANCER RES, V60, P4894; Herzog CR, 2002, CANCER RES, V62, P6424; HERZOG CR, 1995, ONCOGENE, V11, P1811; Keeton AB, 2005, J CELL BIOCHEM, V94, P1190, DOI 10.1002/jcb.20370; Keeton AB, 2004, BBA-GENE STRUCT EXPR, V1679, P248, DOI 10.1016/j.bbaexp.2004.07.002; Kohno T, 1999, CARCINOGENESIS, V20, P1403, DOI 10.1093/carcin/20.8.1403; Koo HM, 1999, CANCER RES, V59, P6057; Ma PC, 2005, CANCER RES, V65, P1479, DOI 10.1158/0008-5472.CAN-04-2650; Ma PC, 2003, CANCER RES, V63, P6272; Mai M, 1998, CANCER RES, V58, P2347; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Miettinen PJ, 1997, DEV BIOL, V186, P224, DOI 10.1006/dbio.1997.8593; Nomoto S, 1998, CANCER RES, V58, P1380; Nomoto S, 2000, GENE CHROMOSOME CANC, V28, P342, DOI 10.1002/1098-2264(200007)28:3<342::AID-GCC13>3.0.CO;2-A; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pante G, 2005, J CELL BIOL, V171, P337, DOI 10.1083/jcb.200502013; Ragnarsson G, 1999, BRIT J CANCER, V79, P1468, DOI 10.1038/sj.bjc.6690234; Sargent LM, 2002, CANCER RES, V62, P1152; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Thiagalingam S, 2002, CURR OPIN ONCOL, V14, P65, DOI 10.1097/00001622-200201000-00012; Tokuchi Y, 1999, BRIT J CANCER, V80, P1623, DOI 10.1038/sj.bjc.6690572; Tsunoda T, 2002, CANCER RES, V62, P5668; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; WICK M, 1995, EXP CELL RES, V219, P527, DOI 10.1006/excr.1995.1261; Xu DZ, 2005, J BIOL CHEM, V280, P2924, DOI 10.1074/jbc.M408907200; Xu J, 2005, BREAST CANCER RES TR, V91, P207, DOI 10.1007/s10549-005-1040-1; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Zhang YW, 2005, P NATL ACAD SCI USA, V102, P11740, DOI 10.1073/pnas.0505171102; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100; Zochbauer-Muller S, 2002, ANNU REV PHYSIOL, V64, P681, DOI 10.1146/annurev.physiol.64.081501.155828	40	101	108	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	2					269	276		10.1038/sj.onc.1209790	http://dx.doi.org/10.1038/sj.onc.1209790			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819504				2022-12-25	WOS:000243398300010
J	Tian, Y; Jackson, P; Gunter, C; Wang, J; Rock, CO; Jackowski, S				Tian, Yong; Jackson, Pamela; Gunter, Christopher; Wang, Jina; Rock, Charles O.; Jackowski, Suzanne			Placental thrombosis and spontaneous fetal death in mice deficient in ethanolamine kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; PHOSPHOLIPID BIOSYNTHESIS; CDP-ETHANOLAMINE; MAMMALIAN-CELLS; PHOSPHATIDYLETHANOLAMINE; GENE; PREGNANCY; MUTATION; LIVER; PHOSPHATIDYLSERINE	Ethanolamine kinase catalyzes the first step in the CDP-ethanolamine pathway for the formation of the major membrane phospholipid phosphatidylethanolamine (PtdEtn). In this work, the predicted Etnk2 cDNA was established as a soluble protein with ethanolamine-specific kinase activity that was most highly expressed in liver. Mice with an inactivated Etnk2 gene were derived, and its absence reduced the rate of PtdEtn synthesis from exogenous ethanolamine in hepatocytes. PtdEtn is a major precursor to phosphatidylcholine in liver; however, Etnk2(-/-) mice did not have reduced amounts of either PtdEtn or phosphatidylcholine or an altered phospholipid molecular species distribution. The knock-out animals were able to adapt to a choline-deficient diet. The Etnk2(-/-) mice exhibited a maternal-specific intrauterine growth retardation phenotype that resulted in a 33% reduction in litter size and frequent perinatal death. Histological analysis of pregnant Etnk2(-/-) females showed that fetal development failed at the late stage of pregnancy in a significant percentage of embryos because of the appearance of extensive placental thrombosis. These results illustrate a non-redundant role for EtnK2 expression in regulating placental hemostasis.	St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Jackowski, S (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale, Memphis, TN 38105 USA.	suzanne.jackowski@stjude.org	Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 45737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoyama C, 2004, PROG LIPID RES, V43, P266, DOI 10.1016/j.plipres.2003.12.001; ARTHUR G, 1991, BIOCHEM J, V273, P121, DOI 10.1042/bj2730121; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; Emoto K, 2005, J BIOL CHEM, V280, P37901, DOI 10.1074/jbc.M504282200; Flury I, 2000, J BIOL CHEM, V275, P24458, DOI 10.1074/jbc.M003844200; Hurley TM, 2004, GENE EXPR PATTERNS, V4, P135, DOI 10.1016/j.modgep.2003.09.010; Isermann B, 2003, NAT MED, V9, P331, DOI 10.1038/nm825; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; Jacobs RL, 2004, J BIOL CHEM, V279, P47402, DOI 10.1074/jbc.M404027200; Kim KS, 1999, J BIOL CHEM, V274, P14857, DOI 10.1074/jbc.274.21.14857; Lay AJ, 2005, J CLIN INVEST, V115, P1552, DOI 10.1172/JCI24030; Lykidis A, 2001, J BIOL CHEM, V276, P2174, DOI 10.1074/jbc.M008794200; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Nyako M, 2001, BIOCHEM GENET, V39, P339, DOI 10.1023/A:1012209030803; Pascual A, 2005, DEV BIOL, V280, P177, DOI 10.1016/j.ydbio.2005.01.017; PAVLIDIS P, 1994, CELL, V79, P23, DOI 10.1016/0092-8674(94)90397-2; Peisach D, 2003, STRUCTURE, V11, P703, DOI 10.1016/S0969-2126(03)00094-7; PORTER TJ, 1990, J BIOL CHEM, V265, P414; Rand JH, 2003, ANNU REV MED, V54, P409, DOI 10.1146/annurev.med.54.101601.152412; Roberts D, 2002, NEW ENGL J MED, V347, P57, DOI 10.1056/NEJMe020061; Robertson SA, 2004, MOL HUM REPROD, V10, P409, DOI 10.1093/molehr/gah058; Rossant J, 2001, NAT REV GENET, V2, P538, DOI 10.1038/35080570; SMIRNOV MD, 1995, J CLIN INVEST, V95, P309, DOI 10.1172/JCI117657; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; Sugi T, 2004, J OBSTET GYNAECOL RE, V30, P326, DOI 10.1111/j.1447-0756.2004.00206.x; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; Thumkeo D, 2003, MOL CELL BIOL, V23, P5043, DOI 10.1128/MCB.23.14.5043-5055.2003; Tong MH, 2005, NAT MED, V11, P153, DOI 10.1038/nm1184; Van Veldhoven PP, 2000, METHOD ENZYMOL, V311, P244; Vance JE, 2004, BIOCHEM CELL BIOL, V82, P113, DOI 10.1139/o03-073; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; Voelker DR, 2003, J LIPID RES, V44, P441, DOI 10.1194/jlr.R200020-JLR200; Waite KA, 2002, J NUTR, V132, P68, DOI 10.1093/jn/132.1.68; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; XU ZL, 1991, J BIOL CHEM, V266, P2143; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249; ZELINSKI TA, 1982, CAN J BIOCHEM CELL B, V60, P817, DOI 10.1139/o82-102; Zhang YM, 2002, J BIOL CHEM, V277, P15558, DOI 10.1074/jbc.M201399200	42	41	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28438	28449		10.1074/jbc.M605861200	http://dx.doi.org/10.1074/jbc.M605861200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16861741	hybrid			2022-12-25	WOS:000240534400081
J	Lebreton, A; Saveanu, C; Decourty, L; Jacquier, A; Fromont-Racine, M				Lebreton, Alice; Saveanu, Cosmin; Decourty, Laurence; Jacquier, Alain; Fromont-Racine, Micheline			Nsa2 is an unstable, conserved factor required for the maturation of 27 SB pre-rRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAIRY-CELL LEUKEMIA; SACCHAROMYCES-CEREVISIAE; PROTEIN COMPLEXES; YEAST; IDENTIFICATION; CYTOPLASM; DISRUPTION; NUCLEOLUS; DELETION; NUCLEUS	In Saccharomyces cerevisiae, a large variety of pre-ribosomal factors have been identified recently, a number of which are still of unknown function. The essential pre-ribosomal 30-kDa protein, Nsa2, was characterized as one of the most conserved proteins from yeast to human. We show here that the expression of the human orthologue TINP1 complements the repression of NSA2 in yeast. Nsa2 was co-purified in several pre-ribosomal complexes and found to be essential for the large ribosomal subunit biogenesis. Like several other factors of the pre-60 S particles, the absence of Nsa2 correlated with a decrease in the 25 S and 5.8 S ribosomal RNA levels, and with an accumulation of 27 SB pre-ribosomal RNA intermediates. We show that Nsa2 is a functional partner of the putative GTPase Nog1. In the absence of Nsa2, Nog1 was still able to associate with pre-ribosomal complexes blocked in maturation. In contrast, in the absence of Nog1, Nsa2 disappeared from pre-60 S complexes. Indeed, when ribosome biogenesis was blocked upstream of Nsa2, this short half-lived protein was largely depleted, suggesting that its cellular levels are tightly regulated.	Inst Pasteur, CNRS, Unite Genet Interact Macromol, URA2171, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Fromont-Racine, M (corresponding author), Inst Pasteur, CNRS, Unite Genet Interact Macromol, URA2171, 25 Rue Dr Roux, F-75724 Paris 15, France.	mfromont@pasteur.fr	Saveanu, Cosmin/Q-1251-2019; Lebreton, Alice/M-8764-2015; Saveanu, Cosmin/K-6494-2015	Saveanu, Cosmin/0000-0002-1677-7936; Lebreton, Alice/0000-0002-6643-902X; Saveanu, Cosmin/0000-0002-1677-7936; JACQUIER, ALAIN/0000-0001-5707-9184; Fromont-Racine, Micheline/0000-0001-9906-0334				Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BaudinBaillieu A, 1997, YEAST, V13, P353, DOI 10.1002/(SICI)1097-0061(19970330)13:4<353::AID-YEA86>3.0.CO;2-P; Brachmann CB, 1998, YEAST, V14, P115; Davy A, 2001, EMBO REP, V2, P821, DOI 10.1093/embo-reports/kve184; Dundr M, 2001, BIOCHEM J, V356, P297, DOI 10.1042/0264-6021:3560297; Fromont-Racine M, 2003, GENE, V313, P17, DOI 10.1016/S0378-1119(03)00629-2; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Harnpicharnchai P, 2001, MOL CELL, V8, P505, DOI 10.1016/S1097-2765(01)00344-6; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Kallstrom G, 2003, MOL CELL BIOL, V23, P4344, DOI 10.1128/MCB.23.12.4344-4355.2003; Krogan NJ, 2004, MOL CELL, V13, P225, DOI 10.1016/S1097-2765(04)00003-6; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; Nissan TA, 2002, EMBO J, V21, P5539, DOI 10.1093/emboj/cdf547; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Saveanu C, 2003, MOL CELL BIOL, V23, P4449, DOI 10.1128/MCB.23.13.4449-4460.2003; Saveanu C, 2001, EMBO J, V20, P6475, DOI 10.1093/emboj/20.22.6475; Shehata M, 2004, J CLIN INVEST, V113, P676, DOI 10.1172/JCI200419540; Stanchi F, 2001, YEAST, V18, P69, DOI 10.1002/1097-0061(200101)18:1<69::AID-YEA647>3.0.CO;2-H; Tschochner H, 2003, TRENDS CELL BIOL, V13, P255, DOI 10.1016/S0962-8924(03)00054-0; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Wu XS, 1999, GENOMICS, V60, P161, DOI 10.1006/geno.1999.5911	23	38	40	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27099	27108		10.1074/jbc.M602199200	http://dx.doi.org/10.1074/jbc.M602199200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16861225	hybrid, Green Published			2022-12-25	WOS:000240397700037
J	Sastry, KSR; Karpova, Y; Kulik, G				Sastry, Konduru S. R.; Karpova, Yelena; Kulik, George			Epidermal growth factor protects prostate cancer cells from apoptosis by inducing BAD phosphorylation via redundant signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH AGONIST BAD; PHOSPHATIDYLINOSITOL 3-KINASE; FACTOR RECEPTOR; MAP KINASE; SURVIVAL; ACTIVATION; RAS; EXPRESSION; INACTIVATION; MITOCHONDRIA	Protection from apoptosis by receptor tyrosine kinases, resistant to the inhibition of phosphatidylinositol 3'-kinase/Akt and Ras/MEK pathways, has been reported in several cell types, including fibroblasts and epithelial prostate cancer cells; however, mechanisms of this effect were not clear. Here we report that in prostate cancer cells, epidermal growth factor activates two antiapoptotic signaling pathways that impinge on the proapoptotic protein BAD. One signaling cascade operates via the Ras/MEK module and induces BAD phosphorylation on Ser(112). Another pathway predominantly relies on Rac/ PAK1 signaling that leads to BAD phosphorylation on Ser(136). Each of these two pathways is sufficient to protect cells from apoptosis, and therefore both have to be inhibited simultaneously to block epidermal growth factor-dependent survival. Redundancy of antiapoptotic signaling pathways should be considered when therapies targeting antiapoptotic mechanisms are designed.	Wake Forest Univ, Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA	Wake Forest University	Kulik, G (corresponding author), Wake Forest Univ, Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA.	gkulik@wfubmc.edu	Sastry, Konduru Seetharama/GQY-6005-2022					Baker NE, 2001, CELL, V104, P699, DOI 10.1016/S0092-8674(02)06076-2; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bergmann A, 2002, DEV CELL, V3, P607, DOI 10.1016/S1534-5807(02)00328-3; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Cairns P, 1997, CANCER RES, V57, P4997; CARSON JP, 2002, THESIS U VIRGINIA CH; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Denmeade SR, 2003, J NATL CANCER I, V95, P990, DOI 10.1093/jnci/95.13.990; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Gilmore AP, 2002, J BIOL CHEM, V277, P27643, DOI 10.1074/jbc.M108863200; Gioeli D, 1999, CANCER RES, V59, P279; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Janumyan YM, 2003, EMBO J, V22, P5459, DOI 10.1093/emboj/cdg533; Kari C, 2003, CANCER RES, V63, P1; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim HG, 1999, HISTOL HISTOPATHOL, V14, P1175, DOI 10.14670/HH-14.1175; Kulik G, 2001, CANCER RES, V61, P2713; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KYPRIANOU N, 1988, ENDOCRINOLOGY, V122, P552, DOI 10.1210/endo-122-2-552; Lin JQ, 1999, CANCER RES, V59, P2891; Lorenzo Giuseppe Di, 2003, Clin Prostate Cancer, V2, P50; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Maslyar DJ, 2001, ONCOGENE, V20, P5087, DOI 10.1038/sj.onc.1204662; McCarty Mark F, 2004, Integr Cancer Ther, V3, P349, DOI 10.1177/1534735404270757; McMenamin ME, 1999, CANCER RES, V59, P4291; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Pi XC, 2004, CIRC RES, V94, P362, DOI 10.1161/01.RES.0000112406.27800.6F; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Royuela M, 2001, EUR CYTOKINE NETW, V12, P654; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Sastry KSR, 2006, J BIOL CHEM, V281, P20891, DOI 10.1074/jbc.M602928200; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Seo SY, 2004, J BIOL CHEM, V279, P42240, DOI 10.1074/jbc.M406775200; She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006; She QB, 2002, J BIOL CHEM, V277, P24039, DOI 10.1074/jbc.M109907200; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Tang DG, 1997, PROSTATE, V32, P284; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Uzgare AR, 2005, INT J BIOCHEM CELL B, V37, P707, DOI 10.1016/j.biocel.2004.11.018; Vadlamudi RK, 2003, CANCER METAST REV, V22, P385, DOI 10.1023/A:1023729130497; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhao ZS, 2005, BIOCHEM J, V386, P201, DOI 10.1042/BJ20041638	70	45	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27367	27377		10.1074/jbc.M511485200	http://dx.doi.org/10.1074/jbc.M511485200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16847055	hybrid			2022-12-25	WOS:000240397700063
J	Wagner, S; Weber, S; Kleinschmidt, MA; Nagata, K; Bauer, UM; Bauer, UM				Wagner, Sabine; Weber, Susanne; Kleinschmidt, Markus A.; Nagata, Kyosuke; Bauer, Uta-Maria; Bauer, Uta-Maria			SET-mediated promoter hypoacetylation is a prerequisite for coactivation of the estrogen-responsive pS2 gene by PRMT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING-FACTOR-I; RECEPTOR-ALPHA; ARGININE METHYLTRANSFERASE; TRANSCRIPTIONAL ACTIVATION; HISTONE H4; PROTEIN METHYLTRANSFERASE; DEACETYLASE INHIBITION; NEGATIVE REGULATION; METHYLATION; ACETYLATION	Induction of transcription requires an ordered recruitment of coregulators and specific combinations of histone modifications at the promoter. Occurrence of histone H4 arginine (Arg) 3 methylation by protein arginine methyltransferase 1 (PRMT1) represents an early promoter event in ER (estrogen receptor)regulated gene activation. However, its in vivo significance in ER signaling and the prerequisites for PRMT1 recruitment to promoters have not been established yet. We show here that endogenous PRMT1 is a crucial and non-redundant coactivator of ER-mediated pS2 gene induction in MCF7 cells. By investigating promoter requirements for PRMT1 recruitment we find that the patient SE translocation (SET) protein, which was reported to protect histone tails from acetylation, associates with the uninduced pS2 gene promoter and dissociates early upon estrogen treatment. Knockdown of SET or trichostatin A (TSA) treatment causes premature acetylation of H4 and abrogation of H4 Arg(3) methylation at the pS2 gene promoter resulting in diminished transcriptional induction. Thus, SET prevents promoter acetylation and is a prerequisite for the initial acetylation-sensitive steps of pS2 gene activation, namely PRMT1 function. Similar to pS2 we identify lactoferrin as a PRMT1-dependent and TSA-sensitive ER target gene. In contrast, we find that the C3 gene, another ER target, is activated in a PRMT1-independent manner and that SET is involved in C3 gene repression. These findings establish the existence of PRMT1-dependent and -independent ER target genes and show that proteins guarding promoter hypoacetylation, like SET, execute a key function in the coactivation process by PRMT1.	[Bauer, Uta-Maria; Bauer, Uta-Maria] Univ Marburg, Inst Mol Biol & Tumor Res, IMT, Emil Mannkopff Str 2, D-35032 Marburg, Germany; Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Infect Biol, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan	Philipps University Marburg; University of Tsukuba; University of Tsukuba	Bauer, UM (corresponding author), Univ Marburg, Inst Mol Biol & Tumor Res, IMT, Emil Mannkopff Str 2, D-35032 Marburg, Germany.	bauer@imt.uni-marburg.de						An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Balint BL, 2005, MOL CELL BIOL, V25, P5648, DOI 10.1128/MCB.25.13.5648-5663.2005; Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013; Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003; Cervoni N, 2002, J BIOL CHEM, V277, P25026, DOI 10.1074/jbc.M202256200; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen SL, 2002, J BIOL CHEM, V277, P4324, DOI 10.1074/jbc.M109835200; Choi YB, 2004, J BIOL CHEM, V279, P50930, DOI 10.1074/jbc.M406831200; Covic M, 2005, EMBO J, V24, P85, DOI 10.1038/sj.emboj.7600500; Daujat S, 2002, CURR BIOL, V12, P2090, DOI 10.1016/S0960-9822(02)01387-8; Fabbrizio E, 2002, EMBO REP, V3, P641, DOI 10.1093/embo-reports/kvf136; Gamble MJ, 2005, MOL CELL BIOL, V25, P797, DOI 10.1128/MCB.25.2.797-807.2005; Huang SM, 2005, GENE DEV, V19, P1885, DOI 10.1101/gad.1333905; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Klinge CM, 2004, J MOL ENDOCRINOL, V33, P387, DOI 10.1677/jme.1.01541; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Kutney SN, 2004, J BIOL CHEM, V279, P30850, DOI 10.1074/jbc.M404969200; Lee YH, 2002, MOL CELL BIOL, V22, P3621, DOI 10.1128/MCB.22.11.3621-3632.2002; Li JW, 2002, MOL CELL BIOL, V22, P5688, DOI 10.1128/MCB.22.16.5688-5697.2002; Loven MA, 2003, MOL ENDOCRINOL, V17, P67, DOI 10.1210/me.2002-0280; Macfarlan T, 2005, J BIOL CHEM, V280, P7346, DOI 10.1074/jbc.M411675200; Margueron R, 2004, J MOL ENDOCRINOL, V32, P583, DOI 10.1677/jme.0.0320583; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; MATSUMOTO K, 1993, J BIOL CHEM, V268, P10582; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Metivier R, 2006, EMBO REP, V7, P161, DOI 10.1038/sj.embor.7400626; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Miyamoto S, 2003, MOL CELL BIOL, V23, P8528, DOI 10.1128/MCB.23.23.8528-8541.2003; Nagata K, 1998, EXP CELL RES, V240, P274, DOI 10.1006/excr.1997.3930; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; Nowak SJ, 2003, MOL CELL BIOL, V23, P6129, DOI 10.1128/MCB.23.17.6129-6138.2003; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Reid G, 2005, ONCOGENE, V24, P4894, DOI 10.1038/sj.onc.1208662; Rezai-Zadeh N, 2003, GENE DEV, V17, P1019, DOI 10.1101/gad.1068003; Saitoh S, 2000, AM J HUM GENET, V66, P1958, DOI 10.1086/302917; Sanchez R, 2002, BIOESSAYS, V24, P244, DOI 10.1002/bies.10066; Schneider R, 2004, J BIOL CHEM, V279, P23859, DOI 10.1074/jbc.C400151200; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Telese F, 2005, EMBO REP, V6, P77, DOI 10.1038/sj.embor.7400309; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781	48	39	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27242	27250		10.1074/jbc.M605172200	http://dx.doi.org/10.1074/jbc.M605172200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16861234	hybrid			2022-12-25	WOS:000240397700051
J	Graham, WV; Wang, FJ; Clayburgh, DR; Cheng, JX; Yoon, B; Wang, YM; Lin, AN; Turner, JR				Graham, W. Vallen; Wang, Fengjun; Clayburgh, Daniel R.; Cheng, Jason X.; Yoon, Bora; Wang, Yingmin; Lin, Anning; Turner, Jerrold R.			Tumor necrosis factor-induced long myosin light chain kinase transcription is regulated by differentiation-dependent signaling events - Characterization of the human long myosin light chain kinase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TIGHT JUNCTION BARRIER; CELL-DIFFERENTIATION; INTESTINAL DISEASE; EPITHELIAL BARRIER; ALPHA MODULATION; GENE-EXPRESSION; HOMEOBOX GENE; IN-VIVO; PHOSPHORYLATION	Myosin light chain kinase (MLCK) is expressed as long and short isoforms from unique transcriptional start sites within a single gene. Tumor necrosis factor (TNF) augments intestinal epithelial long MLCK expression, which is critical to cytoskeletal regulation. We found that TNF increases long MLCK mRNA transcription, both in human enterocytes in vitro and murine enterocytes in vivo. 5'-RACE identified two novel exons, 1A and 1B, which encode alternative long MLCK transcriptional start sites. Chromatin immunoprecipitation (ChIP) and site-directed mutagenesis identified two essential Sp1 sites upstream of the exon 1A long MLCK transcriptional start site. Analysis of deletion and truncation mutants showed that a 102-bp region including these Sp1 sites was necessary for basal transcription. A promoter construct including 4-kb upstream of exon 1A was responsive to TNF, AP-1, or NF kappa B, but all except NF kappa B responses were absent in a shorter 2-kb construct, and all responses were absent in a 1-kb construct. Electrophoretic mobility shift assays, ChIP, and site-directed mutagenesis explained these data by identifying three functional AP-1 sites between 2- and 4-kb upstream of exon 1A and two NF kappa B sites between 1- and 2-kb upstream of exon 1A. Analysis of differentiating epithelia showed that only well differentiated enterocytes activated the 4-kb long MLCK promoter in response to TNF, and consensus promoter reporters demonstrated that TNF-induced NF kappa B activation decreased during differentiation while TNF-induced AP-1 activation increased. Thus either AP-1 or NF kappa B can up-regulate long MLCK transcription, but the mechanisms by which TNF up-regulates intestinal epithelial long MLCK transcription from exon 1A are differentiation-dependent.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; Third Mil Med Univ, State Key Lab Trauma Burns & Combined Injury, Inst Burn Res, Southwest Hosp, Chongqing 400038, Peoples R China	University of Chicago; University of Chicago; Army Medical University	Turner, JR (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave,MC 1089, Chicago, IL 60637 USA.	jturner@bsd.uchicago.edu	Graham, W Vallen/C-4315-2019; Turner, Jerrold/H-1502-2019; Turner, Jerrold R/A-6895-2009; Wang, Fengjun/A-4114-2009; Graham, W/L-2301-2019; wang, yingying/GRS-3058-2022	Graham, W Vallen/0000-0003-3815-7532; Turner, Jerrold R/0000-0003-0627-9455; Graham, W/0000-0003-3815-7532; Clayburgh, Daniel/0000-0002-3296-4926	NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086, R01DK068271, R01DK061931] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007281] Funding Source: NIH RePORTER; NCI NIH HHS [CA14599] Funding Source: Medline; NIDDK NIH HHS [DK68271, DK61931, DK42086] Funding Source: Medline; NIGMS NIH HHS [T32 GM07281] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berglund JJ, 2001, AM J PHYSIOL-GASTR L, V281, pG1487; Blair SA, 2006, LAB INVEST, V86, P191, DOI 10.1038/labinvest.3700373; Blue EK, 2002, AM J PHYSIOL-CELL PH, V282, pC451, DOI 10.1152/ajpcell.00333.2001; CHANDRASENA G, 1992, CELL MOL BIOL, V38, P243; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Clayburgh DR, 2005, J CLIN INVEST, V115, P2702, DOI 10.1172/JCI24970; Clayburgh DR, 2004, LAB INVEST, V84, P282, DOI 10.1038/labinvest.3700050; Clayburgh DR, 2004, J BIOL CHEM, V279, P55506, DOI 10.1074/jbc.M408822200; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Fleet JC, 2003, PHYSIOL GENOMICS, V13, P57, DOI 10.1152/physiolgenomics.00152.2002; GALLAGHER PJ, 1995, J BIOL CHEM, V270, P29090, DOI 10.1074/jbc.270.49.29090; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Garcia JGN, 1997, AM J RESP CELL MOL, V16, P489, DOI 10.1165/ajrcmb.16.5.9160829; Giannone G, 2004, CELL, V116, P431, DOI 10.1016/S0092-8674(04)00058-3; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; Hecht G, 1996, AM J PHYSIOL-CELL PH, V271, pC1678, DOI 10.1152/ajpcell.1996.271.5.C1678; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Herring BP, 1996, AM J PHYSIOL-CELL PH, V270, pC1656, DOI 10.1152/ajpcell.1996.270.6.C1656; ITOH T, 1989, NATURE, V338, P164, DOI 10.1038/338164a0; KAMM KE, 1986, SCIENCE, V232, P80, DOI 10.1126/science.3754063; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Kim S, 2002, GASTROENTEROLOGY, V123, P1163, DOI 10.1053/gast.2002.36043; Kudryashov DS, 1999, FEBS LETT, V463, P67, DOI 10.1016/S0014-5793(99)01591-4; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; Lazar V, 1999, GENOMICS, V57, P256, DOI 10.1006/geno.1999.5774; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Ma TY, 2005, AM J PHYSIOL-GASTR L, V288, pG422, DOI 10.1152/ajpgi.00412.2004; Peterson LJ, 2004, MOL BIOL CELL, V15, P3497, DOI 10.1091/mbc.E03-09-0696; PETERSON MD, 1993, J CELL SCI, V105, P461; PETERSON MD, 1992, J CELL SCI, V102, P581; PINTO M, 1983, BIOL CELL, V47, P323; Russo JM, 2005, GASTROENTEROLOGY, V128, P987, DOI 10.1053/j.gastro.2005.01.004; Shen L, 2006, J CELL SCI, V119, P2095, DOI 10.1242/jcs.02915; SHORTER RG, 1964, AM J DIG DIS, V9, P760, DOI 10.1007/BF02231983; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Suenaert P, 2002, AM J GASTROENTEROL, V97, P2000; Turner JR, 1997, AM J PHYSIOL-CELL PH, V273, pC1378, DOI 10.1152/ajpcell.1997.273.4.C1378; Turner JR, 1996, J BIOL CHEM, V271, P7738, DOI 10.1074/jbc.271.13.7738; VANBEERS EH, 1995, BIOCHEM J, V308, P769, DOI 10.1042/bj3080769; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Wang FJ, 2005, AM J PATHOL, V166, P409, DOI 10.1016/S0002-9440(10)62264-X; YAMAGUCHI Y, 1991, AM J PHYSIOL, V261, pG312, DOI 10.1152/ajpgi.1991.261.2.G312; Ye DM, 2006, AM J PHYSIOL-GASTR L, V290, pG496, DOI 10.1152/ajpgi.00318.2005; Yin F, 2006, AM J PHYSIOL-CELL PH, V290, pC1599, DOI 10.1152/ajpcell.00289.2005; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966; Zolotarevsky Y, 2002, GASTROENTEROLOGY, V123, P163, DOI 10.1053/gast.2002.34235	47	102	108	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26205	26215		10.1074/jbc.M602164200	http://dx.doi.org/10.1074/jbc.M602164200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16835238	hybrid			2022-12-25	WOS:000240249500037
J	Severa, M; Coccia, EM; Fitzgerald, KA				Severa, Martina; Coccia, Eliana M.; Fitzgerald, Katherine A.			Toll-like receptor-dependent and -independent viperin gene expression and counter-regulation by PRDI-binding factor-1/BLIMP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DOUBLE-STRANDED-RNA; HEPATITIS-C VIRUS; RIG-I; ADAPTER PROTEIN; DENDRITIC CELLS; TRANSCRIPTIONAL ACTIVATION; ANTIVIRAL RESPONSE; IKK-EPSILON; INTERFERON	Here we identify Viperin as a highly inducible gene in response to lipopolysaccharide (LPS), double-stranded RNA (poly(I-C)) or Sendai virus (SV). The only known function of Viperin relates to its ability to inhibit human Cytomegalovirus replication. Very little data are available on the regulation of this gene. In silico analysis of the promoter identified two interferon (IFN)-stimulated response elements (ISRE), which in other genes bind IRF3 or the IFN-stimulated gene factor-3 (ISGF3) complex. LPS and poly(I-C) induce very high levels of Viperin in wild type cells but not in cells deficient in TRIF, TBK1, IRF3, or the type I IFN alpha/beta R. SV-induced Viperin gene expression was mediated independently of Toll-like receptor (TLR) signaling by retinoic acid-inducible gene (RIG-I) and the downstream adapter, mitochondrial anti-viral signaling (MAVS). Virus-induced Viperin expression was not attenuated in macrophages deficient in either TBK1 or IKK epsilon alone. Moreover, IRF3-deficient, but not IFN alpha/beta R deficient, macrophages still induced Viperin in response to SV. Promoter reporter studies combined with DNA immunoprecipitation assays identified the ISGF3 complex as the key regulator of Viperin gene expression. Moreover, positive regulatory domain I-binding factor 1 (PRDI-BF1, also called BLIMP1) binds the ISRE sites and competes with ISGF3 binding in a virus inducible manner to inhibit Viperin transcription. Collectively, these studies identify Viperin as a tightly regulated ISGF3 target gene, which is counter-regulated by PRDI-BF1.	Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis & Immunol, Worcester, MA 01605 USA; Ist Super Sanita, Dept Infect Parasit & Immunomediated Dis, I-00161 Rome, Italy	University of Massachusetts System; University of Massachusetts Worcester; Istituto Superiore di Sanita (ISS)	Fitzgerald, KA (corresponding author), Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis & Immunol, Worcester, MA 01605 USA.	kate.fitzgerald@umassmed.edu	Coccia, Eliana M/B-4752-2013; SEVERA, MARTINA/J-8782-2016; Fitzgerald, Katherine/ABE-6317-2020	Coccia, Eliana M/0000-0002-1606-2949; SEVERA, MARTINA/0000-0002-0411-4545; Fitzgerald, Kate/0000-0003-3175-609X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI067497, R37AI067497, R56AI067497] Funding Source: NIH RePORTER; NIAID NIH HHS [AI067497-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101; Bluyssen HAR, 1997, J BIOL CHEM, V272, P4600, DOI 10.1074/jbc.272.7.4600; Boudinot P, 2000, J GEN VIROL, V81, P2675, DOI 10.1099/0022-1317-81-11-2675; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Chen JB, 2004, J INTERF CYTOK RES, V24, P687, DOI 10.1089/jir.2004.24.687; Chin KC, 2001, P NATL ACAD SCI USA, V98, P15125, DOI 10.1073/pnas.011593298; Coccia EM, 2004, EUR J IMMUNOL, V34, P796, DOI 10.1002/eji.200324610; Cui YZ, 2001, GENOMICS, V78, P129, DOI 10.1006/geno.2001.6661; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Doly J, 1998, CELL MOL LIFE SCI, V54, P1109, DOI 10.1007/s000180050240; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Gyory I, 2004, NAT IMMUNOL, V5, P299, DOI 10.1038/ni1046; Helbig KJ, 2005, HEPATOLOGY, V42, P702, DOI 10.1002/hep.20844; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Ihle J N, 1995, Semin Immunol, V7, P247, DOI 10.1006/smim.1995.0029; Ishii KJ, 2006, NAT IMMUNOL, V7, P40, DOI 10.1038/ni1282; Jefferies CA, 2005, TRENDS MOL MED, V11, P403, DOI 10.1016/j.molmed.2005.07.006; Johnson K, 2005, MOL IMMUNOL, V42, P749, DOI 10.1016/j.molimm.2004.06.039; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Khaiboullina SF, 2005, VIROLOGY, V342, P167, DOI 10.1016/j.virol.2005.07.035; Kunzi MS, 2003, AUTOIMMUNITY, V36, P457, DOI 10.1080/08916930310001605855; Lande R, 2003, J IMMUNOL, V170, P1174, DOI 10.4049/jimmunol.170.3.1174; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Menendez C, 1996, FEBS LETT, V391, P101, DOI 10.1016/0014-5793(96)00712-0; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; MOGENSEN KE, 1975, ACTA PATH MICRO IM B, V83, P443; Mogensen KE, 1999, J INTERF CYTOK RES, V19, P1069, DOI 10.1089/107999099313019; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Platanias LC, 2003, PHARMACOL THERAPEUT, V98, P129, DOI 10.1016/S0163-7258(03)00016-0; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; Rothenfusser S, 2005, J IMMUNOL, V175, P5260, DOI 10.4049/jimmunol.175.8.5260; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Verma S, 2006, VIROLOGY, V345, P457, DOI 10.1016/j.virol.2005.10.012; Vogel Stefanie N, 2003, Mol Interv, V3, P466, DOI 10.1124/mi.3.8.466; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yoneyama M, 2005, J IMMUNOL, V175, P2851, DOI 10.4049/jimmunol.175.5.2851; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	44	99	107	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26188	26195		10.1074/jbc.M604516200	http://dx.doi.org/10.1074/jbc.M604516200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16849320	hybrid			2022-12-25	WOS:000240249500035
J	Dias-Gunasekara, S; van Lith, M; Williams, JAG; Kataky, R; Benham, AM				Dias-Gunasekara, Sanjika; van Lith, Marcel; Williams, J. A. Gareth; Kataky, Ritu; Benham, Adam M.			Mutations in the FAD binding domain cause stress-induced misoxidation of the endoplasmic reticulum oxidoreductase Ero1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE-BOND FORMATION; SECRETORY PATHWAY; PROTEIN; GLUTATHIONE; ERO1P; ISOMERASE; OXIDASE; CFTR; ERO1-L-ALPHA; EXPRESSION	Disulfide bond catalysis is an essential component of protein biogenesis in the secretory pathway, from yeast through to man. In the endoplasmic reticulum (ER), protein-disulfide isomerase (PDI) catalyzes the oxidation and isomerization of disulfide bonds and is re-oxidized by an endoplasmic reticulum oxidoreductase (ERO). The elucidation of ERO function was greatly aided by the genetic analysis of two ero mutants, whose impairment results from point mutations in the FAD binding domain of the Ero protein. The ero1-1 and ero1-2 yeast strains have conditional and dithiothreitol-sensitive phenotypes, but the effects of the mutations on the behavior of Ero proteins has not been reported. Here, we show that these Gly to Ser and His to Tyr mutations do not prevent the dimerization of Ero1 beta or the non-covalent interaction of Ero1 beta with PDI. However, the Gly to Ser mutation abolishes disulfide-dependent PDI-Ero1 beta heterodimers. Both the Gly to Ser and His to Tyr mutations make Ero1 beta susceptible to misoxidation and aggregation, particularly during a temperature or redox stress. We conclude that the Ero FAD binding domain is critical for conformational stability, allowing Ero proteins to withstand stress conditions that cause client proteins to misfold.	Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England; Univ Durham, Dept Chem, Durham DH1 3LE, England	Durham University; Durham University	Benham, AM (corresponding author), Univ Durham, Sch Biol & Biomed Sci, South Rd, Durham DH1 3LE, England.	Adam.benham@durham.ac.uk	Williams, J A Gareth/F-6618-2012; Kataky, Ritu/B-1800-2009; Benham, Adam/AAC-6606-2019	Williams, J A Gareth/0000-0002-4688-3000; Kataky, Ritu/0000-0002-6386-9606; Van Lith, Marcel/0000-0003-0225-5501; Benham, Adam/0000-0002-0919-7431	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Benham AM, 2000, EMBO J, V19, P4493, DOI 10.1093/emboj/19.17.4493; Bertoli G, 2004, J BIOL CHEM, V279, P30047, DOI 10.1074/jbc.M403192200; Cabibbo A, 2000, J BIOL CHEM, V275, P4827, DOI 10.1074/jbc.275.7.4827; Chakravarthi S, 2004, J BIOL CHEM, V279, P39872, DOI 10.1074/jbc.M406912200; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; Dias-Gunasekara S, 2005, J BIOL CHEM, V280, P33066, DOI 10.1074/jbc.M505023200; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Frand AR, 2000, MOL BIOL CELL, V11, P2833, DOI 10.1091/mbc.11.9.2833; Gess B, 2003, EUR J BIOCHEM, V270, P2228, DOI 10.1046/j.1432-1033.2003.03590.x; Gross E, 2004, CELL, V117, P601, DOI 10.1016/S0092-8674(04)00418-0; Gross E, 2006, P NATL ACAD SCI USA, V103, P299, DOI 10.1073/pnas.0506448103; Haynes CM, 2004, MOL CELL, V15, P767, DOI 10.1016/j.molcel.2004.08.025; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jessop CE, 2004, J BIOL CHEM, V279, P55341, DOI 10.1074/jbc.M411409200; Kleizen B, 2005, MOL CELL, V20, P277, DOI 10.1016/j.molcel.2005.09.007; Kulp MS, 2006, J BIOL CHEM, V281, P876, DOI 10.1074/jbc.M511764200; Magnuson B, 2005, MOL CELL, V20, P289, DOI 10.1016/j.molcel.2005.08.034; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Molteni SN, 2004, J BIOL CHEM, V279, P32667, DOI 10.1074/jbc.M404992200; Pagani M, 2000, J BIOL CHEM, V275, P23685, DOI 10.1074/jbc.M003061200; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Riordan JR, 2005, ANNU REV PHYSIOL, V67, P701, DOI 10.1146/annurev.physiol.67.032003.154107; Sekijima Y, 2005, CELL, V121, P73, DOI 10.1016/j.cell.2005.01.018; Sevier CS, 2006, MOL BIOL CELL, V17, P2256, DOI 10.1091/mbc.E05-05-0417; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Tsai M, 2002, J CELL BIOL, V159, P207, DOI 10.1083/jcb.200207120; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180	36	7	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25018	25025		10.1074/jbc.M602354200	http://dx.doi.org/10.1074/jbc.M602354200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16822866	hybrid			2022-12-25	WOS:000240031300004
J	Torrents, E; Westman, M; Sahlin, M; Sjoberg, BM				Torrents, Eduard; Westman, MariAnn; Sahlin, Margareta; Sjoberg, Britt-Marie			Ribonucleotide reductase modularity - Atypical duplication of the ATP-cone domain in Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY REGULATION; ESCHERICHIA-COLI; PROTEIN R1; DIPHOSPHATE REDUCTASE; ALLOSTERIC EFFECTORS; SUBUNIT INTERACTION; CRYSTAL-STRUCTURE; IRON; BINDING; ENZYME	The opportunistic pathogen Pseudomonas aeruginosa, which causes serious nosocomial infections, is a gamma-proteobacterium that can live in many different environments. Interestingly P. aeruginosa encodes three ribonucleotide reductases (RNRs) that all differ from other well known RNRs. The RNR enzymes are central for de novo synthesis of deoxyribonucleotides and essential to all living cells. The RNR of this study (class Ia) is a complex of the NrdA protein harboring the active site and the allosteric sites and the NrdB protein harboring a tyrosyl radical necessary to initiate catalysis. P. aeruginosa NrdA contains an atypical duplication of the N-terminal ATP-cone, an allosteric domain that can bind either ATP or dATP and regulates the overall enzyme activity. Here we characterized the wild type NrdA and two truncated NrdA variants with precise N-terminal deletions. The N-terminal ATP-cone (ATP-c1) is allosterically functional, whereas the internal ATP-cone lacks allosteric activity. The P. aeruginosa NrdB is also atypical with an unusually short lived tyrosyl radical, which is efficiently regenerated in presence of oxygen as the iron ions remain tightly bound to the protein. The P. aeruginosa wild type NrdA and NrdB proteins form an extraordinarily tight complex with a suggested alpha(4)beta(4) composition. An alpha(2)beta(2) composition is suggested for the complex of truncated NrdA (lacking ATP-c1) and wild type NrdB. Duplication or triplication of the ATP-cone is found in some other bacterial class Ia RNRs. We suggest that protein modularity built on the common catalytic core of all RNRs plays an important role in class diversification within the RNR family.	Stockholm Univ, Dept Mol Biol & Funct Genom, Arrhenius Labs Nat Sci, SE-10691 Stockholm, Sweden	Stockholm University	Sjoberg, BM (corresponding author), Stockholm Univ, Dept Mol Biol & Funct Genom, Arrhenius Labs Nat Sci, Svante Arrhenius Vag 16-18 F3, SE-10691 Stockholm, Sweden.	britt-marie.sjoberg@molbio.su.se	Torrents, Eduard/C-7184-2008	Torrents, Eduard/0000-0002-3010-1609; Sjoberg, Britt-Marie/0000-0001-5953-3360				Aravind L, 2000, J MOL MICROB BIOTECH, V2, P191; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; Birgander PL, 2005, J BIOL CHEM, V280, P14997, DOI 10.1074/jbc.M500565200; Birgander PL, 2004, J BIOL CHEM, V279, P14496, DOI 10.1074/jbc.M310142200; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BROWN NC, 1969, J MOL BIOL, V46, P25, DOI 10.1016/0022-2836(69)90055-2; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; Eklund H, 2001, PROG BIOPHYS MOL BIO, V77, P177, DOI 10.1016/S0079-6107(01)00014-1; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Fraser HB, 2005, NAT GENET, V37, P351, DOI 10.1038/ng1530; Gleason FK, 2002, J BACTERIOL, V184, P6544, DOI 10.1128/JB.184.23.6544-6550.2002; Jordan A, 1999, J BACTERIOL, V181, P3974, DOI 10.1128/JB.181.13.3974-3980.1999; Kashlan OB, 2003, BIOCHEMISTRY-US, V42, P1696, DOI 10.1021/bi020634d; KUNZ BA, 1994, MUTAT RES-REV GENET, V318, P1, DOI 10.1016/0165-1110(94)90006-X; Larsson KM, 2004, NAT STRUCT MOL BIOL, V11, P1142, DOI 10.1038/nsmb838; Larsson KM, 2001, STRUCTURE, V9, P739, DOI 10.1016/S0969-2126(01)00627-X; Lendzian F, 2005, BBA-BIOENERGETICS, V1707, P67, DOI 10.1016/j.bbabio.2004.02.011; Logan DT, 1999, SCIENCE, V283, P1499, DOI 10.1126/science.283.5407.1499; Nikitin F, 2003, COMPUT BIOL CHEM, V27, P481, DOI 10.1016/j.compbiolchem.2003.09.003; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; Poole AM, 2002, J MOL EVOL, V55, P180, DOI 10.1007/s00239-002-2315-3; Roshick C, 2000, J BIOL CHEM, V275, P38111, DOI 10.1074/jbc.M006367200; SAHLIN M, 1995, J BIOL CHEM, V270, P12361, DOI 10.1074/jbc.270.21.12361; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sintchak MD, 2002, NAT STRUCT BIOL, V9, P293, DOI 10.1038/nsb774; Stubbe J, 2000, CURR OPIN STRUC BIOL, V10, P731, DOI 10.1016/S0959-440X(00)00153-6; Thelander L, 1978, Methods Enzymol, V51, P227; THELANDER L, 1973, J BIOL CHEM, V248, P4591; Torrents E, 2005, J BIOL CHEM, V280, P16571, DOI 10.1074/jbc.M501322200; Torrents E, 2002, J MOL EVOL, V55, P138, DOI 10.1007/s00239-002-2311-7; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; Uppsten M, 2003, J MOL BIOL, V330, P87, DOI 10.1016/S0022-2836(03)00538-2	36	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25287	25296		10.1074/jbc.M601794200	http://dx.doi.org/10.1074/jbc.M601794200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16829681	hybrid			2022-12-25	WOS:000240031300030
J	Mazzieri, R; Furlan, F; D'Alessio, S; Zonari, E; Talotta, F; Verde, P; Blasi, F				Mazzieri, R.; Furlan, F.; D'Alessio, S.; Zonari, E.; Talotta, F.; Verde, P.; Blasi, F.			A direct link between expression of urokinase plasminogen activator receptor, growth rate and oncogenic transformation in mouse embryonic fibroblasts	ONCOGENE			English	Article						urokinase receptor; cell proliferation; Ras; E1A; Ink4a	CELL-SURFACE RECEPTOR; TUMOR-GROWTH; CANCER; PROLIFERATION; METASTASIS; INHIBITION; INVASION; AP-1; ANTAGONISTS; CARCINOMA	In addition to its role in invasion and metastasis of several tumors, the multifunctional urokinase receptor uPAR ( urokinase plasminogen activator receptor) is directly involved in the growth of several cancer cells in vitro and in vivo. We have compared growth rate and oncogenic transformation in wild-type (wt) or uPAR(-/-) mouse embryonic fibroblasts (MEFs). Surprisingly, uPAR(-/-) MEFs grew faster than wt MEFs. This agreed with elevated levels of cell cycle mediators like extracellular signal-regulated protein kinase, p38, AP1 and Cyclin D1. Infection with a uPAR retrovirus reverted the effect, decreasing the growth rate. When MEFs were transformed with H-Ras(V12) and E1A oncogenes, the efficiency of transformation in uPAR(-/-) MEFs was higher than in wt. UPAR(-/-) MEFs grew faster at low serum, produced more colonies in agar and produced tumors in vivo in nude mice with a lower latency period. The properties of the heterozygous uPAR(-/-) MEFs were always intermediate. We conclude therefore that in MEFs uPAR concentration controls cell proliferation and the transforming activity of some oncogenes.	IFOM, FIRC, Inst Mol Oncol, Washington, DC 20016 USA; Univ Vita Salute San Raffaele, Dept Mol Biol & Funct Gen, Milan, Italy	Vita-Salute San Raffaele University	Blasi, F (corresponding author), IFOM, FIRC, Inst Mol Oncol, Via Adamello 16, Washington, DC 20016 USA.	francesco.blasi@ifom-ieo-campus.it	Mazzieri, Roberta/C-9773-2015; Zonari, Erika/K-9638-2016; Danese, Silvio/ABH-9571-2020	Mazzieri, Roberta/0000-0002-5172-0927; Zonari, Erika/0000-0002-7915-3995; Danese, Silvio/0000-0001-7341-1351; Blasi, Francesco/0000-0001-9406-1784				Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; Dano K, 2005, THROMB HAEMOSTASIS, V93, P676, DOI 10.1160/TH05-01-0054; Dewerchin M, 1996, J CLIN INVEST, V97, P870, DOI 10.1172/JCI118489; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; HOYERHANSEN G, 1992, J BIOL CHEM, V267, P18224; Huai Q, 2006, SCIENCE, V311, P656, DOI 10.1126/science.1121143; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kiyan J, 2005, EMBO J, V24, P1787, DOI 10.1038/sj.emboj.7600669; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; Lakka SS, 2001, CLIN CANCER RES, V7, P1087; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Llinas P, 2005, EMBO J, V24, P1655, DOI 10.1038/sj.emboj.7600635; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Mazzieri R, 2006, MOL BIOL CELL, V17, P367, DOI 10.1091/mbc.E05-07-0635; Mazzieri R, 2005, THROMB HAEMOSTASIS, V93, P641, DOI 10.1160/TH05-01-0021; Min HY, 1996, CANCER RES, V56, P2428; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; Ploug M, 2003, CURR PHARM DESIGN, V9, P1499, DOI 10.2174/1381612033454630; Ploug M, 2001, BIOCHEMISTRY-US, V40, P12157, DOI 10.1021/bi010662g; Reuning U, 1998, INT J ONCOL, V13, P893; Selleri C, 2005, BLOOD, V105, P2198, DOI 10.1182/blood-2004-06-2424; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; Stephens RW, 1999, JNCI-J NATL CANCER I, V91, P869, DOI 10.1093/jnci/91.10.869; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Wei L, 2001, BMC Physiol, V1, P3, DOI 10.1186/1472-6793-1-3; WILHELM O, 1994, FEBS LETT, V337, P131, DOI 10.1016/0014-5793(94)80259-9	38	13	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					725	732		10.1038/sj.onc.1209833	http://dx.doi.org/10.1038/sj.onc.1209833			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16878153				2022-12-25	WOS:000243902200009
J	Wu, X; Shell, SM; Liu, Y; Zou, Y				Wu, X.; Shell, S. M.; Liu, Y.; Zou, Y.			ATR-dependent checkpoint modulates XPA nuclear import in response to UV irradiation	ONCOGENE			English	Article						XPA; ATR; nuclear accumulation; DNA damage response; nucleotide excision repair	NUCLEOTIDE EXCISION-REPAIR; PIGMENTOSUM GROUP-A; CYCLOBUTANE PYRIMIDINE DIMERS; CELL-CYCLE CHECKPOINTS; DNA-DAMAGE; S-PHASE; RADIOSENSITIZING AGENT; ATAXIA-TELANGIECTASIA; IONIZING IRRADIATION; KINASE-ACTIVITY	In response to DNA damage, mammalian cells activate various DNA repair pathways to remove DNA lesions and, meanwhile, halt cell cycle progressions to allow sufficient time for repair. The nucleotide excision repair (NER) and the ATR-dependent cell cycle checkpoint activation are two major cellular responses to DNA damage induced by UV irradiation. However, how these two processes are coordinated in the response is poorly understood. Here we showed that the essential NER factor XPA (xeroderma pigmentosum group A) underwent nuclear accumulation upon UV irradiation, and strikingly, such an event occurred in an ATR (Ataxia-Telangiectasia mutated and RAD3-related)-dependent manner. Either treatment of cells with ATR kinase inhibitors or transfection of cells with small interfering RNA targeting ATR compromised the UV-induced XPA nuclear translocation. Consistently, the ATR-deficient cells displayed no substantial XPA nuclear translocation while the translocation remained intact in ATM (AtaxiaTelangiectasia mutated)-deficient cells in response to UV irradiation. Moreover, we found that ATR is required for the UV-induced nuclear focus formation of XPA. Taken together, our results suggested that the ATR checkpoint pathway may modulate NER activity through the regulation of XPA redistribution in human cells upon UV irradiation.	E Tennessee State Univ, James H Quillen Coll Med, Dept Biochem & Mol Biol, Johnson City, TN 37614 USA	East Tennessee State University	Zou, Y (corresponding author), E Tennessee State Univ, James H Quillen Coll Med, Dept Biochem & Mol Biol, 100 CR Rd,Box 70581, Johnson City, TN 37614 USA.	zouy@etsu.edu	Zou, Yue/ABA-8429-2020		NCI NIH HHS [CA86927, R56 CA086927, R01 CA086927-04, R56 CA086927-06A1, R01 CA086927, R01 CA086927-05] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA086927, R01CA086927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699; Barr SM, 2003, CURR BIOL, V13, P1047, DOI 10.1016/S0960-9822(03)00376-2; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Costa RMA, 2003, BIOCHIMIE, V85, P1083, DOI 10.1016/j.biochi.2003.10.017; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Feng ZH, 2004, J BIOL CHEM, V279, P28574, DOI 10.1074/jbc.M404137200; Ford JM, 2005, MUTAT RES-FUND MOL M, V577, P195, DOI 10.1016/j.mrfmmm.2005.04.005; Garinis GA, 2005, EMBO J, V24, P3952, DOI 10.1038/sj.emboj.7600849; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Giannattasio M, 2004, EMBO J, V23, P429, DOI 10.1038/sj.emboj.7600051; Guzder SN, 2006, MOL CELL BIOL, V26, P1135, DOI 10.1128/MCB.26.3.1135-1141.2006; Iakoucheva LM, 2001, PROTEIN SCI, V10, P1353, DOI 10.1110/ps.40101; Jiang H, 1999, CANCER RES, V59, P4529; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Koberle B, 2006, DNA REPAIR, V5, P641, DOI 10.1016/j.dnarep.2005.12.001; Liu Y, 2005, BIOCHEMISTRY-US, V44, P7361, DOI 10.1021/bi047598y; MIURA N, 1991, J BIOL CHEM, V266, P19786; MIYAMOTO I, 1992, J BIOL CHEM, V267, P12182; Neecke H, 1999, EMBO J, V18, P4485, DOI 10.1093/emboj/18.16.4485; Nghiem P, 2002, J BIOL CHEM, V277, P4428, DOI 10.1074/jbc.M106113200; Nitta M, 2000, NUCLEIC ACIDS RES, V28, P4212, DOI 10.1093/nar/28.21.4212; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; Rademakers S, 2003, MOL CELL BIOL, V23, P5755, DOI 10.1128/MCB.23.16.5755-5767.2003; Riedl T, 2003, EMBO J, V22, P5293, DOI 10.1093/emboj/cdg489; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; Thomas RK, 2003, MARK HEALTH SERV, V23, P38; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wang J, 2006, CANCER RES, V66, P1906, DOI 10.1158/0008-5472.CAN-05-3444; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Wu XM, 2006, CANCER RES, V66, P2997, DOI 10.1158/0008-5472.CAN-05-3403; Wu XM, 2005, ONCOGENE, V24, P4728, DOI 10.1038/sj.onc.1208674; Wu YM, 2005, J CELL BIOCHEM, V96, P751, DOI 10.1002/jcb.20577; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yu SR, 2001, MUTAT RES-DNA REPAIR, V485, P229, DOI 10.1016/S0921-8777(01)00061-1; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	44	70	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	5					757	764		10.1038/sj.onc.1209828	http://dx.doi.org/10.1038/sj.onc.1209828			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16862173	Green Accepted			2022-12-25	WOS:000243902200012
J	Deadman, ME; Lundstrom, SL; Schweda, EKH; Moxon, ER; Hood, DW				Deadman, Mary E.; Lundstrom, Susanna L.; Schweda, Elke K. H.; Moxon, E. Richard; Hood, Derek W.			Specific amino acids of the glycosyltransferase LpsA direct the addition of glucose or galactose to the terminal inner core heptose of Haemophilus influenzae lipopolysaccharide via alternative linkages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL-ANALYSIS; SUGAR GLYCOSYLTRANSFERASES; HEMOPHILUS-INFLUENZAE; SIALIC-ACID; STRAIN-RD; BIOSYNTHESIS; MECHANISM; GENES; PHOSPHORYLCHOLINE; CLASSIFICATION	Lipopolysaccharide is the major glycolipid of the cell wall of the bacterium Haemophilus influenzae, a Gram-negative commensal and pathogen of humans. Lipopolysaccharide is both a virulence determinant and a target for host immune responses. Glycosyltransferases have high donor and acceptor substrate specificities that are generally limited to catalysis of one unique glycosidic linkage. The H. influenzae glycosyltransferase LpsA is responsible for the addition of a hexose to the distal heptose of the inner core of the lipopolysaccharide molecule and belongs to the glycosyltransferase family 25. The hexose added can be either glucose or galactose and linkage to the heptose can be either beta 1-2 or beta 1-3. Each H. influenzae strain uniquely produces only one of the four possible combinations of linked sugar in its lipopolysaccharide. We show that, in any given strain, a specific allelic variant of LpsA directs the anomeric linkage and the added hexose, glucose, or galactose. Site-directed mutagenesis of a single key amino acid at position 151 changed the hexose added in vivo from glucose to galactose or vice versa. By constructing chimeric lpsA gene sequences, it was shown that the 3' end of the gene directs the anomeric linkage (beta 1-2 or beta 1-3) of the added hexose. The lpsA gene is the first known example where interstrain variation in lipopolysaccharide core structure is directed by the specific sequence of a genetic locus encoding enzymes directing one of four alternative possible sugar additions from the inner core.	Univ Oxford, Dept Paediat, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England; Karolinska Inst, Clin Res Ctr, S-14186 Huddinge, Sweden; Univ Coll S Stockholm, Novum, S-14186 Huddinge, Sweden	University of Oxford; Karolinska Institutet; Karolinska Institutet; Sodertorn University	Deadman, ME (corresponding author), Univ Oxford, Dept Paediat, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England.	mary.deadman@paediatrics.ox.ac.uk		Lundstrom, Susanna/0000-0003-2363-4287; Deadman, Mary/0000-0002-6074-017X				ALEXANDER HE, 1951, P SOC EXP BIOL MED, V78, P625; ALEXANDER HE, 1965, BACTERIAL MYCOTIC IN, P724; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; ANDERSON P, 1972, J CLIN INVEST, V51, P31, DOI 10.1172/JCI106793; Bouchet V, 2003, P NATL ACAD SCI USA, V100, P8898, DOI 10.1073/pnas.1432026100; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Cody AJ, 2003, INFECT GENET EVOL, V3, P57, DOI 10.1016/S1567-1348(02)00152-1; Coutinho PM, 1999, ROY SOC CH, P3; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Fox KL, 2005, MOL MICROBIOL, V58, P207, DOI 10.1111/j.1365-2958.2005.04814.x; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Griffin R, 2003, MICROBIOL-SGM, V149, P3165, DOI 10.1099/mic.0.26387-0; HERRIOTT RM, 1970, J BACTERIOL, V101, P517, DOI 10.1128/JB.101.2.517-524.1970; Hood DW, 2004, MICROBIOL-SGM, V150, P2089, DOI 10.1099/mic.0.26912-0; Hood DW, 1999, MOL MICROBIOL, V33, P679, DOI 10.1046/j.1365-2958.1999.01509.x; Hood DW, 2004, J BACTERIOL, V186, P7429, DOI 10.1128/JB.186.21.7429-7439.2004; Hood DW, 1996, MOL MICROBIOL, V22, P951, DOI 10.1046/j.1365-2958.1996.01545.x; Kroll JS, 1998, P NATL ACAD SCI USA, V95, P12381, DOI 10.1073/pnas.95.21.12381; Kubo A, 2004, ARCH BIOCHEM BIOPHYS, V429, P198, DOI 10.1016/j.abb.2004.06.021; Lazarus BD, 2002, GLYCOBIOLOGY, V12, P793, DOI 10.1093/glycob/cwf092; Liu J, 2003, PROTEIN SCI, V12, P1418, DOI 10.1110/ps.0302103; Lysenko E, 2000, MOL MICROBIOL, V35, P234, DOI 10.1046/j.1365-2958.2000.01707.x; Mansson M, 2003, EUR J BIOCHEM, V270, P2979, DOI 10.1046/j.1432-1033.2003.03675.x; Mansson M, 2001, EUR J BIOCHEM, V268, P2148, DOI 10.1046/j.1432-1327.2001.02094.x; Mansson M, 2002, EUR J BIOCHEM, V269, P808, DOI 10.1046/j.0014-2956.2001.02707.x; Masoud H, 1997, BIOCHEMISTRY-US, V36, P2091, DOI 10.1021/bi961989y; Moran AP, 1996, FEMS IMMUNOL MED MIC, V16, P105, DOI 10.1111/j.1574-695X.1996.tb00127.x; Preston A, 1996, CRIT REV MICROBIOL, V22, P139, DOI 10.3109/10408419609106458; Richards JC, 2001, ADV EXP MED BIOL, V491, P515; Risberg A, 1999, EUR J BIOCHEM, V261, P171, DOI 10.1046/j.1432-1327.1999.00248.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; Schweda EKH, 2003, CARBOHYD RES, V338, P2731, DOI 10.1016/S0008-6215(03)00385-9; Schweda EKH, 2002, CARBOHYD RES, V337, P409, DOI 10.1016/S0008-6215(02)00002-2; SCHWEDA EKH, 1993, CARBOHYD RES, V246, P319, DOI 10.1016/0008-6215(93)84043-6; Schweda Elke K H, 2003, Methods Mol Med, V71, P161; Shibayama K, 1998, J BACTERIOL, V180, P5313, DOI 10.1128/JB.180.20.5313-5318.1998; Smith HO, 1999, RES MICROBIOL, V150, P603, DOI 10.1016/S0923-2508(99)00130-8; Tarbouriech N, 2001, J MOL BIOL, V314, P655, DOI 10.1006/jmbi.2001.5159; VANALPHEN L, 1983, J INFECT DIS, V148, P75, DOI 10.1093/infdis/148.1.75; Wakarchuk WW, 2001, J BIOL CHEM, V276, P12785, DOI 10.1074/jbc.M011293200; Weiser JN, 1997, INFECT IMMUN, V65, P943, DOI 10.1128/IAI.65.3.943-950.1997; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Yildirim HH, 2005, CARBOHYD RES, V340, P2598, DOI 10.1016/j.carres.2005.09.005	45	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29455	29467		10.1074/jbc.M604908200	http://dx.doi.org/10.1074/jbc.M604908200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16847057	hybrid			2022-12-25	WOS:000240896300008
J	Falkevall, A; Alikhani, N; Bhushan, S; Pavlov, PF; Busch, K; Johnson, KA; Eneqvist, T; Tjernberg, L; Ankarcrona, M; Glaser, E				Falkevall, Annelie; Alikhani, Nyosha; Bhushan, Shashi; Pavlov, Pavel F.; Busch, Katrin; Johnson, Kenneth A.; Eneqvist, Therese; Tjernberg, Lars; Ankarcrona, Maria; Glaser, Elzbieta			Degradation of the amyloid beta-protein by the novel mitochondrial peptidasome, PreP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-DEGRADING ENZYME; ALZHEIMERS-DISEASE; A-BETA; IN-VIVO; DYSFUNCTION; CHLOROPLASTS; INSULYSIN; METALLOPEPTIDASE; PROTEOLYSIS; PROTEASES	Recently we have identified the novel mitochondrial peptidase responsible for degrading presequences and other short unstructured peptides in mitochondria, the presequence peptidase, which we named PreP peptidasome. In the present study we have identified and characterized the human PreP homologue, hPreP, in brain mitochondria, and we show its capacity to degrade the amyloid beta-protein (A beta). PreP belongs to the pitrilysin oligopeptidase family M16C containing an inverted zinc-binding motif. We show that hPreP is localized to the mitochondrial matrix. In situ immuno-inactivation studies in human brain mitochondria using anti-hPreP antibodies showed complete inhibition of proteolytic activity against A beta. We have cloned, overexpressed, and purified recombinant hPreP and its mutant with catalytic base Glu(78) in the inverted zinc-binding motif replaced by Gln. In vitro studies using recombinant hPreP and liquid chromatography nanospray tandem mass spectrometry revealed novel cleavage specificities against A beta-(1-42), A beta-(1-40), and A beta Arctic, a protein that causes increased protofibril formation an early onset familial variant of Alzheimer disease. In contrast to insulin degrading enzyme, which is a functional analogue of hPreP, hPreP does not degrade insulin but does degrade insulin B-chain. Molecular modeling of hPreP based on the crystal structure at 2.1 angstrom resolution of AtPreP allowed us to identify Cys(90) and Cys(527) that form disulfide bridges under oxidized conditions and might be involved in redox regulation of the enzyme. Degradation of the mitochondrial A beta by hPreP may potentially be of importance in the pathology of Alzheimer disease.	Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; Neurotec, KASPAC, SE-14157 Huddinge, Sweden	Stockholm University; Karolinska Institutet	Glaser, E (corresponding author), Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden.	e_glaser@dbb.su.se		Bhushan, Shashi/0000-0002-8514-5959; Ankarcrona, Maria/0000-0002-7022-3694				Abagyan R, 1997, PROTEINS, P29; ABAGYAN R, 1994, PROTEINS, V19, P132, DOI 10.1002/prot.340190206; Aleardi AM, 2005, J BIOENERG BIOMEMBR, V37, P207, DOI 10.1007/s10863-005-6631-3; Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030; Ankarcrona M, 2002, BIOCHEM BIOPH RES CO, V295, P766, DOI 10.1016/S0006-291X(02)00735-0; Arnold I, 2002, BBA-MOL CELL RES, V1592, P89, DOI 10.1016/S0167-4889(02)00267-7; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; Bertram L, 2000, SCIENCE, V290, P2302, DOI 10.1126/science.290.5500.2302; Bhushan S, 2003, EMBO REP, V4, P1073, DOI 10.1038/sj.embor.7400011; Cardoso SM, 2004, J NEUROCHEM, V89, P1417, DOI 10.1111/j.1471-4159.2004.02438.x; Caspersen C, 2005, FASEB J, V19, P2040, DOI 10.1096/fj.05-3735fje; Duckworth WC, 1998, ENDOCR REV, V19, P608, DOI 10.1210/er.19.5.608; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Gavin AC, 2006, NATURE, V440, P631, DOI 10.1038/nature04532; Glabe C, 2001, J MOL NEUROSCI, V17, P137, DOI 10.1385/JMN:17:2:137; Hansson CA, 2004, J BIOL CHEM, V279, P51654, DOI 10.1074/jbc.M404500200; Hashimoto M, 2003, NEUROMOL MED, V4, P21, DOI 10.1385/NMM:4:1-2:21; Higgins D G, 1994, Methods Mol Biol, V25, P307; Johnson KA, 2006, EMBO J, V25, P1977, DOI 10.1038/sj.emboj.7601080; Kambacheld M, 2005, J BIOL CHEM, V280, P20132, DOI 10.1074/jbc.M500398200; Kaser M, 2003, J BIOL CHEM, V278, P46414, DOI 10.1074/jbc.M305584200; Kurochkin IV, 2001, TRENDS BIOCHEM SCI, V26, P421, DOI 10.1016/S0968-0004(01)01876-X; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPIDUS RG, 1993, ARCH BIOCHEM BIOPHYS, V306, P246, DOI 10.1006/abbi.1993.1507; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Leissring MA, 2004, BIOCHEM J, V383, P439, DOI 10.1042/BJ20041081; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; Moberg P, 2003, PLANT J, V36, P616, DOI 10.1046/j.1365-313X.2003.01904.x; Morelli L, 2003, J BIOL CHEM, V278, P23221, DOI 10.1074/jbc.M300276200; Mzhavia N, 1999, DNA CELL BIOL, V18, P369, DOI 10.1089/104454999315268; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; Selkoe DJ, 2001, NEURON, V32, P177, DOI 10.1016/S0896-6273(01)00475-5; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Song ES, 2005, J MOL NEUROSCI, V25, P201, DOI 10.1385/JMN:25:3:201; Song ES, 2001, J BIOL CHEM, V276, P1152, DOI 10.1074/jbc.M008702200; Stahl A, 2005, J MOL BIOL, V349, P847, DOI 10.1016/j.jmb.2005.04.023; Stahl A, 2002, J BIOL CHEM, V277, P41931, DOI 10.1074/jbc.M205500200; Tanzi RE, 2004, NEURON, V43, P605, DOI 10.1016/j.neuron.2004.08.024; Yan SD, 2005, INT J EXP PATHOL, V86, P161, DOI 10.1111/j.0959-9673.2005.00427.x	42	162	169	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29096	29104		10.1074/jbc.M602532200	http://dx.doi.org/10.1074/jbc.M602532200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16849325	hybrid			2022-12-25	WOS:000240680500064
J	Rost, M; Mann, S; Lambert, C; Doring, T; Thome, N; Prange, R				Rost, Martina; Mann, Sylvia; Lambert, Carsten; Doering, Tatjana; Thome, Nicole; Prange, Reinhild			gamma 2-adaptin, a novel ubiquitin-interacting adaptor, and Nedd4 ubiquitin ligase control hepatitis B virus maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE ENVELOPE PROTEIN; MURINE LEUKEMIA-VIRUS; VIRION FORMATION; SORTING PATHWAY; COATED VESICLES; SURFACE-ANTIGEN; GAMMA-ADAPTIN; LATE DOMAIN; HIV-1 GAG; TSG101	Hepatitis B virus (HBV) budding from infected cells is a tightly regulated process that requires both core and envelope structures. Here we report that HBV uses cellular gamma 2-adaptin and Nedd4, possibly in conjunction with ubiquitin, to coordinate its assembly and release. In search of interaction partners of the viral L envelope protein, we previously discovered gamma 2-adaptin, a putative endosomal sorting and trafficking adaptor of the adaptor protein complex family. We now demonstrate that the viral core interacts with the same gamma 2-adaptor and that disruption of the HBV/gamma 2-adaptin interactions inhibits virus production. Mutational analyses revealed a hitherto unknown ubiquitin-binding activity of gamma 2-adaptin, specified by a ubiquitin-interacting motif, which contributes to its interaction with core. For core, the lysine residue at position 96, a potential target for ubiquitination, was identified to be essential for both gamma 2-adaptin-recognition and virus production. The participation of the cellular ubiquitin system in HBV assembly was further suggested by our finding that core interacts with the endosomal ubiquitin ligase Nedd4, partly via its late domain-like PPAY sequence. Overexpression of a catalytically inactive Nedd4 mutant diminished HBV egress, indicating that protein ubiquitination is functionally involved in virus production. Additional evidence for a link of HBV assembly to the endosomal machinery was provided by immunolabeling studies that demonstrated colocalization of core and L with gamma 2-adaptin in compartments positive for the late endosomal marker CD63. Together, these data indicate that an enveloped DNA virus exploits a new ubiquitin receptor together with endosomal pathway functions for egress from hepatocytes.	Univ Mainz, Dept Med Microbiol & Hyg, D-55101 Mainz, Germany	Johannes Gutenberg University of Mainz	Prange, R (corresponding author), Univ Mainz, Dept Med Microbiol & Hyg, Augustuspl, D-55101 Mainz, Germany.	prange@mail.uni-mainz.de		Prange, Reinhild/0000-0001-8312-4970				Bieniasz PD, 2006, VIROLOGY, V344, P55, DOI 10.1016/j.virol.2005.09.044; Blot V, 2004, J CELL SCI, V117, P2357, DOI 10.1242/jcs.01095; Boehm M, 2001, MOL BIOL CELL, V12, P2907, DOI 10.1091/mbc.12.10.2907; Bottcher B, 1997, NATURE, V386, P88, DOI 10.1038/386088a0; Bouamr F, 2003, J VIROL, V77, P11882, DOI 10.1128/JVI.77.22.11882-11895.2003; Bruss V, 2004, VIRUS RES, V106, P199, DOI 10.1016/j.virusres.2004.08.016; Bruss V, 1997, J VIROL, V71, P9350, DOI 10.1128/JVI.71.12.9350-9357.1997; Chen CP, 2005, J BIOL CHEM, V280, P40474, DOI 10.1074/jbc.M509317200; Cooper A, 2003, BBA-BIOMEMBRANES, V1614, P89, DOI 10.1016/S0005-2736(03)00166-4; Dong XH, 2005, CELL, V120, P663, DOI 10.1016/j.cell.2004.12.023; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Hartmann-Stuhler C, 2001, J VIROL, V75, P5343, DOI 10.1128/JVI.75.11.5343-5351.2001; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Hu JM, 2004, J VIROL, V78, P13122, DOI 10.1128/JVI.78.23.13122-13131.2004; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Lambert C, 2003, P NATL ACAD SCI USA, V100, P5199, DOI 10.1073/pnas.0930813100; Lambert C, 2001, J BIOL CHEM, V276, P22265, DOI 10.1074/jbc.M100956200; Lewin DA, 1998, FEBS LETT, V435, P263, DOI 10.1016/S0014-5793(98)01083-7; Loffler-Mary H, 2000, VIROLOGY, V270, P358, DOI 10.1006/viro.2000.0268; MAASSEN A, 1994, ARCH VIROL, V135, P131, DOI 10.1007/BF01309770; Martin-Serrano J, 2005, J CELL BIOL, V168, P89, DOI 10.1083/jcb.200408155; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; Medina G, 2005, TRAFFIC, V6, P880, DOI 10.1111/j.1600-0854.2005.00323.x; Morita E, 2004, ANNU REV CELL DEV BI, V20, P395, DOI 10.1146/annurev.cellbio.20.010403.102350; Nassal M, 1999, INTERVIROLOGY, V42, P100, DOI 10.1159/000024970; Ott DE, 1998, J VIROL, V72, P2962, DOI 10.1128/JVI.72.4.2962-2968.1998; Ott DE, 2000, VIROLOGY, V278, P111, DOI 10.1006/viro.2000.0648; PATZER EJ, 1984, J VIROL, V51, P346, DOI 10.1128/JVI.51.2.346-353.1984; Pelchen-Matthews A, 2004, TRENDS MICROBIOL, V12, P310, DOI 10.1016/j.tim.2004.05.004; Pelchen-Matthews A, 2003, J CELL BIOL, V162, P443, DOI 10.1083/jcb.200304008; Perez OD, 2001, IMMUNITY, V15, P687, DOI 10.1016/S1074-7613(01)00238-2; Ponsel D, 2003, J VIROL, V77, P416, DOI 10.1128/JVI.77.1.416-422.2003; Puertollano R, 2004, NAT CELL BIOL, V6, P244, DOI 10.1038/ncb1106; Puffer BA, 1998, J VIROL, V72, P10218, DOI 10.1128/JVI.72.12.10218-10221.1998; Rabe B, 2003, P NATL ACAD SCI USA, V100, P9849, DOI 10.1073/pnas.1730940100; RADZIWILL G, 1990, J VIROL, V64, P613, DOI 10.1128/JVI.64.2.613-620.1990; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Robinson MS, 2004, TRENDS CELL BIOL, V14, P167, DOI 10.1016/j.tcb.2004.02.002; Roingeard P, 1998, HEPATOLOGY, V28, P1128, DOI 10.1002/hep.510280431; Schubert U, 2000, P NATL ACAD SCI USA, V97, P13057, DOI 10.1073/pnas.97.24.13057; Scott PM, 2004, NAT CELL BIOL, V6, P252, DOI 10.1038/ncb1107; Segura-Morales C, 2005, J BIOL CHEM, V280, P27004, DOI 10.1074/jbc.M413735200; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Takatsu H, 1998, J BIOL CHEM, V273, P24693, DOI 10.1074/jbc.273.38.24693; Vana ML, 2004, J VIROL, V78, P13943, DOI 10.1128/JVI.78.24.13943-13953.2004; Wang Margaret Q, 2003, J Biol, V3, P4, DOI 10.1186/1475-4924-3-4; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339; Zizioli D, 1999, J BIOL CHEM, V274, P5385, DOI 10.1074/jbc.274.9.5385	50	69	77	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29297	29308		10.1074/jbc.M603517200	http://dx.doi.org/10.1074/jbc.M603517200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16867982	hybrid			2022-12-25	WOS:000240680500085
J	Carkaci-Salli, N; Flanagan, JM; Martz, MK; Salli, U; Walther, DJ; Bader, M; Vrana, KE				Carkaci-Salli, Nurgul; Flanagan, John M.; Martz, Matthew K.; Salli, Ugur; Walther, Diego J.; Bader, Michael; Vrana, Kent E.			Functional domains of human tryptophan hydroxylase 2 (hTPH2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PHENYLALANINE-HYDROXYLASE; AMINO-ACID HYDROXYLASES; TYROSINE-HYDROXYLASE; MAJOR DEPRESSION; BRAIN-SEROTONIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; TPH2 GENE; EXPRESSION; ENZYME	Tryptophan hydroxylase (TPH) is the rate-limiting enzyme in serotonin biosynthesis. A novel gene, termed TPH2, has recently been described. This gene is preferentially expressed in the central nervous system, while the original TPH1 is the peripheral gene. We have expressed human tryptophan hydroxylase 2 (hTPH2) and two deletion mutants (N Delta 150 and N Delta 150/C Delta 24) using isopropyl beta-D-thiogalactopyranoside-free autoinduction in Escherichia coli. This expression system produced active wild type TPH2 with relatively low solubility. The solubility was increased for mutants lacking the NH2-terminal regulatory domain. The solubility of hTPH2, N Delta 150, and N Delta 150/C Delta 24 are 6.9, 62, and 97.5%, respectively. Removal of the regulatory domain also produced a more than 6-fold increase in enzyme stability (t(1/2) at 37 degrees C). The wild type hTPH2, like other members of the aromatic amino acid hydroxylase superfamily, exists as a homotetramer ( 236 kDa on size exclusion chromatography). Similarly, N Delta 150 also migrates as a tetramer (168 kDa). In contrast, removal of the NH2-terminal domain and the COOH-terminal, putative leucine zipper tetramerization domain produces monomeric enzyme ( 39 kDa). Interestingly, removal of the NH2-terminal regulatory domain did not affect the Michaelis constants for either substrate but did increase V-max values. These data identify the NH2-terminal regulatory domain as the source of hTPH2 instability and reduced solubility.	Penn State Coll Med, Dept Pharmacol, Hershey, PA 17033 USA; Penn State Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA; Max Planck Inst Mol Genet, Dept Human Genet, D-14195 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Max Planck Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Vrana, KE (corresponding author), Penn State Coll Med, Dept Pharmacol, 500 Univ Dr,H078, Hershey, PA 17033 USA.	kvrana@psu.edu	Bader, Michael/K-2124-2013	Vrana, Kent/0000-0003-4902-7733; Bader, Michael/0000-0003-4780-4164	NIGMS NIH HHS [GM 38981] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen OA, 2002, J MOL BIOL, V320, P1095, DOI 10.1016/S0022-2836(02)00560-0; Cote F, 2003, P NATL ACAD SCI USA, V100, P13525, DOI 10.1073/pnas.2233056100; CRAIG DA, 1993, BRIT J PHARMACOL, V109, P609, DOI 10.1111/j.1476-5381.1993.tb13615.x; DSa CM, 1996, J NEUROCHEM, V67, P900; DSa CM, 1996, J NEUROCHEM, V67, P917; Fitzpatrick PF, 1999, ANNU REV BIOCHEM, V68, P355, DOI 10.1146/annurev.biochem.68.1.355; Goodwill KE, 1997, NAT STRUCT BIOL, V4, P578, DOI 10.1038/nsb0797-578; GRAHAMESMITH DG, 1964, BIOCHEM BIOPH RES CO, V16, P586, DOI 10.1016/0006-291X(64)90197-4; GRENETT HE, 1987, P NATL ACAD SCI USA, V84, P5530, DOI 10.1073/pnas.84.16.5530; GRIDER JR, 1996, AM J PHYSIOL, V270, P778; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAKANSON R., 1967, LIFE SCI, V6, P2577, DOI 10.1016/0024-3205(67)90107-5; Harvey M, 2004, MOL PSYCHIATR, V9, P980, DOI 10.1038/sj.mp.4001557; JACOBS BL, 1992, PHYSIOL REV, V72, P165, DOI 10.1152/physrev.1992.72.1.165; JEQUIER E, 1967, MOL PHARMACOL, V3, P274; Jiang GCT, 2000, J MOL BIOL, V302, P1005, DOI 10.1006/jmbi.2000.4097; Knappskog PM, 1996, EUR J BIOCHEM, V242, P813, DOI 10.1111/j.1432-1033.1996.0813r.x; Kowlessur D, 1999, BBA-PROTEIN STRUCT M, V1434, P317, DOI 10.1016/S0167-4838(99)00184-3; Kumer SC, 1996, J NEUROCHEM, V67, P443; Matsuda M, 2004, DEV CELL, V6, P193, DOI 10.1016/S1534-5807(04)00022-X; McKinney J, 2005, J NEUROCHEM, V92, P311, DOI 10.1111/j.1471-4159.2004.02850.x; McKinney J, 2004, PROTEIN EXPRES PURIF, V33, P185, DOI 10.1016/j.pep.2003.09.014; McKinney J, 2001, BIOCHEMISTRY-US, V40, P15591, DOI 10.1021/bi015722x; Meller J, 2001, PROTEINS, V45, P241, DOI 10.1002/prot.1145; Mockus SM, 1998, J MOL NEUROSCI, V10, P163, DOI 10.1007/BF02761772; Mockus SM, 1997, J MOL NEUROSCI, V9, P35, DOI 10.1007/BF02789393; Patel PD, 2004, BIOL PSYCHIAT, V55, P428, DOI 10.1016/j.biopsych.2003.09.002; REED GE, 1995, BRAIN RES, V682, P1, DOI 10.1016/0006-8993(95)00284-W; REINHARD JF, 1986, LIFE SCI, V39, P2185, DOI 10.1016/0024-3205(86)90395-4; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; Sakowski SA, 2006, J NEUROCHEM, V96, P758, DOI 10.1111/j.1471-4159.2005.03604.x; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Teodorescu O, 2004, PROTEINS, V54, P41, DOI 10.1002/prot.10474; Tinti C, 1997, J BIOL CHEM, V272, P19158, DOI 10.1074/jbc.272.31.19158; Tobi D, 2000, PROTEINS, V41, P40, DOI 10.1002/1097-0134(20001001)41:1<40::AID-PROT70>3.0.CO;2-U; VRANA KE, 1994, J NEUROCHEM, V63, P2014; VRANA SL, 1993, J NEUROSCI METH, V48, P123, DOI 10.1016/S0165-0270(05)80014-7; Walther DJ, 2003, BIOCHEM PHARMACOL, V66, P1673, DOI 10.1016/S0006-2952(03)00556-2; Walther DJ, 2003, CELL, V115, P851, DOI 10.1016/S0092-8674(03)01014-6; Walther DJ, 2003, SCIENCE, V299, P76, DOI 10.1126/science.1078197; Wang L, 2002, BIOCHEMISTRY-US, V41, P12569, DOI 10.1021/bi026561f; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8; Zhang XD, 2004, SCIENCE, V305, P217, DOI 10.1126/science.1097540; Zhang XD, 2005, NEURON, V45, P11, DOI 10.1016/j.neuron.2004.12.014; Zhou ZF, 2005, ARCH GEN PSYCHIAT, V62, P1109, DOI 10.1001/archpsyc.62.10.1109; Zill P, 2004, MOL PSYCHIATR, V9, P1030, DOI 10.1038/sj.mp.4001525	46	38	40	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28105	28112		10.1074/jbc.M602817200	http://dx.doi.org/10.1074/jbc.M602817200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16864580	hybrid			2022-12-25	WOS:000240534400048
J	Edwards, JC; Cohen, C; Xu, WB; Schlesinger, PH				Edwards, John C.; Cohen, Christopher; Xu, Weibing; Schlesinger, Paul H.			c-Src control of chloride channel support for osteoclast HCl transport and bone resorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; EXPRESS HIGH-LEVELS; IN-VITRO; MOLECULAR-CLONING; CELL BIOLOGY; CLIC FAMILY; ION-CHANNEL; KINASE; PROTEIN; P64	Bone degradation by osteoclasts depends upon active transport of hydrogen ions to solubilize bone mineral. This transport is supported by the parallel actions of a proton ATPase and a chloride channel located in the osteoclast ruffled membrane. We have previously identified a novel chloride channel, p62, which appears to be the avian counterpart to CLIC-5b and is expressed coincident with the appearance of acid secretion as avian osteoclasts differentiate in culture. In this article, we show that suppression of CLIC-5b in differentiating avian osteoclasts results in decreased acidification by vesicles derived from these cells and decreased ability of the cells to resorb bone. Acidification is rescued by the presence of valinomycin, consistent with a selective loss of chloride channel but not proton pump activity. Osteoclast bone resorption is known to be dependent on the expression of the tyrosine kinase, c-Src. We show that CLIC-5b from osteoclasts has affinity for both Src SH2 and SH3 domains. We find that suppression of expression of Src in developing osteoclasts results in decreased vesicular acidification, which is rescued by valinomycin, consistent with the loss of chloride conductance in the proton pump-containing vesicles. Suppression of c-Src causes no change in the steady state level of CLIC-5b expression, but does result in failure of proton pump and CLIC-5b to colocalize in cultured osteoclast precursors. We conclude that suppression of c-Src interferes with osteoclast bone resorption by disrupting functional co-localization of proton pump and CLIC-5b.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Kidney Ctr, Chapel Hill, NC 27599 USA; St Louis Univ, Sch Med, Dept Med, St Louis, MO 63104 USA	Washington University (WUSTL); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Saint Louis University	Schlesinger, PH (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA.	paul@cellbiology.wustl.edu	Schlesinger, Paul H/C-6049-2012		NIAMS NIH HHS [R01 AR046539, AR4653904] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046539] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AbuAmer Y, 1997, J CELL BIOL, V137, P247, DOI 10.1083/jcb.137.1.247; ALVAREZ JI, 1991, ENDOCRINOLOGY, V128, P2324, DOI 10.1210/endo-128-5-2324; ARNETT TR, 1987, ENDOCRINOLOGY, V120, P602, DOI 10.1210/endo-120-2-602; Ashley RH, 2003, MOL MEMBR BIOL, V20, P1, DOI 10.1080/09687680210042746; BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BARRY ELR, 1993, BIOTECHNIQUES, V15, P1016; Bastani B, 1996, CALCIFIED TISSUE INT, V58, P332, DOI 10.1007/s002239900054; Berryman M, 2004, J BIOL CHEM, V279, P34794, DOI 10.1074/jbc.M402835200; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BLAIR HC, 1990, BIOCHEM BIOPH RES CO, V171, P920, DOI 10.1016/0006-291X(90)90771-E; Blair HC, 2004, J BONE MINER RES, V19, P1329, DOI 10.1359/JBMR.040403; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; Blair HC, 2002, BIOCHEM J, V364, P329, DOI 10.1042/BJ20020165; BLAIR HC, 1991, AM J PHYSIOL, V260, pC1315, DOI 10.1152/ajpcell.1991.260.6.C1315; Blair HC, 1996, J CELL BIOCHEM, V61, P629, DOI 10.1002/(SICI)1097-4644(19960616)61:4<629::AID-JCB17>3.0.CO;2-A; Boyce BF, 1999, LAB INVEST, V79, P83; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Bruzzaniti A, 2005, MOL BIOL CELL, V16, P3301, DOI 10.1091/mbc.e04-12-1117; CARANO A, 1990, J CLIN INVEST, V85, P456, DOI 10.1172/JCI114459; Chellaiah M, 1998, J BIOL CHEM, V273, P11908, DOI 10.1074/jbc.273.19.11908; Chellaiah MA, 2005, J BIOL CHEM, V280, P32930, DOI 10.1074/jbc.M500154200; Cho GY, 2003, SCIENCE, V300, P1123, DOI 10.1126/science.1078470; Chuang JZ, 1999, J NEUROSCI, V19, P2919; Clerc S, 1998, ANAL BIOCHEM, V259, P104, DOI 10.1006/abio.1998.2639; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; DEMPSTER DW, 1987, J BONE MINER RES, V2, P443; Destaing O, 2005, J CELL SCI, V118, P2901, DOI 10.1242/jcs.02425; Duncan RR, 1997, J BIOL CHEM, V272, P23880, DOI 10.1074/jbc.272.38.23880; Edwards JC, 2000, J BIOL CHEM, V275, P31826, DOI 10.1074/jbc.M005275200; Edwards JC, 1998, J MEMBRANE BIOL, V163, P119; Fernandez-Salas E, 1999, J BIOL CHEM, V274, P36488, DOI 10.1074/jbc.274.51.36488; Grabe M, 2001, J GEN PHYSIOL, V117, P329, DOI 10.1085/jgp.117.4.329; Harrison SC, 2003, CELL, V112, P737, DOI 10.1016/S0092-8674(03)00196-X; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; Hayashi T, 1999, NATURE, V397, P72, DOI 10.1038/16269; Heiss NS, 1997, GENOMICS, V45, P224, DOI 10.1006/geno.1997.4922; Henriksen K, 2004, AM J PATHOL, V164, P1537, DOI 10.1016/S0002-9440(10)63712-1; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; Inoue M, 1999, CELL TISSUE RES, V298, P527; Jentsch TJ, 2005, ANNU REV PHYSIOL, V67, P779, DOI 10.1146/annurev.physiol.67.032003.153245; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Kasper D, 2005, EMBO J, V24, P1079, DOI 10.1038/sj.emboj.7600576; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; KONG YY, 1999, NATURE, V345, P442; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; LANDRY D, 1993, J BIOL CHEM, V268, P14948; LEE B, 1996, AM J PHYSIOL, pC382; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Lepple-Wienhues A, 1998, J CELL BIOL, V141, P281, DOI 10.1083/jcb.141.1.281; Li XH, 2002, ANNU REV PHYSIOL, V64, P609, DOI 10.1146/annurev.physiol.64.090501.145429; MATTSSON JP, 1994, J BIOL CHEM, V269, P24979; Mattsson JP, 2000, EUR J BIOCHEM, V267, P4115, DOI 10.1046/j.1432-1327.2000.01445.x; Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200; NAKAMURA I, 1995, FEBS LETT, V361, P79, DOI 10.1016/0014-5793(95)00153-Z; Nakamura I, 2003, J ELECTRON MICROSC, V52, P527, DOI 10.1093/jmicro/52.6.527; Neuman W.F., 1958, CHEM DYNAMICS BONE M; Nishizawa T, 2000, J BIOL CHEM, V275, P11164, DOI 10.1074/jbc.275.15.11164; ORCHARD PJ, 2002, AM SOC BONE MINER RE, pSA390; Picollo A, 2005, NATURE, V436, P420, DOI 10.1038/nature03720; PRALLET B, 1992, J BONE MINER RES, V7, P405; Recchia I, 2004, BONE, V34, P65, DOI 10.1016/j.bone.2003.06.004; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301-472X(99)00061-2; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Sahni M, 1996, J BIOL CHEM, V271, P33141, DOI 10.1074/jbc.271.51.33141; Saltel F, 2004, MOL BIOL CELL, V15, P5231, DOI 10.1091/mbc.E04-06-0522; Scheel O, 2005, NATURE, V436, P424, DOI [10.1038/nature03860, 10.1038/nature0386O]; SCHLESINGER P, 1994, MINER ELECTOLYTE MET, P31; Schlesinger PH, 1997, J BIOL CHEM, V272, P18636, DOI 10.1074/jbc.272.30.18636; Shanks RA, 2002, J BIOL CHEM, V277, P40973, DOI 10.1074/jbc.M112277200; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; Sobacchi C, 2001, HUM MOL GENET, V10, P1767, DOI 10.1093/hmg/10.17.1767; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; SUNDQUIST K, 1990, BIOCHEM BIOPH RES CO, V168, P309, DOI 10.1016/0006-291X(90)91709-2; Szabo I, 1998, P NATL ACAD SCI USA, V95, P6169, DOI 10.1073/pnas.95.11.6169; TANAKA S, 1992, FEBS LETT, V313, P85, DOI 10.1016/0014-5793(92)81190-W; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; Tulk BM, 2002, AM J PHYSIOL-CELL PH, V282, pC1103, DOI 10.1152/ajpcell.00402.2001; Vaananen HK, 2000, J CELL SCI, V113, P377; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; Warton K, 2002, J BIOL CHEM, V277, P26003, DOI 10.1074/jbc.M203666200; XING L, 1996, J BONE MINER RES, V11, P40; Xing LP, 2001, GENE DEV, V15, P241, DOI 10.1101/gad.840301; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YONEDA T, 1993, J CLIN INVEST, V91, P2791, DOI 10.1172/JCI116521; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	92	44	45	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28011	28022		10.1074/jbc.M605865200	http://dx.doi.org/10.1074/jbc.M605865200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16831863	Green Submitted, Green Accepted, hybrid			2022-12-25	WOS:000240534400038
J	Li, XF; Chen, YS; Liu, YW; Gao, J; Gao, F; Bartlam, M; Wu, JY; Rao, ZH				Li, Xiaofeng; Chen, Yushu; Liu, Yiwei; Gao, Jia; Gao, Feng; Bartlam, Mark; Wu, Jane Y.; Rao, Zihe			Structural basis of robo proline-rich motif recognition by the srGAP1 Src homology 3 domain in the slit-robo signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTORS; GTPASE-ACTIVATING PROTEINS; TERMINAL SH3 DOMAIN; AXON GUIDANCE; RHO-GTPASES; ROUNDABOUT RECEPTOR; NEURONAL MORPHOGENESIS; TYROSINE KINASE; CNS MIDLINE; BINDING	The Slit-Robo (sr) GTPase-activating protein (GAPs) are important components in the intracellular pathway mediating Slit-Robo signaling in axon guidance and cell migration. We report the first crystal structure of the srGAP1 SH3 domain at 1.8-angstrom resolution. The unusual side chain conformation of the conserved Phe-13 in the P1 pocket renders the ligand binding pocket shallow and narrow, which contributes toward the low binding affinity. Moreover, the opposing electrostatic charge and the hydrophobic properties of the P3 specificity pocket are consistent with the observed binding characteristics of the srGAP1 SH3 domain to its ligand. Surface plasmon resonance experiments indicate that the srGAP1 SH3 domain interacts with its natural ligand in a C to N orientation. The srGAP1 SH3 domain can bind to both the CC2 and CC3 motifs in vitro. The N-terminal two acidic residues in the CC3 motif recognition site are necessary for srGAP1 SH3 domain binding. A longer CC3 peptide (CC3-FL) binds with greater affinity than its shorter counterpart, suggesting that the residues surrounding the proline-rich core are important for protein-peptide interactions. Our study reveals previously unknown properties of the srGAP-Robo interaction. Our data provide a structural basis for the srGAP-Robo interaction, consistent with the role of the Robo intracellular domain in interacting with other downstream signaling molecules and mediating versatile and dynamic responses to axon guidance and cell migration cues.	Chinese Acad Sci, Inst Biophys, Natl lab Biomacromol, Beijing 100101, Peoples R China; Nankai Univ, Tianjin 300071, Peoples R China; Tsinghua Univ, Tsinghua Nankai IBP Joint Res Grp Struct Biol, Beijing 100084, Peoples R China; Northwestern Univ, Feinberg Sch Med, Lurie Canc Ctr, Dept Neurol, Chicago, IL 60611 USA	Chinese Academy of Sciences; Institute of Biophysics, CAS; Nankai University; Tsinghua University; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Wu, JY (corresponding author), Chinese Acad Sci, Inst Biophys, Natl lab Biomacromol, Beijing 100101, Peoples R China.	jane-wu@northwestern.edu	Rao, Zihe/HCH-6944-2022; Li, Xiaofeng/F-3735-2011	Bartlam, Mark/0000-0001-5173-5080	NATIONAL CANCER INSTITUTE [R01CA114197] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070967] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA114197-01A2, R01 CA114197] Funding Source: Medline; NEI NIH HHS [R01 EY014576-03, R01 EY014576] Funding Source: Medline; NIGMS NIH HHS [R01 GM070967-02, R01 GM070967] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Bear JE, 2001, CURR OPIN CELL BIOL, V13, P158, DOI 10.1016/S0955-0674(00)00193-9; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAN AWE, 1993, PROTEIN SCI, V2, P1574, DOI 10.1002/pro.5560021004; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fan XP, 2003, NEURON, V40, P113, DOI 10.1016/S0896-6273(03)00591-9; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; Garbe DS, 2004, CRIT REV BIOCHEM MOL, V39, P319, DOI 10.1080/10409230490906797; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Hsouna A, 2003, J NEUROBIOL, V57, P15, DOI 10.1002/neu.10232; Hu HL, 2005, P NATL ACAD SCI USA, V102, P4613, DOI 10.1073/pnas.0409325102; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Larson SM, 2000, PROTEIN SCI, V9, P2170, DOI 10.1110/ps.9.11.2170; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li XF, 2006, BIOCHEM BIOPH RES CO, V339, P407, DOI 10.1016/j.bbrc.2005.10.212; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Lundstrom A, 2004, GENE DEV, V18, P2161, DOI 10.1101/gad.310204; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Luo LQ, 2002, ANNU REV CELL DEV BI, V18, P601, DOI 10.1146/annurev.cellbio.18.031802.150501; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Martinez JC, 1998, NAT STRUCT BIOL, V5, P721, DOI 10.1038/1418; Mayer BJ, 2001, J CELL SCI, V114, P1253; MERILAINEN J, 1993, J CELL SCI, V105, P647; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patel BN, 2002, CURR OPIN CELL BIOL, V14, P221, DOI 10.1016/S0955-0674(02)00308-3; Rao Y, 2002, GENE DEV, V16, P2973, DOI 10.1101/gad.1005802; Rotter B, 2005, BIOCHEM J, V388, P631, DOI 10.1042/BJ20041502; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Shin IJ, 1997, J AM CHEM SOC, V119, P12667, DOI 10.1021/ja972820q; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Yu TW, 2002, NAT NEUROSCI, V5, P1147, DOI 10.1038/nn956; Zallen JA, 1998, CELL, V92, P217, DOI 10.1016/S0092-8674(00)80916-2	44	28	29	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28430	28437		10.1074/jbc.M604135200	http://dx.doi.org/10.1074/jbc.M604135200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16857672	hybrid, Green Accepted			2022-12-25	WOS:000240534400080
J	Yang, CD; McDonald, JG; Patel, A; Zhang, Y; Umetani, M; Xu, F; Westover, EJ; Covey, DF; Mangelsdorf, DJ; Cohen, JC; Hobbs, HH				Yang, Chendong; McDonald, Jeffrey G.; Patel, Amit; Zhang, Yuan; Umetani, Michihisa; Xu, Fang; Westover, Emily J.; Covey, Douglas F.; Mangelsdorf, David J.; Cohen, Jonathan C.; Hobbs, Helen H.			Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-1C; FATTY-ACID SYNTHESIS; HAMSTER OVARY CELLS; LXR-ALPHA; NUCLEAR RECEPTOR; RESPONSE PATHWAY; GENE-EXPRESSION; PLANT STEROLS; MICE; ACTIVATION	The liver X receptors (LXRs) are ligand-activated transcription factors that regulate the expression of genes controlling lipid metabolism. Oxysterols bind LXRs with high affinity in vitro and are implicated as ligands for the receptor. We showed previously that accumulation of selected dietary sterols, in particular stigmasterol, is associated with activation of LXR in vivo. In the course of the defining of structural features of stigmasterol that confer LXR agonist activity, we determined that the presence of an unsaturated bond in the side chain of the sterol was necessary and sufficient for activity, with the C-24 unsaturated cholesterol precursor sterols desmosterol and zymosterol exerting the largest effects. Desmosterol failed to increase expression of the LXR target gene, ABCA1, in LXR alpha/beta-deficient mouse fibroblasts, but was fully active in cells lacking cholesterol 24-, 25-, and 27-hydroxylase; thus, the effect of desmosterol was LXR-dependent and did not require conversion to a side chain oxysterol. Desmosterol bound to purified LXR alpha and LXR beta in vitro and supported the recruitment of steroid receptor coactivator 1. Desmosterol also inhibited processing of the sterol response element-binding protein-2 and reduced expression of hydroxymethylglutaryl-CoA reductase. These observations are consistent with specific intermediates in the cholesterol biosynthetic pathway regulating lipid homeostasis through both the LXR and sterol response element-binding protein pathways.	Univ Texas, SW Med Ctr, Ctr Human Nutr, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Washington University (WUSTL)	Cohen, JC (corresponding author), Univ Texas, SW Med Ctr, Ctr Human Nutr, Dallas, TX 75390 USA.	jonathan.cohen@utsouthwestern.edu; jonathan.cohen@utsouthwestern.edu	Umetani, Michi/AAP-3964-2020	Umetani, Michi/0000-0001-8474-7088; Mangelsdorf, David/0000-0002-4355-0796	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL072304, R01HL072304, P01HL020948, T32HL007275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM069338, P01GM047969] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL72304, T32 HL07275, HL20948] Funding Source: Medline; NIDDK NIH HHS [R01 DK090066] Funding Source: Medline; NIGMS NIH HHS [GM069338, GM47969] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberti S, 2000, GENE, V243, P93, DOI 10.1016/S0378-1119(99)00555-7; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Chen GX, 2004, P NATL ACAD SCI USA, V101, P11245, DOI 10.1073/pnas.0404297101; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; Fowler AJ, 2003, J INVEST DERMATOL, V120, P246, DOI 10.1046/j.1523-1747.2003.12033.x; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; HERZ J, 1990, J BIOL CHEM, V265, P21355; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Joseph SB, 2004, CELL, V119, P299, DOI 10.1016/j.cell.2004.09.032; Kennedy MA, 2001, J BIOL CHEM, V276, P39438, DOI 10.1074/jbc.M105863200; Laffitte BA, 2003, P NATL ACAD SCI USA, V100, P5419, DOI 10.1073/pnas.0830671100; Lange Y, 2004, P NATL ACAD SCI USA, V101, P11664, DOI 10.1073/pnas.0404766101; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; LISCUM L, 1983, J BIOL CHEM, V258, P8450; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Lund EG, 2003, J BIOL CHEM, V278, P22980, DOI 10.1074/jbc.M303415200; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; Pulfer MK, 2005, J PHARMACOL EXP THER, V312, P256, DOI 10.1124/jpet.104.073437; Rawson RB, 1999, J BIOL CHEM, V274, P28549, DOI 10.1074/jbc.274.40.28549; Rawson RB, 1998, J BIOL CHEM, V273, P28261, DOI 10.1074/jbc.273.43.28261; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805; Russell DW, 2000, BBA-MOL CELL BIOL L, V1529, P126, DOI 10.1016/S1388-1981(00)00142-6; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Sever N, 2004, J BIOL CHEM, V279, P43136, DOI 10.1074/jbc.M406406200; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Spencer TA, 2001, J MED CHEM, V44, P886, DOI 10.1021/jm0004749; Sun Y, 2003, J BIOL CHEM, V278, P5813, DOI 10.1074/jbc.M208687200; Svensson S, 2003, EMBO J, V22, P4625, DOI 10.1093/emboj/cdg456; Valledor AF, 2004, P NATL ACAD SCI USA, V101, P17813, DOI 10.1073/pnas.0407749101; Westover EJ, 2004, J MEMBRANE BIOL, V202, P61, DOI 10.1007/s00232-004-0714-7; Westover EJ, 2003, STEROIDS, V68, P159, DOI 10.1016/S0039-128X(02)00174-5; Wiebel FF, 1999, MOL ENDOCRINOL, V13, P1105, DOI 10.1210/me.13.7.1105; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Wilund KR, 2004, ARTERIOSCL THROM VAS, V24, P2326, DOI 10.1161/01.ATV.0000149140.00499.92; Yang CD, 2004, J CLIN INVEST, V114, P813, DOI 10.1172/JCI200422186; Yang J, 2001, P NATL ACAD SCI USA, V98, P13607, DOI 10.1073/pnas.201524598; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001; Yu LQ, 2004, J LIPID RES, V45, P301, DOI 10.1194/jlr.M300377-JLR200; Yu LQ, 2003, J BIOL CHEM, V278, P15565, DOI 10.1074/jbc.M301311200	50	200	210	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27816	27826		10.1074/jbc.M603781200	http://dx.doi.org/10.1074/jbc.M603781200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16857673	hybrid			2022-12-25	WOS:000240534400017
J	Yang, MY; Horii, K; Herr, AB; Kirley, TL				Yang, Mingyan; Horii, Katsunori; Herr, Andrew B.; Kirley, Terence L.			Calcium-dependent dimerization of human soluble calcium activated nucleotidase - Characterization of the dimer interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BRAIN ECTO-APYRASE; E-TYPE ATPASES; ENDOPLASMIC-RETICULUM; MACROMOLECULAR STRUCTURES; BACTERIAL EXPRESSION; CLONING; RESIDUES; BINDING; ENZYME	Mammals express a protein homologous to soluble nucleotidases used by blood-sucking insects to inhibit host blood clotting. These vertebrate nucleotidases may play a role in protein glycosylation. The activity of this enzyme family is strictly dependent on calcium, which induces a conformational change in the secreted, soluble human nucleotidase. The crystal structure of this human enzyme was recently solved; however, the mechanism of calcium activation and the basis for the calcium-induced changes remain unclear. In this study, using analytical ultracentrifugation and chemical cross-linking, we show that calcium or strontium induce noncovalent dimerization of the soluble human enzyme. The location and nature of the dimer interface was elucidated using a combination of site-directed mutagenesis and chemical cross-linking, coupled with crystallographic analyses. Replacement of Ile(170), Ser(172), and Ser(226) with cysteine residues resulted in calcium-dependent, sulfhydryl-specific intermolecular cross- linking, which was not observed after cysteine introduction at other surface locations. Analysis of a super-active mutant, E130Y,revealed that this mutant dimerized more readily than the wild-type enzyme. The crystal structure of the E130Y mutant revealed that the mutated residue is found in the dimer interface. In addition, expression of the full-length nucleotidase revealed that this membrane-bound form can also dimerize and that these dimers are stabilized by spontaneous oxidative cross- linking of Cys(30), located between the single transmembrane helix and the start of the soluble sequence. Thus, calcium-mediated dimerization may also represent a mechanism for regulation of the activity of this nucleotidase in the physiological setting of the endoplasmic reticulum or Golgi.	Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Kirley, TL (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	terry.kirley@uc.edu	Herr, Andrew/R-3049-2019	Herr, Andrew/0000-0002-3598-3399; Kirley, Terence/0000-0002-6211-1414	NHLBI NIH HHS [HL72882] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Burdakov D, 2005, CELL CALCIUM, V38, P303, DOI 10.1016/j.ceca.2005.06.010; CHAMPAGNE DE, 1995, P NATL ACAD SCI USA, V92, P694, DOI 10.1073/pnas.92.3.694; Dai JY, 2004, CELL, V116, P649, DOI 10.1016/S0092-8674(04)00172-2; Ellgaard L, 2004, BIOCHEM SOC T, V32, P663, DOI 10.1042/BST0320663; Failer BU, 2002, J BIOL CHEM, V277, P36978, DOI 10.1074/jbc.M201656200; Fiske CH, 1925, J BIOL CHEM, V66, P375; Herr AB, 2003, J MOL BIOL, V327, P645, DOI 10.1016/S0022-2836(03)00149-9; Ivanenkov VV, 2003, BIOCHEMISTRY-US, V42, P11726, DOI 10.1021/bi035137r; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Mans BJ, 1998, EXP APPL ACAROL, V22, P353, DOI 10.1023/A:1024517209621; Murphy DM, 2003, BIOCHEMISTRY-US, V42, P2412, DOI 10.1021/bi026763b; Murphy DM, 2002, J BIOL CHEM, V277, P6162, DOI 10.1074/jbc.M110105200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Salerno WJ, 2004, NUCLEIC ACIDS RES, V32, pW566, DOI 10.1093/nar/gkh434; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Smith Thomas M, 2006, Purinergic Signal, V2, P327, DOI 10.1007/s11302-005-5300-7; Smith TM, 1999, BIOCHEMISTRY-US, V38, P5849, DOI 10.1021/bi990171k; Smith TM, 1998, BBA-PROTEIN STRUCT M, V1386, P65, DOI 10.1016/S0167-4838(98)00063-6; Smith TM, 1999, BIOCHEMISTRY-US, V38, P321, DOI 10.1021/bi9820457; Smith TM, 2002, ARCH BIOCHEM BIOPHYS, V406, P105, DOI 10.1016/S0003-9861(02)00420-4; STOSCHECK CM, 1990, ANAL BIOCHEM, V184, P111, DOI 10.1016/0003-2697(90)90021-Z; Valenzuela JG, 1998, J BIOL CHEM, V273, P30583, DOI 10.1074/jbc.273.46.30583; Van Baelen K, 2004, BBA-MOL CELL RES, V1742, P103, DOI 10.1016/j.bbamcr.2004.08.018; Yang MY, 2004, BIOCHEMISTRY-US, V43, P9185, DOI 10.1021/bi049565o	24	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28307	28317		10.1074/jbc.M604413200	http://dx.doi.org/10.1074/jbc.M604413200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16835225	hybrid			2022-12-25	WOS:000240534400068
J	Finkielstein, CV; Overduin, M; Capelluto, DGS				Finkielstein, Carla V.; Overduin, Michael; Capelluto, Daniel G. S.			Cell migration and signaling specificity is determined by the phosphatidylserine recognition motif of Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-CASCADE ACTIVATION; RHO-GTPASES; NUCLEAR-LOCALIZATION; PROTEIN INTERACTIONS; CRYSTAL-STRUCTURE; REGULATED KINASE; MEMBRANE-BINDING; POLYBASIC REGION; NADPH OXIDASE; RAF-1 KINASE	dThe Rho guanosine triphosphatases (GTPases) control cell shape and motility and are frequently overexpressed during malignant growth. These proteins act as molecular switches cycling between active GTP- and inactive GDP-bound forms. Despite being membrane anchored via their isoprenylated C-termini, Rho GTPases rapidly translocate between membrane and cytosolic compartments. Here, we show that the Rho GTPase Rac1 preferentially interacts with phosphatidylserine (PS)-containing bilayers through its polybasic motif (PBM). Rac1 isoprenylation contributes to membrane avidity but is not critical for PS recognition. The similar protein Cdc42 (cell division cycle 42), however, only associates with PS when prenylated. Conversely, other Rho GTPases such as Rac2, Rac3, and RhoA do not bind to PS even when they are prenylated. Cell stimulation with PS induces translocation of Rac1 toward the plasma membrane and stimulates GTP loading, membrane ruffling, and filopodia formation. This stimulation also promotes Cdc42 activation and phosphorylation of mitogen-activated protein kinase through Rac1/PS signaling. Consequently, the PBM specifically directs Rac1 to effect cytoskeletal rearrangement and cell migration by selective membrane phospholipid targeting.	Virginia Polytech Inst & State Univ, Dept Chem, Blacksburg, VA 24061 USA; Virginia Polytech Inst & State Univ, Dept Biol Sci, Blacksburg, VA 24061 USA; Univ Birmingham, CR UK Inst Canc Studies, Sch Med, Birmingham B15 2TT, W Midlands, England	Virginia Polytechnic Institute & State University; Virginia Polytechnic Institute & State University; University of Birmingham	Capelluto, DGS (corresponding author), Virginia Polytech Inst & State Univ, Dept Chem, Blacksburg, VA 24061 USA.	capellut@vt.edu	Overduin, Michael/AAG-3632-2020	Overduin, Michael/0000-0002-3114-6585; finkielstein, carla/0000-0002-8417-4643	Biotechnology and Biological Sciences Research Council [BBS/B/10714] Funding Source: Medline; Cancer Research UK [A4592] Funding Source: Medline; Wellcome Trust [071684] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission)		Allan D, 1996, MOL MEMBR BIOL, V13, P81, DOI 10.3109/09687689609160580; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; Capelluto DGS, 2002, NATURE, V419, P726, DOI 10.1038/nature01056; Capelluto DGS, 2005, J BIOCHEM MOL BIOL, V38, P243; Casamayor A, 2003, MOL CELL BIOL, V23, P2762, DOI 10.1128/MCB.23.8.2762-2777.2003; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Coles LC, 2002, ONCOGENE, V21, P2236, DOI 10.1038/sj.onc.1205302; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Elliott JI, 2005, NAT CELL BIOL, V7, P808, DOI 10.1038/ncb1279; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; FUCHS A, 1994, EUR J BIOCHEM, V226, P587, DOI 10.1111/j.1432-1033.1994.tb20084.x; Gadella BM, 2002, BIOL REPROD, V67, P340, DOI 10.1095/biolreprod67.1.340; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; Harding A, 2003, J BIOL CHEM, V278, P16747, DOI 10.1074/jbc.M301015200; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Holt KH, 1996, MOL CELL BIOL, V16, P577; Lanning CC, 2004, J BIOL CHEM, V279, P44197, DOI 10.1074/jbc.M404977200; Ligeti E, 2004, J BIOL CHEM, V279, P5055, DOI 10.1074/jbc.C300547200; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser Edward J, 2002, Methods Mol Biol, V189, P3; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Nadkarni V, 1999, J BIOL CHEM, V274, P20185, DOI 10.1074/jbc.274.29.20185; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; Thapar R, 2002, BIOCHEMISTRY-US, V41, P3875, DOI 10.1021/bi0120087; van Hennik PB, 2003, J BIOL CHEM, V278, P39166, DOI 10.1074/jbc.M307001200; Vance JE, 2005, PROG LIPID RES, V44, P207, DOI 10.1016/j.plipres.2005.05.001; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Williams CL, 2003, CELL SIGNAL, V15, P1071, DOI 10.1016/S0898-6568(03)00098-6; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zhao RX, 2003, J BIOL CHEM, V278, P22609, DOI 10.1074/jbc.M301560200; Zwaal RFA, 1998, BBA-REV BIOMEMBRANES, V1376, P433, DOI 10.1016/S0304-4157(98)00018-5	42	45	45	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27317	27326		10.1074/jbc.M605560200	http://dx.doi.org/10.1074/jbc.M605560200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16861229	hybrid			2022-12-25	WOS:000240397700058
J	Han, W; Nattel, S; Noguchi, T; Shrier, A				Han, Wei; Nattel, Stanley; Noguchi, Tomohiro; Shrier, Alvin			C-terminal domain of Kv4.2 and associated KChIP2 interactions regulate functional expression and gating of Kv4.2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIPPOCAMPAL PYRAMIDAL NEURONS; TRANSIENT OUTWARD CURRENT; POTASSIUM CHANNELS; K+ CHANNEL; CRYSTAL-STRUCTURE; T1 DOMAIN; I-TO; SUBUNIT; FAMILY; CANINE	The Kv4.2 transient voltage-dependent potassium current contributes to the morphology of the cardiac action potential as well as to neuronal excitability and firing frequency. Here we report profound effects of the Kv4.2 C terminus on the surface expression and activation gating properties of Kv4.2 that are modulated by the direct interaction between KChIP2, an auxiliary regulatory subunit, and the C terminus of Kv4.2. We show that increasingly large truncations of the C terminus of rat Kv4.2 (wild type) cause a progressive decrease of Kv4.2 current along with a shift in voltage-dependent activation that is closely correlated with negative charge deletion. Co-expression of more limited Kv4.2 C-terminal truncation mutants (T588 and T528) with KChIP2 results in a doubling of Kv4.2 protein expression and up to an 8-fold increase in Kv4.2 current amplitude. Pulse-chase experiments show that co-expression with KChIP2 slows Kv4.2 wild type degradation 8-fold. Co-expression of KChIP2 with an intermediate-length C-terminal truncation mutant (T474) shifts Kv4.2 activation voltage dependence and enhances expression of Kv4.2 current. The largest truncation mutants (T417 and Delta C) show an intracellular localization with no measurable currents and no response to KChIP2 co-expression. Co-immunoprecipitation and competitive glutathione S-transferase-binding assays indicate a direct interaction between KChIP2 and the Kv4.2 C terminus with a relative binding affinity comparable with that of the N terminus. Overall, these results suggest that the C-terminal domain of Kv4.2 plays a critical role in voltage-dependent activation and functional expression that is mediated by direct interaction between the Kv4.2 C terminus and KChIP2.	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; Montreal Heart Inst, Dept Med, Montreal, PQ H1T 1C8, Canada; Univ Montreal, Montreal, PQ H1T 1C8, Canada	McGill University; McGill University; Universite de Montreal; Universite de Montreal	Shrier, A (corresponding author), McGill Univ, Dept Physiol, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	alvin.shrier@mcgill.ca	Noguchi, Tomohiro/B-6185-2011	Nattel, Stanley/0000-0002-5565-3311; Noguchi, Tomohiro/0000-0002-9354-9793				Akhavan A, 2003, J BIOL CHEM, V278, P40105, DOI 10.1074/jbc.M307837200; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Bahring R, 2001, J BIOL CHEM, V276, P23888, DOI 10.1074/jbc.M101320200; Barry DM, 1998, CIRC RES, V83, P560, DOI 10.1161/01.RES.83.5.560; Birnbaum SG, 2004, PHYSIOL REV, V84, P803, DOI 10.1152/physrev.00039.2003; Callsen B, 2005, J PHYSIOL-LONDON, V568, P397, DOI 10.1113/jphysiol.2005.094359; Cushman SJ, 2000, NAT STRUCT BIOL, V7, P403; Dobson CM, 2004, SEMIN CELL DEV BIOL, V15, P3, DOI 10.1016/j.semcdb.2003.12.008; Han W, 2002, CIRC RES, V91, P790, DOI 10.1161/01.RES.0000039534.18114.D9; Hatano N, 2004, J BIOL CHEM, V279, P5450, DOI 10.1074/jbc.M302034200; Hoffman DA, 1997, NATURE, V387, P869, DOI 10.1038/43119; Jerng HH, 1997, BIOPHYS J, V72, P163, DOI 10.1016/S0006-3495(97)78655-7; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Johnston D, 2000, J PHYSIOL-LONDON, V525, P75, DOI 10.1111/j.1469-7793.2000.00075.x; Kim LA, 2004, NEURON, V41, P513, DOI 10.1016/S0896-6273(04)00050-9; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; Kunjilwar K, 2004, J BIOL CHEM, V279, P54542, DOI 10.1074/jbc.M409721200; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Kuo HC, 2001, CELL, V107, P801, DOI 10.1016/S0092-8674(01)00588-8; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Marten I, 1997, P NATL ACAD SCI USA, V94, P3448, DOI 10.1073/pnas.94.7.3448; Neyroud N, 2002, J MEMBRANE BIOL, V190, P133, DOI 10.1007/s00232-002-1033-5; Ohya S, 2001, LIFE SCI, V68, P1703, DOI 10.1016/S0024-3205(01)00958-4; Patel SP, 2002, J PHYSIOL-LONDON, V539, P649, DOI 10.1113/jphysiol.2001.015156; Petrecca K, 2000, J NEUROSCI, V20, P8736; Rivera JF, 2003, NAT NEUROSCI, V6, P243, DOI 10.1038/nn1020; Rosati B, 2001, J PHYSIOL-LONDON, V533, P119, DOI 10.1111/j.1469-7793.2001.0119b.x; Scannevin RH, 2004, NEURON, V41, P587, DOI 10.1016/S0896-6273(04)00049-2; Shibata R, 2003, J BIOL CHEM, V278, P36445, DOI 10.1074/jbc.M306142200; Sokolova O, 2003, P NATL ACAD SCI USA, V100, P12607, DOI 10.1073/pnas.2235650100; Strang C, 2001, J BIOL CHEM, V276, P28493, DOI 10.1074/jbc.M010540200; Turner GC, 2000, SCIENCE, V289, P2117, DOI 10.1126/science.289.5487.2117; Wickenden AD, 1999, AM J PHYSIOL-HEART C, V276, pH1599, DOI 10.1152/ajpheart.1999.276.5.H1599; Wong W, 2004, J BIOL CHEM, V279, P444, DOI 10.1074/jbc.M304675200; Yang EK, 2001, J BIOL CHEM, V276, P4839, DOI 10.1074/jbc.M004768200; Yi BA, 2001, P NATL ACAD SCI USA, V98, P11016, DOI 10.1073/pnas.191351798; Zicha S, 2004, J PHYSIOL-LONDON, V561, P735, DOI 10.1113/jphysiol.2004.075861	38	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27134	27144		10.1074/jbc.M604843200	http://dx.doi.org/10.1074/jbc.M604843200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16820361	hybrid			2022-12-25	WOS:000240397700041
J	Matsui, T; Kinoshita-Ida, Y; Hayashi-Kisumi, F; Hata, M; Matsubara, K; Chiba, M; Katahira-Tayama, S; Morita, K; Miyachi, Y; Tsukita, S				Matsui, Takeshi; Kinoshita-Ida, Yoko; Hayashi-Kisumi, Fumie; Hata, Masaki; Matsubara, Kaho; Chiba, Megumi; Katahira-Tayama, Sayaka; Morita, Kazumasa; Miyachi, Yoshiki; Tsukita, Shoichiro			Mouse homologue of skin-specific retroviral-like aspartic protease involved in wrinkle formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; STRATUM-CORNEUM; DIFFERENTIATION; KERATINOCYTE; PROTEINASES; INHIBITORS; IDENTIFICATION; DESQUAMATION; CHECKPOINT; EPIDERMIS	Retroviral proteases are encoded in the retroviral genome and are responsible for maturation and assembly of infectious virus particles. A number of retroviral protease sequences with retroviral elements are integrated in every eukaryoticgenomeas endogenous retroviruses. Recently, retroviral-like aspartic proteases that were not embedded within endogenous retroviral elements were identified throughout the eukaryotic and prokaryotic genomes. However, the physiological role of this novel protease family, especially in mammals, is not known. During the high throughput in situ hybridization screening of mouse epidermis, as a granular layer-expressing clone, we identified a mouse homologue of SASPase (SkinASparticProtease), a recently identified retroviral-like aspartic protease. We detected and purified the endogenous 32-kDa (mSASP32) and 15-kDa (mSASP15) forms of mSASP from mouse stratum corneum extracts and determined their amino acid sequences. Next, we bacterially produced recombinant mSASP15 via autoprocessing of GST-mSASP32. Purified recombinant mSASP15 cleaved a quenched fluorogenic peptide substrate, designed from the autoprocessing site for mSASP32 maximally at pH 5.77, which is close to the pH of the epidermal surface. Finally, we generated mSASP-deficient mice that at 5 weeks of age showed fine wrinkles that ran parallel on the lateral trunk without apparent epidermal differentiation defects. These results indicate that the retroviral-like aspartic protease, SASPase, is involved in prevention of fine wrinkle formation via activation in a weakly acidic stratum corneum environment. This study provides the first evidence that retroviral-like aspartic protease is functionally important in mammalian tissue organization.	KAN Res Inst Inc, Shimogyo Ku, Kyoto 6008815, Japan; Kyoto Univ, Grad Sch Med, Dept Dermatol, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Fac Med, Dept Cell Biol, Sakyo Ku, Kyoto 6068501, Japan	KAN Research Institute; Kyoto University; Kyoto University	Matsui, T (corresponding author), KAN Res Inst Inc, Shimogyo Ku, Sci Ctr Bldg 3,Kyoto Res Pk 93, Kyoto 6008815, Japan.	t-matui@kan.gr.jp	Matsui, Takeshi/C-4730-2017					ANDERSON DS, 1951, BRIT J DERMATOL, V63, P283, DOI 10.1111/j.1365-2133.1951.tb13728.x; Barret AJ, 1998, HDB PROTEOLYTIC ENZY; Bernard D, 2005, J INVEST DERMATOL, V125, P278, DOI 10.1111/j.0022-202X.2005.23816.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Christner PJ, 2006, J INVEST DERMATOL, V126, P595, DOI 10.1038/sj.jid.5700100; Clarke DJ, 2001, MOL CELL BIOL, V21, P1997, DOI 10.1128/MCB.21.6.1997-2007.2001; DARKE PL, 1994, METHOD ENZYMOL, V241, P104; DEBOUCK C, 1987, P NATL ACAD SCI USA, V84, P8903, DOI 10.1073/pnas.84.24.8903; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Elias PM, 2005, J INVEST DERMATOL, V125, P183, DOI 10.1111/j.0022-202X.2005.23668.x; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Gardner RD, 2000, TRENDS CELL BIOL, V10, P154, DOI 10.1016/S0962-8924(00)01727-X; Greiner EF, 2000, P NATL ACAD SCI USA, V97, P7160, DOI 10.1073/pnas.97.13.7160; Hashizume H, 2004, J DERMATOL, V31, P603, DOI 10.1111/j.1346-8138.2004.tb00565.x; HELEN CUT, 1994, METHOD ENZYMOL, V241, P46; IMAYAMA S, 1989, AM J PATHOL, V134, P1019; KLIGMAN AM, 1985, BRIT J DERMATOL, V113, P37, DOI 10.1111/j.1365-2133.1985.tb02042.x; Komiya T, 1997, ANAL BIOCHEM, V254, P23, DOI 10.1006/abio.1997.2399; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; Krylov DM, 2001, CURR BIOL, V11, pR584, DOI 10.1016/S0960-9822(01)00357-8; LORINCZ ALLAN L., 1960, ILLINOIS MED JOUR, V117, P59; Lower R, 1996, P NATL ACAD SCI USA, V93, P5177, DOI 10.1073/pnas.93.11.5177; Matsui T, 2004, GENOMICS, V84, P384, DOI 10.1016/j.ygeno.2004.03.010; Milstone LM, 2004, J DERMATOL SCI, V36, P131, DOI 10.1016/j.jdermsci.2004.05.004; Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a; OHMAN H, 1994, ACTA DERM-VENEREOL, V74, P375; Pierard GE, 2000, INT J MOL MED, V6, P217; Puente XS, 2004, GENOME RES, V14, P609, DOI 10.1101/gr.1946304; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; RAO JKM, 1991, BIOCHEMISTRY-US, V30, P4663, DOI 10.1021/bi00233a005; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Rawlings A. V., 2003, International Journal of Cosmetic Science, V25, P63, DOI 10.1046/j.1467-2494.2003.00174.x; SCHADE H., 1928, KLIN WOCHENSCHR, V7, P12, DOI 10.1007/BF01711684; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; TSUJI T, 1987, J CUTAN PATHOL, V14, P158, DOI 10.1111/j.1600-0560.1987.tb00491.x; TSUJI T, 1986, BRIT J DERMATOL, V114, P329, DOI 10.1111/j.1365-2133.1986.tb02824.x; Tsukahara K, 2001, J INVEST DERMATOL, V117, P671, DOI 10.1046/j.0022-202x.2001.01450.x; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; Weber J, 1997, ARCH BIOCHEM BIOPHYS, V341, P62, DOI 10.1006/abbi.1997.9945; WEISS R, 1985, RNA TUMORS VIRUSES; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a; Zeeuwen PLJM, 2004, EUR J CELL BIOL, V83, P761, DOI 10.1078/0171-9335-00388	45	24	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27512	27525		10.1074/jbc.M603559200	http://dx.doi.org/10.1074/jbc.M603559200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16837463	hybrid			2022-12-25	WOS:000240397700078
J	Gaidhu, MP; Fediuc, S; Ceddia, RB				Gaidhu, Mandeep Pinky; Fediuc, Sergiu; Ceddia, Rolando Bacis			5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside-induced AMP-activated protein kinase phosphorylation inhibits basal and insulin-stimulated glucose uptake, lipid synthesis, and fatty acid oxidation in isolated rat adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; SKELETAL-MUSCLE CELLS; MALONYL-COA; 3T3-L1 ADIPOCYTES; WHITE ADIPOCYTES; LEPTIN; AICAR; METABOLISM; TRANSPORT; ADIPOSITY	The objective of this study was to investigate the effects of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)-induced AMP-activated protein kinase (AMPK) activation on basal and insulin-stimulated glucose and fatty acid metabolism in isolated rat adipocytes. AICAR-induced AMPK activation profoundly inhibited basal and insulin-stimulated glucose uptake, lipogenesis, glucose oxidation, and lactate production in fat cells. We also describe the novel findings that AICAR-induced AMPK phosphorylation significantly reduced palmitate (32%) and oleate uptake (41%), which was followed by a 50% reduction in palmitate oxidation despite a marked increase in AMPK and acetyl-CoA carboxylase phosphorylation. Compound C, a selective inhibitor of AMPK, not only completely prevented the inhibitory effect of AICAR on palmitate oxidation but actually caused a 2.2-fold increase in this variable. Compound C also significantly increased palmitate oxidation in the presence of inhibitory concentrations of malonyl-CoA and etomoxir indicating an increase in CPT1 activity. In contrast to skeletal muscle in which AMPK stimulates fatty acid oxidation to provide ATP as a fuel, we propose that AMPK activation inhibits lipogenesis and fatty acid oxidation in adipocytes. Inhibition of lipogenesis would conserve ATP under conditions of cellular stress, although suppression of intra-adipocyte oxidation would spare fatty acids for exportation to other tissues where their utilization is crucial for energy production. Additionally, the stimulatory effect of compound C on long chain fatty acid oxidation provides a novel pharmacological approach to promote energy dissipation in adipocytes, which may be of therapeutic importance for obesity and type II diabetes.	York Univ, Sch Kinesiol & Hlth Sci, N York, ON M3J 1P3, Canada	York University - Canada	Ceddia, RB (corresponding author), York Univ, Sch Kinesiol & Hlth Sci, N York, ON M3J 1P3, Canada.	roceddia@yorku.ca						ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; Bonen A, 2004, P NUTR SOC, V63, P245, DOI 10.1079/PNS2004331; Campbell SE, 2004, J BIOL CHEM, V279, P36235, DOI 10.1074/jbc.M400566200; Ceddia RB, 2000, EUR J BIOCHEM, V267, P5952, DOI 10.1046/j.1432-1327.2000.01664.x; Ceddia RB, 2005, INT J OBESITY, V29, P1175, DOI 10.1038/sj.ijo.0803025; Ceddia RB, 2004, J PHYSIOL-LONDON, V555, P409, DOI 10.1113/jphysiol.2003.056291; Chien D, 2000, AM J PHYSIOL-ENDOC M, V279, pE259, DOI 10.1152/ajpendo.2000.279.2.E259; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; Daval M, 2005, J BIOL CHEM, V280, P25250, DOI 10.1074/jbc.M414222200; Fediuc S, 2006, J LIPID RES, V47, P412, DOI 10.1194/jlr.M500438-JLR200; Frayn KN, 2003, INT J OBESITY, V27, P875, DOI 10.1038/sj.ijo.0802326; Geelen MJH, 2005, ANAL BIOCHEM, V347, P1, DOI 10.1016/j.ab.2005.03.032; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Luiken JJFP, 2004, PFLUG ARCH EUR J PHY, V448, P1, DOI 10.1007/s00424-003-1199-4; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MOELLERING H, 1966, ANAL BIOCHEM, V17, P369, DOI 10.1016/0003-2697(66)90172-2; Moule SK, 1998, FEBS LETT, V439, P287, DOI 10.1016/S0014-5793(98)01392-1; Munday MR, 2002, BIOCHEM SOC T, V30, P1059, DOI 10.1042/bst0301059; MUNDAY MR, 1988, EUR J BIOCHEM, V175, P331, DOI 10.1111/j.1432-1033.1988.tb14201.x; OLEFSKY JM, 1978, BIOCHEM J, V172, P137, DOI 10.1042/bj1720137; Park H, 2002, J BIOL CHEM, V277, P32571, DOI 10.1074/jbc.M201692200; Pold R, 2005, DIABETES, V54, P928, DOI 10.2337/diabetes.54.4.928; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; Ruderman NB, 2003, ENDOCRINOLOGY, V144, P5166, DOI 10.1210/en.2003-0849; Salt IP, 2000, DIABETES, V49, P1649, DOI 10.2337/diabetes.49.10.1649; SELBY PL, 1989, TRENDS PHARMACOL SCI, V10, P495, DOI 10.1016/0165-6147(89)90049-7; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; Villena JA, 2004, DIABETES, V53, P2242, DOI 10.2337/diabetes.53.9.2242; William WN, 2002, J ENDOCRINOL, V175, P735, DOI 10.1677/joe.0.1750735; Yin W, 2003, J BIOL CHEM, V278, P43074, DOI 10.1074/jbc.M308484200; Yu X, 2004, DIABETOLOGIA, V47, P2012, DOI 10.1007/s00125-004-1570-9; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	35	95	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25956	25964		10.1074/jbc.M602992200	http://dx.doi.org/10.1074/jbc.M602992200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16816404	hybrid			2022-12-25	WOS:000240249500010
J	Meyer-Lipp, K; Sery, N; Ganea, C; Basquin, C; Fendler, K; Leblanc, G				Meyer-Lipp, Kerstin; Sery, Natacha; Ganea, Constanta; Basquin, Cecile; Fendler, Klaus; Leblanc, Gerard			The inner interhelix loop 4-5 of the melibiose permease from Escherichia coli takes part in conformational changes after sugar binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL OXALATE TRANSPORTER; TRANSFORM-INFRARED-SPECTROSCOPY; MEMBRANE-SPANNING SEGMENTS; RESONANCE ENERGY-TRANSFER; PROJECTION STRUCTURE; UNIDIRECTIONAL RECONSTITUTION; 3-DIMENSIONAL STRUCTURE; CHARGE TRANSLOCATION; ANGSTROM RESOLUTION; LACTOSE PERMEASE	Cytoplasmic loop 4-5 of the melibiose permease from Escherichia coli is essential for the process of Na+-sugar translocation (Abdel-Dayem, M., Basquin, C., Pourcher, T., Cordat, E., and Leblanc, G. (2003) J. Biol. Chem. 278, 1518-1524). In the present report, we analyze functional consequences of mutating each of the three acidic amino acids in this loop into cysteines. Among the mutants, only the E142C substitution impairs selectively Na+-sugar translocation. Because R141C has a similar defect, we investigated these two mutants in more detail. Liposomes containing purified mutated melibiose permease were adsorbed onto a solid supported lipid membrane, and transient electrical currents resulting from different substrate concentration jumps were recorded. The currents evoked by a melibiose concentration jump in the presence of Na+, previously assigned to an electrogenic conformational transition (Meyer-Lipp, K., Ganea, C., Pourcher, T., Leblanc, G., and Fendler, K. (2004) Biochemistry 43, 12606-12613), were much smaller for the two mutants than the corresponding signals in cysteineless MelB. Furthermore, in R141C the stimulating effect of melibiose on Na+ affinity was lost. Finally, whereas tryptophan fluorescence spectroscopy revealed impaired conformational changes upon melibiose binding in the mutants, fluorescence resonance energy transfer measurements indicated that the mutants still show cooperative modification of their sugar binding sites by Na+. These data suggest that: 1) loop 4-5 contributes to the coordinated interactions between the ion and sugar binding sites; 2) it participates in an electrogenic conformational transition after melibiose binding that is essential for the subsequent obligatory coupled translocation of substrates. A two-step mechanism for substrate translocation in the melibiose permease is suggested.	Max Planck Inst Biophys, D-60438 Frankfurt, Germany; Univ Nice Sophia Antipolis, CEA, LRC 16V, F-06230 Villefranche Sur Mer, France; Carol Davila Med Univ, Dept Biophys, Bucharest 050474, Romania; Univ Nice Sophia Antipolis, CEA, Fac Med, Unite TIRO, F-06107 Nice, France	Max Planck Society; CEA; UDICE-French Research Universities; Universite Cote d'Azur; Carol Davila University of Medicine & Pharmacy; CEA; UDICE-French Research Universities; Universite Cote d'Azur	Fendler, K (corresponding author), Max Planck Inst Biophys, Max Von Laue Str 3, D-60438 Frankfurt, Germany.	klaus.fendler@mpibp-frankfurt.mpg.de	Ganea, Constanta/A-8561-2011	Ganea, Constanta/0000-0003-3489-6901; Fendler, Klaus/0000-0002-5699-7060				Abramson J, 2003, FEBS LETT, V555, P96, DOI 10.1016/S0014-5793(03)01087-1; Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Ambroise Y, 2000, BIOCHEMISTRY-US, V39, P1338, DOI 10.1021/bi9916224; BASSILANA M, 1985, BIOCHEM BIOPH RES CO, V129, P626, DOI 10.1016/0006-291X(85)91937-0; BASSILANA M, 1988, J BIOL CHEM, V263, P9663; BASSILANA M, 1987, J BIOL CHEM, V262, P16865; BOTFIELD MC, 1988, J BIOL CHEM, V263, P12909; BOTFIELD MC, 1992, J BIOL CHEM, V267, P1818; Cordat E, 1998, J BIOL CHEM, V273, P33198, DOI 10.1074/jbc.273.50.33198; Cordat E, 2000, BIOCHEMISTRY-US, V39, P4493, DOI 10.1021/bi991852i; DAMIANOFORANO E, 1986, J BIOL CHEM, V261, P6893; Dave N, 2002, J BIOL CHEM, V277, P3380, DOI 10.1074/jbc.M105466200; Dave N, 2000, BIOPHYS J, V79, P747, DOI 10.1016/S0006-3495(00)76332-6; Dayem MA, 2003, J BIOL CHEM, V278, P1518, DOI 10.1074/jbc.M210053200; Ding PZ, 2004, BBA-BIOMEMBRANES, V1660, P106, DOI 10.1016/j.bbamem.2003.11.005; Ding PZ, 2000, J MEMBRANE BIOL, V174, P135, DOI 10.1007/s002320001038; Ding PZ, 2000, BIOCHEM BIOPH RES CO, V268, P409, DOI 10.1006/bbrc.2000.2149; Ding PZ, 2000, BBA-BIOMEMBRANES, V1509, P123, DOI 10.1016/S0005-2736(00)00286-8; Fang G, 1999, MOL MEMBR BIOL, V16, P297, DOI 10.1080/096876899294517; Ganea C, 2001, BIOCHEMISTRY-US, V40, P13744, DOI 10.1021/bi011223k; Gwizdek C, 1997, BIOCHEMISTRY-US, V36, P8522, DOI 10.1021/bi970312n; Hacksell I, 2002, EMBO J, V21, P3569, DOI 10.1093/emboj/cdf378; HAMA H, 1994, J BIOL CHEM, V269, P1063; Heymann JAW, 2003, J STRUCT BIOL, V144, P320, DOI 10.1016/j.jsb.2003.09.002; Heymann JAW, 2001, EMBO J, V20, P4408, DOI 10.1093/emboj/20.16.4408; Hirai T, 2004, BIOPHYS J, V87, P3600, DOI 10.1529/biophysj.104.049320; Hirai T, 2002, NAT STRUCT BIOL, V9, P597, DOI 10.1038/nsb821; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; JAUCH P, 1986, J MEMBRANE BIOL, V94, P117, DOI 10.1007/BF01871192; Jung H, 1998, BIOCHEMISTRY-US, V37, P11083, DOI 10.1021/bi980684b; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; Knol J, 1996, J BIOL CHEM, V271, P15358, DOI 10.1074/jbc.271.26.15358; Leon X, 2005, BIOCHEMISTRY-US, V44, P3506, DOI 10.1021/bi048301z; Loo DDF, 2005, J GEN PHYSIOL, V125, P13, DOI 10.1085/jgp.200409150; LOPILATO J, 1978, J BACTERIOL, V134, P147, DOI 10.1128/JB.134.1.147-156.1978; Maehrel C, 1998, J BIOL CHEM, V273, P33192, DOI 10.1074/jbc.273.50.33192; Meyer-Lipp K, 2004, BIOCHEMISTRY-US, V43, P12606, DOI 10.1021/bi0489053; MUSVETEAU I, 1995, BIOCHEMISTRY-US, V34, P6775, DOI 10.1021/bi00020a024; MusVeteau I, 1996, BIOCHEMISTRY-US, V35, P12053, DOI 10.1021/bi961372g; Pintschovius J, 1999, BIOPHYS J, V76, P827, DOI 10.1016/S0006-3495(99)77246-2; Poolman B, 1996, MOL MICROBIOL, V19, P911, DOI 10.1046/j.1365-2958.1996.397949.x; POURCHER T, 1991, BIOCHEM BIOPH RES CO, V178, P1176, DOI 10.1016/0006-291X(91)91016-6; POURCHER T, 1990, PHILOS T ROY SOC B, V326, P411, DOI 10.1098/rstb.1990.0021; POURCHER T, 1993, J BIOL CHEM, V268, P3209; POURCHER T, 1995, BIOCHEMISTRY-US, V34, P4412, DOI 10.1021/bi00013a033; Pourcher T, 1996, BIOCHEMISTRY-US, V35, P4161, DOI 10.1021/bi9527496; Purhonen P, 2005, J STRUCT BIOL, V152, P76, DOI 10.1016/j.jsb.2005.07.003; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; RIGAUD JL, 1988, BIOCHEMISTRY-US, V27, P2677, DOI 10.1021/bi00408a007; Weissborn AC, 1997, BBA-BIOMEMBRANES, V1329, P237, DOI 10.1016/S0005-2736(97)00116-8; ZANI ML, 1993, J BIOL CHEM, V268, P3216; ZANI ML, 1994, J BIOL CHEM, V269, P24883	53	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25882	25892		10.1074/jbc.M601259200	http://dx.doi.org/10.1074/jbc.M601259200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16822867	hybrid			2022-12-25	WOS:000240249500003
J	Policha, A; Daneshtalab, N; Chen, L; Dale, LB; Altier, C; Khosravani, H; Thomas, WG; Zamponi, GW; Ferguson, SSG				Policha, Aleksandra; Daneshtalab, Noriko; Chen, Lina; Dale, Lianne B.; Altier, Christophe; Khosravani, Houman; Thomas, Walter G.; Zamponi, Gerald W.; Ferguson, Stephen S. G.			Role of angiotensin II type 1A receptor phosphorylation, phospholipase D, and extracellular calcium in isoform-specific protein kinase C membrane translocation responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; SIGNAL-TRANSDUCTION; CA2+; OSCILLATIONS; CHANNEL; TRAFFICKING; ACTIVATION	The angiotensin II type 1A receptor (AT(1A)R) plays an important role in cardiovascular function and as such represents a primary target for therapeutic intervention. The AT(1A)R is coupled via G(q) to the activation of phospholipase C, the hydrolysis of phosphoinositides, release of calcium from intracellular stores, and the activation of protein kinase C (PKC). We show here that PKC beta I and PKC beta II exhibit different membrane translocation patterns in response to AT(1A)R agonist activation. Whereas PKC beta II translocation to the membrane is transient, PKC beta I displays additional translocation responses: persistent membrane localization and oscillations between the membrane and cytosol following agonist removal. The initial translocation of PKC beta I requires the release of calcium from intracellular stores and the activation of phospholipase C, but persistent membrane localization is dependent upon extracellular calcium influx. The mutation of any of the three PKC phosphorylation consensus sites (Ser-331, Ser-338, and Ser-348) localized within the AT(1A)R C-tail significantly increases the probability that persistent increases in diacylglycerol levels and PKC beta I translocation responses will be observed. The persistent increase in AT(1A)R-mediated diacylglycerol formation is mediated by the activation of phospholipase D. Although the persistent PKC beta I membrane translocation response is absolutely dependent upon the PKC activity-dependent recruitment of an extracellular calcium current, it does not require the activation of phospholipase D. Taken together, we show that the patterning of AT(1A)R second messenger response patterns is regulated by heterologous desensitization and PKC isoform substrate specificity.	Univ Western Ontario, Cell Biol Res Grp, Robarts Res Inst, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5K8, Canada; Univ Calgary, Dept Physiol, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada; Baker Heart Res Inst, Melbourne, Vic 8008, Australia	Western University (University of Western Ontario); Western University (University of Western Ontario); University of Calgary; Baker Heart and Diabetes Institute	Ferguson, SSG (corresponding author), Univ Western Ontario, Cell Biol Res Grp, Robarts Res Inst, 100 Perth Dr,POB 5015, London, ON N6A 5K8, Canada.	ferguson@robarts.ca	Khosravani, Houman/X-2391-2019; Thomas, Walter/I-2208-2015	Thomas, Walter/0000-0003-0685-2952; Zamponi, Gerald W./0000-0002-0644-9066				Babwah AV, 2003, J BIOL CHEM, V278, P5419, DOI 10.1074/jbc.M211053200; Cayouette S, 2004, J BIOL CHEM, V279, P7241, DOI 10.1074/jbc.M312042200; Codazzi F, 2001, CURR BIOL, V11, P1089, DOI 10.1016/S0960-9822(01)00326-8; Cummings R, 2002, MOL CELL BIOCHEM, V234, P99, DOI 10.1023/A:1015944828973; Dale LB, 2001, J BIOL CHEM, V276, P35900, DOI 10.1074/jbc.M103847200; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Du GW, 2004, MOL BIOL CELL, V15, P1024, DOI 10.1091/mbc.E03-09-0673; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson Stephen S. G., 2003, V237, P121; Gaborik Z, 2004, TRENDS ENDOCRIN MET, V15, P286, DOI 10.1016/j.tem.2004.06.009; Huang P, 2005, MOL BIOL CELL, V16, P2614, DOI 10.1091/mbc.E04-12-1124; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; McNaughton NCL, 1997, NEUROPHARMACOLOGY, V36, P895, DOI 10.1016/S0028-3908(97)00085-3; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Qian HW, 1999, BIOCHEM J, V343, P637, DOI 10.1042/0264-6021:3430637; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Smith RD, 1998, MOL PHARMACOL, V54, P935, DOI 10.1124/mol.54.6.935; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Tang H, 1998, CIRC RES, V82, P523, DOI 10.1161/01.RES.82.5.523; Thomas WG, 2003, TRENDS ENDOCRIN MET, V14, P130, DOI 10.1016/S1043-2760(03)00023-7; Touyz RM, 2000, PHARMACOL REV, V52, P639; Toyz RM, 2002, BRAZ J MED BIOL RES, V35, P1001, DOI 10.1590/S0100-879X2002000900001; Uchino M, 2004, J BIOL CHEM, V279, P2254, DOI 10.1074/jbc.M309894200	28	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26340	26349		10.1074/jbc.M605437200	http://dx.doi.org/10.1074/jbc.M605437200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16831865	hybrid			2022-12-25	WOS:000240249500051
J	Choi, JY; Stover, JS; Angel, KC; Chowdhury, G; Rizzo, CJ; Guengerich, FP				Choi, Jeong-Yun; Stover, James S.; Angel, Karen C.; Chowdhury, Goutam; Rizzo, Carmelo J.; Guengerich, F. Peter			Biochemical basis of genotoxicity of heterocyclic arylamine food mutagens - Human DNA polymerase eta selectively produces a two-base deletion in copying the N-2-guanyl adduct of 2-amino-3-methylimidazo[4,5-f] quinoline but not the C-8 adduct at the NarI G3 site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTATION HOT-SPOT; ERROR-PRONE BYPASS; TRANSLESION SYNTHESIS; ESCHERICHIA-COLI; FRAMESHIFT MUTAGENESIS; SEQUENCE CONTEXT; ACETYLAMINOFLUORENE ADDUCT; CRYSTAL-STRUCTURES; MAMMALIAN-CELLS; KAPPA	Heterocyclic arylamines are highly mutagenic and cause tumors in animal models. The mutagenicity is attributed to the C-8- and N-2-G adducts, the latter of which accumulates due to slower repair. The C-8- and N-2-G adducts derived from 2-amino-3- methylimidazo[4,5-f] quinoline (IQ) were placed at the G(1) and G(3) sites of the NarI sequence, in which the G3 site is an established hot spot for frameshift mutation with the model arylamine derivative 2-acetylaminofluorene but G1 is not. Human DNA polymerase (pol) eta extended primers beyond template G-IQ adducts better than did pol kappa and much better than pol iota or delta. In 1-base incorporation studies, pol eta inserted C and A, pol iota inserted T, and pol kappa inserted G. Steady-state kinetic parameters were measured for these dNTPs opposite the C-8- and N-2-IQ adducts at both sites, being most favorable for pol eta. Mass spectrometry of pol eta extension products revealed a single major product in each of four cases; with the G(1) and G(3) C-8- IQ adducts, incorporation was largely error-free. With the G(3) N-2-IQ adduct, a - 2 deletion occurred at the site of the adduct. With the G(3) N-2-IQ adduct, the product was error-free at the site opposite the base and then stalled. Thus, the pol eta products yielded frame-shifts with the N-2 but not the C-8 IQ adducts. We show a role for pol eta and the complexity of different chemical adducts of IQ, DNA position, and DNA polymerases.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Mol Toxicol, Nashville, TN 37232 USA; Ewha Womans Univ, Dept Pharmacol, Seoul 158710, South Korea	Vanderbilt University; Vanderbilt University; Vanderbilt University; Ewha Womans University	Guengerich, FP (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 638 Robinson Res Bldg,23rd & Pierce Aves, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu			NIEHS NIH HHS [P30 ES000267, R01 ES010375, T32 ES007028] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007028, P30ES000267, R01ES010375] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adamson R.H., 2000, FOOD BORNE CARCINOGE, P229; BELAND FA, 1985, ENVIRON HEALTH PERSP, V62, P19, DOI 10.2307/3430089; Bol SAM, 2000, CARCINOGENESIS, V21, P1, DOI 10.1093/carcin/21.1.1; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BURNOUF D, 1989, P NATL ACAD SCI USA, V86, P4147, DOI 10.1073/pnas.86.11.4147; Burnouf DY, 1999, CHEM RES TOXICOL, V12, P144, DOI 10.1021/tx9801920; Cho BP, 1999, BIOCHEMISTRY-US, V38, P7572, DOI 10.1021/bi990182d; Choi JY, 2006, J BIOL CHEM, V281, P21062, DOI 10.1074/jbc.M602246200; Choi JY, 2006, J BIOL CHEM, V281, P12315, DOI 10.1074/jbc.M600112200; Choi JY, 2005, J MOL BIOL, V352, P72, DOI 10.1016/j.jmb.2005.06.079; Dutta S, 2004, P NATL ACAD SCI USA, V101, P16186, DOI 10.1073/pnas.0406516101; Einolf HJ, 2000, J BIOL CHEM, V275, P16316, DOI 10.1074/jbc.M001291200; Elmquist CE, 2004, J AM CHEM SOC, V126, P11189, DOI 10.1021/ja0487022; FELTON JS, 1990, PROG CLIN BIOL RES, V347, P19; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Friedberg E. C., 2006, DNA REPAIR MUTAGENES; FUCHS RPP, 1981, NATURE, V294, P657, DOI 10.1038/294657a0; Gill JP, 2005, BIOCHEMISTRY-US, V44, P15387, DOI 10.1021/bi051437s; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Guengerich FP, 2006, CHEM REV, V106, P420, DOI 10.1021/cr0404693; Haracska L, 2002, P NATL ACAD SCI USA, V99, P16000, DOI 10.1073/pnas.252524999; Hsu GW, 2004, J BIOL CHEM, V279, P50280, DOI 10.1074/jbc.M409224200; Huang XW, 2003, BIOCHEMISTRY-US, V42, P2456, DOI 10.1021/bi026912q; Kim D, 2005, ANNU REV PHARMACOL, V45, P27, DOI 10.1146/annurev.pharmtox.45.120403.100010; KOEHL P, 1989, J MOL BIOL, V207, P355, DOI 10.1016/0022-2836(89)90259-3; KOFFELSCHWARTZ N, 1984, J MOL BIOL, V177, P33, DOI 10.1016/0022-2836(84)90056-1; Kunkel TA, 2004, J BIOL CHEM, V279, P16895, DOI 10.1074/jbc.R400006200; Leong-Morgenthaler PM, 1998, CARCINOGENESIS, V19, P1749, DOI 10.1093/carcin/19.10.1749; MaenhautMichel G, 1997, MOL GEN GENET, V253, P634, DOI 10.1007/s004380050366; Mao B, 1997, BIOCHEMISTRY-US, V36, P14491, DOI 10.1021/bi972206r; MILLER EC, 1966, SCIENCE, V153, P1125, DOI 10.1126/science.153.3740.1125; NAGAO M, 1977, CANCER LETT, V2, P221, DOI 10.1016/S0304-3835(77)80025-6; NAPOLITANO RL, 1994, BIOCHEMISTRY-US, V33, P1311, DOI 10.1021/bi00172a004; Ni JS, 1996, ANAL CHEM, V68, P1989, DOI 10.1021/ac960270t; NOVAK M, 1995, J AM CHEM SOC, V117, P574, DOI 10.1021/ja00106a083; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; Ramos KS, 2005, DRUG METAB REV, V37, P595, DOI 10.1080/03602530500251253; Rechkoblit O, 2002, J BIOL CHEM, V277, P30488, DOI 10.1074/jbc.M201167200; Rehn L, 1895, ARCH KLIN CHIR, V50, P588; Shibutani S, 1999, J BIOL CHEM, V274, P27433, DOI 10.1074/jbc.274.39.27433; Stover JS, 2004, ORG LETT, V6, P4985, DOI 10.1021/ol047851m; Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6; Suzuki N, 2001, BIOCHEMISTRY-US, V40, P15176, DOI 10.1021/bi010702g; Tan XZ, 2002, BIOCHEMISTRY-US, V41, P14255, DOI 10.1021/bi0202878; TEBBS RS, 1994, BIOCHEMISTRY-US, V33, P8998, DOI 10.1021/bi00196a018; Tretyakova N, 2001, CHEM RES TOXICOL, V14, P1058, DOI 10.1021/tx010062i; Turesky RJ, 2004, J CHROMATOGR B, V802, P155, DOI 10.1016/j.jchromb.2003.10.053; Turesky RJ, 2002, DRUG METAB REV, V34, P625, DOI 10.1081/DMR-120005665; Turesky RJ, 1997, MUTAT RES-FUND MOL M, V376, P235, DOI 10.1016/S0027-5107(97)00048-1; Valadez JG, 2004, J BIOL CHEM, V279, P13435, DOI 10.1074/jbc.M312358200; Wang ZW, 2001, ORG LETT, V3, P565, DOI 10.1021/ol006968h; Washington MT, 2002, P NATL ACAD SCI USA, V99, P1910, DOI 10.1073/pnas.032594399; Wogan GN, 2004, SEMIN CANCER BIOL, V14, P473, DOI 10.1016/j.semcancer.2004.06.010; Zang H, 2005, J BIOL CHEM, V280, P29750, DOI 10.1074/jbc.M504756200; Zhang YB, 2002, MUTAT RES-FUND MOL M, V510, P23, DOI 10.1016/S0027-5107(02)00249-X; Zhang YB, 2002, DNA REPAIR, V1, P559, DOI 10.1016/S1568-7864(02)00055-1	56	34	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25297	25306		10.1074/jbc.M605699200	http://dx.doi.org/10.1074/jbc.M605699200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16835218	hybrid			2022-12-25	WOS:000240031300031
J	Sikorski, EM; Uo, T; Morrison, RS; Agarwal, A				Sikorski, Eric M.; Uo, Takuma; Morrison, Richard S.; Agarwal, Anupam			Pescadillo interacts with the cadmium response element of the human heme oxygenase-1 promoter in renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; MEDIATED INDUCTION; RIBOSOME BIOGENESIS; ENDOTHELIAL-CELLS; NUCLEAR-PROTEIN; GENE; RAT; EXPRESSION; METALLOTHIONEIN; PROLIFERATION	Renal tubular cells elicit adaptive responses following exposure to nephrotoxins, such as cadmium. One response is the up-regulation of the 32-kDa redox-sensitive protein, heme oxygenase-1. Exposure of renal proximal tubular epithelial cells to 10 mu M cadmium demonstrated induction (similar to 20-fold) of heme oxygenase-1 mRNA and protein. Using a 4.5-kb human heme oxygenase-1 promoter construct, the importance of a previously identified cadmium response element (TGCTAGAT) in HeLa cells was verified in renal epithelial cells. Specific protein-DNA interaction with this sequence was demonstrated using nuclear extracts from cadmium-treated cells. Yeast one-hybrid screen of a human kidney cDNA library resulted in the identification of pescadillo, a unique nucleolar, developmental protein, as an interacting protein with the cadmium response element and was confirmed by chromatin immunoprecipitation in vivo and gel shift assays with purified glutathione S-transferase-pescadillo protein in vitro. The specificity of the DNA- protein interaction was verified by the absence of a binding complex when the core sequence of the cadmium response element was mutated or deleted. In addition, B23/nucleophosmin, another nucleolar protein, did not interact with the cadmium response sequence. Overexpression of pescadillo resulted in increased activity of the 4.5-kb human heme oxygenase-1 promoter construct but failed to activate this construct when the cadmium response sequence was mutated. The findings demonstrate the important and previously unrecognized role of pescadillo as a DNA-binding protein interacting specifically with the cadmium response element of the human heme oxygenase-1 gene.	Univ Alabama Birmingham, Div Nephrol, Nephrol Res & Training Ctr, Birmingham, AL 35294 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA	University of Alabama System; University of Alabama Birmingham; University of Washington; University of Washington Seattle	Agarwal, A (corresponding author), Univ Alabama Birmingham, Div Nephrol, Nephrol Res & Training Ctr, 703 S 19th St,Zeigler Res Bldg,Rm 614, Birmingham, AL 35294 USA.	agarwal@uab.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035533, R01NS042123] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL068157] Funding Source: Medline; NIDDK NIH HHS [DK59600] Funding Source: Medline; NINDS NIH HHS [NS35533, NS42123] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams CC, 2002, RNA, V8, P150, DOI 10.1017/S1355838202010026; Agarwal A, 2000, J AM SOC NEPHROL, V11, P965, DOI 10.1681/ASN.V115965; Agarwal A, 1998, J AM SOC NEPHROL, V9, P1990; Alam J, 2000, J BIOL CHEM, V275, P27694; Allende ML, 1996, GENE DEV, V10, P3141, DOI 10.1101/gad.10.24.3141; BRUGNERA E, 1994, NUCLEIC ACIDS RES, V22, P3167, DOI 10.1093/nar/22.15.3167; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELINDER CG, 1992, IARC SCI PUBL, V118, P123; Funakoshi T, 1997, TOXICOLOGY, V116, P99, DOI 10.1016/S0300-483X(96)03533-0; Gong Q, 1997, TOXICOLOGY, V119, P179, DOI 10.1016/S0300-483X(96)03608-6; Haque J, 2000, GENOMICS, V70, P201, DOI 10.1006/geno.2000.6375; Hassoun EA, 1996, TOXICOLOGY, V112, P219, DOI 10.1016/0300-483X(96)03404-X; Hayashi S, 2003, PROTEIN EXPRES PURIF, V29, P1, DOI 10.1016/S1046-5928(03)00023-8; Hernandez-Verdun D, 2006, HISTOCHEM CELL BIOL, V125, P127, DOI 10.1007/s00418-005-0046-4; Hill-Kapturczak N, 2003, ARTERIOSCL THROM VAS, V23, P1416, DOI 10.1161/01.ATV.0000081656.76378.A7; Hill-Kapturczak N, 2003, AM J PHYSIOL-RENAL, V285, pF515, DOI 10.1152/ajprenal.00137.2003; Hock TD, 2004, BIOCHEM J, V383, P209, DOI 10.1042/BJ20040794; IMBERT J, 1989, MOL CELL BIOL, V9, P5315, DOI 10.1128/MCB.9.12.5315; Ishikawa T, 1999, BIOCHEM BIOPH RES CO, V254, P566, DOI 10.1006/bbrc.1998.9979; Kinoshita Y, 2001, J BIOL CHEM, V276, P6656, DOI 10.1074/jbc.M008536200; Koizumi T, 1996, TOXICOLOGY, V114, P125, DOI 10.1016/S0300-483X(96)03477-4; Kumar R, 2004, MOL BIOCHEM PARASIT, V133, P297, DOI 10.1016/j.molbiopara.2003.11.005; KUTTY RK, 1994, GENOMICS, V20, P513, DOI 10.1006/geno.1994.1213; Lapik YR, 2004, MOL CELL, V15, P17, DOI 10.1016/j.molcel.2004.05.020; Lerch-Gaggl A, 2002, J BIOL CHEM, V277, P45347, DOI 10.1074/jbc.M208338200; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Maiorana A, 2004, ONCOGENE, V23, P7116, DOI 10.1038/sj.onc.1207916; McCoubrey WK, 1997, J BIOL CHEM, V272, P12568, DOI 10.1074/jbc.272.19.12568; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; NORBERG GF, 1972, ARCH ENVIRON HEALTH, V24, P209, DOI 10.1080/00039896.1972.10666071; Oeffinger M, 2002, RNA, V8, P626, DOI 10.1017/S1355838202020022; Prisco M, 2004, MOL CELL BIOL, V24, P5421, DOI 10.1128/MCB.24.12.5421-5433.2004; RYAN MJ, 1994, KIDNEY INT, V45, P48, DOI 10.1038/ki.1994.6; Sikorski EM, 2004, AM J PHYSIOL-RENAL, V286, pF425, DOI 10.1152/ajprenal.00297.2003; Stein GS, 2000, J CELL SCI, V113, P2527; TAKEDA K, 1994, J BIOL CHEM, V269, P22858; TEMPLETON DM, 1990, J BIOL CHEM, V265, P21764; Waisberg M, 2003, TOXICOLOGY, V192, P95, DOI 10.1016/S0300-483X(03)00305-6; Xie JX, 2006, TOXICOL SCI, V91, P299, DOI 10.1093/toxsci/kfj131; Zhang H, 2005, SCI CHINA SER C, V48, P270, DOI 10.1360/062004-86	41	32	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24423	24430		10.1074/jbc.M602287200	http://dx.doi.org/10.1074/jbc.M602287200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16816389	hybrid			2022-12-25	WOS:000239847800036
J	Aung, HT; Schroder, K; Himes, SR; Brion, K; van Zuylen, W; Trieu, A; Suzuki, H; Hayashizaki, Y; Hume, DA; Sweet, MJ; Ravasi, T				Aung, Hnin Thanda; Schroder, Kate; Himes, Stewart R.; Brion, Kristian; van Zuylen, Wendy; Trieu, Angela; Suzuki, Harukazu; Hayashizaki, Yoshihide; Hume, David A.; Sweet, Matthew J.; Ravasi, Timothy			LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression	FASEB JOURNAL			English	Article						transcriptional regulatory networks; epigenetic; histone code; innate immunity; inflammation	NF-KAPPA-B; INNATE IMMUNE-SYSTEM; TOLL-LIKE RECEPTORS; CYCLOOXYGENASE-2 GENE; MURINE MACROPHAGES; DNA METHYLATION; CHROMATIN; PROMOTER; LIPOPOLYSACCHARIDE; TRANSCRIPTION	Bacterial LPS triggers dramatic changes in gene expression in macrophages. We show here that LPS regulated several members of the histone deacetylase (HDAC) family at the mRNA level in murine bone marrow-derived macrophages (BMM). LPS transiently repressed, then induced a number of HDACs (Hdac-4, 5, 7) in BMM, whereas Hdac-1 mRNA was induced more rapidly. Treatment of BMM with trichostatin A (TSA), an inhibitor of HDACs, enhanced LPS-induced expression of the Cox-2, Cxcl2, and Ifit2 genes. In the case of Cox-2, this effect was also apparent at the promoter level. Overexpression of Hdac-8 in RAW264 murine macrophages blocked the ability of LPS to induce Cox-2 mRNA. Another class of LPS-inducible genes, which included Ccl2, Ccl7, and Edn1, was suppressed by TSA, an effect most likely mediated by PU.1 degradation. Hence, HDACs act as potent and selective negative regulators of proinflammatory gene expression and act to prevent excessive inflammatory responses in macrophages.	Univ Calif San Diego, Dept Bioengn, San Diego, CA 92103 USA; Univ Queensland, Cooperat Res Ctr Chron Inflammatory Dis, St Lucia, Qld 4067, Australia; Univ Queensland, Australian Res Council Special Res Ctr Funct & Ap, Inst Mol Biosci, St Lucia, Qld 4067, Australia; RIKEN, Lab Genome Explorat Res Grp, Genom Sci Ctr, Yokohama Inst,Tsurumi Ku, Yokohama, Kanagawa, Japan	University of California System; University of California San Diego; University of Queensland; University of Queensland; RIKEN	Ravasi, T (corresponding author), Univ Calif San Diego, Dept Bioengn, San Diego, CA 92103 USA.	travasi@bioeng.ucsd.edu	Hume, David A/C-7695-2013; Hayashizaki, Yoshihide/N-6590-2015; Schroder, Kate/C-6132-2008; Sweet, Matthew J/F-2229-2011; Ravasi, Timothy/B-8777-2008	Schroder, Kate/0000-0001-9261-3805; Sweet, Matthew J/0000-0002-0406-8139; Hume, David/0000-0002-2615-1478; Ravasi, Timothy/0000-0002-9950-465X				Akira S, 2003, SCAND J INFECT DIS, V35, P555, DOI 10.1080/00365540310015683; Akira S, 2003, BIOCHEM SOC T, V31, P637, DOI 10.1042/BST0310637; Boekhoudt GH, 2003, J IMMUNOL, V170, P4139, DOI 10.4049/jimmunol.170.8.4139; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Chang S, 1999, J LEUKOCYTE BIOL, V66, P528, DOI 10.1002/jlb.66.3.528; Cosgrove MS, 2005, BIOCHEM CELL BIOL, V83, P468, DOI 10.1139/O05-137; Costelloe EO, 1999, J LEUKOCYTE BIOL, V66, P172, DOI 10.1002/jlb.66.1.172; Dean Ann, 2004, Briefings in Functional Genomics & Proteomics, V2, P344, DOI 10.1093/bfgp/2.4.344; Deng WG, 2004, BLOOD, V103, P2135, DOI 10.1182/blood-2003-09-3131; Duroux M, 2004, PLANT J, V40, P660, DOI 10.1111/j.1365-313X.2004.02242.x; Giacca Mauro, 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P277, DOI 10.2174/1568008043339767; Greene Warner C, 2004, Novartis Found Symp, V259, P208; Himes SR, 2001, J LEUKOCYTE BIOL, V70, P812; Hume D A, 2001, BMC Immunol, V2, P11, DOI 10.1186/1471-2172-2-11; Joo M, 2004, J BIOL CHEM, V279, P6658, DOI 10.1074/jbc.M306267200; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Laribee RN, 2001, J IMMUNOL, V167, P5160, DOI 10.4049/jimmunol.167.9.5160; Lee JY, 2003, J LEUKOCYTE BIOL, V73, P862, DOI 10.1189/jlb.1202618; MADONNA GS, 1985, J IMMUNOL, V135, P3763; Marks PA, 2003, CURR OPIN PHARMACOL, V3, P344, DOI 10.1016/S1471-4892(03)00084-5; Marwick JA, 2004, AM J RESP CELL MOL, V31, P633, DOI 10.1165/rcmb.2004-0006OC; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Mellor J, 2005, MOL CELL, V19, P147, DOI 10.1016/j.molcel.2005.06.023; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Murakami K, 1997, DNA CELL BIOL, V16, P173, DOI 10.1089/dna.1997.16.173; MUSIKACHAROEN T, 2004, BLOOD; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Park GY, 2004, AM J PHYSIOL-LUNG C, V286, pL956, DOI 10.1152/ajplung.00338.2003; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Ram C Venkata S, 2003, Am J Ther, V10, P396, DOI 10.1097/00045391-200311000-00004; Ravasi T, 2002, J IMMUNOL, V168, P44, DOI 10.4049/jimmunol.168.1.44; Rehli M, 1999, J IMMUNOL, V162, P1559; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Schreiber SL, 2002, CELL, V111, P771, DOI 10.1016/S0092-8674(02)01196-0; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Sengupta N, 2004, J CELL BIOCHEM, V93, P57, DOI 10.1002/jcb.20179; Stacey KJ, 1996, J IMMUNOL, V157, P2116; Suuronen T, 2003, J NEUROCHEM, V87, P407, DOI 10.1046/j.1471-4159.2003.02004.x; Suzuki M, 2003, ONCOGENE, V22, P8688, DOI 10.1038/sj.onc.1207182; Sweet MJ, 2002, J IMMUNOL, V168, P392, DOI 10.4049/jimmunol.168.1.392; Thiel G, 2004, EUR J BIOCHEM, V271, P2855, DOI 10.1111/j.1432-1033.2004.04174.x; Toney LM, 2000, NAT IMMUNOL, V1, P214, DOI 10.1038/79749; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wells CA, 2003, GENOME RES, V13, P1360, DOI 10.1101/gr.1056103; Wells Christine A, 2003, BMC Immunol, V4, P5, DOI 10.1186/1471-2172-4-5; Wessells J, 2004, J BIOL CHEM, V279, P49995, DOI 10.1074/jbc.M404246200; Yamamoto M, 2004, NATURE, V430, P218, DOI 10.1038/nature02738; Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008; Zaidi SK, 2005, EMBO REP, V6, P128, DOI 10.1038/sj.embor.7400337; Zhou WS, 2004, P NATL ACAD SCI USA, V101, P2440, DOI 10.1073/pnas.0306002101	50	177	184	1	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1315	1327		10.1096/fj.05-5360com	http://dx.doi.org/10.1096/fj.05-5360com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816106				2022-12-25	WOS:000240266000008
J	Ameri, K; Hammond, EM; Culmsee, C; Raida, M; Katschinski, DM; Wenger, RH; Wagner, E; Davis, RJ; Hai, T; Denko, N; Harris, AL				Ameri, K.; Hammond, E. M.; Culmsee, C.; Raida, M.; Katschinski, D. M.; Wenger, R. H.; Wagner, E.; Davis, R. J.; Hai, T.; Denko, N.; Harris, A. L.			Induction of activating transcription factor 3 by anoxia is independent of p53 and the hypoxic HIF signalling pathway	ONCOGENE			English	Article						ATF3; hypoxia; anoxia; HIF; p53; MKK7/JNK	VASCULAR ENDOTHELIAL-CELLS; JUN NH2-TERMINAL KINASE; GENE-EXPRESSION; ATF3 GENE; C-JUN; INDUCIBLE FACTOR-1; STRESS RESPONSES; OVER-EXPRESSION; MESSENGER-RNA; BINDING	Solid tumors often have an inadequate blood supply, which results in large regions that are subjected to hypoxic or anoxic stress. Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that regulates much of the transcriptional response of cells to hypoxia. Activating transcription factor 3 (ATF3) is another transcription factor that responds to a variety of stresses and is often upregulated in cancer. We investigated the regulation of ATF3 by oxygen deprivation. ATF3 induction occurred most robustly under anoxia, is common, and it is not dependent on presence of HIF-1 or p53, but is sensitive to the inhibition of c-Jun NH2-terminal kinase activation and the antioxidant N-acetylcystein. ATF3 could also be induced by desferrioxamine but not by the mitochondrial poison cyanide or the nonspecific 2-oxoglutarate dioxygenase inhibitor dimethyloxalylglycine. We also show that anoxic ATF3 mRNA is more stable than normoxic mRNA providing a mechanism for this induction. Thus, this study demonstrates that the regulation of ATF3 under anoxia is independent of 2-oxoglutarate dioxygenase, HIF-1 and p53, presumably involving multiple regulatory pathways.	Stanford Univ, Dept Radiat Oncol, Div Radiat & Canc Biol, Sch Med, Stanford, CA 94305 USA; Ctr Drug Res, Dept Pharm, Munich, Germany; Univ Leipzig, Dept Hematol Oncol, D-7010 Leipzig, Germany; Univ Gottingen, Ctr Physiol & Pathophysiol, Dept Heart & Circulatory Physiol, D-3400 Gottingen, Germany; Univ Zurich, Inst Physiol, Zurich, Switzerland; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Ctr Mol Neurobiol, Columbus, OH 43210 USA; Univ Oxford, John Radcliffe Hosp, Canc Res UK, Weatherall Inst Mol Med, Oxford OX3 9DU, England	Stanford University; University of Munich; Leipzig University; University of Gottingen; University of Zurich; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University System of Ohio; Ohio State University; Cancer Research UK; University of Oxford	Ameri, K (corresponding author), Stanford Univ, Dept Radiat Oncol, Div Radiat & Canc Biol, Sch Med, CCSR-S,269 Campus Dr, Stanford, CA 94305 USA.	kameri@stanford.edu	Wagner, Ernst/A-7435-2012; Wagner, Ernst/ABB-5976-2020; Culmsee, Carsten/ABC-3120-2021; Hai, Tsonwin/H-4480-2011; Harris, Adrian L/ABA-3343-2020; Hai, Tsonwin/E-3185-2011; Wenger, Roland H./B-7953-2009; denko, nicholas/F-8444-2010	Wagner, Ernst/0000-0001-8413-0934; Wagner, Ernst/0000-0001-8413-0934; Culmsee, Carsten/0000-0002-5121-5015; Hai, Tsonwin/0000-0003-4510-0315; Harris, Adrian L/0000-0003-1376-8409; Hai, Tsonwin/0000-0003-4510-0315; Wenger, Roland H./0000-0001-7592-4839; Davis, Roger/0000-0002-0130-1652; Hammond, Ester/0000-0002-2335-3146	NIDDK NIH HHS [DK59605] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059605] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alfranca A, 2002, MOL CELL BIOL, V22, P12, DOI 10.1128/MCB.22.1.12-22.2002; Ameri K, 2004, BLOOD, V103, P1876, DOI 10.1182/blood-2003-06-1859; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Bottone FG, 2005, J PHARMACOL EXP THER, V315, P668, DOI 10.1124/jpet.105.089607; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; Chilov D, 1999, J CELL SCI, V112, P1203; Culmsee C, 2003, J NEUROSCI, V23, P8586; Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200; Fan FY, 2002, ONCOGENE, V21, P7488, DOI 10.1038/sj.onc.1205896; Francis JS, 2004, MOL BRAIN RES, V124, P199, DOI 10.1016/j.molbrainres.2003.10.027; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Hammond EM, 2006, MOL CELL BIOL, V26, P3492, DOI 10.1128/MCB.26.9.3492-3504.2006; Hammond EM, 2003, MUTAT RES-FUND MOL M, V532, P205, DOI 10.1016/j.mrfmmm.2003.08.017; Hartman MG, 2004, MOL CELL BIOL, V24, P5721, DOI 10.1128/MCB.24.13.5721-5732.2004; Inoue K, 2004, GENES CELLS, V9, P59, DOI 10.1111/j.1356-9597.2004.00707.x; Ishiguro T, 2000, ONCOL RES, V12, P181; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kaelin WG, 2005, CELL METAB, V1, P357, DOI 10.1016/j.cmet.2005.05.006; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Le QT, 2004, CANCER METAST REV, V23, P293, DOI 10.1023/B:CANC.0000031768.89246.d7; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Lu D, 2006, J BIOL CHEM, V281, P10473, DOI 10.1074/jbc.M509278200; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Okamoto A, 2006, MOL CELL BIOL, V26, P1087, DOI 10.1128/MCB.26.3.1087-1097.2006; Pan YX, 2005, J BIOL CHEM, V280, P34609, DOI 10.1074/jbc.M507802200; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Papandreou I, 2005, CANCER RES, V65, P3171, DOI 10.1158/0008-5472.CAN-04-3395; Ryan HE, 2000, CANCER RES, V60, P4010; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Scott PH, 1998, AM J RESP CRIT CARE, V158, P958, DOI 10.1164/ajrccm.158.3.9712130; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Vecsey-Semjen B, 2002, ONCOGENE, V21, P4646, DOI 10.1038/sj.onc.1205577; Vengellur A, 2005, PHYSIOL GENOMICS, V22, P308, DOI 10.1152/physiolgenomics.00045.2004; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712	41	61	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	2					284	289		10.1038/sj.onc.1209781	http://dx.doi.org/10.1038/sj.onc.1209781			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16847457	Green Accepted			2022-12-25	WOS:000243398300012
J	Chuan, YC; Pang, ST; Cedazo-Minguez, A; Norstedt, G; Pousette, A; Flores-Morales, A				Chuan, Yin-Choy; Pang, See-Tong; Cedazo-Minguez, Angel; Norstedt, Gunnar; Pousette, Ake; Flores-Morales, Amilcar			Androgen induction of prostate cancer cell invasion is mediated by ezrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE/AKT PATHWAY; SIGNAL-TRANSDUCTION PATHWAYS; TUMOR CHARACTERISTICS; EPITHELIAL-CELLS; CONTROLLED-TRIAL; PLASMA-MEMBRANE; RECEPTOR GENE; EXPRESSION; ACTIVATION	Ezrin is a key signaling molecule that regulates cell survival, adhesion migration, and invasion. We have previously shown that ezrin is regulated by androgen in rat prostate and that its expression is increased in prostate cancer and in prostate intraepithelial neoplasia. We have used the androgen-sensitive cell line LNCaP-FGC to investigate the role of ezrin in androgen-induced cell invasion. We found that androgen treatment of LNCaP-FGC cells induces ezrin expression, an effect that is inhibited by the androgen receptor antagonist, bicalutamide. In addition, androgen treatment induces the phosphorylation of ezrin in Thr-567 and Tyr-353 in a sequential manner. This is mediated through protein kinase C alpha and Src tyrosine kinase, respectively. Androgen treatment induces the translocation of both protein kinase C alpha and ezrin to the cell membrane and their association. Inhibition of ezrin function using short interference RNA or the overexpression of T567A and Y353F-ezrin mutants significantly reduces androgen-induced Matrigel invasion but does not affect cell proliferation or cell adhesion. Matrigel invasion of the androgen-insensitive prostate cancer cell lines PC-3 and LNCaP-R is also dependent on ezrin. In summary, we have shown that androgens regulate ezrin at transcriptional and posttranscriptional levels. Hormonal regulation of ezrin phosphorylation is required for androgen-induced cell invasion.	Karolinska Inst, Dept Mol Med & Surg, S-17176 Stockholm, Sweden; Karolinska Inst, Neurotec, Sect Expt Geriatr, S-17176 Stockholm, Sweden; Karolinska Inst, Dept Med, Androl Ctr, S-17176 Stockholm, Sweden; Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Dept Surg,Div Urol, Tao Yuan 333, Taiwan	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Chang Gung Memorial Hospital; Chang Gung University	Flores-Morales, A (corresponding author), Karolinska Hosp, Dept Mol Med & Surg, CMM L8-01, S-17176 Stockholm, Sweden.	Amilcar.Flores@cmm.ki.se	Cedazo-Minguez, Angel/C-6707-2012	Cedazo-Minguez, Angel/0000-0003-4626-4864				Akisawa N, 1999, BIOCHEM BIOPH RES CO, V258, P395, DOI 10.1006/bbrc.1999.0653; Bolla M, 2002, LANCET, V360, P103, DOI 10.1016/S0140-6736(02)09408-4; Bonaccorsi L, 2000, ENDOCRINOLOGY, V141, P3172, DOI 10.1210/en.141.9.3172; Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698; Cheville JC, 2002, CANCER-AM CANCER SOC, V95, P1028, DOI 10.1002/cncr.10788; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; Curto M, 2004, CANCER CELL, V5, P113, DOI 10.1016/S1535-6108(04)00031-5; D'Amico AV, 2004, JAMA-J AM MED ASSOC, V292, P821, DOI 10.1001/jama.292.7.821; Draisma G, 2003, J NATL CANCER I, V95, P868, DOI 10.1093/jnci/95.12.868; Edwards J, 2005, BJU INT, V95, P1327, DOI 10.1111/j.1464-410X.2005.05527.x; Edwards J, 2005, BJU INT, V95, P1320, DOI 10.1111/j.1464-410X.2005.05526.x; Edwards J, 2003, BRIT J CANCER, V89, P552, DOI 10.1038/sj.bjc.6601127; Farla P, 2005, J CELL SCI, V118, P4187, DOI 10.1242/jcs.02546; Fievet BT, 2004, J CELL BIOL, V164, P653, DOI 10.1083/jcb.200307032; Furr BJA, 1996, UROLOGY, V47, P13, DOI 10.1016/S0090-4295(96)80003-3; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; HASENSON M, 1985, PROSTATE, V7, P183, DOI 10.1002/pros.2990070208; Heinlein CA, 2002, MOL ENDOCRINOL, V16, P2181, DOI 10.1210/me.2002-0070; Heiska L, 2005, J BIOL CHEM, V280, P10244, DOI 10.1074/jbc.M411353200; Kang HY, 2004, J BONE MINER RES, V19, P1181, DOI 10.1359/JBMR.040306; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KRIEG J, 1992, J BIOL CHEM, V267, P19258; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; Liu B, 1997, ADV EXP MED BIOL, V400, P707; Makinen T, 2003, CLIN CANCER RES, V9, P2435; Makitie T, 2001, INVEST OPHTH VIS SCI, V42, P2442; Martin TA, 2003, CRIT REV ONCOL HEMAT, V46, P165, DOI 10.1016/S1040-8428(02)00172-5; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Messing EM, 1999, NEW ENGL J MED, V341, P1781, DOI 10.1056/NEJM199912093412401; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Mitchell S, 2000, BJU INT, V85, P932, DOI 10.1046/j.1464-410x.2000.00606.x; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Pang ST, 2006, PROSTATE, V66, P157, DOI 10.1002/pros.20328; Pang ST, 2004, ONCOL REP, V11, P1187; Pang ST, 2004, UROLOGY, V63, P609, DOI 10.1016/j.urology.2003.09.068; Pang ST, 2002, ENDOCRINOLOGY, V143, P4897, DOI 10.1210/en.2002-220327; Papakonstanti EA, 2003, MOL ENDOCRINOL, V17, P870, DOI 10.1210/me.2002-0253; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; Pfitzenmaier J, 2003, J BONE MINER RES, V18, P1882, DOI 10.1359/jbmr.2003.18.10.1882; Pula G, 2005, J BIOL CHEM, V280, P7194, DOI 10.1074/jbc.M409212200; Quang CT, 2000, EMBO J, V19, P4565, DOI 10.1093/emboj/19.17.4565; SCHELLHAMMER P, 1995, UROLOGY, V45, P745, DOI 10.1016/S0090-4295(99)80077-6; Sonnenburg ED, 2001, J BIOL CHEM, V276, P45289, DOI 10.1074/jbc.M107416200; Srivastava J, 2005, MOL BIOL CELL, V16, P1481, DOI 10.1091/mbc.e04-08-0721; Sun M, 2003, J BIOL CHEM, V278, P42992, DOI 10.1074/jbc.M306295200; Taplin ME, 1999, CANCER RES, V59, P2511; Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; Valdman A, 2005, EUR UROL, V48, P852, DOI 10.1016/j.eururo.2005.03.013; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Zhang M, 2004, ONCOGENE, V23, P3080, DOI 10.1038/sj.onc.1207435; Zhao X, 2001, UROLOGY, V57, P860, DOI 10.1016/S0090-4295(01)00946-3; Zhu P, 2006, CELL, V124, P615, DOI 10.1016/j.cell.2005.12.032	57	65	69	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29938	29948		10.1074/jbc.M602237200	http://dx.doi.org/10.1074/jbc.M602237200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16873375	hybrid			2022-12-25	WOS:000240896300055
J	Ding, J; Rainey, JK; Xu, C; Sykes, BD; Fliegel, L				Ding, Jie; Rainey, Jan K.; Xu, Caroline; Sykes, Brian D.; Fliegel, Larry			Structural and functional characterization of transmembrane segment VII of the Na+/H+ exchanger isoform 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSERTION SCANNING MUTAGENESIS; PROTEIN SECONDARY STRUCTURE; HELIX-HELIX INTERACTIONS; CHEMICAL-SHIFT INDEX; MEMBRANE-PROTEIN; LACTOSE PERMEASE; AMINO-ACIDS; SYNTHETIC PEPTIDES; AMILORIDE; IDENTIFICATION	The Na+/ H+ exchanger isoform 1 is an integral membrane protein that regulates intracellular pH by exchanging one intracellular H+ for one extracellular Na+. It is composed of an N-terminal membrane domain of 12 transmembrane segments and an intracellular C-terminal regulatory domain. We characterized the structural and functional aspects of the critical transmembrane segment VII ( TM VII, residues 251 - 273) by using alanine scanning mutagenesis and high resolution NMR. Each residue of TM VII was mutated to alanine, the full-length protein expressed, and its activity characterized. TM VII was sensitive to mutation. Mutations at 13 of 22 residues resulted in severely reduced activity, whereas other mutants exhibited varying degrees of decreases in activity. The impaired activities sometimes resulted from low expression and/ or low surface targeting. Three of the alanine scanning mutant proteins displayed increased, and two displayed decreased resistance to the Na+/ H+ exchanger isoform 1 inhibitor EMD87580. The structure of a peptide of TM VII was determined by using high resolution NMR in dodecylphosphocholine micelles. TM VII is predominantly alpha- helical, with a break in the helix at the functionally critical residues Gly(261)-Glu(262). The relative positions and orientations of the N- and C- terminal helical segments are seen to vary about this extended segment in the ensemble of NMRstructures. Our results show thatTMVII is a critical transmembrane segment structured as an interrupted helix, with several residues that are essential to both protein function and sensitivity to inhibition.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Prot Engn Network Ctr Excellence, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta	Fliegel, L (corresponding author), Univ Alberta, Dept Biochem, 347 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	lfliegel@ualberta.ca	Rainey, Jan K/C-1927-2008	Rainey, Jan K/0000-0003-0793-5573; Jeffery, Caroline C./0000-0002-5536-4915				BONVIN AMJJ, 1995, J MOL BIOL, V250, P80, DOI 10.1006/jmbi.1995.0360; BONVIN AMJJ, 1994, J BIOMOL NMR, V4, P143, DOI 10.1007/BF00178343; Braun P, 1997, J BIOL CHEM, V272, P29566, DOI 10.1074/jbc.272.47.29566; BRUSCHWEILER R, 1991, Journal of Biomolecular NMR, V1, P3, DOI 10.1007/BF01874565; CAVANAGH J, 1990, J MAGN RESON, V87, P110, DOI 10.1016/0022-2364(90)90089-R; Cavanagh J., 1996, PROTEIN NMR SPECTROS; COUNILLON L, 1993, P NATL ACAD SCI USA, V90, P4508, DOI 10.1073/pnas.90.10.4508; Damberg P, 2001, METHOD ENZYMOL, V339, P271, DOI 10.1016/S0076-6879(01)39318-7; DAVIS JH, 1983, BIOCHEMISTRY-US, V22, P5298, DOI 10.1021/bi00292a008; De Beeck AO, 2000, J BIOL CHEM, V275, P31428, DOI 10.1074/jbc.M003003200; De Beeck AO, 2003, J VIROL, V77, P813, DOI 10.1128/JVI.77.2.813-820.2003; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Denker SP, 2002, J CELL BIOL, V159, P1087, DOI 10.1083/jcb.200208050; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P12644, DOI 10.1021/bi00210a012; Eilers M, 2000, P NATL ACAD SCI USA, V97, P5796, DOI 10.1073/pnas.97.11.5796; Fleming KG, 2001, P NATL ACAD SCI USA, V98, P14340, DOI 10.1073/pnas.251367498; Fliegel L, 2001, BASIC RES CARDIOL, V96, P301, DOI 10.1007/s003950170036; Fraysse AS, 2005, J BIOL CHEM, V280, P21785, DOI 10.1074/jbc.M413091200; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; Harris C, 1999, INT J MOL MED, V3, P315; HAWORTH RS, 1993, BIOCHEM J, V289, P637, DOI 10.1042/bj2890637; He MM, 1996, BIOCHEMISTRY-US, V35, P12909, DOI 10.1021/bi960876b; HENRY GD, 1994, METHOD ENZYMOL, V239, P515; Hunt JF, 1997, BIOCHEMISTRY-US, V36, P15156, DOI 10.1021/bi970146j; Hunte C, 2005, NATURE, V435, P1197, DOI 10.1038/nature03692; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Karmazyn M., 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P323, DOI 10.2174/1568006054553417; Karmazyn M, 2003, HYPERTENSION, V42, P1171, DOI 10.1161/01.HYP.0000102863.23854.0B; Katragadda M, 2001, BIOPHYS J, V81, P1029, DOI 10.1016/S0006-3495(01)75760-8; Katragadda M, 2001, J PEPT RES, V58, P79, DOI 10.1034/j.1399-3011.2001.00904.x; Khadilkar A, 2001, J BIOL CHEM, V276, P43792, DOI 10.1074/jbc.M106659200; KUNTZ ID, 1991, J AM CHEM SOC, V113, P1406, DOI 10.1021/ja00004a050; Lang HJ, 2003, SODIUM-HYDROGEN EXCHANGER: FROM MOLECULE TO ITS ROLE IN DISEASE, P239; Li XJ, 2004, BIOCHEMISTRY-US, V43, P16477, DOI 10.1021/bi048538v; Lindhout DA, 2003, PROTEIN SCI, V12, P1786, DOI 10.1110/ps.0376003; Liu H, 1998, J MOL CELL CARDIOL, V30, P685, DOI 10.1006/jmcc.1997.0636; Liu LP, 1998, J BIOL CHEM, V273, P23645, DOI 10.1074/jbc.273.37.23645; Lu ZL, 2001, J BIOL CHEM, V276, P34098, DOI 10.1074/jbc.M104217200; Mentzer RM, 2003, ANN THORAC SURG, V75, pS700, DOI 10.1016/S0003-4975(02)04700-8; MERUTKA G, 1995, J BIOMOL NMR, V5, P14, DOI 10.1007/BF00227466; Mingarro I, 1996, PROTEIN SCI, V5, P1339, DOI 10.1002/pro.5560050712; MURTAZINA BR, 2001, EUR J BIOCHEM, V268, P1; Naider F, 2005, BIOPOLYMERS, V80, P199, DOI 10.1002/bip.20183; Noel J, 2003, BIOCHEMISTRY-US, V42, P15361, DOI 10.1021/bi035296a; OBLATTMONTAL M, 1994, P NATL ACAD SCI USA, V91, P1495, DOI 10.1073/pnas.91.4.1495; Orlowski J, 1996, J BIOL CHEM, V271, P19922, DOI 10.1074/jbc.271.33.19922; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Paradiso A, 2004, BREAST CANCER RES, V6, pR616, DOI 10.1186/bcr922; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Slepkov ER, 2005, J BIOL CHEM, V280, P17863, DOI 10.1074/jbc.M409608200; Slepkov ER, 2004, BIOCHEM J, V379, P31, DOI 10.1042/BJ20030884; Vik SB, 1998, J BIOL CHEM, V273, P16229, DOI 10.1074/jbc.273.26.16229; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; WANG DH, 1995, AM J PHYSIOL-CELL PH, V269, pC392, DOI 10.1152/ajpcell.1995.269.2.C392; WANG JJ, 1995, J AM CHEM SOC, V117, P8627, DOI 10.1021/ja00138a019; Wigley WC, 1998, BIOCHEMISTRY-US, V37, P844, DOI 10.1021/bi972293n; WILLIAMSON MP, 1990, BIOPOLYMERS, V29, P1428; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZHANG YP, 1995, BIOPHYS J, V68, P847, DOI 10.1016/S0006-3495(95)80261-4; [No title captured]	68	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29817	29829		10.1074/jbc.M606152200	http://dx.doi.org/10.1074/jbc.M606152200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16861220	hybrid			2022-12-25	WOS:000240896300044
J	Herrmann, R; Heck, M; Henklein, P; Hofmann, KP; Ernst, OP				Herrmann, Rolf; Heck, Martin; Henklein, Peter; Hofmann, Klaus Peter; Ernst, Oliver P.			Signal transfer from GPCRs to G proteins - Role of the G alpha N-terminal region in rhodopsin-transducin coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-ACTIVATED RHODOPSIN; PHOTORECEPTOR G-PROTEIN; BETA-GAMMA; AMINO-TERMINUS; CONFORMATIONAL-CHANGES; CARBOXYL-TERMINUS; CRYSTAL-STRUCTURE; BINDING-SITES; SUBUNIT; RECEPTOR	Catalysis of nucleotide exchange in heterotrimeric G proteins (G alpha beta gamma) is a key step in cellular signal transduction mediated by G protein-coupled receptors. The G alpha N terminus with its helical stretch is thought to be crucial for G protein/activated receptor (R*) interaction. The N-terminal fatty acylation of G alpha is important for membrane targeting of G proteins. By applying biophysical techniques to the rhodopsin/transducin model system, we studied the effect of N-terminal truncations in G alpha. In G alpha beta gamma, lack of the fatty acid and G alpha truncations up to 33 amino acids had little effect on R* binding and R*-catalyzed nucleotide exchange, implying that this region is not mandatory for R*/G alpha beta gamma interaction. However, when the other hydrophobic modification of G alpha beta gamma, the G gamma C-terminal farnesyl moiety, is lacking, R* interaction requires the fatty acylated G alpha N terminus. This suggests that the two hydrophobic extensions can replace each other in the interaction of G alpha beta gamma with R*. We propose that in native G alpha beta gamma, these two terminal regions are functionally redundant and form a microdomain that serves both to anchor the G protein to the membrane and to establish an initial docking complex with R*. Accordingly, we find that the native fatty acylated G alpha is competent to interact with R* even in the absence of G beta gamma, whereas nonacylated G alpha requires G beta gamma for interaction. Experiments with N-terminally truncated G alpha subunits suggest that in the second step of the catalytic process, the receptor binds to the alpha N/beta 1-loop region of G alpha to reduce nucleotide affinity and to make the G alpha C terminus available for subsequent interaction with R*.	Charite Univ Med Berlin, Inst Med Phys & Biophys, D-10098 Berlin, Germany; Charite Univ Med Berlin, Inst Biochem, D-10098 Berlin, Germany; Humboldt Univ, Zentrum Biophys & Bioinformat, D-10015 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin	Ernst, OP (corresponding author), Charite Univ Med Berlin, Inst Med Phys & Biophys, Schumann Str 20-21, D-10098 Berlin, Germany.	oliver.ernst@charite.de						Abdulaev NG, 2005, J BIOL CHEM, V280, P38071, DOI 10.1074/jbc.M505259200; Anderson LL, 2005, J BIOL CHEM, V280, P31019, DOI 10.1074/jbc.M503690200; Bartl F, 2000, FEBS LETT, V473, P259, DOI 10.1016/S0014-5793(00)01544-1; Beck M, 1998, FEBS LETT, V436, P304, DOI 10.1016/S0014-5793(98)01156-9; BIGAY J, 1994, BIOCHEMISTRY-US, V33, P14081, DOI 10.1021/bi00251a017; Blahos J, 2001, J BIOL CHEM, V276, P3262, DOI 10.1074/jbc.M004880200; Bohm A, 1997, CURR OPIN BIOTECH, V8, P480, DOI 10.1016/S0958-1669(97)80072-9; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Cabrera-Vera TM, 2003, ENDOCR REV, V24, P765, DOI 10.1210/er.2000-0026; Chabre M, 2005, BIOCHEMISTRY-US, V44, P9395, DOI 10.1021/bi050720o; Cherfils J, 2003, TRENDS BIOCHEM SCI, V28, P13, DOI 10.1016/S0968-0004(02)00006-3; DENKER BM, 1992, J BIOL CHEM, V267, P6272; Ernst OP, 2000, METHOD ENZYMOL, V315, P471; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Fanelli F, 2005, CHEM REV, V105, P3297, DOI 10.1021/cr000095n; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; GRAF R, 1992, J BIOL CHEM, V267, P24307; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hamm HE, 2001, P NATL ACAD SCI USA, V98, P4819, DOI 10.1073/pnas.011099798; Heck M, 2000, METHOD ENZYMOL, V315, P329; Heck M, 2001, J BIOL CHEM, V276, P10000, DOI 10.1074/jbc.M009475200; Herrmann R, 2004, J BIOL CHEM, V279, P24283, DOI 10.1074/jbc.M311166200; Hessel E, 2003, J BIOL CHEM, V278, P22853, DOI 10.1074/jbc.M302747200; Hessel E, 2001, J BIOL CHEM, V276, P2538, DOI 10.1074/jbc.M009061200; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; Itoh Y, 2001, P NATL ACAD SCI USA, V98, P4883, DOI 10.1073/pnas.051632998; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; Kisselev OG, 2003, STRUCTURE, V11, P367, DOI 10.1016/S0969-2126(03)00045-5; Kisselev OG, 1998, P NATL ACAD SCI USA, V95, P4270, DOI 10.1073/pnas.95.8.4270; Kisselev OG, 1999, P NATL ACAD SCI USA, V96, P4898, DOI 10.1073/pnas.96.9.4898; Koenig BW, 2002, J MOL BIOL, V322, P441, DOI 10.1016/S0022-2836(02)00745-3; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Marin EP, 2002, BIOCHEMISTRY-US, V41, P6988, DOI 10.1021/bi025514k; Medkova M, 2002, BIOCHEMISTRY-US, V41, P9962, DOI 10.1021/bi0255726; Muradov KG, 2000, BIOCHEMISTRY-US, V39, P3937, DOI 10.1021/bi992156l; Nanoff C, 2006, MOL PHARMACOL, V69, P397, DOI 10.1124/mol.105.016725; Natochin M, 1998, J BIOL CHEM, V273, P21808, DOI 10.1074/jbc.273.34.21808; Natochin M, 1999, J BIOL CHEM, V274, P7865, DOI 10.1074/jbc.274.12.7865; Natochin M, 2001, J NEUROCHEM, V77, P202, DOI 10.1046/j.1471-4159.2001.00221.x; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; OLDHAM W, 2006, IN PRESS NAT STRUCT; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pereira R, 2005, J BIOL CHEM, V280, P35696, DOI 10.1074/jbc.M504935200; Preininger AM, 2003, BIOCHEMISTRY-US, V42, P7931, DOI 10.1021/bi0345438; Ridge KD, 2006, J BIOL CHEM, V281, P7635, DOI 10.1074/jbc.M509851200; Rondard P, 2001, P NATL ACAD SCI USA, V98, P6150, DOI 10.1073/pnas.101136198; Sachs K, 2000, J BIOL CHEM, V275, P6189, DOI 10.1074/jbc.275.9.6189; Seitz HR, 1999, BIOCHEMISTRY-US, V38, P7950, DOI 10.1021/bi990298+; SHICHIDA Y, 2006, IN PRESS PHOTOCHEM P; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; VOSS T, 1993, J BIOL CHEM, V268, P4637; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Yang CS, 1999, J BIOL CHEM, V274, P2379, DOI 10.1074/jbc.274.4.2379; Yeagle PL, 2003, BIOCHEMISTRY-US, V42, P1365, DOI 10.1021/bi0270539; Zhang ZX, 2004, J BIOL CHEM, V279, P33937, DOI 10.1074/jbc.M403404200	70	42	44	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					30234	30241		10.1074/jbc.M600797200	http://dx.doi.org/10.1074/jbc.M600797200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16847064	hybrid			2022-12-25	WOS:000240896300083
J	Doi, H; Iso, T; Sato, H; Yamazaki, M; Matsui, H; Tanaka, T; Manabe, I; Arai, M; Nagai, R; Kurabayashi, M				Doi, Hiroshi; Iso, Tatsuya; Sato, Hiroko; Yamazaki, Miki; Matsui, Hiroki; Tanaka, Toru; Manabe, Ichiro; Arai, Masashi; Nagai, Ryozo; Kurabayashi, Masahiko			Jagged1-selective notch signaling induces smooth muscle differentiation via a RBP-J kappa-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; OSTEOBLASTIC CELL-DIFFERENTIATION; DEVELOPING MAMMALIAN HEART; GENE-EXPRESSION; INTRACELLULAR DOMAIN; ENDOTHELIAL-CELLS; PRIMARY TARGET; MYOCARDIN; ACTIVATION; JAGGED1	The Notch signaling pathway plays a crucial role in specifying cellular fates by interaction between cellular neighbors; however, the molecular mechanism underlying smooth muscle cell (SMC) differentiation by Notch signaling has not been well characterized. Here we demonstrate that Jagged1-Notch signaling promotes SMC differentiation from mesenchymal cells. Overexpression of the Notch intracellular domain, an activated form of Notch, up-regulates the expression of multiple SMC marker genes including SMC-myosin heavy chain (Sm-mhc) in mesenchymal 10T1/2 cells, but not in non-mesenchymal cells. Physiological Notch stimulation by its ligand Jagged1, but not Dll4, directly induces Sm-mhc expression in 10T1/2 cells without de novo protein synthesis, indicative of a ligand-selective effect. Jagged1-induced expression of SM-MHC was blocked by gamma-secretase inhibitor, N-(N-(3,5-difluorophenyl)-L-alanyl)-S-phenylglycine t-butyl ester, which impedes Notch signaling. Using Rbp-j kappa-deficient cells and site-specific mutagenesis of the SM-MHC gene, weshow that such an induction is independent of the myocardin-serum response factor-CArG complex, but absolutely dependent on RBP-J kappa, a major mediator of Notch signaling, and its cognate binding sequence. Of importance, Notch signaling and myocardin synergistically activate SM-MHC gene expression. Taken together, these data suggest that the Jagged1-Notch pathway constitutes an instructive signal for SMC differentiation through an RBP-J kappa-dependent mechanism and augments gene expression mediated by the myocardin-SRF-CArG complex. Given that Notch pathway components are expressed in vascular SMC during normal development and disease, Notch signaling is likely to play a pivotal role in such situations to modulate the vascular smooth muscle cell phenotype.	Gunma Univ, Grad Sch Med, Dept Med & Biol Sci, Maebashi, Gumma 3718511, Japan; Gunma Univ, Grad Sch Med, Educ & Res Ctr, Maebashi, Gumma 3718511, Japan; Gunma Univ, Grad Sch Med, Sci Labs, Maebashi, Gumma 3718511, Japan; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1130033, Japan	Gunma University; Gunma University; Gunma University; University of Tokyo	Kurabayashi, M (corresponding author), Gunma Univ, Grad Sch Med, Dept Med & Biol Sci, 3-39-15 Showa Machi, Maebashi, Gumma 3718511, Japan.	mkuraba@med.gunma-u.ac.jp	Manabe, Ichiro/AAE-5105-2021; Matsui, Hiroki/P-4033-2019; Manabe, Ichiro/E-1529-2014	Matsui, Hiroki/0000-0003-3243-333X; Iso, Tatsuya/0000-0001-5045-1676				Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Anthony TE, 2005, GENE DEV, V19, P1028, DOI 10.1101/gad.1302105; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Cao DS, 2005, MOL CELL BIOL, V25, P364, DOI 10.1128/MCB.25.1.364-376.2005; Chen JY, 2002, J MOL CELL CARDIOL, V34, P1345, DOI 10.1006/jmcc.2002.2086; Chin MT, 2000, J BIOL CHEM, V275, P6381, DOI 10.1074/jbc.275.9.6381; CHUNG CN, 1994, NUCLEIC ACIDS RES, V22, P2938, DOI 10.1093/nar/22.15.2938; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Deregowski V, 2006, J BIOL CHEM, V281, P6203, DOI 10.1074/jbc.M508370200; Doi H, 2005, ARTERIOSCL THROM VAS, V25, P2328, DOI 10.1161/01.ATV.0000185829.47163.32; Domenga V, 2004, GENE DEV, V18, P2730, DOI 10.1101/gad.308904; Du KL, 2003, MOL CELL BIOL, V23, P2425, DOI 10.1128/MCB.23.7.2425-2437.2003; Elagib KE, 2004, MOL CELL BIOL, V24, P7779, DOI 10.1128/MCB.24.17.7779-7794.2004; Garces C, 1997, J BIOL CHEM, V272, P29729, DOI 10.1074/jbc.272.47.29729; GAZIT D, 1993, MOL ENDOCRINOL, V7, P189, DOI 10.1210/me.7.2.189; Geling A, 2002, EMBO REP, V3, P688, DOI 10.1093/embo-reports/kvf124; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Iso T, 2006, BIOCHEM BIOPH RES CO, V341, P708, DOI 10.1016/j.bbrc.2006.01.020; Iso T, 2003, ARTERIOSCL THROM VAS, V23, P543, DOI 10.1161/01.ATV.0000060892.81529.8F; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Iso T, 2002, J BIOL CHEM, V277, P6598, DOI 10.1074/jbc.M110495200; Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001; Itoh F, 2004, EMBO J, V23, P541, DOI 10.1038/sj.emboj.7600065; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Kato H, 1997, DEVELOPMENT, V124, P4133; Kawai-Kowase K, 2004, ARTERIOSCL THROM VAS, V24, P1384, DOI 10.1161/01.ATV.0000136548.17816.07; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; Lardelli M, 1996, MECH DEVELOP, V59, P177, DOI 10.1016/0925-4773(96)00589-8; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; Li SJ, 2003, P NATL ACAD SCI USA, V100, P9366, DOI 10.1073/pnas.1233635100; Loomes KM, 1999, HUM MOL GENET, V8, P2443, DOI 10.1093/hmg/8.13.2443; Loomes KM, 2002, AM J MED GENET, V112, P181, DOI 10.1002/ajmg.10592; LU Y, 1992, BIOCHEM CELL BIOL, V70, P1249, DOI 10.1139/o92-171; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Morrow D, 2005, AM J PHYSIOL-CELL PH, V289, pC1188, DOI 10.1152/ajpcell.00198.2005; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Noseda M, 2004, CIRC RES, V94, P910, DOI 10.1161/01.RES.0000124300.76171.C9; Noseda M, 2006, CIRC RES, V98, P1468, DOI 10.1161/01.RES.0000229683.81357.26; Okajima T, 2002, CELL, V111, P893, DOI 10.1016/S0092-8674(02)01114-5; Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Proweller A, 2005, J BIOL CHEM, V280, P8994, DOI 10.1074/jbc.M413316200; REAUME AG, 1992, DEV BIOL, V154, P377, DOI 10.1016/0012-1606(92)90076-S; Ross DA, 2004, MOL CELL BIOL, V24, P3505, DOI 10.1128/MCB.24.8.3505-3513.2004; Rutz S, 2005, EUR J IMMUNOL, V35, P2443, DOI 10.1002/eji.200526294; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Sciaudone M, 2003, ENDOCRINOLOGY, V144, P5631, DOI 10.1210/en.2003-0463; Shimizu K, 2001, J BIOL CHEM, V276, P25753, DOI 10.1074/jbc.M103473200; Shimizu K, 2000, BIOCHEM BIOPH RES CO, V276, P385, DOI 10.1006/bbrc.2000.3469; Tezuka K, 2002, J BONE MINER RES, V17, P231, DOI 10.1359/jbmr.2002.17.2.231; Ueyama T, 2003, MOL CELL BIOL, V23, P9222, DOI 10.1128/MCB.23.24.9222-9232.2003; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Yang LT, 2005, MOL BIOL CELL, V16, P927, DOI 10.1091/mbc.e04-07-0614; Yoshida T, 2004, ARTERIOSCL THROM VAS, V24, P1596, DOI 10.1161/01.ATV.0000137190.63214.c5; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069	61	117	123	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28555	28564		10.1074/jbc.M602749200	http://dx.doi.org/10.1074/jbc.M602749200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16867989	hybrid			2022-12-25	WOS:000240680500009
J	Hasegawa, M; Yang, KK; Hashimoto, M; Park, JH; Kim, YG; Fujimoto, Y; Nunez, G; Fukase, K; Inohara, N				Hasegawa, Mizuho; Yang, Kangkang; Hashimoto, Masahito; Park, Jong-Hwan; Kim, Yun-Gi; Fujimoto, Yukari; Nunez, Gabriel; Fukase, Koichi; Inohara, Naohiro			Differential release and distribution of Nod1 and Nod2 immunostimulatory molecules among bacterial species and environments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MURAMYL DIPEPTIDE; HOST RECOGNITION; LIPID-A; PEPTIDOGLYCAN; ASSOCIATION; RECEPTOR; SUSCEPTIBILITY; POLYMORPHISMS; INNATE	Nod1 and Nod2 are intracellular proteins that are involved in recognition of bacterial molecules and their genetic variations have been linked to several inflammatory diseases that are strongly affected by environmental factors. However, the distribution of Nod1- and Nod2-stimulatory molecules in different bacterial species and environments is unknown. Here we established a quantitative bioassay to screen and characterize Nod1 and Nod2-stimulatory activities in different environmental sites and bacterial species. Using this system, we found that common environments including foods and soils contain high levels of Nod1- and Nod2-stimulatory activities. Several Bacillus species were identified to possess the highest Nod1- stimulatory activity among soil bacteria. Unlike other immunostimulatory molecules, the higher level of Nod1- stimulatory activity was found in the culture supernatant and not in extracts from whole cell bacteria. Nod1- stimulatory molecules were highly stable at extreme pH and boiling conditions and were synthesized in an amidase- and sltY-independent manner. These results suggest a novel mechanism by which bacteria present in the environment stimulate the host immune system through Nod1.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA; Kagoshima Univ, Dept Nanostruct & Adv Mat, Kagoshima 8900065, Japan; Osaka Univ, Grad Sch Sci, Dept Chem, Toyonaka, Osaka 5600043, Japan	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Kagoshima University; Osaka University	Inohara, N (corresponding author), 1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	ino@umich.edu	Nuñez, Gabriel/A-7160-2014; Fujimoto, Yukari/M-7282-2014	Fujimoto, Yukari/0000-0001-5320-3192				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Backhed F, 2003, MICROBES INFECT, V5, P1057, DOI 10.1016/S1286-4579(03)00207-7; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Foley-Comer AJ, 2002, J CELL SCI, V115, P1383; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; GOTO T, 1987, IMMUNOSTIMULANTS NOW, P99; Granum PE, 1997, FEMS MICROBIOL LETT, V157, P223, DOI 10.1016/S0378-1097(97)00438-2; Guarner F, 2003, LANCET, V361, P512, DOI 10.1016/S0140-6736(03)12489-0; Hajjar AM, 2002, NAT IMMUNOL, V3, P354, DOI 10.1038/ni777; Hashimoto M, 2002, EUR J BIOCHEM, V269, P3715, DOI 10.1046/j.1432-1033.2002.03062.x; Heidrich C, 2001, MOL MICROBIOL, V41, P167, DOI 10.1046/j.1365-2958.2001.02499.x; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; Hosoi T, 2003, INT J FOOD MICROBIOL, V82, P255, DOI 10.1016/S0168-1605(02)00311-2; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Hysi P, 2005, HUM MOL GENET, V14, P935, DOI 10.1093/hmg/ddi087; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; JACOBS C, 1994, EMBO J, V13, P4684, DOI 10.1002/j.1460-2075.1994.tb06792.x; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V111, P813, DOI 10.1067/mai.2003.1336; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Li J, 2004, HUM MOL GENET, V13, P1715, DOI 10.1093/hmg/ddh182; Lin J, 2004, CURR OPIN MOL THER, V6, P629; Mack DR, 2004, CURR OPIN GASTROEN, V20, P22, DOI 10.1097/00001574-200401000-00006; Masumoto J, 2006, J EXP MED, V203, P203, DOI 10.1084/jem.20051229; McGovern DPB, 2005, HUM MOL GENET, V14, P1245, DOI 10.1093/hmg/ddi135; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; PROCTOR RA, 1985, INFECT IMMUN, V49, P286, DOI 10.1128/IAI.49.2.286-290.1985; Rastall RA, 2004, J NUTR, V134, p2022S, DOI 10.1093/jn/134.8.2022S; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Tada H, 2005, INFECT IMMUN, V73, P7967, DOI 10.1128/IAI.73.12.7967-7976.2005; TANAMOTO K, 1984, INFECT IMMUN, V44, P421, DOI 10.1128/IAI.44.2.421-426.1984; Trujillo C, 2003, INT J MED MICROBIOL, V293, P123, DOI 10.1078/1438-4221-00257; van Heel DA, 2005, LANCET, V365, P1794, DOI 10.1016/S0140-6736(05)66582-8; Vavricka SR, 2004, GASTROENTEROLOGY, V127, P1401, DOI 10.1053/j.gastro.2004.07.024; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; WARD PA, 1972, P SOC EXP BIOL MED, V141, P898, DOI 10.3181/00379727-141-36897; Weidinger S, 2005, J ALLERGY CLIN IMMUN, V116, P177, DOI 10.1016/j.jaci.2005.02.034; Weidinger S, 2005, CLIN EXP ALLERGY, V35, P866, DOI 10.1111/j.1365-2222.2005.02269.x; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; YIN ET, 1972, BIOCHIM BIOPHYS ACTA, V261, P284	47	134	135	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29054	29063		10.1074/jbc.M602638200	http://dx.doi.org/10.1074/jbc.M602638200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16870615	hybrid			2022-12-25	WOS:000240680500060
J	Akhtar, MS; Krishnan, MY; Bhakuni, V				Akhtar, Md. Sohail; Krishnan, Manju Yasoda; Bhakuni, Vinod			Insights into the mechanism of action of hyaluronate lyase - Role of C-terminal domain and Ca2+ in the functional regulation of enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS; DEGRADATION; GENE; PURIFICATION; EXPRESSION; BINDING; HYALURONIDASES; SEQUENCE; CLONING; COMPLEX	Hyaluronate lyases (HLs) cleave hyaluronan and certain other chondroitin/chondroitin sulfates. Although native HL from Streptococcus agalactiae is composed of four domains, it finally stabilizes after autocatalytic conversion as a 92-kDa enzyme composed of the N-terminal spacer, middle alpha-, and C-terminal domains. These three domains are independent folding/unfolding units of the enzyme. Comparative structural and functional studies using the enzyme and its various fragments/domains suggest a relatively insignificant role of the N-terminal spacer domain in the 92-kDa enzyme. Functional studies demonstrate that the alpha-domain is the catalytic domain. However, independently it has a maximum of only about 10% of the activity of the 92-kDa enzyme, whereas its complex with the C-terminal domain in vitro shows a significant enhancement (about 6-fold) in the activity. It has been previously proposed that the C-terminal domain modulates the enzymatic activity of HLs. In addition, one of the possible roles for calcium ions was suggested to induce conformational changes in the enzyme loops, making HL more suitable for catalysis. However, we observed that calcium ions do not interact with the enzyme, and its role actually is in modulating the hyaluronan conformation and not in the functional regulation of enzyme.	Cent Drug Res Inst, Div Mol & Struct Biol, Lucknow 226001, Uttar Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI)	Bhakuni, V (corresponding author), Cent Drug Res Inst, Div Mol & Struct Biol, Lucknow 226001, Uttar Pradesh, India.	bhakuniv@rediffmail.com	Akhtar, Sohail/A-2300-2010; Krishnan, Manju Y/B-7195-2009					Akhtar MS, 2003, J BIOL CHEM, V278, P25509, DOI 10.1074/jbc.M301894200; Akhtar MS, 2002, BIOCHEMISTRY-US, V41, P3819, DOI 10.1021/bi0116700; Baker JR, 1997, BIOCHEM J, V327, P65, DOI 10.1042/bj3270065; BERRY AM, 1994, INFECT IMMUN, V62, P1101, DOI 10.1128/IAI.62.3.1101-1108.1994; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; DILLON HC, 1987, J PEDIATR-US, V110, P31, DOI 10.1016/S0022-3476(87)80283-4; Fethiere J, 1999, J MOL BIOL, V288, P635, DOI 10.1006/jmbi.1999.2698; Gase K, 1998, BBA-GENE STRUCT EXPR, V1398, P86, DOI 10.1016/S0167-4781(98)00045-1; Hynes WL, 2000, FEMS MICROBIOL LETT, V183, P201, DOI 10.1111/j.1574-6968.2000.tb08958.x; Jedrzejas MJ, 2000, CRIT REV BIOCHEM MOL, V35, P221, DOI 10.1080/10409230091169195; Jedrzejas MJ, 1998, PROTEIN EXPRES PURIF, V13, P83, DOI 10.1006/prep.1997.0864; Jedrzejas MJ, 2000, ACTA CRYSTALLOGR D, V56, P460, DOI 10.1107/S0907444900000706; Jedrzejas MJ, 2002, J BIOL CHEM, V277, P28287, DOI 10.1074/jbc.M112009200; Jedrzejas MJ, 2001, MICROBIOL MOL BIOL R, V65, P187, DOI 10.1128/MMBR.65.2.187-207.2001; Kelly SJ, 2001, GLYCOBIOLOGY, V11, P297, DOI 10.1093/glycob/11.4.297; KREIL G, 1995, PROTEIN SCI, V4, P1666, DOI 10.1002/pro.5560040902; Li SL, 2000, EMBO J, V19, P1228, DOI 10.1093/emboj/19.6.1228; Li SL, 2001, J BIOL CHEM, V276, P41407, DOI 10.1074/jbc.M106634200; LIN B, 1994, J BIOL CHEM, V269, P30113; Mello LV, 2002, J BIOL CHEM, V277, P36678, DOI 10.1074/jbc.M205140200; PATON JC, 1986, INFECT IMMUN, V54, P50, DOI 10.1128/IAI.54.1.50-55.1986; Ponnuraj K, 2000, J MOL BIOL, V299, P885, DOI 10.1006/jmbi.2000.3817; Pritchard DG, 2000, PROTEINS, V40, P126; PRITCHARD DG, 1994, ARCH BIOCHEM BIOPHYS, V315, P431, DOI 10.1006/abbi.1994.1521; QUI GN, 1996, CHEM PHARM BULL, V44, P1017; Rigden DJ, 2003, PROTEINS, V52, P203, DOI 10.1002/prot.10405; Scott JE, 1999, P NATL ACAD SCI USA, V96, P4850, DOI 10.1073/pnas.96.9.4850; Spellerberg B, 2000, MICROBES INFECT, V2, P1733, DOI 10.1016/S1286-4579(00)01328-9; WINTER WT, 1977, J MOL BIOL, V117, P761, DOI 10.1016/0022-2836(77)90068-7; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; Yildirim AO, 2002, RES VET SCI, V73, P131, DOI 10.1016/S0034-5288(02)00029-2	31	10	11	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28336	28344		10.1074/jbc.M601165200	http://dx.doi.org/10.1074/jbc.M601165200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16854993	hybrid			2022-12-25	WOS:000240534400071
J	Paschinger, K; Hackl, M; Gutternigg, M; Kretschmer-Lubich, D; Stemmer, U; Jantsch, V; Lochnit, G; Wilson, IBH				Paschinger, Katharina; Hackl, Matthias; Gutternigg, Martin; Kretschmer-Lubich, Dorothea; Stemmer, Ute; Jantsch, Verena; Lochnit, Guenter; Wilson, Iain B. H.			A deletion in the Golgi alpha-mannosidase II gene of Caenorhabditis elegans results in unexpected non-wild-type N-glycan structures*	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; DROSOPHILA-MELANOGASTER; INSECT CELLS; GLYCOPROTEIN-SYNTHESIS; MOLECULAR-CLONING; IN-VITRO; IDENTIFICATION; COMPLEX; CDNA; PHOSPHORYLCHOLINE	The processing of N-linked oligosaccharides by alpha-mannosidases in the endoplasmic reticulum and Golgi is a process conserved in plants and animals. After the transfer of a GlcNAc residue to Asn- bound Man(5)GlcNAc(2) by N-acetylglucosaminyl-transferase I, an alpha-mannosidase (EC 3.2.1.114) removes one alpha 1,3- linked and one alpha 1,6- linked mannose residue. In this study, we have identified the relevant alpha-mannosidase II gene (aman- 2; F58H1.1) from Caenorhabditis elegans and have detected its activity in both native and recombinant forms. For comparative studies, the two other cDNAs encoding class II mannosidases aman-1 (F55D10.1) and aman- 3 (F48C1.1) were cloned; the corresponding enzymes are, respectively, a putative lysosomal alpha-mannosidase and a Co(II)-activated alpha-mannosidase. The analysis of the N-glycan structures of an aman- 2 mutant strain demonstrates that the absence of alpha-mannosidase II activity results in a shift to structures not seen in wild-type worms (e. g. N-glycans with the composition Hex(5-7)HexNAc(2-3)Fuc(2)Me) and an accumulation of hybrid oligosaccharides. Paucimannosidic glycans are almost absent from aman-2 worms, indicative also of a general lack of alpha-mannosidase III activity. We hypothesize that there is a tremendous flexibility in the glycosylation pathway of C. elegans that does not impinge, under standard laboratory conditions, on the viability of worms with glycotypes very unlike the wild-type pattern.	Univ Bodenkultur Wien, Dept Chem, A-1190 Vienna, Austria; Vienna Bioctr 2, Abt Chromosomenbiol, A-1030 Vienna, Austria; Univ Giessen, Inst Biochem, D-35292 Giessen, Germany	University of Natural Resources & Life Sciences, Vienna; Vienna Biocenter (VBC); Justus Liebig University Giessen	Wilson, IBH (corresponding author), Univ Bodenkultur Wien, Dept Chem, A-1190 Vienna, Austria.	iain.wilson@boku.ac.at	Wilson, Iain/B-3326-2009; Jantsch, Verena/A-3910-2017	Wilson, Iain/0000-0001-8996-1518; Jantsch, Verena/0000-0002-1978-682X; Paschinger, Katharina/0000-0002-3594-7136; Hackl, Matthias/0000-0002-4136-7293	Austrian Science Fund FWF [P 18447] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Akama TO, 2006, P NATL ACAD SCI USA, V103, P8983, DOI 10.1073/pnas.0603248103; ALLEN SD, 1984, J BIOL CHEM, V259, P6984; ALTMANN F, 1995, J BIOL CHEM, V270, P17344, DOI 10.1074/jbc.270.29.17344; Altmann F, 2001, BIOCHIMIE, V83, P703, DOI 10.1016/S0300-9084(01)01297-4; ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P150, DOI 10.1007/BF00731359; Berg T, 1997, BIOCHEM J, V328, P863, DOI 10.1042/bj3280863; BISCHOFF J, 1990, J BIOL CHEM, V265, P17110; BOLANOWSKI MA, 1983, MECH AGEING DEV, V21, P295, DOI 10.1016/0047-6374(83)90048-9; Chui D, 1997, CELL, V90, P157, DOI 10.1016/S0092-8674(00)80322-0; Chui D, 2001, P NATL ACAD SCI USA, V98, P1142, DOI 10.1073/pnas.98.3.1142; Cipollo JF, 2005, J BIOL CHEM, V280, P26063, DOI 10.1074/jbc.M503828200; Cipollo JF, 2004, J BIOL CHEM, V279, P52893, DOI 10.1074/jbc.M409557200; Cipollo JF, 2004, P NATL ACAD SCI USA, V101, P3404, DOI 10.1073/pnas.0400384101; DEWALD B, 1973, J BIOL CHEM, V248, P7223; DIXON M, 1953, BIOCHEM J, V55, P161, DOI 10.1042/bj0550161; Fabini G, 2001, J BIOL CHEM, V276, P28058, DOI 10.1074/jbc.M100573200; FOSTER JM, 1995, GENE, V154, P183, DOI 10.1016/0378-1119(94)00867-R; Gerdt S, 1999, EUR J BIOCHEM, V266, P952, DOI 10.1046/j.1432-1327.1999.00937.x; Gonzalez DS, 1999, J BIOL CHEM, V274, P21375, DOI 10.1074/jbc.274.30.21375; Hanneman AJ, 2006, GLYCOBIOLOGY, V16, P874, DOI 10.1093/glycob/cwl011; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; Haslam SM, 2003, BIOCHIMIE, V85, P25, DOI 10.1016/S0300-9084(03)00041-5; Haslam SM, 2002, BIOCHEM SOC SYMP, V69, P117; Haslam SM, 1997, MOL BIOCHEM PARASIT, V85, P53, DOI 10.1016/S0166-6851(96)02807-1; Heikinheimo P, 2003, J MOL BIOL, V327, P631, DOI 10.1016/S0022-2836(03)00172-4; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Herscovics A, 2001, BIOCHIMIE, V83, P757, DOI 10.1016/S0300-9084(01)01319-0; Hirabayashi J, 2002, J BIOCHEM, V132, P103, DOI 10.1093/oxfordjournals.jbchem.a003186; Houston KM, 1997, J BIOL CHEM, V272, P1527, DOI 10.1074/jbc.272.3.1527; Howard S, 1998, J BIOL CHEM, V273, P2067, DOI 10.1074/jbc.273.4.2067; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; Kaji H, 2003, NAT BIOTECHNOL, V21, P667, DOI 10.1038/nbt829; Kawar Z, 2001, J BIOL CHEM, V276, P16335, DOI 10.1074/jbc.M100119200; Landis G, 2001, GENETICS, V158, P1167; LEON MA, 1971, BIOCHEMISTRY-US, V10, P1424, DOI 10.1021/bi00784a024; Liao YF, 1996, J BIOL CHEM, V271, P28348, DOI 10.1074/jbc.271.45.28348; Lukacsovich T, 2001, GENETICS, V157, P727; McIlvaine TC, 1921, J BIOL CHEM, V49, P183; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; MISAGO M, 1995, P NATL ACAD SCI USA, V92, P11766, DOI 10.1073/pnas.92.25.11766; MONIS E, 1987, EUR J BIOCHEM, V168, P287, DOI 10.1111/j.1432-1033.1987.tb13419.x; MOREMEN KW, 1991, J CELL BIOL, V115, P1521, DOI 10.1083/jcb.115.6.1521; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; Natsuka S, 2002, J BIOCHEM, V131, P807, DOI 10.1093/oxfordjournals.jbchem.a003169; Nilssen O, 1997, HUM MOL GENET, V6, P717, DOI 10.1093/hmg/6.5.717; NOVIKOFF PM, 1983, P NATL ACAD SCI-BIOL, V80, P4364, DOI 10.1073/pnas.80.14.4364; Numao S, 2000, FEBS LETT, V484, P175, DOI 10.1016/S0014-5793(00)02148-7; Park C, 2005, J BIOL CHEM, V280, P37204, DOI 10.1074/jbc.M508930200; Paschinger K, 2004, J BIOL CHEM, V279, P49588, DOI 10.1074/jbc.M408978200; Paschinger K, 2005, GLYCOBIOLOGY, V15, P463, DOI 10.1093/glycob/cwi028; Praitis V, 2001, GENETICS, V157, P1217; Rabouille C, 1999, J CELL SCI, V112, P3319; Rendic D, 2006, J BIOL CHEM, V281, P3343, DOI 10.1074/jbc.M508334200; Rolls MM, 2002, MOL BIOL CELL, V13, P1778, DOI 10.1091/mbc.01-10-0514; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; Schachter H, 2005, GLYCOBIOLOGY, V15, P1191; Strasser R, 2006, PLANT J, V45, P789, DOI 10.1111/j.1365-313X.2005.02648.x; Strasser R, 2005, BIOCHEM J, V387, P385, DOI 10.1042/BJ20041686; SUZUKI T, 2006, IN PRESS BIOCH J; TABAS I, 1978, J BIOL CHEM, V253, P7779; Tollersrud OK, 1997, EUR J BIOCHEM, V246, P410, DOI 10.1111/j.1432-1033.1997.00410.x; Tremblay LO, 2000, J BIOL CHEM, V275, P31655, DOI 10.1074/jbc.M004935200; Treusch S, 2004, P NATL ACAD SCI USA, V101, P4483, DOI 10.1073/pnas.0400709101; TULSIANI DRP, 1982, J BIOL CHEM, V257, P3660; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227; van den Elsen JMH, 2001, EMBO J, V20, P3008, DOI 10.1093/emboj/20.12.3008; van Die I, 1999, FEBS LETT, V463, P189, DOI 10.1016/S0014-5793(99)01508-2; VONSCHAEWEN A, 1993, PLANT PHYSIOL, V102, P1109, DOI 10.1104/pp.102.4.1109; Weiser JN, 1997, INFECT IMMUN, V65, P943, DOI 10.1128/IAI.65.3.943-950.1997; Wilson IBH, 1998, GLYCOCONJUGATE J, V15, P1055, DOI 10.1023/A:1006960401562; Zhang WL, 2003, BIOCHEM J, V372, P53, DOI 10.1042/BJ20021931; Zhu SX, 2004, BIOCHEM J, V382, P995, DOI 10.1042/BJ20040793	72	35	38	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28265	28277		10.1074/jbc.M602878200	http://dx.doi.org/10.1074/jbc.M602878200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16864579	Green Accepted, hybrid			2022-12-25	WOS:000240534400064
J	Wang, J; Sun, F; Zhang, DW; Ma, YM; Xu, F; Belani, JD; Cohen, JC; Hobbs, HH; Xie, XS				Wang, Jin; Sun, Fang; Zhang, Da-wei; Ma, Yongming; Xu, Fang; Belani, Jitendra D.; Cohen, Jonathan C.; Hobbs, Helen H.; Xie, Xiao-Song			Sterol transfer by ABCG5 and ABCG8 - In vitro assay and reconstitution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN-PROCESSING TAP; MULTIDRUG-RESISTANCE TRANSPORTER; BILIARY CHOLESTEROL SECRETION; GLYCOPROTEIN ATPASE ACTIVITY; NUCLEOTIDE-BINDING DOMAINS; MYOSIN MOTOR DOMAIN; P-GLYCOPROTEIN; DIETARY-CHOLESTEROL; MEMBRANE-VESICLES; RAT-LIVER	ATP-binding cassette transporters G5 and G8 are half-transporters expressed on the apical membranes of enterocytes and hepatocytes that limit intestinal uptake and promote secretion of neutral sterols. Genetic defects that inactivate either half-transporter cause accumulation of cholesterol and plant sterols, resulting in premature coronary atherosclerosis. These observations suggest that G5 and G8 promote the translocation of sterols across membranes, but the primary transport substrate of the G5G8 complex has not been directly determined. Here we report the development of a sterol transfer assay using "insideout" membrane vesicles from Sf9 cells expressing recombinant mouse G5 and G8. Radiolabeled cholesterol or sitosterol was transferred from donor liposomes to G5- and G8-containing membrane vesicles in an ATP-dependent and vanadate-sensitive manner; net transfer of cholesterol was associated with an increase in vesicular cholesterol mass. CTP, GTP, and UTP, as well as ATP, supported transfer but with lesser efficiency (ATP >> CTP > GTP > UTP). Transfer was specific for sterols and was stereoselective; minimal ATP-dependent and vanadate-sensitive transfer of cholesteryl oleate, phosphatidylcholine, or enantiomeric cholesterol was observed. These studies indicate that G5 and G8 are sufficient for reconstitution of sterol transfer activity in vitro and provide the first demonstration that sterols are direct transport substrates of the G5 and G8 heterodimer.	Univ Texas, SW Med Ctr, Eugene McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Human Nutr, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California Irvine	Xie, XS (corresponding author), Univ Texas, SW Med Ctr, Eugene McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA.	xiao-song.xie@UTSouthwestern.edu	Belani, Jitendra/W-5561-2019; Zhang, Dawei/ABD-8990-2022	Zhang, Dawei/0000-0001-8279-8041	NHLBI NIH HHS [R37 HL072304, HL72304, HL20948, P01 HL020948, R01 HL072304] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, R01HL072304, R37HL072304] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albrecht C, 2002, BBA-BIOMEMBRANES, V1567, P133, DOI 10.1016/S0005-2736(02)00608-9; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Biswas EE, 2001, BIOCHEMISTRY-US, V40, P8181, DOI 10.1021/bi0106686; Burg D, 2002, MOL PHARMACOL, V62, P1160, DOI 10.1124/mol.62.5.1160; Cai J, 2002, BIOCHEMISTRY-US, V41, P8058, DOI 10.1021/bi012082p; Chen M, 2003, J BIOL CHEM, V278, P29686, DOI 10.1074/jbc.M302757200; Chen M, 2004, J BIOL CHEM, V279, P46073, DOI 10.1074/jbc.M404042200; Dean M, 2001, J LIPID RES, V42, P1007; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Graf GA, 2004, J BIOL CHEM, V279, P24881, DOI 10.1074/jbc.M402634200; Graf GA, 2003, J BIOL CHEM, V278, P48275, DOI 10.1074/jbc.M310223200; Graf GA, 2002, J CLIN INVEST, V110, P659, DOI 10.1172/JCI200216000; Henriksen U, 2005, J CELL SCI, V118, P1417, DOI 10.1242/jcs.01729; Higgins CF, 2004, NAT STRUCT MOL BIOL, V11, P918, DOI 10.1038/nsmb836; INOUE M, 1983, J BIOL CHEM, V258, P5183; Janvilisri T, 2003, J BIOL CHEM, V278, P20645, DOI 10.1074/jbc.M301358200; Jones PM, 2004, CELL MOL LIFE SCI, V61, P682, DOI 10.1007/s00018-003-3336-9; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; Kipp H, 2000, J BIOL CHEM, V275, P15917, DOI 10.1074/jbc.M909875199; Koch J, 2004, J BIOL CHEM, V279, P10142, DOI 10.1074/jbc.M312816200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lange Y, 2004, P NATL ACAD SCI USA, V101, P11664, DOI 10.1073/pnas.0404766101; Lapinski PE, 2001, J BIOL CHEM, V276, P7526, DOI 10.1074/jbc.M009448200; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; LELONG IH, 1992, FEBS LETT, V304, P256, DOI 10.1016/0014-5793(92)80632-Q; Melin P, 2004, BIOCHEM PHARMACOL, V67, P2187, DOI 10.1016/j.bcp.2004.02.022; MULLER KM, 1994, J BIOL CHEM, V269, P14032; Ozvegy C, 2002, J BIOL CHEM, V277, P47980, DOI 10.1074/jbc.M207857200; Powe AC, 2002, J PHYSIOL-LONDON, V539, P333, DOI 10.1113/jphysiol.2001.013162; RYCHNOVSKY SD, 1992, J ORG CHEM, V57, P2732, DOI 10.1021/jo00035a036; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; Sankaran B, 1997, ARCH BIOCHEM BIOPHYS, V341, P160, DOI 10.1006/abbi.1997.9944; Small DM, 2003, P NATL ACAD SCI USA, V100, P4, DOI 10.1073/pnas.0237205100; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Takahashi K, 2006, J BIOL CHEM, V281, P10760, DOI 10.1074/jbc.M513783200; Tam SP, 2006, AM J PHYSIOL-CELL PH, V291, pC490, DOI 10.1152/ajpcell.00055.2006; Urbatsch IL, 2003, J BIOL CHEM, V278, P23171, DOI 10.1074/jbc.M301957200; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Wang ZL, 2006, BIOCHEMISTRY-US, V45, P9929, DOI 10.1021/bi0608055; XIE XS, 1986, J BIOL CHEM, V261, P2492; XIE XS, 1983, J BIOL CHEM, V258, P4834; XIE XS, 1989, J BIOL CHEM, V264, P1710; Yu LQ, 2002, P NATL ACAD SCI USA, V99, P16237, DOI 10.1073/pnas.252582399; Yu LQ, 2004, J LIPID RES, V45, P301, DOI 10.1194/jlr.M300377-JLR200; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]; Zelcer N, 2003, BIOCHEM J, V371, P361, DOI 10.1042/BJ20021886; Zhang DW, 2006, J BIOL CHEM, V281, P4507, DOI 10.1074/jbc.M512277200	52	67	71	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27894	27904		10.1074/jbc.M605603200	http://dx.doi.org/10.1074/jbc.M605603200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16867993	Green Accepted, hybrid			2022-12-25	WOS:000240534400025
J	Heyes, DJ; Heathcote, P; Rigby, SEJ; Palacios, MA; van Grondelle, R; Hunter, CN				Heyes, Derren J.; Heathcote, Peter; Rigby, Stephen E. J.; Palacios, Miguel A.; van Grondelle, Rienk; Hunter, C. Neil			The first catalytic step of the light-driven enzyme protochlorophyllide oxidoreductase proceeds via a charge transfer complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STARK SPECTROSCOPY; PHOTOSYSTEM-I; RHODOBACTER-SPHAEROIDES; SUBSTRATE-SPECIFICITY; ENDOR SPECTROSCOPY; REDUCTASE; NADPH; PHOTOREDUCTION; RADICALS; IDENTIFICATION	In chlorophyll biosynthesis protochlorophyllide reductase (POR) catalyzes the light-driven reduction of protochlorophyllide (Pchlide) to chlorophyllide, providing a rare opportunity to trap and characterize catalytic intermediates at low temperatures. Moreover, the presence of a chlorophyll-like molecule allows the use of EPR, electron nuclear double resonance, and Stark spectroscopies, previously used for the analysis of photosynthetic systems, to follow catalytic events in the active site of POR. Different models involving the formation of either radical species or charge transfer complexes have been proposed for the initial photochemical step, which forms a nonfluorescent intermediate absorbing at 696nm(A(696)). Our EPR data show that the concentration of the radical species formed in the initial photochemical step is not stoichiometric with conversion of substrate. Instead, a large Stark effect, indicative of charge transfer character, is associated with A(696). Two components were required to fit the Stark data, providing clear evidence that charge transfer complexes are formed during the initial photochemistry. The temperature dependences of both A(696) formation and NADPH oxidation are identical, and we propose that formation of the A(696) state involves hydride transfer from NADPH to form a charge transfer complex. A catalytic mechanism of POR is suggested in which Pchlide absorbs a photon, creating a transient charge separation across the C-17-C-18 double bond, which promotes ultrafast hydride transfer from the pro-S face of NADPH to the C-17 of Pchlide. The resulting A(696) charge transfer intermediate facilitates transfer of a proton to the C-18 of Pchlide during the subsequent first "dark" reaction.	Univ Sheffield, Dept Mol Biol & Biotechnol, Robert Hill Inst Photosynth, Sheffield S10 2TN, S Yorkshire, England; Univ Sheffield, Dept Mol Biol & Biotechnol, Krebs Inst Biomolec Res, Sheffield S10 2TN, S Yorkshire, England; Univ London Queen Mary Coll, Sch Biol Sci, London E1 4NS, England; Vrije Univ Amsterdam, Dept Exact Sci, NL-1081 HV Amsterdam, Netherlands	University of Sheffield; University of Sheffield; University of London; Queen Mary University London; Vrije Universiteit Amsterdam	Heyes, DJ (corresponding author), Univ Manchester, Manchester Interdisciplinary Bioctr, 131 Princess St, Manchester M1 7ND, Lancs, England.	derren.heyes@manchester.ac.uk	Heathcote, Peter/B-3749-2011	Heyes, Derren/0000-0002-7453-1571				BAKER ME, 1994, BIOCHEM J, V300, P605; Beekman LMP, 1997, J PHYS CHEM B, V101, P7284, DOI 10.1021/jp963445b; BEGLEY TP, 1989, J AM CHEM SOC, V111, P3095, DOI 10.1021/ja00190a071; BELYAEVA OB, 1988, PHOTOSYNTH RES, V15, P247, DOI 10.1007/BF00047356; Bublitz GU, 1997, ANNU REV PHYS CHEM, V48, P213, DOI 10.1146/annurev.physchem.48.1.213; Frese R, 1997, PHOTOSYNTH RES, V54, P115, DOI 10.1023/A:1005903613179; Frese RN, 2002, BBA-BIOENERGETICS, V1554, P180, DOI 10.1016/S0005-2728(02)00242-6; GRIFFITHS WT, 1980, BIOCHEM J, V186, P267, DOI 10.1042/bj1860267; HAMMES SL, 1990, P NATL ACAD SCI USA, V87, P5682, DOI 10.1073/pnas.87.15.5682; Heyes DJ, 2005, TRENDS BIOCHEM SCI, V30, P642, DOI 10.1016/j.tibs.2005.09.001; Heyes DJ, 2004, BIOCHEMISTRY-US, V43, P8265, DOI 10.1021/bi049576h; Heyes DJ, 2003, NAT STRUCT BIOL, V10, P491, DOI 10.1038/nsb929; Heyes DJ, 2003, BIOCHEMISTRY-US, V42, P523, DOI 10.1021/bi0268448; Heyes DJ, 2002, P NATL ACAD SCI USA, V99, P11145, DOI 10.1073/pnas.182274199; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Klement H, 1999, EUR J BIOCHEM, V265, P862, DOI 10.1046/j.1432-1327.1999.00627.x; KURRECK H, 1988, ELECT NUCL DOUBLE RE; Lebedev N, 1999, P NATL ACAD SCI USA, V96, P9954, DOI 10.1073/pnas.96.17.9954; LOCKHART DJ, 1988, P NATL ACAD SCI USA, V85, P107, DOI 10.1073/pnas.85.1.107; Lubitz W, 2002, ACCOUNTS CHEM RES, V35, P313, DOI 10.1021/ar000084g; Palacios MA, 2004, BBA-BIOENERGETICS, V1656, P177, DOI 10.1016/j.bbabio.2004.04.002; Palacios MA, 2003, BBA-BIOENERGETICS, V1605, P83, DOI 10.1016/S0005-2728(03)00080-X; Raskin VI, 2002, PHOTOSYNTH RES, V74, P181, DOI 10.1023/A:1020955526882; Rigby SEJ, 2001, BBA-BIOENERGETICS, V1507, P247, DOI 10.1016/S0005-2728(01)00211-0; SCHEER H, 1977, J AM CHEM SOC, V99, P1372, DOI 10.1021/ja00447a015; Scheer H., 1991, CHLOROPHYLLS; Townley HE, 1998, FEBS LETT, V422, P19, DOI 10.1016/S0014-5793(97)01589-5; Townley HE, 2001, PROTEINS, V44, P329, DOI 10.1002/prot.1098; Un S, 2001, APPL MAGN RESON, V21, P341, DOI 10.1007/BF03162413; VALERA V, 1987, BIOCHEM BIOPH RES CO, V148, P515, DOI 10.1016/0006-291X(87)91141-7; WILKS HM, 1995, P NATL ACAD SCI USA, V92, P724, DOI 10.1073/pnas.92.3.724; WILLIAMSSMITH DL, 1978, BIOCHEM J, V170, P365, DOI 10.1042/bj1700365	32	46	49	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26847	26853		10.1074/jbc.M602943200	http://dx.doi.org/10.1074/jbc.M602943200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16867988	Green Published, hybrid			2022-12-25	WOS:000240397700011
J	Cao, SJ; Zhang, X; Edwards, JP; Mosser, DM				Cao, Shanjin; Zhang, Xia; Edwards, Justin P.; Mosser, David M.			NF-kappa B1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; IL-10 GENE-EXPRESSION; C-REACTIVE PROTEIN; TRANSCRIPTIONAL COACTIVATOR; BINDING; ACTIVATION; PROMOTER; GAMMA; INTERLEUKIN-10; BCL-3	NF-kappa B/Rel is a family of transcription factors whose activation has long been linked to the production of inflammatory cytokines. Here, we studied NF-kappa B signaling in the regulation of the anti-inflammatory cytokine, interleukin-10 (IL-10). We identified a role for a single NF-kappa B family member, NF-kappa B1 (p50), in promoting the transcription of IL-10. The NF-kappa B cis-element on IL-10 proximal promoter was located to -55/-46, where p50 can homodimerize and form a complex with the transcriptional co-activator CREB-binding protein to activate transcription. The other Rel family members appear to play a negligible role in IL-10 transcription. Mice lacking p50 were more susceptible to lethal endotoxemia, and macrophages taken from p50(-/)-mice exhibit skewed cytokine responses to lipopolysaccharide, characterized by decreased IL-10 and increased tumor necrosis factor and IL-12. Taken together, our studies demonstrate that NF-kappa B1 (p50) homodimers can be transcriptional activators of IL-10. The reciprocal regulation of pro-and anti-inflammatory cytokine production by NF-kappa B1 (p50) may provide potential new ways to manipulate the innate immune response.	Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Mosser, DM (corresponding author), Univ Maryland, Dept Cell Biol & Mol Genet, 1103 Microbiol Bldg, College Pk, MD 20742 USA.	dmosser@umd.edu	Zhang, Xia/B-8152-2008; Mosser, David M/I-6697-2016	Zhang, Xia/0000-0002-9040-1486; Mosser, David M/0000-0002-9503-4187; Edwards, Justin/0000-0001-8936-2136	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049383] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI049383, AI49383, R01 AI049383-06A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agrawal A, 2001, J IMMUNOL, V166, P2378, DOI 10.4049/jimmunol.166.4.2378; Anderson CF, 2002, J IMMUNOL, V168, P3697, DOI 10.4049/jimmunol.168.8.3697; Benkhart EM, 2000, J IMMUNOL, V165, P1612, DOI 10.4049/jimmunol.165.3.1612; BERG DJ, 1995, J CLIN INVEST, V96, P2339, DOI 10.1172/JCI118290; Bleharski JR, 2003, SCIENCE, V301, P1527, DOI 10.1126/science.1087785; Bondeson J, 1999, J IMMUNOL, V162, P2939; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brightbill HD, 2000, J IMMUNOL, V164, P1940, DOI 10.4049/jimmunol.164.4.1940; Cao SJ, 2005, J IMMUNOL, V174, P3484, DOI 10.4049/jimmunol.174.6.3484; Cappiello MG, 2001, J IMMUNOL, V166, P4498, DOI 10.4049/jimmunol.166.7.4498; Cha-Molstad H, 2000, J IMMUNOL, V165, P4592, DOI 10.4049/jimmunol.165.8.4592; Conti P, 2003, IMMUNOL LETT, V88, P171, DOI 10.1016/S0165-2478(03)00087-7; Deng WG, 2003, J IMMUNOL, V171, P6581, DOI 10.4049/jimmunol.171.12.6581; Deng WG, 2003, J BIOL CHEM, V278, P4770, DOI 10.1074/jbc.M209286200; Feng Biao, 2004, Med Immunol, V3, P1, DOI 10.1186/1476-9433-3-1; Fickenscher H, 2002, TRENDS IMMUNOL, V23, P89, DOI 10.1016/S1471-4906(01)02149-4; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; Fu DX, 2004, J BIOL CHEM, V279, P12819, DOI 10.1074/jbc.M312572200; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Fujiwara Nagatoshi, 2005, Current Drug Targets - Inflammation and Allergy, V4, P281, DOI 10.2174/1568010054022024; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Grutz G, 2005, J LEUKOCYTE BIOL, V77, P3, DOI 10.1189/jlb.0904484; Hiroi M, 2003, J BIOL CHEM, V278, P651, DOI 10.1074/jbc.M204544200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang YH, 2002, ONCOGENE, V21, P6819, DOI 10.1038/sj.onc.1205854; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Kaisho T, 2000, CRIT REV IMMUNOL, V20, P393; Kane MM, 2001, J IMMUNOL, V166, P1141, DOI 10.4049/jimmunol.166.2.1141; Kawai T, 2005, CURR OPIN IMMUNOL, V17, P338, DOI 10.1016/j.coi.2005.02.007; Kemper JK, 2004, MOL CELL BIOL, V24, P7707, DOI 10.1128/MCB.24.17.7707-7719.2004; Kollet JI, 2006, MOL IMMUNOL, V43, P623, DOI 10.1016/j.molimm.2005.04.004; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li-Weber M, 2004, EUR J IMMUNOL, V34, P1111, DOI 10.1002/eji.200324687; Lin SC, 2006, MOL IMMUNOL, V43, P1325, DOI 10.1016/j.molimm.2005.09.007; Liu JJ, 2003, J IMMUNOL, V170, P4489, DOI 10.4049/jimmunol.170.9.4489; Liu SL, 2000, ONCOGENE, V19, P3352, DOI 10.1038/sj.onc.1203675; Liu YW, 2003, J IMMUNOL, V171, P821, DOI 10.4049/jimmunol.171.2.821; Lucas M, 2005, J IMMUNOL, V175, P469, DOI 10.4049/jimmunol.175.1.469; Maloney G, 2005, J BIOL CHEM, V280, P30838, DOI 10.1074/jbc.M501917200; Martin M, 2005, NAT IMMUNOL, V6, P777, DOI 10.1038/ni1221; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Miles SA, 2005, J EXP MED, V201, P747, DOI 10.1084/jem.20041470; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Mori N, 1997, EUR J HAEMATOL, V59, P162; Nemeth ZH, 1998, SHOCK, V10, P49, DOI 10.1097/00024382-199807000-00009; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Riemann M, 2005, J IMMUNOL, V175, P3560, DOI 10.4049/jimmunol.175.6.3560; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Sanjabi S, 2000, P NATL ACAD SCI USA, V97, P12705, DOI 10.1073/pnas.230436397; Saraiva M, 2005, J IMMUNOL, V175, P1041, DOI 10.4049/jimmunol.175.2.1041; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sutterwala FS, 1998, J EXP MED, V188, P217, DOI 10.1084/jem.188.1.217; Tergaonkar V, 2005, NAT CELL BIOL, V7, P921, DOI 10.1038/ncb1296; Tone M, 2000, J IMMUNOL, V165, P286, DOI 10.4049/jimmunol.165.1.286; Wessells J, 2004, J BIOL CHEM, V279, P49995, DOI 10.1074/jbc.M404246200; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986	57	290	293	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26041	26050		10.1074/jbc.M602222200	http://dx.doi.org/10.1074/jbc.M602222200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16835236	Green Accepted, hybrid			2022-12-25	WOS:000240249500019
J	Ding, X; Lichti, K; Kim, I; Gonzalez, FJ; Staudinger, JL				Ding, Xunshan; Lichti, Kristin; Kim, Insook; Gonzalez, Frank J.; Staudinger, Jeff L.			Regulation of constitutive androstane receptor and its target genes by fasting, cAMP, hepatocyte nuclear factor alpha, and the coactivator peroxisome proliferator-activated receptor gamma coactivator-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANE-X-RECEPTOR; THYROID-HORMONE METABOLISM; BILE-ACIDS; TRANSCRIPTIONAL COACTIVATOR; HEPATIC GLUCONEOGENESIS; FACTOR 4-ALPHA; ADAPTIVE THERMOGENESIS; XENOBIOTIC RESPONSE; DRUG-METABOLISM; AGONIST GC-1	Animal studies reveal that fasting and caloric restriction produce increased activity of specific metabolic pathways involved in resistance to weight loss in liver. Evidence suggests that this phenomenon may in part occur through the action of the constitutive androstane receptor ( CAR, NR1I3). Currently, the precise molecular mechanisms that activate CAR during fasting are unknown. We show that fasting coordinately induces expression of genes encoding peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha), CAR, cytochrome P-450 2b10 (Cyp2b10), UDP-glucuronosyltransferase 1a1 (Ugt1a1), sulfotransferase 2a1 (Sult2a1), and organic anion-transporting polypeptide 2 (Oatp2) in liver in mice. Treatments that elevate intracellular cAMP levels also produce increased expression of these genes in cultured hepatocytes. Our data show that PGC-1 alpha interaction with hepatocyte nuclear factor 4 alpha(HNF4 alpha, NR2A1) directly regulates CAR gene expression through a novel and evolutionarily conserved HNF4-response element (HNF4RE) located in its proximal promoter. Expression of PGC-1 alpha in cells increases CAR expression and ligand-independent CAR activity. Genetic studies reveal that hepatic expression of HNF4 alpha is required to produce fasting-inducible CAR expression and activity. Taken together, our data show that fasting produces increased expression of genes encoding key metabolic enzymes and an uptake transporter protein through a network of interactions involving cAMP, PGC-1 alpha, HNF4 alpha, CAR, and CAR target genes in liver. Given the recent finding that mice lacking CAR exhibit a profound decrease in resistance to weight loss during extended periods of caloric restriction, our findings have important implications in the development of drugs for the treatment of obesity and related diseases.	Univ Kansas, Dept Pharmacol & Toxicol, Lawrence, KS 66045 USA; NCI, Lab Metab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	University of Kansas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Staudinger, JL (corresponding author), Univ Kansas, Dept Pharmacol & Toxicol, 1251 Wescoe Hall Dr,5044 Malott Hall, Lawrence, KS 66045 USA.	stauding@ku.edu			NCRR NIH HHS [RR17708, P20 RR017708] Funding Source: Medline; NIDDK NIH HHS [R01 DK068443, R01 DK068443-01A1, R01DK068443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005561] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068443] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe T, 1998, J BIOL CHEM, V273, P22395, DOI 10.1074/jbc.273.35.22395; Assem M, 2004, J BIOL CHEM, V279, P22250, DOI 10.1074/jbc.M314111200; Baxter JD, 2004, TRENDS ENDOCRIN MET, V15, P154, DOI 10.1016/j.tem.2004.03.008; Bianco AC, 2002, ENDOCR REV, V23, P38, DOI 10.1210/er.23.1.38; Blaxter K, 1989, ENERGY METABOLISM AN; Brobst DE, 2004, J PHARMACOL EXP THER, V310, P528, DOI 10.1124/jpet.103.064329; BURCHELL B, 1989, PHARMACOL THERAPEUT, V43, P261, DOI 10.1016/0163-7258(89)90122-8; Ding XS, 2005, J PHARMACOL EXP THER, V314, P120, DOI 10.1124/jpet.105.085225; Ding XS, 2005, BIOCHEM PHARMACOL, V69, P867, DOI 10.1016/j.bcp.2004.11.025; Ding XS, 2005, J PHARMACOL EXP THER, V312, P849, DOI 10.1124/jpet.104.076331; Flier JS, 2004, CELL, V116, P337, DOI 10.1016/S0092-8674(03)01081-X; Goodwin B, 2003, P NATL ACAD SCI USA, V100, P223, DOI 10.1073/pnas.0237082100; Greene M. E., 1995, Gene Expression, V4, P281; Grover GJ, 2004, ENDOCRINOLOGY, V145, P1656, DOI 10.1210/en.2003-0973; Grover GJ, 2003, P NATL ACAD SCI USA, V100, P10067, DOI 10.1073/pnas.1633737100; Handschin C, 2005, CELL, V122, P505, DOI 10.1016/j.cell.2005.06.040; Harvey CB, 2002, THYROID, V12, P441, DOI 10.1089/105072502760143791; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Honkakoski P, 2003, ANN MED, V35, P172, DOI 10.1080/07853890310008224; Hosseinpour F, 2006, MOL PHARMACOL, V69, P1095, DOI 10.1124/mol.105.019505; Huang WD, 2003, P NATL ACAD SCI USA, V100, P4156, DOI 10.1073/pnas.0630614100; Inoue Y, 2006, J LIPID RES, V47, P215, DOI 10.1194/jlr.M500430-JLR200; Jia YZ, 2005, P NATL ACAD SCI USA, V102, P12531, DOI 10.1073/pnas.0506000102; Kahaly GJ, 2005, ENDOCR REV, V26, P704, DOI 10.1210/er.2003-0033; Kamiya A, 2004, FEBS LETT, V578, P63, DOI 10.1016/j.febslet.2004.10.070; Krotkiewski M, 2000, INT J OBESITY, V24, pS116, DOI 10.1038/sj.ijo.0801294; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Maglich JM, 2004, J BIOL CHEM, V279, P19832, DOI 10.1074/jbc.M313601200; Maglich JM, 2002, MOL PHARMACOL, V62, P638, DOI 10.1124/mol.62.3.638; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Mitchell AM, 2005, J ENDOCRINOL, V185, P93, DOI 10.1677/joe.1.06096; MOL JA, 1985, ENDOCRINOLOGY, V117, P8, DOI 10.1210/endo-117-1-8; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Pascussi JM, 2003, MOL ENDOCRINOL, V17, P42, DOI 10.1210/me.2002-0244; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2005, INT J OBESITY, V29, pS5, DOI 10.1038/sj.ijo.0802905; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Qatanani M, 2005, ENDOCRINOLOGY, V146, P995, DOI 10.1210/en.2004-1350; RABAST U, 1981, INT J OBESITY, V5, P305; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Rivera-Rivera I, 2003, BBA-GEN SUBJECTS, V1619, P254, DOI 10.1016/S0304-4165(02)00484-1; Rosenbaum M, 2000, AM J CLIN NUTR, V71, P1421; Saini SPS, 2004, MOL PHARMACOL, V65, P292, DOI 10.1124/mol.65.2.292; Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753; Shiraki T, 2003, J BIOL CHEM, V278, P11344, DOI 10.1074/jbc.M212859200; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Staudinger J, 2001, DRUG METAB DISPOS, V29, P1467; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Staudinger JL, 2003, DRUG METAB DISPOS, V31, P523, DOI 10.1124/dmd.31.5.523; Stroup D, 2000, J LIPID RES, V41, P1; Sugatani J, 2005, MOL PHARMACOL, V67, P845, DOI 10.1124/mol.104.007161; Trost SU, 2000, ENDOCRINOLOGY, V141, P3057, DOI 10.1210/en.141.9.3057; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wei P., 2002, Pharmacogenomics Journal, V2, P117, DOI 10.1038/sj.tpj.6500087; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Wong H, 2005, TOXICOL SCI, V84, P232, DOI 10.1093/toxsci/kfi094; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Xiong H, 2002, DRUG METAB DISPOS, V30, P918, DOI 10.1124/dmd.30.8.918; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	67	110	115	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26540	26551		10.1074/jbc.M600931200	http://dx.doi.org/10.1074/jbc.M600931200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16825189	hybrid, Green Accepted			2022-12-25	WOS:000240249500072
J	Hildebrandt, ER; Gheber, L; Kingsbury, T; Hoyt, MA				Hildebrandt, Emily R.; Gheber, Larisa; Kingsbury, Tami; Hoyt, M. Andrew			Homotetrameric form of Cin8p, a Saccharomyces cerevisiae kinesin-5 motor, is essential for its in vivo function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PREDICTING COILED COILS; MITOTIC SPINDLE; CHROMOSOME SEGREGATION; MICROTUBULE MOTOR; MOLECULAR MOTORS; BIMC FAMILY; PROTEIN; EG5; BIPOLAR	Kinesin-5 motor proteins are evolutionarily conserved and perform essential roles in mitotic spindle assembly and spindle elongation during anaphase. Previous studies demonstrated a specialized homotetrameric structure with two pairs of catalytic domains, one at each end of a dumbbell-shaped molecule. This suggests that they perform their spindle roles by cross-linking and sliding antiparallel spindle microtubules. However, the exact kinesin-5 sequence elements that are important for formation of the tetrameric complexes have not yet been identified. In addition, it has not been demonstrated that the homotetrameric form of these proteins is essential for their biological functions. Thus, we investigated a series of Saccharomyces cerevisiae Cin8p truncations and internal deletions, in order to identify structural elements in the Cin8p sequence that are required for Cin8p functionality, spindle localization, and multimerization. We found that all variants of Cin8p that are functional in vivo form tetrameric complexes. The first coiled-coil domain in the stalk of Cin8p, a feature that is shared by all kinesin-5 homologues, is required for its dimerization, and sequences in the last part of the stalk, specifically those likely involved in coiled-coil formation, are required for Cin8p tetramerization. We also found that dimeric forms of Cin8p that are nonfunctional in vivo can nonetheless bind to microtubules. These findings suggest that binding of microtubules is not sufficient for the functionality of Cin8p and that microtubule cross-linking by the tetrameric complex is essential for Cin8p mitotic functions.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Ben Gurion Univ Negev, Dept Clin Biochem, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Dept Chem, IL-84105 Beer Sheva, Israel	Johns Hopkins University; Ben Gurion University; Ben Gurion University	Hoyt, MA (corresponding author), Johns Hopkins Univ, Dept Biol, 3400 N Charles St, Baltimore, MD 21218 USA.	hoyt@jhu.edu			NIGMS NIH HHS [GM40714, GM18745] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040714, F32GM018745] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asada T, 1997, J CELL SCI, V110, P179; Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Cantor C. R., 1980, BIOPHYSICAL CHEM 2, P539; Chui KK, 2000, J BIOL CHEM, V275, P38005, DOI 10.1074/jbc.M005948200; Cochran JC, 2004, J BIOL CHEM, V279, P38861, DOI 10.1074/jbc.M404203200; COLE DG, 1994, J BIOL CHEM, V269, P22913; DeBonis S, 2003, BIOCHEMISTRY-US, V42, P338, DOI 10.1021/bi026716j; Drummond DR, 1998, J CELL SCI, V111, P853; Endow SA, 1998, SCIENCE, V281, P1200, DOI 10.1126/science.281.5380.1200; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; Ferhat L, 1998, J NEUROSCI, V18, P7822; Gheber L, 1999, J BIOL CHEM, V274, P9564, DOI 10.1074/jbc.274.14.9564; Gordon DM, 1999, J BIOL CHEM, V274, P28779, DOI 10.1074/jbc.274.40.28779; Goshima G, 2005, MOL BIOL CELL, V16, P3896, DOI 10.1091/mbc.E05-02-0118; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; Higuchi H, 2002, CURR OPIN CELL BIOL, V14, P50, DOI 10.1016/S0955-0674(01)00293-9; Hildebrandt ER, 2000, BBA-MOL CELL RES, V1496, P99, DOI 10.1016/S0167-4889(00)00012-4; Hildebrandt ER, 2001, MOL BIOL CELL, V12, P3402, DOI 10.1091/mbc.12.11.3402; Hirokawa N, 2005, NAT REV NEUROSCI, V6, P201, DOI 10.1038/nrn1624; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; Hoyt MA, 1996, ANNU REV GENET, V30, P7, DOI 10.1146/annurev.genet.30.1.7; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; Kapitein LC, 2005, NATURE, V435, P114, DOI 10.1038/nature03503; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; Kashina AS, 1997, BBA-MOL CELL RES, V1357, P257, DOI 10.1016/S0167-4889(97)00037-2; Kasprzak AA, 2002, ACTA BIOCHIM POL, V49, P813; KOHAMA K, 1986, J BIOL CHEM, V261, P8022; KOZIELSKI F, 1997, BIOCHIM BIOPHYS ACTA, V1359, P181; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; Lockhart A, 1996, BIOCHEMISTRY-US, V35, P2365, DOI 10.1021/bi952318n; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Nicolas G, 1997, BIOTECHNIQUES, V22, P430, DOI 10.2144/97223bm11; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; SAUNDERS WS, 1995, J CELL BIOL, V128, P617, DOI 10.1083/jcb.128.4.617; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; Schief WR, 2001, CURR OPIN CELL BIOL, V13, P19, DOI 10.1016/S0955-0674(00)00169-1; Sherman F., 1983, METHODS YEAST GENETI; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Stock MF, 2003, J BIOL CHEM, V278, P52315, DOI 10.1074/jbc.M309419200; Straight AF, 1998, J CELL BIOL, V143, P687, DOI 10.1083/jcb.143.3.687; Touitou I, 2001, J CELL SCI, V114, P481; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	51	39	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26004	26013		10.1074/jbc.M604817200	http://dx.doi.org/10.1074/jbc.M604817200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829678	hybrid			2022-12-25	WOS:000240249500015
J	Pop, SM; Gupta, N; Raza, AS; Ragsdale, SW				Pop, Stelian M.; Gupta, Nirupama; Raza, Ashraf S.; Ragsdale, Stephen W.			Transcriptional activation of dehalorespiration - Identification of redox-active cysteines regulating dimerization and DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCTIVE DEHALOGENASE; ANAEROBIC BACTERIUM; ESCHERICHIA-COLI; DESULFITOBACTERIUM; PURIFICATION; PROTEIN; CLUSTER; FNR; DECHLORINATION; ENZYME	Desulfitobacterium dehalogenans can use chlorinated aromatics including polychlorinated biphenyls as electron acceptors in a process called dehalorespiration. Expression of the cpr gene cluster involved in this process is regulated by CprK, which is a member of the CRP/FNR (cAMP-binding protein/fumarate nitrate reduction regulatory protein) family of helix-turn-helix transcriptional regulators. High affinity interaction of the chlorinated aromatic compound with the effector domain of CprK triggers binding of CprK to an upstream target DNA sequence, which leads to transcriptional activation of the cpr gene cluster. When incubated with oxygen or diamide, CprK undergoes inactivation; subsequent treatment with dithiothreitol restores activity. Using mass spectrometry, this study identifies two classes of redox-active thiol groups that form disulfide bonds upon oxidation. Under oxidative conditions, Cys(105), which is conserved in FNR and most other CprK homologs, forms an intramolecular disulfide bond with Cys(111), whereas an intermolecular disulfide bond is formed between Cys(11) and Cys(200). SDS-PAGE and site-directed mutagenesis experiments indicate that the Cys(11)/Cys(200) disulfide bond links two CprK subunits in an inactive dimer. Isothermal calorimetry and intrinsic fluorescence quenching studies show that oxidation does not change the affinity of CprK for the effector. Therefore, reversible redox inactivation is manifested at the level of DNA binding. Our studies reveal a strategy for limiting expression of a redox-sensitive pathway by using a thiol-based redox switch in the transcription factor.	Univ Nebraska, Dept Biochem, Beadle Ctr, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Pop, SM (corresponding author), Univ Nebraska, Dept Biochem, Beadle Ctr, 19th & Vine St, Lincoln, NE 68588 USA.	sragsdale1@unl.edu	Raza, Faisal/AAG-4567-2021; gupta, nirupama/H-2297-2012	Raza, Faisal/0000-0001-5569-3535; 	NCRR NIH HHS [1P20RR17675] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017675] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Banerjee R, 2003, ANNU REV BIOCHEM, V72, P209, DOI 10.1146/annurev.biochem.72.121801.161828; Boyer A, 2003, BIOCHEM J, V373, P297, DOI 10.1042/BJ20021837; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; Christiansen N, 1998, FEBS LETT, V436, P159, DOI 10.1016/S0014-5793(98)01114-4; Das A, 2005, J BACTERIOL, V187, P2020, DOI 10.1128/JB.187.6.2020-2029.2005; Djaman O, 2004, J BIOL CHEM, V279, P44590, DOI 10.1074/jbc.M406487200; Gostick DO, 1998, MICROBIOL-SGM, V144, P705, DOI 10.1099/00221287-144-3-705; Green J, 1996, BIOCHEM J, V316, P887, DOI 10.1042/bj3160887; Gribble GW, 2003, CHEMOSPHERE, V52, P289, DOI 10.1016/S0045-6535(03)00207-8; Holliger C, 1998, FEMS MICROBIOL REV, V22, P383, DOI 10.1016/S0168-6445(98)00030-8; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Joyce MG, 2006, J BIOL CHEM, V281, P28318, DOI 10.1074/jbc.M602654200; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; Krasotkina J, 2001, J BIOL CHEM, V276, P40991, DOI 10.1074/jbc.M106217200; Miller E, 1998, ARCH MICROBIOL, V169, P497, DOI 10.1007/s002030050602; MOHN WW, 1991, ARCH MICROBIOL, V157, P1; Outten FW, 2004, MOL MICROBIOL, V52, P861, DOI 10.1111/j.1365-2958.2004.04025.x; Paget MSB, 2003, ANNU REV GENET, V37, P91, DOI 10.1146/annurev.genet.37.110801.142538; Polit A, 2003, J BIOL CHEM, V278, P43020, DOI 10.1074/jbc.M306398200; Pop SM, 2004, J BIOL CHEM, V279, P49910, DOI 10.1074/jbc.M409435200; Roberts GP, 2004, MICROBIOL MOL BIOL R, V68, P453, DOI 10.1128/MMBR.68.3.453-473.2004; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Smidt H, 2004, ANNU REV MICROBIOL, V58, P43, DOI 10.1146/annurev.micro.58.030603.123600; Smidt H, 2000, J BACTERIOL, V182, P5683, DOI 10.1128/JB.182.20.5683-5691.2000; Unden G, 1997, MOL MICROBIOL, V25, P205, DOI 10.1046/j.1365-2958.1997.4731841.x; UTKIN I, 1994, INT J SYST BACTERIOL, V44, P612, DOI 10.1099/00207713-44-4-612; van de Pas BA, 2001, APPL ENVIRON MICROB, V67, P3958, DOI 10.1128/AEM.67.9.3958-3963.2001; van de Pas BA, 1999, J BIOL CHEM, V274, P20287, DOI 10.1074/jbc.274.29.20287; Wiegel J, 2000, FEMS MICROBIOL ECOL, V32, P1, DOI 10.1111/j.1574-6941.2000.tb00693.x; Wiegel J, 1999, APPL ENVIRON MICROB, V65, P2217	30	26	27	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26382	26390		10.1074/jbc.M602158200	http://dx.doi.org/10.1074/jbc.M602158200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16840784	hybrid			2022-12-25	WOS:000240249500055
J	Suzuki, N; Nishii, K; Okazaki, T; Ikeno, M				Suzuki, Nobutaka; Nishii, Kazuhiro; Okazaki, Tuneko; Ikeno, Masashi			Human artificial chromosomes constructed using the bottom-up strategy are stably maintained in mitosis and efficiently transmissible to progeny mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERMLINE TRANSMISSION; GENETIC DEFICIENCY; ALPHA-SATELLITE; GENERATION; DNA; HUMAN-CHROMOSOME-21; MINICHROMOSOME; EXPRESSION; MEIOSIS; CELLS	Human artificial chromosomes (HACs) are alternative vectors that promise to overcome problematic transgene expression often occurring with conventional vectors in mammalian cells and bodies. We have successfully generated HACs by multimerization of a cloned long alphoid stretch in a human cell line, HT1080. Furthermore, we developed technologies for cloning large genomic regions into HACs by means of co-transfection of clones with the alphoid array and clones encoding the genomic region of interest. The purpose of this study was to investigate the mitotic and meiotic stability of such HACs in mouse cells and bodies. We transferred a circular HAC containing the guanosine triphosphate cyclohydolase I gene (GCH1-HAC) and a linear HAC containing the human globin gene cluster (globin-HAC) from HT1080 cells into mouse embryonic stem (ES) cells by microcell-mediated chromosome transfer. The HACs were stably maintained in mouse ES cells for 3 months. GCH1-HACs in every ES cell line and globin-HACs in most ES cell lines maintained their structures without detectable rearrangement or acquisition of mouse genomic DNA except one globin-HAC in an ES cell line rearranged and acquired mouse-type centromeric sequences and long telomeres. Creation of chimeric mice using ES cells containing HAC and subsequent crossing showed that both the globin-HAC that had rearranged and acquired mouse type centromeric sequences/ long telomeres and GCH1-HACs were retained in tissues of mice and transmitted to progeny. These results indicate that human artificial chromosomes constructed using the bottom-up strategy based on alphoid DNA are stable in mouse bodies and are transmissible.	Fujita Hlth Univ, Inst Comprehens Med Sci, Toyoake, Aichi 4701192, Japan; Fujita Hlth Univ, Educ & Res Ctr Anim Models Human Dis, Toyoake, Aichi 4701192, Japan	Fujita Health University; Fujita Health University	Ikeno, M (corresponding author), Fujita Hlth Univ, Inst Comprehens Med Sci, 1-98 Kutsukake Cho, Toyoake, Aichi 4701192, Japan.	mikeno@fujita-hu.ac.jp						Cooper JP, 1998, NATURE, V392, P828, DOI 10.1038/33947; Ebersole TA, 2000, HUM MOL GENET, V9, P1623, DOI 10.1093/hmg/9.11.1623; FARR CJ, 1995, EMBO J, V14, P5444, DOI 10.1002/j.1460-2075.1995.tb00228.x; Grimes BR, 2005, CHROMOSOMA, V114, P230, DOI 10.1007/s00412-005-0017-5; Grimes BR, 2001, EMBO REP, V2, P910, DOI 10.1093/embo-reports/kve187; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; Heller R, 1996, P NATL ACAD SCI USA, V93, P7125, DOI 10.1073/pnas.93.14.7125; Henning KA, 1999, P NATL ACAD SCI USA, V96, P592, DOI 10.1073/pnas.96.2.592; IKENO M, 1994, HUM MOL GENET, V3, P1245, DOI 10.1093/hmg/3.8.1245; Ikeno M, 2002, GENES CELLS, V7, P1021, DOI 10.1046/j.1365-2443.2002.00580.x; Ikeno M, 1998, NAT BIOTECHNOL, V16, P431, DOI 10.1038/nbt0598-431; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; Kazuki Y, 2001, J HUM GENET, V46, P600, DOI 10.1007/s100380170028; Koehler KE, 2002, GENETICS, V162, P1367; Kuroiwa Y, 2002, NAT BIOTECHNOL, V20, P889, DOI 10.1038/nbt727; Larin Z, 2002, TRENDS GENET, V18, P313, DOI 10.1016/S0168-9525(02)02679-3; Mee PJ, 2003, CHROMOSOMA, V112, P183, DOI 10.1007/s00412-003-0260-6; Mejia JE, 2001, AM J HUM GENET, V69, P315, DOI 10.1086/321977; Mills W, 1999, HUM MOL GENET, V8, P751, DOI 10.1093/hmg/8.5.751; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; Nimmo ER, 1998, NATURE, V392, P825, DOI 10.1038/33941; O'Doherty A, 2005, SCIENCE, V309, P2033, DOI 10.1126/science.1114535; Ohzeki J, 2002, J CELL BIOL, V159, P765, DOI 10.1083/jcb.200207112; Pfeifer A, 2001, ANNU REV GENOM HUM G, V2, P177, DOI 10.1146/annurev.genom.2.1.177; Shen MH, 2000, CURR BIOL, V10, P31, DOI 10.1016/S0960-9822(99)00261-4; Shen MH, 1997, HUM MOL GENET, V6, P1375, DOI 10.1093/hmg/6.8.1375; Shinohara T, 2000, CHROMOSOME RES, V8, P713, DOI 10.1023/A:1026741321193; Tomizuka K, 1997, NAT GENET, V16, P133, DOI 10.1038/ng0697-133; Voet T, 2003, J CELL BIOL, V162, P795, DOI 10.1083/jcb.200305065; Voet T, 2001, GENOME RES, V11, P124, DOI 10.1101/gr.159901; Wade-Martins R, 2000, NAT BIOTECHNOL, V18, P1311, DOI 10.1038/82444; Willard HF, 1996, P NATL ACAD SCI USA, V93, P6847, DOI 10.1073/pnas.93.14.6847; Wong LH, 2005, J BIOL CHEM, V280, P3954, DOI 10.1074/jbc.M410047200; Yoshimi K, 2000, NAT BIOTECHNOL, V18, P1086, DOI 10.1038/80287	34	54	61	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26615	26623		10.1074/jbc.M603053200	http://dx.doi.org/10.1074/jbc.M603053200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16837455	hybrid			2022-12-25	WOS:000240249500079
J	Chansel, D; Ciroldi, M; Vandermeersch, S; Jackson, LF; Gomez, AM; Henrion, D; Lee, DC; Coffman, TM; Richard, S; Dussaule, JC; Tharaux, PL				Chansel, Dominique; Ciroldi, Magali; Vandermeersch, Sophie; Jackson, Leslie F.; Gomez, Ana-Maria; Henrion, Daniel; Lee, David C.; Coffman, Thomas M.; Richard, Sylvain; Dussaule, Jean-Claude; Tharaux, Pierre-Louis			Heparin binding EGF is necessary for vasospastic response to endothelin	FASEB JOURNAL			English	Article						EGF receptor; calcium; HB-EGF; transactivation; PI3-kinase; human	EPIDERMAL-GROWTH-FACTOR; INDEPENDENT CA2+ CHANNELS; DIPHTHERIA-TOXIN RECEPTOR; ANGIOTENSIN-II; PHOSPHOINOSITIDE 3-KINASE; PROTEIN-KINASE; HB-EGF; METALLOPROTEINASE CLEAVAGE; EXPRESSION CLONING; BLOOD-PRESSURE	Endothelin-1 (ET-1), a powerful vasoconstrictor, is involved in vasospastic diseases such as coronary artery disease and subarachnoidal hemorrhage, as well as in renal and cardiovascular fibrotic remodeling. Transactivation of the epidermal growth factor receptor (EGFR) mediates ET-1 signaling in vascular smooth muscle cells (VSMCs) and isolated arteries. Moreover, EGFR is required for a full constrictive response to ET-1. However, the relevant mechanisms mediating EGFR transactivation in response to ET-1 have not been identified. The present study used isolated arteries and VSMCs to investigate the role of the EGFR ligand heparin binding-epidermal growth factor (HB-EGF) in ET-1-induced transactivation of EGFR, intracellular calcium mobilization, and VSMCs contraction. While baseline blood pressures were similar in HB-EGF-deficient and in wild-type littermate mice, the vasoconstrictor actions of ET-1 were attenuated in HB-EGF-/- animals. In isolated mouse carotid artery segments mounted in an arteriograph, ET-1 caused only a weak increase in isovolumetric tone in HB-EGF-deficient vessels, and this effect was mimicked by inhibition of EGFR tyrosine kinase or phosphoinositide 3-kinase (PI3K) in wild-type arteries with or without endothelium, indicating a specific role in VSMCs. EGFR or PI3K inhibitors had no effect on KCl-induced contraction, which was normal in HB-EGF-deficient mice. To confirm that the abnormal responses in HB-EGF-deficient mice were due to impaired EGFR signaling, we studied VSMCs from waved-2 (wa2) mice; these animals have a mutation causing a partial loss of function of EGFR tyrosine kinase activity. The ET-1induced calcium peak was reduced by 30% in VSMCs from wa2 mice and from HB-EGF-/- mice. This effect was reproduced by preincubation of wild-type VSMCs with EGFR inhibitor AG1478 and PI3K inhibitors LY294002 and wortmannin. ProHB-EGF is bound to the cell membrane and released after cleavage by metalloproteinases; its action may contribute to effects of GPCR agonists on cell growth. Pretreatment of mouse VSMCs with batimastat, a metalloproteinase inhibitor, significantly attenuated ET-1-induced [Ca2+](i) response in wild-type cells. Human proHB-EGF has been shown to be the endogenous receptor for Corynebacterium diphteriae toxin (DT). Mutated DT toxin (CRM197) is devoid of toxicity but it neutralizes HB-EGF binding to EGFR. Pretreatment of human VSMCs from internal mammary arteries with CRM197 significantly blunted ET-1-stimulated calcium transients. In conclusion, these findings suggest that the mechanism of ET-1-induced vasoconstriction involves HB-EGF-mediated transactivation of the EGFR. This functional cascade requires modulation of agonist-induced calcium transient by EGFR and PI3K with extremely fast kinetics, suggesting a novel paradigm for GPCR-mediated calcium signaling, which may offer future therapeutic targets.	Univ Paris 06, Hop Tenon, INSERM U702, F-75020 Paris, France; Univ N Carolina, Dept Biochem & Biophys, Lineberger Comprehens Canc Ctr, Sch Med, Chapel Hill, NC USA; Univ Montpellier I, INSERM U637, Montpellier, France; Univ Angers, Fac Med, CNRS, UMR 6188, Angers, France; Duke Univ, Div Nephrol, Dept Med, Durham, NC USA; Durham Vet Affairs Med Ctr, Durham, NC USA; Univ Paris 06, APHP, Sch Med St Antoine, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite d'Angers; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Sorbonne Universite	Tharaux, PL (corresponding author), Univ Paris 06, Hop Tenon, INSERM U702, 4 Rue Chine, F-75020 Paris, France.	pierre-louis.tharaux@chusa.jussieu.fr	Henrion, Daniel/N-7023-2015; Gomez, Ana M./B-5376-2013; Tharaux, Pierre-Louis/A-9155-2009; Henrion, Daniel/J-8141-2015; Richard, Sylvain/C-9695-2016; Henrion, Daniel/AAK-1995-2021	Henrion, Daniel/0000-0003-1094-0285; Gomez, Ana M./0000-0003-0009-2884; Tharaux, Pierre-Louis/0000-0002-6062-5905; Henrion, Daniel/0000-0003-1094-0285; Henrion, Daniel/0000-0003-1094-0285; Richard, Sylvain/0000-0001-9460-6705; VANDERMEERSCH, sophie/0000-0001-6021-1334	NCI NIH HHS [CA43793] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043793] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asakawa H, 1996, CELL BIOCHEM FUNCT, V14, P181; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; BALDI E, 1994, AM J PHYSIOL, V266, pF957, DOI 10.1152/ajprenal.1994.266.6.F957; BUKOSKI RD, 1994, J HYPERTENS, V12, P15; Chansel D, 2001, EUR J PHARMACOL, V414, P165, DOI 10.1016/S0014-2999(01)00791-9; Che Q, 2002, HYPERTENSION, V40, P700, DOI 10.1161/01.HYP.0000035524.10948.93; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DAY R, 1995, AM J HYPERTENS, V8, P294, DOI 10.1016/0895-7061(95)96213-4; Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO;2-S; Eguchi S, 1999, HYPERTENSION, V33, P201, DOI 10.1161/01.HYP.33.1.201; Ferri C, 1997, CLIN SCI, V93, P35, DOI 10.1042/cs0930035; Flamant M, 2002, FASEB J, V16, P327, DOI 10.1096/fj.02-0115fje; Florian JA, 1999, AM J PHYSIOL-HEART C, V276, pH976, DOI 10.1152/ajpheart.1999.276.3.H976; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; Fukata Y, 2001, TRENDS PHARMACOL SCI, V22, P32, DOI 10.1016/S0165-6147(00)01596-0; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; Gomez AM, 1996, J PHYSIOL-LONDON, V496, P575, DOI 10.1113/jphysiol.1996.sp021708; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hao L, 2004, CIRC RES, V94, P68, DOI 10.1161/01.RES.0000109413.57726.91; Henrion D, 1996, HYPERTENSION, V28, P361, DOI 10.1161/01.HYP.28.3.361; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Igura T, 1996, ARTERIOSCL THROM VAS, V16, P1524, DOI 10.1161/01.ATV.16.12.1524; Ikeda T, 1999, HYPERTENSION, V34, P514, DOI 10.1161/01.HYP.34.3.514; ITO M, 1995, P NATL ACAD SCI USA, V92, P3521, DOI 10.1073/pnas.92.8.3521; Iwasaki H, 1999, ENDOCRINOLOGY, V140, P4659, DOI 10.1210/en.140.10.4659; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Kawanabe Y, 2004, BIOCHEM PHARMACOL, V68, P215, DOI 10.1016/j.bcp.2004.03.025; Kawanabe Y, 2002, MOL PHARMACOL, V62, P756, DOI 10.1124/mol.62.3.756; Kawanabe Y, 2002, AM J PHYSIOL-HEART C, V283, pH2671, DOI 10.1152/ajpheart.00350.2002; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; Le Blanc C, 2004, CIRC RES, V95, P300, DOI 10.1161/01.RES.0000138017.76125.8b; LIU Y, 1992, AM J PHYSIOL, V262, pC941, DOI 10.1152/ajpcell.1992.262.4.C941; Loufrani L, 2001, CIRCULATION, V103, P864, DOI 10.1161/01.CIR.103.6.864; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; Masui H, 2000, LIFE SCI, V68, P363, DOI 10.1016/S0024-3205(00)00942-5; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Northcott CA, 2004, HYPERTENSION, V43, P885, DOI 10.1161/01.HYP.0000118518.20331.e8; Northcott CA, 2002, CIRC RES, V91, P360, DOI 10.1161/01.RES.0000030861.13850.F1; POLLOCK DM, 1995, FASEB J, V9, P1196, DOI 10.1096/fasebj.9.12.7672512; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Quignard JF, 1997, J CLIN INVEST, V99, P185, DOI 10.1172/JCI119146; Reynolds CM, 2002, HYPERTENSION, V39, P525, DOI 10.1161/hy0202.103076; Richard S, 1998, METHOD ENZYMOL, V293, P71; Rossi GP, 1999, CIRCULATION, V99, P1147, DOI 10.1161/01.CIR.99.9.1147; Sabri A, 1998, CIRC RES, V83, P841, DOI 10.1161/01.RES.83.8.841; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Schiffrin EL, 1999, HYPERTENSION, V34, P876, DOI 10.1161/01.HYP.34.4.876; Shah BH, 2004, TRENDS ENDOCRIN MET, V15, P241, DOI 10.1016/j.tem.2004.06.011; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Tharaux PL, 1999, CIRCULATION, V99, P2185, DOI 10.1161/01.CIR.99.16.2185; Viard P, 1999, FASEB J, V13, P685, DOI 10.1096/fasebj.13.6.685; Wang ZF, 2003, J AM SOC NEPHROL, V14, P3147, DOI 10.1097/01.ASN.0000098681.56240.1A; WILKES BM, 1991, AM J PHYSIOL, V260, pF579, DOI 10.1152/ajprenal.1991.260.4.F579; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Zhang H, 2004, CIRC RES, V95, P989, DOI 10.1161/01.RES.0000147962.01036.bb	60	50	51	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1936	+		10.1096/fj.05-5328fje	http://dx.doi.org/10.1096/fj.05-5328fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16877529				2022-12-25	WOS:000240267000036
J	Nam, HJ; Gurda-Whitaker, B; Gan, WY; Ilaria, S; McKenna, R; Mehta, P; Alvarez, RA; Agbandje-McKenna, M				Nam, Hyun-Joo; Gurda-Whitaker, Brittney; Gan, Wand Yee; Ilaria, Shawen; McKenna, Robert; Mehta, Padmaja; Alvarez, Richard A.; Agbandje-McKenna, Mavis			Identification of the sialic acid structures recognized by minute virus of mice and the role of binding affinity in virulence adaptation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING; FELINE PARVOVIRUSES; INFLUENZA HEMAGGLUTININ; PROTOTYPE STRAIN; THEILERS-VIRUS; INFECTION; PATHOGENESIS; PARTICLES; RESIDUES; CANINE	Sialic acid binding is required for infectious cell surface receptor recognition by parvovirus minute virus of mice (MVM). We have utilized a glycan array consisting of similar to 180 different carbohydrate structures to identify the specific sialosides recognized by the prototype (MVMp) and immunosuppressive (MVMi) strains of MVM plus three virulent mutants of MVMp, MVMp-I362S, MVMp-K368R, and MVMp-I362S/K368R. All of the MVM capsids specifically bound to three structures with a terminal sialic acid-linked alpha 2-3 to a common Gal beta 1-4GlcNAc motif: Neu5Ac alpha 2-3Gal beta 1-4GlcNAc beta 1-4Gal beta 1-4GlcNAc (3 ' SiaLN-LN), Neu5Ac alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4GlcNAc (3 ' SiaLN-LN-LN), and Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-3Gal beta 1-4(Fuc alpha 1-3)-GlcNAc(sLe(x)-Le(x)-Le(x)). In addition, MVMi also recognized four multisialylated glycans with terminal alpha 2-8 linkages: Neu5Ac alpha 2-8Neu5Ac alpha 2-8Neu5Ac alpha((Sia)(3)), Neu5Ac alpha 2-8Neu5Ac alpha 2-3Gal beta 1-4Glc(GD3), Neu5Ac alpha 2-8Neu5Ac alpha 2-8Neu5Ac alpha 2-3Gal beta 1-4Glc(GT3), and Neu5Ac alpha 2-8Neu5Ac alpha 2-3(GalNAc alpha 1-4)Gal beta 1-4Glc(GD2). Interestingly, the virulent MVMp-K368R mutant also recognized GT3. Analysis of the relative binding affinities using a surface plasmon resonance biospecific interaction (BIAcore) assay showed the wild-type MVMp and MVMi capsids binding with higher affinity to selected glycans compared with the virulent MVMp mutants. The reduced affinity of the virulent MVMp mutants are consistent with previous in vitro cell binding assays that had shown weaker binding to permissive cells compared with wild-type MVMp. This study identifies the sialic acid structures recognized by MVM. It also provides rationale for the tropism of MVM for malignant transformed cells that contain sLe(x) motifs and the neurotropism of MVMi, which is likely mediated via interactions with multisialylated glycans known to be tumor cell markers. Finally, the observations further implicate a decreased binding affinity for sialic acid in the in vivo adaptation of MVMp to a virulent phenotype.	Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	State University System of Florida; University of Florida; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center	Agbandje-McKenna, M (corresponding author), Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.	mckenna@ufl.edu		Gurda, Brittney/0000-0002-0174-9385; Ilaria, Shawen/0000-0002-0935-8303	NIGMS NIH HHS [GM62116] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agbandje-McKenna M, 1998, STRUCT FOLD DES, V6, P1369, DOI 10.1016/S0969-2126(98)00137-3; ASTELL CR, 1986, J VIROL, V57, P656, DOI 10.1128/JVI.57.2.656-669.1986; BALLGOODRICH LJ, 1992, J VIROL, V66, P3415, DOI 10.1128/JVI.66.6.3415-3423.1992; Bauer PH, 1999, J VIROL, V73, P5826, DOI 10.1128/JVI.73.7.5826-5832.1999; BAUER PH, 1995, J VIROL, V69, P7925, DOI 10.1128/JVI.69.12.7925-7931.1995; Bochner BS, 2005, J BIOL CHEM, V280, P4307, DOI 10.1074/jbc.M412378200; BROWNSTEIN DG, 1991, LAB INVEST, V65, P357; BROWNSTEIN DG, 1992, J VIROL, V66, P3118, DOI 10.1128/JVI.66.5.3118-3124.1992; Chipman PR, 1998, STRUCTURE, V6, P135, DOI 10.1016/S0969-2126(98)00016-1; Cornelis JJ, 2004, CURR GENE THER, V4, P249; COTMORE SF, 1989, J VIROL, V63, P3902, DOI 10.1128/JVI.63.9.3902-3911.1989; D'Abramo AM, 2005, VIROLOGY, V340, P143, DOI 10.1016/j.virol.2005.06.019; GOTTSCHALK A, 1959, CHEM VIRUS RECEPTORS, P51; Govindasamy L, 2003, J VIROL, V77, P12211, DOI 10.1128/JVI.77.22.12211-12221.2003; Hernando E, 2000, VIROLOGY, V267, P299, DOI 10.1006/viro.1999.0123; Hueffer K, 2003, J VIROL, V77, P10099, DOI 10.1128/JVI.77.18.10099-10105.2003; Jnaoui K, 2002, J VIROL, V76, P8138, DOI 10.1128/JVI.76.16.8138-8147.2002; Kannagi R, 2004, CANCER SCI, V95, P377, DOI 10.1111/j.1349-7006.2004.tb03219.x; Kern A, 2003, J VIROL, V77, P11072, DOI 10.1128/JVI.77.20.11072-11081.2003; Kontou M, 2005, J VIROL, V79, P10931, DOI 10.1128/JVI.79.17.10931-10943.2005; Korchagina EY, 2005, GLYCOCONJUGATE J, V22, P127, DOI 10.1007/s10719-005-0508-x; Lopez-Bueno A, 2006, J VIROL, V80, P1563, DOI 10.1128/JVI.80.3.1563-1573.2006; Matrosovich M, 2000, J VIROL, V74, P8502, DOI 10.1128/JVI.74.18.8502-8512.2000; Matrosovich MN, 2004, P NATL ACAD SCI USA, V101, P4620, DOI 10.1073/pnas.0308001101; Opie SR, 2003, J VIROL, V77, P6995, DOI 10.1128/JVI.77.12.6995-7006.2003; Palermo LA, 2003, J VIROL, V77, P8915, DOI 10.1128/JVI.77.16.8915-8923.2003; Ramirez JC, 1996, J VIROL, V70, P8109; ROGERS GN, 1983, NATURE, V304, P76, DOI 10.1038/304076a0; Rubio MP, 2005, J VIROL, V79, P11280, DOI 10.1128/JVI.79.17.11280-11290.2005; Sato C, 2000, J BIOL CHEM, V275, P15422, DOI 10.1074/jbc.275.20.15422; Segovia JC, 1999, J VIROL, V73, P1774, DOI 10.1128/JVI.73.3.1774-1784.1999; SEGOVIA JC, 1995, J VIROL, V69, P3229, DOI 10.1128/JVI.69.5.3229-3232.1995; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; TATTERSALL P, 1977, J MOL BIOL, V111, P375, DOI 10.1016/S0022-2836(77)80060-0; TATTERSALL P, 1976, J VIROL, V20, P273, DOI 10.1128/JVI.20.1.273-289.1976; Xie Q, 2003, ACTA CRYSTALLOGR D, V59, P959, DOI 10.1107/S0907444903005675; Zhou L, 2000, J VIROL, V74, P1477, DOI 10.1128/JVI.74.3.1477-1485.2000	37	51	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25670	25677		10.1074/jbc.M604421200	http://dx.doi.org/10.1074/jbc.M604421200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16822863	hybrid			2022-12-25	WOS:000240031300070
J	Wu, ZR; Xing, X; Bohl, CE; Wisler, JW; Dalton, JT; Bell, CE				Wu, Zengru; Xing, Xu; Bohl, Casey E.; Wisler, James W.; Dalton, James T.; Bell, Charles E.			Domain structure and DNA binding regions of beta protein from bacteriophage lambda	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; COLI RECA PROTEIN; ESCHERICHIA-COLI; PHAGE-LAMBDA; RECOMBINATION; IDENTIFICATION; GENE; RENATURATION; EXONUCLEASE; SYSTEM	beta protein from bacteriophage lambda promotes a single- strand annealing reaction that is central to Red-mediated recombination at double-strand DNA breaks and chromosomal ends. beta protein binds most tightly to an intermediate of annealing formed by the sequential addition of two complementary oligonucleotides. Here we have characterized the domain structure of beta protein in the presence and absence of DNA using limited proteolysis. Residues 1 - 130 form an N-terminal "core" domain that is resistant to proteases in the absence of DNA, residues 131 - 177 form a central region with enhanced resistance to proteases upon DNA complex formation, and the C-terminal residues 178 - 261 of beta protein are sensitive to proteases in both the presence and absence of DNA. We probed the DNA binding regions of beta protein further using biotinylation of lysine residues and mass spectrometry. Several lysine residues within the first 177 residues of beta protein are protected from biotinylation in the DNA complex, whereas none of the lysine residues in the C-terminal portion are protected. The results lead to a model for the domain structure and DNA binding of beta protein in which a stable N-terminal core and a more flexible central domain come together to bind DNA, whereas a C-terminal tail remains disordered. A fragment consisting of residues 1 - 177 of beta protein maintains normal binding to sequentially added complementary oligonucleotides and has significantly enhanced binding to single- strand DNA.	Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Coll Pharm, Div Pharmaceut, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Dalton, JT (corresponding author), Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, 1645 Neil Ave, Columbus, OH 43210 USA.	dalton.1@osu.edu; bell.489@osu.edu		Dalton, James T/0000-0002-3915-7326	NIGMS NIH HHS [GM067947, R01 GM067947-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067947] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 2000, NUCLEIC ACIDS RES, V28, P3417, DOI 10.1093/nar/28.18.3417; CARTER DM, 1971, J BIOL CHEM, V246, P2502; Copeland NG, 2001, NAT REV GENET, V2, P769, DOI 10.1038/35093556; Eggler AL, 2003, J BIOL CHEM, V278, P16389, DOI 10.1074/jbc.M212920200; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hollis T, 2001, P NATL ACAD SCI USA, V98, P9557, DOI 10.1073/pnas.171317698; Iyer LM, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-8; Karakousis G, 1998, J MOL BIOL, V276, P721, DOI 10.1006/jmbi.1997.1573; KMIEC E, 1981, J BIOL CHEM, V256, P2636; KOLODNER R, 1994, MOL MICROBIOL, V11, P23, DOI 10.1111/j.1365-2958.1994.tb00286.x; KULKARNI SK, 1989, GENETICS, V123, P249; KUZMINOV A, 1999, ANNU REV GENET, V28, P49; Kvaratskhelia M, 2002, P NATL ACAD SCI USA, V99, P15988, DOI 10.1073/pnas.252550199; Li Z, 1998, J MOL BIOL, V276, P733, DOI 10.1006/jmbi.1997.1572; LITTLE JW, 1967, J BIOL CHEM, V242, P679; LONBERG N, 1981, J MOL BIOL, V145, P123, DOI 10.1016/0022-2836(81)90337-5; MARSIC N, 1993, J BACTERIOL, V175, P4738; MUNIYAPPA K, 1986, J BIOL CHEM, V261, P7472; Muyrers JPP, 2001, TRENDS BIOCHEM SCI, V26, P325, DOI 10.1016/S0968-0004(00)01757-6; Mythili E, 1996, GENE, V182, P81, DOI 10.1016/S0378-1119(96)00518-5; Passy SI, 1999, P NATL ACAD SCI USA, V96, P4279, DOI 10.1073/pnas.96.8.4279; Poteete AR, 2001, FEMS MICROBIOL LETT, V201, P9, DOI 10.1016/S0378-1097(01)00242-7; Rybalchenko N, 2004, P NATL ACAD SCI USA, V101, P17056, DOI 10.1073/pnas.0408046101; Shell SM, 2005, BIOCHEMISTRY-US, V44, P971, DOI 10.1021/bi048208a; Stone KL, 2002, PROTEIN PROTOCOLS HD, P511; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TATEISHI S, 1992, J MOL BIOL, V223, P115, DOI 10.1016/0022-2836(92)90720-5; WILLIAMS KR, 1978, J BIOL CHEM, V253, P2463; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428	30	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25205	25214		10.1074/jbc.M512450200	http://dx.doi.org/10.1074/jbc.M512450200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16820360	Green Accepted, hybrid			2022-12-25	WOS:000240031300021
J	Chua, HL; Bhat-Nakshatri, P; Clare, SE; Morimiya, A; Badve, S; Nakshatri, H				Chua, H. L.; Bhat-Nakshatri, P.; Clare, S. E.; Morimiya, A.; Badve, S.; Nakshatri, H.			NF-kappa B represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2	ONCOGENE			English	Article						NF-kappa B; breast cancer; EMT; ZEB-1; p63	BREAST-CANCER CELLS; GENE-EXPRESSION; ESTROGEN-RECEPTOR; STEM-CELL; TRANSCRIPTIONAL REPRESSOR; MYOEPITHELIAL CELLS; ACTIVATION; SNAIL; METASTASIS; CARCINOMA	The transcription factor nuclear factor kappa B (NF-kappa B) is constitutively active in both cancer cells and stromal cells of breast cancer; however, the precise role of activated NF-kappa B in cancer progression is not known. Using parental MCF10A cells and a variant that expresses the myoepithelial marker p63 stably overexpressing the constitutively active p65 subunit of NF-kappa B (MCF10A/p65), we show that NF-kappa B suppresses the expression of epithelial specific genes E-cadherin and desmoplakin and induces the expression of the mesenchymal specific gene vimentin. P65 also suppressed the expression of p63 and the putative breast epithelial progenitor marker cytokeratin 5/6. MCF10A/p65 cells were phenotypically similar to cells undergoing epithelial to mesenchymal transition (EMT). MCF10A/p65 cells failed to form characteristic acini in three-dimensional Matrigel. Analysis of parental and MCF10A/p65 cells for genes previously shown to be involved in EMT revealed elevated expression of ZEB-1 and ZEB-2 in MCF10A/p65 cells compared to parental cells. In transient transfection assays, p65 increased ZEB-1 promoter activity. Furthermore, MCF10A cells overexpressing ZEB-1 showed reduced E-cadherin and p63 expression and displayed an EMT phenotype. The siRNA against ZEB-1 or ZEB-2 reduced the number of viable MCF10A/p65 but not parental cells, suggesting the dependence of MCF10A/p65 cells to ZEB-1 and ZEB-2 for cell cycle progression or survival. MCF10A cells chronically exposed to tumor necrosis factor alpha (TNF alpha), a potent NF-kappa B inducer, also exhibited the EMT-like phenotype and ZEB-1/ZEB-2 induction, both of which were reversed following TNFa withdrawal.	Indiana Univ, Sch Med, Dept Surg, Indianapolis, IN 46204 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46204 USA; Walther Canc Inst, Indianapolis, IN USA; Indiana Univ, Sch Med, Dept Pathol, Indianapolis, IN 46204 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46204 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Nakshatri, H (corresponding author), Indiana Canc Res Inst, 1044 W Walnut St,R4-202, Indianapolis, IN 46202 USA.	hnakshat@iupui.edu		Nakshatri, Harikrishna/0000-0001-8876-0052; Badve, Sunil/0000-0001-8861-9980				Adriance MC, 2005, BREAST CANCER RES, V7, P190, DOI 10.1186/bcr1286; Akimaru H, 1997, NAT GENET, V17, P211, DOI 10.1038/ng1097-211; Barbareschi M, 2001, AM J SURG PATHOL, V25, P1054, DOI 10.1097/00000478-200108000-00010; Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj.onc.1205243; Bhat-Nakshatri P, 1998, P NATL ACAD SCI USA, V95, P6971, DOI 10.1073/pnas.95.12.6971; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Boecker W, 2002, J PATHOL, V198, P458, DOI 10.1002/path.1241; Brantley DM, 2001, MOL BIOL CELL, V12, P1445, DOI 10.1091/mbc.12.5.1445; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Clarke CL, 2004, J PATHOL, V204, P147, DOI 10.1002/path.1647; Clarkson RWE, 2000, J BIOL CHEM, V275, P12737, DOI 10.1074/jbc.275.17.12737; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dontu G, 2004, TRENDS ENDOCRIN MET, V15, P193, DOI 10.1016/j.tem.2004.05.011; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Elloul S, 2005, CANCER-AM CANCER SOC, V103, P1631, DOI 10.1002/cncr.20946; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gordon LA, 2003, INT J CANCER, V106, P8, DOI 10.1002/ijc.11172; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; IP MM, 1992, ENDOCRINOLOGY, V130, P2833, DOI 10.1210/en.130.5.2833; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Johnstone PAS, 2002, CURR PROB CANCER, V26, P282, DOI 10.1067/mcn.2002.129997; Jonkers J, 2004, CANCER CELL, V6, P535, DOI 10.1016/j.ccr.2004.12.002; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Keyes WM, 2005, GENE DEV, V19, P1986, DOI 10.1101/gad.342305; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Kumar S, 2003, AM J PATHOL, V163, P2531, DOI 10.1016/S0002-9440(10)63608-5; Kuphal S, 2004, ONCOGENE, V23, P8509, DOI 10.1038/sj.onc.1207831; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; Lu T, 2004, ONCOGENE, V23, P2138, DOI 10.1038/sj.onc.1207332; McKeon F, 2004, GENE DEV, V18, P465, DOI 10.1101/gad.1190504; Meng FY, 2002, J BIOL CHEM, V277, P29674, DOI 10.1074/jbc.M112464200; Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Nozaki S, 2000, BIOCHEM BIOPH RES CO, V275, P60, DOI 10.1006/bbrc.2000.3241; Ozturk N, 2006, P NATL ACAD SCI USA, V103, P2178, DOI 10.1073/pnas.0510877103; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Petersen OW, 2003, AM J PATHOL, V162, P391, DOI 10.1016/S0002-9440(10)63834-5; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Postigo AA, 2003, EMBO J, V22, P2443, DOI 10.1093/emboj/cdg225; Postigo AA, 2000, P NATL ACAD SCI USA, V97, P6391, DOI 10.1073/pnas.97.12.6391; Radisky DC, 2004, SCIENCE, V303, P775, DOI 10.1126/science.1094412; Rapp UR, 2006, CANCER CELL, V9, P9, DOI 10.1016/j.ccr.2005.12.022; Rizki A, 2004, CANCER CELL, V6, P1, DOI 10.1016/j.ccr.2004.06.019; Romieu-Mourez R, 2002, CANCER RES, V62, P6770; Shin SR, 2006, CANCER RES, V66, P2570, DOI 10.1158/0008-5472.CAN-05-3056; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; TAIT L, 1990, CANCER RES, V50, P6087; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Tickle C, 1998, NATURE, V392, P547, DOI 10.1038/33276; Vandewalle C, 2005, NUCLEIC ACIDS RES, V33, P6566, DOI 10.1093/nar/gki965; Villadsen R, 2005, APMIS, V113, P903, DOI 10.1111/j.1600-0463.2005.apm_344.x; Welm B, 2003, CELL PROLIFERAT, V36, P17, DOI 10.1046/j.1365-2184.36.s.1.3.x; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; [No title captured], DOI DOI 10.1126/STKE.2882005PE27	70	490	520	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					711	724		10.1038/sj.onc.1209808	http://dx.doi.org/10.1038/sj.onc.1209808			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16862183				2022-12-25	WOS:000243902200008
J	Bos, CL; Kodach, LL; van den Brink, GR; Diks, SH; van Santen, MM; Richel, DJ; Peppelenbosch, MP; Hardwick, JCH				Bos, C. L.; Kodach, L. L.; van den Brink, G. R.; Diks, S. H.; van Santen, M. M.; Richel, D. J.; Peppelenbosch, M. P.; Hardwick, J. C. H.			Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A	ONCOGENE			English	Article						aspirin; Wnt/beta-catenin; PP2A; colon cancer; chemoprevention	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COLON-CANCER CELLS; FAMILIAL ADENOMATOUS POLYPOSIS; NF-KAPPA-B; BETA-CATENIN; COLORECTAL-CANCER; CYCLOOXYGENASE-2 INHIBITOR; SIGNAL-TRANSDUCTION; CATALYTIC SUBUNIT; OKADAIC ACID	Nonsteroidal anti-inflammatory drugs show chemopreventive efficacy in colon cancer, but the mechanism behind this remains unclear. Elucidating this mechanism is seen as vital to the development of new chemopreventive agents. We studied the effects of aspirin on the oncogenic Wnt/beta-catenin pathway activity in colorectal cancer cell lines and observed that aspirin dose-dependently decreased the activity of this pathway, as judged by TCF-driven luciferase activity, reduced Wnt target gene expression and increased phosphorylation of beta-catenin by immunoblotting. Furthermore, the ubiquitination and cytoplasmic levels of beta-catenin were assessed by immunoblotting, and also the localization of b-catenin was shown by green fluorescent protein-tagged beta-catenin and time-lapse fluorescent imaging. Importantly, aspirin treatment caused increased phosphorylation of protein phosphatase 2A (PP2A), an event associated with inhibition of PP2A enzymatic activity, which was confirmed by a reduction in enzymatic PP2A activity. Moreover, this inhibition of PP2A enzymatic activity was essential for the effects of aspirin on the Wnt/beta-catenin pathway as shown by transient transfection with PP2A constructs. The findings in this article provide a molecular explanation for the efficacy of aspirin in chemoprevention of colorectal cancer and shows biochemical evidence that PP2A is an important regulator of Wnt/beta-catenin pathway activity in these cells.	Univ Amsterdam, Lab Expt Oncol & Radiobiol, Amsterdam, Netherlands; Univ Amsterdam, Dept Oncol, Amsterdam, Netherlands; Univ Amsterdam, Lab Expt Internal Med, Amsterdam, Netherlands; Univ Amsterdam, Dept Gastroenterol, Amsterdam, Netherlands; Univ Groningen, Dept Cell Biol, Groningen, Netherlands	University of Amsterdam; University of Amsterdam; University of Amsterdam; University of Amsterdam; University of Groningen	Hardwick, JCH (corresponding author), Acad Med Ctr, Dept Gastroenterol, C2-112,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	j.c.hardwick@amc.uva.nl	; Hardwick, James/J-4862-2013	Peppelenbosch, Maikel/0000-0001-9112-6028; Hardwick, James/0000-0002-9575-5099; Kodach, Liudmila/0000-0003-2487-3204				Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Boon EMJ, 2002, CANCER RES, V62, P5126; Charalambous D, 1996, J GASTROEN HEPATOL, V11, P307, DOI 10.1111/j.1440-1746.1996.tb01376.x; Chung HY, 1999, BIOCHEMISTRY-US, V38, P10371, DOI 10.1021/bi990902g; Dihlmann S, 2003, MOL CANCER THER, V2, P509; Dihlmann S, 2001, ONCOGENE, V20, P645, DOI 10.1038/sj.onc.1204123; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; Green DW, 2001, J SURG RES, V101, P16, DOI 10.1006/jsre.2001.6241; Gupta RA, 1998, GASTROENTEROLOGY, V114, P1095, DOI 10.1016/S0016-5085(98)70330-0; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Husain SS, 2002, AM J GASTROENTEROL, V97, P542; Kishimoto Y, 2000, GUT, V47, P812, DOI 10.1136/gut.47.6.812; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Marx J, 2001, SCIENCE, V291, P581, DOI 10.1126/science.291.5504.581; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Mistry SJ, 1998, BIOCHEM J, V334, P23, DOI 10.1042/bj3340023; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nunbhakdi-Craig V, 2002, J CELL BIOL, V158, P967, DOI 10.1083/jcb.200206114; Orena SJ, 2000, J BIOL CHEM, V275, P15765, DOI 10.1074/jbc.M910002199; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Oshima H, 1997, CANCER RES, V57, P1644; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Ratcliffe MJ, 2000, J BIOL CHEM, V275, P35680, DOI 10.1074/jbc.C000639200; Roh H, 2001, CANCER RES, V61, P6563; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Smal C, 2004, BIOCHEM PHARMACOL, V68, P95, DOI 10.1016/j.bcp.2004.02.031; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; Stark LA, 2001, FASEB J, V15, P1273, DOI 10.1096/fj.00-0529fje; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Xie HQ, 1998, BRAIN RES, V798, P173, DOI 10.1016/S0006-8993(98)00407-7	42	118	123	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2006	25	49					6447	6456		10.1038/sj.onc.1209658	http://dx.doi.org/10.1038/sj.onc.1209658			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16878161				2022-12-25	WOS:000241395100001
J	Franco, R; Cidlowski, JA				Franco, Rodrigo; Cidlowski, John A.			SLCO/OATP-like transport of glutathione in FasL-induced apoptosis - Glutathione efflux is coupled to an organic anion exchange and is necessary for the progression of the execution phase of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; REDUCED GLUTATHIONE; INTRACELLULAR GLUTATHIONE; CELL-DEATH; MEMBRANE-TRANSPORT; REDOX-REGULATION; MEDIATED APOPTOSIS; VOLUME DECREASE; LEUKEMIA-CELLS; GSH EXTRUSION	Apoptosis is characterized by the activation of specific biochemical pathways that lead to the organized demise of cells. Intracellular GSH depletion has been observed during apoptosis; however, neither the mechanisms involved in the reduction of the intracellular GSH concentration, [ GSH] i, nor its link to the progression of apoptosis have been elucidated. We have studied this issue using Fas ligand ( FasL)- induced apoptosis in Jurkat cells where changes in [GSH](i) can be analyzed biochemically and at the single cell level by flow cytometry. A reduction in the total [ GSH](i) in response to FasL occurs in two distinct stages prior to the loss of membrane integrity. Jurkat cells express several members of the multidrug resistance protein ( ABCC/ MRP), and the organic anion- transporting polypeptide protein ( SLCO/ OATP) families of GSH efflux pumps at the mRNAlevel. Glutathione loss and its accumulation in the extracellular medium, induced by FasL, was trans- stimulated by the organic substrates MK571, probenecid, taurocholic acid, estrone sulfate, and bromosulfophthalein and inhibited by high concentrations of extracellular GSH. Single cell analysis demonstrated that intracellular GSH loss was paralleled by the activation of an organic anion uptake process, supporting the role of an anion exchange mechanism ( SLCO/ OATP- like transport) in GSH efflux induced by FasL. Additionally, high extracellular GSH inhibited the activation of the execution caspases, the cleavage of their substrates poly(ADP-ribose) polymerase ( PARP) and alpha-fodrin, and DNA degradation. In contrast, the trans- stimulation of GSH efflux by MK571 increased the cleavage of the execution caspases and their substrates. Together these results suggest that GSH efflux during FasL- induced apoptosis is mediated by a SLCO/ OATP- like transport mechanism that modulates the progression of the execution phase of apoptosis.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Cidlowski, JA (corresponding author), NIEHS, Lab Signal Transduct, NIH, POB 12233,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	cidlows1@mail.nih.gov	Cidlowski, John A/G-2548-2019; Franco, Rodrigo/D-9470-2013	Cidlowski, John A/0000-0003-1420-0516; Franco, Rodrigo/0000-0003-3241-8615	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090079, ZIAES090079, ZIAES090057, Z01ES090057] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adachi H, 2003, AM J PHYSIOL-RENAL, V285, pF1188, DOI 10.1152/ajprenal.00402.2002; Armstrong JS, 2002, FASEB J, V16, P1263, DOI 10.1096/fj.02-0097fje; Ballatori N, 2005, TOXICOL APPL PHARM, V204, P238, DOI 10.1016/j.taap.2004.09.008; Benlloch M, 2005, J BIOL CHEM, V280, P6950, DOI 10.1074/jbc.M408531200; Bortner CD, 2004, PFLUG ARCH EUR J PHY, V448, P313, DOI 10.1007/s00424-004-1266-5; Bortner CD, 2002, CELL DEATH DIFFER, V9, P1307, DOI 10.1038/sj.cdd.4401126; Chiba T, 1996, EUR J IMMUNOL, V26, P1164, DOI 10.1002/eji.1830260530; Cihlar T, 2000, ANAL BIOCHEM, V283, P49, DOI 10.1006/abio.2000.4633; Clarke G, 2001, HUM MOL GENET, V10, P2269, DOI 10.1093/hmg/10.20.2269; Coppola S, 2000, BIOCHEM SOC T, V28, P56, DOI 10.1042/bst0280056; Curtin JF, 2003, CELL SIGNAL, V15, P983, DOI 10.1016/S0898-6568(03)00093-7; Davis W, 2001, J PHARMACOL EXP THER, V296, P1; Echevarria-Lima J, 2005, IMMUNOLOGY, V114, P468, DOI 10.1111/j.1365-2567.2005.02116.x; FERNANDEZ A, 1995, J IMMUNOL, V155, P5133; Franklin CC, 2002, AM J PATHOL, V160, P1887, DOI 10.1016/S0002-9440(10)61135-2; Friesen C, 2004, CELL DEATH DIFFER, V11, pS73, DOI 10.1038/sj.cdd.4401431; GARCIARUIZ C, 1992, J BIOL CHEM, V267, P22256; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; Green DR, 2003, IMMUNOL REV, V193, P5, DOI 10.1034/j.1600-065X.2003.00045.x; Hagenbuch B, 2004, PFLUG ARCH EUR J PHY, V447, P653, DOI 10.1007/s00424-003-1168-y; Hall AG, 1999, ADV EXP MED BIOL, V457, P199; Hammond CL, 2004, TOXICOL APPL PHARM, V195, P12, DOI 10.1016/j.taap.2003.10.008; Hammond CL, 2001, J HEPATOL, V34, P946, DOI 10.1016/S0168-8278(01)00037-X; Haouzi D, 2001, HEPATOLOGY, V33, P1181, DOI 10.1053/jhep.2001.24235; He YY, 2003, J BIOL CHEM, V278, P8058, DOI 10.1074/jbc.M207781200; HEDLEY DW, 1994, CYTOMETRY, V15, P349, DOI 10.1002/cyto.990150411; Hentze H, 2003, TOXICOL LETT, V139, P111, DOI 10.1016/S0378-4274(02)00425-3; Hentze H, 2002, J BIOL CHEM, V277, P5588, DOI 10.1074/jbc.M110766200; Homolya L, 2003, BIOFACTORS, V17, P103, DOI 10.1002/biof.5520170111; Keppler D, 1999, FREE RADICAL BIO MED, V27, P985, DOI 10.1016/S0891-5849(99)00171-9; Kern JC, 2005, FRONT BIOSCI-LANDMRK, V10, P1727, DOI 10.2741/1656; Kohno T, 1996, J IMMUNOL, V156, P4722; Lee TK, 2001, TOXICOL APPL PHARM, V174, P207, DOI 10.1006/taap.2001.9208; Li LQ, 2000, MOL PHARMACOL, V58, P335, DOI 10.1124/mol.58.2.335; Li LQ, 1998, J BIOL CHEM, V273, P16184, DOI 10.1074/jbc.273.26.16184; Macho A, 1997, J IMMUNOL, V158, P4612; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; Martel J, 1997, LEUKEMIA RES, V21, P1077, DOI 10.1016/S0145-2126(97)00063-5; Miller DS, 1996, AM J PHYSIOL-RENAL, V271, pF508, DOI 10.1152/ajprenal.1996.271.3.F508; Perl A, 2002, ANTIOXID REDOX SIGN, V4, P427, DOI 10.1089/15230860260196227; Pompella A, 2003, BIOCHEM PHARMACOL, V66, P1499, DOI 10.1016/S0006-2952(03)00504-5; Raaijmakers HGP, 2002, CYTOMETRY, V49, P135, DOI 10.1002/cyto.10157; Rius M, 2003, HEPATOLOGY, V38, P374, DOI 10.1053/jhep.2003.50331; Russel FGM, 2002, ANNU REV PHYSIOL, V64, P563, DOI 10.1146/annurev.physiol.64.081501.155913; Salerno M, 2004, BIOCHEM PHARMACOL, V68, P2159, DOI 10.1016/j.bcp.2004.08.010; Sebastia J, 2003, CYTOM PART A, V51A, P16, DOI 10.1002/cyto.a.10003; SOMMER F, 1994, J IMMUNOL, V153, P3523; Sykes D, 2004, AM J PHYSIOL-RENAL, V286, pF972, DOI 10.1152/ajprenal.00356.2003; SZE G, 1993, AM J PHYSIOL, V265, pG1128, DOI 10.1152/ajpgi.1993.265.6.G1128; Ueda S, 1998, J IMMUNOL, V161, P6689; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Varghese J, 2003, APOPTOSIS, V8, P363, DOI 10.1023/A:1024121017841; William R, 1997, BLOOD, V89, P4175, DOI 10.1182/blood.V89.11.4175; Zamek-Gliszczynski MJ, 2003, J PHARMACOL EXP THER, V304, P801, DOI 10.1124/jpet.102.044107	54	92	93	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29542	29557		10.1074/jbc.M602500200	http://dx.doi.org/10.1074/jbc.M602500200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16857677	hybrid			2022-12-25	WOS:000240896300016
J	Graille, M; Baltaze, JP; Leulliot, N; Liger, D; Quevillon-Cheruel, S; van Tilbeurgh, H				Graille, Marc; Baltaze, Jean-Pierre; Leulliot, Nicolas; Liger, Dominique; Quevillon-Cheruel, Sophie; van Tilbeurgh, Herman			Structure-based functional annotation - Yeast YMR099c codes for a D-hexose-6-phosphate mutarotase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE-COMPLEMENTING PROTEIN; HUMAN GALACTOSE METABOLISM; X-RAY STRUCTURE; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; GLUCOSE-6-PHOSPHATE 1-EPIMERASE; ANOMERIC SPECIFICITY; ANGSTROM RESOLUTION; LACTOCOCCUS-LACTIS	Despite the generation of a large amount of sequence information over the last decade, more than 40% of well characterized enzymatic functions still lack associated protein sequences. Assigning protein sequences to documented biochemical functions is an interesting challenge. We illustrate here that structural genomics may be a reasonable approach in addressing these questions. We present the crystal structure of the Saccharomyces cerevisiae YMR099cp, a protein of unknown function. YMR099cp adopts the same fold as galactose mutarotase and shares the same catalytic machinery necessary for the interconversion of the alpha and beta anomers of galactose. The structure revealed the presence in the active site of a sulfate ion attached by an arginine clamp made by the side chain from two strictly conserved arginine residues. This sulfate is ideally positioned to mimic the phosphate group of hexose 6-phosphate. We have subsequently successfully demonstrated that YMR099cp is a hexose-6-phosphate mutarotase with broad substrate specificity. We solved high resolution structures of some substrate enzyme complexes, further confirming our functional hypothesis. The metabolic role of a hexose-6-phosphate mutarotase is discussed. This work illustrates that structural information has been crucial to assign YMR099cp to the orphan EC activity: hexose-phosphate mutarotase.	Univ Paris 11, Inst Biochim & Biophys Mol & Cellulaire, CNRS, UMR 8619,IFR115, F-91405 Orsay, France; Univ Paris 11, Inst Chim Mol & Mat, CNRS, UMR 8182, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Saclay	van Tilbeurgh, H (corresponding author), Univ Paris 11, Inst Biochim & Biophys Mol & Cellulaire, CNRS, UMR 8619,IFR115, F-91405 Orsay, France.	Herman.Van-Tilbeurgh@ibbmc.u-psud.fr	Leulliot, Nicolas/AAA-7160-2019; GRAILLE, Marc/D-3242-2014	Leulliot, Nicolas/0000-0003-0283-4298; GRAILLE, Marc/0000-0002-7853-5852				Assairi L, 2004, PROTEIN SCI, V13, P1295, DOI 10.1110/ps.03566004; CHANCE EM, 1975, EUR J BIOCHEM, V50, P419, DOI 10.1111/j.1432-1033.1975.tb09818.x; Chen Y, 2005, BMC MOL BIOL, V6, DOI 10.1186/1471-2199-6-12; de la Sierra IL, 2001, J MOL BIOL, V311, P87, DOI 10.1006/jmbi.2001.4843; de La Sierra-Gallay IL, 2004, PROTEINS, V54, P776, DOI 10.1002/prot.10596; Egloff MP, 2001, STRUCTURE, V9, P689, DOI 10.1016/S0969-2126(01)00626-8; Frey PA, 1996, FASEB J, V10, P461, DOI 10.1096/fasebj.10.4.8647345; Hazbun TR, 2003, MOL CELL, V12, P1353, DOI 10.1016/S1097-2765(03)00476-3; Holden HM, 2003, J BIOL CHEM, V278, P43885, DOI 10.1074/jbc.R300025200; HOWARD SM, 1965, ARCH BIOCHEM BIOPHYS, V110, P395, DOI 10.1016/0003-9861(65)90140-2; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Karp PD, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-8-401; Kuhn P, 2002, PROTEINS, V49, P142, DOI 10.1002/prot.10202; Lespinet O, 2005, SCIENCE, V307, P42; LIVINGSTONE G, 1977, J SOLUTION CHEM, V6, P203, DOI 10.1007/BF00646739; Majumdar S, 2004, EUR J BIOCHEM, V271, P753, DOI 10.1111/j.1432-1033.2003.03974.x; Mathews II, 2003, STRUCTURE, V11, P677, DOI 10.1016/S0969-2126(03)00097-2; Meyer B, 2003, ANGEW CHEM INT EDIT, V42, P864, DOI 10.1002/anie.200390233; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; Novelli G, 2000, MOL GENET METAB, V71, P62, DOI 10.1006/mgme.2000.3073; PAULY HE, 1975, H-S Z PHYSIOL CHEM, V356, P1613, DOI 10.1515/bchm2.1975.356.2.1613; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Petry KG, 1998, TRENDS GENET, V14, P98, DOI 10.1016/S0168-9525(97)01379-6; Quevillon-Cheruel S, 2004, BIOCHIMIE, V86, P617, DOI 10.1016/j.biochi.2004.09.013; Roberts RJ, 2004, PLOS BIOL, V2, P293, DOI 10.1371/journal.pbio.0020042; ROSE IA, 1973, J BIOL CHEM, V248, P2232; Ryu KS, 2005, J MOL BIOL, V349, P153, DOI 10.1016/j.jmb.2005.03.047; Ryu KS, 2004, J AM CHEM SOC, V126, P9180, DOI 10.1021/ja047911j; Ryu KS, 2004, J BIOL CHEM, V279, P25544, DOI 10.1074/jbc.M402016200; SALAS M, 1965, J BIOL CHEM, V240, P561; Schuldiner O, 1998, CURR GENET, V33, P16, DOI 10.1007/s002940050303; Takaku H, 2003, NUCLEIC ACIDS RES, V31, P2272, DOI 10.1093/nar/gkg337; Thoden JB, 2005, J BIOL CHEM, V280, P21900, DOI 10.1074/jbc.M502411200; Thoden JB, 2004, J BIOL CHEM, V279, P23431, DOI 10.1074/jbc.M402347200; Thoden JB, 2003, PROTEIN SCI, V12, P1051, DOI 10.1110/ps.0243203; Thoden JB, 2002, J BIOL CHEM, V277, P20854, DOI 10.1074/jbc.M201415200; Thoden JB, 2002, J BIOL CHEM, V277, P45458, DOI 10.1074/jbc.M208395200; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WURSTER B, 1972, FEBS LETT, V23, P341, DOI 10.1016/0014-5793(72)80311-9; WURSTER B, 1974, H-S Z PHYSIOL CHEM, V355, P255, DOI 10.1515/bchm2.1974.355.1.255; Wurster B, 1975, Methods Enzymol, V41, P488	43	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					30175	30185		10.1074/jbc.M604443200	http://dx.doi.org/10.1074/jbc.M604443200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16857670	Green Published, hybrid			2022-12-25	WOS:000240896300078
J	Kulikov, R; Winter, M; Blattner, C				Kulikov, Roman; Winter, Markus; Blattner, Christine			Binding of p53 to the central domain of Mdm2 is regulated by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN LIGASE ACTIVITY; ACIDIC DOMAIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; DEGRADATION; PROTEIN; OLIGOMERIZATION; PROMOTES; PATHWAY; RESCUE	The Mdm2 protein is the major regulator of the tumor suppressor protein p53. We show that the p53 protein associates both with the N-terminal and with the central domain of Mdm2. The central p53-binding site of Mdm2 encompasses amino acids 235-300. Binding of p53 to the central domain is significantly enhanced after phosphorylation of the central domain of Mdm2. The N-terminal and central domains of Mdm2 act synergistically in binding to p53. p53 mutants that have mutations in the tetramerization domain and that fail to oligomerize do not show such an enhancement of binding in the presence of the other binding site.	Forschungszentrum Karlsruhe, Inst Toxicol & Genet, D-76021 Karlsruhe, Germany	Helmholtz Association; Karlsruhe Institute of Technology	Blattner, C (corresponding author), Forschungszentrum Karlsruhe, Inst Toxicol & Genet, POB 3640, D-76021 Karlsruhe, Germany.	christine.blattner@itg.fzk.de	Blattner, Christine/H-2105-2013; Blattner, Christine/ABI-2152-2020	Blattner, Christine/0000-0002-7250-5273; Blattner, Christine/0000-0002-7250-5273				Argentini M, 2001, ONCOGENE, V20, P1267, DOI 10.1038/sj.onc.1204241; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Burch LR, 2000, FEBS LETT, V472, P93, DOI 10.1016/S0014-5793(00)01427-7; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Iwakuma T, 2003, MOL CANCER RES, V1, P993; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kawai H, 2003, MOL CELL BIOL, V23, P4939, DOI 10.1128/MCB.23.14.4939-4947.2003; Kohn KW, 2005, BIOCHEM BIOPH RES CO, V331, P816, DOI 10.1016/j.bbrc.2005.03.186; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Lomax ME, 1998, ONCOGENE, V17, P643, DOI 10.1038/sj.onc.1201974; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Nicholls CD, 2002, J BIOL CHEM, V277, P12937, DOI 10.1074/jbc.M108815200; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Shimizu H, 2002, J BIOL CHEM, V277, P28446, DOI 10.1074/jbc.M202296200; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Winter M, 2004, BIOCHEMISTRY-US, V43, P16356, DOI 10.1021/bi0489255; Yu GW, 2006, P NATL ACAD SCI USA, V103, P1227, DOI 10.1073/pnas.0510343103; Zhu QZ, 2001, J BIOL CHEM, V276, P29695, DOI 10.1074/jbc.M102634200	30	55	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28575	28583		10.1074/jbc.M513311200	http://dx.doi.org/10.1074/jbc.M513311200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16870621	hybrid			2022-12-25	WOS:000240680500011
J	Choudhury, B; Leoff, C; Saile, E; Wilkins, P; Quinn, CP; Kannenberg, EL; Carlson, RW				Choudhury, Biswa; Leoff, Christine; Saile, Elke; Wilkins, Patricia; Quinn, Conrad P.; Kannenberg, Elmar L.; Carlson, Russell W.			The structure of the major cell wall polysaccharide of Bacillus anthracis is species-specific	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTRAL POLYSACCHARIDE; CEREUS AHU-1356; IDENTIFICATION; GLYCOPROTEINS; SUBTILIS; SEQUENCE; ACID	In this report we describe the structure of the polysaccharide released from Bacillus anthracis vegetative cell walls by aqueous hydrogen fluoride (HF). This HF-released polysaccharide (HF-PS) was isolated and structurally characterized from the Ames, Sterne, and Pasteur strains of B. anthracis. The HF-PSs were also isolated from the closely related Bacillus cereus ATCC 10987 strain, and from the B. cereus ATCC 14579 type strain and compared with those of B. anthracis. The structure of the B. anthracis HF-PS was determined by glycosyl composition and linkage analyses, matrix-assisted laser desorption-time of flight mass spectrometry, and one- and two-dimensional nuclear magnetic resonance spectroscopy. The HF-PSs from all of the B. anthracis isolates had an identical structure consisting of an amino sugar backbone of -> 6)-alpha-GlcNAc-(1 -> 4)-beta-ManNAc-(1 -> 4)-beta-GlcNAc-(1 ->, in which the alpha-GlcNAc residue is sub-stituted with alpha-Gal and beta-Gal at O-3 and O-4, respectively, and the beta-GlcNAc substituted with alpha-Gal at O-3. There is some variability in the presence of two of these three Gal substitutions. Comparison with the HF-PSs from B. cereus ATCC 10987 and B. cereus ATCC 14579 showed that the B. anthracis structure was clearly different from each of these HF-PSs and, furthermore, that the B. cereus ATCC 10987 HF-PS structure was different from that of B. cereus ATCC 14579. The presence of a B. anthra-cis-specific polysaccharide structure in its vegetative cell wall is discussed with regard to its relationship to those of other Bacillus species.	Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; Univ Tubingen, Dept Microbiol, D-72076 Tubingen, Germany; Univ Tubingen, Dept Biotechnol, D-72076 Tubingen, Germany	University System of Georgia; University of Georgia; Centers for Disease Control & Prevention - USA; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Carlson, RW (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, 220 Riverbend Rd, Athens, GA 30602 USA.	rcarlson@ccrc.uga.edu			NIAID NIH HHS [R21 AI059577] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMANO K, 1977, EUR J BIOCHEM, V75, P513, DOI 10.1111/j.1432-1033.1977.tb11552.x; Brechtel E, 1999, J BACTERIOL, V181, P5017, DOI 10.1128/JB.181.16.5017-5023.1999; BROWN WC, 1973, APPL MICROBIOL, V25, P295, DOI 10.1128/AEM.25.2.295-300.1973; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; EKWUNIFE FS, 1991, FEMS MICROBIOL LETT, V82, P257; Fox A, 2003, J MICROBIOL METH, V54, P143, DOI 10.1016/S0167-7012(03)00095-2; FOX A, 1993, J CLIN MICROBIOL, V31, P887, DOI 10.1128/JCM.31.4.887-894.1993; Han CS, 2006, J BACTERIOL, V188, P3382, DOI 10.1128/JB.188.9.3382-3390.2006; Hoffmaster AR, 2004, P NATL ACAD SCI USA, V101, P8449, DOI 10.1073/pnas.0402414101; IWASAKI H, 1989, EUR J BIOCHEM, V178, P635, DOI 10.1111/j.1432-1033.1989.tb14492.x; KATSUKI H, 1971, ANAL BIOCHEM, V43, P349, DOI 10.1016/0003-2697(71)90263-6; KOJIMA N, 1985, EUR J BIOCHEM, V148, P479, DOI 10.1111/j.1432-1033.1985.tb08864.x; KOJIMA N, 1988, EUR J BIOCHEM, V174, P255, DOI 10.1111/j.1432-1033.1988.tb14091.x; Mayer-Scholl A, 2005, PLOS PATHOG, V1, P179, DOI 10.1371/journal.ppat.0010023; Mesnage S, 2000, EMBO J, V19, P4473, DOI 10.1093/emboj/19.17.4473; Messner P, 1997, GLYCOCONJUGATE J, V14, P3, DOI 10.1023/A:1018551228663; Mock M, 2001, ANNU REV MICROBIOL, V55, P647, DOI 10.1146/annurev.micro.55.1.647; MOLNAR J, 1971, ACTA MICROBIOL HUNG, V18, P105; MURAZUMI N, 1986, EUR J BIOCHEM, V161, P51, DOI 10.1111/j.1432-1033.1986.tb10123.x; Priest FG, 2004, J BACTERIOL, V186, P7959, DOI 10.1128/JB.186.23.7959-7970.2004; Rasko DA, 2004, NUCLEIC ACIDS RES, V32, P977, DOI 10.1093/nar/gkh258; Wang W, 2004, J IMMUNOL, V173, P515, DOI 10.4049/jimmunol.173.1.515; YORK WS, 1986, METHOD ENZYMOL, V118, P3	23	78	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27932	27941		10.1074/jbc.M605768200	http://dx.doi.org/10.1074/jbc.M605768200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16870610	hybrid			2022-12-25	WOS:000240534400029
J	Cruchaga, C; Anso, E; Rouzaut, A; Martinez-Irujo, JJ				Cruchaga, Carlos; Anso, Elena; Rouzaut, Ana; Martinez-Irujo, Juan J.			Selective excision of chain-terminating nucleotides by HIV-1 reverse transcriptase with phosphonoformate as substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PRIMER UNBLOCKING ACTIVITY; 3'-AZIDO-3'-DEOXYTHYMIDINE AZT; SYNERGISTIC INHIBITION; DRUG-RESISTANCE; DNA-POLYMERASE; NONNUCLEOSIDE INHIBITORS; REPLICATION INVITRO; ANTIVIRAL ACTIVITY; AIDS DRUGS	A major mechanism for human immunodeficiency virus 1 (HIV-1) reverse transcriptase (RT) resistance to nucleoside analogs involves the phosphorolytical removal of the chain-terminating nucleotide from the 3'-end of the primer. In this work, we analyzed the effect of phosphonoformate (PFA) and other pyrophosphate (PPi) analogs on PPi- and ATP-dependent phosphorolysis catalyzed by HIV-1 RT. Our experimental data demonstrated that PFA did not behave as a linear inhibitor but as an alternative substrate, allowing RT to remove AZT from a terminated primer through a PFA-dependent mechanism. Interestingly, in non-terminated primers, PFA was not a substrate for this reaction and competitively inhibited PPi- and ATP-dependent phosphorolysis. In fact, binding of PFA to the RT(.)template/primer complex was hindered by the presence of a chain terminator at the 3'-end of the primer. Other pyrophosphate analogs, such as phosphonoacetate, were substrates for the excision reaction with both terminated and non-terminated primers, whereas pamidronate, a bisphosphonate that prevents bone resorption, was not a substrate for these reactions and competitively inhibited the phosphorolytic activity of RT. As expected from their mechanisms of action, pamidronate (but not PFA) synergistically inhibits HIV-1 RT in combination with AZT-triphosphate in the presence of PPi or ATP. These results provide new clues about the mechanism of action of PFA and demonstrate that only certain pyrophosphate analogs can enhance the effect of nucleosidic inhibitors by blocking the excision of chain-terminating nucleotides catalyzed by HIV-1 RT. The relevance of these findings in combined chemotherapy is discussed.	Univ Navarra, Dept Bioquim & Biol Mol, Byron, GA 31008 USA	University of Navarra	Martinez-Irujo, JJ (corresponding author), Univ Navarra, Dept Bioquim & Biol Mol, Calle Irunlarrea S-N, Byron, GA 31008 USA.	jjmirujo@unav.es	Rouzaut, Ana/I-2576-2017; Cruchaga, Carlos/ABF-4065-2020; Martinez-Irujo, Juan/N-3193-2014	Rouzaut, Ana/0000-0003-3226-9162; Cruchaga, Carlos/0000-0002-0276-2899; Martinez-Irujo, Juan/0000-0003-4576-8139				Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Arion D, 2000, J BIOL CHEM, V275, P9251, DOI 10.1074/jbc.275.13.9251; Basavapathruni A, 2004, J BIOL CHEM, V279, P6221, DOI 10.1074/jbc.C300523200; BISSWANGER H, 2002, ENZYME KINETICS PRIN, P106; Borkow G, 1999, ANTIMICROB AGENTS CH, V43, P259, DOI 10.1128/AAC.43.2.259; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; Crespan E, 2005, ANTIMICROB AGENTS CH, V49, P342, DOI 10.1128/AAC.49.1.342-349.2005; Cruchaga C, 2005, BIOCHEMISTRY-US, V44, P3535, DOI 10.1021/bi048129z; DERSE D, 1982, J BIOL CHEM, V257, P251; ERIKSSON B, 1980, BIOCHIM BIOPHYS ACTA, V607, P53, DOI 10.1016/0005-2787(80)90220-8; ERIKSSON BFH, 1989, ANTIMICROB AGENTS CH, V33, P663, DOI 10.1128/AAC.33.5.663; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; Goldschmidt V, 2004, INT J BIOCHEM CELL B, V36, P1687, DOI 10.1016/j.biocel.2004.02.028; GOODY RS, 1991, FEBS LETT, V291, P1, DOI 10.1016/0014-5793(91)81089-Q; Gotte Matthias, 2004, Expert Rev Anti Infect Ther, V2, P707, DOI 10.1586/14789072.2.5.707; Gulick RM, 2004, NEW ENGL J MED, V350, P1850, DOI 10.1056/NEJMoa031772; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JACOBSON MA, 1991, J INFECT DIS, V163, P1219, DOI 10.1093/infdis/163.6.1219; Jamburuthugoda VK, 2005, BIOCHEMISTRY-US, V44, P10635, DOI 10.1021/bi050611+; KONG XB, 1991, ANTIMICROB AGENTS CH, V35, P2003, DOI 10.1128/AAC.35.10.2003; KOSHIDA R, 1989, ANTIMICROB AGENTS CH, V33, P778, DOI 10.1128/AAC.33.5.778; Kukhanova MK, 2005, BIOCHEM BIOPH RES CO, V338, P1335, DOI 10.1016/j.bbrc.2005.10.092; LEINBACH SS, 1976, BIOCHEMISTRY-US, V15, P426, DOI 10.1021/bi00647a029; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; Martinez-Irujo JJ, 1998, BIOCHEM J, V329, P689, DOI 10.1042/bj3290689; Meyer PR, 2003, J VIROL, V77, P6127, DOI 10.1128/JVI.77.11.6127-6137.2003; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; OBERG B, 1989, PHARMACOL THERAPEUT, V40, P213, DOI 10.1016/0163-7258(89)90097-1; Odriozola L, 2003, J BIOL CHEM, V278, P42710, DOI 10.1074/jbc.M212673200; Palmer S, 1996, ANTIMICROB AGENTS CH, V40, P1285, DOI 10.1128/AAC.40.5.1285; PARNIAK MA, 2004, ANTIVIR THER LOND, V9, P32; Ray AS, 2003, BIOCHEMISTRY-US, V42, P8831, DOI 10.1021/bi034435l; Sarafianos SG, 2004, INT J BIOCHEM CELL B, V36, P1706, DOI 10.1016/j.biocel.2004.02.027; Sarafianos SG, 2002, EMBO J, V21, P6614, DOI 10.1093/emboj/cdf637; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; Tachedjian G, 1996, J VIROL, V70, P7171, DOI 10.1128/JVI.70.10.7171-7181.1996; Tchesnokov EP, 2006, J VIROL, V80, P1440, DOI 10.1128/JVI.80.3.1440-1450.2006; Villahermosa ML, 1997, BIOCHEMISTRY-US, V36, P13223, DOI 10.1021/bi970852k; Vivet-Boudou V, 2006, CELL MOL LIFE SCI, V63, P163, DOI 10.1007/s00018-005-5367-x	39	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27744	27752		10.1074/jbc.M603360200	http://dx.doi.org/10.1074/jbc.M603360200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16829515	hybrid			2022-12-25	WOS:000240534400010
J	Kiyonari, S; Takayama, K; Nishida, H; Ishino, Y				Kiyonari, Shinichi; Takayama, Kohei; Nishida, Hirokazu; Ishino, Yoshizumi			Identification of a novel binding motif in Pyrococcus furiosus DNA ligase for the functional interaction with proliferating cell nuclear antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION-FACTOR-C; BIOCHEMICAL-CHARACTERIZATION; HYPERTHERMOPHILIC ARCHAEON; PCNA; PROTEINS; MECHANISM; PARTNERS; COMPLEX; CLAMP	DNA ligase is an essential enzyme for all organisms and catalyzes a nick-joining reaction in the final step of the DNA replication, repair, and recombination processes. Herein, we show the physical and functional interaction between DNA ligase and proliferating cell nuclear antigen ( PCNA) from the hyperthermophilic Euryarchaea Pyrococcus furiosus. The stimulatory effect of P. furiosus PCNA on the enzyme activity of P. furiosus DNA ligase was observed not at low ionic strength, but at a high salt concentration, at which a DNA ligase alone cannot bind to a nicked DNA substrate. On the basis of mutational analyses, we identified the amino acid residues that are critical for PCNA binding in a loop structure located in the N-terminal DNA-binding domain of P. furiosus DNA ligase. We propose that the pentapeptide motif QKSFF is involved in the PCNA-interacting motifs, in which Gln and the first Phe are especially important for stable binding with PCNA.	Kyushu Univ, Fac Agr, Dept Genet Resources Technol, Fukuoka 8128581, Japan; Japan Sci & Technol Agcy, BIRD, Fukuoka 8128581, Japan; Hitachi Ltd, Cent Res Lab, Kokubunji, Tokyo 1858581, Japan	Kyushu University; Japan Science & Technology Agency (JST); Hitachi Limited	Ishino, Y (corresponding author), Kyushu Univ, Fac Agr, Dept Genet Resources Technol, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	ishino@agr.kyushu-u.ac.jp	Kiyonari, Shinichi/I-7329-2014	Nishida, Hirokazu/0000-0003-1738-8331; Ishino, Yoshizumi/0000-0001-9419-0826				Cann IKO, 1999, J BACTERIOL, V181, P6591, DOI 10.1128/JB.181.21.6591-6599.1999; Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398; Dionne I, 2005, BIOCHEM J, V387, P859, DOI 10.1042/BJ20041661; Dionne I, 2003, MOL CELL, V11, P275, DOI 10.1016/S1097-2765(02)00824-9; Doherty AJ, 2000, NUCLEIC ACIDS RES, V28, P4051, DOI 10.1093/nar/28.21.4051; Grabowski B, 2003, ANNU REV MICROBIOL, V57, P487, DOI 10.1146/annurev.micro.57.030502.090709; Hethke C, 1999, GENETICS, V152, P1325; Ho CK, 1997, J VIROL, V71, P1931, DOI 10.1128/JVI.71.3.1931-1937.1997; Jeon SJ, 2003, FEBS LETT, V550, P69, DOI 10.1016/S0014-5793(03)00821-4; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kanoksilapatham Wirojne, 2004, Archaea, V1, P277, DOI 10.1155/2004/513563; Keppetipola N, 2005, J BACTERIOL, V187, P6902, DOI 10.1128/JB.187.20.6902-6908.2005; KLETZIN A, 1992, NUCLEIC ACIDS RES, V20, P5389, DOI 10.1093/nar/20.20.5389; Knibiehler M, 1996, FEBS LETT, V391, P66, DOI 10.1016/0014-5793(96)00702-8; Komori K, 2000, NUCLEIC ACIDS RES, V28, P4544, DOI 10.1093/nar/28.22.4544; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Lai XQ, 2002, EXTREMOPHILES, V6, P469, DOI 10.1007/s00792-002-0284-5; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Martin RC, 2002, EPILEPSY BEHAV, V3, P4, DOI 10.1006/ebeh.2001.0316; Martins A, 2004, J BIOL CHEM, V279, P50654, DOI 10.1074/jbc.M407657200; MATHUR EJ, 1996, Patent No. 5506137; Matsumiya S, 2003, PROTEIN SCI, V12, P823, DOI 10.1110/ps.0234503; Matsumiya S, 2002, GENES CELLS, V7, P911, DOI 10.1046/j.1365-2443.2002.00572.x; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; Nakatani M, 2000, J BACTERIOL, V182, P6424, DOI 10.1128/JB.182.22.6424-6433.2000; Nishida H, 2005, GENES GENET SYST, V80, P83, DOI 10.1266/ggs.80.83; Pascal JM, 2004, NATURE, V432, P473, DOI 10.1038/nature03082; Rolland JL, 2004, FEMS MICROBIOL LETT, V236, P267, DOI 10.1016/j.femsle.2004.05.045; SCHOLZ S, 1992, FEBS LETT, V306, P239, DOI 10.1016/0014-5793(92)81008-A; Sriskanda V, 2000, NUCLEIC ACIDS RES, V28, P2221, DOI 10.1093/nar/28.11.2221; Tom S, 2001, J BIOL CHEM, V276, P24817, DOI 10.1074/jbc.M101673200; Tomkinson AE, 2006, CHEM REV, V106, P687, DOI 10.1021/cr040498d; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; Vivona JB, 2003, FEBS LETT, V546, P167, DOI 10.1016/S0014-5793(03)00622-7; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Wilkinson A, 2001, MOL MICROBIOL, V40, P1241, DOI 10.1046/j.1365-2958.2001.02479.x; Xu H, 2001, BIOCHEMISTRY-US, V40, P4512, DOI 10.1021/bi010103+	38	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28023	28032		10.1074/jbc.M603403200	http://dx.doi.org/10.1074/jbc.M603403200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16829513	hybrid			2022-12-25	WOS:000240534400039
J	Tang, HP; Kambris, Z; Lemaitre, B; Hashimoto, C				Tang, Huaping; Kambris, Zakaria; Lemaitre, Bruno; Hashimoto, Carl			Two proteases defining a melanization cascade in the immune system of Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLOTRICHIA-DIOMPHALIA LARVAE; SERINE-PROTEASE; COLEOPTERAN INSECT; TOLL ACTIVATION; HOST-DEFENSE; SERPIN; PROPHENOLOXIDASE; INFECTION; ADULTS; RESPONSES	The melanization reaction is used as an immune mechanism in arthropods to encapsulate and kill microbial pathogens. In Drosophila, the serpin Spn27A regulates melanization apparently by inhibiting the protease that activates phenoloxidase, the key enzyme in melanin synthesis. Here, we have described the genetic characterization of two immune inducible serine proteases, MP1 and MP2, which act in a melanization cascade regulated by Spn27A. MP1 is required to activate melanization in response to both bacterial and fungal infection, whereas MP2 is mainly involved during fungal infection. Pathogenic bacteria and fungi may therefore trigger two different melanization cascades that use MP1 as a common downstream protease to activate phenoloxidase. We have also shown that the melanization reaction activated by MP1 and MP2 plays an important role in augmenting the effectiveness of other immune reactions, thereby promoting resistance of Drosophila to microbial infection.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France	Yale University; Yale University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Hashimoto, C (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06520 USA.	carl.hashimoto@yale.edu	Lemaitre, Bruno/T-8146-2019	Lemaitre, Bruno/0000-0001-7970-1667	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049370] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49370] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Castillejo-Lopez C, 2005, BIOCHEM BIOPH RES CO, V338, P1075, DOI 10.1016/j.bbrc.2005.10.042; Cerenius L, 2004, IMMUNOL REV, V198, P116, DOI 10.1111/j.0105-2896.2004.00116.x; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; Christensen BM, 2005, TRENDS PARASITOL, V21, P192, DOI 10.1016/j.pt.2005.02.007; De Gregorio E, 2001, P NATL ACAD SCI USA, V98, P12590, DOI 10.1073/pnas.221458698; De Gregorio E, 2002, EMBO J, V21, P2568, DOI 10.1093/emboj/21.11.2568; De Gregorio E, 2002, DEV CELL, V3, P581, DOI 10.1016/S1534-5807(02)00267-8; Duffy JB, 2002, GENESIS, V34, P1, DOI 10.1002/gene.10150; Gobert V, 2003, SCIENCE, V302, P2126, DOI 10.1126/science.1085432; Hashimoto C, 2003, DEV CELL, V5, P945, DOI 10.1016/S1534-5807(03)00338-1; Hedengren M, 1999, MOL CELL, V4, P827, DOI 10.1016/S1097-2765(00)80392-5; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Kambris Z, 2006, CURR BIOL, V16, P808, DOI 10.1016/j.cub.2006.03.020; Kanost Michael R, 2004, Immunol Rev, V198, P97, DOI 10.1111/j.0105-2896.2004.0121.x; Krem MM, 2002, TRENDS BIOCHEM SCI, V27, P67, DOI 10.1016/S0968-0004(01)02007-2; Kwon TH, 2000, EUR J BIOCHEM, V267, P6188, DOI 10.1046/j.1432-1327.2000.01695.x; Leclerc V, 2006, EMBO REP, V7, P231, DOI 10.1038/sj.embor.7400592; Lee SY, 1998, EUR J BIOCHEM, V257, P615, DOI 10.1046/j.1432-1327.1998.2570615.x; Lee YS, 2003, METHODS, V30, P322, DOI 10.1016/S1046-2023(03)00051-3; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; Leulier F, 2002, CURR BIOL, V12, P996, DOI 10.1016/S0960-9822(02)00873-4; Levashina EA, 1999, SCIENCE, V285, P1917, DOI 10.1126/science.285.5435.1917; Ligoxygakis P, 2003, CURR BIOL, V13, P2097, DOI 10.1016/j.cub.2003.10.062; Ligoxygakis P, 2002, EMBO J, V21, P6330, DOI 10.1093/emboj/cdf661; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Nappi AJ, 2005, INSECT BIOCHEM MOLEC, V35, P443, DOI 10.1016/j.ibmb.2005.01.014; Pili-Floury S, 2004, J BIOL CHEM, V279, P12848, DOI 10.1074/jbc.M313324200; PYE AE, 1974, NATURE, V251, P610, DOI 10.1038/251610a0; Rorth P, 1998, MECH DEVELOP, V78, P113, DOI 10.1016/S0925-4773(98)00157-9; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; Takehana A, 2004, EMBO J, V23, P4690, DOI 10.1038/sj.emboj.7600466; Tzou P, 2002, METHOD MICROBIOL, V31, P507, DOI 10.1016/S0580-9517(02)31028-6	34	152	162	5	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28097	28104		10.1074/jbc.M601642200	http://dx.doi.org/10.1074/jbc.M601642200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16861233	hybrid, Green Published			2022-12-25	WOS:000240534400047
J	Born, P; Breukink, E; Vollmer, W				Born, Petra; Breukink, Eefjan; Vollmer, Waldemar			In vitro synthesis of cross-linked murein and its attachment to sacculi by PBP1A from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING PROTEINS; CELL-WALL PEPTIDOGLYCAN; TRANSGLYCOSYLASE; TRANSPEPTIDASE; DIVISION; COMPONENT; MUTANTS; GROWTH; GLYCOSYLTRANSFERASE; BIOSYNTHESIS	The penicillin-binding protein (PBP) 1A is a major murein (peptidoglycan) synthase in Escherichia coli. The murein synthesis activity of PBP1A was studied in vitro with radioactive lipid II substrate. PBP1A produced murein glycan strands by transglycosylation and formed peptide cross-links by transpeptidation. Time course experiments revealed that PBP1A, unlike PBP1B, required the presence of polymerized glycan strands carrying monomeric peptides for cross-linking activity. PBP1A was capable of attaching nascent murein synthesized from radioactive lipid II to nonlabeled murein sacculi. The attachment of the new material occurred by transpeptidation reactions in which monomeric tri- and tetrapeptides in the sacculi were the acceptors.	Univ Tubingen, D-72076 Tubingen, Germany; Univ Utrecht, Inst Biomembranes, Dept Biochem Membranes, Ctr Biomembranes & Lipid Enzymol, NL-3584 CH Utrecht, Netherlands	Eberhard Karls University of Tubingen; Utrecht University	Vollmer, W (corresponding author), Univ Tubingen, Morgenstelle 28, D-72076 Tubingen, Germany.	waldemar.vollmer@uni-tuebingen.de	Breukink, Eefjan/I-3039-2016	Breukink, Eefjan/0000-0002-7311-0660				Barrett DS, 2004, BIOCHEMISTRY-US, V43, P12375, DOI 10.1021/bi049142m; Bertsche U, 2005, J BIOL CHEM, V280, P38096, DOI 10.1074/jbc.M508646200; BISHOP RE, 1993, FEMS MICROBIOL LETT, V114, P349, DOI 10.1111/j.1574-6968.1993.tb06597.x; Breukink E, 2003, J BIOL CHEM, V278, P19898, DOI 10.1074/jbc.M301463200; BURMAN LG, 1984, P NATL ACAD SCI-BIOL, V81, P1844, DOI 10.1073/pnas.81.6.1844; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Charpentier X, 2002, J BACTERIOL, V184, P3749, DOI 10.1128/JB.184.13.3749-3752.2002; COOPER S, 1988, J BACTERIOL, V170, P422, DOI 10.1128/jb.170.1.422-430.1988; DARGIS M, 1994, ANTIMICROB AGENTS CH, V38, P973, DOI 10.1128/AAC.38.5.973; DEJONGE BLM, 1989, J BACTERIOL, V171, P5783, DOI 10.1128/jb.171.11.5783-5794.1989; DELPORTILLO FG, 1990, J BACTERIOL, V172, P5863; DIBERARDINO M, 1996, FEBS LETT, V392, P184; GLAUNER B, 1990, J BIOL CHEM, V265, P18988; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; GLAUNER B, 1988, J BIOL CHEM, V263, P10088; Goffin C, 1998, MICROBIOL MOL BIOL R, V62, P1079, DOI 10.1128/MMBR.62.4.1079-1093.1998; ISHINO F, 1980, BIOCHEM BIOPH RES CO, V97, P287, DOI 10.1016/S0006-291X(80)80166-5; KATO J, 1984, MOL GEN GENET, V196, P449, DOI 10.1007/BF00436192; KOHLRAUSCH U, 1991, FEMS MICROBIOL LETT, V78, P253; KRAUS W, 1987, J BACTERIOL, V169, P3099, DOI 10.1128/jb.169.7.3099-3103.1987; KRAUS W, 1985, J BACTERIOL, V162, P1000, DOI 10.1128/JB.162.3.1000-1004.1985; MATSUHASHI M, 1990, RES MICROBIOL, V141, P89, DOI 10.1016/0923-2508(90)90101-U; NAKAGAWA J, 1984, J BIOL CHEM, V259, P3937; NAKAGAWA J, 1982, BIOCHEM BIOPH RES CO, V105, P1546, DOI 10.1016/0006-291X(82)90964-0; ROJO F, 1984, EUR J BIOCHEM, V144, P571, DOI 10.1111/j.1432-1033.1984.tb08503.x; Schiffer G, 1999, J BIOL CHEM, V274, P32031, DOI 10.1074/jbc.274.45.32031; SPRATT BG, 1977, FEBS LETT, V79, P374, DOI 10.1016/0014-5793(77)80824-7; SUZUKI H, 1978, P NATL ACAD SCI USA, V75, P664, DOI 10.1073/pnas.75.2.664; Terrak M, 1999, MOL MICROBIOL, V34, P350, DOI 10.1046/j.1365-2958.1999.01612.x; TOMIOKA S, 1982, BIOCHEM BIOPH RES CO, V106, P1175, DOI 10.1016/0006-291X(82)91236-0; Vollmer W, 2001, CURR OPIN MICROBIOL, V4, P625, DOI 10.1016/S1369-5274(01)00261-2; WEIDEL W, 1964, ADV ENZYMOL REL S BI, V26, P193; YOUSIF SY, 1985, J GEN MICROBIOL, V131, P2839	33	84	87	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26985	26993		10.1074/jbc.M604083200	http://dx.doi.org/10.1074/jbc.M604083200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16840781	Green Published, hybrid			2022-12-25	WOS:000240397700025
J	Chavez, C; Bowman, EJ; Reidling, JC; Haw, KH; Bowman, BJ				Chavez, Christopher; Bowman, Emma Jean; Reidling, Jack C.; Haw, Kimberly H.; Bowman, Barry J.			Analysis of strains with mutations in six genes encoding subunits of the V-ATPase - Eukaryotes differ in the composition of the V-0 sector of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; NEUROSPORA-CRASSA; SACCHAROMYCES-CEREVISIAE; PROTEOLIPID SUBUNIT; ELECTRON-MICROSCOPY; PUMP; SYNTHASE; POLYPEPTIDE; SEQUENCE	To address questions about the structure of the vacuolar ATPase, we have generated mutant strains of Neurospora crassa defective in six subunits, C, H, a, c, c', and c". Except for strains lacking subunit c', the mutant strains were indistinguishable from each other in most phenotypic characteristics. They did not accumulate arginine in the vacuoles, grew poorly at pH 5.8 with altered morphology, and failed to grow at alkaline pH. Consistent with findings from Saccharomyces cerevisiae, the data indicate that subunits C and H are essential for generation of a functional enzyme. Unlike S. cerevisiae, N. crassa has a single isoform of the a subunit. Analysis of other fungal genomes indicates that only the budding yeasts have a two-gene family for subunit a. It has been unclear whether subunit c', a small proteolipid, is a component of all V-ATPases. Our data suggest that this subunit is present in all fungi, but not in other organisms. Mutation or deletion of the N. crassa gene encoding subunit c' did not completely eliminate V-ATPase function. Unlike other V-ATPase null strains, they grew, although slowly, at alkaline pH, were able to form conidia (asexual spores), and were inhibited by concanamycin, a specific inhibitor of the V-ATPase. The phenotypic character in which strains differed was the ability to go through the sexual cycle to generate mature spores and viable mutant progeny. Strains lacking the integral membrane subunits a, c, c', and c" had more severe defects than strains lacking subunits C or H.	Univ Calif Santa Cruz, Dept Mol Cellular & Dev Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Bowman, BJ (corresponding author), Univ Calif Santa Cruz, Dept Mol Cellular & Dev Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA.	bowman@biology.ucsc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028703, R25GM058903] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28703, GM58903] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan AK, 2005, PHYSIOL GENOMICS, V22, P128, DOI 10.1152/physiolgenomics.00233.2004; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; Bowman EJ, 2000, J BIOL CHEM, V275, P167, DOI 10.1074/jbc.275.1.167; Bowman EJ, 2004, J BIOL CHEM, V279, P33131, DOI 10.1074/jbc.M404638200; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; Bowman EJ, 1997, J BIOL CHEM, V272, P14776, DOI 10.1074/jbc.272.23.14776; Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430; Curtis KK, 2002, J BIOL CHEM, V277, P2716, DOI 10.1074/jbc.M107777200; DAVIS RH, 1986, MICROBIOL REV, V50, P280, DOI 10.1128/MMBR.50.3.280-313.1986; DSCHIDA WJ, 1992, J BIOL CHEM, V267, P18783; Farina C, 2002, CURR PHARM DESIGN, V8, P2033, DOI 10.2174/1381612023393369; FAVIS RH, 2000, NEUROSPORA CONTRIBUT, P283; Fillingame RH, 2002, BBA-BIOENERGETICS, V1555, P29, DOI 10.1016/S0005-2728(02)00250-5; Futai M, 2000, BBA-BIOENERGETICS, V1458, P276, DOI 10.1016/S0005-2728(00)00080-3; Galagan JE, 2003, NATURE, V422, P859, DOI 10.1038/nature01554; Gluck SL, 1998, ACTA PHYSIOL SCAND, V163, P203; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HO MN, 1993, J BIOL CHEM, V268, P18286; Hunt IE, 1997, J BIOENERG BIOMEMBR, V29, P533, DOI 10.1023/A:1022474816665; Hurtado-Lorenzo A, 2006, NAT CELL BIOL, V8, P124, DOI 10.1038/ncb1348; Inoue H, 1999, BBA-BIOENERGETICS, V1413, P130, DOI 10.1016/S0005-2728(99)00096-1; Kane PA, 2006, MICROBIOL MOL BIOL R, V70, P177, DOI 10.1128/MMBR.70.1.177-191.2006; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; Kluge C, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-29; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; MacLeod KJ, 1998, J BIOL CHEM, V273, P150, DOI 10.1074/jbc.273.1.150; Malkus P, 2004, MOL BIOL CELL, V15, P5075, DOI 10.1091/mbc.E04-06-0514; Manolson MF, 2003, J BIOL CHEM, V278, P49271, DOI 10.1074/jbc.M309914200; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Margolin BS, 1997, FUNGAL GENET NEWSLET, V44, P34, DOI [10.4148/1941-4765.1281, DOI 10.1128/EC.00244-07]; Margolles-Clark E, 1999, J BIOENERG BIOMEMBR, V31, P29, DOI 10.1023/A:1005440412633; MELNIK VI, 1996, J BIOL CHEM, V273, P22570; Ninomiya Y, 2004, P NATL ACAD SCI USA, V101, P12248, DOI 10.1073/pnas.0402780101; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Nishi T, 2003, J BIOL CHEM, V278, P5821, DOI 10.1074/jbc.M209875200; Oka T, 2000, J BIOL CHEM, V275, P29556, DOI 10.1074/jbc.M002756200; Pall ML, 1993, FUNGAL GENET NEWSL, V40, P58; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SELKER EU, 1988, P NATL ACAD SCI USA, V85, P6870, DOI 10.1073/pnas.85.18.6870; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SISTA H, 1994, MOL GEN GENET, V243, P82, DOI 10.1007/BF00283879; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Sun-Wada GH, 2004, BBA-BIOENERGETICS, V1658, P106, DOI 10.1016/j.bbabio.2004.04.013; Sze H, 2002, TRENDS PLANT SCI, V7, P157, DOI 10.1016/S1360-1385(02)02240-9; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ueno H, 2005, P NATL ACAD SCI USA, V102, P1333, DOI 10.1073/pnas.0407857102; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; VOGEL HJ, 1964, AM NAT, V98, P435, DOI 10.1086/282338; Wagner CA, 2004, PHYSIOL REV, V84, P1263, DOI 10.1152/physrev.00045.2003; Whyteside G, 2005, FEBS LETT, V579, P2981, DOI 10.1016/j.febslet.2005.04.049; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; XIE XS, 1994, J BIOL CHEM, V269, P25809; Zhong XT, 2000, J BIOL CHEM, V275, P35592, DOI 10.1074/jbc.M006932200; Zhou ZM, 1998, J BIOL CHEM, V273, P5878, DOI 10.1074/jbc.273.10.5878	62	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27052	27062		10.1074/jbc.M603883200	http://dx.doi.org/10.1074/jbc.M603883200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16857684	hybrid			2022-12-25	WOS:000240397700032
J	Duchesne, L; Tissot, B; Rudd, TR; Dell, A; Fernig, DG				Duchesne, Laurence; Tissot, Berangere; Rudd, Timothy R.; Dell, Anne; Fernig, David G.			N-glycosylation of fibroblast growth factor receptor 1 regulates ligand and heparan sulfate co-receptor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; FACTOR FGF; IDENTIFICATION; ACTIVATION; MUTATION; CELLS; OLIGOSACCHARIDES; PROLIFERATION; EXPRESSION; PHOSPHORYLATION	The regulation of cell function by fibroblast growth factors (FGF) occurs through a dual receptor system consisting of a receptor-tyrosine kinase, FGFR and the glycosaminoglycan heparan sulfate (HS). Mutations of some potential N-glycosylation sites in human fgfr lead to phenotypes characteristic of receptor overactivation. To establish how N-glycosylation may affect FGFR function, soluble- and membrane-bound recombinant receptors corresponding to the extracellular ligand binding domain of FGFR1-IIIc were produced in Chinese Hamster Ovary cells. Both forms of FGFR1-IIIc were observed to be heavily N-glycosylated and migrated on SDS-PAGE as a series of multiple bands between 50 and 75 kDa, whereas the deglycosylated receptors migrated at 32 kDa, corresponding to the expected molecular weight of the polypeptides. Optical biosensor and quartz crystal microbalance-dissipation binding assays show that the removal of the N-glycans from FGFR1-IIIc caused an increase in the binding of the receptor to FGF-2 and to heparin-derived oligosaccharides, a proxy for cellular HS. This effect is mediated by N-glycosylation reducing the association rate constant of the receptor for FGF-2 and heparin oligosaccharides. N-Glycans were analyzed by mass spectrometry, which demonstrates a predominance of bi- and tri-antennary core-fucosylated complex type structures carrying one, two, and/or three sialic acids. Modeling of such glycan structures on the receptor protein suggests that at least some may be strategically positioned to interfere with interactions of the receptor with FGF ligand and/or the HS co-receptor. Thus, the N-glycans of the receptor represent an additional pathway for the regulation of the activity of FGFs.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, London SW7 2AZ, England	University of Liverpool; Imperial College London	Duchesne, L (corresponding author), Univ Liverpool, Sch Biol Sci, Biosci Bldg,Crown St, Liverpool L69 7ZB, Merseyside, England.	lduchesn@liv.ac.uk	Fernig, David G/A-3590-2008; Rudd, Tim/M-6129-2019	Fernig, David G/0000-0003-4875-4293; Rudd, Tim/0000-0003-4434-0333; Duchesne, Laurence/0000-0003-1985-6266	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Baker KN, 2001, BIOTECHNOL BIOENG, V73, P188, DOI 10.1002/bit.1051; Bohne-Lang A, 2005, NUCLEIC ACIDS RES, V33, pW214, DOI 10.1093/nar/gki385; Bryant DM, 2005, MOL BIOL CELL, V16, P14, DOI 10.1091/mbc.E04-09-0845; Chang Z, 2000, FASEB J, V14, P137, DOI 10.1096/fasebj.14.1.137; Delehedde M, 2000, J BIOL CHEM, V275, P33905, DOI 10.1074/jbc.M005949200; Delehedde M, 2002, BIOCHEM J, V366, P235, DOI 10.1042/BJ20011718; Delehedde M, 2002, J BIOL CHEM, V277, P12456, DOI 10.1074/jbc.M111345200; Delehedde M, 2001, J MAMMARY GLAND BIOL, V6, P253, DOI 10.1023/A:1011367423085; Detillieux KA, 2003, CARDIOVASC RES, V57, P8, DOI 10.1016/S0008-6363(02)00708-3; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; FERNIG DG, 1990, J CELL PHYSIOL, V142, P108, DOI 10.1002/jcp.1041420114; FERNIG DG, 2001, PROTEOGLYCAN PROTOCA; Freeman KW, 2003, CANCER RES, V63, P6237; Gagneux P, 1999, GLYCOBIOLOGY, V9, P747, DOI 10.1093/glycob/9.8.747; Gonzalez-Martinez D, 2004, J NEUROSCI, V24, P10384, DOI 10.1523/JNEUROSCI.3400-04.2004; GOOCHEE CF, 1990, BIO-TECHNOL, V8, P421, DOI 10.1038/nbt0590-421; GOOCHEE CF, 1991, BIO-TECHNOL, V9, P1347, DOI 10.1038/nbt1291-1347; Groth C, 2002, INT J DEV BIOL, V46, P393; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; Harmer NJ, 2004, J MOL BIOL, V339, P821, DOI 10.1016/j.jmb.2004.04.031; HORTON RM, 1991, DIRECTED MUTAGENESIS; Itoh N, 2004, TRENDS GENET, V20, P563, DOI 10.1016/j.tig.2004.08.007; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; KE YQ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P307, DOI 10.1016/0167-4781(92)90029-Y; Lodge AP, 2000, MOL BRAIN RES, V82, P84, DOI 10.1016/S0169-328X(00)00184-4; Mamluk R, 2002, J BIOL CHEM, V277, P24818, DOI 10.1074/jbc.M200730200; Mangasarian K, 1997, J CELL PHYSIOL, V172, P117, DOI 10.1002/(SICI)1097-4652(199707)172:1<117::AID-JCP13>3.3.CO;2-S; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; NEUFELD G, 1985, J BIOL CHEM, V260, P3860; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Ornitz DM, 2005, CYTOKINE GROWTH F R, V16, P205, DOI 10.1016/j.cytogfr.2005.02.003; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Powell AK, 2002, J BIOL CHEM, V277, P28554, DOI 10.1074/jbc.M111754200; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; Robinson S, 2005, RAPID COMMUN MASS SP, V19, P3681, DOI 10.1002/rcm.2246; Rodahl M, 1997, FARADAY DISCUSS, V107, P229, DOI 10.1039/a703137h; SAUERBREY G, 1959, Z PHYS, V155, P206, DOI 10.1007/BF01337937; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Schmidt TGM, 1996, J MOL BIOL, V255, P753, DOI 10.1006/jmbi.1996.0061; SCHWEIGERER L, 1987, P NATL ACAD SCI USA, V84, P842, DOI 10.1073/pnas.84.3.842; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; Steinberger D, 1996, HUM MUTAT, V8, P386, DOI 10.1002/(SICI)1098-1004(1996)8:4<386::AID-HUMU18>3.3.CO;2-A; Sutton-Smith M, 2005, CELL BIOL LAB HDB; Tuominen H, 2001, PROTEIN EXPRES PURIF, V21, P275, DOI 10.1006/prep.2000.1375; van Rhijn BWG, 2001, CANCER RES, V61, P1265; West DC, 2005, J BIOL CHEM, V280, P13457, DOI 10.1074/jbc.M410924200; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; Williams EJ, 2001, J BIOL CHEM, V276, P43879, DOI 10.1074/jbc.M105876200; Winterpacht A, 2000, PHYSIOL GENOMICS, V2, P9, DOI 10.1152/physiolgenomics.2000.2.1.9; YAN GC, 1992, BIOCHEM BIOPH RES CO, V183, P423, DOI 10.1016/0006-291X(92)90498-A	56	85	88	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27178	27189		10.1074/jbc.M601248200	http://dx.doi.org/10.1074/jbc.M601248200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16829530	hybrid			2022-12-25	WOS:000240397700045
J	Vaidehi, N; Schlyer, S; Trabanino, RJ; Floriano, WB; Abrol, R; Sharma, S; Kochanny, M; Koovakat, S; Dunning, L; Liang, M; Fox, JM; de Mendonca, FL; Pease, JE; Goddard, WA; Horuk, R				Vaidehi, Nagarajan; Schlyer, Sabine; Trabanino, Rene J.; Floriano, Wely B.; Abrol, Ravinder; Sharma, Shantanu; Kochanny, Monica; Koovakat, Sunil; Dunning, Laura; Liang, Meina; Fox, James M.; Lopes de Mendonca, Filipa; Pease, James E.; Goddard, William A., III; Horuk, Richard			Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; FUNCTIONAL EXPRESSION; 3D STRUCTURE; IDENTIFICATION; SITE; MIP-1-ALPHA; MUTAGENESIS; RHODOPSIN; DATABASES; AGONISTS	A major challenge in the application of structure-based drug design methods to proteins belonging to the superfamily of G protein-coupled receptors (GPCRs) is the paucity of structural information (1). The 19 chemokine receptors, belonging to the Class A family of GPCRs, are important drug targets not only for autoimmune diseases like multiple sclerosis but also for the blockade of human immunodeficiency virus type 1 entry (2). Using the MembStruk computational method (3), we predicted the three-dimensional structure of the human CCR1 receptor. In addition, we predicted the binding site of the small molecule CCR1 antagonist BX 471, which is currently in Phase II clinical trials (4). Based on the predicted antagonist binding site we designed 17 point mutants of CCR1 to validate the predictions. Subsequent competitive ligand binding and chemotaxis experiments with these mutants gave an excellent correlation to these predictions. In particular, we find that Tyr-113 and Tyr-114 on transmembrane domain 3 and Ile-259 on transmembrane 6 contribute significantly to the binding of BX 471. Finally, we used the predicted and validated structure of CCR1 in a virtual screening validation of the Maybridge data base, seeded with selective CCR1 antagonists. The screen identified 63% of CCR1 antagonists in the top 5% of the hits. Our results indicate that rational drug design for GPCR targets is a feasible approach.	Berlex Biosci, Dept Immunol, Richmond, CA 94806 USA; Berlex Biosci, Dept Chem, Richmond, CA 94806 USA; Berlex Biosci, Dept Drug Metab & Pharmacol, Richmond, CA 94806 USA; CALTECH, Mat & Proc Simulat Ctr, Pasadena, CA 91125 USA; Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, London SW7 2AZ, England	California Institute of Technology; Imperial College London	Horuk, R (corresponding author), Berlex Biosci, Dept Immunol, 2600 Hilltop Dr, Richmond, CA 94806 USA.	Horuk@pacbell.net	Floriano, Wely/GOK-1319-2022; Pease, James/X-4521-2018; Abrol, Ravinder/B-4980-2010; Abrol, Ravinder/R-3458-2019	Floriano, Wely/0000-0001-8913-0458; Pease, James/0000-0003-3749-0341; Abrol, Ravinder/0000-0001-7333-6793; Fox, James/0000-0002-2473-7029				Auger GA, 2002, EUR J IMMUNOL, V32, P1052, DOI 10.1002/1521-4141(200204)32:4<1052::AID-IMMU1052>3.0.CO;2-L; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Bissantz C, 2004, J CHEM INF COMP SCI, V44, P1162, DOI 10.1021/ci034181a; Bissantz C, 2003, PROTEINS, V50, P5, DOI 10.1002/prot.10237; de Mendonca FL, 2005, J BIOL CHEM, V280, P4808, DOI 10.1074/jbc.M412267200; Dragic T, 2000, P NATL ACAD SCI USA, V97, P5639, DOI 10.1073/pnas.090576697; Evers A, 2005, J MED CHEM, V48, P1088, DOI 10.1021/jm0491804; Floriano WB, 2004, J MED CHEM, V47, P56, DOI 10.1021/jm030271v; Freddolino PL, 2004, P NATL ACAD SCI USA, V101, P2736, DOI 10.1073/pnas.0308751101; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; Hesselgesser J, 1998, J BIOL CHEM, V273, P15687, DOI 10.1074/jbc.273.25.15687; Horuk R, 2001, CYTOKINE GROWTH F R, V12, P313, DOI 10.1016/S1359-6101(01)00014-4; Kalani MYS, 2004, P NATL ACAD SCI USA, V101, P3815, DOI 10.1073/pnas.0400100101; Liang M, 2000, J BIOL CHEM, V275, P19000, DOI 10.1074/jbc.M001222200; Martinelli R, 2001, J BIOL CHEM, V276, P42957, DOI 10.1074/jbc.M103933200; Mirzadegan T, 2000, J BIOL CHEM, V275, P25562, DOI 10.1074/jbc.M000692200; Moro S, 2005, TRENDS PHARMACOL SCI, V26, P44, DOI 10.1016/j.tips.2004.11.006; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NOLLERT P, 2004, DRUG DISCOV TODAY-TA, V4, P2; Onuffer J, 2003, J IMMUNOL, V170, P1910, DOI 10.4049/jimmunol.170.4.1910; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pease JE, 2005, EXPERT OPIN INV DRUG, V14, P785, DOI 10.1517/13543784.14.7.785; Pease JE, 1998, J BIOL CHEM, V273, P19972, DOI 10.1074/jbc.273.32.19972; Ribeiro S, 2005, PHARMACOL THERAPEUT, V107, P44, DOI 10.1016/j.pharmthera.2005.01.004; Shacham S, 2004, PROTEINS, V57, P51, DOI 10.1002/prot.20195; STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038; Trabanino RJ, 2004, BIOPHYS J, V86, P1904, DOI 10.1016/S0006-3495(04)74256-3; TRABANINO RJ, 2004, THESIS CALTECH; Vaidehi N, 2002, P NATL ACAD SCI USA, V99, P12622, DOI 10.1073/pnas.122357199; Zoffmann S, 2002, MOL PHARMACOL, V62, P729, DOI 10.1124/mol.62.3.729	30	85	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27613	27620		10.1074/jbc.M601389200	http://dx.doi.org/10.1074/jbc.M601389200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16837468	Green Accepted, hybrid, Green Submitted			2022-12-25	WOS:000240397700086
J	Warren, CM; Kani, K; Landgraf, R				Warren, Carmen M.; Kani, Kian; Landgraf, Ralf			The N-terminal domains of neuregulin 1 confer signal attenuation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; EGF-LIKE DOMAIN; FACTOR RECEPTOR; ERBB RECEPTORS; CRYSTAL-STRUCTURE; EXTRACELLULAR DOMAIN; HEREGULIN BETA-1; OVARIAN-CANCER; CELL-SURFACE	Degradation of activated ERBB receptors is an important mechanism for signal attenuation. However, compared with epidermal growth factor (EGF) receptor, the ERBB2/ERBB3 signaling pair is considered to be attenuation-deficient. The ERBB2/ERBB3 ligands of the neuregulin family rely on an EGF-like domain for signaling and are generated from larger membrane-bound precursors. In contrast to EGF, which is processed to yield a 6-kDa peptide ligand, mature neuregulins retain a variety of segments N-terminal to the EGF-like domain. Here we evaluate the role of the N-terminal domain of neuregulin 1 in signaling and turnover of ERBB2/ERBB3. Our data suggest that whereas the EGF-like domain of neuregulin 1 is required and sufficient for the formation of active receptor heterodimers, the presence of the N-terminal Ig-like domain is required for efficient signal attenuation. This manifests itself for both ERBB2 and ERBB3 but is more pronounced and coupled directly to degradation for ERBB3. When stimulated with only the EGF-like domain, ERBB3 shows degradation rates comparable with constitutive turnover, but stimulation with full-length neuregulin 1 resulted in receptor degradation at rates that are comparable with activated EGF receptor. Most of the enhancement in down-regulation was maintained after replacing the Ig-like domain with a thioredoxin protein of comparable size but different amino acid composition, suggesting that the physical presence but not specific properties of the Ig-like domain are needed. This sequence-independent effect of the N-terminal domain correlates with an enhanced ability of full-size neuregulin 1 to disrupt higher order oligomers of the ERBB3 extracellular domains in vitro.	Univ Calif Los Angeles, Dept Med Hematol Oncol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Landgraf, R (corresponding author), Univ Calif Los Angeles, Dept Med Hematol Oncol, Box 951678, Los Angeles, CA 90095 USA.	rlandgraf@mednet.ucla.edu		Kani, Kian/0000-0001-7774-265X	NATIONAL CANCER INSTITUTE [R01CA098881] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA098881] Funding Source: Medline; NIGMS NIH HHS [GM07185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Aguilar Z, 2001, J BIOL CHEM, V276, P44099, DOI 10.1074/jbc.M103442200; Baulida J, 1997, EXP CELL RES, V232, P167, DOI 10.1006/excr.1997.3515; Baulida J, 1996, J BIOL CHEM, V271, P5251; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BERCHUCK A, 1990, CANCER RES, V50, P4087; Berger MB, 2004, FEBS LETT, V569, P332, DOI 10.1016/j.febslet.2004.06.014; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Clayton AHA, 2005, J BIOL CHEM, V280, P30392, DOI 10.1074/jbc.M504770200; DOUGALL WC, 1994, ONCOGENE, V9, P2109; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Fischer D, 1997, P NATL ACAD SCI USA, V94, P11929, DOI 10.1073/pnas.94.22.11929; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HO WH, 1995, J BIOL CHEM, V270, P26722; Hobbs SS, 2002, ONCOGENE, V21, P8442, DOI 10.1038/sj.onc.1205960; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HORAN T, 1995, J BIOL CHEM, V270, P24604, DOI 10.1074/jbc.270.41.24604; Jacobsen NE, 1996, BIOCHEMISTRY-US, V35, P3402, DOI 10.1021/bi952626l; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kani K, 2005, J BIOL CHEM, V280, P8238, DOI 10.1074/jbc.M410944200; Landgraf R, 1998, BIOCHEMISTRY-US, V37, P3220, DOI 10.1021/bi972326z; Landgraf R, 2000, BIOCHEMISTRY-US, V39, P8503, DOI 10.1021/bi000953+; Le Gall SM, 2004, REGUL PEPTIDES, V122, P119, DOI 10.1016/j.regpep.2004.06.008; Li QF, 2001, J BIOL CHEM, V276, P38068; LU HS, 1995, J BIOL CHEM, V270, P4784, DOI 10.1074/jbc.270.9.4784; LU HS, 1995, J BIOL CHEM, V270, P4775, DOI 10.1074/jbc.270.9.4775; Magnifico A, 1998, FEBS LETT, V422, P129, DOI 10.1016/S0014-5793(97)01612-8; Mallick P, 2002, P NATL ACAD SCI USA, V99, P16041, DOI 10.1073/pnas.252626399; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Stove C, 2004, CLIN EXP METASTAS, V21, P665, DOI 10.1007/s10585-004-6917-6; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Whitson KB, 2004, ANAL BIOCHEM, V324, P227, DOI 10.1016/j.ab.2003.09.023; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; YOKOTA J, 1988, ONCOGENE, V2, P283	52	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27306	27316		10.1074/jbc.M512887200	http://dx.doi.org/10.1074/jbc.M512887200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16825199	hybrid			2022-12-25	WOS:000240397700057
J	Fahling, M; Mrowka, R; Steege, A; Nebrich, G; Perlewitz, A; Persson, PB; Thiele, BJ				Faehling, Michael; Mrowka, Ralf; Steege, Andreas; Nebrich, Grit; Perlewitz, Andrea; Persson, Pontus B.; Thiele, Bernd J.			Translational control of collagen prolyl 4-hydroxylase-alpha(I) gene expression under hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; PROTEIN DISULFIDE-ISOMERASE; BINDING-PROTEIN; POSTTRANSCRIPTIONAL CONTROL; ENDOTHELIAL-CELLS; ALPHA-SUBUNIT; 3'-UNTRANSLATED REGION; GROWTH-FACTOR; K+ CHANNELS; NUCLEOLIN	Hypoxia is a pro-fibrotic stimulus, which is associated with enhanced collagen synthesis, as well as with augmented collagen prolyl 4-hydroxylase (C-P4H) activity. C-P4H activity is controlled mainly by regulated expression of the alpha C-P4H subunit. In this study we demonstrate that the increased synthesis of C-P4H-alpha(I) protein in human HT1080 fibroblasts under long term hypoxia (36 h, 1% oxygen) is controlled at the translational level. This is mediated by an interaction of RNA-binding protein nucleolin (similar to 64 kDa form) at the 5'-and 3'-untranslated regions (UTR) of themRNA. The 5'/3'-UTR-dependent mechanism elevates the C-P4H-alpha(I) expression rate 2.3-fold, and participates in a 5.3-fold increased protein level under long term hypoxia. The interaction of nucleolin at the 5'-UTR occurs directly and depends on the existence of an AU-rich element. Statistical evaluation of the similar to 64-kDa nucleolin/ RNA interaction studies revealed a core binding sequence, corresponding to UAAAUC or AAAUCU. At the 3'-UTR, nucleolin assembles indirectly via protein/ protein interaction, with the help of another 3'-UTR-binding protein, presumably annexin A2. The increased protein level of the similar to 64-kDa nucleolin under hypoxia can be attributed to an autocatalytic cleavage of a high molecular weight nucleolin form, without alterations in nucleolin mRNA concentration. Thus, the alteration of translational efficiency by nucleolin, which occurs through a hypoxia inducible factor independent pathway, is an important step in C-P4H-alpha(I) regulation under hypoxia.	Univ Med Berlin, Charite, Inst Vegetat Physiol, D-10117 Berlin, Germany; Free Univ Berlin, Inst Biol, D-14195 Berlin, Germany; Univ Med Berlin, Charite, Inst Humangenet, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Fahling, M (corresponding author), Tucholskystr 2, D-10117 Berlin, Germany.	michael.faehling@charite.de	Mrowka, Ralf/AAW-1480-2021; Fähling, Michael/E-5018-2011; Steege, Andreas/F-3885-2010	Mrowka, Ralf/0000-0002-0991-3418; Persson, Pontus/0000-0003-0926-2878; Fahling, Michael/0000-0003-1079-5049				Aley PK, 2005, J BIOL CHEM, V280, P13349, DOI 10.1074/jbc.M413674200; Anderson P, 2006, J CELL BIOL, V172, P803, DOI 10.1083/jcb.200512082; Annunen P, 1997, J BIOL CHEM, V272, P17342, DOI 10.1074/jbc.272.28.17342; Annunen P, 1998, J BIOL CHEM, V273, P5989, DOI 10.1074/jbc.273.11.5989; Berra E, 2006, EMBO REP, V7, P41, DOI 10.1038/sj.embor.7400598; Borggrefe T, 1998, J BIOL CHEM, V273, P17025, DOI 10.1074/jbc.273.27.17025; Bouvet P, 1998, J BIOL CHEM, V273, P19025, DOI 10.1074/jbc.273.30.19025; Bouvet P, 2001, J MOL BIOL, V309, P763, DOI 10.1006/jmbi.2001.4691; Chen CY, 2000, GENE DEV, V14, P1236; Christian S, 2003, J CELL BIOL, V163, P871, DOI 10.1083/jcb.200304132; Conforti L, 2000, J PHYSIOL-LONDON, V524, P783, DOI 10.1111/j.1469-7793.2000.00783.x; D'Angelo G, 2003, J BIOL CHEM, V278, P38183, DOI 10.1074/jbc.M302244200; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Fahling M, 2006, J BIOL CHEM, V281, P9279, DOI 10.1074/jbc.M510925200; Fahling M, 2005, BBA-GENE STRUCT EXPR, V1731, P32, DOI 10.1016/j.bbaexp.2005.08.005; Fahling M, 2004, COMP BIOCHEM PHYS C, V139, P119, DOI 10.1016/j.cca.2004.09.013; Falanga V, 2002, J CELL PHYSIOL, V191, P42, DOI 10.1002/jcp.10065; FALANGA V, 1993, J CELL PHYSIOL, V157, P408, DOI 10.1002/jcp.1041570225; FANG SH, 1993, EXP CELL RES, V208, P48, DOI 10.1006/excr.1993.1221; Filipenko NR, 2004, J BIOL CHEM, V279, P8723, DOI 10.1074/jbc.M311951200; Flanders KC, 2004, INT J EXP PATHOL, V85, P47, DOI 10.1111/j.0959-9673.2004.00377.x; Fouraux MA, 2002, J MOL BIOL, V320, P475, DOI 10.1016/S0022-2836(02)00518-1; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Gilchrist JSC, 2002, J CELL BIOCHEM, V85, P268, DOI 10.1002/jcb.10121; Ginisty H, 1999, J CELL SCI, V112, P761; Hand SC, 1998, J EXP BIOL, V201, P1233; Hartley R, 2002, BMC MOL BIOL, V3, DOI 10.1186/1471-2199-3-8; HELAAKOSKI T, 1994, J BIOL CHEM, V269, P27847; Izumi RE, 2001, VIRUS RES, V76, P17, DOI 10.1016/S0168-1702(01)00240-4; Jiang Y, 2006, MOL CELL BIOL, V26, P2419, DOI 10.1128/MCB.26.6.2419-2429.2006; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; KIVIRIKKO KI, 1990, ANN NY ACAD SCI, V580, P132, DOI 10.1111/j.1749-6632.1990.tb17925.x; Koritzinsky M, 2005, RADIOTHER ONCOL, V76, P177, DOI 10.1016/j.radonc.2005.06.036; Kuersten S, 2003, NAT REV GENET, V4, P626, DOI 10.1038/nrg1125; Kukkola L, 2003, J BIOL CHEM, V278, P47685, DOI 10.1074/jbc.M306806200; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Lo SJ, 2006, CELL RES, V16, P530, DOI 10.1038/sj.cr.7310070; Lumb RA, 2002, EMBO J, V21, P6763, DOI 10.1093/emboj/cdf685; McGary EC, 1997, J BIOL CHEM, V272, P8628, DOI 10.1074/jbc.272.13.8628; MIRANDA GA, 1995, EXP CELL RES, V217, P294, DOI 10.1006/excr.1995.1090; MochizukiOda N, 1997, J NEUROCHEM, V69, P377; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Papakonstantinou E, 2003, CYTOKINE, V24, P25, DOI 10.1016/S1043-4666(03)00253-9; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; Paulding WR, 1999, J BIOL CHEM, V274, P2532, DOI 10.1074/jbc.274.4.2532; Preiss T, 1999, CURR OPIN GENET DEV, V9, P515, DOI 10.1016/S0959-437X(99)00005-2; Sakaguchi M, 2003, J CELL BIOL, V163, P825, DOI 10.1083/jcb.200304017; Sengupta TK, 2004, J BIOL CHEM, V279, P10855, DOI 10.1074/jbc.M309111200; Seta KA, 2004, CELL CALCIUM, V36, P331, DOI 10.1016/j.ceca.2004.02.006; Singh K, 2004, J IMMUNOL, V173, P976, DOI 10.4049/jimmunol.173.2.976; Skalweit A, 2003, CIRC RES, V92, P419, DOI 10.1161/01.RES.0000059300.67152.4E; Spicher A, 1998, MOL CELL BIOL, V18, P7371, DOI 10.1128/MCB.18.12.7371; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Storey KB, 2004, BIOL REV, V79, P207, DOI 10.1017/S1464793103006195; Tajima R, 2001, BBA-MOL CELL RES, V1540, P179, DOI 10.1016/S0167-4889(01)00114-8; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Takahashi Y, 2000, J BIOL CHEM, V275, P14139, DOI 10.1074/jbc.275.19.14139; Thiele BJ, 2004, CIRC RES, V95, P1058, DOI 10.1161/01.RES.0000149166.33833.08; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; Williams SEJ, 2004, SCIENCE, V306, P2093, DOI 10.1126/science.1105010; Wouters BG, 2005, SEMIN CELL DEV BIOL, V16, P487, DOI 10.1016/j.semcdb.2005.03.009	62	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26089	26101		10.1074/jbc.M604939200	http://dx.doi.org/10.1074/jbc.M604939200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16837461	hybrid			2022-12-25	WOS:000240249500024
J	Martins, SM; Frosoni, DJ; Martinez, AMB; De Felice, FG; Ferreira, ST				Martins, Samantha M.; Frosoni, Doris J.; Martinez, Ana M. Blanco; De Felice, Fernanda G.; Ferreira, Sergio T.			Formation of soluble oligomers and amyloid fibrils with physical properties of the scrapie isoform of the prion protein from the C-terminal domain of recombinant murine prion protein mPrP-(121-231)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; MOLECULAR-BASIS; CONVERSION; PRPSC; PH; CONFORMATION; DISEASES; AGGREGATION; MODULATION; TRANSITION	Prion diseases are fatal neurodegenerative disorders associated with conformational conversion of the cellular prion protein, PrPC, into a misfolded, protease-resistant form, PrPSc. Here we show, for the first time, the oligomerization and fibrillization of the C-terminal domain of murine PrP, mPrP-(121-231), which lacks the entire unstructured N-terminal domain of the protein. In particular, the construct we used lacks amino acid residues 106-120 from the so-called amyloidogenic core of PrP (residues 106-126). Amyloid formation was accompanied by acquisition of resistance to proteinase K digestion. Aggregation of mPrP-(121-231) was investigated using a combination of biophysical and biochemical techniques at pH 4.0, 5.5, and 7.0 and at 37 and 65 degrees C. Under partially denaturing conditions (65 degrees C), aggregates of different morphologies ranging from soluble oligomers to mature amyloid fibrils of mPrP-(121-231) were formed. Transmission electron microscopy analysis showed that roughly spherical aggregates were readily formed when the protein was incubated at pH 5.5 and 65 degrees C for 1 h, whereas prolonged incubation led to the formation of mature amyloid fibrils. Samples incubated at 65 degrees C at pH 4.0 or 7.0 presented an initial mixture of oligomers and protofibrils or fibrils. Electrophoretic analysis of samples incubated at 65 degrees C revealed formation of sodium dodecyl sulfate-resistant oligomers (dimers, trimers, and tetramers) and higher molecular weight aggregates of mPrP-(121-231). These results demonstrate that formation of an amyloid form with physical properties of PrPSc can be achieved in the absence of the flexible N-terminal domain and, in particular, of residues 106-120 of PrP and does not require other cellular factors or a PrPSc template.	Univ Fed Rio de Janeiro, Programa Bioquim & Biofis Celular, Inst Bioquim Med, BR-21944590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Dept Histol & Embryol, Inst Ciencias Biomed, BR-21944590 Rio De Janeiro, Brazil; Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Northwestern University	Martins, SM (corresponding author), Univ Fed Rio de Janeiro, Programa Bioquim & Biofis Celular, Inst Bioquim Med, BR-21944590 Rio De Janeiro, Brazil.	ferreira@bioqmed.ufrj.br	Ferreira, Sergio/AAZ-1576-2020; Martinez, Ana/C-6318-2014; De Felice, Fernanda G/M-1074-2017	Ferreira, Sergio/0000-0001-7160-9866; 				Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Alvarez-Martinez MT, 2003, BBA-PROTEINS PROTEOM, V1645, P228, DOI 10.1016/S1570-9639(02)00536-8; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Baskakov IV, 2004, J BIOL CHEM, V279, P7671, DOI 10.1074/jbc.M310594200; Baskakov IV, 2000, BIOCHEMISTRY-US, V39, P2792, DOI 10.1021/bi9923353; Baskakov IV, 2001, J BIOL CHEM, V276, P19687, DOI 10.1074/jbc.C100180200; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; Bocharova OV, 2005, PROTEIN SCI, V14, P1222, DOI 10.1110/ps.041186605; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Calzolai L, 2000, P NATL ACAD SCI USA, V97, P8340, DOI 10.1073/pnas.97.15.8340; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; Chiesa R, 2001, NEUROBIOL DIS, V8, P743, DOI 10.1006/nbdi.2001.0433; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; Dobson CM, 2006, PROTEIN PEPTIDE LETT, V13, P219, DOI 10.2174/092986606775338362; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Ferreira ST, 2001, FEBS LETT, V498, P129, DOI 10.1016/S0014-5793(01)02491-7; Hornemann S, 1996, J MOL BIOL, V261, P614, DOI 10.1006/jmbi.1996.0487; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; Jobling MF, 1999, J NEUROCHEM, V73, P1557, DOI 10.1046/j.1471-4159.1999.0731557.x; Klein WL, 2004, NEUROBIOL AGING, V25, P569, DOI 10.1016/j.neurobiolaging.2004.02.010; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Lawson VA, 2004, J BIOL CHEM, V279, P13689, DOI 10.1074/jbc.M303697200; Lee RJ, 1996, BBA-MOL CELL RES, V1312, P237, DOI 10.1016/0167-4889(96)00041-9; Lee S, 2003, NAT STRUCT BIOL, V10, P725, DOI 10.1038/nsb961; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Lu BY, 2002, BIOCHEM J, V364, P81, DOI 10.1042/bj3640081; Martins SM, 2003, J BIOL CHEM, V278, P50449, DOI 10.1074/jbc.M307354200; Morillas M, 2001, BIOCHEMISTRY-US, V40, P6982, DOI 10.1021/bi010232q; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Nandi PK, 2002, J MOL BIOL, V322, P153, DOI 10.1016/S0022-2836(02)00750-7; Norstrom EM, 2005, J BIOL CHEM, V280, P27236, DOI 10.1074/jbc.M413441200; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Quist A, 2005, P NATL ACAD SCI USA, V102, P10427, DOI 10.1073/pnas.0502066102; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Sokolowski F, 2003, J BIOL CHEM, V278, P40481, DOI 10.1074/jbc.M304391200; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; Swietnicki W, 2000, BIOCHEMISTRY-US, V39, P424, DOI 10.1021/bi991967m; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010; Walsh DM, 2002, BIOCHEM SOC T, V30, P552, DOI 10.1042/BST0300552; Walsh DM, 2004, PROTEIN PEPTIDE LETT, V11, P213, DOI 10.2174/0929866043407174; Weissmann C, 2005, CELL, V122, P165, DOI 10.1016/j.cell.2005.07.001; Wildegger G, 1999, NAT STRUCT BIOL, V6, P550, DOI 10.1038/9323; Zou WQ, 2002, J BIOL CHEM, V277, P43942, DOI 10.1074/jbc.M203611200	54	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26121	26128		10.1074/jbc.M605367200	http://dx.doi.org/10.1074/jbc.M605367200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16844683	hybrid			2022-12-25	WOS:000240249500027
J	Schay, G; Smeller, L; Tsuneshige, A; Yonetani, T; Fidy, J				Schay, Gusztav; Smeller, Laszlo; Tsuneshige, Antonio; Yonetani, Takashi; Fidy, Judit			Allosteric effectors influence the tetramer stability of both R- and T-states of hemoglobin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; HETEROTROPIC EFFECTORS; SUBUNIT INTERACTIONS; STRUCTURAL-CHANGES; HYBRID HEMOGLOBIN; CRYSTAL-STRUCTURE; ELECTRIC-FIELDS; PRESSURE FIELDS; BINDING; FLUORESCENCE	The contribution of heterotropic effectors to hemoglobin allostery is still not completely understood. With the recently proposed global allostery model, this question acquires crucial significance, because it relates tertiary conformational changes to effector binding in both the R- and T-states. In this context, an important question is how far the induced conformational changes propagate from the binding site(s) of the allosteric effectors. We present a study in which we monitored the interdimeric interface when the effectors such as Cl-, 2,3-diphosphoglycerate, inositol hexaphosphate, and bezafibrate were bound. We studied oxy-Hb and a hybrid form (alpha FeO2)(2)-(beta Zn)(2) as the T-state analogue by monitoring heme absorption and Trp intrinsic fluorescence under hydrostatic pressure. We observed a pressure-dependent change in the intrinsic fluorescence, which we attribute to a pressure-induced tetramer to dimer transition with characteristic pressures in the 70 -200-megapascal range. The transition is sensitive to the binding of allosteric effectors. We fitted the data with a simple model for the tetramer-dimer transition and determined the dissociation constants at atmospheric pressure. In the R-state, we observed a stabilizing effect by the allosteric effectors, although in the T-analogue a stronger destabilizing effect was seen. The order of efficiency was the same in both states, but with the opposite trend as inositol hexaphosphate > 2,3-diphosphoglycerate > Cl-. We detected intrinsic fluorescence from bound bezafibrate that introduced uncertainty in the comparison with other effectors. The results support the global allostery model by showing that conformational changes propagate from the effector binding site to the interdimeric interfaces in both quaternary states.	Semmelweis Univ, Dept Biophys & Radiat Biol, H-1444 Budapest, Hungary; Semmelweis Univ, Biophys Res Grp, Hungarian Acad Sci, Fac Med, H-1444 Budapest, Hungary; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Johnson Res Fdn, Philadelphia, PA 19104 USA	Semmelweis University; Hungarian Academy of Sciences; Semmelweis University; University of Pennsylvania	Fidy, J (corresponding author), Semmelweis Univ, Dept Biophys & Radiat Biol, POB 263, H-1444 Budapest, Hungary.	judit@puskin.sote.hu	Smeller, László/G-6205-2011	Smeller, László/0000-0002-3643-3268	FOGARTY INTERNATIONAL CENTER [R03TW005924] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL014508, R01HL014508] Funding Source: NIH RePORTER; FIC NIH HHS [TW005924] Funding Source: Medline; NHLBI NIH HHS [HL14508] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERS GK, 1976, BIOCHEM BIOPH RES CO, V69, P135, DOI 10.1016/S0006-291X(76)80283-5; ADLEN RG, 1989, J BIOL CHEM, V264, P1933; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P110; ARNONE A, 1972, NATURE, V237, P146, DOI 10.1038/237146a0; ATHA DH, 1976, J BIOL CHEM, V251, P5537; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; Balny C, 2002, BBA-PROTEIN STRUCT M, V1595, P3, DOI 10.1016/S0167-4838(01)00331-4; BERJIS M, 1991, ANAL BIOCHEM, V196, P223, DOI 10.1016/0003-2697(91)90457-5; BERMAN M, 1971, ARCH BIOCHEM BIOPHYS, V145, P236; BRITTAIN T, 1994, BIOCHEM J, V300, P553, DOI 10.1042/bj3000553; CHU AH, 1981, J BIOL CHEM, V256, P1199; Coletta M, 1999, BIOPHYS J, V76, P1532, DOI 10.1016/S0006-3495(99)77312-1; DRABKIN DL, 1946, J BIOL CHEM, V164, P703; Fidy J, 1998, BBA-PROTEIN STRUCT M, V1386, P289, DOI 10.1016/S0167-4838(98)00099-5; GOODFORD PJ, 1980, BRIT J PHARMACOL, V68, P741, DOI 10.1111/j.1476-5381.1980.tb10867.x; GRAY RD, 1971, J BIOL CHEM, V249, P4770; GRYCZYNSKI Z, 1992, BIOPHYS J, V63, P648, DOI 10.1016/S0006-3495(92)81657-0; Gryczynski Z, 1997, BIOPHYS CHEM, V64, P81, DOI 10.1016/S0301-4622(96)02224-7; HAIRE RN, 1977, P NATL ACAD SCI USA, V74, P4135, DOI 10.1073/pnas.74.10.4135; Hamdane D, 2005, J BIOL CHEM, V280, P36809, DOI 10.1074/jbc.M506253200; Heremans K, 1998, BBA-PROTEIN STRUCT M, V1386, P353, DOI 10.1016/S0167-4838(98)00102-2; HERSKOVITS TT, 1976, BIOCHEMISTRY-US, V15, P5715, DOI 10.1021/bi00671a006; HIRSCH RE, 1981, J BIOL CHEM, V256, P1080; HIRSCH RE, 1994, BBA-PROTEIN STRUCT M, V1205, P248, DOI 10.1016/0167-4838(94)90240-2; HIRSCH RE, 1980, BIOCHEM BIOPH RES CO, V93, P432, DOI 10.1016/0006-291X(80)91096-7; Huang YW, 1996, BIOPHYS J, V71, P2094, DOI 10.1016/S0006-3495(96)79408-0; IMAI K, 1982, ALLOSTERIC EFFECTS H, P106; JUNG C, 1995, EUR J BIOCHEM, V233, P600, DOI 10.1111/j.1432-1033.1995.600_2.x; KAUPPINEN JK, 1981, APPL SPECTROSC, V35, P271, DOI 10.1366/0003702814732634; Kohler M, 1998, BBA-PROTEIN STRUCT M, V1386, P255, DOI 10.1016/S0167-4838(98)00098-3; Kovesi I, 2006, BBA-PROTEINS PROTEOM, V1764, P516, DOI 10.1016/j.bbapap.2005.12.002; Laberge M, 2005, FEBS LETT, V579, P627, DOI 10.1016/j.febslet.2004.12.033; LAIRD BB, 1989, J CHEM PHYS, V90, P3274, DOI 10.1063/1.455881; LALEZARI I, 1990, BIOCHEMISTRY-US, V29, P1515, DOI 10.1021/bi00458a024; MCLEAN JG, 1975, RES VET SCI, V19, P259, DOI 10.1016/S0034-5288(18)33499-4; Meersman F, 2005, HELV CHIM ACTA, V88, P546, DOI 10.1002/hlca.200590037; Miyazaki G, 1999, J MOL BIOL, V292, P1121, DOI 10.1006/jmbi.1999.3124; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; OGUNMOLA GB, 1977, P NATL ACAD SCI USA, V74, P1, DOI 10.1073/pnas.74.1.1; Park SY, 1996, J MOL BIOL, V255, P726, DOI 10.1006/jmbi.1996.0059; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; Perutz MF, 1998, ANNU REV BIOPH BIOM, V27, P1, DOI 10.1146/annurev.biophys.27.1.1; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; PERUTZ MF, 1964, NATURE, V203, P687, DOI 10.1038/203687a0; PIN S, 1990, BIOCHEMISTRY-US, V29, P9194, DOI 10.1021/bi00491a013; POYART C, 1994, METHOD ENZYMOL, V232, P496; Reshetnyak Ya. K., 1997, Biophysics, V42, P267; Ruan KC, 2000, BIOCHEM BIOPH RES CO, V269, P681, DOI 10.1006/bbrc.2000.2345; Samuni U, 2006, BIOCHEMISTRY-US, V45, P2820, DOI 10.1021/bi050010i; Samuni U, 2004, BIOCHEMISTRY-US, V43, P13674, DOI 10.1021/bi048531d; Samuni U, 2003, BIOCHEMISTRY-US, V42, P8272, DOI 10.1021/bi020648j; Seixas FAV, 1999, ACTA CRYSTALLOGR D, V55, P1914, DOI 10.1107/S0907444999009750; SHIBAYAMA N, 1986, J MOL BIOL, V192, P331, DOI 10.1016/0022-2836(86)90368-2; Shibayama N, 2002, J BIOL CHEM, V277, P38791, DOI 10.1074/jbc.M205461200; SILVA JL, 1993, ANNU REV PHYS CHEM, V44, P89, DOI 10.1146/annurev.pc.44.100193.000513; Silva JL, 2001, TRENDS BIOCHEM SCI, V26, P612, DOI 10.1016/S0968-0004(01)01949-1; SMELLER L, 1995, APPL SPECTROSC, V49, P1538, DOI 10.1366/0003702953965533; Smeller L, 2002, BBA-PROTEIN STRUCT M, V1595, P11, DOI 10.1016/S0167-4838(01)00332-6; SMELLER L, 1996, HIGH PRESSURE SCI TE, P863; STEFANO B, 2000, PROTEIN SCI, V9, P683; SZABO A, 1972, J MOL BIOL, V72, P163, DOI 10.1016/0022-2836(72)90077-0; Tanaka N, 2000, BIOCHEMISTRY-US, V39, P12063, DOI 10.1021/bi001009g; Tsuneshige A, 2002, BIOPHYS CHEM, V98, P49, DOI 10.1016/S0301-4622(02)00084-4; TSUNESHIGE A, 1994, METHOD ENZYMOL, V231, P215; VANBEEK GGM, 1979, EUR J BIOCHEM, V100, P497; Vivian JT, 2001, BIOPHYS J, V80, P2093, DOI 10.1016/S0006-3495(01)76183-8; WHITE SL, 1976, J BIOL CHEM, V251, P4763; WONG PTT, 1989, APPL SPECTROSC, V43, P1279, DOI 10.1366/0003702894203642; Yonetani T, 2002, J BIOL CHEM, V277, P34508, DOI 10.1074/jbc.M203135200; ZOLLFRANK J, 1991, J CHEM PHYS, V94, P8600, DOI 10.1063/1.460042; ZOLLFRANK J, 1991, BIOPHYS J, V59, P305, DOI 10.1016/S0006-3495(91)82224-X	71	23	23	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25972	25983		10.1074/jbc.M604216200	http://dx.doi.org/10.1074/jbc.M604216200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16822864	hybrid			2022-12-25	WOS:000240249500012
J	Xu, Y; Chen, XB				Xu, Yang; Chen, Xinbin			Glyoxalase II, a detoxifying enzyme of glycolysis byproduct methylglyoxal and a target of p63 and p73, is a pro-survival factor of the p53 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; INDUCED APOPTOSIS; OXIDATIVE STRESS; DNA-DAMAGE; CELLS; GENE; EXPRESSION; ACTIVATION; VARIANT; P21	The p53 family proteins are transcription factors and have both common and distinct functions. p53 is a classic tumor suppressor, whereas p63 and p73 have fundamental functions in development. To gain an insight into the functional diversities among the p53 family, target genes specifically regulated by p63 and p73 were examined. Here, we found that the GLX2 gene, which encodes glyoxalase II enzyme, is up-regulated by p63 and p73. Accordingly, a specific responsive element was found in intron 1 of the GLX2 gene, which can be activated and bound by p63 and p73. Wealso found that, upon overexpression, the cytosolic, but not the mitochondrial, GLX2 inhibits the apoptotic response of a cell to methylglyoxal, a by-product of glycolysis. Likewise, we showed that cells deficient in GLX2 are hypersensitive to methylglyoxal-induced apoptosis. Interestingly, a deficiency in GLX2 also enhances the susceptibility of a cell to DNA damage-induced apoptosis in a p53-dependent manner. These observations reveal a novel link between the p53 family and the glyoxalase system. Given that methylglyoxal is frequently generated under both physiological and pathological conditions, we postulate that GLX2 serves as a pro-survival factor of the p53 family and plays a critical role in the normal development and in the pathogenesis of various human diseases, including cancer, diabetes, and neurodegenerative diseases.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), Univ Alabama, Dept Cell Biol, MCLM 660,1530 3rd Ave S, Birmingham, AL 35294 USA.	xchen@uab.edu			NATIONAL CANCER INSTITUTE [R01CA081237, R29CA076069, R01CA076069, R01CA102188] Funding Source: NIH RePORTER; NCI NIH HHS [CA076069, CA102188, CA081237] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amicarelli F, 1998, CHEM-BIOL INTERACT, V114, P177, DOI 10.1016/S0009-2797(98)00048-9; Bito A, 1999, PROTEIN EXPRES PURIF, V17, P456, DOI 10.1006/prep.1999.1151; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen F, 2004, P NATL ACAD SCI USA, V101, P7687, DOI 10.1073/pnas.0402338101; CHEN XB, 1995, CANCER RES, V55, P4257; Cordell PA, 2004, J BIOL CHEM, V279, P28653, DOI 10.1074/jbc.M403470200; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; DEARRIBA SG, 2006, IN PRESS NEUROBIOL A; Dohn Michael, 2003, Methods Mol Biol, V223, P221; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fukunaga M, 2004, BIOCHEM BIOPH RES CO, V320, P689, DOI 10.1016/j.bbrc.2004.06.011; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Godbout JP, 2002, J BIOL CHEM, V277, P2554, DOI 10.1074/jbc.M100385200; Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4; Harms KL, 2005, MOL CELL BIOL, V25, P2014, DOI 10.1128/MCB.25.5.2014-2030.2005; Helton ES, 2006, J BIOL CHEM, V281, P2533, DOI 10.1074/jbc.M507964200; Hovatta I, 2005, NATURE, V438, P662, DOI 10.1038/nature04250; Hsuuw YD, 2005, J CELL PHYSIOL, V205, P379, DOI 10.1002/jcp.20408; Jan CR, 2005, CELL SIGNAL, V17, P847, DOI 10.1016/j.cellsig.2004.11.007; Kalapos MP, 1999, TOXICOL LETT, V110, P145, DOI 10.1016/S0378-4274(99)00160-5; Liu G, 2006, MOL CELL BIOL, V26, P1398, DOI 10.1128/MCB.26.4.1398-1413.2006; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Liu G, 2003, J BIOL CHEM, V278, P17557, DOI 10.1074/jbc.M210696200; Martins AM, 2001, EUR J BIOCHEM, V268, P3930, DOI 10.1046/j.1432-1327.2001.02304.x; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; Mearini E, 2002, EUR J CANCER, V38, P1946, DOI 10.1016/S0959-8049(02)00236-8; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Moll UM, 2004, MOL CANCER RES, V2, P371; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nemet I, 2005, CLIN BIOCHEM, V38, P379, DOI 10.1016/j.clinbiochem.2004.12.008; Nozell S, 2003, ONCOGENE, V22, P4333, DOI 10.1038/sj.onc.1206470; Nozell S, 2002, ONCOGENE, V21, P1285, DOI 10.1038/sj.onc.1205191; Rulli A, 2001, BREAST CANCER RES TR, V66, P67, DOI 10.1023/A:1010632919129; Sakamoto H, 2000, BLOOD, V95, P3214, DOI 10.1182/blood.V95.10.3214; Shinohara M, 1998, J CLIN INVEST, V101, P1142, DOI 10.1172/JCI119885; Thornalley PJ, 2003, BIOCHEM SOC T, V31, P1343; Thornalley PJ, 1996, GEN PHARMACOL-VASC S, V27, P565, DOI 10.1016/0306-3623(95)02054-3; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	44	43	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26702	26713		10.1074/jbc.M604758200	http://dx.doi.org/10.1074/jbc.M604758200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16831876	hybrid			2022-12-25	WOS:000240249500088
J	Nakerakanti, SS; Kapanadze, B; Yamasaki, M; Markiewicz, M; Trojanowska, M				Nakerakanti, Sashidhar S.; Kapanadze, Bagrat; Yamasaki, Masaomi; Markiewicz, Margaret; Trojanowska, Maria			Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA; TRANSCRIPTION FACTOR; DIFFERENTIAL REGULATION; INDUCED EXPRESSION; PROMOTER; FAMILY; BINDING; FIBROBLASTS; ACTIVATION; PROTEINS	CCN2 (connective tissue growth factor), an important regulator of angiogenesis, chondrogenesis, and wound healing, is over-expressed in a majority of fibrotic diseases and in various tumors. This study investigated regulation of CCN2 gene expression by Ets family of transcription factors, focusing on two members, Fli1 and Ets1, with deregulated expression during fibrosis and tumorigenesis. We show that Ets1 and Fli1 have opposite effects on CCN2 gene expression. Ets1 functions as an activator of CCN2 transcription, whereas Fli1 acts as a repressor. A functional Ets binding site was mapped at -114 within the CCN2 promoter. This site not only mediates stimulation by Ets factors, including Ets1, Ets2, and GABP alpha/beta, but is also required for the transforming growth factor ( TGF)-beta response. The contrasting functions of Ets1 and Fli1 in regulation of the CCN2 gene were confirmed by suppressing their endogenous levels using adenoviral vectors expressing specific small interfering RNAs. Additional experiments using chromatin immunoprecipitation assays have revealed that in fibroblasts both Ets1 and Fli1 occupy the CCN2 promoter. TGF-beta stimulation resulted in displacement of Fli1 from the CCN2 promoter and a transient inhibition of Fli1 synthesis. Moreover, reduction of Fli1 expression resulted in up-regulation of COL1A1 and COL1A2 genes and down-regulation of the MMP1 gene. Thus, inhibition of Fli1 recapitulated some of the key effects of TGF-beta, suggesting that Fli1 suppression is involved in activation of the profibrotic gene program in fibroblasts. On the other hand, activation of the CCN2 gene downstream of Ets1 is consistent with its role in angiogenesis and extracellular matrix remodeling. This study strongly supports a critical role of Fli1 and Ets1 in the pathological extracellular matrix regulation during fibrosis and cancer.	Med Univ S Carolina, Div Rheumatol & Immunol, Charleston, SC 29425 USA	Medical University of South Carolina	Trojanowska, M (corresponding author), Med Univ S Carolina, Div Rheumatol & Immunol, 96 Jonathan Lucas St, Charleston, SC 29425 USA.	trojanme@musc.edu		Trojanowska, Maria/0000-0001-9550-7178	NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044883] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA78582] Funding Source: Medline; NIAMS NIH HHS [AR-44883, AR-423341] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aurrekoetxea-Hernandez K, 2004, J VIROL, V78, P2201, DOI 10.1128/JVI.78.5.2201-2211.2004; Blom IE, 2002, MATRIX BIOL, V21, P473, DOI 10.1016/S0945-053X(02)00055-0; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; Bu Shizhong, 2006, FASEB J, V20, P184; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Chambers RC, 2000, J BIOL CHEM, V275, P35584, DOI 10.1074/jbc.M003188200; Czuwara-Ladykowska J, 2002, J BIOL CHEM, V277, P20399, DOI 10.1074/jbc.M200206200; Czuwara-Ladykowska J, 2001, J BIOL CHEM, V276, P20839, DOI 10.1074/jbc.M010133200; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; Finckenberg P, 2003, AM J PATHOL, V163, P355, DOI 10.1016/S0002-9440(10)63659-0; Foulds CE, 2004, MOL CELL BIOL, V24, P10954, DOI 10.1128/MCB.24.24.10954-10964.2004; Graness A, 2006, CELL SIGNAL, V18, P433, DOI 10.1016/j.cellsig.2005.05.011; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; He ZH, 2005, J BIOL CHEM, V280, P15719, DOI 10.1074/jbc.M413493200; Hollenhorst PC, 2004, NUCLEIC ACIDS RES, V32, P5693, DOI 10.1093/nar/gkh906; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Jinnin M, 2004, ONCOGENE, V23, P1656, DOI 10.1038/sj.onc.1207064; Klappacher GW, 2002, CELL, V109, P169, DOI 10.1016/S0092-8674(02)00714-6; Kondo S, 2002, CARCINOGENESIS, V23, P769, DOI 10.1093/carcin/23.5.769; Kubo M, 2003, AM J PATHOL, V163, P571, DOI 10.1016/S0002-9440(10)63685-1; Leivonen SK, 2005, J INVEST DERMATOL, V124, P1162, DOI 10.1111/j.0022-202X.2005.23750.x; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Macauley MS, 2006, J BIOL CHEM, V281, P4164, DOI 10.1074/jbc.M510488200; Masuya M, 2005, BLOOD, V105, P95, DOI 10.1182/blood-2003-12-4345; Muehlich S, 2004, ATHEROSCLEROSIS, V175, P261, DOI 10.1016/j.atherosclerosis.2004.04.011; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Planque N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-15; Pufall MA, 2005, SCIENCE, V309, P142, DOI 10.1126/science.1111915; Rachfal AW, 2005, VITAM HORM, V70, P69, DOI 10.1016/S0083-6729(05)70003-0; Richard L, 1998, EXP CELL RES, V240, P1, DOI 10.1006/excr.1998.3936; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Suzuma K, 2000, J BIOL CHEM, V275, P40725, DOI 10.1074/jbc.M006509200; Trojanowska M, 2000, ONCOGENE, V19, P6464, DOI 10.1038/sj.onc.1204043; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; Xu SW, 2004, J BIOL CHEM, V279, P23098, DOI 10.1074/jbc.M311430200; Yang BS, 1996, MOL CELL BIOL, V16, P538; Zhan YM, 2005, J CLIN INVEST, V115, P2508, DOI 10.1172/JCI24403	44	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25259	25269		10.1074/jbc.M600466200	http://dx.doi.org/10.1074/jbc.M600466200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16829517	hybrid			2022-12-25	WOS:000240031300027
J	Lamounier-Zepter, V; Ehrhart-Bornstein, M; Karczewski, P; Haase, H; Bornstein, SR; Morano, I				Lamounier-Zepter, Valeria; Ehrhart-Bornstein, Monika; Karczewski, Peter; Haase, Hannelore; Bornstein, Stefan R.; Morano, Ingo			Human adipocytes attenuate cardiomyocyte contraction: characterization of an adipocyte-derived negative inotropic activity	FASEB JOURNAL			English	Article						cardiodepressant activity; calcium transient; obesity; heart failure	ADIPOSE-TISSUE; HEART-FAILURE; RAT CARDIOMYOCYTES; ANGIOTENSIN-II; RISK-FACTORS; FOLLOW-UP; OBESITY; PATHOPHYSIOLOGY; INHIBITION; MEDIATORS	The causal relationship between obesity and heart failure is broadly acknowledged; however, the pathophysiological mechanisms involved remain unclear. In this study we investigated whether human adipocytes secrete cardioactive substances that may affect cardiomyocyte contractility. We cultivated adipocytes obtained from human white adipose tissue and incubated isolated rat adult cardiomyocytes with adipocyte-conditioned or control medium. This is the first report to demonstrate that human adipocytes exhibit cardiodepressant activity with a direct and acute effect on cardiomyocyte contraction. This adipocyte-derived negative inotropic activity directly depresses shortening amplitude as well as intracellular systolic peak Ca2+ in cardiomyocytes within a few minutes. The adipocyte-derived cardiodepressant activity was dose-dependent and was completely blunted by heating or by trypsin digestion. Filtration of adipocyte-conditioned medium based on molecular mass characterized the cardiodepressant activity at between 10 and 30 kDa. In summary, adipose tissue exerts highly potent activity with an acute depressant effect directly on cardiomyocytes, which may well contribute to increased heart failure risk in overweight patients	Univ Dresden, Med Clin 3, D-01307 Dresden, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany	Technische Universitat Dresden; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Lamounier-Zepter, V (corresponding author), Univ Dresden, Med Clin 3, Fetscherstr 74, D-01307 Dresden, Germany.	Valeria.Zepter@uniklinikum-dresden.de						Alpert MA, 2001, AM J MED SCI, V321, P225, DOI 10.1097/00000441-200104000-00003; Amadou A, 2002, AM J PHYSIOL-CELL PH, V282, pC1339, DOI 10.1152/ajpcell.00471.2001; Cao CM, 2003, J PHARMACOL EXP THER, V306, P572, DOI 10.1124/jpet.102.048264; Ehrhart-Bornstein M, 2003, P NATL ACAD SCI USA, V100, P14211, DOI 10.1073/pnas.2336140100; Engeli S, 2000, HYPERTENSION, V35, P1270, DOI 10.1161/01.HYP.35.6.1270; Haber EP, 2003, J CELL PHYSIOL, V194, P1, DOI 10.1002/jcp.10187; Hauner H, 2004, PHYSIOL BEHAV, V83, P653, DOI 10.1016/j.physbeh.2004.09.016; He J, 2001, ARCH INTERN MED, V161, P996, DOI 10.1001/archinte.161.7.996; Holycross Bethany J, 2002, Mol Interv, V2, P424, DOI 10.1124/mi.2.7.424; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; Kenchaiah S, 2002, NEW ENGL J MED, V347, P305, DOI 10.1056/NEJMoa020245; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Krug AW, 2005, CELL MOL LIFE SCI, V62, P1359, DOI 10.1007/s00018-005-4555-z; Kumar A, 1996, J EXP MED, V183, P949, DOI 10.1084/jem.183.3.949; LAUER MS, 1991, JAMA-J AM MED ASSOC, V266, P231, DOI 10.1001/jama.266.2.231; Lefroy DC, 1996, AM J PHYSIOL-HEART C, V270, pH2060, DOI 10.1152/ajpheart.1996.270.6.H2060; Lohn M, 2002, FASEB J, V16, P1057, DOI 10.1096/fj.02-0024com; Massie BM, 2002, NEW ENGL J MED, V347, P358, DOI 10.1056/NEJMe020065; Nickola MW, 2000, HYPERTENSION, V36, P501, DOI 10.1161/01.HYP.36.4.501; Shah AM, 1997, CIRC RES, V80, P688, DOI 10.1161/01.RES.80.5.688; Sharma Vijay, 2005, Current Vascular Pharmacology, V3, P169, DOI 10.2174/1570161053586868; Staiger H, 2005, EXP CLIN ENDOCR DIAB, V113, P67, DOI 10.1055/s-2004-830555; Stangl V, 2002, CARDIOVASC RES, V53, P12, DOI 10.1016/S0008-6363(01)00420-5; Stein B, 1996, J MOL CELL CARDIOL, V28, P1631, DOI 10.1006/jmcc.1996.0153; Wajchenberg BL, 2000, ENDOCR REV, V21, P697, DOI 10.1210/er.21.6.697; Watanabe A, 1998, CARDIOVASC RES, V37, P524, DOI 10.1016/S0008-6363(97)00287-3; Wilhelmsen L, 2001, J INTERN MED, V249, P253, DOI 10.1046/j.1365-2796.2001.00801.x; Wong CY, 2004, CIRCULATION, V110, P3081, DOI 10.1161/01.CIR.0000147184.13872.0F; Yang ZK, 1999, AM J PHYSIOL-HEART C, V276, pH623, DOI 10.1152/ajpheart.1999.276.2.H623; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784	31	35	37	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2006	20	10					1653	1659		10.1096/fj.05-5436com	http://dx.doi.org/10.1096/fj.05-5436com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16873888				2022-12-25	WOS:000240266600010
J	Smulski, C; Labovsky, V; Levy, G; Hontebeyrie, M; Hoebeke, J; Levin, MJ				Smulski, C.; Labovsky, V.; Levy, G.; Hontebeyrie, M.; Hoebeke, J.; Levin, M. J.			Structural basis of the cross-reaction between an antibody to the Trypanosoma cruzi ribosomal P2 beta protein and the human beta(1) adrenergic receptor	FASEB JOURNAL			English	Article						ribosomal P proteins; single-chain Fv fragments (scFv); paratope-epitope modeling	CHAGAS HEART-DISEASE; HUMAN BETA-1-ADRENERGIC RECEPTOR; MONOCLONAL-ANTIBODY; VARIABLE FRAGMENT; P-PROTEINS; EPITOPE; AGONIST; COMPLEX; AUTOANTIBODIES; ARRHYTHMIAS	Antibodies from patients with Chagas heart disease and monoclonal antibodies (or mAb) to the carboxy-terminal end (B cell epitope R13) of the ribosomal P2 beta protein of Trypanosoma cruzi (TcP2 beta) cross-react with the beta(1) adrenergic receptor (beta(1)-AR). Two single-chain Fv fragments (scFv) C5 and B7 derived from the variable regions of the anti-R13 mAb 17.2 were expressed. scFv C5 was a dimer and bound to TcP2 beta with an affinity of K-d = 8 nM, whereas scFv B7 was monomeric and had less affinity than scFv C5 for TcP2 beta, K-d = 46 nM. The affinity constant of scFv C5 to the second extracellular loop of the human beta(1)-AR was of 10 mu M. Moreover, scFv C5 induced an increase in cAMP levels of CHO-K cells transfected with the human beta(1)-AR; scFv B7 had no effect but blocked isoproterenol stimulation. The agonist-like activity of scFv C5 and the antagonist activity of scFv B7 were both confirmed in vivo on heart beating frequency after their passive transfer to mice. Molecular modeling of the variable region of mAb 17.2 indicated which amino acids were likely to be involved in recognizing both peptide EDDDMGFGLF, derived from the R13 epitope of TcP2 beta, and peptide ESDEARRCYN from the second extracellular loop of the human beta(1)-AR. It is plausible that the recently described cross-reaction of mAb 17.2 with rhodopsin can also be explained by this model. The physiological effects of this type of anti-T. cruzi antibodies may increase the liability of patients with Chagas disease.	Consejo Nacl Invest Cient & Tecn, INGEBI, Inst Invest Ingn Genet & Biol Mol, LaBMECh,Natl Res Council, RA-1428 Buenos Aires, DF, Argentina; Inst Pasteur, Paris, France; CNRS, IBMC, UPR 9021, Strasbourg, France; INSERM, U567, Inst Cochin Genet Mol, Dept Malad Infect, Paris, France	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Levin, MJ (corresponding author), Consejo Nacl Invest Cient & Tecn, INGEBI, Inst Invest Ingn Genet & Biol Mol, LaBMECh,Natl Res Council, Vta Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	mlevin@dna.uba.ar		Levy, Gabriela Vanesa/0000-0002-7638-3509; Smulski, Cristian/0000-0003-4186-8116				Asano R, 2002, J BIOCHEM, V132, P903, DOI 10.1093/oxfordjournals.jbchem.a003303; Ayub MJ, 2005, GENE, V357, P129, DOI 10.1016/j.gene.2005.06.006; Bergami PL, 1997, FEMS IMMUNOL MED MIC, V18, P75, DOI 10.1016/S0928-8244(97)00026-6; Bergami PL, 2005, CLIN EXP IMMUNOL, V142, P140, DOI 10.1111/j.1365-2249.2005.02885.x; Chiale PA, 2001, CIRCULATION, V103, P1765, DOI 10.1161/01.CIR.103.13.1765; Elies R, 1996, J IMMUNOL, V157, P4203; ELIZARI MV, 1993, J CARDIOVASC ELECTR, V4, P596, DOI 10.1111/j.1540-8167.1993.tb01247.x; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; Giordanengo L, 2000, EUR J IMMUNOL, V30, P3181, DOI 10.1002/1521-4141(200011)30:11&lt;3181::AID-IMMU3181&gt;3.0.CO;2-A; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; HALPERIN C, 2000, ARRHYTHMIA MANAGEMEN, P83; Hernandez-Munain Cristina, 1993, Biological Research, V26, P209; HERNANDEZMUNAIN C, 1992, J EXP MED, V175, P1473, DOI 10.1084/jem.175.6.1473; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; Kaplan D, 1997, P NATL ACAD SCI USA, V94, P10301, DOI 10.1073/pnas.94.19.10301; Klco JM, 2005, NAT STRUCT MOL BIOL, V12, P320, DOI 10.1038/nsmb913; Kortt AA, 1997, PROTEIN ENG, V10, P423, DOI 10.1093/protein/10.4.423; KORTT AA, 1994, EUR J BIOCHEM, V221, P151, DOI 10.1111/j.1432-1033.1994.tb18724.x; LEVIN MJ, 1993, PARASITOL TODAY, V9, P381, DOI 10.1016/0169-4758(93)90088-W; LEVITUS G, 1991, CLIN EXP IMMUNOL, V85, P413, DOI 10.1111/j.1365-2249.1991.tb05741.x; LOPEZBERGAMI P, 2001, FASEB J, V15, P2602; Mahler E, 2004, CLIN EXP IMMUNOL, V136, P527, DOI 10.1111/j.1365-2249.2004.02480.x; Mahler E, 2001, EUR J IMMUNOL, V31, P2210, DOI 10.1002/1521-4141(200107)31:7&lt;2210::AID-IMMU2210&gt;3.0.CO;2-J; Matsumoto SC, 2006, FASEB J, V20, P550, DOI 10.1096/fj.05-4654fje; MESRI EA, 1990, J CLIN MICROBIOL, V28, P1219, DOI 10.1128/JCM.28.6.1219-1224.1990; Mijares A, 2000, MOL PHARMACOL, V58, P373, DOI 10.1124/mol.58.2.373; Mousli M, 1999, FEBS LETT, V442, P183, DOI 10.1016/S0014-5793(98)01647-0; MULLER S, 1985, BIOCHIM BIOPHYS ACTA, V827, P235, DOI 10.1016/0167-4838(85)90208-0; Peter JC, 2004, J BIOL CHEM, V279, P55697, DOI 10.1074/jbc.M407213200; Peter JC, 2003, J BIOL CHEM, V278, P36740, DOI 10.1074/jbc.M306877200; RichaletSecordel PM, 1997, ANAL BIOCHEM, V249, P165, DOI 10.1006/abio.1997.2183; ROSENBAUM MB, 1994, J CARDIOVASC ELECTR, V5, P367, DOI 10.1111/j.1540-8167.1994.tb01174.x; Sepulveda P, 2000, INFECT IMMUN, V68, P5114, DOI 10.1128/IAI.68.9.5114-5119.2000; SNARY D, 1983, CLIN EXP IMMUNOL, V54, P617; STERINBORDA L, 1986, INT J IMMUNOPHARMACO, V8, P581, DOI 10.1016/0192-0561(86)90029-9	35	29	33	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1396	1406		10.1096/fj.05-5699com	http://dx.doi.org/10.1096/fj.05-5699com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816115				2022-12-25	WOS:000240266000017
J	Briz, O; Romero, MR; Martinez-Becerra, P; Macias, RIR; Perez, MJ; Jimenez, F; San Martin, FG; Marin, JJG				Briz, Oscar; Romero, Marta R.; Martinez-Becerra, Pablo; Macias, Rocio I. R.; Perez, Maria J.; Jimenez, Felipe; San Martin, Francisco G.; Marin, Jose J. G.			OATP8/1B3-mediated cotransport of bile acids and glutathione - An export pathway for organic anions from hepatocytes?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOBILIARY TRANSPORTER EXPRESSION; REDUCED GLUTATHIONE; FUNCTIONAL-CHARACTERIZATION; INTRACELLULAR GLUTATHIONE; INTRAHEPATIC CHOLESTASIS; SUBSTRATE-SPECIFICITY; HUMAN LIVER; OATP-B; POLYPEPTIDE; MEMBRANE	In cholestasis, the accumulation of organic anions in hepato-cytes is reduced by transporters (multidrug resistance-associated proteins and OST alpha-OST beta) able to extrude them across the basolateral membrane. Here we investigated whether organic anion-transporting polypeptides (OATPs) may contribute to this function. Xenopus laevis oocytes expressing human carboxylesterase-1 efficiently loaded cholic acid (CA) methyl ester, which was cleaved to CA and exported. Expression of OATP8/1B3 enhanced CA efflux, which was trans-activated by taurocholate but trans-inhibited by reduced (GSH) and oxidized (GSSG) glutathione. Moreover, taurocholate and estradiol 17 beta-D-glucuronide, but not bicarbonate and glutamate, cis-inhibited OATP8/1B3-mediated bile acid transport, whereas glutathione cis-stimulated this process, which involved the transport of glutathione itself with a stoichiometry of 2:1 (GSH/bile acid). No cis-activation by glutathione of OATP-C/1B1 was found. Using real time quantitative reverse transcription-PCR, the absolute abundance of OATP-A/1A2, OATP-C/1B1, and OATP8/1B3 mRNA in human liver biopsies was measured. In healthy liver, expression levels of OATP-C/1B1 were similar to 5-fold those of OATP8/1B3 and > 100-fold those of OATP-A/1A2. This situation was not substantially modified in several cholestatic liver diseases studied here. In conclusion, although both OATP-C/1B1 and OATP8/1B3 are highly expressed, and able to transport bile acids, their mechanisms of action are different. OATP-C/1B1 may be involved in uptake processes, whereas OATP8/1B3 may mediate the extrusion of organic anions by symporting with glutathione as a normal route of exporting metabolites produced by hepatocytes or preventing their intracellular accumulation when their vectorial traffic toward the bile is impaired.	Univ Hosp Salamanca, Res Unit, Salamanca, Spain; Univ Salamanca, Lab Expt Hepatol & Drug Targeting, Salamanca 37007, Spain; Univ Salamanca Hosp, Div Gastroenterol, Salamanca 37007, Spain	University of Salamanca; University of Salamanca	Marin, JJG (corresponding author), Dept Physiol & Pharmacol, Campus Miguel Unamuno,ED S-09, Salamanca 37007, Spain.	jjgmarin@usal.es	Macias, Rocio/ABG-8938-2020; Macias, Rocio I.R./A-9617-2017; Perez, Maria Jose/A-9830-2017; Marin, Jose J. G./D-5017-2011; Romero, Marta Rodriguez/B-1596-2017; Briz Sanchez, Oscar/A-9634-2017	Macias, Rocio/0000-0002-4748-0326; Macias, Rocio I.R./0000-0002-4748-0326; Perez, Maria Jose/0000-0003-4917-6413; Marin, Jose J. G./0000-0003-1186-6849; Romero, Marta Rodriguez/0000-0001-6729-0215; Briz Sanchez, Oscar/0000-0001-6891-1554				Ballatori N, 2005, TOXICOL APPL PHARM, V204, P238, DOI 10.1016/j.taap.2004.09.008; Ballatori N, 1998, SEMIN LIVER DIS, V18, P377, DOI 10.1055/s-2007-1007171; Ballatori N, 1996, AM J PHYSIOL-REG I, V270, pR1156, DOI 10.1152/ajpregu.1996.270.5.R1156; Boyer JL, 2006, AM J PHYSIOL-GASTR L, V290, pG1124, DOI 10.1152/ajpgi.00539.2005; Briz O, 2003, BIOCHEM J, V371, P897, DOI 10.1042/BJ20030034; Briz O, 2002, MOL PHARMACOL, V61, P853, DOI 10.1124/mol.61.4.853; Chignard N, 2001, HEPATOLOGY, V33, P496, DOI 10.1053/jhep.2001.22345; Hagenbuch B, 2003, BBA-BIOMEMBRANES, V1609, P1, DOI 10.1016/S0005-2736(02)00633-8; Hagenbuch B, 2004, PFLUG ARCH EUR J PHY, V447, P653, DOI 10.1007/s00424-003-1168-y; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; Keitel V, 2005, HEPATOLOGY, V41, P1160, DOI 10.1002/hep.20682; Koepsell H, 2004, PFLUG ARCH EUR J PHY, V447, P666, DOI 10.1007/s00424-003-1089-9; Konig J, 2000, J BIOL CHEM, V275, P23161, DOI 10.1074/jbc.M001448200; Konig J, 2000, AM J PHYSIOL-GASTR L, V278, pG156, DOI 10.1152/ajpgi.2000.278.1.G156; Kullak-Ublick GA, 2004, GASTROENTEROLOGY, V126, P322, DOI 10.1053/j.gastro.2003.06.005; Kullak-Ublick GA, 2001, GASTROENTEROLOGY, V120, P525, DOI 10.1053/gast.2001.21176; KULLAKUBLICK GA, 1995, GASTROENTEROLOGY, V109, P1274, DOI 10.1016/0016-5085(95)90588-X; Lee TK, 2001, TOXICOL APPL PHARM, V174, P207, DOI 10.1006/taap.2001.9208; Letschert K, 2004, PHARMACOGENETICS, V14, P441, DOI 10.1097/01.fpc.0000114744.08559.92; Li LQ, 2000, MOL PHARMACOL, V58, P335, DOI 10.1124/mol.58.2.335; Li LQ, 1998, J BIOL CHEM, V273, P16184, DOI 10.1074/jbc.273.26.16184; Marin JJG, 2003, BBA-BIOMEMBRANES, V1611, P249, DOI 10.1016/S0005-2736(03)00080-4; MARIN JJG, 2005, MED HYPOTHESES RES, V2, P425; Noe B, 1997, P NATL ACAD SCI USA, V94, P10346, DOI 10.1073/pnas.94.19.10346; Nozawa T, 2004, J PHARMACOL EXP THER, V308, P438, DOI 10.1124/jpet.103.060194; Oswald M, 2001, LIVER, V21, P247, DOI 10.1034/j.1600-0676.2001.021004247.x; Rius M, 2006, AM J PHYSIOL-GASTR L, V290, pG640, DOI 10.1152/ajpgi.00354.2005; Satlin LM, 1997, J BIOL CHEM, V272, P26340, DOI 10.1074/jbc.272.42.26340; SHI XY, 1995, J BIOL CHEM, V270, P25591, DOI 10.1074/jbc.270.43.25591; SORSCHER S, 1992, BIOCHEM BIOPH RES CO, V186, P1455, DOI 10.1016/S0006-291X(05)81570-0; Suzuki H, 2000, SEMIN LIVER DIS, V20, P251, DOI 10.1055/s-2000-8408; Tamai I, 2000, BIOCHEM BIOPH RES CO, V273, P251, DOI 10.1006/bbrc.2000.2922; Vallejo M, 2006, J HEPATOL, V44, P1150, DOI 10.1016/j.jhep.2005.09.017; Zollner G, 2003, J HEPATOL, V38, P717, DOI 10.1016/S0168-8278(03)00096-5; Zollner G, 2001, HEPATOLOGY, V33, P633, DOI 10.1053/jhep.2001.22646	35	64	67	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30326	30335		10.1074/jbc.M602048200	http://dx.doi.org/10.1074/jbc.M602048200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16877380	hybrid			2022-12-25	WOS:000241075900006
J	Lundgren, TK; Scott, RP; Smith, M; Pawson, T; Ernfors, P				Lundgren, T. Kalle; Scott, Rizaldy P.; Smith, Matthew; Pawson, Tony; Ernfors, Patrik			Engineering the recruitment of phosphotyrosine binding domain-containing adaptor proteins reveals distinct roles for RET receptor-mediated cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; ENTERIC NERVOUS-SYSTEM; TYROSINE KINASE; INSULIN-RECEPTOR; SH2 DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; PTB DOMAINS; PROTOONCOGENE; ACTIVATION	The RET receptor tyrosine kinase is important for several different biological functions during development. The recruitment at the phosphorylated Tyr1062 site in RET of a number of different phosphotyrosine binding ( PTB) domain-containing adaptor proteins, including Shc and Frs2, plays a dominant role for the multiple different biological functions of the RET receptor during development, including stimulation of cell survival. Here, we demonstrate that a competitive recruitment of Shc as opposed to Frs2 mediates the survival signaling arising from RET activation. Based on results from a peptide array, we have genetically engineered the PTB domain binding site of RET to rewire its recruitment of the PTB proteins Shc and Frs2. An engineered RET that has a competitive interaction with Shc at the expense of Frs2, but not a RET receptor that only recruits Frs2, activates cell survival signaling pathways and is protective from cell death in neuronal SK- N- MC cells. Thus, cell type- specific functions involve a competitive recruitment of different PTB adaptor molecules by RET that activate selective signaling pathways.	Karolinska Inst, Dept Med Biochem & Biophys, Mol Neurobiol Unit, S-17177 Stockholm, Sweden; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Karolinska Institutet; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Ernfors, P (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Mol Neurobiol Unit, S-17177 Stockholm, Sweden.	Patrik.Ernfors@ki.se	Smith, Matthew J/AAI-8060-2020; Scott, Rizaldy/AAC-5264-2020; Lundgren, Kalle/E-9056-2015; Scott, Rizaldy/Y-7584-2019; Pawson, Tony J/E-4578-2013	Smith, Matthew J/0000-0003-2896-9350; Lundgren, Kalle/0000-0001-6781-762X; Scott, Rizaldy/0000-0002-0288-8862; Ernfors, Patrik/0000-0002-1140-3986				Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Barlow A, 2003, NEURON, V40, P905, DOI 10.1016/S0896-6273(03)00730-X; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; de Graaff E, 2001, GENE DEV, V15, P2433, DOI 10.1101/gad.205001; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Encinas M, 2004, J BIOL CHEM, V279, P18262, DOI 10.1074/jbc.M400505200; Eng C, 1999, J CLIN ONCOL, V17, P380, DOI 10.1200/JCO.1999.17.1.380; Enomoto H, 2001, DEVELOPMENT, V128, P3963; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Fukuda T, 2002, J BIOL CHEM, V277, P19114, DOI 10.1074/jbc.M200643200; Gianino S, 2003, DEVELOPMENT, V130, P2187, DOI 10.1242/dev.00433; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Heuckeroth RO, 1999, NEURON, V22, P253, DOI 10.1016/S0896-6273(00)81087-9; HUTCHINSON EG, 1994, PROTEIN SCI, V3, P2207, DOI 10.1002/pro.5560031206; Jain S, 2006, GENE DEV, V20, P321, DOI 10.1101/gad.1387206; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Jijiwa M, 2004, MOL CELL BIOL, V24, P8026, DOI 10.1128/MCB.24.18.8026-8036.2004; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; KUROKAWA K, 1996, J INTERN MED, V3, P627; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Marone R, 2004, NAT CELL BIOL, V6, P515, DOI 10.1038/ncb1134; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Melillo RM, 2001, ONCOGENE, V20, P209, DOI 10.1038/sj.onc.1204049; Murakami H, 2002, J BIOL CHEM, V277, P32781, DOI 10.1074/jbc.M202336200; Natarajan D, 2002, DEVELOPMENT, V129, P5151; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Scott RP, 2005, J BIOL CHEM, V280, P13442, DOI 10.1074/jbc.M500507200; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Taraviras S, 1999, DEVELOPMENT, V126, P2785; van der Geer P, 1999, ONCOGENE, V18, P3071, DOI 10.1038/sj.onc.1202879; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619; Worley DS, 2000, DEVELOPMENT, V127, P4383; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Young HM, 2001, DEV BIOL, V229, P503, DOI 10.1006/dbio.2000.0100; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	57	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29886	29896		10.1074/jbc.M600473200	http://dx.doi.org/10.1074/jbc.M600473200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16847065	hybrid			2022-12-25	WOS:000240896300050
J	Hiromura, M; Suizu, F; Narita, M; Kinowaki, K; Noguchi, M				Hiromura, Makoto; Suizu, Futoshi; Narita, Masumi; Kinowaki, Keiichi; Noguchi, Masayuki			Identification of nerve growth factor-responsive element of the TCL1 promoter as a novel negative regulatory element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN STEROID-RECEPTOR; AKT KINASE-ACTIVITY; T-CELL; NGFI-B; DIFFERENTIAL REGULATION; TRANSCRIPTION FACTOR; EXPRESSION; GENE; ACTIVATION; APOPTOSIS	The serine/threonine kinase, Akt ( protein kinase B) plays a central role in the regulation of intracellular cell survival. Recently, we demonstrated that the proto-oncogene TCL1, overexpressed in human T-cell prolymphocytic leukemia, is an Akt kinase co-activator. Tightly restricted TCL1 gene expression in early developmental cells suggested that the TCL1 gene is regulated at a transcriptional level. To characterize how TCL1 gene expression is regulated, we cloned the 5'-promoter of the TCL1 gene located at human chromosome 14q32. The 5'-TCL1 promoter region contains a TATA box with cis-regulatory elements for Nur77/NGFI-B (nerve growth factor-responsive element (NBRE), CCAAGGTCA), NF kappa B, and fork head transcription factor. Nur77/NGFI-B, an orphan receptor superfamily transcription factor implicated in T-cell apoptosis, is a substrate for Akt. We hypothesized that TCL1 transactivity is regulated through Akt-induced phosphorylation of Nur77/NGFI-B in vivo. In an electrophoretic mobility shift assay with chromosomal immunoprecipitation assays, wild-type Nur77, but not S350A mutant Nur77, could specifically bind to TCL1-NBRE. A luciferase assay demonstrated that TCL1-NBRE is required for inhibition of TCL1 transactivity upon nerve growth factor/platelet-derived growth factor stimulation, which activates Akt and phosphorylates Nur77. Using a chromosomal immunoprecipitation assay with reverse transcription-PCR, nerve growth factor stimulation inhibited binding of endogenous Nur77 to TCL1-NBRE, in turn, suppressing TCL1 gene expression. The results together establish that TCL1-NBRE is a novel negative regulatory element of Nur77 (NGFI-B). To the best of our knowledge, TCL1-NBRE is the first direct target of Nur77 involving the regulation of intracellular cell death survival. This Akt-induced inhibitory mechanism of TCL1 should play an important role in immunological and/or neuronal development in vivo.	Hokkaido Univ, Inst Med Genet, Div Canc Biol, Sapporo, Hokkaido 0600815, Japan	Hokkaido University	Noguchi, M (corresponding author), Hokkaido Univ, Inst Med Genet, Div Canc Biol, Sapporo, Hokkaido 0600815, Japan.	m_noguch@igm.hokudai.ac.jp	Suizu, Futoshi/G-3530-2019	Suizu, Futoshi/0000-0003-0206-4289				Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CRAWFORD PA, 1995, MOL CELL BIOL, V15, P4331; Croce CM, 1999, CANCER RES, V59, p1778S; Du KY, 2005, ONCOGENE, V24, P7401, DOI 10.1038/sj.onc.1209099; French SW, 2003, J BIOL CHEM, V278, P948, DOI 10.1074/jbc.M207166200; Hallas C, 1999, P NATL ACAD SCI USA, V96, P14418, DOI 10.1073/pnas.96.25.14418; Hiromura M, 2004, J BIOL CHEM, V279, P53407, DOI 10.1074/jbc.M403775200; Hoyer KK, 2005, J IMMUNOL, V175, P864, DOI 10.4049/jimmunol.175.2.864; Hoyer KK, 2002, P NATL ACAD SCI USA, V99, P14392, DOI 10.1073/pnas.212410199; Kang SM, 2005, BLOOD, V105, P1288, DOI 10.1182/blood-2004-04-1453; Katagiri Y, 1997, J BIOL CHEM, V272, P31278, DOI 10.1074/jbc.272.50.31278; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Kunstle G, 2002, MOL CELL BIOL, V22, P1513, DOI 10.1128/MCB.22.5.1513-1525.2002; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Laine J, 2002, J BIOL CHEM, V277, P3743, DOI 10.1074/jbc.M107069200; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Lock RB, 2003, INT J BIOCHEM CELL B, V35, P1614, DOI 10.1016/S1357-2725(03)00146-8; Maruyama K, 1997, NEUROENDOCRINOLOGY, V65, P2, DOI 10.1159/000127158; Maruyama K, 1998, INT J ONCOL, V12, P1237; MATSUYAMA N, 2001, J BIOL CHEM, V274, P32799; Meinke G, 1999, NAT STRUCT BIOL, V6, P471; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Narducci MG, 2000, CANCER RES, V60, P2095; NOGUCHI M, 1994, J BIOL CHEM, V269, P29161; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Pekarsky Y, 2001, ONCOGENE, V20, P5638, DOI 10.1038/sj.onc.1204596; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; Rajpal A, 2003, EMBO J, V22, P6526, DOI 10.1093/emboj/cdg620; Takizawa J, 1998, JPN J CANCER RES, V89, P712, DOI 10.1111/j.1349-7006.1998.tb03275.x; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Teague TK, 1999, P NATL ACAD SCI USA, V96, P12691, DOI 10.1073/pnas.96.22.12691; Teitell M, 1999, P NATL ACAD SCI USA, V96, P9809, DOI 10.1073/pnas.96.17.9809; Teitell MA, 2005, NAT REV CANCER, V5, P640, DOI 10.1038/nrc1672; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; Virgilio L, 1998, P NATL ACAD SCI USA, V95, P3885, DOI 10.1073/pnas.95.7.3885; Weih F, 1996, P NATL ACAD SCI USA, V93, P5533, DOI 10.1073/pnas.93.11.5533; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Winoto A, 2002, CELL, V109, pS57, DOI 10.1016/S0092-8674(02)00710-9; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0	45	11	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27753	27764		10.1074/jbc.M602420200	http://dx.doi.org/10.1074/jbc.M602420200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16835233	hybrid, Green Published			2022-12-25	WOS:000240534400011
J	Macdonald, PR; Progias, P; Ciani, B; Patel, S; Mayer, U; Steinmetz, MO; Kammerer, RA				Macdonald, Philip R.; Progias, Pavlos; Ciani, Barbara; Patel, Sanjai; Mayer, Ulrike; Steinmetz, Michel O.; Kammerer, Richard A.			Structure of the extracellular domain of tie receptor tyrosine kinases and localization of the angiopoietin-binding epitope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURES; NIDOGEN BINDING; ANGIOGENESIS; EXPRESSION; LIGAND; MICE; GENE; HEMANGIOMA; COMPLEXES	Angiogenesis is essential for tissue repair and regeneration during wound healing but also plays important roles in many pathological processes including tumor growth and metastasis. The receptor protein tyrosine kinase Tie2 and its ligands, the angiopoietins, have important functions in the regulation of angiogenesis. Here, we report a detailed structural and functional characterization of the extracellular region of Tie2. Sequence analysis of the extracellular domain revealed an additional immunoglobulin-like domain resulting in a tandem repeat of immunoglobulin-like domains at the N terminus of the protein. The same domain organization was also found for the Tie1 receptor that shares a high degree of homology with Tie2. Based on structural similarities to other receptor tyrosine kinases and cell adhesion molecules, we demonstrate that the N-terminal two immunoglobulin-like domains of Tie2 harbor the angiopoietin-binding site. Using transmission electron microscopy we furthermore show that the extracellular domain of Tie receptors consists of a globular head domain and a short rod-like stalk that probably forms a spacer between the cell surface and the angiopoietin-binding site. Mutational analysis demonstrated that the head domain consists of the three immunoglobulin-like domains and the three epidermal growth factor-like modules and that the stalk is formed by the three fibronectin type III repeats. These findings might be of particular interest for drug development because Tie receptors are potential targets for treatment of angiogenesis-associated diseases.	Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Univ E Anglia, Sch Biol Sci, Biomed Res Ctr, Norwich NR4 7TJ, Norfolk, England; Paul Scherrer Inst, Biomol Res Struct Biol, CH-5232 Villigen, Switzerland	University of Manchester; University of East Anglia; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Kammerer, RA (corresponding author), Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	richard.kammerer@manchester.ac.uk	Steinmetz, Michel O/AAA-3349-2022; Ciani, Barbara/A-1679-2012	Steinmetz, Michel O/0000-0001-6157-3687; Ciani, Barbara/0000-0001-7223-4154; Mayer, Ulrike/0000-0003-2328-0052; Kammerer, Richard/0000-0003-4570-5197				Aguilar HC, 2006, J VIROL, V80, P4878, DOI 10.1128/JVI.80.10.4878-4889.2006; Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Barton WA, 2006, NAT STRUCT MOL BIOL, V13, P524, DOI 10.1038/nsmb1101; Calvert JT, 1999, HUM MOL GENET, V8, P1279, DOI 10.1093/hmg/8.7.1279; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cho CH, 2004, P NATL ACAD SCI USA, V101, P5547, DOI 10.1073/pnas.0307574101; CO MS, 1993, MOL IMMUNOL, V30, P1361; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Du Lingling, 2003, New England Journal of Medicine, V348, P500, DOI 10.1056/NEJMoa021650; DUMONT DJ, 1992, ONCOGENE, V7, P1471; Eklund L, 2006, EXP CELL RES, V312, P630, DOI 10.1016/j.yexcr.2005.09.002; Fiedler U, 2003, J BIOL CHEM, V278, P1721, DOI 10.1074/jbc.M208550200; FOWLER WE, 1983, J ULTRA MOL STRUCT R, V83, P319, DOI 10.1016/S0022-5320(83)90139-9; Frank S, 2002, J BIOL CHEM, V277, P19071, DOI 10.1074/jbc.M202146200; Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4; Hafizi S, 2006, CYTOKINE GROWTH F R, V17, P295, DOI 10.1016/j.cytogfr.2006.04.004; Heiring C, 2004, J BIOL CHEM, V279, P6952, DOI 10.1074/jbc.M311750200; Holden PH, 1997, NAT BIOTECHNOL, V15, P668, DOI 10.1038/nbt0797-668; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kim I, 2000, ONCOGENE, V19, P4549, DOI 10.1038/sj.onc.1203800; Kontos CD, 2002, MOL CELL BIOL, V22, P1704, DOI 10.1128/MCB.22.6.1704-1713.2002; Kuroda K, 2001, J INVEST DERMATOL, V116, P713, DOI 10.1046/j.1523-1747.2001.01316.x; Lee HJ, 2004, FASEB J, V18, P1200, DOI 10.1096/fj.03-1466com; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Marron MB, 2000, ADV EXP MED BIOL, V476, P35; Marron MB, 2000, J BIOL CHEM, V275, P39741, DOI 10.1074/jbc.M007189200; MARTIN S, 1993, ANTIMICROB AGENTS CH, V37, P1278, DOI 10.1128/AAC.37.6.1278; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; POSCHL E, 1994, EMBO J, V13, P3741, DOI 10.1002/j.1460-2075.1994.tb06683.x; Puri MC, 2003, P NATL ACAD SCI USA, V100, P12753, DOI 10.1073/pnas.2133552100; Saharinen P, 2005, J CELL BIOL, V169, P239, DOI 10.1083/jcb.200411105; Sasaki T, 2006, EMBO J, V25, P80, DOI 10.1038/sj.emboj.7600912; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; Shewchuk LM, 2000, STRUCTURE, V8, P1105, DOI 10.1016/S0969-2126(00)00516-5; Springer TA, 1998, J MOL BIOL, V283, P837, DOI 10.1006/jmbi.1998.2115; Stetefeld J, 1996, J MOL BIOL, V257, P644, DOI 10.1006/jmbi.1996.0191; Sullivan CC, 2003, P NATL ACAD SCI USA, V100, P12331, DOI 10.1073/pnas.1933740100; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Tait CR, 2004, J PATHOL, V204, P1, DOI 10.1002/path.1618; Tate CG, 2003, BBA-BIOMEMBRANES, V1610, P141, DOI 10.1016/S0005-2736(02)00719-8; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thurston G, 2003, CELL TISSUE RES, V314, P61, DOI 10.1007/s00441-003-0749-6; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; Voskas D, 2005, AM J PATHOL, V166, P843, DOI 10.1016/S0002-9440(10)62305-X; Wang H, 2004, ONCOGENE, V23, P8700, DOI 10.1038/sj.onc.1208006; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yu Y, 2001, AM J PATHOL, V159, P2271, DOI 10.1016/S0002-9440(10)63077-5	53	26	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28408	28414		10.1074/jbc.M605219200	http://dx.doi.org/10.1074/jbc.M605219200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16849318	Green Published, hybrid			2022-12-25	WOS:000240534400078
J	Tamura, S; Yasutake, S; Matsumoto, N; Fujiki, Y				Tamura, Shigehiko; Yasutake, Shinobu; Matsumoto, Naomi; Fujiki, Yukio			Dynamic and functional assembly of the AAA peroxins, Pex1p and Pex6p, and their membrane receptor Pex26p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FUSION PROTEIN; CHO-CELL MUTANT; BIOGENESIS DISORDERS; COMPLEMENTATION GROUP; ZELLWEGER-SYNDROME; TERMINAL DOMAIN; PTS1 RECEPTOR; CDNA CLONING; ATPASE; INTERACTS	Two AAA peroxins, Pex1p and Pex6p, are encoded by PEX1 and PEX6, the causal genes for peroxisome biogenesis disorders of complementation group 1 (CG1) and CG4, respectively. PEX26 responsible for peroxisome biogenesis disorders of CG8 encodes Pex26p, the recruiter of Pex1p (.) Pex6p complexes to peroxisomes. We herein assigned the binding regions between human Pex1p and Pex6p and elucidated pivotal roles of the AAA cassettes, called D1 and D2 domains, in Pex1p - Pex6p interaction and peroxisome biogenesis. ATP binding in both AAA cassettes but not ATP hydrolysis in D2 of both Pex1p and Pex6p was prerequisite for Pex1p - Pex6p interaction and their peroxisomal localization. The AAA cassettes, D1 and D2, were essential for peroxisome-restoring activity of Pex1p and Pex6p. In HEK293 cells, endogenous Pex1p was partly localized likely as a homo-oligomer in the cytoplasm, while Pex6p and Pex26p were predominantly localized on peroxisomes. Interaction of Pex1p with Pex6p conferred a conformational change and dissociation of the Pex1p oligomer. These results suggested that Pex1p possesses two distinct oligomeric forms, a homo-oligomer in the cytosol and a hetero-oligomer on peroxisome membranes, possibly playing distinct functions in peroxisome biogenesis.	Kyushu Univ, Dept Biol, Fac Sci, Grad Sch,Higashi Ku, Fukuoka 8128581, Japan; SORST, Japan Sci & Technol Agcy, Kawaguchi, Saitama 3320012, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Fujiki, Y (corresponding author), Kyushu Univ, Dept Biol, Fac Sci, Grad Sch,Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	yfujiscb@mbox.nc.kyushu-u.ac.jp	Matsumoto, Naomi/AFL-4833-2022; Matsumoto, Naomi/AAD-3468-2022					Beyer A, 1997, PROTEIN SCI, V6, P2043; Birschmann I, 2005, FEBS J, V272, P47, DOI 10.1111/j.1432-1033.2004.04393.x; Birschmann I, 2003, MOL BIOL CELL, V14, P2226, DOI 10.1091/mbc.E02-11-0752; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; Eckert JH, 2003, REV PHYSIOL BIOCH P, V147, P75, DOI 10.1007/s10254-003-0007-z; Faber KN, 1998, MOL CELL BIOL, V18, P936, DOI 10.1128/MCB.18.2.936; Furuki S, 2006, J BIOL CHEM, V281, P1317, DOI 10.1074/jbc.M510044200; Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Imamura A, 1998, HUM MOL GENET, V7, P2089, DOI 10.1093/hmg/7.13.2089; Lupas AN, 2002, CURR OPIN STRUC BIOL, V12, P746, DOI 10.1016/S0959-440X(02)00388-3; Matsumoto N, 2003, NAT CELL BIOL, V5, P454, DOI 10.1038/ncb982; Matsumoto N, 2001, J HUM GENET, V46, P273, DOI 10.1007/s100380170078; May AP, 2001, J BIOL CHEM, V276, P21991, DOI 10.1074/jbc.R100013200; May AP, 1999, NAT CELL BIOL, V1, P175, DOI 10.1038/11097; Miyata N, 2005, MOL CELL BIOL, V25, P10822, DOI 10.1128/MCB.25.24.10822-10832.2005; Neuwald AF, 1999, GENOME RES, V9, P27; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Okumoto K, 2000, J BIOL CHEM, V275, P25700, DOI 10.1074/jbc.M003303200; Okumoto K, 1998, MOL CELL BIOL, V18, P4324, DOI 10.1128/MCB.18.7.4324; Otera H, 2000, J BIOL CHEM, V275, P21703, DOI 10.1074/jbc.M000720200; Otera H, 1998, MOL CELL BIOL, V18, P388, DOI 10.1128/MCB.18.1.388; Otera H, 2002, MOL CELL BIOL, V22, P1639, DOI 10.1128/MCB.22.6.1639-1655.2002; Platta HW, 2005, NAT CELL BIOL, V7, P817, DOI 10.1038/ncb1281; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; Shimozawa N, 2004, HUM MUTAT, V23, P552, DOI 10.1002/humu.20032; Shiozawa K, 2004, J BIOL CHEM, V279, P50060, DOI 10.1074/jbc.M407837200; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; Tamura S, 1998, BIOCHEM BIOPH RES CO, V245, P883, DOI 10.1006/bbrc.1998.8522; Tamura S, 1998, P NATL ACAD SCI USA, V95, P4350, DOI 10.1073/pnas.95.8.4350; Tamura S, 2001, BIOCHEM J, V357, P417, DOI 10.1042/0264-6021:3570417; Titorenko VI, 2000, J CELL BIOL, V150, P881, DOI 10.1083/jcb.150.4.881; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Weller S, 2005, AM J HUM GENET, V76, P987, DOI 10.1086/430637; Weller S, 2003, ANNU REV GENOM HUM G, V4, P165, DOI 10.1146/annurev.genom.4.070802.110424; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; Whiteheart SW, 2004, J STRUCT BIOL, V146, P32, DOI 10.1016/j.jsb.2003.09.015; Yan MD, 2005, CURR OPIN CELL BIOL, V17, P376, DOI 10.1016/j.ceb.2005.06.003	40	47	47	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27693	27704		10.1074/jbc.M605159200	http://dx.doi.org/10.1074/jbc.M605159200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16854980	hybrid			2022-12-25	WOS:000240534400005
J	Herrick-Davis, K; Weaver, BA; Grinde, E; Mazurkiewicz, JE				Herrick-Davis, Katharine; Weaver, Barbara A.; Grinde, Ellinor; Mazurkiewicz, Joseph E.			Serotonin 5-HT2C receptor homodimer biogenesis in the endoplasmic reticulum - Real-time visualization with confocal fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; LIGAND-INDEPENDENT DIMERIZATION; LIVING CELLS; HORMONE RECEPTOR; SURFACE; HETERODIMERIZATION; TRAFFICKING; OLIGOMERIZATION; INHIBITION; INTERFACE	Dimerization is a common property of G-protein-coupled receptors (GPCR). While the formation of GPCR dimers/oligomers has been reported to play important roles in regulating receptor expression, ligand binding, and second messenger activation, less is known about how and where GPCR dimerization occurs. The present study was performed to identify the precise cellular compartment in which class A GPCR dimer/oligomer biogenesis occurs. We addressed this issue using confocal microscopy and fluorescence resonance energy transfer (FRET) to monitor GPCR proximity within discrete intracellular compartments of intact living cells. Time-lapse confocal imaging was used to follow CFP- and YFP-tagged serotonin 5-HT2C receptors during biosynthesis in the endoplasmic reticulum (ER), trafficking through the Golgi apparatus and subsequent expression on the plasma membrane. Real-time monitoring of FRET between CFP- and YFP-tagged 5-HT2C receptors was performed by acceptor photobleaching within discrete regions of the ER, Golgi, and plasma membrane. The FRET signal was dependent on the ratio of CFP- to YFP-tagged 5-HT2C receptors expressed in each region and was independent of receptor expression level, as predicted for proteins in a non-random, clustered distribution. FRET efficiencies measured in the ER, Golgi, and plasma membrane were similar. These experiments provide direct evidence for homodimerization/oligomerization of class A GPCR in the ER and Golgi of intact living cells, and suggest that dimer/oligomer formation is a naturally occurring step in 5-HT2C receptor maturation and processing.	Albany Med Coll, Ctr Neuropharmacol & Neurosci, Albany, NY 12208 USA	Albany Medical College	Herrick-Davis, K (corresponding author), Albany Med Coll, Ctr Neuropharmacol & Neurosci, MC-136,47 New Scotland Ave, Albany, NY 12208 USA.	daviskh@mail.amc.edu			NCRR NIH HHS [RR017926] Funding Source: Medline; NIMH NIH HHS [MH057019] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR017926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057019] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Ayoub MA, 2002, J BIOL CHEM, V277, P21522, DOI 10.1074/jbc.M200729200; Babcock GJ, 2003, J BIOL CHEM, V278, P3378, DOI 10.1074/jbc.M210140200; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Bastiaens PIH, 1996, EMBO J, V15, P4246, DOI 10.1002/j.1460-2075.1996.tb00799.x; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; Cornea A, 2001, J BIOL CHEM, V276, P2153, DOI 10.1074/jbc.M007850200; Dinger MC, 2003, J BIOL CHEM, V278, P10562, DOI 10.1074/jbc.M205747200; Fotiadis D, 2004, FEBS LETT, V564, P281, DOI 10.1016/S0014-5793(04)00194-2; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Goudet C, 2005, J BIOL CHEM, V280, P24380, DOI 10.1074/jbc.M502642200; Guo W, 2005, P NATL ACAD SCI USA, V102, P17495, DOI 10.1073/pnas.0508950102; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Hamm HE, 2001, P NATL ACAD SCI USA, V98, P4819, DOI 10.1073/pnas.011099798; Herrick-Davis K, 2005, J BIOL CHEM, V280, P40144, DOI 10.1074/jbc.M507396200; Herrick-Davis K, 1999, J NEUROCHEM, V73, P1711, DOI 10.1046/j.1471-4159.1999.731711.x; Herrick-Davis K, 2004, BIOCHEMISTRY-US, V43, P13963, DOI 10.1021/bi048398p; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Karpa KD, 2000, MOL PHARMACOL, V58, P677, DOI 10.1124/mol.58.4.677; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kenworthy AK, 1998, J CELL BIOL, V142, P69, DOI 10.1083/jcb.142.1.69; Kong MMC, 2005, CONTEMPORARY CLIN NE, P287; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lee SP, 2004, J BIOL CHEM, V279, P35671, DOI 10.1074/jbc.M401923200; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; O'Dowd BF, 2005, J BIOL CHEM, V280, P37225, DOI 10.1074/jbc.M504562200; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Salahpour A, 2004, J BIOL CHEM, V279, P33390, DOI 10.1074/jbc.M403363200; SANDERSBUSH E, 1990, J PHARMACOL EXP THER, V252, P984; Shioda T, 2001, J VIROL, V75, P3462, DOI 10.1128/JVI.75.7.3462-3468.2001; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; Uberti MA, 2005, J PHARMACOL EXP THER, V313, P16, DOI 10.1124/jpet.104.079541; Villemure JF, 2005, BIOCHEM J, V388, P47, DOI 10.1042/BJ20041435; Wallrabe H, 2003, BIOPHYS J, V85, P559, DOI 10.1016/S0006-3495(03)74500-7; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	42	95	96	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27109	27116		10.1074/jbc.M604390200	http://dx.doi.org/10.1074/jbc.M604390200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16857671	hybrid			2022-12-25	WOS:000240397700038
J	Buis, JM; Cheek, J; Kalliri, E; Broderick, JB				Buis, Jeffrey M.; Cheek, Jennifer; Kalliri, Efthalia; Broderick, Joan B.			Characterization of an active spore photoproduct lyase, a DNA repair enzyme in the radical S-adenosylmethionine superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE FORMATE-LYASE; BACILLUS-SUBTILIS SPORES; IRON-SULFUR PROTEINS; ACTIVATING ENZYME; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; LIPOYL SYNTHASE; 4FE-4S CLUSTERS; THYMINE DIMERS; BINDS	The major photoproduct in UV-irradiated Bacillus spore DNA is a unique thymine dimer called spore photoproduct (SP, 5-thyminyl-5,6-dihydrothymine). The enzyme spore photoproduct lyase (SP lyase) has been found to catalyze the repair of SP dimers to thymine monomers in a reaction that requires S-adenosylmethionine. We present here the first detailed characterization of catalytically active SP lyase, which has been anaerobically purified from overexpressing Escherichia coli. Anaerobically purified SP lyase is monomeric and is red-brown in color. The purified enzyme contains similar to 3.1 iron and 3.0 acid-labile S-2-per protein and has a UV-visible spectrum characteristic of iron-sulfur proteins (410 nm (11.9 mM(-1) cm(-1)) and 450 nm (10.5 mM(-1) cm(-1))). The X-band EPR spectrum of the purified enzyme shows a nearly isotropic signal (g = 2.02) characteristic of a [3Fe-4S](1+) cluster; reduction of SP lyase with dithionite results in the appearance of a new EPR signal (g = 2.03, 1.93, and 1.89) with temperature dependence and g values consistent with its assignment to a [4Fe-4S](1+) cluster. The reduced purified enzyme is active in SP repair, with a specific activity of 0.33 mu mol/min/mg. Only a catalytic amount of S-adenosylmethionine is required for DNA repair, and no irreversible cleavage of S-adenosylmethionine into methionine and 5'-deoxyadenosine is observed during the reaction. Label transfer from [5'-3H] S-adenosylmethionine to repaired thymine is observed, providing evidence to support a mechanism in which a 5'-deoxyadenosyl radical intermediate directly abstracts a hydrogen from SP C-6 to generate a substrate radical, and subsequent to radical-mediated beta-scission, a product thymine radical abstracts a hydrogen from 5'-deoxyadenosine to regenerate the 5'-deoxyadenosyl radical. Together, our results support a mechanism in which S-adenosylmethionine acts as a catalytic cofactor, not a substrate, in the DNA repair reaction.	Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA; Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA	Montana State University System; Montana State University Bozeman; Michigan State University	Broderick, JB (corresponding author), Montana State Univ, Dept Chem & Biochem, Gaines Hall 108, Bozeman, MT 59717 USA.	jbroderick@chemistry.montana.edu		Broderick, Joan/0000-0001-7057-9124	NIGMS NIH HHS [R01 GM067804, GM20315, GM67804] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067804] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beinert H, 2000, J BIOL INORG CHEM, V5, P2, DOI 10.1007/s007750050002; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Beinert H, 1978, Methods Enzymol, V54, P435; Berkovitch F, 2004, SCIENCE, V303, P76, DOI 10.1126/science.1088493; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broderick J. B, 2004, COMPREHENSIVE COORDI, V1st, P739, DOI [10.1016/B0-08-043748-6/08214-1, DOI 10.1016/B0-08-043748-6/08214-1]; Broderick JB, 2000, BIOCHEM BIOPH RES CO, V269, P451, DOI 10.1006/bbrc.2000.2313; Cheek J, 2002, J AM CHEM SOC, V124, P2860, DOI 10.1021/ja017784g; Cheek J, 2001, J BIOL INORG CHEM, V6, P209, DOI 10.1007/s007750100210; Cicchillo RM, 2004, BIOCHEMISTRY-US, V43, P11770, DOI 10.1021/bi0488505; DONNELLAN JE, 1965, SCIENCE, V149, P308, DOI 10.1126/science.149.3681.308; DONNELLAN JE, 1968, BIOPHYS J, V8, P17, DOI 10.1016/S0006-3495(68)86471-9; FAJARDOCAVAZOS P, 1993, J BACTERIOL, V175, P1735, DOI 10.1128/JB.175.6.1735-1744.1993; FISH WW, 1978, METHOD ENZYMOL, V54, P357; Fontecave M, 2001, CURR OPIN CHEM BIOL, V5, P506, DOI 10.1016/S1367-5931(00)00237-4; Freire E., 1995, DNA REPAIR MUTAGENES, P191; Frey PA, 2003, CHEM REV, V103, P2129, DOI 10.1021/cr020422m; Friedel MG, 2006, CHEM COMMUN, P445, DOI 10.1039/b514103f; GARBOCZI DN, 1988, J BIOL CHEM, V263, P15694; Hanzelmann P, 2004, P NATL ACAD SCI USA, V101, P12870, DOI 10.1073/pnas.0404624101; Henshaw TF, 2000, J AM CHEM SOC, V122, P8331, DOI 10.1021/ja002012q; IRETON K, 1992, J BACTERIOL, V174, P3185, DOI 10.1128/jb.174.10.3185-3195.1992; Jarrett JT, 2003, CURR OPIN CHEM BIOL, V7, P174, DOI 10.1016/S1367-5931(03)00022-X; Krebs C, 2002, J AM CHEM SOC, V124, P912, DOI 10.1021/ja017562i; Krebs C, 2000, J AM CHEM SOC, V122, P12497, DOI 10.1021/ja003335p; Layer G, 2003, EMBO J, V22, P6214, DOI 10.1093/emboj/cdg598; Lepore BW, 2005, P NATL ACAD SCI USA, V102, P13819, DOI 10.1073/pnas.0505726102; Lieder KW, 1998, BIOCHEMISTRY-US, V37, P2578, DOI 10.1021/bi972417w; Mehl RA, 1999, ORG LETT, V1, P1065, DOI 10.1021/ol9908676; Miller JR, 2000, BIOCHEMISTRY-US, V39, P15166, DOI 10.1021/bi002060n; MUNAKATA N, 1972, J BACTERIOL, V11, P192, DOI 10.1128/JB.111.1.192-198.1972; MUNAKATA N, 1974, MOL GEN GENET, V130, P239, DOI 10.1007/BF00268802; Nicholson WL, 2000, MICROBIOL MOL BIOL R, V64, P548, DOI 10.1128/MMBR.64.3.548-572.2000; Nicholson WL, 1997, MOL GEN GENET, V255, P587, DOI 10.1007/s004380050532; NICHOLSON WL, 1991, P NATL ACAD SCI USA, V88, P8288, DOI 10.1073/pnas.88.19.8288; Padovani D, 2001, BIOCHEMISTRY-US, V40, P6713, DOI 10.1021/bi002936q; Rebeil R, 2001, P NATL ACAD SCI USA, V98, P9038, DOI 10.1073/pnas.161278998; Rebeil R, 1998, J BACTERIOL, V180, P4879, DOI 10.1128/JB.180.18.4879-4885.1998; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; SETLOW B, 1992, J BACTERIOL, V174, P2312, DOI 10.1128/JB.174.7.2312-2322.1992; SETLOW P, 1994, REGULATION OF BACTERIAL DIFFERENTIATION, P181; SETLOW P, 1992, MOL MICROBIOL, V6, P563, DOI 10.1111/j.1365-2958.1992.tb01501.x; SETLOW P, 1995, ANNU REV MICROBIOL, V49, P29, DOI 10.1146/annurev.mi.49.100195.000333; SETLOW P, 1988, ANNU REV MICROBIOL, V42, P319, DOI 10.1146/annurev.mi.42.100188.001535; Slieman TA, 2000, J BACTERIOL, V182, P6412, DOI 10.1128/JB.182.22.6412-6417.2000; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; STUY JH, 1955, BIOCHIM BIOPHYS ACTA, V17, P206, DOI 10.1016/0006-3002(55)90351-6; SUN YB, 1994, ANAL BIOCHEM, V221, P61, DOI 10.1006/abio.1994.1379; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; VARGHESE AJ, 1970, BIOCHEM BIOPH RES CO, V38, P484, DOI 10.1016/0006-291X(70)90739-4; Walsby CJ, 2002, J AM CHEM SOC, V124, P11270, DOI 10.1021/ja027078v; Walsby CJ, 2005, INORG CHEM, V44, P727, DOI 10.1021/ic0484811; Walsby CJ, 2002, J AM CHEM SOC, V124, P3143, DOI 10.1021/ja012034s; Yasbin Ronald E., 1993, P529	54	58	59	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25994	26003		10.1074/jbc.M603931200	http://dx.doi.org/10.1074/jbc.M603931200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829680	hybrid			2022-12-25	WOS:000240249500014
J	Okumura, K; Mendoza, M; Bachoo, RM; DePinho, RA; Cavenee, WK; Furnari, FB				Okumura, Koichi; Mendoza, Michelle; Bachoo, Robert M.; DePinho, Ronald A.; Cavenee, Webster K.; Furnari, Frank B.			PCAF modulates PTEN activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; PHOSPHATASE-ACTIVITY; HISTONE ACETYLASES; GROWTH SUPPRESSION; CHROMOSOME-10 PTEN; PROTEIN STABILITY; NUCLEAR PTEN; MUTATIONS; GENE; PHOSPHORYLATION	The PTEN protein has a single catalytic domain possessing both lipid phosphoinositol and protein phosphatase activities. The lipid phosphoinositol phosphatase activity is essential for PTEN to block the cell cycle in the G1 phase and thereby to suppress tumor formation and progression (Cantley, L. C., and Neel, B. G. (1999) Proc. Natl. Acad. Sci. U.S.A. 96, 4240-4245), although the mechanisms governing PTEN activity under normal and neoplastic growth conditions remain unclear. Here, we report that PTEN interacts physically and functionally with PCAF, a histone acetyltransferase that regulates gene transcription through interaction with p300/CBP and various sequence-specific transcription factors (Nakatani, Y. (2001) Genes Cells 6, 79 -86). Expression of PCAF results in increased acetylation of lysine residues (Lys(125) and Lys(128)) within the catalytic cleft of PTEN, a structure essential for phosphatidylinositol 3,4,5-trisphosphate specificity (Lee, J. O., Yang, H., Georgescu, M. M., Di Cristofano, A., Maehama, T., Shi, Y., Dixon, J. E., Pandolfi, P., and Pavletich, N. P. (1999) Cell 99, 323 -334). The acetylation of PTEN caused by PCAF expression depends on the presence of growth factors. Reduction of endogenous PCAF activity using shRNA results in a loss of PTEN acetylation in response to growth factors and restores the ability of PTEN to down-regulate phosphatidylinositol 3-kinase signaling and to induce G1 cell cycle arrest. The retention of phosphatidylinositol 3-kinase/AKT signaling and cell cycle regulatory activities of acetylation-resistant PTEN K125R and K128R mutants in the presence of enforced PCAF expression suggest a causal relationship. Together, these findings indicate a mechanism of PTEN regulation that forges a link between distinct cancer-relevant pathways central to the control of growth factor signaling and gene expression.	Univ Calif San Diego, Ludwig Inst Canc Res, San Diego Branch, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Med, Dallas, TX 75390 USA; Harvard Univ, Sch Med, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Furnari, FB (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, San Diego Branch, La Jolla, CA 92093 USA.	ffurnari@ucsd.edu		Furnari, Frank/0000-0003-1909-4361; DePinho, Ronald/0000-0002-5625-577X	NCI NIH HHS [CA95616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA095616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chung JH, 2005, CANCER RES, V65, P8096, DOI 10.1158/0008-5472.CAN-05-1888; Chung JH, 2005, CANCER RES, V65, P4108, DOI 10.1158/0008-5472.CAN-05-0124; Debes JD, 2003, CANCER RES, V63, P7638; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; Larsen M, 2003, NAT REV MOL CELL BIO, V4, P700, DOI 10.1038/nrm1199; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Liu JL, 2005, MOL CELL BIOL, V25, P6211, DOI 10.1128/MCB.25.14.6211-6224.2005; Maehama T, 2000, ANAL BIOCHEM, V279, P248, DOI 10.1006/abio.2000.4497; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Nakatani Y, 2001, GENES CELLS, V6, P79, DOI 10.1046/j.1365-2443.2001.00411.x; Nishimori H, 2000, J NEURO-ONCOL, V46, P17, DOI 10.1023/A:1006404110073; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Torres J, 2003, J BIOL CHEM, V278, P30652, DOI 10.1074/jbc.M212610200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Yamagoe S, 2003, MOL CELL BIOL, V23, P1025, DOI 10.1128/MCB.23.3.1025-1033.2003; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	34	159	169	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26562	26568		10.1074/jbc.M605391200	http://dx.doi.org/10.1074/jbc.M605391200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829519	hybrid			2022-12-25	WOS:000240249500074
J	Yamniuk, AP; Ishida, H; Vogel, HJ				Yamniuk, Aaron P.; Ishida, Hiroaki; Vogel, Hans J.			The interaction between calcium- and integrin-binding protein 1 and the alpha IIb integrin cytoplasmic domain involves a novel C-terminal displacement mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-RESONANCE EXPERIMENTS; NMR-SPECTROSCOPY; METHIONINE RESIDUES; BACKBONE DYNAMICS; CIB BINDING; CALMODULIN; N-15; ACTIVATION; ALPHA(IIB)BETA(3); RECOGNITION	Calcium- and integrin-binding protein 1 (CIB1) regulates platelet aggregation in hemostasis through a specific interaction with the alpha IIb cytoplasmic domain of platelet integrin alpha IIb alpha 3. In this work we report the structural characteristics of CIB1 in solution and the mechanistic details of its interaction with a synthetic peptide derived from the alpha IIb cytoplasmic domain. NMR spectroscopy experiments using perdeuterated CIB1 together with heteronuclear nuclear Overhauser effect experiments have revealed a well folded alpha-helical structure for both the ligand-free and alpha IIb-bound forms of the protein. Residual dipolar coupling experiments have shown that the N and C domains of CIB1 are positioned side by side, and chemical shift perturbation mapping has identified the alpha IIb-binding site as a hydrophobic channel spanning the entire C domain and part of the N domain. Data obtained with a truncated version of CIB1 suggest that the extreme C-terminal end of the protein weakly interacts with this channel in the absence of a biological target, but it is displaced by the alpha IIb cytoplasmic domain, suggesting a novel mechanism to increase binding specificity.	Univ Calgary, Dept Biol Sci, Struct Biol Res Grp, Calgary, AB T2N 1N4, Canada	University of Calgary	Vogel, HJ (corresponding author), Univ Calgary, Dept Biol Sci, Struct Biol Res Grp, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	vogel@ucalgary.ca						ANGLISTER J, 1995, FEBS LETT, V375, P108, DOI 10.1016/0014-5793(95)01192-H; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; Barry WT, 2002, J BIOL CHEM, V277, P28877, DOI 10.1074/jbc.M202983200; Behan MWH, 2004, POSTGRAD MED J, V80, P155, DOI 10.1136/pgmj.2003.007062; Blamey CJ, 2005, PROTEIN SCI, V14, P1214, DOI 10.1110/ps.041270805; BLAZEJCZYK M, 2005, BIOCHIM BIOPHYS ACTA, V1762, P66; CALVETE JJ, 1990, FEBS LETT, V263, P43, DOI 10.1016/0014-5793(90)80701-J; Cordier F, 1999, J BIOMOL NMR, V13, P175, DOI 10.1023/A:1008301415843; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dizhoor AM, 1998, J BIOL CHEM, V273, P17311, DOI 10.1074/jbc.273.28.17311; DRAKENBERG T, 1987, J BIOL CHEM, V262, P672; Eletsky A, 2001, J BIOMOL NMR, V20, P177, DOI 10.1023/A:1011265430149; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Gardner KH, 1998, ANNU REV BIOPH BIOM, V27, P357, DOI 10.1146/annurev.biophys.27.1.357; GELLMAN SH, 1991, BIOCHEMISTRY-US, V30, P6633, DOI 10.1021/bi00241a001; Gentry HR, 2005, J BIOL CHEM, V280, P8407, DOI 10.1074/jbc.M411515200; Ginsberg MH, 2005, CURR OPIN CELL BIOL, V17, P509, DOI 10.1016/j.ceb.2005.08.010; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; Hers I, 2000, ARTERIOSCL THROM VAS, V20, P1651, DOI 10.1161/01.ATV.20.6.1651; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hwang PM, 2000, J MOL RECOGNIT, V13, P83, DOI 10.1002/(SICI)1099-1352(200003/04)13:2<83::AID-JMR491>3.0.CO;2-A; Ikura M, 2006, P NATL ACAD SCI USA, V103, P1159, DOI 10.1073/pnas.0508640103; Jiang GH, 2003, BIOL CHEM, V384, P1299, DOI 10.1515/BC.2003.145; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kennedy MT, 1996, J BIOL CHEM, V271, P26517, DOI 10.1074/jbc.271.43.26517; Liu SC, 2000, J CELL SCI, V113, P3563; McFerran BW, 1999, J BIOL CHEM, V274, P30258, DOI 10.1074/jbc.274.42.30258; Naik UP, 2003, BLOOD, V102, P1355, DOI 10.1182/blood-2003-02-0591; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Naoe Y, 2005, J BIOL CHEM, V280, P32372, DOI 10.1074/jbc.M503390200; Ni HY, 2003, TRANSFUS APHER SCI, V28, P257, DOI 10.1016/S1473-0502(03)00044-2; Salzmann M, 1999, J AM CHEM SOC, V121, P844, DOI 10.1021/ja9834226; Salzmann M, 1998, P NATL ACAD SCI USA, V95, P13585, DOI 10.1073/pnas.95.23.13585; Shan X, 1998, J BIOMOL NMR, V11, P307, DOI 10.1023/A:1008257803130; Shan X, 1996, J AM CHEM SOC, V118, P6570, DOI 10.1021/ja960627a; Shock DD, 1999, BIOCHEM J, V342, P729, DOI 10.1042/0264-6021:3420729; Sobczak A, 2005, ACTA BIOCHIM POL, V52, P469; Stabler SM, 1999, J CELL BIOL, V145, P1277, DOI 10.1083/jcb.145.6.1277; Stefansson A, 2004, J BIOL CHEM, V279, P21200, DOI 10.1074/jbc.M400771200; Tachibanaki S, 2000, J BIOL CHEM, V275, P3313, DOI 10.1074/jbc.275.5.3313; THULIN E, 1984, BIOCHEMISTRY-US, V23, P1862, DOI 10.1021/bi00303a043; Tsuboi S, 2002, J BIOL CHEM, V277, P1919, DOI 10.1074/jbc.M110643200; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; WALSH M, 1978, BIOCHEMISTRY-US, V17, P3924, DOI 10.1021/bi00612a006; Weljie AM, 2003, PROTEIN SCI, V12, P228, DOI 10.1110/ps.0226203; Wintrode PL, 1997, J MOL BIOL, V266, P1050, DOI 10.1006/jmbi.1996.0785; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Wishart DS, 1998, BIOCHEM CELL BIOL, V76, P153, DOI 10.1139/bcb-76-2-3-153; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Yamniuk AP, 2005, PROTEIN SCI, V14, P1429, DOI 10.1110/ps.041312805; Yamniuk AP, 2004, BIOCHEMISTRY-US, V43, P2558, DOI 10.1021/bi035432b; Yamniuk AP, 2004, MOL BIOTECHNOL, V27, P33, DOI 10.1385/MB:27:1:33; Yuan T, 1999, J BIOL CHEM, V274, P8411, DOI 10.1074/jbc.274.13.8411; Yuan WP, 2006, J CELL BIOL, V172, P169, DOI 10.1083/jcb.200505131; Zhou W, 2004, NEURON, V41, P573, DOI 10.1016/S0896-6273(04)00045-5; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908	56	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26455	26464		10.1074/jbc.M603963200	http://dx.doi.org/10.1074/jbc.M603963200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16825200	hybrid			2022-12-25	WOS:000240249500063
J	Frantz, S; Hu, K; Bayer, B; Gerondakis, S; Strotmann, J; Adamek, A; Ertl, G; Bauersachs, J				Frantz, Stefan; Hu, Kai; Bayer, Barbara; Gerondakis, Steve; Strotmann, Joerg; Adamek, Anna; Ertl, Georg; Bauersachs, Johann			Absence of NF-kappa B subunit p50 improves heart failure after myocardial infarction	FASEB JOURNAL			English	Article						inflammation; NF kappa B; interleukins; collagen	LEFT-VENTRICULAR ENLARGEMENT; CARDIAC MYOCYTES; TARGETED DELETION; ANGIOTENSIN-II; IN-VIVO; MICE; ACTIVATION; CARDIOMYOPATHY; INFLAMMATION; HYPERTROPHY	Background: NF kappa B (NF-kappa B) is a ubiquitous transcription factor activated by various stimuli implicated in heart failure progression including reactive oxygen species (ROS), hypoxia, and inflammatory cytokines. Although NF-kappa B is involved in ischemic preconditioning, unstable angina pectoris, and atherogenesis, its role in heart failure has not been determined. Therefore, we investigated left ventricular remodeling in mice with a targeted deletion of the NF-kappa B subunit p50/ NF-kappa B1 after myocardial infarction. Methods and results: p50 knockout (KO) and wild-type (WT) animals underwent coronary artery ligation. Transthoracic echocardiography was performed at days 0, 21, and 56 at midpapillary levels. Early mortality was significantly lower in KO than in WT animals. Moreover, p50 KOs exhibited significantly reduced ventricular dilatation over 8 wk compared to WT controls (end-systolic diameters by transthoracic echocardiography, WT vs. KO, 0.55 +/- 0.04 vs. 0.34 +/- 0.03 cm) and preserved left ventricular contractility. Collagen content and matrixmetalloproteinase (MMP) -9 expression were significantly lower in KO mice after myocardial infarction and may account for improved left ventricular remodeling. Conclusions: Absence of the NF-kappa B subunit p50 improves early survival and reduces left ventricular dilatation after myocardial infarction. NF-kappa B might therefore be an attractive target to treat heart failure.	Univ Wurzburg, Med Klin & Poliklin 1, Herzkreislauf Zentrum, D-97080 Wurzburg, Germany; Walter & Eliza Hall Inst Med Res, Parcville, Vic, Australia	University of Wurzburg; Walter & Eliza Hall Institute	Frantz, S (corresponding author), Univ Wurzburg, Med Klin & Poliklin 1, Herzkreislauf Zentrum, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	frantz_s@medizin.uni-wuerzburg.de	Frantz, Stefan/G-1723-2012					Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BOURCIER T, 1999, METHODS MOL MED VASC, P159; Buttner C, 2004, J CELL PHYSIOL, V198, P248, DOI 10.1002/jcp.10395; Chatterjee PK, 2004, CARDIOVASC RES, V61, P630, DOI 10.1016/j.cardiores.2003.10.024; Ducharme A, 2000, J CLIN INVEST, V106, P55, DOI 10.1172/JCI8768; Frantz S, 2004, BRIT J PHARMACOL, V141, P9, DOI 10.1038/sj.bjp.0705585; Frantz S, 2003, J MOL CELL CARDIOL, V35, P685, DOI 10.1016/S0022-2828(03)00113-5; Frantz S, 1999, J CLIN INVEST, V104, P271, DOI 10.1172/JCI6709; Frantz S, 2001, J BIOL CHEM, V276, P5197, DOI 10.1074/jbc.M009160200; Freund C, 2005, CIRCULATION, V111, P2319, DOI 10.1161/01.CIR.0000164237.58200.5A; Kawamura N, 2005, CARDIOVASC RES, V66, P520, DOI 10.1016/j.cardiores.2005.02.007; Kawano S, 2005, CARDIOVASC RES, V67, P689, DOI 10.1016/j.cardiores.2005.04.030; Kubota T, 1997, CIRC RES, V81, P627, DOI 10.1161/01.RES.81.4.627; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; Misra A, 2003, CIRCULATION, V108, P3075, DOI 10.1161/01.CIR.0000108929.93074.0B; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; Nahrendorf M, 2006, CIRCULATION, V113, P1196, DOI 10.1161/CIRCULATIONAHA.105.602094; Norman DAM, 1998, CARDIOVASC RES, V39, P434, DOI 10.1016/S0008-6363(98)00118-7; Nwogu JI, 2001, CIRCULATION, V104, P2216, DOI 10.1161/hc4301.097193; Rohde LE, 1999, CIRCULATION, V99, P3063, DOI 10.1161/01.CIR.99.23.3063; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Vanhoutte D, 2006, CARDIOVASC RES, V69, P604, DOI 10.1016/j.cardiores.2005.10.002; Wencker D, 2003, J CLIN INVEST, V111, P1497, DOI 10.1172/JCI200317664	23	111	124	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2006	20	11					1918	+		10.1096/fj.05-5133fje	http://dx.doi.org/10.1096/fj.05-5133fje			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16837548				2022-12-25	WOS:000240267000030
J	Hu, J; Verkman, AS				Hu, Jie; Verkman, A. S.			Increased migration and metastatic potential of tumor cells expressing aquaporin water channels	FASEB JOURNAL			English	Article						aquaporin; water channel; tumor metastasis; cell migration; cancer	PERMEABILITY; MICE; REDISTRIBUTION; ANGIOGENESIS; LOCALIZATION; DIVERSITY; NEOPLASMS; OVARY	Aquaporin (AQP) water channels are expressed in high-grade tumor cells of different tissue origins. Based on the involvement of AQPs in angiogenesis and cell migration, we tested whether AQP expression in tumor cells might enhance their migration and metastatic potential. Transfection of B16F10 and 4T1 tumor cells with AQP1 did not affect their appearance, size, growth, or substrate adherence but increased their plasma membrane osmotic water permeability by 5- to 10-fold. In vitro analysis of cell migration by transwell assay, wound healing and video microscopy showed a 2- to 3-fold accelerated migration of the AQP1-expressing tumor cells compared to control cells. In mice, AQP1 expression increased tumor cell extravasation by > 1.5-fold as quantified by counting tumor cells in lung at 6 h after tail vein injection of a mixture of fluorescently tagged AQP1-expressing and control tumor cells. AQP1 expression also increased by 3-fold the number of lung metastases 14 days after tail vein injection of tumor cells, with alveolar wall infiltration seen with AQP1-expressing tumor cells. Our results provide evidence for AQP-facilitated tumor cell migration and spread, suggesting a novel function for AQP expression in high-grade tumors. AQP inhibition may thus reduce the metastatic potential of some tumors.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Dept Med, 1246 Hlth Sci E, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu			NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL73856] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124, DK72517] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073856, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072517, R01DK035124, R37DK035124] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Boon K, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-39; Endo M, 1999, MICROVASC RES, V58, P89, DOI 10.1006/mvre.1999.2158; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Hara M, 2003, P NATL ACAD SCI USA, V100, P7360, DOI 10.1073/pnas.1230416100; Hara-Chikuma M, 2005, J BIOL CHEM, V280, P15493, DOI 10.1074/jbc.C500028200; Hara-Chikuma M, 2006, J AM SOC NEPHROL, V17, P39, DOI 10.1681/ASN.2005080846; Kafe H, 2004, VIRCHOWS ARCH, V445, P637, DOI 10.1007/s00428-004-1124-z; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MA TH, 1993, J BIOL CHEM, V268, P22756; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; Mazal PR, 2005, MODERN PATHOL, V18, P535, DOI 10.1038/modpathol.3800320; Mobasheri A, 2005, INT J ONCOL, V26, P1149; Moon C, 2003, ONCOGENE, V22, P6699, DOI 10.1038/sj.onc.1206762; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; Oshio K, 2005, NEUROSURGERY, V56, P375, DOI 10.1227/01.NEU.0000148904.57841.6B; Oshio K, 2003, ACTA NEUROCHIR SUPPL, V86, P499; Padmawar P, 2005, NAT METHODS, V2, P825, DOI 10.1038/NMETH801; Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460; Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680; Saadoun S, 2002, J NEUROL NEUROSUR PS, V72, P262, DOI 10.1136/jnnp.72.2.262; Schwab A, 2001, AM J PHYSIOL-RENAL, V280, pF739, DOI 10.1152/ajprenal.2001.280.5.F739; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; Thiagarajah JR, 2002, J BIOL CHEM, V277, P19139, DOI 10.1074/jbc.M202071200; Verkman AS, 2005, J CELL SCI, V118, P3225, DOI 10.1242/jcs.02519; Warth A, 2005, ACTA NEUROPATHOL, V109, P418, DOI 10.1007/s00401-005-0984-x; Warth A, 2004, ACTA NEUROPATHOL, V107, P311, DOI 10.1007/s00401-003-0812-0; Yang JH, 2006, GYNECOL ONCOL, V100, P294, DOI 10.1016/j.ygyno.2005.08.054	31	251	299	0	38	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1892	+		10.1096/fj.06-5930fje	http://dx.doi.org/10.1096/fj.06-5930fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16818469				2022-12-25	WOS:000240267000021
J	Lee, TS; Karl, R; Moosmang, S; Lenhardt, P; Klugbauer, N; Hofmann, F; Kleppisch, T; Welling, A				Lee, Tae-Seong; Karl, Rosi; Moosmang, Sven; Lenhardt, Peter; Klugbauer, Norbert; Hofmann, Franz; Kleppisch, Thomas; Welling, Andrea			Calmodulin kinase II is involved in voltage-dependent facilitation of the L-type Ca(v)1.2 calcium channel - Identification of the phosphorylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED CA2+ CHANNELS; RABBIT VENTRICULAR MYOCYTES; SLOW INWARD CURRENT; EF-HAND MOTIF; PROTEIN-KINASE; SMOOTH-MUSCLE; CA2+-DEPENDENT INACTIVATION; CA2+-SENSITIVE INACTIVATION; FUNCTIONAL EXPRESSION; CHROMAFFIN CELLS	Calcium-dependent facilitation of L-type calcium channels has been reported to depend on the function of calmodulin kinase II. In contrast, the mechanism for voltage-dependent facilitation is not clear. In HEK 293 cells expressing Ca(v)1.2, Ca-v beta 2a, and calmodulin kinase II, the calcium current measured at +30mV was facilitated up to 1.5-fold by a 200-ms-long prepulse to +160mV. This voltage dependent facilitation was prevented by the calmodulin kinase II inhibitors KN93 and the autocamtide-2-related peptide. In cells expressing the Cav1.2 mutation I1649E, a residue critical for the binding of Ca2+-bound calmodulin, facilitation was also abolished. Calmodulin kinase II was coimmunoprecipitated with the Cav1.2 channel from murine heart and HEK 293 cells expressing Cav1.2 and calmodulin kinase II. The precipitated Ca(v)1.2 channel was phosphorylated in the presence of calmodulin and Ca2+. Fifteen putative calmodulin kinase II phosphorylation sites were identified mostly in the carboxyl-terminal tail of Ca(v)1.2. Neither truncation at amino acid 1728 nor changing the II-III loop serines 808 and 888 to alanines affected facilitation of the calcium current. In contrast, facilitation was decreased by the single mutations S1512A and S1570A and abolished by the double mutation S1512A/ S1570A. These serines flank the carboxyl-terminal EF-hand motif. Immunoprecipitation of calmodulin kinase II with the Ca(v)1.2 channel was not affected by the mutation S1512A/S1570A. The phosphorylation of the Ca(v)1.2 protein was strongly decreased in the S1512A/ S1570A double mutant. These results suggest that voltage dependent facilitation of the Ca(v)1.2 channel depends on the phosphorylation of Ser1512/Ser1570 by calmodulin kinase II.	Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany; Tech Univ Munich, Inst Mol Med, D-80802 Munich, Germany	Technical University of Munich; Technical University of Munich	Welling, A (corresponding author), Tech Univ Munich, Inst Pharmakol & Toxikol, Biedersteiner Str 29, D-80802 Munich, Germany.	Welling@ipt.med.tu-muenchen.de	Welling, Andrea/K-6674-2017	Welling, Andrea/0000-0002-5364-4980				Anderson ME, 2004, TRENDS CARDIOVAS MED, V14, P152, DOI 10.1016/j.tcm.2004.02.005; ANDERSON ME, 1994, CIRC RES, V75, P854, DOI 10.1161/01.RES.75.5.854; ARTALEJO CR, 1990, NATURE, V348, P239, DOI 10.1038/348239a0; Bartel S, 2000, J MOL CELL CARDIOL, V32, P2173, DOI 10.1006/jmcc.2000.1243; Bernatchez G, 1998, BIOPHYS J, V75, P1727, DOI 10.1016/S0006-3495(98)77614-3; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; Catterall WA, 2003, PHARMACOL REV, V55, P579, DOI 10.1124/pr.55.4.8; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Cens T, 1998, J BIOL CHEM, V273, P18308, DOI 10.1074/jbc.273.29.18308; Dai SP, 1999, FEBS LETT, V442, P70, DOI 10.1016/S0014-5793(98)01632-9; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; Dzhura I, 2002, J PHYSIOL-LONDON, V545, P399, DOI 10.1113/jphysiol.2002.021881; Dzhura I, 2000, NAT CELL BIOL, V2, P173, DOI 10.1038/35004052; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; Erickson MG, 2003, NEURON, V39, P97, DOI 10.1016/S0896-6273(03)00395-7; Erxleben C, 2006, P NATL ACAD SCI USA, V103, P3932, DOI 10.1073/pnas.0511322103; Gao TY, 2000, J BIOL CHEM, V275, P25436, DOI 10.1074/jbc.M003465200; Garcia AG, 1996, TRENDS NEUROSCI, V19, P383, DOI 10.1016/S0166-2236(96)20035-9; Hamilton S. L., 2005, SCI STKE; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; Hudmon A, 2005, J CELL BIOL, V171, P537, DOI 10.1083/jcb.200505155; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Hutchins JRA, 2003, MOL BIOL CELL, V14, P4003, DOI 10.1091/mbc.E03-02-0061; Ivanina T, 2000, J BIOL CHEM, V275, P39846, DOI 10.1074/jbc.M005881200; JAHN H, 1988, EUR J BIOCHEM, V178, P535, DOI 10.1111/j.1432-1033.1988.tb14480.x; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; Kim J, 2004, NEURON, V41, P745, DOI 10.1016/S0896-6273(04)00081-9; KLEPPISCH T, 1994, EMBO J, V13, P2502, DOI 10.1002/j.1460-2075.1994.tb06538.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Markoulaki S, 2004, DEV BIOL, V272, P15, DOI 10.1016/j.ydbio.2004.04.008; MCCARRON JG, 1992, NATURE, V357, P74, DOI 10.1038/357074a0; Moosmang S, 2003, EMBO J, V22, P6027, DOI 10.1093/emboj/cdg583; NOBLE S, 1981, J PHYSIOL-LONDON, V310, P57, DOI 10.1113/jphysiol.1981.sp013537; NOBLE S, 1981, J PHYSIOL-LONDON, V310, P77, DOI 10.1113/jphysiol.1981.sp013538; O-Uchi J, 2005, P NATL ACAD SCI USA, V102, P9400, DOI 10.1073/pnas.0503569102; Pate P, 2000, J BIOL CHEM, V275, P39786, DOI 10.1074/jbc.M007158200; Peterson BZ, 2000, BIOPHYS J, V78, P1906, DOI 10.1016/S0006-3495(00)76739-7; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; PIETROBON D, 1990, NATURE, V346, P651, DOI 10.1038/346651a0; Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; SEISENBERGER C, 1995, N-S ARCH PHARMACOL, V352, P662; Soderling TR, 1996, BBA-PROTEIN STRUCT M, V1297, P131, DOI 10.1016/S0167-4838(96)00105-7; Soderling TR, 2001, J BIOL CHEM, V276, P3719, DOI 10.1074/jbc.R000013200; Tang W, 2003, BIOPHYS J, V85, P1538, DOI 10.1016/S0006-3495(03)74586-X; Van Petegem F, 2005, NAT STRUCT MOL BIOL, V12, P1108, DOI 10.1038/nsmb1027; Welling A, 1997, CIRC RES, V81, P526, DOI 10.1161/01.RES.81.4.526; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; Wu YJ, 2001, J PHYSIOL-LONDON, V535, P679, DOI 10.1111/j.1469-7793.2001.t01-1-00679.x; XIAO RP, 1994, P NATL ACAD SCI USA, V91, P9659, DOI 10.1073/pnas.91.20.9659; YUAN WL, 1994, AM J PHYSIOL, V267, pH982, DOI 10.1152/ajpheart.1994.267.3.H982; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301; Zuhlke RD, 2000, J BIOL CHEM, V275, P21121, DOI 10.1074/jbc.M002986200; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	57	91	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25560	25567		10.1074/jbc.M508661200	http://dx.doi.org/10.1074/jbc.M508661200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16820363	hybrid			2022-12-25	WOS:000240031300059
J	Yu, JZ; Rasenick, MM				Yu, Jiang-Zhou; Rasenick, Mark M.			Tau associates with actin in differentiating PC12 cells	FASEB JOURNAL			English	Article						microtubule-associated protein; cytoskeleton; growth cone; nerve growth factor; neurite outgrowth and tubulin	MICROTUBULE-ASSOCIATED PROTEINS; NERVE GROWTH-FACTOR; FILAMENTS; PHOSPHORYLATION; LOCALIZATION; BINDING; DOMAIN; CONES; INHIBITION; INTERACTS	The microtubule-associated protein tau may be involved in cell morphogenesis and axonal maintenance. In addition to microtubules, tau has been shown to interact with actin in vitro. In the present study interaction of tau and actin was investigated in PC12 cells. No interaction between tau and actin was observed without NGF treatment. Under NGF stimulation, tau distributed at ends of cellular extensions, where it associated with actin in a microtubule-independent manner. F-actin disruption revealed that relocalization and assembly of F-actin at the ends of cellular extensions were necessary for NGF-induced tau reorganization and association with actin. A truncated tau-GFP (tau(1-186)-GFP, N-terminal of tau) did not associate with actin. However, tau23(174-352)-GFP (carboxyl-terminal of Tau23) did associate with actin and the requirement for NGF was lost. Nevertheless, NGF boosted tau23(174-352)-GFP interaction with actin and promoted colocalization at the ends of cellular extensions. This suggests that the C-terminal of tau is required for associating with actin and the tau N-terminal may play a regulatory role in this process. A possible role for tau-actin interaction in neurite outgrowth is postulated.	Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Psychiat, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Yu, JZ (corresponding author), Univ Illinois, Coll Med, Dept Physiol & Biophys, 835 S Wolcott Ave MC 901, Chicago, IL 60612 USA.	yujz64@uic.edu; raz@uic.edu			NIA NIH HHS [AG 15482] Funding Source: Medline; NIMH NIH HHS [MH 39595, MH57391] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039595, R01MH057391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015482] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARREGUI CO, 1994, J NEUROSCI, V14, P6967; Biernat J, 1999, MOL BIOL CELL, V10, P727, DOI 10.1091/mbc.10.3.727; Black MM, 1996, J NEUROSCI, V16, P3601; BRANDT R, 1995, J CELL BIOL, V131, P1327, DOI 10.1083/jcb.131.5.1327; Bunker JM, 2004, MOL BIOL CELL, V15, P2720, DOI 10.1091/mbc.E04-01-0062; CORREAS I, 1990, BIOCHEM J, V269, P61, DOI 10.1042/bj2690061; CROSS D, 1993, J CELL SCI, V105, P51; Dawson HN, 2001, J CELL SCI, V114, P1179; DITELLA M, 1994, CELL MOTIL CYTOSKEL, V29, P117, DOI 10.1002/cm.970290204; DRUBIN D, 1988, J CELL BIOL, V106, P1583, DOI 10.1083/jcb.106.5.1583; DRUBIN DG, 1985, J CELL BIOL, V101, P1799, DOI 10.1083/jcb.101.5.1799; Farias GA, 2002, J CELL BIOCHEM, V85, P315, DOI 10.1002/jcb.10133; FERREIRA A, 1989, DEV BRAIN RES, V49, P215, DOI 10.1016/0165-3806(89)90023-0; GRIFFITH LM, 1982, J BIOL CHEM, V257, P9143; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; Hashiguchi M, 2000, J BIOL CHEM, V275, P25247, DOI 10.1074/jbc.M003738200; Hely TA, 1998, P ROY SOC B-BIOL SCI, V265, P1801, DOI 10.1098/rspb.1998.0505; HOSHI M, 1987, FEBS LETT, V217, P237, DOI 10.1016/0014-5793(87)80670-1; Jenkins SM, 1998, NEUROREPORT, V9, P67, DOI 10.1097/00001756-199801050-00014; Kempf M, 1996, J NEUROSCI, V16, P5583; Lee G, 1998, J CELL SCI, V111, P3167; LEGER JG, 1994, J CELL SCI, V107, P3403; LESSARD JL, 1988, CELL MOTIL CYTOSKEL, V10, P349, DOI 10.1002/cm.970100302; Lohse K, 1996, DEV BRAIN RES, V96, P83, DOI 10.1016/0165-3806(96)00076-4; LOPRESTI P, 1995, P NATL ACAD SCI USA, V92, P10369, DOI 10.1073/pnas.92.22.10369; Maas T, 2000, J BIOL CHEM, V275, P15733, DOI 10.1074/jbc.M000389200; MORAGA DM, 1993, J NEUROCHEM, V61, P979, DOI 10.1111/j.1471-4159.1993.tb03611.x; PAVES H, 1990, EXP CELL RES, V186, P218, DOI 10.1016/0014-4827(90)90299-P; Pigino G, 2003, J NEUROSCI, V23, P4499; Planel E, 2001, J BIOL CHEM, V276, P34298, DOI 10.1074/jbc.M102780200; Posern G, 2000, J CELL PHYSIOL, V183, P416, DOI 10.1002/(SICI)1097-4652(200006)183:3<416::AID-JCP15>3.0.CO;2-R; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Roger B, 2004, CURR BIOL, V14, P363, DOI 10.1016/j.cub.2004.01.058; Samsonov A, 2004, J CELL SCI, V117, P6129, DOI 10.1242/jcs.01531; SCHOENFELD TA, 1994, INT REV CYTOL, V151, P67, DOI 10.1016/S0074-7696(08)62631-5; SELDEN SC, 1983, J BIOL CHEM, V258, P7064; SELDEN SC, 1986, ANN NY ACAD SCI, V466, P803, DOI 10.1111/j.1749-6632.1986.tb38464.x; TISCHLER AS, 1983, CELL TISSUE RES, V228, P641; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; YAMAUCHI PS, 1993, BIOCHEM BIOPH RES CO, V190, P710, DOI 10.1006/bbrc.1993.1107; Yu JZ, 2002, J NEUROSCI RES, V67, P625, DOI 10.1002/jnr.10152; Zmuda JF, 2000, J CELL SCI, V113, P2797	42	45	45	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1452	1461		10.1096/fj.05-5206com	http://dx.doi.org/10.1096/fj.05-5206com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816120				2022-12-25	WOS:000240266000022
J	Raafat, A; Zoltan-Jones, A; Strizzi, L; Bargo, S; Kimura, K; Salomon, D; Callahan, R				Raafat, A.; Zoltan-Jones, A.; Strizzi, L.; Bargo, S.; Kimura, K.; Salomon, D.; Callahan, R.			Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis	ONCOGENE			English	Article						Kit; PDGFR-alpha; Notch4/Int3; Gleevec; phosphorylation; siRNA	GASTROINTESTINAL STROMAL TUMORS; TRUNCATED INT3 GENE; C-KIT; GROWTH-FACTOR; NEOPLASTIC TRANSFORMATION; ENDOTHELIAL-CELLS; BREAST-CANCER; MOUSE MODEL; STEM-CELLS; MAMMARY	Transgenic mice overexpressing Notch4 intracellular domain (Int3) under the control of the whey acidic protein (WAP) or mouse mammary tumor virus-long terminal repeat promoters, develop mammary tumors. Microarray analysis of these tumors revealed high levels of c-Kit expression. Gleevec is a tyrosine kinase inhibitor that targets c-Kit, platelet-derived growth factor receptors (PDGFRs) and c-Abl. This led us to speculate that tyrosine kinase receptor activity might be a driving force in the development of Int3 mammary tumors. WAP-Int3 tumor-bearing mice were treated with continuous release of Gleevec using subcutaneously implanted Alzet pumps. Phoshorylation of c-Kit, PDGFRs and c-Abl is inhibited in Int3 transgenic mammary tumors by Gleevec. Inhibition of these enzymes is associated with a decrease in cell proliferation and angiogenesis, and an induction of apoptosis. To examine the signaling mechanisms underlying Notch4/Int3 tumorigenesis, we employed small interfering RNA (siRNA) to knock down c-Kit, PDGFRs and c-Abl alone or in combination and observed the effects on soft agar growth of HC11 cells overexpressing Int3. Only siRNA constructs for c-Kit and/or PDGFR-alpha were able to inhibit HC11-Int3colony formation in soft agar. Our data demonstrate an inhibitory effect of Gleevec on Int3-induced transformation of HC11 cells and mammary tumors and indicate an oncogenic role for c-Kit and PDGFR-alpha tyrosine kinases in the context of Int3 signaling.	NCI, Mammary Biol & Tumorigenesis Lab, Oncogenet Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Callahan, R (corresponding author), NCI, Mammary Biol & Tumorigenesis Lab, Oncogenet Sect, NIH, 37 Convent Dr,Bldg 37,Rm 1118A, Bethesda, MD 20892 USA.	rc54d@nih.gov						Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Basciani S, 2005, CANCER RES, V65, P1897, DOI 10.1158/0008-5472.CAN-04-2181; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Betsholtz Christer, 2003, Birth Defects Research, V69, P272, DOI 10.1002/bdrc.10030; Callahan R, 2001, J MAMMARY GLAND BIOL, V6, P23, DOI 10.1023/A:1009512414430; Chiaramonte R, 2005, CANCER LETT, V219, P113, DOI 10.1016/j.canlet.2004.07.022; Cortes J, 2004, BLOOD, V104, P2204, DOI 10.1182/blood-2004-04-1335; Dang TP, 2000, J NATL CANCER I, V92, P1355, DOI 10.1093/jnci/92.16.1355; Dang TP, 2003, ONCOGENE, V22, P1988, DOI 10.1038/sj.onc.1206230; Das AV, 2004, DEV BIOL, V273, P87, DOI 10.1016/j.ydbio.2004.05.023; De Jong JS, 1998, J PATHOL, V184, P44; Diallo R, 2006, HUM PATHOL, V37, P205, DOI 10.1016/j.humpath.2005.10.015; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Gallahan D, 1996, CANCER RES, V56, P1775; GALLAHAN D, 1987, J VIROL, V61, P218, DOI 10.1128/JVI.61.1.218-220.1987; Ghatak S, 2002, J BIOL CHEM, V277, P38013, DOI 10.1074/jbc.M202404200; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Hwang RF, 2003, CLIN CANCER RES, V9, P6534; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Kim MK, 2000, APPL IMMUNOHISTO M M, V8, P147, DOI 10.1097/00022744-200006000-00009; Lasota J, 1999, AM J PATHOL, V154, P53, DOI 10.1016/S0002-9440(10)65250-9; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Marley SB, 2005, CLIN SCI, V109, P13, DOI 10.1042/CS20040336; Matsui J, 2004, J BIOL CHEM, V279, P18600, DOI 10.1074/jbc.M311643200; Noseda M, 2004, CIRC RES, V94, P910, DOI 10.1161/01.RES.0000124300.76171.C9; Pear WS, 2004, CURR OPIN HEMATOL, V11, P426, DOI 10.1097/01.moh.0000143965.90813.70; Raafat A, 2004, ONCOGENE, V23, P9401, DOI 10.1038/sj.onc.1208187; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; SMITH GH, 1995, CELL GROWTH DIFFER, V6, P563; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Taniguchi M, 1999, CANCER RES, V59, P4297; Tsuda H, 2005, CANCER SCI, V96, P333, DOI 10.1111/j.1349-7006.2005.00060.x; Tsuda H, 2005, CANCER SCI, V96, P48, DOI 10.1111/j.1349-7006.2005.00009.x; Uehara H, 2003, J NATL CANCER I, V95, P458, DOI 10.1093/jnci/95.6.458; Ulivi P, 2004, BREAST CANCER RES TR, V83, P33, DOI 10.1023/B:BREA.0000010694.35023.9e; VARVALHO I, 2005, BREAST CANCER RES, V7, pR788; Wang DG, 1999, CANCER RES, V59, P1464; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754	46	14	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					662	672		10.1038/sj.onc.1209823	http://dx.doi.org/10.1038/sj.onc.1209823			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16878155				2022-12-25	WOS:000243902200004
J	Theocharis, AD; Seidel, C; Borset, M; Dobra, K; Baykov, V; Labropoulou, V; Kanakis, I; Dalas, E; Karamanos, NK; Sundan, A; Hjerpe, A				Theocharis, Achilleas D.; Seidel, Carina; Borset, Magne; Dobra, Katalin; Baykov, Vadim; Labropoulou, Vassiliki; Kanakis, Ioannis; Dalas, Evangelos; Karamanos, Nikos K.; Sundan, Anders; Hjerpe, Anders			Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; HYDROXYAPATITE CRYSTAL-GROWTH; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING; MULTIPLE-MYELOMA; BINDING; GRANULE; SURFACE; MATRIX-METALLOPROTEINASE-9; SYNDECAN-1	Although the biological significance of proteoglycans (PGs) has previously been highlighted in multiple myeloma (MM), little is known about serglycin, which is a hematopoietic cell granule PG. In this study, we describe the expression and highly constitutive secretion of serglycin in several MM cell lines. Serglycin messenger RNA was detected in six MM cell lines. PGs were purified from conditioned medium of four MM cell lines, and serglycin substituted with 4-sulfated chondroitin sulfate was identified as the predominant PG. Flow cytometry and confocal microscopy showed that serglycin was also present intracellularly and on the cell surface, and attachment to the cell surface was at least in part dependent on intact glycosaminoglycan side chains. Immunohistochemical staining of bone marrow biopsies showed the presence of serglycin both in benign and malignant plasma cells. Immunoblotting in bone marrow aspirates from a limited number of patients with newly diagnosed MM revealed highly increased levels of serglycin in 30% of the cases. Serglycin isolated from myeloma plasma cells was found to influence the bone mineralization process through inhibition of the crystal growth rate of hydroxyapatite. This rate reduction was attributed to adsorption and further blocking of the active growth sites on the crystal surface. The apparent order of the crystallization reaction was found to be n = 2, suggesting a surface diffusion-controlled spiral growth mechanism. Our findings suggest that serglycin release is a constitutive process, which may be of fundamental biological importance in the study of MM.	Univ Patras, Dept Chem, Biochem Lab, Patras 26500, Greece; F46 Huddinge Univ Hosp, Dept Lab Med, Div Pathol, Karolinska Inst, SE-14186 Stockholm, Sweden; Norwegian Univ Sci & Technol, Inst Canc Res & Mol Med, N-7489 Trondheim, Norway; Univ Hosp Patras, Dept Internal Med, Patras 26500, Greece; Univ Patras, Chem Phys Lab, Dept Chem, Patras 26500, Greece	University of Patras; Karolinska Institutet; Norwegian University of Science & Technology (NTNU); University of Patras; University of Patras	Seidel, C (corresponding author), Univ Patras, Dept Chem, Biochem Lab, Patras 26500, Greece.	atheoch@upatras.gr; Carina.Seidel@dll.se	Kanakis, Ioannis/E-3206-2018; Karamanos, Nikos/A-3616-2008; Borset, Magne/AAY-1713-2021; theocharis, achilleas/F-6903-2010; Kanakis, Ioannis/N-7874-2019	Kanakis, Ioannis/0000-0001-6410-1482; Karamanos, Nikos/0000-0003-3618-0288; Kanakis, Ioannis/0000-0001-6410-1482; Theocharis, Achilleas/0000-0001-8611-2297; Borset, Magne/0000-0001-5179-2835				Abecassis I, 2003, EXP CELL RES, V291, P363, DOI 10.1016/j.yexcr.2003.08.006; Abrink M, 2004, J BIOL CHEM, V279, P40897, DOI 10.1074/jbc.M405856200; AVRAHAM S, 1989, P NATL ACAD SCI USA, V86, P3763, DOI 10.1073/pnas.86.10.3763; Biederbick A, 2003, EUR J CELL BIOL, V82, P19, DOI 10.1078/0171-9335-00287; BORSET M, 1994, EUR J HAEMATOL, V53, P31; BOURDON MA, 1985, P NATL ACAD SCI USA, V82, P1321, DOI 10.1073/pnas.82.5.1321; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; Brenne AT, 2002, BLOOD, V99, P3756, DOI 10.1182/blood.V99.10.3756; Cowland JB, 1999, J LEUKOCYTE BIOL, V66, P989, DOI 10.1002/jlb.66.6.989; Derksen PWB, 2002, BLOOD, V99, P1405, DOI 10.1182/blood.V99.4.1405; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; Grujic M, 2005, J BIOL CHEM, V280, P33411, DOI 10.1074/jbc.M501708200; Heider U, 2005, BIOCHEM BIOPH RES CO, V338, P687, DOI 10.1016/j.bbrc.2005.09.146; Ho HCK, 2001, BIOL REPROD, V64, P1667, DOI 10.1095/biolreprod64.6.1667; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Jiang HD, 2005, J BIOL CHEM, V280, P42061, DOI 10.1074/jbc.M412280200; Karamanos N K, 2001, Methods Mol Biol, V171, P181; Kolset SO, 1996, J LEUKOCYTE BIOL, V59, P545, DOI 10.1002/jlb.59.4.545; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; Koutsopoulos S, 2000, LANGMUIR, V16, P6745, DOI 10.1021/la000070j; KOUTSOUKOS P, 1980, J AM CHEM SOC, V102, P1553, DOI 10.1021/ja00525a015; LEVITT D, 1989, CELL IMMUNOL, V98, P78; Manes S, 1999, J BIOL CHEM, V274, P6935, DOI 10.1074/jbc.274.11.6935; Nancollas GH., 1989, BIOMINERALISATION, P156; OLDBERG A, 1981, J BIOL CHEM, V256, P847; Olson MW, 1998, J BIOL CHEM, V273, P10672, DOI 10.1074/jbc.273.17.10672; Oshima T, 2005, BLOOD, V106, P3160, DOI 10.1182/blood-2004-12-4940; PASCHALAKIS P, 1993, BIOCHIM BIOPHYS ACTA, V1158, P129, DOI 10.1016/0304-4165(93)90006-T; Raja SM, 2005, J BIOL CHEM, V280, P20752, DOI 10.1074/jbc.M501181200; Rees SG, 2002, BIOCHEM BIOPH RES CO, V292, P727, DOI 10.1006/bbrc.2002.6699; RIDLEY RC, 1993, BLOOD, V81, P767; SALI A, 1993, J BIOL CHEM, V268, P9023; SANDERSON RD, 1992, J IMMUNOL, V148, P3902; SCHICK BP, 1995, J CELL PHYSIOL, V165, P96, DOI 10.1002/jcp.1041650113; Schick BP, 2003, BBA-MOL CELL RES, V1593, P259, DOI 10.1016/S0167-4889(02)00396-8; SCHICK BP, 1988, J BIOL CHEM, V263, P1052; SCHICK BP, 1992, BIOCHEM J, V282, P651, DOI 10.1042/bj2820651; Schick BP, 2001, BLOOD, V97, P449, DOI 10.1182/blood.V97.2.449; Schick BP, 1997, J CELL PHYSIOL, V172, P87, DOI 10.1002/(SICI)1097-4652(199707)172:1<87::AID-JCP10>3.0.CO;2-L; Seidel C, 2000, BLOOD, V96, P3139, DOI 10.1182/blood.V96.9.3139.h8003139_3139_3146; Standal T, 2002, BLOOD, V100, P3002, DOI 10.1182/blood-2002-04-1190; Tanaka Y, 1993, Curr Top Microbiol Immunol, V184, P99; Theocharis AD, 2002, BBA-MOL BASIS DIS, V1588, P165, DOI 10.1016/S0925-4439(02)00161-8; ToyamaSorimachi N, 1997, J BIOL CHEM, V272, P26714, DOI 10.1074/jbc.272.42.26714; TOYAMASORIMACHI N, 1995, J BIOL CHEM, V270, P7437, DOI 10.1074/jbc.270.13.7437; Wijdenes J, 1996, BRIT J HAEMATOL, V94, P318, DOI 10.1046/j.1365-2141.1996.d01-1811.x; Winberg JO, 2000, J MOL BIOL, V304, P669, DOI 10.1006/jmbi.2000.4235; Yang Y, 2003, J BIOL CHEM, V278, P12888, DOI 10.1074/jbc.M209440200; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35	50	75	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35116	35128		10.1074/jbc.M601061200	http://dx.doi.org/10.1074/jbc.M601061200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16870619	hybrid			2022-12-25	WOS:000241933700045
J	Dorfman, T; Moore, MJ; Guth, AC; Choe, H; Farzan, M				Dorfman, Tatyana; Moore, Michael J.; Guth, Alexander C.; Choe, Hyeryun; Farzan, Michael			A tyrosine-sulfated peptide derived from the heavy-chain CDR3 region of an HIV-1-neutralizing antibody binds gp120 and inhibits HIV-1 infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; AMINO-TERMINAL DOMAIN; CHEMOKINE RECEPTORS; ENVELOPE GLYCOPROTEIN; CORECEPTOR USAGE; DISTINCT CCR5; N-TERMINUS; ENTRY; MACROPHAGE; RESIDUES	Sulfated tyrosines at the amino terminus of the principal HIV-1 coreceptor CCR5 play a critical role in its ability to bind the HIV-1 envelope glycoprotein gp120 and mediate HIV-1 entry. Human antibodies that recognize the CCR5-binding region of gp120 are also modified by tyrosine sulfation, which is necessary for their ability to neutralize HIV-1. Here we demonstrate that a sulfated peptide derived from the CDR3 region of one of these antibodies, E51, can efficiently bind gp120. Association of this peptide, pE51, with gp120 requires tyrosine sulfation and is enhanced by, but not dependent on, CD4. Alteration of any of four pE51 tyrosines, or alteration of gp120 residues 420, 421, or 422, critical for association with CCR5, prevents gp120 association with pE51. pE51 neutralizes HIV-1 more effectively than peptides based on the CCR5 amino terminus and may be useful as a fusion partner with other protein inhibitors of HIV-1 entry. Our data provide further insight into the association of the CCR5 amino terminus with gp120, show that a conserved, sulfate-binding region of gp120 is accessible to inhibitors in the absence of CD4, and suggest that soluble mimetics of CCR5 can be more effective than previously appreciated.	Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Dept Microbiol & Mol Genet, Southborough, MA 01772 USA; Harvard Univ, Sch Med, Childrens Hosp, Div Pulm, Boston, MA 02115 USA	Harvard University; Harvard University; Boston Children's Hospital; Harvard Medical School	Farzan, M (corresponding author), Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Dept Microbiol & Mol Genet, 1 Pine Hill Dr, Southborough, MA 01772 USA.	farzan@hms.harvard.edu		Farzan, Michael/0000-0002-2990-5319	NIAID NIH HHS [R01 AI043891] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043891] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571; Blanpain C, 1999, J BIOL CHEM, V274, P34719, DOI 10.1074/jbc.274.49.34719; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Choe H, 2003, CELL, V114, P161, DOI 10.1016/S0092-8674(03)00508-7; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Cormier EG, 2000, P NATL ACAD SCI USA, V97, P5762, DOI 10.1073/pnas.97.11.5762; Cormier EG, 2001, J VIROL, V75, P5541, DOI 10.1128/JVI.75.12.5541-5549.2001; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Doranz BJ, 1997, J VIROL, V71, P6305, DOI 10.1128/JVI.71.9.6305-6314.1997; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648; Farzan M, 2000, J BIOL CHEM, V275, P33516, DOI 10.1074/jbc.M007228200; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Farzan M, 2002, J BIOL CHEM, V277, P29484, DOI 10.1074/jbc.M203361200; Farzan M, 2002, J BIOL CHEM, V277, P40397, DOI 10.1074/jbc.M206784200; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; Farzan M, 2001, J EXP MED, V193, P1059, DOI 10.1084/jem.193.9.1059; Farzan M, 1998, J VIROL, V72, P1160, DOI 10.1128/JVI.72.2.1160-1164.1998; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Huang CC, 2004, P NATL ACAD SCI USA, V101, P2706, DOI 10.1073/pnas.0308527100; Lu ZH, 1997, P NATL ACAD SCI USA, V94, P6426, DOI 10.1073/pnas.94.12.6426; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; Picard L, 1997, VIROLOGY, V231, P105, DOI 10.1006/viro.1997.8506; Poignard P, 2001, ANNU REV IMMUNOL, V19, P253, DOI 10.1146/annurev.immunol.19.1.253; Rabut GEE, 1998, J VIROL, V72, P3464, DOI 10.1128/JVI.72.4.3464-3468.1998; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; ROBEN P, 1994, J VIROL, V68, P4821, DOI 10.1128/JVI.68.8.4821-4828.1994; Ross TM, 1998, J VIROL, V72, P1918, DOI 10.1128/JVI.72.3.1918-1924.1998; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Sullivan N, 1998, J VIROL, V72, P4694, DOI 10.1128/JVI.72.6.4694-4703.1998; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001	42	54	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28529	28535		10.1074/jbc.M602732200	http://dx.doi.org/10.1074/jbc.M602732200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16849323	hybrid			2022-12-25	WOS:000240680500006
J	Shenton, D; Smirnova, JB; Selley, JN; Carroll, K; Hubbard, SJ; Pavitt, GD; Ashe, MP; Grant, CM				Shenton, Daniel; Smirnova, Julia B.; Selley, Julian N.; Carroll, Kathleen; Hubbard, Simon J.; Pavitt, Graham D.; Ashe, Mark P.; Grant, Chris M.			Global translational responses to oxidative stress impact upon multiple levels of protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TRANSLATION; GENE-EXPRESSION; YEAST-CELLS; ACID; GLUTATHIONE; ELONGATION; INITIATION; HYDROPEROXIDE; RESISTANCE; EIF2	Global inhibition of protein synthesis is a common response to stress conditions. We have analyzed the regulation of protein synthesis in response to oxidative stress induced by exposure to H2O2 in the yeast Saccharomyces cerevisiae. Our data show that H2O2 causes an inhibition of translation initiation dependent on the Gcn2 protein kinase, which phosphorylates the alpha-subunit of eukaryotic initiation factor-2. Additionally, our data indicate that translation is regulated in a Gcn2-independent manner because protein synthesis was still inhibited in response to H2O2 in a gcn2 mutant. Polysome analysis indicated that H2O2 causes a slower rate of ribosomal runoff, consistent with an inhibitory effect on translation elongation or termination. Furthermore, analysis of ribosomal transit times indicated that oxidative stress increases the average mRNA transit time, confirming a post-initiation inhibition of translation. Using microarray analysis of polysome- and monosome-associated mRNA pools, we demonstrate that certain mRNAs, including mRNAs encoding stress protective molecules, increase in association with ribosomes following H2O2 stress. For some candidate mRNAs, we show that a low concentration of H2O2 results in increased protein production. In contrast, a high concentration of H2O2 promotes polyribosome association but does not necessarily lead to increased protein production. We suggest that these mRNAs may represent an mRNA store that could become rapidly activated following relief of the stress condition. In summary, oxidative stress elicits complex translational reprogramming that is fundamental for adaptation to the stress.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Grant, CM (corresponding author), Univ Manchester, Fac Life Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	chris.grant@manchester.ac.uk	Pavitt, Graham D/A-1363-2010; Hubbard, Simon J/B-9006-2009	Pavitt, Graham D/0000-0002-8593-2418; Cain, Kathleen/0000-0002-1446-5170; Grant, Chris/0000-0002-0616-6576; Selley, Julian/0000-0003-4618-6691; Hubbard, Simon/0000-0002-8601-9524	Biotechnology and Biological Sciences Research Council [C20436] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Ashe MP, 2000, MOL BIOL CELL, V11, P833, DOI 10.1091/mbc.11.3.833; Avery AM, 2001, J BIOL CHEM, V276, P33730, DOI 10.1074/jbc.M105672200; Ayala A, 1996, J BIOL CHEM, V271, P23105, DOI 10.1074/jbc.271.38.23105; Beilharz Traude H., 2004, Briefings in Functional Genomics & Proteomics, V3, P103, DOI 10.1093/bfgp/3.2.103; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Biteau B, 2003, NATURE, V425, P980, DOI 10.1038/nature02075; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Cherkasova VA, 2003, GENE DEV, V17, P859, DOI 10.1101/gad.1069003; Clemens MJ, 2001, PROG MOLEC, V27, P57; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Ding QX, 2005, J NEUROSCI, V25, P9171, DOI 10.1523/JNEUROSCI.3040-05.2005; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gasch Audrey P, 2002, Funct Integr Genomics, V2, P181, DOI 10.1007/s10142-002-0058-2; Grant CM, 1996, CURR GENET, V29, P511, DOI 10.1007/BF02426954; Grant CM, 1997, FEBS LETT, V410, P219, DOI 10.1016/S0014-5793(97)00592-9; GUTTERIDGE JMC, 1993, FREE RADICAL RES COM, V19, P141, DOI 10.3109/10715769309111598; HALLIWELL B, 1991, AM J MED S3C, V91, P14, DOI DOI 10.1016/0002-9343(91)90279-7; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hinnebusch AG, 2005, ANNU REV MICROBIOL, V59, P407, DOI 10.1146/annurev.micro.59.031805.133833; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; Holmes LEA, 2004, MOL CELL BIOL, V24, P2998, DOI 10.1128/MCB.24.7.2998-3010.2004; Honda K, 2005, J BIOL CHEM, V280, P20978, DOI 10.1074/jbc.M500526200; Izawa S, 1996, BIOCHEM J, V320, P61, DOI 10.1042/bj3200061; Jorgensen P, 2004, GENE DEV, V18, P2491, DOI 10.1101/gad.1228804; Kapp LD, 2004, ANNU REV BIOCHEM, V73, P657, DOI 10.1146/annurev.biochem.73.030403.080419; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Lu PD, 2004, J CELL BIOL, V167, P27, DOI 10.1083/jcb.200408003; LUCCHINI G, 1984, MOL CELL BIOL, V4, P1326, DOI 10.1128/MCB.4.7.1326; MATHEWS MB, 2000, MONOGRAPH, V39, P1; Narasimhan J, 2004, J BIOL CHEM, V279, P22820, DOI 10.1074/jbc.M402228200; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; NIELSEN PJ, 1980, J CELL PHYSIOL, V104, P269, DOI 10.1002/jcp.1041040302; Patel J, 2002, EUR J BIOCHEM, V269, P3076, DOI 10.1046/j.1432-1033.2002.02992.x; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; Pohl A, 2005, BBA-MOL CELL BIOL L, V1733, P29, DOI 10.1016/j.bbalip.2004.12.007; Poljak A, 2003, REDOX REP, V8, P371, DOI 10.1179/135100003225003401; Preiss T, 2003, NAT STRUCT BIOL, V10, P1039, DOI 10.1038/nsb1015; Proud C, 2000, COLD SPRING HARBOR M, V39, P719; Proud CG, 2005, SEMIN CELL DEV BIOL, V16, P3, DOI 10.1016/j.semcdb.2004.11.004; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; ROPER MD, 1978, P NATL ACAD SCI USA, V75, P140, DOI 10.1073/pnas.75.1.140; Rudra D, 2004, GENE DEV, V18, P2431, DOI 10.1101/gad.1256704; Rutherford JC, 2003, J BIOL CHEM, V278, P27636, DOI 10.1074/jbc.M300076200; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Shenton D, 2003, BIOCHEM J, V374, P513, DOI 10.1042/BJ20030414; Sherman F., 1974, METHODS YEAST GENETI; Smirnova JB, 2005, MOL CELL BIOL, V25, P9340, DOI 10.1128/MCB.25.21.9340-9349.2005; Srinivasan C, 2000, J BIOL CHEM, V275, P29187, DOI 10.1074/jbc.M004239200; Stadtman ER, 2003, AMINO ACIDS, V25, P207, DOI 10.1007/s00726-003-0011-2; TAKAHASHI R, 1990, ARCH BIOCHEM BIOPHYS, V277, P228, DOI 10.1016/0003-9861(90)90573-H; Tanaka T, 2005, J BIOL CHEM, V280, P42078, DOI 10.1074/jbc.M508622200; Temple MD, 2005, TRENDS CELL BIOL, V15, P319, DOI 10.1016/j.tcb.2005.04.003; Tuite MF, 1998, METHOD MICROBIOL, V26, P351; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x	58	298	301	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29011	29021		10.1074/jbc.M601545200	http://dx.doi.org/10.1074/jbc.M601545200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16849329	hybrid			2022-12-25	WOS:000240680500056
J	Erdogan, E; Lamark, T; Stallings-Mann, M; Jamieson, L; Pellechia, M; Thompson, EA; Johansen, T; Fields, AP				Erdogan, Eda; Lamark, Trond; Stallings-Mann, Melody; Jamieson, Lee; Pellechia, Mauricio; Thompson, E. Aubrey; Johansen, Terje; Fields, Alan P.			Aurothiomalate inhibits transformed growth by targeting the PB1 domain of protein kinase C iota	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CELL-POLARITY; ATYPICAL PKC; PAR6; ZETA; LINKS; ACTIVATION; COMPLEX; DNA; OVEREXPRESSION	We recently identified the gold compound aurothiomalate (ATM) as a potent inhibitor of the Phox and Bem1p (PB1)-PB1 domain interaction between protein kinase C (PKC) iota and the adaptor molecule Par6. ATM also blocks oncogenic PKC iota signaling and the transformed growth of human lung cancer cells. Here we demonstrate that ATM is a highly selective inhibitor of PB1-PB1 domain interactions between PKC iota and the two adaptors Par6 and p62. ATM has no appreciable inhibitory effect on other PB1-PB1 domain interactions, including p62-p62, p62-NBR1, and MEKK3-MEK5 interactions. ATM can form thio-gold adducts with cysteine residues on target proteins. Interestingly, PKC iota (and PKC zeta) contains a unique cysteine residue, Cys-69, within its PB1 domain that is not present in other PB1 domain containing proteins. Cys-69 resides within the OPR, PC, and AID motif of PKC iota at the binding interface between PKC iota and Par6 where it interacts with Arg-28 on Par6. Molecular modeling predicts formation of a cysteinyl-aurothiomalate adduct at Cys-69 that protrudes into the binding cleft normally occupied by Par6, providing a plausible structural explanation for ATM inhibition. Mutation of Cys-69 of PKC iota to isoleucine or valine, residues frequently found at this position in other PB1 domains, has little or no effect on the affinity of PKC iota for Par6 but confers resistance to ATM-mediated inhibition of Par6 binding. Expression of the PKC iota C69I mutant in human non-small cell lung cancer cells confers resistance to the inhibitory effects of ATM on transformed growth. We conclude that ATM inhibits cellular transformation by selectively targeting Cys-69 within the PB1 domain of PKC iota.	Mayo Clin, Coll Med, Dept Canc Biol, Jacksonville, FL 32224 USA; Univ Tromso, Inst Med Biol, Dept Biochem, N-9037 Tromso, Norway; Burnham Inst, La Jolla, CA 92037 USA	Mayo Clinic; UiT The Arctic University of Tromso; Sanford Burnham Prebys Medical Discovery Institute	Fields, AP (corresponding author), Mayo Clin, Coll Med, Dept Canc Biol, 4500 San Pablo Rd,Griffin Canc Res Bldg,312, Jacksonville, FL 32224 USA.	fields.alan@mayo.edu	Johansen, Terje/N-2971-2015; Johansen, Terje/AAY-1753-2021	Johansen, Terje/0000-0003-1451-9578; Johansen, Terje/0000-0003-1451-9578; Stallings-Mann, Melody/0000-0003-3227-6063; Lamark, Trond/0000-0001-6338-3342				Balsara BR, 1997, CANCER RES, V57, P2116; Brass N, 1997, CANCER RES, V57, P2290; Bratt J, 2000, CLIN EXP IMMUNOL, V120, P79, DOI 10.1046/j.1365-2249.2000.01190.x; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Erdogan E, 2005, MOL BIOTECHNOL, V30, P21, DOI 10.1385/MB:30:1:021; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Grunicke HH, 2003, ADV ENZYME REGUL, V43, P213, DOI 10.1016/S0065-2571(02)00032-8; Hirano Y, 2005, J BIOL CHEM, V280, P9653, DOI 10.1074/jbc.M409823200; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Jeon KI, 2000, J IMMUNOL, V164, P5981, DOI 10.4049/jimmunol.164.11.5981; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Moscat J, 2001, ADV ENZYME REGUL, V41, P99, DOI 10.1016/S0065-2571(00)00009-1; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; Murray NR, 2004, J CELL BIOL, V164, P797, DOI 10.1083/jcb.200311011; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Noda Y, 2001, GENES CELLS, V6, P107, DOI 10.1046/j.1365-2443.2001.00404.x; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Rigobello MP, 2004, J INORG BIOCHEM, V98, P1634, DOI 10.1016/j.jinorgbio.2004.04.020; Sakurai A, 2004, J CELL PHYSIOL, V198, P22, DOI 10.1002/jcp.10377; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Smith AD, 1999, J NUTR, V129, P194, DOI 10.1093/jn/129.1.194; Stallings-Mann M, 2006, CANCER RES, V66, P1767, DOI 10.1158/0008-5472.CAN-05-3405; Suzuki A, 2003, J BIOCHEM, V133, P9, DOI 10.1093/jb/mvg018; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Verdonk ML, 2003, PROTEINS, V52, P609, DOI 10.1002/prot.10465; Wilson MI, 2003, MOL CELL, V12, P39, DOI 10.1016/S1097-2765(03)00246-6; Wooten MW, 2001, J BIOL CHEM, V276, P7709, DOI 10.1074/jbc.C000869200; Yamashita M, 2003, J PHARM PHARMACOL, V55, P245, DOI 10.1211/002235702513; YANG JP, 1995, FEBS LETT, V361, P89, DOI 10.1016/0014-5793(95)00157-5; Zhang L, 2006, CANCER RES, V66, P4627, DOI 10.1158/0008-5472.CAN-05-4527	43	88	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28450	28459		10.1074/jbc.M606054200	http://dx.doi.org/10.1074/jbc.M606054200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16861740	hybrid			2022-12-25	WOS:000240534400082
J	Wessels, E; Notebaart, RA; Duijsings, D; Lanke, K; Vergeer, B; Melchers, WJG; van Kuppeveld, FJM				Wessels, Els; Notebaart, Richard A.; Duijsings, Daniel; Lanke, Kjerstin; Vergeer, Bart; Melchers, Willem J. G.; van Kuppeveld, Frank J. M.			Structure-function analysis of the coxsackievirus protein 3A - Identification of residues important for dimerization, viral RNA replication, and transport inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE 3D(POL); HYDROPHOBIC DOMAIN; POLIOVIRUS; SECRETION; 2B; STIMULATION; DISSECTION; BINDING; GENOME	The coxsackievirus B3 3A protein forms homodimers and plays important roles in both viral RNA (vRNA) replication and the viral inhibition of intracellular protein transport. The molecular determinants that are required for each of these functions are yet poorly understood. Based on the NMR structure of the closely related poliovirus 3A protein, a molecular model of the coxsackievirus B3 3A protein was constructed. Using this structural model, specific mutants were designed to study the structure-function relationship of 3A. The mutants were tested for their capacity to dimerize, support vRNA replication, and block protein transport. A hydrophobic interaction between the monomers and an intermolecular salt bridge were identified as major determinants required for dimerization. We show that dimerization is important for both efficient vRNA replication and inhibition of protein transport. In addition, determinants were identified that were not required for dimerization but that were essential for either one of the biological functions of 3A. The combination of the in silico and in vivo results obtained in this study provides important insights in both the structural and functional aspects of 3A.	Univ Nijmegen, Radboud Med Ctr, Dept Med Microbiol, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Ctr Mol & Biomol Informat, NL-6500 GL Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	van Kuppeveld, FJM (corresponding author), Univ Nijmegen, Radboud Med Ctr, Dept Med Microbiol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	f.vankuppeveld@ncmls.ru.nl	Melchers, Willem/C-8819-2015; Notebaart, Richard/A-1459-2014	Melchers, Willem/0000-0002-5446-2230; van Kuppeveld, Frank/0000-0001-5800-749X; Duijsings, Daniel/0000-0001-5434-9038				BERNSTEIN HD, 1986, J VIROL, V60, P1040, DOI 10.1128/JVI.60.3.1040-1049.1986; CHINEA G, 1995, PROTEINS, V23, P415, DOI 10.1002/prot.340230315; Choe SS, 2005, VIROLOGY, V337, P18, DOI 10.1016/j.virol.2005.03.036; de Jong AS, 2002, J GEN VIROL, V83, P783, DOI 10.1099/0022-1317-83-4-783; Deitz SB, 2000, P NATL ACAD SCI USA, V97, P13790, DOI 10.1073/pnas.250483097; Dodd DA, 2001, J VIROL, V75, P8158, DOI 10.1128/JVI.75.17.8158-8165.2001; Doedens JR, 1997, J VIROL, V71, P9054, DOI 10.1128/JVI.71.12.9054-9064.1997; DOEDENS JR, 1995, EMBO J, V14, P894, DOI 10.1002/j.1460-2075.1995.tb07071.x; GIACHETTI C, 1992, J VIROL, V66, P6045, DOI 10.1128/JVI.66.10.6045-6057.1992; HARRIS KS, 1994, J BIOL CHEM, V269, P27004; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Hope DA, 1997, J VIROL, V71, P9490, DOI 10.1128/JVI.71.12.9490-9498.1997; Krieger E, 2002, PROTEINS, V47, P393, DOI 10.1002/prot.10104; LAMA J, 1994, J BIOL CHEM, V269, P66; Lyle JM, 2002, SCIENCE, V296, P2218, DOI 10.1126/science.1070585; MOLLA A, 1994, J BIOL CHEM, V269, P27015; Neznanov N, 2001, J VIROL, V75, P10409, DOI 10.1128/JVI.75.21.10409-10420.2001; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; PAUL AV, 1994, J BIOL CHEM, V269, P29173; PORTER AG, 1993, J VIROL, V67, P6917, DOI 10.1128/JVI.67.12.6917-6921.1993; Strauss DM, 2003, J MOL BIOL, V330, P225, DOI 10.1016/S0022-2836(03)00577-1; Towner JS, 1996, J BIOL CHEM, V271, P26810, DOI 10.1074/jbc.271.43.26810; van Ooij MJM, 2006, J GEN VIROL, V87, P103, DOI 10.1099/vir.0.81297-0; van Ooij MJM, 2006, J GEN VIROL, V87, P689, DOI 10.1099/vir.0.81558-0; VANKUPPEVELD FJM, 1995, J VIROL, V69, P7782, DOI 10.1128/JVI.69.12.7782-7790.1995; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wessels E, 2005, J VIROL, V79, P5163, DOI 10.1128/JVI.79.8.5163-5173.2005; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033; Xiang WK, 1995, RNA, V1, P892	29	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28232	28243		10.1074/jbc.M601122200	http://dx.doi.org/10.1074/jbc.M601122200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16867984	hybrid, Green Published			2022-12-25	WOS:000240534400061
J	Pizzo, E; Buonanno, P; Di Maro, A; Ponticelli, S; De Falco, S; Quarto, N; Cubellis, MV; D'Alessio, G				Pizzo, Elio; Buonanno, Pasquale; Di Maro, Antimo; Ponticelli, Salvatore; De Falco, Sandro; Quarto, Natalina; Cubellis, Maria Vittoria; D'Alessio, Giuseppe			Ribonucleases and angiogenins from fish	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; A SUPERFAMILY; INHIBITOR; RECOGNITION; PROTEINS; SEQUENCE; EMBRYO	For the first time fish RNases have been isolated and characterized. Their functional and structural properties indicate that they belong to the RNase A superfamily (or tetrapod RNase superfamily), now more appropriately described as the vertebrate RNase superfamily. Our findings suggest why previously repeated efforts to isolate RNases from fish tissues have met with no success; fish RNases have a very low ribonucleolytic activity, and their genes have a low sequence identity with those of mammalian RNases. The investigated RNases are from the bony fish Danio rerio ( or zebrafish). Their cDNAs have been cloned and expressed, and the three recombinant proteins have been purified to homogeneity. Their characterization has revealed that they have indeed a very low RNA-degrading activity, when compared with that of RNase A, the superfamily prototype, but comparable with that of mammalian angiogenins; that two of them have angiogenic activity that is inhibited by the cytosolic RNase inhibitor. These data and a phylogenetic analysis indicate that angiogenic fish RNases are the earliest diverging members of the vertebrate superfamily, suggesting that ribonucleases with angiogenic activity were the ancestors of all ribonucleases in the superfamily. They later evolved into both mammalian angiogenins and, through a successful phylogenesis, RNases endowed with digestive features or with diverse bioactivities.	Univ Naples Federico II, Dept Struct & Funct Biol, I-80126 Naples, Italy; Univ Naples 2, Dept Life Sci, I-81100 Caserta, Italy; CNR, Inst Genet & Biophys A Buzzati Traverso, I-80131 Naples, Italy	University of Naples Federico II; Universita della Campania Vanvitelli; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	D'Alessio, G (corresponding author), Univ Naples Federico II, Dept Struct & Funct Biol, Complesso MS Angelo,Via Cintia, I-80126 Naples, Italy.	dalessio@unina.it	De Falco, Sandro/P-6724-2015; Pizzo, Elio/Q-4722-2017	Pizzo, Elio/0000-0002-3652-8865; Di Maro, Antimo/0000-0002-9595-9665; cubellis, maria vittoria/0000-0001-6147-6553; De Falco, Sandro/0000-0002-6501-1697; Buonanno, Pasquale/0000-0001-7933-6209				Adams S A, 1999, Angiogenesis, V3, P189, DOI 10.1023/A:1009015512200; Beintema J.J., 1997, RIBONUCLEASES STRUCT, P245; Beintema JJ, 1998, CELL MOL LIFE SCI, V54, P825, DOI 10.1007/s000180050211; BLANK A, 1982, ANAL BIOCHEM, V120, P267, DOI 10.1016/0003-2697(82)90347-5; Childs S, 2002, DEVELOPMENT, V129, P973; Cho S, 2005, GENOMICS, V85, P208, DOI 10.1016/j.ygeno.2004.10.008; Cubellis MV, 2005, PROTEINS, V58, P880, DOI 10.1002/prot.20327; D'Alessio G., 1997, RIBONUCLEASES STRUCT, P383; D'Alessio Giuseppe, 1993, Trends in Cell Biology, V3, P106, DOI 10.1016/0962-8924(93)90166-X; Dickson KA, 2005, PROG NUCLEIC ACID RE, V80, P349, DOI 10.1016/S0079-6603(05)80009-1; Hofsteenge J., 1997, RIBONUCLEASES STRUCT, P621, DOI [10.1016/b978-012588945-2/50020-0, DOI 10.1016/B978-012588945-2/50020-0]; Hooper LV, 2003, NAT IMMUNOL, V4, P269, DOI 10.1038/ni888; Hu GF, 1997, P NATL ACAD SCI USA, V94, P2204, DOI 10.1073/pnas.94.6.2204; KANZAWA S, 1993, ANN PLAS SURG, V30, P244, DOI 10.1097/00000637-199303000-00008; Kelemen BR, 1999, NUCLEIC ACIDS RES, V27, P3696, DOI 10.1093/nar/27.18.3696; KNIGHTON D, 1977, BRIT J CANCER, V35, P347, DOI 10.1038/bjc.1977.49; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LAWLEY TJ, 1989, J INVEST DERMATOL, V93, pS59, DOI 10.1111/1523-1747.ep12581070; LEE FS, 1993, PROG NUCLEIC ACID RE, V44, P1, DOI 10.1016/S0079-6603(08)60215-9; MELO F, 1997, P INT C INTELL SYST, V5, P187; MOROIANU J, 1994, BIOCHEMISTRY-US, V33, P12535, DOI 10.1021/bi00208a001; Papageorgiou AC, 1997, EMBO J, V16, P5162, DOI 10.1093/emboj/16.17.5162; RIORDAN JF, 1997, RIBONUCLEASES STRUCT, P446; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Serbedzija G N, 1999, Angiogenesis, V3, P353, DOI 10.1023/A:1026598300052; SHAPIRO R, 1987, P NATL ACAD SCI USA, V86, P1573; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Staton CA, 2004, INT J EXP PATHOL, V85, P233, DOI 10.1111/j.0959-9673.2004.00396.x; Strydom DJ, 1998, CELL MOL LIFE SCI, V54, P811, DOI 10.1007/s000180050210; WU YN, 1995, J BIOL CHEM, V270, P17476, DOI 10.1074/jbc.270.29.17476; Xu ZP, 2003, BIOCHEMISTRY-US, V42, P121, DOI 10.1021/bi020465x	32	34	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27454	27460		10.1074/jbc.M605505200	http://dx.doi.org/10.1074/jbc.M605505200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16861230	hybrid			2022-12-25	WOS:000240397700072
J	Maklashina, E; Hellwig, P; Rothery, RA; Kotlyar, V; Sher, Y; Weiner, JH; Cecchini, G				Maklashina, Elena; Hellwig, Petra; Rothery, Richard A.; Kotlyar, Violetta; Sher, Yelizaveta; Weiner, Joel H.; Cecchini, Gary			Differences in protonation of ubiquinone and menaquinone in fumarate reductase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME BC(1) COMPLEX; SITE-DIRECTED MUTAGENESIS; FTIR SPECTROSCOPIC CHARACTERIZATION; ELECTRON-PARAMAGNETIC-RESONANCE; PHOTOSYNTHETIC REACTION CENTERS; QUINONE BINDING-SITES; SUCCINATE-DEHYDROGENASE; RHODOPSEUDOMONAS-VIRIDIS; PARACOCCUS-DENITRIFICANS; WOLINELLA-SUCCINOGENES	Escherichia coli quinol-fumarate reductase operates with both natural quinones, ubiquinone (UQ) and menaquinone (MQ), at a single quinone binding site. We have utilized a combination of mutagenesis, kinetic, EPR, and Fourier transform infrared methods to study the role of two residues, Lys-B228 and Glu-C29, at the quinol-fumarate reductase quinone binding site in reactions with MQ and UQ. The data demonstrate that LysB228 provides a strong hydrogen bond to MQ and is essential for reactions with both quinone types. Substitution of Glu-C29 with Leu and Phe caused a dramatic decrease in enzymatic reactions with MQ in agreement with previous studies, however, the succinate-UQ reductase reaction remains unaffected. Elimination of a negative charge in Glu-C29 mutant enzymes resulted in significantly increased stabilization of both UQ. and MQ(-.) semiquinones. The data presented here suggest similar hydrogen bonding of the C1 carbonyl of both MQ and UQ, whereas there is different hydrogen bonding for their C4 carbonyls. The differences are shown by a single point mutation of Glu-C29, which transforms the enzyme from one that is predominantly a menaquinol-fumarate reductase to one that is essentially only functional as a succinate-ubiquinone reductase. These findings represent an example of how enzymes that are designed to accommodate either UQ or MQ at a single Q binding site may nevertheless develop sufficient plasticity at the binding pocket to react differently with MQ and UQ.	Vet Affairs Med Ctr, Div Mol Biol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Goethe Univ Frankfurt, Inst Biophys, D-60438 Frankfurt, Germany; Univ Alberta, Dept Biochem, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; Goethe University Frankfurt; University of Alberta	Cecchini, G (corresponding author), Vet Affairs Med Ctr, Div Mol Biol, 4150 Clement St,151-S, San Francisco, CA 94121 USA.	Gary.Cecchini@ucsf.edu		Rothery, Richard/0000-0003-3265-1783; hellwig, petra/0000-0001-6294-5163	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061606] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61606] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramson J, 2000, NAT STRUCT BIOL, V7, P910; Baymann F, 1999, BIOCHEMISTRY-US, V38, P13188, DOI 10.1021/bi990565b; Berry EA, 2003, FEBS LETT, V555, P13, DOI 10.1016/S0014-5793(03)01099-8; Bertero MG, 2003, NAT STRUCT BIOL, V10, P681, DOI 10.1038/nsb969; BRETON J, 1994, BIOCHEMISTRY-US, V33, P4953, DOI 10.1021/bi00182a026; BRETON J, 1994, BIOCHEMISTRY-US, V33, P14378, DOI 10.1021/bi00252a002; Brondijk THC, 2002, MOL MICROBIOL, V44, P245, DOI 10.1046/j.1365-2958.2002.02875.x; BUCHANAN S, 1992, BIOCHEMISTRY-US, V31, P1314, DOI 10.1021/bi00120a006; CAMMACK R, 1986, BIOCHIM BIOPHYS ACTA, V870, P545, DOI 10.1016/0167-4838(86)90264-5; Cecchini G, 2003, ANNU REV BIOCHEM, V72, P77, DOI 10.1146/annurev.biochem.72.121801.161700; Cecchini G, 2002, BBA-BIOENERGETICS, V1553, P140, DOI 10.1016/S0005-2728(01)00238-9; COLLINS MD, 1981, MICROBIOL REV, V45, P316, DOI 10.1128/MMBR.45.2.316-354.1981; CONDON C, 1988, MOL MICROBIOL, V2, P43, DOI 10.1111/j.1365-2958.1988.tb00005.x; Crofts AR, 2004, ANNU REV PHYSIOL, V66, P689, DOI 10.1146/annurev.physiol.66.032102.150251; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; Esser L, 2004, J MOL BIOL, V341, P281, DOI 10.1016/j.jmb.2004.05.065; Fisher N, 2000, J MOL BIOL, V296, P1153, DOI 10.1006/jmbi.2000.3509; Gao XG, 2003, BIOCHEMISTRY-US, V42, P9067, DOI 10.1021/bi0341814; GEST H, 1980, FEMS MICROBIOL LETT, V7, P73, DOI 10.1111/j.1574-6941.1980.tb01579.x; Grimaldi S, 2003, BIOCHEMISTRY-US, V42, P5632, DOI 10.1021/bi034010z; GUEST JR, 1981, J GEN MICROBIOL, V122, P171; Haas AH, 2005, BIOCHEMISTRY-US, V44, P13949, DOI 10.1021/bi051011d; Hagerhall C, 1999, J BIOL CHEM, V274, P26157, DOI 10.1074/jbc.274.37.26157; Hastings SF, 2000, EUR J BIOCHEM, V267, P5638, DOI 10.1046/j.1432-1327.2000.01643.x; Hastings SF, 1998, EUR J BIOCHEM, V255, P317, DOI 10.1046/j.1432-1327.1998.2550317.x; Hellwig P, 1999, BIOCHEMISTRY-US, V38, P14683, DOI 10.1021/bi991267h; Hellwig P, 2003, BIOCHEMISTRY-US, V42, P6179, DOI 10.1021/bi0205348; Hellwig P, 1998, BIOCHEMISTRY-US, V37, P7390, DOI 10.1021/bi9725576; Hellwig P, 2002, BIOCHEMISTRY-US, V41, P10675, DOI 10.1021/bi012146w; Hellwig P, 2000, BIOCHEMISTRY-US, V39, P10884, DOI 10.1021/bi000842a; Horsefield R, 2006, J BIOL CHEM, V281, P7309, DOI 10.1074/jbc.M508173200; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iverson TM, 2002, J BIOL CHEM, V277, P16124, DOI 10.1074/jbc.M200815200; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; Kolling DRJ, 2003, J BIOL CHEM, V278, P39747, DOI 10.1074/jbc.M305913200; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; Lancaster CRD, 1997, STRUCTURE, V5, P1339, DOI 10.1016/S0969-2126(97)00285-2; Lancaster CRD, 2002, BBA-BIOENERGETICS, V1553, P84, DOI 10.1016/S0005-2728(01)00230-4; Maklashina E, 2006, J BIOL CHEM, V281, P11357, DOI 10.1074/jbc.M512544200; Maklashina E, 1999, ARCH BIOCHEM BIOPHYS, V369, P223, DOI 10.1006/abbi.1999.1359; Maklashina E, 2001, J BIOL CHEM, V276, P18968, DOI 10.1074/jbc.M011270200; MAROTI P, 1988, BIOCHIM BIOPHYS ACTA, V934, P329, DOI 10.1016/0005-2728(88)90092-8; MCPHERSON PH, 1988, BIOCHIM BIOPHYS ACTA, V934, P348, DOI 10.1016/0005-2728(88)90093-X; MIKI T, 1992, ARCH BIOCHEM BIOPHYS, V293, P61, DOI 10.1016/0003-9861(92)90365-4; MOSS D, 1990, EUR J BIOCHEM, V187, P565, DOI 10.1111/j.1432-1033.1990.tb15338.x; Mulkidjanian AY, 2005, BBA-BIOENERGETICS, V1709, P5, DOI 10.1016/j.bbabio.2005.03.009; Nabedryk E, 2005, BIOCHEMISTRY-US, V44, P14519, DOI 10.1021/bi051328d; Nabedryk E, 2004, BIOCHEMISTRY-US, V43, P7236, DOI 10.1021/bi049342y; Ohnishi T, 2005, FEBS LETT, V579, P500, DOI 10.1016/j.febslet.2004.11.107; PINCHAS S, 1977, INFRARED SPECTRA LAB; Ritter M, 2003, BIOCHEMISTRY-US, V42, P12391, DOI 10.1021/bi035103j; Rothery RA, 1996, BIOCHEMISTRY-US, V35, P3247, DOI 10.1021/bi951584y; Rothery RA, 2005, FEBS J, V272, P313, DOI 10.1111/j.1742-4658.2004.04469.x; SALERNO JC, 1980, BIOCHEM J, V192, P769, DOI 10.1042/bj1920769; Stowell MHB, 1997, SCIENCE, V276, P812, DOI 10.1126/science.276.5313.812; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1243, DOI 10.1002/bip.360301309; Waldeck AR, 1997, J BIOL CHEM, V272, P19373, DOI 10.1074/jbc.272.31.19373; WERTH MT, 1990, P NATL ACAD SCI USA, V87, P8965, DOI 10.1073/pnas.87.22.8965; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; Wolpert M, 2006, SPECTROCHIM ACTA A, V64, P987, DOI 10.1016/j.saa.2005.08.025; Wraight CA, 2005, RSC BIOMOLEC SCI, P273; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; Yankovskaya V, 1996, J BIOL CHEM, V271, P21020, DOI 10.1074/jbc.271.35.21020; Zhang J, 2002, BIOCHEMISTRY-US, V41, P4612, DOI 10.1021/bi011784b	64	32	32	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26655	26664		10.1074/jbc.M602938200	http://dx.doi.org/10.1074/jbc.M602938200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829675	hybrid			2022-12-25	WOS:000240249500083
J	Chaudhry, Y; Nayak, A; Bordeleau, ME; Tanaka, J; Pelletier, J; Belsham, GJ; Roberts, LO; Goodfellow, IG				Chaudhry, Yasmin; Nayak, Arabinda; Bordeleau, Marie-Eve; Tanaka, Junichi; Pelletier, Jerry; Belsham, Graham J.; Roberts, Lisa O.; Goodfellow, Ian G.			Caliciviruses differ in their functional requirements for eIF4F components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC TRANSLATION INITIATION; PORCINE ENTERIC CALICIVIRUS; RIBOSOME ENTRY SITES; CAP-BINDING PROTEIN; HEPATITIS-C VIRUS; FELINE CALICIVIRUS; MAMMALIAN TRANSLATION; MOSAIC-VIRUS; IN-VITRO; RNA	Two classes of viruses, namely members of the Potyviridae and Caliciviridae, use a novel mechanism for the initiation of protein synthesis that involves the interaction of translation initiation factors with a viral protein covalently linked to the viral RNA, known as VPg. The calicivirus VPg proteins can interact directly with the initiation factors eIF4E and eIF3. Translation initiation on feline calicivirus (FCV) RNA requires eIF4E because it is inhibited by recombinant 4E-BP1. However, to date, there have been no functional studies carried out with respect to norovirus translation initiation, because of a lack of a suitable source of VPg-linked viral RNA. We have now used the recently identified murine norovirus (MNV) as a model system for norovirus translation and have extended our previous studies with FCV RNA to examine the role of the other eIF4F components in translation initiation. We now demonstrate that, as with FCV, MNV VPg interacts directly with eIF4E, although, unlike FCV RNA, translation of MNV RNA is not sensitive to 4E-BP1, eIF4E depletion, or foot-and-mouth disease virus Lb protease-mediated cleavage of eIF4G. We also demonstrate that both FCV and MNV RNA translation require the RNA helicase component of the eIF4F complex, namely eIF4A, because translation was sensitive (albeit to different degrees) to a dominant negative form and to a small molecule inhibitor of eIF4A (hippuristanol). These results suggest that calicivirus RNAs differ with respect to their requirements for the components of the eIF4F translation initiation complex.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, London W2 1PG, England; Biotechnol & Biol Sci Res Council, Inst Anim Hlth, Woking GU24 0NF, Surrey, England; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Univ Ryukyus, Dept Chem Biol & Marine Sci, Nishihara, Okinawa 9030213, Japan; Univ Surrey, Sch Biomed & Mol Sci, Guildford GU2 7XH, Surrey, England	Imperial College London; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; McGill University; University of the Ryukyus; University of Surrey	Goodfellow, IG (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, St Marys Campus,Norfolk Pl, London W2 1PG, England.	I.Goodfellow@imperial.ac.uk	Roberts, Lisa/E-6365-2010; Belsham, Graham/J-3132-2019; Belsham, Graham J./H-8589-2019	Belsham, Graham/0000-0003-1187-4873; Belsham, Graham J./0000-0003-1187-4873; Goodfellow, Ian/0000-0002-9483-510X; Tanaka, Junichi/0000-0002-8672-7379	BBSRC [BB/D007755/1, BB/D007607/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/D007607/1, BB/D007755/1] Funding Source: Medline; Wellcome Trust [069526] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Asanaka M, 2005, P NATL ACAD SCI USA, V102, P10327, DOI 10.1073/pnas.0408529102; Belsham GJ, 2000, COLD SPRING HARBOR M, V39, P869; Bordeleau ME, 2006, NAT CHEM BIOL, V2, P213, DOI 10.1038/nchembio776; Bordeleau ME, 2005, P NATL ACAD SCI USA, V102, P10460, DOI 10.1073/pnas.0504249102; Bushell M, 2002, J CELL BIOL, V158, P395, DOI 10.1083/jcb.200205044; Chang KO, 2005, J VIROL, V79, P1409, DOI 10.1128/JVI.79.3.1409-1416.2005; Chang KO, 2004, P NATL ACAD SCI USA, V101, P8733, DOI 10.1073/pnas.0401126101; Chang KO, 2002, VIROLOGY, V304, P302, DOI 10.1006/viro.2002.1665; Chard LS, 2006, J VIROL, V80, P1271, DOI 10.1128/JVI.80.3.1271-1279.2006; Daughenbaugh KF, 2003, EMBO J, V22, P2852, DOI 10.1093/emboj/cdg251; DEVANEY MA, 1988, J VIROL, V62, P4407, DOI 10.1128/JVI.62.11.4407-4409.1988; GEHRKE L, 1983, BIOCHEMISTRY-US, V22, P5157, DOI 10.1021/bi00291a015; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Goodfellow I, 2005, EMBO REP, V6, P968, DOI 10.1038/sj.embor.7400510; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Herbert TP, 1997, J GEN VIROL, V78, P1033, DOI 10.1099/0022-1317-78-5-1033; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; Kapp LD, 2004, ANNU REV BIOCHEM, V73, P657, DOI 10.1146/annurev.biochem.73.030403.080419; Karst SM, 2003, SCIENCE, V299, P1575, DOI 10.1126/science.1077905; Korneeva NL, 2005, J BIOL CHEM, V280, P1872, DOI 10.1074/jbc.M406168200; KRAUSSLICH HG, 1987, J VIROL, V61, P2711; Leonard S, 2000, J VIROL, V74, P7730, DOI 10.1128/JVI.74.17.7730-7737.2000; Leonard S, 2004, J GEN VIROL, V85, P1055, DOI 10.1099/vir.0.19706-0; Leonard S, 2002, J GEN VIROL, V83, P2085, DOI 10.1099/0022-1317-83-8-2085; LLOYD RE, 1988, J VIROL, V62, P4216, DOI 10.1128/JVI.62.11.4216-4223.1988; Lopmam BA, 2003, EMERG INFECT DIS, V9, P90; Low WK, 2005, MOL CELL, V20, P709, DOI 10.1016/j.molcel.2005.10.008; McKendrick L, 2001, EUR J BIOCHEM, V268, P5375, DOI 10.1046/j.0014-2956.2001.02478.x; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; Pestova TV, 2002, GENE DEV, V16, P2906, DOI 10.1101/gad.1020902; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Pisarev AV, 2004, J VIROL, V78, P4487, DOI 10.1128/JVI.78.9.4487-4497.2004; Ptushkina M, 1999, EMBO J, V18, P4068, DOI 10.1093/emboj/18.14.4068; RAY BK, 1985, J BIOL CHEM, V260, P7651; Richter-Cook NJ, 1998, J BIOL CHEM, V273, P7579, DOI 10.1074/jbc.273.13.7579; Rogers GW, 1999, J BIOL CHEM, V274, P12236, DOI 10.1074/jbc.274.18.12236; SOSNOVTSEV S, 1995, VIROLOGY, V210, P383, DOI 10.1006/viro.1995.1354; Svitkin YV, 2005, MOL CELL BIOL, V25, P10556, DOI 10.1128/MCB.25.23.10556-10565.2005; Svitkin YV, 2001, RNA, V7, P1743; Willcocks MM, 2004, J GEN VIROL, V85, P1125, DOI 10.1099/vir.0.19564-0; Wittmann S, 1997, VIROLOGY, V234, P84, DOI 10.1006/viro.1997.8634; Wobus CE, 2004, PLOS BIOL, V2, P2076, DOI 10.1371/journal.pbio.0020432	45	99	102	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25315	25325		10.1074/jbc.M602230200	http://dx.doi.org/10.1074/jbc.M602230200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16835235	hybrid, Green Submitted			2022-12-25	WOS:000240031300033
J	Dragusin, M; Wehner, S; Kelly, S; Wang, E; Merrill, AH; Kalff, JC; van Echten-Deckert, G				Dragusin, Mihaela; Wehner, Sven; Kelly, Samuel; Wang, Elaine; Merrill, Alfred H., Jr.; Kalff, Joerg C.; van Echten-Deckert, Gerhild			Effects of sphingosine-1-phosphate and ceramide-1-phosphate on rat intestinal smooth muscle cells: implications for postoperative ileus	FASEB JOURNAL			English	Article						sphingolipids; inflammation; COX-2; PGE(2)	SPHINGOSINE 1-PHOSPHATE; GENE-EXPRESSION; INFLAMMATION; CYCLOOXYGENASE-2; SPHINGOLIPIDS; MANIPULATION; METABOLISM; RECEPTORS; PATHWAYS; CERAMIDE	Postoperative ileus, a major cause of morbidity after abdominal surgery, is characterized by intestinal dysmotility and inflammation. The aim was to investigate the involvement of sphingolipids in postoperative intestinal inflammation using a standardized rat model of intestinal surgical manipulation. Sphingolipid analysis (ESI-MS) of intestinal muscularis after manipulation revealed a time-dependent increase of sphingosine 1-phosphate (S1P) and of ceramide 1-phosphate (C1P). We therefore established a culture system of primary rat intestinal smooth muscle cells and examined the potential role of these sphingolipids in intestinal inflammation. Incubation of cells with either of the two sphingolipid-phosphates resulted in an elevated production of PGE2. Further analysis revealed that S1P enhances cyclooxygenase 2 (COX-2) expression whereas C1P increases release of arachidonic acid, indicating an enhanced phospholipase A(2) activity. S1P-induced COX-2 expression was pertussis toxin sensitive, suggesting the involvement of Gi/o protein-coupled S1P receptors. Further downstream mediators of S1P induced COX-2 expression appear to be extracellular regulated kinase (ERK) and p38 mitogen-activated protein kinase (MAPK). Collectively, our results demonstrate that intestinal smooth muscle cells represent a major target for both C1P and S1P activity. Thus, the sustained elevated concentration of the two bioactive sphingolipids in this tissue could at least in part explain postoperative intestinal dysmotility.	Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany; Univ Bonn, Dept Surg, D-53121 Bonn, Germany; Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA; Georgia Inst Technol, Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA	University of Bonn; University of Bonn; University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology	van Echten-Deckert, G (corresponding author), Univ Bonn, Kekule Inst Organ Chem & Biochem, Gerhard Domagk Str 1, D-53121 Bonn, Germany.	g.echten.deckert@uni-bonn.de	Wehner, Sven/X-6326-2019; Kalff, Joerg C/U-8580-2017	Merrill, Alfred/0000-0002-6673-968X; Wehner, Sven/0000-0002-8632-7631	NIGMS NIH HHS [GM069338] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM069338] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ammit AJ, 2001, FASEB J, V15, P1212, DOI 10.1096/fj.00-0742fje; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BALLOU LR, 1990, J IMMUNOL, V145, P4245; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chalfant CE, 2005, J CELL SCI, V118, P4605, DOI 10.1242/jcs.02637; Damirin A, 2005, MOL PHARMACOL, V67, P1177, DOI 10.1124/mol.104.004317; Dempke W, 2001, J CANCER RES CLIN, V127, P411, DOI 10.1007/s004320000225; Donati C, 2004, FASEB J, V18, P449, DOI 10.1096/fj.04-1780fje; Eskandari MK, 1997, AM J PHYSIOL-GASTR L, V273, pG727, DOI 10.1152/ajpgi.1997.273.3.G727; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kalff JC, 1998, ANN SURG, V228, P652, DOI 10.1097/00000658-199811000-00004; Kalff JC, 1999, SURGERY, V126, P498, DOI 10.1016/S0039-6060(99)70091-7; KHAN I, 1995, GASTROENTEROLOGY, V108, P1720, DOI 10.1016/0016-5085(95)90133-7; Kim JI, 2003, J BIOL CHEM, V278, P31731, DOI 10.1074/jbc.M300625200; KUEHL FA, 1980, SCIENCE, V210, P978, DOI 10.1126/science.6254151; Luckey A, 2003, ARCH SURG-CHICAGO, V138, P206, DOI 10.1001/archsurg.138.2.206; Merrill AH, 2005, METHODS, V36, P207, DOI 10.1016/j.ymeth.2005.01.009; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Pettus BJ, 2005, MOL PHARMACOL, V68, P330, DOI 10.1124/mol.104.008722; Pettus BJ, 2004, CURR MOL MED, V4, P405, DOI 10.2174/1566524043360573; Pettus BJ, 2003, J BIOL CHEM, V278, P38206, DOI 10.1074/jbc.M304816200; Pettus BJ, 2004, J BIOL CHEM, V279, P11320, DOI 10.1074/jbc.M309262200; Salinthone S, 2004, AM J PHYSIOL-GASTR L, V287, pG627, DOI 10.1152/ajpgi.00462.2003; Schwarz NT, 2001, GASTROENTEROLOGY, V121, P1354, DOI 10.1053/gast.2001.29605; Spiegel S, 2003, BIOCHEM SOC T, V31, P1216; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Turini ME, 2002, ANNU REV MED, V53, P35, DOI 10.1146/annurev.med.53.082901.103952; Wehner S, 2005, SURGERY, V137, P436, DOI 10.1016/j.surg.2004.11.003	30	24	24	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1930	+		10.1096/fj.05-5518fje	http://dx.doi.org/10.1096/fj.05-5518fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16877527				2022-12-25	WOS:000240267000034
J	Liao, XD; Liu, JM; Du, L; Tang, AH; Shang, YL; Wang, SQ; Chen, LY; Chen, Q				Liao, Xudong; Liu, Jun-Ming; Du, Lei; Tang, Aihui; Shang, Yingli; Wang, Shi Qiang; Chen, Lan-Ying; Chen, Quan			Nitric oxide signaling in stretch-induced apoptosis of neonatal rat cardiomyocytes	FASEB JOURNAL			English	Article						hypertension; Ca2+; eNOS; iNOS; signal transduction	HEART-FAILURE; MECHANICAL STRETCH; CARDIAC MYOCYTES; ANGIOTENSIN-II; CELL-DEATH; SYNTHASE; INOS; HYPERTENSION; HYPERTROPHY; FIBROBLASTS	Pressure overload associated with hypertension is an important pathological factor leading to heart remodeling and ultimately heart failure partially due to cardiomyocyte apoptosis. Here we show that endogenous NO signaling plays a critical role in mechanical stretch-induced cardiomyocyte apoptosis. Mechanical stretch induced elevated expression of both eNOS and inducible NO synthase (iNOS) and increased synthesis of NO. A sustained increase in iNOS expression was also found in hearts of hypertensive rats in vivo. Blockade of NO signaling by inhibitors of NOS (L-NAME and AMT) or downstream guanylyl cyclase (ODQ) strongly inhibited stretch-induced apoptosis, mitochondria depolarization, and cytochrome c release, suggesting that NO is required in stretch-induced cardiomyocyte apoptosis. The expression of iNOS, but not eNOS, was blocked by L-NAME and ODQ, indicating that the iNOS induction is NO dependent. The initial elevation of NO is likely due to Ca2+-dependent activation of eNOS because elimination of intracellular calcium by EGTA-AM inhibited both iNOS induction and NO elevation. Other calcium signaling inhibitors (nifedipine, ryanodine, thapsigargin, and ionic gadolinium) also attenuated the initial NO elevation. These data indicate that mechanical signals initiate Ca2+-dependent NO synthesis, which is further amplified by activation of NO-induced iNOS expression, to regulate cardiomyocyte apoptosis.-Liao, X., Liu, J-M., Du, Lei, Tang, A., Shang, Y., Wang, S. Q., Chen, L-Y, Chen, Q. Nitric oxide signaling in stretch-induced apoptosis of neonatal rat cardiomyocytes.	Chinese Acad Sci, State Key Lab Biomembrane & Membrane Biotechnol, Inst Zool, Beijing 100080, Peoples R China; Cardiovasc Inst, Beijing, Peoples R China; Fu Wai Hosp, Peking Union Med Coll, Beijing, Peoples R China; Chinese Acad Med Sci, Beijing 100037, Peoples R China; Peking Univ, Coll Life Sci, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100871, Peoples R China	Chinese Academy of Sciences; Institute of Zoology, CAS; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking University	Chen, Q (corresponding author), Chinese Acad Sci, State Key Lab Biomembrane & Membrane Biotechnol, Inst Zool, 25 Beisihuanxi Rd, Beijing 100080, Peoples R China.	lanyingchen@hotmail.com; chenq@ioz.ac.cn	Tang, Ai-Hui/D-4311-2009	Tang, Ai-Hui/0000-0003-3715-6714; Chen, Quan/0000-0001-7539-8728; Wang, Shi-Qiang/0000-0001-7784-4461				Aizawa T, 2000, HYPERTENSION, V35, P800, DOI 10.1161/01.HYP.35.3.800; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Arstall MA, 1999, CORONARY ARTERY DIS, V10, P301, DOI 10.1097/00019501-199907000-00005; Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602; Bishopric Nanette H., 2001, Current Opinion in Pharmacology, V1, P141, DOI 10.1016/S1471-4892(01)00032-7; Fortuno MA, 2001, HYPERTENSION, V38, P1406, DOI 10.1161/hy1201.099615; Gill C, 2002, FASEB J, V16, P135, DOI 10.1096/fj.01-0629com; Hare JM, 2003, J MOL CELL CARDIOL, V35, P719, DOI 10.1016/S0022-2828(03)00143-3; Ing DJ, 1999, CIRC RES, V84, P21; Jones WK, 1999, J MOL CELL CARDIOL, V31, P1469, DOI 10.1006/jmcc.1999.0983; Kang PM, 2003, TRENDS MOL MED, V9, P177, DOI 10.1016/S1471-4914(03)00025-X; Khadour FH, 1997, AM J PHYSIOL-HEART C, V273, pH1223, DOI 10.1152/ajpheart.1997.273.3.H1223; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Lee AA, 1996, AM J PHYSIOL-CELL PH, V271, pC1400, DOI 10.1152/ajpcell.1996.271.4.C1400; Leri A, 1998, J CLIN INVEST, V101, P1326, DOI 10.1172/JCI316; Liao XD, 2005, LIFE SCI, V77, P160, DOI 10.1016/j.lfs.2004.11.029; Liao XD, 2004, CELL RES, V14, P16, DOI 10.1038/sj.cr.7290198; Liao XD, 2003, BIOCHEM BIOPH RES CO, V310, P405, DOI 10.1016/j.bbrc.2003.09.023; Linke A, 2003, HEART FAIL REV, V8, P87, DOI 10.1023/A:1022151106019; Meghji P, 1997, J MOL CELL CARDIOL, V29, P3147, DOI 10.1006/jmcc.1997.0545; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Mungrue IN, 2002, J CLIN INVEST, V109, P735, DOI 10.1172/JCI200213265; Narula J, 2000, CURR OPIN CARDIOL, V15, P183, DOI 10.1097/00001573-200005000-00011; Petroff MGV, 2001, NAT CELL BIOL, V3, P867, DOI 10.1038/ncb1001-867; Pimentel DR, 2001, CIRC RES, V89, P453, DOI 10.1161/hh1701.096615; Pinsky DJ, 1999, AM J PHYSIOL-HEART C, V277, pH1189, DOI 10.1152/ajpheart.1999.277.3.H1189; Razavi HM, 2005, PHARMACOL THERAPEUT, V106, P147, DOI 10.1016/j.pharmthera.2004.11.006; Schonhoff CM, 2003, J BIOL CHEM, V278, P18265, DOI 10.1074/jbc.M212459200; Song W, 2000, CARDIOVASC RES, V45, P595, DOI 10.1016/S0008-6363(99)00395-8; Sun Y, 2005, HYPERTENSION, V46, P1355, DOI 10.1161/01.HYP.0000192651.06674.3f; SWYNGHEDAUW B, 1982, PATHOBIOL ANN, V12, P137; Szabolcs M, 1996, CIRCULATION, V94, P1665, DOI 10.1161/01.CIR.94.7.1665; Valenti L, 2003, CELL IMMUNOL, V221, P50, DOI 10.1016/S0008-8749(03)00064-9; van Kesteren CAM, 1999, CARDIOVASC RES, V43, P148, DOI 10.1016/S0008-6363(99)00057-7; Wu B, 2002, FREE RADICAL BIO MED, V33, P649, DOI 10.1016/S0891-5849(02)00917-6; Xu L, 2004, J HYPERTENS, V22, P1579, DOI 10.1097/01.hjh.0000133717.48334.cf; Yamamoto K, 1998, J BIOL CHEM, V273, P11862, DOI 10.1074/jbc.273.19.11862; Yoshioka Y, 2003, BRIT J PHARMACOL, V139, P28, DOI 10.1038/sj.bjp.0705206	38	31	33	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2006	20	11					1883	+		10.1096/fj.06-5717fje	http://dx.doi.org/10.1096/fj.06-5717fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16877524				2022-12-25	WOS:000240267000018
J	Miyoshi, T; Hirohata, S; Ogawa, H; Doi, M; Obika, M; Yonezawa, T; Sado, Y; Kusachi, S; Kyo, S; Kondo, S; Shiratori, Y; Hudson, BG; Ninomiya, Y				Miyoshi, Toru; Hirohata, Satoshi; Ogawa, Hiroko; Doi, Masayuki; Obika, Masanari; Yonezawa, Tomoko; Sado, Yoshikazu; Kusachi, Shozo; Kyo, Satoru; Kondo, Seiji; Shiratori, Yasushi; Hudson, Billy G.; Ninomiya, Yoshifumi			Tumor-specific expression of the RGD-alpha 3(IV)NC1 domain suppresses endothelial tube formation and tumor growth in mice	FASEB JOURNAL			English	Article						adenovirus; angiogenesis; basement membrane; cancer dormancy; hTERT	TELOMERASE REVERSE-TRANSCRIPTASE; DISTINCT ANTITUMOR PROPERTIES; CATALYTIC SUBUNIT HTERT; MALIGNANT GLIOMA-CELLS; HUMAN BONE-MARROW; IV COLLAGEN; BASEMENT-MEMBRANE; MYOCARDIAL-INFARCTION; GENE-TRANSFER; NC1 DOMAIN	Angiogenesis plays an essential role in tumor growth. This study investigated expression of the noncollagenous domain of alpha 3(IV) collagen (alpha 3(IV) NC1) transduced into tumors and its inhibition of tumor growth. We hypothesized that if a human telomerase reverse transcriptase (hTERT) promoter-driven RGD motif containing alpha 3(IV) NC1 (hTERT/ RGD-alpha 3(IV) NC1) were expressed in telomerase-expressing tumor cells, it would inhibit tumor growth by its anti-angiogenic property. Adenoviral transduction of hTERT/ RGD-alpha 3(IV) NC1 expressed RGD-alpha 3(IV) NC1 in hTERT-positive tumor cell lines. However, hTERT/ RGD-alpha 3(IV) NC1 did not express RGD-alpha 3(IV) NC1 in hTERT-negative cells such as keratinocytes and fibroblasts. The secreted RGD-alpha 3(IV) NC1 in the conditioned medium from tumor cells inhibited cell proliferation as well as tube formation in cultured endothelial cells, but had no effect on other types of cells. In an in vivo model, adenoviral hTERT/ RGD-alpha 3(IV) NC1 gene therapy showed limited expression of RGD-alpha 3(IV) NC1 in tumors and resulted in a significant decrease of vessel density in tumors. The growth of subcutaneous (s. c.) tumors in nude mice was significantly suppressed by treatment with hTERT/ RGD-alpha 3(IV) NC1. In addition, long-term inhibition of tumor growth was achieved by intermittent administration of hTERT/ RGD-alpha 3(IV) NC1. In conclusion, our findings demonstrate that tumor-specific antiangiogenic gene therapy utilizing RGD-alpha 3(IV) NC1 under the hTERT promoter inhibited angiogenesis in tumors, resulting in an antitumor effect.	Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Mol Biol & Biochem, Okayama 7008558, Japan; Okayama Univ, Dept Med & Med Sci, Grad Sch Med Dent & Pharmaceut Sci, Okayama 7008558, Japan; Shigei Med Res Inst, Div Immunol, Okayama, Japan; Okayama Univ, Sch Med, Fac Hlth Sci, Dept Med Technol, Okayama 700, Japan; Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 920, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA	Okayama University; Okayama University; Okayama University; Kanazawa University; University of Texas System; UTMD Anderson Cancer Center; Vanderbilt University	Ninomiya, Y (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Mol Biol & Biochem, 2-5-1,Shikatacho, Okayama 7008558, Japan.	yoshinin@cc.okayama-u.ac.jp	Kusachi, Shozo/B-1779-2011	Hudson, Billy/0000-0002-5420-4100; YONEZAWA, Tomoko/0000-0002-3380-8298	NIDDK NIH HHS [DK 18381] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018381, R01DK018381] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; De Bouard S, 2003, HUM GENE THER, V14, P883, DOI 10.1089/104303403765701178; Demircan K, 2005, ARTHRITIS RHEUM-US, V52, P1451, DOI 10.1002/art.21010; Eskens FALM, 2004, BRIT J CANCER, V90, P1, DOI 10.1038/sj.bjc.6601401; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fujisaki H, 2002, EXP CELL RES, V280, P255, DOI 10.1006/excr.2002.5639; Furumatsu T, 2002, J BIOCHEM, V131, P619, DOI 10.1093/oxfordjournals.jbchem.a003142; Gu J, 2000, CANCER RES, V60, P5359; Hirohata S, 2002, J BIOL CHEM, V277, P12182, DOI 10.1074/jbc.M109665200; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; Hopfer H, 2003, FASEB J, V17, P860, DOI 10.1096/fj.02-0746com; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; Hudson BG, 2003, NEW ENGL J MED, V348, P2543, DOI 10.1056/NEJMra022296; Indraccolo S, 2002, GENE THER, V9, P867, DOI 10.1038/sj.gt.3301703; Ito H, 2005, HUM GENE THER, V16, P685, DOI 10.1089/hum.2005.16.685; Kim KS, 2004, CANCER GENE THER, V11, P441, DOI 10.1038/sj.cgt.7700716; Koga S, 2000, HUM GENE THER, V11, P1397, DOI 10.1089/10430340050057477; Komata T, 2002, HUM GENE THER, V13, P1015, DOI 10.1089/104303402753812421; Kuroiwa M, 2003, J PEDIATR SURG, V38, P1499, DOI 10.1016/S0022-3468(03)00503-7; Kyo S, 2003, AM J PATHOL, V163, P859, DOI 10.1016/S0002-9440(10)63446-3; Maeshima Y, 2000, J BIOL CHEM, V275, P23745, DOI 10.1074/jbc.C000186200; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Maeshima Y, 2001, J BIOL CHEM, V276, P15240, DOI 10.1074/jbc.M007764200; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura K, 2004, J BIOCHEM, V136, P439, DOI 10.1093/jb/mvh138; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; Netzer KO, 1999, J BIOL CHEM, V274, P11267, DOI 10.1074/jbc.274.16.11267; Ogawa H, 2004, MATRIX BIOL, V23, P287, DOI 10.1016/j.matbio.2004.07.001; Pasco S, 2004, EXP CELL RES, V301, P251, DOI 10.1016/j.yexcr.2004.07.036; Pedchenko V, 2004, J BIOL CHEM, V279, P2772, DOI 10.1074/jbc.M311901200; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; SADO Y, 1995, HISTOCHEM CELL BIOL, V104, P267, DOI 10.1007/BF01464322; SAUS J, 1988, J BIOL CHEM, V263, P13374; Sezaki S, 2005, EXP BIOL MED, V230, P621; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Sudhakar A, 2005, J CLIN INVEST, V115, P2801, DOI 10.1172/JCI24813; Sudhakar A, 2003, P NATL ACAD SCI USA, V100, P4766, DOI 10.1073/pnas.0730882100; Takakura M, 1999, CANCER RES, V59, P551; Toeda K, 2005, MOL CELL BIOCHEM, V280, P47, DOI 10.1007/s11010-005-8051-4; Tonini T, 2003, ONCOGENE, V22, P6549, DOI 10.1038/sj.onc.1206816; Watanabe T, 1996, BLOOD, V87, P5032, DOI 10.1182/blood.V87.12.5032.bloodjournal87125032; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; Won J, 2004, P NATL ACAD SCI USA, V101, P11328, DOI 10.1073/pnas.0401801101; Wright WE, 1996, DEV GENET, V18, P173; Yao B, 2005, HUM GENE THER, V16, P1075, DOI 10.1089/hum.2005.16.1075; ZHANG XM, 1994, DEV BIOL, V164, P10, DOI 10.1006/dbio.1994.1176	53	35	39	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1904	+		10.1096/fj.05-5565fje	http://dx.doi.org/10.1096/fj.05-5565fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16877525	Green Submitted			2022-12-25	WOS:000240267000025
J	Tenhunen, O; Soini, Y; Ilves, M; Rysa, J; Tuukkanen, J; Serpi, R; Pennanen, H; Ruskoaho, H; Leskinen, H				Tenhunen, Olli; Soini, Ylermi; Ilves, Mika; Rysa, Jaana; Tuukkanen, Juha; Serpi, Raisa; Pennanen, Harri; Ruskoaho, Heikki; Leskinen, Hanna			p38 kinase rescues failing myocardium after myocardial infarction: evidence for angiogenic and antiapoptotic mechanisms	FASEB JOURNAL			English	Article						remodeling; signal transduction; gene therapy	ACTIVATED PROTEIN-KINASE; IMPROVES CARDIAC-FUNCTION; MAP KINASE; CARDIOMYOCYTE APOPTOSIS; HEART-FAILURE; GENE-TRANSFER; INHIBITION; GROWTH; ISCHEMIA; DYSFUNCTION	As a leading cause of heart failure, postinfarction left ventricular remodeling represents an important target for therapeutic interventions. Mitogen-activated protein kinases regulate critical cellular processes including stress response and survival, but their role in left ventricular remodeling is unknown. In the present study, rats were subjected to myocardial infarction by ligating the left anterior descending coronary artery. Western blot and kinase assay analysis revealed an inactivation of p38 kinase after myocardial infarction. Local adenovirus-mediated cotransfection of wild-type (WT) p38 kinase and constitutively active MKK3b reduced infarct size (26 +/- 3% vs. 47 +/- 4%, P < 0.05 vs. LacZ-treated control) associated with improved ejection fraction (66.9 +/- 5.5% vs. 44.4 +/- 4.0%, P < 0.001), fractional shortening (30.2 +/- 2.1% vs. 19.7 +/- 2.2%, P < 0.001), and decreased left ventricular diastolic diameter (8.5 +/- 0.4 mm vs. 9.5 +/- 0.2 mm, P < 0.01). p38 kinase gene transfer increased capillary density (2423 +/- 107/ mm(2) vs. 1934 +/- 86/mm(2), P < 0.001) and resulted in microvessel enlargement in the ischemic border zone. Apoptosis (35 +/- 7 vs. 69 +/- 13 cells, P < 0.01) and fibrosis (16 +/- 3% vs. 34 +/- 8%, P < 0.05) were reduced, while the number of c-kit positive cardiac stem-like cells remained unchanged. These results indicate that reduced p38 signaling predisposes to adverse postinfarction remodeling. The rescue of failing myocardium with p38 kinase may be a potential new therapy for heart failure after myocardial infarction.	Univ Oulu, Dept Pharmacol & Toxicol, Fac Med, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Oulu, Dept Pathol, FIN-90014 Oulu, Finland; Univ Oulu, Dept Physiol, FIN-90014 Oulu, Finland; Univ Oulu, Dept Anat & Cell Biol, FIN-90014 Oulu, Finland	University of Oulu; University of Oulu; University of Oulu; University of Oulu	Ruskoaho, H (corresponding author), Univ Oulu, Dept Pharmacol & Toxicol, Fac Med, Bioctr Oulu, POB 5000, FIN-90014 Oulu, Finland.	heikki.ruskoaho@oulu.fi	Tuukkanen, Juha/R-3728-2018	Tuukkanen, Juha/0000-0002-1723-6461; Rysa, Jaana/0000-0003-2205-6323; Serpi, Raisa/0000-0002-8207-4673				Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; Anversa P, 2002, NATURE, V415, P240, DOI 10.1038/415240a; Braz JC, 2003, J CLIN INVEST, V111, P1475, DOI 10.1172/JCI200317295; Gheorghiade M, 1998, CIRCULATION, V97, P282, DOI 10.1161/01.CIR.97.3.282; Harfouche R, 2003, FASEB J, V17, P1523, DOI 10.1096/fj.02-0698fje; Jackson JR, 1998, J PHARMACOL EXP THER, V284, P687; Kaiser RA, 2004, J BIOL CHEM, V279, P15524, DOI 10.1074/jbc.M313717200; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162-3109(00)00206-X; Lemke LE, 2001, J MOL CELL CARDIOL, V33, P1527, DOI 10.1006/jmcc.2001.1415; Li YW, 2003, CIRCULATION, V107, P2499, DOI 10.1161/01.CIR.0000065579.19126.B8; Liao P, 2001, P NATL ACAD SCI USA, V98, P12283, DOI 10.1073/pnas.211086598; Liu CL, 2005, PATTERN RECOGN, V38, P11, DOI 10.1016/j.patcog.2004.05.013; Ma XL, 1999, CIRCULATION, V99, P1685, DOI 10.1161/01.CIR.99.13.1685; Majalahti-Palviainen T, 2000, ENDOCRINOLOGY, V141, P731, DOI 10.1210/en.141.2.731; Martindale JJ, 2005, J BIOL CHEM, V280, P669, DOI 10.1074/jbc.M406690200; Nishida K, 2004, MOL CELL BIOL, V24, P10611, DOI 10.1128/MCB.24.24.10611-10620.2004; Pfeffer MA, 1979, CIRC RES, V13, P293; Ravingerova T, 2003, MOL CELL BIOCHEM, V247, P127, DOI 10.1023/A:1024119224033; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Rutanen J, 2004, CIRCULATION, V109, P1029, DOI 10.1161/01.CIR.0000115519.03688.A2; See F, 2004, J AM COLL CARDIOL, V44, P1679, DOI 10.1016/j.jacc.2004.07.038; Soini Y, 1996, BRIT J CANCER, V73, P1025, DOI 10.1038/bjc.1996.199; Sutton MGS, 2000, CIRCULATION, V101, P2981, DOI 10.1161/01.CIR.101.25.2981; Szatkowski ML, 2001, J CLIN INVEST, V107, P191, DOI 10.1172/JCI9862; Tenhunen O, 2004, J BIOL CHEM, V279, P24852, DOI 10.1074/jbc.M314317200; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; West JB, 2001, HIGH ALT MED BIOL, V2, P1, DOI 10.1089/152702901750067846; Widder J, 2004, CARDIOVASC RES, V63, P161, DOI 10.1016/j.cardiores.2004.03.008; Wilson JM, 1996, NEW ENGL J MED, V334, P1185, DOI 10.1056/NEJM199605023341809; Yla-Herttuala S, 2003, NAT MED, V9, P694, DOI 10.1038/nm0603-694	32	51	53	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1907	+		10.1096/fj.05-5618fje	http://dx.doi.org/10.1096/fj.05-5618fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16849392				2022-12-25	WOS:000240267000026
J	Boutte, AM; Woltjer, RL; Zimmerman, LJ; Stamer, SL; Montine, KS; Manno, MV; Cimino, PJ; Liebler, DC; Montine, TJ				Boutte, Angela M.; Woltjer, Randall L.; Zimmerman, Lisa J.; Stamer, Sheryl L.; Montine, Kathleen S.; Manno, Michael V.; Cimino, Patrick J.; Liebler, Daniel C.; Montine, Thomas J.			Selectively increased oxidative modifications mapped to detergent-insoluble forms of A beta and beta-III tubulin in Alzheimer's disease	FASEB JOURNAL			English	Article						PTMs; gene expression; paired helical filament; dendrites	AMYLOID-BETA; TAU-PROTEIN; PROTEOMIC IDENTIFICATION; LIPID-PEROXIDATION; METHIONINE; BRAIN; MICROTUBULES; BINDING; GLYCOXIDATION; PATHOGENESIS	Deleterious post-translational modifications (PTMs)to the neuronal cytoskeleton are a proposed mechanistic link between accumulation of amyloid (A) beta peptides and subsequent abnormalities of tau and neurodegeneration in Alzheimer's disease (AD). Here we tested the hypothesis that PTMs on neuronal tubulins selectively accumulate in a pathological protein fraction in AD. We used new software, P-MOD, to identify comprehensively and map PTMs using mass spectral data from soluble (normal) and detergent-insoluble (pathological) protein fractions from AD, as well as total extracts from controls, for selected proteins: A beta, tau, apolipoprotein (apo) E, glial fibrillary acidic protein (GFAP), alpha-III tubulin, and beta-III tubulin. Our results confirmed direct observations of others by identifying methionine (M) sulfoxides at A beta position 35 and numerous sites of tau phosphorylation in detergent-insoluble protein from AD, while no PTMs were enriched on primarily astrocyte-derived apoE or GFAP in this fraction. P-MOD mapped several abundant M sulfoxides to neuron-enriched alpha-III tubulin but not its heterodimeric partner, neuron-enriched alpha-III tubulin, a result confirmed by selective suppression of CNBr-mediated cleavage of alpha-III tubulin. These findings are the first comprehensive assessment of PTMs in AD and point to oxidative modification of beta-III tubulin as a potential contributor to the neuronal cytoskeletal disruption that is characteristic of AD.	Univ Washington, Harborview Med Ctr, Dept Pathol, Seattle, WA 98104 USA; Vanderbilt Univ, Ctr Mol Neurosci, Nashville, TN USA; Vanderbilt Univ, Dept Biochem, Nashville, TN USA; Vanderbilt Univ, Mass Spectrometry Res Ctr, Nashville, TN USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Harborview Medical Center; University of Washington; University of Washington Seattle; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Washington; University of Washington Seattle	Montine, TJ (corresponding author), Univ Washington, Harborview Med Ctr, Dept Pathol, Box 359791, Seattle, WA 98104 USA.	tmontine@u.washington.edu		Liebler, Daniel/0000-0002-7873-3031; Montine, Kathleen/0000-0003-2110-8363; Cimino, P.J./0000-0003-0441-4502	NATIONAL INSTITUTE ON AGING [P50AG005136, F31AG023483, K01AG022040, R01AG024011] Funding Source: NIH RePORTER; NIA NIH HHS [AG24011, AG05136, AG023483, AG022040] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ali FE, 2005, J PEPT SCI, V11, P353, DOI 10.1002/psc.626; Ball M, 1997, NEUROBIOL AGING, V18, pS1, DOI 10.1016/s0197-4580(97)00057-2; Barnham KJ, 2003, J BIOL CHEM, V278, P42959, DOI 10.1074/jbc.M305494200; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Buee Luc, 2002, Journal de la Societe de Biologie, V196, P103; Butterfield DA, 2005, BBA-PROTEINS PROTEOM, V1703, P149, DOI 10.1016/j.bbapap.2004.10.014; Castegna A, 2002, J NEUROCHEM, V82, P1524, DOI 10.1046/j.1471-4159.2002.01103.x; Castegna A, 2002, FREE RADICAL BIO MED, V33, P562, DOI 10.1016/S0891-5849(02)00914-0; Christie RH, 1996, J NEUROPATH EXP NEUR, V55, P491, DOI 10.1097/00005072-199604000-00012; dePereda JM, 1996, BIOCHEMISTRY-US, V35, P14184, DOI 10.1021/bi961356j; Dong J, 2003, BIOCHEMISTRY-US, V42, P2768, DOI 10.1021/bi0272151; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Gamblin TC, 2003, BIOCHEMISTRY-US, V42, P2252, DOI 10.1021/bi0272510; Gong CX, 2005, J NEURAL TRANSM, V112, P813, DOI 10.1007/s00702-004-0221-0; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; Hansen BT, 2005, J PROTEOME RES, V4, P358, DOI 10.1021/pr0498234; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001; Hollemeyer K, 2002, PROTEOMICS, V2, P1524, DOI 10.1002/1615-9861(200211)2:11<1524::AID-PROT1524>3.0.CO;2-7; Ichihashi K, 2001, J BIOL CHEM, V276, P23903, DOI 10.1074/jbc.M101947200; Iqbal Khalid, 1993, Acta Neurobiologiae Experimentalis (Warsaw), V53, P325; Jing Z, 2005, NEUROBIOL AGING, V26, P207, DOI 10.1016/j.neurobiolaging.2004.03.012; Kaiser R, 1999, ANAL BIOCHEM, V266, P1, DOI 10.1006/abio.1998.2945; Kuo YM, 2001, J BIOL CHEM, V276, P12991, DOI 10.1074/jbc.M007859200; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; McLaughlin L, 1997, BRAIN RES BULL, V43, P501, DOI 10.1016/S0361-9230(97)80003-2; Mirra SS, 1997, NEUROBIOL AGING, V18, pS91, DOI 10.1016/S0197-4580(97)00058-4; Montine TJ, 2002, FREE RADICAL BIO MED, V33, P620, DOI 10.1016/S0891-5849(02)00807-9; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; Neely MD, 2005, BRAIN RES, V1037, P90, DOI 10.1016/j.brainres.2004.12.027; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Nogales E, 1999, CELL MOL LIFE SCI, V56, P133, DOI 10.1007/s000180050012; Oddo S, 2003, NEUROBIOL AGING, V24, P1063, DOI 10.1016/j.neurobiolaging.2003.08.012; Pamplona R, 2005, J BIOL CHEM, V280, P21522, DOI 10.1074/jbc.M502255200; Perez M, 2001, BIOCHEMISTRY-US, V40, P5983, DOI 10.1021/bi002961w; Praprotnik D, 1996, ACTA NEUROPATHOL, V91, P226, DOI 10.1007/s004010050420; SCHEFF SW, 1990, NEUROBIOL AGING, V11, P29, DOI 10.1016/0197-4580(90)90059-9; Schiewe AJ, 2004, PHARM RES-DORDR, V21, P1094, DOI 10.1023/B:PHAM.0000032994.36343.02; Sengupta A, 1998, ARCH BIOCHEM BIOPHYS, V357, P299, DOI 10.1006/abbi.1998.0813; SHECHTER Y, 1975, BIOCHEMISTRY-US, V14, P4497, DOI 10.1021/bi00691a025; Shibata N, 2001, BRAIN RES, V917, P97, DOI 10.1016/S0006-8993(01)02926-2; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; Terry RD, 1996, J NEUROPATH EXP NEUR, V55, P1023, DOI 10.1097/00005072-199655100-00001; Vanacore RM, 2005, J BIOL CHEM, V280, P29300, DOI 10.1074/jbc.M502752200; Wang Q, 2005, FASEB J, V19, P869, DOI 10.1096/fj.04-3210fje; Woltjer RL, 2005, FASEB J, V19, P1923, DOI 10.1096/fj.05-4263fje; Zhou Y, 2004, J BIOL CHEM, V279, P39155, DOI 10.1074/jbc.M405456200	47	26	27	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1473	1483		10.1096/fj.06-5920com	http://dx.doi.org/10.1096/fj.06-5920com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816122				2022-12-25	WOS:000240266000024
J	Amorino, GP; Deeble, PD; Parsons, SJ				Amorino, G. P.; Deeble, P. D.; Parsons, S. J.			Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway	ONCOGENE			English	Article						neurotensin; EGFR; Tyr(845); Src; Stat5b; prostate cancer	EPIDERMAL-GROWTH-FACTOR; EGF RECEPTOR TRANSACTIVATION; PROTEIN-COUPLED RECEPTORS; FOCAL ADHESION KINASE; NEUROENDOCRINE DIFFERENTIATION; TYROSINE KINASE; DNA-SYNTHESIS; TUMOR-CELLS; MAP-KINASE; C-SRC	Neuroendocrine (NE)-like cells are hypothesized to contribute to the progression of prostate cancer by producing factors that enhance the growth, survival or metastatic capabilities of surrounding tumor cells. Many of the factors known to be secreted by NE-like cells, such as neurotensin (NT), parathyroid hormone-related peptide, serotonin, bombesin, etc., are agonists for G-protein-coupled receptors, but the signaling pathways activated by these agonists in prostate tumor cells are not fully defined. Identification of such pathways could provide insights into novel methods of treating late-stage disease. Using conditioned culture medium (CM) from LNCaP-derived NE-like cells (as a source of these agonists) or NT (a prototypical component of CM) to treat PC3 cells, we found that the epidermal growth factor (EGF) receptor (EGFR) was transactivated and that such activation was required for maximal PC3 cell mitogenesis, as measured by 5-bromo-20-deoxy-uridine incorporation or cell number. NT also induced a time-dependent increase in EGFR Tyr(845) phosphorylation and phosphorylation of c-Src and signal transducer and activator of transcription 5b (Stat5b) (a downstream effector of Tyr845), events that were blocked by specific inhibition of c-Src (which mediates Tyr845 phosphorylation of EGFR) or of EGFR. Introduction of mutant forms of EGFR (Tyr845) or Stat5b in PC3 cells, or treatment with selective, catalytic inhibitors of EGFR, c-Src and matrix metalloproteinases (MMPs) resulted in the loss of NT-induced stimulation of DNA synthesis, relative to wild-type controls. These data indicate that the mitogenic effect of NT on prostate cancer cells requires transactivation of the EGFR by MMPs and a novel downstream pathway involving c-Src, phosphorylation of EGFR Tyr845 and activation of Stat5b.	Univ Virginia, Dept Microbiol, Hlth Sci Ctr, Ctr Canc, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Ctr Canc, Dept Radiat Oncol, Charlottesville, VA USA; Mary Baldwin Coll, Dept Biol, Staunton, VA USA	University of Virginia; University of Virginia	Parsons, SJ (corresponding author), Univ Virginia, Dept Microbiol, Hlth Sci Ctr, Ctr Canc, POB 800734, Charlottesville, VA 22908 USA.	sap@virginia.edu			NCI NIH HHS [R01 CA71449] Funding Source: Medline; NIDDK NIH HHS [T32 DK007646] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007646] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrahamsson PA, 1999, PROSTATE, V39, P135, DOI 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO;2-S; Amorino GP, 2004, CRIT REV EUKAR GENE, V14, P287, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i4.40; Aprikian AG, 1997, INT J CANCER, V72, P498, DOI 10.1002/(SICI)1097-0215(19970729)72:3<498::AID-IJC19>3.3.CO;2-P; Aprikian AG, 1996, J MOL ENDOCRINOL, V16, P297, DOI 10.1677/jme.0.0160297; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Boerner JL, 2005, MOL CARCINOGEN, V44, P262, DOI 10.1002/mc.20138; Boerner JL, 2004, MOL CELL BIOL, V24, P7059, DOI 10.1128/MCB.24.16.7059-7071.2004; BOLOGNA M, 1989, CANCER, V63, P1714; Cox ME, 1999, CANCER RES, V59, P3821; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Dal Farra C, 2001, INT J CANCER, V92, P503, DOI 10.1002/ijc.1225; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Deeble PD, 2001, MOL CELL BIOL, V21, P8471, DOI 10.1128/MCB.21.24.8471-8482.2001; DISANTAGNESE PA, 1992, CANCER-AM CANCER SOC, V70, P254, DOI 10.1002/1097-0142(19920701)70:1+<254::AID-CNCR2820701312>3.0.CO;2-E; GULLY D, 1993, P NATL ACAD SCI USA, V90, P65, DOI 10.1073/pnas.90.1.65; Hassan S, 2006, REGUL PEPTIDES, V133, P105, DOI 10.1016/j.regpep.2005.09.031; Hassan S, 2004, REGUL PEPTIDES, V120, P155, DOI 10.1016/j.regpep.2004.03.004; IWAMURA M, 1994, UROLOGY, V43, P675, DOI 10.1016/0090-4295(94)90183-X; Jongsma J, 2000, PROSTATE, V42, P34, DOI 10.1002/(SICI)1097-0045(20000101)42:1<34::AID-PROS5>3.0.CO;2-2; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; Kloth MT, 2002, J BIOL CHEM, V277, P8693, DOI 10.1074/jbc.M111884200; Labbe-Jullie C, 1998, J BIOL CHEM, V273, P16351, DOI 10.1074/jbc.273.26.16351; LARRAN LJ, 2000, ACTAS UROL ESP, V24, P779; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Madarame J, 2003, PROSTATE, V57, P187, DOI 10.1002/pros.10295; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; Petit T, 2001, ANTI-CANCER DRUG, V12, P133, DOI 10.1097/00001813-200102000-00006; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; REILE H, 1994, PROSTATE, V25, P29, DOI 10.1002/pros.2990250105; Santiskulvong C, 2003, EXP CELL RES, V290, P437, DOI 10.1016/S0014-4827(03)00355-0; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Seethalakshmi L, 1997, PROSTATE, V31, P183, DOI 10.1002/(SICI)1097-0045(19970515)31:3<183::AID-PROS7>3.0.CO;2-M; SEHGAL I, 1994, P NATL ACAD SCI USA, V91, P4673, DOI 10.1073/pnas.91.11.4673; Sepulveda VAT, 2002, REGUL PEPTIDES, V105, P109, DOI 10.1016/S0167-0115(02)00007-1; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Wright JD, 1996, BBA-MOL CELL RES, V1312, P85, DOI 10.1016/0167-4889(96)00027-4; Xiao DM, 2003, CELL SIGNAL, V15, P945, DOI 10.1016/S0898-6568(03)00059-7; Xiao DM, 2002, REGUL PEPTIDES, V109, P141, DOI 10.1016/S0167-0115(02)00197-0; Yano S, 2004, BONE, V35, P664, DOI 10.1016/j.bone.2004.04.014; Zhao DZ, 2004, J BIOL CHEM, V279, P43547, DOI 10.1074/jbc.M401453200	46	66	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					745	756		10.1038/sj.onc.1209814	http://dx.doi.org/10.1038/sj.onc.1209814			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16862179				2022-12-25	WOS:000243902200011
J	Anderson, JP; Walker, DE; Goldstein, JM; de Laat, R; Banducci, K; Caccavello, RJ; Barbour, R; Huang, JP; Kling, K; Lee, M; Diep, L; Keim, PS; Shen, XF; Chataway, T; Schlossmacher, MG; Seubert, P; Schenk, D; Sinha, S; Gai, WP; Chilcote, TJ				Anderson, John P.; Walker, Donald E.; Goldstein, Jason M.; de laat, Rian; Banducci, Kelly; Caccavello, Russell J.; Barbour, Robin; Huang, Jiping; Kling, Kristin; Lee, Michael; Diep, Linnea; Keim, Pamela S.; Shen, Xiaofeng; Chataway, Tim; Schlossmacher, Michael G.; Seubert, Peter; Schenk, Dale; Sinha, Sukanto; Gai, Wei Ping; Chilcote, Tamie J.			Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; UBIQUITINATION; INCLUSIONS; BODIES; AGGREGATION; DUPLICATION; PROTEASOME	A comprehensive, unbiased inventory of synuclein forms present in Lewy bodies from patients with dementia with Lewy bodies was carried out using two- dimensional immunoblot analysis, novel sandwich enzyme- linked immunosorbent assays with modification- specific synuclein antibodies, and mass spectroscopy. The predominant modification of alpha-synuclein in Lewy bodies is a single phosphorylation at Ser-129. In addition, there is a set of characteristic modifications that are present to a lesser extent, including ubiquitination at Lys residues 12, 21, and 23 and specific truncations at Asp- 115, Asp- 119, Asn-122, Tyr- 133, and Asp- 135. No other modifications are detectable by tandem mass spectrometry mapping, except for a ubiquitous N- terminal acetylation. Small amounts of Ser- 129 phosphorylated and Asp- 119- truncated alpha- synuclein are present in the soluble fraction of both normal and disease brains, suggesting that these Lewy body-associated forms are produced during normal metabolism of alpha-synuclein. In contrast, ubiquitination is only detected in Lewy bodies and is primarily present on phosphorylated synuclein; it therefore likely occurs after phosphorylated synuclein has deposited into Lewy bodies. This invariant pattern of specific phosphorylation, truncation, and ubiquitination is also present in the detergent- insoluble fraction of brain from patients with familial Parkinson's disease ( synuclein A53T mutation) as well as multiple system atrophy, suggesting a common pathogenic pathway for both genetic and sporadic Lewy body diseases. These observations are most consistent with a model in which preferential accumulation of normally produced Ser- 129 phosphorylated alpha- synuclein is the key event responsible for the formation of Lewy bodies in various Lewy body diseases.	Elan Pharmaceut, San Francisco, CA 94080 USA; Flinders Univ S Australia, Sch Med, Bedford Pk, SA 5042, Australia; Harvard Univ, Brigham & Womens Hosp, Ctr Neurol Dis, Sch Med, Boston, MA 02115 USA	Flinders University South Australia; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Chilcote, TJ (corresponding author), ActiveSite Pharmaceut, 187 Megellan Ave, San Francisco, CA 94116 USA.	tamie.chilcote@activesitepharma.com	Gai, Wei-Ping/A-3700-2008	Chataway, Tim/0000-0003-0254-8099; Schlossmacher, Michael/0000-0002-0394-0300	NINDS NIH HHS [P50-NS40256] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS040256] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRADSHAW RA, 1989, TRENDS BIOCHEM SCI, V14, P276, DOI 10.1016/0968-0004(89)90063-7; Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; Duda JE, 2002, ACTA NEUROPATHOL, V104, P7, DOI 10.1007/s00401-002-0563-3; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Gai WP, 2000, EXP NEUROL, V166, P324, DOI 10.1006/exnr.2000.7527; Gai WP, 1999, J NEUROCHEM, V73, P2093; Golbe LI, 1996, ANN NEUROL, V40, P767, DOI 10.1002/ana.410400513; Hasegawa M, 2002, J BIOL CHEM, V277, P49071, DOI 10.1074/jbc.M208046200; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Ibanez P, 2004, LANCET, V364, P1169, DOI 10.1016/S0140-6736(04)17104-3; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jensen PH, 2000, J BIOL CHEM, V275, P21500, DOI 10.1074/jbc.M000099200; Kahle PJ, 2002, EMBO REP, V3, P583, DOI 10.1093/embo-reports/kvf109; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; KUZUHARA S, 1988, ACTA NEUROPATHOL, V75, P345, DOI 10.1007/BF00687787; Li WX, 2005, P NATL ACAD SCI USA, V102, P2162, DOI 10.1073/pnas.0406976102; Liu CW, 2005, J BIOL CHEM, V280, P22670, DOI 10.1074/jbc.M501508200; Miake H, 2002, J BIOL CHEM, V277, P19213, DOI 10.1074/jbc.M110551200; Mishizen-Eberz AJ, 2003, J NEUROCHEM, V86, P836, DOI 10.1046/j.1471-4159.2003.01878.x; Murray IVJ, 2003, BIOCHEMISTRY-US, V42, P8530, DOI 10.1021/bi027363r; Nonaka T, 2005, BIOCHEMISTRY-US, V44, P361, DOI 10.1021/bi0485528; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rideout HJ, 2004, J BIOL CHEM, V279, P46915, DOI 10.1074/jbc.M405146200; Sampathu DM, 2003, AM J PATHOL, V163, P91, DOI 10.1016/S0002-9440(10)63633-4; Schlossmacher Michael G., 2005, V301, P351; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Smith WW, 2005, J NEUROSCI, V25, P5544, DOI 10.1523/JNEUROSCI.0482-05.2005; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spira PJ, 2001, ANN NEUROL, V49, P313, DOI 10.1002/ana.67; Tofaris GK, 2003, J BIOL CHEM, V278, P44405, DOI 10.1074/jbc.M308041200	35	862	888	1	62	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29739	29752		10.1074/jbc.M600933200	http://dx.doi.org/10.1074/jbc.M600933200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16847063	hybrid			2022-12-25	WOS:000240896300036
J	Dulebohn, DP; Cho, HJ; Karzai, AW				Dulebohn, Daniel P.; Cho, Hye Jin; Karzai, A. Wali			Role of conserved surface amino acids in binding of SmpB protein to SsrA RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-MESSENGER RNA; ELONGATION-FACTOR TU; TRANS-TRANSLATION; THERMUS-THERMOPHILUS; RIBOSOME RESCUE; TMRNA; SYSTEM; DEGRADATION; PROTEOLYSIS; DOMAIN	Bacteria possess a unique salvage mechanism for rescuing ribosomes stalled on aberrant mRNAs. A complex of SmpB protein and SsrA RNA orchestrates this salvage process. The specific and direct binding of SmpB facilitates recognition and delivery of SsrA RNA to stalled ribosomes. The SmpB protein is conserved throughout the bacterial kingdom and contains several conserved amino acid sequence motifs. We present evidence to demonstrate that amino acid residues Glu-31, Leu-91, and Lys-124, which are highly conserved and clustered along an exposed surface of the protein, play a crucial role in the SsrA-mediated peptide tagging process. Our analysis suggests that the peptide-tagging defect exhibited by these SmpB variants is due to their inability to facilitate the delivery of SsrA RNA to stalled ribosomes. Moreover, we present evidence to demonstrate that the ribosome association defect of these variants is due to their reduced SsrA binding affinity. Consistent with these findings, we present biochemical evidence to demonstrate that residues Glu-31, Leu-91, and Lys-124 are essential for the SsrA binding activity of SmpB protein. Furthermore, we have investigated the interactions of SmpB . SsrA orthologues from the thermophilic bacterium Thermoanaerobacter tengcongensis. Our investigations demonstrate an analogous role for the equivalent T. tengcongensis residues in SmpB.SsrA interactions, hence further validating our findings for the Escherichia coli SmpB.SsrA system. These results demonstrate the functional significance of this cluster of conserved residues in SmpB binding to SsrA RNA, suggesting they might represent a core contact surface for recognition of SsrA RNA.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Infect Dis, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Karzai, AW (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	akarzai@ms.cc.sunysb.edu						Barends S, 2001, J MOL BIOL, V314, P9, DOI 10.1006/jmbi.2001.5114; Berggrun A, 2000, J MOL BIOL, V301, P959, DOI 10.1006/jmbi.2000.4007; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Dong G, 2002, EMBO J, V21, P1845, DOI 10.1093/emboj/21.7.1845; Felden B, 1998, EMBO J, V17, P3188, DOI 10.1093/emboj/17.11.3188; Gillet R, 2001, MOL MICROBIOL, V42, P879, DOI 10.1046/j.1365-2958.2001.02701.x; Grzymski EC, 2003, NAT STRUCT BIOL, V10, P321, DOI 10.1038/nsb0503-321; Gutmann S, 2003, NATURE, V424, P699, DOI 10.1038/nature01831; Hanawa-Suetsugu K, 2002, NUCLEIC ACIDS RES, V30, P1620, DOI 10.1093/nar/30.7.1620; Huang CH, 2000, EMBO J, V19, P1098, DOI 10.1093/emboj/19.5.1098; Hutchison CA, 1999, SCIENCE, V286, P2165, DOI 10.1126/science.286.5447.2165; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Karzai AW, 1999, EMBO J, V18, P3793, DOI 10.1093/emboj/18.13.3793; Keiler KC, 2000, P NATL ACAD SCI USA, V97, P7778, DOI 10.1073/pnas.97.14.7778; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Okan Nihal A., 2006, PLoS Pathogens, V2, P50; Rudinger-Thirion J, 1999, RNA, V5, P989, DOI 10.1017/S135583829999101X; Someya T, 2003, FEBS LETT, V535, P94, DOI 10.1016/S0014-5793(02)03880-2; Stepanov VG, 2003, EUR J BIOCHEM, V270, P463, DOI 10.1046/j.1432-1033.2003.03401.x; Sundermeier TR, 2005, P NATL ACAD SCI USA, V102, P2316, DOI 10.1073/pnas.0409694102; Withey JH, 2003, ANNU REV MICROBIOL, V57, P101, DOI 10.1146/annurev.micro.57.030502.090945; Zvereva ME, 2000, MOL BIOL+, V34, P927, DOI 10.1023/A:1026692229336; Zwieb C, 2001, BIOCHEMISTRY-US, V40, P9587, DOI 10.1021/bi010443v	23	14	16	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28536	28545		10.1074/jbc.M605137200	http://dx.doi.org/10.1074/jbc.M605137200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16867994	hybrid			2022-12-25	WOS:000240680500007
J	Ramm, G; Larance, M; Guilhaus, M; James, DE				Ramm, Georg; Larance, Mark; Guilhaus, Michael; James, David E.			A role for 14-3-3 in insulin-stimulated GLUT4 translocation through its interaction with the RabGAP AS160	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING-PROTEIN; SIGNALING PROTEINS; TUMOR-SUPPRESSOR; GENE-PRODUCT; PHOSPHORYLATION; TRAFFICKING; REGULATOR; TUBERIN; BINDING; TSC2	Translocation of the insulin-regulated glucose transporter GLUT4 to the cell surface is dependent on the phosphatidylinositol 3-kinase/Akt pathway. The RabGAP (Rab GTPase-activating protein) AS160 (Akt substrate of 160 kDa) is a direct substrate of Akt and plays an essential role in the regulation of GLUT4 trafficking. We have used liquid chromatography tandem mass spectrometry to identify several 14-3-3 isoforms as AS160-interacting proteins. 14-3-3 proteins interact with AS160 in an insulin- and Akt-dependent manner via an Akt phosphorylation site, Thr-642. This correlates with the dominant negative effect of both the AS160(T642A) and the AS160(4P) mutants on insulin- stimulated GLUT4 translocation. Introduction of a constitutive 14-3-3 binding site into AS160(4P) restored 14-3-3 binding without disrupting AS160- IRAP (insulin- responsive amino peptidase) interaction and reversed the inhibitory effect of AS160(4P) on GLUT4 translocation. These data show that the insulin- dependent association of 14-3-3 with AS160 plays an important role in GLUT4 trafficking in adipocytes.	Garvan Inst Med Res, Diabet & Obes Program, Darlinghurst, NSW 2010, Australia; Univ New S Wales, Bioanalyt Mass Spectrometry Facil, Sydney, NSW 2052, Australia	Garvan Institute of Medical Research; University of New South Wales Sydney	Ramm, G (corresponding author), Garvan Inst Med Res, Diabet & Obes Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	g.ramm@garvan.org.au; d.james@garvan.org.au	Larance, Mark/AAG-8613-2019	James, David/0000-0001-5946-5257; Ramm, Georg/0000-0003-3596-2288; Larance, Mark/0000-0002-8579-2267				Beguin P, 2005, J CELL SCI, V118, P1923, DOI 10.1242/jcs.02321; Benzing T, 2000, J BIOL CHEM, V275, P28167; Benzing T, 2002, J BIOL CHEM, V277, P32954, DOI 10.1074/jbc.M200859200; Bernards A, 2005, GROWTH FACTORS, V23, P143, DOI 10.1080/08977190500130480; Bernards A, 2004, TRENDS CELL BIOL, V14, P377, DOI 10.1016/j.tcb.2004.05.003; Bernards A, 2003, BBA-REV CANCER, V1603, P47, DOI 10.1016/S0304-419X(02)00082-3; BRIDGES D, 2005, SCI STKE, pRE10, DOI DOI 10.1126/STKE.2962005RE10; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Cai SL, 2006, J CELL BIOL, V173, P279, DOI 10.1083/jcb.200507119; Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171; Eguez L, 2005, CELL METAB, V2, P263, DOI 10.1016/j.cmet.2005.09.005; Feng LP, 2004, FEBS LETT, V557, P275, DOI 10.1016/S0014-5793(03)01507-2; Hekman M, 2004, J BIOL CHEM, V279, P14074, DOI 10.1074/jbc.M309620200; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Larance M, 2005, J BIOL CHEM, V280, P37803, DOI 10.1074/jbc.M503897200; Li Y, 2003, J BIOL CHEM, V278, P13663, DOI 10.1074/jbc.M300862200; Li Y, 2002, J BIOL CHEM, V277, P44593, DOI 10.1074/jbc.C200510200; Liu J, 2003, J BIOL CHEM, V278, P36754, DOI 10.1074/jbc.M300664200; Mackintosh C, 2004, BIOCHEM J, V381, P329, DOI 10.1042/BJ20031332; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Miinea CP, 2005, BIOCHEM J, V391, P87, DOI 10.1042/BJ20050887; Nellist M, 2002, J BIOL CHEM, V277, P39417, DOI 10.1074/jbc.M204802200; Ramm G, 2005, CELL METAB, V2, P150, DOI 10.1016/j.cmet.2005.08.008; Sano H, 2003, J BIOL CHEM, V278, P14599, DOI 10.1074/jbc.C300063200; Scheffzek K, 2005, CELL MOL LIFE SCI, V62, P3014, DOI 10.1007/s00018-005-5136-x; Shewan AM, 2003, MOL BIOL CELL, V14, P973, DOI 10.1091/mbc.E02-06-0315; Shumway SD, 2003, J BIOL CHEM, V278, P2089, DOI 10.1074/jbc.C200499200; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Ward RJ, 2005, MOL PHARMACOL, V68, P1821, DOI 10.1124/moi.105.015073; Watson RT, 2004, ENDOCR REV, V25, P177, DOI 10.1210/er.2003-0011; Welsh GL, 2005, BIOCHEM SOC T, V33, P346, DOI 10.1042/BST0330346; Wilker E, 2004, J MOL CELL CARDIOL, V37, P633, DOI 10.1016/j.yjmcc.2004.04.015; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zeigerer A, 2004, MOL BIOL CELL, V15, P4406, DOI 10.1091/mbc.e04-04-0333	34	164	167	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29174	29180		10.1074/jbc.M603274200	http://dx.doi.org/10.1074/jbc.M603274200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16880201	hybrid			2022-12-25	WOS:000240680500072
J	Sun, JP; Zhuang, FF; Mullersman, JE; Chen, H; Robertson, EJ; Warburton, D; Liu, YH; Shi, W				Sun, Jianping; Zhuang, Feng-Feng; Mullersman, Jerald E.; Chen, Hui; Robertson, Elizabeth J.; Warburton, David; Liu, Yi-Hsin; Shi, Wei			BMP4 activation and secretion are negatively regulated by an intracellular gremlin-BMP4 interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEINS; TGF-BETA; ANTAGONIST; GENE; SCLEROSTIN; EXPRESSION; XENOPUS; INHIBITION; CERBERUS; SIGNALS	Bone morphogenetic protein 4 (BMP4) is a potent growth factor that is involved in many important biological processes. Regulation of the level of secreted mature BMP4 determines the biological effects of BMP4 on cells in the local microenvironment. Previous studies suggested that Gremlin, a member of DAN family proteins, antagonizes BMP4 activity by sequestering extracellular BMP4. Herein, we report a novel intracellular regulatory mechanism by which Gremlin interacts with BMP4 precursor, prevents secretion of mature BMP4, and therefore inhibits BMP4 activity more efficiently. Furthermore, we also defined a 30-amino acid peptide sequence within the Gremlin DAN domain that is essential for BMP4 interaction. This novel Gremlin-mediated BMP4 posttranslational regulatory mechanism implies that the level of BMP4 mRNA expression does not truly reflect BMP4 activity when Gremlin and BMP4 are coexpressed within the same cell. Similar regulatory mechanisms may be utilized by other DAN family proteins.	Childrens Hosp Los Angeles, Dept Surg, Dev Biol Program, Saban Res Inst, Los Angeles, CA 90027 USA; Univ So Calif, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA; E Tennessee State Univ, Dept Pathol, Johnson City, TN 37614 USA; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England	Children's Hospital Los Angeles; University of Southern California; East Tennessee State University; University of Oxford; Wellcome Centre for Human Genetics	Shi, W (corresponding author), Childrens Hosp Los Angeles, Dept Surg, Dev Biol Program, Saban Res Inst, 4650 Sunset Blvd,MS 35, Los Angeles, CA 90027 USA.	wshi@chla.usc.edu	zhuang, Fengfeng/A-5822-2018; Warburton, David/AAD-5709-2020	zhuang, Fengfeng/0000-0001-7888-0827; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068597, R01HL061286] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68597, R01 HL068597-05A1, R01 HL068597, HL61286] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdolzade-Bavil A, 2004, PROTEOMICS, V4, P1397, DOI 10.1002/pmic.200300710; Avsian-Kretchmer O, 2004, MOL ENDOCRINOL, V18, P1, DOI 10.1210/me.2003-0227; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Bell E, 2003, DEVELOPMENT, V130, P1381, DOI 10.1242/dev.00344; Constam DB, 1999, J CELL BIOL, V144, P139, DOI 10.1083/jcb.144.1.139; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; De Robertis EM, 2004, ANNU REV CELL DEV BI, V20, P285, DOI 10.1146/annurev.cellbio.20.011403.154124; Ghosh RN, 1998, J CELL BIOL, V142, P923, DOI 10.1083/jcb.142.4.923; Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245; HAMMONDS RG, 1991, MOL ENDOCRINOL, V5, P149, DOI 10.1210/mend-5-1-149; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Khokha MK, 2003, NAT GENET, V34, P303, DOI 10.1038/ng1178; Kishigami S, 2005, CYTOKINE GROWTH F R, V16, P265, DOI 10.1016/j.cytogfr.2005.04.002; Kusu N, 2003, J BIOL CHEM, V278, P24113, DOI 10.1074/jbc.M301716200; Michos O, 2004, DEVELOPMENT, V131, P3401, DOI 10.1242/dev.01251; Minabe-Saegusa C, 1998, DEV GROWTH DIFFER, V40, P343; Nickel J, 2001, J BONE JOINT SURG AM, V83A, pS7; OZAKI T, 1993, P NATL ACAD SCI USA, V90, P2593, DOI 10.1073/pnas.90.7.2593; Pearce JJH, 1999, DEV BIOL, V209, P98, DOI 10.1006/dbio.1999.9240; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Shi W, 2003, DEV BIOL, V261, P371, DOI 10.1016/S0012-1606(03)00315-4; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Simmons DG, 2002, BIOL REPROD, V67, P1638, DOI 10.1095/biolreprod.102.006858; Topol LZ, 1997, MOL CELL BIOL, V17, P4801, DOI 10.1128/MCB.17.8.4801; van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454; Wilkinson L, 2003, J BIOL CHEM, V278, P34181, DOI 10.1074/jbc.M301247200; Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; Yanagita M, 2005, CYTOKINE GROWTH F R, V16, P309, DOI 10.1016/j.cytogfr.2005.02.007	32	65	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29349	29356		10.1074/jbc.M603833200	http://dx.doi.org/10.1074/jbc.M603833200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16880207	hybrid, Green Published			2022-12-25	WOS:000240680500090
J	Takahara, T; Hara, K; Yonezawa, K; Sorimachi, H; Maeda, T				Takahara, Terunao; Hara, Kenta; Yonezawa, Kazuyoshi; Sorimachi, Hiroyuki; Maeda, Tatsuya			Nutrient-dependent multimerization of the mammalian target of rapamycin through the N-terminal HEAT repeat region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; CELL-GROWTH; BINDING PARTNER; AMINO-ACIDS; EIF-4E BP1; MTOR; TOR; ACTIVATION; PROTEIN; RAPTOR	The mammalian target of rapamycin ( mTOR) plays a pivotal role in the regulation of cell growth in response to a variety of signals such as nutrients and growth factors. mTOR forms two distinct complexes in vivo. mTORC1(mTOR complex 1) is rapamycin-sensitive and regulates the rate of protein synthesis in part by phosphorylating two well established effectors, S6K1 (p70 ribosomal S6 kinase 1) and 4E-BP1 (eukaryotic initiation factor 4E-binding protein 1). mTORC2 is rapamycin-insensitive and likely regulates actin organization and activates Akt/protein kinase B. Here, we show that mTOR forms a multimer via its N-terminal HEAT repeat region in mammalian cells. mTOR multimerization is promoted by amino acid sufficiency, although the state of multimerization does not directly correlate with the phosphorylation state of S6K1. mTOR multimerization was insensitive to rapamycin treatment but hindered by butanol treatment, which inhibits phosphatidic acid production by phospholipase D. We also found that mTOR forms a multimer in both mTORC1 and mTORC2. In addition, Saccharomyces cerevisiae TOR proteins Tor1p and Tor2p also exist as homo-multimers. These results suggest that TOR multimerization is a conserved mechanism for TOR functioning.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Kobe Univ, Sch Med, Dept Geriatr Med, Kobe, Hyogo 6500017, Japan; Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo 6578501, Japan; Tokyo Metropolitan Inst Med Sci, Dept Enzymat Regulat Cell Funct, Tokyo 1138613, Japan	University of Tokyo; Kobe University; Kobe University; Tokyo Metropolitan Institute of Medical Science	Maeda, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	maeda@iam.u-tokyo.ac.jp	Maeda, Tatsuya/L-5540-2019; Sorimachi, Hiroyuki/C-6448-2009	Sorimachi, Hiroyuki/0000-0001-9509-6727				ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200; Choi JH, 2002, EMBO REP, V3, P988, DOI 10.1093/embo-reports/kvf197; Crespo JL, 2002, MICROBIOL MOL BIOL R, V66, P579, DOI 10.1128/MMBR.66.4.579-591.2002; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Farrar MA, 2000, METHOD ENZYMOL, V327, P421, DOI 10.1016/S0076-6879(00)27293-5; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Harris Thurl E, 2003, Sci STKE, V2003, pre15; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Long XM, 2005, J BIOL CHEM, V280, P23433, DOI 10.1074/jbc.C500169200; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; Oshiro N, 2004, GENES CELLS, V9, P359, DOI 10.1111/j.1356-9597.2004.00727.x; Perry J, 2003, CELL, V112, P151, DOI 10.1016/S0092-8674(03)00033-3; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Reinke A, 2004, J BIOL CHEM, V279, P14752, DOI 10.1074/jbc.M313062200; Sabatini DM, 1999, SCIENCE, V284, P1161, DOI 10.1126/science.284.5417.1161; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; Wedaman KP, 2003, MOL BIOL CELL, V14, P1204, DOI 10.1091/mbc.E02-09-0609; Wu SL, 2002, BBA-MOL CELL RES, V1542, P41, DOI 10.1016/S0167-4889(01)00164-1; Wullschleger S, 2005, J BIOL CHEM, V280, P30697, DOI 10.1074/jbc.M505553200; Zhang Y, 2006, GENETICS, V172, P355, DOI 10.1534/genetics.105.051979	43	60	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28605	28614		10.1074/jbc.M606087200	http://dx.doi.org/10.1074/jbc.M606087200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16870609	hybrid			2022-12-25	WOS:000240680500014
J	Khan, MA; Miyoshi, H; Ray, S; Natsuaki, T; Suehiro, N; Goss, DJ				Khan, Mateen A.; Miyoshi, Hiroshi; Ray, Sibnath; Natsuaki, Tomohide; Suehiro, Noriko; Goss, Dixie J.			Interaction of genome-linked protein (VPg) of turnip mosaic virus with wheat germ translation initiation factors eIFiso4E and eIFiso4F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO ETCH VIRUS; YEAST 2-HYBRID SYSTEM; CAP-BINDING-PROTEINS; MESSENGER-RNA; RESISTANCE-BREAKING; ISOZYME FORM; FACTOR 4F; POTYVIRUS; COMPLEX; IDENTIFICATION	The interaction between VPg of turnip mosaic virus and wheat germ eukaryotic translation initiation factors eIFiso4E and eIFiso4F ( the complex of eIFiso4E and eIFiso4G) were measured and compared. The fluorescence quenching data showed the presence of one binding site on eIFiso4E for VPg. Scatchard analysis revealed the binding affinity (K-a) and average binding sites (n) for VPg were (8.51 +/- 0.21) x 10(6) M-1 and 1.0, respectively. The addition of eIFiso4G to the eIFiso4E increased the binding affinity 1.5-fold for VPg as compared with eIFiso4E alone. However, eIFiso4G alone did not bind with VPg. The van't Hoff analyses showed that VPg binding is enthalpy-driven and entropy-favorable with a large negative Delta H degrees (-29.32 +/- 0.13 kJmol(-1)) and positive Delta S degrees (36.88 +/- 0.25 Jmol(-1) K-1). A Lineweaver-Burk plot indicates mixed-type competitive ligand binding between VPg and anthraniloyl-7- methylguanosine triphosphate for eIFiso4E. Fluorescence stopped-flow studies of eIFiso4E and eIFiso4F with VPg show rapid binding, suggesting kinetic competition between VPg and m(7)G cap. The VPg protein binds much faster than cap analogs. The activation energies for binding of eIFiso4E and eIFiso4F with VPg were 50.70 +/- 1.27 and 75.37 +/- 2.95 kJmol(-1) respectively. Enhancement of eIFiso4F-VPg binding with the addition of a structured RNA derived from tobacco etch virus suggests that translation initiation involving VPg occurs at internal ribosomal entry sites. Furthermore, the formation of a protein-RNA complex containing VPg suggests the possibility of direct participation of VPg in the translation of the viral genome.	CUNY Hunter Coll, Dept Chem, New York, NY 10021 USA; CUNY, Grad Ctr, New York, NY 10021 USA; St Marianna Univ, Sch Med, Dept Microbiol, Kawasaki, Kanagawa 2168511, Japan; Utsunomiya Univ, Genome Res Inst, Utsunomiya, Tochigi 3218505, Japan	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Saint Marianna University; Utsunomiya University	Goss, DJ (corresponding author), CUNY Hunter Coll, Dept Chem, New York, NY 10021 USA.	dgoss@hunter.cuny.edu	NATSUAKI, Tomohide/AAG-1963-2020; Ray, Sibnath/C-7369-2008	Ray, Sibnath/0000-0002-6313-3930; Khan, Mateen A./0000-0002-2300-4595; Natsuaki, Tomohide/0000-0003-1823-7308; Miyoshi, Hiroshi/0000-0002-0489-9848	NCRR NIH HHS [RR-03037] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABRAMSON RD, 1988, J BIOL CHEM, V263, P5462; BALASTA ML, 1993, J BIOL CHEM, V268, P18599; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNING KS, 1992, J BIOL CHEM, V267, P10096; CARRINGTON JC, 1990, J VIROL, V64, P1590, DOI 10.1128/JVI.64.4.1590-1597.1990; Daughenbaugh KF, 2003, EMBO J, V22, P2852, DOI 10.1093/emboj/cdg251; Fellers J, 1998, J GEN VIROL, V79, P2043, DOI 10.1099/0022-1317-79-8-2043; Gale M, 2000, MICROBIOL MOL BIOL R, V64, P239, DOI 10.1128/MMBR.64.2.239-280.2000; GARLAND DL, 1978, BIOCHEMISTRY-US, V17, P4266, DOI 10.1021/bi00613a024; Goodfellow I, 2005, EMBO REP, V6, P968, DOI 10.1038/sj.embor.7400510; Haghighat A, 1996, J VIROL, V70, P8444, DOI 10.1128/JVI.70.12.8444-8450.1996; Herbert TP, 1997, J GEN VIROL, V78, P1033, DOI 10.1099/0022-1317-78-5-1033; HONG YL, 1995, VIROLOGY, V214, P159, DOI 10.1006/viro.1995.9944; Keller KE, 1998, MOL PLANT MICROBE IN, V11, P124, DOI 10.1094/MPMI.1998.11.2.124; Khan MA, 2005, BIOCHEMISTRY-US, V44, P4510, DOI 10.1021/bi047298g; Khan MA, 2004, BIOCHEMISTRY-US, V43, P9092, DOI 10.1021/bi049602b; Khan MA, 2002, INT J BIOL MACROMOL, V30, P243, DOI 10.1016/S0141-8130(02)00038-7; LAX S, 1985, P NATL ACAD SCI USA, V82, P330, DOI 10.1073/pnas.82.2.330; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; Leonard S, 2000, J VIROL, V74, P7730, DOI 10.1128/JVI.74.17.7730-7737.2000; LEVINE RL, 1977, CLIN CHEM, V23, P2292; Li XH, 1997, J VIROL, V71, P1598, DOI 10.1128/JVI.71.2.1598-1607.1997; Masuta C, 1999, PHYTOPATHOLOGY, V89, P118, DOI 10.1094/PHYTO.1999.89.2.118; Michon T, 2006, FEBS J, V273, P1312, DOI 10.1111/j.1742-4658.2006.05156.x; Miyoshi H, 2006, BIOCHIMIE, V88, P329, DOI 10.1016/j.biochi.2005.09.002; MURPHY JF, 1990, VIROLOGY, V178, P285, DOI 10.1016/0042-6822(90)90405-G; Nicolas O, 1996, ARCH VIROL, V141, P1535, DOI 10.1007/BF01718253; Nicolas O, 1997, VIROLOGY, V237, P452, DOI 10.1006/viro.1997.8780; Noueiry AO, 2000, P NATL ACAD SCI USA, V97, P12985, DOI 10.1073/pnas.240460897; OLSEN K, 1993, BIOCHEMISTRY-US, V32, P9686, DOI 10.1021/bi00088a021; Ren JH, 1996, NUCLEIC ACIDS RES, V24, P3629, DOI 10.1093/nar/24.18.3629; RIECHMANN JL, 1992, J GEN VIROL, V73, P1, DOI 10.1099/0022-1317-73-1-1; RIECHMANN JL, 1989, J GEN VIROL, V70, P2785, DOI 10.1099/0022-1317-70-10-2785; Rodriguez CM, 1998, PLANT J, V13, P465, DOI 10.1046/j.1365-313X.1998.00047.x; Schaad MC, 1997, J VIROL, V71, P8624, DOI 10.1128/JVI.71.11.8624-8631.1997; Schaad MC, 2000, VIROLOGY, V273, P300, DOI 10.1006/viro.2000.0416; SIAW MFE, 1985, VIROLOGY, V142, P134, DOI 10.1016/0042-6822(85)90428-3; Suehiro N, 2004, J GEN VIROL, V85, P2087, DOI 10.1099/vir.0.79825-0; Thompson SR, 2000, CURR OPIN MICROBIOL, V3, P366, DOI 10.1016/S1369-5274(00)00106-5; VANHEERDEN A, 1994, J BIOL CHEM, V269, P17454; Wei CC, 1998, BIOCHEMISTRY-US, V37, P1910, DOI 10.1021/bi9724570; Wittmann S, 1997, VIROLOGY, V234, P84, DOI 10.1006/viro.1997.8634; Zeenko V, 2005, J BIOL CHEM, V280, P26813, DOI 10.1074/jbc.M503576200	44	54	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28002	28010		10.1074/jbc.M605479200	http://dx.doi.org/10.1074/jbc.M605479200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16880203	hybrid			2022-12-25	WOS:000240534400037
J	Kuroda, K; Ito, M; Shikano, T; Awaji, T; Yoda, A; Takeuchi, H; Kinoshita, K; Miyazaki, S				Kuroda, Keiji; Ito, Masahiko; Shikano, Tomohide; Awaji, Takeo; Yoda, Ayako; Takeuchi, Hiroyuki; Kinoshita, Katsuyuki; Miyazaki, Shunichi			The role of X/Y linker region and N-terminal EF-hand domain in nuclear translocation and Ca2+ oscillation-inducing activities of phospholipase C zeta, a mammalian egg-activating factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE OOCYTES; INOSITOL 1,4,5-TRISPHOSPHATE; FLUORESCENT PROTEIN; SPERM; PLC; FERTILIZATION; EMBRYOS; SITE; TRANSIENTS; CONTAINS	Sperm-specific phospholipase C-zeta (PLC zeta) causes intracellular Ca2+ oscillations and thereby egg activation and is accumulated into the formed pronucleus (PN) when expressed in mouse eggs by injection of cRNA encoding PLC zeta, which consists of four EF-hand domains (EF1-EF4) in the N terminus, X and Y catalytic domains, and C-terminal C2 domain. Those activities were analyzed by expressing PLC zeta mutants tagged with fluorescent protein Venus by injection of cRNA into unfertilized eggs or 1-cell embryos after fertilization. Nuclear localization signal (NLS) existed at 374 - 381 in the X/Y linker region. Nuclear translocation was lost by replacement of Arg(376), Lys(377), Arg(378), Lys(379), or Lys(381) with glutamate, whereas Ca2+ oscillations were conserved. Nuclear targeting was also absent for point mutation of Lys(299) and/or Lys(301) in the C terminus of X domain, or Trp(13), Phe(14), or Val(18) in the N terminus of EF1. Ca2+ oscillation-inducing activity was lost by the former mutation and was remarkably inhibited by the latter. Ashort sequence 374 - 383 fused with Venus showed active translocation into the nucleus of COS-7 cells, but 296 - 309 or 1 - 19 did not. Despite the presence of these special regions, both activities were deprived by deletion of not only EF1 but also EF2 - 4 or C2 domain. Thus, PLC zeta is driven into the nucleus primarily by the aid of NLS and putative regulatory sites, but coordinated three-dimensional structure, possibly formed by a folding in the X/Y linker and close EF/C2 contact as in PLC delta 1, seems to be required not only for enzymatic activity but also for nuclear translocation ability.	Tokyo Womens Med Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1628666, Japan; Juntendo Univ, Sch Med, Dept Obstet & Gynecol, Bunkyo Ku, Tokyo 1138241, Japan	Tokyo Women's Medical University; Juntendo University	Ito, M (corresponding author), Tokyo Womens Med Univ, Sch Med, Dept Physiol, Shinjuku Ku, 8-1 Kawado Cho, Tokyo 1628666, Japan.	mito@research.twmu.ac.jp						Aida T, 2001, MOL HUM REPROD, V7, P1039, DOI 10.1093/molehr/7.11.1039; Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; Ananthanarayanan B, 2002, J BIOL CHEM, V277, P3568, DOI 10.1074/jbc.M109705200; Avazeri N, 2000, MOL BIOL CELL, V11, P4369, DOI 10.1091/mbc.11.12.4369; Awaji T, 2001, BIOCHEM BIOPH RES CO, V289, P457, DOI 10.1006/bbrc.2001.6004; Birbach A, 2004, J CELL SCI, V117, P3615, DOI 10.1242/jcs.01224; Brind S, 2000, DEV BIOL, V223, P251, DOI 10.1006/dbio.2000.9728; Chen MH, 2005, J BIOL CHEM, V280, P10599, DOI 10.1074/jbc.M413194200; Corpet F, 2000, NUCLEIC ACIDS RES, V28, P267, DOI 10.1093/nar/28.1.267; Deguchi R, 2000, DEV BIOL, V218, P299, DOI 10.1006/dbio.1999.9573; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Ellis MV, 1998, J BIOL CHEM, V273, P11650, DOI 10.1074/jbc.273.19.11650; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GOSS VL, 1994, J BIOL CHEM, V269, P19074; Irvine RF, 2003, NAT REV MOL CELL BIO, V4, P349, DOI 10.1038/nrm1100; Jellerette T, 2000, DEV BIOL, V223, P238, DOI 10.1006/dbio.2000.9675; JONES KT, 1995, DEVELOPMENT, V121, P3259; Jones KT, 1998, INT J DEV BIOL, V42, P1; Jones KT, 2000, DEV BIOL, V225, P1, DOI 10.1006/dbio.2000.9826; Knott JG, 2005, BIOL REPROD, V72, P992, DOI 10.1095/biolreprod.104.036244; Kono T, 1996, J CELL BIOL, V132, P915, DOI 10.1083/jcb.132.5.915; KONO T, 1995, DEVELOPMENT, V121, P1123; Kouchi Z, 2005, J BIOL CHEM, V280, P21015, DOI 10.1074/jbc.M412123200; Kouchi Z, 2004, J BIOL CHEM, V279, P10408, DOI 10.1074/jbc.M313801200; Kumakiri J, 2003, DEV BIOL, V260, P522, DOI 10.1016/S0012-1606(03)00273-2; Kurokawa M, 2005, DEV BIOL, V285, P376, DOI 10.1016/j.ydbio.2005.06.029; Larman MG, 2004, J CELL SCI, V117, P2513, DOI 10.1242/jcs.01109; Marangos P, 2003, DEVELOPMENT, V130, P1461, DOI 10.1242/dev.00340; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Nomikos M, 2005, J BIOL CHEM, V280, P31011, DOI 10.1074/jbc.M500629200; Oda S, 1999, DEV BIOL, V209, P172, DOI 10.1006/dbio.1999.9233; Okada M, 2002, GENES CELLS, V7, P985, DOI 10.1046/j.1365-2443.2002.00577.x; Saunders CM, 2002, DEVELOPMENT, V129, P3533; Shirakawa H, 2004, BIOPHYS J, V86, P1739, DOI 10.1016/S0006-3495(04)74242-3; Sone Y, 2005, BIOCHEM BIOPH RES CO, V330, P690, DOI 10.1016/j.bbrc.2005.03.032; Swann K, 2004, REPRODUCTION, V127, P431, DOI 10.1530/rep.1.00169; Swann K, 1996, Rev Reprod, V1, P33, DOI 10.1530/ror.0.0010033; Williams RL, 1999, BBA-MOL CELL BIOL L, V1441, P255, DOI 10.1016/S1388-1981(99)00150-X; Yamaga M, 1999, J BIOL CHEM, V274, P28537, DOI 10.1074/jbc.274.40.28537; Yoda A, 2004, DEV BIOL, V268, P245, DOI 10.1016/j.ydbio.2003.12.028	42	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27794	27805		10.1074/jbc.M603473200	http://dx.doi.org/10.1074/jbc.M603473200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16854985	hybrid			2022-12-25	WOS:000240534400015
J	Pietri, M; Caprini, A; Mouillet-Richard, S; Pradines, E; Ermonval, M; Grassi, J; Kellermann, O; Schneider, B				Pietri, Mathea; Caprini, Andrea; Mouillet-Richard, Sophie; Pradines, Elodie; Ermonval, Myriam; Grassi, Jacques; Kellermann, Odile; Schneider, Benoit			Overstimulation of PrPC signaling pathways by prion peptide 106-126 causes oxidative injury of bioaminergic neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH-SY5Y NEUROBLASTOMA-CELLS; AMYLOID-BETA PEPTIDE; PROTEIN-FRAGMENT; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; NADPH-OXIDASE; ACTIVATION; SCRAPIE; NEUROTOXICITY; KINASE	Transmissible spongiform encephalopathies, also called prion diseases, are characterized by neuronal loss linked to the accumulation of PrPSc, a pathologic variant of the cellular prion protein ( PrPC). Although the molecular and cellular bases of PrPSc-induced neuropathogenesis are not yet fully understood, increasing evidence supports the view that PrPSc accumulation interferes with PrPC normal function(s) in neurons. In the present work, we exploit the properties of PrP(106-126), a synthetic peptide encompassing residues 106 126 of PrP, to investigate into the mechanisms sustaining prion-associated neuronal damage. This peptide shares many physicochemical properties with PrPSc and is neurotoxic in vitro and in vivo. We examined the impact of PrP-(106-126) exposure on 1C11 neuroepithelial cells, their neuronal progenies, and GT1-7 hypothalamic cells. This peptide triggers reactive oxygen species overflow, mitogen-activated protein kinase (ERK1/2), and SAPK (p38 and JNK1/2) sustained activation, and apoptotic signals in 1C11-derived serotonergic and noradrenergic neuronal cells, while having no effect on 1C11 precursor and GT1-7 cells. The neurotoxic action of PrP-(106-126) relies on cell surface expression of PrPC, recruitment of a PrPC-Caveolin-Fyn signaling platform, and overstimulation of NADPH- oxidase activity. Altogether, these findings provide actual evidence that PrP-(106-126)induced neuronal injury is caused by an amplification of PrPC-associated signaling responses, which notably promotes oxidative stress conditions. Distorsion of PrPC signaling in neuronal cells could hence represent a causal event in transmissible spongiform encephalopathy pathogenesis.	CNRS, FRE 2937, Differenciat Cellulaire & Prions, Inst Andre Lwoff, F-94801 Villejuif, France; Inst Pasteur, Dept Biol Cellulaire & Infect, F-75724 Paris 15, France; CEA Saclay, Serv Pharmacol & Immunol, Commissariat Energie Atom, F-91191 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Paris Saclay	Kellermann, O (corresponding author), CNRS, FRE 2937, Differenciat Cellulaire & Prions, Inst Andre Lwoff, 7 Rue Guy Moquet, F-94801 Villejuif, France.	okellerm@vjf.cnrs.fr	Mouillet, Sophie/E-4960-2017; Schneider, Benoit/AAF-3850-2019	Mouillet, Sophie/0000-0002-8950-1949; Ermonval, Myriam/0000-0002-9685-9826; PIETRI, Mathea/0000-0002-1819-2878; Schneider, Benoit/0000-0002-1377-2670				Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; Belichenko PV, 2000, NEUROPATH APPL NEURO, V26, P143, DOI 10.1046/j.1365-2990.2000.026002143.x; Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; BROWN DR, 1994, NEUROREPORT, V5, P2057, DOI 10.1097/00001756-199410270-00017; Budka H, 2003, BRIT MED BULL, V66, P121, DOI 10.1093/bmb/66.1.121; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Carimalo J, 2005, EUR J NEUROSCI, V21, P2311, DOI 10.1111/j.1460-9568.2005.04080.x; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chesebro B, 2005, SCIENCE, V308, P1435, DOI 10.1126/science.1110837; Chiesa R, 2003, J VIROL, V77, P7611, DOI 10.1128/JVI.77.13.7611-7622.2003; Chiesa R, 2000, P NATL ACAD SCI USA, V97, P5574, DOI 10.1073/pnas.97.10.5574; Contestabile Antonio, 2001, Current Topics in Medicinal Chemistry, V1, P553, DOI 10.2174/1568026013394723; Cooper AJL, 1997, BIOL CHEM, V378, P793; Corsaro A, 2003, ANN NY ACAD SCI, V1010, P610, DOI 10.1196/annals.1299.114; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Della-Bianca V, 2001, J BIOL CHEM, V276, P38929, DOI 10.1074/jbc.M107454200; Dupiereux I, 2005, BIOCHEM BIOPH RES CO, V331, P894, DOI 10.1016/j.bbrc.2005.04.012; Ettaiche M, 2000, J BIOL CHEM, V275, P36487, DOI 10.1074/jbc.C000579200; Fabrizi C, 2001, J BIOL CHEM, V276, P25692, DOI 10.1074/jbc.M100133200; Fioriti L, 2005, MOL CELL NEUROSCI, V28, P165, DOI 10.1016/j.mcn.2004.09.006; Florio T, 2003, J NEUROCHEM, V85, P62, DOI 10.1046/j.1471-4159.2003.01664.x; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Gavin R, 2005, FEBS LETT, V579, P4099, DOI 10.1016/j.febslet.2005.06.037; Gu YP, 2002, J BIOL CHEM, V277, P2275, DOI 10.1074/jbc.M104345200; Hetz C, 2003, TRENDS MOL MED, V9, P237, DOI 10.1016/S1471-4914(03)00069-8; Hugel B, 2004, CELL MOL LIFE SCI, V61, P2998, DOI 10.1007/s00018-004-4318-2; Ishikura N, 2005, P NATL ACAD SCI USA, V102, P886, DOI 10.1073/pnas.0408612101; Jamieson E, 2001, NEUROREPORT, V12, P3567, DOI 10.1097/00001756-200111160-00039; Jeffrey M, 2001, J COMP PATHOL, V124, P20, DOI 10.1053/jcpa.2000.0423; Jellinger KA, 2003, J NEURAL TRANSM-SUPP, P101; Kourie JI, 2001, CHEM-BIOL INTERACT, V138, P1, DOI 10.1016/S0009-2797(01)00228-9; Kovacs GG, 2001, NEUROBIOL DIS, V8, P881, DOI 10.1006/nbdi.2001.0418; Kulich SM, 2001, J NEUROCHEM, V77, P1058, DOI 10.1046/j.1471-4159.2001.00304.x; Lee HP, 2005, J NEUROCHEM, V95, P584, DOI 10.1111/j.1471-4159.2005.03429.x; Mallucci G, 2004, CURR OPIN NEUROL, V17, P641, DOI 10.1097/00019052-200412000-00002; Mallucci G, 2003, SCIENCE, V302, P871, DOI 10.1126/science.1090187; Marcus DL, 1998, EXP NEUROL, V150, P40, DOI 10.1006/exnr.1997.6750; Milhavet O, 2002, BRAIN RES REV, V38, P328, DOI 10.1016/S0165-0173(01)00150-3; Monnet C, 2004, FEBS LETT, V576, P114, DOI 10.1016/j.febslet.2004.08.076; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Mouillet-Richard S, 1999, MICROBES INFECT, V1, P969, DOI 10.1016/S1286-4579(99)80514-0; Mouillet-Richard S, 2000, J BIOL CHEM, V275, P9186, DOI 10.1074/jbc.275.13.9186; MULLER WEG, 1993, EUR J PHARM-MOLEC PH, V246, P261, DOI 10.1016/0922-4106(93)90040-G; Nixon RR, 2005, J BIOL CHEM, V280, P2455, DOI 10.1074/jbc.M410883200; O'Donovan CN, 2001, J BIOL CHEM, V276, P43516, DOI 10.1074/jbc.M103894200; Pearce RKB, 1997, J NEURAL TRANSM, V104, P661, DOI 10.1007/BF01291884; Perez M, 2003, BIOCHEM J, V372, P129, DOI 10.1042/BJ20021596; PERRY TL, 1982, NEUROSCI LETT, V33, P305, DOI 10.1016/0304-3940(82)90390-1; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rodolfo K, 1999, NEUROREPORT, V10, P3639, DOI 10.1097/00001756-199911260-00032; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Salmona M, 1997, NEUROBIOL DIS, V4, P47, DOI 10.1006/nbdi.1997.0133; Schneider B, 2003, P NATL ACAD SCI USA, V100, P13326, DOI 10.1073/pnas.2235648100; Silveira JR, 2005, NATURE, V437, P257, DOI 10.1038/nature03989; Stanciu M, 2002, J BIOL CHEM, V277, P4010, DOI 10.1074/jbc.M104479200; Stuermer CAO, 2004, FASEB J, V18, P1731, DOI 10.1096/fj.04-2150fje; Thellung S, 2002, NEUROBIOL DIS, V9, P69, DOI 10.1006/nbdi.2001.0461; White AR, 2001, NEUROBIOL DIS, V8, P299, DOI 10.1006/nbdi.2001.0386; White AR, 2001, J NEUROCHEM, V76, P1509, DOI 10.1046/j.1471-4159.2001.00178.x	59	63	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28470	28479		10.1074/jbc.M602774200	http://dx.doi.org/10.1074/jbc.M602774200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16864581	hybrid			2022-12-25	WOS:000240534400084
J	Adli, M; Baldwin, AS				Adli, Mazhar; Baldwin, Albert S.			IKK-i/IKK epsilon controls constitutive, cancer cell-associated NF-kappa B activity via regulation of Ser-536 p65/RelA phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-RELATED KINASES; RELA/P65 SUBUNIT; ACTIVATION; P65; TRANSACTIVATION; TBK1; LIPOPOLYSACCHARIDE; EXPRESSION; SERINE-536; SIGNALS	Nuclear factor kappa B(NF-kappa B) has been studied extensively as an inducible transcriptional regulator of the immune and inflammatory response. NF-kappa B activation downstream of lipopolysaccharide or cytokine stimulation is controlled by the I kappa B kinase complex, which contains IKK alpha and IKK beta. Significantly, the constitutive activity of NF-kappa B has been implicated as an important aspect of many cancer cells, but mechanisms associated with this activity are poorly understood. An inducible kinase, IKK-i/IKK epsilon, related to the catalytic forms of the I kappa B kinase, has been studied as an anti-viral, innate immune regulator through its ability to control the activity of the transcription factors IRF-3 and IRF-7. Here, we demonstrate that IKK-i/IKK epsilon is expressed in a number of cancer cells and is involved in regulating NF-kappa B activity through its ability to control basal/constitutive, but not cytokine-induced, p65/RelA phosphorylation at Ser-536, a modification proposed to contribute to the transactivation function of NF-kappa B. Knockdown of IKK-i/IKK epsilon or expression of a S536A mutant form of p65 suppresses HeLa cell proliferation. The data indicate a role for IKK-i/IKK epsilon in controlling proliferation of certain cancer cells through regulation of constitutive NF-kappa B activity.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Baldwin, AS (corresponding author), Univ N Carolina, Sch Med, Lineberger Canc Ctr 22000, CB 7295, Chapel Hill, NC 27599 USA.	abaldwin@med.unc.edu			NATIONAL CANCER INSTITUTE [R01CA075080, R01CA073756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035098, R01AI035098] Funding Source: NIH RePORTER; NCI NIH HHS [CA75080, CA73756] Funding Source: Medline; NIAID NIH HHS [AI35098] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Buss H, 2004, J BIOL CHEM, V279, P49571, DOI 10.1074/jbc.C400442200; Campbell KJ, 2004, BIOCHEM SOC T, V32, P1087, DOI 10.1042/BST0321087; Doyle SL, 2005, J BIOL CHEM, V280, P23496, DOI 10.1074/jbc.C500053200; Eddy SF, 2005, CANCER RES, V65, P11375, DOI 10.1158/0008-5472.CAN-05-1602; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fujita F, 2003, MOL CELL BIOL, V23, P7780, DOI 10.1128/MCB.23.21.7780-7793.2003; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kishore N, 2002, J BIOL CHEM, V277, P13840, DOI 10.1074/jbc.M110474200; Kravchenko VV, 2003, J BIOL CHEM, V278, P26612, DOI 10.1074/jbc.M303001200; Leung TH, 2004, CELL, V118, P453, DOI 10.1016/j.cell.2004.08.007; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Mattioli I, 2006, J BIOL CHEM, V281, P6175, DOI 10.1074/jbc.M508045200; Mayo MW, 2001, METHOD ENZYMOL, V333, P73; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Natoli G, 2006, FEBS LETT, V580, P2843, DOI 10.1016/j.febslet.2006.02.072; Nomura F, 2000, GENES CELLS, V5, P191; Perry AK, 2004, J EXP MED, V199, P1651, DOI 10.1084/jem.20040528; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Peters RT, 2001, BBA-REV CANCER, V1471, pM57, DOI 10.1016/S0304-419X(00)00024-X; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sankar S, 2006, CELL SIGNAL, V18, P982, DOI 10.1016/j.cellsig.2005.08.006; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Takeuchi O, 2004, J ENDOTOXIN RES, V10, P252, DOI 10.1179/096805104225005896; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wang NZ, 2005, GENE, V353, P118, DOI 10.1016/j.gene.2005.04.013; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	40	125	139	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26976	26984		10.1074/jbc.M603133200	http://dx.doi.org/10.1074/jbc.M603133200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16840782	Green Published, hybrid			2022-12-25	WOS:000240397700024
J	Devin, A; Dejean, L; Beauvoit, B; Chevtzoff, C; Averet, N; Bunoust, O; Rigoulet, M				Devin, Anne; Dejean, Laurent; Beauvoit, Bertrand; Chevtzoff, Cyrille; Averet, Nicole; Bunoust, Odile; Rigoulet, Michel			Growth yield homeostasis in respiring yeast is due to a strict mitochondrial content adjustment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; COLI AEROBIC GROWTH; SACCHAROMYCES-CEREVISIAE; RESPIRATORY-CHAIN; HEAT-PRODUCTION; ENERGY BALANCES; SUCCINIC ACID; METABOLISM; CELLS; EFFICIENCY	In living cells, growth is the result of coupling between substrate catabolism and multiple metabolic processes taking place during net biomass formation and cell property maintenance. A crucial parameter for growth description is its yield, i.e. the efficiency of the transformation from substrate consumption to biomass formation. Using numerous yeast strains growing on different respiratory media, we have shown that the growth yield is identical regardless of the strain, growth phase, and respiratory substrate used. This homeostasis is the consequence of a strict linear relationship between growth and respiratory rates. Moreover, in all conditions tested, the oxygen consumption rate was strictly controlled by the cellular content of respiratory chain compounds in such a way that, in vivo, the steady state of oxidative phosphorylation was kept constant. Thus, the growth yield homeostasis depends on the tight adjustment of the cellular content of respiratory chain compounds to the growth rate. Any process leading to a defect in this adjustment allows an energy waste and consequently an energy yield decrease.	Univ Bordeaux 2, IBGC, Bioenerget Lab, CNRS,UMR 5095, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Rigoulet, M (corresponding author), Univ Bordeaux 2, IBGC, Bioenerget Lab, CNRS,UMR 5095, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	michel.rigoulet@ibgc.u-bordeaux2.fr		Beauvoit, Bertrand/0000-0002-7666-6429				Aguilaniu H, 2001, J BIOL CHEM, V276, P35396, DOI 10.1074/jbc.M101796200; Boumans H, 1998, J BIOL CHEM, V273, P4872, DOI 10.1074/jbc.273.9.4872; Boumans H, 1998, BIOCHEM J, V331, P877, DOI 10.1042/bj3310877; Bunoust O, 2005, J BIOL CHEM, V280, P3407, DOI 10.1074/jbc.M407746200; CLARK DG, 1979, BIOCHEM J, V184, P501, DOI 10.1042/bj1840501; Dejean L, 2000, BBA-BIOENERGETICS, V1457, P45, DOI 10.1016/S0005-2728(00)00053-0; Dejean L, 2002, BBA-BIOENERGETICS, V1554, P159, DOI 10.1016/S0005-2728(02)00240-2; Dejean L, 2002, BIOCHEM BIOPH RES CO, V293, P1383, DOI 10.1016/S0006-291X(02)00391-1; Dejean L, 2001, BBA-BIOENERGETICS, V1503, P329, DOI 10.1016/S0005-2728(00)00210-3; DERMOUN Z, 1979, J BACTERIOL, V140, P377, DOI 10.1128/JB.140.2.377-380.1979; DERMOUN Z, 1980, J BACTERIOL, V143, P742, DOI 10.1128/JB.143.2.742-746.1980; Duvezin-Caubet S, 2003, P NATL ACAD SCI USA, V100, P13235, DOI 10.1073/pnas.2135169100; GNAIGER E, 1990, BIOCHIM BIOPHYS ACTA, V1016, P328, DOI 10.1016/0005-2728(90)90164-Y; Guan Y., 1996, BIOTHERMOKINETICS LI, P387; GUSTAFSSON L, 1991, THERMOCHIM ACTA, V193, P145, DOI 10.1016/0040-6031(91)80181-H; HOFFNER SES, 1985, CYTOBIOS, V42, P71; HOOGERHEIDE JC, 1975, RADIAT ENVIRON BIOPH, V12, P281, DOI 10.1007/BF01323416; JARRETT IG, 1979, BIOCHEM J, V180, P631, DOI 10.1042/bj1800631; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; Kemp R.B., 1996, BIOTHERMOKINETICS LI, P398; KEMP RB, 1989, ENERGY TRANSFORMATIO, P91; LARSSON C, 1991, BIOTECHNOL BIOENG, V38, P447, DOI 10.1002/bit.260380503; SAMUELSSON MO, 1988, APPL ENVIRON MICROB, V54, P2220, DOI 10.1128/AEM.54.9.2220-2225.1988; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; vanKleeff BHA, 1996, BIOTECHNOL PROGR, V12, P510, DOI 10.1021/bp960033b; VANURK H, 1988, YEAST, V4, P283, DOI 10.1002/yea.320040406; VONSTOCKAR U, 1993, BIOCHIM BIOPHYS ACTA, V1183, P221, DOI 10.1016/0005-2728(93)90225-5; VONSTOCKAR U, 1989, BIOTECHNOL BIOENG, V34, P86, DOI 10.1002/bit.260340112; WESTERHOFF HV, 1983, P NATL ACAD SCI-BIOL, V80, P305, DOI 10.1073/pnas.80.1.305	29	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26779	26784		10.1074/jbc.M604800200	http://dx.doi.org/10.1074/jbc.M604800200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16849319	hybrid			2022-12-25	WOS:000240397700004
J	Smith, MJ; Pozo, K; Brickley, K; Stephenson, FA				Smith, Miriam J.; Pozo, Karine; Brickley, Kieran; Stephenson, F. Anne			Mapping the GRIF-1 binding domain of the kinesin, KIF5C, substantiates a role for GRIF-1 as an adaptor protein in the anterograde trafficking of cargoes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; AXONAL-TRANSPORT; HEAVY-CHAIN; GLCNAC TRANSFERASE; TAIL DOMAIN; O-GLCNAC; IN-VIVO; MITOCHONDRIA; RECEPTOR; NEURONS	gamma-Aminobutyric acid, type A (GABA(A)) receptor interacting factor-1 (GRIF-1) and N-acetylglucosamine transferase interacting protein (OIP) 106 are both members of a newly identified coiled-coil family of proteins. They are kinesin-associated proteins proposed to function as adaptors in the anterograde trafficking of organelles to synapses. Here we have studied in more detail the interaction between the prototypic kinesin heavy chain, KIF5C, kinesin light chain, and GRIF-1. The GRIF-1 binding site of KIF5C was mapped using truncation constructs in yeast two-hybrid interaction assays, co-immunoprecipitations, and co-localization studies following expression in mammalian cells. Using these approaches, it was shown that GRIF-1 and the KIF5C binding domain of GRIF-1, GRIF-1-(124-283), associated with the KIF5C non-motor domain. Refined studies using yeast two-hybrid interactions and co-immunoprecipitations showed that GRIF-1 and GRIF-1-(124-283) associated with the cargo binding region within the KIF5C non-motor domain. Substantiation that the GRIF-1-KIF5C interaction was direct was shown by fluorescence resonance energy transfer analyses using fluorescently tagged GRIF-1 and KIF5C constructs. A significant fluorescence resonance energy transfer value was found between the C-terminal EYFP-tagged KIF5C and ECFP-GRIF-1, the C-terminal EYFP-tagged KIF5C non-motor domain and ECFP-GRIF-1, but not between the N-terminal EYFP-tagged KIF5C nor the EYFP-KIF5C motor domain and ECFP-GRIF-1, thus confirming direct association between the two proteins at the KIF5C C-terminal and GRIF-1 N-terminal regions. Co-immunoprecipitation and confocal imaging strategies further showed that GRIF-1 can bind to the tetrameric kinesin light-chain/kinesin heavy-chain complex. These findings support a role for GRIF-1 as a kinesin adaptor molecule requisite for the anterograde delivery of defined cargoes such as mitochondria and/or vesicles incorporating beta 2 subunit-containing GABA(A) receptors, in the brain.	Univ London, Sch Pharm, Dept Pharmaceut & Biol Chem, London WC1N 1AX, England	University of London; University College London; University of London School of Pharmacy	Stephenson, FA (corresponding author), Univ London, Sch Pharm, Dept Pharmaceut & Biol Chem, 29-39 Brunswick Sq, London WC1N 1AX, England.	anne.stephenson@pharmacy.ac.uk	Smith, Miriam/J-4001-2015; Pozo, Karine/J-2943-2019	Smith, Miriam/0000-0002-3184-0817; 				Beck M, 2002, J BIOL CHEM, V277, P30079, DOI 10.1074/jbc.M200438200; Brickley K, 2005, J BIOL CHEM, V280, P14723, DOI 10.1074/jbc.M409095200; Cai Q, 2005, J CELL BIOL, V170, P959, DOI 10.1083/jcb.200506042; Ceccarini M, 2005, J MOL BIOL, V354, P872, DOI 10.1016/j.jmb.2005.09.069; Coy DL, 1999, NAT CELL BIOL, V1, P288, DOI 10.1038/13001; Fransson A, 2006, BIOCHEM BIOPH RES CO, V344, P500, DOI 10.1016/j.bbrc.2006.03.163; Gilbert SL, 2006, NAT GENET, V38, P245, DOI 10.1038/ng1715; Glater EE, 2006, J CELL BIOL, V173, P545, DOI 10.1083/jcb.200601067; Goldstein LSB, 2003, NEURON, V40, P415, DOI 10.1016/S0896-6273(03)00630-5; Gorska-Andrzejak J, 2003, J COMP NEUROL, V463, P372, DOI 10.1002/cne.10750; Guillaud L, 2003, J NEUROSCI, V23, P131; Guo XF, 2005, NEURON, V47, P379, DOI 10.1016/j.neuron.2005.06.027; Hackney DD, 2000, NAT CELL BIOL, V2, P257, DOI 10.1038/35010525; He LS, 2003, CYTOM PART A, V53A, P39, DOI 10.1002/cyto.a.10037; Hirokawa N, 2005, NAT REV NEUROSCI, V6, P201, DOI 10.1038/nrn1624; Iyer SPN, 2003, J BIOL CHEM, V278, P5399, DOI 10.1074/jbc.M209384200; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Liu J, 2004, J BIOL CHEM, V279, P55924, DOI 10.1074/jbc.M410024200; Love DC, 2003, J CELL SCI, V116, P647, DOI 10.1242/jcs.00246; Macioce P, 2003, J CELL SCI, V116, P4847, DOI 10.1242/jcs.00805; Miki H, 2005, TRENDS CELL BIOL, V15, P467, DOI 10.1016/j.tcb.2005.07.006; Nashmi R, 2003, J NEUROSCI, V23, P11554; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; Pozo K, 2006, BIOCHEM SOC T, V34, P48, DOI 10.1042/BST0340048; Setou M, 2002, NATURE, V417, P83, DOI 10.1038/nature743; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Stowers RS, 2002, NEURON, V36, P1063, DOI 10.1016/S0896-6273(02)01094-2; Su QN, 2004, NAT CELL BIOL, V6, P941, DOI 10.1038/ncb1169; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714	30	67	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27216	27228		10.1074/jbc.M600522200	http://dx.doi.org/10.1074/jbc.M600522200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16835241	hybrid			2022-12-25	WOS:000240397700049
J	Isenberg, JS; Ridnour, LA; Dimitry, J; Frazier, WA; Wink, DA; Roberts, DD				Isenberg, Jeff S.; Ridnour, Lisa A.; Dimitry, Julie; Frazier, William A.; Wink, David A.; Roberts, David D.			CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; INTEGRIN-ASSOCIATED PROTEIN; FACTOR-INDUCED ANGIOGENESIS; C-TERMINAL DOMAIN; TYPE-1 REPEATS; IN-VITRO; RECEPTOR; ADHESION; ALPHA(V)BETA(3); PROLIFERATION	CD36 is necessary for inhibition of some angiogenic responses by the matricellular glycoprotein thrombospondin-1 and is therefore assumed to be the receptor that mediates its anti-angiogenic activities. Although ligation of CD36 by antibodies, recombinant type 1 repeats of thrombospondin-1, or CD36-binding peptides was sufficient to inhibit nitric oxide (NO)-stimulated responses in both endothelial and vascular smooth muscle cells, picomolar concentrations of native thrombospondin-1 similarly inhibited NO signaling in vascular cells from wild-type and CD36-null mice. Ligation of the thrombospondin-1 receptor CD47 by recombinant C-terminal regions of thrombospondin-1, thrombospondin-1 peptides, or CD47 antibodies was also sufficient to inhibit NO-stimulated phenotypic responses and cGMP signaling in vascular cells. Thrombospondin-1 did not inhibit NO signaling in CD47-null vascular cells or NO-stimulated vascular outgrowth from CD47-null muscle explants in three-dimensional cultures. Furthermore, the CD36-binding domain of thrombospondin-1 and anti-angiogenic peptides derived from this domain failed to inhibit NO signaling in CD47-null cells. Therefore, ligation of either CD36 or CD47 is sufficient to inhibit NO-stimulated vascular cell responses and cGMP signaling, but only CD47 is necessary for this activity of thrombospondin-1 at physiological concentrations.	NCI, Pathol Lab, Canc Res Ctr, Lab Pathol,NIH, Bethesda, MD 20892 USA; NCI, Pathol Lab, Canc Res Ctr, Radiat Biol Branch,NIH, Bethesda, MD 20892 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Washington University (WUSTL)	Roberts, DD (corresponding author), NCI, Pathol Lab, Canc Res Ctr, Lab Pathol,NIH, Bldg 10,Rm 2A33,10 Ctr Dr,MSC1500, Bethesda, MD 20892 USA.	droberts@helix.nih.gov	Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981; Wink, David/0000-0002-5652-7480; Ridnour, Lisa A./0000-0001-9446-8349; Azad, Mahan/0000-0002-8633-3513	Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [HL54390] Funding Source: Medline; NIGMS NIH HHS [GM57573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01SC009172] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054390, R56HL054390] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057573] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agah A, 2002, AM J PATHOL, V161, P831, DOI 10.1016/S0002-9440(10)64243-5; Bamberger ME, 2003, J NEUROSCI, V23, P2665; Barazi HO, 2002, J BIOL CHEM, V277, P42859, DOI 10.1074/jbc.M206849200; Bocci G, 2003, P NATL ACAD SCI USA, V100, P12917, DOI 10.1073/pnas.2135406100; Bonnefoy A, 2001, J BIOL CHEM, V276, P5605, DOI 10.1074/jbc.M010091200; Calzada MJ, 2004, J BIOL CHEM, V279, P41734, DOI 10.1074/jbc.M406267200; Calzada MJ, 2004, CIRC RES, V94, P462, DOI 10.1161/01.RES.0000115555.05668.93; Carlson CB, 2005, NAT STRUCT MOL BIOL, V12, P910, DOI 10.1038/nsmb997; Chandrasekaran L, 2000, MOL BIOL CELL, V11, P2885, DOI 10.1091/mbc.11.9.2885; Chen DH, 1999, CIRCULATION, V100, P849, DOI 10.1161/01.CIR.100.8.849; Cooke JP, 2003, ATHEROSCLEROSIS SUPP, V4, P53, DOI 10.1016/S1567-5688(03)00034-5; Crombie R, 1998, J BIOL CHEM, V273, P4855, DOI 10.1074/jbc.273.9.4855; Dawson DW, 1999, MOL PHARMACOL, V55, P332, DOI 10.1124/mol.55.2.332; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; Elzie CA, 2004, INT J BIOCHEM CELL B, V36, P1090, DOI 10.1016/j.biocel.2003.12.012; Frazier WA, 1999, J BIOL CHEM, V274, P8554, DOI 10.1074/jbc.274.13.8554; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; Isenberg JS, 2005, P NATL ACAD SCI USA, V102, P13141, DOI 10.1073/pnas.0502977102; Isenberg JS, 2005, MATRIX BIOL, V24, P110, DOI 10.1016/j.matbio.2005.01.002; ISENBERG JS, 2006, IN PRESS CARDIOVASC; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kanda S, 1999, EXP CELL RES, V252, P262, DOI 10.1006/excr.1999.4622; Kvansakul M, 2004, EMBO J, V23, P1223, DOI 10.1038/sj.emboj.7600166; Lawler J, 2004, INT J BIOCHEM CELL B, V36, P1038, DOI 10.1016/j.biocel.2004.01.008; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; Lawler J, 2001, AM J PATHOL, V159, P1949, DOI 10.1016/S0002-9440(10)63042-8; Li ZQ, 2002, J CELL BIOL, V157, P509, DOI 10.1083/jcb.200109098; Li ZQ, 2001, J IMMUNOL, V166, P2427, DOI 10.4049/jimmunol.166.4.2427; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; Magnetto S, 1998, CELL BIOCHEM FUNCT, V16, P211, DOI 10.1002/(SICI)1099-0844(199809)16:3<211::AID-CBF788>3.3.CO;2-Q; MAMKOONG S, 2005, EXP MOL MED, V37, P588; McDonald JF, 2004, J BIOL CHEM, V279, P17301, DOI 10.1074/jbc.M312782200; McDonald JF, 2003, BIOCHEMISTRY-US, V42, P10001, DOI 10.1021/bi0341408; Misenheimer TM, 2000, J BIOL CHEM, V275, P40938, DOI 10.1074/jbc.M007022200; Moore KJ, 2002, J BIOL CHEM, V277, P47373, DOI 10.1074/jbc.M208788200; MOSHER DF, 1992, ANN NY ACAD SCI, V667, P64, DOI 10.1111/j.1749-6632.1992.tb51598.x; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Ray Jenna Lynn, 2001, Methods in Cell Science, V23, P185; Ridnour LA, 2005, P NATL ACAD SCI USA, V102, P13147, DOI 10.1073/pnas.0502979102; Riessen R, 1998, AM HEART J, V135, P357, DOI 10.1016/S0002-8703(98)70105-X; Roberts David D., 1994, Journal of Tissue Culture Methods, V16, P217, DOI 10.1007/BF01540654; Shizukuda Y, 1999, CIRC RES, V85, P247, DOI 10.1161/01.RES.85.3.247; Short SM, 2005, J CELL BIOL, V168, P643, DOI 10.1083/jcb.200407060; Stenina OI, 2004, INT J BIOCHEM CELL B, V36, P1013, DOI 10.1016/j.biocel.2004.01.005; Tan KM, 2002, J CELL BIOL, V159, P373, DOI 10.1083/jcb.200206062; TSAO PW, 1995, J BIOL CHEM, V270, P23747, DOI 10.1074/jbc.270.40.23747; VOGEL T, 1993, J CELL BIOCHEM, V53, P74, DOI 10.1002/jcb.240530109; Wang SJ, 2003, DEV DYNAM, V228, P630, DOI 10.1002/dvdy.10412; Wang XQ, 1999, J CELL BIOL, V147, P389, DOI 10.1083/jcb.147.2.389; Wilson KE, 1999, J IMMUNOL, V163, P3621; Yano K, 2004, J INVEST DERMATOL, V122, P201, DOI 10.1046/j.0022-202X.2003.22101.x; Zeng YC, 2003, J BIOL CHEM, V278, P45931, DOI 10.1074/jbc.M307722200; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	57	192	203	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26069	26080		10.1074/jbc.M605040200	http://dx.doi.org/10.1074/jbc.M605040200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16835222	hybrid			2022-12-25	WOS:000240249500022
J	Slaaby, R; Schaffer, L; Lautrup-Larsen, I; Andersen, AS; Shaw, AC; Mathiasen, IS; Brandt, J				Slaaby, Rita; Schaffer, Lauge; Lautrup-Larsen, Inger; Andersen, Asser Sloth; Shaw, Allan Christian; Mathiasen, Ida Stenfeldt; Brandt, Jakob			Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; FACTOR SYSTEM; BETA-SUBUNIT; EXPRESSION; ISOFORM; CANCER; DETERMINANTS; PURIFICATION; SPECIFICITY; ANTIBODIES	sInsulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) are both from the same subgroup of receptor tyrosine kinases that exist as covalently bound receptor dimers at the cell surface. For both IR and IGF-IR, the most described forms are homodimer receptors. However, hybrid receptors consisting of one-half IR and one-half IGF-IR are also present at the cell surface. Two splice variants of IR are expressed that enable formation of two isoforms of the IGF-IR/IR hybrid receptor. In this study, these two splice variants of hybrid receptors were studied with respect to binding affinities of insulin, insulin-like growth factor I (IGF-I), and insulin-like growth factor II (IGF-II). Unlike previously published data, in which semipurified receptors have been studied, we found that the two hybrid receptor splice variants had similar binding characteristics with respect to insulin, IGF-I, and IGF-II binding. We studied both semipurified and purified hybrid receptors. In all cases we found that IGF-I had at least 50-fold higher affinity than insulin, irrespective of the splice variant. The binding characteristics of insulin and IGF-I to both splice variants of the hybrid receptors were similar to classical homodimer IGF-IR.	Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark	Novo Nordisk	Slaaby, R (corresponding author), Novo Nordisk AS, Novo Alle, DK-2880 Bagsvaerd, Denmark.	risl@novonordisk.com						Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; Bailyes EM, 1997, BIOCHEM J, V327, P209, DOI 10.1042/bj3270209; Chisalita SI, 2005, DIABETOLOGIA, V48, P2155, DOI 10.1007/s00125-005-1890-4; De Meyts P, 2002, NAT REV DRUG DISCOV, V1, P769, DOI 10.1038/nrd917; Denley A, 2005, CYTOKINE GROWTH F R, V16, P421, DOI 10.1016/j.cytogfr.2005.04.004; Entingh-Pearsall A, 2004, J BIOL CHEM, V279, P38016, DOI 10.1074/jbc.M313201200; Federici M, 1999, DIABETES, V48, P2277, DOI 10.2337/diabetes.48.12.2277; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; GANDERTON RH, 1992, BIOCHEM J, V288, P195, DOI 10.1042/bj2880195; Heald A, 2006, DIABETIC MED, V23, P19, DOI 10.1111/j.1464-5491.2006.01833f.x; KASUYA J, 1993, BIOCHEMISTRY-US, V32, P13531, DOI 10.1021/bi00212a019; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Li GL, 2005, ENDOCRINOLOGY, V146, P4690, DOI 10.1210/en.2005-0505; Modan-Moses D, 1998, BIOCHEM J, V333, P825, DOI 10.1042/bj3330825; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; Nakae J, 2001, ENDOCR REV, V22, P818, DOI 10.1210/edrv.22.6.0452; Nitert MD, 2005, MOL CELL ENDOCRINOL, V229, P31, DOI 10.1016/j.mce.2004.10.003; Pandini G, 1999, CLIN CANCER RES, V5, P1935; Pandini G, 2002, J BIOL CHEM, V277, P39684, DOI 10.1074/jbc.M202766200; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Sachdev D, 2006, CANCER RES, V66, P2391, DOI 10.1158/0008-5472.CAN-05-3126; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SEELY BL, 1995, ENDOCRINOLOGY, V136, P1635, DOI 10.1210/en.136.4.1635; Siddle Kenneth, 1999, V17, P199; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; SOOS MA, 1993, BIOCHEM J, V290, P419, DOI 10.1042/bj2900419; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Valensise H, 1996, DIABETOLOGIA, V39, P952; White MF, 2003, SCIENCE, V302, P1710, DOI 10.1126/science.1092952	32	140	152	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25869	25874		10.1074/jbc.M605189200	http://dx.doi.org/10.1074/jbc.M605189200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16831875	hybrid			2022-12-25	WOS:000240249500001
J	Tsuda, S; Okudaira, S; Moriya-Ito, K; Shimamoto, C; Tanaka, M; Aoki, J; Arai, H; Murakami-Murofushi, K; Kobayashi, T				Tsuda, Satomi; Okudaira, Shinichi; Moriya-Ito, Keiko; Shimamoto, Chie; Tanaka, Masayuki; Aoki, Junken; Arai, Hiroyuki; Murakami-Murofushi, Kimiko; Kobayashi, Tetsuyuki			Cyclic phosphatidic acid is produced by autotaxin in blood	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYSARUM LYSOPHOSPHATIDIC ACID; DNA POLYMERASE-ALPHA; LYSOPHOSPHOLIPASE-D; PHOSPHOLIPASE-D; NUCLEOTIDE PYROPHOSPHATASES/PHOSPHODIESTERASES; ESCHERICHIA-COLI; LIPID MEDIATOR; RAT PLASMA; INHIBITION; PHYLPA	Cyclic phosphatidic acid (cPA), an analog of lysophosphatidic acid (LPA), was previously identified in human serum. Although cPA possesses distinct physiological activities not elicited by LPA, its biochemical origins have scarcely been studied. In the present study, we assayed cPA formation from lysophosphatidylcholine in fetal bovine serum and found significant activity of transphosphatidylation that generated cPA. The cPA-producing enzyme was purified from fetal bovine serum using five chromatographic steps yielding a 100-kDa protein with cPA biosynthetic activity. Matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry of its tryptic peptides revealed that the enzyme shared identical fragments with human autotaxin, a serum lysophospholipase D that produces LPA. Western blot analysis demonstrated that the 100-kDa protein was specifically recognized by an anti-human autotaxin antibody. Moreover, recombinant rat autotaxin was found to generate cPA in addition to LPA. No significant cPA-or LPA-producing activity was detected in autotaxin-depleted serum from bovine or human prepared by immunoprecipitation with an anti-autotaxin monoclonal antibody. These results indicate that the generation of cPA and LPA in serum is mainly attributed to autotaxin.	Ochanomizu Univ, Fac Sci, Dept Biol, Bunkyo Ku, Tokyo 1128610, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Agcy, Precur Res Embryon Sci & Technol, Saitama 3320012, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Saitama 3320012, Japan	Ochanomizu University; University of Tokyo; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Kobayashi, T (corresponding author), Ochanomizu Univ, Fac Sci, Dept Biol, Bunkyo Ku, 2-1-1 Ohtsuka, Tokyo 1128610, Japan.	tetkoba@cc.ocha.ac.jp	Kobayashi, Tetsuyuki/AAH-2985-2020	Kobayashi, Tetsuyuki/0000-0002-9285-0859; Aoki, Junken/0000-0001-9435-1896				Altman P.L., 1974, BIOL DATA BOOK, P1598; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Aoki J, 2004, SEMIN CELL DEV BIOL, V15, P477, DOI 10.1016/j.semcdb.2004.05.001; Aoki J, 2002, J BIOL CHEM, V277, P48737, DOI 10.1074/jbc.M206812200; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; BILLAH MM, 1993, CURR OPIN IMMUNOL, V5, P114; Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; Cimpean A, 2004, BIOCHEM J, V381, P71, DOI 10.1042/BJ20040465; Clair T, 2003, CANCER RES, V63, P5446; Fischer DJ, 1998, MOL PHARMACOL, V54, P979, DOI 10.1124/mol.54.6.979; Friedman P, 1996, J BIOL CHEM, V271, P953, DOI 10.1074/jbc.271.2.953; Fujiwara Y, 2005, J BIOL CHEM, V280, P35038, DOI 10.1074/jbc.M504351200; Fujiwara Y, 2003, J NEUROCHEM, V87, P1272, DOI 10.1046/j.1471-4159.2003.02106.x; HOMMA H, 1981, BIOCHIM BIOPHYS ACTA, V663, P1, DOI 10.1016/0005-2760(81)90189-2; Ishihara R, 2004, INT J CANCER, V110, P188, DOI 10.1002/ijc.20069; Kishimoto T, 2003, CLIN CHIM ACTA, V333, P59, DOI 10.1016/S0009-8981(03)00165-7; Kobayashi T, 2001, WORLD REV NUTR DIET, V88, P228; Kobayashi T, 1999, LIFE SCI, V65, P2185, DOI 10.1016/S0024-3205(99)00483-X; Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Mukai M, 1999, INT J CANCER, V81, P918, DOI 10.1002/(SICI)1097-0215(19990611)81:6<918::AID-IJC13>3.0.CO;2-E; Mukai M, 2003, INT J ONCOL, V22, P1247; Murakami-Murofushi K, 2002, BBA-MOL CELL BIOL L, V1582, P1, DOI 10.1016/S1388-1981(02)00131-2; MURAKAMIMUROFUSHI K, 1992, J BIOL CHEM, V267, P21512; MURAKAMIMUROFUSHI K, 1995, BBA-LIPID LIPID MET, V1258, P57; MURAKAMIMUROFUSHI K, 1993, CELL STRUCT FUNCT, V18, P363, DOI 10.1247/csf.18.363; NISHIJIMA M, 1978, BIOCHIM BIOPHYS ACTA, V528, P107; NISHIJIMA M, 1974, J BIOL CHEM, V249, P5658; Ren J, 2006, CANCER RES, V66, P3006, DOI 10.1158/0008-5472.CAN-05-1292; Rich JO, 2001, BIOTECHNOL BIOENG, V72, P374, DOI 10.1002/1097-0290(20010205)72:3<374::AID-BIT16>3.0.CO;2-E; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; TAKAHASHI Y, 1993, CELL STRUCT FUNCT, V18, P135, DOI 10.1247/csf.18.135; Tanaka M, 2004, FEBS LETT, V571, P197, DOI 10.1016/j.febslet.2004.06.083; Tokumura A, 2004, J CELL BIOCHEM, V92, P869, DOI 10.1002/jcb.20147; Tokumura A, 1998, LIPIDS, V33, P1009, DOI 10.1007/s11745-998-0299-2; Tokumura A, 2002, BBA-MOL CELL BIOL L, V1582, P18, DOI 10.1016/S1388-1981(02)00133-6; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; TOKUMURA A, 1986, BIOCHIM BIOPHYS ACTA, V875, P31; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Xu J, 2000, J BIOL CHEM, V275, P27520; YANG SF, 1967, J BIOL CHEM, V242, P477	42	54	57	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26081	26088		10.1074/jbc.M602925200	http://dx.doi.org/10.1074/jbc.M602925200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16837466	hybrid			2022-12-25	WOS:000240249500023
J	Song, BL; DeBose-Boyd, RA				Song, Bao-Liang; DeBose-Boyd, Russell A.			Insig-dependent ubiquitination and degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase stimulated by delta- and gamma-tocotrienols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG-COA REDUCTASE; STEROL-SENSING DOMAIN; PREGNANE-X-RECEPTOR; CLEAVAGE-ACTIVATING PROTEIN; OMEGA-HYDROXYLASE PATHWAY; VITAMIN-E; CHOLESTEROL-BIOSYNTHESIS; ENDOPLASMIC-RETICULUM; FEEDBACK-REGULATION; MESSENGER-RNA	Sterol-regulated ubiquitination marks 3-hydroxy-3-methylglutaryl coenzyme A reductase, a rate-determining enzyme in cholesterol synthesis, for endoplasmic reticulum (ER)-associated degradation by 26 S proteasomes. This degradation, which results from sterol-induced binding of reductase to ER membrane proteins called Insigs, contributes to the complex, multivalent feedback regulation of the enzyme. Degradation of HMG-CoA reductase is also stimulated by various forms of vitamin E, a generic term for alpha-, beta-, delta-, and gamma-tocopherols and tocotrienols, which are primarily recognized for their potent antioxidant activity. Here, we show that gamma-tocotrienol stimulates ubiquitination and degradation of reductase and blocks processing of sterol regulatory element-binding proteins (SREBPs), another sterolmediated action of Insigs. The gamma-tocotrienol analog is more selective in enhancing reductase ubiquitination and degradation than blocking SREBP processing. Other forms of vitamin E neither accelerate reductase degradation nor block SREBP processing. In vitro assays indicate that gamma- and gamma-tocotrienol trigger reductase ubiquitination directly and do not require further metabolism for activity. Taken together, these results provide a biochemical mechanism for the hypocholesterolemic effects of vitamin E that have been observed in animals and humans.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Song, BL (corresponding author), Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, Shanghai, Peoples R China.	BLSONG@sibs.ac.cn; Russell.DeBose-Boyd@utsouthwestern.edu		Song, Bao-Liang/0000-0002-6397-5935	NHLBI NIH HHS [HL20948, HL70441] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, K01HL070441] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams CM, 2004, J BIOL CHEM, V279, P52772, DOI 10.1074/jbc.M410302200; Berkhout TA, 1997, ATHEROSCLEROSIS, V133, P203, DOI 10.1016/S0021-9150(97)00131-7; Birringer M, 2002, J NUTR, V132, P3113, DOI 10.1093/jn/131.10.3113; Brigelius-Flohe R, 1999, FASEB J, V13, P1145, DOI 10.1096/fasebj.13.10.1145; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1978, J BIOL CHEM, V253, P1121; BROWN MS, 1980, J LIPID RES, V21, P505; CHIKU S, 1984, J LIPID RES, V25, P40; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; CORRELL CC, 1994, J BIOL CHEM, V269, P633; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Engelking LJ, 2005, J CLIN INVEST, V115, P2489, DOI 10.1172/JCI25614; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Gould AL, 1998, CIRCULATION, V97, P946; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Illingworth DR, 2001, ADV PROTEIN CHEM, V56, P77; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; Kliewer SA, 2003, J NUTR, V133, p2444S, DOI 10.1093/jn/133.7.2444S; Landes N, 2003, BIOCHEM PHARMACOL, V65, P269, DOI 10.1016/S0006-2952(02)01520-4; Lee PCW, 2005, J BIOL CHEM, V280, P25242, DOI 10.1074/jbc.M502989200; LISCUM L, 1985, J BIOL CHEM, V260, P522; LISCUM L, 1983, J BIOL CHEM, V258, P8450; Lodge JK, 2001, LIPIDS, V36, P43, DOI 10.1007/s11745-001-0666-z; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; Nesaretnam K, 1998, LIPIDS, V33, P461, DOI 10.1007/s11745-998-0229-3; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; PARKER RA, 1993, J BIOL CHEM, V268, P11230; Parker RS, 2004, ANN NY ACAD SCI, V1031, P13, DOI 10.1196/annals.1331.002; PEARCE BC, 1994, J MED CHEM, V37, P526, DOI 10.1021/jm00030a012; PEARCE BC, 1992, J MED CHEM, V35, P3595, DOI 10.1021/jm00098a002; PEDERSEN TR, 1994, LANCET, V344, P1383; QURESHI AA, 1991, AM J CLIN NUTR, V53, pS1021, DOI 10.1093/ajcn/53.4.1021S; QURESHI AA, 1995, LIPIDS, V30, P1171, DOI 10.1007/BF02536620; QURESHI AA, 1986, J BIOL CHEM, V261, P544; Qureshi AA, 1996, J NUTR, V126, P389, DOI 10.1093/jn/126.2.389; QURESHI AA, 1991, AM J CLIN NUTR, V53, pS1042, DOI 10.1093/ajcn/53.4.1042S; Radhakrishnan A, 2004, MOL CELL, V15, P259, DOI 10.1016/j.molcel.2004.06.019; Ravid T, 2000, J BIOL CHEM, V275, P35840, DOI 10.1074/jbc.M004793200; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; SATO R, 1993, P NATL ACAD SCI USA, V90, P9261, DOI 10.1073/pnas.90.20.9261; SCHULTZ M, 1995, AM J CLIN NUTR, V62, P1527, DOI 10.1093/ajcn/62.6.1527S; Sen CK, 2006, LIFE SCI, V78, P2088, DOI 10.1016/j.lfs.2005.12.001; Sever N, 2004, J BIOL CHEM, V279, P43136, DOI 10.1074/jbc.M406406200; Sever N, 2003, J BIOL CHEM, V278, P52479, DOI 10.1074/jbc.M310053200; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; SINGER II, 1984, P NATL ACAD SCI-BIOL, V81, P5556, DOI 10.1073/pnas.81.17.5556; Song BL, 2005, CELL METAB, V1, P179, DOI 10.1016/j.cmet.2005.01.001; Song BL, 2004, J BIOL CHEM, V279, P28798, DOI 10.1074/jbc.M402442200; Song BL, 2005, MOL CELL, V19, P829, DOI 10.1016/j.molcel.2005.08.009; Sontag TJ, 2002, J BIOL CHEM, V277, P25290, DOI 10.1074/jbc.M201466200; SUZUKI Y, 1993, BIOCHEMISTRY-US, V32, P10692, DOI 10.1021/bi00091a020; Theriault A, 1999, CLIN BIOCHEM, V32, P309, DOI 10.1016/S0009-9120(99)00027-2; Wechter WJ, 1996, P NATL ACAD SCI USA, V93, P6002, DOI 10.1073/pnas.93.12.6002; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Ylitalo R, 2000, GEN PHARMACOL-VASC S, V35, P287, DOI 10.1016/S0306-3623(01)00121-5; Zhou CC, 2004, DRUG METAB DISPOS, V32, P1075, DOI 10.1124/dmd.104.000299	66	133	137	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25054	25061		10.1074/jbc.M605575200	http://dx.doi.org/10.1074/jbc.M605575200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16831864	hybrid			2022-12-25	WOS:000240031300007
J	Jeong, KW; Kim, HZ; Kim, S; Kim, YS; Choe, J				Jeong, K. W.; Kim, H-Z; Kim, S.; Kim, Y. S.; Choe, J.			Human papillomavirus type 16 E6 protein interacts with cystic fibrosis transmembrane regulator-associated ligand and promotes E6-associated protein-mediated ubiquitination and proteasomal degradation	ONCOGENE			English	Article						HPV; E6; E6AP; proteasome; ubiquitination	CERVICAL-CANCER CELLS; GOLGI PROTEIN; ADENOVIRUS E4-ORF1; EARLY GENES; HPV-18 E6; IN-VITRO; P53; IDENTIFICATION; BINDING; ONCOPROTEINS	The PDZ proteins such as hDLG, hScrib and MAGIs function as the membrane-associated protein scaffolds and have been shown to interact with the high-risk human papillomavirus (HPV) E6s. In this report, we identify a Golgi-associated PDZ protein, cystic fibrosis transmembrane regulator-associated ligand (CAL) as a cellular target of HPV16 E6 by the proteomic approach. The carboxy-terminal PDZ-binding motif of HPV16 E6 specifically interacts with the PDZ domain of CAL, and the interaction enhances proteasome-mediated degradation of CAL. HPV16 E6 interacts with CAL more strongly and degrades it better than HPV18 E6 owing to the more compatible PDZ-binding motif. CAL is ubiquitinated by the E6/E6-associated protein (E6AP) complex or by E6AP alone, albeit less efficiently, which indicates that it could be a normal target of E6AP. Although it downregulates CAL at the transcript level, small interfering RNA-induced depletion of HPV16 E6 in Caski cells stabilizes CAL at the protein level, suggesting that HPV16 E6 mediates the proteasomal degradation of CAL in HPV-positive cervical cancer cells. HPV16 E6 may tightly regulate the vesicular trafficking processes by interacting with CAL, and such a modification can contribute to the development of cervical cancer.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Yonsei Univ, Dept Biochem, Seoul 120749, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Yonsei University	Choe, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 373-1 Guseong Dong, Taejon 305701, South Korea.	jchoe@kaist.ac.kr	Choe, Joonho/F-3066-2011					Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894; Charest A, 2001, J BIOL CHEM, V276, P29456, DOI 10.1074/jbc.M104137200; Cheng J, 2004, J BIOL CHEM, V279, P1892, DOI 10.1074/jbc.M308640200; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Cuadra AE, 2004, J NEUROSCI, V24, P7491, DOI 10.1523/JNEUROSCI.1255-04.2004; Gao QS, 2002, CANCER RES, V62, P3315; Gentzsch M, 2003, J BIOL CHEM, V278, P6440, DOI 10.1074/jbc.M211050200; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grassmann K, 1996, J VIROL, V70, P2339, DOI 10.1128/JVI.70.4.2339-2349.1996; Hassel B, 2003, J BIOL CHEM, V278, P40136, DOI 10.1074/jbc.M305577200; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; KANDA T, 1991, VIROLOGY, V185, P536, DOI 10.1016/0042-6822(91)90523-E; Kao WH, 2000, J VIROL, V74, P6408, DOI 10.1128/JVI.74.14.6408-6417.2000; Kelley ML, 2005, J VIROL, V79, P3737, DOI 10.1128/JVI.79.6.3737-3747.2005; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Kumar S, 1999, J BIOL CHEM, V274, P18785, DOI 10.1074/jbc.274.26.18785; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; NAKAGAWA S, 1995, VIROLOGY, V212, P535, DOI 10.1006/viro.1995.1511; Neudauer CL, 2001, BIOCHEM BIOPH RES CO, V280, P541, DOI 10.1006/bbrc.2000.4160; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; Piserchio A, 2005, BIOCHEMISTRY-US, V44, P16158, DOI 10.1021/bi0516475; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHNEIDERGADICKE A, 1988, CANCER RES, V48, P2969; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 2005, ONCOGENE, V24, P6222, DOI 10.1038/sj.onc.1208757; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Yao RJ, 2002, P NATL ACAD SCI USA, V99, P11211, DOI 10.1073/pnas.162027899; Yao RJ, 2001, BIOCHEM BIOPH RES CO, V286, P771, DOI 10.1006/bbrc.2001.5430; Yoshinouchi M, 2003, MOL THER, V8, P762, DOI 10.1016/j.ymthe.2003.08.004; Yue ZY, 2002, NEURON, V35, P921, DOI 10.1016/S0896-6273(02)00861-9; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	48	35	37	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					487	499		10.1038/sj.onc.1209837	http://dx.doi.org/10.1038/sj.onc.1209837			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16878151				2022-12-25	WOS:000243731600002
J	Ji, Z; Degerny, C; Vintonenko, N; Deheuninck, J; Foveau, B; Leroy, C; Coll, J; Tulasne, D; Baert, JL; Fafeur, V				Ji, Z.; Degerny, C.; Vintonenko, N.; Deheuninck, J.; Foveau, B.; Leroy, C.; Coll, J.; Tulasne, D.; Baert, J-L; Fafeur, V.			Regulation of the Ets-1 transcription factor by sumoylation and ubiquitinylation	ONCOGENE			English	Article						Ets-1; transcription factor; SUMO; ubiquitin	DNA-BINDING; MOLECULAR-BIOLOGY; SUMO MODIFICATION; GENE-EXPRESSION; PHOSPHORYLATION; RECEPTOR; DOMAIN; COACTIVATOR; REPRESSION; INHIBITION	Sumoylation and ubiquitinylation reversibly regulate the activity of transcription factors through covalent attachment to lysine residues of target proteins. We examined whether the Ets-1 transcription factor is modified by sumoylation and/or ubiquitinylation. Among four potential SUMO motifs in Ets-1, we identified lysines 15 and 227 within the (LKYE)-Y-15 and IK(227)QE motifs, as being the sumoylation acceptor sites. Using transfection of Ets-1 wildtype (WT) or its sumoylation deficient version (Ets-1 K15R/K227R), as well as WT or mutant proteins of the SUMO pathway, we further demonstrated that the E2 SUMO-conjugating enzyme Ubc9 and a E3 SUMO ligase, PIASy, can enhance Ets-1 sumoylation, while a SUMO protease, SENP1, can desumoylate Ets-1. We also found that Ets-1 is modified by K48-linked polyubiquitinylation independently of the sumoylation acceptor sites and is degraded through the 26S proteasome pathway, while sumoylation of Ets-1 does not affect its stability. Finally, sumoylation of Ets-1 leads to reduced transactivation and we demonstrated that previously identified critical lysine residues in Synergistic Control motifs are the sumoylation acceptor sites of Ets-1. These data show that Ets-1 can be modified by sumoylation and/or ubiquitinylation, with sumoylation repressing transcriptional activity of Ets-1 and having no clear antagonistic action on the ubiquitin-proteasome degradation pathway.	Univ Lille 1, Inst Biol Lille, CNRS, UMR 8161,Inst Pasteur Lille,Univ Lille 2, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Fafeur, V (corresponding author), Univ Lille 1, Inst Biol Lille, CNRS, UMR 8161,Inst Pasteur Lille,Univ Lille 2, 1 Rue Calmette,BP 447, F-59021 Lille, France.	veronique.fafeur@ibl.fr	Tulasne, David/AAR-5287-2020; Fafeur, Veronique/L-9072-2018; Tulasne, David/A-8705-2008	Tulasne, David/0000-0002-6764-7242; 				Bohren KM, 2004, J BIOL CHEM, V279, P27233, DOI 10.1074/jbc.M402273200; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Cheng JK, 2004, MOL CELL BIOL, V24, P6021, DOI 10.1128/MCB.24.13.6021-6028.2004; Cowley DO, 2000, GENE DEV, V14, P366; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; de Launoit Y, 1998, ONCOGENE, V16, P2065, DOI 10.1038/sj.onc.1201726; Degerny C, 2005, J BIOL CHEM, V280, P24330, DOI 10.1074/jbc.M411250200; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; Dohmen RJ, 2004, BBA-MOL CELL RES, V1695, P113, DOI 10.1016/j.bbamcr.2004.09.021; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Herrera FJ, 2004, CURR BIOL, V14, pR622, DOI 10.1016/j.cub.2004.07.046; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Janknecht R, 1996, ONCOGENE, V12, P1961; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Kurihara I, 2005, J BIOL CHEM, V280, P6721, DOI 10.1074/jbc.M411820200; Leight ER, 2005, DEVELOPMENT, V132, P1047, DOI 10.1242/dev.01664; Macauley MS, 2006, J BIOL CHEM, V281, P4164, DOI 10.1074/jbc.M510488200; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Perdomo J, 2005, MOL CELL BIOL, V25, P1549, DOI 10.1128/MCB.25.4.1549-1559.2005; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Rabault B, 1996, ONCOGENE, V13, P877; Reveneau S, 2003, ANN NY ACAD SCI, V1010, P100, DOI 10.1196/annals.1299.016; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Takahashi A, 2005, BIOCHEM BIOPH RES CO, V327, P575, DOI 10.1016/j.bbrc.2004.12.045; Tulasne D, 2004, MOL CELL BIOL, V24, P10328, DOI 10.1128/MCB.24.23.10328-10339.2004; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; van den Akker E, 2005, J BIOL CHEM, V280, P38035, DOI 10.1074/jbc.M502938200; Wasylyk C, 2005, ONCOGENE, V24, P820, DOI 10.1038/sj.onc.1208226; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Yang SH, 2005, EMBO J, V24, P2161, DOI 10.1038/sj.emboj.7600690; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X	53	40	41	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					395	406		10.1038/sj.onc.1209789	http://dx.doi.org/10.1038/sj.onc.1209789			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16862185				2022-12-25	WOS:000243544000008
J	Fleishman, SJ; Sabag, AD; Ophir, E; Avraham, KB; Ben-Tal, N				Fleishman, Sarel J.; Sabag, Adi D.; Ophir, Eran; Avraham, Karen B.; Ben-Tal, Nir			The structural context of disease-causing mutations in gap junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE PROTEIN STRUCTURES; GATING PROPERTIES; SALT BRIDGES; CONNEXIN-26; PREDICTION; TOPOLOGY; CHANNELS; MUTANTS; MODEL; SITE	Gap junctions form intercellular channels that mediate metabolic and electrical signaling between neighboring cells in a tissue. Lack of an atomic resolution structure of the gap junction has made it difficult to identify interactions that stabilize its transmembrane domain. Using a recently computed model of this domain, which specifies the locations of each amino acid, we postulated the existence of several interactions and tested them experimentally. We introduced mutations within the transmembrane domain of the gap junction-forming protein connexin that were previously implicated in genetic diseases and that apparently destabilized the gap junction, as evidenced here by the absence of the protein from the sites of cell-cell apposition. The model structure helped identify positions on adjacent helices where second-site mutations restored membrane localization, revealing possible interactions between residue pairs. We thus identified two putative salt bridges and one pair involved in packing interactions in which one disease-causing mutation suppressed the effects of another. These results seem to reveal some of the physical forces that underlie the structural stability of the gap junction transmembrane domain and suggest that abrogation of such interactions bring about some of the effects of disease-causing mutations.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel	Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Ben-Tal, N (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel.	nirb@tauex.tau.ac.il		Avraham, Karen B/0000-0002-4913-251X; Fleishman, Sarel/0000-0003-3177-7560; Ben-Tal, Nir/0000-0001-6901-832X	NIDCD NIH HHS [R01 DC005641] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC005641] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Aasen T, 2003, ONCOGENE, V22, P7969, DOI 10.1038/sj.onc.1206709; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; CASCIO M, 1995, J BIOL CHEM, V270, P18643, DOI 10.1074/jbc.270.31.18643; Dall'Acqua W, 1998, BIOCHEMISTRY-US, V37, P7981, DOI 10.1021/bi980148j; Das Sarma J, 2001, J CELL SCI, V114, P4013; Evans WH, 2002, MOL MEMBR BIOL, V19, P121, DOI 10.1080/09687680210139839; Fleishman SJ, 2006, CURR OPIN STRUC BIOL, V16, P496, DOI 10.1016/j.sbi.2006.06.003; Fleishman SJ, 2006, TRENDS BIOCHEM SCI, V31, P106, DOI 10.1016/j.tibs.2005.12.005; Fleishman SJ, 2004, BIOPHYS J, V87, P3448, DOI 10.1529/biophysj.104.046417; Fleishman SJ, 2004, MOL CELL, V15, P879, DOI 10.1016/j.molcel.2004.08.016; Fleishman SJ, 2004, J MOL BIOL, V340, P307, DOI 10.1016/j.jmb.2004.04.064; Gottfried I, 2002, HUM MOL GENET, V11, P1311, DOI 10.1093/hmg/11.11.1311; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; HOROVITZ A, 1994, J MOL BIOL, V238, P133, DOI 10.1006/jmbi.1994.1275; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; Hu XG, 1999, FEBS LETT, V451, P113, DOI 10.1016/S0014-5793(99)00558-X; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Kenna MA, 2001, ARCH OTOLARYNGOL, V127, P1037, DOI 10.1001/archotol.127.9.1037; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kronengold J, 2003, J GEN PHYSIOL, V122, P389, DOI 10.1085/jgp.200308861; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Marlin S, 2001, ARCH OTOLARYNGOL, V127, P927, DOI 10.1001/archotol.127.8.927; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mese G, 2004, HUM GENET, V115, P191, DOI 10.1007/s00439-004-1142-6; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; Numakura C, 2002, HUM MUTAT, V20, P392, DOI 10.1002/humu.10134; Pitts JD, 1998, BIOESSAYS, V20, P1047, DOI 10.1002/(SICI)1521-1878(199812)20:12<1047::AID-BIES11>3.0.CO;2-0; Ressot C, 1996, HUM GENET, V98, P172, DOI 10.1007/s004390050183; Roisman LC, 2001, P NATL ACAD SCI USA, V98, P13231, DOI 10.1073/pnas.221290398; Skerrett IM, 2002, J CELL BIOL, V159, P349, DOI 10.1083/jcb.200207060; Trexler EB, 2000, BIOPHYS J, V79, P3036, DOI 10.1016/S0006-3495(00)76539-8; Unger VM, 1999, SCIENCE, V283, P1176, DOI 10.1126/science.283.5405.1176; Vanslyke JK, 2000, MOL BIOL CELL, V11, P1933, DOI 10.1091/mbc.11.6.1933; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; YEAGER M, 1992, J MOL BIOL, V223, P929, DOI 10.1016/0022-2836(92)90253-G	39	11	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28958	28963		10.1074/jbc.M605764200	http://dx.doi.org/10.1074/jbc.M605764200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16864573	hybrid			2022-12-25	WOS:000240680500050
J	Bang, IS; Liu, LM; Vazquez-Torres, A; Crouch, ML; Stamler, JS; Fang, FC				Bang, Iel-Soo; Liu, Limin; Vazquez-Torres, Andres; Crouch, Marie-Laure; Stamler, Jonathan S.; Fang, Ferric C.			Maintenance of nitric oxide and redox homeostasis by the Salmonella flavohemoglobin Hmp	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI FLAVOHAEMOGLOBIN HMP; ENTERICA SEROVAR TYPHIMURIUM; HEMOGLOBIN-LIKE PROTEIN; ESCHERICHIA-COLI; NITROSATIVE STRESS; OXIDATIVE STRESS; GENE-EXPRESSION; BACTERIAL HEMOGLOBINS; MYCOBACTERIUM-BOVIS; REACTIVE OXYGEN	Intracellular pathogens must resist the antimicrobial actions of nitric oxide (NO.) produced by host cells. To this end pathogens possess several NO.-metabolizing enzymes. Here we show that the flavohemoglobin Hmp is the principal enzyme responsible for aerobic NO. metabolism by Salmonella enterica serovar typhimurium. We further show that Hmp is required for Salmonella virulence in mice, in contrast to S-nitrosoglutathione reductase, flavorubredoxin, or cytochrome c nitrite reductase. Abrogation of murine-inducible NO. synthase restores virulence to hmp mutant bacteria. In the presence of nitrosative stress, Hmp-deficient Salmonella exhibits reduced NO. consumption, impaired growth, increased protein S-nitrosylation, and filamentous morphology. However, under aerobic conditions in the absence of nitrosative stress, elevated hmp expression increases S. typhimurium susceptibility to hydrogen peroxide. Both the heme binding and flavoreductase domains are required for resistance to NO., whereas the flavoreductase domain is responsible for iron-dependent susceptibility to oxidative stress. This provides a rationale for the regulation of hmp expression by the transcriptional repressor NsrR in response to both nitrosative stress and intracellular free iron concentration. The Hmp flavohemoglobin plays a central role in the response of Salmonella to nitrosative stress but requires precise regulation to avoid the exacerbation of oxidative stress that can result if electrons are shuttled to extraneous iron.	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Lab Med, Seattle, WA 98195 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Aurora, CO 80010 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Duke University; Duke University; University of Colorado System; University of Colorado Anschutz Medical Campus	Fang, FC (corresponding author), Univ Washington, Sch Med, Dept Microbiol, 1959 Pacific St NE,Box 357242, Seattle, WA 98195 USA.	fcfang@u.washington.edu		Stamler, Jonathan/0000-0002-6866-1572; Fang, Ferric/0000-0002-3243-110X	NIAID NIH HHS [AI54959, AI39557, AI50660] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039557, R01AI054959, R21AI039557, R56AI054959, R01AI050660] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS SC, 1992, FEBS LETT, V302, P247, DOI 10.1016/0014-5793(92)80452-M; Bang IS, 2000, J BACTERIOL, V182, P2245, DOI 10.1128/JB.182.8.2245-2252.2000; Bang IS, 2005, MOL MICROBIOL, V56, P811, DOI 10.1111/j.1365-2958.2005.04580.x; BENJAMIN N, 1999, NITRIC OXIDE INFECT, P215; Bjarnason J, 2003, J BACTERIOL, V185, P4973, DOI 10.1128/JB.185.16.4973-4982.2003; Bodenmiller DM, 2006, J BACTERIOL, V188, P874, DOI 10.1128/JB.188.3.874-881.2006; Crawford MJ, 2006, J BIOL CHEM, V281, P3752; Crawford MJ, 1998, J BIOL CHEM, V273, P34028, DOI 10.1074/jbc.273.51.34028; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; de Jesus-Berrios M, 2003, CURR BIOL, V13, P1963, DOI 10.1016/j.cub.2003.10.029; DEGROOTE MA, 1995, P NATL ACAD SCI USA, V92, P6399, DOI 10.1073/pnas.92.14.6399; DeGroote MA, 1997, P NATL ACAD SCI USA, V94, P13997, DOI 10.1073/pnas.94.25.13997; Eriksson S, 2003, MOL MICROBIOL, V47, P103, DOI 10.1046/j.1365-2958.2003.03313.x; Ermler U, 1995, EMBO J, V14, P6067, DOI 10.1002/j.1460-2075.1995.tb00297.x; ESCHENBRENNER M, 1994, BIOCHEM BIOPH RES CO, V198, P127, DOI 10.1006/bbrc.1994.1018; Eu JP, 2000, BIOCHEMISTRY-US, V39, P1040, DOI 10.1021/bi992046e; Fang FC, 2004, NAT REV MICROBIOL, V2, P820, DOI 10.1038/nrmicro1004; Fang FC, 1999, P NATL ACAD SCI USA, V96, P7502, DOI 10.1073/pnas.96.13.7502; Freitas TAK, 2004, P NATL ACAD SCI USA, V101, P6675, DOI 10.1073/pnas.0308657101; Frey AD, 2002, APPL ENVIRON MICROB, V68, P4835, DOI 10.1128/AEM.68.10.4835-4840.2002; Frey AD, 2003, FEMS MICROBIOL REV, V27, P525, DOI 10.1016/S0168-6445(03)00056-1; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Gardner AM, 2002, J BIOL CHEM, V277, P8172, DOI 10.1074/jbc.M110471200; Gomes CM, 2002, J BIOL CHEM, V277, P25273, DOI 10.1074/jbc.M203886200; Hausladen A, 2001, P NATL ACAD SCI USA, V98, P10108, DOI 10.1073/pnas.181199698; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Hernandez-Urzua E, 2003, J BIOL CHEM, V278, P34975, DOI 10.1074/jbc.M303629200; Ilari A, 2002, J BIOL CHEM, V277, P23725, DOI 10.1074/jbc.M202228200; IOANNIDIS N, 1992, BIOCHEM J, V288, P649, DOI 10.1042/bj2880649; Justino MC, 2005, J BIOL CHEM, V280, P2636, DOI 10.1074/jbc.M411070200; Kim SO, 1999, FEBS LETT, V445, P389, DOI 10.1016/S0014-5793(99)00157-X; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; Makarova O, 2000, BIOTECHNIQUES, V29, P970, DOI 10.2144/00295bm08; Marchler-Bauer A, 2004, NUCLEIC ACIDS RES, V32, pW327, DOI 10.1093/nar/gkh454; Membrillo-Hernandez J, 1998, MOL MICROBIOL, V29, P1101, DOI 10.1046/j.1365-2958.1998.01000.x; MembrilloHernandez J, 1996, FEBS LETT, V382, P141, DOI 10.1016/0014-5793(96)00154-8; Mills CE, 2001, BIOCHEM J, V353, P207, DOI 10.1042/0264-6021:3530207; Monack DM, 2004, J EXP MED, V199, P231, DOI 10.1084/jem.20031319; MOORE WM, 1994, J MED CHEM, V37, P3886, DOI 10.1021/jm00049a007; MORLEY D, 1993, J CARDIOVASC PHARM, V21, P670, DOI 10.1097/00005344-199304000-00023; Mukhopadhyay P, 2004, P NATL ACAD SCI USA, V101, P745, DOI 10.1073/pnas.0307741100; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Ouellett H, 2002, P NATL ACAD SCI USA, V99, P5902, DOI 10.1073/pnas.092017799; Poock SR, 2002, J BIOL CHEM, V277, P23664, DOI 10.1074/jbc.M200731200; Poole RK, 1996, J BACTERIOL, V178, P5487, DOI 10.1128/jb.178.18.5487-5492.1996; Poole RK, 2005, BIOCHEM SOC T, V33, P176, DOI 10.1042/BST0330176; Poole RK, 1997, MICROBIOL-SGM, V143, P1557, DOI 10.1099/00221287-143-5-1557; POOLE RK, 1994, P ROY SOC B-BIOL SCI, V255, P251, DOI 10.1098/rspb.1994.0036; Rodionov DA, 2005, PLOS COMPUT BIOL, V1, P415, DOI 10.1371/journal.pcbi.0010055; SALE FO, 1984, ANAL BIOCHEM, V142, P347, DOI 10.1016/0003-2697(84)90475-5; Sambrook J, 2001, MOL CLONING LAB MANU; Schapiro JM, 2003, P NATL ACAD SCI USA, V100, P8496, DOI 10.1073/pnas.1033133100; Seyler RW, 2001, INFECT IMMUN, V69, P4034, DOI 10.1128/IAI.69.6.4034-4040.2001; Simon J, 2002, FEMS MICROBIOL REV, V26, P285, DOI 10.1111/j.1574-6976.2002.tb00616.x; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Stevanin TM, 2002, INFECT IMMUN, V70, P4399, DOI 10.1128/IAI.70.8.4399-4405.2002; Stevanin TM, 2000, J BIOL CHEM, V275, P35868, DOI 10.1074/jbc.M002471200; VASUDEVAN SG, 1995, FEMS MICROBIOL LETT, V125, P219, DOI 10.1016/0378-1097(94)00501-H; Vazquez-Torres A, 2000, J EXP MED, V192, P227, DOI 10.1084/jem.192.2.227; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WILSON TM, 1995, MOL MICROBIOL, V15, P1009, DOI 10.1111/j.1365-2958.1995.tb02276.x; Woodmansee AN, 2002, J BIOL CHEM, V277, P34055, DOI 10.1074/jbc.M203977200	63	156	161	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28039	28047		10.1074/jbc.M605174200	http://dx.doi.org/10.1074/jbc.M605174200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16873371	hybrid			2022-12-25	WOS:000240534400041
J	Coustou, V; Biran, M; Besteiro, S; Riviere, L; Baltz, T; Franconi, JM; Bringaud, F				Coustou, Virginie; Biran, Marc; Besteiro, Sebastien; Riviere, Loic; Baltz, Theo; Franconi, Jean-Michel; Bringaud, Frederic			Fumarate is an essential intermediary metabolite produced by the procyclic Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE EXPRESSION SYSTEM; SUCCINATE COA-TRANSFERASE; RNA INTERFERENCE RNAI; BLOOD-STREAM FORM; MOLECULAR CHARACTERIZATION; ESCHERICHIA-COLI; DIHYDROOROTATE DEHYDROGENASE; SACCHAROMYCES-CEREVISIAE; CARBOHYDRATE-METABOLISM; ENERGY GENERATION	The procyclic stage of Trypanosoma brucei, a parasitic protist responsible for sleeping sickness in humans, converts most of the consumed glucose into excreted succinate, by succinic fermentation. Succinate is produced by the glycosomal and mitochondrial NADH-dependent fumarate reductases, which are not essential for parasite viability. To further explore the role of the succinic fermentation pathways, we studied the trypanosome fumarases, the enzymes providing fumarate to fumarate reductases. The T. brucei genome contains two class I fumarase genes encoding cytosolic (FHc) and mitochondrial (FHm) enzymes, which account for total cellular fumarase activity as shown by RNA interference. The growth arrest of a double RNA interference mutant cell line showing no fumarase activity indicates that fumarases are essential for the parasite. Interestingly, addition of fumarate to the medium rescues the growth phenotype, indicating that fumarate is an essential intermediary metabolite of the insect stage trypanosomes. We propose that trypanosomes use fumarate as an essential electron acceptor, as exemplified by the fumarate dependence previously reported for an enzyme of the essential de novo pyrimidine synthesis.	Univ Bordeaux 2, Lab Genom Fonct Trypanosomatides, CNRS, UMR 5162, F-33076 Bordeaux, France; Univ Bordeaux 2, CNRS, UMR 5536, F-33076 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Bringaud, F (corresponding author), Univ Bordeaux 2, Lab Genom Fonct Trypanosomatides, CNRS, UMR 5162, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	bringaud@u-bordeaux2.fr	Besteiro, Sébastien/F-3622-2014	Besteiro, Sébastien/0000-0003-1853-1494				Annoura T, 2005, J MOL EVOL, V60, P113, DOI 10.1007/s00239-004-0078-8; Barrett MP, 2003, LANCET, V362, P1469, DOI 10.1016/S0140-6736(03)14694-6; Bastin P, 1996, MOL BIOCHEM PARASIT, V77, P235, DOI 10.1016/0166-6851(96)02598-4; Berens Randolph L., 1995, P89, DOI 10.1016/B978-012473345-9/50007-6; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; Besteiro S, 2005, TRENDS PARASITOL, V21, P185, DOI 10.1016/j.pt.2005.02.008; Besteiro S, 2002, J BIOL CHEM, V277, P38001, DOI 10.1074/jbc.M201759200; Bringaud F, 1995, MOL BIOCHEM PARASIT, V74, P119, DOI 10.1016/0166-6851(95)02486-7; Bringaud F, 2000, MOL BIOCHEM PARASIT, V111, P283, DOI 10.1016/S0166-6851(00)00319-4; Bringaud F, 1998, P NATL ACAD SCI USA, V95, P7963, DOI 10.1073/pnas.95.14.7963; BRUN R, 1979, ACTA TROP, V36, P289; CAZZULO JJ, 1992, FASEB J, V6, P3153, DOI 10.1096/fasebj.6.13.1397837; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Colasante C, 2006, PROTEOMICS, V6, P3275, DOI 10.1002/pmic.200500668; Coustou V, 2005, J BIOL CHEM, V280, P16559, DOI 10.1074/jbc.M500343200; Coustou V, 2003, J BIOL CHEM, V278, P49625, DOI 10.1074/jbc.M307872200; CZOK R, 1974, METHOD ENZYMAT AN, P1600; DaRocha WD, 2004, MOL BIOCHEM PARASIT, V133, P175, DOI 10.1016/j.molbiopara.2003.10.005; El-Sayed NM, 2005, SCIENCE, V309, P409, DOI 10.1126/science.1112631; Fairlamb A. H., 1986, Carbohydrate metabolism in cultured cells., P183; Fang J, 2002, BIOCHEMISTRY-US, V41, P3065, DOI 10.1021/bi015989w; Fang J, 2001, EUR J BIOCHEM, V268, P3075, DOI 10.1046/j.1432-1327.2001.02205.x; Gao GH, 1999, J MOL BIOL, V285, P149, DOI 10.1006/jmbi.1998.2293; GEST H, 1980, FEMS MICROBIOL LETT, V7, P73, DOI 10.1111/j.1574-6941.1980.tb01579.x; GUEST JR, 1985, J GEN MICROBIOL, V131, P2971; Hannaert Veronique, 2003, Kinetoplastid Biology and Disease, V2, pUnpaginated; Harlow E., 1988, ANTIBODIES LAB MANUA; HUNTER FRISSELL R., 1960, EXPTL PARASITOL, V9, P271, DOI 10.1016/0014-4894(60)90035-7; Ivens AC, 2005, SCIENCE, V309, P436, DOI 10.1126/science.1112680; Lamour N, 2005, J BIOL CHEM, V280, P11902, DOI 10.1074/jbc.M414274200; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; Michels PAM, 2000, PARASITOL TODAY, V16, P482, DOI 10.1016/S0169-4758(00)01810-X; Murray HW, 2005, LANCET, V366, P1561, DOI 10.1016/S0140-6736(05)67629-5; Nast G, 1996, PLANT PHYSIOL, V112, P1219, DOI 10.1104/pp.112.3.1219; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; OPPERDOES FR, 1977, EUR J BIOCHEM, V76, P21, DOI 10.1111/j.1432-1033.1977.tb11566.x; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; Pines O, 1996, APPL MICROBIOL BIOT, V46, P393, DOI 10.1007/s002530050835; Riviere L, 2004, J BIOL CHEM, V279, P45337, DOI 10.1074/jbc.M407513200; Robinson KA, 2003, MOL BIOCHEM PARASIT, V128, P217, DOI 10.1016/S0166-6851(03)00079-3; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SUZUKI T, 1989, J BIOL CHEM, V264, P2581; Takashima E, 2002, MOL BIOCHEM PARASIT, V122, P189, DOI 10.1016/S0166-6851(02)00100-7; Tetaud E, 2001, MOL BIOCHEM PARASIT, V116, P171, DOI 10.1016/S0166-6851(01)00320-6; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tielens AGM, 1998, PARASITOL TODAY, V14, P265, DOI 10.1016/S0169-4758(98)01263-0; TONER JJ, 1972, BIOCHEM BIOPH RES CO, V46, P652, DOI 10.1016/S0006-291X(72)80190-6; Turner MA, 1997, P NATL ACAD SCI USA, V94, P9063, DOI 10.1073/pnas.94.17.9063; Van Hellemond JJ, 1998, P NATL ACAD SCI USA, V95, P3036, DOI 10.1073/pnas.95.6.3036; van Weelden SWH, 2005, J BIOL CHEM, V280, P12451, DOI 10.1074/jbc.M412447200; van Weelden SWH, 2003, J BIOL CHEM, V278, P12854, DOI 10.1074/jbc.M213190200; WEAVER TM, 1995, NAT STRUCT BIOL, V2, P654, DOI 10.1038/nsb0895-654; Wickstead B, 2002, MOL BIOCHEM PARASIT, V125, P211, DOI 10.1016/S0166-6851(02)00238-4; WILLIAMS SE, 1992, BIOCHEMISTRY-US, V31, P9768, DOI 10.1021/bi00155a033; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WOODS SA, 1988, BIOCHIM BIOPHYS ACTA, V954, P14, DOI 10.1016/0167-4838(88)90050-7; WU M, 1987, J BIOL CHEM, V262, P12275	57	43	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26832	26846		10.1074/jbc.M601377200	http://dx.doi.org/10.1074/jbc.M601377200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16857679	hybrid			2022-12-25	WOS:000240397700010
J	Gibbard, RJ; Morley, PJ; Gay, NJ				Gibbard, Rebecca J.; Morley, Peter J.; Gay, Nicholas J.			Conserved features in the extracellular domain of human toll-like receptor 8 are essential for pH-dependent signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-3; BACTERIAL-DNA; CPG-DNA; RECOGNITION; BINDING; CELLS; TLR9; RESPONSIVENESS; ACTIVATION; IMIQUIMOD	Toll-like receptor (TLR) 8 has an important role in initiating immune responses to viral single-stranded RNA and the antiviral compound resiquimod. Together with TLR3, -7, and -9, it forms a subgroup of the TLRs that are localized intracellularly and signal in response to pathogen-derived nucleic acids. In this work, we have used site-directed mutagenesis to identify regions of the TLR8 extracellular domain that are required for stimulus-induced signal transduction. We have shown that a cysteine-rich sequence predicted to form a loop projecting from the sole-noidal ectodomain structure at leucine-rich repeat 8 is essential for signaling in response to both single-stranded RNA and resiquimod. A second region, centered on an aspartic acid residue in leucine-rich repeat 17, is also required for TLR8 function. The corresponding residue in TLR9 is known to be important for pH-dependent binding and signaling in response to unmethylated CpG DNA, suggesting that the TLR7/8/9 subgroups share a common signaling mechanism. We have also shown that TLR8 is localized predominantly in the endoplasmic reticulum but that signaling is completely abolished by an inhibitor of vesicle-type H+ ATPases. This indicates that TLR8 is present at low levels in an acidified compartment and that a lowered pH is required for receptor function. We propose that pH-dependent changes in the ligand facilitate activation of the receptor. The protonated form of resiquimod, a cell-permeable weak base, is likely to concentrate significantly (similar to 100x) in acidified compartments, and this may potentiate low affinity interactions with either the receptor or a specific binding protein.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; GlaxoSmithKline Med Res Ctr, Stevenage SG1 2NY, Herts, England	University of Cambridge; GlaxoSmithKline	Gay, NJ (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	njg11@mole.bio.cam.ac.uk			MRC [G0400007] Funding Source: UKRI; Medical Research Council [G1000133, G0400007] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Barton GM, 2006, NAT IMMUNOL, V7, P49, DOI 10.1038/ni1280; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Beignon AS, 2005, J CLIN INVEST, V115, P3265, DOI 10.1172/JCI26032; Bell JK, 2003, TRENDS IMMUNOL, V24, P528, DOI 10.1016/S1471-4906(03)00242-4; Bell JK, 2005, P NATL ACAD SCI USA, V102, P10976, DOI 10.1073/pnas.0505077102; Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253; Chollet JL, 1999, PHARM DEV TECHNOL, V4, P35, DOI 10.1081/PDT-100101337; de Bouteiller O, 2005, J BIOL CHEM, V280, P38133, DOI 10.1074/jbc.M507163200; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Gangloff M, 2004, TRENDS BIOCHEM SCI, V29, P294, DOI 10.1016/j.tibs.2004.04.008; Gorden KB, 2005, J IMMUNOL, V174, P1259, DOI 10.4049/jimmunol.174.3.1259; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; Levy O, 2004, J IMMUNOL, V173, P4627, DOI 10.4049/jimmunol.173.7.4627; Mizel SB, 2003, J BIOL CHEM, V278, P23624, DOI 10.1074/jbc.M303481200; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124; Rutz M, 2004, EUR J IMMUNOL, V34, P2541, DOI 10.1002/eji.200425218; Weber ANR, 2005, J BIOL CHEM, V280, P22793, DOI 10.1074/jbc.M502074200; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955; Wu MM, 2000, CHEM BIOL, V7, P197, DOI 10.1016/S1074-5521(00)00088-0; Yasuda K, 2006, EUR J IMMUNOL, V36, P431, DOI 10.1002/eji.200535210; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	29	71	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27503	27511		10.1074/jbc.M605003200	http://dx.doi.org/10.1074/jbc.M605003200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16857668	hybrid			2022-12-25	WOS:000240397700077
J	Xu, H; Wickner, W				Xu, Hao; Wickner, William			Bem1p is a positive regulator of the homotypic fusion of yeast vacuoles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR MEMBRANE-FUSION; NSF ATTACHMENT PROTEINS; VERTEX RING DOMAIN; SACCHAROMYCES-CEREVISIAE; PX DOMAIN; NUCLEOTIDE EXCHANGE; KINASE CASCADE; ALPHA-SNAP; DOCKING; COMPLEX	Docked vacuoles are believed to undergo rapid lipid mixing during hemifusion and then a slow, rate-limiting completion of fusion and mixing of lumenal contents. Previous genomic analysis has suggested that Bem1p, a scaffold protein critical for cell polarity, may support vacuole fusion. We now report that bem1 Delta strains have fragmented vacuoles (vps class B and C). During in vitro fusion reactions, vacuoles from bem1 Delta strains showed a strong reduction in the rate of lipid mixing when compared with vacuoles from the BEM1 parent. The reduction in the overall rate of fusion with bem1 Delta vacuoles was modest, consistent with lipid mixing as a non-rate-limiting step in the pathway. Although the fusion of either BEM1 (wild-type) or bem1 Delta vacuoles is stimulated by recombinant Bem1p, the lipid mixing of docked bem1 Delta vacuoles is highly dependent on rBem1p under certain reaction conditions. Bem1p-stimulated lipid mixing is blocked by well characterized fusion inhibitors including lipid ligands and antibodies to Ypt7p, Vps33p, and Vam3p. Although full-length Bem1p is required for maximal stimulation, a truncation mutant comprising the SH3 domains and the Phox homology (PX) domain retains modest stimulatory activity. In contrast to an earlier report (Han, B. K., Bogomolnaya, L. M., Totten, J. M., Blank, H. M., Dangott, L. J., and Polymenis, M. (2005) Genes Dev. 19, 2606-2618), we did not find phosphorylation of Bem1p at Ser-72 to be required for Bem1p-stimulated fusion. Taken together, Bem1p is a positive regulator of lipid mixing during vacuole hemifusion and fusion.	Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Wickner, W (corresponding author), Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.	Bill.Wickner@Dartmouth.edu	Xu, Hao/B-3194-2011	Xu, Hao/0000-0002-5776-0276				Ago T, 2001, BIOCHEM BIOPH RES CO, V287, P733, DOI 10.1006/bbrc.2001.5629; Andrews NW, 2005, TRENDS CELL BIOL, V15, P626, DOI 10.1016/j.tcb.2005.09.001; Bose I, 2001, J BIOL CHEM, V276, P7176, DOI 10.1074/jbc.M010546200; Brachmann CB, 1998, YEAST, V14, P115; Burgoyne RD, 2003, BBA-MOL CELL RES, V1641, P137, DOI 10.1016/S0167-4889(03)00089-2; Butty AC, 2002, EMBO J, V21, P1565, DOI 10.1093/emboj/21.7.1565; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; Eitzen G, 2003, BBA-MOL CELL RES, V1641, P175, DOI 10.1016/S0167-4889(03)00087-9; Eitzen G, 2002, J CELL BIOL, V158, P669, DOI 10.1083/jcb.200204089; Eitzen G, 2001, EMBO J, V20, P5650, DOI 10.1093/emboj/20.20.5650; Fratti RA, 2004, J CELL BIOL, V167, P1087, DOI 10.1083/jcb.200409068; Gaits F, 1999, MOL BIOL CELL, V10, P2647, DOI 10.1091/mbc.10.8.2647; Gerst JE, 2003, BBA-MOL CELL RES, V1641, P99, DOI 10.1016/S0167-4889(03)00096-X; Giraudo CG, 2005, J CELL BIOL, V170, P249, DOI 10.1083/jcb.200501093; GUELMAN R, 2002, BONE, V30, P23; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Haas Albert, 1995, Methods in Cell Science, V17, P283, DOI 10.1007/BF00986234; Han BK, 2005, GENE DEV, V19, P2606, DOI 10.1101/gad.1361505; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hiesinger PR, 2005, CELL, V121, P607, DOI 10.1016/j.cell.2005.03.012; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Huynh H, 2004, NAT CELL BIOL, V6, P831, DOI 10.1038/ncb1164; Ito T, 2001, EMBO J, V20, P3938, DOI 10.1093/emboj/20.15.3938; Jahn R, 2000, NEURON, V27, P201, DOI 10.1016/S0896-6273(00)00029-5; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; Lu XB, 2005, J BIOL CHEM, V280, P30538, DOI 10.1074/jbc.M506862200; Lyons DM, 1996, MOL CELL BIOL, V16, P4095; Mayer A, 2002, ANNU REV CELL DEV BI, V18, P289, DOI 10.1146/annurev.cellbio.18.032202.114809; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Muller O, 2001, EMBO J, V20, P5657, DOI 10.1093/emboj/20.20.5657; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Peters C, 1999, SCIENCE, V285, P1084, DOI 10.1126/science.285.5430.1084; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; SAMBROOK J, 1989, MOL CLONING LAB MANU, pA1; Sato TK, 2000, MOL CELL, V6, P661, DOI 10.1016/S1097-2765(00)00064-2; Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402; Seeley ES, 2002, MOL BIOL CELL, V13, P782, DOI 10.1091/mbc.01-10-0512; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Steel GJ, 1998, FEBS LETT, V423, P113, DOI 10.1016/S0014-5793(98)00072-6; Stroupe C, 2006, EMBO J, V25, P1579, DOI 10.1038/sj.emboj.7601051; Thorngren N, 2004, EMBO J, V23, P2765, DOI 10.1038/sj.emboj.7600286; Ungermann C, 2005, J CELL SCI, V118, P3819, DOI 10.1242/jcs.02561; Vollert CS, 2004, MOL CELL PROTEOMICS, V3, P1053, DOI 10.1074/mcp.M400081-MCP200; WADA Y, 1992, J BIOL CHEM, V267, P18671; Wang L, 2003, J CELL BIOL, V160, P365, DOI 10.1083/jcb.200209095; Wang L, 2002, CELL, V108, P357, DOI 10.1016/S0092-8674(02)00632-3; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Weixel KM, 2005, J BIOL CHEM, V280, P10501, DOI 10.1074/jbc.M414304200; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; Wickner W, 2002, EMBO J, V21, P1241, DOI 10.1093/emboj/21.6.1241; Wurmser AE, 2000, J CELL BIOL, V151, P551, DOI 10.1083/jcb.151.3.551; Xu YB, 2005, NAT STRUCT MOL BIOL, V12, P417, DOI 10.1038/nsmb921; Yu JW, 2001, J BIOL CHEM, V276, P44179, DOI 10.1074/jbc.M108811200; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	58	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27158	27166		10.1074/jbc.M605592200	http://dx.doi.org/10.1074/jbc.M605592200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16854988	hybrid			2022-12-25	WOS:000240397700043
J	Matsuda, K; Matsuda, S; Gladding, CM; Yuzaki, M				Matsuda, Keiko; Matsuda, Shinji; Gladding, Clare M.; Yuzaki, Michisuke			Characterization of the delta 2 glutamate receptor-binding protein delphilin - Splicing variants with differential palmitoylation and an additional PDZ domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM DEPRESSION; CRYSTAL-STRUCTURE; PURKINJE-CELLS; MEDIATED MULTIMERIZATION; SYNAPTIC PLASTICITY; TARGET RECOGNITION; STRUCTURAL BASIS; COMPLEX REVEALS; FIBER SYNAPSES; PSD-95	The glutamate receptor delta 2 (GluR delta 2) is predominantly expressed at parallel fiber-Purkinje cell postsynapses and plays crucial roles in synaptogenesis and synaptic plasticity. Although the mechanism by which GluR delta 2 functions remains unclear, its lack of channel activity and its role in controlling the endocytosis of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate ( AMPA) receptors have suggested that GluR delta 2 may convey signals by interacting with intracellular signaling molecules. Among several proteins that interact with GluR delta 2, delphilin is unique in that it is selectively expressed at parallel fiber-Purkinje cell synapses and that, in addition to a single PDZ domain, it contains a formin homology domain that is thought to regulate actin dynamics. Here, we report a new isoform of delphilin, designated as L-delphilin, that has alternatively spliced N-terminal exons encoding an additional PDZ domain. Although original delphilin, designated S-delphilin, was palmitoylated at the N terminus, this region was spliced out in L-delphilin. As a result, S-delphilin was associated with plasma membranes in COS cells and dendritic spines in hippocampal neurons, whereas L-delphilin formed clusters in soma and dendritic shafts. In addition, S-delphilin, but not L-delphilin, facilitated the expression of GluR delta 2 on the cell surface. These results indicate that, like PSD-95 and GRIP/ABP, delphilin isoforms with differential palmitoylation and clustering capabilities may provide two separate intracellular and surface GluR delta 2 pools and may control GluR delta 2 signaling in Purkinje cells.	Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1608582, Japan; Univ Bristol, Dept Anat, Bristol BS8 1TD, Avon, England	Keio University; University of Bristol	Yuzaki, M (corresponding author), Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.	myuzaki@sc.itc.keio.ac.jp	Gladding, Clare/E-9719-2012; Matsuda, Keiko/L-5778-2013; Matsuda, Shinji/L-4727-2013; Yuzaki, Michisuke/K-5328-2013; Matsuda, Shinji/GRR-5226-2022	Yuzaki, Michisuke/0000-0002-5750-3544; 				Boudin H, 2001, J BIOL CHEM, V276, P30270, DOI 10.1074/jbc.M102991200; Chetkovich DM, 2002, J NEUROSCI, V22, P6415; Christopherson KS, 2003, J CELL SCI, V116, P3213, DOI 10.1242/jcs.00617; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; DeSouza S, 2002, J NEUROSCI, V22, P3493; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Feng W, 2003, NAT STRUCT BIOL, V10, P972, DOI 10.1038/nsb992; Hirai H, 2003, NAT NEUROSCI, V6, P869, DOI 10.1038/nn1086; Hirai H, 2001, EUR J NEUROSCI, V14, P73, DOI 10.1046/j.0953-816x.2001.01630.x; Hironaka K, 2000, J BIOL CHEM, V275, P16167, DOI 10.1074/jbc.M909302199; Hsueh YP, 1999, J BIOL CHEM, V274, P532, DOI 10.1074/jbc.274.1.532; Im YJ, 2003, J BIOL CHEM, V278, P48099, DOI 10.1074/jbc.M306919200; Im YJ, 2003, J BIOL CHEM, V278, P8501, DOI 10.1074/jbc.M212263200; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; KANO M, 1987, NATURE, V325, P276, DOI 10.1038/325276a0; KASHIWABUCHI N, 1995, CELL, V81, P245, DOI 10.1016/0092-8674(95)90334-8; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Long JF, 2003, J MOL BIOL, V327, P203, DOI 10.1016/S0022-2836(03)00113-X; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Matsuda K, 2003, J NEUROSCI, V23, P10064; Matsuda S, 2000, EMBO J, V19, P2765, DOI 10.1093/emboj/19.12.2765; Matsuda S, 2004, EUR J NEUROSCI, V19, P1683, DOI 10.1111/j.1460-9568.2004.03307.x; Matsuda S, 2002, EUR J NEUROSCI, V16, P1507, DOI 10.1046/j.1460-9568.2002.02219.x; MAYAT E, 1995, J NEUROSCI, V15, P2533, DOI 10.1523/JNEUROSCI.15-03-02533.1995; Miyagi Y, 2002, J NEUROSCI, V22, P803, DOI 10.1523/JNEUROSCI.22-03-00803.2002; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Roche KW, 1999, J NEUROSCI, V19, P3926; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; Uemura T, 2004, MOL CELL NEUROSCI, V26, P330, DOI 10.1016/j.mcn.2004.02.007; Van't Hof W, 2000, METHOD ENZYMOL, V327, P317, DOI 10.1016/S0076-6879(00)27287-X; Wang YT, 2000, NEURON, V25, P635, DOI 10.1016/S0896-6273(00)81066-1; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Yamashita T, 2005, MOL BRAIN RES, V141, P83, DOI 10.1016/j.molbrainres.2005.08.006; Yamazaki M, 2001, NEUROSCI LETT, V304, P81, DOI 10.1016/S0304-3940(01)01766-9; Yuzaki M, 2004, CEREBELLUM, V3, P89, DOI 10.1080/14734220410028921; Yuzaki M, 2003, NEUROSCI RES, V46, P11, DOI 10.1016/S0168-0102(03)00036-1; Zhao HM, 1997, J NEUROCHEM, V68, P1041	40	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25577	25587		10.1074/jbc.M602044200	http://dx.doi.org/10.1074/jbc.M602044200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16835239	hybrid			2022-12-25	WOS:000240031300061
J	Sasai, K; Kakumoto, K; Hanafusa, H; Akagi, T				Sasai, K.; Kakumoto, K.; Hanafusa, H.; Akagi, T.			The Ras-MAPK pathway downregulates Caveolin-1 in rodent fibroblast but not in human fibroblasts: implications in the resistance to oncogene-mediated transformation	ONCOGENE			English	Article						caveolin-1; hTERT; normal human diploid fibroblast; oncogenic transformation; Ras-MAPK pathway	HUMAN-DIPLOID FIBROBLASTS; CANCER; CELLS; INVASIVENESS; EXPRESSION; KINASE	Normal human diploid fibroblasts (HDFs) are refractory to oncogene-mediated transformations in vitro, compared with rodent fibroblasts. As successful oncogene-mediated transformations of normal HDFs have been reported using the human telomerase catalytic subunit, it has been considered that telomerase activity contributes to the species-specific transformability. However, these transformed HDFs are much less malignant compared with those of rodent cells, suggesting the existence of undetermined mechanisms that render HDFs resistant to malignant transformation. Here, cDNA microarray analysis identified caveolin-1 as one of the possible cellular factors involved in such mechanisms. The mitogen-activated protein kinases ( MAPK) pathway downregulates Caveolin-1 in rodent fibroblasts, transformed by coexpression of the SV40 early region and activated H-Ras. In contrast, the coexpression of these two oncogenes in HDFs failed to reduce the expression level of Caveolin-1. These results strongly suggest the presence of critical differences in events following the phosphorylation of ERK during the activation process of the MAPK signaling pathway between human and rodent cells, as the ERK protein was similarly phosphorylated in both systems. Furthermore, the small interfering RNA-mediated suppression of Caveolin-1 facilitated the oncogene-mediated transformation of normal HDFs, clearly indicating that the differences in the transformability between human and rodent cells are due, at least in part, to the mechanism responsible for the resistance to Ras-induced Caveolin-1 downregulation in HDFs.	Osaka Biosci Inst, Oncol Mol Lab, Ibaraki, Osaka 5670085, Japan		Akagi, T (corresponding author), Osaka Biosci Inst, Oncol Mol Lab, Saito Boincubator Rm204,7-7-15 Saito Asagi, Ibaraki, Osaka 5670085, Japan.	takagi@obi.or.jp						Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Akagi T, 2004, TRENDS MOL MED, V10, P542, DOI 10.1016/j.molmed.2004.09.001; Akagi T, 2003, P NATL ACAD SCI USA, V100, P13567, DOI 10.1073/pnas.1834876100; Akagi T, 2002, MOL CELL BIOL, V22, P7015, DOI 10.1128/MCB.22.20.7015-7023.2002; Chi JT, 2003, P NATL ACAD SCI USA, V100, P6343, DOI 10.1073/pnas.1037853100; Cho KA, 2003, J BIOL CHEM, V278, P27789, DOI 10.1074/jbc.M208105200; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Galbiati F, 2001, MOL BIOL CELL, V12, P2229, DOI 10.1091/mbc.12.8.2229; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Ge SJ, 2004, J BIOL CHEM, V279, P6688, DOI 10.1074/jbc.M311769200; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Kakumoto K, 2006, P NATL ACAD SCI USA, V103, P5490, DOI 10.1073/pnas.0601222103; Razani B, 2001, J BIOL CHEM, V276, P38121; Sasai K, 2003, J BIOL CHEM, V278, P25295, DOI 10.1074/jbc.M301913200; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Sukezane T, 2005, ONCOGENE, V24, P5648, DOI 10.1038/sj.onc.1208724; Tang W, 2004, MOL BIOL CELL, V15, P4043, DOI 10.1091/mbc.E04-05-0402; van den Heuvel APJ, 2005, BIOCHEM J, V385, P795, DOI 10.1042/BJ20041449; Volonte D, 2002, MOL BIOL CELL, V13, P2502, DOI 10.1091/mbc.01-11-0529; Williams TM, 2004, J BIOL CHEM, V279, P24745, DOI 10.1074/jbc.M402064200; Zhao JJ, 2004, TRENDS MOL MED, V10, P344, DOI 10.1016/j.molmed.2004.05.005	22	16	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					449	455		10.1038/sj.onc.1209792	http://dx.doi.org/10.1038/sj.onc.1209792			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832346				2022-12-25	WOS:000243544000013
J	Ibrahim, M; Kerby, RL; Puranik, M; Wasbotten, IH; Youn, H; Roberts, GP; Spiro, TG				Ibrahim, Mohammed; Kerby, Robert L.; Puranik, Mrinalini; Wasbotten, Ingar H.; Youn, Hwan; Roberts, Gary P.; Spiro, Thomas G.			Heme displacement mechanism of CooA activation - Mutational and Raman spectroscopic evidence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSING TRANSCRIPTIONAL ACTIVATOR; DNA-BINDING; REGULATOR COOA; AXIAL LIGAND; HISTIDINE 77; C-HELIX; PROTEIN; RESOLUTION; POCKET; SENSOR	The heme-containing protein CooA of Rhodospirillum rubrum regulates the expression of genes involved in CO oxidation. CooA binds its target DNA sequence in response to CO binding to its heme. Activity measurements and resonance Raman (RR) spectra are reported for CooA variants that bind DNA even in the absence of CO, those in which the wild-type residues at the 121-126 positions, TSCMRT, are replaced by the residues AYLLRL or RYLLRL, and also for variants that bind DNA poorly in the presence of CO, such as L120S and L120F. The Fe-C and C-O stretching resonance Raman ( RR) frequencies of all CooAs examined deviate from the expected back-bonding correlation in a manner indicating weakening of the Fe-His-77 proximal ligand bond, and the extent of weakening correlates positively with DNA binding activity. The (A/R) YLLRL variants have detectable populations of a 5-coordinate heme resulting from partial dissociation of the endogenous distal ligand, Pro-2. Selective excitation of this population reveals downshifted Fe-His-77-stretching RR bands, confirming the proximal bond weakening. These results support our previous hypothesis that the conformational change required for DNA binding is initiated by displacement of the heme into an adjacent hydrophobic cavity once CO displaces the Pro-2 ligand. Examination of the crystal structure reveals a physical basis for these results, and a mechanism is proposed to link heme displacement to conformational change.	Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	Princeton University; University of Wisconsin System; University of Wisconsin Madison	Spiro, TG (corresponding author), Princeton Univ, Dept Chem, Princeton, NJ 08544 USA.	spiro@princeton.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053228, R01GM033576] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM033576-40, R01 GM033576, GM33576, R01 GM053228, R01 GM053228-13, GM53228] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiyama S, 2004, J MOL BIOL, V341, P651, DOI 10.1016/j.jmb.2004.06.040; Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Aono S, 2003, ACCOUNTS CHEM RES, V36, P825, DOI 10.1021/ar020097p; Clark RW, 2006, P NATL ACAD SCI USA, V103, P891, DOI 10.1073/pnas.0505919103; Coyle CM, 2003, J BIOL CHEM, V278, P35384, DOI 10.1074/jbc.M301000200; Franzen S, 2001, J AM CHEM SOC, V123, P12578, DOI 10.1021/ja0108988; Gilles-Gonzalez MA, 2005, J INORG BIOCHEM, V99, P1, DOI 10.1016/j.jinorgbio.2004.11.006; Kerby RL, 2003, J MOL BIOL, V325, P809, DOI 10.1016/S0022-2836(02)01203-2; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; Kubo M, 2006, J BIOL CHEM, V281, P11271, DOI 10.1074/jbc.M513261200; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; Marti MA, 2003, J BIOL INORG CHEM, V8, P595, DOI 10.1007/s00775-003-0452-9; Parkinson G, 1996, J MOL BIOL, V260, P395, DOI 10.1006/jmbi.1996.0409; Passner JM, 2000, J MOL BIOL, V304, P847, DOI 10.1006/jmbi.2000.4231; Puranik M, 2004, J BIOL CHEM, V279, P21096, DOI 10.1074/jbc.M400613200; Reynolds MF, 2000, BIOCHEMISTRY-US, V39, P388, DOI 10.1021/bi991378g; Roberts GP, 2005, J INORG BIOCHEM, V99, P280, DOI 10.1016/j.jinorgbio.2004.10.032; Rubtsov IV, 2001, J AM CHEM SOC, V123, P10056, DOI 10.1021/ja011023w; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; SMULEVICH G, 1988, BIOCHEMISTRY-US, V27, P5477, DOI 10.1021/bi00415a014; Spiro TG, 2005, J INORG BIOCHEM, V99, P34, DOI 10.1016/j.jinorgbio.2004.09.026; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; Thorsteinsson MV, 2000, BIOCHEMISTRY-US, V39, P8284, DOI 10.1021/bi000327c; Thorsteinsson MV, 2001, J BIOL CHEM, V276, P26807, DOI 10.1074/jbc.M102758200; Thorsteinsson MV, 2000, J BIOL CHEM, V275, P39332, DOI 10.1074/jbc.M007691200; Uchida T, 1998, J BIOL CHEM, V273, P19988, DOI 10.1074/jbc.273.32.19988; Uchida T, 2000, BIOCHEMISTRY-US, V39, P12747, DOI 10.1021/bi0011476; Uchida T, 2005, ACCOUNTS CHEM RES, V38, P662, DOI 10.1021/ar030267d; Uchida T, 2005, J BIOL CHEM, V280, P21358, DOI 10.1074/jbc.M412350200; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; Yamamoto K, 2001, J BIOL CHEM, V276, P11473, DOI 10.1074/jbc.C100047200; Yamashita T, 2004, J BIOL CHEM, V279, P47320, DOI 10.1074/jbc.M407766200; Youn H, 2005, J BACTERIOL, V187, P2573, DOI 10.1128/JB.187.8.2573-2581.2005; Youn H, 2004, J BACTERIOL, V186, P1320, DOI 10.1128/JB.186.5.1320-1329.2004; Youn H, 2003, J BIOL CHEM, V278, P2333, DOI 10.1074/jbc.M210825200; Youn H, 2002, J BIOL CHEM, V277, P33616, DOI 10.1074/jbc.M203684200; Youn H, 2001, J BIOL CHEM, V276, P41603, DOI 10.1074/jbc.M106165200	37	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29165	29173		10.1074/jbc.M605568200	http://dx.doi.org/10.1074/jbc.M605568200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16873369	hybrid, Green Accepted			2022-12-25	WOS:000240680500071
J	Monroe, DG; Secreto, FJ; Hawse, JR; Subramaniam, M; Khosla, S; Spelsberg, TC				Monroe, David G.; Secreto, Frank J.; Hawse, John R.; Subramaniam, Malayannan; Khosla, Sundeep; Spelsberg, Thomas C.			Estrogen receptor isoform-specific regulation of the retinoblastoma-binding protein 1 (RBBP1) gene - Roles of AF1 and enhancer elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; ACTIVATION FUNCTION 1; ER-ALPHA; TRANSCRIPTIONAL ACTIVATION; MCF-7 CELLS; TRANSACTIVATION DOMAINS; OSTEOSARCOMA CELLS; STEROID-RECEPTORS; BINDING PROTEIN; TARGET GENES	Estrogen (E2) is involved in mediating many important functions relevant to osteoblast biology through the actions of the estrogen receptors (ER) alpha and beta. To further understand the mechanisms of ER-specific regulation, we used microarray and reverse transcription-PCR analyses of E2-treated U2OS-ER alpha or -ER beta cells and identified retinoblastoma-binding protein 1 (RBBP1) as a major E2-regulated gene. RBBP1 is a retinoblastoma cofactor involved in the control of osteoblastic proliferation. Although RBBP1 mRNA levels rapidly increased after 2 h of E2 treatment in both U2OS-ER-expressing lines, a sustained induction was only observed in U2OS-ER alpha cells. Examination of the RBBP1 genomic sequence revealed an ER response element and a Sp1 site located within the first intron. Chromatin immunoprecipitation analyses demonstrated that E2-dependent ER alpha binding to the intron 1 enhancer region was constitutive, whereas ER beta binding was transient, consistent with the mRNA time course. Interestingly, transient transfection and receptor mutational studies revealed that RBBP1 induction by ER alpha only requires the Sp1 site, whereas ER beta utilizes both the Sp1 and estrogen response elements binding sites for maximal E2-dependent activation. Stable U2OS transfectants containing a deletion of the ER alpha activation function 1 (AF1) resulted in a temporal mRNA induction profile similar to that of wild type ER beta. Further, overexpression and chromatin immunoprecipitation analyses also demonstrated that E2-dependent RBBP1 induction is SRC2-dependent for both ER isoforms. These results describe an E2-dependent, ER isoform-specific transcriptional activation of the RBBP1 gene, which in part, is explained by the differential activity of ER AF1 and enhancer element binding.	Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Endocrine Res Unit, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Monroe, DG (corresponding author), Mayo Clin, Coll Med, Dept Biochem & Mol Biol, 1601C Guggenheim,200 1st St SW, Rochester, MN 55905 USA.	Monroe.David@mayo.edu	Khosla, Sundeep/AAE-6170-2020	Khosla, Sundeep/0000-0002-2936-4372	NIA NIH HHS [P01-AG04875-21] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG004875] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Benecke A, 2000, EMBO REP, V1, P151, DOI 10.1093/embo-reports/kvd028; Binda O, 2006, MOL CELL BIOL, V26, P1917, DOI 10.1128/MCB.26.5.1917-1931.2006; Delaunay F, 2000, MOL PHARMACOL, V58, P584, DOI 10.1124/mol.58.3.584; Denger S, 2001, MOL ENDOCRINOL, V15, P2064, DOI 10.1210/me.15.12.2064; Dutertre M, 2003, MOL ENDOCRINOL, V17, P1296, DOI 10.1210/me.2001-0316; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Flototto T, 2004, J STEROID BIOCHEM, V88, P131, DOI 10.1016/j.jsbmb.2003.11.004; Flouriot G, 2000, EMBO J, V19, P4688, DOI 10.1093/emboj/19.17.4688; HARRIS RD, 2000, PRINCIPLES BONE BIOL, P655; Jakacka M, 2001, J BIOL CHEM, V276, P13615, DOI 10.1074/jbc.M008384200; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; Kawashima H, 2003, BIOCHEM J, V369, P163, DOI 10.1042/BJ20020743; Khan S, 2003, ENDOCRINOLOGY, V144, P2325, DOI 10.1210/en.2002-0149; Kim K, 2005, MOL ENDOCRINOL, V19, P843, DOI 10.1210/me.2004-0326; Kim K, 2003, MOL ENDOCRINOL, V17, P804, DOI 10.1210/me.2002-0406; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lai A, 1999, ONCOGENE, V18, P2091, DOI 10.1038/sj.onc.1202520; Laj A, 1999, MOL CELL BIOL, V19, P6632; Lambert Jr, 2001, METH MOL B, V176, P273; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LEES JA, 1989, J STEROID BIOCHEM, V34, P33, DOI 10.1016/0022-4731(89)90063-0; Lonard DM, 2006, CELL, V125, P411, DOI 10.1016/j.cell.2006.04.021; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Merot Y, 2004, J BIOL CHEM, V279, P26184, DOI 10.1074/jbc.M402148200; Monroe DG, 2003, J ENDOCRINOL, V176, P349, DOI 10.1677/joe.0.1760349; Monroe DG, 2004, ADV MOL CEL, V34, P39, DOI 10.1016/S1569-2558(03)34003-2; Monroe DG, 2005, MOL ENDOCRINOL, V19, P1555, DOI 10.1210/me.2004-0381; Monroe DG, 2003, J CELL BIOCHEM, V90, P315, DOI 10.1002/jcb.10633; MONROE DG, 2004, PRIMER METABOLIC BON, P32; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; Penot G, 2005, ENDOCRINOLOGY, V146, P5474, DOI 10.1210/en.2005-0866; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Qin CH, 1999, ENDOCRINOLOGY, V140, P2501, DOI 10.1210/en.140.6.2501; Qin CH, 2004, MOL CARCINOGEN, V40, P160, DOI 10.1002/mc.20030; Salvatori L, 2003, ONCOGENE, V22, P4875, DOI 10.1038/sj.onc.1206784; Samudio I, 2001, ENDOCRINOLOGY, V142, P1000, DOI 10.1210/en.142.3.1000; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Saville B, 2002, J BIOL CHEM, V277, P2485, DOI 10.1074/jbc.M109021200; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Stoner M, 2004, ONCOGENE, V23, P1052, DOI 10.1038/sj.onc.1207201; Stossi F, 2004, ENDOCRINOLOGY, V145, P3473, DOI 10.1210/en.2003-1682; Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882; Tee MK, 2004, MOL BIOL CELL, V15, P1262, DOI 10.1091/mbc.E03-06-0360; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Wu XY, 2001, J BIOL CHEM, V276, P23962, DOI 10.1074/jbc.M101041200; Xie W, 1999, ENDOCRINOLOGY, V140, P219, DOI 10.1210/en.140.1.219	57	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28596	28604		10.1074/jbc.M605226200	http://dx.doi.org/10.1074/jbc.M605226200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16873370	hybrid			2022-12-25	WOS:000240680500013
J	Potter, CS; Peterson, RL; Barth, JL; Pruett, ND; Jacobs, DF; Kern, MJ; Argraves, WS; Sundberg, JP; Awgulewitsch, A				Potter, Christopher S.; Peterson, Ron L.; Barth, Jeremy L.; Pruett, Nathanael D.; Jacobs, Donna F.; Kern, Michael J.; Argraves, W. Scott; Sundberg, John P.; Awgulewitsch, Alexander			Evidence that the satin hair mutant gene Foxq1 is among multiple and functionally diverse regulatory targets for Hoxc13 during hair follicle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER-ROOT-SHEATH; MURINE HAIR; STEM-CELLS; EXPRESSION; PROTEINS; KERATIN; MICE; MODEL; MOUSE; IDENTIFICATION	It is increasingly evident that the molecular mechanisms underlying hair follicle differentiation and cycling recapitulate principles of embryonic patterning and organ regeneration. Here we used Hoxc13-overexpressing transgenic mice (also known as GC13 mice), known to develop severe hair growth defects and alopecia, as a tool for defining pathways of hair follicle differentiation. Gene array analysis performed with RNA from postnatal skin revealed differential expression of distinct subsets of genes specific for cells of the three major hair shaft compartments ( cuticle, cortex, and medulla) and their precursors. This finding correlates well with the structural defects observed in each of these compartments and implicates Hoxc13 in diverse pathways of hair follicle differentiation. The group of medulla-specific genes was particularly intriguing because this included the developmentally regulated transcription factor-encoding gene Foxq1 that is altered in the medulla-defective satin mouse hair mutant. We provide evidence that Foxq1 is a downstream target for Hoxc13 based on DNA binding studies as well as co-transfection and chromatin immunoprecipitation assays. Expression of additional medulla-specific genes down-regulated upon overexpression of Hoxc13 requires functional Foxq1 as their expression is ablated in hair follicles of satin mice. Combined, these results demonstrate that Hoxc13 and Foxq1 control medulla differentiation through a common regulatory pathway. The apparent regulatory interactions between members of the mammalian Hox and Fox gene families shown here may establish a paradigm for "cross-talk" between these two conserved regulatory gene families in different developmental contexts including embryonic patterning as well as organ development and renewal.	Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Cell Biol, Charleston, SC 29425 USA; Novartis Inst Biomed Res, Div Integrat Express Profiling, Cambridge, MA 02139 USA; Jackson Lab, Bar Harbor, ME 04609 USA	Medical University of South Carolina; Medical University of South Carolina; Novartis; Jackson Laboratory	Awgulewitsch, A (corresponding author), Med Univ S Carolina, Dept Med, 96 Jonathan Lucas St,Suite 912 CSB, Charleston, SC 29425 USA.	awgulewa@musc.edu			NCI NIH HHS [R24CA95841] Funding Source: Medline; NCRR NIH HHS [RR00173, P20 RR016434, C06-RR015455, RR-16434] Funding Source: Medline; NIAMS NIH HHS [AR47204-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA095841] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016434, C06RR015455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047204] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AUBER L., 1952, TRANS ROY SOC EDINBURGH, V62, P191; Awgulewitsch A, 2003, NATURWISSENSCHAFTEN, V90, P193, DOI 10.1007/s00114-003-0417-4; Bechtold LS, 2000, SYSTEMATIC APPROACH TO EVALUATION OF MOUSE MUTATIONS, P121; BIEBERICH CJ, 1991, ANN NY ACAD SCI, V642, P346; Capecchi MR, 1997, COLD SPRING HARB SYM, V62, P273, DOI 10.1101/SQB.1997.062.01.034; Chen K, 2002, MOL BIOL CELL, V13, P1953, DOI 10.1091/mbc.02-02-0022; Chuong CM, 1999, J INVEST DERM SYMP P, V4, P307, DOI 10.1038/sj.jidsp.5640235; CHUONG CM, 1990, DEVELOPMENT, V110, P1021; CHUONG CM, 1993, BIOESSAYS, V15, P513, DOI 10.1002/bies.950150804; DasGupta R, 1999, DEVELOPMENT, V126, P4557; DUBOULE D, 1992, BIOESSAYS, V14, P375, DOI 10.1002/bies.950140606; Frank S, 1998, DNA CELL BIOL, V17, P679, DOI 10.1089/dna.1998.17.679; Fuchs E, 2001, DEV CELL, V1, P13, DOI 10.1016/S1534-5807(01)00022-3; Galant R, 2002, DEVELOPMENT, V129, P3115; Gebelein B, 2004, NATURE, V431, P653, DOI 10.1038/nature02946; Godwin AR, 1998, GENE DEV, V12, P11, DOI 10.1101/gad.12.1.11; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hong HK, 2001, GENESIS, V29, P163, DOI 10.1002/gene.1020; Jave-Suarez LF, 2006, ARCH DERMATOL RES, V297, P372, DOI 10.1007/s00403-005-0623-3; Jave-Suarez LF, 2002, J BIOL CHEM, V277, P3718, DOI 10.1074/jbc.M101616200; Johns SA, 2005, DEV DYNAM, V232, P1062, DOI 10.1002/dvdy.20278; KANZLER B, 1994, INT J DEV BIOL, V38, P633; KOZAK M, 1983, MICROBIOL REV, V47, P1; Langbein L, 2005, INT REV CYTOL, V243, P1, DOI 10.1016/S0074-7696(05)43001-6; Langbein L, 2003, J INVEST DERMATOL, V120, P512, DOI 10.1046/j.1523-1747.2003.12087.x; Langbein L, 2002, J INVEST DERMATOL, V118, P789, DOI 10.1046/j.1523-1747.2002.01711.x; Legue E, 2005, DEVELOPMENT, V132, P4143, DOI 10.1242/dev.01975; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lin KK, 2004, P NATL ACAD SCI USA, V101, P15955, DOI 10.1073/pnas.0407114101; Liu X, 2001, P NATL ACAD SCI USA, V98, P9139, DOI 10.1073/pnas.161016098; Liu XY, 1999, NAT GENET, V22, P182, DOI 10.1038/9700; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; Mann RS, 1998, CURR OPIN GENET DEV, V8, P423, DOI 10.1016/S0959-437X(98)80113-5; MANN SJ, 1962, ANAT RECORD, V144, P135, DOI 10.1002/ar.1091440208; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Merabet S, 2005, TRENDS GENET, V21, P477, DOI 10.1016/j.tig.2005.07.001; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Murtaugh LC, 1999, GENE DEV, V13, P225, DOI 10.1101/gad.13.2.225; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; Norris RA, 2001, J BIOL CHEM, V276, P26829, DOI 10.1074/jbc.M100239200; Oro AE, 1998, CELL, V95, P575, DOI 10.1016/S0092-8674(00)81624-4; Pennisi D, 2000, MOL CELL BIOL, V20, P9331, DOI 10.1128/MCB.20.24.9331-9336.2000; Peterson RL, 2005, J INVEST DERM SYMP P, V10, P238, DOI 10.1111/j.1087-0024.2005.10114.x; PETERSON RL, 2002, PHARMACOGENOMICS, V2, P283; Pinsonneault J, 1997, EMBO J, V16, P2032, DOI 10.1093/emboj/16.8.2032; Pruett ND, 2004, J BIOL CHEM, V279, P51524, DOI 10.1074/jbc.M404331200; Reid AI, 2002, INT J DEV BIOL, V46, P209; Ren B, 2004, METHOD ENZYMOL, V376, P304; Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews3004; Saleh M, 2000, MOL CELL BIOL, V20, P8623, DOI 10.1128/MCB.20.22.8623-8633.2000; Schlake T, 2005, DEVELOPMENT, V132, P2981, DOI 10.1242/dev.01873; Schmidt-Ullrich R, 2005, BIOESSAYS, V27, P247, DOI 10.1002/bies.20184; Stenn KS, 1996, DERMATOL CLIN, V14, P543, DOI 10.1016/S0733-8635(05)70383-1; STENN KS, 1988, CELL TISSUE BIOL, P541; Sundberg JP., 1994, HDB MOUSE MUTATIONS, P57; Suzuki M, 2003, J BIOL CHEM, V278, P30148, DOI 10.1074/jbc.M303932200; Tkatchenko AV, 2001, DEVELOPMENT, V128, P1547; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Williams TM, 2005, DEV BIOL, V277, P457, DOI 10.1016/j.ydbio.2004.10.004; WOOD L, 1990, J BIOL CHEM, V265, P21375	60	53	60	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29245	29255		10.1074/jbc.M603646200	http://dx.doi.org/10.1074/jbc.M603646200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16835220	hybrid			2022-12-25	WOS:000240680500080
J	Soksawatmaekhin, W; Uemura, T; Fukiwake, N; Kashiwagi, K; Igarashi, K				Soksawatmaekhin, Waraporn; Uemura, Takeshi; Fukiwake, Natsuko; Kashiwagi, Keiko; Igarashi, Kazuei			Identification of the cadaverine recognition site on the cadaverine-lysine antiporter CadB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREFERENTIAL UPTAKE SYSTEM; PROTON MOTIVE FORCE; ESCHERICHIA-COLI; POLYAMINE TRANSPORT; CRYSTAL-STRUCTURE; LACTOSE PERMEASE; PUTRESCINE; OPERON; RECEPTOR; PROTEIN	Amino acid residues involved in cadaverine uptake and cadaverine-lysine antiporter activity were identified by site-directed mutagenesis of the CadB protein. It was found that Tyr(73), Tyr(89), Tyr(90), Glu(204), Tyr(235), Asp(303), and Tyr(423) were strongly involved in both uptake and excretion and that Tyr(55), Glu(76), Tyr(246), Tyr(310), Cys(370), and Glu(377) were moderately involved in both activities. Mutations of Trp(43), Tyr(57), Tyr(107), Tyr(366), and Tyr(368) mainly affected uptake activity, and Trp(41), Tyr(174), Asp(185), and Glu(408) had weak effects on uptake. The decrease in the activities of the mutants was reflected by an increase in the K-m value. Mutation of Arg(299) mainly affected excretion, suggesting that Arg(299) is involved in the recognition of the carboxyl group of lysine. These results indicate that amino acid residues involved in both uptake and excretion, or solely in excretion, are located in the cytoplasmic loops and the cytoplasmic side of transmembrane segments, whereas residues involved in uptake were located in the periplasmic loops and the transmembrane segments. The SH group of Cys(370) seemed to be important for uptake and excretion, because both were inhibited by the existence of Cys(125), Cys(389), or Cys(394) together with Cys(370). The relative topology of 12 transmembrane segments was determined by inserting cysteine residues at various sites and measuring the degree of inhibition of transport through crosslinking with Cys(370). The results suggest that a hydrophilic cavity is formed by the transmembrane segments II, III, IV, VI, VII, X, XI, and XII.	Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Chiba 2608675, Japan; Chiba Inst Sci, Fac Pharmaceut Sci, Chiba 2880025, Japan	Chiba University	Igarashi, K (corresponding author), Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, 1-8-1 Inohana, Chiba 2608675, Japan.	iga16077@p.chiba-u.ac.jp		Igarashi, Kazuei/0000-0003-3751-3187				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Cohen S A, 1998, Guttmacher Rep Public Policy, V1, P1; Gong S, 2003, J BACTERIOL, V185, P4402, DOI 10.1128/JB.185.15.4402-4409.2003; Hirai T, 2003, J BACTERIOL, V185, P1712, DOI 10.1128/JB.185.5.1712-1718.2003; HOUNG HS, 1986, J BACTERIOL, V168, P1040, DOI 10.1128/jb.168.2.1040-1044.1986; IGARASHI K, 1986, J BACTERIOL, V166, P128, DOI 10.1128/jb.166.1.128-134.1986; Igarashi K, 2001, RES MICROBIOL, V152, P271, DOI 10.1016/S0923-2508(01)01198-6; Igarashi K, 1999, BIOCHEM J, V344, P633, DOI 10.1042/0264-6021:3440633; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Kashiwagi K, 2000, J BIOL CHEM, V275, P36007, DOI 10.1074/jbc.M006083200; KASHIWAGI K, 1991, J BIOL CHEM, V266, P20922; KASHIWAGI K, 1992, P NATL ACAD SCI USA, V89, P4529, DOI 10.1073/pnas.89.10.4529; Kashiwagi K, 1996, J BIOL CHEM, V271, P12205, DOI 10.1074/jbc.271.21.12205; KASHIWAGI K, 1986, J BACTERIOL, V165, P972, DOI 10.1128/jb.165.3.972-977.1986; KASHIWAGI K, 1988, J BACTERIOL, V170, P3131, DOI 10.1128/jb.170.7.3131-3135.1988; Kashiwagi K, 2002, J BIOL CHEM, V277, P24212, DOI 10.1074/jbc.M202849200; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MENG SY, 1992, J BACTERIOL, V174, P2659, DOI 10.1128/jb.174.8.2659-2669.1992; MOLENAAR D, 1993, J BACTERIOL, V175, P2864, DOI 10.1128/JB.175.10.2864-2870.1993; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; Neely MN, 1996, J BACTERIOL, V178, P5522, DOI 10.1128/jb.178.18.5522-5528.1996; NIELSEN PJ, 1982, J BIOL CHEM, V257, P2316; PEGG AE, 1988, CANCER RES, V48, P759; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; Sahin-Toth M, 2002, BIOCHEMISTRY-US, V41, P13039, DOI 10.1021/bi0203076; SAMBROOK J, MOL CLONING LAB MANU; Soksawatmaekhin W, 2004, MOL MICROBIOL, V51, P1401, DOI 10.1046/j.1365-2958.2003.03913.x; Sugiyama S, 1996, J BIOL CHEM, V271, P9519, DOI 10.1074/jbc.271.16.9519; TAKAYAMA M, 1994, MOL MICROBIOL, V11, P913, DOI 10.1111/j.1365-2958.1994.tb00370.x; Vassylyev DG, 1998, J BIOL CHEM, V273, P17604, DOI 10.1074/jbc.273.28.17604; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327; WATSON N, 1992, J BACTERIOL, V174, P530, DOI 10.1128/jb.174.2.530-540.1992	33	39	42	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29213	29220		10.1074/jbc.M600754200	http://dx.doi.org/10.1074/jbc.M600754200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16877381	hybrid			2022-12-25	WOS:000240680500076
J	Sbodio, JI; Hicks, SW; Simon, D; Machamer, CE				Sbodio, Juan I.; Hicks, Stuart W.; Simon, Dan; Machamer, Carolyn E.			GCP60 preferentially interacts with a caspase-generated golgin-160 fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ASSOCIATED PROTEIN; SECRETORY PATHWAY; MEDIATED CLEAVAGE; APOPTOSIS; COMPLEX; APPARATUS; PAP7; STEROIDOGENESIS; IDENTIFICATION; AUTOANTIGENS	Golgin-160, a ubiquitous protein in vertebrates, localizes to the cytoplasmic face of the Golgi complex. Golgin-160 has a large coiled-coil C-terminal domain and a non-coiled-coil N-terminal ("head") domain. The head domain contains important motifs, including a nuclear localization signal, a Golgi targeting domain, and three aspartates that are recognized by caspases during apoptosis. Some of the caspase cleavage products accumulate in the nucleus when overexpressed. Expression of a non-cleavable form of golgin-160 impairs apoptosis induced by some pro-apoptotic stimuli; thus cleavage of golgin-160 appears to play a role in apoptotic signaling. We used a yeast two-hybrid assay to screen for interactors of the golgin-160 head and identified GCP60 (Golgi complex-associated protein of 60 kDa). Further analysis demonstrated that GCP60 interacts preferentially with one of the golgin-160 caspase cleavage fragments (residues 140 - 311). This strong interaction prevented the golgin-160 fragment from accumulating in the nucleus when this fragment and GCP60 were overexpressed. In addition, cells overexpressing GCP60 were more sensitive to apoptosis induced by staurosporine, suggesting that nuclear-localized golgin-160-(140 - 311) might promote cell survival. Our results suggest a potential mechanism for regulating the nuclear translocation and potential functions of golgin-160 fragments.	Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA	Johns Hopkins University	Machamer, CE (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, 725 Wolfe St, Baltimore, MD 21205 USA.	machamer@jhmi.edu	Hicks, Stuart/R-9815-2019	Simon, Dan/0000-0001-7041-4450	NIGMS NIH HHS [GM42522] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anantharaman V, 2002, GENOME BIOL, V3; Barr FA, 2003, CURR OPIN CELL BIOL, V15, P405, DOI 10.1016/S0955-0674(03)00054-1; Chiu R, 2002, J CELL BIOL, V159, P637, DOI 10.1083/jcb.200208013; Farquhar MG, 1998, TRENDS CELL BIOL, V8, P2, DOI 10.1016/S0962-8924(97)01187-2; Hicks SW, 2005, BBA-MOL CELL RES, V1744, P406, DOI 10.1016/j.bbamcr.2005.03.002; Hicks SW, 2005, J BIOL CHEM, V280, P28944, DOI 10.1074/jbc.M504937200; Hicks SW, 2002, J BIOL CHEM, V277, P35833, DOI 10.1074/jbc.M206280200; Lane JD, 2002, J CELL BIOL, V156, P495, DOI 10.1083/jcb.200110007; Li H, 2001, MOL ENDOCRINOL, V15, P2211, DOI 10.1210/me.15.12.2211; Liu J, 2003, J STEROID BIOCHEM, V85, P275, DOI 10.1016/S0960-0760(03)00213-9; Liu J, 2003, GENE, V308, P1, DOI 10.1016/S0378-1119(03)00453-0; Lowe M, 2004, J CELL SCI, V117, P1139, DOI 10.1242/jcs.00950; Maag RS, 2005, MOL BIOL CELL, V16, P3019, DOI 10.1091/mbc.E04-11-0971; Maag RS, 2003, CURR OPIN CELL BIOL, V15, P456, DOI 10.1016/S0955-0674(03)00075-9; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Marsh BJ, 2002, NAT REV MOL CELL BIO, V3, P789, DOI 10.1038/nrm933; Misumi Y, 1997, J BIOL CHEM, V272, P23851, DOI 10.1074/jbc.272.38.23851; Nozawa K, 2005, AUTOIMMUN REV, V4, P35, DOI 10.1016/j.autrev.2004.06.002; Nozawa K, 2002, ARTHRITIS RES, V4, DOI 10.1186/ar422; Short B, 2005, BBA-MOL CELL RES, V1744, P383, DOI 10.1016/j.bbamcr.2005.02.001; Sohda M, 2001, J BIOL CHEM, V276, P45298, DOI 10.1074/jbc.M108961200	21	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27924	27931		10.1074/jbc.M603276200	http://dx.doi.org/10.1074/jbc.M603276200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16870622	hybrid			2022-12-25	WOS:000240534400028
J	Daryadel, A; Grifone, RF; Simon, HU; Yousefi, S				Daryadel, Arezoo; Grifone, Remo Filippo; Simon, Hans-Uwe; Yousefi, Shida			Apoptotic neutrophils release macrophage migration inhibitory factor upon stimulation with tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH PATHWAY; CELL-DEATH; FACTOR MIF; INFLAMMATION; HYPERSENSITIVITY; PHAGOCYTOSIS; TRANSPORTER; ACTIVATION; SECRETION; CYTOKINE	Macrophage migration inhibitory factor (MIF) is an important cytokine involved in the regulation of innate immunity and present at increased levels during inflammatory responses. Here we demonstrate that mature blood and tissue neutrophils constitutively express MIF as a cytosolic protein not associated with azurophil granules. Functionally active MIF, but not proteases stored in azurophil granules, was released from apoptotic neutrophils following short term tumor necrosis factor (TNF)-alpha stimulation in a caspase-dependent manner and prior to any detectable phagocytosis by monocyte-derived macrophages. Moreover, TNF-alpha-mediated MIF release was blocked by glyburide and propenicide, both inhibitors of ATP-binding cassette-type transporters, suggesting that this transporter system is activated during neutrophil apoptosis. Taken together, apoptotic mature neutrophils release MIF upon short term TNF-alpha stimulation. Therefore, apoptosis may not always occur without the induction of pro-inflammatory mechanisms.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland	University of Bern	Yousefi, S (corresponding author), Univ Bern, Dept Pharmacol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.	shida.yousefi@pki.unibe.ch	Simon, Hans-Uwe/AAU-5079-2020; Simon, Hans-Uwe/AAU-7410-2020; Yousefi, Shida/AAU-7986-2020; Yousefi, Shida/L-9689-2016	Simon, Hans-Uwe/0000-0002-9404-7736; Yousefi, Shida/0000-0002-9855-4305; Yousefi, Shida/0000-0002-9855-4305				Altznauer F, 2004, J BIOL CHEM, V279, P5947, DOI 10.1074/jbc.M308576200; Altznauer F, 2004, J EXP MED, V199, P1343, DOI 10.1084/jem.20032033; Baumann R, 2003, FASEB J, V17, P2221, DOI 10.1096/fj.03-0110com; Baumann R, 2004, EUR J IMMUNOL, V34, P2268, DOI 10.1002/eji.200424863; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; Bruno A, 2005, J IMMUNOL, V174, P8090, DOI 10.4049/jimmunol.174.12.8090; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; Chen WJ, 2001, IMMUNITY, V14, P715, DOI 10.1016/S1074-7613(01)00147-9; Cowburn AS, 2005, BLOOD, V105, P2970, DOI 10.1182/blood-2004-07-2870; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Flieger O, 2003, FEBS LETT, V551, P78, DOI 10.1016/S0014-5793(03)00900-1; Gando S, 2001, INTENS CARE MED, V27, P1187, DOI 10.1007/s001340000818; Gao YK, 1998, J EXP MED, V188, P887, DOI 10.1084/jem.188.5.887; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; Koebernick H, 2002, P NATL ACAD SCI USA, V99, P13681, DOI 10.1073/pnas.212488699; Lehmann LE, 2001, INTENS CARE MED, V27, P1412, DOI 10.1007/s001340101022; Liu CY, 2003, BLOOD, V101, P295, DOI 10.1182/blood-2001-12-0266; Maianski NA, 2003, BLOOD, V101, P1987, DOI 10.1182/blood-2002-02-0522; Martinelli S, 2004, J BIOL CHEM, V279, P44123, DOI 10.1074/jbc.M405883200; Miwa K, 1998, NAT MED, V4, P1287, DOI 10.1038/3276; Riedemann NC, 2004, J IMMUNOL, V173, P1355, DOI 10.4049/jimmunol.173.2.1355; Rossi AG, 1998, J CLIN INVEST, V101, P2869, DOI 10.1172/JCI1524; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SIMON HU, 1994, J IMMUNOL, V153, P364; Simon HU, 2003, IMMUNOL REV, V193, P101, DOI 10.1034/j.1600-065X.2003.00038.x; van den Berg JM, 2001, J LEUKOCYTE BIOL, V69, P467; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; von Gunten S, 2005, BLOOD, V106, P1423, DOI 10.1182/blood-2004-10-4112; WEISER WY, 1989, P NATL ACAD SCI USA, V86, P7522, DOI 10.1073/pnas.86.19.7522	34	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27653	27661		10.1074/jbc.M604051200	http://dx.doi.org/10.1074/jbc.M604051200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16861224	hybrid			2022-12-25	WOS:000240397700090
J	Sammons, M; Wan, SS; Vogel, NL; Mientjes, EJ; Grosveld, G; Ashburner, BP				Sammons, Morgan; Wan, Shan Shan; Vogel, Nancy L.; Mientjes, Edwin J.; Grosveld, Gerard; Ashburner, Brian P.			Negative regulation of the RelA/p65 transactivation function by the product of the DEK proto-oncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTIONAL COACTIVATORS; DEACETYLASE INHIBITORS; MEDIATED TRANSCRIPTION; PROTEIN; ACTIVATION; ALPHA; P300; INDUCTION; CHROMATIN	NF-kappa B-mediated transcriptional activation is controlled at several levels including interaction with coregulatory proteins. To identify new proteins capable of modulating NF-kappa B-mediated activation, a cytoplasmic two-hybrid screen was performed using the p65 C-terminal transactivation domain as bait and identified the product of the DEK proto-oncogene. DEK is a ubiquitous nuclear protein that has been implicated in several types of cancer and autoimmune diseases. DEK appears to function in several nuclear processes including transcriptional repression and modulation of chromatin structure. Our data indicate that DEK functions as a transcriptional corepressor to repress NF-kappa B activity. DEK expression blocked p65-mediated activation of an NF-kappa B-dependent reporter gene and also inhibited TNF alpha-induced activation of the reporter gene. Chromatin Immunoprecipitation (ChIP) assays showed that DEK associates with the promoters of the NF-kappa B-regulated cIAP2 and IL-8 genes in untreated cells and dissociates from these promoters upon NF-kappa B-binding in response to TNF alpha treatment. Moreover, the expression levels of an NF-kappa B-dependent reporter gene as well as the NF-kappa B-regulated Mcp-1 and I kappa B alpha genes is increased in DEK-/- cells compared with wild-type cells. ChIP assays on these promoters show enhanced and prolonged binding of p65 and increased recruitment of the P/CAF coactivator. Overall, these data provide further evidence that DEK functions to negatively regulate transcription.	Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA; Univ Toledo, Undergrad Honors Program, Toledo, OH 43606 USA; St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA	University System of Ohio; University of Toledo; University System of Ohio; University of Toledo; St Jude Children's Research Hospital	Ashburner, BP (corresponding author), Univ Toledo, Dept Biol Sci, MS 601,2801 W Bancroft St, Toledo, OH 43606 USA.	brian.ashburner@utoledo.edu	Wan, Shanshan/C-3800-2013		NIGMS NIH HHS [1 R15 GM071405-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM071405] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam E, 2003, MOL CELL BIOL, V23, P6200, DOI 10.1128/MCB.23.17.6200-6209.2003; Agarwal ML, 1997, ONCOGENE, V15, P1035, DOI 10.1038/sj.onc.1201274; Alexiadis V, 2000, GENE DEV, V14, P1308; Asamitsu K, 2003, J BIOL CHEM, V278, P26879, DOI 10.1074/jbc.M211831200; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bubulya A, 2001, J BIOL CHEM, V276, P44704, DOI 10.1074/jbc.M107346200; Campillos M, 2003, NUCLEIC ACIDS RES, V31, P1571, DOI 10.1093/nar/gkg247; Casas S, 2003, LEUKEMIA LYMPHOMA, V44, P1935, DOI 10.1080/1042819031000119299; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Cleary J, 2005, J BIOL CHEM, V280, P31760, DOI 10.1074/jbc.M500884200; Dong XW, 2000, ARTHRITIS RHEUM-US, V43, P85, DOI 10.1002/1529-0131(200001)43:1<85::AID-ANR11>3.0.CO;2-D; Faulkner NE, 2001, J BIOL CHEM, V276, P25804, DOI 10.1074/jbc.M006454200; FORNEROD M, 1995, ONCOGENE, V10, P1739; Fu GK, 1997, P NATL ACAD SCI USA, V94, P1811, DOI 10.1073/pnas.94.5.1811; Gao ZG, 2005, J BIOL CHEM, V280, P21091, DOI 10.1074/jbc.M500754200; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GUALBERTO A, 1995, MOL CELL BIOL, V15, P3450; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006; Hollenbach AD, 2002, J CELL SCI, V115, P3319; Kasper LH, 2006, MOL CELL BIOL, V26, P789, DOI 10.1128/MCB.26.3.789-809.2006; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko SI, 2006, FEBS LETT, V580, P3217, DOI 10.1016/j.febslet.2006.04.081; Lee C, 1999, J BIOL CHEM, V274, P26767, DOI 10.1074/jbc.274.38.26767; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Mayo MW, 2003, J BIOL CHEM, V278, P18980, DOI 10.1074/jbc.M211695200; McGarvey T, 2000, J CELL BIOL, V150, P309, DOI 10.1083/jcb.150.2.309; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Savkur RS, 2004, J PEPT RES, V63, P207, DOI 10.1111/j.1399-3011.2004.00126.x; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Sitwala KV, 2003, ANTICANCER RES, V23, P2155; Tetsuka T, 2000, J BIOL CHEM, V275, P4383, DOI 10.1074/jbc.275.6.4383; Uranishi H, 2001, J BIOL CHEM, V276, P13395, DOI 10.1074/jbc.M011176200; Waldmann T, 2004, GENE, V343, P1, DOI 10.1016/j.gene.2004.08.029; Waldmann T, 2003, NUCLEIC ACIDS RES, V31, P7003, DOI 10.1093/nar/gkg864; Werbajh S, 2000, FEBS LETT, V485, P195, DOI 10.1016/S0014-5793(00)02223-7; Yamagoe S, 2003, MOL CELL BIOL, V23, P1025, DOI 10.1128/MCB.23.3.1025-1033.2003; Yang JP, 1999, J BIOL CHEM, V274, P15662, DOI 10.1074/jbc.274.22.15662; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	54	47	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26802	26812		10.1074/jbc.M600915200	http://dx.doi.org/10.1074/jbc.M600915200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16829531	hybrid			2022-12-25	WOS:000240397700007
J	Vertii, A; Hakim, C; Kotlyarov, A; Gaestel, M				Vertii, Anastassiia; Hakim, Cosima; Kotlyarov, Alexey; Gaestel, Matthias			Analysis of properties of small heat shock protein Hsp25 in MAPK-activated protein kinase 2 (MK2)-deficient cells - MK2-dependent insolubilization of Hsp25 oligomers correlates with susceptibility to stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF-ALPHA; ACTIN POLYMERIZATION; OXIDATIVE STRESS; CELLULAR THERMORESISTANCE; PROTECTIVE ACTIVITY; KINASE INHIBITORS; CRYSTAL-STRUCTURE; MOTOR NEUROPATHY; PHOSPHORYLATION; SUBSTRATE	Small heat shock proteins (sHsps) exist in dynamic oligomeric complexes and display diverse biological functions ranging from chaperone properties to modulator of apoptosis. So far, the role of stress-dependent phosphorylation of mammalian sHsps for its structure and function has been analyzed by using various phosphorylation site mutants overexpressed in different cell types as well as by non-exclusive inhibitors of the p38 MAPK cascade. Here we investigate the role of phosphorylation of endogenous sHsp in a genetic model lacking the major Hsp25 kinase, the MAP kinase-activated protein kinase MK2. We demonstrate that in MK2- deficient fibroblasts, where no stress-dependent phosphorylation of Hsp25 at Ser(86) and no in vitro binding to 14-3-3 was detectable, stress-dependent disaggregation of endogenous Hsp25 complexes is impared and kinetics of arsenite-dependent, H2O2-dependent, and sublethal heat shock-induced insolubilization of Hsp25 is delayed. Similarly, green fluorescent protein- tagged Hsp25 shows retarded subcellular accumulation into stress granules in MK2-deficient cells after arsenite treatment. Decreased insolubilization of Hsp25 in MK2-deficient cells correlates with increased resistance against arsenite, H2O2, and sublethal heat shock treatment and with decreased apoptosis. In contrast, after severe, lethal heat shock MK2-deficient embryonic fibroblasts cells show fast and complete insolubilization of Hsp25 independent of MK2 and no increased stress resistance. Hence, MK2-dependent formation of insoluble stress granules and irreversible cell damage by oxidative stresses and sublethal heat shock correlate and only upon severe, lethal heat shock MK2-independent processes could determine insolubilization of Hsp25 and are more relevant for cellular stress damage.	Hannover Med Sch, Inst Biochem, D-30625 Hannover, Germany	Hannover Medical School	Gaestel, M (corresponding author), Hannover Med Sch, Inst Biochem, Carl Neuberg Str 1, D-30625 Hannover, Germany.	gaestel.matthias@mh-hannover.de	Gaestel, Matthias/A-6560-2013	Gaestel, Matthias/0000-0002-4944-4652; Vertii, Anastassiia/0000-0002-0939-0389				Abraham RT, 2005, MOL CELL, V17, P163, DOI 10.1016/j.molcel.2005.01.005; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Butt E, 2001, J BIOL CHEM, V276, P7108, DOI 10.1074/jbc.M009234200; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; CRETE P, 1990, RADIAT RES, V121, P320, DOI 10.2307/3577783; Cuesta R, 2000, GENE DEV, V14, P1460; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Doppler H, 2005, J BIOL CHEM, V280, P15013, DOI 10.1074/jbc.C400575200; Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171; Dreiza CM, 2004, FASEB J, V18, P261, DOI 10.1096/fj.04-2911fje; Evgrafov OV, 2004, NAT GENET, V36, P602, DOI 10.1038/ng1354; Eyers CE, 2005, BIOCHEM J, V389, P127, DOI 10.1042/BJ20050387; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Gaestel M, 2006, NAT REV MOL CELL BIO, V7, P120, DOI 10.1038/nrm1834; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; Gaestel M, 2002, Prog Mol Subcell Biol, V28, P151; Garrido C, 2002, CELL DEATH DIFFER, V9, P483, DOI 10.1038/sj.cdd.4401005; Geum D, 2002, J BIOL CHEM, V277, P19913, DOI 10.1074/jbc.M104396200; Godl K, 2003, P NATL ACAD SCI USA, V100, P15434, DOI 10.1073/pnas.2535024100; Guay J, 1997, J CELL SCI, V110, P357; Haslbeck M, 2005, NAT STRUCT MOL BIOL, V12, P842, DOI 10.1038/nsmb993; Huot J, 1996, CANCER RES, V56, P273; Irobi J, 2004, NAT GENET, V36, P597, DOI 10.1038/ng1328; Kappe G, 2003, CELL STRESS CHAPERON, V8, P53, DOI 10.1379/1466-1268(2003)8<53:THGECS>2.0.CO;2; KATO K, 1994, J BIOL CHEM, V269, P11274; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kotlyarov A, 2002, MOL CELL BIOL, V22, P4827, DOI 10.1128/MCB.22.13.4827-4835.2002; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1992, J BIOL CHEM, V267, P794; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Loktionova SA, 1996, FEBS LETT, V392, P100, DOI 10.1016/0014-5793(96)00792-2; Lukas SM, 2004, BIOCHEMISTRY-US, V43, P9950, DOI 10.1021/bi049508v; Maizels ET, 1998, BIOCHEM J, V332, P703, DOI 10.1042/bj3320703; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Porras A, 2004, MOL BIOL CELL, V15, P922, DOI 10.1091/mbc.E03-08-0592; Preville X, 1998, CELL STRESS CHAPERON, V3, P177, DOI 10.1379/1466-1268(1998)003<0177:PINEFP>2.3.CO;2; Preville X, 1998, J CELL BIOCHEM, V69, P436, DOI 10.1002/(SICI)1097-4644(19980615)69:4<436::AID-JCB5>3.0.CO;2-O; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; Shi Y, 2003, MOL CELL BIOL, V23, P7732, DOI 10.1128/MCB.23.21.7732-7741.2003; Singh S, 2003, J BIOL CHEM, V278, P36410, DOI 10.1074/jbc.M306428200; Stoecklin G, 2004, EMBO J, V23, P1313, DOI 10.1038/sj.emboj.7600163; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	60	32	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26966	26975		10.1074/jbc.M602134200	http://dx.doi.org/10.1074/jbc.M602134200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16840785	hybrid			2022-12-25	WOS:000240397700023
J	Frangie, C; Zhang, WH; Perez, J; Dubois, YCX; Haymann, JP; Baud, L				Frangie, Carlos; Zhang, Wenhui; Perez, Joelle; Dubois, Yi-Chun Xu; Haymann, Jean-Philippe; Baud, Laurent			Extracellular calpains increase tubular epithelial cell mobility - Implications for kidney repair after ischemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; INTEGRIN; MIGRATION; ADHESION; INJURY; DEATH; PATHOPHYSIOLOGY; DEGRADATION; PROTEOLYSIS; INHIBITION	Calpains are intracellular Ca2+-dependent cysteine proteases that are released in the extracellular milieu by tubular epithelial cells following renal ischemia. Here we show that externalized calpains increase epithelial cell mobility and thus are critical for tubule repair. In vitro, exposure of human tubular epithelial cells (HK-2 cells) to mu-calpain limited their adhesion to extracellular matrix and increased their mobility. Calpains acted primarily by promoting the cleavage of fibronectin, thus preventing fibronectin binding to the integrin alpha(v)beta(3). Analyzing downstream integrin effects, we found that the cyclic AMP-dependent protein kinase A pathway was activated in response to alpha(v)beta(3) disengagement and was essential for calpain-mediated increase in HK-2 cell mobility. In a murine model of ischemic acute renal failure, injection of a fragment of calpastatin, which specifically blocked calpain activity in extracellular milieu, markedly delayed tubule repair, increasing functional and histological lesions after 24 and 48 h of reperfusion. These findings suggest that externalized calpains are critical for tubule repair process in acute renal failure.	INSERM, U702, F-75020 Paris, France; Univ Paris 06, F-75020 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Baud, L (corresponding author), Hop Tenon, INSERM, U702, 4 Rue Chine, F-75020 Paris, France.	laurent.baud@tnn.ap-hop-paris.fr						Abe M, 1998, J CELL PHYSIOL, V174, P186, DOI 10.1002/(SICI)1097-4652(199802)174:2<186::AID-JCP6>3.0.CO;2-K; Adair BD, 2005, J CELL BIOL, V168, P1109, DOI 10.1083/jcb.200410068; Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; Bellocq A, 1999, J BIOL CHEM, V274, P36891, DOI 10.1074/jbc.274.52.36891; Bonventre JV, 2003, J AM SOC NEPHROL, V14, P2199, DOI 10.1097/01.ASN.0000079785.13922.F6; Bush KT, 2000, J CLIN INVEST, V106, P621, DOI 10.1172/JCI10968; Chatterjee PK, 2005, BIOCHEM PHARMACOL, V69, P1121, DOI 10.1016/j.bcp.2005.01.003; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; DESHPANDE RV, 1995, J BIOL CHEM, V270, P2497, DOI 10.1074/jbc.270.6.2497; Dourdin N, 1997, EXP CELL RES, V235, P385, DOI 10.1006/excr.1997.3684; Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175; Fushimi K, 2004, OSTEOARTHR CARTILAGE, V12, P895, DOI 10.1016/j.joca.2004.08.001; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Glynne PA, 2001, J AM SOC NEPHROL, V12, P2370, DOI 10.1681/ASN.V12112370; GOLIGORSKY MS, 1993, AM J PHYSIOL, V264, pF1, DOI 10.1152/ajprenal.1993.264.1.F1; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Harriman JF, 2002, CELL DEATH DIFFER, V9, P734, DOI 10.1038/sj.cdd.4401029; Howe AK, 2004, BBA-MOL CELL RES, V1692, P159, DOI 10.1016/j.bbamcr.2004.03.005; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; KARTHA S, 1992, J CLIN INVEST, V90, P288, DOI 10.1172/JCI115851; Kifor O, 2003, J BIOL CHEM, V278, P31167, DOI 10.1074/jbc.M303377200; Kim S, 2002, J CLIN INVEST, V110, P933, DOI 10.1172/JCI200214268; Lee HT, 2002, AM J PHYSIOL-RENAL, V282, pF844, DOI 10.1152/ajprenal.00195.2001; Leonard MO, 2003, J BIOL CHEM, V278, P40296, DOI 10.1074/jbc.M302560200; Letavernier E, 2005, J AM SOC NEPHROL, V16, P2395, DOI 10.1681/ASN.2004090802; Li XH, 2002, P NATL ACAD SCI USA, V99, P9260, DOI 10.1073/pnas.132051799; Liu XL, 2003, J PHARMACOL EXP THER, V304, P63, DOI 10.1124/jpet.102.043406; Liu XL, 2001, AM J PHYSIOL-RENAL, V281, pF728, DOI 10.1152/ajprenal.2001.281.4.F728; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; McDonald JF, 2004, J BIOL CHEM, V279, P17301, DOI 10.1074/jbc.M312782200; Mehendale HM, 2005, TRENDS PHARMACOL SCI, V26, P232, DOI 10.1016/j.tips.2005.03.008; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; Nishihara H, 2001, BIOCHEM BIOPH RES CO, V285, P845, DOI 10.1006/bbrc.2001.5242; Nony PA, 2003, J PHARMACOL EXP THER, V304, P905, DOI 10.1124/jpet.102.035022; Padanilam BJ, 2003, AM J PHYSIOL-RENAL, V284, pF608, DOI 10.1152/ajprenal.00284.2002; Paller MS, 1997, KIDNEY INT, pS52; Schrier RW, 2004, J CLIN INVEST, V114, P5, DOI 10.1172/JC1200422353; Seiffert D, 1996, J BIOL CHEM, V271, P11170, DOI 10.1074/jbc.271.19.11170; Sheridan AM, 2000, CURR OPIN NEPHROL HY, V9, P427, DOI 10.1097/00041552-200007000-00015; Shi YX, 2000, AM J PHYSIOL-RENAL, V279, pF509, DOI 10.1152/ajprenal.2000.279.3.F509; Zuk A, 1998, AM J PHYSIOL-CELL PH, V275, pC711, DOI 10.1152/ajpcell.1998.275.3.C711	41	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26624	26632		10.1074/jbc.M603007200	http://dx.doi.org/10.1074/jbc.M603007200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16822870	hybrid			2022-12-25	WOS:000240249500080
J	O'Brien, JE; Peterson, TJ; Tong, MH; Lee, EJ; Pfaff, LE; Hewitt, SC; Korach, KS; Weiss, J; Jameson, JL				O'Brien, Jeanne E.; Peterson, Theresa J.; Tong, Ming Han; Lee, Eun-Jig; Pfaff, Liza E.; Hewitt, Sylvia C.; Korach, Kenneth S.; Weiss, Jeffrey; Jameson, J. Larry			Estrogen-induced proliferation of uterine epithelial cells is independent of estrogen receptor alpha binding to classical estrogen response elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CYCLIN D1; BETA ER-BETA; PROGESTERONE-RECEPTOR; IN-VIVO; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; MOUSE; DISRUPTION; KNOCKOUT; UTERUS	Acting via the estrogen receptor (ER), estradiol exerts pleomorphic effects on the uterus, producing cyclical waves of cellular proliferation and differentiation in preparation for embryo implantation. In the classical pathway, the ER binds directly to an estrogen response element to activate or repress gene expression. However, emerging evidence supports the existence of nonclassical pathways in which the activated ER alters gene expression through protein-protein tethering with transcription factors such as c-Fos/ c-Jun B (AP-1) and Sp1. In this report, we examined the relative roles of classical and nonclassical ER signaling in vivo by comparing the estrogen-dependent uterine response in mice that express wild-type ER alpha, a mutant ER alpha (E207A/G208A) that selectively lacks ERE binding, or ER alpha null. In the compound heterozygote (AA/-) female, the nonclassical allele (AA) was insufficient to mediate an acute uterotrophic response to 17 beta-estradiol (E-2). The uterine epithelial proliferative response to E-2 and 4-hydroxytamoxifen was retained in the AA/-females, and uterine luminal epithelial height increased commensurate with the extent of ER alpha signaling. This proliferative response was confirmed by 5-bromo-2 '-deoxyuridine incorporation. Microarray experiments identified cyclin-dependent kinase inhibitor 1A as a nonclassical pathway-responsive gene, and transient expression experiments using the cyclin-dependent kinase inhibitor 1A promoter confirmed transcriptional responses to the ER alpha (E207A/ G208A) mutant. These results indicate that nonclassical ER alpha signaling is sufficient to restore luminal epithelial proliferation but not other estrogen-responsive events, such as fluid accumulation and hyperemia. We conclude that nonclassical pathway signaling via ER alpha plays a critical physiologic role in the uterine response to estrogen.	Northwestern Univ, Feinberg Sch Med, Ctr Genet Med, Div Reprod Endocrinol & Infertil, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Ctr Genet Med, Div Endocrinol Metab & Mol Med, Chicago, IL 60611 USA; Yonsei Univ, Coll Med, Div Endocrinol, Seoul 120749, South Korea; NIEHS, NIH, Receptor Biol Sect, Lab Reprod & Dev Toxicol, Res Triangle Pk, NC 27709 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Yonsei University; Yonsei University Health System; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Jameson, JL (corresponding author), Northwestern Univ, Feinberg Sch Med, Ctr Genet Med, Div Reprod Endocrinol & Infertil, Lurie 7-220,303 E Superior St, Chicago, IL 60611 USA.	ljameson@northwestern.edu	Hewitt, Sylvia/W-8752-2019	Hewitt, Sylvia/0000-0001-7713-0805; Lee, Eun Jig/0000-0002-9876-8370; Jameson, James/0000-0001-9538-4059; Korach, Kenneth/0000-0002-7765-418X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD021921] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES070065] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NICHD NIH HHS [P01 HD21921, T32 HD07068] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Carthew P, 1999, TOXICOL APPL PHARM, V158, P24, DOI 10.1006/taap.1999.8679; Cato A.C., 2002, SCI STKE, V2002, pre9, DOI [10.1126/stke.2002.138.re9, DOI 10.1126/STKE.2002.138.RE9]; Chen B, 2003, MOL ENDOCRINOL, V17, P1368, DOI 10.1210/me.2003-0036; Coleman KM, 2001, FRONT BIOSCI, V6, pD1379, DOI 10.2741/Coleman; Cooke PS, 1997, P NATL ACAD SCI USA, V94, P6535, DOI 10.1073/pnas.94.12.6535; Couse JF, 1997, ENDOCRINOLOGY, V138, P4613, DOI 10.1210/en.138.11.4613; COUSE JF, 1995, MOL ENDOCRINOL, V9, P1441, DOI 10.1210/me.9.11.1441; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Cunha GR, 2004, ARCH HISTOL CYTOL, V67, P417, DOI 10.1679/aohc.67.417; De Siervi A, 2004, CANCER RES, V64, P743, DOI 10.1158/0008-5472.CAN-03-2505; Dupont S, 2000, DEVELOPMENT, V127, P4277; Enmark E, 1999, J INTERN MED, V246, P133, DOI 10.1046/j.1365-2796.1999.00545.x; Geum DH, 1997, MOL REPROD DEV, V46, P450, DOI 10.1002/(SICI)1098-2795(199704)46:4&lt;450::AID-MRD2&gt;3.0.CO;2-N; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Hewitt SC, 2005, ANNU REV PHYSIOL, V67, P285, DOI 10.1146/annurev.physiol.67.040403.115914; Hewitt SC, 2005, MOL ENDOCRINOL, V19, P657, DOI 10.1210/me.2004-0142; Hewitt SC, 2003, MOL ENDOCRINOL, V17, P2070, DOI 10.1210/me.2003-0146; Igarashi TM, 2005, FERTIL STERIL, V84, P67, DOI 10.1016/j.fertnstert.2005.01.113; Jakacka M, 2001, J BIOL CHEM, V276, P13615, DOI 10.1074/jbc.M008384200; Jakacka M, 2002, MOL ENDOCRINOL, V16, P2188, DOI 10.1210/me.2001-0174; Jensen EV, 2003, CLIN CANCER RES, V9, P1980; Jordan VC, 2002, CANCER CELL, V1, P215, DOI 10.1016/S1535-6108(02)00050-8; Katzenellenbogen B S, 1979, Recent Prog Horm Res, V35, P259; Kazi AA, 2005, MOL ENDOCRINOL, V19, P2006, DOI 10.1210/me.2004-0388; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kurita T, 2000, BIOL REPROD, V62, P821, DOI 10.1095/biolreprod62.4.831; Kurita T, 2001, BIOL REPROD, V64, P272, DOI 10.1095/biolreprod64.1.272; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Lai MD, 2002, ENDOCRINE, V17, P233, DOI 10.1385/ENDO:17:3:233; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MARTIN L, 1973, J ENDOCRINOL, V56, P133, DOI 10.1677/joe.0.0560133; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Mulac-Jericevic B, 2000, SCIENCE, V289, P1751, DOI 10.1126/science.289.5485.1751; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; POLLARD JW, 1987, CELL TISSUE RES, V249, P533; RAY A, 1994, J BIOL CHEM, V269, P12940; RIDER V, 1994, J ENDOCRINOL, V140, P239, DOI 10.1677/joe.0.1400239; Rockwell LC, 2002, BIOL REPROD, V67, P1804, DOI 10.1095/biolreprod.102.006700; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; SAVOURET JF, 1991, EMBO J, V10, P1875, DOI 10.1002/j.1460-2075.1991.tb07713.x; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Tibbetts TA, 1998, BIOL REPROD, V59, P1143, DOI 10.1095/biolreprod59.5.1143; Tong W, 1999, MOL CELL BIOL, V19, P2251; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; Verkman AS, 2000, AM J PHYSIOL-RENAL, V278, pF13, DOI 10.1152/ajprenal.2000.278.1.F13; WHITE R, 1987, MOL ENDOCRINOL, V1, P735, DOI 10.1210/mend-1-10-735; Zhang HF, 2005, J ENDOCRINOL, V184, P129, DOI 10.1677/joe.1.05987	54	94	102	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26683	26692		10.1074/jbc.M601522200	http://dx.doi.org/10.1074/jbc.M601522200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16847062	hybrid			2022-12-25	WOS:000240249500086
J	Simon, GM; Cravatt, BF				Simon, Gabriel M.; Cravatt, Benjamin F.			Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL ARACHIDONYL FLUOROPHOSPHONATE; ACID AMIDE HYDROLASE; CANNABINOID RECEPTOR; PHOSPHOLIPASE-D; MOLECULAR CHARACTERIZATION; ACYLETHANOLAMINE PHOSPHOLIPIDS; ANANDAMIDE HYDROLYSIS; BRAIN; A(2); PHOSPHODIESTERASE	N-Acyl ethanolamines (NAEs) are a large class of signaling lipids implicated in diverse physiological processes, including nociception, cognition, anxiety, appetite, and inflammation. It has been proposed that NAEs are biosynthesized from their corresponding N-acyl phosphatidylethanolamines (NAPEs) in a single enzymatic step catalyzed by a phospholipase D (NAPE-PLD). The recent generation of NAPE-PLD(-/-) mice has revealed that these animals possess lower brain levels of saturated NAEs but essentially unchanged concentrations of polyunsaturated NAEs, including the endogenous cannabinoid anandamide. These findings suggest the existence of additional enzymatic routes for the production of NAEs in vivo. Here, we report evidence for an alternative pathway for NAE biosynthesis that proceeds through the serine hydrolase-catalyzed double-deacylation of NAPE to generate glycerophospho-NAE, followed by the phosphodiesterase-mediated cleavage of this intermediate to liberate NAE. Furthermore, we describe the functional proteomic isolation and identification of a heretofore uncharacterized enzyme alpha/beta-hydrolase 4 (Abh4) as a lysophospholipase/phospholipase B that selectively hydrolyzes NAPEs and lysoNAPEs. Abh4 accepts lysoNAPEs bearing both saturated and polyunsaturated N-acyl chains as substrates and displays a distribution that closely mirrors lysoNAPE-lipase activity in mouse tissues. These results support the existence of an NAPE-PLD-independent route for NAE biosynthesis and suggest that Abh4 plays a role in this metabolic pathway by acting as a (lyso) NAPE-selective lipase.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Cravatt, BF (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	cravatt@scripps.edu			NIDA NIH HHS [R01 DA015197-04, P01 DA017259-03, P01 DA017259, DA017259, R01 DA015197, DA015197] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015197, P01DA017259] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; Cravatt BF, 2004, P NATL ACAD SCI USA, V101, P10821, DOI 10.1073/pnas.0401292101; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; Deutsch DG, 1997, BIOCHEM PHARMACOL, V53, P255, DOI 10.1016/S0006-2952(96)00830-1; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Fernandez Jose R, 2004, Curr Opin Investig Drugs, V5, P430; Gaetani S, 2003, TRENDS MOL MED, V9, P474, DOI 10.1016/j.molmed.2003.09.005; Jessani N, 2005, NAT METHODS, V2, P691, DOI 10.1038/NMETH778; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; Kraemer FB, 2002, J LIPID RES, V43, P1585, DOI 10.1194/jlr.R200009-JLR200; Lambert DM, 2002, CURR MED CHEM, V9, P663, DOI 10.2174/0929867023370707; Leiros I, 2000, STRUCTURE, V8, P655, DOI 10.1016/S0969-2126(00)00150-7; Leung D, 2006, BIOCHEMISTRY-US, V45, P4720, DOI 10.1021/bi060163l; Lichtman AH, 2004, PAIN, V109, P319, DOI 10.1016/j.pain.2004.01.022; Lichtman AH, 2002, PROSTAG LEUKOTR ESS, V66, P269, DOI 10.1054/plef.2001.0351; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; Liu YS, 1999, P NATL ACAD SCI USA, V96, P14694, DOI 10.1073/pnas.96.26.14694; Marsicano G, 2002, NATURE, V418, P530, DOI 10.1038/nature00839; Massa F, 2004, J CLIN INVEST, V113, P1202, DOI 10.1172/JCI200419465; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; NATARAJAN V, 1984, J NEUROCHEM, V42, P1613, DOI 10.1111/j.1471-4159.1984.tb12750.x; NATARAJAN V, 1982, BIOCHIM BIOPHYS ACTA, V712, P342, DOI 10.1016/0005-2760(82)90352-6; Okamoto Y, 2004, J BIOL CHEM, V279, P5298, DOI 10.1074/jbc.M306642200; Patricelli MP, 2001, PROTEOMICS, V1, P1067, DOI 10.1002/1615-9861(200109)1:9<1067::AID-PROT1067>3.0.CO;2-4; Renault L, 2005, CHEM-BIOL INTERACT, V157, P339, DOI 10.1016/j.cbi.2005.10.100; SCHMID PC, 1983, J BIOL CHEM, V258, P9302; SIEGEL GJ, 1994, BASIC NEUROCHEMISTRY, P182; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sun YX, 2004, BIOCHEM J, V380, P749, DOI 10.1042/BJ20040031; Ueda N, 2001, BBA-MOL CELL BIOL L, V1532, P121, DOI 10.1016/S1388-1981(01)00120-2; WAITE M, 1985, J LIPID RES, V26, P1379; Walker JM, 1999, P NATL ACAD SCI USA, V96, P12198, DOI 10.1073/pnas.96.21.12198; WALSH CT, 1979, ENZYMATIC REACTION M, P92	38	273	283	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26465	26472		10.1074/jbc.M604660200	http://dx.doi.org/10.1074/jbc.M604660200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16818490	hybrid			2022-12-25	WOS:000240249500064
J	Yi, XP; Hargett, SR; Frankel, LK; Bricker, TM				Yi, Xiaoping; Hargett, Stefan R.; Frankel, Laurie K.; Bricker, Terry M.			The PsbQ protein is required in Arabidopsis for photosystem II assembly/stability and photoautotrophy under low light conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC OXYGEN EVOLUTION; STABILIZING PROTEIN; EVOLVING COMPLEX; CHLOROPLAST; TRANSFORMATION; TRANSITIONS; COMPONENTS; RNA	RNA interference was used to simultaneously suppress the expression of the two genes that encode the PsbQ proteins of Photosystem II (PS II) in Arabidopsis thaliana, psbQ-1 (At4g21280) and psbQ-2 (At4g05180). Two independent PsbQ-deficient plant lines were examined. These plant lines produced little detectable PsbQ protein. Under normal growth light conditions, the wild type and mutant plants were visually indistinguishable. Additionally, analysis of steady state oxygen evolution rates and chlorophyll fluorescence characteristics indicated little alteration of photosynthetic capacity in the mutant plants. No loss of other PS II proteins was evident. Interestingly, flash oxygen yield analysis performed on thylakoid membranes isolated from the mutant and wild type plants indicated that the oxygen-evolving complex was quite unstable in the mutants. Furthermore, the lifetime of the S-2 state of the oxygen-evolving complex appeared to be increased in these plants. Incubation of the wild type and mutant plants under low light growth conditions led to a significantly stronger observed phenotype in the mutants. The mutant plants progressively yellowed (after 2 weeks) and eventually died (after 3-4 weeks). The wild type plants exhibited only slight yellowing after 4 weeks under low light conditions. The mutant plants exhibited a large loss of a number of PS II components, including CP47 and the D2 protein, under low light conditions. Additionally, significant alterations of their fluorescence characteristics were observed, including an increased F-O and decreased F-V, yielding a large loss in PS II quantum efficiency (F-V/F-M). Analysis of Q(A)(-) decay kinetics in the absence of 3-(3,4-dichlorophenyl)-1,1-dimethyl urea indicated a defect in electron transfer from Q(A)(-) to Q(B), whereas experiments performed in the presence of this herbicide indicated that the recombination rate between Q(A)(-) and the S2 state was strongly retarded. These results indicate that the loss of the PsbQ protein induces significant changes in Photosystem II function, particularly in low light-grown plants, and that the PsbQ protein is required for photoautotrophic growth under low light conditions.	Louisiana State Univ, Dept Biol Sci, Biochem & Mol Biol Sect, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Bricker, TM (corresponding author), Louisiana State Univ, Dept Biol Sci, Biochem & Mol Biol Sect, Baton Rouge, LA 70803 USA.	btbric@lsu.edu						ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Bricker TM, 2005, ADV PHOTO RESPIRAT, V22, P95; BRICKER TM, 1992, BIOCHEMISTRY-US, V31, P4623, DOI 10.1021/bi00134a012; BRICKER TM, 1996, OXYGENIC PHOTOSYNTHE, P113; BURNAP RL, 1991, BIOCHEMISTRY-US, V30, P440, DOI 10.1021/bi00216a020; CHU HA, 1994, BIOCHEMISTRY-US, V33, P6137, DOI 10.1021/bi00186a013; Chuang CF, 2000, P NATL ACAD SCI USA, V97, P4985, DOI 10.1073/pnas.060034297; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DEMMIG B, 1983, PLANT PHYSIOL, V73, P169, DOI 10.1104/pp.73.1.169; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; FRANKEL LK, 1990, CURRENT RESEARCH IN PHOTOSYNTHESIS, VOLS 1-4, pA639; HAILTON AJ, 1999, SCIENCE, V286, P950; HOLSTERS M, 1978, MOL GEN GENET, V163, P181, DOI 10.1007/BF00267408; Ifuku K, 2005, PLANT PHYSIOL, V139, P1175, DOI 10.1104/pp.105.068643; IKEUCHI M, 1989, FEBS LETT, V242, P263, DOI 10.1016/0014-5793(89)80482-X; Lazar D, 2006, FUNCT PLANT BIOL, V33, P9, DOI 10.1071/FP05095; MEUNIER PC, 1993, PHOTOSYNTH RES, V36, P111, DOI 10.1007/BF00016276; MIYAO M, 1985, FEBS LETT, V180, P303, DOI 10.1016/0014-5793(85)81091-7; MURATA N, 1984, BIOCHIM BIOPHYS ACTA, V765, P363, DOI 10.1016/0005-2728(84)90177-4; Peltier JB, 2000, PLANT CELL, V12, P319, DOI 10.1105/tpc.12.3.319; Schubert M, 2002, J BIOL CHEM, V277, P8354, DOI 10.1074/jbc.M108575200; SCHULDINER S, 1971, EUR J BIOCHEM, V19, P227, DOI 10.1111/j.1432-1033.1971.tb01308.x; Suorsa M, 2006, J BIOL CHEM, V281, P145, DOI 10.1074/jbc.M510600200; Thornton LE, 2004, PLANT CELL, V16, P2164, DOI 10.1105/tpc.104.023515; Waterhouse PM, 2003, NAT REV GENET, V4, P29, DOI 10.1038/nrg982; Wesley SV, 2001, PLANT J, V27, P581, DOI 10.1046/j.1365-313X.2001.01105.x; Wincencjusz H, 1997, BIOCHEMISTRY-US, V36, P3663, DOI 10.1021/bi9626719; Yi XP, 2005, J BIOL CHEM, V280, P16170, DOI 10.1074/jbc.M501550200; ZHAO D, 2003, PLANT PHYSIOL, V133, P1	29	79	85	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26260	26267		10.1074/jbc.M603582200	http://dx.doi.org/10.1074/jbc.M603582200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16822865	Green Published, hybrid			2022-12-25	WOS:000240249500043
J	Gao, S; Laughon, A				Gao, Sheng; Laughon, Allen			Decapentaplegic-responsive silencers contain overlapping Mad-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; DNA-BINDING; SMAD7 PROMOTER; DROSOPHILA EMBRYO; TRANSCRIPTIONAL ACTIVATION; MORPHOGEN GRADIENT; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; DPP TARGETS; STEM-CELLS	Smad proteins regulate transcription in response to transforming growth factor-beta signaling pathways by binding to two distinct types of DNA sites. The sequence GTCT is recognized by all receptor-activated Smads and by Smad4. The subset of Smads that responds to bone morphogenetic protein signaling recognizes a distinct class of GC-rich sites in addition to GTCT. Recent work has shown that Drosophila Mad protein, the homologue of bone morphogenetic protein rSmads, binds to GRCGNC sites through the same MH1 domain beta-hairpin interface used to contact GTCT sites. However, binding to GRCGNC requires base-specific contact by two Mad proteins, and here we provide evidence that this is achieved by contact of the two Mad subunits that overlap across the two central base pairs of the site. This topology is supported by results indicating that His-93, which is located at the tip of the Mad beta-hairpin, is in close proximity to base pairs 2 and 5. Also consistent with the model is disruption of binding by mutation of Glu-39 and Glu-40, which are predicted to lie at the interface of the two overlapping Mad MH1 domains. As predicted from the overlapping model, binding is disrupted by insertion of 1 bp in the middle of the site, whereas insertion of 2 bp creates abutting sites that can be bound by the Mad-Medea heterotrimer without requiring Glu-39 and Glu-40. Overlapping Mad sites predominate in decapentaplegic response elements, consistent with a high degree of specificity in response to signaling.	Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Laughon, A (corresponding author), Univ Wisconsin, Genet Lab, 425G Henry Mall, Madison, WI 53706 USA.	alaughon@wisc.edu						Affolter M, 2001, EMBO J, V20, P3298, DOI 10.1093/emboj/20.13.3298; Ashe HL, 2000, DEVELOPMENT, V127, P3305; Benchabane H, 2003, MOL CELL BIOL, V23, P6646, DOI 10.1128/MCB.23.18.6646-6661.2003; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Brugger SM, 2004, DEVELOPMENT, V131, P5153, DOI 10.1242/dev.01390; Campbell G, 1999, CELL, V96, P553, DOI 10.1016/S0092-8674(00)80659-5; Chacko BM, 2004, MOL CELL, V15, P813, DOI 10.1016/j.molcel.2004.07.016; Chai JJ, 2003, J BIOL CHEM, V278, P20327, DOI 10.1074/jbc.C300134200; Chen DH, 2003, CURR BIOL, V13, P1786, DOI 10.1016/j.cub.2003.09.033; Chen DH, 2003, DEVELOPMENT, V130, P1159, DOI 10.1242/dev.00325; De Robertis EM, 2004, ANNU REV CELL DEV BI, V20, P285, DOI 10.1146/annurev.cellbio.20.011403.154124; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Dooley S, 2000, HEPATOLOGY, V31, P1094, DOI 10.1053/he.2000.6126; Dorfman R, 2001, DEVELOPMENT, V128, P965; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Gao S, 2005, J BIOL CHEM, V280, P36158, DOI 10.1074/jbc.M506882200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Halfon MS, 2000, CELL, V103, P63, DOI 10.1016/S0092-8674(00)00105-7; Hart PJ, 2002, NAT STRUCT BIOL, V9, P203, DOI 10.1038/nsb766; Henningfeld KA, 2000, J BIOL CHEM, V275, P21827, DOI 10.1074/jbc.M000978200; Hogan BLM, 2002, NAT REV GENET, V3, P513, DOI 10.1038/nrg840; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Jazwinska A, 1999, CELL, V96, P563, DOI 10.1016/S0092-8674(00)80660-1; Johnson K, 1999, J BIOL CHEM, V274, P20709, DOI 10.1074/jbc.274.29.20709; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Karaulanov E, 2004, EMBO J, V23, P844, DOI 10.1038/sj.emboj.7600101; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kirkpatrick H, 2001, J BIOL CHEM, V276, P18216, DOI 10.1074/jbc.M101365200; Knirr S, 2001, DEV BIOL, V238, P13, DOI 10.1006/dbio.2001.0397; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Kusanagi K, 2001, J BIOL CHEM, V276, P28155, DOI 10.1074/jbc.M103371200; Lee HH, 2005, DEVELOPMENT, V132, P1429, DOI 10.1242/dev.01687; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; Marty T, 2000, NAT CELL BIOL, V2, P745, DOI 10.1038/35036383; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; Minami M, 1999, NATURE, V398, P242, DOI 10.1038/18451; Mishra L, 2005, SCIENCE, V310, P68, DOI 10.1126/science.1118389; Muller B, 2003, CELL, V113, P221, DOI 10.1016/S0092-8674(03)00241-1; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Niswander L, 2003, NAT REV GENET, V4, P133, DOI 10.1038/nrg1001; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; Pyrowolakis G, 2004, DEV CELL, V7, P229, DOI 10.1016/j.devcel.2004.07.008; Raftery LA, 2003, TRENDS GENET, V19, P701, DOI 10.1016/j.tig.2003.10.009; Rushlow C, 2001, GENE DEV, V15, P340, DOI 10.1101/gad.861401; Rusten TE, 2002, DEVELOPMENT, V129, P3575; SAWANO A, 2000, NUCLEIC ACIDS RES, V28, P78, DOI DOI 10.1093/NAR/28.16.E78; Seki K, 2004, J BIOL CHEM, V279, P18544, DOI 10.1074/jbc.M311592200; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Sivasankaran R, 2000, EMBO J, V19, P6162, DOI 10.1093/emboj/19.22.6162; Tanimoto H, 2000, MOL CELL, V5, P59, DOI 10.1016/S1097-2765(00)80403-7; Vlahovicek K, 2003, NUCLEIC ACIDS RES, V31, P3686, DOI 10.1093/nar/gkg559; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Wharton SJ, 2004, CURR BIOL, V14, P1550, DOI 10.1016/j.cub.2004.08.053; Xu M, 2005, DEVELOPMENT, V132, P1637, DOI 10.1242/dev.01722; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang HL, 2001, GENE DEV, V15, P261, DOI 10.1101/gad.861201	61	9	11	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25781	25790		10.1074/jbc.M603371200	http://dx.doi.org/10.1074/jbc.M603371200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16829514	hybrid			2022-12-25	WOS:000240031300080
J	Nyborg, AC; Ladd, TB; Jansen, K; Kukar, T; Golde, TE				Nyborg, Andrew C.; Ladd, Thomas B.; Jansen, Karen; Kukar, Thomas; Golde, Todd E.			Intramembrane proteolytic cleavage by human signal peptide peptidase like 3 and malaria signal peptide peptidase	FASEB JOURNAL			English	Article						gamma-secretase; aspartyl protease; hepatitis C virus; MHC class I; Plasmodium falciparum	GAMMA-SECRETASE ACTIVITY; RETICULUM STRESS-RESPONSE; PLASMODIUM-FALCIPARUM; PRESENILIN HOMOLOGS; TRANSCRIPTIONAL INDUCTION; PROTEASE INHIBITORS; ASPARTIC PROTEASES; POTENT INHIBITORS; PLASMEPSIN-II; BETA-APP	Signal peptide peptidase (SPP) is an intramembrane cleaving protease (I-CLiP) identified by its cleavage of several type II membrane signal peptides. To date, only human SPP has been directly shown to have proteolytic activity. Here we demonstrate that the most closely related human homologue of SPP, signal peptide peptidase like 3 (SPPL3), cleaves a SPP substrate, but a more distantly related homologue, signal peptide peptidase like 2b (SPPL2b), does not. These data provide strong evidence that the SPP and SPPL3 have conserved active sites and suggest that the active sites SPPL2b is distinct. We have also synthesized a cDNA designed to express the single SPP gene present in Plasmodium falciparum and cloned this into a mammalian expression vector. When the malaria SPP protein is expressed in mammalian cells it cleaves a SPP substrate. Notably, several human SPP inhibitors block the proteolytic activity of malarial SPP (mSPP). Studies from several model organisms that express multiple SPP homologs demonstrate that the silencing of a single SPP homologue is lethal. Based on these data, we hypothesize that mSPP is a potential a novel therapeutic target for malaria.	Mayo Clin, Coll Med, Mayo Clin Jacksonville, Dept Neurosci, Jacksonville, FL 32224 USA	Mayo Clinic	Golde, TE (corresponding author), Mayo Clin, Coll Med, Mayo Clin Jacksonville, Dept Neurosci, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	tgolde@mayo.edu	Kukar, Thomas/AAW-2612-2021	Kukar, Thomas/0000-0002-3750-6262	NINDS NIH HHS [NS44734, NS39072] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS044734, R01NS039072] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andrews KT, 2006, ANTIMICROB AGENTS CH, V50, P639, DOI 10.1128/AAC.50.2.639-648.2006; Beher D, 2005, EXPERT OPIN INV DRUG, V14, P1385, DOI 10.1517/13543784.14.11.1385; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Casso DJ, 2005, GENETICS, V170, P139, DOI 10.1534/genetics.104.039933; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Friedmann E, 2004, J BIOL CHEM, V279, P50790, DOI 10.1074/jbc.M407898200; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gelb MH, 2002, SCIENCE, V297, P343, DOI 10.1126/science.1073126; GOLDE TE, 2003, SCI STKE, pRE4; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grigorenko AP, 2004, P NATL ACAD SCI USA, V101, P14955, DOI 10.1073/pnas.0406462101; Grigorenko AP, 2002, BIOCHEMISTRY-MOSCOW+, V67, P826, DOI 10.1023/A:1016365227942; Johansson PO, 2005, J MED CHEM, V48, P4400, DOI 10.1021/jm040884n; Johansson PO, 2004, J MED CHEM, V47, P3353, DOI 10.1021/jm031106i; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Krawitz P, 2005, J BIOL CHEM, V280, P39515, DOI 10.1074/jbc.M501645200; Lanz TA, 2004, J PHARMACOL EXP THER, V309, P49, DOI 10.1124/jpet.103.060715; Lemberg MK, 2004, FEBS LETT, V564, P213, DOI 10.1016/S0014-5793(04)00192-9; Lemberg MK, 2001, J IMMUNOL, V167, P6441, DOI 10.4049/jimmunol.167.11.6441; Marlow L, 2003, BIOCHEM BIOPH RES CO, V305, P502, DOI 10.1016/S0006-291X(03)00797-6; Martoglio B, 2003, BIOCHEM SOC T, V31, P1243; Martoglio B, 2003, HUM MOL GENET, V12, pR201, DOI 10.1093/hmg/ddg303; Moliaka YK, 2004, FEBS LETT, V557, P185, DOI 10.1016/S0014-5793(03)01489-3; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Nomura T, 2001, J INFECT DIS, V183, P1653, DOI 10.1086/320707; Nyborg AC, 2004, J BIOL CHEM, V279, P43148, DOI 10.1074/jbc.M405879200; Nyborg AC, 2004, J BIOL CHEM, V279, P15153, DOI 10.1074/jbc.M309305200; Okamoto K, 2004, J VIROL, V78, P6370, DOI 10.1128/JVI.78.12.6370-6380.2004; Ponting CP, 2002, HUM MOL GENET, V11, P1037, DOI 10.1093/hmg/11.9.1037; Rosenthal PJ, 1996, ANTIMICROB AGENTS CH, V40, P1600, DOI 10.1128/AAC.40.7.1600; Sibley CH, 2001, IUBMB LIFE, V52, P285, DOI 10.1080/152165401317291138; Sibley CH, 2001, TRENDS PARASITOL, V17, P582, DOI 10.1016/S1471-4922(01)02085-2; Siemers E, 2005, CLIN NEUROPHARMACOL, V28, P126, DOI 10.1097/01.wnf.0000167360.27670.29; Sun LQ, 2005, CELL CYCLE, V4, P3, DOI 10.4161/cc.4.1.1341; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; Urban S, 2001, CELL, V107, P173, DOI 10.1016/S0092-8674(01)00525-6; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Wang J, 2006, J NEUROCHEM, V96, P218, DOI 10.1111/j.1471-4159.2005.03548.x; Wang J, 2004, NEUROBIOL DIS, V15, P654, DOI 10.1016/j.nbd.2003.12.008; Wang Y, 2000, J BIOL CHEM, V275, P27013; Weihofen A, 2003, J BIOL CHEM, V278, P16528, DOI 10.1074/jbc.M301372200; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Xia WM, 2003, J CELL SCI, V116, P2839, DOI 10.1242/jcs.00651; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	52	37	42	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1671	1679		10.1096/fj.06-5762com	http://dx.doi.org/10.1096/fj.06-5762com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16873890				2022-12-25	WOS:000240266600012
J	Su, YC; Cui, ZQ; Li, ZZ; Block, ER				Su, Yunchao; Cui, Zhaoqiang; Li, Zhaozhong; Block, Edward R.			Calpain-2 regulation of VEGF-mediated angiogenesis	FASEB JOURNAL			English	Article						calpains; actin; calpastatin	ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; IN-VITRO; CELL-MIGRATION; FAMILY-MEMBERS; ACTIVATION; CALPASTATIN; INVOLVEMENT; TRANSFORMATION; ORGANIZATION	Angiogenesis is a complex process involving endothelial cell migration, proliferation, and differentiation as well as tube formation. These processes are stimulated by a variety of growth factors such as vascular endothelial growth factor (VEGF). VEGF-induced cytoskeletal reorganization plays a crucial role in the angiogenic processes. In the present study, we evaluated the role of calpain in VEGF-induced angiogenesis in vitro and in vivo. Human pulmonary microvascular endothelial cells (PMEC) were incubated with VEGF (10-60 ng/ml) for 2-24 h, after which we measured calpain activities, protein contents of the calpain subunits and of calpastatin, endothelial monolayer wound repair, tube formation, and actin cytoskeleton changes. Incubation of PMEC with VEGF resulted in dose- and time-dependent increases in calpain activity and protein content of calpain-2. VEGF did not change the protein contents of calpain-1 and the small subunit or of calpastatin. Incubation of PMEC with a VEGF receptor blocker prevented the VEGF-induced increase in calpain activity. Inhibition of calpain activity by siRNA directed against calpain-2 and by overexpression of calpastatin prevented VEGF-induced increases in actin stress fibers in endothelial cells and angiogenesis. Overexpression of calpastatin also inhibits vessel formation in subcutaneous (s.c.) matrigel plugs in mice. These results indicate that calpain mediates VEGF-induced angiogenic effects by modulating actin cytoskeletal organization.	Univ Florida, Dept Med, Coll Med, Gainesville, FL 32610 USA; Malcom Randall Vet Affairs Med Ctr, Res Serv, Gainesville, FL USA	State University System of Florida; University of Florida	Su, YC (corresponding author), Univ Florida, Dept Med, Coll Med, MSB M452,Box 100225,1600 SW Archer Rd, Gainesville, FL 32610 USA.	ysu@ufl.edu			NHLBI NIH HHS [HL52136, HL67951] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067951, R01HL052136, R37HL052136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amerongen GPV, 2003, ARTERIOSCL THROM VAS, V23, P211, DOI 10.1161/01.ATV.0000054198.68894.88; Boussat S, 2000, AM J PHYSIOL-LUNG C, V279, pL371, DOI 10.1152/ajplung.2000.279.2.L371; Carragher NO, 2002, INT J BIOCHEM CELL B, V34, P1539, DOI 10.1016/S1357-2725(02)00069-9; Carragher NO, 2002, MOL CELL BIOL, V22, P257, DOI 10.1128/MCB.22.1.257-269.2002; Cui ZQ, 2005, AM J RESP CELL MOL, V33, P513, DOI 10.1165/rcmb.2005-0046OC; Dedieu S, 2004, EXP CELL RES, V292, P187, DOI 10.1016/j.yexcr.2003.08.014; Deroanne CF, 2001, CARDIOVASC RES, V49, P647, DOI 10.1016/S0008-6363(00)00233-9; Dourdin N, 2001, J BIOL CHEM, V276, P48382, DOI 10.1074/jbc.M108893200; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Ferrara N, 2001, ACTA HAEMATOL-BASEL, V106, P148, DOI 10.1159/000046610; Forsberg NE, 2000, METH MOL B, V144, P319; Fox JEB, 1999, THROMB HAEMOSTASIS, V82, P385; Franco S, 2004, EXP CELL RES, V299, P179, DOI 10.1016/j.yexcr.2004.05.021; Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175; Frelin C, 2000, ANN ENDOCRINOL-PARIS, V61, P70; Fujitani K, 1997, J CELL BIOCHEM, V66, P197, DOI 10.1002/(SICI)1097-4644(19970801)66:2<197::AID-JCB7>3.0.CO;2-L; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Hoang MV, 2004, P NATL ACAD SCI USA, V101, P1874, DOI 10.1073/pnas.0308525100; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; Khorchid A, 2002, NAT STRUCT BIOL, V9, P239, DOI 10.1038/nsb0402-239; Kliche S, 2001, IUBMB LIFE, V52, P61, DOI 10.1080/15216540252774784; Kulkarni S, 1999, J BIOL CHEM, V274, P21265, DOI 10.1074/jbc.274.30.21265; Kulkarni S, 2002, J BIOL CHEM, V277, P24435, DOI 10.1074/jbc.M203457200; Lee PC, 2000, MICROVASC RES, V60, P269, DOI 10.1006/mvre.2000.2265; Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3; Linz-McGillem LA, 2004, STEM CELLS DEV, V13, P496, DOI 10.1089/1547328042417282; Min JK, 2004, CANCER RES, V64, P644, DOI 10.1158/0008-5472.CAN-03-3250; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Newcomb JK, 2000, METH MOL B, V144, P219; Perrin BJ, 2002, INT J BIOCHEM CELL B, V34, P722, DOI 10.1016/S1357-2725(02)00009-2; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; Shiraha H, 2002, MOL CELL BIOL, V22, P2716, DOI 10.1128/MCB.22.8.2716-2727.2002; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; Su YC, 2004, AM J PHYSIOL-LUNG C, V287, pL794, DOI 10.1152/ajplung.00079.2004; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; SUZUKI K, 2004, DIABETES, V53, P12; Tamada Y, 2000, J OCUL PHARMACOL TH, V16, P271, DOI 10.1089/jop.2000.16.271; Thuringer D, 2002, J BIOL CHEM, V277, P2028, DOI 10.1074/jbc.M109493200; Wendt A, 2004, BIOL CHEM, V385, P465, DOI 10.1515/BC.2004.054; Xu Y, 2002, J BIOL CHEM, V277, P21474, DOI 10.1074/jbc.M111689200; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6	43	62	65	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1443	1451		10.1096/fj.05-5354com	http://dx.doi.org/10.1096/fj.05-5354com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816119				2022-12-25	WOS:000240266000021
J	Woodruff, TM; Crane, JW; Proctor, LM; Buller, KM; Shek, AB; de Vos, K; Pollitt, S; Williams, HM; Shiels, IA; Monk, PN; Taylor, SM				Woodruff, Trent M.; Crane, James W.; Proctor, Lavinia M.; Buller, Kathryn M.; Shek, Annie B.; de Vos, Kurt; Pollitt, Sandra; Williams, Hua M.; Shiels, Ian A.; Monk, Peter N.; Taylor, Stephen M.			Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration	FASEB JOURNAL			English	Article						complement system; inflammation; 3-nitropropionic acid	TOXIN 3-NITROPROPIONIC ACID; INFLAMMATORY-BOWEL-DISEASE; CENTRAL-NERVOUS-SYSTEM; HUNTINGTONS-DISEASE; ALZHEIMERS-DISEASE; COMPLEMENT-SYSTEM; ANAPHYLATOXIN C5A; STRIATAL LESIONS; HUMAN LEUKOCYTES; EXPRESSION	The complement system is thought to be involved in the pathogenesis of numerous neurological diseases, although its precise role remains controversial. In this study we used orally active C5a receptor antagonists (PMX53 and PMX205) developed in our laboratories in a rat model of 3-nitropropionic acid (3-NP) -induced Huntington's disease. Administration of the C5a antagonists (10 mg/kg/day, oral) either 48 h pre- or 48 h post-toxin significantly reduced body weight loss, anorexia, and behavioral and motor deficits associated with 3-NP intoxication. Striatal lesion size, apoptosis, neutrophil infiltration, and hemorrhage were also significantly reduced in C5a antagonist-treated rats. Immunohistochemical analysis demonstrated marked deposition of C3 and C9, and upregulation of C5a receptors on neuronal cells at the time of lesion formation. Inhibition of prostaglandins or TNF-alpha with ibuprofen or infliximab had no effect in this model. The C5a antagonists did not affect 3-NP-induced cell death when added directly to rat striatal neuronal cultures, indicating a secondary mechanism of action in vivo. Our findings demonstrate for the first time that complement activation in the brain, particularly C5a, is a key event in the pathogenesis of this disease model, and suggest a future role for inhibitors of C5a in the treatment of neurodegenerative diseases.	Univ Queensland, Promics Ltd, Brisbane, Qld 4072, Australia; Univ Queensland, Queensland Brain Inst, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Univ Sheffield, Sch Med, Dept Neurol, Sheffield, S Yorkshire, England	University of Queensland; University of Queensland; University of Queensland; University of Sheffield	Woodruff, TM (corresponding author), Univ Queensland, Promics Ltd, Brisbane, Qld 4072, Australia.	trent.woodruff@promics.com	De Vos, Kurt/D-8380-2011; Monk, Peter/C-6155-2008; Woodruff, Trent M/B-4861-2009; Buller, Kathryn/F-1227-2010; Woodruff, Trent/AAS-4629-2020; Shiels, Ian/C-8046-2009	De Vos, Kurt/0000-0003-2161-6309; Monk, Peter/0000-0003-4637-3059; Woodruff, Trent M/0000-0003-1382-911X; Woodruff, Trent/0000-0003-1382-911X; Crane, James/0000-0002-4601-0189	Wellcome Trust [072231] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arumugam TV, 2004, SHOCK, V21, P401, DOI 10.1097/00024382-200405000-00002; Barnum SR, 2002, IMMUNOL RES, V26, P7, DOI 10.1385/IR:26:1-3:007; Benard M, 2004, J BIOL CHEM, V279, P43487, DOI 10.1074/jbc.M404124200; Brouillet E, 1999, PROG NEUROBIOL, V59, P427, DOI 10.1016/S0301-0082(99)00005-2; Cain SA, 2002, J BIOL CHEM, V277, P7165, DOI 10.1074/jbc.C100714200; Farkas I, 1998, NEUROSCIENCE, V86, P903, DOI 10.1016/S0306-4522(98)00108-0; Farkas I, 2003, J IMMUNOL, V170, P5764, DOI 10.4049/jimmunol.170.11.5764; Garcia M, 2002, J NEUROSCI, V22, P2174, DOI 10.1523/JNEUROSCI.22-06-02174.2002; Gasque P, 2002, MOL NEUROBIOL, V25, P1, DOI 10.1385/MN:25:1:001; Gavrilyuk V, 2005, J NEUROCHEM, V92, P1140, DOI 10.1111/j.1471-4159.2004.02942.x; Girardi G, 2003, J CLIN INVEST, V112, P1644, DOI 10.1172/JCI200318817; GOLDSTEIN I, 1973, P NATL ACAD SCI USA, V70, P2916, DOI 10.1073/pnas.70.10.2916; GOLDSTEIN IM, 1975, J CLIN INVEST, V56, P1155, DOI 10.1172/JCI108191; Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835; Guyot MC, 1997, NEUROSCIENCE, V79, P45, DOI 10.1016/S0306-4522(96)00602-1; Harkin DW, 2004, J VASC SURG, V39, P196, DOI 10.1016/j.jvs.2003.07.001; Hillebrandt S, 2005, NAT GENET, V37, P835, DOI 10.1038/ng1599; Hosokawa M, 2003, GLIA, V42, P417, DOI 10.1002/glia.10234; Hua Y, 2000, J NEUROSURG, V92, P1016, DOI 10.3171/jns.2000.92.6.1016; Huber-Lang M, 2005, J IMMUNOL, V174, P1104, DOI 10.4049/jimmunol.174.2.1104; Huber-Lang MS, 2002, FASEB J, V16, P1567, DOI 10.1096/fj.02-0209com; Klegeris Andis, 2005, Current Alzheimer Research, V2, P355, DOI 10.2174/1567205054367883; Kohl J, 2001, MOL IMMUNOL, V38, P175, DOI 10.1016/S0161-5890(01)00041-4; Kulkarni AP, 2004, ANN NY ACAD SCI, V1035, P147, DOI 10.1196/annals.1332.010; Lan Min-Yu, 2005, Chang Gung Med J, V28, P77; Leventhal L, 2000, J COMP NEUROL, V425, P471, DOI 10.1002/1096-9861(20001002)425:4<471::AID-CNE1>3.0.CO;2-U; March DR, 2004, MOL PHARMACOL, V65, P868, DOI 10.1124/mol.65.4.868; Mittoux V, 2002, J NEUROSCI, V22, P4478, DOI 10.1523/JNEUROSCI.22-11-04478.2002; Mukherjee P, 2000, J NEUROIMMUNOL, V105, P124, DOI 10.1016/S0165-5728(99)00261-1; Nataf S, 1999, TRENDS NEUROSCI, V22, P397, DOI 10.1016/S0166-2236(98)01390-3; NISHINO H, 1995, NEUROSCI LETT, V186, P161, DOI 10.1016/0304-3940(95)11311-J; Osaka H, 1999, NEUROSCIENCE, V88, P1073, DOI 10.1016/S0306-4522(98)00372-8; Osaka H, 1999, J CELL BIOCHEM, V73, P303, DOI 10.1002/(SICI)1097-4644(19990601)73:3<303::AID-JCB2>3.0.CO;2-2; Ouary S, 2000, NEUROSCIENCE, V97, P521, DOI 10.1016/S0306-4522(00)00020-8; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Singhrao SK, 1999, EXP NEUROL, V159, P362, DOI 10.1006/exnr.1999.7170; Stahel PF, 1997, MOL BRAIN RES, V50, P205, DOI 10.1016/S0169-328X(97)00189-7; Van Beek J, 2003, ANN NY ACAD SCI, V992, P56; Van Beek J, 2000, EXP NEUROL, V161, P373, DOI 10.1006/exnr.1999.7273; Vis JC, 2001, NEUROPATH APPL NEURO, V27, P68, DOI 10.1046/j.0305-1846.2001.00305.x; Woodruff TM, 2005, J PHARMACOL EXP THER, V314, P811, DOI 10.1124/jpet.105.086835; Woodruff TM, 2003, J IMMUNOL, V171, P5514, DOI 10.4049/jimmunol.171.10.5514; Woodruff TM, 2002, ARTHRITIS RHEUM-US, V46, P2476, DOI 10.1002/art.10449; Yasojima K, 1999, AM J PATHOL, V154, P927, DOI 10.1016/S0002-9440(10)65340-0	44	114	118	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2006	20	9					1407	1417		10.1096/fj.05-5814com	http://dx.doi.org/10.1096/fj.05-5814com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816116				2022-12-25	WOS:000240266000018
J	Lin, R; Maeda, S; Liu, C; Karin, M; Edgington, TS				Lin, R.; Maeda, S.; Liu, C.; Karin, M.; Edgington, T. S.			A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas	ONCOGENE			English	Article						large noncoding RNA; carcinoma; hepcarcin; MALAT-1	GENE-EXPRESSION; TRANSCRIPTION FACTOR; XIST GENE; H19 GENE; TUMOR; CANCER; LIVER; HEPATOCARCINOGENESIS; IDENTIFICATION; TRANSLOCATION	Tumor markers can facilitate understanding molecular cell biology of neoplasia and provide potential targets for the diagnosis and insight for intervention. We here identify a novel murine gene, hepcarcin (hcn), encoding a 7-kb mRNA-like transcript. The gene appears to be the murine ortholog of the human alpha gene, that is, MALAT-1. The gene and homologs lack credible open reading frames, consistent with a highly conserved large noncoding RNA (ncRNA). In all nodules of procarcinogen-induced murine hepatocellular carcinomas (HCCs) and human HCCs, expression was markedly elevated compared to the uninvolved liver. Quantitative analyses indicated a 6-7-fold increased RNA level in HCCs versus uninvolved liver, advancing this as a molecule of interest. This ncRNA was overexpressed in all five non-hepatic human carcinomas analysed, consistent with a potential marker for neoplastic cells and potential participant in the molecular cell biology of neoplasia.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Calif San Diego, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	Scripps Research Institute; University of California System; University of California San Diego	Edgington, TS (corresponding author), Scripps Res Inst, Dept Immunol, 10666 N Torrey Pines Rd,SP258, La Jolla, CA 92037 USA.	ruilin@scripp.edu; tse@scripps.edu		Lin, Rui/0000-0002-1859-7904	NCI NIH HHS [CA-75924] Funding Source: Medline; NHLBI NIH HHS [HL-16411] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA075924] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Davis IJ, 2003, P NATL ACAD SCI USA, V100, P6051, DOI 10.1073/pnas.0931430100; Eddy SR, 2001, NAT REV GENET, V2, P919, DOI 10.1038/35103511; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Erdmann VA, 2001, NUCLEIC ACIDS RES, V29, P189, DOI 10.1093/nar/29.1.189; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kuiper RP, 2003, HUM MOL GENET, V12, P1661, DOI 10.1093/hmg/ddg178; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Lottin S, 2002, CARCINOGENESIS, V23, P1885, DOI 10.1093/carcin/23.11.1885; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Manoharan H, 2003, MOL CARCINOGEN, V38, P40, DOI 10.1002/mc.10144; Meltzer PS, 2005, NATURE, V435, P745, DOI 10.1038/435745a; Numata K, 2003, GENOME RES, V13, P1301, DOI 10.1101/gr.1011603; O'Neill MJ, 2005, HUM MOL GENET, V14, pR113, DOI 10.1093/hmg/ddi108; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285; Plath K, 2002, ANNU REV GENET, V36, P233, DOI 10.1146/annurev.genet.36.042902.092433; Prasanth KV, 2005, CELL, V123, P249, DOI 10.1016/j.cell.2005.08.033; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Reis EM, 2004, ONCOGENE, V23, P6684, DOI 10.1038/sj.onc.1207880; SARMA DSR, 1986, CANCER SURV, V5, P781; Scherer SW, 2003, SCIENCE, V300, P767, DOI 10.1126/science.1083423; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; van Asseldonk M, 2000, GENOMICS, V66, P35, DOI 10.1006/geno.2000.6194; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Willingham AT, 2005, SCIENCE, V309, P1570, DOI 10.1126/science.1115901; Xu L, 2001, CANCER RES, V61, P3176; Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398; Yamada K, 2006, CANCER SCI, V97, P106, DOI 10.1111/j.1349-7006.2006.00147.x; Yan MD, 2005, HUM MOL GENET, V14, P1465, DOI 10.1093/hmg/ddi156	36	432	485	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					851	858		10.1038/sj.onc.1209846	http://dx.doi.org/10.1038/sj.onc.1209846			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16878148				2022-12-25	WOS:000244063800006
J	Paltoglou, S; Roberts, BJ				Paltoglou, S.; Roberts, B. J.			HIF-1 alpha and EPAS ubiquitination mediated by the VHL tumour suppressor involves flexibility in the ubiquitination mechanism, similar to other RING E3 ligases	ONCOGENE			English	Article						HIF-1 alpha; HIF-2 alpha; VHL; EPAS; ubiquitin; SCF	HIPPEL-LINDAU PROTEIN; INDUCIBLE FACTOR-I; PROLYL HYDROXYLATION/; HIF-ALPHA; DEGRADATION; DOMAINS; DESTRUCTION; COMPLEX; FAMILY; SIC1	Hypoxia-inducible factor 1 alpha (HIF-1 alpha) degradation under normoxia is critical to modulating vascular growth. This degradation is mediated during normoxia by the von Hippel-Lindau tumour suppressor protein (VHL)-E3 ubiquitin ligase in partnership with the E2 enzyme UbcH5. In current models of the functionally similar Skp1, cullin, F-box (SCF)-E3 ligase, the E3 binds the target protein and the E2 catalyses ubiquitin transfer to lysines in an appropriately positioned domain. In the present study, we report that for efficient ubiquitination of HIF-1 alpha to occur, three conserved lysines are required in both the HIF-1 alpha and endothelial Per-ARNT-Sim domain protein (EPAS) sequences. The site of ubiquitin attachment via UbcH5 was mapped, and is shown to involve three HIF-1 alpha lysines, K532, K538 and K547, and the same aligned lysines in EPAS. Only one of these lysines need to be intact for full ubiquitination to occur, analogous to the mechanism of Sic1 ubiquitination by the SCF/Cdc34 complex and further strengthening the functional link between the VHL and SCF-E3 ubiquitin ligases. We also report that lysines can be moved around the HIF-1 alpha sequence with only minor losses in ubiquitination efficiency, thus suggesting HIF-1 alpha and EPAS regulation by hypoxia depends primarily on an interaction with VHL per se, rather than the highly specific positioning of flanking lysine acceptors.	Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, Adelaide, SA 5000, Australia	University of South Australia	Roberts, BJ (corresponding author), Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, 4 Froome Rd, Adelaide, SA 5000, Australia.	Ben.Roberts@unisa.edu.au						Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Chan DA, 2005, MOL CELL BIOL, V25, P6415, DOI 10.1128/MCB.25.15.6415-6426.2005; Deffenbaugh AE, 2003, CELL, V114, P611, DOI 10.1016/S0092-8674(03)00641-X; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jackson PK, 2002, MOL CELL, V9, P923, DOI 10.1016/S1097-2765(02)00538-5; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; Kondo K, 2001, EXP CELL RES, V264, P117, DOI 10.1006/excr.2000.5139; Lewis MD, 2004, ONCOGENE, V23, P2315, DOI 10.1038/sj.onc.1207384; Lewis MD, 2003, ONCOGENE, V22, P3992, DOI 10.1038/sj.onc.1206683; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maynard MA, 2003, J BIOL CHEM, V278, P11032, DOI 10.1074/jbc.M208681200; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; Pugh CW, 2003, SEMIN CANCER BIOL, V13, P83, DOI 10.1016/S1044-579X(02)00103-7; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Yu F, 2001, CANCER RES, V61, P4136; Zhou MI, 2002, J BIOL CHEM, V277, P39887, DOI 10.1074/jbc.M205040200	23	42	43	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2007	26	4					604	609		10.1038/sj.onc.1209818	http://dx.doi.org/10.1038/sj.onc.1209818			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16862177				2022-12-25	WOS:000243731600012
J	Anders, A; Lilie, H; Franke, K; Kapp, L; Stelling, J; Gilles, ED; Breunig, KD				Anders, Alexander; Lilie, Hauke; Franke, Kathlen; Kapp, Lutz; Stelling, Joerg; Gilles, Ernst D.; Breunig, Karin D.			The galactose switch in Kluyveromyces lactis depends on nuclear competition between Gal4 and Gal1 for Gal80 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-FRUCTOSE OXIDOREDUCTASE; NEGATIVE REGULATORY PROTEIN; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; GAL4P-ACTIVATED GENES; FUNCTIONAL HOMOLOGY; TERMINAL FRAGMENT; ESCHERICHIA-COLI; AMINO-ACIDS; YEAST	The Gal4 protein represents a universally functional transcription activator, which in yeast is regulated by protein-protein interaction of its transcription activation domain with the inhibitor Gal80. Gal80 inhibition is relieved via galactose-mediated Gal80-Gal1-Gal3 interaction. The Gal4-Gal80-Gal1/3 regulatory module is conserved between Saccharomyces cerevisiae and Kluyveromyces lactis. Here we demonstrate that K. lactis Gal80 (KlGal80) is a nuclear protein independent of the Gal4 activity status, whereas KlGal1 is detected throughout the entire cell, which implies that KlGal80 and KlGal1 interact in the nucleus. Consistently KlGal1 accumulates in the nucleus upon KlGAL80 overexpression. Furthermore, we show that the KlGal80-KlGal1 interaction blocks the galactokinase activity of KlGal1 and is incompatible with KlGal80-KlGal4-AD interaction. Thus, we propose that dissociation of KlGal80 from the AD forms the basis of KlGal4 activation in K. lactis. Quantitation of the dissociation constants for the KlGal80 complexes gives a much lower affinity for KlGal1 as compared with Gal4. Mathematical modeling shows that with these affinities a switch based on competition between Gal1 and Gal4 for Gal80 binding is nevertheless efficient provided two monomeric Gal1 molecules interact with dimeric Gal80. Consistent with such a mechanism, analysis of the sedimentation behavior by analytical ultracentrifugation demonstrates the formation of a heterotetrameric KlGal80-KlGal1 complex of 2:2 stoichiometry.	Univ Halle Wittenberg, Genet Inst, D-06099 Halle, Germany; Univ Halle Wittenberg, Inst Biotechnol, D-06099 Halle, Germany; Max Planck Inst Dynam Komplexer Tech Syst, D-39106 Magdeburg, Germany	Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Max Planck Society	Breunig, KD (corresponding author), Univ Halle Wittenberg, Genet Inst, D-06099 Halle, Germany.	karin.breunig@genetik.uni-halle.de	Stelling, Joerg/F-7499-2010	Stelling, Joerg/0000-0002-1145-891X; Anders, Alexander/0000-0002-9845-3491				ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; Ansari AZ, 1998, P NATL ACAD SCI USA, V95, P13543, DOI 10.1073/pnas.95.23.13543; Behlke J, 1997, BIOCHEMISTRY-US, V36, P5149, DOI 10.1021/bi962755h; BHAT PJ, 1992, MOL CELL BIOL, V12, P2701, DOI 10.1128/MCB.12.6.2701; Bhaumik SR, 2004, GENE DEV, V18, P333, DOI 10.1101/gad.1148404; Blank TE, 1997, MOL CELL BIOL, V17, P2566, DOI 10.1128/MCB.17.5.2566; BREUNIG KD, 1987, MOL CELL BIOL, V7, P4400, DOI 10.1128/MCB.7.12.4400; BROACH JR, 1979, J MOL BIOL, V131, P41, DOI 10.1016/0022-2836(79)90300-0; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; Carrozza MJ, 2002, J BIOL CHEM, V277, P24648, DOI 10.1074/jbc.M201965200; DAS S, 1985, EMBO J, V4, P793, DOI 10.1002/j.1460-2075.1985.tb03699.x; DICKSON RC, 1983, J BACTERIOL, V154, P1245, DOI 10.1128/JB.154.3.1245-1251.1983; ENGELS R, 1999, THESIS HEINRICHHEINE; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, V2, P195; JOHNSTON SA, 1987, CELL, V50, P143, DOI 10.1016/0092-8674(87)90671-4; Kingston RL, 1996, STRUCTURE, V4, P1413, DOI 10.1016/S0969-2126(96)00149-9; KODADEK TJ, 1994, TRANSCRIPTION MECH R, P505; LACY LR, 1981, MOL CELL BIOL, V1, P629, DOI 10.1128/MCB.1.7.629; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LODI T, 1991, J GEN MICROBIOL, V137, P1039, DOI 10.1099/00221287-137-5-1039; Lott JS, 2000, J MOL BIOL, V304, P575, DOI 10.1006/jmbi.2000.4245; LUE NF, 1987, MOL CELL BIOL, V7, P3446, DOI 10.1128/MCB.7.10.3446; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; Maru Y, 1996, J BIOL CHEM, V271, P15353, DOI 10.1074/jbc.271.26.15353; Melcher K, 2005, GENETICS, V171, P469, DOI 10.1534/genetics.105.045237; Melcher K, 2001, EMBO J, V20, P841, DOI 10.1093/emboj/20.4.841; Menezes RA, 2003, J MOL BIOL, V333, P479, DOI 10.1016/j.jmb.2003.08.034; MEYER J, 1991, MOL CELL BIOL, V11, P5454, DOI 10.1128/MCB.11.11.5454; NOGI Y, 1989, MOL CELL BIOL, V9, P3009, DOI 10.1128/MCB.9.7.3009; Peng G, 2000, MOL CELL BIOL, V20, P5140, DOI 10.1128/MCB.20.14.5140-5148.2000; Peng G, 2002, P NATL ACAD SCI USA, V99, P8548, DOI 10.1073/pnas.142100099; Pilauri V, 2005, GENETICS, V169, P1903, DOI 10.1534/genetics.104.036723; Platt A, 2000, P NATL ACAD SCI USA, V97, P3154, DOI 10.1073/pnas.97.7.3154; Platt A, 1998, EMBO J, V17, P4086, DOI 10.1093/emboj/17.14.4086; Reece RJ, 1997, BIOESSAYS, V19, P1001, DOI 10.1002/bies.950191110; REECE RJ, 1993, GENE, V126, P105, DOI 10.1016/0378-1119(93)90596-U; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; RILEY MI, 1987, MOL CELL BIOL, V7, P780, DOI 10.1128/MCB.7.2.780; SALMERON JM, 1990, GENETICS, V125, P21; SALMERON JM, 1986, NUCLEIC ACIDS RES, V14, P7767, DOI 10.1093/nar/14.19.7767; SALMERON JM, 1989, MOL CELL BIOL, V9, P2950, DOI 10.1128/MCB.9.7.2950; SCHULZ WA, 1993, BIOL CHEM H-S, V374, P313, DOI 10.1515/bchm3.1993.374.1-6.313; SELLECK SB, 1987, MOL CELL BIOL, V7, P3260, DOI 10.1128/MCB.7.9.3260; Sherman F, 1986, LAB COURSE MANUAL ME, P3; Sil AK, 1999, MOL CELL BIOL, V19, P7828; SuzukiFujimoto T, 1996, MOL CELL BIOL, V16, P2504; Thoden JB, 2005, J BIOL CHEM, V280, P36905, DOI 10.1074/jbc.M508446200; Timson DJ, 2002, BIOCHEM J, V363, P515, DOI 10.1042/0264-6021:3630515; Timson DJ, 2002, BIOCHIMIE, V84, P265, DOI 10.1016/S0300-9084(02)01399-8; Verma M, 2004, EUR J BIOCHEM, V271, P4064, DOI 10.1111/j.1432-1033.2004.04344.x; Verma M, 2003, J BIOL CHEM, V278, P48764, DOI 10.1074/jbc.M303526200; Winey M, 1997, MOL BIOL CELL, V8, P2119, DOI 10.1091/mbc.8.11.2119; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Wu YB, 1996, EMBO J, V15, P3951, DOI 10.1002/j.1460-2075.1996.tb00769.x; Yano KI, 1997, P NATL ACAD SCI USA, V94, P1721, DOI 10.1073/pnas.94.5.1721; ZACHARIAE W, 1993, MOL CELL BIOL, V13, P3058, DOI 10.1128/MCB.13.5.3058; ZACHARIAE W, 1994, THESIS HEINRICHHEINE; ZENKE FT, 1993, MOL CELL BIOL, V13, P7566, DOI 10.1128/MCB.13.12.7566; Zenke FT, 1999, BIOL CHEM, V380, P419, DOI 10.1515/BC.1999.056; Zenke FT, 1996, SCIENCE, V272, P1662, DOI 10.1126/science.272.5268.1662	62	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29337	29348		10.1074/jbc.M604271200	http://dx.doi.org/10.1074/jbc.M604271200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16867978	hybrid			2022-12-25	WOS:000240680500089
J	Kinghorn, KJ; Crowther, DC; Sharp, LK; Nerelius, C; Davis, RL; Chang, HT; Green, C; Gubb, DC; Johansson, J; Lomas, DA				Kinghorn, Kerri J.; Crowther, Damian C.; Sharp, Lynda K.; Nerelius, Charlotte; Davis, Richard L.; Chang, Howard T.; Green, Clare; Gubb, David C.; Johansson, Jan; Lomas, David A.			Neuroserpin binds A beta and is a neuroprotective component of amyloid plaques in Alzheimer disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-STATE NMR; TISSUE-PLASMINOGEN ACTIVATOR; NUCLEAR-MAGNETIC-RESONANCE; SERINE-PROTEASE INHIBITOR; LONG-TERM POTENTIATION; APOLIPOPROTEIN-E; FORMS POLYMERS; IN-VITRO; FAMILIAL ENCEPHALOPATHY; ELECTRON-MICROSCOPY	Alzheimer disease is characterized by extracellular plaques composed of A beta peptides. We show here that these plaques also contain the serine protease inhibitor neuroserpin and that neuroserpin forms a 1:1 binary complex with the N-terminal or middle parts of the A beta(1-42) peptide. This complex inactivates neuroserpin as an inhibitor of tissue plasminogen activator and blocks the loop-sheet polymerization process that is characteristic of members of the serpin superfamily. In contrast neuroserpin accelerates the aggregation of A beta(1-42) with the resulting species having an appearance that is distinct from the mature amyloid fibril. Neuroserpin reduces the cytotoxicity of A beta(1-42) when assessed using standard cell assays, and the interaction has been confirmed in vivo in novel Drosophila models of disease. Taken together, these data show that neuroserpin interacts with A beta(1-42) to form off-pathway non-toxic oligomers and so protects neurons in Alzheimer disease.	Univ Cambridge, Dept Med, Inst Med Res, Cambridge CB2 2XY, England; Swedish Univ Agr Sci, Dept Mol Biosci Med Biochem, Biomed Ctr, S-75123 Uppsala, Sweden; SUNY Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England; Ctr Invest Cooperat Biogune, Derio 48160, Spain	University of Cambridge; Swedish University of Agricultural Sciences; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Cambridge	Crowther, DC (corresponding author), Univ Cambridge, Dept Med, Inst Med Res, Wellcome Trust Med Res Council Bldg,Hills Rd, Cambridge CB2 2XY, England.	dcc26@cam.ac.uk		Skipper, Lynda/0000-0002-1463-5811; Johansson, Jan/0000-0002-8719-4703; Kinghorn, Kerri J/0000-0003-2048-4332	MRC [G0500306] Funding Source: UKRI; Medical Research Council [G0500306] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; Antzutkin ON, 2000, P NATL ACAD SCI USA, V97, P13045, DOI 10.1073/pnas.230315097; Antzutkin ON, 2003, BIOPHYS J, V84, P3326, DOI 10.1016/S0006-3495(03)70057-5; Antzutkin ON, 2002, BIOCHEMISTRY-US, V41, P15436, DOI 10.1021/bi0204185; Asante EA, 2002, EMBO J, V21, P6358, DOI 10.1093/emboj/cdf653; Balbach JJ, 2002, BIOPHYS J, V83, P1205, DOI 10.1016/S0006-3495(02)75244-2; Belorgey D, 2004, EUR J BIOCHEM, V271, P3360, DOI 10.1111/j.1432-1033.2004.04270.x; Belorgey D, 2002, J BIOL CHEM, V277, P17367, DOI 10.1074/jbc.M200680200; Centonze D, 2002, EUR J NEUROSCI, V16, P713, DOI 10.1046/j.1460-9568.2002.02106.x; Cinelli P, 2001, MOL CELL NEUROSCI, V18, P443, DOI 10.1006/mcne.2001.1028; Collinge J, 2005, J NEUROL NEUROSUR PS, V76, P906, DOI 10.1136/jnnp.2004.048660; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Costa DA, 2004, J ALZHEIMERS DIS, V6, P509; Crowther DC, 2005, NEUROSCIENCE, V132, P123, DOI 10.1016/j.neuroscience.2004.12.025; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; Davis RL, 2002, LANCET, V359, P2242, DOI 10.1016/S0140-6736(02)09293-0; De Gregorio E, 2002, DEV CELL, V3, P581, DOI 10.1016/S1534-5807(02)00267-8; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; Dolev I, 2004, P NATL ACAD SCI USA, V101, P13909, DOI 10.1073/pnas.0404458101; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; ERIKSSON S, 1995, P NATL ACAD SCI USA, V92, P2313, DOI 10.1073/pnas.92.6.2313; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; FRASER PE, 1993, J NEUROCHEM, V61, P298, DOI 10.1111/j.1471-4159.1993.tb03568.x; Hastings GA, 1997, J BIOL CHEM, V272, P33062, DOI 10.1074/jbc.272.52.33062; Huang THJ, 2000, J MOL BIOL, V297, P73, DOI 10.1006/jmbi.2000.3559; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lashuel HA, 2003, J MOL BIOL, V332, P795, DOI 10.1016/S0022-2836(03)00927-6; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; Miranda E, 2004, J BIOL CHEM, V279, P28283, DOI 10.1074/jbc.M313166200; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Onda M, 2005, J BIOL CHEM, V280, P13735, DOI 10.1074/jbc.M413282200; Osterwalder T, 1996, EMBO J, V15, P2944, DOI 10.1002/j.1460-2075.1996.tb00657.x; Petkova AT, 2005, SCIENCE, V307, P262, DOI 10.1126/science.1105850; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Renatus M, 1997, J BIOL CHEM, V272, P21713, DOI 10.1074/jbc.272.35.21713; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; Selkoe DJ, 2000, ANN NY ACAD SCI, V924, P17; SERPELL LC, 1995, J MOL BIOL, V254, P113, DOI 10.1006/jmbi.1995.0604; Skinner R, 1998, J MOL BIOL, V283, P9, DOI 10.1006/jmbi.1998.2083; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; TSAI MS, 1994, AM J HUM GENET, V54, P643; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang XY, 2002, NEUROBIOL AGING, V23, P377, DOI 10.1016/S0197-4580(01)00322-0; WILCOCK GK, 1982, J NEUROL SCI, V56, P343, DOI 10.1016/0022-510X(82)90155-1; Wilkins A, 2001, GLIA, V36, P48, DOI 10.1002/glia.1094; Williams AD, 2004, J MOL BIOL, V335, P833, DOI 10.1016/j.jmb.2003.11.008; Xue YF, 1998, STRUCT FOLD DES, V6, P627, DOI 10.1016/S0969-2126(98)00064-1; Yepes M, 2002, J CLIN INVEST, V109, P1571, DOI 10.1172/JCI200214308; Yepes M, 2000, BLOOD, V96, P569	56	66	67	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29268	29277		10.1074/jbc.M600690200	http://dx.doi.org/10.1074/jbc.M600690200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16849336	hybrid			2022-12-25	WOS:000240680500082
J	Oloo, EO; Fung, EY; Tieleman, DP				Oloo, Eliud O.; Fung, Eric Y.; Tieleman, D. Peter			The dynamics of the MgATP-driven closure of MalK, the energy-transducing subunit of the maltose ABC transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-CASSETTE TRANSPORTER; PARTICLE MESH EWALD; ATP-BINDING; ESCHERICHIA-COLI; MOLECULAR-DYNAMICS; NUCLEOTIDE-BINDING; INDUCER EXCLUSION; PHOSPHOTRANSFERASE SYSTEM; MEMBRANE-PROTEINS; STRUCTURAL MODEL	The nucleotide binding domains (NBDs) are the energy supplying subunits of ATP-binding cassette (ABC) proteins. They power transport by binding and hydrolyzing ATP. Tracing the pathway between different conformational states of the NBDs during ATP binding, hydrolysis, and release has, however, proven difficult. We have used molecular dynamics simulations to study the ATP-driven association of the NBDs of the maltose ABC transporter, MalK, based on the crystal structures of its open and semiopen dimers. When MgATP was introduced into the binding pockets, the semiopen dimer transitioned to a closed conformation, whereas the open dimer evolved to a semiopen state. In the absence of docked MgATP, however, the twin NBDs of both the open and semiopen starting configurations drifted further apart. Both the presence of MgATP and direct cross-interface protein-protein hydrogen bonds, primarily involving the D-loop, quite likely play a key role in initiating closure. The simulations of the MgATP-docked semiopen form indicate that completion of closure is driven mainly by cross-interface contacts between the gamma-phosphate of ATP and residues in the signature motif. Our simulations also give insight into possible interactions of MalK with the regulatory proteins MalT and enzyme IIA(glc).	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada	University of Calgary	Tieleman, DP (corresponding author), Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada.	tieleman@ucalgary.ca	Tieleman, D. Peter/A-4790-2011	Tieleman, D. Peter/0000-0001-5507-0688				Antes I, 2003, BIOPHYS J, V85, P695, DOI 10.1016/S0006-3495(03)74513-5; Ash WL, 2004, BBA-BIOMEMBRANES, V1666, P158, DOI 10.1016/j.bbamem.2004.04.012; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Bohm A, 2002, J BIOL CHEM, V277, P3708, DOI 10.1074/jbc.M107905200; Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Campbell JD, 2005, FEBS LETT, V579, P4193, DOI 10.1016/j.febslet.2005.06.027; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Chen J, 2001, P NATL ACAD SCI USA, V98, P1525, DOI 10.1073/pnas.041542498; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; DEAN DA, 1990, J BIOL CHEM, V265, P21005; Dean M, 2001, J LIPID RES, V42, P1007; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Ehrmann M, 1998, MOL MICROBIOL, V29, P685, DOI 10.1046/j.1365-2958.1998.00915.x; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; Feenstra KA, 1999, J COMPUT CHEM, V20, P786, DOI 10.1002/(SICI)1096-987X(199906)20:8<786::AID-JCC5>3.0.CO;2-B; Feese MD, 1997, BIOCHEMISTRY-US, V36, P16087, DOI 10.1021/bi971999e; Hansson T, 2002, CURR OPIN STRUC BIOL, V12, P190, DOI 10.1016/S0959-440X(02)00308-1; HERMANS J, 1984, BIOPOLYMERS, V23, P1513, DOI 10.1002/bip.360230807; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; Hubbard S. J., 1993, NACCESS; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Hunke S, 2000, J BIOL CHEM, V275, P15526, DOI 10.1074/jbc.275.20.15526; HURLEY JH, 1993, SCIENCE, V259, P673, DOI 10.1126/science.8430315; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Karplus M, 2002, NAT STRUCT BIOL, V9, P646, DOI 10.1038/nsb0902-646; KUHNAU S, 1991, J BACTERIOL, V173, P2180; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Liao JC, 2004, EUR BIOPHYS J BIOPHY, V33, P29, DOI 10.1007/s00249-003-0339-2; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Lu G, 2005, P NATL ACAD SCI USA, V102, P17969, DOI 10.1073/pnas.0506039102; MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Mourez M, 1997, EMBO J, V16, P3066, DOI 10.1093/emboj/16.11.3066; Oloo EO, 2004, J BIOL CHEM, V279, P45013, DOI 10.1074/jbc.M405084200; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Reyes CL, 2005, SCIENCE, V308, P1028, DOI 10.1126/science.1107733; Samanta S, 2003, J BIOL CHEM, V278, P35265, DOI 10.1074/jbc.M301171200; Scheffel F, 2005, FEBS LETT, V579, P2953, DOI 10.1016/j.febslet.2005.04.017; Scott WRP, 1999, J PHYS CHEM A, V103, P3596, DOI 10.1021/jp984217f; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Sondej M, 2000, BIOCHEMISTRY-US, V39, P2931, DOI 10.1021/bi9919596; Stein A, 2002, EUR J BIOCHEM, V269, P4074, DOI 10.1046/j.1432-1033.2002.03099.x; Valdar WSJ, 2001, J MOL BIOL, V313, P399, DOI 10.1006/jmbi.2001.5034; Verdon G, 2003, J MOL BIOL, V330, P343, DOI 10.1016/S0022-2836(03)00575-8; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382; Zaitseva J, 2005, EMBO J, V24, P1901, DOI 10.1038/sj.emboj.7600657	53	53	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28397	28407		10.1074/jbc.M513614200	http://dx.doi.org/10.1074/jbc.M513614200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16877382	hybrid			2022-12-25	WOS:000240534400077
J	Semba, S; Han, SY; Qin, HR; McCorkell, KA; Iliopoulos, D; Pekarsky, Y; Druck, T; Trapasso, F; Croce, CM; Huebner, K				Semba, Shuho; Han, Shuang-Yin; Qin, Haiyan R.; McCorkell, Kelly A.; Iliopoulos, Dimitrios; Pekarsky, Yuri; Druck, Teresa; Trapasso, Francesco; Croce, Carlo M.; Huebner, Kay			Biological functions of mammalian NIT1, the counterpart of the invertebrate NitFhit Rosetta Stone protein, a possible tumor suppressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION INDUCES APOPTOSIS; FHIT GENE; CANCER-CELLS; LUNG; TUMORIGENICITY; NITRILASE; RESTORATION; CARCINOMA; BREAST; 3P14.2	The "Rosetta Stone" hypothesis proposes that the existence of a fusion protein in some organisms predicts that the separate polypeptides function in the same biochemical pathway in other organisms and may physically interact. In Drosophila melanogaster and Caenorhabditis elegans, NitFhit protein is composed of two domains, a fragile histidine triad homolog and a bacterial and plant nitrilase homolog. Weassessed the biological effects of mammalian Nit1 expression in comparison with Fhit and observed that: 1) Nit1 expression was observed in most normal tissues and overlapped partially with Fhit expression; 2) Nit1-deficient mouse kidney cells exhibited accelerated proliferation, resistance to DNA damagestress, and increased cyclin D1 expression; 3) cyclin D1 was up-regulated in Nit1 null mammary gland and skin; 4) Nit1 overexpression induced caspase-dependent apoptosis in vitro; and 5) Nit1 allele deficiency led to increased incidence of N-nitrosomethylbenzylamine-induced murine forestomach tumors. Thus, the biological effects of Nit1 expression are similar to Fhit effects. Adenoviruses carrying recombinant NIT1 and FHIT induced apoptosis in Fhit- and Nit1-deficient cells, respectively, suggesting that Nit1-Fhit interaction is not essential for function of either protein. The results suggest that Nit1 and Fhit share tumor suppressor signaling pathways, while localization of the NIT1 gene at a stable, rather than fragile, chromosome site explains the paucity of gene alterations and infrequent loss of expression of the NIT1 gene inhuman malignancies.	Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Stanford Univ, Med Ctr, Stanford, CA 94305 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Magna Graecia Univ Catanzaro, Med Sch Catanzaro, Dept Expt & Clin Med, I-88100 Catanzaro, Italy	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Stanford University; Jefferson University; Magna Graecia University of Catanzaro	Huebner, K (corresponding author), Ohio State Univ, Ctr Comprehens Canc, 455C Wiseman Hall,410 W 12th Ave, Columbus, OH 43210 USA.	kay.huebner@osumc.edu	Iliopoulos, Dimitrios/AAE-9106-2019; Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	NCI NIH HHS [P01 CA77738, P01 CA78890] Funding Source: Medline; NHLBI NIH HHS [T32-HL07780] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077738, P01CA078890] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007780] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Casimiro I, 2001, PLANT CELL, V13, P843, DOI 10.1105/tpc.13.4.843; Croce CM, 1999, J CLIN ONCOL, V17, P1618, DOI 10.1200/JCO.1999.17.5.1618; Cutler SR, 2005, BMC PLANT BIOL, V5, DOI 10.1186/1471-2229-5-4; Deans AJ, 2004, ONCOGENE, V23, P6136, DOI 10.1038/sj.onc.1207805; Dumon KR, 2001, CANCER RES, V61, P4827; Enright AJ, 1999, NATURE, V402, P86, DOI 10.1038/47056; Enright AJ, 2001, GENOME BIOL, V2; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; Fujishita T, 2004, BRIT J CANCER, V91, P1571, DOI 10.1038/sj.bjc.6602182; Garrison PN, 2005, BIOCHEMISTRY-US, V44, P6286, DOI 10.1021/bi047670s; Grsic-Rausch S, 2000, PLANT PHYSIOL, V122, P369, DOI 10.1104/pp.122.2.369; Hu BC, 2005, J CELL PHYSIOL, V202, P518, DOI 10.1002/jcp.20139; Huebner K, 2003, BRIT J CANCER, V88, P1501, DOI 10.1038/sj.bjc.6600937; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Iliopoulos D, 2005, ONCOGENE, V24, P1625, DOI 10.1038/sj.onc.1208398; Ishii H, 2001, CANCER RES, V61, P1578; Ji L, 1999, CANCER RES, V59, P3333; Junttila TT, 2003, CLIN CANCER RES, V9, P5346; Kuroki T, 2003, CANCER RES, V63, P3724; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Normanly J, 1997, PLANT CELL, V9, P1781, DOI 10.1105/tpc.9.10.1781; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Ottey M, 2004, BRIT J CANCER, V91, P1669, DOI 10.1038/sj.bjc.6602058; Pace HC, 1998, P NATL ACAD SCI USA, V95, P5484, DOI 10.1073/pnas.95.10.5484; Pace HC, 2000, CURR BIOL, V10, P907, DOI 10.1016/S0960-9822(00)00621-7; Pace HC, 2001, GENOME BIOL, V2; Pekarsky Y, 2004, P NATL ACAD SCI USA, V101, P3775, DOI 10.1073/pnas.0400481101; Pekarsky Y, 1998, P NATL ACAD SCI USA, V95, P8744, DOI 10.1073/pnas.95.15.8744; Qi C, 2004, J BIOL CHEM, V279, P33696, DOI 10.1074/jbc.M401266200; Reinhardt D, 2000, PLANT CELL, V12, P507, DOI 10.1105/tpc.12.4.507; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; Semba S, 2006, ONCOGENE, V25, P2860, DOI 10.1038/sj.onc.1209323; Sevignani C, 2003, CANCER RES, V63, P1183; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Trapasso F, 2003, P NATL ACAD SCI USA, V100, P1592, DOI 10.1073/pnas.0437915100; Veitia RA, 2002, GENOME BIOL, V3; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898; ZANESI N, 1995, CANCER RES, V65, P6576	39	36	39	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28244	28253		10.1074/jbc.M603590200	http://dx.doi.org/10.1074/jbc.M603590200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16864578	hybrid			2022-12-25	WOS:000240534400062
J	Garg, RP; Gonzalez, JM; Parry, RJ				Garg, Ram P.; Gonzalez, Jose M.; Parry, Ronald J.			Biochemical characterization of VlmL, a seryl-tRNA synthetase encoded by the valanimycin biosynthetic gene cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-VIRIDIFACIENS MG456-HF10; ISOBUTYLAMINE N-HYDROXYLASE; ELAIOMYCIN; PRODUCER; OVEREXPRESSION; ANTIBIOTICS; CLONING	Previous studies have shown that the valanimycin producer Streptomyces viridifaciens contains two genes encoding proteins that are similar to seryl- tRNA synthetases (SerRSs). One of these proteins (SvsR) is presumed to function in protein biosynthesis, because it exhibits a high degree of similarity to the single SerRS of Streptomyces coelicolor. The second protein (VlmL), which exhibits a low similarity to the S. coelicolor SerRS, is hypothesized to play a role in valanimycin biosynthesis, because the vlmL gene resides within the valanimycin biosynthetic gene cluster. To investigate the role of VlmL in valanimycin biosynthesis, VlmL and SvsR have been overproduced in soluble form in Escherichia coli, and the biochemical properties of both proteins have been analyzed and compared. Both proteins were found to catalyze a serine- dependent exchange of P-32-labeled pyrophosphate into ATP and to aminoacylate total E. coli tRNA with L-serine. Kinetic parameters for the two enzymes show that SvsR is catalytically more efficient than VlmL. The results of these experiments suggest that the role of VlmL in valanimycin biosynthesis is to produce seryl-tRNA, which is then utilized for a subsequent step in the biosynthetic pathway. Orthologs of VlmL were identified in two other actinomycetes species that also contain orthologs of the S. coelicolor SerRS. The significance of these findings is herein discussed.	Rice Univ, Dept Chem, Houston, TX 77005 USA; Univ La Laguna, Fac Farm, Dept Microbiol & Biol Celular, E-38206 San Cristobal la Laguna, Tenerife, Spain	Rice University; Universidad de la Laguna	Parry, RJ (corresponding author), Rice Univ, Dept Chem, Houston, TX 77005 USA.	parry@rice.edu	Gonzalez, Jose M./C-3333-2013	Gonzalez, Jose M./0000-0002-9926-3323	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053818] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM053818] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Couch R, 2002, BIOTECHNIQUES, V32, P1230, DOI 10.2144/02326bm03; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Francklyn C, 2002, RNA, V8, P1363, DOI 10.1017/S1355838202021180; FUJIU M, 1994, J ANTIBIOT, V47, P833, DOI 10.7164/antibiotics.47.833; Garg RP, 2002, MOL MICROBIOL, V46, P505, DOI 10.1046/j.1365-2958.2002.03169.x; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; IMAMURA N, 1989, J ANTIBIOT, V42, P156, DOI 10.7164/antibiotics.42.156; JAHN D, 1992, TRENDS BIOCHEM SCI, V17, P215, DOI 10.1016/0968-0004(92)90380-R; LANGLEY BW, 1951, CHEM IND-LONDON, P75; LYTHGOE B, 1949, J CHEM SOC, P2716, DOI 10.1039/jr9490002716; Ma YQ, 2000, MICROBIOL-UK, V146, P345, DOI 10.1099/00221287-146-2-345; Martinis SA, 1999, BIOCHIMIE, V81, P683, DOI 10.1016/S0300-9084(99)80126-6; Parry RJ, 1997, J BACTERIOL, V179, P409, DOI 10.1128/jb.179.2.409-416.1997; PARRY RJ, 1992, J AM CHEM SOC, V114, P10062, DOI 10.1021/ja00051a049; Parry RJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P47, DOI 10.1006/abbi.1996.9857; Parry RJ, 1997, J BIOL CHEM, V272, P23303, DOI 10.1074/jbc.272.37.23303; RIGGS NV, 1956, CHEM IND-LONDON, P926; Schimmel P, 2000, TRENDS BIOCHEM SCI, V25, P207, DOI 10.1016/S0968-0004(00)01553-X; STEVENS CL, 1958, J AM CHEM SOC, V80, P6088, DOI 10.1021/ja01555a048; STEVENS CL, 1959, J AM CHEM SOC, V81, P1435, DOI 10.1021/ja01515a037; STEVENS CL, 1956, J AM CHEM SOC, V78, P3229, DOI 10.1021/ja01594a078; TAKAHASHI Y, 1989, J ANTIBIOT, V42, P1541, DOI 10.7164/antibiotics.42.1541; Tao T, 2003, ORG LETT, V5, P1213, DOI 10.1021/ol0340989; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; YAMATO M, 1986, J ANTIBIOT, V39, P184	29	31	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26785	26791		10.1074/jbc.M603675200	http://dx.doi.org/10.1074/jbc.M603675200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16857674	hybrid			2022-12-25	WOS:000240397700005
J	Liu, FL; Yoo, BC; Lee, JY; Pan, W; Harmon, AC				Liu, Fenglong; Yoo, Byung-Chun; Lee, Jung-Youn; Pan, Wei; Harmon, Alice C.			Calcium-regulated phosphorylation of soybean serine acetyltransferase in response to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; O-ACETYLSERINE SULFHYDRYLASE; CYSTEINE BIOSYNTHESIS; PROTEIN-KINASE; ARABIDOPSIS-THALIANA; MOLECULAR-CLONING; ESCHERICHIA-COLI; GLUTATHIONE METABOLISM; SULFUR ASSIMILATION; EXPRESSION ANALYSIS	Glycinemaxserine acetyltransferase 2;1 (GmSerat2;1) is a member of a family of enzymes that catalyze the first reaction in the biosynthesis of cysteine from serine. It was identified by interaction cloning as a protein that binds to calcium-dependent protein kinase. In vitro phosphorylation assays showed that GmSerat2; 1, but not GmSerat2;1 mutants (S378A or S378D), were phosphorylated by soybean calcium-dependent protein kinase isoforms. Recombinant GmSerat2;1 was also phosphorylated by soybean cell extract in a Ca2+-dependent manner. Phosphorylation of recombinant GmSerat2;1 had no effect on its catalytic activity but rendered the enzyme in sensitive to the feedback inhibition by cysteine. In transient expression analyses, fluorescently tagged GmSerat2;1 localized in the cytoplasm and with plastids. Phosphorylation state-specific antibodies showed that an increase in GmSerat2;1 phosphorylation occurred in vivo within 5 min of treatment of soybean cells with 0.5 mM hydrogen peroxide, whereas GmSerat2;1 protein synthesis was not significantly induced until 1 h after oxidant challenge. Internal Ca2+ was required in the induction of both GmSerat2;1 phosphorylation and synthesis. Treatment of cells with calcium antagonists showed that externally derived Ca2+ was important for retaining GmSerat2;1 at a basal level of phosphorylation but was not necessary for its hydrogen peroxide-induced synthesis. Protein phosphatase type 1, but not type 2A or alkaline phosphatase, dephosphorylated native GmSerat2;1 in vitro. These results support the hypothesis that GmSerat2;1 is regulated by calcium-dependent protein kinase phosphorylation in vivo and suggest that increased GmSerat2;1 synthesis and phosphorylation in response to active oxygen species could play a role in anti-oxidative stress response.	Univ Florida, Program Plant Mol & Cellular Biol, Gainesville, FL 32611 USA; Univ Florida, Dept Bot, Gainesville, FL 32611 USA; Univ Delaware, Dept Plant & Soil Sci, Newark, DE 19711 USA; Univ Delaware, Delaware Biotechnol Inst, Newark, DE 19711 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Delaware; University of Delaware	Harmon, AC (corresponding author), Univ Florida, Canc Genet Complex,POB 103610, Gainesville, FL 32610 USA.	harmon@ufl.edu	Pan, Wei/G-7547-2015	Pan, Wei/0000-0002-8827-8650; Lee, Jinkee/0000-0001-5590-0549; Lee, Jung-Youn/0000-0003-4604-7974	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015588] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR-15588] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bachmann M, 1996, PLANT CELL, V8, P505, DOI 10.1105/tpc.8.3.505; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Blume B, 2000, PLANT CELL, V12, P1425, DOI 10.1105/tpc.12.8.1425; Bonner ER, 2005, J BIOL CHEM, V280, P38803, DOI 10.1074/jbc.M505313200; BUWALDA F, 1993, J PLANT PHYSIOL, V142, P281, DOI 10.1016/S0176-1617(11)80423-2; Cessna SG, 2001, PLANTA, V214, P126, DOI 10.1007/s004250100596; Chronis D, 2004, PLANTA, V218, P417, DOI 10.1007/s00425-003-1123-3; Dammann C, 2003, PLANT PHYSIOL, V132, P1840, DOI 10.1104/pp.103.020008; DEKOK LJ, 1986, PHYSIOL PLANTARUM, V68, P477; DENK D, 1987, J GEN MICROBIOL, V133, P515; DHINDSA RS, 1991, PLANT PHYSIOL, V95, P648, DOI 10.1104/pp.95.2.648; Droux M, 2003, PLANT PHYSIOL BIOCH, V41, P619, DOI 10.1016/S0981-9428(03)00083-4; Droux M, 1998, EUR J BIOCHEM, V255, P235, DOI 10.1046/j.1432-1327.1998.2550235.x; FARAGO S, 1994, J PLANT PHYSIOL, V144, P433, DOI 10.1016/S0176-1617(11)82119-X; HARMON AC, 1994, BIOCHEMISTRY-US, V33, P7278, DOI 10.1021/bi00189a032; Harmon AC, 2000, TRENDS PLANT SCI, V5, P154, DOI 10.1016/S1360-1385(00)01577-6; Harper JF, 2005, NAT REV MOL CELL BIO, V6, P555, DOI 10.1038/nrm1679; He JX, 2002, P NATL ACAD SCI USA, V99, P10185, DOI 10.1073/pnas.152342599; Herschbach C, 2000, PLANT PHYSIOL, V124, P461, DOI 10.1104/pp.124.1.461; Howarth JR, 2003, PLANT MOL BIOL, V51, P589, DOI 10.1023/A:1022349623951; Huang B, 2005, J BACTERIOL, V187, P3201, DOI 10.1128/JB.187.9.3201-3205.2005; Inoue K, 1999, EUR J BIOCHEM, V266, P220, DOI 10.1046/j.1432-1327.1999.00847.x; JONES DH, 1991, BIOTECHNIQUES, V10, P62; JONESMOR.MC, 1968, BIOCHEM J, V110, P597, DOI 10.1042/bj1100597; Kawano T, 2000, PLANT CELL PHYSIOL, V41, P1251, DOI 10.1093/pcp/pcd052; Kawashima CG, 2005, PLANT PHYSIOL, V137, P220, DOI 10.1104/pp.104.045377; Knight H, 1996, PLANT CELL, V8, P489, DOI 10.1105/tpc.8.3.489; Knight H, 1997, PLANT J, V12, P1067, DOI 10.1046/j.1365-313X.1997.12051067.x; Kocsy G, 1996, PLANTA, V198, P365, DOI 10.1007/BF00620052; Kocsy G, 2001, PLANT PHYSIOL, V127, P1147, DOI 10.1104/pp.010107; Kopriva S, 2006, ANN BOT-LONDON, V97, P479, DOI 10.1093/aob/mcl006; KREDICH NM, 1966, J BIOL CHEM, V241, P4955; Lecourieux D, 2002, PLANT CELL, V14, P2627, DOI 10.1105/tpc.005579; Lee JY, 2005, PLANT CELL, V17, P2817, DOI 10.1105/tpc.105.034330; Lee JY, 1998, BIOCHEMISTRY-US, V37, P6801, DOI 10.1021/bi980062q; Li JX, 2002, NATURE, V418, P793, DOI 10.1038/nature00936; Liszewska F, 2001, ACTA BIOCHIM POL, V48, P647; MacKintosh C, 2001, CELL MOL LIFE SCI, V58, P205, DOI 10.1007/PL00000848; May MJ, 1996, PLANT PHYSIOL, V110, P1367, DOI 10.1104/pp.110.4.1367; McManus MT, 2005, PHYTOCHEMISTRY, V66, P1407, DOI 10.1016/j.phytochem.2005.04.034; Murillo M, 1995, CELL MOL BIOL RES, V41, P425; NAKAMURA K, 1987, PLANT CELL PHYSIOL, V28, P885, DOI 10.1093/oxfordjournals.pcp.a077370; Noctor G, 2002, J EXP BOT, V53, P1283, DOI 10.1093/jexbot/53.372.1283; Noctor G, 1996, PLANT PHYSIOL, V112, P1071, DOI 10.1104/pp.112.3.1071; Noji M, 1998, J BIOL CHEM, V273, P32739, DOI 10.1074/jbc.273.49.32739; Noji M, 2002, AMINO ACIDS, V22, P231, DOI 10.1007/s007260200011; Noji M, 2001, PLANT CELL PHYSIOL, V42, P627, DOI 10.1093/pcp/pce078; Olsen LR, 2004, BIOCHEMISTRY-US, V43, P6013, DOI 10.1021/bi0358521; PRICE AH, 1994, PLANT CELL, V6, P1301, DOI 10.1105/tpc.6.9.1301; Rentel MC, 2004, PLANT PHYSIOL, V135, P1471, DOI 10.1104/pp.104.042663; SAITO K, 1995, J BIOL CHEM, V270, P16321, DOI 10.1074/jbc.270.27.16321; SAITO K, 1994, PLANT PHYSIOL, V106, P887, DOI 10.1104/pp.106.3.887; Saito K, 2000, CURR OPIN PLANT BIOL, V3, P188, DOI 10.1016/S1369-5266(00)00063-7; Sirko A, 2004, J EXP BOT, V55, P1881, DOI 10.1093/jxb/erh151; SMITH IK, 1969, BIOCHEM BIOPH RES CO, V35, P939, DOI 10.1016/0006-291X(69)90715-3; STONE JM, 1994, SCIENCE, V266, P793, DOI 10.1126/science.7973632; Urano Y, 2000, GENE, V257, P269, DOI 10.1016/S0378-1119(00)00399-1; Wirtz M, 2003, AMINO ACIDS, V24, P195, DOI 10.1007/s00726-002-0313-9	58	37	46	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27405	27415		10.1074/jbc.M604548200	http://dx.doi.org/10.1074/jbc.M604548200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16854983	hybrid			2022-12-25	WOS:000240397700067
J	Sikder, D; Johnston, SA; Kodadek, T				Sikder, Devanjan; Johnston, Stephen Albert; Kodadek, Thomas			Widespread, but non-identical, association of proteasomal 19 and 20 S proteins with yeast chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; NUCLEOTIDE EXCISION-REPAIR; REGULATORY PARTICLE; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; 26S PROTEASOME; TRANSCRIPTION; ACTIVATION; TURNOVER; COMPLEX	It has recently become clear that various aspects of nucleic acid metabolism and the ubiquitin-proteasome pathway intersect in several direct and important ways. To begin to assess the scope of some of these activities in the yeast Saccharomyces cerevisiae, we assessed the physical and functional association of proteasomal proteins from both the 20 S core and 19 S regulatory particles with similar to 6400 yeast genes. Genome-wide chromatin immunoprecipitation analyses revealed that proteasome substituents are associated with the majority of yeast genes. Many of these associations correlated strongly with expression levels and the presence of RNA polymerase II. Although the data support the presence of the intact 26 S proteasome on most genes, several hundred yeast genes were cross-linked to either the 20 or 19 S complex but not both, consistent with some degree of independent function for the proteasomal subcomplexes.	Univ Texas, SW Med Ctr, Div Translat Res, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kodadek, T (corresponding author), Univ Texas, SW Med Ctr, Ctr Biomed Invent, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Thomas.Kodadek@utsouthwestern.edu		Kodadek, Thomas/0000-0003-1930-4795	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066380] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HV-28185] Funding Source: Medline; NIGMS NIH HHS [GM066380] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auld KL, 2006, MOL CELL, V21, P861, DOI 10.1016/j.molcel.2006.02.020; Babbitt SE, 2005, CELL, V121, P553, DOI 10.1016/j.cell.2005.03.028; Bajorek M, 2003, CURR BIOL, V13, P1140, DOI 10.1016/S0960-9822(03)00417-2; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Collins GA, 2006, CURR OPIN GENET DEV, V16, P197, DOI 10.1016/j.gde.2006.02.009; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; DEMBLARAJPAL N, 2004, BIOCHIM BIOPHYS ACTA, V1680, P33; Ezhkova E, 2004, MOL CELL, V13, P435, DOI 10.1016/S1097-2765(04)00026-7; Ferdous A, 2002, BIOCHEMISTRY-US, V41, P12798, DOI 10.1021/bi020425t; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Fleming JA, 2002, P NATL ACAD SCI USA, V99, P1461, DOI 10.1073/pnas.032516399; Gillette TG, 2004, P NATL ACAD SCI USA, V101, P5904, DOI 10.1073/pnas.0305411101; Gillette TG, 2001, GENE DEV, V15, P1528, DOI 10.1101/gad.869601; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1999, MOL BIOL REP, V26, P21, DOI 10.1023/A:1006928316738; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Horak CE, 2002, METHOD ENZYMOL, V350, P469, DOI 10.1016/S0076-6879(02)50979-4; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; Lee DY, 2005, CELL, V123, P423, DOI 10.1016/j.cell.2005.08.015; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; Lipford JR, 2005, NATURE, V438, P113, DOI 10.1038/nature04098; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Morris MC, 2003, NATURE, V423, P1009, DOI 10.1038/nature01720; Nawaz Z, 2004, MOL ENDOCRINOL, V18, P493, DOI 10.1210/me.2003-0388; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; Ottosen S, 2002, SCIENCE, V296, P479, DOI 10.1126/science.1071270; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Russell SJ, 1999, J BIOL CHEM, V274, P21943, DOI 10.1074/jbc.274.31.21943; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Sauer RT, 2004, CELL, V119, P9, DOI 10.1016/j.cell.2004.09.020; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Sikder D, 2005, CURR OPIN CHEM BIOL, V9, P38, DOI 10.1016/j.cbpa.2004.12.008; Sulahian R, 2006, NUCLEIC ACIDS RES, V34, P1351, DOI 10.1093/nar/gkl012; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; Tanaka K, 1998, IMMUNOL REV, V163, P161; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; XU QL, 1995, MOL CELL BIOL, V15, P6025	42	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27346	27355		10.1074/jbc.M604706200	http://dx.doi.org/10.1074/jbc.M604706200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16837462	hybrid			2022-12-25	WOS:000240397700061
J	Wang, XD; Bryan, NS; MacArthur, PH; Rodriguez, J; Gladwin, MT; Feelisch, M				Wang, Xunde; Bryan, Nathan S.; MacArthur, Peter H.; Rodriguez, Juan; Gladwin, Mark T.; Feelisch, Martin			Measurement of nitric oxide levels in the red cell - Validation of tri-iodide-based chemiluminescence with acid-sulfanilamide pretreatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-NITROSOTHIOLS; BLOOD-CELLS; NO; NITROSOHEMOGLOBIN; NITROSOALBUMIN; HEMOGLOBIN; FLOW; TRANSDUCTION; PROTEINS; IRON	The tri-iodide-based chemiluminescence assay is the most widely used methodology for the detection of S-nitrosothiols (RSNOs) in biological samples. Because of the low RSNO levels detected in a number of biological compartments using this assay, criticism has been raised that this method underestimates the true values in biological samples. This claim is based on the beliefs that (i) acidified sulfanilamide pretreatment, required to remove nitrite, leads to RSNO degradation and (ii) that there is auto- capture of released NO by heme in the reaction vessel. Because our laboratories have used this assay extensively without ever encountering evidence that corroborated these claims, we sought to experimentally address these issues using several independent techniques. We find that RSNOs of glutathione, cysteine, albumin, and hemoglobin are stable in acidified sulfanilamide as determined by the tri-iodide method, copper/cysteine assay, Griess-Saville assay and spectrophotometric analysis. Quantitatively there was no difference in S-nitroso-hemoglobin (SNOHb) or S-nitroso-albumin (SNOA1b) using the tri-iodide method and a recently described modified assay using a ferricyanide-enhanced reaction mix at biologically relevant NO: heme ratios. Levels of SNOHb detected in human blood ranged from 20-100 nM with no arterial-venous gradient. We further find that 90% of the total NO-related signal in blood is caused by erythrocytic nitrite, which may partly be bound to hemoglobin. We conclude that all claims made thus far that the tri-iodide assay underestimates RSNO levels are unsubstantiated and that this assay remains the "gold standard" for sensitive and specific measurement of RSNOs in biological matrices.	NHLBI, Vasc Med Branch, NIH, Bethesda, MD 20892 USA; Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Gladwin, MT (corresponding author), NHLBI, Vasc Med Branch, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	mgladwin@nhlbi.nih.gov; feelisch@bu.edu	Feelisch, Martin/C-3042-2008	Feelisch, Martin/0000-0003-2320-1158	Intramural NIH HHS Funding Source: Medline; NCRR NIH HHS [P20 RR16456] Funding Source: Medline; NHLBI NIH HHS [HL 69029] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016456] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069029] Funding Source: NIH RePORTER; CLINICAL CENTER [Z01CL008050] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); CLINICAL CENTER		Baker PRS, 2004, P NATL ACAD SCI USA, V101, P11577, DOI 10.1073/pnas.0402587101; Bjorne H, 2004, J CLIN INVEST, V113, P106, DOI [10.1172/JCI200419019, 10.1172/JCI19019]; Bryan NS, 2004, NITRIC OXIDE-BIOL CH, V10, P221, DOI 10.1016/j.niox.2004.04.008; Bryan NS, 2005, NAT CHEM BIOL, V1, P290, DOI 10.1038/nchembio734; Crawford JH, 2004, BLOOD, V104, P1375, DOI 10.1182/blood-2004-03-0880; Daiber A, 2003, NITRIC OXIDE-BIOL CH, V9, P44, DOI 10.1016/j.niox.2003.08.002; Dejam A, 2005, BLOOD, V106, P734, DOI 10.1182/blood-2005-02-0567; Dejam A, 2003, FREE RADICAL BIO MED, V35, P1551, DOI 10.1016/j.freeradbiomed.2003.09.009; Doctor A, 2005, P NATL ACAD SCI USA, V102, P5709, DOI 10.1073/pnas.0407490102; DRABKIN DL, 1971, P NATL ACAD SCI USA, V68, P609, DOI 10.1073/pnas.68.3.609; Feelisch M, 2002, FASEB J, V16, P1775, DOI 10.1096/fj.02-0363com; Funai EF, 1997, BIOCHEM BIOPH RES CO, V239, P875, DOI 10.1006/bbrc.1997.7565; Giustarini D, 2004, TRENDS PHARMACOL SCI, V25, P311, DOI 10.1016/j.tips.2004.04.009; Giustarini D, 2003, CLIN CHIM ACTA, V330, P85, DOI 10.1016/S0009-8981(03)00046-9; Gladwin MT, 2002, J BIOL CHEM, V277, P27818, DOI 10.1074/jbc.M203236200; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P11482, DOI 10.1073/pnas.97.21.11482; Gladwin MT, 2004, CIRC RES, V94, P851, DOI 10.1161/01.RES.0000126697.64381.37; Ishibashi T, 2000, NITRIC OXIDE-BIOL CH, V4, P516, DOI 10.1006/niox.2000.0302; Kleinbongard P, 2006, BLOOD, V107, P2943, DOI 10.1182/blood-2005-10-3992; Marley R, 2000, FREE RADICAL RES, V32, P1, DOI 10.1080/10715760000300011; McMahon TJ, 2002, NAT MED, V8, P711, DOI 10.1038/nm718; Rassaf T, 2002, J CLIN INVEST, V109, P1241, DOI 10.1172/JCI200214995; Rassaf T, 2004, FREE RADICAL BIO MED, V36, P413, DOI 10.1016/j.freeradbiomed.2003.11.011; Rassaf T, 2003, NAT MED, V9, P481, DOI 10.1038/nm0503-481; Rassaf T, 2002, FREE RADICAL BIO MED, V33, P1590, DOI 10.1016/S0891-5849(02)01183-8; Rogers SC, 2005, J BIOL CHEM, V280, P26720, DOI 10.1074/jbc.M501179200; Rossi R, 2001, CIRC RES, V89; Samouilov A, 1998, ANAL BIOCHEM, V258, P322, DOI 10.1006/abio.1998.2609; Schopfer FJ, 2005, J BIOL CHEM, V280, P19289, DOI 10.1074/jbc.M414689200; Singel DJ, 2005, ANNU REV PHYSIOL, V67, P99, DOI 10.1146/annurev.physiol.67.060603.090918; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Stamler JS, 2004, CIRC RES, V94, P414, DOI 10.1161/01.RES.0000122071.55721.BC; Svensson PH, 2003, CHEM REV, V103, P1649, DOI 10.1021/cr0204101; Tsikas D, 2003, NITRIC OXIDE-BIOL CH, V9, P53, DOI 10.1016/S1089-8603(03)00044-2; Tsikas D, 2002, CIRC RES, V90, pE39; Tyurin VA, 2001, CIRC RES, V88, P1210, DOI 10.1161/hh1101.092179; Wang XD, 2004, P NATL ACAD SCI USA, V101, P11477, DOI 10.1073/pnas.0402201101; Xu XL, 2003, P NATL ACAD SCI USA, V100, P11303, DOI 10.1073/pnas.2033883100; Yang BK, 2003, FREE RADICAL RES, V37, P1, DOI 10.1080/1071576021000033112; Zhang YH, 2004, P NATL ACAD SCI USA, V101, P7891, DOI 10.1073/pnas.0401167101	41	71	71	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26994	27002		10.1074/jbc.M603953200	http://dx.doi.org/10.1074/jbc.M603953200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16845122	hybrid			2022-12-25	WOS:000240397700026
J	Pak, JE; Arnoux, P; Zhou, SH; Sivarajah, P; Satkunarajah, M; Xing, XK; Rini, JM				Pak, John E.; Arnoux, Pascal; Zhou, Sihong; Sivarajah, Prashanth; Satkunarajah, Malathy; Xing, Xuekun; Rini, James M.			X-ray crystal structure of leukocyte type core 2 beta 1,6-N-acetylglucosaminyltransferase - Evidence for a convergence of metal ion-independent glycosyltransferase mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE 2 BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE; ELECTRON-DENSITY MAPS; SULFATE BIOSYNTHESIS; MOLECULAR-CLONING; MUCIN SYNTHESIS; UDP-GLUCOSE; CHO-CELLS; EXPRESSION; BETA-6-N-ACETYLGLUCOSAMINYLTRANSFERASE; GLUCOSYLTRANSFERASE	Leukocyte type core 2 beta 1,6-N-acetylglucosaminyltransferase (C2GnT-L) is a key enzyme in the biosynthesis of branched O-glycans. It is an inverting, metal ion-independent family 14 glycosyltransferase that catalyzes the formation of the core 2 O-glycan (Gal beta 1-3[GlcNAc beta 1-6]GalNAc-O-Ser/ Thr) from its donor and acceptor substrates, UDP-GlcNAc and the core 1 O-glycan (Gal beta 1-3GalNAc-O-Ser/ Thr), respectively. Reported here are the x-ray crystal structures of murine C2GnT-L in the absence and presence of the acceptor substrate Gal beta 1 -3GalNAc at 2.0 and 2.7 angstrom resolution, respectively. C2GnT-L was found to possess the GT-A fold; however, it lacks the characteristic metal ion binding DXD motif. The Gal beta 1-3GalNAc complex defines the determinants of acceptor substrate binding and shows that Glu-320 corresponds to the structurally conserved catalytic base found in other inverting GT-A fold glycosyltransferases. Comparison of the C2GnT-L structure with that of other GT-A fold glycosyltransferases further suggests that Arg-378 and Lys-401 serve to electrostatically stabilize the nucleoside disphosphate leaving group, a role normally played by metalionin GT-A structures. The use of basic amino acid side chains in this way is strikingly similar to that seen in a number of metal ion-independent GT-B fold glycosyltransferases and suggests a convergence of catalytic mechanism shared by both GT-A and GT-B fold glycosyltransferases.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Rini, JM (corresponding author), Univ Toronto, Dept Mol & Med Genet, Med Sci Bldg,Rm 5360,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	james.rini@utoronto.ca	Arnoux, Pascal/B-3600-2010	ARNOUX, Pascal/0000-0003-4609-4893				BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Boix E, 2002, J BIOL CHEM, V277, P28310, DOI 10.1074/jbc.M202631200; Bourne Y, 2001, CURR OPIN STRUC BIOL, V11, P593, DOI 10.1016/S0959-440X(00)00253-0; BROCKHAUSEN I, 1986, EUR J BIOCHEM, V157, P463, DOI 10.1111/j.1432-1033.1986.tb09690.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buschiazzo A, 2004, EMBO J, V23, P3196, DOI 10.1038/sj.emboj.7600324; Chiu CPC, 2004, NAT STRUCT MOL BIOL, V11, P163, DOI 10.1038/nsmb720; Claiborne A, 2001, ADV PROTEIN CHEM, V58, P215; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; El-Battari A, 2003, GLYCOBIOLOGY, V13, P941, DOI 10.1093/glycob/cwg117; Flint J, 2005, NAT STRUCT MOL BIOL, V12, P608, DOI 10.1038/nsmb950; Garinot-Schneider C, 2000, J BIOL CHEM, V275, P31407, DOI 10.1074/jbc.M004524200; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; Gibson RP, 2004, J BIOL CHEM, V279, P1950, DOI 10.1074/jbc.M307643200; Gibson RP, 2002, CHEM BIOL, V9, P1337, DOI 10.1016/S1074-5521(02)00292-2; Hagisawa S, 2005, GLYCOBIOLOGY, V15, P1016, DOI 10.1093/glycob/cwi086; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; Jabs A, 1999, J MOL BIOL, V286, P291, DOI 10.1006/jmbi.1998.2459; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawashima H, 2005, NAT IMMUNOL, V6, P1096, DOI 10.1038/ni1259; KLEYWEGT GJ, 1994, CCP4 P, P59; KUHNS W, 1993, GLYCOCONJUGATE J, V10, P381, DOI 10.1007/BF00731043; LAFORTELLE E, 1997, METHOD ENZYMOL, V276, P472; Lairson LL, 2004, J BIOL CHEM, V279, P28339, DOI 10.1074/jbc.M400451200; Lairson LL, 2004, CHEM COMMUN, P2243, DOI 10.1039/b406490a; Lariviere L, 2003, J MOL BIOL, V330, P1077, DOI 10.1016/S0022-2836(03)00635-1; Lowe JB, 2003, CURR OPIN CELL BIOL, V15, P531, DOI 10.1016/j.ceb.2003.08.002; Lutteke T, 2005, NUCLEIC ACIDS RES, V33, pD242; Machida E, 2001, CANCER RES, V61, P2226; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mulichak AM, 2004, BIOCHEMISTRY-US, V43, P5170, DOI 10.1021/bi036130c; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Offen W, 2006, EMBO J, V25, P1396, DOI 10.1038/sj.emboj.7600970; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Pedersen LC, 2003, J BIOL CHEM, V278, P14420, DOI 10.1074/jbc.M210532200; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Qasba PK, 2005, TRENDS BIOCHEM SCI, V30, P53, DOI 10.1016/j.tibs.2004.11.005; Ramakrishnan B, 2001, J MOL BIOL, V310, P205, DOI 10.1006/jmbi.2001.4757; RINI JM, 1995, CURR OPIN STRUC BIOL, V5, P617, DOI 10.1016/0959-440X(95)80053-0; ROPP PA, 1991, J BIOL CHEM, V266, P23863; Schwientek T, 2000, J BIOL CHEM, V275, P11106, DOI 10.1074/jbc.275.15.11106; SEGEL IH, 1993, ENZYME KINETICS, P818; Shimodaira K, 1997, CANCER RES, V57, P5201; Sinacore MS, 2000, MOL BIOTECHNOL, V15, P249, DOI 10.1385/MB:15:3:249; Sperandio M, 2001, BLOOD, V97, P3812, DOI 10.1182/blood.V97.12.3812; Takahashi T, 2000, GLYCOBIOLOGY, V10, P503, DOI 10.1093/glycob/10.5.503; Tarbouriech N, 2001, J MOL BIOL, V314, P655, DOI 10.1006/jmbi.2001.5159; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; WILLIAMS D, 1980, J BIOL CHEM, V255, P1253; Wilson IBH, 2002, J BIOL CHEM, V277, P21207, DOI 10.1074/jbc.M201634200; Yang XJ, 2003, BBA-PROTEINS PROTEOM, V1648, P62, DOI 10.1016/S1570-9639(03)00105-5; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; Yen TY, 2003, J BIOL CHEM, V278, P45864, DOI 10.1074/jbc.M303851200; Zeng S, 1997, BIOCHEM BIOPH RES CO, V237, P653, DOI 10.1006/bbrc.1997.7209; [No title captured]	58	48	49	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26693	26701		10.1074/jbc.M603534200	http://dx.doi.org/10.1074/jbc.M603534200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829524	hybrid			2022-12-25	WOS:000240249500087
J	Spasic, D; Tolia, A; Dillen, K; Baert, V; De Strooper, B; Vrijens, S; Annaert, W				Spasic, Dragana; Tolia, Alexandra; Dillen, Katleen; Baert, Veerle; De Strooper, Bart; Vrijens, Stefan; Annaert, Wim			Presenilin-1 maintains a nine-transmembrane topology throughout the secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE; GOLGI COMPARTMENTS; CELL-SURFACE; C-TERMINUS; PRE-GOLGI; NICASTRIN; COMPLEX; TRAFFICKING; EXPRESSION	Presenilin-1 is a polytopic membrane protein that assembles with nicastrin, PEN-2, and APH-1 into an active gamma-secretase complex required for intramembrane proteolysis of type I transmembrane proteins. Although essential for a correct understanding of structure-function relationships, its exact topology remains an issue of strong controversy. We revisited presenilin-1 topology by inserting glycosylation consensus sequences in human PS1 and expressing the obtained mutants in a presenilin-1 and 2 knock-out background. Based on the glycosylation status of these variants we provide evidence that presenilin-1 traffics through the Golgi after a conformational change induced by complex assembly. Based on our glycosylation variants of presenilin-1 we hypothesize that complex assembly occurs during transport between the endoplasmic reticulum and the Golgi apparatus. Furthermore, our data indicate that presenilin-1 has a nine-transmembrane domain topology with the COOH terminus exposed to the lumen/ extracellular surface. This topology is independently underscored by lysine mutagenesis, cell surface biotinylation, and cysteine derivation strategies and is compatible with the different physiological functions assigned to presenilin-1.	Katholieke Univ Leuven VIB, Lab Membrane Trafficking, Dept & Ctr Human Genet, B-3000 Louvain, Belgium; Katholieke Univ Leuven VIB, Lab Neuronal Cell Biol, Dept Human Genet, B-3000 Louvain, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven	Annaert, W (corresponding author), Katholieke Univ Leuven VIB, Lab Membrane Trafficking, Dept & Ctr Human Genet, Rm 9-969, B-3000 Louvain, Belgium.	Willem.Annaert@med.kuleuven.be	De Strooper, Bart/F-6507-2012; de+Strooper, Bart/Z-1638-2019	De Strooper, Bart/0000-0001-5455-5819; Spasic, Dragana/0000-0001-9882-5091				Annaert W, 2002, ANNU REV CELL DEV BI, V18, P25, DOI 10.1146/annurev.cellbio.18.020402.142302; Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Annaert WG, 2001, NEURON, V32, P579, DOI 10.1016/S0896-6273(01)00512-8; Bonnon C, 2003, J BIOL CHEM, V278, P48339, DOI 10.1074/jbc.M309120200; Capell A, 2005, J BIOL CHEM, V280, P6471, DOI 10.1074/jbc.M409106200; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Dewji NN, 2004, P NATL ACAD SCI USA, V101, P1057, DOI 10.1073/pnas.0307290101; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Esselens C, 2004, J CELL BIOL, V166, P1041, DOI 10.1083/jcb.200406060; Hauri HP, 2002, BIOCHEM SOC SYMP, V69, P73; Hendriks G, 2004, J BIOL CHEM, V279, P2975, DOI 10.1074/jbc.M310767200; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Heusser K, 2005, CURR OPIN NEUROBIOL, V15, P364, DOI 10.1016/j.conb.2005.04.001; Juschke C, 2005, J CELL BIOL, V169, P613, DOI 10.1083/jcb.200503033; Kaether C, 2004, EMBO J, V23, P4738, DOI 10.1038/sj.emboj.7600478; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; Kim J, 2005, J BIOL CHEM, V280, P7758, DOI 10.1074/jbc.M411091200; Kim J, 2004, P NATL ACAD SCI USA, V101, P905, DOI 10.1073/pnas.0307297101; Kim SH, 2005, J BIOL CHEM, V280, P1992, DOI 10.1074/jbc.M412404200; Ladinsky MS, 2002, MOL BIOL CELL, V13, P2810, DOI 10.1091/mbc.01-12-0593; Lau KF, 2000, MOL CELL NEUROSCI, V16, P557, DOI 10.1006/mcne.2000.0898; Laudon H, 2005, J BIOL CHEM, V280, P35352, DOI 10.1074/jbc.M507217200; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; Nakai T, 1999, J BIOL CHEM, V274, P23647, DOI 10.1074/jbc.274.33.23647; Nyabi O, 2003, J BIOL CHEM, V278, P43430, DOI 10.1074/jbc.M306957200; Oh YS, 2005, BIOCHEMISTRY-US, V44, P11821, DOI 10.1021/bi0509494; Oh YS, 2005, AM J PHYSIOL-CELL PH, V289, pC576, DOI 10.1152/ajpcell.00636.2004; Periz G, 2004, J NEUROSCI RES, V77, P309, DOI 10.1002/jnr.20203; Raemaekers T, 2005, BIOCHEM SOC T, V33, P559, DOI 10.1042/BST0330559; Rechards M, 2003, TRAFFIC, V4, P553, DOI 10.1034/j.1600-0854.2003.t01-1-00114.x; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Shirotani K, 2003, J BIOL CHEM, V278, P16474, DOI 10.1074/jbc.C300095200; Vullo A, 2004, BIOINFORMATICS, V20, P653, DOI 10.1093/bioinformatics/btg463; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Xu XM, 1999, J BIOL CHEM, V274, P32543, DOI 10.1074/jbc.274.46.32543; Yoo JS, 2002, J BIOL CHEM, V277, P11401, DOI 10.1074/jbc.M110263200	39	96	101	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26569	26577		10.1074/jbc.M600592200	http://dx.doi.org/10.1074/jbc.M600592200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16846981	hybrid			2022-12-25	WOS:000240249500075
J	Bird, AJ; Swierczek, S; Qiao, W; Eide, DJ; Winge, DR				Bird, Amanda J.; Swierczek, Sabina; Qiao, Wei; Eide, David J.; Winge, Dennis R.			Zinc metalloregulation of the zinc finger pair domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZAP1 TRANSCRIPTIONAL ACTIVATOR; SACCHAROMYCES-CEREVISIAE; DNA-BINDING; PROTEIN; YEAST; EXPRESSION; GENOME	The yeast transcriptional activator Zap1 contains two uncommon structural motifs designated zinc finger pair domains. The hallmark of this domain is the packing of two zinc finger motifs in one globular unit. One finger pair domain in Zap1 contains the AD2 transactivation domain. Zn(II) binding to this domain (ZF1/2) is kinetically labile yielding a zinc-regulated transactivator. The second finger pair domain (ZF3/4) lies within the DNA-binding domain, and it stably binds Zn(II). The goal of this study was to map the determinant conferring lability in Zn(II) binding by using finger pair chimeras. Whereas ZF2 contains the transactivation function, zinc regulation is dependent on the presence of ZF1. ZF3 can functionally replace ZF1, and a ZF3/2 finger pair retains limited zinc regulation. Replacement of ZF3 by ZF1 creating a ZF1/4 chimera was found to stably bind Zn(II), suggesting that the presence of a stable motif (ZF4) can impart binding stability on a labile motif (ZF1). Zn(II) binding in finger pair domains is dependent on the presence of both motifs. Mutations in one finger motif markedly attenuate Zn( II) binding to the second motif. Kinetic lability in Zn(II) binding was mapped to the alpha-helix of ZF2. A ZF1/ZF beta 2 alpha 4 chimera resembles ZF3/4 in Zn(II) binding stability in incubation studies with the Zn(II) chelators. The present results demonstrate that zinc regulation of AD activity of ZF2 is dependent on determinants in ZF1 as well as the alpha-helix segment of ZF2.	Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA; Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA	University of Wisconsin System; University of Wisconsin Madison; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Eide, DJ (corresponding author), Univ Wisconsin, Dept Nutr Sci, 1415 Linden Dr,Rm 340B, Madison, WI 53706 USA.	eide@nutrisci.wisc.edu; dennis.winge@hsc.utah.edu	Winge, Dennis/G-3611-2010; Bird, Amanda Jane/ABD-2295-2021	Bird, Amanda Jane/0000-0002-1846-7050	NIGMS NIH HHS [GM56285] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056285] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bird A, 2000, J BIOL CHEM, V275, P16160, DOI 10.1074/jbc.M000664200; Bird AJ, 2000, EMBO J, V19, P3704, DOI 10.1093/emboj/19.14.3704; Bird AJ, 2003, EMBO J, V22, P5137, DOI 10.1093/emboj/cdg484; Dohrmann PR, 1996, MOL CELL BIOL, V16, P1746; Elrod-Erickson M, 1998, STRUCTURE, V6, P451, DOI 10.1016/S0969-2126(98)00047-1; Fernandez-Martinez J, 2003, J MOL BIOL, V334, P667, DOI 10.1016/j.jmb.2003.09.072; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Herbig A, 2005, MOL MICROBIOL, V57, P834, DOI 10.1111/j.1365-2958.2005.04734.x; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; Muratani M, 2005, CELL, V120, P887, DOI 10.1016/j.cell.2004.12.025; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; Wang ZH, 2006, J MOL BIOL, V357, P1167, DOI 10.1016/j.jmb.2006.01.010; Zhao H, 1998, J BIOL CHEM, V273, P28713, DOI 10.1074/jbc.273.44.28713; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044	17	15	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25326	25335		10.1074/jbc.M600655200	http://dx.doi.org/10.1074/jbc.M600655200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16829533	hybrid			2022-12-25	WOS:000240031300034
J	Hu, L; Wada, K; Mores, N; Krsmanovic, LZ; Catt, KJ				Hu, Lian; Wada, Keiko; Mores, Nadia; Krsmanovic, Lazar Z.; Catt, Kevin J.			Essential role of G protein-gated inwardly rectifying potassium channels in gonadotropin-induced regulation of GnRH neuronal firing and pulsatile neurosecretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE RECEPTOR; HYPOTHALAMIC NEURONS; RAT HYPOTHALAMUS; RHESUS-MONKEY; GIRK CHANNELS; 5-HYDROXYTRYPTAMINE1A RECEPTORS; PRESYNAPTIC INHIBITION; SIGNALING PATHWAYS; ADENYLYL-CYCLASE; PULSE-GENERATOR	Activation of the luteinizing hormone/human chorionic gonadotropin (LH/hCG) receptor (LHR) in cultured hypothalamic cells and immortalized GnRH ( gonadotropin-releasing hormone) neurons (GT1-7 cells) transiently stimulates and subsequently inhibits cAMP production and pulsatile GnRH release. The marked and delayed impairment of cAMP signaling and episodic GnRH release in GT1-7 cells is prevented by pertussis toxin (PTX). This, and the LH-induced release of membrane-bound G alpha(s) and G alpha(i3) subunits, are indicative of differential G protein coupling to the LHR. Action potential (AP) firing in identified GnRH neurons also initially increased and then progressively decreased during LH treatment. The inhibitory action of LH on AP firing was also prevented by PTX. Reverse transcriptase-PCR analysis of GT1-7 neurons revealed the expression of G protein-gated inwardly rectifying potassium (GIRK) channels in these cells. The LH-induced currents were inhibited by PTX and were identified as GIRK currents. These responses indicate that agonist stimulation of endogenous LHR expressed in GnRH neurons activates GIRK channels, leading to suppression of membrane excitability and inhibition of AP firing. These findings demonstrate that regulation of GIRK channel function is a dominant factor in gonadotropin-induced abolition of pulsatile GnRH release. Furthermore, this mechanism could contribute to the suppression of pituitary function during pregnancy.	NICHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Mores, N (corresponding author), NICHD, Endocrinol & Reprod Res Branch, NIH, Bldg 49,Rm 6A-36, Bethesda, MD 20892 USA.	lazar@mail.nih.gov		MORES, Nadia/0000-0002-4197-0914	Intramural NIH HHS Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000184] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000184] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AlHader AA, 1997, BIOL REPROD, V56, P1071, DOI 10.1095/biolreprod56.5.1071; ARANEDA R, 1991, NEUROSCIENCE, V40, P399, DOI 10.1016/0306-4522(91)90128-B; BEYER C, 1967, EXP NEUROL, V18, P313, DOI 10.1016/0014-4886(67)90051-9; Blackmer T, 2005, NAT NEUROSCI, V8, P421, DOI 10.1038/nn1423; Blackmer T, 2001, SCIENCE, V292, P293, DOI 10.1126/science.1058803; Charles A, 2001, MOL ENDOCRINOL, V15, P997, DOI 10.1210/me.15.6.997; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DELAESCALERA G, 1995, NEUROENDOCRINOLOGY, V61, P310, DOI 10.1159/000126853; DROUVA SV, 1981, NEUROENDOCRINOLOGY, V32, P155, DOI 10.1159/000123149; Dufau ML, 1998, ANNU REV PHYSIOL, V60, P461, DOI 10.1146/annurev.physiol.60.1.461; El Majdoubi M, 2002, ENDOCRINOLOGY, V143, P2441, DOI 10.1210/en.143.6.2441; EMANUELE N, 1984, BRAIN RES, V309, P271; FUJITA K, 1979, J BIOL CHEM, V254, P8567; Gerachshenko T, 2005, NAT NEUROSCI, V8, P597, DOI 10.1038/nn1439; Grosse R, 2000, J BIOL CHEM, V275, P9193, DOI 10.1074/jbc.275.13.9193; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HAMON M, 1990, NEUROPSYCHOPHARMACOL, V3, P349; Herrlich A, 1996, J BIOL CHEM, V271, P16764, DOI 10.1074/jbc.271.28.16764; Hill RH, 2003, EUR J NEUROSCI, V18, P2919, DOI 10.1111/j.1460-9568.2003.03051.x; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Hiruma H, 1997, J NEUROENDOCRINOL, V9, P835, DOI 10.1046/j.1365-2826.1997.00645.x; Ikeda K, 2000, NEUROSCI RES, V38, P113, DOI 10.1016/S0168-0102(00)00144-9; Kalra SP, 1997, J NEUROENDOCRINOL, V9, P569, DOI 10.1046/j.1365-2826.1997.00619.x; KNOBIL E, 1988, HUM REPROD, V3, P29, DOI 10.1093/oxfordjournals.humrep.a136647; Krsmanovic LZ, 1999, ENDOCRINOLOGY, V140, P1423, DOI 10.1210/en.140.3.1423; KRSMANOVIC LZ, 1991, P NATL ACAD SCI USA, V88, P11124, DOI 10.1073/pnas.88.24.11124; KRSMANOVIC LZ, 1992, P NATL ACAD SCI USA, V89, P8462, DOI 10.1073/pnas.89.18.8462; Krsmanovic LZ, 2003, P NATL ACAD SCI USA, V100, P2969, DOI 10.1073/pnas.0535708100; Krsmanovic LZ, 1998, ENDOCRINOLOGY, V139, P4037, DOI 10.1210/en.139.10.4037; Leaney JL, 2004, AM J PHYSIOL-CELL PH, V287, pC182, DOI 10.1152/ajpcell.00540.2003; Lewis DL, 1997, NEUROENDOCRINOLOGY, V66, P235, DOI 10.1159/000127244; LUKACS H, 1995, HORM BEHAV, V29, P42, DOI 10.1006/hbeh.1995.1004; Martinez-Fuentes AJ, 2004, MOL ENDOCRINOL, V18, P1808, DOI 10.1210/me.2003-0321; MARTINEZFUENTES AJ, 2000, 82 ANN M END SOC CHE, P21; MARTINI L, 1968, ENDOCRINOLOGY HUMAN, P175; McArdle C. A., 2002, Archives of Physiology and Biochemistry, V110, P113, DOI 10.1076/apab.110.1.113.893; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MILENKOVIC I, 1994, P NATL ACAD SCI USA, V91, P1244, DOI 10.1073/pnas.91.4.1244; Mores N, 1996, ENDOCRINOLOGY, V137, P5731, DOI 10.1210/en.137.12.5731; ORDOG T, 1995, P NATL ACAD SCI USA, V92, P5813, DOI 10.1073/pnas.92.13.5813; PORTER JC, 1978, CLIN OBSTET GYNAECOL, V5, P271; Pun RYK, 2003, BIOPHYS J, V84, P3425, DOI 10.1016/S0006-3495(03)70064-2; RAMIREZ VD, 1980, J ENDOCRINOL INVEST, V3, P29, DOI 10.1007/BF03348214; Sadja R, 2003, NEURON, V39, P9, DOI 10.1016/S0896-6273(03)00402-1; Skynner MJ, 1999, ENDOCRINOLOGY, V140, P5195, DOI 10.1210/en.140.11.5195; Stanislaus D, 1998, BIOL REPROD, V59, P579, DOI 10.1095/biolreprod59.3.579; Terasawa E, 1998, GEN COMP ENDOCR, V112, P283, DOI 10.1006/gcen.1998.7155; Terasawa E, 1999, J NEUROSCI, V19, P5898, DOI 10.1523/JNEUROSCI.19-14-05898.1999; TERASAWA E, 1969, AM J PHYSIOL, V217, P1119, DOI 10.1152/ajplegacy.1969.217.4.1119; TURGEON JL, 1976, ENDOCRINOLOGY, V98, P639, DOI 10.1210/endo-98-3-639; URBAN RJ, 1989, ENDOCRINOLOGY, V124, P2541, DOI 10.1210/endo-124-5-2541; Van Goor F, 1999, P NATL ACAD SCI USA, V96, P4101, DOI 10.1073/pnas.96.7.4101; Van Goor F, 1999, MOL ENDOCRINOL, V13, P587, DOI 10.1210/me.13.4.587; Vitalis EA, 2000, P NATL ACAD SCI USA, V97, P1861, DOI 10.1073/pnas.040545197; Wada K, 2006, MOL ENDOCRINOL, V20, P125, DOI 10.1210/me.2005-0109; WEINER RI, 1992, FRONT NEUROENDOCRIN, V13, P95; WUTTKE W, 1974, EXP BRAIN RES, V19, P205; ZGOMBICK JM, 1989, MOL PHARMACOL, V35, P484; Zhang QL, 2002, J PHYSIOL-LONDON, V545, P355, DOI 10.1113/jphysiol.2002.032151	59	13	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25231	25240		10.1074/jbc.M603768200	http://dx.doi.org/10.1074/jbc.M603768200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16825187	hybrid			2022-12-25	WOS:000240031300024
J	Zhou, Y; Martin, CT				Zhou, Yi; Martin, Craig T.			Observed instability of T7 RNA polymerase elongation complexes can be dominated by collision-induced "bumping"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR CONFORMATIONAL-CHANGES; LAC UV5 PROMOTER; TRANSCRIPTION ELONGATION; STRUCTURAL TRANSITIONS; INITIATION; MECHANISM; RELEASE; TRANSLOCATION; DISPLACEMENT; PROCESSIVITY	T7 RNA polymerase elongates RNA at a relatively high rate and can displace many tightly bound protein-DNA complexes. Despite these properties, measurements of the stability of stalled elongation complexes have shown lifetimes that are much shorter than those of the multisubunit RNA polymerases. In this work, we demonstrate that the apparent instability of stalled complexes actually arises from the action of trailing RNA polymerases (traveling in the same direction) displacing the stalled complex. Moreover, the instability caused by collision between two polymerases is position dependent. A second polymerase is blocked from promoter binding when a leading complex is stalled 12 bp or less from the promoter. The trailing complex can bind and make abortive transcripts when the leading complex is between 12 and 20 bp from the promoter, but it cannot displace the first complex since it is in a unstable initiation conformation. Only when the leading complex is stalled more than 20 bp away from the promoter can a second polymerase bind, initiate, and displace the leading complex.	Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA; Univ Massachusetts, Program Mol & Cellular Biol, Amherst, MA 01003 USA; Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst	Martin, CT (corresponding author), Univ Massachusetts, Dept Chem, 701 LGRC,710 N Pleasant St, Amherst, MA 01003 USA.	cmartin@chem.umass.edu	Martin, Craig T/L-3596-2013	Martin, Craig T/0000-0003-1029-5239	NIGMS NIH HHS [1R01 GM55002, T32 GM008515, T32 GM08515] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008515, R01GM055002] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAMPBELL FE, 1991, MOL CELL BIOL, V11, P3978, DOI 10.1128/MCB.11.8.3978; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CLARK DJ, 1992, CELL, V71, P11, DOI 10.1016/0092-8674(92)90262-B; Epshtein V, 2003, EMBO J, V22, P4719, DOI 10.1093/emboj/cdg452; Epshtein V, 2003, SCIENCE, V300, P801, DOI 10.1126/science.1083219; Ferrari R, 2004, BIOCHEM BIOPH RES CO, V315, P376, DOI 10.1016/j.bbrc.2004.01.071; GALLEGO F, 1995, BIOCHEMISTRY-US, V34, P6711, DOI 10.1021/bi00020a016; Gong P, 2004, J BIOL CHEM, V279, P44277, DOI 10.1074/jbc.M409118200; GRALLA JD, 1980, BIOCHEMISTRY-US, V19, P5864, DOI 10.1021/bi00566a031; Guajardo R, 1998, J MOL BIOL, V281, P777, DOI 10.1006/jmbi.1998.1988; Guo Q, 2005, J MOL BIOL, V353, P256, DOI 10.1016/j.jmb.2005.08.016; He B, 1997, PROTEIN EXPRES PURIF, V9, P142, DOI 10.1006/prep.1996.0663; Hsu LM, 2002, BBA-GENE STRUCT EXPR, V1577, P191, DOI 10.1016/S0167-4781(02)00452-9; Jiang ML, 2004, MOL CELL, V15, P777, DOI 10.1016/j.molcel.2004.07.019; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; Kubori T, 1997, NUCLEIC ACIDS RES, V25, P2640, DOI 10.1093/nar/25.13.2640; Ma KY, 2002, J BIOL CHEM, V277, P43206, DOI 10.1074/jbc.M206658200; Martin CT, 2005, PROG NUCLEIC ACID RE, V80, P323, DOI 10.1016/S0079-6603(05)80008-X; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MCALLISTER WT, 1993, CELL MOL BIOL RES, V39, P385; Mentesana PE, 2000, J MOL BIOL, V302, P1049, DOI 10.1006/jmbi.2000.4114; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Mukherjee S, 2002, CELL, V110, P81, DOI 10.1016/S0092-8674(02)00815-2; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; OAKLEY JL, 1977, P NATL ACAD SCI USA, V74, P4266, DOI 10.1073/pnas.74.10.4266; Santangelo TJ, 2004, MOL CELL, V14, P117, DOI 10.1016/S1097-2765(04)00154-6; SCHICK C, 1993, BIOCHEMISTRY-US, V32, P4275, DOI 10.1021/bi00067a016; Song HS, 2001, GENES CELLS, V6, P291, DOI 10.1046/j.1365-2443.2001.00420.x; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; Temiakov D, 2000, P NATL ACAD SCI USA, V97, P14109, DOI 10.1073/pnas.250473197; Theis K, 2004, BIOCHEMISTRY-US, V43, P12709, DOI 10.1021/bi0486987; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; WANG FJ, 1993, BIOCHEM MOL BIOL INT, V30, P969; Wilson KS, 1999, J MOL BIOL, V289, P1179, DOI 10.1006/jmbi.1999.2814; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464; Zhang X, 1997, J MOL BIOL, V269, P10, DOI 10.1006/jmbi.1997.1016	36	26	26	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24441	24448		10.1074/jbc.M604369200	http://dx.doi.org/10.1074/jbc.M604369200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16816387	hybrid			2022-12-25	WOS:000239847800038
J	Patel, VI; Daniel, S; Longo, CR; Shrikhande, GV; Scali, ST; Czismadia, E; Groft, CM; Shukri, T; Motley-Dore, C; Ramsey, HE; Fisher, MD; Grey, ST; Arvelo, MB; Ferran, C				Patel, Virendra I.; Daniel, Soizic; Longo, Christopher R.; Shrikhande, Gautam V.; Scali, Salvatore T.; Czismadia, Eva; Groft, Caroline M.; Shukri, Tala; Motley-Dore, Christina; Ramsey, Haley E.; Fisher, Mark D.; Grey, Shane T.; Arvelo, Maria B.; Ferran, Christiane			A20, a modulator of smooth muscle cell proliferation and apoptosis, prevents and induces regression of neointimal hyperplasia	FASEB JOURNAL			English	Article						NO; cell cycle; intimal hyperplasia	NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; IN-VITRO; HUMAN ATHEROSCLEROSIS; MEDIATED APOPTOSIS; ENDOTHELIAL INJURY; DEFICIENT MICE; VESSEL WALL; ACTIVATION	A20 is a NF-kappa B-dependent gene that has dual anti-inflammatory and antiapoptotic functions in endothelial cells (EC). The function of A20 in smooth muscle cells (SMC) is unknown. We demonstrate that A20 is induced in SMC in response to inflammatory stimuli and serves an anti-inflammatory function via blockade of NF-kappa B and NF-kappa B-dependent proteins ICAM-1 and MCP-1. A20 inhibits SMC proliferation via increased expression of cyclin-dependent kinase inhibitors p21(waf1) and p27(kip1). Surprisingly, A20 sensitizes SMC to cytokine- and Fas-mediated apoptosis through a novel NO-dependent mechanism. In vivo, adenoviral delivery of A20 to medial rat carotid artery SMC after balloon angioplasty prevents neointimal hyperplasia by blocking SMC proliferation and accelerating re-endothelialization, without causing apoptosis. However, expression of A20 in established neointimal lesions leads to their regression through increased apoptosis. This is the first demonstration that A20 exerts two levels of control of vascular remodeling and healing. A20 prevents neointimal hyperplasia through combined anti-inflammatory and antiproliferative functions in medial SMC. If SMC evade this first barrier and neointima is formed, A20 has a therapeutic potential by uniquely sensitizing neointimal SMC to apoptosis. A20-based therapies hold promise for the prevention and treatment of neointimal disease.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Vasc Surg, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Transplant Ctr,Dept Surg, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Nephrol,Dept Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Ferran, C (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr, Res N Rm 370F,99 Brookline Ave, Boston, MA 02215 USA.	cferran@caregroup.harvard.edu	Grey, Shane T/B-3020-2008	Grey, Shane T/0000-0003-2160-1625	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021796, T32HL007734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063275] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07734, R01 HL08013, R01 HL021796] Funding Source: Medline; NIDDK NIH HHS [R01 DK063275] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abid MR, 2005, J BIOL CHEM, V280, P29864, DOI 10.1074/jbc.M502149200; Beck KF, 1996, FEBS LETT, V394, P263, DOI 10.1016/0014-5793(96)00966-0; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; BLANCBRUDE OP, 2002, NAT MED, V9, P987; Bornfeldt KE, 2003, CIRC RES, V92, P345, DOI 10.1161/01.RES.0000061765.06145.10; Bourcier T, 1997, J BIOL CHEM, V272, P15817, DOI 10.1074/jbc.272.25.15817; Chan SW, 2000, CIRC RES, V86, P1038, DOI 10.1161/01.RES.86.10.1038; Chen LH, 2000, CIRC RES, V86, P520, DOI 10.1161/01.RES.86.5.520; Cimbrone A, 1995, AM J CARDIOL, V75, P67, DOI 10.1016/0002-9149(95)80016-L; CLOWES AW, 1983, LAB INVEST, V49, P208; Collins RG, 2000, J EXP MED, V191, P189, DOI 10.1084/jem.191.1.189; Cooke JP, 2003, ATHEROSCLEROSIS SUPP, V4, P53, DOI 10.1016/S1567-5688(03)00034-5; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; Coulombe P, 2004, MOL CELL BIOL, V24, P6140, DOI 10.1128/MCB.24.14.6140-6150.2004; Daniel S, 2004, BLOOD, V104, P2376, DOI 10.1182/blood-2003-02-0635; Ferran C, 1998, BLOOD, V91, P2249, DOI 10.1182/blood.V91.7.2249.2249_2249_2258; Fukumoto Y, 1997, CIRCULATION, V96, P3104, DOI 10.1161/01.CIR.96.9.3104; Fukuo K, 1996, HYPERTENSION, V27, P823, DOI 10.1161/01.HYP.27.3.823; Geng YJ, 1996, ARTERIOSCL THROM VAS, V16, P19, DOI 10.1161/01.ATV.16.1.19; Gomes D, 2001, J VASC SURG, V34, P707, DOI 10.1067/mva.2001.116802; Grey ST, 1999, J EXP MED, V190, P1135, DOI 10.1084/jem.190.8.1135; HANSSON GK, 1994, J EXP MED, V180, P733, DOI 10.1084/jem.180.2.733; HARIRI RJ, 1986, J EXP MED, V164, P1171, DOI 10.1084/jem.164.4.1171; Hsieh JK, 2000, ARTERIOSCL THROM VAS, V20, P973, DOI 10.1161/01.ATV.20.4.973; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; Iwashina M, 1998, CIRCULATION, V98, P1212, DOI 10.1161/01.CIR.98.12.1212; Kockx MM, 2000, CARDIOVASC RES, V45, P736, DOI 10.1016/S0008-6363(99)00235-7; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Kunter U, 2003, TRANSPLANTATION, V75, P3, DOI 10.1097/00007890-200301150-00002; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Libby P, 2001, IMMUNITY, V14, P387, DOI 10.1016/S1074-7613(01)00119-4; Longo CR, 2003, CIRCULATION, V108, P1113, DOI 10.1161/01.CIR.0000083718.76889.D0; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; Moussa I, 2004, CIRCULATION, V109, P2273, DOI 10.1161/01.CIR.0000129767.45513.71; Ni WH, 2001, CIRCULATION, V103, P2096; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; Pollman MJ, 1998, NAT MED, V4, P222, DOI 10.1038/nm0298-222; Rembold C, 1996, PERSPECT BIOL MED, V39, P405; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sata M, 1998, P NATL ACAD SCI USA, V95, P1213, DOI 10.1073/pnas.95.3.1213; Schaub FJ, 2000, NAT MED, V6, P790, DOI 10.1038/77521; Schreyer SA, 1996, J BIOL CHEM, V271, P26174, DOI 10.1074/jbc.271.42.26174; SERRUYS PW, 1988, CIRCULATION, V77, P361, DOI 10.1161/01.CIR.77.2.361; Shears LL, 1997, J CLIN INVEST, V100, P2035, DOI 10.1172/JCI119736; Storz P, 2005, BIOCHEM J, V387, P47, DOI 10.1042/BJ20041443; Stroka DM, 1999, BLOOD, V93, P3803, DOI 10.1182/blood.V93.11.3803.411a27_3803_3810; Wang BY, 1999, CIRCULATION, V99, P1236, DOI 10.1161/01.CIR.99.9.1236; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Xu QB, 2003, CIRC RES, V93, pE76, DOI 10.1161/01.RES.0000097864.24725.60; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; Yu ZY, 2004, J BIOL CHEM, V279, P46954, DOI 10.1074/jbc.M407192200	52	69	72	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2006	20	9					1418	1430		10.1096/fj.05-4981com	http://dx.doi.org/10.1096/fj.05-4981com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816117	Green Submitted			2022-12-25	WOS:000240266000019
J	Zhang, YJ; Xu, YF; Liu, YH; Yin, J; Li, HL; Wang, Q; Wang, JZ				Zhang, Yong-Jie; Xu, Ya-Fei; Liu, Ying-Hua; Yin, Jun; Li, Hong-Lian; Wang, Qun; Wang, Jian-Zhi			Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms	FASEB JOURNAL			English	Article						tau; glycogen synthase kinase-3 beta; p38 MAPKs; proteasome	NITRIC-OXIDE SYNTHASE; BETA-AMYLOID STIMULATION; PAIRED HELICAL FILAMENTS; OXIDATIVE STRESS; GROWTH-FACTOR; PROTEIN-TAU; URIC-ACID; TYROSINE NITRATION; PHOSPHORYLATES TAU; ENDOTHELIAL-CELLS	To investigate the upstream effector that led to tau hyperphosphorylation, nitration, and accumulation as seen in Alzheimer's disease brain, and the underlying mechanisms, we bilaterally injected SIN-1, a recognized peroxynitrite donor, into the hippocampus of rat brain. We observed that the level of nitrated and hyperphosphorylated tau was markedly increased in rat hippocampus 24 h after drug administration, and these alterations were prevented by preinjection of uric acid, a natural scavenger of peroxynitrite. Concomitantly, we detected a significant activation in glycogen synthase kinase-3 beta (GSK-3 beta) and p38 MAPKs, including p38 alpha, p38 beta, and p38 delta, but no obvious change was measured in the activity of p38 gamma, ERK, and c-Jun amino-terminal kinase (JNK). Both nitrated tau and hyperphosphorylated tau were aggregated in the hippocampus, in which the activity of 20S proteasome was significantly arrested in SIN-1-injected rats. Further studies demonstrated that the hyperphosphorylated tau was degraded as efficiently as normal tau by 20S proteasome, but the nitrated tau with an unorderly secondary structure became more resistant to the proteolysis. These results provide the first in vivo evidence showing that peroxynitrite simultaneously induces tau hyperphosphorylation, nitration, and accumulation, and that activation of GSK-3 beta, p38 beta, p38 delta, p38 delta isoforms and the inhibition of proteasome activity are respectively responsible for the peroxynitrite-induced tau hyperphosphorylation and accumulation. Our findings reveal a common upstream stimulator and a potential therapeutic target for Alzheimer-like neurodegeneration.	Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Pathophysiol, Key Lab Neurol Dis Hubei Prov, Wuhan 430030, Peoples R China	Huazhong University of Science & Technology	Wang, JZ (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Pathophysiol, Key Lab Neurol Dis Hubei Prov, Wuhan 430030, Peoples R China.	wangjz@mails.tjmu.edu.cn	Zhang, Yong-Jie/G-3378-2011; LIU, YING/GZL-7252-2022; liu, ying/GXF-4294-2022					Akama KT, 2000, J BIOL CHEM, V275, P7918, DOI 10.1074/jbc.275.11.7918; Bao F, 2002, NEUROSCIENCE, V115, P839, DOI 10.1016/S0306-4522(02)00506-7; Bapat S, 2001, FEBS LETT, V499, P21, DOI 10.1016/S0014-5793(01)02511-X; Cardozo C, 2002, ARCH BIOCHEM BIOPHYS, V408, P103, DOI 10.1016/S0003-9861(02)00493-9; Castegna A, 2003, J NEUROCHEM, V85, P1394, DOI 10.1046/j.1471-4159.2003.01786.x; Cho JH, 2003, J BIOL CHEM, V278, P187, DOI 10.1074/jbc.M206236200; Combs CK, 2001, J NEUROSCI, V21, P1179; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; David DC, 2002, J NEUROCHEM, V83, P176, DOI 10.1046/j.1471-4159.2002.01137.x; El-Remessy AB, 2005, J CELL SCI, V118, P243, DOI 10.1242/jcs.01612; El-Remessy AB, 2003, AM J PATHOL, V162, P1995, DOI 10.1016/S0002-9440(10)64332-5; Feijoo C, 2005, J CELL SCI, V118, P397, DOI 10.1242/jcs.01655; Freels JL, 2002, J IMMUNOL, V169, P4568, DOI 10.4049/jimmunol.169.8.4568; Go YM, 1999, AM J PHYSIOL-HEART C, V277, pH1647, DOI 10.1152/ajpheart.1999.277.4.H1647; Goedert M, 1997, FEBS LETT, V409, P57, DOI 10.1016/S0014-5793(97)00483-3; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; Goldbaum O, 2003, J NEUROSCI, V23, P8872; Good PF, 1996, AM J PATHOL, V149, P21; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; Hellberg CB, 1998, BIOCHEM BIOPH RES CO, V252, P313, DOI 10.1006/bbrc.1998.9581; Hensley K, 1998, J NEUROSCI, V18, P8126; Hensley K, 1999, J NEUROCHEM, V72, P2053, DOI 10.1046/j.1471-4159.1999.0722053.x; Hickman-Davis J, 1999, P NATL ACAD SCI USA, V96, P4953, DOI 10.1073/pnas.96.9.4953; Hodara R, 2004, J BIOL CHEM, V279, P47746, DOI 10.1074/jbc.M408906200; Hooper DC, 1998, P NATL ACAD SCI USA, V95, P675, DOI 10.1073/pnas.95.2.675; Hooper DC, 2000, FASEB J, V14, P691, DOI 10.1096/fasebj.14.5.691; Horiguchi T, 2003, AM J PATHOL, V163, P1021, DOI 10.1016/S0002-9440(10)63462-1; Hyun DH, 2003, J NEUROCHEM, V86, P363, DOI 10.1046/j.1471-4159.2003.01841.x; Iqbal K, 2005, BBA-MOL BASIS DIS, V1739, P198, DOI 10.1016/j.bbadis.2004.09.008; Johansson AC, 2003, CELL DEATH DIFFER, V10, P1253, DOI 10.1038/sj.cdd.4401290; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Koppal T, 1999, J NEUROCHEM, V72, P310, DOI 10.1046/j.1471-4159.1999.0720310.x; Lam YA, 2000, P NATL ACAD SCI USA, V97, P9902, DOI 10.1073/pnas.170173897; Lee HG, 2005, TRENDS MOL MED, V11, P164, DOI 10.1016/j.molmed.2005.02.008; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Lee VMY, 2004, TRENDS NEUROSCI, V27, P129, DOI 10.1016/j.tins.2004.01.007; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Liu SJ, 2004, J BIOL CHEM, V279, P50078, DOI 10.1074/jbc.M406109200; Liu SJ, 2002, ACTA PHARMACOL SIN, V23, P183; Luth HJ, 2002, BRAIN RES, V953, P135, DOI 10.1016/S0006-8993(02)03280-8; McDonald DR, 1997, J NEUROSCI, V17, P2284; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Morsch R, 1999, J NEUROPATH EXP NEUR, V58, P188, DOI 10.1097/00005072-199902000-00008; Muyderman H, 2004, J NEUROSCI, V24, P8019, DOI 10.1523/JNEUROSCI.1103-04.2004; Oh-hashi K, 1999, BIOCHEM BIOPH RES CO, V263, P504, DOI 10.1006/bbrc.1999.1237; Oh-Hashi K, 2001, FREE RADICAL BIO MED, V30, P213, DOI 10.1016/S0891-5849(00)00461-5; Osna NA, 2004, HEPATOLOGY, V40, P574, DOI 10.1002/hep.20352; Pei JJ, 1999, J NEUROPATH EXP NEUR, V58, P1010, DOI 10.1097/00005072-199909000-00011; Pesse B, 2005, J MOL CELL CARDIOL, V38, P765, DOI 10.1016/j.yjmcc.2005.02.020; Possel H, 2002, GLIA, V38, P339, DOI 10.1002/glia.10066; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Reynolds CH, 1997, J NEUROCHEM, V69, P191; Reynolds MR, 2005, BIOCHEMISTRY-US, V44, P1690, DOI 10.1021/bi047982v; Salon ML, 2000, J NEUROSCI RES, V62, P302, DOI 10.1002/1097-4547(20001015)62:2<302::AID-JNR15>3.0.CO;2-L; Schildknecht S, 2005, FASEB J, V19, P1169, DOI 10.1096/fj.04-3465fje; Scott GS, 2005, P NATL ACAD SCI USA, V102, P3483, DOI 10.1073/pnas.0500307102; Shiurba RA, 1996, BRAIN RES, V737, P119, DOI 10.1016/0006-8993(96)00717-2; Shringarpure R, 2001, CELL MOL LIFE SCI, V58, P1442, DOI 10.1007/PL00000787; Smith MA, 1997, J NEUROSCI, V17, P2653; Spear N, 1997, J NEUROCHEM, V69, P53; Sun AY, 2003, EXP NEUROL, V183, P394, DOI 10.1016/S0014-4886(03)00180-8; Tohgi H, 1999, NEUROSCI LETT, V269, P52, DOI 10.1016/S0304-3940(99)00406-1; Tran MH, 2001, FASEB J, V15, P1407, DOI 10.1096/fj.00-0719fje; Tsujio I, 2000, FEBS LETT, V469, P111, DOI 10.1016/S0014-5793(00)01234-5; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; Wang JZ, 1998, FEBS LETT, V436, P28, DOI 10.1016/S0014-5793(98)01090-4; Wang QW, 2004, J NEUROSCI, V24, P6049, DOI 10.1523/JNEUROSCI.0233-04.2004; Whiteman M, 2004, FASEB J, V18, P1395, DOI 10.1096/fj.03-1096fje; Zhang P, 2000, J BIOL CHEM, V275, P22479, DOI 10.1074/jbc.M910425199; Zhang YJ, 2005, FEBS LETT, V579, P2421, DOI 10.1016/j.febslet.2005.03.041; Zhu XW, 2000, J NEUROPATH EXP NEUR, V59, P880, DOI 10.1093/jnen/59.10.880; Zhu XW, 2001, J NEUROCHEM, V79, P311, DOI 10.1046/j.1471-4159.2001.00597.x; Zouki C, 2001, FASEB J, V15, P25	74	65	70	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1431	1442		10.1096/fj.05-5223com	http://dx.doi.org/10.1096/fj.05-5223com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816118				2022-12-25	WOS:000240266000020
J	Iyer, NG; Xian, J; Chin, SF; Bannister, AJ; Daigo, Y; Aparicio, S; Kouzarides, T; Caldas, C				Iyer, N. G.; Xian, J.; Chin, S-F; Bannister, A. J.; Daigo, Y.; Aparicio, S.; Kouzarides, T.; Caldas, C.			p300 is required for orderly G1/S transition in human cancer cells	ONCOGENE			English	Article						RB; retinoblastoma; hyperphosphorylation; Cdk; HCT116	DNA-DAMAGE; C-MYC; RETINOBLASTOMA PROTEIN; G(1) EXIT; IN-VITRO; ACETYLATION; CBP; P53; MUTATIONS; BINDING	The role of the transcriptional coactivator p300 in cell cycle control has not been analysed in detail due to the lack of appropriate experimental systems. We have now examined cell cycle progression of p300-deficient cancer cell lines, where p300 was disrupted either by gene targeting (p300(-) cells) or knocked down using RNAi. Despite significant proliferation defects under normal growth conditions, p300(-) deficient cells progressed rapidly through G1 with premature S-phase entry. Accelerated G1/S transition was associated with early retinoblastoma (RB) hyperphosphorylation and activation of E2F targets. The p300(-) acetylase activity was dispensable since expression of a HAT-deficient p300 mutant reversed these changes. Co-immunoprecipitation showed p300/RB interaction occurs in vivo during G1, and this interaction has two peaks: in early G1 with unphosphorylated RB and in late G1 with phosphorylated RB. In vitro kinase assays showed that p300 directly inhibits cdk6-mediated RB phosphorylation, suggesting p300 acts in early G1 to prevent RB hyperphosphorylation and delay premature S-phase entry. Paradoxically, continued cycling of p300(-) cells despite prolonged serum depletion was observed, and this occurred in association with persistent RB hyperphosphorylation. Altogether, these results suggest that p300 has an important role in G1/S control, possibly by modulating RB phosphorylation.	Univ Cambridge, Canc Genom Program, Hutchison MRC Res Ctr, Dept Oncol, Cambridge CB2 2XZ, England; Univ Cambridge, Wellcome Trust CRUK Gurdon Inst, Cambridge, England	University of Cambridge; University of Cambridge	Caldas, C (corresponding author), Univ Cambridge, Canc Genom Program, Hutchison MRC Res Ctr, Dept Oncol, Hills Rd, Cambridge CB2 2XZ, England.	cc234@cam.ac.uk	Caldas, Carlos/A-7543-2008; Caldas, Carlos/U-7250-2019	Caldas, Carlos/0000-0003-3547-1489; Kouzarides, Tony/0000-0002-8918-4162; Aparicio, Samuel/0000-0002-0487-9599; chin, suet-feung/0000-0001-5697-1082; Bannister, Andrew/0000-0002-6312-4436; Daigo, Yataro/0000-0002-0915-3025				Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Baluchamy S, 2003, P NATL ACAD SCI USA, V100, P9524, DOI 10.1073/pnas.1633700100; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dimitrova DS, 1999, J CELL BIOL, V146, P709, DOI 10.1083/jcb.146.4.709; Dolbeare F, 1990, Methods Cell Biol, V33, P207; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Goodman RH, 2000, GENE DEV, V14, P1553; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; Iyer NG, 2004, P NATL ACAD SCI USA, V101, P7386, DOI 10.1073/pnas.0401002101; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Kolli S, 2001, P NATL ACAD SCI USA, V98, P4646, DOI 10.1073/pnas.081141998; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Liu L, 1999, MOL CELL BIOL, V19, P1202; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Ozdag H, 2002, BRIT J CANCER, V87, P1162, DOI 10.1038/sj.bjc.6600554; Rajabi HN, 2005, J BIOL CHEM, V280, P361, DOI 10.1074/jbc.M408633200; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Suganuma T, 2002, P NATL ACAD SCI USA, V99, P13073, DOI 10.1073/pnas.192586699; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; WALDMAN T, 1995, CANCER RES, V55, P5187; Ward R, 2005, J MED GENET, V42, P514, DOI 10.1136/jmg.2004.025080; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yuan ZM, 1999, ONCOGENE, V18, P5714, DOI 10.1038/sj.onc.1202930	33	49	50	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					21	29		10.1038/sj.onc.1209771	http://dx.doi.org/10.1038/sj.onc.1209771			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16878158				2022-12-25	WOS:000243236500003
J	Shiraishi, K; Yamasaki, K; Nanba, D; Inoue, H; Hanakawa, Y; Shirakata, Y; Hashimoto, K; Higashiyama, S				Shiraishi, K.; Yamasaki, K.; Nanba, D.; Inoue, H.; Hanakawa, Y.; Shirakata, Y.; Hashimoto, K.; Higashiyama, S.			Pre-B-cell leukemia transcription factor 1 is a major target of promyelocytic leukemia zinc-finger-mediated melanoma cell growth suppression	ONCOGENE			English	Article						Pbx1; PLZF; Hox; melanoma	PLZF-RAR-ALPHA; DNA-BINDING; TRANSLOCATION PROTEIN; GENE; PROLIFERATION; EXPRESSION; HOXB7; ANGIOGENESIS; REPRESSION; CARCINOMA	Promyelocytic leukemia zinc-finger ( PLZF) is a transcriptional repressor and tumor suppressor. PLZF is expressed in melanocytes but not in melanoma cells, and recovery of PLZF expression markedly suppresses melanoma cell growth. Several target genes regulated by PLZF have been identified, but the precise function of PLZF remains uncertain. Here, we searched for candidate target genes of PLZF by DNA microarray analysis. Pre-B-cell leukemia transcription factor 1 (Pbx1) was one of the prominently suppressed genes. Pbx1 was highly expressed in melanoma cells, and its expression was reduced by transduction with the PLZF gene. Moreover, the growth suppression mediated by PLZF was reversed by enforced expression of Pbx1. Knockdown of Pbx1 by specific small interfering RNAs suppressed melanoma cell growth. We also found that Pbx1 binds HoxB7. Reverse transcription-polymerase chain reaction analysis demonstrated that repression of Pbx1 by PLZF reduces the expression of HoxB7 target genes, including tumor-associated neoangiogenesis factors such as basic fibroblast growth factor, angiopoietin-2 and matrix metalloprotease 9. These findings suggest that deregulation of Pbx1 expression owing to loss of PLZF expression contributes to the progression and/or pathogenesis of melanoma.	Ehime Univ, Grad Sch Med, Dept Biochem & Mol Genet, Toon, Ehime 7910295, Japan; Ehime Univ, Grad Sch Med, Dept Dermatol, Toon, Ehime 7910295, Japan; Japan Sci & Technol Corp JST, PRESTO, Kawaguchi, Saitama, Japan	Ehime University; Ehime University; Japan Science & Technology Agency (JST)	Higashiyama, S (corresponding author), Ehime Univ, Grad Sch Med, Dept Biochem & Mol Genet, Toon, Ehime 7910295, Japan.	shigeki@m.ehime-u.ac.jp	Yamasaki, Kenshi/C-8905-2018	Yamasaki, Kenshi/0000-0002-5495-4956				Ahmad SA, 2001, CANCER RES, V61, P1255; Barna M, 2002, DEV CELL, V3, P499, DOI 10.1016/S1534-5807(02)00289-7; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; Care A, 1998, ONCOGENE, V16, P3285, DOI 10.1038/sj.onc.1201875; Care A, 1996, MOL CELL BIOL, V16, P4842; Care A, 2001, CANCER RES, V61, P6532; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; Etoh T, 2001, CANCER RES, V61, P2145; Felicetti F, 2004, ONCOGENE, V23, P4567, DOI 10.1038/sj.onc.1207597; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Johnson C, 2004, CIRC RES, V94, P262, DOI 10.1161/01.RES.0000111527.42357.62; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Shanmugam K, 1997, J BIOL CHEM, V272, P19081, DOI 10.1074/jbc.272.30.19081; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Tanaka M, 2004, J BIOL CHEM, V279, P41950, DOI 10.1074/jbc.M400086200; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375	27	41	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					339	348		10.1038/sj.onc.1209800	http://dx.doi.org/10.1038/sj.onc.1209800			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16862184				2022-12-25	WOS:000243544000003
J	Galander, M; Uppsten, M; Uhlin, U; Lendzian, F				Galander, Marcus; Uppsten, Malin; Uhlin, Ulla; Lendzian, Friedhelm			Orientation of the tyrosyl radical in Salmonella typhimurium class Ib ribonucleotide reductase determined by high field EPR of R2F single crystals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; ESCHERICHIA-COLI; MYCOBACTERIUM-TUBERCULOSIS; PEPTIDE INHIBITORS; ACTIVE FORM; AMINO-ACID; PROTEIN; MECHANISM; COFACTOR; SUBUNIT	The R2 protein of class I ribonucleotide reductase (RNR) generates and stores a tyrosyl radical, located next to a diferric iron center, which is essential for ribonucleotide reduction and thus DNA synthesis. X-ray structures of class Ia and Ib proteins from various organisms served as bases for detailed mechanistic suggestions. The active site tyrosine in R2F of class Ib RNR of Salmonella typhimurium is located at larger distance to the diiron site, and shows a different side chain orientation, as compared with the tyrosine in R2 of class Ia RNR from Escherichia coli. No structural information has been available for the active tyrosyl radical in R2F. Here we report on high field EPR experiments of single crystals of R2F from S. typhimurium, containing the radical Tyr-105(.). Full rotational pattern of the spectra were recorded, and the orientation of the g-tensor axes were determined, which directly reflect the orientation of the radical Tyr-105 (.) in the crystal frame. Comparison with the orientation of the reduced tyrosine Tyr-105-OH from the x-ray structure reveals a rotation of the tyrosyl side chain, which reduces the distance between the tyrosyl radical and the nearest iron ligands toward similar values as observed earlier for Tyr-122 (.) in E. coli R2. Presence of the substrate binding subunit R1E did not change the EPR spectra of Tyr-105(.), indicating that binding of R2E alone induces no structural change of the diiron site. The present study demonstrates that structural and functional information about active radical states can be obtained by combining x-ray and high-field-EPR crystallography.	Swedish Univ Agr Sci, Uppsala Biomed Ctr, Dept Biol Mol, S-75007 Uppsala, Sweden; Tech Univ Berlin, Max Volmer Lab Biophys Chem, D-10623 Berlin, Germany	Swedish University of Agricultural Sciences; Technical University of Berlin	Uhlin, U (corresponding author), Swedish Univ Agr Sci, Uppsala Biomed Ctr, Dept Biol Mol, Box 590, S-75007 Uppsala, Sweden.	uhlin@molbio.lu; f.lendzian@tu-berlin.de						Allard P, 1996, J AM CHEM SOC, V118, P895, DOI 10.1021/ja9529192; Atherton N. M, 1993, PRINCIPLES ELECT SPI; Bar G, 2001, J AM CHEM SOC, V123, P3569, DOI 10.1021/ja003108n; Bennati M, 2005, J AM CHEM SOC, V127, P15014, DOI 10.1021/ja054991y; Bennati M, 2005, BIOL CHEM, V386, P1007, DOI 10.1515/BC.2005.117; Bleifuss G, 2001, BIOCHEMISTRY-US, V40, P15362, DOI 10.1021/bi010707d; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8024, DOI 10.1021/ja00097a009; Duboc-Toia C, 2003, J AM CHEM SOC, V125, P38, DOI 10.1021/ja026690j; EATON JW, 1998, OCTAVE COMPUTER PROG; Eklund H, 2001, PROG BIOPHYS MOL BIO, V77, P177, DOI 10.1016/S0079-6107(01)00014-1; Eliasson R, 1996, J BIOL CHEM, V271, P26582, DOI 10.1074/jbc.271.43.26582; Engstrom M, 2000, J PHYS CHEM A, V104, P5149, DOI 10.1021/jp0006633; Eriksson M, 1998, BIOCHEMISTRY-US, V37, P13359, DOI 10.1021/bi981380s; Fontecave M, 2002, PROG NUCLEIC ACID RE, V72, P95, DOI 10.1016/S0079-6603(02)72068-0; Ge J, 2003, BIOCHEMISTRY-US, V42, P10071, DOI 10.1021/bi034374r; Gerfen GJ, 1996, J AM CHEM SOC, V118, P8192, DOI 10.1021/ja960363s; HELLER C, 1960, J CHEM PHYS, V32, P1535, DOI 10.1063/1.1730955; Himo F, 1997, BIOPHYS J, V72, P1556, DOI 10.1016/S0006-3495(97)78803-9; Hofbauer W, 2001, P NATL ACAD SCI USA, V98, P6623, DOI 10.1073/pnas.101127598; Hoganson CW, 1996, J AM CHEM SOC, V118, P4672, DOI 10.1021/ja953979a; Hogbom M, 2003, P NATL ACAD SCI USA, V100, P3209, DOI 10.1073/pnas.0536684100; Hogbom M, 2002, BIOCHEMISTRY-US, V41, P1381, DOI 10.1021/bi011429l; Huque Y, 2000, J BIOL CHEM, V275, P25365, DOI 10.1074/jbc.M002751200; Ivancich A, 2001, BIOCHEMISTRY-US, V40, P6860, DOI 10.1021/bi002826j; Jordan A, 1996, J BIOL CHEM, V271, P8779, DOI 10.1074/jbc.271.15.8779; JORDAN A, 1994, J BACTERIOL, V176, P3420, DOI 10.1128/jb.176.11.3420-3427.1994; JORDAN A, 1994, P NATL ACAD SCI USA, V91, P12892, DOI 10.1073/pnas.91.26.12892; Jordan A, 1996, MOL MICROBIOL, V19, P777, DOI 10.1046/j.1365-2958.1996.424950.x; Jordan A, 1995, GENE, V167, P75, DOI 10.1016/0378-1119(95)00656-7; Kolberg M, 2004, BBA-PROTEINS PROTEOM, V1699, P1, DOI 10.1016/j.bbapap.2004.02.007; Lendzian F, 1996, J AM CHEM SOC, V118, P8111, DOI 10.1021/ja960917r; Lendzian F, 2005, BBA-BIOENERGETICS, V1707, P67, DOI 10.1016/j.bbabio.2004.02.011; Licht S, 1996, SCIENCE, V271, P477, DOI 10.1126/science.271.5248.477; Liu A, 1998, BIOCHEMISTRY-US, V37, P16369, DOI 10.1021/bi981471p; Liu A, 1998, BIOCHEM BIOPH RES CO, V246, P740, DOI 10.1006/bbrc.1998.8701; Liu AM, 2000, J AM CHEM SOC, V122, P1974, DOI 10.1021/ja990123n; Logan DT, 1999, SCIENCE, V283, P1499, DOI 10.1126/science.283.5407.1499; LYCKSELL PO, 1994, BIOCHEMISTRY-US, V33, P2838, DOI 10.1021/bi00176a013; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; Mezzetti A, 1999, J PHYS CHEM A, V103, P9636, DOI 10.1021/jp9903763; Ollagnier S, 1996, J BIOL CHEM, V271, P9410, DOI 10.1074/jbc.271.16.9410; Pellegrini M, 2000, BIOCHEMISTRY-US, V39, P12210, DOI 10.1021/bi001323a; Pender BA, 2001, J MED CHEM, V44, P36, DOI 10.1021/jm000335r; Press WH., 2002, NUMERICAL RECIPES C, V2; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; Schmidt PP, 1996, J BIOL CHEM, V271, P23615, DOI 10.1074/jbc.271.39.23615; Schunemann V, 2004, J BIOL CHEM, V279, P10919, DOI 10.1074/jbc.M307884200; Scotti C, 1996, MICROBIOL-SGM, V142, P2995, DOI 10.1099/13500872-142-11-2995; Seyedsayamdost MR, 2006, J AM CHEM SOC, V128, P1562, DOI 10.1021/ja055927j; Siegbahn PEM, 1998, J PHYS CHEM B, V102, P10622, DOI 10.1021/jp9827835; Siegbahn PEM, 1998, J AM CHEM SOC, V120, P8417, DOI 10.1021/ja9736065; Sintchak MD, 2002, NAT STRUCT BIOL, V9, P293, DOI 10.1038/nsb774; Sjoberg BM, 1997, STRUCT BOND, V88, P139; SJOBERG BM, 1983, J BIOL CHEM, V258, P8060; SJOBERG BM, 1994, STRUCTURE, V2, P793, DOI 10.1016/S0969-2126(94)00080-8; Sjoberg BM, 2002, METHOD ENZYMOL, V348, P1; STESMANS A, 1989, REV SCI INSTRUM, V60, P2949, DOI 10.1063/1.1140633; Stubbe J, 2003, CHEM REV, V103, P2167, DOI 10.1021/cr020421u; Stubbe J, 1998, TRENDS BIOCHEM SCI, V23, P438, DOI 10.1016/S0968-0004(98)01296-1; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; THELANDER L, 1976, J BIOL CHEM, V251, P1398; Torrents E, 2005, P NATL ACAD SCI USA, V102, P17946, DOI 10.1073/pnas.0506410102; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; UHLIN U, 1993, FEBS LETT, V336, P148, DOI 10.1016/0014-5793(93)81629-E; Un S, 2001, J AM CHEM SOC, V123, P3048, DOI 10.1021/ja003650b; Uppsten M, 2004, FEBS LETT, V569, P117, DOI 10.1016/j.febslet.2004.05.059; Uppsten M, 2003, ACTA CRYSTALLOGR D, V59, P1081, DOI 10.1107/S0907444903006942; Uppsten M, 2006, J MOL BIOL, V359, P365, DOI 10.1016/j.jmb.2006.03.035; van Dam PJ, 1998, J AM CHEM SOC, V120, P5080, DOI 10.1021/ja9737127; van der Donk WA, 1998, BIOCHEMISTRY-US, V37, P6419, DOI 10.1021/bi9729357; YANG FD, 1994, J BACTERIOL, V176, P6738, DOI 10.1128/JB.176.21.6738-6743.1994	73	14	14	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31743	31752		10.1074/jbc.M605089200	http://dx.doi.org/10.1074/jbc.M605089200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16854982	Bronze			2022-12-25	WOS:000241235300061
J	Aisenbrey, C; Sizun, C; Koch, J; Herget, M; Abele, R; Bechinger, B; Tampe, R				Aisenbrey, Christopher; Sizun, Christina; Koch, Joachim; Herget, Meike; Abele, Rupert; Bechinger, Burkhard; Tampe, Robert			Structure and dynamics of membrane-associated ICP47, a viral inhibitor of the MHC I antigen-processing machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE NMR-SPECTROSCOPY; VIRUS PROTEIN ICP47; MAGNETIC-RESONANCE-SPECTROSCOPY; PEPTIDE-BINDING; ATP HYDROLYSIS; ACTIVE DOMAIN; TAP; POLYPEPTIDES; COMPLEX; N-15	To evade the host's immune response, herpes simplex virus employs the immediate early gene product ICP47 (IE12) to suppress antigen presentation to cytotoxic T-lymphocytes by inhibition of the ATP-binding cassette transporter associated with antigen processing (TAP). ICP47 is a membrane-associated protein adopting an alpha-helical conformation. Its active domain was mapped to residues 3-34 and shown to encode all functional properties of the full-length protein. The active domain of ICP47 was reconstituted into oriented phospholipid bilayers and studied by proton-decoupled N-15 and H-2 solid-state NMR spectroscopy. In phospholipid bilayers, the protein adopts a helix-loop-helix structure, where the average tilt angle of the helices relative to the membrane surface is similar to 15 degrees (+/- 7 degrees). The alignment of both structured domains exhibits a mosaic spread of similar to 10 degrees. A flexible dynamic loop encompassing residues 17 and 18 separates the two helices. Refinement of the experimental data indicates that helix 1 inserts more deeply into the membrane. These novel insights into the structure of ICP47 represent an important step toward a molecular understanding of the immune evasion mechanism of herpes simplex virus and are instrumental for the design of new therapeutics.	Univ Strasbourg 1, Inst Fac Chim, CNRS, LC3,UMR 7177, F-67070 Strasbourg, France; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Frankfurt, Inst Biochem, Bioctr, D-60438 Frankfurt, Germany	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Max Planck Society; Goethe University Frankfurt	Bechinger, B (corresponding author), Univ Strasbourg 1, Inst Fac Chim, CNRS, LC3,UMR 7177, 4 Rue Blaise Pascal, F-67070 Strasbourg, France.	bechinger@chimie.u-strasbg.fr; tampe@em.uni-frankfurt.de	Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160; Sizun, Christina/0000-0002-5760-2614				Abele R, 2004, PHYSIOLOGY, V19, P216, DOI 10.1152/physiol.00002.2004; Ahn K, 1996, EMBO J, V15, P3247, DOI 10.1002/j.1460-2075.1996.tb00689.x; Aisenbrey C, 2004, J AM CHEM SOC, V126, P16676, DOI 10.1021/ja0468675; Aisenbrey C, 2004, BIOCHEMISTRY-US, V43, P10502, DOI 10.1021/bi049409h; Antoniou AN, 2002, IMMUNOLOGY, V106, P182, DOI 10.1046/j.1365-2567.2002.01415.x; Bangia N, 2005, IMMUNOLOGY, V114, P346, DOI 10.1111/j.1365-2567.2005.02103.x; Bechinger B, 1999, BIOPOLYMERS, V51, P174, DOI 10.1002/(SICI)1097-0282(1999)51:3<174::AID-BIP2>3.0.CO;2-7; Bechinger B, 2004, BBA-BIOMEMBRANES, V1666, P190, DOI 10.1016/j.bbamem.2004.08.008; BECHINGER B, 1991, J MAGN RESON, V95, P585, DOI 10.1016/0022-2364(91)90173-Q; Bechinger B., 2003, CONCEPT MAGN RESON A, V18A, P130; Beinert D, 1997, BIOCHEMISTRY-US, V36, P4694, DOI 10.1021/bi962940v; Chen M, 2003, J BIOL CHEM, V278, P29686, DOI 10.1074/jbc.M302757200; DAVIS JH, 1976, CHEM PHYS LETT, V42, P390, DOI 10.1016/0009-2614(76)80392-2; Davis JH, 1999, PROG NUCL MAG RES SP, V35, P1, DOI 10.1016/S0079-6565(99)00009-6; Ducarme P, 1998, PROTEINS, V30, P357, DOI 10.1002/(SICI)1097-0134(19980301)30:4<357::AID-PROT3>3.0.CO;2-G; FRUH K, 1995, NATURE, V375, P415, DOI 10.1038/375415a0; Galocha B, 1997, J EXP MED, V185, P1565, DOI 10.1084/jem.185.9.1565; Gorbulev S, 2001, P NATL ACAD SCI USA, V98, P3732, DOI 10.1073/pnas.061467898; Gromme M, 2002, MOL IMMUNOL, V39, P181, DOI 10.1016/S0161-5890(02)00101-3; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; Koch J, 2006, CELL MOL LIFE SCI, V63, P653, DOI 10.1007/s00018-005-5462-z; Koch J, 2004, J BIOL CHEM, V279, P10142, DOI 10.1074/jbc.M312816200; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lehner PJ, 2004, CURR OPIN IMMUNOL, V16, P82, DOI 10.1016/j.coi.2003.11.012; LEVITT MH, 1986, J CHEM PHYS, V84, P4243, DOI 10.1063/1.450046; Luca S, 2003, ACCOUNTS CHEM RES, V36, P858, DOI 10.1021/ar020232y; Neumann L, 1997, J MOL BIOL, V272, P484, DOI 10.1006/jmbi.1997.1282; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; Pfander R, 1999, BIOCHEMISTRY-US, V38, P13692, DOI 10.1021/bi9909647; SCHWYZER R, 1995, BIOPOLYMERS, V37, P5, DOI 10.1002/bip.360370104; TENG Q, 1989, J MAGN RESON, V85, P439, DOI 10.1016/0022-2364(89)90235-7; Tomazin R, 1996, EMBO J, V15, P3256, DOI 10.1002/j.1460-2075.1996.tb00690.x; Watts A, 1999, CURR OPIN BIOTECH, V10, P48, DOI 10.1016/S0958-1669(99)80009-3; Whitley RJ, 1998, CLIN INFECT DIS, V26, P541, DOI 10.1086/514600; Yewdell JW, 2005, ANNU REV IMMUNOL, V23, P651, DOI 10.1146/annurev.immunol.23.021704.115702; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1	38	58	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30365	30372		10.1074/jbc.M603000200	http://dx.doi.org/10.1074/jbc.M603000200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16835230	hybrid			2022-12-25	WOS:000241075900010
J	Hua, QX; Mayer, JP; Jia, WH; Zhang, JW; Weiss, MA				Hua, Qing-xin; Mayer, John P.; Jia, Wenhua; Zhang, Jingwen; Weiss, Michael A.			The folding nucleus of the insulin superfamily - A flexible peptide model foreshadows the native state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; SOLID-PHASE SYNTHESIS; IGF-I; STRUCTURAL INFORMATION; TRANSITION-STATE; DISULFIDE BONDS; KINETIC ROLE; PROTEIN; BINDING; GENE	Oxidative folding of insulin-like growth factor I (IGF-I) and single-chain insulin analogs proceeds via one- and two- disulfide intermediates. A predominant one- disulfide intermediate in each case contains the canonical A20 - B19 disulfide bridge (cystines 18 - 61 in IGF-I and 19 - 85 in human proinsulin). Here, we describe a disulfide-linked peptide model of this on-pathway intermediate. One peptide fragment ( 19 amino acids) spans IGF-I residues 7 - 25 ( canonical positions B8-B26 in the insulin superfamily); the other ( 18 amino acids) spans IGF-I residues 53 - 70 ( positions A12-A21 and D1-D8). Containing only half of the IGF-I sequence, the disulfide-linked polypeptide ( designated IGF-p) is not well ordered. Nascent helical elements corresponding to native alpha-helices are nonetheless observed at 4 degrees C. Furthermore, C-13-edited nuclear Overhauser effects establish transient formation of a native-like partial core; no non-native nuclear Overhauser effects are observed. Together, these observations suggest that early events in the folding of insulin-related polypeptides are nucleated by a native-like molten subdomain containing Cys(A20) and Cys(B19). We propose that nascent interactions within this subdomain orient the A20 and B19 thiolates for disulfide bond formation and stabilize the one- disulfide intermediate once formed. Substitutions in the corresponding region of insulin are associated with inefficient chain combination and impaired biosynthetic expression. The intrinsic conformational propensities of a flexible disulfide-linked peptide thus define a folding nucleus, foreshadowing the structure of the native state.	Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA; Amgen Inc, Thousand Oaks, CA 91320 USA	Case Western Reserve University; Eli Lilly; Amgen	Weiss, MA (corresponding author), 10900 Euclid Ave, Cleveland, OH 44106 USA.	maw21@case.edu			NIDDK NIH HHS [DK0697674] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Atherton E., 1990, SOLID PHASE PEPTIDE; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BALDWIN RL, 1995, J BIOMOL NMR, V5, P103; BALDWIN TO, 1993, J BIOL CHEM, V268, P10766; Bathgate RAD, 2002, J BIOL CHEM, V277, P1148, DOI 10.1074/jbc.M107882200; Bernado P, 2005, P NATL ACAD SCI USA, V102, P17002, DOI 10.1073/pnas.0506202102; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Brzozowski AM, 2002, BIOCHEMISTRY-US, V41, P9389, DOI 10.1021/bi020084j; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; BURKHARDT E, 1994, HUM GENET, V94, P91, DOI 10.1007/BF02272850; CHASSIN D, 1995, GENOMICS, V29, P465, DOI 10.1006/geno.1995.9980; Chen Y, 2004, BIOCHEMISTRY-US, V43, P9225, DOI 10.1021/bi049710y; Conklin D, 1999, GENOMICS, V60, P50, DOI 10.1006/geno.1999.5899; COOKE RM, 1991, BIOCHEMISTRY-US, V30, P5484, DOI 10.1021/bi00236a022; CREIGHTON T, 1995, PHILOS T ROY SOC B, V348, P5, DOI 10.1098/rstb.1995.0039; Creighton T.E., 1997, PROTEIN STRUCTURE PR; Creighton TE, 1997, BIOL CHEM, V378, P731; Creighton TE, 1996, FASEB J, V10, P110, DOI 10.1096/fasebj.10.1.8566531; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CREIGHTON TE, 1992, BIOESSAYS, V14, P195, DOI 10.1002/bies.950140310; De Meyts P, 2002, NAT REV DRUG DISCOV, V1, P769, DOI 10.1038/nrd917; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; DULL TJ, 1984, NATURE, V310, P777, DOI 10.1038/310777a0; Dyson HJ, 1996, ANNU REV PHYS CHEM, V47, P369, DOI 10.1146/annurev.physchem.47.1.369; Guo ZY, 2001, BIOL CHEM, V382, P443, DOI 10.1515/BC.2001.054; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 2002, DIABETES, V51, pS455, DOI 10.2337/diabetes.51.2007.S455; HOBER S, 1992, BIOCHEMISTRY-US, V31, P1749, DOI 10.1021/bi00121a024; Hsu SY, 1999, MOL ENDOCRINOL, V13, P2163, DOI 10.1210/me.13.12.2163; Hua QX, 2004, PROG BIOCHEM BIOPHYS, V31, P1; Hua QX, 1996, J MOL BIOL, V259, P297, DOI 10.1006/jmbi.1996.0320; HUA QX, 1995, NAT STRUCT BIOL, V2, P129, DOI 10.1038/nsb0295-129; Hua QX, 2002, BIOCHEMISTRY-US, V41, P14700, DOI 10.1021/bi0202981; Hua QX, 2002, J BIOL CHEM, V277, P43443, DOI 10.1074/jbc.M206107200; Hua QX, 1996, J MOL BIOL, V264, P390, DOI 10.1006/jmbi.1996.0648; HUA QX, 1991, NATURE, V354, P238, DOI 10.1038/354238a0; Hua QX, 2001, BIOCHEMISTRY-US, V40, P12299, DOI 10.1021/bi011021o; HUA QX, 1993, J MOL BIOL, V230, P387, DOI 10.1006/jmbi.1993.1156; Huang K, 2004, J MOL BIOL, V341, P529, DOI 10.1016/j.jmb.2004.05.023; HUDSON P, 1984, EMBO J, V3, P2333, DOI 10.1002/j.1460-2075.1984.tb02135.x; HUDSON P, 1983, NATURE, V301, P628, DOI 10.1038/301628a0; Jacoby E, 1996, J MOL BIOL, V258, P136, DOI 10.1006/jmbi.1996.0239; Jansson M, 1998, J BIOL CHEM, V273, P24701, DOI 10.1074/jbc.273.38.24701; Jha AK, 2005, P NATL ACAD SCI USA, V102, P13099, DOI 10.1073/pnas.0506078102; Katugampola S, 2003, TRENDS PHARMACOL SCI, V24, P30, DOI 10.1016/S0165-6147(02)00007-X; Krishna MMG, 2004, METHODS, V34, P51, DOI 10.1016/j.ymeth.2004.03.005; Lazaridis T, 1997, SCIENCE, V278, P1928, DOI 10.1126/science.278.5345.1928; Liu M, 2005, J BIOL CHEM, V280, P13209, DOI 10.1074/jbc.C400475200; MARKUSSEN J, 1985, INT J PEPT PROT RES, V25, P431; Matagne A, 1997, J MOL BIOL, V267, P1068, DOI 10.1006/jmbi.1997.0963; MATSUEDA GR, 1981, PEPTIDES, V2, P45, DOI 10.1016/S0196-9781(81)80010-1; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; MILLER JA, 1993, BIOCHEMISTRY-US, V32, P5203, DOI 10.1021/bi00070a032; Milner SJ, 1999, BIOTECHNOL BIOENG, V62, P693; NARHI LO, 1993, BIOCHEMISTRY-US, V32, P5214, DOI 10.1021/bi00070a033; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; Ohnishi S, 2004, BIOCHEMISTRY-US, V43, P4064, DOI 10.1021/bi049879b; Onuchic JN, 1997, ANNU REV PHYS CHEM, V48, P545, DOI 10.1146/annurev.physchem.48.1.545; PTITSYN OB, 1991, FEBS LETT, V285, P176, DOI 10.1016/0014-5793(91)80799-9; Qiao ZS, 2001, BIOCHEMISTRY-US, V40, P2662, DOI 10.1021/bi001613r; Raleigh DP, 2005, PROTEIN PEPTIDE LETT, V12, P117, DOI 10.2174/0929866053005809; ROTWEIN P, 1986, J BIOL CHEM, V261, P4828; Rumbley J, 2001, P NATL ACAD SCI USA, V98, P105, DOI 10.1073/pnas.98.1.105; SALI A, 1994, NATURE, V369, P248, DOI 10.1038/369248a0; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SATO A, 1993, INT J PEPT PROT RES, V41, P433; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; STALEY JP, 1992, P NATL ACAD SCI USA, V89, P1519, DOI 10.1073/pnas.89.5.1519; TANG JG, 1990, BIOCHEM J, V268, P429, DOI 10.1042/bj2680429; Vajdos FF, 2001, BIOCHEMISTRY-US, V40, P11022, DOI 10.1021/bi0109111; WANG CC, 1991, TRENDS BIOCHEM SCI, V16, P279, DOI 10.1016/0968-0004(91)90114-B; WANG SS, 1973, J AM CHEM SOC, V95, P1328, DOI 10.1021/ja00785a602; Weiss MA, 2002, BIOCHEMISTRY-US, V41, P809, DOI 10.1021/bi011839+; Weiss MA, 2000, BIOCHEMISTRY-US, V39, P15429, DOI 10.1021/bi001905s; WEISSMAN JS, 1992, P NATL ACAD SCI USA, V89, P9900, DOI 10.1073/pnas.89.20.9900; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yan H, 2003, PROTEIN SCI, V12, P768, DOI 10.1110/ps.0237203; Yokota A, 2000, J MOL BIOL, V295, P1275, DOI 10.1006/jmbi.1999.3442; Zhang YS, 1996, SCI CHINA SER C, V39, P225; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	84	41	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28131	28142		10.1074/jbc.M602616200	http://dx.doi.org/10.1074/jbc.M602616200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16864583	hybrid			2022-12-25	WOS:000240534400051
J	Raine, A; Lovmar, M; Wikberg, J; Ehrenberg, M				Raine, Amanda; Lovmar, Martin; Wikberg, Jarl; Ehrenberg, Mans			Trigger factor binding to ribosomes with nascent peptide chains of varying lengths and sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; ESCHERICHIA-COLI RIBOSOME; PROTEINS; CHAPERONE; DNAK; L23; ISOMERASE; MEMBRANE; DOMAIN; SITE	Trigger factor (TF) is the first protein-folding chaperone to interact with a nascent peptide chain as it emerges from the ribosome. Here, we have used a spin down assay to estimate the affinities for the binding of TF to ribosome nascent chain complexes (RNCs) with peptides of varying lengths and sequences. An in vitro system for protein synthesis assembled from purified Escherichia coli components was used to produce RNCs stalled on truncated mRNAs. The affinity of TF to RNCs exposing RNA polymerase sequences increased with the length of the nascent peptides. TF bound to RNA polymerase RNCs with significantly higher affinity than to inner membrane protein leader peptidase and bacterioopsin RNCs. The latter two RNCs are substrates for signal recognition particle, suggesting complementary affinities of TF and signal recognition particle to nascent peptides targeted for cytoplasm and membrane.	Uppsala Univ, Dept Cell & Mol Biol, Biomed Ctr, S-75124 Uppsala, Sweden; Uppsala Univ, Dept Pharmaceut Biosci, Biomed Ctr, S-75124 Uppsala, Sweden	Uppsala University; Uppsala University	Ehrenberg, M (corresponding author), Uppsala Univ, Dept Cell & Mol Biol, Biomed Ctr, Box 596, S-75124 Uppsala, Sweden.	ehrenberg@xray.bmc.uu.se	Raine, Amanda/L-1354-2019	Raine, Amanda/0000-0002-2775-6516				Antoun Ayman, 2004, Biol Proced Online, V6, P35, DOI 10.1251/bpo71; Deuerling E, 2003, MOL MICROBIOL, V47, P1317, DOI 10.1046/j.1365-2958.2003.03370.x; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Ehrenberg M, 1990, RIBOSOMES PROTEIN SY, P101; Eisner G, 2003, J CELL BIOL, V163, P35, DOI 10.1083/jcb.200306069; Ferbitz L, 2004, NATURE, V431, P590, DOI 10.1038/nature02899; Flanagan JJ, 2003, J BIOL CHEM, V278, P18628, DOI 10.1074/jbc.M300173200; Genevaux P, 2004, EMBO REP, V5, P195, DOI 10.1038/sj.embor.7400067; Gu SQ, 2003, RNA, V9, P566, DOI 10.1261/rna.2196403; Hesterkamp T, 1997, J BIOL CHEM, V272, P21865, DOI 10.1074/jbc.272.35.21865; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; Hundley HA, 2005, SCIENCE, V308, P1032, DOI 10.1126/science.1109247; Kramer G, 2004, J BIOL CHEM, V279, P14165, DOI 10.1074/jbc.M313635200; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; Lovmar M, 2004, J BIOL CHEM, V279, P53506, DOI 10.1074/jbc.M401625200; Ludlam AV, 2004, P NATL ACAD SCI USA, V101, P13436, DOI 10.1073/pnas.0405868101; Maier R, 2003, J MOL BIOL, V326, P585, DOI 10.1016/S0022-2836(02)01427-4; Maier R, 2001, J MOL BIOL, V314, P1181, DOI 10.1006/jmbi.2000.5192; Pal S, 1999, J BIOL CHEM, V274, P32771, DOI 10.1074/jbc.274.46.32771; Patzelt H, 2001, P NATL ACAD SCI USA, V98, P14244, DOI 10.1073/pnas.261432298; Raine A, 2003, BIOCHIMIE, V85, P659, DOI 10.1016/S0300-9084(03)00130-5; Raine A, 2004, BIOCHIMIE, V86, P495, DOI 10.1016/j.biochi.2004.05.004; Rauch T, 2005, MOL MICROBIOL, V57, P357, DOI 10.1111/j.1365-2958.2005.04690.x; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; Ullers RS, 2004, P NATL ACAD SCI USA, V101, P7583, DOI 10.1073/pnas.0402398101; Ullers RS, 2003, J CELL BIOL, V161, P679, DOI 10.1083/jcb.200302130; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; Woolhead CA, 2004, CELL, V116, P725, DOI 10.1016/S0092-8674(04)00169-2	28	31	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28033	28038		10.1074/jbc.M605753200	http://dx.doi.org/10.1074/jbc.M605753200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16829677	hybrid			2022-12-25	WOS:000240534400040
J	Kerssen, D; Hambruch, E; Klaas, W; Platta, HW; de Kruijff, B; Erdmann, R; Kunau, WH; Schliebs, W				Kerssen, Daniela; Hambruch, Eva; Klaas, Wibke; Platta, Harald W.; de Kruijff, Ben; Erdmann, Ralf; Kunau, Wolf-H.; Schliebs, Wolfgang			Membrane association of the cycling peroxisome import receptor Pex5p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGETING SIGNAL RECEPTOR; MATRIX PROTEIN IMPORT; SACCHAROMYCES-CEREVISIAE; PTS1 RECEPTOR; BINDING-SITES; RAT-LIVER; ALCOHOL OXIDASE; IDENTIFICATION; MACHINERY; DOCKING	Peroxisomal proteins carrying a peroxisome targeting signal type 1 (PTS1) are recognized in the cytosol by the cycling import receptor Pex5p. The receptor-cargo complex docks at the peroxisomal membrane where it associates with multimeric protein complexes, referred to as the docking and RING finger complexes. Here we have identified regions within the Saccharomyces cerevisiae Pex5p sequence that interconnect the receptor-cargo complex with the docking complex. Site-directed mutagenesis of the conserved tryptophan residue within a reverse WXXXF motif abolished two-hybrid binding with the N-terminal half of Pex14p. In combination with an additional mutation introduced into the Pex13p-binding site, we generated a Pex5p mutant defective in a stable association not only with the docking complex but also with the RING finger peroxins at the membrane. Surprisingly, PTS1 proteins are still imported into peroxisomes in these mutant cells. Because these mutations had no significant effect on the membrane binding properties of Pex5p, we examined yeast and human Pex5p for intrinsic lipid binding activity. In vitro analyses demonstrated that both proteins have the potential to insert spontaneously into phospholipid membranes. Altogether, these data strongly suggest that a translocation-competent state of the PTS1 receptor enters the membrane via protein-lipid interactions before it tightly associates with other peroxins.	Ruhr Univ Bochum, Inst Physiol Chem, Abt Syst Biol, D-44780 Bochum, Germany; Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Dept Biochem Membranes, NL-3584 CH Utrecht, Netherlands	Ruhr University Bochum; Utrecht University	Schliebs, W (corresponding author), Ruhr Univ Bochum, Inst Physiol Chem, Abt Syst Biol, D-44780 Bochum, Germany.	wolfgang.schliebs@rub.de	Platta, Harald Wolfgang/G-7423-2014	Platta, Harald Wolfgang/0000-0001-8968-7280; Schliebs, Wolfgang/0000-0003-2762-3403				Agne B, 2003, MOL CELL, V11, P635, DOI 10.1016/S1097-2765(03)00062-5; Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Barnett P, 2000, EMBO J, V19, P6382, DOI 10.1093/emboj/19.23.6382; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Choe J, 2003, BIOCHEMISTRY-US, V42, P10915, DOI 10.1021/bi034248n; Dammai V, 2001, CELL, V105, P187, DOI 10.1016/S0092-8674(01)00310-5; Demel R A, 1994, Subcell Biochem, V23, P83; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; Eckert JH, 2003, REV PHYSIOL BIOCH P, V147, P75, DOI 10.1007/s10254-003-0007-z; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; ELGERSMA Y, 1996, J BIOL CHEM, V271, P185; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P2432; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; Gouveia AM, 2003, J BIOL CHEM, V278, P4389, DOI 10.1074/jbc.C200650200; Gouveia AMM, 2000, J BIOL CHEM, V275, P32444, DOI 10.1074/jbc.M004366200; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Gunkel K, 2004, MOL BIOL CELL, V15, P1347, DOI 10.1091/mbc.E03-04-0258; HARDEMAN D, 1990, INT J BIOCHEM, V22, P1413, DOI 10.1016/0020-711X(90)90231-Q; Hazra PP, 2002, TRAFFIC, V3, P560, DOI 10.1034/j.1600-0854.2002.30806.x; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Huhse B, 1998, J CELL BIOL, V140, P49, DOI 10.1083/jcb.140.1.49; Kal AJ, 1999, MOL BIOL CELL, V10, P1859, DOI 10.1091/mbc.10.6.1859; Kikuchi M, 2004, J BIOL CHEM, V279, P421, DOI 10.1074/jbc.M305623200; Klein ATJ, 2002, J BIOL CHEM, V277, P25011, DOI 10.1074/jbc.M203254200; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; KRAGLER F, 1993, J CELL BIOL, V120, P665, DOI 10.1083/jcb.120.3.665; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; Lazarow PB, 2003, CURR OPIN CELL BIOL, V15, P489, DOI 10.1016/S0955-0674(03)00082-6; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; Nair DM, 2004, J CELL BIOL, V167, P599, DOI 10.1083/jcb.200407119; Niederhoff K, 2005, J BIOL CHEM, V280, P35571, DOI 10.1074/jbc.M502460200; Nito K, 2002, PLANT CELL PHYSIOL, V43, P355, DOI 10.1093/pcp/pcf057; Oliveira MEM, 2002, BBA-BIOMEMBRANES, V1567, P13, DOI 10.1016/S0005-2736(02)00635-1; Otera H, 2002, MOL CELL BIOL, V22, P1639, DOI 10.1128/MCB.22.6.1639-1655.2002; Parkes JA, 2003, MOL MEMBR BIOL, V20, P61, DOI 10.1080/0968768031000047859; Platta HW, 2005, NAT CELL BIOL, V7, P817, DOI 10.1038/ncb1281; Rehling P, 2000, J BIOL CHEM, V275, P3593, DOI 10.1074/jbc.275.5.3593; Rehling P, 1996, EMBO J, V15, P2901, DOI 10.1002/j.1460-2075.1996.tb00653.x; ROUSER G, 1970, LIPIDS, V5, P496; Saidowsky J, 2001, J BIOL CHEM, V276, P34524, DOI 10.1074/jbc.M104647200; Salomons FA, 2000, J BIOL CHEM, V275, P12603, DOI 10.1074/jbc.275.17.12603; Schafer A, 2004, MOL CELL BIOL, V24, P8895, DOI 10.1128/MCB.24.20.8895-8906.2004; Schell-Steven A, 2005, MOL CELL BIOL, V25, P3007, DOI 10.1128/MCB.25.8.3007-3018.2005; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Schnell DJ, 2003, CELL, V112, P491, DOI 10.1016/S0092-8674(03)00110-7; Sparkes IA, 2002, MOL MEMBR BIOL, V19, P171, DOI 10.1080/09687680210159422; Stein K, 2002, MOL CELL BIOL, V22, P6056, DOI 10.1128/MCB.22.17.6056-6069.2002; TERLECKY SR, 1995, EMBO J, V14, P3627, DOI 10.1002/j.1460-2075.1995.tb00032.x; van der Klei IJ, 2002, CURR OPIN CELL BIOL, V14, P500, DOI 10.1016/S0955-0674(02)00354-X; vanRaalte ALJ, 1996, EUR J BIOCHEM, V235, P207; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; Williams C, 2005, FEBS LETT, V579, P3416, DOI 10.1016/j.febslet.2005.05.011	59	85	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27003	27015		10.1074/jbc.M509257200	http://dx.doi.org/10.1074/jbc.M509257200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16849337	hybrid			2022-12-25	WOS:000240397700027
J	Schuttelkopf, AW; Andersen, OA; Rao, FV; Allwood, M; Lloyd, C; Eggleston, IM; Van Aalten, DMF				Schuttelkopf, Alexander W.; Andersen, Ole A.; Rao, Francesco V.; Allwood, Matthew; Lloyd, Clare; Eggleston, Ian M.; Van Aalten, Daan M. F.			Screening-based discovery and structural dissection of a novel family 18 chitinase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRODUCT CYCLOPENTAPEPTIDE INHIBITORS; PLASMA CHITOTRIOSIDASE ACTIVITY; SACCHAROMYCES-CEREVISIAE; CELL-SEPARATION; DRUG DISCOVERY; ALLOSAMIDIN; RESOLUTION; SUBSTRATE; COMPLEX; MIMICRY	Family 18 chitinases play key roles in the life cycles of a variety of organisms ranging from bacteria to man. Very recently it has been shown that one of the mammalian chitinases is highly overexpressed in the asthmatic lung and contributes to the pathogenic process through recruitment of inflammatory cells. Although several potent natural product chitinase inhibitors have been identified, their chemotherapeutic potential or their use as cell biological tools is limited due to their size, complex chemistry, and limited availability. We describe a virtual screening-based approach to identification of a novel, purine-based, chitinase inhibitor. This inhibitor acts in the low micromolar (K-i = 2.8 +/- 0.2 mu M) range in a competitive mode. Dissection of the binding mode by x-ray crystallography reveals that the compound, which consists of two linked caffeine moieties, binds in the active site through extensive and not previously observed stacking interactions with conserved, solvent exposed tryptophans. Such exposed aromatics are also present in the structures of many other carbohydrate processing enzymes. The compound exhibits favorable chemical properties and is likely to be useful as a general scaffold for development of pan-family 18 chitinase inhibitors.	Univ Dundee, Div Biol Chem & Mol Microbiol, Wellcome Trust Bioctr, Sch Life Sci, Dundee DD1 5EH, Scotland; Univ London Imperial Coll Sci & Technol, Leukocyte Biol Sect, Fac Med, London SW7 2AZ, England	University of Dundee; Imperial College London	Van Aalten, DMF (corresponding author), Univ Dundee, Div Biol Chem & Mol Microbiol, Wellcome Trust Bioctr, Sch Life Sci, Dow St, Dundee DD1 5EH, Scotland.	dava@davapc1.bioch.dundee.ac.uk	eggleston, Ian/E-2375-2011	van Aalten, Daan/0000-0002-1499-6908; Lloyd, Clare/0000-0001-8977-6726; Eggleston, Ian/0000-0003-0569-0082; Andersen, Ole Andreas/0000-0002-0408-645X	Medical Research Council [G0400503B] Funding Source: researchfish; Wellcome Trust [087618] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Wellcome Trust(Wellcome TrustEuropean Commission)		Andersen OA, 2005, NAT PROD REP, V22, P563, DOI 10.1039/b416660b; Arai N, 2000, CHEM PHARM BULL, V48, P1442, DOI 10.1248/cpb.48.1442; Boot RG, 1998, J BIOL CHEM, V273, P25680, DOI 10.1074/jbc.273.40.25680; Braendvang M, 2005, BIOORGAN MED CHEM, V13, P6360, DOI 10.1016/j.bmc.2005.06.054; CABIB E, 1992, J GEN MICROBIOL, V138, P97, DOI 10.1099/00221287-138-1-97; Carr RAE, 2005, DRUG DISCOV TODAY, V10, P987, DOI 10.1016/S1359-6446(05)03511-7; Cavallaro RA, 1999, J MED CHEM, V42, P2527, DOI 10.1021/jm980469t; Chiosis G, 2003, CURR CANCER DRUG TAR, V3, P371, DOI 10.2174/1568009033481778; Erlanson DA, 2004, J MED CHEM, V47, P3463, DOI 10.1021/jm040031v; Fusetti F, 2002, J BIOL CHEM, V277, P25537, DOI 10.1074/jbc.M201636200; Gray N, 1999, CURR MED CHEM, V6, P859; Guo YF, 1995, J INHERIT METAB DIS, V18, P717, DOI 10.1007/BF02436762; HOLLAK CEM, 1994, J CLIN INVEST, V93, P1288, DOI 10.1172/JCI117084; Hopkins AL, 2004, DRUG DISCOV TODAY, V9, P430, DOI 10.1016/S1359-6446(04)03069-7; Houston DR, 2002, BIOCHEM J, V368, P23, DOI 10.1042/BJ20021034; Houston DR, 2002, P NATL ACAD SCI USA, V99, P9127, DOI 10.1073/pnas.132060599; Izumida H, 1996, J ANTIBIOT, V49, P76, DOI 10.7164/antibiotics.49.76; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOLLMAN P, 1993, CHEM REV, V93, P2395, DOI 10.1021/cr00023a004; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; Labadaridis I, 2005, ARCH DIS CHILD-FETAL, V90, pF531, DOI 10.1136/adc.2004.051284; Leatherbarrow R.J., 2001, GRAFIT VERSION 5; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; Rao FV, 2005, CHEM BIOL, V12, P973, DOI 10.1016/j.chembiol.2005.07.009; Rao FV, 2005, CHEM BIOL, V12, P65, DOI 10.1016/j.chembiol.2004.10.013; Rao FV, 2003, J BIOL CHEM, V278, P20110, DOI 10.1074/jbc.M300362200; SAKUDA S, 1986, TETRAHEDRON LETT, V27, P2475, DOI 10.1016/S0040-4039(00)84560-8; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Shiomi K, 2000, TETRAHEDRON LETT, V41, P2141, DOI 10.1016/S0040-4039(00)00099-X; Takaya N, 1998, BIOSCI BIOTECH BIOCH, V62, P60, DOI 10.1271/bbb.62.60; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANSCHELTINGA ACT, 1995, BIOCHEMISTRY-US, V34, P15619, DOI 10.1021/bi00048a003; Vivet-Boudou V, 2006, CELL MOL LIFE SCI, V63, P163, DOI 10.1007/s00018-005-5367-x	37	48	54	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27278	27285		10.1074/jbc.M604048200	http://dx.doi.org/10.1074/jbc.M604048200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16844689	hybrid			2022-12-25	WOS:000240397700054
J	Kammanadiminti, SJ; Chadee, K				Kammanadiminti, Srinivas J.; Chadee, Kris			Suppression of NF-kappa B activation by Entamoeba histolytica in intestinal epithelial cells is mediated by heat shock Protein 27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; CYSTEINE PROTEINASES; APOPTOSIS UPSTREAM; GENE-EXPRESSION; KINASE PATHWAY; TISSUE-DAMAGE; IMMUNE CELLS; IN-VITRO; ALPHA; INDUCTION	Little is known about the pathogenesis of Entamoeba histolytica and how epithelial cells respond to the parasite. Herein, we characterized the interactions between E. histolytica and colonic epithelial cells and the role macrophages play in modulating epithelial cell responses. The human colonic epithelial cell lines Caco-2 and T84 were grown either as monoculture or co-cultured in transwell plates with differentiated human THP-1 macrophages for 24 h before stimulation with soluble amebic proteins (SAP). In naive epithelial cells, prolonged stimulation with SAP reduced the levels of heat shock protein (Hsp) 27 and 72. However in THP-1 conditioned intestinal epithelial cells SAP enhanced Hsp27 and Hsp72, which was dependent on the activation of ERK MAP kinase. Hsp synthesis induced by SAP conferred protection against oxidative and apoptotic injuries. Treatment with SAP inhibited NF-kappa B activation induced by interleukin-1 beta; specifically, the NF-kappa B-DNA binding, nuclear translocation of p65 subunit, and phosphorylation of I kappa B-alpha were reduced. Gene silencing by small interfering RNA confirmed the role of Hsp27 in suppressing NF-kappa B activation at I kappa B kinase ( IKK) level. By co-immunoprecipitation studies, we found that Hsp27 interacts with IKK-alpha and IKK-beta, and this association was increased in SAP-treated conditioned epithelial cells. Overexpression of wild type Hsp27 amplified the effects of SAP, whereas a phosphorylation-deficient mutant of Hsp27 abrogated SAP-induced NF-kappa B inhibition. In conditioned epithelial cells, Hsp27 was phosphorylated at serine 15 after prolonged exposure to SAP. This mechanism may explain the absence of colonic inflammation seen in the majority of individuals infected with E. histolytica.	Univ Calgary, Fac Med, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada	University of Calgary	Chadee, K (corresponding author), Univ Calgary, Fac Med, Dept Microbiol & Infect Dis, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	kchadee@ucalgary.ca						ASSEFFA A, 1993, ONCOL RES, V5, P11; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beere HM, 2004, J CELL SCI, V117, P2641, DOI 10.1242/jcs.01284; Boettner DR, 2005, INFECT IMMUN, V73, P3422, DOI 10.1128/IAI.73.6.3422-3430.2005; Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705; Clemons NJ, 2005, J BIOL CHEM, V280, P9005, DOI 10.1074/jbc.M414165200; DEITCH EA, 1995, CRIT CARE MED, V23, P1371, DOI 10.1097/00003246-199508000-00010; ECKMANN L, 1995, J CLIN INVEST, V96, P1269, DOI 10.1172/JCI118161; Garrido C, 2003, CELL CYCLE, V2, P579, DOI 10.4161/cc.2.6.521; Gerhard R, 2005, J BIOL CHEM, V280, P1499, DOI 10.1074/jbc.M406014200; Gilchrist CA, 1999, CURR OPIN MICROBIOL, V2, P433, DOI 10.1016/S1369-5274(99)80076-9; Guzhova IV, 1997, CELL STRESS CHAPERON, V2, P132, DOI 10.1379/1466-1268(1997)002<0132:MSPHIW>2.3.CO;2; Haller D, 2004, IMMUNOLOGY, V112, P310, DOI 10.1111/j.1365-2567.2004.01874.x; Haller D, 2000, GUT, V47, P79, DOI 10.1136/gut.47.1.79; Hecht G, 1999, AM J PHYSIOL-CELL PH, V277, pC351, DOI 10.1152/ajpcell.1999.277.3.C351; HOSOKAWA N, 1992, MOL CELL BIOL, V12, P3490, DOI 10.1128/MCB.12.8.3490; Hurley Bryan P, 2004, Curr Gastroenterol Rep, V6, P355, DOI 10.1007/s11894-004-0050-1; Huston CD, 2003, INFECT IMMUN, V71, P964, DOI 10.1128/IAI.71.2.964-972.2003; Kanzato H, 2001, BIOSCI BIOTECH BIOCH, V65, P449, DOI 10.1271/bbb.65.449; Kim SH, 1999, BIOCHEM BIOPH RES CO, V262, P516, DOI 10.1006/bbrc.1999.1229; Kohn G, 2002, SHOCK, V17, P91, DOI 10.1097/00024382-200202000-00002; Kojima K, 2003, GASTROENTEROLOGY, V124, P1395, DOI 10.1016/S0016-5085(03)00215-4; Liu TS, 2003, AM J PHYSIOL-CELL PH, V284, pC1073, DOI 10.1152/ajpcell.00134.2002; Malago JJ, 2002, CELL STRESS CHAPERON, V7, P191, DOI 10.1379/1466-1268(2002)007<0191:THSRAC>2.0.CO;2; Malhotra V, 2002, BIOCHEM BIOPH RES CO, V291, P453, DOI 10.1006/bbrc.2002.6470; McKay DM, 1996, AM J PHYSIOL-CELL PH, V270, pC418, DOI 10.1152/ajpcell.1996.270.2.C418; Moncada D, 2003, INFECT IMMUN, V71, P838, DOI 10.1128/IAI.71.2.838-844.2003; Musch MW, 2004, INFECT IMMUN, V72, P3187, DOI 10.1128/IAI.72.6.3187-3194.2004; NAGAI N, 1995, BIOCHEM BIOPH RES CO, V208, P1099, DOI 10.1006/bbrc.1995.1447; Parcellier A, 2003, MOL CELL BIOL, V23, P5790, DOI 10.1128/MCB.23.16.5790-5802.2003; Park KJ, 2003, J BIOL CHEM, V278, P35272, DOI 10.1074/jbc.M305095200; Pittet JF, 2005, J IMMUNOL, V174, P384, DOI 10.4049/jimmunol.174.1.384; Sasaki H, 2002, J IMMUNOL, V168, P5178, DOI 10.4049/jimmunol.168.10.5178; Schmitz H, 2002, AIDS, V16, P983, DOI 10.1097/00002030-200205030-00004; Schutze N, 2004, MOL CELL ENDOCRINOL, V213, P115, DOI 10.1016/j.mce.2003.10.078; Seydel KB, 1998, GASTROENTEROLOGY, V115, P1446, DOI 10.1016/S0016-5085(98)70023-X; Seydel KB, 1997, INFECT IMMUN, V65, P1631, DOI 10.1128/IAI.65.5.1631-1639.1997; Sim S, 2005, J IMMUNOL, V174, P4279, DOI 10.4049/jimmunol.174.7.4279; Stauffer W, 2003, CURR OPIN INFECT DIS, V16, P479, DOI 10.1097/00001432-200310000-00016; Steel R, 2004, J BIOL CHEM, V279, P51490, DOI 10.1074/jbc.M401314200; Tao Y, 2006, AM J PHYSIOL-CELL PH, V290, pC1018, DOI 10.1152/ajpcell.00131.2005; Tsuji M, 2000, NEUROSCI LETT, V282, P41, DOI 10.1016/S0304-3940(00)00844-2; World Health Organization W, 1998, QUAL CONTR METH MED; Yoo CG, 2000, J IMMUNOL, V164, P5416, DOI 10.4049/jimmunol.164.10.5416; Yu Y, 1997, GASTROENTEROLOGY, V112, P1536, DOI 10.1016/S0016-5085(97)70035-0; Zhang Z, 2000, MOL MICROBIOL, V37, P542, DOI 10.1046/j.1365-2958.2000.02037.x	46	61	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26112	26120		10.1074/jbc.M601988200	http://dx.doi.org/10.1074/jbc.M601988200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16840786	hybrid			2022-12-25	WOS:000240249500026
J	Kang, YJ; Seit-Nebi, A; Davis, RJ; Han, JH				Kang, Young Jun; Seit-Nebi, Alim; Davis, Roger J.; Han, Jiahuai			Multiple activation mechanisms of p38 alpha mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETRACTED ARTICLE. SEE; INDEPENDENT ACTIVATION; SIGNAL-TRANSDUCTION; MAP KINASES; JNK; AUTOPHOSPHORYLATION; ORGANIZATION; PATHWAYS; TYROSINE; TAK1	The p38 alpha MAPK participates in a variety of biological processes. Activation of p38 alpha is mediated by phosphorylation on specific regulatory tyrosine and threonine sites, and the three dual kinases, MAPK kinase 3 (MKK3), MKK4, and MKK6, are known to be the upstream activators of p38 alpha. In addition to activation by upstream kinases, p38 alpha can autoactivate when interacting with transforming growth factor-beta-activated protein kinase 1-binding protein 1 (TAB1). Here we used MKK3 and MKK6 double knock-out (MKK3/6 DKO) and MKK4/7 DKO mouse embryonic fibroblast (MEF) cells to examine activation mechanisms of p38 alpha. We confirmed that the MKK3/6 pathway is a primary mechanism for p38 alpha phosphorylation in MEF cells, and we also showed the presence of other p38 alpha activation pathways. We show that TAB1-mediated p38 alpha phosphorylation in MEF cells did not need MKK3/4/6, and it accounted for a small portion of the total p38 alpha phosphorylation that was induced by hyperosmolarity and anisomycin. We observed that a portion of peroxynitrite-induced phospho-p38 alpha is associated with an similar to 85-kDa disulfide complex in wild-type MEF cells. Peroxynitrite-induced phosphorylation of p38 alpha in the similar to 85-kDa complex is independent from MKK3/6 because only phospho-p38 alpha not associated with the disulfide complex was diminished in MKK3/6DKO cells. In addition, our data suggest interference among different pathways because TAB1 had an inhibitory effect on p38 alpha phosphorylation in the peroxynitrite-induced similar to 85-kDa complex. Mutagenesis analysis of the cysteines in p38 alpha revealed that no disulfide bond forms between p38 alpha and other proteins in the similar to 85-kDa complex, suggesting it is a p38 alpha binding partner(s) that forms disulfide bonds, which enable it to bind to p38 alpha. Therefore, multiple mechanisms of p38 alpha activation exist that can influence each other, be simultaneously activated by a given stimulus, and/or be selectively used by different stimuli in a cell type-specific manner.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Mol Med, Worcester, MA 01605 USA	Scripps Research Institute; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Han, JH (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jhan@scripps.edu	Han, J/G-4671-2010	Kang, Young Jun/0000-0001-9778-1963	NIAID NIH HHS [AI054796, AI041637] Funding Source: Medline; NIGMS NIH HHS [GM067101, GM037696] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041637, R01AI054796] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067101, P01GM037696] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe Y, 2000, J BIOL CHEM, V275, P21525, DOI 10.1074/jbc.M909629199; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Ge BX, 2003, J BIOL CHEM, V278, P2286, DOI 10.1074/jbc.M210918200; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kim L, 2005, J IMMUNOL, V174, P4178, DOI 10.4049/jimmunol.174.7.4178; Matsuyama W, 2003, J IMMUNOL, V171, P3520, DOI 10.4049/jimmunol.171.7.3520; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Ohkusu-Tsukada K, 2004, MOL CELL BIOL, V24, P6957, DOI 10.1128/MCB.24.16.6957-6966.2004; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Salvador JM, 2005, NAT IMMUNOL, V6, P390, DOI 10.1038/ni1177; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Tanno M, 2003, CIRC RES, V93, P254, DOI 10.1161/01.RES.0000083490.43943.85; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Veal EA, 2004, MOL CELL, V15, P129, DOI 10.1016/j.molcel.2004.06.021; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257	29	73	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26225	26234		10.1074/jbc.M606800200	http://dx.doi.org/10.1074/jbc.M606800200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16849316	hybrid			2022-12-25	WOS:000240249500039
J	Latreille, M; Larose, L				Latreille, Mathieu; Larose, Louise			Nck in a complex containing the catalytic subunit of protein phosphatase 1 regulates eukaryotic initiation factor 2 alpha signaling and cell survival to endoplasmic reticulum stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; INDUCED GENE-EXPRESSION; MESSENGER-RNA; TRANSLATIONAL CONTROL; ADAPTER PROTEIN; ER STRESS; GAMMA(1)34.5 PROTEIN; INHIBITION; ATF6; BINDING	Stress imposed on the endoplasmic reticulum (ER) induces the phosphorylation of the alpha-subunit of the eukaryotic initiation factor 2 (eIF2) on Ser(51). This results in transient inhibition of general translation initiation while concomitantly activating a signaling pathway that promotes the expression of genes whose products improve ER function. Conversely, dephosphorylation of eIF2 alpha Ser(51) is accomplished by protein phosphatase 1 (PP1c) complexes containing either the protein CReP or GADD34, which target PP1c to eIF2. Here, we demonstrate that the Src homology (SH) domain-containing adaptor Nck is a key component of a molecular complex that controls eIF2 alpha phosphorylation and signaling in response to ER stress. We show that overexpression of Nck decreases basal and ER stress-induced eIF2 alpha phosphorylation and the attendant induction of ATF4 and CHOP. In contrast, we demonstrate that the mouse embryonic fibroblasts lacking both isoforms of Nck (Nck1(-/)-Nck2(-/-)) show higher levels of eIF2 alpha phosphorylation and premature induction of ATF4, CHOP, and GADD34 in response to ER stress and finally, are more resistant to cell death induced by prolonged ER stress conditions. We establish that a significant amount of Nck protein localizes at the ER and is in a complex with eIF2 subunits. Further analysis of this complex revealed that it also contains the Ser/ Thr phosphatase PP1c, its regulatory subunit CReP, and dephosphorylates eIF2 alpha on Ser(51) in vitro. Overall, we demonstrate that Nck as a component of the CReP/ PP1c holophosphatase complex contributes to maintain eIF2 alpha in a hypophosphorylated state. In this manner, Nck modulates translation and eIF2 alpha signaling in response to ER stress.	McGill Univ, Polypeptide Lab, Dept Med, Montreal, PQ H3A 2B2, Canada	McGill University	Larose, L (corresponding author), McGill Univ, Polypeptide Lab, Dept Med, Strathcona Bldg,3640 Univ St,Rm W315 Montreal, Montreal, PQ H3A 2B2, Canada.	louise.larose@mcgill.ca		Latreille, Mathieu/0000-0001-8542-749X				Bladt F, 2003, MOL CELL BIOL, V23, P4586, DOI 10.1128/MCB.23.13.4586-4597.2003; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Braverman LE, 1999, J BIOL CHEM, V274, P5542, DOI 10.1074/jbc.274.9.5542; Buday L, 2002, CELL SIGNAL, V14, P723, DOI 10.1016/S0898-6568(02)00027-X; CHEN J, 2000, HEME REGULATED EIF2A, P529; Chen M, 1998, J BIOL CHEM, V273, P25171, DOI 10.1074/jbc.273.39.25171; Chen M, 2000, MOL CELL BIOL, V20, P7867, DOI 10.1128/MCB.20.21.7867-7880.2000; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Cohen PTW, 2002, J CELL SCI, V115, P241; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; Cowan CA, 2001, NATURE, V413, P174, DOI 10.1038/35093123; deHaro C, 1996, FASEB J, V10, P1378, DOI 10.1096/fasebj.10.12.8903508; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harding HP, 2002, DIABETES, V51, pS455, DOI 10.2337/diabetes.51.2007.S455; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; He B, 1998, J BIOL CHEM, V273, P20737, DOI 10.1074/jbc.273.33.20737; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; HU QJ, 1995, MOL CELL BIOL, V15, P1169; Iyer S, 2004, ACTA PAEDIATR, V93, P1195, DOI 10.1080/08035250410029362; Jousse C, 2003, J CELL BIOL, V163, P767, DOI 10.1083/jcb.200308075; KAUFMAN RJ, 2000, DOUBLE STANDED RNA A; Kebache S, 2004, J BIOL CHEM, V279, P9662, DOI 10.1074/jbc.M310535200; Kebache S, 2002, P NATL ACAD SCI USA, V99, P5406, DOI 10.1073/pnas.082483399; Kudo T, 2002, ANN NY ACAD SCI, V977, P349, DOI 10.1111/j.1749-6632.2002.tb04837.x; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; Li W, 2000, HISTOL HISTOPATHOL, V15, P947, DOI 10.14670/HH-15.947; Li XD, 2002, J BIOL CHEM, V277, P37788, DOI 10.1074/jbc.M205428200; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Lu PD, 2004, J CELL BIOL, V167, P27, DOI 10.1083/jcb.200408003; Luo SZ, 2003, J BIOL CHEM, V278, P37375, DOI 10.1074/jbc.M303619200; Lussier G, 1997, J BIOL CHEM, V272, P2688, DOI 10.1074/jbc.272.5.2688; Ma YJ, 2003, J BIOL CHEM, V278, P34864, DOI 10.1074/jbc.M301107200; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; Nguyen DT, 2004, MOL BIOL CELL, V15, P4248, DOI 10.1091/mbc.E03-11-0851; Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; O'Loghlen A, 2003, ARCH BIOCHEM BIOPHYS, V417, P194, DOI 10.1016/S0003-9861(03)00368-0; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Piper M, 2004, ANNU REV CELL DEV BI, V20, P505, DOI 10.1146/annurev.cellbio.20.010403.111746; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Song JB, 2003, SCIENCE, V300, P502, DOI 10.1126/science.1081203; Stephens SB, 2005, MOL BIOL CELL, V16, P5819, DOI 10.1091/mbc.E05-07-0685; Tan S, 2001, J CELL BIOL, V152, P997, DOI 10.1083/jcb.152.5.997; Tirasophon W, 2000, GENE DEV, V14, P2725, DOI 10.1101/gad.839400; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; VOROBIEVA N, 1995, CYTOGENET CELL GENET, V68, P91, DOI 10.1159/000133898; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zhu SH, 1996, J BIOL CHEM, V271, P24989, DOI 10.1074/jbc.271.40.24989	65	49	56	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26633	26644		10.1074/jbc.M513556200	http://dx.doi.org/10.1074/jbc.M513556200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16835242	hybrid			2022-12-25	WOS:000240249500081
J	Liu, J; Qian, N; Morrical, SW				Liu, Jie; Qian, Na; Morrical, Scott W.			Dynamics of bacteriophage T4 presynaptic filament assembly from extrinsic fluorescence measurements of GP32-single-stranded DNA interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; PROTEIN-PROTEIN INTERACTIONS; UVSY RECOMBINATION PROTEIN; GENE 59 PROTEIN; BINDING-PROTEIN; NONCOOPERATIVE BINDING; MEDIATOR PROTEINS; REPLICATION FORK; NUCLEIC-ACIDS; GP32	In the bacteriophage T4 homologous recombination system, presynaptic filament assembly on single-stranded (ssDNA) DNA requires UvsX recombinase, UvsY mediator, and Gp32 ssDNA-binding proteins. Gp32 exerts both positive and negative effects on filament assembly: positive by denaturing ssDNA secondary structure, and negative by competing with UvsX for ssDNA binding sites. UvsY is believed to help UvsX displace Gp32 from the ssDNA. To test this model we developed a real-time fluorescence assay for Gp32-ssDNA interactions during presynapsis, based on changes in the fluorescence of a 6-iodoacetamidofluorescein-Gp32 conjugate. Results demonstrate that the formation of UvsX presynaptic filaments progressively disrupts Gp32-ssDNA interactions. Under stringent salt conditions the disruption of Gp32-ssDNA by UvsX is both ATP- and UvsY-dependent. The displacement of Gp32 from ssDNA during presynapsis requires ATP binding, but not ATP hydrolysis, by UvsX protein. Likewise, UvsY-mediated presynapsis strongly requires UvsY-ssDNA interactions, and is optimal at a 1: 1 stoichiometry of UvsY to UvsX and/or ssDNA binding sites. Presynaptic filaments formed in the presence of UvsY undergo assembly/collapse that is tightly coupled to the ATP hydrolytic cycle and to stringent competition for ssDNA binding sites between Gp32 and various nucleotide-liganded forms of UvsX. The data directly support the Gp32 displacement model of UvsY-mediated presynaptic filament assembly, and demonstrate that the transient induction of high affinity UvsX-ssDNA interactions by ATP are essential, although not sufficient, for Gp32 displacement. The underlying dynamics of protein-ssDNA interactions within presynaptic filaments suggests that rearrangements of UvsX, UvsY, and Gp32 proteins on ssDNA may be coupled to central processes in T4 recombination metabolism.	Univ Vermont, Coll Med, Dept Biochem & Microbiol, Vermont Canc Ctr, Winooski, VT 05404 USA; Univ Vermont, Coll Med, Dept Mol Genet, Vermont Canc Ctr, Winooski, VT 05404 USA	University of Vermont; University of Vermont	Morrical, SW (corresponding author), Univ Vermont, Coll Med, Dept Biochem & Microbiol, Vermont Canc Ctr, B407 Given Bldg, Winooski, VT 05404 USA.	smorrica@zoo.uvm.edu			NIGMS NIH HHS [GM48847] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM048847, R01GM048847] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ando RA, 1998, J MOL BIOL, V283, P785, DOI 10.1006/jmbi.1998.2124; Beernink HTH, 1999, TRENDS BIOCHEM SCI, V24, P385, DOI 10.1016/S0968-0004(99)01451-6; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; BIRDSALL B, 1983, ANAL BIOCHEM, V132, P353, DOI 10.1016/0003-2697(83)90020-9; Bleuit JS, 2004, J BIOL CHEM, V279, P6077, DOI 10.1074/jbc.M311557200; Bleuit JS, 2001, P NATL ACAD SCI USA, V98, P8298, DOI 10.1073/pnas.131007498; CASASFINET JR, 1992, P NATL ACAD SCI USA, V89, P1050, DOI 10.1073/pnas.89.3.1050; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CUNNINGHAM RP, 1977, VIROLOGY, V80, P67, DOI 10.1016/0042-6822(77)90381-6; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; GIEDROC DP, 1990, J BIOL CHEM, V265, P11444; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRIFFITH J, 1985, J BIOL CHEM, V260, P4484; HARRIS LD, 1989, J MOL BIOL, V206, P19, DOI 10.1016/0022-2836(89)90520-2; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; Ishmael FT, 2001, J BIOL CHEM, V276, P25236, DOI 10.1074/jbc.M100783200; JIANG H, 1993, J BIOL CHEM, V268, P7904; Jiang H, 1997, BIOCHEM BIOPH RES CO, V231, P600, DOI 10.1006/bbrc.1997.6160; Karpel R.L., 1990, BIOL NONSPECIFIC DNA, P103; Karpel RL, 2002, IUBMB LIFE, V53, P161, DOI 10.1080/15216540212332; KODADEK T, 1989, J BIOL CHEM, V264, P16451; KODADEK T, 1988, J BIOL CHEM, V263, P9427; KODADEK T, 1990, J BIOL CHEM, V265, P20966; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; KOWALCZYKOWSKI SC, 1990, LANDOLTBORNSTEIN NUM, P244; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; Krogh BO, 2004, ANNU REV GENET, V38, P233, DOI 10.1146/annurev.genet.38.072902.091500; Lefebvre SD, 1997, J MOL BIOL, V272, P312, DOI 10.1006/jmbi.1997.1264; Lefebvre SD, 1999, J BIOL CHEM, V274, P22830, DOI 10.1074/jbc.274.32.22830; Liu J, 2006, BIOCHEMISTRY-US, V45, P5493, DOI 10.1021/bi0525167; LOHMAN TM, 1981, J MOL BIOL, V152, P67, DOI 10.1016/0022-2836(81)90096-6; Ma YJ, 2004, J BIOL CHEM, V279, P19035, DOI 10.1074/jbc.M311738200; MCGHEE JD, 1976, J MOL BIOL, V103, P679; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MELAMEDE RJ, 1977, J VIROL, V24, P28, DOI 10.1128/JVI.24.1.28-40.1977; MELAMEDE RJ, 1978, FEBS LETT, V87, P12, DOI 10.1016/0014-5793(78)80122-7; MELAMEDE RJ, 1980, MOL GEN GENET, V177, P501, DOI 10.1007/BF00271490; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MILLER H, 1987, METHOD ENZYMOL, V152, P145; MORRICA LS, 2003, Patent No. 60440059; MORRICAL S, 2004, Patent No. 2004000665; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; MORRICAL SW, 1990, J BIOL CHEM, V265, P15096; Morrical SW, 1996, J BIOL CHEM, V271, P20198, DOI 10.1074/jbc.271.33.20198; Mosig G, 1997, VIROLOGY, V230, P72, DOI 10.1006/viro.1997.8464; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; RECORD MT, 1977, BIOCHEMISTRY-US, V16, P4791, DOI 10.1021/bi00641a005; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; Sugiyama T, 2002, J BIOL CHEM, V277, P31663, DOI 10.1074/jbc.M203494200; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; Sweezy MA, 1997, J MOL BIOL, V266, P927, DOI 10.1006/jmbi.1996.0829; Sweezy MA, 1999, BIOCHEMISTRY-US, V38, P936, DOI 10.1021/bi9817055; Williams Kenneth R., 1994, P301; Xu H, 2001, BIOCHEMISTRY-US, V40, P7651, DOI 10.1021/bi010116n; XU H, 2005, BIOCHEMISTRY; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; Yassa DS, 1997, BIOCHIMIE, V79, P275, DOI 10.1016/S0300-9084(97)83515-8; YONESAKI T, 1989, J BIOL CHEM, V264, P7814; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x	61	26	26	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26308	26319		10.1074/jbc.M604349200	http://dx.doi.org/10.1074/jbc.M604349200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829679	hybrid			2022-12-25	WOS:000240249500048
J	Pochynyuk, O; Medina, J; Gamper, N; Genth, H; Stockand, JD; Staruschenko, A				Pochynyuk, Oleh; Medina, Jorge; Gamper, Nikita; Genth, Harald; Stockand, James D.; Staruschenko, Alexander			Rapid translocation and insertion of the epithelial Na+ channel in response to RhoA signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-OH KINASE; PLASMA-MEMBRANE; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; SUBUNIT STOICHIOMETRY; SECRETORY GRANULES; MAST-CELLS; EXOCYTOSIS; ACTIVATION; GTPASES; RAS	Activity of the epithelial Na+ channel (ENaC) is limiting for Na+ absorption across many epithelia. Consequently, ENaC is a central effector impacting systemic blood volume and pressure. Two members of the Ras superfamily of small GTPases, K-Ras and RhoA, activate ENaC. K-Ras activates ENaC via a signaling pathway involving phosphatidylinositol 3-kinase and production of phosphatidylinositol 3,4,5-trisphosphate with the phospholipid directly interacting with the channel to increase open probability. How RhoA increases ENaC activity is less clear. Here we report that RhoA and K-Ras activate ENaC through independent signaling pathways and final mechanisms of action. Activation of RhoA signaling rapidly increases the membrane levels of ENaC likely by promoting channel insertion. This process dramatically increases functional ENaC current, resulting in tight spatial-temporal control of these channels. RhoA signals to ENaC via a transduction pathway, including the downstream effectors Rho kinase and phosphatidylinositol-4-phosphate 5-kinase. Phosphatidylinositol 4,5-biphosphate produced by activated phosphatidylinositol 4-phosphate 5-kinase may play a role in targeting vesicles containing ENaC to the plasma membrane.	Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA; Univ Leeds, Inst Membrane & Syst Biol, Leeds LS2 9JT, W Yorkshire, England; Hannover Med Sch, Inst Toxikol, D-30625 Hannover, Germany	University of Texas System; University of Texas Health San Antonio; University of Leeds; Hannover Medical School	Stockand, JD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Physiol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	stockand@uthscsa.edu	Genth, Harald/HHS-0118-2022	Stockand, James/0000-0002-3817-4319; Staruschenko, Alexander/0000-0002-5190-8356; Gamper, Nikita/0000-0001-5806-0207	NIDDK NIH HHS [R01-DK-59594] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059594] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander RT, 2005, P NATL ACAD SCI USA, V102, P12253, DOI 10.1073/pnas.0409197102; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Aoyagi K, 2005, J BIOL CHEM, V280, P17346, DOI 10.1074/jbc.M413307200; Bender K, 2002, FEBS LETT, V529, P356, DOI 10.1016/S0014-5793(02)03426-9; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Birukova AA, 2004, FASEB J, V18, P1879, DOI 10.1096/fj.04-2328com; Booth RE, 2003, J BIOL CHEM, V278, P41367, DOI 10.1074/jbc.M305400200; Brown AM, 1998, MOL BIOL CELL, V9, P1053, DOI 10.1091/mbc.9.5.1053; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Doussau F, 2000, J BIOL CHEM, V275, P7764, DOI 10.1074/jbc.275.11.7764; Doussau F, 2000, BIOCHIMIE, V82, P353, DOI 10.1016/S0300-9084(00)00217-0; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Gamper Nikita, 2005, Journal of Pharmacological and Toxicological Methods, V51, P177, DOI 10.1016/j.vascn.2004.08.008; Genth H, 2003, J BIOL CHEM, V278, P28523, DOI 10.1074/jbc.M301915200; Hendron E, 2002, MOL BIOL CELL, V13, P3042, DOI 10.1091/mbc.E02-05-0260; Holz RW, 2000, J BIOL CHEM, V275, P17878, DOI 10.1074/jbc.M000925200; Hong-Geller E, 2000, J CELL BIOL, V148, P481, DOI 10.1083/jcb.148.3.481; Imamura Y, 2004, NEUROSCIENCE, V127, P973, DOI 10.1016/j.neuroscience.2004.05.051; Imamura Y, 2003, NEUROREPORT, V14, P1203, DOI 10.1097/00001756-200307010-00003; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Kanzaki M, 2004, J BIOL CHEM, V279, P30622, DOI 10.1074/jbc.M401443200; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Li Y, 2005, J NEUROSCI, V25, P9825, DOI 10.1523/JNEUROSCI.2597-05.2005; Pinxteren JA, 2000, BIOCHIMIE, V82, P385, DOI 10.1016/S0300-9084(00)00197-8; Pochynyuk O, 2005, J BIOL CHEM, V280, P37565, DOI 10.1074/jbc.M509071200; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Snyder PM, 2005, ENDOCRINOLOGY, V146, P5079, DOI 10.1210/en.2005-0894; Staruschenko A, 2005, J BIOL CHEM, V280, P39161, DOI 10.1074/jbc.M509608200; Staruschenko A, 2005, BIOPHYS J, V88, P3966, DOI 10.1529/biophysj.104.056804; Staruschenko A, 2005, BBA-BIOMEMBRANES, V1669, P108, DOI 10.1016/j.bbamem.2005.01.005; Staruschenko A, 2004, J BIOL CHEM, V279, P49989, DOI 10.1074/jbc.M409812200; Staruschenko A, 2004, J BIOL CHEM, V279, P37771, DOI 10.1074/jbc.M402176200; Staruschenko A, 2004, J BIOL CHEM, V279, P27729, DOI 10.1074/jbc.M404169200; Steyer JA, 2001, NAT REV MOL CELL BIO, V2, P268, DOI 10.1038/35067069; Storey NM, 2002, CURR BIOL, V12, P27, DOI 10.1016/S0960-9822(01)00625-X; Symons M, 2003, CURR BIOL, V13, pR409, DOI 10.1016/S0960-9822(03)00324-5; Tamma G, 2003, J CELL SCI, V116, P1519, DOI 10.1242/jcs.00355; Tamma G, 2001, AM J PHYSIOL-RENAL, V281, pF1092, DOI 10.1152/ajprenal.0091.2001; Taraska JW, 2003, P NATL ACAD SCI USA, V100, P2070, DOI 10.1073/pnas.0337526100; Tong QS, 2004, J BIOL CHEM, V279, P22654, DOI 10.1074/jbc.M401004200; Waselle L, 2005, MOL ENDOCRINOL, V19, P3097, DOI 10.1210/me.2004-0530; Weernink PAO, 2004, J BIOL CHEM, V279, P7840, DOI 10.1074/jbc.M312737200; Yang SA, 2004, J BIOL CHEM, V279, P42331, DOI 10.1074/jbc.M404335200; Yatani A, 2005, AM J PHYSIOL-HEART C, V288, pH650, DOI 10.1152/ajpheart.00268.2004; YATANI A, 1991, J BIOL CHEM, V266, P22222	52	54	56	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26520	26527		10.1074/jbc.M603716200	http://dx.doi.org/10.1074/jbc.M603716200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829523	hybrid			2022-12-25	WOS:000240249500070
J	Maragathavally, KJ; Kaminski, JM; Coates, CJ				Maragathavally, K. J.; Kaminski, J. M.; Coates, C. J.			Chimeric Mos1 and piggyBac transposases result in site-directed integration	FASEB JOURNAL			English	Article						mariner; Gal4-UAS; transposition assay	TARGETED GENE-EXPRESSION; DROSOPHILA-MELANOGASTER; DNA-BINDING; GERMLINE TRANSFORMATION; GENOME MODIFICATION; BACULOVIRUS GENOME; SILENT CHROMATIN; PRECISE EXCISION; ELEMENT MARINER; AEDES-AEGYPTI	Genetic transformation systems based on Mos1 and piggyBac transposable elements are used to achieve stable chromosomal integration. However, integration sites are randomly distributed in the genome and transgene expression can be influenced by position effects. We developed a novel technology that utilizes chimeric transposases to direct integration into specific sites on a target DNA molecule. The Gal4 DNA binding domain was fused to the NH2 terminus of the Mos1 and piggyBac transposases and a target plasmid was created that contained upstream activating sequences (UAS), to which the Gal4 DBD binds with high affinity. The transpositional activity of the Gal4-Mos1 transposase was 12.7-fold higher compared to controls where the Gal4-UAS interaction was absent and 96% of the recovered transposition products were identical, with integration occurring at the same TA site. In a parallel experiment, a Gal4-piggyBac transposase resulted in an 11.6-fold increase in transpositional activity compared to controls, with 67% of the integrations occurring at a single TTAA site. This technology has the potential to minimize nonspecific integration events that may result in insertional mutagenesis and reduced fitness. Site-directed integration will be advantageous to the manipulation of genomes, study of gene function, and for the development of gene therapy techniques.-Maragathavally, K. J., Kaminski, J. M., Coates, C. J. Chimeric Mos1 and piggyBac transposases result in site-directed integration.	Texas A&M Univ, Dept Entomol, College Stn, TX 77843 USA; Med Coll Georgia, Dept Radiol, Augusta, GA 30912 USA	Texas A&M University System; Texas A&M University College Station; University System of Georgia; Augusta University	Coates, CJ (corresponding author), Texas A&M Univ, Dept Entomol, College Stn, TX 77843 USA.	ccoates@tamu.edu	Kaminski, Joseph/AAB-6493-2020; Wilson, Matthew H/K-3193-2013	Kaminski, Joseph/0000-0002-7518-4962	NIAID NIH HHS [AI047303] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047303] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akopian A, 2003, P NATL ACAD SCI USA, V100, P8688, DOI 10.1073/pnas.1533177100; Atkinson PW, 2001, ANNU REV ENTOMOL, V46, P317, DOI 10.1146/annurev.ento.46.1.317; AUGEGOUILLOU C, 1995, FEBS LETT, V368, P541, DOI 10.1016/0014-5793(95)00735-R; Boisnard-Lorig C, 2001, PLANT CELL, V13, P495, DOI 10.1105/tpc.13.3.495; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brown SE, 2001, GENETICS, V157, P1299; Carlson CM, 2003, GENETICS, V165, P243; Chen Y, 2000, MOL CELL, V6, P885, DOI 10.1016/S1097-2765(05)00088-2; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; Coates CJ, 2005, TRENDS BIOTECHNOL, V23, P407, DOI 10.1016/j.tibtech.2005.06.009; Coates CJ, 1997, MOL GEN GENET, V253, P728, DOI 10.1007/s004380050377; Coates CJ, 1999, GENE, V226, P317, DOI 10.1016/S0378-1119(98)00557-5; COATES CJ, 1995, MOL GEN GENET, V249, P246, DOI 10.1007/BF00290372; Ding S, 2005, CELL, V122, P473, DOI 10.1016/j.cell.2005.07.013; Dupuy AJ, 2002, P NATL ACAD SCI USA, V99, P4495, DOI 10.1073/pnas.062630599; FRASER MJ, 1995, VIROLOGY, V211, P397, DOI 10.1006/viro.1995.1422; Fraser MJ, 1996, INSECT MOL BIOL, V5, P141, DOI 10.1111/j.1365-2583.1996.tb00048.x; Frisch M, 2002, GENOME RES, V12, P349, DOI 10.1101/gr.206602.ArticlepublishedonlinebeforeprintinJanuary2002; GARCIAFERNANDEZ J, 1995, MOL BIOL EVOL, V12, P421; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; Groth AC, 2004, GENETICS, V166, P1775, DOI 10.1534/genetics.166.4.1775; Handler AM, 2002, INSECT BIOCHEM MOLEC, V32, P1211, DOI 10.1016/S0965-1748(02)00084-X; Hartley KO, 2002, P NATL ACAD SCI USA, V99, P1377, DOI 10.1073/pnas.022646899; Hartung M, 1998, J BIOL CHEM, V273, P22884, DOI 10.1074/jbc.273.36.22884; Henikoff S, 1992, CURR OPIN GENET DEV, V2, P907, DOI 10.1016/S0959-437X(05)80114-5; Horn C, 2005, P NATL ACAD SCI USA, V102, P12483, DOI 10.1073/pnas.0504305102; Horn PJ, 2002, SCIENCE, V297, P1824, DOI 10.1126/science.1074200; Jarvik T, 1998, GENETICS, V149, P1569; Kaminski JM, 2002, FASEB J, V16, DOI 10.1096/fj.02-0127hyp; Kawakami K, 2004, DEV CELL, V7, P133, DOI 10.1016/j.devcel.2004.06.005; Kolb AF, 2005, TRENDS BIOTECHNOL, V23, P399, DOI 10.1016/j.tibtech.2005.06.005; Konev AY, 2003, GENETICS, V165, P2039; Li X, 2001, INSECT MOL BIOL, V10, P447, DOI 10.1046/j.0962-1075 .2001.00283.x; LIDHOLM DA, 1993, GENETICS, V134, P859; Lobo N, 1999, MOL GEN GENET, V261, P803, DOI 10.1007/s004380050024; Malla S, 2005, NUCLEIC ACIDS RES, V33, P6101, DOI 10.1093/nar/gki922; MORGAN GT, 1995, J MOL BIOL, V254, P1, DOI 10.1006/jmbi.1995.0593; O'Brochta DA, 2004, METH MOL B, V260, P227, DOI 10.1385/1-59259-755-6:227; O'Brochta DA, 2003, J EXP BIOL, V206, P3823, DOI 10.1242/jeb.00638; Oberstein A, 2005, NAT METHODS, V2, P583, DOI 10.1038/NMETH775; OBrochta DA, 1996, INSECT BIOCHEM MOLEC, V26, P739, DOI 10.1016/S0965-1748(96)00022-7; Pabo CO, 2001, ANNU REV BIOCHEM, V70, P313, DOI 10.1146/annurev.biochem.70.1.313; Phelps CB, 1998, METHODS, V14, P367, DOI 10.1006/meth.1998.0592; PIRROTTA V, 1994, BIOESSAYS, V16, P549, DOI 10.1002/bies.950160808; Plasterk RHA, 1999, TRENDS GENET, V15, P326, DOI 10.1016/S0168-9525(99)01777-1; Ringrose L, 1998, J MOL BIOL, V284, P363, DOI 10.1006/jmbi.1998.2149; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBERTSON HM, 1995, J INSECT PHYSIOL, V41, P99, DOI 10.1016/0022-1910(94)00082-R; ROBERTSON HM, 1993, NATURE, V362, P241, DOI 10.1038/362241a0; Rowan KH, 2004, INSECT BIOCHEM MOLEC, V34, P695, DOI 10.1016/j.ibmb.2004.03.022; Sarkar A, 1997, INSECT BIOCHEM MOLEC, V27, P359, DOI 10.1016/S0965-1748(97)00018-0; Scheer N, 1999, MECH DEVELOP, V80, P153, DOI 10.1016/S0925-4773(98)00209-3; Schotta G, 2003, SEMIN CELL DEV BIOL, V14, P67, DOI 10.1016/S1084-9521(02)00138-6; SEDENSKY MM, 1994, NUCLEIC ACIDS RES, V22, P1719, DOI 10.1093/nar/22.9.1719; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; Sumitani M, 2003, INSECT BIOCHEM MOLEC, V33, P449, DOI 10.1016/S0965-1748(03)00009-2; Szuts D, 2000, P NATL ACAD SCI USA, V97, P5351, DOI 10.1073/pnas.97.10.5351; Thibault ST, 1999, INSECT MOL BIOL, V8, P119, DOI 10.1046/j.1365-2583.1999.810119.x; Thyagarajan B, 2001, MOL CELL BIOL, V21, P3926, DOI 10.1128/MCB.21.12.3926-3934.2001; Thyagarajan B, 2000, GENE, V244, P47, DOI 10.1016/S0378-1119(00)00008-1; Wang AB, 2003, EXP CELL RES, V290, P1, DOI 10.1016/S0014-4827(03)00313-6; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; Wilson MH, 2005, FEBS LETT, V579, P6205, DOI 10.1016/j.febslet.2005.10.004; Wilson R, 2003, INSECT BIOCHEM MOLEC, V33, P853, DOI 10.1016/S0965-1748(03)00044-4; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217; Xie WW, 2001, MOL CELL BIOL, V21, P6606, DOI 10.1128/MCB.21.19.6606-6614.2001; Yant SR, 2005, MOL CELL BIOL, V25, P2085, DOI 10.1128/MCB.25.6.2085-2094.2005; Yant SR, 2000, NAT GENET, V25, P35, DOI 10.1038/75568; Yusa K, 2004, MOL CELL BIOL, V24, P4004, DOI 10.1128/MCB.24.9.4004-4018.2004; Zhu YX, 2003, P NATL ACAD SCI USA, V100, P5891, DOI 10.1073/pnas.1036705100; Zou S, 1997, P NATL ACAD SCI USA, V94, P7412, DOI 10.1073/pnas.94.14.7412	72	50	63	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1880	+		10.1096/fj.05-5485fje	http://dx.doi.org/10.1096/fj.05-5485fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16877528				2022-12-25	WOS:000240267000017
J	Wu, YH; Fischer, DF; Kalsbeek, A; Garidou-Boof, ML; van der Vliet, J; van Heijningen, C; Liu, RY; Zhou, JN; Swaab, DF				Wu, Ying-Hui; Fischer, David F.; Kalsbeek, Andries; Garidou-Boof, Marie-Laure; van der Vliet, Jan; van Heijningen, Caroline; Liu, Rong-Yu; Zhou, Jiang-Ning; Swaab, Dick F.			Pineal clock gene oscillation is disturbed in Alzheimer's disease, due to functional disconnection from the "master clock"	FASEB JOURNAL			English	Article						circadian system; clock gene; vasopressin mRNA; superchiasmatic nucleus	ARYLALKYLAMINE N-ACETYLTRANSFERASE; HUMAN SUPRACHIASMATIC NUCLEUS; MAMMALIAN CIRCADIAN CLOCK; MESSENGER-RNA LEVELS; RAT PINEAL; MELATONIN SYNTHESIS; PARAVENTRICULAR NUCLEUS; EXPRESSION; GLAND; RHYTHM	The suprachiasmatic nucleus (SCN) is the "master clock" of the mammalian brain. It coordinates the peripheral clocks in the body, including the pineal clock that receives SCN input via a multisynaptic noradrenergic pathway. Rhythmic pineal melatonin production is disrupted in Alzheimer's disease (AD). Here we show that the clock genes hBmal1, hCry1, and hPer1 were rhythmically expressed in the pineal of controls (Braak 0). Moreover, hPer1 and h beta 1-adrenergic receptor (h beta 1-ADR) mRNA were positively correlated and showed a similar daily pattern. In contrast, in both preclinical (Braak I-II) and clinical AD patients (Braak V-VI), the rhythmic expression of clock genes was lost as well as the correlation between hPer1 and h beta 1-ADR mRNA. Intriguingly, hCry1 mRNA was increased in clinical AD. These changes are probably due to a disruption of the SCN control, as they were mirrored in the rat pineal deprived of SCN control. Indeed, a functional disruption of the SCN was observed from the earliest AD stages onward, as shown by decreased vasopressin mRNA, a clock- controlled major output of the SCN. Thus, a functional disconnection between the SCN and the pineal from the earliest AD stage onward could account for the pineal clock gene changes and underlie the circadian rhythm disturbances in AD. Wu, Y-H., Fischer, D. F., Kalsbeek, A., Garidou-Boof, M-L., van der Vliet, J., van Heijningen, C., Liu, R-Y., Zhou, J-N., Swaab, D. F. Pineal clock gene oscillation is disturbed in Alzheimer's disease, due to functional disconnection from the "master clock."	Netherlands Inst Neurosci, NL-1105 BA Amsterdam, Netherlands; Anhui Med Univ, Affiliated Hosp 1, Anhui Geriatr Inst, Hefei, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Dept Neurobiol, Hefei, Peoples R China	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Anhui Medical University; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Swaab, DF (corresponding author), Netherlands Inst Neurosci, Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.	d.f.swaab@nin.knaw.nl	Zhou, JiangNing/N-3374-2013; Kalsbeek, Andries/H-3076-2019	Kalsbeek, Andries/0000-0001-9606-8453; Swaab, Dick/0000-0002-9665-7845; Fischer, David/0000-0002-6690-0197				Abe M, 2002, J NEUROSCI, V22, P350, DOI 10.1523/JNEUROSCI.22-01-00350.2002; ARENDT J, 1985, J CLIN ENDOCR METAB, V60, P1166, DOI 10.1210/jcem-60-6-1166; BARTON AJL, 1993, J NEUROCHEM, V61, P1, DOI 10.1111/j.1471-4159.1993.tb03532.x; Bell-Pedersen D, 2005, NAT REV GENET, V6, P544, DOI 10.1038/nrg1633; BERLIN I, 1995, LIFE SCI, V56, pPL325; Bjarnason GA, 2002, CHRONOBIOL INT, V19, P129, DOI 10.1081/CBI-120002595; Boivin DB, 2003, BLOOD, V102, P4143, DOI 10.1182/blood-2003-03-0779; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Brzezinski Amnon, 1997, New England Journal of Medicine, V336, P186; Buijs RM, 2001, NAT REV NEUROSCI, V2, P521, DOI 10.1038/35081582; BURKE WJ, 1991, MOL BRAIN RES, V11, P37, DOI 10.1016/0169-328X(91)90018-S; CARTER DA, 1993, ENDOCRINOLOGY, V133, P2263, DOI 10.1210/en.133.5.2263; CARTER DA, 1992, MOL BRAIN RES, V12, P315, DOI 10.1016/0169-328X(92)90133-V; CASSONE VM, 1986, PHYSIOL BEHAV, V36, P1111, DOI 10.1016/0031-9384(86)90488-9; Coon SL, 2002, J CLIN ENDOCR METAB, V87, P4699, DOI 10.1210/jc.2002-020683; Coon SL, 2001, J BIOL CHEM, V276, P24097, DOI 10.1074/jbc.M011298200; Engel L, 2005, EUR J NEUROSCI, V21, P2297, DOI 10.1111/j.1460-9568.2005.04040.x; Etchegaray JP, 2003, NATURE, V421, P177, DOI 10.1038/nature01314; Friedland R P, 1990, Int Psychogeriatr, V2, P36; Fukuhara C, 2005, J NEUROCHEM, V93, P156, DOI 10.1111/j.1471-4159.2004.03008.x; Fukuhara C, 2004, J NEUROSCI, V24, P1803, DOI 10.1523/JNEUROSCI.4988-03.2004; Fukuhara C, 2000, NEUROSCI LETT, V286, P167, DOI 10.1016/S0304-3940(00)01129-0; Garidou ML, 2001, NEUROSCIENCE, V105, P721, DOI 10.1016/S0306-4522(01)00197-X; Gastel JA, 1998, SCIENCE, V279, P1358, DOI 10.1126/science.279.5355.1358; Grady CL, 2001, BRAIN, V124, P739, DOI 10.1093/brain/124.4.739; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Hida A, 2000, GENOMICS, V65, P224, DOI 10.1006/geno.2000.6166; HOFMAN MA, 1994, BRAIN RES, V651, P134, DOI 10.1016/0006-8993(94)90689-0; Ingram CD, 1998, PROG BRAIN RES, V119, P351; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Johnston JD, 2004, NEUROSCIENCE, V124, P789, DOI 10.1016/j.neuroscience.2004.01.011; Kalsbeek A, 2000, EUR J NEUROSCI, V12, P3146, DOI 10.1046/j.1460-9568.2000.00202.x; Kalsbeek A, 1996, J NEUROSCI, V16, P5555, DOI 10.1523/jneurosci.16-17-05555.1996; Klein D. C., 1997, RECENT PROG HORM RES, V52, p[307, 357]; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; KLEIN DC, 1985, CIBA F SYMP, V117, P38; Liu RY, 2000, J NEUROPATH EXP NEUR, V59, P314, DOI 10.1093/jnen/59.4.314; Liu RY, 1999, J CLIN ENDOCR METAB, V84, P323, DOI 10.1210/jc.84.1.323; Lowrey PL, 2000, ANNU REV GENET, V34, P533, DOI 10.1146/annurev.genet.34.1.533; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; PARDO CA, 1990, ACTA NEUROPATHOL, V80, P535, DOI 10.1007/BF00294615; Perreau-Lenz S, 2004, EUR J NEUROSCI, V19, P318, DOI 10.1111/j.0953-816X.2003.03132.x; Perreau-Lenz S, 2003, EUR J NEUROSCI, V17, P221, DOI 10.1046/j.1460-9568.2003.02442.x; Pfeffer M, 1998, EUR J NEUROSCI, V10, P2896, DOI 10.1111/j.1460-9568.1998.00309.x; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; RAVID R, 1992, PROG BRAIN RES, V93, P83; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; SCHWARTZ WJ, 1987, BRAIN RES, V424, P249, DOI 10.1016/0006-8993(87)91468-5; Selkoe DJ, 2002, ANNU REV GENOM HUM G, V3, P67, DOI 10.1146/annurev.genom.3.022502.103022; Simonneaux V, 2004, MOL BRAIN RES, V120, P164, DOI 10.1016/j.molbrainres.2003.10.019; SKENE DJ, 1990, BRAIN RES, V528, P170, DOI 10.1016/0006-8993(90)90214-V; Steeves TDL, 1999, GENOMICS, V57, P189, DOI 10.1006/geno.1998.5675; Stopa EG, 1999, J NEUROPATH EXP NEUR, V58, P29, DOI 10.1097/00005072-199901000-00004; SWAAB DF, 1985, BRAIN RES, V342, P27; Takekida S, 2000, EUR J NEUROSCI, V12, P4557, DOI 10.1046/j.0953-816X.2000.01324.x; Tousson E, 2004, J NEUROSCI, V24, P2983, DOI 10.1523/JNEUROSCI.5044-03.2004; Travnickova-Bendova Z, 2002, P NATL ACAD SCI USA, V99, P7728, DOI 10.1073/pnas.102075599; vanSomeren EJW, 1996, BIOL PSYCHIAT, V40, P259, DOI 10.1016/0006-3223(95)00370-3; VAUGHAN GM, 1976, J CLIN ENDOCR METAB, V42, P752, DOI 10.1210/jcem-42-4-752; von Gall C, 2001, J NEUROENDOCRINOL, V13, P313, DOI 10.1046/j.1365-2826.2001.00643.x; Wu YH, 2003, J CLIN ENDOCR METAB, V88, P5898, DOI 10.1210/jc.2003-030833; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Yoo SH, 2004, P NATL ACAD SCI USA, V101, P5339, DOI 10.1073/pnas.0308709101; Zanello SB, 2000, J INVEST DERMATOL, V115, P757, DOI 10.1046/j.1523-1747.2000.00121.x	65	126	135	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2006	20	11					1874	+		10.1096/fj.05-4446fje	http://dx.doi.org/10.1096/fj.05-4446fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16818472				2022-12-25	WOS:000240267000015
J	Ghoumari, AM; Piochon, C; Tomkiewicz, C; Eychenne, B; Levenes, C; Dusart, I; Schumacher, M; Baulieu, EE				Ghoumari, A. M.; Piochon, C.; Tomkiewicz, C.; Eychenne, B.; Levenes, C.; Dusart, I.; Schumacher, M.; Baulieu, E. E.			Neuroprotective effect of mifepristone involves neuron depolarization	FASEB JOURNAL			English	Article						Purkinje cells; Na+/K+-ATPase; rat cerebella	CEREBELLAR GRANULE CELLS; VESICULAR GLUTAMATE TRANSPORTERS; ELECTRO-PHYSIOLOGICAL PROPERTIES; POSTNATAL MOUSE CEREBELLUM; DEVELOPING RAT CEREBELLUM; PURKINJE-CELL; IN-VITRO; MULTIPLE INNERVATION; SYNAPTIC POTENTIALS; AXONAL REGENERATION	In several regions of the developing nervous system, neurons undergo programmed cell death. In the rat cerebellum, Purkinje cell apoptosis is exacerbated when cerebellar slices are cultured during the first postnatal week. To understand the mechanism of this developmental apoptosis, we took advantage of its inhibition by the steroid analog mifepristone. This effect did not involve the classical steroid nuclear receptors. Microarray analysis revealed that mifepristone down-regulated mRNA levels of the Na+/K+-ATPase alpha 3 subunit more than three times. Consistent with the down-regulation of the Na+/K+-ATPase, mifepristone caused Purkinje cell membrane depolarization. Depolarizing agents like ouabain (1 mu M), tetraethylammonium (2 mM), and veratridine (2 mu M) protected Purkinje cells from apoptosis. These results suggest a role of excitatory inputs in Purkinje cell survival during early postnatal development. Indeed, coculturing cerebellar slices with glutamatergic inferior olivary neuron preparations allowed rescue of Purkinje cells. These findings reveal a new neuroprotective mechanism of mifepristone and support a pivotal role for excitatory inputs in the survival of Purkinje neurons. Mifepristone may be a useful lead compound in the development of novel therapeutic approaches for maintaining the resting potential of neurons at values favorable for their survival under neuropathological conditions.	Univ Paris 11, Le Kremlin Bicetre, France; INSERM UMR 788, Le Kremlin Bicetre, France; Univ Paris 06, CNRS, UMR7102, Paris, France; INSERM, U490, Paris, France	UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Ghoumari, AM (corresponding author), INSERM, U488, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	ghoumari@kb.inserm.fr	Schumacher, Michael/G-3581-2013	Schumacher, Michael/0000-0001-6117-5371; Levenes, Carole/0000-0002-1345-180X; Dusart, Isabelle/0000-0002-3211-4323				ARMENGOL JA, 1991, DEV BRAIN RES, V64, P95, DOI 10.1016/0165-3806(91)90213-3; AUDINAT E, 1992, NEUROSCIENCE, V49, P903, DOI 10.1016/0306-4522(92)90366-A; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; Behl C, 1997, EUR J NEUROSCI, V9, P912, DOI 10.1111/j.1460-9568.1997.tb01442.x; Biser PS, 2000, DEV BRAIN RES, V123, P165, DOI 10.1016/S0165-3806(00)00084-5; COUSIN MA, 1995, J NEUROCHEM, V64, P2097; CREPEL F, 1978, BRAIN RES, V155, P176, DOI 10.1016/0006-8993(78)90321-9; CREPEL F, 1971, BRAIN RES, V35, P272, DOI 10.1016/0006-8993(71)90617-2; CREPEL F, 1976, J NEUROBIOL, V7, P567, DOI 10.1002/neu.480070609; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; De Angelis C, 1998, AM J PHYSIOL-RENAL, V274, pF182, DOI 10.1152/ajprenal.1998.274.1.F182; Dusart I, 1997, J NEUROSCI, V17, P3710; GALLO V, 1987, J NEUROSCI, V7, P2203; Gardette R, 1985, Brain Res, V352, P97; Genet S, 1997, PFLUG ARCH EUR J PHY, V434, P559, DOI 10.1007/s004240050436; Ghoumari AM, 2000, EUR J NEUROSCI, V12, P2935, DOI 10.1046/j.1460-9568.2000.00186.x; Ghoumari AM, 2003, P NATL ACAD SCI USA, V100, P7953, DOI 10.1073/pnas.1332667100; Ghoumari AM, 2002, J NEUROSCI, V22, P3531; Gonzalez S, 1996, NEUROREPORT, V7, P1041, DOI 10.1097/00001756-199604100-00017; Hioki H, 2003, NEUROSCIENCE, V117, P1, DOI 10.1016/S0306-4522(02)00943-0; Isaev NK, 2000, NEUROSCI LETT, V283, P41, DOI 10.1016/S0304-3940(00)00903-4; ITO M, 1984, JPN J PHYSIOL, V34, P781, DOI 10.2170/jjphysiol.34.781; KANEKO T, 1989, NEUROSCIENCE, V32, P79, DOI 10.1016/0306-4522(89)90109-7; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P171, DOI 10.1113/jphysiol.1980.sp013357; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P197, DOI 10.1113/jphysiol.1980.sp013358; MARIANI J, 1981, J NEUROSCI, V1, P696, DOI 10.1523/JNEUROSCI.01-07-00696.1981; Marin-Teva JL, 2004, NEURON, V41, P535, DOI 10.1016/S0896-6273(04)00069-8; MASON CA, 1990, J COMP NEUROL, V297, P77, DOI 10.1002/cne.902970106; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; McKay BE, 2005, J PHYSIOL-LONDON, V567, P829, DOI 10.1113/jphysiol.2005.089383; Miyazaki T, 2003, EUR J NEUROSCI, V17, P2563, DOI 10.1046/j.1460-9568.2003.02698.x; MURPHY TH, 1988, BRAIN RES, V460, P155, DOI 10.1016/0006-8993(88)91216-4; MUSZBEK L, 1977, ANAL BIOCHEM, V77, P286, DOI 10.1016/0003-2697(77)90315-3; Orlov SN, 2004, PFLUG ARCH EUR J PHY, V448, P335, DOI 10.1007/s00424-004-1262-9; Orlov SN, 1999, J BIOL CHEM, V274, P16545, DOI 10.1074/jbc.274.23.16545; Orlov SN, 2001, J HYPERTENS, V19, P1559, DOI 10.1097/00004872-200109000-00007; Peng L, 1997, J NEUROSCI, V17, P3488; Salthun-Lassalle B, 2004, J NEUROSCI, V24, P5922, DOI 10.1523/JNEUROSCI.5668-03.2004; Scelfo B, 2005, EUR J NEUROSCI, V21, P971, DOI 10.1111/j.1460-9568.2005.03933.x; SCOTT BS, 1970, EXP NEUROL, V27, P16, DOI 10.1016/0014-4886(70)90197-4; SHIMONO T, 1976, BRAIN RES, V108, P279, DOI 10.1016/0006-8993(76)90186-4; TANAKA S, 1995, DEV BIOL, V168, P166, DOI 10.1006/dbio.1995.1069; Yu SP, 2003, BIOCHEM PHARMACOL, V66, P1601, DOI 10.1016/S0006-2952(03)00531-8; Zhou XM, 2001, BIOCHEM BIOPH RES CO, V285, P46, DOI 10.1006/bbrc.2001.5126	45	25	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2006	20	9					1377	1386		10.1096/fj.05-5832com	http://dx.doi.org/10.1096/fj.05-5832com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816113				2022-12-25	WOS:000240266000015
J	Morales, A; Paris, R; Villanueva, A; Llavuna, L; Garcia-Ruiz, C; Fernandez-Checa, JC				Morales, A.; Paris, R.; Villanueva, A.; Llavuna, L.; Garcia-Ruiz, C.; Fernandez-Checa, J. C.			Pharmacological inhibition or small interfering RNA targeting acid ceramidase sensitizes hepatoma cells to chemotherapy and reduces tumor growth in vivo	ONCOGENE			English	Article						cancer therapy; ceramide; sphingosine-1-phosphate; mitochondria; apoptosis	MITOCHONDRIAL PERMEABILITY TRANSITION; DAUNORUBICIN-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; SPHINGOSINE 1-PHOSPHATE; GD3 GANGLIOSIDE; SPHINGOSINE-1-PHOSPHATE; GENERATION; KINASE; DEATH; NECROSIS	Ceramidases (CDases) play a key role in cancer therapy through enhanced conversion of ceramide into sphingosine 1-phosphate (S1P), but their involvement in hepatocarcinogenesis is unknown. Here, we report that daunorubicin (DNR) activated acid CDase post-transcriptionally in established human (HepG2 cells) or mouse (Hepa1c1c7) hepatoma cell lines as well as in primary cells from murine liver tumors, but not in cultured mouse hepatocytes. Acid CDase silencing by small interfering RNA (siRNA) or pharmacological inhibition with N-oleoylethanolamine (NOE) enhanced the ceramide to S1P balance compared to DNR alone, sensitizing hepatoma cells (HepG2, Hep-3B, SK-Hep and Hepa1c1c7) to DNR-induced cell death. DNR plus NOE or acid CDase siRNA-induced cell death was preceded by ultrastructural changes in mitochondria, stimulation of reactive oxygen species generation, release of Smac/DIABLO and cytochrome c and caspase-3 activation. In addition, in vivo siRNA treatment targeting acid CDase reduced tumor growth in liver tumor xenografts of HepG2 cells and enhanced DNR therapy. Thus, acid CDase promotes hepatocarcinogenesis and its antagonism may be a promising strategy in the treatment of liver cancer.	Hosp Clin Barcelona, Liver Unit, Inst Malalties Digest, Inst Invest Biomed August Pi & Sunyer,IDIBAPS, Barcelona 08036, Spain; IDIBELL, Inst Invest Bellvitge, Inst Catala Oncol, Lab Recerca Translac, Barcelona, Spain; CSIC, Inst Invest Biomed, Dept Expt Pathol, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB)	Fernandez-Checa, JC (corresponding author), Hosp Clin Barcelona, Liver Unit, Inst Malalties Digest, Inst Invest Biomed August Pi & Sunyer,IDIBAPS, C Villarroel 170, Barcelona 08036, Spain.	checa229@yahoo.com	Garcia-Ruiz, Carmen/L-8211-2014; Fernández-Checa, José Carlos/L-8342-2014; Morales, Albert/E-2988-2013	Garcia-Ruiz, Carmen/0000-0002-2652-6102; Fernández-Checa, José Carlos/0000-0003-3422-2990; Morales, Albert/0000-0001-8702-2269	NIAAA NIH HHS [P50 AA11999, 1R21 AA014135-01] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA014135, P50AA011999] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; Block TM, 2003, ONCOGENE, V22, P5093, DOI 10.1038/sj.onc.1206557; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Burek C, 2001, ONCOGENE, V20, P6493, DOI 10.1038/sj.onc.1204841; Colell Anna, 2001, FASEB Journal, V15, P1068; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 2001, BLOOD, V98, P2828, DOI 10.1182/blood.V98.9.2828; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; Franzen R, 2001, J BIOL CHEM, V276, P35382, DOI 10.1074/jbc.M102153200; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; Garcia-Ruiz C, 2002, J BIOL CHEM, V277, P36443, DOI 10.1074/jbc.M206021200; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Gilot D, 2005, CARCINOGENESIS, V26, P2086, DOI 10.1093/carcin/bgi187; Gruber C, 2004, BIOCHEM PHARMACOL, V67, P1859, DOI 10.1016/j.bcp.2004.01.026; Hara S, 2004, CELL DEATH DIFFER, V11, P853, DOI 10.1038/sj.cdd.4401428; HASSLER DF, 1993, ADV LIPID RES, V26, P49; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Kawaguchi K, 2005, BIOCHEM BIOPH RES CO, V329, P370, DOI 10.1016/j.bbrc.2005.01.128; Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Li CM, 1999, GENOMICS, V62, P223, DOI 10.1006/geno.1999.5940; Liu YY, 2001, FASEB J, V15, P719, DOI 10.1096/fj.00-0223com; Matsko CM, 2001, BIOCHEM BIOPH RES CO, V287, P1112, DOI 10.1006/bbrc.2001.5696; Monick MM, 2004, J IMMUNOL, V173, P123, DOI 10.4049/jimmunol.173.1.123; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Paris F, 2002, NAT MED, V8, P901, DOI 10.1038/nm0902-901; Paris R, 2002, J BIOL CHEM, V277, P49870, DOI 10.1074/jbc.M208303200; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; Payne SG, 2002, FEBS LETT, V531, P54, DOI 10.1016/S0014-5793(02)03480-4; Prinetti A, 2006, BIOCHEM J, V395, P311, DOI 10.1042/BJ20051184; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Selzner M, 2001, CANCER RES, V61, P1233; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Strelow A, 2000, J EXP MED, V192, P601, DOI 10.1084/jem.192.5.601; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; Suzuki E, 2004, P NATL ACAD SCI USA, V101, P14788, DOI 10.1073/pnas.0406536101; Yatomi Y, 1996, BIOCHEMISTRY-US, V35, P626, DOI 10.1021/bi9515533	46	83	87	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					905	916		10.1038/sj.onc.1209834	http://dx.doi.org/10.1038/sj.onc.1209834			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16862171				2022-12-25	WOS:000244063800011
J	Roesch-Ely, M; Nees, M; Karsai, S; Ruess, A; Bogumil, R; Warnken, U; Schnolzer, M; Dietz, A; Plinkert, PK; Hofele, C; Bosch, FX				Roesch-Ely, M.; Nees, M.; Karsai, S.; Ruess, A.; Bogumil, R.; Warnken, U.; Schnoelzer, M.; Dietz, A.; Plinkert, P. K.; Hofele, C.; Bosch, F. X.			Proteomic analysis reveals successive aberrations in protein expression from healthy mucosa to invasive head and neck cancer	ONCOGENE			English	Article						proteomics; SELDI-TOF-MS; HNSCC; field cancerization; protein biomarkers	SQUAMOUS-CELL CARCINOMA; GENETICALLY ALTERED FIELDS; HUMAN NEUTROPHIL PEPTIDE-1; TUMOR-DISTANT EPITHELIA; LYMPH-NODE METASTASIS; CLINICAL-IMPLICATIONS; HUMAN-PAPILLOMAVIRUS; IN-SITU; IDENTIFICATION; CANCERIZATION	Development of head and necksquamous cell carcinoma (HNSCC) is a multistep process and in many cases involves a phenomenon coined 'field cancerization'. In order to identify changes in protein expression occurring at different stages of tumorigenesis and field cancerization, we analysed 113 HNSCCs and 73 healthy, 99 tumor-distant and 18 tumor-adjacent squamous mucosae by SELDI-TOF-MS on IMAC30 ProteinChip Arrays. Forty-eight protein peaks were differentially expressed between healthy mucosa and HNSCC. Calgizarrin (S100A11), the Cystein proteinase inhibitor Cystatin A, Acyl-CoA-binding protein, Stratifin (14-3-3 sigma), Histone H4, alpha- and beta-Hemoglobin, a C-terminal fragment of beta-hemoglobin and the alpha-defensins 1-3 were identified by mass spectrometry. The alpha-defensins showed various alterations in expression as validated by immunohistochemistry (IHC). Supervised prediction analysis revealed excellent classification of healthy mucosa (94.5% correctly classified) and tumor samples (92.9% correctly classified). Application of this classifier to the tumor-adjacent and tumor-distant mucosa samples disclosed dramatic changes: only 59.6% of the tumor-distant biopsies were classified as normal, 27.3% were predicted as aberrant or HNSCC. Strikingly, 72% of the tumor-adjacent mucosae were predicted as aberrant. These data provide evidence for the existence of genetically altered fields with inconspicuous histology. Comparison of the protein profiles in the tumor-distant-samples with clinical outcome of 32 patients revealed a significant association between aberrant profiles with tumor relapse events (P = 0.018; Fisher's exact test, two-tailed). We conclude that proteomic pro. ling in conjunction with protein identification greatly outperforms histopathological diagnosis and may have significant predictive power for clinical outcome and personalized risk assessment.	Univ Heidelberg, Dept Otolaryngol Head & Neck Surg, Mol Biol Lab, D-69120 Heidelberg, Germany; Ciphergan Biosyst GmbH, Berlin, Germany; German Canc Res Ctr, Prot Anal Facil, D-6900 Heidelberg, Germany; Univ Leipzig, Dept Ear Nose & Throat, D-7010 Leipzig, Germany; Univ Heidelberg, Dept Oral & Maxillofacial Surg, Heidelberg, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Leipzig University; Ruprecht Karls University Heidelberg	Bosch, FX (corresponding author), Univ Heidelberg, Dept Otolaryngol Head & Neck Surg, Mol Biol Lab, INF 400, D-69120 Heidelberg, Germany.	franz.bosch@med.uni-heidelberg.de	Hofele, Christof/D-4882-2015; Nees, Matthias/AAT-5577-2020; Roesch-Ely, Mariana/H-5981-2013; Nees, Matthias/W-6596-2018	Hofele, Christof/0000-0002-6332-5684; Nees, Matthias/0000-0002-9034-301X				Abrahamson M, 2003, BIOCHEM SOC SYMP, V70, P179, DOI 10.1042/bss0700179; Ai H, 1999, MUTAT RES-GEN TOX EN, V439, P223, DOI 10.1016/S1383-5718(98)00199-5; Ai H, 2001, LARYNGOSCOPE, V111, P1853, DOI 10.1097/00005537-200110000-00034; Albrethsen J, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-8; ALHO H, 1995, CELL GROWTH DIFFER, V6, P309; Andl T, 1998, CANCER RES, V58, P5; Bedi GC, 1996, CANCER RES, V56, P2484; Braakhuis BJM, 2005, SEMIN CANCER BIOL, V15, P113, DOI 10.1016/j.semcancer.2004.08.004; Braakhuis BJM, 2002, HEAD NECK-J SCI SPEC, V24, P198, DOI 10.1002/hed.10042.abs; Braakhuis BJM, 2003, CANCER RES, V63, P1727; Buhimschi IA, 2005, BJOG-INT J OBSTET GY, V112, P173, DOI 10.1111/j.1471-0528.2004.00340.x; Califano J, 1996, CANCER RES, V56, P2488; Carr S, 2004, MOL CELL PROTEOMICS, V3, P531, DOI 10.1074/mcp.T400006-MCP200; Chavakis T, 2004, FASEB J, V18, P1306, DOI 10.1096/fj.03-1009fje; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; Ely MR, 2005, EUR J CELL BIOL, V84, P431, DOI 10.1016/j.ejcb.2005.01.003; Freier K, 2003, CANCER RES, V63, P1179; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Garcia SB, 1999, J PATHOL, V187, P61, DOI 10.1002/(SICI)1096-9896(199901)187:1<61::AID-PATH247>3.0.CO;2-I; Gasco M, 2002, CANCER RES, V62, P2072; Hegedus CM, 2005, LEUKEMIA, V19, P1713, DOI 10.1038/sj.leu.2403897; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Homann N, 2001, CLIN CANCER RES, V7, P290; Kerkhoff C, 1998, BBA-MOL CELL RES, V1448, P200, DOI 10.1016/S0167-4889(98)00144-X; Le Bihan MC, 2004, PROTEOMICS, V4, P2739, DOI 10.1002/pmic.200300759; Lundy FT, 2004, ORAL ONCOL, V40, P139, DOI 10.1016/S1368-8375(03)00142-8; Melle C, 2004, CANCER RES, V64, P4099, DOI 10.1158/0008-5472.CAN-03-3807; Muller CA, 2002, AM J PATHOL, V160, P1311, DOI 10.1016/S0002-9440(10)62558-8; NEES M, 1993, CANCER RES, V53, P4189; Partridge M, 2000, CANCER RES, V60, P3893; Petrescu AD, 2003, J BIOL CHEM, V278, P51813, DOI 10.1074/jbc.M303858200; Prevo LJ, 1999, CANCER RES, V59, P4784; Shiraishi T, 1998, INT J CANCER, V79, P175, DOI 10.1002/(SICI)1097-0215(19980417)79:2<175::AID-IJC13>3.3.CO;2-P; Sinha AA, 2002, CANCER-AM CANCER SOC, V94, P3141, DOI 10.1002/cncr.10604; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; SmithMcCune K, 1997, OBSTET GYNECOL, V89, P482, DOI 10.1016/S0029-7844(97)80037-3; SODER AI, 1995, CANCER RES, V55, P5030; Tabor MP, 2004, CLIN CANCER RES, V10, P3607, DOI 10.1158/1078-0432.CCR-03-0632; Tabor MP, 2001, CLIN CANCER RES, V7, P1523; Tolson JR, 2006, PROTEOMICS, V6, P697, DOI 10.1002/pmic.200500033; Vlahou A, 2001, AM J PATHOL, V158, P1491, DOI 10.1016/S0002-9440(10)64100-4; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812; Wiesner A, 2004, CURR PHARM BIOTECHNO, V5, P45, DOI 10.2174/1389201043489675; Wilkins MR, 2006, PROTEOMICS, V6, P4, DOI 10.1002/pmic.200500856; Wolf C, 2004, LARYNGOSCOPE, V114, P698, DOI 10.1097/00005537-200404000-00019; Wright George L Jr, 2002, Expert Rev Mol Diagn, V2, P549, DOI 10.1586/14737159.2.6.549	47	94	99	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 4	2007	26	1					54	64		10.1038/sj.onc.1209770	http://dx.doi.org/10.1038/sj.onc.1209770			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16819514				2022-12-25	WOS:000243236500006
J	Alvarado, D; Evans, TA; Sharma, R; Lemmon, MA; Duffy, JB				Alvarado, Diego; Evans, Timothy A.; Sharma, Raghav; Lemmon, Mark A.; Duffy, Joseph B.			Argos mutants define an affinity threshold for Spitz inhibition in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; DROSOPHILA EGF RECEPTOR; FEEDBACK LOOP; CELL FATE; VENTRAL ECTODERM; SIGNALING GENES; CHORDIN; EYE; EXPRESSION; OOGENESIS	Argos, a secreted antagonist of Drosophila epidermal growth factor receptor (dEGFR) signaling, acts by sequestering the activating ligand Spitz. To understand how different domains in Argos contribute to efficient Spitz sequestration, we performed a genetic screen aimed at uncovering modifiers of an Argos misexpression phenotype in the developing eye. We identified a series of suppressors mapping to the Argos transgene that affect its activity in multiple developmental contexts. These point mutations map to both the N- and C- terminal cysteine-rich regions, implicating both domains in Argos function. We show by surface plasmon resonance that these Argos mutants are deficient in their ability to bind Spitz in vitro. Our data indicate that a mere similar to 2-fold decrease in K-D is sufficient to compromise Argos activity in vivo. This effect could be recapitulated in a cell-based assay, where a higher molar concentration of mutant Argos was needed to inhibit Spitz-dependent dEGFR phosphorylation. In contrast, a similar to 37-fold decrease in the binding constant nearly abolishes Argos activity in vivo and in cellular assays. In agreement with previously reported computational studies, our results define an affinity threshold for optimal Argos inhibition of dEGFR signaling during development.	Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	University of Pennsylvania; Indiana University System; Indiana University Bloomington	Alvarado, D (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA.	dalvarad@mail.med.upenn.edu; jduffy@wpi.edu	Garzon-Alvarado, Diego/AAD-6607-2019	Lemmon, Mark/0000-0002-3379-5319; Evans, Timothy/0000-0002-2756-8064	NATIONAL CANCER INSTITUTE [R01CA079992] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA079992, R01-CA079992] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abreu JG, 2002, GENE, V287, P39, DOI 10.1016/S0378-1119(01)00827-7; Alvarado D, 2004, GENETICS, V167, P187, DOI 10.1534/genetics.167.1.187; Arteaga CL, 2003, EXP CELL RES, V284, P122, DOI 10.1016/S0014-4827(02)00104-0; Ashburner M., 1989, DROSOPHILA LAB HDB; Ben-Shlomo Izhar, 2003, Sci STKE, V2003, pRE9, DOI 10.1126/stke.2003.187.re9; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brodu V, 2004, DEV CELL, V7, P885, DOI 10.1016/j.devcel.2004.10.016; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chang J, 2003, MOL CELLS, V15, P186; Chang J, 2001, INT J DEV BIOL, V45, P715; Clemmons DR, 2001, ENDOCR REV, V22, P800, DOI 10.1210/er.22.6.800; Cohen MH, 2004, CLIN CANCER RES, V10, P1212, DOI 10.1158/1078-0432.CCR-03-0564; Duffy JB, 2002, GENESIS, V34, P1, DOI 10.1002/gene.10150; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FREEMAN M, 1994, DEVELOPMENT, V120, P2297; Freeman M, 1997, DEVELOPMENT, V124, P261; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; Gazdar AF, 2004, TRENDS MOL MED, V10, P481, DOI 10.1016/j.molmed.2004.08.008; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; Golembo M, 1999, GENE DEV, V13, P158, DOI 10.1101/gad.13.2.158; Golembo M, 1996, DEVELOPMENT, V122, P3363; Golembo M, 1996, DEVELOPMENT, V122, P223; Gonzalez-Reyes A, 1998, DEVELOPMENT, V125, P2837; Graham J, 2004, NAT REV DRUG DISCOV, V3, P549, DOI 10.1038/nrd1445; Guichard A, 1999, DEVELOPMENT, V126, P2663; Gur G, 2004, EMBO J, V23, P3270, DOI 10.1038/sj.emboj.7600342; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Howes R, 1998, J BIOL CHEM, V273, P4275, DOI 10.1074/jbc.273.7.4275; Klein DE, 2004, NATURE, V430, P1040, DOI 10.1038/nature02840; MacLaren CM, 2004, DEV GENES EVOL, V214, P360, DOI 10.1007/s00427-004-0414-4; Martin-Blanco E, 1999, DEVELOPMENT, V126, P5739; Nilson LA, 1999, CURR TOP DEV BIOL, V44, P203; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Reeves GT, 2005, DEV BIOL, V284, P523, DOI 10.1016/j.ydbio.2005.05.013; Reich A, 2002, EMBO J, V21, P4287, DOI 10.1093/emboj/cdf439; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; Shilo BZ, 2005, DEVELOPMENT, V132, P4017, DOI 10.1242/dev.02006; Simcox A, 1997, MECH DEVELOP, V62, P41, DOI 10.1016/S0925-4773(96)00643-0; Simcox AA, 1996, DEV BIOL, V177, P475, DOI 10.1006/dbio.1996.0179; Siwanowicz I, 2005, STRUCTURE, V13, P155, DOI 10.1016/j.str.2004.11.009; Stein RA, 2000, J MOL EVOL, V50, P397, DOI 10.1007/s002390010043; Taguchi A, 2000, GENETICS, V154, P1639; Tio M, 1997, DEVELOPMENT, V124, P343; TIO M, 1994, MECH DEVELOP, V48, P13, DOI 10.1016/0925-4773(94)90002-7; Wasserman JD, 1998, CELL, V95, P355, DOI 10.1016/S0092-8674(00)81767-5; Wessells RJ, 1999, DEV BIOL, V216, P243, DOI 10.1006/dbio.1999.9459	48	3	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28993	29001		10.1074/jbc.M603782200	http://dx.doi.org/10.1074/jbc.M603782200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16870613	hybrid			2022-12-25	WOS:000240680500054
J	Blake, AW; McCartney, L; Flint, JE; Bolam, DN; Boraston, AB; Gilbert, HJ; Knox, JP				Blake, Anthony W.; McCartney, Lesley; Flint, James E.; Bolam, David N.; Boraston, Alisdair B.; Gilbert, Harry J.; Knox, J. Paul			Understanding the biological rationale for the diversity of cellulose-directed carbohydrate-binding modules in prokaryotic enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT-CELL WALL; REESEI CELLOBIOHYDROLASE-I; TRICHODERMA-REESEI; PSEUDOMONAS XYLANASE; CLOSTRIDIUM-CELLULOVORANS; NONCRYSTALLINE CELLULOSE; CATALYTIC-ACTIVITY; SUBSTRATE-BINDING; CRYSTAL-STRUCTURE; FAMILY	Plant cell walls are degraded by glycoside hydrolases that often contain noncatalytic carbohydrate-binding modules (CBMs), which potentiate degradation. There are currently 11 sequence-based cellulose-directed CBM families; however, the biological significance of the structural diversity displayed by these protein modules is uncertain. Here we interrogate the capacity of eight cellulose-binding CBMs to bind to cell walls. These modules target crystalline cellulose (type A) and are located in families 1, 2a, 3a, and 10 (CBM1, CBM2a, CBM3a, and CBM10, respectively); internal regions of amorphous cellulose (type B; CBM4-1, CBM17, CBM28); and the ends of cellulose chains (type C; CBM9-2). Type A CBMs bound particularly effectively to secondary cell walls, although they also recognized primary cell walls. Type A CBM2a and CBM10, derived from the same enzyme, displayed differential binding to cell walls depending upon cell type, tissue, and taxon of origin. Type B CBMs and the type C CBM displayed much weaker binding to cell walls than type A CBMs. CBM17 bound more extensively to cell walls than CBM4-1, even though these type B modules display similar binding to amorphous cellulose in vitro. The thickened primary cell walls of celery collenchyma showed significant binding by some type B modules, indicating that in these walls the cellulose chains do not form highly ordered crystalline structures. Pectate lyase treatment of sections resulted in an increased binding of cellulose-directed CBMs, demonstrating that decloaking cellulose microfibrils of pectic polymers can increase CBM access. The differential recognition of cell walls of diverse origin provides a biological rationale for the diversity of cellulose-directed CBMs that occur in cell wall hydrolases and conversely reveals the variety of cellulose microstructures in primary and secondary cell walls.	Univ Leeds, Ctr Plant Sci, Leeds LS2 9JT, W Yorkshire, England; Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada	University of Leeds; Newcastle University - UK; University of Victoria	Knox, JP (corresponding author), Univ Leeds, Ctr Plant Sci, Leeds LS2 9JT, W Yorkshire, England.	j.p.knox@leeds.ac.uk	Knox, Paul/H-4577-2012	Knox, Paul/0000-0002-9231-6891; Flint, James/0000-0003-2923-7813; Boraston, Alisdair/0000-0001-6417-0592; Bolam, David/0000-0003-0314-3122	Biotechnology and Biological Sciences Research Council [BB/C005074/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Bayer EA, 2004, ANNU REV MICROBIOL, V58, P521, DOI 10.1146/annurev.micro.57.030502.091022; Black GW, 1997, J BIOTECHNOL, V57, P59, DOI 10.1016/S0168-1656(97)00089-8; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; Boraston AB, 2003, J BIOL CHEM, V278, P6120, DOI 10.1074/jbc.M209554200; Boraston AB, 2002, J MOL BIOL, V319, P1143, DOI 10.1016/S0022-2836(02)00374-1; Boraston AB, 2002, BIOCHEM J, V361, P35, DOI 10.1042/0264-6021:3610035; Boraston AB, 2001, BIOCHEMISTRY-US, V40, P6240, DOI 10.1021/bi0101695; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; Boraston AB, 2000, BIOCHEMISTRY-US, V39, P11129, DOI 10.1021/bi0007728; Brown IE, 2001, BIOCHEM J, V355, P155, DOI 10.1042/0264-6021:3550155; Carrard G, 2000, P NATL ACAD SCI USA, V97, P10342, DOI 10.1073/pnas.160216697; Clausen MH, 2003, CARBOHYD RES, V338, P1797, DOI 10.1016/S0008-6215(03)00272-6; Cosgrove DJ, 2005, NAT REV MOL CELL BIO, V6, P850, DOI 10.1038/nrm1746; FERREIRA LMA, 1990, BIOCHEM J, V269, P261, DOI 10.1042/bj2690261; GILBERT HJ, 1990, MOL MICROBIOL, V4, P759, DOI 10.1111/j.1365-2958.1990.tb00646.x; Gill J, 1999, BIOCHEM J, V342, P473, DOI 10.1042/0264-6021:3420473; Hilden L, 2003, BIOTECHNOL LETT, V25, P553, DOI 10.1023/A:1022846304826; Hogg D, 2003, BIOCHEM J, V371, P1027, DOI 10.1042/BJ20021860; Jamal S, 2004, J MOL BIOL, V339, P253, DOI 10.1016/j.jmb.2004.03.069; KELLETT LE, 1990, BIOCHEM J, V272, P369, DOI 10.1042/bj2720369; Kormos J, 2000, BIOCHEMISTRY-US, V39, P8844, DOI 10.1021/bi000607s; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; Lehtio J, 2003, P NATL ACAD SCI USA, V100, P484, DOI 10.1073/pnas.212651999; LINDER M, 1995, PROTEIN SCI, V4, P1056, DOI 10.1002/pro.5560040604; MAGLIONE G, 1992, APPL ENVIRON MICROB, V58, P3593, DOI 10.1128/AEM.58.11.3593-3597.1992; McCartney L, 2006, P NATL ACAD SCI USA, V103, P4765, DOI 10.1073/pnas.0508887103; McCartney L, 2004, ANAL BIOCHEM, V326, P49, DOI 10.1016/j.ab.2003.11.011; McKie VA, 2001, BIOCHEM J, V355, P167, DOI 10.1042/0264-6021:3550167; McLean BW, 2002, J BIOL CHEM, V277, P50245, DOI 10.1074/jbc.M204433200; McLean BW, 2000, PROTEIN ENG, V13, P801, DOI 10.1093/protein/13.11.801; Murashima K, 2005, J BACTERIOL, V187, P7146, DOI 10.1128/JB.187.20.7146-7149.2005; Notenboom V, 2001, J MOL BIOL, V314, P797, DOI 10.1006/jmbi.2001.5153; Ponyi T, 2000, BIOCHEMISTRY-US, V39, P985, DOI 10.1021/bi9921642; Raghothama S, 2000, BIOCHEMISTRY-US, V39, P978, DOI 10.1021/bi992163+; REINIKAINEN T, 1992, PROTEINS, V14, P475, DOI 10.1002/prot.340140408; Simpson PJ, 2000, J BIOL CHEM, V275, P41137, DOI 10.1074/jbc.M006948200; TOMME P, 1988, EUR J BIOCHEM, V170, P575, DOI 10.1111/j.1432-1033.1988.tb13736.x; Tomme P, 1996, BIOCHEMISTRY-US, V35, P13885, DOI 10.1021/bi961185i; Tomme P, 1995, Adv Microb Physiol, V37, P1, DOI 10.1016/S0065-2911(08)60143-5; Tormo J, 1996, EMBO J, V15, P5739, DOI 10.1002/j.1460-2075.1996.tb00960.x; Willats WGT, 2001, PLANTA, V213, P37, DOI 10.1007/s004250000481; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011	42	195	211	2	71	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29321	29329		10.1074/jbc.M605903200	http://dx.doi.org/10.1074/jbc.M605903200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16844685	hybrid			2022-12-25	WOS:000240680500087
J	Feller, A; Hernandez, JM; Grotewold, E				Feller, Antje; Hernandez, J. Marcela; Grotewold, Erich			An ACT-like domain participates in the dimerization of several plant basic-helix-loop-helix transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; EPIDERMAL-CELL FATE; DNA-BINDING; PHOSPHOGLYCERATE DEHYDROGENASE; ENDOPLASMIC-RETICULUM; ARABIDOPSIS-THALIANA; NUCLEAR-LOCALIZATION; ESCHERICHIA-COLI; FUSION PROTEINS; BHLH PROTEINS	The maize basic-helix-loop-helix ( bHLH) factor R belongs to a group of proteins with important functions in the regulation of metabolism and development through the cooperation with R2R3-MYB transcription factors. Here we show that in addition to the bHLH and the R2R3-MYB-interacting domains, R contains a dimerization region located C-terminal to the bHLH motif. This protein-protein interaction domain is important for the regulation of anthocyanin pigment biosynthesis by contributing to the recruitment of the C1 R2R3-MYB factor to the C1 binding sites present in the promoters of flavonoid biosynthetic genes. The R dimerization region bares structural similarity to the ACT domain present in several metabolic enzymes. Protein fold recognition analyses resulted in the identification of similar ACT-like domains in several other plant bHLH proteins. We show that at least one of these related motifs is capable of mediating homodimer formation. These findings underscore the function of R as a docking site for multiple protein-protein interactions and provide evidence for the presence of a novel dimerization domain in multiple plant bHLH proteins.	Ohio State Univ, Dept Plant Cellular & Mol Biol, Columbus, OH 43210 USA; Ohio State Univ, Mol Cellular & Dev Biol Program, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Grotewold, E (corresponding author), Ohio State Univ, Dept Plant Cellular & Mol Biol, 206 Rightmire Hall,1060 Carmack Rd, Columbus, OH 43210 USA.	grotewold.1@osu.edu	Feller, Antje C/B-8188-2011	Grotewold, Erich/0000-0002-4720-7290				Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Atchley WR, 2000, MOL BIOL EVOL, V17, P164, DOI 10.1093/oxfordjournals.molbev.a026229; BAILEY TL, 1994, P 2 INT C INT SYST M, P28; Baudry A, 2004, PLANT J, V39, P366, DOI 10.1111/j.1365-313X.2004.02138.x; Bell JK, 2004, BIOCHEMISTRY-US, V43, P3450, DOI 10.1021/bi035462e; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bernhardt C, 2005, DEVELOPMENT, V132, P291, DOI 10.1242/dev.01565; Bernhardt C, 2003, DEVELOPMENT, V130, P6431, DOI 10.1242/dev.00880; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BODEAU JP, 1992, MOL GEN GENET, V233, P379, DOI 10.1007/BF00265434; Buck MJ, 2003, J MOL EVOL, V56, P742, DOI 10.1007/s00239-002-2449-3; Chipman DM, 2001, CURR OPIN STRUC BIOL, V11, P694, DOI 10.1016/S0959-440X(01)00272-X; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GOFF SA, 1991, GENE DEV, V5, P298, DOI 10.1101/gad.5.2.298; GOFF SA, 1992, GENE DEV, V6, P864, DOI 10.1101/gad.6.5.864; GORDONKAMM WJ, 1999, MOL IMPROVEMENT CERE, P189; Grotewold E, 2000, P NATL ACAD SCI USA, V97, P13579, DOI 10.1073/pnas.250379897; Grotewold E, 1998, PLANT CELL, V10, P721, DOI 10.1105/tpc.10.5.721; GROTEWOLD E, 1994, CELL, V76, P543, DOI 10.1016/0092-8674(94)90117-1; Grotewold E, 2006, ANNU REV PLANT BIOL, V57, P761, DOI 10.1146/annurev.arplant.57.032905.105248; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Heil G, 2002, MICROBIOL-SGM, V148, P2203, DOI 10.1099/00221287-148-7-2203; Heim MA, 2003, MOL BIOL EVOL, V20, P735, DOI 10.1093/molbev/msg088; Herman E, 2004, PLANT PHYSIOL, V136, P3440, DOI 10.1104/pp.104.051722; Hernandez JM, 2004, J BIOL CHEM, V279, P48205, DOI 10.1074/jbc.M407845200; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; James P, 1996, GENETICS, V144, P1425; Khanna R, 2004, PLANT CELL, V16, P3033, DOI 10.1105/tpc.104.025643; Kobe B, 1999, NAT STRUCT BIOL, V6, P442, DOI 10.1038/8247; Lesnick ML, 1998, PLANT PHYSIOL, V117, P437, DOI 10.1104/pp.117.2.437; Liberles JS, 2005, AMINO ACIDS, V28, P1, DOI 10.1007/s00726-004-0152-y; Liu YH, 1996, P NATL ACAD SCI USA, V93, P7816, DOI 10.1073/pnas.93.15.7816; LLOYD AM, 1994, SCIENCE, V266, P436, DOI 10.1126/science.7939683; LUDWIG SR, 1990, CELL, V62, P849, DOI 10.1016/0092-8674(90)90259-H; Mas-Droux C, 2006, PLANT CELL, V18, P1681, DOI 10.1105/tpc.105.040451; Matsushima R, 2004, PLANT CELL, V16, P1536, DOI 10.1105/tpc.021154; Morgenstern B, 1999, MOL BIOL EVOL, V16, P1654, DOI 10.1093/oxfordjournals.molbev.a026079; Moriguchi K, 2005, PLANT CELL, V17, P389, DOI 10.1105/tpc.104.028456; Mount R C, 1996, Methods Mol Biol, V53, P239; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1992, TRANSCRIPTIONAL REGU; Nesi N, 2000, PLANT CELL, V12, P1863, DOI 10.1105/tpc.12.10.1863; Payne CT, 2000, GENETICS, V156, P1349; Pollastri G, 2002, PROTEINS, V47, P228, DOI 10.1002/prot.10082; Pooma W, 2002, GENETICS, V161, P793; Quattrocchio F., 2006, SCI FLAVONOIDS, P97, DOI [DOI 10.1007/978-0-387-28822-2_4, 10.1007/978-0-387-28822-2_4]; Sainz MB, 1997, MOL CELL BIOL, V17, P115, DOI 10.1128/MCB.17.1.115; Sainz MB, 1997, PLANT CELL, V9, P611, DOI 10.1105/tpc.9.4.611; SCHUDSON M, 1995, FORBES MEDIA CRITIC, V2, P76; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; SHIEH MW, 1993, PLANT PHYSIOL, V101, P353, DOI 10.1104/pp.101.2.353; Thompson JR, 2005, BIOCHEMISTRY-US, V44, P5763, DOI 10.1021/bi047944b; Toledo-Ortiz G, 2003, PLANT CELL, V15, P1749, DOI 10.1105/tpc.013839; Voinnet O, 2003, PLANT J, V33, P949, DOI 10.1046/j.1365-313X.2003.01676.x; Williams CE, 1997, J BIOL CHEM, V272, P563, DOI 10.1074/jbc.272.1.563; Zhang F, 2003, DEVELOPMENT, V130, P4859, DOI 10.1242/dev.00681; Zimmermann IM, 2004, PLANT J, V40, P22, DOI 10.1111/j.1365-313X.2004.02183.x	57	95	99	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28964	28974		10.1074/jbc.M603262200	http://dx.doi.org/10.1074/jbc.M603262200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16867983	hybrid			2022-12-25	WOS:000240680500051
J	Suzuki, Y; Zhang, H; Saito, N; Kojima, I; Urano, T; Mogami, H				Suzuki, Yuko; Zhang, Hui; Saito, Naoaki; Kojima, Itaru; Urano, Tetsumei; Mogami, Hideo			Glucagon-like peptide 1 activates protein kinase C through Ca2+-dependent activation of phospholipase C in insulin-secreting cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; K-ATP CHANNELS; INTRACELLULAR DELIVERY; SELECTIVE-INHIBITION; CA2+ RELEASE; TRANSLOCATION; CALCIUM; PHOSPHORYLATION; EXOCYTOSIS; RECEPTOR	Although the stimulatory effect of glucagon-like peptide 1(GLP1), a cAMP-generating agonist, on Ca2+ signal and insulin secretion is well established, the underlying mechanisms remain to be fully elucidated. We recently discovered that Ca2+ influx alone can activate conventional protein kinase C (PKC) as well as novel PKC in insulin-secreting (INS-1) cells. Building on this earlier finding, here we examined whether GLP-1-evoked Ca2+ signaling can activate PKC alpha and PKC epsilon at a substimulatory concentration of glucose (3 mM) in INS-1 cells. We first showed that GLP-1 translocated endogenous PKC alpha and PKC epsilon from the cytosol to the plasma membrane. Next, we assessed the phosphorylation state of the PKC substrate, myristoylated alanine-rich C kinase substrate ( MARCKS), by using MARCKS-GFP. GLP-1 translocated MARCKS-GFP to the cytosol in a Ca2+-dependent manner, and the GLP-1-evoked translocation of MARCKS-GFP was blocked by PKC inhibitors, either a broad PKC inhibitor, bisindolylmaleimide I, or a PKC epsilon inhibitor peptide, antennapedia peptide-fused pseudosubstrate PKC epsilon-(149-164) (antp-PKC epsilon) and a conventional PKC inhibitor, Go-6976. Furthermore, forskolin-induced translocation of MARCKS-GFP was almost completely inhibited by U73122, a putative inhibitor of phospholipase C. These observations were verified in two different ways by demonstrating 1) forskolin-induced translocation of the GFP-tagged C1 domain of PKC gamma and 2) translocation of PKC alpha-DsRed and PKC alpha-GFP. In addition, PKC inhibitors reduced forskolin-induced insulin secretion in both INS-1 cells and rat islets. Thus, GLP-1 can activate PKC alpha and PKC epsilon, and these GLP-1-activated PKCs may contribute considerably to insulin secretion at a substimulatory concentration of glucose.	Hamamatsu Univ Sch Med, Dept Physiol, Hamamatsu, Shizuoka 4313192, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Maebashi, Gumma 3718512, Japan; Kobe Univ, Biosignal Res Ctr, Mol Pharmacol Lab, Nada Ku, Kobe, Hyogo 6578501, Japan	Hamamatsu University School of Medicine; Gunma University; Kobe University	Mogami, H (corresponding author), Hamamatsu Univ Sch Med, Dept Physiol, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	hmogami@hama-med.ac.jp						Almholt K, 1999, BIOCHEM J, V337, P211, DOI 10.1042/0264-6021:3370211; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; DILLON JS, 1993, ENDOCRINOLOGY, V133, P1907, DOI 10.1210/en.133.4.1907; Fischer PM, 2000, J PEPT RES, V55, P163, DOI 10.1034/j.1399-3011.2000.00163.x; GROMADA J, 1995, DIABETES, V44, P767, DOI 10.2337/diabetes.44.7.767; Gromada J, 1998, PFLUG ARCH EUR J PHY, V435, P583, DOI 10.1007/s004240050558; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; Harris TE, 1999, MOL CELL ENDOCRINOL, V155, P61, DOI 10.1016/S0303-7207(99)00114-8; Holz GG, 2004, DIABETES, V53, P5, DOI 10.2337/diabetes.53.1.5; HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0; HOLZ GG, 1995, J BIOL CHEM, V270, P17749, DOI 10.1074/jbc.270.30.17749; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; MacDonald PE, 2002, DIABETES, V51, pS434, DOI 10.2337/diabetes.51.2007.S434; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Mashima H, 1996, J CLIN INVEST, V97, P1647, DOI 10.1172/JCI118591; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mendez CF, 2003, J BIOL CHEM, V278, P44753, DOI 10.1074/jbc.M308664200; Mogami H, 2003, J BIOL CHEM, V278, P9896, DOI 10.1074/jbc.M210653200; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Ohmori S, 2000, J BIOL CHEM, V275, P26449, DOI 10.1074/jbc.M003588200; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Suga S, 1997, DIABETES, V46, P1755, DOI 10.2337/diabetes.46.11.1755; Tian YM, 1996, MOL CELL ENDOCRINOL, V119, P185, DOI 10.1016/0303-7207(96)03811-7; Toft-Nielsen M, 1998, DIABETOLOGIA, V41, P1180, DOI 10.1007/s001250051049; Toker A., 1998, FRONT BIOSCI-LANDMRK, V3, P1134, DOI 10.2741/A350; Tsuboi T, 2003, BIOCHEM J, V369, P287, DOI 10.1042/BJ20021288; Uchino M, 2004, J BIOL CHEM, V279, P2254, DOI 10.1074/jbc.M309894200; WOLLHEIM CB, 1988, EMBO J, V7, P2443, DOI 10.1002/j.1460-2075.1988.tb03090.x; Yamada S, 2002, ENDOCRINOLOGY, V143, P4203, DOI 10.1210/en.2002-220368; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417; Zhang H, 2004, J PHYSIOL-LONDON, V561, P133, DOI 10.1113/jphysiol.2004.071241; ZOUKHRI D, 1997, AM J PHYSIOL, V272, P263	43	45	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28499	28507		10.1074/jbc.M604291200	http://dx.doi.org/10.1074/jbc.M604291200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16870611	hybrid			2022-12-25	WOS:000240680500003
J	Martin, E; Berka, V; Bogatenkova, E; Murad, F; Tsai, AL				Martin, Emil; Berka, Vladimir; Bogatenkova, Elena; Murad, Ferid; Tsai, Ah-Lim			Ligand selectivity of soluble guanylyl cyclase - Effect of the hydrogen-bonding tyrosine in the distal heme pocket on binding of oxygen, nitric oxide, and carbon monoxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-BASIS; BOVINE LUNG; NO; ACTIVATION; DISSOCIATION; PROTEINS; DOMAIN; SENSOR; IDENTIFICATION; HEMOGLOBIN	Although soluble guanylyl cyclase(sGC) functions in an environment in which O-2, NO, and CO are potential ligands for its heme moiety, the enzyme displays a high affinity for only its physiological ligand, NO, but has a limited affinity for CO and no affinity for O-2. Recent studies of a truncated version of the sGC beta(1)-subunit containing the heme-binding domain (Boon, E. M., Huang, S H., and Marletta, M.A. (2005) Nat. Chem. Biol., 1, 53 - 59) showed that introduction of the hydrogen-bonding tyrosine into the distal heme pocket changes the ligand specificity of the heme moiety and results in an oxygen-binding sGC. The hypothesis that the absence of hydrogen-bonding residues in the distal heme pocket is sufficient to provide oxygen discrimination by sGC was put forward. We tested this hypothesis in a context of a complete sGC heterodimer containing both the intact alpha(1)- and beta(1)-subunits. We found that the I145Y substitution in the full-length beta-subunit of the sGC heterodimer did not produce an oxygen-binding enzyme. However, this substitution impeded the association of NO and destabilized the NO (.) heme complex. The tyrosine in the distal heme pocket also impeded both the binding and dissociation of the CO ligand. We propose that the mechanism of oxygen exclusion by sGC not only involves the lack of hydrogen bonding in the distal heme pocket, but also depends on structural elements from other domains of sGC.	Univ Texas, Hlth Sci Ctr, Brown Fdn Inst Mol Med, Houston, TX 77030 USA; Univ Texas, Sch Med, Div Hematol, Dept Internal Med, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System	Martin, E (corresponding author), Univ Texas, Hlth Sci Ctr, Brown Fdn Inst Mol Med, Houston, TX 77030 USA.	emil.martin@uth.tmc.edu; ferid.murad@uth.tmc.edu; ah-lim.tsai@uth.tmc.edu		Martin, Emil/0000-0002-9094-4165	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056818, R01GM061731] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64221] Funding Source: Medline; NIDDK NIH HHS [DK065153-17] Funding Source: Medline; NIGMS NIH HHS [GM61731, GM56818] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berka V, 1996, J BIOL CHEM, V271, P33293, DOI 10.1074/jbc.271.52.33293; Boon EM, 2006, J BIOL CHEM, V281, P21892, DOI 10.1074/jbc.M600557200; Boon EM, 2005, J INORG BIOCHEM, V99, P892, DOI 10.1016/j.jinorgbio.2004.12.016; Boon EM, 2005, NAT CHEM BIOL, V1, P53, DOI 10.1038/nchembio704; Boon EM, 2005, CURR OPIN CHEM BIOL, V9, P441, DOI 10.1016/j.cbpa.2005.08.015; Cary SPL, 2006, TRENDS BIOCHEM SCI, V31, P231, DOI 10.1016/j.tibs.2006.02.003; Cary SPL, 2005, P NATL ACAD SCI USA, V102, P13064, DOI 10.1073/pnas.0506289102; Condorelli P, 2001, BIOPHYS J, V80, P2110, DOI 10.1016/S0006-3495(01)76184-X; Deinum G, 1996, BIOCHEMISTRY-US, V35, P1540; Draghi F, 2002, J BIOL CHEM, V277, P7509, DOI 10.1074/jbc.M109206200; Foerster J, 1996, EUR J BIOCHEM, V240, P380, DOI 10.1111/j.1432-1033.1996.0380h.x; Friebe A, 1996, EMBO J, V15, P6863, DOI 10.1002/j.1460-2075.1996.tb01078.x; GERZER R, 1981, FEBS LETT, V132, P71, DOI 10.1016/0014-5793(81)80429-2; Hoenicka M, 1999, J MOL MED-JMM, V77, P14, DOI 10.1007/s001090050292; IGNARRO LJ, 1982, P NATL ACAD SCI-BIOL, V79, P2870, DOI 10.1073/pnas.79.9.2870; Karow DS, 2004, BIOCHEMISTRY-US, V43, P10203, DOI 10.1021/bi049374l; Kharitonov VG, 1997, BIOCHEMISTRY-US, V36, P6814, DOI 10.1021/bi970201o; Kharitonov VG, 1997, BIOCHEM BIOPH RES CO, V239, P284, DOI 10.1006/bbrc.1997.7470; Lee YC, 2000, P NATL ACAD SCI USA, V97, P10763, DOI 10.1073/pnas.190333697; Lucas KA, 2000, PHARMACOL REV, V52, P375; Makino R, 1999, J BIOL CHEM, V274, P7714, DOI 10.1074/jbc.274.12.7714; Martin E, 2005, METHOD ENZYMOL, V396, P478, DOI 10.1016/S0076-6879(05)96040-0; Martin E, 2003, P NATL ACAD SCI USA, V100, P9208, DOI 10.1073/pnas.1633590100; MARTIN E, 2005, NITRIC OXIDE CELL SI, P167; McCleverty JA, 2004, CHEM REV, V104, P403, DOI 10.1021/cr020623q; MOMENTEAU M, 1994, CHEM REV, V94, P659, DOI 10.1021/cr00027a006; Nioche P, 2004, SCIENCE, V306, P1550, DOI 10.1126/science.1103596; OERTLING WA, 1990, INORG CHEM, V29, P2633, DOI 10.1021/ic00339a021; Pellicena P, 2004, P NATL ACAD SCI USA, V101, P12854, DOI 10.1073/pnas.0405188101; Pesce A, 2004, J BIOL CHEM, V279, P33662, DOI 10.1074/jbc.M403597200; Pesce A, 2001, J MOL BIOL, V309, P1153, DOI 10.1006/jmbi.2001.4731; ROSE EJ, 1983, J AM CHEM SOC, V105, P2866, DOI 10.1021/ja00347a056; Russwurm M, 2004, EMBO J, V23, P4443, DOI 10.1038/sj.emboj.7600422; Schelvis JPM, 1998, BIOCHEMISTRY-US, V37, P16289, DOI 10.1021/bi981547h; Schmidt PM, 2005, EUR J PHARMACOL, V513, P67, DOI 10.1016/j.ejphar.2005.02.046; Schmidt PM, 2004, J BIOL CHEM, V279, P3025, DOI 10.1074/jbc.M310141200; Stasch JP, 2001, NATURE, V410, P212, DOI 10.1038/35065611; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; TSAI AL, 1994, FEBS LETT, V341, P141, DOI 10.1016/0014-5793(94)80445-1; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753; Zhao Y, 1998, BIOCHEMISTRY-US, V37, P4502, DOI 10.1021/bi972686m	43	78	81	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27836	27845		10.1074/jbc.M601078200	http://dx.doi.org/10.1074/jbc.M601078200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16864588	hybrid			2022-12-25	WOS:000240534400019
J	Rosental, N; Bendahan, A; Kanner, BI				Rosental, Noa; Bendahan, Annie; Kanner, Baruch I.			Multiple consequences of mutating two conserved beta-bridge forming residues in the translocation cycle of a neuronal glutamate transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC-ACID TRANSPORTER; RAT-BRAIN; MEMBRANE-VESICLES; CHLORIDE CHANNEL; REENTRANT LOOP; GLT-1; SUBSTRATE; EXPRESSION; BINDING; FLUXES	Glutamate transporters remove this neurotransmitter from the synapse in an electrogenic process. After sodium-coupled glutamate translocation, the cycle is completed by obligatory outward translocation of potassium. In the crystal structure of an archaeal homologue, two conserved residues form a beta-bridge, which points away from the binding pocket. In the neuronal glutamate transporter EAAC1, the equivalent residues are asparagine 366 and aspartate 368. Substitution mutants N366Q and D368E, but not N366D and D368N, show glutamate-induced inwardly rectifying steady-state currents, but their apparent substrate affinity is dramatically decreased. Such currents, which reflect electrogenic net uptake of substrate are not observed with the reciprocal double mutant N366D/D368N. Remarkably, the double mutant exhibits slow substrate-induced voltage-dependent capacitative transient currents. These currents apparently reflect the reversible sodium-coupled glutamate translocation step, because the interaction of the double mutant with potassium is largely impaired. Moreover, when the analogous double mutant in the glutamate transporter GLT-1 is reconstituted into liposomes, a slow exchange of radioactive and unlabeled acidic amino acids is observed. Our results suggest that it is the interaction of asparagine 366 and aspartate 368 that is important during the glutamate translocation step. On the other hand, the side chains of these residues themselves are required for the subsequent potassium relocation step.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Kanner, BI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, POB 12272, IL-91120 Jerusalem, Israel.	kannerb@cc.huji.ac.il			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS016708, R01NS016708] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 16708] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Bendahan A, 2000, J BIOL CHEM, V275, P37436, DOI 10.1074/jbc.M006536200; Bennett ER, 2000, J BIOL CHEM, V275, P34106, DOI 10.1074/jbc.M004229200; Borre L, 2004, J BIOL CHEM, V279, P2513, DOI 10.1074/jbc.M311446200; Borre L, 2002, J BIOL CHEM, V277, P13501, DOI 10.1074/jbc.M110861200; Borre L, 2001, J BIOL CHEM, V276, P40396, DOI 10.1074/jbc.M104926200; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; Brocke L, 2002, J BIOL CHEM, V277, P3985, DOI 10.1074/jbc.M107735200; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Holmseth S, 2005, NEUROSCIENCE, V136, P649, DOI 10.1016/j.neuroscience.2005.07.022; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; PINES G, 1995, J BIOL CHEM, V270, P17093, DOI 10.1074/jbc.270.29.17093; PINES G, 1990, BIOCHEMISTRY-US, V29, P11209, DOI 10.1021/bi00503a008; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Ryan RM, 2004, J BIOL CHEM, V279, P20742, DOI 10.1074/jbc.M304433200; Ryan RM, 2002, J BIOL CHEM, V277, P13494, DOI 10.1074/jbc.M109970200; Seal RP, 2001, P NATL ACAD SCI USA, V98, P15324, DOI 10.1073/pnas.011400198; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Tao Z, 2006, J BIOL CHEM, V281, P10263, DOI 10.1074/jbc.M510739200; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Wadiche JI, 1998, J NEUROSCI, V18, P7650; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Zarbiv R, 1998, J BIOL CHEM, V273, P14231, DOI 10.1074/jbc.273.23.14231; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710; Zhang YM, 1998, P NATL ACAD SCI USA, V95, P751, DOI 10.1073/pnas.95.2.751	41	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27905	27915		10.1074/jbc.M600331200	http://dx.doi.org/10.1074/jbc.M600331200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16870620	hybrid			2022-12-25	WOS:000240534400026
J	van den Hemel, D; Brige, A; Savvides, SN; Van Beeumen, J				van den Hemel, Debbie; Brige, Ann; Savvides, Savvas N.; Van Beeumen, Jozef			Ligand-induced conformational changes in the capping subdomain of a bacterial old yellow enzyme homologue and conserved sequence fingerprints provide new insights into substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENTAERYTHRITOL TETRANITRATE REDUCTASE; GLYCEROL TRINITRATE REDUCTASE; OXIDATIVE STRESS-RESPONSE; ENTEROBACTER-CLOACAE PB2; ACTIVE-SITE RESIDUES; MORPHINONE REDUCTASE; SHEWANELLA-ONEIDENSIS; CRYSTAL-STRUCTURE; LIPID-PEROXIDATION; FLAVIN REACTIVITY	We have recently reported that Shewanella oneidensis, a Gram-negative gamma-proteobacterium with a rich arsenal of redox proteins, possesses four old yellow enzyme (OYE) homologues. Here, we report a series of high resolution crystal structures for one of these OYEs, Shewanella yellow enzyme 1 (SYE1), in its oxidized form at 1.4 angstrom resolution, which binds a molecule of PEG 400 in the active site, and in its NADH-reduced and p-hydroxybenzaldehyde and p-hydroxyacetophenone-bound forms at 1.7 angstrom resolution. Although the overall structure of SYE1 reveals a monomeric enzyme based on the alpha(8)beta(8) barrel scaffold observed for other OYEs, the active site exhibits a unique combination of features: a strongly butterfly-bent FMN cofactor both in the oxidized and NADH-reduced forms, a collapsed and narrow active site tunnel, and a novel combination of conserved residues involved in the binding of phenolic ligands. Furthermore, we identify a second p-hydroxybenzaldehyde- binding site in a hydrophobic cleft next to the entry of the active site tunnel in the capping subdomain, formed by a restructuring of Loop 3 to an "open" conformation. This constitutes the first evidence to date for the entire family of OYEs that Loop 3 may indeed play a dynamic role in ligand binding and thus provides insights into the elusive NADH complex and into substrate binding in general. Structure-based sequence alignments indicate that the novelties we observe in SYE1 are supported by conserved residues in a number of structurally uncharacterized OYEs from the beta- and gamma-proteobacteria, suggesting that SYE1 represents a new subfamily of bacterial OYEs.	Univ Ghent, Dept Biochem Physiol & Microbiol, Lab Prot Biochem & Prot Engn, B-9000 Ghent, Belgium	Ghent University	Savvides, SN (corresponding author), Univ Ghent, Dept Biochem Physiol & Microbiol, Lab Prot Biochem & Prot Engn, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	savvas.savvides@ugent.be; jozef.vanbeeumen@ugent.be	Savvides, Savvas/E-1938-2011	Savvides, Savvas/0000-0003-3420-5947				Abboud R, 2005, APPL ENVIRON MICROB, V71, P811, DOI 10.1128/AEM.71.2.811-816.2005; ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5327; Barna T, 2002, J BIOL CHEM, V277, P30976, DOI 10.1074/jbc.M202846200; Barna TM, 2001, J MOL BIOL, V310, P433, DOI 10.1006/jmbi.2001.4779; Blehert DS, 1997, J BACTERIOL, V179, P6912, DOI 10.1128/jb.179.22.6912-6920.1997; Blehert DS, 1999, J BACTERIOL, V181, P6254, DOI 10.1128/JB.181.20.6254-6263.1999; Bowman JP, 1997, INT J SYST BACTERIOL, V47, P1040, DOI 10.1099/00207713-47-4-1040; Breithaupt C, 2001, STRUCTURE, V9, P419, DOI 10.1016/S0969-2126(01)00602-5; Brige A, 2006, BIOCHEM J, V394, P335, DOI 10.1042/BJ20050979; Brown BJ, 1998, J BIOL CHEM, V273, P32753, DOI 10.1074/jbc.273.49.32753; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bruns CM, 1999, J MOL BIOL, V288, P427, DOI 10.1006/jmbi.1999.2697; Craig DH, 2001, BIOCHEM J, V359, P315, DOI 10.1042/0264-6021:3590315; CROFT KPC, 1993, PLANT PHYSIOL, V101, P13, DOI 10.1104/pp.101.1.13; Duax WL, 2003, PROTEINS, V53, P931, DOI 10.1002/prot.10512; Fitzpatrick TB, 2003, J BIOL CHEM, V278, P19891, DOI 10.1074/jbc.M211778200; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; FRENCH CE, 1994, BIOCHEM J, V301, P97, DOI 10.1042/bj3010097; French CE, 1998, APPL ENVIRON MICROB, V64, P2864; French CE, 1996, J BACTERIOL, V178, P6623, DOI 10.1128/jb.178.22.6623-6627.1996; Haarer BK, 2004, MOL BIOL CELL, V15, P4522, DOI 10.1091/mbc.E04-06-0445; Haynes CA, 2002, J BIOL CHEM, V277, P11513, DOI 10.1074/jbc.M111334200; Heidelberg JF, 2002, NAT BIOTECHNOL, V20, P1118, DOI 10.1038/nbt749; Khan H, 2002, J BIOL CHEM, V277, P21906, DOI 10.1074/jbc.M200637200; Kitzing K, 2005, J BIOL CHEM, V280, P27904, DOI 10.1074/jbc.M502587200; Koder RL, 2002, BIOCHEMISTRY-US, V41, P14197, DOI 10.1021/bi025805t; Kohli RM, 1998, J BIOL CHEM, V273, P32763, DOI 10.1074/jbc.273.49.32763; Komduur JA, 2002, CURR GENET, V41, P401, DOI 10.1007/s00294-002-0321-z; Kubata BK, 2002, J EXP MED, V196, P1241, DOI 10.1084/jem.20020885; Kubo I, 2004, J APPL MICROBIOL, V96, P693, DOI 10.1111/j.1365-2672.2003.02175.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Marshall SJ, 2004, J BACTERIOL, V186, P1802, DOI 10.1128/JB.186.6.1802-1810.2004; Meah Y, 2000, P NATL ACAD SCI USA, V97, P10733, DOI 10.1073/pnas.190345597; Meah Y, 2001, P NATL ACAD SCI USA, V98, P8560, DOI 10.1073/pnas.151249098; Messiha HL, 2005, J BIOL CHEM, V280, P27103, DOI 10.1074/jbc.M502293200; MIRANDA M, 1995, YEAST, V11, P459, DOI 10.1002/yea.320110509; NIINO YS, 1995, J BIOL CHEM, V270, P1983, DOI 10.1074/jbc.270.5.1983; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pak JW, 2000, APPL ENVIRON MICROB, V66, P4742, DOI 10.1128/AEM.66.11.4742-4750.2000; Reekmans R, 2005, FEMS YEAST RES, V5, P711, DOI 10.1016/j.femsyr.2004.12.010; Schaller F, 1997, J BIOL CHEM, V272, P28066, DOI 10.1074/jbc.272.44.28066; Snape JR, 1997, J BACTERIOL, V179, P7796, DOI 10.1128/jb.179.24.7796-7802.1997; STEWART RC, 1985, J BIOL CHEM, V260, P3639; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; STOTT K, 1993, J BIOL CHEM, V268, P6097; Strassner J, 1999, J BIOL CHEM, V274, P35067, DOI 10.1074/jbc.274.49.35067; VAZ ADN, 1995, BIOCHEMISTRY-US, V34, P4246, DOI 10.1021/bi00013a014; Wada M, 2003, APPL ENVIRON MICROB, V69, P933, DOI 10.1128/AEM.69.2.933-937.2003; Williams RE, 2002, MICROBIOL-SGM, V148, P1607, DOI 10.1099/00221287-148-6-1607; Williams RE, 2004, APPL ENVIRON MICROB, V70, P3566, DOI 10.1128/AEM.70.6.3566-3574.2004; Xu D, 1999, P NATL ACAD SCI USA, V96, P3556, DOI 10.1073/pnas.96.7.3556	52	28	30	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28152	28161		10.1074/jbc.M603946200	http://dx.doi.org/10.1074/jbc.M603946200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16857682	hybrid			2022-12-25	WOS:000240534400053
J	Wilkes, MC; Leof, EB				Wilkes, Mark C.; Leof, Edward B.			Transforming growth factor beta activation of c-Abl is independent of receptor internalization and regulated by phosphatidylinositol 3-kinase and PAK2 in mesenchymal cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; TYROSINE KINASE; EARLY ENDOSOMES; FAMILY KINASES; SMAD; DIFFERENTIATION; TRANSCRIPTION; SPECIFICITY; MECHANISMS; INHIBITION	Transforming growth factor beta(TGF-beta) modulates a number of cellular phenotypes as divergent as growth stimulation and growth inhibition. Although the Smad pathway is critical for many of these responses, recent evidence indicates that Smad-independent pathways may also have a critical role. One such protein previously shown to regulate TGF-beta action independent of the Smad proteins is the c-Abl nonreceptor tyrosine kinase. In the current study we determined that TGF-beta receptor signaling activates c-Abl kinase activity in a subset of fibroblast but not epithelial cultures. This cell type-specific response occurs in a membrane-proximal locale independent of receptor internalization and upstream of dynamin action. Although c-Abl activation by TGF-beta is independent of Smad2 or Smad3, it is prevented by inhibitors of phosphatidylinositol 3-kinase or PAK2. Thus, c-Abl represents a target downstream of phosphatidylinositol 3-kinase-activated PAK2, which differentiates TGF-beta signaling in fibroblasts and epithelial cell lines and integrates serine/threonine receptor kinases with tyrosine kinase pathways.	Mayo Clin & Mayo Fdn, Coll Med, Dept Biochem & Mol Biol, Thorac Dis Res Unit, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Ctr Canc, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Leof, EB (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Dept Biochem & Mol Biol, Thorac Dis Res Unit, 200 1st St SW,Stabile 8-58, Rochester, MN 55905 USA.	leof.edward@mayo.edu		Wilkes, Mark/0000-0002-9600-6831	NIGMS NIH HHS [R01 GM54200, R01 GM55816] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055816, R01GM054200] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anders RA, 1998, J BIOL CHEM, V273, P23118, DOI 10.1074/jbc.273.36.23118; Anders RA, 1996, J BIOL CHEM, V271, P21758, DOI 10.1074/jbc.271.36.21758; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Cogan JG, 2002, J BIOL CHEM, V277, P36433, DOI 10.1074/jbc.M203232200; Daniels CE, 2004, J CLIN INVEST, V114, P1308, DOI 10.1175/JCI200419603; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Flanders KC, 2004, INT J EXP PATHOL, V85, P47, DOI 10.1111/j.0959-9673.2004.00377.x; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; Hernandez SE, 2004, TRENDS CELL BIOL, V14, P36, DOI 10.1016/j.tcb.2003.11.003; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; LEOF EB, 1986, J CELL PHYSIOL, V127, P83, DOI 10.1002/jcp.1041270111; Levy L, 2005, MOL CELL BIOL, V25, P8108, DOI 10.1128/MCB.25.18.8108-8125.2005; Lu ZX, 2002, J BIOL CHEM, V277, P29363, DOI 10.1074/jbc.M203495200; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOSES HL, 1981, CANCER RES, V41, P2842; MOSES HL, 1985, CANCER CELL, V3, P65; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; ROBERTS AB, 1992, MOL REPROD DEV, V32, P91, DOI 10.1002/mrd.1080320203; ROBERTS AB, 1982, NATURE, V295, P417, DOI 10.1038/295417a0; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; Roig J, 2000, J BIOL CHEM, V275, P16933, DOI 10.1074/jbc.M001627200; Runyan CE, 2005, J BIOL CHEM, V280, P8300, DOI 10.1074/jbc.M407939200; Sharma DK, 2003, J BIOL CHEM, V278, P7564, DOI 10.1074/jbc.M210457200; Smith JM, 2002, FRONT BIOSCI, V7, pD31; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; WANG JYJ, 1984, CELL, V36, P349; Wang SN, 2005, FASEB J, V19, P1, DOI 10.1096/fj.04-2370com; Wang YX, 2001, P NATL ACAD SCI USA, V98, P14865, DOI 10.1073/pnas.251249298; Wilkes MC, 2005, CANCER RES, V65, P10431, DOI 10.1158/0008-5472.CAN-05-1522; Wilkes MC, 2003, MOL CELL BIOL, V23, P8878, DOI 10.1128/MCB.23.23.8878-8889.2003; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Woodring PJ, 2002, J CELL BIOL, V156, P879, DOI 10.1083/jcb.200110014; Woodring PJ, 2001, J BIOL CHEM, V276, P27104, DOI 10.1074/jbc.M100559200; Yue JB, 2001, PHARMACOL THERAPEUT, V91, P1, DOI 10.1016/S0163-7258(01)00143-7; Zhu JY, 2004, CURR TOP DEV BIOL, V59, P165, DOI 10.1016/S0070-2153(04)59007-5	49	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27846	27854		10.1074/jbc.M603721200	http://dx.doi.org/10.1074/jbc.M603721200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16867995	hybrid			2022-12-25	WOS:000240534400020
J	Liang, F; Seyrantepe, V; Landry, K; Ahmad, R; Ahmad, A; Stamatos, NM; Pshezhetsky, AV				Liang, Feng; Seyrantepe, Volkan; Landry, Karine; Ahmad, Rasheed; Ahmad, Ali; Stamatos, Nicholas M.; Pshezhetsky, Alexey V.			Monocyte differentiation up-regulates the expression of the lysosomal sialidase, Neu1, and triggers its targeting to the plasma membrane via major histocompatibility complex class II-positive compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN-FIBROBLASTS; TRANSCRIPTION FACTOR AP-1; LEUKEMIA-CELL LINE; GENE-EXPRESSION; T-CELLS; PROTECTIVE PROTEIN; DENDRITIC CELLS; C-FOS; NEURAMINIDASE; JUN	Human sialidase (neuraminidase) Neu1 catalyzes lysosomal catabolism of sialylated glycoconjugates. Here we show that during the differentiation of monocytes and the monocytic cell line, THP-1, into macrophages, the majority of Neu1 relocalizes from the lysosomes to the cell surface. In contrast to other cellular sialidases Neu2, Neu3, and Neu4, whose expression either remains unchanged or is down-regulated, Neu1 mRNA, protein and activity are specifically increased during the phorbol 12-myristate 13-acetate-induced differentiation, consistent with a significant induction of the transcriptional activity of the Neu1 gene promoter. The lysosomal carboxypeptidase, cathepsin A, which forms a complex with and activates Neu1 in the lysosome, is sorted to the plasma membrane of the differentiating cells similarly to Neu1. Both proteins are first targeted to the lysosome and then are sorted to the LAMP-2-negative, major histocompatibility complex II-positive vesicles, which later merge with the plasma membrane. Similar trafficking was observed for the internalized fluorescent dextran or horseradish peroxidase initially stored in the lysosomal/endosomal compartment. The suppression of Neu1 expression in the THP-1-derived macrophages by small interfering RNA or with anti-Neu1 antibodies significantly reduced the ability of the cells to engulf bacteria or to produce cytokines. Altogether our data suggest that the upregulation of the Neu1 expression is important for the primary function of macrophages and establish the link between Neu1 and the cellular immune response.	Hop St Justine, Serv Genet Med, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Dept Pediat, Montreal, PQ H3T 1C5, Canada; Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA; Univ Maryland, Med Ctr, Dept Med, Div Infect Dis, Baltimore, MD 21201 USA	Universite de Montreal; Universite de Montreal; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Pshezhetsky, AV (corresponding author), Hop St Justine, Serv Genet Med, 3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada.	alexei.pchejetski@umontreal.ca		Ahmad, Ali/0000-0001-7689-7115; A, Pshezhetsky/0000-0002-6612-1062	NHLBI NIH HHS [K08 HL72176-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL072176] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; AMIGORENA S, 1995, J EXP MED, V181, P1729, DOI 10.1084/jem.181.5.1729; AUWERX J, 1991, EXPERIENTIA, V47, P22, DOI 10.1007/BF02041244; Bergmeyer H.U., 1974, METHODS ENZYMATIC AN, V2, P495; Bonten E, 1996, GENE DEV, V10, P3156, DOI 10.1101/gad.10.24.3156; BONTEN EJ, 1995, J BIOL CHEM, V270, P26441, DOI 10.1074/jbc.270.44.26441; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bryant P, 2004, CURR OPIN IMMUNOL, V16, P96, DOI 10.1016/j.coi.2003.11.011; Chen XP, 1997, J IMMUNOL, V158, P3070; Chen XP, 2000, CYTOKINE, V12, P972, DOI 10.1006/cyto.1999.0596; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; Crocker PR, 2002, CURR OPIN STRUC BIOL, V12, P609, DOI 10.1016/S0959-440X(02)00375-5; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; d'Azzo A., 2001, METABOLIC MOL BASES, V3, P3811; GALJART NJ, 1991, J BIOL CHEM, V266, P14754; Gee K, 2003, J BIOL CHEM, V278, P37275, DOI 10.1074/jbc.M302309200; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; Katoh S, 1999, J IMMUNOL, V162, P5058; LANDOLFI NF, 1986, MOL IMMUNOL, V23, P297, DOI 10.1016/0161-5890(86)90057-X; LANDOLFI NF, 1985, IMMUNOGENETICS, V22, P159, DOI 10.1007/BF00563513; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Li SC, 2001, BIOCHEM J, V360, P233, DOI 10.1042/0264-6021:3600233; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Lukong KE, 2001, J BIOL CHEM, V276, P46172, DOI 10.1074/jbc.M104547200; Lukong KE, 1999, BIOCHEMISTRY-US, V38, P73, DOI 10.1021/bi981324r; MANZI AE, 2003, CURRENT PROTOCOLS MO, V3; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Milner CM, 1997, J BIOL CHEM, V272, P4549, DOI 10.1074/jbc.272.7.4549; MIYAGI T, 1993, GLYCOCONJUGATE J, V10, P45, DOI 10.1007/BF00731186; Monti E, 1999, GLYCOBIOLOGY, V9, P1313, DOI 10.1093/glycob/9.12.1313; Pierre P, 1996, IMMUNITY, V4, P229, DOI 10.1016/S1074-7613(00)80431-8; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; Pshezhetsky AV, 1997, NAT GENET, V15, P316, DOI 10.1038/ng0397-316; Pshezhetsky AV, 2001, PROG NUCLEIC ACID RE, V69, P81, DOI 10.1016/S0079-6603(01)69045-7; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; Rottier RJ, 1998, HUM MOL GENET, V7, P313, DOI 10.1093/hmg/7.2.313; RYAZANOV AG, 1988, EUR J BIOCHEM, V171, P301, DOI 10.1111/j.1432-1033.1988.tb13790.x; SCHMIDT E, 1974, METHOD ENZYMAT AN, V2, P650; SCHNEIDERJAKOB HR, 1991, BIOL CHEM H-S, V372, P443, DOI 10.1515/bchm3.1991.372.1.443; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; Seyrantepe V, 2004, J BIOL CHEM, V279, P37021, DOI 10.1074/jbc.M404531200; Seyrantepe V, 2003, HUM MUTAT, V22, P343, DOI 10.1002/humu.10268; Stamatos NM, 2005, FEBS J, V272, P2545, DOI 10.1111/j.1742-4658.2005.04679.x; Tanaka C, 1997, BIOCHEM BIOPH RES CO, V232, P568, DOI 10.1006/bbrc.1997.6264; Thomas G.H., METABOLIC MOL BASES, V3, P3507; TRANCHEMONTAGNE J, 1990, BIOCHEM BIOPH RES CO, V168, P22, DOI 10.1016/0006-291X(90)91669-J; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; TSUCHIYA S, 1982, CANCER RES, V42, P1530; Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522; VANDERHORST GTJ, 1989, J BIOL CHEM, V264, P1317; Vinogradova MV, 1998, BIOCHEM J, V330, P641; Wang P, 2004, BIOCHEM J, V380, P425, DOI 10.1042/BJ20031896; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; YAMAMOTO N, 1993, J IMMUNOL, V151, P2794	59	108	112	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27526	27538		10.1074/jbc.M605633200	http://dx.doi.org/10.1074/jbc.M605633200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16835219	hybrid			2022-12-25	WOS:000240397700079
J	Panizzi, P; Boxrud, PD; Verhamme, IM; Bock, PE				Panizzi, Peter; Boxrud, Paul D.; Verhamme, Ingrid M.; Bock, Paul E.			Binding of the COOH-terminal lysine residue of streptokinase to plasmin(ogen) kringles enhances formation of the streptokinase center dot plasmin(ogen) catalytic complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN ACTIVATOR COMPLEX; CONFORMATIONAL ACTIVATION; DOMAIN INTERACTIONS; KINETIC MECHANISM; ALPHA-DOMAIN; SITE; FIBRINOLYSIS; GENERATION; PROTEASES; SEQUENCE	Streptokinase (SK) activates human fibrinolysis by inducing non-proteolytic activation of the serine proteinase zymogen, plasminogen (Pg), in the SK center dot Pg* catalytic complex. SK center dot Pg* proteolytically activates Pg to plasmin (Pm). SK-induced Pg activation is enhanced by lysine-binding site (LBS) interactions with kringles on Pg and Pm, as evidenced by inhibition of the reactions by the lysine analogue, 6- aminohexanoic acid. Equilibrium binding analysis and [Lys] Pg activation kinetics with wild-type SK, carboxypeptidase B-treated SK, and a COOH-terminal Lys(414) deletion mutant (SK Delta K414) demonstrated a critical role for Lys414 in the enhancement of [Lys] Pg and [Lys] Pm binding and conformational [Lys] Pg activation. The LBS-independent affinity ofSKfor [Glu] Pg was unaffected by deletion of Lys(414). By contrast, removal of SK Lys414 caused 19- and 14-fold decreases in SK affinity for [Lys] Pg and [ Lys] Pm binding in the catalytic mode, respectively. In kinetic studies of the coupled conformational and proteolytic activation of [Lys] Pg, SK Delta K-414 exhibited a corresponding 17-fold affinity decrease for formation of the SK Delta K-414[Lys]Pg* complex. SK Delta K414 binding to [Lys] Pg and [Lys] Pm and conformational [Lys] Pg activation were LBS-independent, whereas [Lys] Pg substrate binding and proteolytic [Lys] Pm generation remained LBS-dependent. We conclude that binding of SK Lys414 to [Lys] Pg and [Lys] Pm kringles enhances SK[Lys] Pg* and SK[Lys] Pm catalytic complex formation. This interaction is distinct structurally and functionally from LBS-dependent Pg substrate recognition by these complexes.	Vanderbilt Univ, Sch Med, Dept Pathol, Med Ctr N, Nashville, TN 37232 USA	Vanderbilt University	Bock, PE (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, Med Ctr N, C3321A, Nashville, TN 37232 USA.	paul.bock@vanderbilt.edu	Panizzi, Peter/A-6072-2019	Panizzi, Peter/0000-0003-0141-8807	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056181, R00HL094533] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL056181-12, R01 HL056181, R00 HL094533, HL056181] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bean RR, 2005, J BIOL CHEM, V280, P7504, DOI 10.1074/jbc.M411637200; Bock PE, 1996, J BIOL CHEM, V271, P1072, DOI 10.1074/jbc.271.2.1072; BOK RA, 1985, BIOCHEMISTRY-US, V24, P3279, DOI 10.1021/bi00334a031; Boxrud PD, 2000, J BIOL CHEM, V275, P14579, DOI 10.1074/jbc.275.19.14579; Boxrud PD, 2000, BIOCHEMISTRY-US, V39, P13974, DOI 10.1021/bi000594i; Boxrud PD, 2004, J BIOL CHEM, V279, P36633, DOI 10.1074/jbc.M405264200; Boxrud PD, 2004, J BIOL CHEM, V279, P36642, DOI 10.1074/jbc.M405265200; Boxrud PD, 2001, J BIOL CHEM, V276, P26084, DOI 10.1074/jbc.M101966200; Castellino FJ, 1997, CIBA F SYMP, V212, P46; Chaudhary A, 1999, PROTEIN SCI, V8, P2791; CLEMMENSEN I, 1986, EUR J BIOCHEM, V156, P327, DOI 10.1111/j.1432-1033.1986.tb09586.x; COLLEN D, 1991, BLOOD, V78, P3114; Conejero-Lara F, 1998, PROTEIN SCI, V7, P2190, DOI 10.1002/pro.5560071017; Dhar J, 2002, J BIOL CHEM, V277, P13257, DOI 10.1074/jbc.M108422200; GONZALEZGRONOW M, 1978, J BIOL CHEM, V253, P1090; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V155, P591, DOI 10.1016/S0006-291X(88)80535-7; JACKSON KW, 1982, BIOCHEMISTRY-US, V21, P6620, DOI 10.1021/bi00269a001; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LIJNEN HR, 1980, J BIOL CHEM, V255, P214; Lin LF, 2000, BIOCHEMISTRY-US, V39, P4740, DOI 10.1021/bi992028x; Loy JA, 2001, BIOCHEMISTRY-US, V40, P14686, DOI 10.1021/bi011309d; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; MARSHALL JM, 1994, BIOCHEMISTRY-US, V33, P3599, DOI 10.1021/bi00178a017; MCCANCE SG, 1995, BIOCHEMISTRY-US, V34, P9581, DOI 10.1021/bi00029a035; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; PONTING CP, 1992, BIOCHIM BIOPHYS ACTA, V1159, P155, DOI 10.1016/0167-4838(92)90020-E; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; Sazonova IY, 2004, J BIOL CHEM, V279, P24994, DOI 10.1074/jbc.M400253200; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHICK LA, 1974, BIOCHEM BIOPH RES CO, V57, P47, DOI 10.1016/S0006-291X(74)80355-4; VIOLAND BN, 1978, J BIOL CHEM, V253, P5395; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662; WIMAN B, 1978, NATURE, V272, P549, DOI 10.1038/272549a0; WIMAN B, 1978, EUR J BIOCHEM, V84, P573, DOI 10.1111/j.1432-1033.1978.tb12200.x; WOHL RC, 1980, J BIOL CHEM, V255, P2005	36	23	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26774	26778		10.1074/jbc.C600171200	http://dx.doi.org/10.1074/jbc.C600171200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16857686	Green Accepted, hybrid			2022-12-25	WOS:000240397700003
J	Pani, B; Banerjee, S; Chalissery, J; Abishek, M; Loganathan, RM; Suganthan, RB; Sen, R				Pani, Bibhusita; Banerjee, Sharmistha; Chalissery, Jisha; Abishek, Muralimohan; Loganathan, Ramya Malarini; Suganthan, Ragan Babu; Sen, Ranjan			Mechanism of inhibition of Rho-dependent transcription termination by bacteriophage P4 protein Psu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RNA-BINDING; ANTIBIOTIC BICYCLOMYCIN; ATP HYDROLYSIS; POLARITY; ANTITERMINATION; MUTANTS; P4; SUPPRESSION; DOMAIN	Psu, a coat protein from bacteriophage P4, has been shown to inhibit Rho-dependent transcription termination in vivo. Co-overexpression of Psu and Rho led to the loss of viability of the cells, which is the consequence of the anti-Rho activity of the protein. The antitermination property of Psu is abolished either by the deletion of 10 or 20 amino acids from its C terminus or by a mutation, Y80C, in Rho. All these experiments indicated probable interactions between Rho and Psu. Purified Psu protein is alpha-helical in nature and appeared to be a dimer. Co-purification of Rho and wild-type Psu on an affinity matrix and co-elution of both of them in Superose-6 gel filtration suggests a direct association of these proteins, whereas a C terminus 10-amino acid deletion derivative of Psu failed to be pulled down in this assay. This indicates that the loss of the function of these mutants is correlated with their inability to interact with each other. In vitro termination assays revealed that Psu can inhibit Rho-dependent termination specifically in a concentration-dependent manner. The presence of Psu affected the affinity of ATP and reduced the rate of ATPase activity of Rho but did not affect either primary or secondary RNA binding activities. In the presence of Psu, Rho was also observed to release RNA very slowly from a stalled elongation complex. We propose that Psu inhibits Rho-dependent termination by slowing down the translocation of Rho along the RNA because of its slow ATPase activity.	Ctr DNA Fingerprinting & Diagnost, Lab Transcript Biol, Hyderabad 500076, Andhra Pradesh, India	Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD)	Sen, R (corresponding author), Ctr DNA Fingerprinting & Diagnost, Lab Transcript Biol, ECIL Rd, Hyderabad 500076, Andhra Pradesh, India.	rsen@cdfd.org.in	Chalissery, Jisha/AAI-3438-2021; Sen, Ranjan/AAP-7075-2021	Chalissery, Jisha/0000-0002-1738-2987; Pani, Bibhusita/0000-0003-1513-5189	Wellcome Trust [070012] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Banerjee S, 2006, J MICROBIOL, V44, P11; Bogden CE, 1999, MOL CELL, V3, P487, DOI 10.1016/S1097-2765(00)80476-1; Cheeran A, 2005, J MOL BIOL, V352, P28, DOI 10.1016/j.jmb.2005.06.052; Chen X, 2004, J BIOL CHEM, V279, P16301, DOI 10.1074/jbc.M313640200; DAS A, 1976, P NATL ACAD SCI USA, V73, P1959, DOI 10.1073/pnas.73.6.1959; DOKLAND T, 1993, VIROLOGY, V194, P682, DOI 10.1006/viro.1993.1308; DOLAN JW, 1990, J BIOL CHEM, V265, P5747; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; Harinarayanan R, 2003, J MOL BIOL, V332, P31, DOI 10.1016/S0022-2836(03)00753-8; ISAKSEN ML, 1992, VIROLOGY, V188, P831, DOI 10.1016/0042-6822(92)90538-Z; LINDEROTH NA, 1991, J BACTERIOL, V173, P6722, DOI 10.1128/jb.173.21.6722-6731.1991; Linderoth NA, 1997, VIROLOGY, V227, P131, DOI 10.1006/viro.1996.8325; Magyar A, 1999, J BIOL CHEM, V274, P7316, DOI 10.1074/jbc.274.11.7316; Magyar A, 1996, J BIOL CHEM, V271, P25369, DOI 10.1074/jbc.271.41.25369; Martinez A, 1996, J MOL BIOL, V257, P895, DOI 10.1006/jmbi.1996.0210; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; Nowatzke W, 1996, METHOD ENZYMOL, V274, P353; Pereira S, 1995, J BIOL CHEM, V270, P30401, DOI 10.1074/jbc.270.51.30401; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; Richardson JP, 2003, CELL, V114, P157, DOI 10.1016/S0092-8674(03)00554-3; Richardson JP, 2002, BBA-GENE STRUCT EXPR, V1577, P251, DOI 10.1016/S0167-4781(02)00456-6; SAUER B, 1981, J MOL BIOL, V145, P29, DOI 10.1016/0022-2836(81)90333-8; Skordalakes E, 2005, STRUCTURE, V13, P99, DOI 10.1016/j.str.2004.10.013; STITT BL, 1988, J BIOL CHEM, V263, P11130; SUNSHINE M, 1976, J MOL BIOL, V106, P673, DOI 10.1016/0022-2836(76)90258-8; Wei RR, 2001, J MOL BIOL, V314, P1007, DOI 10.1006/jmbi.2000.5207; Weisberg RA, 1999, J BACTERIOL, V181, P359, DOI 10.1128/JB.181.2.359-367.1999; YANG JT, 1986, METHOD ENZYMOL, V130, P208	30	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26491	26500		10.1074/jbc.M603982200	http://dx.doi.org/10.1074/jbc.M603982200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829521	Green Accepted, hybrid			2022-12-25	WOS:000240249500067
J	Cisterna, B; Necchi, D; Prosperi, E; Biggiogera, M				Cisterna, Barbara; Necchi, Daniela; Prosperi, Ennio; Biggiogera, Marco			Small ribosomal subunits associate with nuclear myosin and actin in transit to the nuclear pores	FASEB JOURNAL			English	Article						ribosomal protein S6; ultrastructural immunocytochemistry; ribosome movement; nucleocytoplasmic transport; ribosome biogenesis	RNA; TRANSCRIPTION; NUCLEOLUS; VISUALIZATION; COMPONENT; BODIES; EXPORT; SITES; CELLS; BODY	We have followed at high resolution the ribosomal protein S6 entering the nucleus of HeLa cells, stopping in some (not all) interchromatin granules clusters and reaching, via Cajal bodies, the nucleolus. There, S6 is assembled with other proteins and rRNA into small ribosomal subunit (SSU), released in the nucleoplasm, and exported through the nuclear pores. We show for the first time the spatial association of nuclear myosin I (NMI) and actin with the SSU already at the nucleolar periphery to the nuclear pore. A blockade of NMI or actin induces an upstream accumulation of the S6 protein en route to the nucleolus, and a temperature lower than normal influences RNA export. Our data strongly suggest a functional relationship of SSU with NMI and actin. In our hypothesis, an active, myosin-driven movement of the small ribosomal subunit can be responsible for the export of similar to 10% of SSUs. This hypothesis is supported by ultrastructural, immunofluorescence, and biochemical analyses. The currently accepted model for the subunit release suggests a diffusive, temperature-independent mechanism. However, the advantage of the double mechanism would assure that the movement of a part of the subunits could be modulated, increased, or decreased according to the needs of the cell at a specific moment in the cell cycle.	Univ Pavia, Dipartimento Biol Anim, Lab Biol Cellulare & Neurobiol, I-27100 Pavia, Italy; Univ Pavia, Ist Genet Mol, CNR, Sez Istochim & Citometria, I-27100 Pavia, Italy	University of Pavia; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Pavia	Biggiogera, M (corresponding author), Univ Pavia, Dipartimento Biol Anim, Lab Biol Cellulare & Neurobiol, Piazza Botta 10, I-27100 Pavia, Italy.	marcobig@unipv.it	Prosperi, Ennio/A-3439-2014; Biggiogera, Marco/AAH-3543-2019	Prosperi, Ennio/0000-0001-5391-5157; 				BERNHARD W, 1969, J ULTRA MOL STRUCT R, V27, P250, DOI 10.1016/S0022-5320(69)80016-X; BIGGIOGERA M, 1990, MOL REPROD DEV, V26, P150, DOI 10.1002/mrd.1080260209; Biggiogera M, 2001, J CELL SCI, V114, P3199; Biggiogera M, 1998, J HISTOCHEM CYTOCHEM, V46, P389, DOI 10.1177/002215549804600313; CLEVENGER CV, 1984, EXP CELL RES, V151, P194, DOI 10.1016/0014-4827(84)90368-9; Fakan S, 2004, EUR J HISTOCHEM, V48, P5; Gleizes PE, 2001, J CELL BIOL, V155, P923, DOI 10.1083/jcb.200108142; Hofmann WA, 2004, NAT CELL BIOL, V6, P1094, DOI 10.1038/ncb1182; JEFFERIS HBJ, 1996, TRANSLATIONAL CONTRO; JIMENEZGARCIA LF, 1994, MOL BIOL CELL, V5, P955, DOI 10.1091/mbc.5.9.955; Johnson AW, 2002, TRENDS BIOCHEM SCI, V27, P580, DOI 10.1016/S0968-0004(02)02208-9; Nowak G, 1997, J BIOL CHEM, V272, P17176, DOI 10.1074/jbc.272.27.17176; Olson MOJ, 2002, INT REV CYTOL, V219, P199; Osheim YN, 2004, MOL CELL, V16, P943, DOI 10.1016/j.molcel.2004.11.031; Pestic-Dragovich L, 2000, SCIENCE, V290, P337, DOI 10.1126/science.290.5490.337; Philimonenko VV, 2004, NAT CELL BIOL, V6, P1165, DOI 10.1038/ncb1190; Platani M, 2002, NAT CELL BIOL, V4, P502, DOI 10.1038/ncb809; Politz JC, 1999, CURR BIOL, V9, P285, DOI 10.1016/S0960-9822(99)80136-5; Politz JCR, 2003, MOL BIOL CELL, V14, P4805, DOI 10.1091/mbc.E03-06-0395; PUVIONDUTILLEUL F, 1995, J CELL SCI, V108, P1143; Raska I, 2004, BIOL CELL, V96, P579, DOI 10.1016/j.biolcel.2004.04.015; Riva F, 2004, EXP CELL RES, V293, P357, DOI 10.1016/j.yexcr.2003.10.025; Saitoh N, 2004, MOL BIOL CELL, V15, P3876, DOI 10.1091/mbc.E04-03-0253; SHEA TB, 1991, BIOTECHNIQUES, V10, P288; THIRY M, 1996, NUCLEOLUS CELL CYCLE; Tschochner H, 2003, TRENDS CELL BIOL, V13, P255, DOI 10.1016/S0962-8924(03)00054-0; Tseng Y, 2004, J CELL SCI, V117, P2159, DOI 10.1242/jcs.01073; UDEM SA, 1973, J BIOL CHEM, V248, P1412	28	41	42	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1901	+		10.1096/fj.05-5278fje	http://dx.doi.org/10.1096/fj.05-5278fje			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16877530				2022-12-25	WOS:000240267000024
J	Karpanen, T; Heckman, CA; Keskitalo, S; Jeltsch, M; Ollila, H; Neufeld, G; Tamagnone, L; Alitalo, K				Karpanen, Terhi; Heckman, Caroline A.; Keskitalo, Salla; Jeltsch, Michael; Ollila, Hanna; Neufeld, Gera; Tamagnone, Luca; Alitalo, Kari			Functional interaction of VEGF-C and VEGF-D with neuropilin receptors	FASEB JOURNAL			English	Article						lymphatic endothelial cell; VEGFR-3; NP2	ENDOTHELIAL GROWTH-FACTOR; TUMOR-CELLS; BINDING; LYMPHANGIOGENESIS; SPECIFICITY; FACTOR-2; SIGNALS; MORPHOGENESIS; INHIBITION; ANTIBODIES	Lymphatic vascular development is regulated by vascular endothelial growth factor receptor-3 (VEGFR-3), which is activated by its ligands VEGF-C and VEGF-D. Neuropilin-2 (NP2), known to be involved in neuronal development, has also been implicated to play a role in lymphangiogenesis. We aimed to elucidate the mechanism by which NP2 is involved in lymphatic endothelial cell signaling. By in vitro binding studies we found that both VEGF-C and VEGF-D interact with NP2, VEGF-C in a heparin-independent and VEGF-D in a heparin-dependent manner. We also mapped the domains of VEGF-C and NP2 required for their binding. The functional importance of the interaction of NP2 with the lymphangiogenic growth factors was demonstrated by cointernalization of NP2 along with VEGFR-3 in endocytic vesicles of lymphatic endothelial cells upon stimulation with VEGF-C or VEGF-D. NP2 also interacted with VEGFR-3 in coprecipitation studies. Our results show that NP2 is directly involved in an active signaling complex with the key regulators of lymphangiogenesis and thus suggest a mechanism by which NP2 functions in the development of the lymphatic vasculature.	Univ Helsinki, Biomedicum Helsinki, Lab Mol Canc Biol, Haartman Inst, FI-00014 Helsinki, Finland; Univ Helsinki, Ludwig Inst Canc Res, Biomedicum Helsinki, Haartman Inst, FI-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FI-00014 Helsinki, Finland; Technion Israel Inst Technol, Dept Cell Biol & Anat, Rappaport Family Inst Res Med Sci, Haifa, Israel; Univ Turin, Sch Med, IRCC, Inst Canc Res & Treatment, Turin, Italy	University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Alitalo, K (corresponding author), Univ Helsinki, Biomedicum Helsinki, Lab Mol Canc Biol, Haartman Inst, POB 63, FI-00014 Helsinki, Finland.	kari.alitalo@helsinki.fi	Tamagnone, Luca/J-8948-2018; Neufeld, Gera/F-1524-2019; Alitalo, Kari K/J-5013-2014; Ollila, Hanna M/I-8552-2017; Ollila, Hanna M/GQA-6308-2022; Jeltsch, Michael/I-5340-2012	Tamagnone, Luca/0000-0002-2884-7946; Alitalo, Kari K/0000-0002-7331-0902; Ollila, Hanna M/0000-0002-5302-6429; Ollila, Hanna M/0000-0002-5302-6429; Jeltsch, Michael/0000-0003-2890-7790; Karpanen, Terhi/0000-0002-2803-083X; Keskitalo, Salla/0000-0001-5555-1975; Heckman, Caroline/0000-0002-4324-8706	NHLBI NIH HHS [5 R01 HL075183-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075183] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baldwin ME, 2001, J BIOL CHEM, V276, P19166, DOI 10.1074/jbc.M100097200; Chen H, 2000, NEURON, V25, P43, DOI 10.1016/S0896-6273(00)80870-3; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Feiner L, 2001, DEVELOPMENT, V128, P3061; Fuh G, 2000, J BIOL CHEM, V275, P26690; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; Giger RJ, 2000, NEURON, V25, P29, DOI 10.1016/S0896-6273(00)80869-7; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Herzog Y, 2001, MECH DEVELOP, V109, P115, DOI 10.1016/S0925-4773(01)00518-4; Jekely G, 2005, DEV CELL, V9, P197, DOI 10.1016/j.devcel.2005.06.004; Jeltsch M, 2006, J BIOL CHEM, V281, P12187, DOI 10.1074/jbc.M511593200; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Jussila L, 1998, CANCER RES, V58, P1599; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Karkkainen MJ, 2004, NAT IMMUNOL, V5, P74, DOI 10.1038/ni1013; Karpanen T, 2001, CANCER RES, V61, P1786; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Kessler O, 2004, CANCER RES, V64, P1008, DOI 10.1158/0008-5472.CAN-03-3090; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Lyon M, 2002, J BIOL CHEM, V277, P1040, DOI 10.1074/jbc.M107506200; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; Mamluk R, 2002, J BIOL CHEM, V277, P24818, DOI 10.1074/jbc.M200730200; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; Moyon D, 2001, DEVELOPMENT, V128, P3359; Ober EA, 2004, EMBO REP, V5, P78, DOI 10.1038/sj.embor.7400047; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; Robinson CJ, 2001, J CELL SCI, V114, P853; Serini G, 2003, NATURE, V424, P391, DOI 10.1038/nature01784; Shen JK, 2004, MOL MED, V10, P12, DOI 10.2119/2004-00017.Campochiaro; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; Stacker SA, 1999, J BIOL CHEM, V274, P32127, DOI 10.1074/jbc.274.45.32127; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Uutela M, 2004, BLOOD, V104, P3198, DOI 10.1182/blood-2004-04-1485; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang L, 2003, J BIOL CHEM, V278, P48848, DOI 10.1074/jbc.M310047200; Witzenbichler B, 1998, AM J PATHOL, V153, P381, DOI 10.1016/S0002-9440(10)65582-4; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yuan L, 2002, DEVELOPMENT, V129, P4797; Zhu Z, 2003, LEUKEMIA, V17, P604, DOI 10.1038/sj.leu.2402831	53	223	241	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1462	1472		10.1096/fj.05-5646com	http://dx.doi.org/10.1096/fj.05-5646com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816121				2022-12-25	WOS:000240266000023
J	White, D; Musse, AA; Wang, J; London, E; Merrill, AR				White, Dawn; Musse, Abdiwahab A.; Wang, Jie; London, Erwin; Merrill, A. Rod			Toward elucidating the membrane topology of helix two of the colicin E1 channel domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-FORMING COLICINS; BCL-2 FAMILY PROTEINS; E1 CHANNEL; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; LIPID-BILAYERS; ION-CHANNEL; ANGSTROM RESOLUTION; DIPHTHERIA-TOXIN; MOLECULAR-BASIS	The membrane-bound closed state of the colicin E1 channel domain was investigated by site-directed fluorescence labeling using a bimane fluorophore attached to each single cysteine residue within helix 2 of each mutant protein. The fluorescence properties of the bimane fluorophore were measured for the membrane-associated form of the closed channel and included fluorescence emission maximum, fluorescence anisotropy, apparent polarity, surface accessibility, and membrane bilayer penetration depth. The fluorescence data show that helix 2 is an amphipathic alpha-helix that is situated parallel to the membrane surface, but it is less deeply embedded within the bilayer interfacial region than is helix 1 in the closed channel. A least squares fit of the various data sets to a harmonic wave function indicated that the periodicity and angular frequency for helix 2 in the membrane-bound state are typical for an amphipathic alpha-helix (3.8 +/- 0.1 residues per turn and 94 +/- 4 degrees, respectively) that is located at an interfacial region of a membrane bilayer. Dual quencher analysis also revealed that helix 2 is peripherally membrane associated, with one face of the helix dipping into the interfacial region of the lipid bilayer and the other face projecting outwardly into the aqueous solvent. Finally, our data show that helices 1 and 2 remain independent helices upon membrane association with a short connector link (Tyr(363)-Gly(364)) and that short amphipathic alpha-helices participate in the formation of a lipid-dependent, toroidal pore for this colicin.	Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	University of Guelph; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Merrill, AR (corresponding author), Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada.	rmerrill@uoguelph.ca	Merrill, Rod/M-8313-2014		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031986] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 31986] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS CK, 1991, J GEN PHYSIOL, V98, P77, DOI 10.1085/jgp.98.1.77; Alvarez C, 2003, CHEM PHYS LIPIDS, V122, P97, DOI 10.1016/S0009-3084(02)00181-0; Anderluh G, 2003, J BIOL CHEM, V278, P45216, DOI 10.1074/jbc.M305916200; Basanez G, 2002, J BIOL CHEM, V277, P49360, DOI 10.1074/jbc.M206069200; Berne S, 2005, BIOCHEMISTRY-US, V44, P11137, DOI 10.1021/bi051013y; BRUNDEN KR, 1984, J BIOL CHEM, V259, P190; Caputo GA, 2003, BIOCHEMISTRY-US, V42, P3265, DOI 10.1021/bi026696l; COOPER PC, 1984, J GEN MICROBIOL, V130, P209; CORNETTE JL, 1987, J MOL BIOL, V195, P659, DOI 10.1016/0022-2836(87)90189-6; CRAMER WA, 1995, ANNU REV BIOPH BIOM, V24, P611, DOI 10.1146/annurev.biophys.24.1.611; DANKERT JR, 1982, J BIOL CHEM, V257, P3857; Dempsey CE, 2003, BIOCHEMISTRY-US, V42, P402, DOI 10.1021/bi026328h; Elkins P, 1997, STRUCTURE, V5, P443, DOI 10.1016/S0969-2126(97)00200-1; Eraso JM, 1996, J BACTERIOL, V178, P1928, DOI 10.1128/jb.178.7.1928-1935.1996; Eun SY, 2006, MOL CELLS, V21, P229; Filloux A, 2002, BIOCHIMIE, V84, P489, DOI 10.1016/S0300-9084(02)01412-8; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; Garcia-Saez AJ, 2004, BIOCHEMISTRY-US, V43, P10930, DOI 10.1021/bi036044c; Gouaux E, 1997, STRUCTURE, V5, P313, DOI 10.1016/S0969-2126(97)00188-3; GOULD JM, 1977, J BIOL CHEM, V252, P5491; HARKNESS RE, 1989, J BIOL CHEM, V264, P6177; Hayashibara M, 2005, BIOCHEMISTRY-US, V44, P2183, DOI 10.1021/bi0482093; Hilsenbeck JL, 2004, MOL MICROBIOL, V51, P711, DOI 10.1111/j.1365-2958.2003.03884.x; Jakes KS, 1999, Q REV BIOPHYS, V32, P189, DOI 10.1017/S0033583599003492; Kim Y, 1998, PROTEIN SCI, V7, P342; Ladokhin AS, 2002, BIOCHEMISTRY-US, V41, P13617, DOI 10.1021/bi0264418; Lakey JH, 2001, CURR TOP MICROBIOL, V257, P131; Lazdunski CJ, 1998, J BACTERIOL, V180, P4993, DOI 10.1128/JB.180.19.4993-5002.1998; Lindeberg M, 2000, J MOL BIOL, V295, P679, DOI 10.1006/jmbi.1999.3396; Malenbaum SE, 1998, J NAT TOXINS, V7, P269; Masaki H, 2002, BIOCHIMIE, V84, P433, DOI 10.1016/S0300-9084(02)01425-6; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P8529, DOI 10.1021/bi00489a004; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Musse AA, 2003, J BIOL CHEM, V278, P24491, DOI 10.1074/jbc.M302371200; Musse AA, 2006, J BIOL CHEM, V281, P885, DOI 10.1074/jbc.M511140200; PALMER LR, 1994, J BIOL CHEM, V269, P4187; PARKER MW, 1992, J MOL BIOL, V224, P639, DOI 10.1016/0022-2836(92)90550-4; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; RICHMOND TJ, 1978, J MOL BIOL, V119, P537, DOI 10.1016/0022-2836(78)90201-2; Salwinski L, 1999, PROTEIN SCI, V8, P562; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Schendel SL, 2000, METHOD ENZYMOL, V322, P274; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; Slatin SL, 2004, J MEMBRANE BIOL, V202, P73, DOI 10.1007/s00232-004-0720-9; Sobko AA, 2004, FEBS LETT, V576, P205, DOI 10.1016/j.febslet.2004.09.016; Sobko AA, 2006, J BIOL CHEM, V281, P14408, DOI 10.1074/jbc.M513634200; SONG HY, 1991, J BACTERIOL, V173, P2935, DOI 10.1128/JB.173.9.2935-2943.1991; STEER BA, 1995, BIOCHEMISTRY-US, V34, P7225, DOI 10.1021/bi00021a038; Stroud RM, 1998, CURR OPIN STRUC BIOL, V8, P525, DOI 10.1016/S0959-440X(98)80132-2; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Taylor R, 1998, J BIOL CHEM, V273, P31113, DOI 10.1074/jbc.273.47.31113; Tory MC, 2002, BBA-BIOMEMBRANES, V1564, P435, DOI 10.1016/S0005-2736(02)00493-5; Tory MC, 1999, J BIOL CHEM, V274, P24539, DOI 10.1074/jbc.274.35.24539; Vetter IR, 1998, STRUCTURE, V6, P863, DOI 10.1016/S0969-2126(98)00088-4; Wiener M, 1997, NATURE, V385, P461, DOI 10.1038/385461a0; Yan L, 2003, FEBS LETT, V555, P545, DOI 10.1016/s0014-5793(03)01346-2; Zakharov SD, 1999, BIOCHEMISTRY-US, V38, P11325, DOI 10.1021/bi9903087; Zakharov SD, 1998, P NATL ACAD SCI USA, V95, P4282, DOI 10.1073/pnas.95.8.4282; Zakharov SD, 2004, BBA-BIOMEMBRANES, V1666, P239, DOI 10.1016/j.bbamem.2004.07.001; Zakharov SD, 2004, FRONT BIOSCI-LANDMRK, V9, P1311, DOI 10.2741/1334; Zakharov SD, 2002, BBA-BIOMEMBRANES, V1565, P333, DOI 10.1016/S0005-2736(02)00579-5; Zakharov SD, 2002, BIOCHIMIE, V84, P465, DOI 10.1016/S0300-9084(02)01453-0; ZHANG YL, 1992, PROTEIN SCI, V1, P1666, DOI 10.1002/pro.5560011215; Zhao G, 2005, BIOCHEMISTRY-US, V44, P4488, DOI 10.1021/bi047705o	65	10	10	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32375	32384		10.1074/jbc.M605880200	http://dx.doi.org/10.1074/jbc.M605880200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16854987	hybrid			2022-12-25	WOS:000241414500035
J	Zhao, H; Kim, A; Song, SH; Dean, A				Zhao, Hui; Kim, AeRi; Song, Sang-Hyun; Dean, Ann			Enhancer blocking by chicken beta-globin 5 '-HS4 - Role of enhancer strength and insulator nucleosome depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; RNA-POLYMERASE-II; TRANSCRIPTIONALLY SILENT CHROMATIN; HISTONE ACETYLATION PATTERN; HYPERSENSITIVE SITE 2; INTERGENIC TRANSCRIPTION; PROMOTER COMMUNICATION; BARRIER FUNCTION; IN-VIVO; GENE	The 5'-HS4 chicken beta-globin insulator functions as a positional enhancer blocker on chromatinized episomes in human cells, blocking the HS2 enhancer of the human beta-globin locus control region from activating a downstream epsilon-globin gene. 5'-HS4 interrupted formation of a domain of histone H3 and H4 acetylation encompassing the 6-kb minilocus and inhibited transfer of RNA polymerase from the enhancer to the gene promoter. We found that the enhancer blocking phenotype was amplified when the insulated locus contained a weakened HS2 enhancer in which clustered point mutations eliminated interaction of the transcription factor GATA-1. The GATA-1 mutation compromised recruitment of histone acetyltransferases and RNA polymerase II to HS2. Enhancer blocking correlated with a significant depletion of nucleosomes in the core region of the insulator as revealed by micrococcal nuclease and DNase I digestion studies. Nucleosome depletion at 5'-HS4 was dependent on interaction of the insulator protein CCCTC-binding factor (CTCF) and was required for enhancer blocking. These findings provide evidence that a domain of active chromatin is formed by spreading from an enhancer to a target gene and can be blocked by a nucleosome-free gap in an insulator.	NIDDK, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Pusan National University	Dean, A (corresponding author), NIDDK, Cellular & Dev Biol Lab, NIH, Bldg 50,Rm 3154,50 South Dr,MSC 8028, Bethesda, MD 20892 USA.	anndean@helix.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK015508, Z01DK015508] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bi X, 2004, MOL CELL BIOL, V24, P2118, DOI 10.1128/MCB.24.5.2118-2131.2004; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; Bulger M, 2003, MOL CELL BIOL, V23, P5234, DOI 10.1128/MCB.23.15.5234-5244.2003; Bulger M, 2002, CURR OPIN GENET DEV, V12, P170, DOI 10.1016/S0959-437X(02)00283-6; CAI H, 1995, NATURE, V376, P533, DOI 10.1038/376533a0; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Chiu YH, 2003, GENETICS, V165, P115; Cho DH, 2005, MOL CELL, V20, P483, DOI 10.1016/j.molcel.2005.09.002; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; Dean A, 2006, TRENDS GENET, V22, P38, DOI 10.1016/j.tig.2005.11.001; Elefant F, 2000, J BIOL CHEM, V275, P13827, DOI 10.1074/jbc.275.18.13827; Elgin SCR, 2003, CURR BIOL, V13, pR895, DOI 10.1016/j.cub.2003.11.006; Elnitski L, 1997, J BIOL CHEM, V272, P369; Farrell CM, 2002, MOL CELL BIOL, V22, P3820, DOI 10.1128/MCB.22.11.3820-3831.2002; Filippova GN, 2001, NAT GENET, V28, P335, DOI 10.1038/ng570; Forsberg EC, 2001, BIOESSAYS, V23, P820, DOI 10.1002/bies.1117; Forsberg EC, 2000, P NATL ACAD SCI USA, V97, P14494, DOI 10.1073/pnas.97.26.14494; Fourel G, 2004, BIOESSAYS, V26, P523, DOI 10.1002/bies.20028; Gerasimova TI, 2000, MOL CELL, V6, P1025, DOI 10.1016/S1097-2765(00)00101-5; Gong QH, 1996, MOL CELL BIOL, V16, P6055; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; Hatzis P, 2002, MOL CELL, V10, P1467, DOI 10.1016/S1097-2765(02)00786-4; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Im H, 2005, P NATL ACAD SCI USA, V102, P17065, DOI 10.1073/pnas.0506164102; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnson KD, 2002, METHODS, V26, P27, DOI 10.1016/S1046-2023(02)00005-1; Johnson KD, 2002, P NATL ACAD SCI USA, V99, P11760, DOI 10.1073/pnas.192285999; Johnson KD, 2001, MOL CELL, V8, P465, DOI 10.1016/S1097-2765(01)00309-4; Kanduri C, 2000, CURR BIOL, V10, P449, DOI 10.1016/S0960-9822(00)00442-5; Kanduri M, 2002, MOL CELL BIOL, V22, P3339, DOI 10.1128/MCB.22.10.3339-3344.2002; Kim A, 2004, P NATL ACAD SCI USA, V101, P7028, DOI 10.1073/pnas.0307985101; Kim A, 2003, MOL CELL BIOL, V23, P8099, DOI 10.1128/MCB.23.22.8099-8109.2003; Krawczyk M, 2004, J IMMUNOL, V173, P6200, DOI 10.4049/jimmunol.173.10.6200; Lam LT, 1996, J BIOL CHEM, V271, P32421, DOI 10.1074/jbc.271.50.32421; Letting DL, 2003, MOL CELL BIOL, V23, P1334, DOI 10.1128/MCB.23.4.1334-1340.2003; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Masternak K, 2003, NAT IMMUNOL, V4, P132, DOI 10.1038/ni883; McDowell JC, 1999, MOL CELL BIOL, V19, P7600; Morshead KB, 2003, P NATL ACAD SCI USA, V100, P11577, DOI 10.1073/pnas.1932643100; Mutskov VJ, 2002, GENE DEV, V16, P1540, DOI 10.1101/gad.988502; Oki M, 2005, MOL CELL, V19, P707, DOI 10.1016/j.molcel.2005.07.022; Oki M, 2002, CURR OPIN CELL BIOL, V14, P299, DOI 10.1016/S0955-0674(02)00327-7; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; Parnell TJ, 2000, EMBO J, V19, P5864, DOI 10.1093/emboj/19.21.5864; Prioleau MN, 1999, EMBO J, V18, P4035, DOI 10.1093/emboj/18.14.4035; Recillas-Targa F, 2002, P NATL ACAD SCI USA, V99, P6883, DOI 10.1073/pnas.102179399; Scott KC, 1999, GENETICS, V153, P787; Scott KS, 1995, EMBO J, V14, P6258, DOI 10.1002/j.1460-2075.1995.tb00316.x; Steinwaerder DS, 2000, GENE THER, V7, P556, DOI 10.1038/sj.gt.3301139; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; West AG, 2005, HUM MOL GENET, V14, pR101, DOI 10.1093/hmg/ddi104; West AG, 2004, MOL CELL, V16, P453, DOI 10.1016/j.molcel.2004.10.005; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702; Yang XJ, 2004, BIOESSAYS, V26, P1076, DOI 10.1002/bies.20104; Yu Q, 2006, J BIOL CHEM, V281, P3980, DOI 10.1074/jbc.M510140200; Yusufzai TM, 2004, MOL CELL, V13, P291, DOI 10.1016/S1097-2765(04)00029-2; Zhao H, 2005, BIOCHEM CELL BIOL, V83, P516, DOI 10.1139/O05-054; Zhao H, 2004, NUCLEIC ACIDS RES, V32, P4903, DOI 10.1093/nar/gkh832	61	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30573	30580		10.1074/jbc.M606803200	http://dx.doi.org/10.1074/jbc.M606803200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16877759	hybrid			2022-12-25	WOS:000241075900033
J	Leighton, BH; Seal, RP; Watts, SD; Skyba, MO; Amara, SG				Leighton, Barbara H.; Seal, Rebecca P.; Watts, Spencer D.; Skyba, Mary O.; Amara, Susan G.			Structural rearrangements at the translocation pore of the human glutamate transporter, EAAT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; SCANNING MUTAGENESIS REVEALS; RAT-BRAIN; REENTRANT LOOP; FUNCTIONAL-CHARACTERIZATION; CONFORMATIONAL-CHANGES; GLT-1; SUBSTRATE; EXPRESSION; BINDING	Structure- function studies of mammalian and bacterial excitatory amino acid transporters ( EAATs), as well as the crystal structure of a related archaeal glutamate transporter, supportamodelin which TM7, TM8, and the re- entrant loops HP1 and HP2 participate in forming a substrate translocation pathway within each subunit of a trimer. However, the transport mechanism, including precise binding sites for substrates and co-transported ions and changes in the tertiary structure underlying transport, is still not known. In this study, we used chemical cross-linking of introduced cysteine pairs in a cysteine- less version of EAAT1 to examine the dynamics of key domains associated with the translocation pore. Here we show that cysteine substitution at Ala- 395, Ala- 367, and Ala- 440 results in functional single and double cysteine transporters and that in the absence of glutamate or DL- threo-beta-benzyloxyaspartate ( DL- TBOA), A395C in the highly conserved TM7 can be cross- linked to A367C in HP1 and to A440C in HP2. The formation of these disulfide bonds is reversible and occurs intra-molecularly. Interestingly, cross- linking A395C to A367C appears to abolish transport, whereas cross- linking A395C to A440C lowers the affinities for glutamate and DL- TBOA but does not change the maximal transport rate. Additionally, glutamate and DL- TBOA bindingpreventcross- linkinginbothdoublecysteinetransporters, whereas sodium binding facilitates cross- linking in the A395C/ A367C transporter. These data provide evidence that within each subunit of EAAT1, Ala- 395 inTM7resides close to a residue at the tip of each re- entrant loop ( HP1 and HP2) and that these residues are repositioned relative to one another at different steps in the transport cycle. Such behavior likely reflects rearrangements in the tertiary structure of the translocation pore during transport and thus provides constraints for modeling the structural dynamics associated with transport.	Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA 15261 USA; Oregon Hlth & Sci Univ, Howard Hughes Med Inst, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Howard Hughes Medical Institute; Oregon Health & Science University; Oregon Health & Science University; University of California System; University of California San Francisco	Amara, SG (corresponding author), Univ Pittsburgh, Dept Neurobiol, E1440 Biomed Sci Tower, Pittsburgh, PA 15261 USA.	amaras@pitt.edu		Seal, Rebecca/0000-0003-4955-703X; Amara, Susan/0000-0001-8914-1106	NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH011673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033273] Funding Source: NIH RePORTER; NIMH NIH HHS [F31 MH011673] Funding Source: Medline; NINDS NIH HHS [NS33273] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amara SG, 2002, NEUROCHEM INT, V41, P313, DOI 10.1016/S0197-0186(02)00018-9; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Bendahan A, 2000, J BIOL CHEM, V275, P37436, DOI 10.1074/jbc.M006536200; Borre L, 2004, J BIOL CHEM, V279, P2513, DOI 10.1074/jbc.M311446200; Bridges RJ, 2005, PHARMACOL THERAPEUT, V107, P271, DOI 10.1016/j.pharmthera.2005.01.002; Brocke L, 2002, J BIOL CHEM, V277, P3985, DOI 10.1074/jbc.M107735200; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Gendreau S, 2004, J BIOL CHEM, V279, P39505, DOI 10.1074/jbc.M408038200; Grewer C, 2005, BIOCHEMISTRY-US, V44, P11913, DOI 10.1021/bi050987n; GRUNEWALD M, 1995, J BIOL CHEM, V270, P17017, DOI 10.1074/jbc.270.28.17017; Grunewald M, 2002, J BIOL CHEM, V277, P26074, DOI 10.1074/jbc.M202248200; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Hinoi E, 2005, CNS NEUROL DISORD-DR, V4, P211, DOI 10.2174/1568007053544093; Kanai Y, 2004, PFLUG ARCH EUR J PHY, V447, P469, DOI 10.1007/s00424-003-1146-4; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; Koch HP, 2005, J NEUROSCI, V25, P1730, DOI 10.1523/JNEUROSCI.4138-04.2005; Larsson HP, 2004, P NATL ACAD SCI USA, V101, P3951, DOI 10.1073/pnas.0306737101; Leighton BH, 2002, J BIOL CHEM, V277, P29847, DOI 10.1074/jbc.M202508200; Lolkema JS, 1998, CURR OPIN MICROBIOL, V1, P248, DOI 10.1016/S1369-5274(98)80018-0; PINES G, 1995, J BIOL CHEM, V270, P17093, DOI 10.1074/jbc.270.29.17093; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; Slotboom DJ, 2001, J BIOL CHEM, V276, P10775, DOI 10.1074/jbc.M011064200; Sobczak M, 2005, CURR OPIN MICROBIOL, V8, P161, DOI 10.1016/j.mib.2005.02.005; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Tao Z, 2006, J BIOL CHEM, V281, P10263, DOI 10.1074/jbc.M510739200; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Yernool D, 2003, BIOCHEMISTRY-US, V42, P12981, DOI 10.1021/bi030161q; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Zarbiv R, 1998, J BIOL CHEM, V273, P14231, DOI 10.1074/jbc.273.23.14231; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710; Zhang YM, 1998, P NATL ACAD SCI USA, V95, P751, DOI 10.1073/pnas.95.2.751	43	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29788	29796		10.1074/jbc.M604991200	http://dx.doi.org/10.1074/jbc.M604991200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16877378	hybrid			2022-12-25	WOS:000240896300041
J	Botta, D; Shi, S; White, CC; Dabrowski, MJ; Keener, CL; Srinouanprachanh, SL; Farin, FM; Ware, CB; Ladiges, WC; Pierce, RH; Fausto, N; Kavanagh, TJ				Botta, Dianne; Shi, Shengli; White, Collin C.; Dabrowski, Michael J.; Keener, Cassie L.; Srinouanprachanh, Sengkeo L.; Farin, Federico M.; Ware, Carol B.; Ladiges, Warren C.; Pierce, Robert H.; Fausto, Nelson; Kavanagh, Terrance J.			Acetaminophen-induced liver injury is attenuated in male glutamate-cysteine ligase transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; HAMSTER V79 CELLS; MITOCHONDRIAL PERMEABILITY TRANSITION; INDUCED HEPATIC NECROSIS; MODIFIER SUBUNIT GENE; NITRIC-OXIDE SYNTHASE; INDUCED HEPATOTOXICITY; GLUTATHIONE SYNTHESIS; CATALYTIC SUBUNIT; PEROXYNITRITE FORMATION	Acetaminophen overdose is a leading cause of drug-related acute liver failure in the United States. Glutathione, a tripeptide antioxidant protects cells against oxidative damage from reactive oxygen species and plays a crucial role in the detoxification of xenobiotics, including acetaminophen. Glutathione is synthesized in a two-step enzymatic reaction. Glutamate-cysteine ligase carries out the rate-limiting and first step in glutathione synthesis. We have generated C57Bl/6 mice that conditionally overexpress glutamate-cysteine ligase, and report here their resistance to acetaminophen-induced liver injury. Indices of liver injury included histopathology and serum alanine aminotransferase activity. Male transgenic mice induced to overexpress glutamate-cysteine ligase exhibited resistance to acetaminophen-induced liver injury when compared with acetaminophen-treated male mice carrying, but not expressing glutamate-cysteine ligase transgenes, or to female glutamate-cysteine ligase transgenic mice. We conclude that glutamate-cysteine ligase activity is an important factor in determining acetaminophen-induced liver injury in C57Bl/6 male mice. Because people are known to vary in their glutamate-cysteine ligase activity, this enzyme may also be an important determinant of sensitivity to acetaminophen-induced liver injury in humans.	Univ Washington, NIEHS, Ctr Ecogenet & Environm Hlth, Seattle, WA 98105 USA; Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98105 USA; Univ Washington, Dept Comparat Med, Seattle, WA 98105 USA; Univ Washington, Dept Pathol, Seattle, WA 98105 USA; Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY 14642 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Rochester	Kavanagh, TJ (corresponding author), Univ Washington, Box 354695, Seattle, WA 98195 USA.	tjkav@u.washington.edu		Pierce, MD, Robert Hamilton/0000-0002-2677-144X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033, P42ES004696, R01ES010849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG001751] Funding Source: NIH RePORTER; NIA NIH HHS [5P01AG001751] Funding Source: Medline; NIEHS NIH HHS [5R01ES010849, 5P42ES004696, 2P30ES007033] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bajt ML, 2003, J PHARMACOL EXP THER, V307, P67, DOI 10.1124/jpet.103.052506; BARTOLONE JB, 1988, BIOCHEM PHARMACOL, V37, P4763, DOI 10.1016/0006-2952(88)90350-4; Bessems JGM, 2001, CRIT REV TOXICOL, V31, P55, DOI 10.1080/20014091111677; Botta D, 2004, FREE RADICAL BIO MED, V37, P632, DOI 10.1016/j.freeradbiomed.2004.05.027; DAHLIN DC, 1984, P NATL ACAD SCI-BIOL, V81, P1327, DOI 10.1073/pnas.81.5.1327; Dai GL, 2006, TOXICOL SCI, V92, P33, DOI 10.1093/toxsci/kfj192; Dickinson DA, 2004, FREE RADICAL BIO MED, V37, P1152, DOI 10.1016/j.freeradbiomed.2004.06.011; Eaton DL, 1999, TOXICOL SCI, V49, P156, DOI 10.1093/toxsci/49.2.156; Franklin CC, 2003, FASEB J, V17, P1535, DOI 10.1096/fj.02-0867fje; Franklin CC, 2002, AM J PATHOL, V160, P1887, DOI 10.1016/S0002-9440(10)61135-2; Gardner CR, 2002, TOXICOL APPL PHARM, V184, P27, DOI 10.1006/taap.2002.9474; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; Hinson JA, 1998, CHEM RES TOXICOL, V11, P604, DOI 10.1021/tx9800349; Hinson JA, 2004, DRUG METAB REV, V36, P805, DOI 10.1081/DMR-200033494; HUANG CS, 1993, J BIOL CHEM, V268, P20578; Ito Y, 2003, MICROCIRCULATION, V10, P391, DOI 10.1038/sj.mn.7800204; Ito Yoshiya, 2004, Comp Hepatol, V3 Suppl 1, pS33, DOI 10.1186/1476-5926-2-S1-S33; Jaeschke H, 2002, TOXICOL SCI, V65, P166, DOI 10.1093/toxsci/65.2.166; Jaeschke H, 2003, TOXICOL LETT, V144, P279, DOI 10.1016/S0378-4274(03)00239-X; James LP, 2003, DRUG METAB DISPOS, V31, P1499, DOI 10.1124/dmd.31.12.1499; James LP, 2003, FREE RADICAL RES, V37, P1289, DOI 10.1080/10715760310001617776; James LP, 2003, TOXICOL SCI, V75, P458, DOI 10.1093/toxsci/kfg181; JOLLOW DJ, 1973, J PHARMACOL EXP THER, V187, P195; Kitteringham NR, 2000, HEPATOLOGY, V32, P321, DOI 10.1053/jhep.2000.9602; Knight Tamara R, 2004, Comp Hepatol, V3 Suppl 1, pS46, DOI 10.1186/1476-5926-2-S1-S46; Knight TR, 2003, TOXICOL SCI, V76, P229, DOI 10.1093/toxsci/kfg220; Knight TR, 2002, J PHARMACOL EXP THER, V303, P468, DOI 10.1124/jpet.102.038968; Knight TR, 2001, TOXICOL SCI, V62, P212, DOI 10.1093/toxsci/62.2.212; Koide S, 2003, J AM COLL CARDIOL, V41, P539, DOI 10.1016/S0735-1097(02)02866-8; Lee WM, 2004, HEPATOLOGY, V40, P6, DOI 10.1002/hep.20293; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Michael SL, 2001, NITRIC OXIDE-BIOL CH, V5, P432, DOI 10.1006/niox.2001.0385; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P211; Muldrew KL, 2002, DRUG METAB DISPOS, V30, P446, DOI 10.1124/dmd.30.4.446; Nakamura S, 2002, CIRCULATION, V105, P2968, DOI 10.1161/01.CIR.0000019739.66514.1E; Nakamura S, 2003, CIRCULATION, V108, P1425, DOI 10.1161/01.CIR.0000091255.63645.98; NELSON SD, 1990, SEMIN LIVER DIS, V10, P267, DOI 10.1055/s-2008-1040482; Ochi T, 1995, ARCH TOXICOL, V70, P96, DOI 10.1007/BF02733669; Ochi T, 1997, ARCH TOXICOL, V71, P730, DOI 10.1007/s002040050454; Ochi T, 1996, TOXICOLOGY, V112, P45, DOI 10.1016/0300-483X(96)03348-3; ODwyer PJ, 1996, J CLIN INVEST, V98, P1210, DOI 10.1172/JCI118904; PUMFORD NR, 1990, TOXICOL APPL PHARM, V104, P521, DOI 10.1016/0041-008X(90)90174-S; REED DJ, 1990, ANNU REV PHARMACOL, V30, P603, DOI 10.1146/annurev.pa.30.040190.003131; Reid AB, 2005, J PHARMACOL EXP THER, V312, P509, DOI 10.1124/jpet.104.075945; Reid LL, 1997, BBA-GENE STRUCT EXPR, V1352, P233, DOI 10.1016/S0167-4781(97)00058-4; Reid LL, 1997, BBA-GENE STRUCT EXPR, V1353, P107, DOI 10.1016/S0167-4781(97)00092-4; Rzucidlo SJ, 2000, VET HUM TOXICOL, V42, P146; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sekhar KR, 1997, BIOCHEM BIOPH RES CO, V234, P588, DOI 10.1006/bbrc.1997.6697; Thompson SA, 1999, TOXICOL LETT, V110, P1, DOI 10.1016/S0378-4274(99)00133-2; Wang YL, 1997, NAT BIOTECHNOL, V15, P239, DOI 10.1038/nbt0397-239; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; White CC, 2003, ANAL BIOCHEM, V318, P175, DOI 10.1016/S0003-2697(03)00143-X; WHITE CC, 1999, CURRENT PROTOCOLS TO	56	46	48	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28865	28875		10.1074/jbc.M605143200	http://dx.doi.org/10.1074/jbc.M605143200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16840778	hybrid			2022-12-25	WOS:000240680500041
J	Oshima, H; Taketo, MM; Oshima, M				Oshima, Hiroko; Taketo, Makoto Mark; Oshima, Masanobu			Destruction of pancreatic beta-cells by transgenic induction of prostaglandin E-2 in the islets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETES-MELLITUS; CYCLOOXYGENASE-2; INTERLEUKIN-1; EXPRESSION; MICE; LANGERHANS; GLUCOSE; HYPERGLYCEMIA; INHIBITION; ACTIVATION	Type 2 diabetes mellitus is characterized by insulin resistance of peripheral tissues and dysfunction of pancreatic beta-cells. Furthermore, the number of pancreatic beta-cells decreases as a secondary effect of advanced type 2 diabetes, although the molecular mechanism has not been elucidated. Recently, it has been shown that hyperglycemic conditions induce the expression of cyclooxygenase-2 in pancreatic islets and increase the downstream product prostaglandin E-2 (PGE(2)). To investigate whether high glucose-induced PGE(2) has an adverse effect on pancreatic beta-cells, we generated transgenic mice (RIP-C2mE) that express cyclooxygenase-2 and microsomal prostaglandin E synthase-1 in their beta-cells using the rat insulin-2 gene promoter (RIP). The homozygous RIP-C2mE (Tg/Tg) mice showed severe hyperglycemia from six weeks of age. Although the heterozygous RIP-C2mE (Tg/-) mice showed normal blood glucose levels throughout their lifetime, this level increased significantly compared with that of wild-type mice when glucose was loaded. The relative number of beta-cells to the total islet cell number was reduced to 54 and 14% in the RIP-C2mE (Tg/-) and (Tg/Tg) mice, respectively, whereas that in the wild-type mice was 84%. Importantly, the proliferation rate in the islets of the RIP-C2mE (Tg/Tg) mice at four weeks of age decreased significantly in comparison to that in the wild-type mice. Because beta-cells replicate not only during the postnatal period but also in the adult pancreas at a basal level, it is possible that increased PGE2 signaling thus contributes to the reduction of the pancreatic beta-cell mass through inhibition of proliferation, thereby aggravating diabetes further.	Kanazawa Univ, Div Genet, Inst Canc Res, Kanazawa, Ishikawa 9200934, Japan; Kyoto Univ, Grad Sch Med, Dept Pharmacol, Kyoto 6068501, Japan	Kanazawa University; Kyoto University	Oshima, M (corresponding author), Kanazawa Univ, Div Genet, Inst Canc Res, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.	oshimam@kenroku.kanazawa-u.ac.jp	Oshima, Masanobu/F-9958-2014	Oshima, Masanobu/0000-0002-3304-0004; Oshima, Hiroko/0000-0001-6855-4008				BENDTZEN K, 1986, SCIENCE, V232, P1545, DOI 10.1126/science.3086977; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; CORBETT JA, 1993, BIOCHEMISTRY-US, V32, P13767, DOI 10.1021/bi00213a002; Deng SP, 2004, DIABETES, V53, P624, DOI 10.2337/diabetes.53.3.624; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; FINEGOOD DT, 1995, DIABETES, V44, P249, DOI 10.2337/diabetes.44.3.249; Giannoukakis N, 1999, DIABETES, V48, P1730, DOI 10.2337/diabetes.48.9.1730; Konheim YL, 2003, HUM GENET, V113, P377, DOI 10.1007/s00439-003-1000-y; Lingohr MK, 2002, TRENDS MOL MED, V8, P375, DOI 10.1016/S1471-4914(02)02377-8; Maedler K, 2002, J CLIN INVEST, V110, P851, DOI 10.1172/JCI200215318; Mandrup-Poulsen T, 2003, ANN NY ACAD SCI, V1005, P32, DOI 10.1196/annals.1288.005; MandrupPoulsen T, 1996, DIABETOLOGIA, V39, P1005, DOI 10.1007/BF00400649; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Oshima H, 2004, EMBO J, V23, P1669, DOI 10.1038/sj.emboj.7600170; Persaud SJ, 2004, DIABETES, V53, pS190, DOI 10.2337/diabetes.53.2007.S190; Robertson RP, 1998, DIABETES, V47, P1379, DOI 10.2337/diabetes.47.9.1379; Sakuraba H, 2002, DIABETOLOGIA, V45, P85, DOI 10.1007/s125-002-8248-z; Schmidt MI, 1999, LANCET, V353, P1649, DOI 10.1016/S0140-6736(99)01046-6; Shanmugam N, 2006, DIABETOLOGIA, V49, P100, DOI 10.1007/s00125-005-0065-7; Sorli CH, 1998, P NATL ACAD SCI USA, V95, P1788, DOI 10.1073/pnas.95.4.1788; Svenstrup K, 2002, APMIS, V110, P372, DOI 10.1034/j.1600-0463.2002.100502.x; Tabatabaie T, 2000, BIOCHEM BIOPH RES CO, V273, P699, DOI 10.1006/bbrc.2000.2959; Tran POT, 1999, J BIOL CHEM, V274, P31245, DOI 10.1074/jbc.274.44.31245; Uchida T, 2005, NAT MED, V11, P175, DOI 10.1038/nm1187; UNGER RH, 1985, DIABETOLOGIA, V28, P119; Vozarova B, 2002, DIABETES, V51, P455, DOI 10.2337/diabetes.51.2.455	27	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29330	29336		10.1074/jbc.M602424200	http://dx.doi.org/10.1074/jbc.M602424200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16873378	hybrid, Green Submitted			2022-12-25	WOS:000240680500088
J	Chen, GP; Frohlich, O; Yang, Y; Klein, JD; Sands, JM				Chen, Guangping; Frohlich, Otto; Yang, Yuan; Klein, Janet D.; Sands, Jeff M.			Loss of N-linked glycosylation reduces urea transporter UT-A1 response to vasopressin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL COLLECTING DUCT; PLASMA-MEMBRANE; EXPRESSION; TRAFFICKING; AQUAPORIN-2; SITES; WATER; IMCD; RATS; PERMEABILITY	The vasopressin-regulated urea transporter (UT)-A1 is a transmembrane protein with two glycosylated forms of 97 and 117 kDa; both are derived from a single 88-kDa core protein. However, the precise molecular sites and the function for UT-A1 N-glycosylation are not known. In this study, we compared Madin-Darby canine kidney cells stably expressing wildtype (WT) UT-A1 to Madin-Darby canine kidney cell lines stably expressing mutant UT-A1 lacking one (A1m1, A1m2) or both glycosylation sites (m1m2). Site-directed mutagenesis revealed that UT-A1 has two glycosylation sites at Asn-279 and -742. Urea flux is stimulated by 10 nM vasopressin (AVP) or 10 mu M forskolin (FSK) in WT cells. In contrast, m1m2 cells have a delayed and significantly reduced maximal urea flux. A 15-min treatment with AVP and FSK significantly increased UT-A1 cell surface expression in WT but not in m1m2 cells, as measured by biotinylation. We confirmed this finding using immunostaining. Membrane fractionation of the plasma membrane, Golgi, and endoplasmic reticulum revealed that AVP or FSK treatment increases UT-A1 abundance in both Golgi and plasma membrane compartments in WT but not in m1m2 cells. Pulse-chase experiments showed that UT-A1 half-life is reduced in m1m2 cells compared with WT cells. Our results suggest that mutation of the N-linked glycosylation sites reduces urea flux by reducing UT-A1 half-life and decreasing its accumulation in the apical plasma membrane. In vivo, inner medullary collecting duct cells may regulate urea uptake by altering UT-A1 glycosylation in response to AVP stimulation.	Emory Univ, Sch Med, Renal Div, Dept Med, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA	Emory University; Emory University	Chen, GP (corresponding author), Emory Univ, Sch Med, Renal Div, Dept Med, WMRB Rm 338,1639 Pierce Dr,NE, Atlanta, GA 30322 USA.	gchen3@emory.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063657, R01DK041707, P01DK061521] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK041707, P01 DK61521, R01-DK63657, R01 DK41707] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bradford AD, 2001, AM J PHYSIOL-RENAL, V281, pF133, DOI 10.1152/ajprenal.2001.281.1.F133; Diop NK, 2005, BIOCHEMISTRY-US, V44, P5420, DOI 10.1021/bi0479858; Fenton RA, 2004, P NATL ACAD SCI USA, V101, P7469, DOI 10.1073/pnas.0401704101; Frohlich O, 2004, AM J PHYSIOL-CELL PH, V286, pC1264, DOI 10.1152/ajpcell.00499.2003; FROHLICH O, 2006, IN PRESS AM J PHYSL, V291; Gatto C, 2001, AM J PHYSIOL-CELL PH, V281, pC982, DOI 10.1152/ajpcell.2001.281.3.C982; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hendriks G, 2004, J BIOL CHEM, V279, P2975, DOI 10.1074/jbc.M310767200; Hoover RS, 2003, J AM SOC NEPHROL, V14, P271, DOI 10.1097/01.ASN.0000043903.93452.D0; Inoue T, 1999, AM J PHYSIOL-RENAL, V276, pF559, DOI 10.1152/ajprenal.1999.276.4.F559; Kim D, 2003, AM J PHYSIOL-RENAL, V285, pF303, DOI 10.1152/ajprenal.00438.2002; KLEIN JD, 2006, IN PRESS J AM SOC NE, V17; Laughery MD, 2003, J BIOL CHEM, V278, P34794, DOI 10.1074/jbc.M302899200; Lee TK, 2003, AM J PHYSIOL-GASTR L, V285, pG371, DOI 10.1152/ajpgi.00358.2002; Li HY, 2003, AM J PHYSIOL-CELL PH, V285, pC1188, DOI 10.1152/ajpcell.00162.2003; Li LB, 2004, J BIOL CHEM, V279, P21012, DOI 10.1074/jbc.M311972200; Lucien N, 2002, J BIOL CHEM, V277, P34101, DOI 10.1074/jbc.M205073200; Marr N, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000027355.41663.14; Matsuda K, 2004, J NEUROCHEM, V89, P928, DOI 10.1111/j.1471-4159.2004.02377.x; Mistry AC, 2005, AM J PHYSIOL-RENAL, V288, pF455, DOI 10.1152/ajprenal.00296.2004; Napp J, 2005, J BIOL CHEM, V280, P29506, DOI 10.1074/jbc.M504228200; Pech V, 2005, AM J PHYSIOL-RENAL, V289, pF531, DOI 10.1152/ajprenal.00125.2005; Petrecca K, 1999, J PHYSIOL-LONDON, V515, P41, DOI 10.1111/j.1469-7793.1999.041ad.x; Sands JM, 1998, AM J PHYSIOL-RENAL, V274, pF978, DOI 10.1152/ajprenal.1998.274.5.F978; Sands JM, 2002, J AM SOC NEPHROL, V13, P2795, DOI 10.1097/01.ASN.0000035084.94743.7C; SANDS JM, 1987, AM J PHYSIOL, V253, pF823, DOI 10.1152/ajprenal.1987.253.5.F823; Smith CP, 2004, AM J PHYSIOL-CELL PH, V287, pC1087, DOI 10.1152/ajpcell.00363.2003; Snyder PM, 2005, ENDOCRINOLOGY, V146, P5079, DOI 10.1210/en.2005-0894; Terris J, 1998, J AM SOC NEPHROL, V9, P729; WALL SM, 1992, AM J PHYSIOL, V262, pF989, DOI 10.1152/ajprenal.1992.262.6.F989; Yoshimi M, 2000, BIOCHEM BIOPH RES CO, V276, P965, DOI 10.1006/bbrc.2000.3565; YOU GF, 1993, NATURE, V365, P844, DOI 10.1038/365844a0	32	44	45	3	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27436	27442		10.1074/jbc.M605525200	http://dx.doi.org/10.1074/jbc.M605525200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16849333	hybrid			2022-12-25	WOS:000240397700070
J	Hall, BS; Gabernet-Castello, C; Voak, A; Goulding, D; Natesan, SK; Field, MC				Hall, Belinda S.; Gabernet-Castello, Carme; Voak, Andrew; Goulding, David; Natesan, Senthil Kumar; Field, Mark C.			TbVps34, the trypanosome orthologue of Vps34, is required for Golgi complex segregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; RETROGRADE TRANSPORT; RNA INTERFERENCE; RAB5 EFFECTORS; FYVE FINGERS; PI 3-KINASE; CELL-CYCLE; YEAST; BRUCEI	Phosphoinositides are important regulators of numerous cellular functions. The yeast class III phosphatidylinositol 3-kinase Vps34p, and its human orthologue hVPS34, are implicated in control of several key pathways, including endosome to lysosome transport, retrograde endosome to Golgi traffic, multivesicular body formation, and autophagy. We have identified the Vps34p orthologue in the African trypanosome, TbVps34. Knockdown of TbVps34 expression by RNA interference induces a severe growth defect, with a post-mitotic block to cytokinesis accompanied by a variety of morphological abnormalities. GFP2xFYVE, a chimeric protein that specifically binds phosphatidylinositol 3-phosphate, localizes to the trypanosome endosomal system and is delocalized under TbVps34 RNA interference (RNAi), confirming that TbVps34 is an authentic phosphatidylinositol 3-kinase. Expression of GFP2xFYVE enhances the TbVps34 RNAi-associated growth defect, suggesting a synthetic interaction via competition for phosphatidylinositol 3-phosphate-binding sites with endogenous FYVE domain proteins. Endocytosis of a fluid phase marker is unaffected by TbVps34 RNAi, but receptor-mediated endocytosis of transferrin and transport of concanavalin A to the lysosome are both impaired, confirming a role in membranous endocytic trafficking for TbVps34. TbVps34 knockdown inhibits export of variant surface glycoprotein, indicating a function in exocytic transport. Ultrastructural analysis revealed a highly extended Golgi apparatus following TbVps34 RNAi, whereas expression of the Golgi marker red fluorescent protein-GRASP (Grp1 (general receptor for phosphoinositides-1)-associated scaffold protein) demonstrated that trypanosomes are able to duplicate the Golgi complex but failed to complete segregation during mitosis, despite faithful replication and segregation of basal bodies and the kinetoplast. These observations implicate TbVps34 as having a role in coordinating segregation of the Golgi complex at cell division.	Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AY, England	University of Cambridge; Imperial College London	Field, MC (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.	mcf34@cam.ac.uk	Field, Mark/AAD-6455-2021; Hall, Belinda/AGU-6214-2022	Field, Mark/0000-0002-4866-2885; Hall, Belinda/0000-0002-3753-1978; Voak, Andrew/0000-0002-1010-4781	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allen CL, 2003, EMBO J, V22, P4991, DOI 10.1093/emboj/cdg481; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BERGGREN MI, 1993, CANCER RES, V53, P4297; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; BRICKMAN MJ, 1995, J CELL SCI, V108, P3611; Brown RA, 2001, BIOCHEM SOC T, V29, P535, DOI 10.1042/BST0290535; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; Bunney TD, 2000, PLANT CELL, V12, P1679, DOI 10.1105/tpc.12.9.1679; Burda P, 2002, J CELL SCI, V115, P3889, DOI 10.1242/jcs.00090; Carlton J, 2004, CURR BIOL, V14, P1791, DOI 10.1016/j.cub.2004.09.077; Carlton JG, 2005, TRENDS CELL BIOL, V15, P540, DOI 10.1016/j.tcb.2005.08.005; Cheung PCF, 2001, BIOCHEM J, V355, P113, DOI 10.1042/bj3550113; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; di Campli A, 1999, CELL MOTIL CYTOSKEL, V43, P334, DOI 10.1002/(SICI)1097-0169(1999)43:4<334::AID-CM6>3.0.CO;2-3; Domin J, 2000, J BIOL CHEM, V275, P11943, DOI 10.1074/jbc.275.16.11943; Engstler M, 2004, J CELL SCI, V117, P1105, DOI 10.1242/jcs.00938; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; Fernandez-Borja M, 1999, CURR BIOL, V9, P55, DOI 10.1016/S0960-9822(99)80048-7; Field H, 2000, MOL BIOCHEM PARASIT, V106, P21, DOI 10.1016/S0166-6851(99)00192-9; Field MC, 2005, TRENDS PARASITOL, V21, P447, DOI 10.1016/j.pt.2005.08.008; FIELD MC, 2006, EVOLUTION EUKARYOTIC; Foster FM, 2003, J CELL SCI, V116, P3037, DOI 10.1242/jcs.00609; Gaidarov I, 2001, MOL CELL, V7, P443, DOI 10.1016/S1097-2765(01)00191-5; GALE M, 1993, MOL BIOCHEM PARASIT, V59, P111, DOI 10.1016/0166-6851(93)90012-M; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; GRAB DJ, 1992, EUR J CELL BIOL, V59, P398; Grunfelder CG, 2003, MOL BIOL CELL, V14, P2029, DOI 10.1091/mbc.E02-10-0640; Hall B, 2004, MOL BIOCHEM PARASIT, V138, P67, DOI 10.1016/j.molbiopara.2004.07.007; Hall BS, 2005, EUKARYOT CELL, V4, P971, DOI 10.1128/EC.4.5.971-980.2005; Hall BS, 2004, J BIOL CHEM, V279, P45047, DOI 10.1074/jbc.M407271200; He CY, 2004, J CELL BIOL, V165, P313, DOI 10.1083/jcb.200311076; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; Hirosako K, 2004, BIOCHEM BIOPH RES CO, V316, P845, DOI 10.1016/j.bbrc.2004.02.119; Kelley RJ, 1995, MOL BIOCHEM PARASIT, V74, P167, DOI 10.1016/0166-6851(95)02493-X; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; Marone Maria, 2001, Biological Procedures Online, V3, P19, DOI 10.1251/bpo20; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; Morgan GW, 2002, TRENDS PARASITOL, V18, P491, DOI 10.1016/S1471-4922(02)02391-7; Pal A, 2003, BIOCHEM J, V374, P443, DOI 10.1042/BJ20030469; Pal A, 2002, J BIOL CHEM, V277, P9529, DOI 10.1074/jbc.M110055200; Peterson MR, 1999, CURR BIOL, V9, P159, DOI 10.1016/S0960-9822(99)80071-2; Petiot A, 2003, J CELL BIOL, V162, P971, DOI 10.1083/jcb.200303018; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Pirola L, 2001, J BIOL CHEM, V276, P21544, DOI 10.1074/jbc.M011330200; Redmond S, 2003, MOL BIOCHEM PARASIT, V128, P115, DOI 10.1016/S0166-6851(03)00045-8; ROBINSON DR, 1995, J CELL BIOL, V128, P1163, DOI 10.1083/jcb.128.6.1163; Rog O, 2005, CURR GENET, V47, P18, DOI 10.1007/s00294-004-0548-y; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; Santa-Rita RM, 2004, J ANTIMICROB CHEMOTH, V54, P704, DOI 10.1093/jac/dkh380; Sheader K, 2005, P NATL ACAD SCI USA, V102, P8716, DOI 10.1073/pnas.0501886102; Shin HW, 2005, J CELL BIOL, V170, P607, DOI 10.1083/jcb.200505128; Shorter J, 1999, EMBO J, V18, P4949, DOI 10.1093/emboj/18.18.4949; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; STACK JH, 1994, J BIOL CHEM, V269, P31552; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; Stein MP, 2003, TRAFFIC, V4, P754, DOI 10.1034/j.1600-0854.2003.00133.x; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Thyberg J, 1998, EUR J CELL BIOL, V76, P33, DOI 10.1016/S0171-9335(98)80015-0; Vassella E, 2001, MOL MICROBIOL, V41, P33, DOI 10.1046/j.1365-2958.2001.02471.x; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Wetzker R, 2004, CURR PHARM DESIGN, V10, P1915, DOI 10.2174/1381612043384402; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9	68	60	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27600	27612		10.1074/jbc.M602183200	http://dx.doi.org/10.1074/jbc.M602183200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16835237	hybrid			2022-12-25	WOS:000240397700085
J	Shi, GB; Boyle, SC; Sparrow, DB; Dunwoodie, SL; Shioda, T; de Caestecker, MP				Shi, Genbin; Boyle, Scott C.; Sparrow, Duncan B.; Dunwoodie, Sally L.; Shioda, Toshi; de Caestecker, Mark P.			The transcriptional activity of CITED1 is regulated by phosphorylation in a cell cycle-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PROTEIN; GENE-EXPRESSION; BINDING-PROTEIN; MSG1; FAMILY; DOMAIN; MEMBER; MRG1; RICH; TRANSACTIVATOR	CITED1 is the founding member of the CITED family of cofactors that are involved in regulating a wide variety of CBP/p300-dependent transcriptional responses. In the present study, we show that the phosphorylation status of CITED1 changes during the cell cycle and affects its transcriptional cofactor activity. Tryptic mapping and mutagenesis studies identified five phosphorylated serine residues in CITED1. Phosphorylation of these residues did not affect CRM1-dependent nuclear export, but did decrease CITED1 binding to p300 and inhibited CITED1-dependent transactivation of Smad4 and p300. These results suggest that CITED1 functions as a cell cycle-dependent transcriptional cofactor whose activity is regulated by phosphorylation.	Vanderbilt Univ, Med Ctr, Div Nephrol, Sch Med,Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Massachusetts Gen Hosp, Ctr Canc, Dept Tumor Biol, Charlestown, MA 02129 USA; Univ New S Wales, Victor Chang Cardiac Res Inst, Sydney, NSW 2010, Australia	Vanderbilt University; Vanderbilt University; Harvard University; Massachusetts General Hospital; University of New South Wales Sydney; Victor Chang Cardiac Research Institute	de Caestecker, MP (corresponding author), Vanderbilt Univ, Med Ctr, Div Nephrol, Sch Med,Dept Med, S-3223,Med Ctr N,1161 21st St S, Nashville, TN 37232 USA.	Mark.de.Caestecker@vanderbilt.edu	Dunwoodie, Sally L/M-4019-2018; Sparrow, Duncan/B-3994-2008	Dunwoodie, Sally L/0000-0002-2069-7349; Sparrow, Duncan/0000-0002-1141-6613	NIDDK NIH HHS [R01DK61558] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061558] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andrews JE, 2000, MECH DEVELOP, V95, P305, DOI 10.1016/S0925-4773(00)00362-2; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Braganca J, 2003, J BIOL CHEM, V278, P16021, DOI 10.1074/jbc.M208144200; Braganca J, 2002, J BIOL CHEM, V277, P8559, DOI 10.1074/jbc.M110850200; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Dunwoodie SL, 1998, MECH DEVELOP, V72, P27, DOI 10.1016/S0925-4773(98)00011-2; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; Fox SB, 2004, CANCER RES, V64, P6075, DOI 10.1158/0008-5472.CAN-04-0708; Gawantka V, 1998, MECH DEVELOP, V77, P95, DOI 10.1016/S0925-4773(98)00115-4; Glenn DJ, 1999, J BIOL CHEM, V274, P36159, DOI 10.1074/jbc.274.51.36159; Graham John M., 2002, TheScientificWorldJOURNAL, V2, P1638; Harper Jane V., 2004, V296, P157; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Howlin J, 2006, ONCOGENE, V25, P1532, DOI 10.1038/sj.onc.1209183; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kutay U, 2005, TRENDS CELL BIOL, V15, P121, DOI 10.1016/j.tcb.2005.01.005; Li HC, 1998, EXP CELL RES, V242, P478, DOI 10.1006/excr.1998.4123; LOVVORN HN, 2006, IN PRESS J PEDIAT SU; Ng PKS, 2003, COMP BIOCHEM PHYS B, V136, P163, DOI 10.1016/S1096-4959(03)00224-0; Plisov S, 2005, J AM SOC NEPHROL, V16, P1632, DOI 10.1681/ASN.2004060476; Prasad ML, 2005, MODERN PATHOL, V18, P48, DOI 10.1038/modpathol.3800235; Prasad ML, 2004, THYROID, V14, P169, DOI 10.1089/105072504773297830; Robinson J.P., 1997, CURRENT PROTOCOLS CY; Rodriguez TA, 2004, MOL CELL BIOL, V24, P228, DOI 10.1128/MCB.24.1.228-244.2004; Sedghizadeh PP, 2005, MED SCI MONITOR, V11, pBR189; Shioda T, 1996, P NATL ACAD SCI USA, V93, P12298, DOI 10.1073/pnas.93.22.12298; Shioda T, 1997, GENE, V204, P235, DOI 10.1016/S0378-1119(97)00551-9; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Tien ES, 2004, J BIOL CHEM, V279, P24053, DOI 10.1074/jbc.M401489200; Yahata T, 2000, J BIOL CHEM, V275, P8825, DOI 10.1074/jbc.275.12.8825; Yahata T, 2002, GENOMICS, V80, P601, DOI 10.1006/geno.2002.7005; Yahata T, 2001, GENE DEV, V15, P2598, DOI 10.1101/gad.906301; Younes MN, 2005, MOL CANCER THER, V4, P1146, DOI 10.1158/1535-7163.MCT-05-0078	36	18	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27426	27435		10.1074/jbc.M602631200	http://dx.doi.org/10.1074/jbc.M602631200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16864582	hybrid			2022-12-25	WOS:000240397700069
J	Trible, RP; Emert-Sedlak, L; Smithgall, TE				Trible, Ronald P.; Emert-Sedlak, Lori; Smithgall, Thomas E.			HIV-1 Nef selectively activates Src family kinases Hck, Lyn, and c-Src through direct SH3 domain interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; VIRUS TYPE-1 NEF; SIMIAN IMMUNODEFICIENCY VIRUS; HERPESVIRUS-SAIMIRI; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; IN-VIVO; PROMOTES SURVIVAL; TRANSGENIC MICE; CONSERVED CORE	Nef is an HIV-1 virulence factor that promotes viral pathogenicity by altering host cell signaling pathways. Nef binds several members of the Src kinase family, and these interactions have been implicated in the pathogenesis of HIV/AIDS. However, the direct effect of Nef interaction on Src family kinase (SFK) regulation and activity has not been systematically addressed. We explored this issue using Saccharomyces cerevisiae, a well defined model system for the study of SFK regulation. Previous studies have shown that ectopic expression of c-Src arrests yeast cell growth in a kinase-dependent manner. We expressed Fgr, Fyn, Hck, Lck, Lyn, and Yes as well as c-Src in yeast and found that each kinase was active and induced growth suppression. Co-expression of the negative regulatory kinase Csk suppressed SFK activity and reversed the growth-inhibitory effect. We then co-expressed each SFK with HIV-1 Nef in the presence of Csk. Nef strongly activated Hck, Lyn, and c-Src but did not detectably affect Fgr, Fyn, Lck, or Yes. Mutagenesis of the Nef PXXP motif essential for SH3 domain binding greatly reduced the effect of Nef on Hck, Lyn, and c-Src, suggesting that Nef activates these Src family members through allosteric displacement of intramolecular SH3-linker interactions. These data show that Nef selectively activates Hck, Lyn, and c-Src among SFKs, identifying these kinases as proximal effectors of Nef signaling and potential targets for anti-HIV drug discovery.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Smithgall, TE (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, E1240 Biomed Sci Tower, Pittsburgh, PA 15261 USA.	tsmithga@pitt.edu			NATIONAL CANCER INSTITUTE [R01CA081398] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057083] Funding Source: NIH RePORTER; NCI NIH HHS [CA81398, R01 CA081398-07, R01 CA081398] Funding Source: Medline; NIAID NIH HHS [R01 AI057083, AI057083] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams JA, 2003, BIOCHEMISTRY-US, V42, P601, DOI 10.1021/bi020617o; Arold S, 1998, BIOCHEMISTRY-US, V37, P14683, DOI 10.1021/bi980989q; Arold S, 1997, STRUCTURE, V5, P1361, DOI 10.1016/S0969-2126(97)00286-4; Arold ST, 2001, TRENDS BIOCHEM SCI, V26, P356, DOI 10.1016/S0968-0004(01)01846-1; Baur AS, 1997, IMMUNITY, V6, P283, DOI 10.1016/S1074-7613(00)80331-3; BIESINGER B, 1995, J BIOL CHEM, V270, P4729, DOI 10.1074/jbc.270.9.4729; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; Briese L, 2005, J BIOMED SCI, V12, P451, DOI 10.1007/s11373-005-6797-z; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Briggs SD, 2000, BIOCHEMISTRY-US, V39, P489, DOI 10.1021/bi992504j; Briggs SD, 2001, J BIOL CHEM, V276, P25605, DOI 10.1074/jbc.M103244200; BRUGGE JS, 1987, MOL CELL BIOL, V7, P2180, DOI 10.1128/MCB.7.6.2180; Cheng H, 1999, VIROLOGY, V264, P5, DOI 10.1006/viro.1999.9937; Choi HJ, 2004, J MOL BIOL, V343, P1255, DOI 10.1016/j.jmb.2004.09.015; Choi HJ, 2004, J BIOL CHEM, V279, P51688, DOI 10.1074/jbc.M410068200; Chong YP, 2005, GROWTH FACTORS, V23, P233, DOI 10.1080/08977190500178877; Chong YP, 2005, BBA-PROTEINS PROTEOM, V1754, P210, DOI 10.1016/j.bbapap.2005.07.027; Collette Y, 1997, RES VIROLOGY, V148, P52, DOI 10.1016/S0923-2516(97)81914-0; Collette Y, 2000, J BIOL CHEM, V275, P4171, DOI 10.1074/jbc.275.6.4171; Collette Y, 1996, J BIOL CHEM, V271, P6333, DOI 10.1074/jbc.271.11.6333; COOPER JA, 1987, ONCOGENE RES, V1, P297; Cowan-Jacob SW, 2005, STRUCTURE, V13, P861, DOI 10.1016/j.str.2005.03.012; Crowe S, 2003, J LEUKOCYTE BIOL, V74, P635, DOI 10.1189/jlb.0503204; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; Dutartre H, 1998, VIROLOGY, V247, P200, DOI 10.1006/viro.1998.9244; Fackler OT, 2002, IMMUNITY, V16, P493, DOI 10.1016/S1074-7613(02)00307-2; FLORIO M, 1994, MOL BIOL CELL, V5, P283, DOI 10.1091/mbc.5.3.283; Geffin R, 2000, AIDS RES HUM RETROV, V16, P1855, DOI 10.1089/08892220050195810; GESSLER M, 1984, BIOSCIENCE REP, V4, P757, DOI 10.1007/BF01128817; Geyer M, 2001, EMBO REP, V2, P580, DOI 10.1093/embo-reports/kve141; Greenway A, 1996, J VIROL, V70, P6701, DOI 10.1128/JVI.70.10.6701-6708.1996; GREENWAY A, 1995, J VIROL, V69, P1842, DOI 10.1128/JVI.69.3.1842-1850.1995; Greenway AL, 1999, J VIROL, V73, P6152, DOI 10.1128/JVI.73.7.6152-6158.1999; Hanna Z, 2001, J VIROL, V75, P9378, DOI 10.1128/JVI.75.19.9378-9392.2001; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; Hartley DK, 1999, J BIOL CHEM, V274, P20056, DOI 10.1074/jbc.274.29.20056; He JCJ, 2004, J CLIN INVEST, V114, P643, DOI 10.1172/JCI200421004; Joseph AM, 2005, CURR HIV RES, V3, P87, DOI 10.2174/1570162052773013; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Kharbanda S, 1996, CANCER RES, V56, P3617; Kirchhoff F, 1999, J VIROL, V73, P5497, DOI 10.1128/JVI.73.7.5497-5508.1999; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; Kjellen P, 2002, VIROLOGY, V297, P281, DOI 10.1006/viro.2002.1419; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; Komuro I, 2003, J EXP MED, V198, P443, DOI 10.1084/jem.20022018; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; Learmont JC, 1999, NEW ENGL J MED, V340, P1715, DOI 10.1056/NEJM199906033402203; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; Lerner EC, 2002, NAT STRUCT BIOL, V9, P365, DOI 10.1038/nsb782; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; Lund T, 1997, J VIROL, V71, P378, DOI 10.1128/JVI.71.1.378-382.1997; Martin JC, 1999, J ACQ IMMUN DEF SYND, V22, P413; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1991, J BIOL CHEM, V266, P24249; Orenstein JM, 2001, IMMUNOBIOLOGY, V204, P598, DOI 10.1078/0171-2985-00098; Palacios EH, 2004, ONCOGENE, V23, P7990, DOI 10.1038/sj.onc.1208074; Piguet V, 1999, REV MED VIROL, V9, P111, DOI 10.1002/(SICI)1099-1654(199904/06)9:2&lt;111::AID-RMV245&gt;3.0.CO;2-P; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; Renkema GH, 2000, FRONT BIOSCI-LANDMRK, V5, pD268, DOI 10.2741/Renkema; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Sawai ET, 2000, J VIROL, V74, P2038, DOI 10.1128/JVI.74.4.2038-2045.2000; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; Takashima Y, 2003, BIOCHEMISTRY-US, V42, P3567, DOI 10.1021/bi0272499; Walkenhorst J, 1996, ONCOGENE, V12, P1513; WHATMORE AM, 1995, J VIROL, V69, P5117, DOI 10.1128/JVI.69.8.5117-5123.1995; Wiese N, 1996, J BIOL CHEM, V271, P847, DOI 10.1074/jbc.271.2.847; Ye HH, 2004, BIOCHEMISTRY-US, V43, P15775, DOI 10.1021/bi048712f; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	75	117	122	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27029	27038		10.1074/jbc.M601128200	http://dx.doi.org/10.1074/jbc.M601128200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16849330	Green Accepted, hybrid			2022-12-25	WOS:000240397700029
J	Al-Ramahi, I; Lam, YC; Chen, HK; de Gouyon, B; Zhang, MH; Perez, AM; Branco, J; de Haro, M; Patterson, C; Zoghbi, HY; Botas, J				Al-Ramahi, Ismael; Lam, Yung C.; Chen, Hung-Kai; de Gouyon, Beatrice; Zhang, Minghang; Perez, Alma M.; Branco, Joana; de Haro, Maria; Patterson, Cam; Zoghbi, Huda Y.; Botas, Juan			CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCA1 TRANSGENIC MICE; POLYGLUTAMINE-INDUCED DISEASE; QUALITY-CONTROL; MEDIATES NEURODEGENERATION; MOLECULAR CHAPERONES; CARBOXYL-TERMINUS; AXH DOMAIN; LIGASE; AGGREGATION; PROTEINS	CHIP (C terminus of Hsc-70 interacting protein) is an E3 ligase that links the protein folding machinery with the ubiquitin-proteasome system and has been implicated in disorders characterized by protein misfolding and aggregation. Here we investigate the role of CHIP in protecting from ataxin-1-induced neurodegeneration. Ataxin-1 is a polyglutamine protein whose expansion causes spinocerebellar ataxia type-1 (SCA1) and triggers the formation of nuclear inclusions (NIs). We find that CHIP and ataxin-1 proteins directly interact and co-localize in NIs both in cell culture and SCA1 postmortem neurons. CHIP promotes ubiquitination of expanded ataxin-1 both in vitro and in cell culture. The Hsp70 chaperone increases CHIP-mediated ubiquitination of ataxin-1 in vitro, and the tetratricopeptide repeat domain, which mediates CHIP interactions with chaperones, is required for ataxin-1 ubitiquination in cell culture. Interestingly, CHIP also interacts with and ubiquitinates unexpanded ataxin-1. Overexpression of CHIP in a Drosophila model of SCA1 decreases the protein steady-state levels of both expanded and unexpanded ataxin-1 and suppresses their toxicity. Finally we investigate the ability of CHIP to protect against toxicity caused by expanded polyglutamine tracts in different protein contexts. We find that CHIP is not effective in suppressing the toxicity caused by a bare 127Q tract with only a short hemaglutinin tag, but it is very efficient in suppressing toxicity caused by a 128Q tract in the context of an N-terminal huntingtin backbone. These data underscore the importance of the protein framework for modulating the effects of polyglutamine-induced neurodegeneration.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ Autonoma Madrid, Dept Biol, Fac Ciencias, E-28049 Madrid, Spain	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Autonomous University of Madrid	Botas, J (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.	jbotas@bcm.tmc.edu	Perez, Alma/AAG-7616-2021; Al-Ramahi, Ismael/B-4000-2017	Al-Ramahi, Ismael/0000-0002-1275-1114; Chen, Hung-Kai/0000-0002-2169-4924; de Haro, Maria/0000-0002-8654-2526; Perez, Alma/0000-0002-0746-5439; Zoghbi, Huda/0000-0002-0700-3349	NICHD NIH HHS [HD24062] Funding Source: Medline; NINDS NIH HHS [NS42179, NS27699] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042179, R56NS042179, R01NS027699, R37NS027699] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; Choi JS, 2004, BIOCHEM BIOPH RES CO, V321, P574, DOI 10.1016/j.bbrc.2004.07.010; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; Emamian ES, 2003, NEURON, V38, P375, DOI 10.1016/S0896-6273(03)00258-7; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Gatchel JR, 2005, NAT REV GENET, V6, P743, DOI 10.1038/nrg1691; Hatakeyama S, 2004, J NEUROCHEM, V91, P299, DOI 10.1111/j.1471-4159.2004.02713.x; Hatakeyama S, 2004, GENES CELLS, V9, P533, DOI 10.1111/j.1356-9597.2004.00742.x; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Jana NR, 2005, J BIOL CHEM, V280, P11635, DOI 10.1074/jbc.M412042200; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kampinga HH, 2003, MOL CELL BIOL, V23, P4948, DOI 10.1128/MCB.23.14.4948-4958.2003; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Matilla A, 1998, J NEUROSCI, V18, P5508, DOI 10.1523/JNEUROSCI.18-14-05508.1998; Miller VM, 2005, J NEUROSCI, V25, P9152, DOI 10.1523/JNEUROSCI.3001-05.2005; Mizutani A, 2005, EMBO J, V24, P3339, DOI 10.1038/sj.emboj.7600785; Murata S, 2003, INT J BIOCHEM CELL B, V35, P572, DOI 10.1016/S1357-2725(02)00394-1; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Shin YG, 2005, J BIOL CHEM, V280, P23727, DOI 10.1074/jbc.M503326200; Tsai CC, 2004, P NATL ACAD SCI USA, V101, P4047, DOI 10.1073/pnas.0400615101; Tsuda H, 2005, CELL, V122, P633, DOI 10.1016/j.cell.2005.06.012; Urushitani M, 2004, J NEUROCHEM, V90, P231, DOI 10.1111/j.1471-4159.2004.02486.x; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wiederkehr T, 2002, CURR BIOL, V12, pR26, DOI 10.1016/S0960-9822(01)00644-3; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Zhang MH, 2005, MOL CELL, V20, P525, DOI 10.1016/j.molcel.2005.09.023; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217; Zu T, 2004, J NEUROSCI, V24, P8853, DOI 10.1523/JNEUROSCI.2978-04.2004	38	154	158	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26714	26724		10.1074/jbc.M601603200	http://dx.doi.org/10.1074/jbc.M601603200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16831871	hybrid			2022-12-25	WOS:000240249500089
J	Cheng, NH; Liu, JZ; Brock, A; Nelsono, RS; Hirschi, KD				Cheng, Ning-Hui; Liu, Jian-Zhong; Brock, Amanda; Nelsono, Richard S.; Hirschi, Kendal D.			AtGRXcp, an Arabidopsis chloroplastic glutaredoxin, is critical for protection against protein oxidative damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRX5 MONOTHIOL GLUTAREDOXIN; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SIGNAL-TRANSDUCTION; H+/CA2+ ANTIPORTER; HOMOLOGY DOMAIN; PLANT-GROWTH; STRESS; THIOREDOXIN; GLUTATHIONE	Glutaredoxins (Grxs) are ubiquitous small heat-stable disulfide oxidoreductases and members of the thioredoxin (Trx) fold protein family. In bacterial, yeast, and mammalian cells, Grxs appear to be involved in maintaining cellular redox homeostasis. However, in plants, the physiological roles of Grxs have not been fully characterized. Recently, an emerging subgroup of Grxs with one cysteine residue in the putative active motif (monothiol Grxs) has been identified but not well characterized. Here we demonstrate that a plant protein, AtGRXcp, is a chloroplast-localized monothiol Grx with high similarity to yeast Grx5. In yeast expression assays, AtGRXcp localized to the mitochondria and suppressed the sensitivity of yeast grx5 cells to H2O2 and protein oxidation. AtGRXcp expression can also suppress iron accumulation and partially rescue the lysine auxotrophy of yeast grx5 cells. Analysis of the conserved monothiol motif suggests that the cysteine residue affects AtGRXcp expression and stability. In planta, AtGRXcp expression was elevated in young cotyledons, green tissues, and vascular bundles. Analysis of atgrxcp plants demonstrated defects in early seedling growth under oxidative stresses. In addition, atgrxcp lines displayed increased protein carbonylation within chloroplasts. Thus, this work describes the initial functional characterization of a plant monothiol Grx and suggests a conserved biological function in protecting cells against protein oxidative damage.	USDA ARS, Plant Physiol Grp, Childrens Nutr Res Ctr, Dept Pediat,Baylor Coll Med, Houston, TX 77030 USA; Samuel Roberts Noble Fdn Inc, Div Plant Biol, Ardmore, OK 73402 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Texas A&M Univ, Vegetable & Fruit Improvement Ctr, College Stn, TX 77845 USA	Baylor College of Medicine; United States Department of Agriculture (USDA); Noble Research Institute; Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station	Cheng, NH (corresponding author), USDA ARS, Plant Physiol Grp, Childrens Nutr Res Ctr, Dept Pediat,Baylor Coll Med, 1100 Bates St, Houston, TX 77030 USA.	ncheng@bcm.tmc.edu	hirschi, kendal/GNP-0351-2022	Liu, Jianzhong/0000-0001-7826-7045				Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Apel K, 2004, ANNU REV PLANT BIOL, V55, P373, DOI 10.1146/annurev.arplant.55.031903.141701; AUSUBEL F, 1996, CURRENT PROTOCOLS MO, V2, P5; Balk J, 2005, TRENDS PLANT SCI, V10, P324, DOI 10.1016/j.tplants.2005.05.002; Becamel C, 2002, EMBO J, V21, P2332, DOI 10.1093/emboj/21.10.2332; Belli G, 2002, J BIOL CHEM, V277, P37590, DOI 10.1074/jbc.M201688200; Buchanan BB, 2005, ANNU REV PLANT BIOL, V56, P187, DOI 10.1146/annurev.arplant.56.032604.144246; Buchanan BB, 2002, PHOTOSYNTH RES, V73, P215, DOI 10.1023/A:1020407432008; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Cheng NH, 2004, FEBS LETT, V559, P99, DOI 10.1016/S0014-5793(04)00036-5; Cheng NH, 2003, J BIOL CHEM, V278, P6503, DOI 10.1074/jbc.M210883200; Cheng NH, 2003, PLANT CELL, V15, P347, DOI 10.1105/tpc.007385; Davletova S, 2005, PLANT CELL, V17, P268, DOI 10.1105/tpc.104.026971; Fernandes AP, 2005, J BIOL CHEM, V280, P24544, DOI 10.1074/jbc.M500678200; Fernandes AP, 2004, ANTIOXID REDOX SIGN, V6, P63, DOI 10.1089/152308604771978354; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fitzpatrick LM, 2001, PLANT J, V27, P59, DOI 10.1046/j.0960-7412.2001.01061.x; Fladvad M, 2005, J BIOL CHEM, V280, P24553, DOI 10.1074/jbc.M500679200; Fobert PR, 2005, CURR OPIN PLANT BIOL, V8, P378, DOI 10.1016/j.pbi.2005.05.003; Foyer CH, 2005, PLANT CELL, V17, P1866, DOI 10.1105/tpc.105.033589; Gechev TS, 2005, J CELL BIOL, V168, P17, DOI 10.1083/jcb.200409170; Grant CM, 2001, MOL MICROBIOL, V39, P533, DOI 10.1046/j.1365-2958.2001.02283.x; Havlin J.L., 1989, COMMUN SOIL SCI PLAN, V14, P969, DOI DOI 10.1080/00103628009367096; Henmi K, 2005, PLANT CELL PHYSIOL, V46, P1757, DOI 10.1093/pcp/pci198; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Isakov N, 2000, TRENDS BIOCHEM SCI, V25, P537, DOI 10.1016/S0968-0004(00)01685-6; Jablonowski D, 2001, GENETICS, V159, P1479; Job C, 2005, PLANT PHYSIOL, V138, P790, DOI 10.1104/pp.105.062778; Johansson E, 2004, J BIOL CHEM, V279, P22204, DOI 10.1074/jbc.M402652200; Lemaire SD, 2004, PHOTOSYNTH RES, V79, P305, DOI 10.1023/B:PRES.0000017174.60951.74; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Lillig CH, 2005, P NATL ACAD SCI USA, V102, P8168, DOI 10.1073/pnas.0500735102; Lopreiato R, 2004, BIOCHEM J, V377, P395, DOI 10.1042/BJ20030638; Molina MM, 2004, J BIOL CHEM, V279, P51923, DOI 10.1074/jbc.M410219200; Muhlenhoff U, 2003, EMBO J, V22, P4815, DOI 10.1093/emboj/cdg446; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Nathan DF, 1999, P NATL ACAD SCI USA, V96, P1409, DOI 10.1073/pnas.96.4.1409; Nystrom T, 2005, EMBO J, V24, P1311, DOI 10.1038/sj.emboj.7600599; Ogawa K, 2005, ANTIOXID REDOX SIGN, V7, P973, DOI 10.1089/ars.2005.7.973; Ortenberg R, 2004, P NATL ACAD SCI USA, V101, P7439, DOI 10.1073/pnas.0401965101; Rahlfs S, 2001, J BIOL CHEM, V276, P37133, DOI 10.1074/jbc.M105524200; Rhoads DM, 2006, PLANT PHYSIOL, V141, P357, DOI 10.1104/pp.106.079129; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Rouhier N, 2004, CELL MOL LIFE SCI, V61, P1266, DOI 10.1007/s00018-004-3410-y; Rouhier N, 2003, ANTIOXID REDOX SIGN, V5, P15, DOI 10.1089/152308603321223504; Shigaki T, 2001, J BIOL CHEM, V276, P43152, DOI 10.1074/jbc.M106637200; Tamarit J, 2003, J BIOL CHEM, V278, P25745, DOI 10.1074/jbc.M303477200; Trelease RN, 1996, PROTOPLASMA, V195, P156, DOI 10.1007/BF01279194; Versaw WK, 2002, PLANT CELL, V14, P1751, DOI 10.1105/tpc.002220; Vert G, 2002, PLANT CELL, V14, P1223, DOI 10.1105/tpc.001388; Vranova E, 2002, J EXP BOT, V53, P1227, DOI 10.1093/jexbot/53.372.1227; Wingert RA, 2005, NATURE, V436, P1035, DOI 10.1038/nature03887; Witte S, 2000, J BIOL CHEM, V275, P1902, DOI 10.1074/jbc.275.3.1902; Xing SP, 2005, DEVELOPMENT, V132, P1555, DOI 10.1242/dev.01725; Yanagida M, 2004, PLANT CELL PHYSIOL, V45, P129, DOI 10.1093/pcp/pch030	57	114	121	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26280	26288		10.1074/jbc.M601354200	http://dx.doi.org/10.1074/jbc.M601354200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829529	hybrid			2022-12-25	WOS:000240249500045
J	Nair, RR; Solway, J; Boyd, DD				Nair, Rajesh R.; Solway, Julian; Boyd, Douglas D.			Expression cloning identifies transgelin (SM22) as a novel repressor of 92-kDa type IV collagenase (MMP-9) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MESSENGER-RNA STABILITY; SQUAMOUS-CELL CARCINOMA; IN-SITU HYBRIDIZATION; HUMAN PROSTATE-CANCER; HUMAN COLON-CANCER; GENE-EXPRESSION; TRANSCRIPTION FACTOR; TISSUE INHIBITOR; EPITHELIAL-CELLS	The 92-kDa gelatinase (MMP-9) expression is prerequisite for tissue remodeling in physiology and cancer. However, there are few known regulators of MMP-9 expression. Using an expression cloning strategy, we identified transgelin (SM22), a 22-25-kDa actin-binding protein localized to the cell membrane and cytoplasm, as a novel regulator of MMP-9 expression. Overexpression of a SM22 cDNA in HT1080 cells decreased MMP-9 mRNA/protein levels and diminished in vitro invasion of the latter rescued with exogenous MMP-9. Conversely, small interfering RNA-mediated knockdown of SM22 elevated MMP-9 synthesis, and uterus from SM22-null mice showed strong MMP-9 immunoreactivity compared with wild type animals. The ability of SM22 to repress MMP-9 expression required an intact amino terminus calponin homology domain. MMP-9 expression is driven by ERK signaling and SM22 targeted this pathway as evidenced by (a) the transience in MAPK activation and (b) blunted stimulation of the MMP-9 promoter by a constitutively active MEK expression vector. Progressive deletion analysis located the SM22 responsive region of the MMP-9 promoter to the proximal 90-bp region harboring an AP-1 motif subsequently implicated by site-directed mutagenesis. Furthermore, nuclear extract from the SM22 transfectants showed diminished c-Fos binding to this motif and SM22 expression reduced the activity of an AP-1-driven reporter by 75%. Thus, SM22 adds to a short list of repressors of MMP-9 expression, achieving this by reducing AP-1-dependent trans-activation of the gene by way of compromised ERK activation. Diminished transgelin expression in several cancers may thus partly account for the elevated MMP-9 expression evident in these tumors.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Texas System; UTMD Anderson Cancer Center; University of Chicago	Boyd, DD (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Box 173,1515 Holcombe Blvd, Houston, TX 77030 USA.	dboyd@mdanderson.org	Solway, Julian/B-1116-2008	Solway, Julian/0000-0002-0898-8530	NATIONAL CANCER INSTITUTE [R01CA058311, R56CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845] Funding Source: NIH RePORTER; NCI NIH HHS [CA58311] Funding Source: Medline; NIDCR NIH HHS [R01DE10845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Camoretti-Mercado B, 1998, GENOMICS, V49, P452, DOI 10.1006/geno.1998.5267; Cho A, 2002, CIRC RES, V91, P845, DOI 10.1161/01.RES.0000040420.17366.2E; COLLIER IE, 1991, GENOMICS, V9, P429, DOI 10.1016/0888-7543(91)90408-7; Dechow TN, 2004, P NATL ACAD SCI USA, V101, P10602, DOI 10.1073/pnas.0404100101; Deryugina EI, 2005, CANCER RES, V65, P10959, DOI 10.1158/0008-5472.CAN-05-2228; Eberhardt W, 2002, J BIOL CHEM, V277, P33518, DOI 10.1074/jbc.M202008200; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af; Fu YP, 2000, J APPL PHYSIOL, V89, P1985, DOI 10.1152/jappl.2000.89.5.1985; Galis ZS, 2002, CIRC RES, V91, P852, DOI 10.1161/01.RES.0000041036.86977.14; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gimona M, 2002, FEBS LETT, V513, P98, DOI 10.1016/S0014-5793(01)03240-9; Goodman A, 2003, MOL BIOL CELL, V14, P2617, DOI 10.1091/mbc.E03-01-0028; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Handsley MM, 2005, INT J CANCER, V115, P849, DOI 10.1002/ijc.20945; Hanzawa M, 2000, CARCINOGENESIS, V21, P1079, DOI 10.1093/carcin/21.6.1079; Higashi N, 2004, GENES CELLS, V9, P233, DOI 10.1111/j.1356-9597.2004.00715.x; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Hua J, 1996, CANCER RES, V56, P5279; HURWITZ A, 1993, ENDOCRINOLOGY, V132, P2709, DOI 10.1210/en.132.6.2709; Iyer V, 2005, J CELL SCI, V118, P1185, DOI 10.1242/jcs.01708; Jiang Y, 2002, CANCER RES, V62, P1910; Jodele S, 2005, CANCER RES, V65, P3200, DOI 10.1158/0008-5472.CAN-04-3770; Jorda M, 2005, J CELL SCI, V118, P3371, DOI 10.1242/jcs.02465; Kobayashi T, 2004, J INVEST DERMATOL, V122, P278, DOI 10.1046/j.0022-202X.2004.22210.x; LaTulippe E, 2002, CANCER RES, V62, P4499; Lengyel E, 1997, ONCOGENE, V14, P2563, DOI 10.1038/sj.onc.1201098; Linn R, 1996, CYTOGENET CELL GENET, V72, P159, DOI 10.1159/000134175; Ma ZD, 2004, MOL CELL BIOL, V24, P5496, DOI 10.1128/MCB.24.12.5496-5509.2004; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Menice CB, 1997, J BIOL CHEM, V272, P25157, DOI 10.1074/jbc.272.40.25157; Mohan R, 2000, J BIOL CHEM, V275, P10405, DOI 10.1074/jbc.275.14.10405; Moses MA, 1998, CANCER RES, V58, P1395; Mukhopadhyay S, 2004, J BIOL CHEM, V279, P33139, DOI 10.1074/jbc.M405194200; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nielsen BS, 1996, INT J CANCER, V65, P57, DOI 10.1002/(SICI)1097-0215(19960103)65:1<57::AID-IJC10>3.0.CO;2-F; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; PUTNINS EE, 1995, J INVEST DERMATOL, V104, P989, DOI 10.1111/1523-1747.ep12606233; PYKE C, 1993, AM J PATHOL, V142, P359; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1993, ONCOGENE, V8, P395; Sato T, 2002, CANCER RES, V62, P1025; Schenker T, 1998, EXP CELL RES, V239, P161, DOI 10.1006/excr.1997.3896; Sehgal I, 1999, MOL BIOL CELL, V10, P407, DOI 10.1091/mbc.10.2.407; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; SHAPLAND C, 1993, J CELL BIOL, V121, P1065, DOI 10.1083/jcb.121.5.1065; Shields JM, 2002, J BIOL CHEM, V277, P9790, DOI 10.1074/jbc.M110086200; Simon C, 1998, CANCER RES, V58, P1135; SOINI Y, 1994, J HISTOCHEM CYTOCHEM, V42, P945, DOI 10.1177/42.7.8014478; Stuelten CH, 2005, J CELL SCI, V118, P2143, DOI 10.1242/jcs.02334; TESTA JE, 1992, CANCER RES, V52, P5597; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang H, 2004, J BIOL CHEM, V279, P22674, DOI 10.1074/jbc.M401257200; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Wood M, 1997, CLIN EXP METASTAS, V15, P246, DOI 10.1023/A:1018421431388; Yan CH, 2001, J BIOL CHEM, V276, P1164, DOI 10.1074/jbc.M008681200; Yan CH, 2004, FASEB J, V18, P540, DOI 10.1096/fj.03-0960fje; Yan CH, 2003, J BIOL CHEM, V278, P2309, DOI 10.1074/jbc.M210369200; Yao PM, 1996, J BIOL CHEM, V271, P15580, DOI 10.1074/jbc.271.26.15580; Yu Q, 2000, GENE DEV, V14, P163; Zhang JCL, 2001, MOL CELL BIOL, V21, P1336, DOI 10.1128/MCB.2001.21.4.1336-1344.2001; Zi XL, 2005, CANCER RES, V65, P9762, DOI 10.1158/0008-5472.CAN-05-0103; ZUCKER S, 1993, CANCER RES, V53, P140	70	98	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26424	26436		10.1074/jbc.M602703200	http://dx.doi.org/10.1074/jbc.M602703200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16835221	hybrid			2022-12-25	WOS:000240249500060
J	Yaar, M; Wu, C; Park, HY; Panova, I; Schutz, G; Gilchrest, BA				Yaar, Mina; Wu, Christina; Park, Hee-Young; Panova, Izabela; Schutz, Gunther; Gilchrest, Barbara A.			Bone morphogenetic protein-4, a novel modulator of melanogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MOUSE MELANOMA-CELLS; GROWTH-FACTOR; HUMAN MELANOCYTES; DNA-DAMAGE; TRANSCRIPTION FACTORS; ULTRAVIOLET-LIGHT; TYROSINASE GENE; HUMAN-SKIN; PROLIFERATION	Bone morphogenetic proteins (BMPs), members of the transforming growth factor-beta family, signal in many cells including neural precursors. Two receptors, types 1 and 2, coordinately mediate BMP signaling, and type 1 receptor has two forms: A and B. Using RT-PCR we found that neural crest-derived human melanocytes express BMP receptor-1A, -1B, and -2. Furthermore, melanocytes and the surrounding keratinocytes express BMP-4, suggesting both autocrine and paracrine effects of this molecule. Moreover, BMP-4 supplementation of cultured human melanocytes decreases melanin synthesis, tyrosinase mRNA, and protein. The mechanism of this BMP-4 effect on tyrosinase and ultimately on melanogenesis involves modest decreases of tyrosinase transcription rate and mRNA stability. Moreover, ultraviolet irradiation, the best recognized environmental stimulator of melanogenesis, down-regulated the mRNA of BMP receptor-1B in melanocytes. Our data provide evidence of a novel regulatory pathway for melanogenesis in human skin.	Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA	Boston University	Gilchrest, BA (corresponding author), Boston Univ, Sch Med, Dept Dermatol, J-508,609 Albany St, Boston, MA 02118 USA.	bgilchre@bu.edu		Park, Hee-Young/0000-0001-8981-6484				BECKER MM, 1984, NATURE, V309, P682, DOI 10.1038/309682a0; BHARDWAJ RS, 1994, ARCH DERMATOL RES, V287, P85, DOI 10.1007/BF00370724; Bilodeau ML, 2001, PIGM CELL RES, V14, P328, DOI 10.1034/j.1600-0749.2001.140504.x; Botchkarev VA, 2003, J INVEST DERMATOL, V120, P36, DOI 10.1046/j.1523-1747.2003.12002.x; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; ELLER MS, 1994, NATURE, V372, P413, DOI 10.1038/372413a0; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FRIEDMANN PS, 1987, J CELL PHYSIOL, V133, P88, DOI 10.1002/jcp.1041330111; Furuta Y, 1997, DEVELOPMENT, V124, P2203; Gilchrest BA, 1996, PHOTOCHEM PHOTOBIOL, V63, P1, DOI 10.1111/j.1751-1097.1996.tb02988.x; GILCHREST BA, 1979, J INVEST DERMATOL, V72, P219, DOI 10.1111/1523-1747.ep12530769; GILCHREST BA, 1985, IN VITRO CELL DEV B, V21, P114; Graham A, 1996, MOL CELL NEUROSCI, V8, P76, DOI 10.1006/mcne.1996.0046; Gross RE, 1996, NEURON, V17, P595, DOI 10.1016/S0896-6273(00)80193-2; HALABAN R, 1988, ANN NY ACAD SCI, V548, P180, DOI 10.1111/j.1749-6632.1988.tb18805.x; Halaban R, 2003, FITZPATRICKS DERMATO, V1, P127; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; HUGHES FJ, 1995, ENDOCRINOLOGY, V136, P2671, DOI 10.1210/en.136.6.2671; Imokawa G, 2004, PIGM CELL RES, V17, P96, DOI 10.1111/j.1600-0749.2003.00126.x; Imokawa G, 1997, PIGM CELL RES, V10, P218, DOI 10.1111/j.1600-0749.1997.tb00488.x; IMOKAWA G, 1995, J INVEST DERMATOL, V105, P32, DOI 10.1111/1523-1747.ep12312500; IMOKAWA G, 1992, J BIOL CHEM, V267, P24675; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; KLUPPEL M, 1991, P NATL ACAD SCI USA, V88, P3777, DOI 10.1073/pnas.88.9.3777; Krishnan V, 2001, ENDOCRINOLOGY, V142, P940, DOI 10.1210/en.142.2.940; Li H, 1998, ENDOCRINOLOGY, V139, P3855, DOI 10.1210/en.139.9.3855; Li WW, 1998, J NEUROSCI, V18, P8853; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Martinez-Esparza M, 2001, INT J BIOCHEM CELL B, V33, P971, DOI 10.1016/S1357-2725(01)00068-1; MartinezEsparza M, 1997, J BIOL CHEM, V272, P3967, DOI 10.1074/jbc.272.7.3967; Mehler MF, 2000, DEV NEUROSCI-BASEL, V22, P74, DOI 10.1159/000017429; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Mohan RR, 1998, INVEST OPHTH VIS SCI, V39, P2626; MORELLI JG, 1993, J INVEST DERMATOL, V100, pS191; NORDLUND JJ, 1986, J INVEST DERMATOL, V86, P433, DOI 10.1111/1523-1747.ep12285717; Panchision DM, 2001, GENE DEV, V15, P2094, DOI 10.1101/gad.894701; Park HY, 1999, J BIOL CHEM, V274, P16470, DOI 10.1074/jbc.274.23.16470; POMERANTZ SH, 1964, BIOCHEM BIOPH RES CO, V16, P188, DOI 10.1016/0006-291X(64)90359-6; Reinartz J, 1996, EXP CELL RES, V228, P334, DOI 10.1006/excr.1996.0333; RHEINWALD JG, 1983, HUMAN CARCINOGENESIS, P85; Sharov AA, 2005, P NATL ACAD SCI USA, V102, P93, DOI 10.1073/pnas.0408455102; STIERNER U, 1988, PHOTODERMATOLOGY, V5, P218; SWOPE VB, 1991, J INVEST DERMATOL, V96, P180, DOI 10.1111/1523-1747.ep12460991; SWOPE VB, 1994, J INVEST DERMATOL, V102, P749, DOI 10.1111/1523-1747.ep12376970; TORNALETTI S, 1995, J MOL BIOL, V249, P714, DOI 10.1006/jmbi.1995.0331; Verdier-Sevain S, 2004, FASEB J, V18, P1252, DOI 10.1096/fj.03-1088fje; WERNINGHAUS K, 1991, PHOTODERMATOL PHOTO, V8, P236; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YAAR M, 1994, J CLIN INVEST, V94, P1550, DOI 10.1172/JCI117496; YAAR M, 1993, EXP CELL RES, V206, P235, DOI 10.1006/excr.1993.1143; Yoshida K, 2004, ONCOGENE, V23, P6250, DOI 10.1038/sj.onc.1207829; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhao HC, 2000, CANCER RES, V60, P6276	56	30	32	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25307	25314		10.1074/jbc.M600580200	http://dx.doi.org/10.1074/jbc.M600580200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16837459	hybrid			2022-12-25	WOS:000240031300032
J	Wu, Q; Chen, X; Zhang, JQ; Loh, YH; Low, TY; Zhang, WW; Zhang, WS; Sze, SK; Lim, B; Ng, HH				Wu, Qiang; Chen, Xi; Zhang, Jinqiu; Loh, Yuin-Han; Low, Teck-Yew; Zhang, Weiwei; Zhang, Wensheng; Sze, Siu-Kwan; Lim, Bing; Ng, Huck-Hui			Sall4 interacts with nanog and co-occupies nanog genomic sites in embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL-OCULAR SYNDROME; OKIHIRO-SYNDROME; TRANSCRIPTIONAL REGULATION; PLURIPOTENCY; EXPRESSION; MUTATIONS; OCT4; SOX2; DIFFERENTIATION; CLONING	Embryonic stem (ES) cells are pluripotent cells with self-renewing property. Nanogis a homeobox transcription factor required to maintain ES cells in a non-differentiated state. Using affinity purification coupled to liquid chromatography-tandem mass spectrometry analysis, we identified Sall4 as a Nanog co-purified protein. Co-immunoprecipitation and glutathione S-transferase pulldown experiments confirmed the interaction between Nanog and Sall4. We showed that Nanog and Sall4 co-occupied Nanog and Sall4 enhancer regions in living ES cells. Knockdown of Nanog or Sall4 by RNA interference led to a reduction in Nanog and Sall4 enhancer activities, providing evidence that these factors are positively regulating these enhancers. Importantly, co-transfection of Sall4 with these ES cell-specific enhancers led to transactivation in heterologous somatic cells. Chromatin immunoprecipitation experiments also showed that Sall4 co-occupied many Nanog binding sites in ES cells. Our data implicate Sall4 as an important component of the transcription regulatory networks in ES cells by cooperating with Nanog. We suggest that Sall4 and Nanog form a regulatory circuit similar to that of Oct4 and Sox2. This study highlights the extensive regulatory loops connecting genes, which encode for key transcription factors in ES cells.	Genome Inst Singapore, Gene Regulat Lab, Singapore 138672, Singapore; Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Ng, HH (corresponding author), Genome Inst Singapore, Gene Regulat Lab, 60 Biopolis St,02-01,Genome Bldg, Singapore 138672, Singapore.	nghh@gis.a-star.edu.sg	Low, Teck Yew/J-4403-2014; Chen, Xi/C-6889-2012; Ng, Huck Hui/A-1135-2009; Loh, Yuin-Han/E-1096-2014; Low, Teck Yew/Q-5946-2019; Sze, Siu Kwan/AAO-3342-2020; Sze, Siu_kwan Newman/A-2199-2011	Low, Teck Yew/0000-0001-7878-7534; Loh, Yuin-Han/0000-0002-4715-6454; Low, Teck Yew/0000-0001-7878-7534; Sze, Siu Kwan/0000-0002-5652-1687; Sze, Siu_kwan Newman/0000-0002-5652-1687; Wu, Qiang/0000-0003-2049-1639; NG, HUCK HUI/0000-0001-6352-8417; Chen, Xi/0000-0002-7995-6202				Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chew JL, 2005, MOL CELL BIOL, V25, P6031, DOI 10.1128/MCB.25.14.6031-6046.2005; Kohlhase J, 2002, HUM MOL GENET, V11, P2979, DOI 10.1093/hmg/11.23.2979; Kohlhase J, 2005, HUM MUTAT, V26, P176, DOI 10.1002/humu.20215; Kohlhase J, 2002, CYTOGENET GENOME RES, V98, P274, DOI 10.1159/000071048; Kohlhase J, 2003, J MED GENET, V40, P473, DOI 10.1136/jmg.40.7.473; Koshiba-Takeuchi K, 2006, NAT GENET, V38, P175, DOI 10.1038/ng1707; Kuroda T, 2005, MOL CELL BIOL, V25, P2475, DOI 10.1128/MCB.25.6.2475-2485.2005; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Loebel DAF, 2003, DEV BIOL, V264, P1, DOI 10.1016/S0012-1606(03)00390-7; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Pan GJ, 2005, J BIOL CHEM, V280, P1401, DOI 10.1074/jbc.M407847200; Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200; Sakaki-Yumoto M, 2006, DEVELOPMENT, V133, P3005, DOI 10.1242/dev.02457; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; Yoshikawa T, 2006, GENE EXPR PATTERNS, V6, P213, DOI 10.1016/j.modgep.2005.06.003	21	224	246	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24090	24094		10.1074/jbc.C600122200	http://dx.doi.org/10.1074/jbc.C600122200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16840789	hybrid			2022-12-25	WOS:000239847800003
J	Bignone, PA; Lee, KY; Liu, Y; Emilion, G; Finch, J; Soosay, AER; Charnock, FML; Beck, S; Dunham, I; Mungall, AJ; Ganesan, TS				Bignone, P. A.; Lee, K. Y.; Liu, Y.; Emilion, G.; Finch, J.; Soosay, A. E. R.; Charnock, F. M. L.; Beck, S.; Dunham, I.; Mungall, A. J.; Ganesan, T. S.			RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer	ONCOGENE			English	Article						ovarian cancer; RPS6KA2; chromosome 6q27; tumour suppressor gene	SIGNAL-REGULATED KINASE; COFFIN-LOWRY SYNDROME; RIBOSOMAL S6 KINASE; CELL-CYCLE ARREST; MONOALLELIC EXPRESSION; NUCLEAR TRANSLOCATION; HOMOZYGOUS DELETIONS; CHROMOSOME 6Q27; ALLELE LOSS; MAP	We had previously defined by allele loss studies a minimal region at 6q27 (between D6S264 and D6S297) to contain a putative tumour suppressor gene. The p90 ribosomal S6 kinase-3 gene (p90 Rsk-3, RPS6KA2) maps in this interval. It is a serine-threonine kinase that signals downstream of the mitogen-activated protein kinase pathway. It is expressed in normal ovarian epithelium, whereas reduced or absent in tumours or cell lines. We show that RPS6KA2 is monoallelically expressed in the ovary suggesting that loss of a single expressed allele is sufficient to cause complete loss of expression in cancer cells. Further, we have identified two new isoforms of RPS6KA2 with an alternative start codon. Homozygous deletions were identified within the RPS6KA2 gene in two cell lines. Re-expression of RPS6KA2 in ovarian cancer cell lines suppressed colony formation. In UCI101 cells, the expression of RPS6KA2 reduced proliferation, caused G1 arrest, increased apoptosis, reduced levels of phosphorylated extracellular signal-regulated kinase and altered other cell cycle proteins. In contrast, small interfering RNA against RPS6KA2 showed the opposite effect in 41M cells. The above results suggest that RPS6KA2 is a putative tumour suppressor gene to explain allele loss at 6q27.	John Radcliffe Hosp, Mol Oncol Labs, Ovarian Canc Grp, Weatherall Inst Mol Med, Oxford OX3 9DS, England; Sanger Ctr, Cambridge, England	University of Oxford; Wellcome Trust Sanger Institute	Ganesan, TS (corresponding author), John Radcliffe Hosp, Mol Oncol Labs, Ovarian Canc Grp, Weatherall Inst Mol Med, Oxford OX3 9DS, England.	ganesan@cancer.org.uk	Mungall, Andrew J./U-7067-2018; GANESAN, Trivadi Sundaram/AAU-1499-2020; Soosay, Ashley/D-8060-2012; Bignone, Paola/K-3797-2012	Mungall, Andrew J./0000-0002-0905-2742; GANESAN, Trivadi Sundaram/0000-0002-4671-8099; Soosay, Ashley/0000-0002-7443-4472; Dunham, Ian/0000-0003-2525-5598; Bignone, Paola/0000-0003-2296-7039	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abdollahi A, 2003, J BIOL CHEM, V278, P6041, DOI 10.1074/jbc.M210361200; Acquati F, 2001, ONCOGENE, V20, P980, DOI 10.1038/sj.onc.1204178; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; Bothos J, 2005, CANCER RES, V65, P6568, DOI 10.1158/0008-5472.CAN-05-0862; Bruning JC, 2000, P NATL ACAD SCI USA, V97, P2462, DOI 10.1073/pnas.97.6.2462; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; ChenevixTrench G, 1997, GENE CHROMOSOME CANC, V18, P75, DOI 10.1002/(SICI)1098-2264(199702)18:2<75::AID-GCC1>3.0.CO;2-Y; Conover CA, 1998, EXP CELL RES, V238, P439, DOI 10.1006/excr.1997.3861; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; Cooke IE, 1996, MAMM GENOME, V7, P157, DOI 10.1007/s003359900040; Cox C, 2005, P NATL ACAD SCI USA, V102, P4542, DOI 10.1073/pnas.0408593102; Douville E, 1997, ONCOGENE, V15, P373, DOI 10.1038/sj.onc.1201214; Dufresne SD, 2001, MOL CELL BIOL, V21, P81, DOI 10.1128/MCB.21.1.81-87.2001; Dummler BA, 2005, J BIOL CHEM, V280, P13304, DOI 10.1074/jbc.M408194200; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; FUCHTNER C, 1993, GYNECOL ONCOL, V48, P203, DOI 10.1006/gyno.1993.1034; Goldmit M, 2004, IMMUNOL REV, V200, P197, DOI 10.1111/j.0105-2896.2004.00158.x; Horgan AM, 2003, EXP CELL RES, V285, P208, DOI 10.1016/S0014-4827(03)00037-5; Jirtle RL, 1999, EXP CELL RES, V248, P18, DOI 10.1006/excr.1999.4453; KALSCHEUER VM, 1993, NAT GENET, V5, P74, DOI 10.1038/ng0993-74; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAL S, 1994, CELL GROWTH DIFFER, V5, P1173; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Lin BH, 2001, J FOOD PROD MARK, V6, P63, DOI 10.1300/J038v06n04_06; Liu Y, 2002, ONCOGENE, V21, P387, DOI 10.1038/sj.onc.1205067; Liu Y, 2002, BMC GENET, V3, DOI 10.1186/1471-2156-3-20; Liu Y, 2002, REPRODUCTION, V123, P341, DOI 10.1530/reprod/123.3.341; Lo HS, 2003, GENOME RES, V13, P1855, DOI 10.1101/gr.1006603; Luedi PP, 2005, GENOME RES, V15, P875, DOI 10.1101/gr.3303505; Modesitt SC, 2001, CLIN CANCER RES, V7, P1765; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; Morison IM, 2005, TRENDS GENET, V21, P457, DOI 10.1016/j.tig.2005.06.008; Myers AP, 2004, MOL CELL BIOL, V24, P4255, DOI 10.1128/MCB.24.10.4255-4266.2004; Nikaido L, 2003, GENOME RES, V13, P1402, DOI 10.1101/gr.1055303; Ohlsson R, 1998, TRENDS GENET, V14, P435, DOI 10.1016/S0168-9525(98)01583-2; Ohtani Naoko, 2004, J Med Invest, V51, P146, DOI 10.2152/jmi.51.146; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pineau P, 2003, INT J CANCER, V106, P216, DOI 10.1002/ijc.11214; Reik W, 2005, NAT REV GENET, V6, P403, DOI 10.1038/nrg1602; Rougeulle C, 1997, NAT GENET, V17, P14, DOI 10.1038/ng0997-14; SAITO S, 1992, CANCER RES, V52, P5815; Sano Y, 2001, GENOME RES, V11, P1833, DOI 10.1101/gr.194301; Schinelli S, 2001, J NEUROSCI, V21, P8842, DOI 10.1523/JNEUROSCI.21-22-08842.2001; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Suzuki Y, 2004, NUCLEIC ACIDS RES, V32, pD78, DOI 10.1093/nar/gkh076; Teng DHF, 1997, CANCER RES, V57, P4177; Tibiletti MB, 2000, CLIN CANCER RES, V6, P1422; Tibiletti MG, 1996, CANCER RES, V56, P4493; Tibiletti MG, 1998, ONCOGENE, V16, P1639, DOI 10.1038/sj.onc.1201654; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Trubia M, 1997, GENOMICS, V42, P342, DOI 10.1006/geno.1997.4679; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Yntema HG, 1999, GENOMICS, V62, P332, DOI 10.1006/geno.1999.6004; Yoo LI, 2002, NAT REV CANCER, V2, P529, DOI 10.1038/nrc843; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214; Zeniou M, 2002, HUM MOL GENET, V11, P2929, DOI 10.1093/hmg/11.23.2929; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	69	77	82	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					683	700		10.1038/sj.onc.1209827	http://dx.doi.org/10.1038/sj.onc.1209827			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16878154				2022-12-25	WOS:000243902200006
J	Letessier, A; Garrido-Urbani, S; Ginestier, C; Fournier, G; Esterni, B; Monville, F; Adelaide, J; Geneix, J; Xerri, L; Dubreuil, P; Viens, P; Charafe-Jauffret, E; Jacquemier, J; Birnbaum, D; Lopez, M; Chaffanet, M				Letessier, A.; Garrido-Urbani, S.; Ginestier, C.; Fournier, G.; Esterni, B.; Monville, F.; Adelaide, J.; Geneix, J.; Xerri, L.; Dubreuil, P.; Viens, P.; Charafe-Jauffret, E.; Jacquemier, J.; Birnbaum, D.; Lopez, M.; Chaffanet, M.			Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer	ONCOGENE			English	Article						Afadin; AF-6 gene; breast cancer; FRA6E; Parkin; PARK2 gene; tissue microarrays	RECESSIVE JUVENILE PARKINSONISM; ACUTE LYMPHOBLASTIC-LEUKEMIA; TUMOR-SUPPRESSOR GENE; COMMON FRAGILE SITES; CELL-CELL JUNCTIONS; LONG ARM; HEPATOCELLULAR-CARCINOMA; TYROSINE KINASE; BINDING PROTEIN; LUNG-CANCER	Common fragile sites (CFSs) are regions of chromosomal break that may play a role in oncogenesis. The most frequent alteration occurs at FRA3B, within the FHIT gene, at chromosomal region 3p14. We studied a series of breast carcinomas for break of a CFS at 6q26, FRA6E, and its associated gene PARK2, using fluorescence in situ hybridization on tissue microarrays (TMA). We found break of PARK2 in 6% of cases. We studied the PARK2-encoded protein Parkin by using immunohistochemistry on the same TMA. Loss of Parkin was found in 13% of samples but was not correlated with PARK2 break. PARK2 break but not Parkin expression was correlated with prognosis. Alteration of PARK2/FRA6E may cause haplo-insufficiency of one or several telomeric potential tumor suppressor genes (TSG). The AF-6/MLLT4 gene, telomeric of PARK2, encodes the Afadin scaffold protein, which is essential for epithelial integrity. Loss of Afadin was found in 14.5% of cases, and 36% of these cases showed PARK2 break. Loss of Afadin had prognostic impact, suggesting that AF-6 may be a TSG. Loss of Afadin was correlated with loss of FHIT expression, suggesting fragility of FRA6E and FRA3B in a certain proportion of breast tumors.	Ctr Rech Cancerol Marseille, UMR599, Dept Mol Oncol, INSERM, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Biostat, F-13009 Marseille, France; INSERM, UMR599, Dept Med Oncol, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept BioPathol, F-13009 Marseille, France; Univ Mediterranee, Fac Med, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite	Birnbaum, D (corresponding author), Ctr Rech Cancerol Marseille, UMR599, Dept Mol Oncol, INSERM, 27 Bd Lei Roure, F-13009 Marseille, France.	birnbaum@marseille.inserm.fr	Letessier, Anne/M-3431-2017; CHAFFANET, Max/AAU-5743-2020; ADELAIDE, José JA/O-4390-2017; dubreuil, patrice/F-5346-2011; Ginestier, Christophe/M-8828-2017; Dubreuil, Patrice/V-4816-2019; Charafe-Jauffret, emmanuelle/P-6009-2017	Letessier, Anne/0000-0002-1894-4072; ADELAIDE, José JA/0000-0003-4364-9857; dubreuil, patrice/0000-0003-1155-1150; Ginestier, Christophe/0000-0002-7477-3837; Dubreuil, Patrice/0000-0003-1155-1150; CHAFFANET, Max/0000-0002-2344-1488; Charafe-Jauffret, emmanuelle/0000-0002-0286-1299				Agirre X, 2006, INT J CANCER, V118, P1945, DOI 10.1002/ijc.21584; Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Bobinnec Y, 1998, CELL MOTIL CYTOSKEL, V39, P223, DOI 10.1002/(SICI)1097-0169(1998)39:3<223::AID-CM5>3.3.CO;2-3; Bobinnec Y, 1998, J CELL BIOL, V143, P1575, DOI 10.1083/jcb.143.6.1575; Bonnet C, 2001, J BIOL CHEM, V276, P12839, DOI 10.1074/jbc.M011380200; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100; Charafe-Jauffret E, 2005, INT J ONCOL, V27, P1307; Chin SF, 2003, J CLIN PATHOL-MOL PA, V56, P275, DOI 10.1136/mp.56.5.275; Delaval B, 2005, CANCER RES, V65, P7231, DOI 10.1158/0008-5472.CAN-04-4167; Denison SR, 2003, GENE CHROMOSOME CANC, V38, P40, DOI 10.1002/gcc.10236; Denison SR, 2003, ONCOGENE, V22, P8370, DOI 10.1038/sj.onc.1207072; Dhillon VS, 2003, TERATOGEN CARCIN MUT, P35, DOI 10.1002/tcm.10068; Fabbri M, 2005, P NATL ACAD SCI USA, V102, P15611, DOI 10.1073/pnas.0505485102; Ginestier C, 2003, INT J CANCER, V107, P854, DOI 10.1002/ijc.11462; Ginestier C, 2002, AM J PATHOL, V161, P1223, DOI 10.1016/S0002-9440(10)64399-4; Guasch G, 2004, BLOOD, V103, P309, DOI 10.1182/blood-2003-05-1690; Guler G, 2005, PATHOL INT, V55, P471, DOI 10.1111/j.1440-1827.2005.01855.x; HAYASHI Y, 1990, BLOOD, V76, P1626; Huang Tie-Jun, 2004, Hepatobiliary Pancreat Dis Int, V3, P62; Huebner K, 2003, BRIT J CANCER, V88, P1501, DOI 10.1038/sj.bjc.6600937; Huebner K, 1998, RECENT RES CANCER, V154, P200; Huebner K, 2001, NAT REV CANCER, V1, P214, DOI 10.1038/35106058; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Ishii H, 2003, FASEB J, V17, P1768, DOI 10.1096/fj.03-0241fje; Johnson SAS, 2003, CELL CYCLE, V2, P442, DOI 10.4161/cc.2.5.493; Johnson SAS, 2003, MOL CELL BIOL, V23, P3043, DOI 10.1128/MCB.23.9.3043-3051.2003; Kerangueven F, 1997, CANCER RES, V57, P5469; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Marin I, 2004, PHYSIOL GENOMICS, V17, P253, DOI 10.1152/physiolgenomics.00226.2003; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P26, DOI 10.1002/gcc.2870100105; Miki H, 2005, TRENDS CELL BIOL, V15, P467, DOI 10.1016/j.tcb.2005.07.006; MILLIKIN D, 1991, CANCER RES, V51, P5449; NEGRINI M, 1994, CANCER RES, V54, P1331; Noviello C, 1996, CLIN CANCER RES, V2, P1601; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Park SW, 2004, BRIT J CANCER, V91, P753, DOI 10.1038/sj.bjc.6602023; Picchio MC, 2004, CLIN CANCER RES, V10, P2720, DOI 10.1158/1078-0432.CCR-03-0086; Popescu NC, 2003, CANCER LETT, V192, P1, DOI 10.1016/S0304-3835(02)00596-7; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; PRASAD R, 1993, CANCER RES, V53, P5624; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Rodriguez C, 2000, GENE CHROMOSOME CANC, V27, P76, DOI 10.1002/(SICI)1098-2264(200001)27:1<76::AID-GCC10>3.0.CO;2-E; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; SAITO S, 1992, CANCER RES, V52, P5815; Sato T, 2006, J BIOL CHEM, V281, P5288, DOI 10.1074/jbc.M510070200; Seki N, 2001, INT J ONCOL, V19, P305; Smith DI, 1998, INT J ONCOL, V12, P187; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; Taki T, 1996, ONCOGENE, V13, P2121; Teixeira MR, 2002, GENE CHROMOSOME CANC, V33, P1, DOI 10.1002/gcc.1206; Tibiletti MG, 1996, CANCER RES, V56, P4493; van der Burg M, 2004, LEUKEMIA, V18, P895, DOI 10.1038/sj.leu.2403340; Wang F, 2004, GENE CHROMOSOME CANC, V40, P85, DOI 10.1002/gcc.20020; Whitcomb BP, 2003, CLIN CANCER RES, V9, P2277; Zhadanov AB, 1999, CURR BIOL, V9, P880, DOI 10.1016/S0960-9822(99)80392-3	61	64	65	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					298	307		10.1038/sj.onc.1209772	http://dx.doi.org/10.1038/sj.onc.1209772			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819513				2022-12-25	WOS:000243398300014
J	Vogler, M; Durr, K; Jovanovic, M; Debatin, KM; Fulda, S				Vogler, M.; Duerr, K.; Jovanovic, M.; Debatin, K-M; Fulda, S.			Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells	ONCOGENE			English	Article						apoptosis; TRAIL; pancreatic cancer; XIAP; resistance	X-LINKED INHIBITOR; DRUG-INDUCED APOPTOSIS; DOWN-REGULATION; CANCER-CELLS; EXPRESSION; PROTEINS; DEATH; BCL-2; REGRESSION; RESISTANT	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a promising candidate for cancer therapy because of its relative tumor selectivity. However, many cancers including pancreatic cancer remain resistant towards TRAIL. To develop TRAIL for cancer therapy of pancreatic carcinoma, it will therefore be pivotal to elucidate the molecular mechanisms of TRAIL resistance. Here, we identify X-linked inhibitor of apoptosis (XIAP) as a regulator of TRAIL sensitivity in pancreatic carcinoma cells. Full activation of effector caspases, loss of mitochondrial membrane potential and cytochrome c release following TRAIL treatment were markedly impaired in pancreatic carcinoma cell lines, which poorly responded to TRAIL (PaTuII, PancTu1, ASPC1, DanG), compared to TRAIL-sensitive Colo357 pancreatic carcinoma cells. Stable downregulation of XIAP by RNA interference significantly reduced survival and enhanced TRAIL-induced apoptosis in pancreatic carcinoma cells. Also, downregulation of XIAP significantly increased CD95-induced cell death. Importantly, knockdown of XIAP strongly inhibited clonogenicity of pancreatic cancer cells treated with TRAIL indicating that XIAP promotes clonogenic survival of pancreatic carcinoma cells. Thus, our findings for the first time indicate that targeting XIAP represents a promising strategy to enhance the antitumor activity of TRAIL in pancreatic cancer, which has important clinical implications.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany	Ulm University	Fulda, S (corresponding author), Univ Ulm, Childrens Hosp, Eythstr 24, D-89075 Ulm, Germany.	simone.fulda@uniklinik-ulm.de	Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014; Duerr, Katharina/A-6975-2015	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417; Vogler, Meike/0000-0003-2650-586X; Duerr, Katharina/0000-0002-3245-4088				Amantana A, 2004, MOL CANCER THER, V3, P699; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Burstein E, 2004, EMBO J, V23, P244, DOI 10.1038/sj.emboj.7600031; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Fulda S, 2004, CURR CANCER DRUG TAR, V4, P569, DOI 10.2174/1568009043332763; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2004, VITAM HORM, V67, P275; Gerhard MC, 2002, BRIT J CANCER, V86, P893, DOI 10.1038/sj.bjc.6600171; Hao YY, 2004, NAT CELL BIOL, V6, P849, DOI 10.1038/ncb1159; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Hu YP, 2003, CLIN CANCER RES, V9, P2826; Ibrahim SM, 2001, PANCREAS, V23, P72, DOI 10.1097/00006676-200107000-00011; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lima RT, 2004, CANCER GENE THER, V11, P309, DOI 10.1038/sj.cgt.7700706; McManus DC, 2004, ONCOGENE, V23, P8105, DOI 10.1038/sj.onc.1207967; Mohr A, 2004, CELL DEATH DIFFER, V11, P1153, DOI 10.1038/sj.cdd.4401480; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sasaki H, 2000, CANCER RES, V60, P5659; Satoh K, 2001, PANCREAS, V23, P251, DOI 10.1097/00006676-200110000-00005; Schneider G, 2005, GASTROENTEROLOGY, V128, P1606, DOI 10.1053/j.gastro.2005.04.001; Tomita Y, 2003, INT J CANCER, V104, P400, DOI 10.1002/ijc.10956; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Trauzold A, 2001, ONCOGENE, V20, P4258, DOI 10.1038/sj.onc.1204559; Trauzold A, 2003, BRIT J CANCER, V89, P1714, DOI 10.1038/sj.bjc.6601330; Vischioni B, 2006, HUM PATHOL, V37, P78, DOI 10.1016/j.humpath.2005.09.022; Westphal Sabine, 2003, Mol Cancer, V2, P6, DOI 10.1186/1476-4598-2-6; Wolff RA, 2000, INVEST NEW DRUG, V18, P43, DOI 10.1023/A:1006383831045; Yang L, 2003, CANCER RES, V63, P6815	38	95	97	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					248	257		10.1038/sj.onc.1209776	http://dx.doi.org/10.1038/sj.onc.1209776			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16832350				2022-12-25	WOS:000243398300008
J	Dikshit, P; Chatterjee, M; Goswami, A; Mishra, A; Jana, NR				Dikshit, Priyanka; Chatterjee, Mou; Goswami, Anand; Mishra, Amit; Jana, Nihar Ranjan			Aspirin induces apoptosis through the inhibition of proteasome function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NF-KAPPA-B; COLON ADENOCARCINOMA CELLS; CYTOCHROME-C RELEASE; CANCER-CELLS; OXIDATIVE STRESS; SODIUM-SALICYLATE; MEDIATED APOPTOSIS; ANTICANCER AGENTS; MULTIPLE-MYELOMA	Aspirin and other nonsteroidal anti-inflammatory drugs inhibit cell proliferation and induce apoptosis in various cancer cell lines, which is considered to be an important mechanism for their anti-tumor activity and prevention of carcinogenesis. However, the molecular mechanisms through which these compounds induce apoptosis are not well understood. Here we have found that aspirin treatment of the mouse Neuro 2a cells impaired the proteasome function and caused severe mitochondrial abnormalities. Treatment with aspirin lead to a dose- and time-dependent decrease in proteasome activity and an increase in the accumulation of ubiquitylated proteins in the cells, which correlated with its effect on cell death. Aspirin exposure also resulted in an increase in the half-life of pd1EGFP, a model substrate of proteasome, as well as various intracellular substrates like Bax, I kappa B-alpha, p53, and p27(kip1). Aspirin-induced proteasomal malfunction might be responsible, at least in part, for the down-regulation of NF-kappa B activity and neurite outgrowth. Finally, we have shown that aspirin treatment caused changes in the mitochondrial membrane potential, release of cytochrome c from mitochondria, and activation of caspase-9 and -3, which could be because of the proteasomal dysfunction.	Natl Brain Res Ctr, Mol & Cellular Neurosci Lab, Manesar 122050, Gurgaon, India	Department of Biotechnology (DBT) India; National Brain Research Centre (NBRC)	Jana, NR (corresponding author), Natl Brain Res Ctr, Mol & Cellular Neurosci Lab, Manesar 122050, Gurgaon, India.	nihar@nbrc.ac.in		Jana, Nihar/0000-0002-6549-4211; Mishra, Amit/0000-0001-9401-4400				Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; Bellosillo B, 1998, BLOOD, V92, P1406, DOI 10.1182/blood.V92.4.1406.416k17_1406_1414; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Ding QX, 2001, J NEUROCHEM, V77, P1010, DOI 10.1046/j.1471-4159.2001.00302.x; Drexler HCA, 2000, FASEB J, V14, P65, DOI 10.1096/fasebj.14.1.65; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Gao JC, 2004, CANCER SCI, V95, P901, DOI 10.1111/j.1349-7006.2004.tb02200.x; Gao JJ, 2005, P NATL ACAD SCI USA, V102, P17207, DOI 10.1073/pnas.0506893102; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goswami A, 2006, BIOCHEM BIOPH RES CO, V342, P184, DOI 10.1016/j.bbrc.2006.01.136; GREENBERG ER, 1993, JNCI-J NATL CANCER I, V85, P912, DOI 10.1093/jnci/85.11.912; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Gu Q, 2005, CARCINOGENESIS, V26, P541, DOI 10.1093/carcin/bgh345; Gupta RA, 1998, GASTROENTEROLOGY, V114, P1095, DOI 10.1016/S0016-5085(98)70330-0; Ho CC, 2003, EUR J CLIN INVEST, V33, P875, DOI 10.1046/j.1365-2362.2003.01240.x; Huang YC, 2002, MOL PHARMACOL, V62, P1515, DOI 10.1124/mol.62.6.1515; Insel PA, 1996, PHARMACOL BASIS THER, P617; Jana NR, 2004, J BIOL CHEM, V279, P11680, DOI 10.1074/jbc.M310369200; Jana NR, 2001, HUM MOL GENET, V10, P1049, DOI 10.1093/hmg/10.10.1049; Kim KM, 2005, J BIOL CHEM, V280, P41047, DOI 10.1074/jbc.M503713200; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Marra DE, 2000, CIRCULATION, V102, P2124, DOI 10.1161/01.CIR.102.17.2124; Menendez-Benito V, 2005, HUM MOL GENET, V14, P2787, DOI 10.1093/hmg/ddi312; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Mitsiades N, 2002, BLOOD, V99, P4079, DOI 10.1182/blood.V99.11.4079; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; Piazza GA, 1997, CANCER RES, V57, P2452; Pique M, 2000, FEBS LETT, V480, P193, DOI 10.1016/S0014-5793(00)01922-0; Rao CV, 2004, CURR CANCER DRUG TAR, V4, P29, DOI 10.2174/1568009043481632; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; Shiff SJ, 1996, EXP CELL RES, V222, P179, DOI 10.1006/excr.1996.0023; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Stark LA, 2001, FASEB J, V15, P1273, DOI 10.1096/fj.00-0529fje; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Tsutsumi S, 2004, CELL DEATH DIFFER, V11, P1009, DOI 10.1038/sj.cdd.4401436; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhou XM, 2001, CARCINOGENESIS, V22, P1393, DOI 10.1093/carcin/22.9.1393; Zimmermann KC, 2000, NEOPLASIA, V2, P505, DOI 10.1038/sj.neo.7900120	46	101	107	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29228	29235		10.1074/jbc.M602629200	http://dx.doi.org/10.1074/jbc.M602629200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16880202	hybrid			2022-12-25	WOS:000240680500078
J	Rosenfeld, Y; Barra, D; Simmaco, M; Shai, Y; Mangoni, ML				Rosenfeld, Yosef; Barra, Donatella; Simmaco, Maurizio; Shai, Yechiel; Mangoni, Maria Luisa			A synergism between temporins toward gram-negative bacteria overcomes resistance imposed by the lipopolysaccharide protective layer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FROG RANA-TEMPORARIA; ANTIMICROBIAL PEPTIDES; ESCHERICHIA-COLI; SKIN SECRETIONS; MAMMALIAN DEFENSINS; BOMBINA-VARIEGATA; ACTIVE PEPTIDES; LIPID-BILAYERS; CECROPIN LOCUS; HOST-DEFENSE	Temporins are short and homologous antimicrobial peptides (AMPs) isolated from the frog skin of Rana genus. To date, very little is known about the biological significance of the presence of closely related AMPs in single living organisms. Here we addressed this question using temporins A, B, and L isolated from Rana temporaria. We found that temporins A and B are only weakly active toward Gram-negative bacteria. However, a marked synergism occurs when each is mixed with temporin L. To shed light on the underlying mechanisms involved in these activities, we used various experimental strategies to investigate: (i) the effect of the peptides' interaction on both the viability and membrane permeability of intact bacteria and spheroplasts; (ii) their interaction with lipopolysaccharides (LPS) and the effect of LPS on the oligomeric state of temporins, alone or combining one with another; (iii) their structure in solution and when bound to LPS, by using circular dichroism and ATR-FTIR spectroscopies. Our data reveal that temporin L synergizes with A and B by preventing their oligomerization in LPS. This should promote their translocation across the outer membrane into the cytoplasmic membrane. To the best of our knowledge, this is the first study that explains how a combination of native AMPs from the same species can overcome bacterial resistance imposed by the LPS leaflet.	Univ Roma La Sapienza, Fac Med & Chirurg 2, Unita Diagnost Mol Avanzata, Azienda Osped S Andrea, I-00189 Rome, Italy; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Univ Roma La Sapienza, Ist Pasteur, Fdn Cenci Bolognetti, Dipartimento Sci Biochim, I-00189 Rome, Italy	Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; Weizmann Institute of Science; Fondazione Cenci Bolognetti; Sapienza University Rome	Mangoni, ML (corresponding author), Univ Roma La Sapienza, Fac Med & Chirurg 2, Unita Diagnost Mol Avanzata, Azienda Osped S Andrea, Via Grottarossa,1035, I-00189 Rome, Italy.	marialuisa.mangoni@uniroma1.it	Simmaco, Maurizio/AAC-2870-2019; Barra, Donatella/D-1236-2011	Simmaco, Maurizio/0000-0003-4164-1472; Mangoni, Maria Luisa/0000-0002-5991-5868				AGGER WA, 1985, J CLIN MICROBIOL, V21, P909, DOI 10.1128/JCM.21.6.909-913.1985; Beisswenger C, 2005, CURR PROTEIN PEPT SC, V6, P255, DOI 10.2174/1389203054065428; Bera A, 2003, MOL BIOCHEM PARASIT, V127, P23, DOI 10.1016/S0166-6851(02)00300-6; Boman HG, 2000, IMMUNOL REV, V173, P5, DOI 10.1034/j.1600-065X.2000.917301.x; Brown KL, 2006, CURR OPIN IMMUNOL, V18, P24, DOI 10.1016/j.coi.2005.11.004; Conlon JM, 2004, BBA-PROTEINS PROTEOM, V1696, P1, DOI 10.1016/j.bbapap.2003.09.004; Cunningham AA, 1996, PHILOS T ROY SOC B, V351, P1539, DOI 10.1098/rstb.1996.0140; De Smet K, 2005, BIOTECHNOL LETT, V27, P1337, DOI 10.1007/s10529-005-0936-5; del Castillo FJ, 2001, J BACTERIOL, V183, P2137, DOI 10.1128/JB.183.6.2137-2140.2001; DEODHAR LP, 1991, J CLIN MICROBIOL, V29, P853, DOI 10.1128/JCM.29.5.853-856.1991; FREY S, 1991, BIOPHYS J, V60, P922, DOI 10.1016/S0006-3495(91)82126-9; Ganz T, 2005, COMB CHEM HIGH T SCR, V8, P209, DOI 10.2174/1386207053764594; Ghosh JK, 1997, J BIOL CHEM, V272, P31609, DOI 10.1074/jbc.272.50.31609; Giacometti A, 2006, ANTIMICROB AGENTS CH, V50, P2478, DOI 10.1128/AAC.01553-05; GIBSON BW, 1991, J BIOL CHEM, V266, P23103; Goraya J, 2000, EUR J BIOCHEM, V267, P894, DOI 10.1046/j.1432-1327.2000.01074.x; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GUDMUNDSSON GH, 1991, J BIOL CHEM, V266, P11510; Gutsmann T, 2000, J MEMBRANE BIOL, V176, P223, DOI 10.1007/s002320001092; Hancock REW, 2002, FEMS MICROBIOL LETT, V206, P143, DOI 10.1016/S0378-1097(01)00480-3; Hara T, 2001, BIOCHEMISTRY-US, V40, P12395, DOI 10.1021/bi011413v; Hatha M, 2005, INT J FOOD MICROBIOL, V98, P131, DOI 10.1016/j.ijfoodmicro.2004.05.017; Hong J, 1999, BIOCHEMISTRY-US, V38, P16963, DOI 10.1021/bi991850y; Hong RW, 2003, ANTIMICROB AGENTS CH, V47, P1, DOI 10.1128/AAC.47.1.1-6.2003; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; Kliger Y, 2000, J MOL BIOL, V301, P905, DOI 10.1006/jmbi.2000.4004; Kragol G, 2001, BIOCHEMISTRY-US, V40, P3016, DOI 10.1021/bi002656a; KYLSTEN P, 1990, EMBO J, V9, P217, DOI 10.1002/j.1460-2075.1990.tb08098.x; Lauth X, 2005, J BIOL CHEM, V280, P9272, DOI 10.1074/jbc.M411154200; Lehrer RI, 2004, NAT REV MICROBIOL, V2, P727, DOI 10.1038/nrmicro976; Mangoni ML, 2006, CELL MOL LIFE SCI, V63, P1060, DOI 10.1007/s00018-005-5536-y; Mangoni ML, 2005, J BIOL CHEM, V280, P984, DOI 10.1074/jbc.M410795200; Mangoni ML, 2000, PEPTIDES, V21, P1673, DOI 10.1016/S0196-9781(00)00316-8; Mangoni ML, 2004, BIOCHEM J, V380, P859, DOI 10.1042/BJ20031975; Mangoni ML, 2000, EUR J BIOCHEM, V267, P1447, DOI 10.1046/j.1432-1327.2000.01143.x; Matsuzaki K, 1999, FEBS LETT, V449, P221, DOI 10.1016/S0014-5793(99)00443-3; Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P15144, DOI 10.1021/bi9811617; MIGNOGNA G, 1993, EMBO J, V12, P4829, DOI 10.1002/j.1460-2075.1993.tb06172.x; MOR A, 1994, BIOCHEMISTRY-US, V33, P6642, DOI 10.1021/bi00187a034; MOR A, 1994, J BIOL CHEM, V269, P31635; MOR A, 1994, EUR J BIOCHEM, V219, P145, DOI 10.1111/j.1432-1033.1994.tb19924.x; MORIKAWA N, 1992, BIOCHEM BIOPH RES CO, V189, P184, DOI 10.1016/0006-291X(92)91542-X; Nagaoka I, 2000, INFLAMM RES, V49, P73, DOI 10.1007/s000110050561; Oren Z, 1999, EUR J BIOCHEM, V259, P360, DOI 10.1046/j.1432-1327.1999.00047.x; Pag U, 2004, J ANTIMICROB CHEMOTH, V53, P230, DOI 10.1093/jac/dkh083; Papo N, 2005, J BIOL CHEM, V280, P10378, DOI 10.1074/jbc.M412865200; Papo N, 2002, J BIOL CHEM, V277, P33913, DOI 10.1074/jbc.M204928200; Park CB, 1998, BIOCHEM BIOPH RES CO, V244, P253, DOI 10.1006/bbrc.1998.8159; Park Y, 2005, J BIOCHEM MOL BIOL, V38, P507; Patrzykat A, 2002, ANTIMICROB AGENTS CH, V46, P605, DOI 10.1128/AAC.46.3.605-614.2002; Rinaldi AC, 2002, BIOCHEM J, V368, P91, DOI 10.1042/BJ20020806; Rollins-Smith LA, 2002, DEV COMP IMMUNOL, V26, P63, DOI 10.1016/S0145-305X(01)00041-6; Saavedra MJ, 2004, INT MICROBIOL, V7, P207; Sal-Man N, 2002, BIOCHEMISTRY-US, V41, P11921, DOI 10.1021/bi0260482; Scott MG, 1999, INFECT IMMUN, V67, P2005; Selsted ME, 2005, NAT IMMUNOL, V6, P551, DOI 10.1038/ni1206; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Sharon M, 1999, BIOCHEMISTRY-US, V38, P15305, DOI 10.1021/bi991225t; SIMMACO M, 1991, EUR J BIOCHEM, V199, P217, DOI 10.1111/j.1432-1033.1991.tb16112.x; SIMMACO M, 1994, J BIOL CHEM, V269, P11956; Simmaco M, 1996, EUR J BIOCHEM, V242, P788, DOI 10.1111/j.1432-1033.1996.0788r.x; Sinha S, 2004, J MED MICROBIOL, V53, P527, DOI 10.1099/jmm.0.05269-0; Sitaram N, 2006, CURR MED CHEM, V13, P679, DOI 10.2174/092986706776055689; SORAVIA E, 1988, FEBS LETT, V228, P337, DOI 10.1016/0014-5793(88)80027-9; Sullivan CJ, 2005, ULTRAMICROSCOPY, V105, P96, DOI 10.1016/j.ultramic.2005.06.023; Tamm LK, 1997, Q REV BIOPHYS, V30, P365, DOI 10.1017/S0033583597003375; Thevissen K, 1999, APPL ENVIRON MICROB, V65, P5451; Trent MS, 2004, BIOCHEM CELL BIOL, V82, P71, DOI 10.1139/o03-070; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; Yamamoto T, 2004, J CLIN GASTROENTEROL, V38, P911, DOI 10.1097/00004836-200411000-00018; Yang D, 2002, TRENDS IMMUNOL, V23, P291, DOI 10.1016/S1471-4906(02)02246-9; Yu HB, 2005, APPL ENVIRON MICROB, V71, P4469, DOI 10.1128/AEM.71.8.4469-4477.2005; Zanetti M, 2005, CURR ISSUES MOL BIOL, V7, P179, DOI 10.21775/cimb.007.179; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zhang LJ, 2000, BIOCHEMISTRY-US, V39, P14504, DOI 10.1021/bi0011173	77	112	114	3	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28565	28574		10.1074/jbc.M606031200	http://dx.doi.org/10.1074/jbc.M606031200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16867990	hybrid			2022-12-25	WOS:000240680500010
J	Iwamoto, M; Shimizu, H; Inoue, F; Konno, T; Sasaki, YC; Oiki, S				Iwamoto, Masayuki; Shimizu, Hirofumi; Inoue, Fumiko; Konno, Takashi; Sasaki, Yuji C.; Oiki, Shigetoshi			Surface structure and its dynamic rearrangements of the KcsA potassium channel upon gating and tetrabutylammonium blocking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; K+-CHANNEL; RECEPTOR; DOMAIN; SITE	KcsA is the first potassium channel for which the molecular structure was revealed. However, the high resolution structural information is limited to the transmembrane domain, and the dynamic picture of the full KcsA channel remains unsolved. We have developed a new approach to investigate the surface structure of proteins, and we applied this method to investigate the full length of the KcsA channel. Single-cysteine substitution was introduced into 25 sites, and specific reaction of these mutated channels to a bare surface of a flat gold plate was evaluated by surface plasmon resonance measurements. The surface plasmon resonance signals revealed the highest exposure for the mutant of the C-terminal end. When the gate of the KcsA channel is kept closed at pH 7.5, the extent of exposure showed periodic patterns for the consecutive sites located in the cytoplasmic (CP) and N-terminal domain. This suggests that these stretches take the alpha-helical structure. When the channel was actively gated at pH 4.0, many sites in the CP domain became exposed. Compared with the rigid structure in pH 7.5, these results indicate that the CP domain became loosely packed upon active gating. The C-terminal end of the M2 helix is a moving part of the gate, and it is exposed to the outer surface slightly at pH 4.0. By adding a channel blocker, tetrabutylammonium, the gate is further exposed. This suggests that in the active gating tetrabutylammonium keeps the gate open rather than being trapped in the central cavity.	Univ Fukui, Fac Med Sci, Dept Mol Physiol & Biophys, JST,CREST, Eiheiji, Fukui 9101193, Japan; Japan Synchrotron Radiat Res Inst, Mikazuki, Hyogo 6795198, Japan	Japan Science & Technology Agency (JST); University of Fukui; Japan Synchrotron Radiation Research Institute	Oiki, S (corresponding author), Univ Fukui, Fac Med Sci, Dept Mol Physiol & Biophys, JST,CREST, 23-3 Matsuoka Shimoaizuki, Eiheiji, Fukui 9101193, Japan.	oiki-fki@umin.ac.jp	SASAKI, Yuji/N-6880-2016	SASAKI, Yuji/0000-0003-3403-237X; Iwamoto, Masayuki/0000-0001-9505-2652				AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Chill JH, 2006, PROTEIN SCI, V15, P684, DOI 10.1110/ps.051954706; Cortes DM, 2001, J GEN PHYSIOL, V117, P165, DOI 10.1085/jgp.117.2.165; Corvini PFX, 2000, MICROBIOL-SGM, V146, P2671, DOI 10.1099/00221287-146-10-2671; Cuello LG, 1998, BIOCHEMISTRY-US, V37, P3229, DOI 10.1021/bi972997x; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; Gulbis JM, 2000, SCIENCE, V289, P123, DOI 10.1126/science.289.5476.123; Heginbotham L, 1999, J GEN PHYSIOL, V114, P551, DOI 10.1085/jgp.114.4.551; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; IWAMOTO M, 2003, RECENT RES DEV CHEM, V1, P15; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2001, NEURON, V29, P593, DOI 10.1016/S0896-6273(01)00236-7; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; LeMasurier M, 2001, J GEN PHYSIOL, V118, P303, DOI 10.1085/jgp.118.3.303; Lenaeus MJ, 2005, NAT STRUCT MOL BIOL, V12, P454, DOI 10.1038/nsmb929; NEHER E, 1978, J PHYSIOL-LONDON, V277, P153, DOI 10.1113/jphysiol.1978.sp012267; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; SAHINTOTH M, 1993, PROTEIN SCI, V2, P1024, DOI 10.1002/pro.5560020615; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; Shi N, 2006, NATURE, V440, P570, DOI 10.1038/nature04508; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500; Zimmer J, 2006, BIOPHYS J, V90, P1752, DOI 10.1529/biophysj.105.071175	27	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28379	28386		10.1074/jbc.M602018200	http://dx.doi.org/10.1074/jbc.M602018200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16835240	hybrid			2022-12-25	WOS:000240534400075
J	Majerciak, V; Yamanegi, K; Nie, SH; Zheng, ZM				Majerciak, Vladimir; Yamanegi, Koji; Nie, Sarah H.; Zheng, Zhi-Ming			Structural and functional analyses of Kaposi sarcoma-associated herpesvirus ORF57 nuclear localization signals in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEIN ICP27; MESSENGER-RNA EXPORT; OPEN READING FRAME; VIRUS SM PROTEIN; MULTICENTRIC CASTLEMANS-DISEASE; PRIMARY EFFUSION LYMPHOMA; SIMPLEX-VIRUS; GENE-EXPRESSION; IN-VIVO; POSTTRANSCRIPTIONAL REGULATOR	Kaposi sarcoma-associated herpesvirus (KSHV) ORF57 is a multifunctional, nuclear protein involved in post-transcriptional regulation of a subset of viral genes during lytic replication. Three nuclear localization signals (NLSs), NLS1 (amino acids (aa 101 - 107), NLS2 (aa 121 - 130), and NLS3 (aa 143 - 152), were identified in the N terminus of the ORF57 protein, and each of the three represents a short stretch of basic amino acid residues. Disruption of all three NLSs prevented localization of ORF57 in the nucleus. Insertion of individual NLSs into a heterologous cytoplasmic protein converted it into a nuclear protein, confirming that each NLS functions independently and is sufficient to promote protein nuclear localization. Although it exhibits a function similar to that of Epstein-Barr virus EB2 in promoting KSHV ORF59 expression, KSHV ORF57 differs from the herpes simplex virus ICP27 protein, and its function could be disrupted by point mutations of single or two NLSs in random combination, despite the proper localization of the mutant protein in the nucleus. The dysfunctional ORF57 containing NLS mutations also had low affinity with ORF59 RNA and the RNA export factor REF. However, the REF binding of ORF57 in vivo appeared to have no effect on ORF57-mediated enhancement of ORF59 expression. Thus, the three NLSs identified in ORF57 provide at least two functions, nuclear localization of ORF57 and up-regulation of ORF59 expression.	NCI, HIV & AIDS Malignancy Branch, Canc Res Ctr, Natl Inst Hlth, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zheng, ZM (corresponding author), NCI, HIV & AIDS Malignancy Branch, Canc Res Ctr, Natl Inst Hlth, 10 Ctr Dr,Rm 10 S255,MSC-1868, Bethesda, MD 20892 USA.	zhengt@exchange.nih.gov	Zheng, Zhi-Ming/L-6383-2019	Zheng, Zhi-Ming/0000-0001-5547-7912; Majerciak, Vladimir/0000-0003-2907-4583	NATIONAL CANCER INSTITUTE [Z01SC010357, ZIASC010357] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bryant HE, 2001, J VIROL, V75, P4376, DOI 10.1128/JVI.75.9.4376-4385.2001; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Cannon JS, 2000, J VIROL, V74, P10187, DOI 10.1128/JVI.74.21.10187-10193.2000; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen IHB, 2005, J VIROL, V79, P3949, DOI 10.1128/JVI.79.7.3949-3961.2005; COOK ID, 1994, VIROLOGY, V205, P217, DOI 10.1006/viro.1994.1637; Cooper M, 1999, J GEN VIROL, V80, P1311, DOI 10.1099/0022-1317-80-5-1311; Fakhari FD, 2002, J VIROL, V76, P6213, DOI 10.1128/JVI.76.12.6213-6223.2002; Gatfield D, 2002, J CELL BIOL, V159, P579, DOI 10.1083/jcb.200207128; Goodwin DJ, 1999, J VIROL, V73, P10519, DOI 10.1128/JVI.73.12.10519-10524.1999; Goodwin DJ, 2001, J BIOL CHEM, V276, P19905, DOI 10.1074/jbc.M009513200; Gupta AK, 2000, J VIROL, V74, P1038, DOI 10.1128/JVI.74.2.1038-1044.2000; HARDY WR, 1994, J VIROL, V68, P7790, DOI 10.1128/JVI.68.12.7790-7799.1994; Hayward GS, 2003, CANCER CELL, V3, P1, DOI 10.1016/S1535-6108(03)00002-3; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; HIBBARD MK, 1995, J VIROL, V69, P4656, DOI 10.1128/JVI.69.8.4656-4667.1995; Hiriart E, 2003, J BIOL CHEM, V278, P335, DOI 10.1074/jbc.M208656200; Kirshner JR, 2000, J VIROL, V74, P3586, DOI 10.1128/JVI.74.8.3586-3597.2000; Koffa MD, 2001, EMBO J, V20, P5769, DOI 10.1093/emboj/20.20.5769; Lindberg A, 2002, VIROLOGY, V294, P189, DOI 10.1006/viro.2001.1301; Longman D, 2003, RNA, V9, P881, DOI 10.1261/rna.5420503; Lukac DM, 1999, J VIROL, V73, P9348, DOI 10.1128/JVI.73.11.9348-9361.1999; Malik P, 2004, NUCLEIC ACIDS RES, V32, P5553, DOI 10.1093/nar/gkh876; Malik P, 2004, J BIOL CHEM, V279, P33001, DOI 10.1074/jbc.M313008200; Mears WE, 1996, J VIROL, V70, P7445, DOI 10.1128/JVI.70.11.7445-7453.1996; MEARS WE, 1995, J VIROL, V69, P935, DOI 10.1128/JVI.69.2.935-947.1995; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Nishimura K, 2004, VIROLOGY, V325, P364, DOI 10.1016/j.virol.2004.04.041; Pearson A, 2004, J VIROL, V78, P23, DOI 10.1128/JVI.78.1.23-32.2004; PERERA LP, 1994, J VIROL, V68, P2468, DOI 10.1128/JVI.68.4.2468-2477.1994; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Rodrigues JP, 2001, P NATL ACAD SCI USA, V98, P1030, DOI 10.1073/pnas.98.3.1030; Ruvolo V, 1998, P NATL ACAD SCI USA, V95, P8852, DOI 10.1073/pnas.95.15.8852; Ruvolo V, 2001, J VIROL, V75, P6033, DOI 10.1128/JVI.75.13.6033-6041.2001; Sandri-Goldin RM, 1998, GENE DEV, V12, P868, DOI 10.1101/gad.12.6.868; SandriGoldin RM, 1996, J VIROL, V70, P108, DOI 10.1128/JVI.70.1.108-118.1996; SANDRIGOLDIN RM, 1995, J VIROL, V69, P6063, DOI 10.1128/JVI.69.10.6063-6076.1995; Sciabica KS, 2003, EMBO J, V22, P1608, DOI 10.1093/emboj/cdg166; Sokolowski M, 2003, J BIOL CHEM, V278, P33540, DOI 10.1074/jbc.M302063200; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Staskus KA, 1999, J VIROL, V73, P4181, DOI 10.1128/JVI.73.5.4181-4187.1999; Sun R, 1998, P NATL ACAD SCI USA, V95, P10866, DOI 10.1073/pnas.95.18.10866; Tang S, 2006, J VIROL, V80, P4249, DOI 10.1128/JVI.80.9.4249-4263.2006; Tao MF, 2003, J VIROL, V77, P13232, DOI 10.1128/JVI.77.24.13232-13247.2003; Viejo-Borbolla Abel, 2003, Curr Infect Dis Rep, V5, P169, DOI 10.1007/s11908-003-0054-2; Whitehouse A, 1998, J VIROL, V72, P857, DOI 10.1128/JVI.72.1.857-861.1998; Williams BJL, 2005, BIOCHEM J, V387, P295, DOI 10.1042/BJ20041223; WINKLER M, 1994, J VIROL, V68, P3943, DOI 10.1128/JVI.68.6.3943-3954.1994; Zheng ZM, 2000, J VIROL, V74, P10612, DOI 10.1128/JVI.74.22.10612-10622.2000; Zhong WD, 1996, P NATL ACAD SCI USA, V93, P6641, DOI 10.1073/pnas.93.13.6641; Zhou FC, 2002, J VIROL, V76, P6185, DOI 10.1128/JVI.76.12.6185-6196.2002	52	59	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28365	28378		10.1074/jbc.M603095200	http://dx.doi.org/10.1074/jbc.M603095200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16829516	hybrid			2022-12-25	WOS:000240534400074
J	Dikanov, SA; Kolling, DRJ; Endeward, B; Samoilova, RI; Prisner, TF; Nair, SK; Crofts, AR				Dikanov, Sergei A.; Kolling, Derrick R. J.; Endeward, Burkhard; Samoilova, Rimma I.; Prisner, Thomas F.; Nair, Satish K.; Crofts, Antony R.			Identification of hydrogen bonds to the Rieske cluster through the weakly coupled nitrogens detected by electron spin echo envelope modulation spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME BC(1) COMPLEX; IRON-SULFUR PROTEIN; NUCLEAR-QUADRUPOLE RESONANCE; PHTHALATE DIOXYGENASE; 2-DIMENSIONAL ESEEM; PSEUDOMONAS-CEPACIA; MUTATIONAL ANALYSIS; REDOX POTENTIALS; 2FE-2S CLUSTER; 2 HISTIDINES	The interactionofthereduced[2Fe-2S] cluster of isolated Rieske fragment from the bc(1) complex of Rhodobacter sphaeroides with nitrogens (N-14 and N-15) from the local protein environment has been studied by X- and S-band pulsed EPR spectroscopy. The two-dimensional electron spin echo envelope modulation spectra of uniformly N-15-labeled protein show two well resolved cross-peaks with weak couplings of similar to 0.3-0.4 and 1.1 MHz in addition to couplings in the range of 6-8 MHz from two coordinating N-delta of histidine ligands. The quadrupole coupling constants for weakly coupled nitrogens determined from S-band electron spin echo envelope modulation spectra identify them as N-delta of histidine ligands and peptide nitrogen (N-p), respectively. Analysis of the line intensities in orientation-selected S-band spectra indicated that N-p is the backbone N-atom of Leu-132 residue. The hyperfine couplings from N-epsilon and N-p demonstrate the predominantly isotropic character resulting from the transfer of unpaired spin density onto the 2s orbitals of the nitrogens. Spectra also show that other peptide nitrogens in the protein environment must carry a 5-10 times smaller amount of spin density than the Np of Leu-132 residue. The appearance of the excess unpaired spin density on the N-p of Leu-132 residue indicates its involvement in hydrogen bond formation with the bridging sulfur of the Rieske cluster. The configuration of the hydrogen bond therefore provides a preferred path for spin density transfer. Observation of similar splittings in the N-15 spectra of other Rieske-type proteins and [2Fe-2S] ferredoxins suggests that a hydrogen bond between the bridging sulfur and peptide nitrogen is a common structural feature of [2Fe-2S] clusters.	Univ Illinois, Dept Clin Vet Med, Urbana, IL 61801 USA; Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA; Goethe Univ Frankfurt, Inst Phys & Theoret Chem, D-60438 Frankfurt, Germany; Russian Acad Sci, Inst Chem Kinet & Combust, Novosibirsk 630090, Russia; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Goethe University Frankfurt; Russian Academy of Sciences; Voevodsky Institute of Chemical Kinetics & Combustion SB RAS; University of Illinois System; University of Illinois Urbana-Champaign	Dikanov, SA (corresponding author), Univ Illinois, Dept Clin Vet Med, Urbana, IL 61801 USA.	dikanov@uiuc.edu; a-crofts@life.uiuc.edu	Nair, Satish/AAY-2510-2021; Samoilova, Rimma Ivanovna/T-7956-2017	Samoilova, Rimma Ivanovna/0000-0002-1649-1487; Endeward, Burkhard/0000-0001-7790-1024; Prisner, Thomas F./0000-0003-2850-9573	FIC NIH HHS [1 R03 TW 01495] Funding Source: Medline; NCRR NIH HHS [S10-RR15878] Funding Source: Medline; NIGMS NIH HHS [GM 62954, GM 35438] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW001495] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062954, R01GM035438] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBY CIH, 1978, J AM CHEM SOC, V100, P6057, DOI 10.1021/ja00487a014; ASHBY CIH, 1980, J AM CHEM SOC, V102, P2990, DOI 10.1021/ja00529a020; Benetis NP, 2005, J MAGN RESON, V175, P124, DOI 10.1016/j.jmr.2005.03.012; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; BLINC R, 1974, CHEM PHYS LETT, V28, P158, DOI 10.1016/0009-2614(74)80041-2; Bowman MK, 2004, BIOCHEMISTRY-US, V43, P430, DOI 10.1021/bi034620z; BRITT RD, 1991, BIOCHEMISTRY-US, V30, P1892, DOI 10.1021/bi00221a023; Carrell CJ, 1997, STRUCTURE, V5, P1613, DOI 10.1016/S0969-2126(97)00309-2; COLANERI MJ, 1992, J AM CHEM SOC, V114, P5335, DOI 10.1021/ja00039a051; Crofts AR, 2004, BBA-BIOENERGETICS, V1655, P77, DOI 10.1016/j.bbabio.2003.10.012; Crofts AR, 2004, ANNU REV PHYSIOL, V66, P689, DOI 10.1146/annurev.physiol.66.032102.150251; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3342, DOI 10.1021/bi00128a006; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3351, DOI 10.1021/bi00128a007; Denke E, 1998, J BIOL CHEM, V273, P9085, DOI 10.1074/jbc.273.15.9085; Dikanov SA, 1998, J BIOL INORG CHEM, V3, P18, DOI 10.1007/s007750050204; DIKANOV SA, 1995, J AM CHEM SOC, V117, P10579, DOI 10.1021/ja00147a023; Dikanov SA, 2004, J BIOL INORG CHEM, V9, P753, DOI 10.1007/s00775-004-0571-y; DIKANOV SA, 1982, CHEM PHYS LETT, V90, P149, DOI 10.1016/0009-2614(82)83630-0; Dikanov SA, 1996, J AM CHEM SOC, V118, P8408, DOI 10.1021/ja960781x; DIKANOV SA, 1995, J MAGN RESON SER B, V108, P99, DOI 10.1006/jmrb.1995.1110; DIKANOV SA, 1992, ELECT SPIN ECHO ENVE, P412; EDMONDS DT, 1971, PHYS LETT A, VA 34, P325, DOI 10.1016/0375-9601(71)90894-2; EDMONDS DT, 1973, J MAGN RESON, V12, P134, DOI 10.1016/0022-2364(73)90136-4; Elmi F, 2005, J PHYS CHEM A, V109, P1729, DOI 10.1021/jp046216v; GATTI DL, 1989, J MOL BIOL, V205, P421, DOI 10.1016/0022-2836(89)90352-5; Guergova-Kuras M, 1999, PROTEIN EXPRES PURIF, V15, P370, DOI 10.1006/prep.1998.1018; Guergova-Kuras M, 2000, BIOCHEMISTRY-US, V39, P7436, DOI 10.1021/bi992491+; Gurbiel RJ, 1996, BIOCHEMISTRY-US, V35, P7834, DOI 10.1021/bi960380u; GURBIEL RJ, 1989, BIOCHEMISTRY-US, V28, P4861, DOI 10.1021/bi00437a051; GURBIEL RJ, 1991, BIOCHEMISTRY-US, V30, P11579, DOI 10.1021/bi00113a013; Hong SJ, 1999, J BIOL CHEM, V274, P33931, DOI 10.1074/jbc.274.48.33931; HUNT MJ, 1976, J MAGN RESON, V22, P295, DOI 10.1016/0022-2364(76)90304-8; HUNT MJ, 1975, CHEM PHYS LETT, V34, P473, DOI 10.1016/0009-2614(75)85542-4; Iwasaki T, 2006, J AM CHEM SOC, V128, P2170, DOI 10.1021/ja0562393; Iwasaki T, 2004, J AM CHEM SOC, V126, P13902, DOI 10.1021/ja045898x; Iwasaki T, 2004, J AM CHEM SOC, V126, P4788, DOI 10.1021/ja031976p; Iwasaki T, 2006, PROTEIN SCI, V15, P2019, DOI 10.1110/ps.052035406; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; JIANG F, 1990, J AM CHEM SOC, V112, P9035, DOI 10.1021/ja00181a002; Klingen AR, 2004, BIOCHEMISTRY-US, V43, P12383, DOI 10.1021/bi0488606; Leggate EJ, 2005, BIOCHEMISTRY-US, V44, P7048, DOI 10.1021/bi050189x; Li J, 1998, J PHYS CHEM A, V102, P6311, DOI 10.1021/jp980753w; Link TA, 1999, ADV INORG CHEM, V47, P83, DOI 10.1016/S0898-8838(08)60077-X; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; MIMS WB, 1978, J CHEM PHYS, V69, P4921, DOI 10.1063/1.436479; PALMER M, 1984, Z NATURFORSCH A, V39, P1108, DOI 10.1515/zna-1984-1115; RABBANI SR, 1987, J MAGN RESON, V72, P230, DOI 10.1016/0022-2364(87)90285-X; REIJERSE EJ, 1987, J MAGN RESON, V71, P83, DOI 10.1016/0022-2364(87)90129-6; Schroter T, 1998, EUR J BIOCHEM, V255, P100, DOI 10.1046/j.1432-1327.1998.2550100.x; Schweiger A., 2001, PRINCIPLES PULSE ELE, P578; Shergill JK, 1995, BIOCHEMISTRY-US, V34, P16533, DOI 10.1021/bi00051a001; SHERGILL JK, 1994, BBA-BIOENERGETICS, V1185, P35, DOI 10.1016/0005-2728(94)90190-2; Snyder C, 1998, BBA-BIOENERGETICS, V1365, P125, DOI 10.1016/S0005-2728(98)00052-8; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Ullmann GM, 2002, J BIOL INORG CHEM, V7, P632, DOI 10.1007/s00775-002-0342-6; VANDOREN SR, 1993, BIOCHEMISTRY-US, V32, P8083, DOI 10.1021/bi00083a005; WEBER A, 1998, P 29 C AMPERE 13 ISM, V2, P1138; WEIL JA, 1994, ELECT PARAMAGNETIC R, P308; Xia B, 1999, BIOCHEMISTRY-US, V38, P727, DOI 10.1021/bi981851a; [No title captured]	61	24	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27416	27425		10.1074/jbc.M604103200	http://dx.doi.org/10.1074/jbc.M604103200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16854984	hybrid			2022-12-25	WOS:000240397700068
J	Albor, A; El-Hizawi, S; Horn, EJ; Laederich, M; Frosk, P; Wrogemann, K; Kulesz-Martin, M				Albor, Amador; El-Hizawi, Sally; Horn, Elizabeth J.; Laederich, Melanie; Frosk, Patrick; Wrogemann, Klaus; Kulesz-Martin, Molly			The interaction of Piasy with Trim32, an E3-ubiquitin ligase mutated in limb-girdle muscular dystrophy type 2H, promotes Piasy degradation and regulates UVB-induced keratinocyte apoptosis through NF kappa b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING FINGER; SUMO-1 MODIFICATION; PROTEIN INHIBITOR; STAGE PROGRESSION; UBIQUITIN LIGASE; GENE-ACTIVATION; DNA MICROARRAY; FAMILY-MEMBER; NUCLEAR; PATHWAY	Protein inhibitors of activated STATs (PIAS) family members are ubiquitin-protein isopeptide ligase-small ubiquitin-like modifier ligases for diverse transcription factors. However, the regulation of PIAS protein activity in cells is poorly understood. Previously, we reported that expression of Trim32, a RING domain ubiquitin-protein isopeptide ligase-ubiquitin ligase mutated in human limb-girdle muscular dystrophy type 2H (LGMD2H) and Bardet-Biedl syndrome, is elevated during mouse skin carcinogenesis, protecting keratinocytes from apoptosis induced by UVB and tumor necrosis factor-alpha (TNF alpha). Here we report that Trim32 interacts with Piasy and promotes Piasy ubiquitination and degradation. Ubiquitination of Piasy by Trim32 could be reproduced in vitro using purified components. Their interaction was induced by treatment with UVB/TNF alpha and involved redistribution of Piasy from the nucleus to the cytoplasm, where it accumulated in cytoplasmic granules that colocalized with Trim32. Piasy destabilization and ubiquitination required an intact RING domain in Trim32. The LGMD2H-associated missense point mutation prevented Trim32 binding to Piasy, and human Piasy failed to colocalize with human Trim32 in fibroblasts isolated from an LGMD2H patient. Trim32 expression increased the transcriptional activity of NF kappa B in epidermal keratinocytes, both under basal treatment and after UVB/TNF alpha treatment. Conversely, Piasy inhibited NF kappa B activity under the same conditions and sensitized keratinocytes to apoptosis induced by TNF alpha and UVB. Our results indicate that, by controlling Piasy stability, Trim32 regulates UVB-induced keratinocyte apoptosis through induction of NF kappa B and suggests loss of function of Trim32 in LGMD2H.	Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Cell & Mol Biol Program, Portland, OR 97239 USA; Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB R3E 0W3, Canada	Oregon Health & Science University; Oregon Health & Science University; University of Manitoba	Albor, A (corresponding author), Oregon Hlth & Sci Univ, Dept Dermatol, Mail Code OP06,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	albora@ohsu.edu		Frosk, Patrick/0000-0002-9673-795X	NCI NIH HHS [CA69533, CA098577, R01 CA098577] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA069533, R01CA098577] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Baghdiguian S, 2001, J MOL MED, V79, P254, DOI 10.1007/s001090100225; Baghdiguian S, 1999, NAT MED, V5, P503, DOI 10.1038/8385; Banno T, 2005, J BIOL CHEM, V280, P18973, DOI 10.1074/jbc.M411758200; Betz A, 2001, P NATL ACAD SCI USA, V98, P9563, DOI 10.1073/pnas.171302098; Cao TY, 1998, J CELL SCI, V111, P1319; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; Chiang AP, 2006, P NATL ACAD SCI USA, V103, P6287, DOI 10.1073/pnas.0600158103; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Duval D, 2003, FEBS LETT, V554, P111, DOI 10.1016/S0014-5793(03)01116-5; Frosk P, 2005, HUM MUTAT, V25, P38, DOI 10.1002/humu.20110; Frosk P, 2002, AM J HUM GENET, V70, P663, DOI 10.1086/339083; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Glasscock E, 2005, GENETICS, V170, P1677, DOI 10.1534/genetics.105.043174; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Horn EJ, 2004, CARCINOGENESIS, V25, P157, DOI 10.1093/carcin/bgh003; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Kudryashova E, 2005, J MOL BIOL, V354, P413, DOI 10.1016/j.jmb.2005.09.068; KULESZMARTIN MF, 1988, CARCINOGENESIS, V9, P171, DOI 10.1093/carcin/9.1.171; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; Matsuura T, 2005, EXP CELL RES, V308, P65, DOI 10.1016/j.yexcr.2005.04.022; Meroni G, 2005, BIOESSAYS, V27, P1147, DOI 10.1002/bies.20304; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Nair R, 2003, NUCLEIC ACIDS RES, V31, P397, DOI 10.1093/nar/gkg001; Nelson V, 2001, APOPTOSIS, V6, P221, DOI 10.1023/A:1011392811628; Ohmine K, 2001, ONCOGENE, V20, P8249, DOI 10.1038/sj.onc.1205029; Okubo S, 2004, J BIOL CHEM, V279, P31455, DOI 10.1074/jbc.M403561200; Qin JZ, 1999, J BIOL CHEM, V274, P37957, DOI 10.1074/jbc.274.53.37957; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Roth W, 2004, J IMMUNOL, V173, P6189, DOI 10.4049/jimmunol.173.10.6189; Saenko V, 2003, MUTAT RES-FUND MOL M, V527, P81, DOI 10.1016/S0027-5107(03)00056-3; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schoser BGH, 2005, ANN NEUROL, V57, P591, DOI 10.1002/ana.20441; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Shuai K, 2005, NAT REV IMMUNOL, V5, P593, DOI 10.1038/nri1667; Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2; Slack FJ, 1998, TRENDS BIOCHEM SCI, V23, P474, DOI 10.1016/S0968-0004(98)01299-7; Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343; Sturm S, 2000, J MOL NEUROSCI, V14, P107, DOI 10.1385/JMN:14:1-2:107; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; Takahashi Y, 2005, J BIOL CHEM, V280, P35822, DOI 10.1074/jbc.M506794200; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Tan JA, 2002, J BIOL CHEM, V277, P16993, DOI 10.1074/jbc.M109217200; Tussie-Luna MI, 2002, J BIOL CHEM, V277, P43185, DOI 10.1074/jbc.M207635200; Ueda M, 2003, BRIT J HAEMATOL, V123, P288, DOI 10.1046/j.1365-2141.2003.04601.x; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Wong KA, 2004, MOL CELL BIOL, V24, P5577, DOI 10.1128/MCB.24.12.5577-5586.2004; Zhang J, 2004, FEBS LETT, V570, P97, DOI 10.1016/j.febslet.2004.05.081; Zoumpoulidou G, 2004, MOL ENDOCRINOL, V18, P1988, DOI 10.1210/me.2003-0467	56	69	73	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25850	25866		10.1074/jbc.M601655200	http://dx.doi.org/10.1074/jbc.M601655200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16816390	hybrid			2022-12-25	WOS:000240031300087
J	Wei, CC; Zhang, SL; Chen, YW; Guo, DF; Ingelfinger, JR; Bomsztyk, K; Chan, JSD				Wei, Chih-Chang; Zhang, Shao-Ling; Chen, Yun-Wen; Guo, Deng-Fu; Ingelfinger, Julie R.; Bomsztyk, Karol; Chan, John S. D.			Heterogeneous nuclear ribonucleoprotein K modulates angiotensinogen gene expression in kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PROXIMAL TUBULE; PROTEIN-KINASE PATHWAY; HNRNP-K; MOLECULAR-CLONING; RESPONSE ELEMENT; BINDING-PROTEIN; MESSENGER-RNA; INSULIN; DNA; GLUCOSE	The present studies aimed to identify the 70-kDa nuclear protein that binds to an insulin-responsive element in the rat angiotensinogen gene promoter and to define its action on angiotensinogen gene expression. Nuclear proteins were isolated from rat kidney proximal tubular cells and subjected to two-dimensional electrophoresis. The 70-kDa nuclear protein was detected by Southwestern blotting and subsequently identified by mass spectrometry, which revealed that it was identical to 65-kDa heterogeneous nuclear ribonucleoprotein K (hnRNP K). hnRNP K bound to the insulin-responsive element of the rat angiotensinogen gene was revealed by a gel mobility shift assay and chromatin immunoprecipitation assay. hnRNP K inhibited angiotensinogen mRNA expression and promoter activity. In contrast, hnRNP K down-expression by small interference RNA enhanced angiotensinogen mRNA expression. Moreover, hnRNP K interacted with hnRNP F in pulldown and co-immunoprecipitation assays. Co-transfection of hnRNP K and hnRNP F further suppressed angiotensinogen mRNA expression. Finally, in vitro and in vivo studies demonstrated that high glucose increases and insulin inhibits hnRNP K expression in rat kidney proximal tubular cells. In conclusion, our experiments revealed that hnRNP K is a nuclear protein that binds to the insulin-responsive element of the rat angiotensinogen gene promoter and modulates angiotensinogen gene transcription in the kidney.	Ctr Hosp Univ Montreal, Hotel Dieu, Ctr Rech, Montreal, PQ H2W 1T8, Canada; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Pediat Nephrol Unit, Boston, MA 02114 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	Laval University; Universite de Montreal; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Washington; University of Washington Seattle	Chan, JSD (corresponding author), Ctr Hosp Univ Montreal, Hotel Dieu, Ctr Rech, Montreal, PQ H2W 1T8, Canada.	john.chan@umontreal.ca			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048455] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48455] Funding Source: Medline; NIDDK NIH HHS [DK49578] Funding Source: Medline; NIGMS NIH HHS [GM45134] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen S, 2000, KIDNEY INT, V57, P601, DOI 10.1046/j.1523-1755.2000.t01-1-00880.x; ANDERSON S, 1993, AM J PHYSIOL, V265, pF477, DOI 10.1152/ajprenal.1993.265.4.F477; BAKRIS GL, 1993, ANN INTERN MED, V118, P643, DOI 10.7326/0003-4819-118-8-199304150-00013; BERNEG RTV, 1996, ANN INTERN MED, V121, P912; Bomsztyk K, 2004, BIOESSAYS, V26, P629, DOI 10.1002/bies.20048; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; CHAN JSD, 1990, PEDIATR NEPHROL, V4, P429, DOI 10.1007/BF00862531; CHEN M, 1994, J CLIN INVEST, V94, P237, DOI 10.1172/JCI117312; Chen X, 2001, ENDOCRINOLOGY, V142, P2577, DOI 10.1210/en.142.6.2577; Da Silva N, 2002, BLOOD, V100, P3536, DOI 10.1182/blood.V100.10.3536; DEJGAARD K, 1994, J MOL BIOL, V236, P33, DOI 10.1006/jmbi.1994.1116; Denisenko ON, 1996, J BIOL CHEM, V271, P27701, DOI 10.1074/jbc.271.44.27701; Diabet Control Complications DCCT Res Grp, 1995, KIDNEY INT, V47, P1703; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Du Q, 1998, J BIOL CHEM, V273, P19877, DOI 10.1074/jbc.273.31.19877; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DZAU VJ, 1989, J HYPERTENS S7, V7, P53; Groggel GC, 1996, ARCH FAM MED, V5, P513, DOI 10.1001/archfami.5.9.513; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; Hsieh TJ, 2003, ENDOCRINOLOGY, V144, P4338, DOI 10.1210/en.2003-0220; Hsieh TJ, 2002, ENDOCRINOLOGY, V143, P2975, DOI 10.1210/en.143.8.2975; Ingelfinger JR, 1999, AM J PHYSIOL-RENAL, V276, pF218, DOI 10.1152/ajprenal.1999.276.2.F218; INGELFINGER JR, 1990, J CLIN INVEST, V85, P417, DOI 10.1172/JCI114454; ITO K, 1994, NUCLEIC ACIDS RES, V22, P53, DOI 10.1093/nar/22.1.53; JOHNSTON CI, 1993, KIDNEY INT       S42, V44, P559; KAGEYAMA R, 1984, BIOCHEMISTRY-US, V23, P3603, DOI 10.1021/bi00311a006; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; KWASTWELFELD J, 1993, J BIOL CHEM, V268, P19581; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lau JS, 2000, J CELL BIOCHEM, V79, P395, DOI 10.1002/1097-4644(20001201)79:3<395::AID-JCB50>3.0.CO;2-M; LAVERMAN GD, 2004, J AM SOC NEPHROL S1, V15, P60; Li NJ, 2005, AM J PHYSIOL-RENAL, V288, pF353, DOI 10.1152/ajprenal.00144.2004; LoghmanAdham M, 1997, KIDNEY INT, V52, P229, DOI 10.1038/ki.1997.325; MATSUNIS MJ, 1992, MOL CELL BIOL, V12, P164; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; NAKAMURA T, 1995, J AM SOC NEPHROL, V5, P1492; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OHKUBO H, 1983, P NATL ACAD SCI-BIOL, V80, P2196, DOI 10.1073/pnas.80.8.2196; Ostrowski J, 2003, NUCLEIC ACIDS RES, V31, P3954, DOI 10.1093/nar/gkg452; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; Ravid M, 1996, ARCH INTERN MED, V156, P286, DOI 10.1001/archinte.156.3.286; Ritchie SA, 2003, NUCLEIC ACIDS RES, V31, P1502, DOI 10.1093/nar/gkg246; Sachetelli S, 2006, KIDNEY INT, V69, P1016, DOI 10.1038/sj.ki.5000210; SEUNINGEN I, 1995, J BIOL CHEM, V270, P26976; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shannon H, 2000, NEW ENGL J MED, V342, P381; Shnyreva M, 2000, J BIOL CHEM, V275, P15498, DOI 10.1074/jbc.275.20.15498; Stains JP, 2005, BIOCHEM J, V385, P613, DOI 10.1042/BJ20040680; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TANG SS, 1995, AM J PHYSIOL-RENAL, V268, pF435, DOI 10.1152/ajprenal.1995.268.3.F435; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; US Renal Data System, 2005, US REN DAT SYST USRD; VINAY P, 1981, AM J PHYSIOL, V241, pF403, DOI 10.1152/ajprenal.1981.241.4.F403; Wang LS, 1998, KIDNEY INT, V53, P287, DOI 10.1046/j.1523-1755.1998.00759.x; Wei CC, 2005, J AM SOC NEPHROL, V16, P616, DOI 10.1681/ASN.2004080715; Wolf G, 2005, KIDNEY INT, V67, P799, DOI 10.1111/j.1523-1755.2005.00145.x; WOLF G, 1992, KIDNEY INT S 39, V43, P100; Zhang SL, 1999, KIDNEY INT, V55, P454, DOI 10.1046/j.1523-1755.1999.00271.x; Zhang SL, 2002, ENDOCRINOLOGY, V143, P4627, DOI 10.1210/en.2002-220408; Zhang SL, 2002, J AM SOC NEPHROL, V13, P302, DOI 10.1681/ASN.V132302; Zhang SL, 2002, J ENDOCRINOL, V172, P333, DOI 10.1677/joe.0.1720333; Zhang SL, 2001, EXP NEPHROL, V9, P109; Zhang SL, 1999, ENDOCRINOLOGY, V140, P5285, DOI 10.1210/en.140.11.5285; Zhang SL, 2000, ENDOCRINOLOGY, V141, P4637, DOI 10.1210/endo.141.12.7844	66	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25344	25355		10.1074/jbc.M601945200	http://dx.doi.org/10.1074/jbc.M601945200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16837467	hybrid			2022-12-25	WOS:000240031300036
J	D'Abramo, CM; Deval, J; Cameron, CE; Cellai, L; Gotte, M				D'Abramo, Claudia M.; Deval, Jerome; Cameron, Craig E.; Cellai, Luciano; Gotte, Matthias			Control of template positioning during de novo initiation of RNA synthesis by the bovine viral diarrhea virus NS5B polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; PROTEIN 5B POLYMERASE; CRYSTAL-STRUCTURE; IDENTIFICATION; POLYMERIZATION; REQUIREMENTS; EXPRESSION; MECHANISM; BINDING; REGION	The RNA-dependent RNA polymerase of the hepatitis C virus and the bovine viral diarrhea virus (BVDV) is able to initiate RNA synthesis de novo in the absence of a primer. Previous crystallographic data have pointed to the existence of a GTP-specific binding site (G-site) that is located in the vicinity of the active site of the BVDV enzyme. Here we have studied the functional role of the G-site and present evidence to show that specific GTP binding affects the positioning of the template during de novo initiation. Following the formation of the first phosphodiester bond, the polymerase translocates relative to the newly synthesized dinucleotide, which brings the 5'-end of the primer into the G-site, releasing the previously bound GTP. At this stage, the 3'-end of the template can remain opposite to the 5'-end of the primer or be repositioned to its original location before RNA synthesis proceeds. We show that the template can freely move between the two locations, and both complexes can isomerize to equilibrium. These data suggest that the bound GTP can stabilize the interaction between the 3'-end of the template and the priming nucleotide, preventing the template to overshoot and extend beyond the active site during de novo initiation. The hepatitis C virus enzyme utilizes a dinucleotide primer exclusively from the blunt end; the existence of a functionally equivalent G-site is therefore uncertain. For the BVDV polymerase we showed that de novo initiation is severely compromised by the T320A mutant that likely affects hydrogen bonding between the G-site and the guanine base. Dinucleotide-primed reactions are not influenced by this mutation, which supports the notion that the G-site is located in close proximity but not at the active site of the enzyme.	McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2B4, Canada; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; CNR, Ist Cristallog, I-00016 Rome, Italy	McGill University; McGill University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Consiglio Nazionale delle Ricerche (CNR); Istituto Di Cristallografia (IC-CNR)	Gotte, M (corresponding author), McGill Univ, Dept Microbiol & Immunol, Duff Med Bldg,D-6,3775 Univ St, Montreal, PQ H3A 2B4, Canada.	matthias.gotte@mcgill.ca			NIAID NIH HHS [AI060563] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060563, R56AI060563] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Cai ZH, 2005, J VIROL, V79, P11607, DOI 10.1128/JVI.79.18.11607-11617.2005; Choi KH, 2004, P NATL ACAD SCI USA, V101, P4425, DOI 10.1073/pnas.0400660101; D'Abramo CM, 2004, J MOL BIOL, V337, P1, DOI 10.1016/j.jmb.2004.01.030; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; Ferron F, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-255; Ishii K, 1999, HEPATOLOGY, V29, P1227, DOI 10.1002/hep.510290448; Jager Joachim, 1999, Current Opinion in Structural Biology, V9, P21, DOI 10.1016/S0959-440X(99)80004-9; Kao CC, 2001, VIROLOGY, V287, P251, DOI 10.1006/viro.2001.1039; Kao CC, 1999, VIROLOGY, V253, P1, DOI 10.1006/viro.1998.9517; Kao CC, 2000, J VIROL, V74, P11121, DOI 10.1128/JVI.74.23.11121-11128.2000; Kim MJ, 2000, J VIROL, V74, P10312, DOI 10.1128/JVI.74.22.10312-10322.2000; Lai VCH, 1999, J VIROL, V73, P10129, DOI 10.1128/JVI.73.12.10129-10136.1999; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Leveque VJP, 2003, J VIROL, V77, P9020, DOI 10.1128/JVI.77.16.9020-9028.2003; Lohmann V, 1999, J BIOL CHEM, V274, P10807, DOI 10.1074/jbc.274.16.10807; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; Mendez E, 1998, J VIROL, V72, P4737, DOI 10.1128/JVI.72.6.4737-4745.1998; O'Farrell D, 2003, J MOL BIOL, V326, P1025, DOI 10.1016/S0022-2836(02)01439-0; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; Qin WP, 2002, J BIOL CHEM, V277, P2132, DOI 10.1074/jbc.M106880200; Ranjith-Kumar CT, 2002, J VIROL, V76, P12526, DOI 10.1128/JVI.76.24.12526-12536.2002; Ranjith-Kumar CT, 2002, J VIROL, V76, P12513, DOI 10.1128/JVI.76.24.12513-12525.2002; Ranjith-Kumar CT, 2001, J VIROL, V75, P8615, DOI 10.1128/JVI.75.18.8615-8623.2001; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; Shim JH, 2002, J VIROL, V76, P7030, DOI 10.1128/JVI.76.14.7030-7039.2002; Steitz T A, 1997, Harvey Lect, V93, P75; Sun XL, 2000, BIOCHEM BIOPH RES CO, V268, P798, DOI 10.1006/bbrc.2000.2120; van Dijk AA, 2004, J GEN VIROL, V85, P1077, DOI 10.1099/vir.0.19731-0; Wang QM, 2002, J VIROL, V76, P3865, DOI 10.1128/JVI.76.8.3865-3872.2002; Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479; Yuan ZH, 1997, BIOCHEM BIOPH RES CO, V232, P231, DOI 10.1006/bbrc.1997.6249; Zhong WD, 2000, J VIROL, V74, P2017, DOI 10.1128/JVI.74.4.2017-2022.2000; Zhong WD, 1998, J VIROL, V72, P9365, DOI 10.1128/JVI.72.11.9365-9369.1998; Zhong WD, 2000, J VIROL, V74, P9134, DOI 10.1128/JVI.74.19.9134-9143.2000	41	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24991	24998		10.1074/jbc.M600474200	http://dx.doi.org/10.1074/jbc.M600474200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16831816	Green Published, hybrid			2022-12-25	WOS:000239847800091
J	Seng, TJ; Low, JSW; Li, H; Cui, Y; Goh, HK; Wong, MLY; Srivastava, G; Sidransky, D; Califano, J; Steenbergen, RDM; Rha, SY; Tan, J; Hsieh, WS; Ambinder, RF; Lin, X; Chan, ATC; Tao, Q				Seng, T. J.; Low, J. S. W.; Li, H.; Cui, Y.; Goh, H. K.; Wong, M. L. Y.; Srivastava, G.; Sidransky, D.; Califano, J.; Steenbergen, R. D. M.; Rha, S. Y.; Tan, J.; Hsieh, W-S; Ambinder, R. F.; Lin, X.; Chan, A. T. C.; Tao, Q.			The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation	ONCOGENE			English	Article						DLC1; 8p22; tumor suppressor gene; methylation; nasopharyngeal carcinoma; esophageal carcinoma; cervical carcinoma	EPSTEIN-BARR-VIRUS; COMPARATIVE GENOMIC HYBRIDIZATION; STRESS-RESPONSIVE GENE; HUMAN BREAST-CANCER; PROMOTER HYPERMETHYLATION; P53 GENE; EPIGENETIC INACTIVATION; SUSCEPTIBILITY LOCUS; TSLC1 GENE; MULTIPLE	Identification of tumor suppressor genes (TSG) silenced by methylation uncovers mechanisms of tumorigenesis and identifies new epigenetic tumor markers for early cancer detection. Both nasopharyngeal carcinoma (NPC) and esophageal carcinoma are major tumors in Southern China and Southeast Asia. Through expression subtraction of NPC, we identified Deleted in Liver Cancer 1 (DLC1)/ARHGAP7 (NM_006094) - an 8p22 TSG as a major downregulated gene. Although expressed in all normal tissues, DLC1 was silenced or downregulated in 11/12 (91%) NPC, 6/15 (40%) esophageal, 5/8 (63%) cervical and 3/9 (33%) breast carcinoma cell lines. No genetic deletion of DLC1 was detected in NPC although a hemizygous deletion at 8p22-11 was found by 1-Mb array-CGH in some cell lines. We then located the functional DLC1 promoter by 5'-RACE and promoter activity assays. This promoter was frequently methylated in all downregulated cell lines and in a large collection of primary tumors including 89% (64/72) NPC (endemic and sporadic types), 51% (48/94) esophageal, 87% (7/8) cervical and 36% (5/14) breast carcinomas, but seldom in paired surgical marginal tissues and not in any normal epithelial tissue. The transcriptional silencing of DLC1 could be reversed by 5-aza-20-deoxycytidine or genetic double knock-out of DNMT1 and DNMT3B. Furthermore, ectopic expression of DLC1 in NPC and esophageal carcinoma cells strongly inhibited their colony formation. We thus found frequent epigenetic silencing of DLC1 in NPC, esophageal and cervical carcinomas, and a high correlation of methylation with its downregulation, suggesting a predominant role of epigenetic inactivation. DLC1 appears to be a major TSG implicated in the pathogenesis of these tumors, and should be further tested as a molecular biomarker in patients with these cancers.	Chinese Univ Hong Kong, Ctr Canc, Canc Epigenet Lab, Dept Clin Oncol,PWH, Hong Kong, Hong Kong, Peoples R China; Johns Hopkins Singapore, Biopolis, Singapore, Singapore; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Johns Hopkins Med Inst, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA; Vrije Univ Amsterdam, Med Ctr, Dept Pathol, NL-1081 HV Amsterdam, Netherlands; Yonsei Univ, Coll Med, Ctr Canc, Seoul 120749, South Korea; Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA	Chinese University of Hong Kong; Prince of Wales Hospital; Johns Hopkins University; Johns Hopkins Medicine; University of Hong Kong; Johns Hopkins University; Johns Hopkins Medicine; Vrije Universiteit Amsterdam; Yonsei University; Yonsei University Health System; Johns Hopkins University; Johns Hopkins Medicine	Tao, Q (corresponding author), Chinese Univ Hong Kong, Ctr Canc, Canc Epigenet Lab, Dept Clin Oncol,PWH, Hong Kong, Hong Kong, Peoples R China.	qtao@clo.cuhk.edu.hk	Tao, Qian/T-4743-2018; Chan, Anthony Tak Cheung/R-3940-2018	Tao, Qian/0000-0001-5383-4808; Chan, Anthony Tak Cheung/0000-0002-6912-8091; Rha, Sun Young/0000-0002-2512-4531; Steenbergen, Renske/0000-0002-2327-9839	NATIONAL CANCER INSTITUTE [P01CA015396] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA15396] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; Chen YJ, 1999, GENE CHROMOSOME CANC, V25, P169, DOI 10.1002/(SICI)1098-2264(199906)25:2<169::AID-GCC13>3.3.CO;2-9; Cheng Y, 2002, GENE CHROMOSOME CANC, V34, P97, DOI 10.1002/gcc.10048; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Deng W, 2004, ONCOGENE, V23, P9090, DOI 10.1038/sj.onc.1208119; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feng BJ, 2002, NAT GENET, V31, P395, DOI 10.1038/ng932; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; Gulley ML, 1998, AM J PATHOL, V152, P865; HILDESHEIM A, 1993, EPIDEMIOL REV, V15, P466, DOI 10.1093/oxfordjournals.epirev.a036130; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; Hui ABY, 2003, MOL CARCINOGEN, V38, P170, DOI 10.1002/mc.10156; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Kim TM, 2005, CLIN CANCER RES, V11, P79; Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573; Lo KW, 2000, CANCER RES, V60, P3348; LO KW, 1995, CANCER RES, V55, P2039; LU SJ, 1990, NATURE, V346, P470, DOI 10.1038/346470a0; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Murray PG, 2004, ONCOGENE, V23, P1326, DOI 10.1038/sj.onc.1207313; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; Plaumann M, 2003, J CANCER RES CLIN, V129, P349, DOI 10.1007/s00432-003-0440-z; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Raab-Traub N, 2002, SEMIN CANCER BIOL, V12, P431, DOI 10.1016/S1044579X0200086X; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; SPRUCK CH, 1992, CANCER RES, V52, P4787; Srivastava G, 2000, BLOOD, V95, P2443, DOI 10.1182/blood.V95.7.2443.007k18_2443_2445; Steenbergen RDM, 2004, JNCI-J NATL CANCER I, V96, P294, DOI 10.1093/jnci/djh031; Steenbergen RDM, 1996, ONCOGENE, V13, P1249; SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516; Tang JCO, 2001, CANCER GENET CYTOGEN, V124, P36, DOI 10.1016/S0165-4608(00)00317-4; Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7; Tao Q, 1998, J VIROL, V72, P7075, DOI 10.1128/JVI.72.9.7075-7083.1998; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Tao Q, 2006, FRONT BIOSCI-LANDMRK, V11, P2672, DOI 10.2741/2000; Teramoto A, 2004, ONCOL REP, V12, P141; Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2; Wang DZM, 1997, CANCER RES, V57, P2478; Wilson PJ, 2000, HUM MUTAT, V15, P156, DOI 10.1002/(SICI)1098-1004(200002)15:2<156::AID-HUMU4>3.0.CO;2-4; Wong CM, 2003, CANCER RES, V63, P7646; Wong ML, 2006, INT J ONCOL, V28, P767; Xiong W, 2004, CANCER RES, V64, P1972, DOI 10.1158/0008-5472.CAN-03-3253; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Yu MC, 2002, SEMIN CANCER BIOL, V12, P421, DOI 10.1016/S1044579X02000858; Yuan BZ, 1998, CANCER RES, V58, P2196; Yuan BZ, 2003, CANCER GENET CYTOGEN, V140, P113, DOI 10.1016/S0165-4608(02)00674-X; Yuan BZ, 2004, ONCOGENE, V23, P1405, DOI 10.1038/sj.onc.1207291; Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064; Zhou L, 2005, NEOPLASIA, V7, P809, DOI 10.1593/neo.05217	53	104	118	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2007	26	6					934	944		10.1038/sj.onc.1209839	http://dx.doi.org/10.1038/sj.onc.1209839			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16862168				2022-12-25	WOS:000244063800013
J	Mathur, M; Samuels, HH				Mathur, M.; Samuels, H. H.			Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas	ONCOGENE			English	Article						PSF-TFE3; siRNA; growth inhibition; apoptosis; transformation; dedifferentiation	PROXIMAL TUBULE CELLS; SOFT PART SARCOMA; TUMOR-CELLS; GENE FUSION; CLEAR-CELL; TFE3; CLASSIFICATION; CONTEXT; TYPE-1; GROWTH	A subset of papillary renal cell carcinomas (RCC) is characterized by the expression of a TFE3 fusion protein, where the fusion partner can be any of the several proteins identified so far such as PSF (PTB associated splicing factor), NonO, PRCC, CLTC and ASPL. These proteins result from chromosomal translocations involving the TFE3 gene located on the X chromosome. Our present study documents the central role of PSF-TFE3 in oncogenic transformation. We show that the inhibition of PSF-TFE3 expression through siRNA or shRNA leads to impaired growth, proliferation, invasion potential and long-term survival of UOK-145 papillary renal carcinoma-derived cells, which endogenously express PSF-TFE3. The oncogenic potential of PSF-TFE3 became evident by stable expression of PSF-TFE3 in NIH-3T3 mouse fibroblast cells, which leads to the acquisition of anchorage-independent growth as revealed by soft agar assay. In addition, the expression of PSF-TFE3 in normal renal proximal tubular epithelial cells from where such tumors originate leads to dedifferentiation and loss of some key functional proteins, which may reflect an initial step in the multistep process of tumor development. This suggests that the expression of PSF-TFE3 in renal epithelial cells plays an important role in the initiation and maintenance of oncogenic phenotype in papillary RCC.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA	New York University; New York University	Mathur, M (corresponding author), NYU, Sch Med, Dept Pharmacol, MSB-411,550 1st Ave, New York, NY 10016 USA.	mathum01@med.nyu.edu; herbert.samuels@med.nyu.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR002083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK016636, R37DK016636, R01DK016636] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR02083] Funding Source: Medline; NIDDK NIH HHS [DK16636] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBINI A, 1987, CANCER RES, V47, P3239; Argani P, 2003, ONCOGENE, V22, P5374, DOI 10.1038/sj.onc.1206686; Argani P, 2001, AM J PATHOL, V159, P179, DOI 10.1016/S0002-9440(10)61684-7; Bennicelli JL, 2002, CURR OPIN ONCOL, V14, P412, DOI 10.1097/00001622-200207000-00008; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Bodmer D, 2002, HUM MOL GENET, V11, P2489, DOI 10.1093/hmg/11.20.2489; Gao CF, 2005, P NATL ACAD SCI USA, V102, P10528, DOI 10.1073/pnas.0504367102; Guo Hong-feng, 2004, Zhonghua Wai Ke Za Zhi, V42, P196; Kolb RJ, 2004, HYPERTENSION, V44, P352, DOI 10.1161/01.HYP.0000136645.90116.1a; Kovacs G, 1997, J PATHOL, V183, P131, DOI 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G; Ladanyi M, 2001, ONCOGENE, V20, P48, DOI 10.1038/sj.onc.1204074; Le TH, 2004, PHYSIOL GENOMICS, V18, P290, DOI 10.1152/physiolgenomics.00120.2003; Lindor NM, 2001, GENET TEST, V5, P101, DOI 10.1089/109065701753145547; Mathur M, 2003, ONCOGENE, V22, P5031, DOI 10.1038/sj.onc.1206643; Morrissey C, 2001, CANCER RES, V61, P7277; Murer H, 2000, PHYSIOL REV, V80, P1373, DOI 10.1152/physrev.2000.80.4.1373; Orosz DE, 2004, IN VITRO CELL DEV-AN, V40, P22; Radisky D, 2001, SEMIN CANCER BIOL, V11, P87, DOI 10.1006/scbi.2000.0360; Sanders ME, 2002, AM J PATHOL, V161, P997, DOI 10.1016/S0002-9440(10)64260-5; Skalsky YM, 2001, ONCOGENE, V20, P178, DOI 10.1038/sj.onc.1204056; Storkel S, 1997, CANCER, V80, P987, DOI 10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R; Weterman MAJ, 2001, ONCOGENE, V20, P1414, DOI 10.1038/sj.onc.1204213; Weterman MAJ, 2001, P NATL ACAD SCI USA, V98, P13808, DOI 10.1073/pnas.241304198; Wiesener MS, 2001, CANCER RES, V61, P5215; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491	25	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					277	283		10.1038/sj.onc.1209783	http://dx.doi.org/10.1038/sj.onc.1209783			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16832349				2022-12-25	WOS:000243398300011
J	Quignon, F; Rozier, L; Lachages, AM; Bieth, A; Simili, M; Debatisse, M				Quignon, F.; Rozier, L.; Lachages, A. -M.; Bieth, A.; Simili, M.; Debatisse, M.			Sustained mitotic block elicits DNA breaks: one-step alteration of ploidy and chromosome integrityin mammalian cells	ONCOGENE			English	Article						double strand breaks; chromosome rearrangements; mitotic slippage; DNA damage checkpoint; spindle checkpoint; tetraploidy	GENOMIC INSTABILITY; P53; TETRAPLOIDY; INHIBITION; ANEUPLOIDY; REREPLICATION; FIBROBLASTS; CHECKPOINTS; MECHANISM; APOPTOSIS	Following prolonged mitotic spindle disruption by microtubule poisons, mammalian cells delay their entry into anaphase, then progressively slip out of mitosis and become tetraploid. Normal cells then stop cycling before S-phase onset, but the mechanisms underlying this arrest are still unclear. Here we show that a double block prevents endo-reduplication. First, cells that exit mitosis without a functional microtubule network are driven toward G0. Reconstitution of the network unmasks a second block that relies on DNA double-strand breaks occurring early in the G1 phase that follows the mitotic block. We propose that a stress signal elicited upon mitotic impairment triggers breakage, which couples the leaky spindle checkpoint to the stringent DNA damage response. Consistent with this finding, cells defective for the damage response continue cycling and acquire, within a single cell cycle, both chromosome rearrangements and abnormal chromosome numbers that remarkably mimic the complex genetic hallmark of tumorigenesis.	Univ Paris 06, Sect Rech, UMR 7147, Inst Curie,CNRS, F-75248 Paris 05, France; CNR, Inst Fisiol Clin, Area Ric, I-56100 Pisa, Italy	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Consiglio Nazionale delle Ricerche (CNR)	Debatisse, M (corresponding author), Univ Paris 06, Sect Rech, UMR 7147, Inst Curie,CNRS, 26 Rue Ulm, F-75248 Paris 05, France.	michelle.debatisse@curie.fr	Quignon, Frédérique/P-4249-2017	Lachages, Anne-Marie/0000-0003-1771-1880				Aardema MJ, 1998, MUTAT RES-REV MUTAT, V410, P3, DOI 10.1016/S1383-5742(97)00029-X; Anglana M, 2001, J BIOL CHEM, V276, P36639, DOI 10.1074/jbc.M104501200; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Casenghi M, 1999, EXP CELL RES, V250, P339, DOI 10.1006/excr.1999.4554; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; Dutrillaux B, 1995, ADV CANCER RES, V67, P59, DOI 10.1016/S0065-230X(08)60710-1; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Halappanavar SS, 2004, CELL CYCLE, V3, P335; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; Khan SH, 1998, CANCER RES, V58, P396; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Mantel CR, 2002, CELL CYCLE, V1, P327, DOI 10.4161/cc.1.5.150; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Martin SS, 2004, BBA-MOL CELL RES, V1692, P145, DOI 10.1016/j.bbamcr.2004.02.008; Masuda A, 2002, ONCOGENE, V21, P6884, DOI 10.1038/sj.onc.1205566; Pusapati RV, 2006, P NATL ACAD SCI USA, V103, P1446, DOI 10.1073/pnas.0507367103; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; STUBBLEFIELD ELTON, 1964, SYMP INT SOC CELL BIOL, V3, P223; TOLEDO F, 1992, EMBO J, V11, P2665, DOI 10.1002/j.1460-2075.1992.tb05332.x; Tritarelli A, 2004, MOL BIOL CELL, V15, P3751, DOI 10.1091/mbc.E03-12-0900; Tsuiki H, 2001, ONCOGENE, V20, P420, DOI 10.1038/sj.onc.1204126; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Wong C, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-6	31	47	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					165	172		10.1038/sj.onc.1209787	http://dx.doi.org/10.1038/sj.onc.1209787			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16832348				2022-12-25	WOS:000243398300001
J	Ferretti, E; Di Marcotullio, L; Gessi, M; Mattei, T; Greco, A; Po, A; De Smaele, E; Giangaspero, F; Riccardi, R; Di Rocco, C; Pazzaglia, S; Maroder, M; Alimandi, M; Screpanti, I; Gulino, A				Ferretti, E.; Di Marcotullio, L.; Gessi, M.; Mattei, T.; Greco, A.; Po, A.; De Smaele, E.; Giangaspero, F.; Riccardi, R.; Di Rocco, C.; Pazzaglia, S.; Maroder, M.; Alimandi, M.; Screpanti, I.; Gulino, A.			Alternative splicing of the ErbB-4 cytoplasmic domain and its regulation by hedgehog signaling identify distinct medulloblastoma subsets	ONCOGENE			English	Article						medulloblastoma; ErbB-4; alternative splicing; hedgehog; Gli1	CHILDHOOD MEDULLOBLASTOMA; EXPRESSION; ISOFORM; CELLS; CANCER; PROLIFERATION; TRANSCRIPTION; RECEPTORS; RENKCTD11; VARIANTS	Medulloblastoma (MB) results from aberrant development of cerebellar neurons in which altered hedgehog (Hh) signalling plays a major role. We investigated the possible influence of Hh signalling on ErbB-receptor expression in MB, in particular that of the ErbB-4 CYT-1 and CYT-2 isoforms generated by alternative splicing of the cytoplasmic domain. ErbB-4 expression was downregulated in Hh-induced MBs from Patched- 1(+/-) mice. Hh signalling (reflected by enhanced expression of the Gli1 transcription factor) inhibited ErbB-4 expression in mouse cerebellar granule progenitors and human MB cells. Analysis of 26 human primary MBs revealed a subset of 11 tumors characterized by low Gli1 levels, upregulated ErbB-4 expression and increased CYT-1: CYT-2 ratios. Interestingly, CYT-1 and Gli1 levels were inversely correlated. ErbB-4 CYT-1 and CYT-2 had different phenotypic effects in cultured MB cells: in response to neuregulin treatment, CYT-2 overexpression inhibited proliferation whereas CYT-1, which includes a phosphatidylinositol 3-kinase (PI3K)-binding site that is missing in CYT-2, enhanced resistance to starvation- and etoposide-induced apoptosis by activating PI3K/Akt signalling. CYT-1: CYT-2 ratios displayed correlation with tumor histotype and ErbB-2 levels, which are established prognostic indices for MB. These findings demonstrate that low-level Hh signalling in human MB is associated with the selective maintenance of high ErbB-4 CYT-1 expression, an alteration that exerts tumor-promoting effects.	Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy; Natl Neurol Inst C Besta, Div Neuropathol, Milan, Italy; Neuromed Inst, Isernia, Italy; Catholic Univ Rome, Dept Pediat, Rome, Italy; Catholic Univ Rome, Inst Neurosurg, Rome, Italy; ENEA CR, Biotechnol Unit, Rome, Italy; Cenci Bolognetti Fdn, Inst Pasteur, Rome, Italy	Sapienza University Rome; IRCCS Istituto Neurologico Besta; IRCCS Neuromed; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Italian National Agency New Technical Energy & Sustainable Economics Development; Fondazione Cenci Bolognetti	Gulino, A (corresponding author), Univ Roma La Sapienza, Dept Expt Med & Pathol, 324 Viale Regina Elena, I-00161 Rome, Italy.	alberto.gulino@uniroma1.it	Po, Agnese/AEQ-0192-2022; Giangaspero, Felice/Z-4961-2019; Mattei, Tobias A./U-7166-2019; Gessi, Marco/K-2572-2018; Giangaspero, Felice/AAH-9253-2020; De Smaele, Enrico/C-1124-2013; Alimandi, Maurizio/AAG-9246-2019; Po, Agnese/G-8754-2015; Ferretti, Elisabetta/G-5413-2013	Po, Agnese/0000-0002-9346-8782; Giangaspero, Felice/0000-0001-5382-2380; Giangaspero, Felice/0000-0001-5382-2380; De Smaele, Enrico/0000-0003-4524-4423; Alimandi, Maurizio/0000-0002-1409-6803; Po, Agnese/0000-0002-9346-8782; RICCARDI, RICCARDO/0000-0001-7515-6622; Ferretti, Elisabetta/0000-0001-7265-6429; DI MARCOTULLIO, LUCIA/0000-0003-0274-7178	Telethon [GGP04168] Funding Source: Medline	Telethon(Fondazione Telethon)		Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Argenti B, 2005, J NEUROSCI, V25, P8338, DOI 10.1523/JNEUROSCI.2438-05.2005; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; Di Marcotullio L, 2004, P NATL ACAD SCI USA, V101, P10833, DOI 10.1073/pnas.0400690101; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Elenius K, 1999, ONCOGENE, V18, P2607, DOI 10.1038/sj.onc.1202612; Ferretti E, 2005, TRENDS MOL MED, V11, P537, DOI 10.1016/j.molmed.2005.10.005; Fox IJ, 2005, J NEUROSCI RES, V79, P584, DOI 10.1002/jnr.20381; Gajjar A, 2004, J CLIN ONCOL, V22, P984, DOI 10.1200/JCO.2004.06.032; Gambarotta G, 2004, J BIOL CHEM, V279, P48808, DOI 10.1074/jbc.M408374200; GIANGASPERO F, 2002, PATHOLOGY GENETICS T, P129; Gilbertson R, 2001, GENE CHROMOSOME CANC, V31, P288, DOI 10.1002/gcc.1146; Gilbertson RJ, 1998, CANCER RES, V58, P3932; Gilbertson RJ, 1997, CANCER RES, V57, P3272; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Junttila TT, 2000, TRENDS CARDIOVAS MED, V10, P304, DOI 10.1016/S1050-1738(01)00065-2; Junttila TT, 2003, CLIN CANCER RES, V9, P5346; Kainulainen V, 2000, J BIOL CHEM, V275, P8641, DOI 10.1074/jbc.275.12.8641; Marti E, 2002, TRENDS NEUROSCI, V25, P89, DOI 10.1016/S0166-2236(02)02062-3; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Omerovic J, 2004, EXP CELL RES, V294, P469, DOI 10.1016/j.yexcr.2003.12.002; Ozaki M, 1998, NEUROSCI RES, V30, P351, DOI 10.1016/S0168-0102(98)00013-3; Pazzaglia S, 2002, ONCOGENE, V21, P7580, DOI 10.1038/sj.onc.1205973; Rieff HI, 1999, J NEUROSCI, V19, P10757, DOI 10.1523/JNEUROSCI.19-24-10757.1999; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	29	39	40	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	55					7267	7273		10.1038/sj.onc.1209716	http://dx.doi.org/10.1038/sj.onc.1209716			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16878160				2022-12-25	WOS:000242244700005
J	Kunzelmann, S; Praefcke, GJK; Herrmann, C				Kunzelmann, Simone; Praefcke, Gerrit J. K.; Herrmann, Christian			Transient kinetic investigation of GTP hydrolysis catalyzed by interferon-gamma-induced hGBP1 (human guanylate binding protein 1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-1 HGBP1; DOMINANT OPTIC ATROPHY; NUCLEOTIDE-BINDING; MEDIATED ENDOCYTOSIS; ANTIVIRAL ACTIVITY; DYNAMIN; MECHANISM; MXA; IDENTIFICATION; MICROTUBULES	Within the family of large GTP-binding proteins, human guanylate binding protein 1 (hGBP1) belongs to a subgroup of interferon-inducible proteins. GTP hydrolysis activity of these proteins is much higher compared with members of other GTPase families and underlies mechanisms that are not understood. The large GTP-binding proteins form self-assemblies that lead to stimulation of the catalytic activity. The unique result of GTP hydrolysis catalyzed by hGBP1 is GDP and GMP. We investigated this reaction mechanism by transient kinetic methods using radioactively labeled GTP as well as fluorescent probes. Substrate binding and formation of the hGBP1 homodimer are fast as no lag phase is observed in the time courses of GTP hydrolysis. Instead, multiple turnover experiments show a rapid burst of Pi formation prior to the steady state phase, indicating a rate-limiting step after GTP cleavage. Both molecules are catalytically active and cleave off a phosphate ion in the first step. Then bifurcation into catalytic inactivation, probably by irreversible dissociation of the dimer, and into GDP hydrolysis is observed. The second cleavage step is even faster than the first step, implying a rapid rearrangement of the nucleotide within the catalytic center of hGBP1. We could also show that the release of the products, including the phosphate ions, is fast and not limiting the steady state activity. We suggest that slow dissociation of the GMP-bound homodimer gives rise to the burst behavior and controls the steady state. The assembled forms of the GDP- and GMP-bound states of hGBP1 are accessible only through GTP binding and hydrolysis and achieve a lifetime of a few seconds.	Ruhr Univ Bochum, Fak Chem & Biochem, D-44780 Bochum, Germany; Univ Cologne, Genet Inst, Ctr Mol Med Cologne, D-50674 Cologne, Germany	Ruhr University Bochum; University of Cologne	Herrmann, C (corresponding author), Ruhr Univ Bochum, Fak Chem & Biochem, D-44780 Bochum, Germany.	chr.herrmann@rub.de		Praefcke, Gerrit/0000-0001-8818-1499				Accola MA, 2002, J BIOL CHEM, V277, P21829, DOI 10.1074/jbc.M201641200; Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; Anderson SL, 1999, VIROLOGY, V256, P8, DOI 10.1006/viro.1999.9614; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Binns DD, 2000, BIOCHEMISTRY-US, V39, P7188, DOI 10.1021/bi000033r; Bitoun M, 2005, NAT GENET, V37, P1207, DOI 10.1038/ng1657; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Brune M, 1998, BIOCHEMISTRY-US, V37, P10370, DOI 10.1021/bi9804277; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Fersht A., 1999, STRUCTURE MECH PROTE, P153; Flohr F, 1999, FEBS LETT, V463, P24, DOI 10.1016/S0014-5793(99)01598-7; Geeves MA, 2005, ADV PROTEIN CHEM, V71, P161, DOI 10.1016/S0065-3233(04)71005-0; Ghosh A, 2006, NATURE, V440, P101, DOI 10.1038/nature04510; Haller O, 2002, TRAFFIC, V3, P710, DOI 10.1034/j.1600-0854.2002.31003.x; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Janzen C, 2000, J VIROL, V74, P8202, DOI 10.1128/JVI.74.17.8202-8206.2000; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; Kunzelmann S, 2005, METHOD ENZYMOL, V404, P512, DOI 10.1016/S0076-6879(05)04045-0; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Modiano N, 2005, P NATL ACAD SCI USA, V102, P8680, DOI 10.1073/pnas.0503227102; NOWAK E, 1988, BIOCHEMISTRY-US, V27, P8613, DOI 10.1021/bi00423a016; Praefcke GJK, 2004, J MOL BIOL, V344, P257, DOI 10.1016/j.jmb.2004.09.026; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Praefcke GJK, 1999, J MOL BIOL, V292, P321, DOI 10.1006/jmbi.1999.3062; Prakash B, 2000, NATURE, V403, P567, DOI 10.1038/35000617; Sauter S M, 2004, Hum Mutat, V23, P98, DOI 10.1002/humu.9205; SCHWEMMLE M, 1994, J BIOL CHEM, V269, P11299; Sever S, 2000, J CELL BIOL, V150, P1137, DOI 10.1083/jcb.150.5.1137; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; TRENTHAM DR, 1976, Q REV BIOPHYS, V9, P217, DOI 10.1017/S0033583500002419; Uthaiah RC, 2003, J BIOL CHEM, V278, P29336, DOI 10.1074/jbc.M211973200; Zhang PJ, 2001, NAT CELL BIOL, V3, P922, DOI 10.1038/ncb1001-922	38	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28627	28635		10.1074/jbc.M604911200	http://dx.doi.org/10.1074/jbc.M604911200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16873363	hybrid			2022-12-25	WOS:000240680500016
J	Weeks, CS; Tanabe, H; Cummings, JE; Crampton, SP; Sheynis, T; Jelinek, R; Vanderlick, TK; Cocco, MJ; Ouellette, AJ				Weeks, Colby S.; Tanabe, Hiroki; Cummings, Jason E.; Crampton, Steve P.; Sheynis, Tanya; Jelinek, Raz; Vanderlick, T. Kyle; Cocco, Melanie J.; Ouellette, Andre J.			Matrix metalloproteinase-7 activation of mouse Paneth cell pro-alpha-defensins - SER43 down arrow ILE44 proteolysis enables membrane-disruptive activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE DEFENSINS; SMALL-INTESTINE; HOST-DEFENSE; CRYPTDIN-4; RESISTANCE; MICE; DETERMINANTS; CYTOLYSIS; MECHANISM; PROTEINS	Small intestinal Paneth cells secrete alpha-defensin microbicidal peptides as mediators of innate enteric immunity. In mice, production of mature Paneth cell alpha-defensins, termed cryptdins (Crps), requires proteolytic activation of inactive precursors (pro-Crps) by the convertase matrix metalloproteinase-7. Proteolysis of mouse (pro-Crp4)(20-92) produces the specific cleavage intermediates pro-Crp4(44-92), pro-Crp4(54-92), and pro-Crp4(59-92). To identify which cleavage event enables bactericidal activity, recombinant pro-Crp4-processing intermediates were purified to homogeneity and assayed for bactericidal peptide activity. The in vitro bactericidal activities of pro-Crp4-processing intermediates were very similar to fully processed Crp4, contrasting the lack of bactericidal and membrane-disruptive activity shown by pro-Crp4(20-92). Thus, cleavage of proCrp4(20-92) at Ser(43)down arrow Ile(44) is sufficient to activate bactericidal activity, and amino acids in the pro-Crp4(20-43) of the proregion maintain the precursor in an inactive state. Because cationic Arg residues are determinants of Crp4 bactericidal peptide activity, we hypothesized that Asp and Glu residues in proCrp4(20-43) neutralize Crp4 Arg side chains in pro-Crp4(20-92). Therefore, a pro-Crp4(20-92) variant with Gly substitutions at all pro-Crp4(20-43) Asp and Glu positions ((DE/G)-pro-Crp4) was prepared, and it was bactericidal and lysed phospholipid vesicles under conditions where native pro-Crp4(20-92) lacks activity. These findings show that MMP-7 proteolysis of pro-Crp4(20-92) at Ser(43)down arrow Ile(44) converts inactive precursors to bactericidal forms by removal of covalently associated, inhibitory acidic amino acids from proximity with the Crp4 component of the molecule.	Univ Calif Irvine, Coll Hlth Sci, Sch Med, Dept Pathol & Lab Med, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Hlth Sci, Sch Med, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Hlth Sci, Sch Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Hlth Sci, Sch Med, Ctr Immunol, Irvine, CA 92697 USA; Asahikawa Med Coll, Dept Internal Med 3, Asahikawa, Hokkaido 078, Japan; Princeton Univ, Dept Chem Engn, Princeton, NJ 08544 USA; Ben Gurion Univ Negev, Dept Chem, IL-84105 Beer Sheva, Israel	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; Asahikawa Medical College; Princeton University; Ben Gurion University	Ouellette, AJ (corresponding author), Univ Calif Irvine, Coll Hlth Sci, Sch Med, Dept Pathol & Lab Med, C440, Irvine, CA 92697 USA.	aouellet@uci.edu	Cocco, Melanie J/B-7929-2010; JELINEK, RAZ/F-2023-2012	Cocco, Melanie J/0000-0003-4039-5863; jelinek, raz/0000-0002-0336-1384	NIDDK NIH HHS [DK044632] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK044632, R01DK044632] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayabe T, 2002, J BIOL CHEM, V277, P5219, DOI 10.1074/jbc.M109410200; Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Clarke LL, 2004, AM J PHYSIOL-GASTR L, V286, pG1050, DOI 10.1152/ajpgi.00393.2003; Cummings JE, 2003, AUST J CHEM, V56, P1031, DOI 10.1071/CH03110; DAHER KA, 1988, P NATL ACAD SCI USA, V85, P7327, DOI 10.1073/pnas.85.19.7327; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FIELDS PI, 1989, SCIENCE, V243, P1059, DOI 10.1126/science.2646710; Ghosh D, 2002, NAT IMMUNOL, V3, P583, DOI 10.1038/ni797; Hristova K, 1996, BIOCHEMISTRY-US, V35, P11888, DOI 10.1021/bi961100d; Jelinek R, 2001, BIOTECHNOL ADV, V19, P109, DOI 10.1016/S0734-9750(00)00064-1; Jing WG, 2004, BIOCHEMISTRY-US, V43, P15759, DOI 10.1021/bi048645p; Kolusheva S, 2000, BIOCHEMISTRY-US, V39, P15851, DOI 10.1021/bi000570b; LICHTENSTEIN A, 1986, BLOOD, V68, P1407; LICHTENSTEIN AK, 1988, J IMMUNOL, V140, P2686; LIU L, 1995, BLOOD, V85, P1095, DOI 10.1182/blood.V85.4.1095.bloodjournal8541095; Maemoto A, 2004, J BIOL CHEM, V279, P44188, DOI 10.1074/jbc.M406154200; MICHAELSON D, 1992, J LEUKOCYTE BIOL, V51, P634, DOI 10.1002/jlb.51.6.634; MILLER SI, 1990, INFECT IMMUN, V58, P3706, DOI 10.1128/IAI.58.11.3706-3710.1990; Norkina O, 2004, INFECT IMMUN, V72, P6040, DOI 10.1128/IAI.72.10.6040-6049.2004; OKRENT DG, 1990, AM REV RESPIR DIS, V141, P179, DOI 10.1164/ajrccm/141.1.179; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Putsep K, 2000, J BIOL CHEM, V275, P40478, DOI 10.1074/jbc.M007816200; Salzman NH, 2003, NATURE, V422, P522, DOI 10.1038/nature01520; Satchell DP, 2003, PEPTIDES, V24, P1795, DOI 10.1016/j.peptides.2003.08.020; Satchell DP, 2003, J BIOL CHEM, V278, P13838, DOI 10.1074/jbc.M212115200; Selsted ME, 2005, NAT IMMUNOL, V6, P551, DOI 10.1038/ni1206; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; Shirafuji Y, 2003, J BIOL CHEM, V278, P7910, DOI 10.1074/jbc.M210600200; SMOLARSKY M, 1977, J IMMUNOL METHODS, V15, P255, DOI 10.1016/0022-1759(77)90063-1; Tanabe H, 2004, J BIOL CHEM, V279, P11976, DOI 10.1074/jbc.M310251200; Valore EV, 1996, J CLIN INVEST, V97, P1624, DOI 10.1172/JCI118588; VALORE EV, 1992, BLOOD, V79, P1538; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; WIMLEY WC, 1994, PROTEIN SCI, V3, P1362, DOI 10.1002/pro.5560030902; Wu Z, 2003, J PEPT RES, V62, P53, DOI 10.1034/j.1399-3011.2003.00068.x; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	36	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28932	28942		10.1074/jbc.M602041200	http://dx.doi.org/10.1074/jbc.M602041200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16822871	hybrid			2022-12-25	WOS:000240680500047
J	Zanzouri, M; Lauritzen, I; Duprat, F; Mazzuca, M; Lesage, F; Lazdunski, M; Patel, A				Zanzouri, Marc; Lauritzen, Inger; Duprat, Fabrice; Mazzuca, Michel; Lesage, Florian; Lazdunski, Michel; Patel, Amanda			Membrane potential-regulated transcription of the resting K+ conductance TASK-3 via the calcineurin pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; DOMAIN POTASSIUM CHANNEL; SUBUNIT MESSENGER-RNA; INDUCED DEPOLARIZATION; RECEPTOR SUBUNITS; RAT-BRAIN; NEURONS; EXPRESSION; ACID; NEUROTRANSMITTERS	The 2P domain K+ channel TASK-3 is highly expressed in cerebellar granule neurons where it has been proposed to underlie the K+ leak conductance, IKso. In a previous work we showed that expression of TASK-3 increases in cerebellar granule neurons as they mature in culture. Here we show that within the cerebellum, levels of TASK-3 mRNA increase as granule neurons migrate to their adult positions and receive excitatory mossy fiber input. To understand the mechanism of this increase in TASK-3 expression we used an in vitro model culturing the neurons in either depolarizing conditions mimicking neuronal activity (25K, 25 mM KCl) or in conditions which approach deafferentation (5K, 5 mM KCl). An important increase in TASK-3 mRNA is uniquely observed in 25K and is specific since other background K+ channel levels remain unchanged or decrease. The rise in TASK-3 mRNA leads to an increase in TASK-3 protein and the IKso conductance resulting in hyperpolarization. Blocking L-type calcium channels or their downstream effector calcineurin, abrogates TASK-3 expression and IKso, leading to hyperexcitability. This is the first study demonstrating that depolarization-induced Ca2+ entry can directly regulate cellular excitability by dynamically regulating the transcription of a resting K+ conductance. The appearance of this conductance may play an important role in the transition of depolarized immature neurons to their mature hyperpolarized state during neuronal development.	CNRS, UMR 6097, IPMC, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Patel, A (corresponding author), CNRS, UMR 6097, IPMC, 660 Route Lucioles, F-06560 Valbonne, France.	patel@ipmc.cnrs.fr	Duprat, Fabrice/D-1221-2013; Lesage, Florian/P-9780-2019; Lesage, Florian/D-5097-2011; Lauritzen, Inger/AAE-9927-2022; Lauritzen, Inger/AFF-7261-2022	Duprat, Fabrice/0000-0001-8774-1220; Lesage, Florian/0000-0002-4406-7106; Lesage, Florian/0000-0002-4406-7106; lauritzen, inger/0000-0002-2011-1387				Aller MI, 2005, J NEUROSCI, V25, P11455, DOI 10.1523/JNEUROSCI.3153-05.2005; BALAZS R, 1988, DEV BRAIN RES, V40, P269, DOI 10.1016/0165-3806(88)90139-3; Berg AP, 2004, J NEUROSCI, V24, P6693, DOI 10.1523/JNEUROSCI.1408-04.2004; BESSHO Y, 1994, NEURON, V12, P87, DOI 10.1016/0896-6273(94)90154-6; Blaeser F, 2000, J BIOL CHEM, V275, P197, DOI 10.1074/jbc.275.1.197; Brickley SG, 2001, NATURE, V409, P88, DOI 10.1038/35051086; Buckler KJ, 2000, J PHYSIOL-LONDON, V525, P135, DOI 10.1111/j.1469-7793.2000.00135.x; Buckler KJ, 1997, J PHYSIOL-LONDON, V498, P649, DOI 10.1113/jphysiol.1997.sp021890; Carafoli E, 1999, BIOCHEM BIOPH RES CO, V266, P624, DOI 10.1006/bbrc.1999.1879; Chemin J, 2003, EMBO J, V22, P5403, DOI 10.1093/emboj/cdg528; Clarke CE, 2004, J PHYSIOL-LONDON, V560, P51, DOI 10.1113/jphysiol.2004.070292; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Czirjak G, 2002, J BIOL CHEM, V277, P5426, DOI 10.1074/jbc.M107138200; Czirjak G, 2003, MOL PHARMACOL, V63, P646, DOI 10.1124/mol.63.3.646; Czirjak G, 2002, MOL ENDOCRINOL, V16, P621, DOI 10.1210/me.16.3.621; Czirjak G, 2001, AM J PHYSIOL-CELL PH, V281, pC700, DOI 10.1152/ajpcell.2001.281.2.C700; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Engblom AC, 2003, J BIOL CHEM, V278, P16543, DOI 10.1074/jbc.M300548200; GALLO V, 1987, J NEUROSCI, V7, P2203; Gault LM, 1997, J NEUROSCI, V17, P2391; Han J, 2002, J PHYSIOL-LONDON, V542, P431, DOI 10.1113/jphysiol.2002.017590; HAN TH, 1995, MOL CELL BIOL, V15, P2907; Herrup K, 1997, ANNU REV NEUROSCI, V20, P61, DOI 10.1146/annurev.neuro.20.1.61; Kang DW, 2004, J PHYSIOL-LONDON, V554, P64, DOI 10.1113/jphysiol.2003.054387; Kim Y, 2000, J BIOL CHEM, V275, P9340, DOI 10.1074/jbc.275.13.9340; Kramer D, 2003, MOL CELL NEUROSCI, V23, P325, DOI 10.1016/S1044-7431(03)00057-5; LAURIE DJ, 1992, J NEUROSCI, V12, P4151; Lauritzen I, 2003, J BIOL CHEM, V278, P32068, DOI 10.1074/jbc.M302631200; Leonoudakis D, 1998, J NEUROSCI, V18, P868; Lesage F, 1996, EMBO J, V15, P6400, DOI 10.1002/j.1460-2075.1996.tb01031.x; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Lossi L, 2002, NEUROSCIENCE, V112, P509, DOI 10.1016/S0306-4522(02)00112-4; Macian F, 2002, CELL, V109, P719, DOI 10.1016/S0092-8674(02)00767-5; Mao ZX, 1999, J BIOL CHEM, V274, P31102, DOI 10.1074/jbc.274.43.31102; Marley PD, 1996, BIOCHEM BIOPH RES CO, V221, P15, DOI 10.1006/bbrc.1996.0536; Mathie A, 2003, CEREBELLUM, V2, P11, DOI 10.1080/14734220310015593; Mellor JR, 1998, J PHYSIOL-LONDON, V506, P377, DOI 10.1111/j.1469-7793.1998.377bw.x; Meuth SG, 2003, J NEUROSCI, V23, P6460; Millar JA, 2000, P NATL ACAD SCI USA, V97, P3614, DOI 10.1073/pnas.050012597; NAKANISHI S, 2006, IN PRESS J PHYSL LON; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; Patel AJ, 2004, PFLUG ARCH EUR J PHY, V448, P261, DOI 10.1007/s00424-004-1255-8; RESINK A, 1995, EUR J NEUROSCI, V7, P1700, DOI 10.1111/j.1460-9568.1995.tb00691.x; RESINK A, 1995, J NEUROCHEM, V64, P558; ROSS CA, 1990, TRENDS NEUROSCI, V13, P216, DOI 10.1016/0166-2236(90)90163-5; Sato M, 2005, P NATL ACAD SCI USA, V102, P5874, DOI 10.1073/pnas.0501972102; Sirois JE, 2002, J PHYSIOL-LONDON, V541, P717, DOI 10.1113/jphysiol.2002.018119; Takayasu Y, 2003, J NEUROSCI, V23, P6200; Talley EM, 2001, J NEUROSCI, V21, P7491, DOI 10.1523/JNEUROSCI.21-19-07491.2001; Talley EM, 2002, J BIOL CHEM, V277, P17733, DOI 10.1074/jbc.M200502200; Talley EM, 2000, NEURON, V25, P399, DOI 10.1016/S0896-6273(00)80903-4; Voogd J, 1998, TRENDS NEUROSCI, V21, P370, DOI 10.1016/S0166-2236(98)01318-6; Washburn CP, 2002, J NEUROSCI, V22, P1256, DOI 10.1523/JNEUROSCI.22-04-01256.2002; Watkins CS, 1996, J PHYSIOL-LONDON, V491, P401, DOI 10.1113/jphysiol.1996.sp021224; ZHENG T, 1993, DEV BRAIN RES, V75, P91, DOI 10.1016/0165-3806(93)90068-L	56	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28910	28918		10.1074/jbc.M606092200	http://dx.doi.org/10.1074/jbc.M606092200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16864570	hybrid			2022-12-25	WOS:000240680500045
J	Hashmi, S; Zhang, J; Oksov, Y; Ji, QM; Lustigman, S				Hashmi, Sarwar; Zhang, Jun; Oksov, Yelena; Ji, Qiongmei; Lustigman, Sara			The Caenorhabditis elegans CPI-2a cystatin-like inhibitor has an essential regulatory role during oogenesis and fertilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEINASE-INHIBITORS; MOUSE EMBRYO IMPLANTATION; OOCYTE MEIOTIC MATURATION; CATHEPSIN-L; ONCHOCERCA-VOLVULUS; MOLECULAR-CLONING; YOLK PROTEINS; C-ELEGANS; EXPRESSION PATTERNS; PROTEASE INHIBITOR	In the present study, we characterized a sterile cpi-2a(ok1256) deletion mutant in Caenorhabditis elegans and showed that CPI-2a has an essential regulatory role during oogenesis and fertilization. We have also shown that the CPI2a inhibitor and both Ce-CPL-1 and Ce-CPZ-1 enzymes are present in the myo-epithelial sheath surrounding germ cells, oocytes, and embryos as well as in the yolk granules within normal oocytes. Staining of mutant worms with anti-yolk protein antibodies has indicted that the proteins are not present in the mature oocytes. Moreover, green fluorescent protein expression was absence or reduced in cpi-2a/yp170:gfp mutant oocytes, although it was expressed in one of the successfully developed embryos. Based on these results, we hypothesize that the sterility in cpi2a(ok1256) mutant worms is potentially caused by two possible mechanisms: 1) defects in the uptake and/or processing of yolk proteins by the growing oocytes and 2) indirect induction of defects in cell-cell signaling that is critical for promoting germ line development, oocyte maturation, ovulation, and fertilization. A defect in any of these processes would have detrimental effects on the development of normal embryos and consequently normal production of progenies as we observed in cpi-2a mutant worms. This is the first study that demonstrates the expression of cysteine proteases and their endogenous inhibitor in the gonadal sheath cells surrounding germ cells and oocytes, which indirectly have established their potential involvement in proteolytic processing of molecules within the gonadal sheath cells, such as components of the extracellular matrix or the cytoskeletal proteins, which are essential for proper cell-cell signaling activities of the gonadal sheath cells during normal maturation and ovulation processes.	New York Blood Ctr, Lab Mol Parasitol, Lindsley F Kimball Res Inst, New York, NY 10021 USA; New York Blood Ctr, Lab Electron Microscopy, Lindsley F Kimball Res Inst, New York, NY 10021 USA; New York Blood Ctr, Lab Biochem & Mol Genet, Lindsley F Kimball Res Inst, New York, NY 10021 USA	New York Blood Center; New York Blood Center; New York Blood Center	Hashmi, S (corresponding author), New York Blood Ctr, Lab Mol Parasitol, Lindsley F Kimball Res Inst, 310 E 67th St, New York, NY 10021 USA.	shashmi@nybloodcenter.org			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048057, R21AI048057] Funding Source: NIH RePORTER; NIAID NIH HHS [AI48057] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAMSON M, 1987, J BIOL CHEM, V262, P9688; ABRAHAMSON M, 1994, METHOD ENZYMOL, V244, P685; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; Afonso S, 1997, DEVELOPMENT, V124, P3415; Alexander CM, 1996, DEVELOPMENT, V122, P1723; BARRETT AJ, 1984, BIOCHEM BIOPH RES CO, V120, P631, DOI 10.1016/0006-291X(84)91302-0; BARRETT AJ, 1986, BIOCHEM J, V236, P312, DOI 10.1042/bj2360312; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BODE VC, 1988, GENETICS, V118, P299; BRENNER S, 1974, GENETICS, V77, P71; Britton C, 2004, J CELL SCI, V117, P5133, DOI 10.1242/jcs.01387; BROMME D, 1991, BIOMED BIOCHIM ACTA, V50, P631; Carnevali O, 1999, BIOL REPROD, V61, P785, DOI 10.1095/biolreprod61.3.785; Carnevali O, 1999, BIOL REPROD, V60, P140, DOI 10.1095/biolreprod60.1.140; Chagas JR, 1997, MOL BIOCHEM PARASIT, V88, P85, DOI 10.1016/S0166-6851(97)00085-6; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; Cho WL, 1999, J BIOL CHEM, V274, P13311, DOI 10.1074/jbc.274.19.13311; CORNWALL GA, 1992, MOL ENDOCRINOL, V6, P1653, DOI 10.1210/me.6.10.1653; Coulibaly S, 1999, INT J CANCER, V83, P526, DOI 10.1002/(SICI)1097-0215(19991112)83:4<526::AID-IJC15>3.3.CO;2-D; Cram EJ, 2003, J CELL SCI, V116, P3871, DOI 10.1242/jcs.00705; DASTON GP, 1991, TERATOLOGY, V43, P253, DOI 10.1002/tera.1420430309; Fabra M, 2004, MOL REPROD DEV, V67, P282, DOI 10.1002/mrd.20018; FAGOTTO F, 1990, ARCH INSECT BIOCHEM, V14, P237, DOI 10.1002/arch.940140404; FAGOTTO F, 1990, ARCH INSECT BIOCHEM, V14, P217, DOI 10.1002/arch.940140403; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Grant B, 1999, MOL BIOL CELL, V10, P4311, DOI 10.1091/mbc.10.12.4311; GRUBB JD, 1991, PLACENTA, V12, P143, DOI 10.1016/0143-4004(91)90018-B; Guiliano DB, 2004, MOL BIOCHEM PARASIT, V136, P227, DOI 10.1016/j.molbiopara.2004.03.015; Hall DH, 1999, DEV BIOL, V212, P101, DOI 10.1006/dbio.1999.9356; Hartmann S, 1997, EUR J IMMUNOL, V27, P2253, DOI 10.1002/eji.1830270920; Hashmi S, 2002, J BIOL CHEM, V277, P3477, DOI 10.1074/jbc.M106117200; Hashmi S, 2004, J BIOL CHEM, V279, P6035, DOI 10.1074/jbc.M312346200; Henskens YMC, 1996, BIOL CHEM H-S, V377, P71; Iwasaki K, 1996, J CELL BIOL, V134, P699, DOI 10.1083/jcb.134.3.699; Janke DL, 1997, GENOME RES, V7, P974, DOI 10.1101/gr.7.10.974; Johnstone IL, 1996, EMBO J, V15, P3633, DOI 10.1002/j.1460-2075.1996.tb00732.x; Jokimaa V, 2001, MOL HUM REPROD, V7, P73, DOI 10.1093/molehr/7.1.73; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kestemont P, 1999, FISH PHYSIOL BIOCHEM, V21, P59, DOI 10.1023/A:1007714314072; KIMBLE J, 1983, DEV BIOL, V96, P189, DOI 10.1016/0012-1606(83)90322-6; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; Kwon JY, 2001, BIOL REPROD, V65, P1701, DOI 10.1095/biolreprod65.6.1701; LAH TT, 1989, BIOCHIM BIOPHYS ACTA, V993, P63, DOI 10.1016/0304-4165(89)90144-X; Lee M, 2001, J BIOL CHEM, V276, P36404, DOI 10.1074/jbc.M105795200; Liu XD, 1996, J BIOL CHEM, V271, P33344, DOI 10.1074/jbc.271.52.33344; Lustigman S, 1996, J BIOL CHEM, V271, P30181, DOI 10.1074/jbc.271.47.30181; Lustigman S, 2002, TRENDS PARASITOL, V18, P135, DOI 10.1016/S1471-4922(01)02211-5; LUSTIGMAN S, 1991, MOL BIOCHEM PARASIT, V45, P65, DOI 10.1016/0166-6851(91)90028-5; LUSTIGMAN S, 1992, J BIOL CHEM, V267, P17339; Lustigmana S, 2004, MOL BIOCHEM PARASIT, V138, P165, DOI 10.1016/j.molbiopara.2004.08.003; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; Manoury B, 2001, CURR BIOL, V11, P447, DOI 10.1016/S0960-9822(01)00118-X; McCarter J, 1997, DEV BIOL, V181, P121, DOI 10.1006/dbio.1996.8429; McCarter J, 1999, DEV BIOL, V205, P111, DOI 10.1006/dbio.1998.9109; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Miller DM, 1995, METHOD CELL BIOL, V48, P365; Miller MA, 2001, SCIENCE, V291, P2144, DOI 10.1126/science.1057586; Morales FC, 2004, MOL BIOCHEM PARASIT, V134, P65, DOI 10.1016/j.molbiopara.2003.10.016; Myers CD, 1996, J CELL BIOL, V132, P1061, DOI 10.1083/jcb.132.6.1061; Newlands GFJ, 2001, PARASITOLOGY, V122, P371, DOI 10.1017/S0031182001007302; Oksjoki S, 2001, MOL HUM REPROD, V7, P27, DOI 10.1093/molehr/7.1.27; Ono K, 2004, MOL BIOL CELL, V15, P2782, DOI 10.1091/mbc.E04-03-0179; OPRESKO LK, 1987, CELL, V51, P557, DOI 10.1016/0092-8674(87)90125-5; ORLOWSKI M, 1983, MOL CELL BIOCHEM, V52, P49; Peloille S, 1997, EUR J BIOCHEM, V244, P140, DOI 10.1111/j.1432-1033.1997.00140.x; Pfaff AW, 2002, INT J PARASITOL, V32, P171, DOI 10.1016/S0020-7519(01)00350-2; RAWLINGS ND, 1990, J MOL EVOL, V30, P60, DOI 10.1007/BF02102453; RETZEK H, 1992, DNA CELL BIOL, V11, P661, DOI 10.1089/dna.1992.11.661; RIBOLLA PEM, 1993, INSECT BIOCHEM MOLEC, V23, P217, DOI 10.1016/0965-1748(93)90002-A; Rose KL, 1997, DEV BIOL, V192, P59, DOI 10.1006/dbio.1997.8728; Saftig P, 2000, ADV EXP MED BIOL, V477, P293; SCHEDL T, 1997, C ELEGANS, V2, P241; Schierack P, 2003, INFECT IMMUN, V71, P2422, DOI 10.1128/IAI.71.5.2422-2429.2003; SHARROCK WJ, 1990, J BIOL CHEM, V265, P14422; SHARROCK WJ, 1984, J MOL BIOL, V174, P419, DOI 10.1016/0022-2836(84)90329-2; SHARROCK WJ, 1983, DEV BIOL, V96, P182, DOI 10.1016/0012-1606(83)90321-4; SLOANE BF, 1990, BIOL CHEM H-S, V371, P193; STOKA V, 1995, FEBS LETT, V370, P101, DOI 10.1016/0014-5793(95)00798-E; TAKAHASHI SY, 1993, J BIOCHEM, V114, P267, DOI 10.1093/oxfordjournals.jbchem.a124165; Tepel C, 2000, J CELL SCI, V113, P4487; Troeberg L, 1996, EUR J BIOCHEM, V238, P728, DOI 10.1111/j.1432-1033.1996.0728w.x; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; WOESSNER S, 1991, Sangre (Saragossa), V36, P301; Woessner S, 1982, Sangre (Barc), V27, P739; Xu XJ, 2006, EXP CELL RES, V312, P1475, DOI 10.1016/j.yexcr.2006.01.006; YAMAMOTO Y, 1993, COMP BIOCHEM PHYS B, V106, P35, DOI 10.1016/0305-0491(93)90004-O; Yoshizaki N, 1998, DEV GROWTH DIFFER, V40, P659	89	18	26	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28415	28429		10.1074/jbc.M600254200	http://dx.doi.org/10.1074/jbc.M600254200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16857685	hybrid			2022-12-25	WOS:000240534400079
J	Lebrun, AH; Wunder, C; Hildebrand, J; Churin, Y; Zahringer, U; Lindner, B; Meyer, TF; Heinz, E; Warnecke, D				Lebrun, Anne-Helene; Wunder, Christian; Hildebrand, Janosch; Churin, Yuri; Zaehringer, Ulrich; Lindner, Buko; Meyer, Thomas F.; Heinz, Ernst; Warnecke, Dirk			Cloning of a cholesterol-alpha-glucosyltransferase from Helicobacter pylori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-SEQUENCE SIMILARITIES; PICHIA-PASTORIS; FUNCTIONAL EXPRESSION; ESCHERICHIA-COLI; STEROL GLUCOSYLTRANSFERASES; BORRELIA-BURGDORFERI; STRUCTURAL-ANALYSIS; HEAT-SHOCK; GLYCOSYLTRANSFERASES; GLUCOSIDE	O-Glycans of the human gastric mucosa show antimicrobial activity against the pathogenic bacterium Helicobacter pylori by inhibiting the bacterial cholesterol-alpha-glucosyltransferase (Kawakubo, M., Ito, Y., Okimura, Y., Kobayashi, M., Sakura, K., Kasama, S., Fukuda, M. N., Fukuda, M., Katsuyama, T., and Nakayama, J. (2004) Science 305, 1003 - 1006). This enzyme catalyzes the first step in the biosynthesis of four unusual glycolipids: cholesteryl-alpha-glucoside, cholesteryl-6'-O-acyl-alpha-glucoside, cholesteryl-6'-O-phosphatidyl-alpha-glucoside, and cholesteryl-6'-O-lysophosphatidyl-alpha-glucoside. Here we report the identification, cloning, and functional characterization of the cholesterol-alpha-glucosyltransferase from H. pylori. The hypothetical protein HP0421 from H. pylori belongs to the glycosyltransferase family 4 and shows similarities to some bacterial diacylglycerol-alpha-glucosyltransferases. Deletion of the HP0421 gene in H. pylori resulted in the loss of cholesteryl-alpha-glucoside and all of its three derivatives. Heterologous expression of HP0421 in the yeast Pichia pastoris led to the biosynthesis of ergosteryl-alpha-lucoside as demonstrated by purification of the lipid and subsequent structural analysis by nuclear magnetic resonance spectroscopy and mass spectrometry. In vitro enzyme assays were performed with cell-free homogenates obtained from cells of H. pylori or from transgenic Escherichia coli, which express HP0421. These assays revealed that the enzyme represents a membrane-bound, UDP-glucose-dependent cholesterol-alpha-glucosyltransferase.	Univ Hamburg, Bioctr Klein Flottbek & Bot Garden, D-22609 Hamburg, Germany; Max Planck Inst Infect Biol, Dept Mol Biol, D-10117 Berlin, Germany; Leibniz Ctr Med & Biosci, Res Ctr, D-23845 Borstel, Germany	University of Hamburg; Max Planck Society; Forschungszentrum Borstel	Warnecke, D (corresponding author), Univ Hamburg, Bioctr Klein Flottbek & Bot Garden, Ohnhorststr 18, D-22609 Hamburg, Germany.	warnecke@botanik.uni-hamburg.de	Wunder, Christian/K-8542-2017; Meyer, Thomas F. F/J-2485-2013; Lindner, Buko/G-9731-2014	Wunder, Christian/0000-0001-9091-0080; Meyer, Thomas F. F/0000-0002-6120-8679; Hildebrand, Janosch/0000-0001-7030-7495				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ben-Menachem G, 2003, P NATL ACAD SCI USA, V100, P7913, DOI 10.1073/pnas.1232451100; Berg S, 2001, J BIOL CHEM, V276, P22056, DOI 10.1074/jbc.M102576200; Bok JW, 1999, PHYTOCHEMISTRY, V51, P891, DOI 10.1016/S0031-9422(99)00128-4; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cereghino GPL, 2001, GENE, V263, P159, DOI 10.1016/S0378-1119(00)00576-X; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; Dormann P, 1999, SCIENCE, V284, P2181, DOI 10.1126/science.284.5423.2181; Edman M, 2003, J BIOL CHEM, V278, P8420, DOI 10.1074/jbc.M211492200; FOLCH J, 1957, J BIOL CHEM, V226, P497; Geremia RA, 1996, BIOCHEM J, V318, P133, DOI 10.1042/bj3180133; HAQUE M, 1995, J BACTERIOL, V177, P5334, DOI 10.1128/jb.177.18.5334-5337.1995; Hillig I, 2003, FEBS LETT, V553, P365, DOI 10.1016/S0014-5793(03)01058-5; HIRAI Y, 1995, J BACTERIOL, V177, P5327, DOI 10.1128/jb.177.18.5327-5333.1995; Holzl G, 2005, PLANT CELL PHYSIOL, V46, P1766, DOI 10.1093/pcp/pci189; Holzl G, 2005, GLYCOBIOLOGY, V15, P874, DOI 10.1093/glycob/cwi066; Hu Y, 2004, CHEM BIOL, V11, P703, DOI 10.1016/j.chembiol.2004.02.024; Jorasch P, 1998, MOL MICROBIOL, V29, P419, DOI 10.1046/j.1365-2958.1998.00930.x; Jorasch P, 2000, EUR J BIOCHEM, V267, P3770, DOI 10.1046/j.1432-1327.2000.01414.x; Kawakubo M, 2004, SCIENCE, V305, P1003, DOI 10.1126/science.1099250; Kim YK, 2002, PLANT J, V30, P177, DOI 10.1046/j.1365-313X.2002.01284.x; Kunimoto S, 2003, CELL STRUCT FUNCT, V28, P179; Kunimoto S, 2000, CELL STRESS CHAPERON, V5, P3, DOI 10.1379/1466-1268(2000)005<0003:EOCGBH>2.0.CO;2; Leipelt M, 2001, J BIOL CHEM, V276, P33621, DOI 10.1074/jbc.M104952200; LIVERMORE BP, 1978, INFECT IMMUN, V20, P215, DOI 10.1128/IAI.20.1.215-220.1978; MAYBERRY WR, 1983, BIOCHIM BIOPHYS ACTA, V752, P434, DOI 10.1016/0005-2760(83)90273-4; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Oku M, 2003, EMBO J, V22, P3231, DOI 10.1093/emboj/cdg331; PATEL KR, 1978, J BACTERIOL, V136, P829, DOI 10.1128/JB.136.2.829-831.1978; Peng LC, 2002, SCIENCE, V295, P147, DOI 10.1126/science.1064281; Sakaki T, 2001, YEAST, V18, P679, DOI 10.1002/yea.720; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schroder NWJ, 2003, J BIOL CHEM, V278, P33645, DOI 10.1074/jbc.M305799200; Shimomura H, 2004, FEMS MICROBIOL LETT, V237, P407, DOI 10.1016/j.femsle.2004.07.004; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SMITH PF, 1971, J BACTERIOL, V108, P986, DOI 10.1128/JB.108.3.986-991.1971; Stasyk OV, 2003, CELL BIOL INT, V27, P947, DOI 10.1016/j.cellbi.2003.08.004; Tannaes T, 2000, APMIS, V108, P349, DOI 10.1034/j.1600-0463.2000.d01-67.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Warnecke D, 1999, J BIOL CHEM, V274, P13048, DOI 10.1074/jbc.274.19.13048; Warnecke DC, 1997, PLANT MOL BIOL, V35, P597, DOI 10.1023/A:1005806119807; WARNECKE DC, 1994, PLANT PHYSIOL, V105, P1067, DOI 10.1104/pp.105.4.1067; Yu B, 2002, P NATL ACAD SCI USA, V99, P5732, DOI 10.1073/pnas.082696499	44	71	76	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27765	27772		10.1074/jbc.M603345200	http://dx.doi.org/10.1074/jbc.M603345200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16844692	hybrid			2022-12-25	WOS:000240534400012
J	Lopez, JJ; Salido, GM; Pariente, JA; Rosado, JA				Lopez, Jose J.; Salido, Gines M.; Pariente, Jose A.; Rosado, Juan A.			Interaction of STIM1 with endogenously expressed human canonical TRP1 upon depletion of intracellular Ca2+ stores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; HUMAN PLATELETS; ACTIN CYTOSKELETON; PLASMA-MEMBRANE; GENE FAMILY; CHANNELS; ACTIVATION; CELLS; SENSOR	STIM1 ((s) under bar tromal (i) under bar nteraction (m) under bar olecule (1) under bar) has recently been proposed to communicate the intracellular Ca2+ stores with the plasma membrane to mediate store-operated Ca2+ entry. Here we describe for the first time that Ca2+ store depletion stimulates rapid STIM1 surface expression and association with endogenously expressed human canonical TRP1 (hTRPC1) independently of rises in cytosolic free Ca2+ concentration. These events require the support of the actin cytoskeleton in human platelets, as reported for the coupling between type II inositol 1,4,5-trisphosphate receptor in the Ca2+ stores and hTRPC1 in the plasma membrane, which has been suggested to underlie the activation of store-operated Ca2+ entry in these cells. Electrotransjection of cells with anti-STIM1 antibody, directed toward the N-terminal sequence that includes the Ca2+- binding region, prevented the migration of STIM1 toward the plasma membrane, the interaction between STIM1 and hTRPC1, the coupling between hTRPC1 and type II inositol 1,4,5-trisphosphate receptor, and reduced store-operated Ca2+ entry. These findings provide evidence for a role of STIM1 in the activation of store- operated Ca2+ entry probably acting as a Ca2+ sensor.	Univ Extremadura, Dept Physiol, Cellular Physiol Res Grp, Caceres 10071, Spain	Universidad de Extremadura	Rosado, JA (corresponding author), Univ Extremadura, Dept Physiol, Cellular Physiol Res Grp, Caceres 10071, Spain.	jarosado@unex.es	Rosado, Juan A/H-3488-2015; Lopez, Jose J/F-4602-2016; Salido, Gines M/A-4292-2009	Rosado, Juan A/0000-0002-9749-2325; Lopez, Jose J/0000-0002-5234-1478; Salido, Gines M/0000-0002-8687-2445; PARIENTE, JOSE ANTONIO/0000-0002-9094-9943				Ben-Amor N, 2006, J PHYSIOL-LONDON, V570, P309, DOI 10.1113/jphysiol.2005.100800; Berridge Michael, 2004, Sci STKE, V2004, ppe33; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bolotina VM, 2005, TRENDS BIOCHEM SCI, V30, P378, DOI 10.1016/j.tibs.2005.05.009; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Brownlow SL, 2003, BIOCHEM J, V375, P697, DOI 10.1042/BJ20030929; CARNELLO C, 2000, CURR BIOL, V10, P161; CHAKRABARTI R, 1989, J BIOL CHEM, V264, P15494; DHAR A, 1994, J BIOL CHEM, V269, P9123; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Heemskerk JWM, 1997, EUR J BIOCHEM, V249, P547, DOI 10.1111/j.1432-1033.1997.00547.x; HISATSUNE C, 2005, SCI STKE, pPE53, DOI DOI 10.1126/STKE.3132005PE53; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Manji SSM, 2000, BBA-PROTEIN STRUCT M, V1481, P147, DOI 10.1016/S0167-4838(00)00105-9; Marchant JS, 2005, CURR BIOL, V15, pR493, DOI 10.1016/j.cub.2005.06.035; Mercer JC, 2006, J BIOL CHEM, V281, P24979, DOI 10.1074/jbc.M604589200; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Putney Jr JW, 2004, SCI STKE, ppe37; Putney JW, 2005, J CELL BIOL, V169, P381, DOI 10.1083/jcb.200503161; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 2001, J CELL SCI, V114, P2223; Putney JW, 1999, P NATL ACAD SCI USA, V96, P14669, DOI 10.1073/pnas.96.26.14669; Redondo PC, 2003, BIOCHEM J, V370, P255, DOI 10.1042/BJ20021505; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Rosado JA, 2000, BIOCHEM J, V351, P429, DOI 10.1042/0264-6021:3510429; Rosado JA, 2000, J BIOL CHEM, V275, P7527, DOI 10.1074/jbc.275.11.7527; Rosado JA, 2000, BIOCHEM J, V350, P631, DOI 10.1042/0264-6021:3500631; Rosado JA, 2000, BIOCHEM J, V347, P183, DOI 10.1042/0264-6021:3470183; Rosado JA, 2005, J CELL PHYSIOL, V205, P262, DOI 10.1002/jcp.20399; Rosado JA, 2002, J BIOL CHEM, V277, P42157, DOI 10.1074/jbc.M207320200; Rosado JA, 2001, BIOCHEM J, V356, P191, DOI 10.1042/0264-6021:3560191; SCRUTON MC, 1996, PRACT APPROACH SER, P47; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P4040, DOI 10.1073/pnas.0510050103; Stamboulian S, 2005, DEV BIOL, V286, P326, DOI 10.1016/j.ydbio.2005.08.006; Treves S, 2004, J CELL BIOL, V166, P537, DOI 10.1083/jcb.200404079; Williams RT, 2001, BIOCHEM J, V357, P673, DOI 10.1042/0264-6021:3570673; WILSON AK, 1991, AM J PHYSIOL, V260, pC355, DOI 10.1152/ajpcell.1991.260.2.C355; Xu SZ, 2001, CIRC RES, V88, P84, DOI 10.1161/01.RES.88.1.84; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	42	172	175	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28254	28264		10.1074/jbc.M604272200	http://dx.doi.org/10.1074/jbc.M604272200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16870612	hybrid			2022-12-25	WOS:000240534400063
J	Vauloup-Fellous, C; Pene, V; Garaud-Aunis, J; Harper, F; Bardin, S; Suire, Y; Pichard, E; Schmitt, A; Sogni, P; Pierron, G; Briand, P; Rosenberg, AR				Vauloup-Fellous, Christelle; Pene, Veronique; Garaud-Aunis, Julie; Harper, Francis; Bardin, Sabine; Suire, Yannick; Pichard, Evelyne; Schmitt, Alain; Sogni, Philippe; Pierron, Gerard; Briand, Pascale; Rosenberg, Arielle R.			Signal peptide peptidase-catalyzed cleavage of hepatitis C virus core protein is dispensable for virus budding but destabilizes the viral capsid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-GRADIENT CENTRIFUGATION; HCV-INFECTED PATIENTS; INTRAMEMBRANE PROTEOLYSIS; INSECT CELLS; STRUCTURAL PROTEINS; ION-CHANNEL; P7 PROTEIN; ENDOPLASMIC-RETICULUM; FUNCTIONAL-ANALYSIS; ASPARTIC PROTEASES	The capsid of hepatitis C virus (HCV) particles is considered to be composed of the mature form (p21) of core protein. Maturation to p21 involves cleavage of the transmembrane domain of the precursor form (p23) of core protein by signal peptide peptidase (SPP), a cellular protease embedded in the endoplasmic reticulum membrane. Here we have addressed whether SPP-catalyzed maturation to p21 is a prerequisite for HCV particle morphogenesis in the endoplasmic reticulum. HCV structural proteins were expressed by using recombinant Semliki Forest virus replicon in mammalian cells or recombinant baculovirus in insect cells, because these systems have been shown to allow the visualization of HCV budding events and the isolation of HCV-like particles, respectively. Inhibition of SPP-catalyzed cleavage of core protein by either an SPP inhibitor or HCV core mutations not only did not prevent but instead tended to facilitate the observation of viral buds and the recovery of virus-like particles. Remarkably, although maturation to p21 was only partially inhibited by mutations in insect cells, p23 was the only form of core protein found in HCV-like particles. Finally, newly developed assays demonstrated that p23 capsids are more stable than p21 capsids. These results show that SPP-catalyzed cleavage of core protein is dispensable for HCV budding but decreases the stability of the viral capsid. We propose a model in which p23 is the form of HCV core protein committed to virus assembly, and cleavage by SPP occurs during and/or after virus budding to predispose the capsid to subsequent disassembly in a new cell.	INSERM, Inst Cochin, Equipe AVENIR, F-75014 Paris, France; Univ Paris 11, Fac Med, APHP, Hop Antoine Beclere, F-92141 Clamart, France; CNRS, FRE 2937, Inst Andre Lwoff, F-94801 Villejuif, France; INSERM, U 567, CNRS, UMR 8104,Inst Cochin,Plateforme Microscopie Elect, F-75014 Paris, France; Univ Paris Descartes, Fac Med, APHP, Grp Hosp Cochin St Vincent Paul, F-75014 Paris, France; Univ Paris Descartes, Fac Med, APHP, Grp Hosp Cochin St Vincent Paul, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Antoine-Beclere - APHP; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Rosenberg, AR (corresponding author), INSERM, Inst Cochin, Equipe AVENIR, F-75014 Paris, France.	arielle@cochin.inserm.fr	Vauloup-Fellous, Christelle/AAE-5567-2021; Vauloup-Fellous, Christelle/D-1333-2015; Vauloup-Fellous, Christelle/AAG-2302-2021	Vauloup-Fellous, Christelle/0000-0002-3674-5093; Rosenberg, Arielle/0000-0003-2085-8146				Andre P, 2002, J VIROL, V76, P6919, DOI 10.1128/JVI.76.14.6919-6928.2002; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Baumert TF, 1999, GASTROENTEROLOGY, V117, P1397, DOI 10.1016/S0016-5085(99)70290-8; Baumert TF, 1998, J VIROL, V72, P3827, DOI 10.1128/JVI.72.5.3827-3836.1998; Blanchard E, 2003, J VIROL, V77, P10131, DOI 10.1128/JVI.77.18.10131-10138.2003; Blanchard E, 2002, J VIROL, V76, P4073, DOI 10.1128/JVI.76.8.4073-4079.2002; Bosman C, 1998, RES VIROLOGY, V149, P311, DOI 10.1016/S0923-2516(99)89011-6; Casso DJ, 2005, GENETICS, V170, P139, DOI 10.1534/genetics.104.039933; Clayton RF, 2002, J VIROL, V76, P7672, DOI 10.1128/JVI.76.15.7672-7682.2002; Crawshaw SG, 2004, BIOCHEM J, V384, P9, DOI 10.1042/BJ20041216; De Beeck AO, 2003, REV MED VIROL, V13, P233, DOI 10.1002/rmv.391; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Elbers K, 1996, J VIROL, V70, P4131, DOI 10.1128/JVI.70.6.4131-4135.1996; Falcon V, 2005, BIOCHEM BIOPH RES CO, V329, P1320, DOI 10.1016/j.bbrc.2005.02.107; FLINT SJ, 2003, PRINCIPLES VIROLOGY, P450; Forshey BM, 2002, J VIROL, V76, P5667, DOI 10.1128/JVI.76.11.5667-5677.2002; Friedmann E, 2004, J BIOL CHEM, V279, P50790, DOI 10.1074/jbc.M407898200; Girard C, 2004, J GEN VIROL, V85, P3659, DOI 10.1099/vir.0.79909-0; Griffin SDC, 2004, J GEN VIROL, V85, P451, DOI 10.1099/vir.0.19634-0; Griffin SDC, 2003, FEBS LETT, V535, P34, DOI 10.1016/S0014-5793(02)03851-6; Heimann M, 2006, J VIROL, V80, P1915, DOI 10.1128/JVI.80.4.1915-1921.2006; HELENIUS A, 1992, CELL, V69, P577, DOI 10.1016/0092-8674(92)90219-3; Hope RG, 2000, J GEN VIROL, V81, P1913, DOI 10.1099/0022-1317-81-8-1913; Hussy P, 1996, VIROLOGY, V224, P93, DOI 10.1006/viro.1996.0510; Ishida S, 2001, HEPATOL RES, V20, P335, DOI 10.1016/S1386-6346(01)00080-8; KANTO T, 1994, HEPATOLOGY, V19, P296; Kato T, 2004, HEPATOL RES, V30, P204, DOI 10.1016/j.hepres.2004.10.002; Kewalramani VN, 1996, VIROLOGY, V218, P159, DOI 10.1006/viro.1996.0176; Klein KC, 2004, J VIROL, V78, P9257, DOI 10.1128/JVI.78.17.9257-9269.2004; Kobayashi M, 2006, J VIROL, V80, P1817, DOI 10.1128/JVI.80.4.1817-1825.2006; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANZREIN M, 1994, BIOCHEM J, V302, P313, DOI 10.1042/bj3020313; Lavillette D, 2006, J BIOL CHEM, V281, P3909, DOI 10.1074/jbc.M509747200; Lemberg MK, 2003, ANAL BIOCHEM, V319, P327, DOI 10.1016/S0003-2697(03)00298-7; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; Lemberg MK, 2001, J IMMUNOL, V167, P6441, DOI 10.4049/jimmunol.167.11.6441; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; LINDENBACH BD, 2001, FIELDS VIROLOGY, V1, P991; Liu QY, 1997, J VIROL, V71, P657, DOI 10.1128/JVI.71.1.657-662.1997; MacKenzie JM, 2001, J VIROL, V75, P10787, DOI 10.1128/JVI.75.22.10787-10799.2001; Majeau N, 2005, J GEN VIROL, V86, P3055, DOI 10.1099/vir.0.81174-0; Martoglio B, 2003, HUM MOL GENET, V12, pR201, DOI 10.1093/hmg/ddg303; McLauchlan J, 2000, J VIRAL HEPATITIS, V7, P2; McLauchlan J, 2002, EMBO J, V21, P3980, DOI 10.1093/emboj/cdf414; MIYAMOTO H, 1992, J GEN VIROL, V73, P715, DOI 10.1099/0022-1317-73-3-715; Moliaka YK, 2004, FEBS LETT, V557, P185, DOI 10.1016/S0014-5793(03)01489-3; Moradpour D, 1996, VIROLOGY, V222, P51, DOI 10.1006/viro.1996.0397; Mukhopadhyay S, 2002, J VIROL, V76, P11128, DOI 10.1128/JVI.76.21.11128-11132.2002; Nielsen SU, 2004, J GEN VIROL, V85, P1497, DOI 10.1099/vir.0.79967-0; Ogino T, 2004, J VIROL, V78, P11766, DOI 10.1128/JVI.78.21.11766-11777.2004; Okamoto K, 2004, J VIROL, V78, P6370, DOI 10.1128/JVI.78.12.6370-6380.2004; Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983; Owsianka A, 2001, J GEN VIROL, V82, P1877, DOI 10.1099/0022-1317-82-8-1877; PARK J, 1993, VIROLOGY, V194, P843, DOI 10.1006/viro.1993.1328; Pavlovic D, 2003, P NATL ACAD SCI USA, V100, P6104, DOI 10.1073/pnas.1031527100; Petit MA, 2005, VIROLOGY, V336, P144, DOI 10.1016/j.virol.2005.03.023; Pietschmann T, 2002, J VIROL, V76, P4008, DOI 10.1128/JVI.76.8.4008-4021.2002; Schwer B, 2004, J VIROL, V78, P7958, DOI 10.1128/JVI.78.15.7958-7968.2004; Shimizu YK, 1996, HEPATOLOGY, V23, P205; TAKAHASHI K, 1992, VIROLOGY, V191, P431, DOI 10.1016/0042-6822(92)90204-3; Thomssen R, 2002, MED MICROBIOL IMMUN, V191, P17, DOI 10.1007/s00430-001-0106-x; Tscherne DM, 2006, J VIROL, V80, P1734, DOI 10.1128/JVI.80.4.1734-1741.2006; Urny J, 2003, GENE EXPR PATTERNS, V3, P685, DOI 10.1016/S1567-133X(03)00094-2; Vogt VM, 1996, CURR TOP MICROBIOL, V214, P95; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Weihofen A, 2003, J BIOL CHEM, V278, P16528, DOI 10.1074/jbc.M301372200; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wu CM, 2004, BIOCHEM BIOPH RES CO, V322, P585, DOI 10.1016/j.bbrc.2004.07.160; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998; Yi M, 2006, P NATL ACAD SCI USA, V103, P2310, DOI 10.1073/pnas.0510727103; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102	72	34	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27679	27692		10.1074/jbc.M602587200	http://dx.doi.org/10.1074/jbc.M602587200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16849324	hybrid			2022-12-25	WOS:000240534400004
J	Owen, RP; Badagnani, I; Giacomini, KM				Owen, Ryan P.; Badagnani, Ilaria; Giacomini, Kathleen M.			Molecular determinants of specificity for synthetic nucleoside analogs in the concentrative nucleoside transporter, CNT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; PYRIMIDINE; CLONING; PURINE; IDENTIFICATION; INACTIVATION; SELECTIVITY; EXPRESSION; HCNT2; CELLS	Members of the concentrative nucleoside transporter ( CNT) family (SLC28) mediate the transport of naturally-occurring nucleosides, and nucleoside analog drugs across the plasma membrane of epithelial cells. Each of the three CNT family members has a distinct specificity for naturally occurring nucleosides, and residues that contribute to the specificity of each transporter have been identified. In contrast, the molecular determinants of specificity for synthetic nucleoside analogs are not known. In this study, we take advantage of the large species difference that exists between human and rat CNT2 (hCNT2 and rCNT2) in their ability to transport the nucleoside analog drug cladribine, 2CdA, (rCNT2 > > > hCNT2) to identify the critical domains and amino acid residues that contribute to the observed difference in specificity between CNT2 orthologs. Using chimeric proteins of human and rat CNT2, we determined that the C-terminal half of CNT2 contained the determinants of 2CdA selectivity. We replaced key residues in the C terminus of hCNT2 with the equivalent residue in rCNT2. One residue in the C-terminal portion of CNT2 was found to significantly contribute to 2CdA selectivity: hCNT2-S354A. This mutant caused an increase of 5 -6-fold over hCNT2. The 2-chloro pharmacophore, rather than the 2'-deoxyribose was responsible for the reduced 2CdA uptake by hCNT2. Our data are consistent with a model in which an increased capability for hydrogen bonding in critical amino acids that reside in the C terminus of rCNT2 contributes to its enhanced selectivity for 2CdA.	Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94158 USA	University of California System; University of California San Francisco	Giacomini, KM (corresponding author), Univ Calif San Francisco, Dept Biopharmaceut Sci, 1550 4th St, San Francisco, CA 94158 USA.	kmg@itsa.ucsf.edu	Giacomini, Kathleen/AEF-2452-2022		NIGMS NIH HHS [GM36780, GM42230, GM61390] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036780, U01GM061390, U19GM061390, R01GM042230] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Byrd John C, 2004, Hematology Am Soc Hematol Educ Program, P163; Chang C, 2004, MOL PHARMACOL, V65, P558, DOI 10.1124/mol.65.3.558; Fischer U, 2005, ONCOGENE, V24, P1231, DOI 10.1038/sj.onc.1208290; Gerstin KM, 2000, PHARMACEUT RES, V17, P906, DOI 10.1023/A:1007510801253; Gerstin KM, 2002, AM J PHYSIOL-RENAL, V283, pF344, DOI 10.1152/ajprenal.00274.2001; Gray JH, 2004, PFLUG ARCH EUR J PHY, V447, P728, DOI 10.1007/s00424-003-1107-y; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; Jegla T, 1997, J NEUROSCI, V17, P32, DOI 10.1523/JNEUROSCI.17-01-00032.1997; Loewen SK, 1999, J BIOL CHEM, V274, P24475, DOI 10.1074/jbc.274.35.24475; Owen RP, 2005, PHARMACOGENET GENOM, V15, P83, DOI 10.1097/01213011-200502000-00004; Pennycooke M, 2001, BIOCHEM BIOPH RES CO, V280, P951, DOI 10.1006/bbrc.2000.4205; Ritzel MWL, 2001, J BIOL CHEM, V276, P2914, DOI 10.1074/jbc.M007746200; Wang J, 1997, J BIOL CHEM, V272, P28845, DOI 10.1074/jbc.272.46.28845; Wang J, 1999, J BIOL CHEM, V274, P2298, DOI 10.1074/jbc.274.4.2298; Wang J, 1997, AM J PHYSIOL-RENAL, V273, pF1058, DOI 10.1152/ajprenal.1997.273.6.F1058; Wang J, 1999, MOL PHARMACOL, V55, P234, DOI 10.1124/mol.55.2.234; Yin YZ, 2001, LEUKEMIA RES, V25, P423, DOI 10.1016/S0145-2126(00)00147-8	17	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26675	26682		10.1074/jbc.M513421200	http://dx.doi.org/10.1074/jbc.M513421200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16840788	hybrid			2022-12-25	WOS:000240249500085
J	Wang, YS; Bogenhagen, DF				Wang, Yousong; Bogenhagen, Daniel F.			Human mitochondrial DNA nucleoids are linked to protein folding machinery and metabolic enzymes at the mitochondrial inner membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M-AAA PROTEASE; BINDING-PROTEIN; MESSENGER-RNA; TRANSCRIPTION; NUCLEAR; INITIATION; COMPLEXES; MOUSE; PHOSPHORYLATION; IDENTIFICATION	Mitochondrial DNA (mtDNA) is packaged into bacterial nucleoid-like structures, each containing several mtDNA molecules. The distribution of nucleoids during mitochondrial fission and fusion events and during cytokinesis is important to the segregation of mitochondrial genomes in heteroplasmic cells bearing a mixture of wild-type and mutant mtDNA molecules. We report fractionation of HeLa cell mtDNA nucleoids into two subsets of complexes that differ in their sedimentation velocity and their association with cytoskeletal proteins. Pulse labeling studies indicated that newly replicated mtDNA molecules are evenly represented in the rapidly and slowly sedimenting fractions. Slowly sedimenting nucleoids were immunoaffinity purified using antibodies to either of two abundant mtDNA-binding proteins, TFAM or mtSSB. These two different immunoaffinity procedures yielded very similar sets of proteins, with 21 proteins in common, including most of the proteins previously shown to play roles in mtDNA replication and transcription. In addition to previously identified mitochondrial proteins, multiple peptides were observed for one novel DNA metabolic protein, the DEAH-box helicase DHX30. Antibodies raised against a recombinant fragment of this protein confirmed the mitochondrial localization of a specific isoform of DHX30.	SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Bogenhagen, DF (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.	dan@pharm.sunysb.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029681] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01ES012039] Funding Source: Medline; NIGMS NIH HHS [R01GM29681] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams DJ, 2003, J BIOL CHEM, V278, P44894, DOI 10.1074/jbc.M307782200; Alam TI, 2003, NUCLEIC ACIDS RES, V31, P1640, DOI 10.1093/nar/gkg251; ALBRING M, 1977, P NATL ACAD SCI USA, V74, P1348, DOI 10.1073/pnas.74.4.1348; ALFANO C, 1989, J BIOL CHEM, V264, P10709; ANTOSHECHKIN I, 1995, MOL CELL BIOL, V15, P7032; Banfi S, 1999, GENOMICS, V59, P51, DOI 10.1006/geno.1999.5818; BARAT M, 1985, EXP CELL RES, V157, P207, DOI 10.1016/0014-4827(85)90163-6; Battersby BJ, 2003, NAT GENET, V33, P183, DOI 10.1038/ng1073; Berger KH, 1998, MOL CELL BIOL, V18, P4043, DOI 10.1128/MCB.18.7.4043; BOGENHAGEN D, 1978, J MOL BIOL, V119, P49, DOI 10.1016/0022-2836(78)90269-3; Bogenhagen DF, 2003, MOL CELL PROTEOMICS, V2, P1205, DOI 10.1074/mcp.M300035-MCP200; Boldogh IR, 2003, MOL BIOL CELL, V14, P4618, DOI 10.1091/mbc.E03-04-0225; Chen XJ, 2005, SCIENCE, V307, P714, DOI 10.1126/science.1106391; Chen XJ, 2005, NAT REV GENET, V6, P815, DOI 10.1038/nrg1708; Cheng XL, 2005, J BIOCHEM, V138, P673, DOI 10.1093/jb/mvi169; Ciesla J, 2006, ACTA BIOCHIM POL, V53, P11; Da Cruz S, 2003, J BIOL CHEM, V278, P41566, DOI 10.1074/jbc.M304940200; DellOrco RT, 1996, EXP GERONTOL, V31, P245, DOI 10.1016/0531-5565(95)02009-8; Dimmer KS, 2005, J CELL BIOL, V168, P103, DOI 10.1083/jcb.200410030; Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909; Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399; HIGUCHI Y, 1995, J BIOL CHEM, V270, P7950, DOI 10.1074/jbc.270.14.7950; Hobbs AEA, 2001, J CELL BIOL, V152, P401, DOI 10.1083/jcb.152.2.401; Iborra FJ, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-9; Jackson DA, 1996, NUCLEIC ACIDS RES, V24, P1212, DOI 10.1093/nar/24.7.1212; John GB, 2005, MOL BIOL CELL, V16, P1543, DOI 10.1091/mbc.e04-08-0697; Kanki T, 2004, ANN NY ACAD SCI, V1011, P61, DOI 10.1196/annals.1293.007; Kaufman BA, 2003, J CELL BIOL, V163, P457, DOI 10.1083/jcb.200306132; Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Legros F, 2004, J CELL SCI, V117, P2653, DOI 10.1242/jcs.01134; Liu T, 2004, J BIOL CHEM, V279, P13902, DOI 10.1074/jbc.M309642200; Malka F, 2006, BBA-MOL CELL RES, V1763, P463, DOI 10.1016/j.bbamcr.2006.04.001; Martin M, 2005, CELL, V123, P1227, DOI 10.1016/j.cell.2005.09.040; Meeusen S, 1999, J CELL BIOL, V145, P291, DOI 10.1083/jcb.145.2.291; Meeusen S, 2003, J CELL BIOL, V163, P503, DOI 10.1083/jcb.200304040; MEGRAW TL, 1993, J BIOL CHEM, V268, P12758; Minczuk M, 2002, NUCLEIC ACIDS RES, V30, P5074, DOI 10.1093/nar/gkf647; Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Nolden M, 2005, CELL, V123, P277, DOI 10.1016/j.cell.2005.08.003; Nutt LK, 2005, CELL, V123, P89, DOI 10.1016/j.cell.2005.07.032; Odgren PR, 1996, J CELL SCI, V109, P2253; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; Schagger H, 2001, J BIOL CHEM, V276, P37861; Shen EL, 2001, NUCLEIC ACIDS RES, V29, P2822, DOI 10.1093/nar/29.13.2822; Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058; Steglich G, 1999, MOL CELL BIOL, V19, P3435; Stillman B, 2005, FEBS LETT, V579, P877, DOI 10.1016/j.febslet.2004.12.011; THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418; TIRANTI V, 1991, NUCLEIC ACIDS RES, V19, P4291, DOI 10.1093/nar/19.15.4291; Tolstonog GV, 2001, DNA CELL BIOL, V20, P531, DOI 10.1089/104454901317094954; Tsuchiya N, 2004, BIOCHEM BIOPH RES CO, V317, P736, DOI 10.1016/j.bbrc.2004.03.103; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; VANTUYLE GC, 1985, J CELL BIOL, V100, P251, DOI 10.1083/jcb.100.1.251; WHITFORD T, 1993, THESIS STATE U NY ST; Youngman MJ, 2004, J CELL BIOL, V164, P677, DOI 10.1083/jcb.200308012	60	224	233	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25791	25802		10.1074/jbc.M604501200	http://dx.doi.org/10.1074/jbc.M604501200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16825194	hybrid			2022-12-25	WOS:000240031300081
J	Chen, XH; Kokkotou, EG; Mustafa, N; Bhaskar, KR; Sougioultzis, S; O'Brien, M; Pothoulakis, C; Kelly, CP				Chen, Xinhua; Kokkotou, Efi G.; Mustafa, Nasima; Bhaskar, K. Ramakrishnan; Sougioultzis, Stavros; O'Brien, Michael; Pothoulakis, Charalabos; Kelly, Ciaran P.			Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; T84 CELLS; PREVENTS CYTOKINE; CHOLERA-TOXIN; RABBIT ILEUM; RAT ILEUM; KAPPA-B; RECEPTOR; INDUCTION; INTESTINE	Saccharomyces boulardii (Sb), a probiotic yeast, protects against intestinal injury and inflammation caused by a wide variety of enteric pathogens, including Clostridium difficile. Given the broad range of protective effects of Sb in multiple gastrointestinal disorders, we hypothesize that Sb modulates host signaling pathways involved in intestinal inflammatory responses. In this study, we found that Sb culture supernatant (SbS) inhibits interleukin-8 production induced by C. difficile toxin A or IL-1 beta in human colonocyte NCM460 cells in a dose-dependent fashion. Furthermore, SbS inhibited IL-1 beta and toxin A induced Erk1/2 and JNK/SAPK but not p38 activation in NCM460 cells. To test whether this inhibition also occurs in vivo, we used a previously established mouse ileal loop model. On its own, SbS had no significant effect on basal fluid secretion or intestinal histology. However, Erk1/2 activation was significantly inhibited by SbS in toxin A exposed mouse ileal mucosa. In control loops, toxin A increased fluid secretion (2.2-fold), histological score (3.3-fold), and levels of the chemokine KC (4.5-fold). SbS pretreatment completely normalized toxin A mediated fluid secretion (p < 0.01), and histopathologic changes (p < 0.01) and substantially inhibited toxin A-associated KC increases (p < 0.001). In summary, the probiotic yeast S. boulardii inhibits C. difficile toxin A-associated enteritis by blocking the activation of Erk1/2 MAP kinases. This study indicates a new mechanism whereby Sb protects against intestinal inflammation and supports the hypothesis that Sb modulates host inflammatory signaling pathways to exert its beneficial effects.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA; Boston Univ, Dept Pathol, Sch Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Pediat Gastroenterol & Nutr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston University; Harvard University; Harvard Medical School; Massachusetts General Hospital	Kelly, CP (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Dana 601A,330 Brookline Ave, Boston, MA 02215 USA.	ckelly2@bidmc.harvard.edu		O'Brien, Michael J/0000-0003-1124-3537	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK033506] Funding Source: NIH RePORTER; NIAID NIH HHS [AI53069] Funding Source: Medline; NIDDK NIH HHS [P01 DK033506] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTLETT JG, 1978, NEW ENGL J MED, V298, P531, DOI 10.1056/NEJM197803092981003; Brandao RL, 1998, APPL ENVIRON MICROB, V64, P564; BUTS JP, 1986, PEDIATR RES, V20, P192, DOI 10.1203/00006450-198602000-00020; BUTS JP, 1990, DIGEST DIS SCI, V35, P251, DOI 10.1007/BF01536771; Castagliuolo I, 1996, INFECT IMMUN, V64, P5225, DOI 10.1128/IAI.64.12.5225-5232.1996; Castagliuolo I, 1999, INFECT IMMUN, V67, P302, DOI 10.1128/IAI.67.1.302-307.1999; Castagliuolo I, 1998, J CLIN INVEST, V101, P1547, DOI 10.1172/JCI2039; Czerucka D, 1999, DIGEST DIS SCI, V44, P2359, DOI 10.1023/A:1026689628136; CZERUCKA D, 1994, GASTROENTEROLOGY, V106, P65, DOI 10.1016/S0016-5085(94)94403-2; Czerucka D, 2002, MICROBES INFECT, V4, P733, DOI 10.1016/S1286-4579(02)01592-7; Czerucka D, 2000, INFECT IMMUN, V68, P5998, DOI 10.1128/IAI.68.10.5998-6004.2000; Dahan S, 2003, INFECT IMMUN, V71, P766, DOI 10.1128/IAI.71.2.766-773.2003; DOVE CH, 1990, INFECT IMMUN, V58, P480, DOI 10.1128/IAI.58.2.480-488.1990; Elmer GW, 1996, JAMA-J AM MED ASSOC, V275, P870, DOI 10.1001/jama.275.11.870; Guslandi M, 2000, DIGEST DIS SCI, V45, P1462, DOI 10.1023/A:1005588911207; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Keates S, 2001, J BIOL CHEM, V276, P48127, DOI 10.1074/jbc.M107630200; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lee Sang Kil, 2005, Korean J Gastroenterol, V45, P328; MCFARLAND LV, 1989, NEW ENGL J MED, V320, P204, DOI 10.1056/NEJM198901263200402; Petrof EO, 2004, GASTROENTEROLOGY, V127, P1474, DOI 10.1053/j.gastro.2004.09.001; POTHOULAKIS C, 1991, J CLIN INVEST, V88, P119, DOI 10.1172/JCI115267; POTHOULAKIS C, 1993, GASTROENTEROLOGY, V104, P1108, DOI 10.1016/0016-5085(93)90280-P; Qamar A, 2001, INFECT IMMUN, V69, P2762, DOI 10.1128/IAI.69.4.2762-2765.2001; Rodrigues ACP, 1996, J APPL BACTERIOL, V81, P251, DOI 10.1111/j.1365-2672.1996.tb04325.x; Scherle PA, 1998, J IMMUNOL, V161, P5681; Sougioultzis S, 2006, BIOCHEM BIOPH RES CO, V343, P69, DOI 10.1016/j.bbrc.2006.02.080; Sullivan A, 2002, INT J ANTIMICROB AG, V20, P313, DOI 10.1016/S0924-8579(02)00199-1; TORRES J, 1990, GUT, V31, P781, DOI 10.1136/gut.31.7.781; TRIADAFILOPOULOS G, 1989, GASTROENTEROLOGY, V97, P1186, DOI 10.1016/0016-5085(89)91689-2; TRIADAFILOPOULOS G, 1987, GASTROENTEROLOGY, V93, P273, DOI 10.1016/0016-5085(87)91014-6; Warny M, 2000, J CLIN INVEST, V105, P1147, DOI 10.1172/JCI7545; Xavier RJ, 2000, SCIENCE, V289, P1483, DOI 10.1126/science.289.5484.1483; Yan F, 2002, J BIOL CHEM, V277, P50959, DOI 10.1074/jbc.M207050200	37	112	116	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24449	24454		10.1074/jbc.M605200200	http://dx.doi.org/10.1074/jbc.M605200200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16816386	hybrid			2022-12-25	WOS:000239847800039
J	Leong, CTC; Ong, CK; Tay, SK; Huynh, H				Leong, C. T. C.; Ong, C. K.; Tay, S. K.; Huynh, H.			Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro	ONCOGENE			English	Article						HuUO-44; CUB; zona pellucida; cisplatin; RNAi and ovarian cancer	GENE-EXPRESSION; APOPTOSIS; INHIBITION; PACLITAXEL; PROTEIN; LINES; RESISTANCE; THERAPY; UTERUS; GROWTH	Ovarian cancer is currently the second leading cause of gynecological malignancy and cisplatin or cisplatin-based regimens have been the standard of care for the treatment of advance epithelial ovarian cancers. However, the efficacy of cisplatin treatment is often limited by the development of drug resistance either through the inhibition of apoptotic genes or activation of antiapoptotic genes. We have previously reported the overexpression of human UO-44 (HuUO-44) in ovarian cancers and the HuUO-44 antisera markedly inhibitedNIH-OVCAR3 ovarian cancer cell attachment and proliferation (Oncogene 23: 5707-5718, 2004). In the present study, we observed through the cancer cell line pro. ling array that the expression of HuUO-44 was suppressed in the ovarian cancer cell line (SKOV-3) after treatment with several chemotherapeutic drugs. Similarly, this suppression in HuUO-44 expression was also correlated to the cisplatin sensitivity in two other ovarian cancer cell lines NIH-OVCAR3 and OV-90 in a dose-dependent manner. To elucidate the function of HuUO-44 in cisplatin chemoresistance in ovarian cancer cell, small interfering RNAs (siRNAs) were employed to mediate HuUO-44 silencing in ovarian cancer cell line, NIH-OVCAR3. HuUO-44 RNA interference (RNAi) resulted in the inhibition of cell growth and proliferation. Importantly, HuUO-44 RNAi significantly increased sensitivity of NIH-OVCAR3 to cytotoxic stress induced by cisplatin (P < 0.01). Strikingly, we have also demonstrated that overexpression of HuUO-44 significantly conferred cisplatin resistance in NIH-OVCAR3 cells (P < 0.05). Taken together, UO-44 is involved in conferring cisplatin resistance; the described HuUO-44-specific siRNA oligonucleotides that can potently silence HuUO-44 gene expression may prove to be valuable pretreatment targets for antitumor therapy or other pathological conditions that involves aberrant HuUO-44 expression.	Natl Canc Ctr, Div Cellular & Mol Res, Mol Endocrinol Lab, Singapore 169610, Singapore; Natl Univ Singapore, Dept Pharmacol, Singapore 117548, Singapore; Singapore Gen Hosp, Dept Obstet & Gynaecol, Singapore 0316, Singapore	National Cancer Centre Singapore (NCCS); National University of Singapore; Singapore General Hospital	Huynh, H (corresponding author), Natl Canc Ctr, Div Cellular & Mol Res, Mol Endocrinol Lab, Singapore 169610, Singapore.	cmrhth@nccs.com.sg		Ong, Choon Kiat/0000-0001-6402-4288				Chen JY, 1999, ELECTROCHEM COMMUN, V1, P274, DOI 10.1016/S1388-2481(99)00056-9; Choudhury A, 2004, INT J CANCER, V108, P71, DOI 10.1002/ijc.11497; Cioca DP, 2003, CANCER GENE THER, V10, P125, DOI 10.1038/sj.cgt.7700544; DEVI GR, 2006, IN PRESS CANC GENE T; Duan ZF, 2004, MOL CANCER THER, V3, P833; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Harborth J, 2001, J CELL SCI, V114, P4557; Huynh H, 2001, ENDOCRINOLOGY, V142, P2985, DOI 10.1210/en.142.7.2985; Imamura T, 2002, J BIOL CHEM, V277, P50725, DOI 10.1074/jbc.M204159200; Judson PL, 1999, CANCER RES, V59, P2425; July LV, 2004, MOL CANCER THER, V3, P223; Kasik JW, 1998, BIOCHEM J, V330, P947; Leong CTC, 2004, ONCOGENE, V23, P5707, DOI 10.1038/sj.onc.1207754; McGuire WP, 2003, BRIT J CANCER, V89, pS3, DOI 10.1038/sj.bjc.6601494; Menendez JA, 2004, P NATL ACAD SCI USA, V101, P10715, DOI 10.1073/pnas.0403390101; Miyamoto S, 2004, CANCER RES, V64, P5720, DOI 10.1158/0008-5472.CAN-04-0811; Muggia FM, 2000, J CLIN ONCOL, V18, P106, DOI 10.1200/JCO.2000.18.1.106; Ryther RCC, 2005, GENE THER, V12, P5, DOI 10.1038/sj.gt.3302356; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Tebes SJ, 2005, GYNECOL ONCOL, V99, P736, DOI 10.1016/j.ygyno.2005.08.031; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; vanEngeland M, 1996, CYTOMETRY, V24, P131, DOI 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Yang G, 2003, ONCOGENE, V22, P5694, DOI 10.1038/sj.onc.1206858; Yang G, 2004, J BIOL CHEM, V279, P4339, DOI 10.1074/jbc.M311153200	25	14	15	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					870	880		10.1038/sj.onc.1209836	http://dx.doi.org/10.1038/sj.onc.1209836			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16862170				2022-12-25	WOS:000244063800008
J	Syed, DN; Afaq, F; Kweon, MH; Hadi, N; Bhatia, N; Spiegelman, VS; Mukhtar, H				Syed, D. N.; Afaq, F.; Kweon, M-H; Hadi, N.; Bhatia, N.; Spiegelman, V. S.; Mukhtar, H.			Green tea polyphenol EGCG suppresses cigarette smoke condensate-induced NF-kappa B activation in normal human bronchial epithelial cells	ONCOGENE			English	Article						(-)-epigallocatechin-3-gallate; cigarette smoke condensate; normal human bronchial epithelial cells; nuclear factor-kappa B	LUNG-CANCER; NITRIC-OXIDE; GROWTH; EXPRESSION; TARGET; TUMOR; PROLIFERATION; INFLAMMATION; INDUCTION; TUMORIGENESIS	Cigarette smoke is a powerful inducer of inflammatory responses resulting in disruption of major cellular pathways with transcriptional and genomic alterations driving the cells towards carcinogenesis. Cell culture and animal model studies indicate that (-)-epigallocatechin-3-gallate (EGCG), the major polyphenol present in green tea, possesses potent anti-inflammatory and antiproliferative activity capable of selectively inhibiting cell growth and inducing apoptosis in cancer cells without adversely affecting normal cells. Here, we demonstrate that EGCG pretreatment (20-80 mu M) of normal human bronchial epithelial cells (NHBE) resulted in significant inhibition of cigarette smoke condensate (CSC)-induced cell proliferation. Nuclear factor-kappa B (NF-kappa B) controls the transcription of genes involved in immune and inflammatory responses. In most cells, NF-kappa B prevents apoptosis by mediating cell survival signals. Pretreatment of NHBE cells with EGCG suppressed CSC-induced phosphorylation of I kappa B alpha, and activation and nuclear translocation of NF-kappa B/p65. NHBE cells transfected with a luciferase reporter plasmid containing an NF-kappa B-inducible promoter sequence showed an increased reporter activity after CSC exposure that was specifically inhibited by EGCG pretreatment. Immunoblot analysis showed that pretreatment of NHBE cells with EGCG resulted in a significant downregulation of NF-kappa B-regulated proteins cyclin D1, MMP-9, IL-8 and iNOS. EGCG pretreatment further inhibited CSC-induced phosphorylation of ERK1/2, JNK and p38 MAPKs and resulted in a decreased expression of PI3K, AKT and mTOR signaling molecules. Taken together, our data indicate that EGCG can suppress NF-kappa B activation as well as other pro-survival pathways such as PI3K/AKT/mTOR and MAPKs in NHBE cells, which may contribute to its ability to suppress inflammation, proliferation and angiogenesis induced by cigarette smoke.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Mukhtar, H (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Room B25,1300 Univ Ave, Madison, WI 53706 USA.	hmukhtar@wisc.edu		Spiegelman, Vladimir S/0000-0003-4847-155X	NATIONAL CANCER INSTITUTE [R01CA078809, P30CA014520, R01CA101039] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 78809, R01 CA 101039, 5P30 CA 14520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson GP, 2003, TRENDS PHARMACOL SCI, V24, P71, DOI 10.1016/S0165-6147(02)00052-4; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Doss MX, 2005, J NUTR BIOCHEM, V16, P259, DOI 10.1016/j.jnutbio.2004.11.003; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ho YS, 2005, TOXICOL APPL PHARM, V205, P133, DOI 10.1016/j.taap.2004.09.019; HUNNINGHAKE GW, 1983, AM REV RESPIR DIS, V128, P833; Jin ZH, 2004, J BIOL CHEM, V279, P23837, DOI 10.1074/jbc.M402566200; Johnson MK, 2000, MUTAT RES-DNA REPAIR, V459, P211, DOI 10.1016/S0921-8777(99)00074-9; Kisley LR, 2002, CANCER RES, V62, P6850; Konopka TE, 2001, CANCER RES, V61, P3182; Kurie JM, 1996, CLIN CANCER RES, V2, P1787; Kyosseva SV, 2004, INT REV NEUROBIOL, V59, P201; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Magnani M., 2000, Current Drug Targets, V1, P387, DOI 10.2174/1389450003349056; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Miller DP, 2003, INT J CANCER, V104, P758, DOI 10.1002/ijc.10989; Mossman BT, 2006, AM J RESP CELL MOL, V34, P666, DOI 10.1165/rcmb.2006-0047SF; Nishikawa M, 1999, AM J RESP CELL MOL, V20, P189, DOI 10.1165/ajrcmb.20.2.3305; Ozlu T, 2005, TUBERK TORAK, V53, P200; Patel JD, 2005, J CLIN ONCOL, V23, P3212, DOI 10.1200/JCO.2005.11.486; PERRY WJ, 2003, LUNG CANCER S1, V41, pS155; Philip M, 2004, SEMIN CANCER BIOL, V14, P433, DOI 10.1016/j.semcancer.2004.06.006; Rao CV, 2004, MUTAT RES-FUND MOL M, V555, P107, DOI 10.1016/j.mrfmmm.2004.05.022; Rusznak C, 2001, CLIN EXP ALLERGY, V31, P226, DOI 10.1046/j.1365-2222.2001.01000.x; Sahnoun Z, 1998, THERAPIE, V53, P315; Sasco AJ, 2004, LUNG CANCER, V45, pS3, DOI 10.1016/j.lungcan.2004.07.998; Shiraga M, 2002, CANCER RES, V62, P5967; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Takeyama K, 2001, AM J PHYSIOL-LUNG C, V280, pL165, DOI 10.1152/ajplung.2001.280.1.L165; Tsao AS, 2003, CANCER EPIDEM BIOMAR, V12, P660; Tsurutani J, 2005, CARCINOGENESIS, V26, P1182, DOI 10.1093/carcin/bgi072; Valen G, 2001, J AM COLL CARDIOL, V38, P307, DOI 10.1016/S0735-1097(01)01377-8; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; Vlahos R, 2006, AM J PHYSIOL-LUNG C, V290, pL931, DOI 10.1152/ajplung.00201.2005; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Wislez M, 2005, CANCER RES, V65, P3226, DOI 10.1158/0008-5472.CAN-04-4420; Wistuba II, 2002, ONCOGENE, V21, P7298, DOI 10.1038/sj.onc.1205806; Xu WM, 2002, CELL RES, V12, P311, DOI 10.1038/sj.cr.7290133; Yamamoto T, 2003, J PHARMACOL EXP THER, V307, P230, DOI 10.1124/jpet.103.054676; Yang CS, 2005, EXP LUNG RES, V31, P135, DOI 10.1080/01902140490495525; Zhang Q, 2005, AM J RESP CELL MOL, V32, P72, DOI 10.1165/rcmb.2004-0198OC; Zhong CY, 2005, CARCINOGENESIS, V26, P2187, DOI 10.1093/carcin/bgi189	43	107	120	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					673	682		10.1038/sj.onc.1209829	http://dx.doi.org/10.1038/sj.onc.1209829			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16862172				2022-12-25	WOS:000243902200005
J	Chen, YJ; Chang, JT; Lee, L; Wang, HM; Liao, CT; Chiu, CC; Chen, PJ; Cheng, AJ				Chen, Y-J; Chang, J. T.; Lee, L.; Wang, H-M; Liao, C-T; Chiu, C-C; Chen, P-J; Cheng, A-J			DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis	ONCOGENE			English	Article						DSG3; head neck cancer; clinical association; migration and invasion; therapeutic target	SQUAMOUS-CELL CARCINOMA; INTERMEDIATE FILAMENTS; PEMPHIGUS-VULGARIS; EXPRESSION; DESMOGLEIN; ADHESION; TELOMERASE	To identify genes that could potentially serve as molecular therapeutic markers for human head and neck cancer ( HNC), we employed differential display analysis to compare the gene expression profiles between HNC and histopathologically normal epithelial tissues. Using reverse transcription - polymerase chain reaction and Western blot analysis, desmoglein 3 (DSG3) was identified as being differentially expressed at both the RNA and protein levels. Of 56 patients assayed, 34 (61%) had overexpression of DSG3, which correlated statistically with T stage (P=0.009), N stage (P = 0.047), overall stage (P = 0.011), tumor depth (P = 0.009) and extracapsular spread in lymph nodes (P = 0.044), suggesting that DSG3 participates in carcinogenesis of HNC. Consistent with the clinical findings, inhibition of DSG3 by RNA interference (RNAi) significantly reduced cell growth and colony formation to 57 - 21% in three HNC cell lines. Use of an in vitro wound healing and Matrigel invasion assays, we found that cell migration and invasive ability were also inhibited to 30 - 48% in three cell lines tested. An in vivo xenograft study showed that administration of DSG3-RNAi plasmid significantly inhibited tumor growth for 2 months in BALB/C nude mice. In conclusion, DSG3 is identified overexpressed in HNC, with the degree of overexpression associated with clinicopathologic features of the tumor. Inhibition of DSG3 significantly suppresses carcinogenic potential in cellular and in vivo animal studies. These findings suggest that DSG3 is a potential molecular target in the development of adjuvant therapy for HNC.	Chang Gung Univ, Sch Med Technol, Grad Inst Basic Med Sci, Tao Yuan 333, Taiwan; Chang Gung Mem Hosp, Dept Radiat Oncol, Tao Yuan, Taiwan; Chang Gung Mem Hosp, Dept Surg Pathol, Tao Yuan, Taiwan; Chang Gung Mem Hosp, Dept Internal Med, Div Hematol Oncol, Tao Yuan, Taiwan; Chang Gung Mem Hosp, Dept Otorhinolaryngol Head & Neck Surg, Tao Yuan, Taiwan; Chang Gung Univ, Grad Inst Med Biotechnol, Tao Yuan 333, Taiwan	Chang Gung University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University	Cheng, AJ (corresponding author), Chang Gung Univ, Sch Med Technol, Grad Inst Basic Med Sci, 259 Wen Hwa 1st Rd, Tao Yuan 333, Taiwan.	ajchen@mail.cgu.edu.tw	Chun-Ta, Liao/B-9589-2011; Chiu, Ching-Chi/AAB-3093-2020; Cheng, Ann-Joy/AAI-4374-2020	Chiu, Ching-Chi/0000-0002-1827-8049; Cheng, Ann-Joy/0000-0002-1317-0725				AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; Amagai M, 1998, J CLIN INVEST, V102, P775, DOI 10.1172/JCI3647; Chang JT, 2006, BRIT J CANCER, V94, P870, DOI 10.1038/sj.bjc.6603008; Chang JT, 2005, INT J CANCER, V114, P942, DOI 10.1002/ijc.20663; Chang JT, 2002, CLIN BIOCHEM, V35, P591, DOI 10.1016/S0009-9120(02)00403-4; Chung CH, 2004, CANCER CELL, V5, P489, DOI 10.1016/S1535-6108(04)00112-6; CLAYMAN GL, 1996, CANC MED, P1645; DECKER J, 1982, NEW ENGL J MED, V306, P1151, DOI 10.1056/NEJM198205133061905; Garrod DR, 2002, CURR OPIN CELL BIOL, V14, P537, DOI 10.1016/S0955-0674(02)00366-6; Gordon LA, 2003, INT J CANCER, V106, P8, DOI 10.1002/ijc.11172; Green KJ, 2000, NAT REV MOL CELL BIO, V1, P208, DOI 10.1038/35043032; Hanakawa Y, 2002, J INVEST DERMATOL, V119, P1231, DOI 10.1046/j.1523-1747.2002.19648.x; Hanakawa Y, 2002, J INVEST DERMATOL, V119, P27, DOI 10.1046/j.1523-1747.2002.01780.x; Harada H, 1996, ACTA DERM-VENEREOL, V76, P417; IMAI K, 1995, HEAD NECK-J SCI SPEC, V17, P204, DOI 10.1002/hed.2880170307; Krunic ALJ, 1996, ACTA DERM-VENEREOL, V76, P394; Liao CT, 2004, HEAD NECK-J SCI SPEC, V26, P504, DOI 10.1002/hed.20007; Liao SK, 1998, CANCER GENET CYTOGEN, V103, P52, DOI 10.1016/S0165-4608(97)00416-0; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Yang C C, 2001, Zhonghua Yi Xue Za Zhi (Taipei), V64, P357; Yin TF, 2004, SEMIN CELL DEV BIOL, V15, P665, DOI 10.1016/j.semcdb.2004.09.005	21	89	91	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					467	476		10.1038/sj.onc.1209802	http://dx.doi.org/10.1038/sj.onc.1209802			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16878157				2022-12-25	WOS:000243544000016
J	Davalos, V; Dopeso, H; Velho, S; Ferreira, AM; Cirnes, L; Diaz-Chico, N; Bilbao, C; Ramirez, R; Rodriguez, G; Falcon, O; Leon, L; Niessen, RC; Keller, G; Dallenbach-Hellweg, G; Espin, E; Armengol, M; Plaja, A; Perucho, M; Imai, K; Yamamoto, H; Gebert, JF; Diaz-Chico, JC; Hofstra, RM; Woerner, SM; Seruca, R; Schwartz, S; Arango, D				Davalos, V.; Dopeso, H.; Velho, S.; Ferreira, A. M.; Cirnes, L.; Diaz-Chico, N.; Bilbao, C.; Ramirez, R.; Rodriguez, G.; Falcon, O.; Leon, L.; Niessen, R. C.; Keller, G.; Dallenbach-Hellweg, G.; Espin, E.; Armengol, M.; Plaja, A.; Perucho, M.; Imai, K.; Yamamoto, H.; Gebert, J. F.; Diaz-Chico, J. C.; Hofstra, R. M.; Woerner, S. M.; Seruca, R.; Schwartz, S., Jr.; Arango, D.			High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability	ONCOGENE			English	Article						EPHB2; cancer; microsatellite instability; colorectal; stomach; endometrium	RECEPTOR TYROSINE KINASE; FRAMESHIFT MUTATIONS; COLORECTAL TUMORS; TARGET GENES; CANCER; EXPRESSION	The EPH/EFN family of receptor tyrosine kinases regulates cell adhesion and migration and has an important role in controlling cell positioning in the normal intestinal epithelium. Inactivation of EPHB2 has recently been shown to accelerate tumorigenesis in the colon and rectum, and we have previously demonstrated frequent frameshift mutations (41%) in an A9 coding microsatellite repeat in exon 17 of EPHB2 in colorectal tumors with microsatellite instability (MSI). In this study, we extended these analyses to extracolonic MSI cancers, and found frameshift EPHB2 mutations in 39% (25/64) of gastric tumors and 14% (8/56) of endometrial tumors. Regression analysis of these EPHB2 mutation data on the basis of our previously proposed statistical model identified EPHB2 as a selective target of frameshift mutations in MSI gastric cancers but not in MSI endometrial carcinomas. These results suggest a functional role for EPHB2 in gastric tumor progression, and emphasize the differences between the tumorigenic processes in MSI gastrointestinal and endometrial cancer.	Valle Hebron Hosp Res Inst, CIBBIM, Funct Genom Program, Mol Oncol & Aging Grp,Mol Biol & Biochem Res Ctr, Barcelona 08035, Spain; Valle Hebron Hosp Res Inst, Mol Oncol Program, Mol Oncol & Aging Grp, Barcelona 08035, Spain; Univ Porto, Inst Mol Pathol & Immunol, IPATIMUP, P-4100 Oporto, Portugal; Univ Groningen, Med Ctr, Dept Genet, Groningen, Netherlands; Canc Res Inst Canary Isl, Endometrial Canc Study Grp, ICIC, Canary Isl, Spain; Univ Las Palmas Gran Canaria, Fac Hlth Sci, Dept Biochem & Physiol, Las Palmas Gran Canaria, Canary Islands, Spain; Tech Univ Munich, Inst Pathol, D-8000 Munich, Germany; Hosp Univ Materno Infantil Canarias, Dept Obstet & Gynecol, Las Palmas Gran Canaria, Canary Islands, Spain; Dr Falcon Gynecol Inst, Las Palmas Gran Canaria, Canary Islands, Spain; Hosp Univ Materno Infantil Canarias, Dept Pathol, Las Palmas Gran Canaria, Canary Islands, Spain; Inst Pathol, Mannheim, Germany; Vall Hebron Hosp Res Inst, CIBBIM, Program Cytogenet & Epigenet, Mol Oncol & Aging Grp,Mol Biol & Biochem Res Ctr, Barcelona 08035, Spain; Burnham Inst Med Res, La Jolla, CA USA; Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido, Japan; Inst Pathol, ATB, Dept Appl Tumor Biol, Heidelberg, Germany	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Universidade do Porto; University of Groningen; Universidad de Las Palmas de Gran Canaria; Technical University of Munich; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Sanford Burnham Prebys Medical Discovery Institute; Sapporo Medical University	Arango, D (corresponding author), Valle Hebron Hosp Res Inst, CIBBIM, Funct Genom Program, Mol Oncol & Aging Grp,Mol Biol & Biochem Res Ctr, Passeig Vall Hebron 119-129, Barcelona 08035, Spain.	darango@ir.vhebron.net	seruca, raquel/F-8187-2011; Schwartz, Simo/H-7776-2012; Dopeso, Higinio/H-7575-2019; Arango, Diego/AFW-0125-2022; Diaz-Chico, Juan/H-1527-2015; Ramírez, Raquel/GSO-1079-2022; Ramirez-Moreno, Raquel/J-4905-2018; SIEYRO, CRISTINA BILBAO/R-6779-2018; Velho, Sérgia/B-8501-2013; Woerner, Stefan/A-2187-2010; Davalos, Veronica/AAR-8547-2020; Arango, Diego/M-5667-2016; Davalos, Veronica/S-1668-2016	Dopeso, Higinio/0000-0003-0060-1861; Arango, Diego/0000-0003-2953-3284; Diaz-Chico, Juan/0000-0002-0944-990X; Ramirez-Moreno, Raquel/0000-0002-0351-9073; SIEYRO, CRISTINA BILBAO/0000-0002-4796-1445; Velho, Sérgia/0000-0002-7104-8234; Arango, Diego/0000-0003-2953-3284; Perucho, Manuel/0000-0002-2169-2662; Rodriguez Gonzalez, Francisco G/0000-0002-8509-0804; Espin-Basany, Eloy/0000-0002-9139-4548; Schwartz, Simo/0000-0001-8297-7971; Ferreira, Ana/0000-0001-6290-1320; Davalos, Veronica/0000-0003-4077-5137; Diaz Chico, Bonifacio Nicolas/0000-0001-5633-6185; Hofstra, Robert/0000-0001-7498-3829; Armengol, Manuel/0000-0002-3211-3195; Seruca, Raquel/0000-0002-8851-4166	NCI NIH HHS [R37 CA63585] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA063585] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alazzouzi H, 2005, CANCER RES, V65, P10170, DOI 10.1158/0008-5472.CAN-05-2580; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Bilbao C, 2006, INT J CANCER, V119, P563, DOI 10.1002/ijc.21862; Duval A, 2002, CANCER RES, V62, P1609; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Guo DL, 2006, CARCINOGENESIS, V27, P454, DOI 10.1093/carcin/bgi259; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holder N, 1999, DEVELOPMENT, V126, P2033; Huet S., 2003, STAT TOOLS NONLINEAR; Lugli A, 2005, CLIN CANCER RES, V11, P6450, DOI 10.1158/1078-0432.CCR-04-2458; Schwartz S, 1999, CANCER RES, V59, P2995; Woerner SM, 2003, ONCOGENE, V22, P2226, DOI 10.1038/sj.onc.1206421; Yamamoto H, 1999, J EXP CLIN CANC RES, V18, P103	15	35	43	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	2					308	311		10.1038/sj.onc.1209780	http://dx.doi.org/10.1038/sj.onc.1209780			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819508				2022-12-25	WOS:000243398300015
J	de Nigris, F; Botti, C; Rossiello, R; Crimi, E; Sica, V; Napoli, C				de Nigris, F.; Botti, C.; Rossiello, R.; Crimi, E.; Sica, V.; Napoli, C.			Cooperation between Myc and YY1 provides novel silencing transcriptional targets of alpha 3 beta 1-integrin in tumour cells	ONCOGENE			English	Article						YY1; integrin; c-myc; tumours	C-MYC; IN-VIVO; OSTEOSARCOMA CELLS; SIGNALING PATHWAYS; OVER-EXPRESSION; INTEGRINS; CANCER; MECHANISMS; BETA-1-INTEGRIN; ACTIVATION	We show that human osteosarcoma cells (Saos-2) have downregulation of alpha 3 beta 1-integrin compared to normal bone cells; this was further described in human osteosarcomas and in a primary murine sarcoma. The alpha 3 gene was silenced in Saos-2 cells causing a low expression of alpha 3 beta 1-integrin and reduction in collagen attachment with increasing migratory capacity. Chromatin immunoprecipitation assay performed on alpha 3 promoter established that Myc and Yin Yang protein (YY1) cooperate in tandem to downregulate the alpha 3 gene. This silencing mechanism involves the binding of Myc and YY1 to DNA and formation of complexes among Myc/Max, YY1, CREB-binding protein and deacetylation activity. The promoter containing deletions of E-boxes or YY1 cassettes failed to downregulate the transcription of a reporter gene as well as the inhibition of deacetylation activity. Overexpression of both Myc and YY1 was necessary to determine the alpha 3-integrin promoter downregulation in normal osteoblasts. This downregulation of alpha 3 beta 1-integrin can contribute to the acquisition of a more aggressive phenotype. YY1 regulated negatively the Myc activity through a direct interaction with the Myc/Max and deacetylase complexes. This represents a novel silencing mechanism with broad implications in the transcription machinery of tumours.	Univ Naples 2, Sch Med 1, Dept Gen Pathol, Div Clin Pathol, I-80138 Naples, Italy; Univ Naples 2, Sch Med 2, Div Human Pathol, I-80138 Naples, Italy; Berkshire Med Ctr, Dept Internal Med, Pittsfield, MA USA	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli	Napoli, C (corresponding author), Univ Naples 2, Sch Med 1, Dept Gen Pathol, Div Clin Pathol, Via Luigi Crecchio 7,Complesso S Maria Dame, I-80138 Naples, Italy.	claudio.napoli@unina2.it		Napoli, Claudio/0000-0002-5455-555X				Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507; Brockbank EC, 2005, BRIT J CANCER, V92, P102, DOI 10.1038/sj.bjc.6602255; Dang CV, 1997, J BIOMED SCI, V4, P269, DOI 10.1007/BF02258350; Davie JR, 1998, J CELL BIOCHEM, P203; de Nigris F, 2000, CIRCULATION, V102, P2111, DOI 10.1161/01.CIR.102.17.2111; de Nigris F, 2002, BRIT J CANCER, V87, P1479, DOI 10.1038/sj.bjc.6600636; de Nigris F, 2001, CANCER RES, V61, P2267; de Nigris F, 2003, CELL CYCLE, V2, P325, DOI 10.4161/cc.2.4.414; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Judware R, 1997, CLIN EXP METASTAS, V15, P228, DOI 10.1023/A:1018417330479; Judware R, 1995, ONCOGENE, V11, P2599; Kawashima A, 2001, CELL BIOL INT, V25, P319, DOI 10.1006/cbir.2000.0652; LEE TC, 1994, ONCOGENE, V9, P1047; Napoli C, 2000, FASEB J, V14, P1996, DOI 10.1096/fj.99-0986com; Napoli C, 2002, NEOPLASIA, V4, P185, DOI 10.1038/sj.neo.7900232; Parise LV, 2000, SEMIN CANCER BIOL, V10, P407, DOI 10.1006/scbi.2000.0337; PIGNATELLI M, 1991, J PATHOL, V165, P25, DOI 10.1002/path.1711650106; PULVERER BJ, 1994, ONCOGENE, V9, P59; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; Seales EC, 2005, CANCER RES, V65, P4645, DOI 10.1158/0008-5472.CAN-04-3117; Seales EC, 2003, ONCOGENE, V22, P7137, DOI 10.1038/sj.onc.1206834; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Ye JP, 1996, MOL CELL BIOL, V16, P4744	34	35	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					382	394		10.1038/sj.onc.1209804	http://dx.doi.org/10.1038/sj.onc.1209804			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16878156				2022-12-25	WOS:000243544000007
J	Kol, S; Turrell, BR; de Keyzer, J; van der Laan, M; Nouwen, N; Driessen, AJM				Kol, Stefan; Turrell, Bryony R.; de Keyzer, Jeanine; van der Laan, Martin; Nouwen, Nico; Driessen, Arnold J. M.			YidC-mediated membrane insertion of assembly mutants of subunit C of the F1F0 ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI INNER MEMBRANE; ESCHERICHIA-COLI; PROTEIN INSERTION; ADENOSINE-TRIPHOSPHATASE; SACCHAROMYCES-CEREVISIAE; F-0 COMPLEX; SYNTHASE; BIOGENESIS; SECYEG; REQUIREMENTS	YidC is a member of the OxaI family of membrane proteins that has been implicated in the membrane insertion of inner membrane proteins in Escherichia coli. We have recently demonstrated that proteoliposomes containing only YidC support both the stable membrane insertion and the oligomerization of the c subunit of the F1F0 ATP synthase (F(0)c). Here we have shown that two mutants of F(0)c unable to form a functional F1F0 ATPase interact with YidC, require YidC for membrane insertion, but fail to oligomerize. These data show that oligomerization is not essential for the stable YidC- dependent membrane insertion of F(0)c consistent with a function of YidC as a membrane protein insertase.	Univ Groningen, Dept Mol Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands; Univ Groningen, Mat Sci Ctr Plus, NL-9751 NN Haren, Netherlands	University of Groningen; University of Groningen	Driessen, AJM (corresponding author), Univ Groningen, Dept Mol Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands.	a.j.m.driessen@rug.nl	Driessen, Arnold J.M./D-1876-2012	Driessen, Arnold J.M./0000-0001-9258-9104; van der Laan, Martin/0000-0003-0789-9912; Kol, Stefan/0000-0002-1992-8242				Akiyama Y, 1996, FEBS LETT, V399, P26, DOI 10.1016/S0014-5793(96)01283-5; Altamura N, 1996, FEBS LETT, V382, P111, DOI 10.1016/0014-5793(96)00165-2; Arechaga I, 2002, FEBS LETT, V515, P189, DOI 10.1016/S0014-5793(02)02447-X; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; Capaldi RA, 2002, TRENDS BIOCHEM SCI, V27, P154, DOI 10.1016/S0968-0004(01)02051-5; Celebi N, 2006, J MOL BIOL, V357, P1428, DOI 10.1016/j.jmb.2006.01.030; Chen MY, 2002, J BIOL CHEM, V277, P7670, DOI 10.1074/jbc.M110644200; de Gier JWL, 2003, EMBO REP, V4, P939, DOI 10.1038/sj.embor.embor921; DeckersHebestreit G, 1996, ANNU REV MICROBIOL, V50, P791, DOI 10.1146/annurev.micro.50.1.791; DEVRIJE T, 1987, BIOCHIM BIOPHYS ACTA, V900, P63, DOI 10.1016/0005-2736(87)90278-1; DOWNIE JA, 1981, J BACTERIOL, V145, P200, DOI 10.1128/JB.145.1.200-210.1981; du Plessis DJF, 2006, J BIOL CHEM, V281, P12248, DOI 10.1074/jbc.M600048200; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; Fillingame RH, 2002, BBA-BIOENERGETICS, V1555, P29, DOI 10.1016/S0005-2728(02)00250-5; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; HERMOLIN J, 1995, J BIOL CHEM, V270, P2815, DOI 10.1074/jbc.270.6.2815; Herskovits AA, 2000, MOL MICROBIOL, V38, P927, DOI 10.1046/j.1365-2958.2000.02198.x; Houben ENG, 2000, FEBS LETT, V476, P229, DOI 10.1016/S0014-5793(00)01735-X; JANS DA, 1983, BIOCHEM J, V211, P717, DOI 10.1042/bj2110717; Krebstakies T, 2005, J BIOL CHEM, V280, P33338, DOI 10.1074/jbc.M506251200; Kuhn A, 2003, TRENDS CELL BIOL, V13, P510, DOI 10.1016/j.tcb.2003.08.005; KUHN A, 1995, FEMS MICROBIOL REV, V17, P185; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lemaire C, 2000, J BIOL CHEM, V275, P23471, DOI 10.1074/jbc.M002045200; Luirink J, 2001, FEBS LETT, V501, P1, DOI 10.1016/S0014-5793(01)02616-3; Meier T, 2005, SCIENCE, V308, P659, DOI 10.1126/science.1111199; MILLER MJ, 1989, J BIOL CHEM, V264, P305; Moore M, 2000, J BIOL CHEM, V275, P1529, DOI 10.1074/jbc.275.3.1529; Nagamori S, 2004, J CELL BIOL, V165, P53, DOI 10.1083/jcb.200402067; Ono S, 2004, J BIOL CHEM, V279, P33409, DOI 10.1074/jbc.M404993200; Preuss M, 2005, J BIOL CHEM, V280, P13004, DOI 10.1074/jbc.M414093200; Rubinstein JL, 2003, EMBO J, V22, P6182, DOI 10.1093/emboj/cdg608; Russel M, 1997, GENE, V192, P23, DOI 10.1016/S0378-1119(96)00801-3; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; Stalz WD, 2003, J BIOL CHEM, V278, P27068, DOI 10.1074/jbc.M302027200; STEFFENS K, 1984, EUR J BIOCHEM, V138, P617, DOI 10.1111/j.1432-1033.1984.tb07959.x; van Bloois E, 2006, J BIOL CHEM, V281, P10002, DOI 10.1074/jbc.M511357200; van Bloois E, 2004, FEBS LETT, V576, P97, DOI 10.1016/j.febslet.2004.08.069; van der Laan M, 2005, CURR OPIN MICROBIOL, V8, P182, DOI 10.1016/j.mib.2005.02.004; van der Laan M, 2004, J CELL BIOL, V165, P213, DOI 10.1083/jcb.200402100; van der Laan M, 2004, J BIOL CHEM, V279, P1659, DOI 10.1074/jbc.M306527200; van der Laan M, 2003, P NATL ACAD SCI USA, V100, P5801, DOI 10.1073/pnas.0636761100; van der Laan M, 2001, EMBO REP, V2, P519, DOI 10.1093/embo-reports/kve106; VIK SB, 1987, J BIOL CHEM, V262, P8340; Vonck J, 2002, J MOL BIOL, V321, P307, DOI 10.1016/S0022-2836(02)00597-1; Weber J, 2003, FEBS LETT, V545, P61, DOI 10.1016/S0014-5793(03)00394-6; Yi L, 2003, BIOCHEMISTRY-US, V42, P10537, DOI 10.1021/bi034309h; Yi L, 2004, J BIOL CHEM, V279, P39260, DOI 10.1074/jbc.M405490200; Yi L, 2005, MOL MEMBR BIOL, V22, P101, DOI 10.1080/09687860500041718	52	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29762	29768		10.1074/jbc.M605317200	http://dx.doi.org/10.1074/jbc.M605317200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16880204	Green Published, hybrid			2022-12-25	WOS:000240896300038
J	Yesilaltay, A; Kocher, O; Pal, R; Leiva, A; Quinones, V; Rigotti, A; Krieger, M				Yesilaltay, Ayce; Kocher, Olivier; Pal, Rinku; Leiva, Andrea; Quinones, Veronica; Rigotti, Attilio; Krieger, Monty			PDZK1 is required for maintaining hepatic scavenger receptor, class B, type I (SR-BI) steady state levels but not its surface localization or function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; DOMAIN-CONTAINING PROTEIN; TARGETED DISRUPTION; LIPID-METABOLISM; FREE-CHOLESTEROL; EXPRESSION; HDL; IDENTIFICATION; LIVER; GENE	PDZK1 is a multi-PDZ domain-containing adaptor protein that binds to the C terminus of the high density lipoprotein receptor, scavenger receptor, class B, type I (SR-BI), and controls the posttranscriptional, tissue-specific expression of this lipoprotein receptor. In the absence of PDZK1 (PDZK1(-/-) mice), murine hepatic SR-BI protein levels are very low (< 5% of control). As a consequence, abnormal plasma lipoprotein metabolism (similar to 1.5-1.7-fold increased total plasma cholesterol carried in both normal size and abnormally large high density lipoprotein particles) resembles, but is not as severely defective as, that in SR-BI(-/-) mice. Here we show that the total plasma cholesterol levels and size distribution of lipoproteins are virtually identical in SR-BI(-/-) and SR-BI(-/-)/ PDZK1(-/-) mice, indicating that most, if not all of the effects of PDZK1 on lipoprotein metabolism are likely because of the effects of PDZK1 on SR-BI. Hepatic overexpression of wild-type SR-BI in PDZK1(-/-) mice restored near or greater than normal levels of cell surface-expressed, functional SR-BI protein levels in the livers of SR-BI(-/-)/ PDZK1(-/-) mice and consequently restored apparently normal lipoprotein metabolism in the absence of PDZK1. Thus, PDZK1 is important for maintaining adequate steady state levels of SR-BI in the liver but is not essential for cell surface expression or function of hepatic SR-BI.	MIT, Dept Biol, Cambridge, MA 02139 USA; Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Pontificia Univ Catolica Chile, Fac Med, Dept Gastroenterol, Santiago 8330024, Chile	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Pontificia Universidad Catolica de Chile	Krieger, M (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave,Rm 68-483, Cambridge, MA 02139 USA.	krieger@mit.edu			FOGARTY INTERNATIONAL CENTER [R03TW006153] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064737, P01HL066105] Funding Source: NIH RePORTER; FIC NIH HHS [TW006153] Funding Source: Medline; NHLBI NIH HHS [HL66105, HL64737] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Anzai N, 2004, J BIOL CHEM, V279, P45942, DOI 10.1074/jbc.M406724200; Braun A, 2003, P NATL ACAD SCI USA, V100, P7283, DOI 10.1073/pnas.1237725100; Covey SD, 2003, ARTERIOSCL THROM VAS, V23, P1589, DOI 10.1161/01.ATV.0000083343.19940.A0; Gentzsch M, 2003, J BIOL CHEM, V278, P6440, DOI 10.1074/jbc.M211050200; Gisler SM, 2003, KIDNEY INT, V64, P1733, DOI 10.1046/j.1523-1755.2003.00266.x; Gisler SM, 2001, J BIOL CHEM, V276, P9206, DOI 10.1074/jbc.M008745200; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Ikemoto M, 2000, P NATL ACAD SCI USA, V97, P6538, DOI 10.1073/pnas.100114397; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; Kato Y, 2005, MOL PHARMACOL, V67, P734, DOI 10.1124/mol.104.002212; Kato Y, 2004, PHARM RES-DORDR, V21, P1886, DOI 10.1023/B:PHAM.0000045244.83999.43; Kocher O, 1998, LAB INVEST, V78, P117; Kocher O, 2003, J BIOL CHEM, V278, P52820, DOI 10.1074/jbc.M310482200; Kocher O, 2003, MOL CELL BIOL, V23, P1175, DOI 10.1128/MCB.23.4.1175-1180.2003; Kocher O, 1999, LAB INVEST, V79, P1161; KONOPKA JB, 1991, CELL REGUL, V2, P439, DOI 10.1091/mbc.2.6.439; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; Mardones P, 2003, J BIOL CHEM, V278, P7884, DOI 10.1074/jbc.M211627200; Mardones P, 2001, J LIPID RES, V42, P170; Miettinen HE, 2001, J CLIN INVEST, V108, P1717, DOI 10.1172/JCI13288; Nakamura T, 2005, P NATL ACAD SCI USA, V102, P13404, DOI 10.1073/pnas.0506679102; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Rigotti A, 2003, ENDOCR REV, V24, P357, DOI 10.1210/er.2001-0037; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; ROTHMAN JH, 1986, P NATL ACAD SCI USA, V83, P3248, DOI 10.1073/pnas.83.10.3248; Silver DL, 2002, J BIOL CHEM, V277, P34042, DOI 10.1074/jbc.M206584200; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; Stangl H, 2002, J ENDOCRINOL, V175, P663, DOI 10.1677/joe.0.1750663; STEIN Y, 1983, BIOCHIM BIOPHYS ACTA, V752, P98, DOI 10.1016/0005-2760(83)90237-0; Sun BM, 2004, MOL BIOL CELL, V15, P1397, DOI 10.1091/mbc.E03-09-0682; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Thomson RB, 2005, P NATL ACAD SCI USA, V102, P13331, DOI 10.1073/pnas.0506578102; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Trigatti BL, 2003, ARTERIOSCL THROM VAS, V23, P1732, DOI 10.1161/01.ATV.0000091363.28501.84; Ueda Y, 2000, J BIOL CHEM, V275, P20368, DOI 10.1074/jbc.M000730200; Ueda Y, 1999, J BIOL CHEM, V274, P7165, DOI 10.1074/jbc.274.11.7165; Van Eck M, 2003, J BIOL CHEM, V278, P23699, DOI 10.1074/jbc.M211233200; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Wente W, 2005, J BIOL CHEM, V280, P32419, DOI 10.1074/jbc.M507198200; Yancey PG, 2000, J BIOL CHEM, V275, P36596, DOI 10.1074/jbc.M006924200; Yesilaltay A, 2006, ENDOCRINOLOGY, V147, P1577, DOI 10.1210/en.2005-1286; Yesilaltay A, 2005, CURR OPIN LIPIDOL, V16, P147, DOI 10.1097/01.mol.0000162319.54795.e5; Zhang SW, 2005, CIRCULATION, V111, P3457, DOI 10.1161/CIRCULATIONAHA.104.523563	50	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28975	28980		10.1074/jbc.M603802200	http://dx.doi.org/10.1074/jbc.M603802200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16867981	hybrid			2022-12-25	WOS:000240680500052
J	Chang, HC; Tan, KM; Hsu, YM				Chang, Hsiu-Ching; Tan, Kemin; Hsu, Yen-Ming			CD8 alpha beta has two distinct binding modes of interaction with peptide-major histocompatibility complex class I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; CD8 CORECEPTOR FUNCTION; DIFFERENTIAL EXPRESSION; STRUCTURAL BASIS; CD8-BETA CHAINS; LIGAND-BINDING; ALPHA-3 DOMAIN; LYMPHOCYTES-T; CELL; TCR	Interaction of CD8 (CD8 alpha alpha or CD8 alpha beta) with the peptide-major histocompatibility complex (MHC) class I (pMHCI) is critical for the development and function of cytolytic T cells. Although the crystal structure of CD8 alpha alpha(.)pMHCI complex revealed that two symmetric CD8 alpha subunits interact with pMHCI asymmetrically, with one subunit engaged in more extensive interaction than the other, the details of the interaction between the CD8 alpha beta heterodimer and pMHCI remained unknown. The Ig-like domains of mouse CD8 alpha beta and CD8 alpha alpha are similar in the size, shape, and surface electrostatic potential of their pMHCI-binding regions, suggesting that their interactions with pMHCI could be very similar. Indeed, we found that the CD8 alpha variants CD8 alpha(R8A) and CD8 alpha(E27A), which were functionally inactive as homodimers, could form an active co-receptor with wildtype (WT) CD8 beta as a CD8 alpha(R8A)beta or CD8 alpha(E27A)beta heterodimer. We also identified CD8 beta variants that could form active receptors with WT CD8 beta but not with CD8 alpha(R8A). This observation is consistent with the notion that the CD8 beta subunit may replace either CD8 beta subunit in CD8 alpha alpha(.) pMHCI complex. In addition, we showed that both anti-CD8 alpha and anti-CD8 beta antibodies were unable to completely block the co-receptor activity of WT CD8 alpha beta. We propose that CD8 alpha beta binds to pMHCI in at least two distinguishable orientations.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Biogen Inc, Mol Discovery Dept, Cambridge, MA 02142 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Biogen	Chang, HC (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 77 Ave Louis Pasteur,HIM-442, Boston, MA 02115 USA.	hsiu-ching_chang@dfci.harvard.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045789] Funding Source: NIH RePORTER; NIAID NIH HHS [AI45789] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arcaro A, 2001, J EXP MED, V194, P1485, DOI 10.1084/jem.194.10.1485; AUPHAN N, 1991, MOL IMMUNOL, V28, P827, DOI 10.1016/0161-5890(91)90046-M; Bosselut R, 2000, IMMUNITY, V12, P409, DOI 10.1016/S1074-7613(00)80193-4; Buslepp J, 2003, IMMUNITY, V19, P595, DOI 10.1016/S1074-7613(03)00269-3; CANTOR H, 1975, J EXP MED, V141, P1376, DOI 10.1084/jem.141.6.1376; Chang HC, 2005, IMMUNITY, V23, P661, DOI 10.1016/j.immuni.2005.11.002; Chang HC, 1997, J MOL BIOL, V271, P278, DOI 10.1006/jmbi.1997.1169; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; DETOTERO D, 1992, BLOOD, V80, P1765; Devine L, 1999, J IMMUNOL, V162, P846; Devine L, 2000, J IMMUNOL, V164, P833, DOI 10.4049/jimmunol.164.2.833; Doucey MA, 2004, NAT IMMUNOL, V5, P328, DOI 10.1038/ni1043; Gangadharan D, 2004, CURR OPIN IMMUNOL, V16, P264, DOI 10.1016/j.coi.2004.03.015; Gao GF, 2002, TRENDS IMMUNOL, V23, P408, DOI 10.1016/S1471-4906(02)02282-2; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Hayday A, 2001, NAT IMMUNOL, V2, P997, DOI 10.1038/ni1101-997; Irie HY, 1998, J IMMUNOL, V161, P183; Kern PS, 1998, IMMUNITY, V9, P519, DOI 10.1016/S1074-7613(00)80635-4; Konig R, 2002, CURR OPIN IMMUNOL, V14, P75, DOI 10.1016/S0952-7915(01)00300-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; MOEBIUS U, 1991, EUR J IMMUNOL, V21, P1793, DOI 10.1002/eji.1830210803; Moody AM, 2001, CELL, V107, P501, DOI 10.1016/S0092-8674(01)00577-3; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Priatel JJ, 2000, IMMUNITY, V12, P273, DOI 10.1016/S1074-7613(00)80180-6; REINHERZ EL, 1980, CELL, V19, P821, DOI 10.1016/0092-8674(80)90072-0; Renard V, 1996, J EXP MED, V184, P2439, DOI 10.1084/jem.184.6.2439; Rudolph MG, 2002, CURR OPIN IMMUNOL, V14, P52, DOI 10.1016/S0952-7915(01)00298-9; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; Stewart-Jones GBE, 2003, NAT IMMUNOL, V4, P657, DOI 10.1038/ni942; Sun JR, 1997, J IMMUNOL, V159, P6077; TERRY LA, 1990, TISSUE ANTIGENS, V35, P82, DOI 10.1111/j.1399-0039.1990.tb01761.x; Wheeler CJ, 1998, J IMMUNOL, V160, P4199; Witte T, 1999, CELL IMMUNOL, V191, P90, DOI 10.1006/cimm.1998.1412; Wong JS, 2003, J IMMUNOL, V171, P867, DOI 10.4049/jimmunol.171.2.867; Zuniga-Pflucker J C, 1991, Semin Immunol, V3, P167	36	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28090	28096		10.1074/jbc.M604931200	http://dx.doi.org/10.1074/jbc.M604931200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16840780	hybrid			2022-12-25	WOS:000240534400046
J	Liew, CW; Rand, KD; Simpson, RJY; Yung, WW; Mansfield, RE; Crossley, M; Proetorius-Ibba, M; Nerlov, C; Poulsen, FM; Mackay, JP				Liew, Chu Wai; Rand, Kasper D.; Simpson, Raina J. Y.; Yung, Wendy W.; Mansfield, Robyn E.; Crossley, Merlin; Proetorius-Ibba, Mette; Nerlov, Claus; Poulsen, Flemming M.; Mackay, Joel P.			Molecular analysis of the interaction between the hematopoietic master transcription factors GATA-1 and PU.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; ERYTHROID-DIFFERENTIATION; ERYTHROLEUKEMIA-CELLS; FAMILY PROTEINS; ETS-DOMAIN; EXPRESSION; ACETYLATION; ACTIVATION; SPI-1/PU.1; INHIBITION	GATA-1 and PU.1 are transcription factors that control erythroid and myeloid development, respectively. The two proteins have been shown to function in an antagonistic fashion, with GATA-1 repressing PU.1 activity during erythropoiesis and PU.1 repressing GATA-1 function during myelopoiesis. It has also become clear that this functional antagonism involves direct interactions between the two proteins. However, the molecular basis for these interactions is not known, and a number of inconsistencies exist in the literature. We have used a range of biophysical methods to define the molecular details of the GATA-1-PU.1 interaction. A combination of NMR titration data and extensive mutagenesis revealed that the PU.1-Ets domain and the GATA-1 C-terminal zinc finger (CF) form a low affinity interaction in which specific regions of each protein are implicated. Surprisingly, the interaction cannot be disrupted by single alanine substitution mutations, suggesting that binding is distributed over an extended interface. The C-terminal basic tail region of CF appears to be sufficient to mediate an interaction with PU.1-Ets, and neither acetylation nor phosphorylation of a peptide corresponding to this region disrupts binding, indicating that the interaction is not dominated by electrostatic interactions. The CF basic tail shares significant sequence homology with the PU.1 interacting motif from c-Jun, suggesting that GATA-1 and c-Jun might compete to bind PU.1. Taken together, our data provide a molecular perspective on the GATA-1-PU.1 interaction, resolving several issues in the existing data and providing insight into the mechanisms through which these two proteins combine to regulate blood development.	Univ Copenhagen, Inst Mol Biol, Dept Prot Chem, DK-1168 Copenhagen, Denmark; Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia; Univ Copenhagen Hosp, Lab Gene Therapy Res, DK-2100 Copenhagen, Denmark; European Mol Biol Lab, Mouse Biol Unit, I-00016 Monterotondo, Italy	University of Copenhagen; University of Sydney; University of Copenhagen; European Molecular Biology Laboratory (EMBL)	Poulsen, FM (corresponding author), Univ Copenhagen, Inst Mol Biol, Dept Prot Chem, DK-1168 Copenhagen, Denmark.	fmp@apk.molbio.ku.dk	Crossley, Merlin/D-7888-2011; Mackay, Joel P/D-6834-2011; Rand, Kasper/ABG-7446-2021; Poulsen, Flemming M/E-6848-2010	Crossley, Merlin/0000-0003-2057-3642; Mackay, Joel P/0000-0001-7508-8033; Simpson, Richard/0000-0002-9834-0796; Rand, Kasper/0000-0002-6337-5489				Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Cai ML, 1998, J BIOMOL NMR, V11, P97, DOI 10.1023/A:1008222131470; Cantor AB, 2001, CURR OPIN GENET DEV, V11, P513, DOI 10.1016/S0959-437X(00)00226-4; Carrere S, 1998, ONCOGENE, V16, P3261, DOI 10.1038/sj.onc.1201868; CROSSLEY M, 1994, J BIOL CHEM, V269, P16589; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Eisbacher M, 2003, MOL CELL BIOL, V23, P3427, DOI 10.1128/MCB.23.10.3427-3441.2003; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GODDARD TD, 2001, SPARKY, V3; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GUERRASIO A, 1994, LEUKEMIA, V8, P1034; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; Hong W, 2002, MOL CELL BIOL, V22, P3729, DOI 10.1128/MCB.22.11.3729-3743.2002; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Jia X, 1999, J MOL BIOL, V292, P1083, DOI 10.1006/jmbi.1999.3123; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; Kowalski K, 2002, J BIOL CHEM, V277, P35720, DOI 10.1074/jbc.M204663200; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; Nemoto Y, 1996, J BIOL CHEM, V271, P13542, DOI 10.1074/jbc.271.23.13542; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Rekhtman N, 2003, MOL CELL BIOL, V23, P7460, DOI 10.1128/MCB.23.21.7460-7474.2003; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Simpson RJY, 2003, J BIOL CHEM, V278, P28011, DOI 10.1074/jbc.M211146200; Stopka T, 2005, EMBO J, V24, P3712, DOI 10.1038/sj.emboj.7600834; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Velyvis A, 2003, NAT STRUCT BIOL, V10, P558, DOI 10.1038/nsb938; VISVADER JE, 1992, EMBO J, V11, P4557, DOI 10.1002/j.1460-2075.1992.tb05557.x; Worrall JAR, 2003, BIOCHEMISTRY-US, V42, P7068, DOI 10.1021/bi0342968; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zimmerman DE, 1997, J MOL BIOL, V269, P592, DOI 10.1006/jmbi.1997.1052	49	50	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28296	28306		10.1074/jbc.M602830200	http://dx.doi.org/10.1074/jbc.M602830200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16861236	hybrid			2022-12-25	WOS:000240534400067
J	Ferri-Fioni, ML; Fromant, M; Bouin, AP; Aubard, C; Lazennec, C; Plateau, P; Blanquet, S				Ferri-Fioni, Maria-Laura; Fromant, Michel; Bouin, Anne-Pascale; Aubard, Caroline; Lazennec, Christine; Plateau, Pierre; Blanquet, Sylvain			Identification in archaea of a novel D-Tyr-tRNA(Tyr) deacylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA HYDROLASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; SULFOLOBUS-SOLFATARICUS; ANGSTROM RESOLUTION; ARABIDOPSIS; SYNTHETASES; METABOLISM; PROTEIN	Most bacteria and eukarya contain an enzyme capable of specifically hydrolyzing D-aminoacyl-tRNA. Here, the archaea Sulfolobus solfataricus is shown to also contain an enzyme activity capable of recycling misaminoacylated D-Tyr-tRNA(Tyr). N-terminal sequencing of this enzyme identifies open reading frame SS02234 (dtd2), the product of which does not present any sequence homology with the known D-Tyr-tRNA(Tyr) deacylases of bacteria or eukaryotes. On the other hand, homologs of dtd2 occur in archaea and plants. The Pyrococcus abyssi dtd2 ortholog (PAB2349) was isolated. It rescues the sensitivity to D-tyrosine of a mutant Escherichia coli strain lacking dtd, the gene of its endogeneous D-Tyr-tRNATyr deacylase. Moreover, in vitro, the PAB2349 product, which behaves as a monomer and carries 2 mol of zinc/mol of protein, catalyzes the cleavage of D-Tyr-tRNATyr. The three-dimensional structure of the product of the Archaeoglobus fulgidus dtd2 ortholog has been recently solved by others through a structural genomics approach (Protein Data Bank code 1YQE). This structure does not resemble that of Escherichia coli D-Tyr-tRNATyr deacylase. Instead, it displays homology with that of a bacterial peptidyl-tRNA hydrolase. We show, however, that the archaeal PAB2349 enzyme does not act against diacetyl-Lys-tRNA(Lys), a model substrate of peptidyl-tRNA hydrolase. Based on the Protein Data Bank 1YQE structure, site-directed mutagenesis experiments were undertaken to remove zinc from the PAB2349 enzyme. Several residues involved in zinc binding and supporting the activity of the deacylase were identified. Taken together, these observations suggest evolutionary links between the various hydrolases in charge of the recycling of metabolically inactive tRNAs during translation.	Ecole Polytech, Biochim Lab, UMR 7654, CNRS,Dept Biol, F-91128 Palaiseau, France; Ecole Polytech, Lab Mecanismes React, UMR 7651, CNRS,Dept Chim, F-91128 Palaiseau, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut Polytechnique de Paris; Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris	Plateau, P (corresponding author), Ecole Polytech, Biochim Lab, UMR 7654, CNRS,Dept Biol, F-91128 Palaiseau, France.	plateau@bioc.polytechnique.fr	bouin, anne pascale/M-2734-2013	bouin, anne pascale/0000-0002-9616-6173; launay, caroline/0000-0002-6587-6631				BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1690, DOI 10.1021/bi00869a034; CALENDAR R, 1967, J MOL BIOL, V26, P39, DOI 10.1016/0022-2836(67)90259-8; de Pereda JM, 2004, J BIOL CHEM, V279, P8111, DOI 10.1074/jbc.M311449200; Ferri-Fioni ML, 2001, J BIOL CHEM, V276, P47285, DOI 10.1074/jbc.M106550200; Fromant M, 2003, NUCLEIC ACIDS RES, V31, P3227, DOI 10.1093/nar/gkg428; Fromant M, 2005, BIOCHEMISTRY-US, V44, P4294, DOI 10.1021/bi047711k; Fujishige N, 2004, PLANT CELL PHYSIOL, V45, P659, DOI 10.1093/pcp/pch086; GIEGE R, 1972, BIOCHIMIE, V54, P1245, DOI 10.1016/S0300-9084(72)80065-8; Goodall JJ, 2004, BIOCHEMISTRY-US, V43, P4583, DOI 10.1021/bi0302200; Guillon L, 2005, BIOCHEMISTRY-US, V44, P15594, DOI 10.1021/bi051514j; Hirayama T, 2004, PLANT CELL PHYSIOL, V45, P703, DOI 10.1093/pcp/pch078; HIREL PH, 1988, BIOCHIMIE, V70, P773, DOI 10.1016/0300-9084(88)90107-1; Jenkins BD, 2001, EMBO J, V20, P872, DOI 10.1093/emboj/20.4.872; Koonin EV, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-r7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MILLER HI, 1980, CELL, V20, P711, DOI 10.1016/0092-8674(80)90317-7; Schmitt E, 1997, EMBO J, V16, P4760, DOI 10.1093/emboj/16.15.4760; Soutourina J, 2000, J BIOL CHEM, V275, P32535, DOI 10.1074/jbc.M005166200; Soutourina J, 1999, J BIOL CHEM, V274, P19109, DOI 10.1074/jbc.274.27.19109; Soutourina J, 2000, J BIOL CHEM, V275, P11626, DOI 10.1074/jbc.275.16.11626; Soutourina O, 2004, J BIOL CHEM, V279, P42560, DOI 10.1074/jbc.M402931200; Takayama T, 2005, BIOSCI BIOTECH BIOCH, V69, P1040, DOI 10.1271/bbb.69.1040; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; YARUS M, 1976, ARCH BIOCHEM BIOPHYS, V174, P350, DOI 10.1016/0003-9861(76)90355-6; ZILLIG W, 1994, SYST APPL MICROBIOL, V16, P609	26	23	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27575	27585		10.1074/jbc.M605860200	http://dx.doi.org/10.1074/jbc.M605860200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16844682	hybrid			2022-12-25	WOS:000240397700083
J	Garrey, SM; Voelker, R; Berglund, JA				Garrey, Stephen M.; Voelker, Rodger; Berglund, J. Andrew			An extended RNA binding site for the yeast branch point-binding protein and the role of its zinc knuckle domains in RNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; HIV-1 NUCLEOCAPSID PROTEIN; IMMUNODEFICIENCY-VIRUS TYPE-1; KH-DOMAIN; SACCHAROMYCES-CEREVISIAE; STAR PROTEIN; C-ELEGANS; IN-VIVO; THERMODYNAMIC PARAMETERS; SECONDARY STRUCTURE	The highly conserved branch point sequence (BPS) of UAC-UAAC in Saccharomyces cerevisiae is initially recognized by the branch point-binding protein (BBP). Using systematic evolution of ligands by exponential enrichment we have determined that yeast BBP binds the branch point sequence UACUAAC with highest affinity and prefers an additional adenosine downstream of the BPS. Furthermore, we also found that a stem-loop upstream of the BPS enhances binding both to an artificially designed RNA(30-fold effect) and to an RNA from a yeast intron (3-fold effect). The zinc knuckles of BBP are partially responsible for the enhanced binding to the stem-loop but do not appear to have a significant role in the binding of BBP to single-strand RNA substrates. C-terminal deletions of BBP reveal that the linker regions between the two zinc knuckles and between the N-terminal RNA binding domains (KH and QUA2 domains) and the first zinc knuckle are important for binding to RNA. The lack of involvement of the second highly conserved zinc knuckle in RNA binding suggests that this zinc knuckle plays a different role in RNA processing than enhancing the binding of BBP to the BPS.	Univ Oregon, Dept Chem, Eugene, OR 97403 USA; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University of Oregon; University of Oregon	Berglund, JA (corresponding author), Univ Oregon, Dept Chem, Eugene, OR 97403 USA.	aberglund@molbio.uoregon.edu	Berglund, Andrew/AAS-1065-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007759] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-07759] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; ANTAO VP, 1992, NUCLEIC ACIDS RES, V20, P819, DOI 10.1093/nar/20.4.819; ANTAO VP, 1991, NUCLEIC ACIDS RES, V19, P5901, DOI 10.1093/nar/19.21.5901; Berglund JA, 1997, NUCLEIC ACIDS RES, V25, P1042, DOI 10.1093/nar/25.5.1042; Berglund JA, 1998, RNA, V4, P998, DOI 10.1017/S1355838298980499; Berglund JA, 1997, CELL, V89, P781, DOI 10.1016/S0092-8674(00)80261-5; Berglund JA, 1998, GENE DEV, V12, P858, DOI 10.1101/gad.12.6.858; BERKOWITZ RD, 1995, J VIROL, V69, P6445, DOI 10.1128/JVI.69.10.6445-6456.1995; BERKOWITZ RD, 1993, J VIROL, V67, P7190, DOI 10.1128/JVI.67.12.7190-7200.1993; BERKOWITZ RD, 1994, VIROLOGY, V202, P233, DOI 10.1006/viro.1994.1339; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Cavaloc Y, 1999, RNA, V5, P468, DOI 10.1017/S1355838299981967; Charpentier B, 1996, RNA, V2, P509; Chen TP, 1998, MOL CELL BIOL, V18, P4863, DOI 10.1128/MCB.18.8.4863; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; CLEVER J, 1995, J VIROL, V69, P2101, DOI 10.1128/JVI.69.4.2101-2109.1995; Clifford R, 2000, DEVELOPMENT, V127, P5265; DANNULL J, 1994, EMBO J, V13, P1525, DOI 10.1002/j.1460-2075.1994.tb06414.x; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; Di Fruscio M, 1998, J BIOL CHEM, V273, P30122, DOI 10.1074/jbc.273.46.30122; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Galarneau A, 2005, NAT STRUCT MOL BIOL, V12, P691, DOI 10.1038/nsmb963; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; Howe KJ, 1997, P NATL ACAD SCI USA, V94, P12467, DOI 10.1073/pnas.94.23.12467; Jan E, 1999, EMBO J, V18, P258, DOI 10.1093/emboj/18.1.258; Jensen KB, 2000, P NATL ACAD SCI USA, V97, P5740, DOI 10.1073/pnas.090553997; Kuwabara PE, 2001, BIOESSAYS, V23, P596, DOI 10.1002/bies.1085; Larocque D, 2005, NAT NEUROSCI, V8, P27, DOI 10.1038/nn1359; Larocque D, 2002, NEURON, V36, P815, DOI 10.1016/S0896-6273(02)01055-3; Lehmann-Blount KA, 2005, J MOL BIOL, V346, P91, DOI 10.1016/j.jmb.2004.11.049; Li ZZ, 2000, J NEUROSCI, V20, P4944; LIBRI D, 1995, RNA, V1, P425; Lin KT, 2004, MOL CELL BIOL, V24, P9176, DOI 10.1128/MCB.24.20.9176-9185.2004; Lin Q, 1997, J BIOL CHEM, V272, P27274, DOI 10.1074/jbc.272.43.27274; Liu ZH, 2001, SCIENCE, V294, P1098, DOI 10.1126/science.1064719; Lopez PJ, 1999, RNA, V5, P1135, DOI 10.1017/S135583829999091X; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; Maguire ML, 2005, J MOL BIOL, V348, P265, DOI 10.1016/j.jmb.2005.02.058; Manceau V, 2006, FEBS J, V273, P577, DOI 10.1111/j.1742-4658.2005.05091.x; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; Morellet N, 1998, J MOL BIOL, V283, P419, DOI 10.1006/jmbi.1998.2098; NEWMAN A, 1987, EMBO J, V6, P3833, DOI 10.1002/j.1460-2075.1987.tb02720.x; Rain JC, 1997, EMBO J, V16, P1759, DOI 10.1093/emboj/16.7.1759; Rain JC, 1998, RNA, V4, P551, DOI 10.1017/S1355838298980335; Rutz B, 1999, RNA, V5, P819, DOI 10.1017/S1355838299982286; Ryder SP, 2004, RNA, V10, P1449, DOI 10.1261/rna.7780504; Ryder SP, 2004, NAT STRUCT MOL BIOL, V11, P20, DOI 10.1038/nsmb706; Saccomanno L, 1999, P NATL ACAD SCI USA, V96, P12605, DOI 10.1073/pnas.96.22.12605; Schumacher B, 2005, CELL, V120, P357, DOI 10.1016/j.cell.2004.12.009; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SMITH CWJ, 1998, RNA PROTEIN INTERACT, P40; Spingola M, 1999, RNA, V5, P221, DOI 10.1017/S1355838299981682; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; Wu J, 1999, J BIOL CHEM, V274, P29202, DOI 10.1074/jbc.274.41.29202; Wu JI, 2002, P NATL ACAD SCI USA, V99, P4233, DOI 10.1073/pnas.072090399; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	63	24	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27443	27453		10.1074/jbc.M603137200	http://dx.doi.org/10.1074/jbc.M603137200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16861232	hybrid			2022-12-25	WOS:000240397700071
J	Plaisance, V; Abderrahmani, A; Perret-Menoud, V; Jacquemin, P; Lemaigre, F; Regazzi, R				Plaisance, Valerie; Abderrahmani, Amar; Perret-Menoud, Veronique; Jacquemin, Patrick; Lemaigre, Frederic; Regazzi, Romano			MicroRNA-9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOCRINE; GRANULES; EXOCYTOSIS; BINDING; DIFFERENTIATION; PROLIFERATION; INVOLVEMENT; EXOCRINE; RAB27; MOUSE	Insulin release from pancreatic beta-cells plays an essential role in blood glucose homeostasis. Several proteins controlling insulin exocytosis have been identified, but the factors determining the expression of the components of the secretory machinery of beta-cells remain largely unknown. MicroRNAs are newly discovered small non-coding RNAs acting as repressors of gene expression. We found that overexpression of mir-9 in insulin-secreting cells causes a reduction in exocytosis elicited by glucose or potassium. We show that mir-9 acts by diminishing the expression of the transcription factor Onecut-2 and, in turn, by increasing the level of Granuphilin/Slp4, a Rab GTPase effector associated with beta-cell secretory granules that exerts a negative control on insulin release. Indeed, electrophoretic mobility shift assays, chromatin immunoprecipitation, and transfection experiments demonstrated that Onecut-2 is able to bind to the granuphilin promoter and to repress its transcriptional activity. Moreover, we show that silencing of Onecut-2 by RNA interference increases Granuphilin expression and mimics the effect of mir-9 on stimulus-induced exocytosis. Our data provide evidence that in insulin-producing cells adequate levels of mir-9 are mandatory for maintaining appropriate Granuphilin levels and optimal secretory capacity.	Univ Lausanne, Dept Cell Biol & Morphol, CH-1005 Lausanne, Switzerland; CHU Vaudois, Dept Internal Med, CH-1005 Lausanne, Switzerland; Catholic Univ Louvain, Inst Cellular Pathol, Hormone & Metab Res Unit, B-1200 Brussels, Belgium	University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Universite Catholique Louvain	Regazzi, R (corresponding author), Univ Lausanne, Dept Cell Biol & Morphol, Rue Bugnon 9, CH-1005 Lausanne, Switzerland.	Romano.Regazzi@unil.ch	Abderrahmani, Amar/O-3124-2017; Jacquemin, Patrick/ABA-7932-2021	Abderrahmani, Amar/0000-0003-0752-0343; Regazzi, Romano/0000-0002-9773-2915				Abderrahmani A, 2001, MOL CELL BIOL, V21, P7256, DOI 10.1128/MCB.21.21.7256-7267.2001; Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Bartel B, 2003, PLANT PHYSIOL, V132, P709, DOI 10.1104/pp.103.023630; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Briancon N, 2004, J BIOL CHEM, V279, P33398, DOI 10.1074/jbc.M405312200; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Cheviet S, 2004, MOL ENDOCRINOL, V18, P117, DOI 10.1210/me.2003-0300; Cheviet S, 2004, TRENDS CELL BIOL, V14, P525, DOI 10.1016/j.tcb.2004.08.001; Coppola T, 2002, MOL BIOL CELL, V13, P1906, DOI 10.1091/mbc.02-02-0025; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Esau C, 2004, J BIOL CHEM, V279, P52361, DOI 10.1074/jbc.C400438200; Gannon M, 2000, DEVELOPMENT, V127, P2883; Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200; Gomi H, 2005, J CELL BIOL, V171, P99, DOI 10.1083/jcb.200505179; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; Iezzi M, 2000, FEBS LETT, V474, P66, DOI 10.1016/S0014-5793(00)01572-6; Izumi T, 2003, CELL STRUCT FUNCT, V28, P465, DOI 10.1247/csf.28.465; Jacquemin P, 2000, MOL CELL BIOL, V20, P4445, DOI 10.1128/MCB.20.12.4445-4454.2000; Jacquemin P, 2003, GENE EXPR PATTERNS, V3, P639, DOI 10.1016/S1567-133X(03)00110-8; Jacquemin P, 2003, DEV BIOL, V258, P105, DOI 10.1016/S0012-1606(03)00115-5; Jacquemin P, 1999, J BIOL CHEM, V274, P2665, DOI 10.1074/jbc.274.5.2665; Johnston RJ, 2003, NATURE, V426, P845, DOI 10.1038/nature02255; Kasai K, 2005, J CLIN INVEST, V115, P388, DOI 10.1172/JCI200522955; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372; Matsumoto M, 2004, P NATL ACAD SCI USA, V101, P8313, DOI 10.1073/pnas.0306709101; Palatnik JF, 2003, NATURE, V425, P257, DOI 10.1038/nature01958; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Pierreux CE, 1999, P NATL ACAD SCI USA, V96, P8961, DOI 10.1073/pnas.96.16.8961; Plaisance V, 2005, J BIOL CHEM, V280, P401, DOI 10.1074/jbc.M411825200; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Rausa F, 1997, DEV BIOL, V192, P228, DOI 10.1006/dbio.1997.8744; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; SUTTON R, 1986, TRANSPLANTATION, V42, P689, DOI 10.1097/00007890-198612000-00022; Torii S, 2002, MOL CELL BIOL, V22, P5518, DOI 10.1128/MCB.22.15.5518-5526.2002; Wang J, 1999, J BIOL CHEM, V274, P28542, DOI 10.1074/jbc.274.40.28542; Waselle L, 2003, MOL BIOL CELL, V14, P4103, DOI 10.1091/mbc.E03-01-0022; Wilding L, 2004, DIABETES-METAB RES, V20, P114, DOI 10.1002/dmrr.429; Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1; Xu PZ, 2004, TRENDS GENET, V20, P617, DOI 10.1016/j.tig.2004.09.010; Yaekura K, 2003, J BIOL CHEM, V278, P9715, DOI 10.1074/jbc.M211352200; Yi Z, 2002, MOL CELL BIOL, V22, P1858, DOI 10.1128/MCB.22.6.1858-1867.2002; Zeng Y, 2004, NUCLEIC ACIDS RES, V32, P4776, DOI 10.1093/nar/gkh824; Zhao SL, 2002, ENDOCRINOLOGY, V143, P1817, DOI 10.1210/en.143.5.1817	50	273	295	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26932	26942		10.1074/jbc.M601225200	http://dx.doi.org/10.1074/jbc.M601225200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16831872	hybrid			2022-12-25	WOS:000240397700020
J	Chaudhary, K; Ting, LM; Kim, K; Roos, DS				Chaudhary, Kshitiz; Ting, Li Min; Kim, Kami; Roos, David S.			Toxoplasma gondii purine nucleoside phosphorylase biochemical characterization, inhibitor profiles, and comparison with the Plasmodium falciparum ortholog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; ESCHERICHIA-COLI; SEQUENCE; MALARIA; CLONING; TOOLS	Purine nucleoside phosphorylase ( PNP) is an important component of the nucleotide salvage pathway in apicomplexan parasites and a potential target for drug development. The intracellular pathogen Toxoplasma gondii was therefore tested for sensitivity to immucillins, transition state analogs that exhibit high potency against PNP in the malaria parasite Plasmodium falciparum. Growth of wild-type T. gondii is unaffected by up to 10 mu M immucillin-H (ImmH), but mutants lacking the ( redundant) purine salvage pathway enzyme adenosine kinase are susceptible to the drug, with an IC50 of 23 nM. This effect is rescued by the reaction product hypoxanthine, but not the substrate inosine, indicating that ImmH acts via inhibition of T. gondii PNP. The primary amino acid sequence of TgPNP is > 40% identical to PfPNP, and recombinant enzymes exhibit similar kinetic parameters for most substrates. Unlike the Plasmodium enzyme, however, TgPNP cannot utilize 5'-methylthio- inosine (MTI). Moreover, TgPNP is insensitive to methylthio-immucillin-H (MT-ImmH), which inhibits PfPNP with a K*(i) of 2.7 nM. MTI arises through the deamination of methylthio-adenosine, a product of the polyamine biosynthetic pathway, and its further metabolism to hypoxanthine involves PfPNP in purine recycling ( in addition to salvage). Remarkably, analysis of the recently completed T. gondii genome indicates that polyamine biosynthetic machinery is completely lacking in this species, obviating the need for TgPNP to metabolize MTI. Differences in purine and polyamine metabolic pathways among members of the phylum Apicomplexa and these parasites and their human hosts are likely to influence drug target selection strategies. Targeting T. gondii PNP alone is unlikely to be efficacious for treatment of toxoplasmosis.	Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA	University of Pennsylvania; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Roos, DS (corresponding author), Univ Penn, Dept Biol, 415 S Univ Ave, Philadelphia, PA 19104 USA.	droos@sas.upenn.edu		Roos, David Siker/0000-0001-6725-4089; Kim, Kami/0000-0003-3384-152X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Berens R. I., 1995, BIOCH MOL BIOL PARAS, P323; Chaudhary K, 2005, J BIOL CHEM, V280, P22053, DOI 10.1074/jbc.M503178200; Chaudhary K, 2004, J BIOL CHEM, V279, P31221, DOI 10.1074/jbc.M404232200; Donald RGK, 1996, J BIOL CHEM, V271, P14010, DOI 10.1074/jbc.271.24.14010; Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a; Hill D, 2002, CLIN MICROBIOL INFEC, V8, P634, DOI 10.1046/j.1469-0691.2002.00485.x; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; Keithly JS, 1997, MOL BIOCHEM PARASIT, V88, P35, DOI 10.1016/S0166-6851(97)00063-7; Kicska GA, 2002, J BIOL CHEM, V277, P3226, DOI 10.1074/jbc.M105906200; Kicska GA, 2002, J BIOL CHEM, V277, P3219, DOI 10.1074/jbc.M105905200; Kissinger JC, 2003, NUCLEIC ACIDS RES, V31, P234, DOI 10.1093/nar/gkg072; KRUG EC, 1989, J BIOL CHEM, V264, P10601; Li L, 2003, GENOME RES, V13, P2178, DOI 10.1101/gr.1224503; Mao C, 1997, STRUCTURE, V5, P1373, DOI 10.1016/S0969-2126(97)00287-6; Miles RW, 1998, BIOCHEMISTRY-US, V37, P8615, DOI 10.1021/bi980658d; MORGUNOVA EY, 1995, FEBS LETT, V367, P183, DOI 10.1016/0014-5793(95)00489-V; Muller S, 2000, J BIOL CHEM, V275, P8097, DOI 10.1074/jbc.275.11.8097; Pugmire MJ, 2002, BIOCHEM J, V361, P1, DOI 10.1042/0264-6021:3610001; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schramm VL, 1998, ANNU REV BIOCHEM, V67, P693, DOI 10.1146/annurev.biochem.67.1.693; Seabra SH, 2004, J PARASITOL, V90, P455, DOI 10.1645/GE-179R; Shi WX, 2004, J BIOL CHEM, V279, P18103, DOI 10.1074/jbc.C400068200; Sullivan WJ, 1999, MOL BIOCHEM PARASIT, V103, P1, DOI 10.1016/S0166-6851(99)00114-0; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Ting LM, 2005, J BIOL CHEM, V280, P9547, DOI 10.1074/jbc.M412693200; WILLIAMS SR, 1984, NUCLEIC ACIDS RES, V12, P5779, DOI 10.1093/nar/12.14.5779	28	38	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25652	25658		10.1074/jbc.M602624200	http://dx.doi.org/10.1074/jbc.M602624200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16829527	hybrid			2022-12-25	WOS:000240031300068
J	Dommange, F; Cartron, G; Espanel, C; Gallay, N; Domenech, J; Benboubker, L; Ohresser, M; Colombat, P; Binet, C; Watier, H; Herault, O				Dommange, Florence; Cartron, Guillaume; Espanel, Claire; Gallay, Nathalie; Domenech, Jorge; Benboubker, Lotfi; Ohresser, Marc; Colombat, Philippe; Binet, Chistian; Watier, Herve; Herault, Olivier		GOELAMS Study Group	CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia	FASEB JOURNAL			English	Article						SDF-1; CXCR4; blast cells; microenvironment	BREAST-CANCER METASTASIS; CHEMOKINE RECEPTOR CXCR4; FACTOR-I; STROMAL CELLS; TUMOR-CELLS; STEM-CELLS; EXPRESSION; BONE; GENE; MIGRATION	Stromal cell-derived factor 1 (SDF-1), a chemokine abundantly produced by the bone marrow microenvironment, and its receptor CXCR4 have crucial roles in malignant cell trafficking. In acute myeloid leukemia (AML), blasts invade the bloodstream and may localize in extramedullar sites, with variations from one patient to another. We hypothesized that a polymorphism in the SDF-1 coding gene (CXCL12 G801A) could influence blast dissemination and tissue infiltration in AML. CXCL12 G801A polymorphism was determined in 86 adult patients and 100 healthy volunteers. The allelic status and CXCR4 expression on bone marrow blasts were analyzed in relation to peripheral blood blast (PBB) counts and frequency of extramedullar tumor sites. 801A carrier status (801G/A, 801A/A) was found to be associated with a higher PBB count compared with 801G/G homozygous patients (P = 0.031) and higher frequency of extramedullar tumor sites (odds ratio 2.92, 95% confidence interval 1.18 -7.21, P = 0.018). Moreover, the PBB count was correlated with CXCR4 expression (correlation coefficient 0.546, P = 0.001) when considering 801A carriers. In conclusion, a polymorphism in the SDF-1 gene is shown for the first time to be associated with the clinical presentation of a malignant hematological disease and more generally with the risk of distant tissue infiltration by tumor cells.	CHRU, Labs Hematol & Immunol, F-37044 Tours, France; CHRU, Serv Hematol & Therapie Cellulaire, F-37044 Tours, France; Univ Tours, Equipe EA 3853, Tours, France; Univ Tours, Equipe EA 3855, Tours, France; INSERM, Equipe ESPRI Microenvironm Hematopoiese & Cellule, Tours, France	CHU Tours; CHU Tours; Universite de Tours; Universite de Tours; Institut National de la Sante et de la Recherche Medicale (Inserm)	Herault, O (corresponding author), CHRU, Hop Bretonneau, Hematol Lab, Equipe Inserm ESPRI EA3855, 2 Bd Tonnelle, F-37044 Tours, France.	olivier.herault@med.univ-tours.fr		, Nathalie GALLAY/0000-0002-4236-4780; Cartron, Guillaume/0000-0003-0659-9635; Herault, Olivier/0000-0002-7419-1124				Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Arai J, 2000, EUR J HAEMATOL, V64, P323, DOI 10.1034/j.1600-0609.2000.90147.x; Benboubker L, 2001, BRIT J HAEMATOL, V113, P247, DOI 10.1046/j.1365-2141.2001.02717.x; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Burger JA, 1999, BLOOD, V94, P3658, DOI 10.1182/blood.V94.11.3658.423k11_3658_3667; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Howell WM, 2002, GENES IMMUN, V3, P229, DOI 10.1038/sj.gene.6363851; Kimura R, 2005, HUM MOL GENET, V14, P1579, DOI 10.1093/hmg/ddi166; Koshiba T, 2000, CLIN CANCER RES, V6, P3530; Kucia M, 2005, STEM CELLS, V23, P879, DOI 10.1634/stemcells.2004-0342; Lacombe F, 1997, LEUKEMIA, V11, P1878, DOI 10.1038/sj.leu.2400847; Liang ZX, 2005, CANCER RES, V65, P967; Magierowska M, 1998, IMMUNOGENETICS, V48, P417, DOI 10.1007/s002510050454; Mohle R, 2000, BRIT J HAEMATOL, V110, P563, DOI 10.1046/j.1365-2141.2000.02157.x; Mohle R, 1998, BLOOD, V91, P4523, DOI 10.1182/blood.V91.12.4523.412k04_4523_4530; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Poulain S, 2003, BLOOD, V102, p669A; Russell HV, 2004, J PEDIATR SURG, V39, P1506, DOI 10.1016/j.jpedsurg.2004.06.019; Scotton CJ, 2002, CANCER RES, V62, P5930; Soriano A, 2002, J INFECT DIS, V186, P922, DOI 10.1086/343741; Taichman RS, 2002, CANCER RES, V62, P1832; Tavor S, 2004, CANCER RES, V64, P2817, DOI 10.1158/0008-5472.CAN-03-3693; Voermans C, 2002, LEUKEMIA, V16, P650, DOI 10.1038/sj.leu.2402431; Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389	26	50	53	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2006	20	11					1913	+		10.1096/fj.05-5667fje	http://dx.doi.org/10.1096/fj.05-5667fje			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16818471				2022-12-25	WOS:000240267000028
J	Chen, SL; Lin, ST; Tsai, TC; Hsiao, WC; Tsao, YP				Chen, S-L; Lin, S-T; Tsai, T-C; Hsiao, W-C; Tsao, Y-P			ErbB4 (JM-b/CYT-1)-induced expression and phosphorylation of c-Jun is abrogated by human papillomavirus type 16 E5 protein	ONCOGENE			English	Article						c-jun; ErbB4; HPV-16 E5; phosphorylation; proliferation	EPIDERMAL-GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; FACTOR RECEPTOR; TRANSCRIPTIONAL ACTIVITY; PRODUCTIVE INTERACTION; TRANSMEMBRANE MUTANTS; GENE-EXPRESSION; MESSENGER-RNA; MICE LACKING; HA-RAS	Human papillomavirus type 16 E5 (HPV-16 E5) is a highly hydrophobic membrane protein with weak-transforming activity, which is associated with ErbB4 receptor in HPV-16-infected cervical lesions. Presently, we investigated the transforming mechanisms of E5 involving ErbB4 signaling. Firstly, we report a role for ErbB4 (JM-b/CYT-1) receptor that activates c-jun gene expression and phosphorylating at Ser63 and Ser73 of the c-Jun protein in ligand-independent and Ras-c-jun NH2-terminal kinase-dependent pathway. Secondly, we show that HPV-16 E5 protein can form a complex with ErbB4 via binding to the extracellular and transmembrane domains of ErbB4 (JM-b/CYT-1). When co-expressing HPV-16 E5 and ErbB4 in cells, E5 can abrogate ErbB4-induced c-Jun protein expression and phosphorylation resulted in increasing cell proliferation compared to ErbB4-expressing cells. The interaction between of HPV-16 E5 and ErbB4 provides more insight into the mechanisms of HPV-16 E5 transformation induction.	Natl Taiwan Univ, Grad Inst Microbiol, Coll Med, Dept Microbiol, Taipei, Taiwan; Natl Def Univ, Natl Def Med Ctr, Dept Microbiol & Immunol, Taipei, Taiwan; Asia Univ, Dept Biotechnol & Bioinformat, Taichung, Taiwan; Mackay Mem Hosp, Dept Ophthalmol, Taipei, Taiwan	National Taiwan University; National Defense Medical Center; National Defense University - Taiwan; Asia University Taiwan; Mackay Memorial Hospital	Chen, SL (corresponding author), Natl Taiwan Univ, Grad Inst Microbiol, Coll Med, Dept Microbiol, 7F,1,Sec 1,Jen Ai Rd, Taipei, Taiwan.	showlic@ha.mc.ntu.edu.tw						Adduci AJ, 1999, J BIOL CHEM, V274, P10249, DOI 10.1074/jbc.274.15.10249; Aqeilan RI, 2005, CANCER RES, V65, P6764, DOI 10.1158/0008-5472.CAN-05-1150; Bacus SS, 1996, AM J PATHOL, V148, P549; BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Bouyain S, 2005, P NATL ACAD SCI USA, V102, P15024, DOI 10.1073/pnas.0507591102; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; Chang JL, 2001, J BIOMED SCI, V8, P206, DOI 10.1007/BF02256414; Chen SL, 1998, VIROLOGY, V244, P521, DOI 10.1006/viro.1998.9109; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Clark DE, 2005, J BIOL CHEM, V280, P24175, DOI 10.1074/jbc.M414044200; CULOUSCOU JM, 1995, J BIOL CHEM, V270, P12857, DOI 10.1074/jbc.270.21.12857; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DiMaio D, 2001, ONCOGENE, V20, P7866, DOI 10.1038/sj.onc.1204915; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Gambarotta G, 2004, J BIOL CHEM, V279, P48808, DOI 10.1074/jbc.M408374200; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Golding JP, 2000, NAT CELL BIOL, V2, P103, DOI 10.1038/35000058; Graber HU, 1999, INT J CANCER, V84, P24, DOI 10.1002/(SICI)1097-0215(19990219)84:1<24::AID-IJC5>3.0.CO;2-2; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Gullick WJ, 2003, J PATHOL, V200, P279, DOI 10.1002/path.1335; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Hsieh CH, 2000, ARCH VIROL, V145, P2273, DOI 10.1007/s007050070020; HWANG ES, 1995, VIROLOGY, V211, P227, DOI 10.1006/viro.1995.1395; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Kainulainen V, 2000, J BIOL CHEM, V275, P8641, DOI 10.1074/jbc.275.12.8641; Knowlden JM, 1998, ONCOGENE, V17, P1949, DOI 10.1038/sj.onc.1202107; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Lai CC, 2005, J VIROL, V79, P1924, DOI 10.1128/JVI.79.3.1924-1929.2005; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lee SA, 2001, J BIOL CHEM, V276, P11783, DOI 10.1074/jbc.M004517200; Li BS, 2002, EMBO J, V21, P324, DOI 10.1093/emboj/21.3.324; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Lyne JC, 1997, CANCER J SCI AM, V3, P21; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; Memon AA, 2004, BRIT J CANCER, V91, P2034, DOI 10.1038/sj.bjc.6602251; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Nappi VM, 2002, J BIOL CHEM, V277, P47149, DOI 10.1074/jbc.M209582200; Nappi VM, 2002, J VIROL, V76, P7976, DOI 10.1128/JVI.76.16.7976-7986.2002; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Riese DJ, 1996, ONCOGENE, V12, P345; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; Sparkowski J, 1996, J VIROL, V70, P2420, DOI 10.1128/JVI.70.4.2420-2430.1996; Srinivasan R, 1998, J PATHOL, V185, P236, DOI 10.1002/(SICI)1096-9896(199807)185:3<236::AID-PATH118>3.0.CO;2-7; TALOR P, 2006, IN PRESS J CELL 0303; Thomasson M, 2004, ACTA ONCOL, V43, P453, DOI 10.1080/02841860410028574; Tsai TC, 2003, ARCH VIROL, V148, P1445, DOI 10.1007/s00705-003-0111-z; TSAO YP, 1995, CANCER LETT, V95, P201, DOI 10.1016/0304-3835(95)03894-3; Tsao YP, 1996, J VIROL, V70, P7535, DOI 10.1128/JVI.70.11.7535-7539.1996; Vidal GA, 2005, J BIOL CHEM, V280, P19777, DOI 10.1074/jbc.M412457200; Weiss FU, 1997, J CELL PHYSIOL, V173, P187, DOI 10.1002/(SICI)1097-4652(199711)173:2<187::AID-JCP19>3.0.CO;2-D; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Williams SMG, 2005, CANCER RES, V65, P6534, DOI 10.1158/0008-5472.CAN-05-0083; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	66	32	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					42	53		10.1038/sj.onc.1209768	http://dx.doi.org/10.1038/sj.onc.1209768			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16819515				2022-12-25	WOS:000243236500005
J	Lee, HJ; Yun, CH; Lim, SH; Kim, BC; Baik, KG; Kim, JM; Kim, WH; Kim, SJ				Lee, H-J; Yun, C-H; Lim, S. H.; Kim, B-C; Baik, K. G.; Kim, J-M; Kim, W-H; Kim, S-J			SRF is a nuclear repressor of Smad3-mediated TGF-beta signaling	ONCOGENE			English	Article						SRF; TGF-beta; Smad; signaling; transcription; suppression	SERUM RESPONSE FACTOR; GROWTH-FACTOR-BETA; CELL-CYCLE ARREST; DNA-BINDING ACTIVITY; PHOSPHORYLATION SITES; CDK INHIBITOR; C-MYC; TRANSFORMING GROWTH-FACTOR-BETA-1; TRANSCRIPTIONAL ACTIVATORS; RECEPTOR COMPLEX	Serum response factor (SRF) is a widely expressed transcription factor involved in immediate-early and tissue-specific gene expression, cell proliferation and differentiation. We defined a new role of SRF as a nuclear repressor of the tumor growth factor beta 1 (TGF-beta 1) growth-inhibitory signal during cell proliferation. We show that SRF significantly inhibits the TGF-beta 1/Smad-dependent transcription by associating with Smad3. SRF causes resistance to the TGF-beta 1 cytostatic response by directly repressing the Smad transcriptional activity and Smad binding to DNA. Furthermore, we demonstrated that overexpression of SRF markedly decreases the level of Smad3 complex binding to the promoters of Smad3 target genes, p15(INK4b) and p21(Cip1). This leads to the inhibition of expression of TGF-beta 1-responsive genes. SRF therefore acts as a nuclear repressor of Smad3-mediated TGF-beta 1 signaling.	NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; KRIBB, Div Mol Therapeut, Taejon, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Kangweon Natl Univ, Div Life Sci, Chunchon, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Advanced Institute of Science & Technology (KAIST); Kangwon National University; Seoul National University (SNU)	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA.	kims@mail.nih.gov	Kim, Wooho/G-3703-2011	Lim, Seunghwan/0000-0001-8920-0890	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005617] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM SE, 1992, MOL BIOL CELL, V3, P655, DOI 10.1091/mbc.3.6.655; ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Chai J, 2002, J PHYSIOL PHARMACOL, V53, P147; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Depoortere F, 2000, MOL BIOL CELL, V11, P1061, DOI 10.1091/mbc.11.3.1061; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; GARRIGUEANTAR L, 1995, J IMMUNOL METHODS, V186, P267, DOI 10.1016/0022-1759(95)00151-Y; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Iavarone A, 1997, NATURE, V387, P417; Iyer D, 2006, P NATL ACAD SCI USA, V103, P4516, DOI 10.1073/pnas.0505338103; Iyer D, 2003, BIOCHEMISTRY-US, V42, P7477, DOI 10.1021/bi030045n; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; Kang SH, 1999, BRIT J CANCER, V80, P1144, DOI 10.1038/sj.bjc.6690478; Kim BC, 2004, MOL CELL BIOL, V24, P2251, DOI 10.1128/MCB.24.6.2251-2262.2004; KIM JH, 1994, J BIOL CHEM, V269, P13740; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; Lee HJ, 2004, J BIOL CHEM, V279, P2666, DOI 10.1074/jbc.M310591200; Lee MH, 2003, CANCER METAST REV, V22, P435, DOI 10.1023/A:1023785332315; LIU SH, 1993, J BIOL CHEM, V268, P21147; Mack CP, 1999, CIRC RES, V84, P852; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; Massague J, 2000, GENE DEV, V14, P627; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Psichari E, 2002, J BIOL CHEM, V277, P29490, DOI 10.1074/jbc.M112368200; Qiu P, 2003, J MOL CELL CARDIOL, V35, P1407, DOI 10.1016/j.yjmcc.2003.09.002; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Schratt G, 2001, MOL CELL BIOL, V21, P2933, DOI 10.1128/MCB.21.8.2933-2943.2001; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	51	31	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	2					173	185		10.1038/sj.onc.1209774	http://dx.doi.org/10.1038/sj.onc.1209774			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819512				2022-12-25	WOS:000243398300002
J	Allard, B; Magloire, H; Couble, ML; Maurin, JC; Bleicher, F				Allard, Bruno; Magloire, Henry; Couble, Marie Lise; Maurin, Jean Christophe; Bleicher, Francoise			Voltage-gated sodium channels confer excitability to human odontoblasts - Possible role in tooth pain transmission	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; RAT; PULP; LOCALIZATION; CELLS; ANKYRIN; PROTEIN; INACTIVATION; GENES; AXONS	Odontoblasts are responsible for the dentin formation. They are suspected to play a role in tooth pain transmission as sensor cells because of their close relationship with nerve, but this role has never been evidenced. We demonstrate here that human odontoblasts in vitro produce voltage-gated tetrodotoxin-sensitive Na+ currents in response to depolarization under voltage clamp conditions and are able to generate action potentials. Odontoblasts express neuronal isoforms of alpha 2 and beta 2 subunits of sodium channels. Co-cultures of odontoblasts with trigeminal neurons indicate a clustering of alpha 2 and alpha 2 sodium channel subunits and, at the sites of cell-cell contact, a co-localization of odontoblasts beta 2 subunits with peripherin. In vivo, sodium channels are expressed in odontoblasts. Ankyrin(G) and beta 2 co-localize, suggesting a link for signal transduction between axons and odontoblasts. Evidence for excitable properties of odontoblasts and clustering of key molecules at the site of odontoblast-nerve contact strongly suggest that odontoblasts may operate as sensor cells that initiate tooth pain transmission.	Univ Lyon 1, F-69100 Villeurbanne, France; CNRS, UMR 5123, F-69100 Villeurbanne, France; Univ Lyon 1, EA 1892, IFR 62, Fac Odontol, F-69008 Lyon, France; INSERM, ERI 16, F-69008 Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm)	Magloire, H (corresponding author), Univ Lyon 1, F-69100 Villeurbanne, France.	magloire@sante.univ-lyon1.fr	ALLARD, Bruno/O-1852-2017	ALLARD, Bruno/0000-0001-8547-5483				Allard B, 2000, J BIOL CHEM, V275, P25556, DOI 10.1074/jbc.M002327200; ARMSTRONG CM, 1973, J GEN PHYSIOL, V62, P375, DOI 10.1085/jgp.62.4.375; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Bennett V, 2001, CURR OPIN CELL BIOL, V13, P61, DOI 10.1016/S0955-0674(00)00175-7; Black JA, 1996, DEV NEUROSCI-BASEL, V18, P139, DOI 10.1159/000111403; BLACK JA, 1995, MOL BRAIN RES, V34, P89, DOI 10.1016/0169-328X(95)00141-E; Bleicher F, 1999, MATRIX BIOL, V18, P133, DOI 10.1016/S0945-053X(99)00007-4; Bokil H, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-20-j0004.2001; BRODY BA, 1989, J NEUROSCI, V9, P2391; Buchaille R, 2000, MATRIX BIOL, V19, P421, DOI 10.1016/S0945-053X(00)00091-3; BYERS MR, 1984, INT REV NEUROBIOL, V25, P39, DOI 10.1016/S0074-7742(08)60677-7; Byers MR, 2003, MICROSC RES TECHNIQ, V60, P503, DOI 10.1002/jemt.10291; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Couble ML, 2000, CALCIFIED TISSUE INT, V66, P129, DOI 10.1007/PL00005833; Davidson RM, 2000, J MEMBRANE BIOL, V178, P21, DOI 10.1007/s002320010011; DAVIDSON RM, 1994, ARCH ORAL BIOL, V39, P613, DOI 10.1016/0003-9969(94)90137-6; HILDEBRAND C, 1995, PROG NEUROBIOL, V45, P165, DOI 10.1016/0301-0082(94)00045-J; Ibuki T, 1996, J DENT RES, V75, P1963, DOI 10.1177/00220345960750120801; Isom LL, 2002, FRONT BIOSCI, V7, P12; Kamermans M, 2004, CURR OPIN NEUROBIOL, V14, P531, DOI 10.1016/j.conb.2004.08.016; Kaplan MR, 2001, NEURON, V30, P105, DOI 10.1016/S0896-6273(01)00266-5; KIRSCH J, 1995, J NEUROSCI, V15, P4148; Kobayashi N, 1998, CELL TISSUE RES, V291, P163, DOI 10.1007/s004410050988; Magloire H, 2003, J DENT RES, V82, P542, DOI 10.1177/154405910308200711; MAGLOIRE H, 1979, J BIOL BUCCALE, V7, P251; Malhotra JD, 2000, J BIOL CHEM, V275, P11383, DOI 10.1074/jbc.275.15.11383; Maurin JC, 2004, MATRIX BIOL, V23, P277, DOI 10.1016/j.matbio.2004.06.005; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; Novakovic SD, 2001, TRENDS NEUROSCI, V24, P473, DOI 10.1016/S0166-2236(00)01884-1; OXFORD GS, 1978, J GEN PHYSIOL, V71, P227, DOI 10.1085/jgp.71.3.227; SEUX D, 1994, ARCH ORAL BIOL, V39, P167, DOI 10.1016/0003-9969(94)90113-9; USHIYAMA J, 1989, CELL TISSUE RES, V258, P611; Van Wart A, 2005, MOL CELL NEUROSCI, V28, P661, DOI 10.1016/j.mcn.2004.11.012; Yu FH, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-207; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	36	75	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29002	29010		10.1074/jbc.M601020200	http://dx.doi.org/10.1074/jbc.M601020200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16831873	hybrid			2022-12-25	WOS:000240680500055
J	Feller, A; Boeckstaens, M; Marini, AM; Dubois, E				Feller, Andre; Boeckstaens, Melanie; Marini, Anna Maria; Dubois, Evelyne			Transduction of the nitrogen signal activating Gln3-mediated transcription is independent of Npr1 kinase and Rsp5-Bul1/2 ubiquitin ligase in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID PERMEASE; UPTAKE SYSTEMS; AMMONIUM TRANSPORTERS; CATABOLITE REPRESSION; NUCLEAR-LOCALIZATION; CARBON STARVATION; GAP1 PERMEASE; YEAST; GENE; GLN3	Nitrogen Catabolite Repression (NCR) allows the adaptation of yeast cells to the quality of nitrogen supply by inhibiting the transcription of genes encoding proteins involved in transport and degradation of nonpreferred nitrogen sources. In cells using ammonium or glutamine, the GATA transcription factor Gln3 is sequestered in the cytoplasm by Ure2 whereas it enters the nucleus after a shift to a nonpreferred nitrogen source like proline or upon addition of rapamycin, the TOR complex inhibitor. Recently, the Npr1 kinase and the Rsp5, Bul1/2 ubiquitin ligase complex were reported to have antagonistic roles in the nuclear import and Gln3-mediated activation. The Npr1 kinase controls the activity of various permeases including transporters for nitrogen sources that stimulate NCR such as the Mep ammonium transport systems. Combining data from growth tests, Northern blot analysis and Gln3 immunolocalization, we show that the Npr1 kinase is not a direct negative regulator of Gln3-dependent transcription. The derepression of Gln3-activated genes in ammonium-grown npr1 cells results from the reduced uptake of the nitrogen-repressing compound because NCR could be restored in npr1 cells by repairing ammonium-uptake defects through different means. Finally, we show that the impairment of the ubiquitin ligase complex does not prevent induction of NCR genes under nonpreferred nitrogen conditions. The apparent Rsp5-, Bul1/2- dependent Gln3 activation keeps to the cellular status, as it is only observed in cells having left the balanced phase of exponential growth.	Univ Libre Bruxelles, Inst Rech Microbiol JM Wiame, Microbiol Lab, B-1070 Brussels, Belgium; Univ Libre Bruxelles, Inst Biol & Med Mol, Lab Physiol Mol Cellule, B-6041 Gosselies, Belgium	Universite Libre de Bruxelles; Universite Libre de Bruxelles	Dubois, E (corresponding author), Univ Libre Bruxelles, Inst Rech Microbiol JM Wiame, Microbiol Lab, Ave Emile Gryzon,1, B-1070 Brussels, Belgium.			Boeckstaens, Melanie/0000-0003-1629-7403				Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bihler H, 1998, FEBS LETT, V432, P59, DOI 10.1016/S0014-5793(98)00832-1; Bihler H, 2002, BBA-BIOMEMBRANES, V1558, P109, DOI 10.1016/S0005-2736(01)00414-X; Cox KH, 2004, J BIOL CHEM, V279, P19294, DOI 10.1074/jbc.M309240200; Cox KH, 2004, J BIOL CHEM, V279, P10270, DOI 10.1074/jbc.M312023200; Cox KH, 2002, J BIOL CHEM, V277, P37559, DOI 10.1074/jbc.M204879200; Crespo JL, 2004, J BIOL CHEM, V279, P37512, DOI 10.1074/jbc.M407372200; De Craene JO, 2001, J BIOL CHEM, V276, P43939, DOI 10.1074/jbc.M102944200; DUBOIS E, 1979, MOL GEN GENET, V175, P67, DOI 10.1007/BF00267857; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; GRENSON M, 1983, EUR J BIOCHEM, V133, P141, DOI 10.1111/j.1432-1033.1983.tb07439.x; GRENSON M, 1983, EUR J BIOCHEM, V133, P135, DOI 10.1111/j.1432-1033.1983.tb07438.x; GRENSON M, 1982, EUR J BIOCHEM, V121, P643, DOI 10.1111/j.1432-1033.1982.tb05834.x; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; JACOBS P, 1980, J MOL BIOL, V139, P691, DOI 10.1016/0022-2836(80)90055-8; JAUNIAUX JC, 1987, EUR J BIOCHEM, V164, P601, DOI 10.1111/j.1432-1033.1987.tb11169.x; Javelle A, 2003, TRENDS MICROBIOL, V11, P53, DOI 10.1016/S0966-842X(02)00012-4; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Magasanik B, 2005, P NATL ACAD SCI USA, V102, P16537, DOI 10.1073/pnas.0507116102; Magasanik B, 2002, GENE, V290, P1, DOI 10.1016/S0378-1119(02)00558-9; Marini AM, 1997, MOL CELL BIOL, V17, P4282, DOI 10.1128/MCB.17.8.4282; Mathie A, 2006, PHARMACOL THERAPEUT, V111, P567, DOI 10.1016/j.pharmthera.2005.11.004; Nikko E, 2003, J BIOL CHEM, V278, P50732, DOI 10.1074/jbc.M306953200; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Roberts SK, 1999, J BACTERIOL, V181, P291, DOI 10.1128/JB.181.1.291-297.1999; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Soetens O, 2001, J BIOL CHEM, V276, P43949, DOI 10.1074/jbc.M102945200; Springael JY, 1999, BIOCHEM BIOPH RES CO, V257, P561, DOI 10.1006/bbrc.1999.0505; Springael JY, 2002, FEBS LETT, V517, P103, DOI 10.1016/S0014-5793(02)02586-3; Springael JY, 1998, MOL BIOL CELL, V9, P1253, DOI 10.1091/mbc.9.6.1253; Tate JJ, 2005, J BIOL CHEM, V280, P27195, DOI 10.1074/jbc.M504052200; VANDENBOL M, 1987, EUR J BIOCHEM, V164, P607, DOI 10.1111/j.1432-1033.1987.tb11170.x; WIAME JM, 1985, ADV MICROB PHYSIOL, V26, P1, DOI 10.1016/S0065-2911(08)60394-X; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	35	29	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28546	28554		10.1074/jbc.M605551200	http://dx.doi.org/10.1074/jbc.M605551200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16864574	hybrid			2022-12-25	WOS:000240680500008
J	Chrencik, JE; Brooun, A; Kraus, ML; Recht, MI; Kolatkar, AR; Han, GW; Seifert, JM; Widmer, H; Auer, M; Kuhn, P				Chrencik, Jill E.; Brooun, Alexei; Kraus, Michelle L.; Recht, Michael I.; Kolatkar, Anand R.; Han, Gye Won; Seifert, Jan Marcus; Widmer, Hans; Auer, Manfred; Kuhn, Peter			Structural and biophysical characterization of the EphB4(center dot)ephrinB2 protein-protein interaction and receptor specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE EPHB4; CRYSTAL-STRUCTURE; EXPRESSION; EPHRINS; BINDING; DESIGN; ANGIOGENESIS; ANTAGONIST; LIGANDS; FAMILY	Increasing evidence implicates the interaction of the EphB4 receptor with its preferred ligand, ephrinB2, in pathological forms of angiogenesis and in tumorigenesis. To identify the molecular determinants of the unique specificity of EphB4 for ephrinB2, we determined the crystal structure of the ligand binding domain of EphB4 in complex with the extracellular domain of ephrinB2. This structural analysis suggested that one amino acid, Leu-95, plays a particularly important role in defining the structural features that confer the ligand selectivity of EphB4. Indeed, all other Eph receptors, which promiscuously bind many ephrins, have a conserved arginine at the position corresponding to Leu-95 of EphB4. We have also found that amino acid changes in the EphB4 ligand binding cavity, designed based on comparison with the crystal structure of the more promiscuous EphB2 receptor, yield EphB4 variants with altered binding affinity for ephrinB2 and an antagonistic peptide. Isothermal titration calorimetry experiments with an EphB4 Leu-95 to arginine mutant confirmed the importance of this amino acid in conferring high affinity binding to both ephrinB2 and the antagonistic peptide ligand. Isothermal titration calorimetry measurements also revealed an interesting thermodynamic discrepancy between ephrinB2 binding, which is an entropically driven process, and peptide binding, which is an enthalpically driven process. These results provide critical information on the EphB4 center dot ephrinB2 protein interfaces and their mode of interaction, which will facilitate development of small molecule compounds inhibiting the EphB4 center dot ephrinB2 interaction as novel cancer therapeutics.	Scripps Res Inst, Dept Cellular Biol, La Jolla, CA 92037 USA; Palo Alto Res Ctr, Scripps PARC Inst Adv Biomed Sci, Palo Alto, CA 94304 USA; Novartis Inst Biomed Res GmbH & Co KG, Discovery Technol Innovat Screening Technol, A-1235 Vienna, Austria; Novartis Inst Biomed Res, CH-4002 Basel, Switzerland	Scripps Research Institute; Scripps Research Institute; Novartis; Novartis	Kuhn, P (corresponding author), Scripps Res Inst, Dept Cellular Biol, 10550 N Torrey Pines Rd,CB 265, La Jolla, CA 92037 USA.	pkuhn@scripps.edu	Han, Gye Won/GLQ-8673-2022; Han, Gye Won/GLT-1531-2022; Han, Gye Won/GLQ-8724-2022	Han, Gye Won/0000-0003-4107-835X; Auer, Manfred/0000-0001-8920-3522				ANDRES AC, 1994, ONCOGENE, V9, P1461; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berclaz G, 1996, BIOCHEM BIOPH RES CO, V226, P869, DOI 10.1006/bbrc.1996.1442; Berclaz G, 2003, ANN ONCOL, V14, P220, DOI 10.1093/annonc/mdg072; Blits-Huizinga CT, 2004, IUBMB LIFE, V56, P257, DOI 10.1080/15216540412331270076; Chrencik JE, 2006, STRUCTURE, V14, P321, DOI 10.1016/j.str.2005.11.011; Committee E., 1997, CELL, V90, P403; Day B, 2005, J BIOL CHEM, V280, P26526, DOI 10.1074/jbc.M504972200; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Himanen JP, 2002, ACTA CRYSTALLOGR D, V58, P533, DOI 10.1107/S0907444902000264; Himanen JP, 1998, NATURE, V396, P486, DOI 10.1038/24904; Himanen JP, 2004, NAT NEUROSCI, V7, P501, DOI 10.1038/nn1237; Himanen JP, 2001, NATURE, V414, P933, DOI 10.1038/414933a; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Hopkins AL, 2006, CURR OPIN STRUC BIOL, V16, P127, DOI 10.1016/j.sbi.2006.01.013; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kertesz N, 2006, BLOOD, V107, P2330, DOI 10.1182/blood-2005-04-1655; Koolpe M, 2005, J BIOL CHEM, V280, P17301, DOI 10.1074/jbc.M500363200; Liu WB, 2002, CANCER, V94, P934, DOI 10.1002/cncr.10122; Martiny-Baron G, 2004, NEOPLASIA, V6, P248, DOI 10.1593/neo.03457; Munarini N, 2002, J CELL SCI, V115, P25; Nakamoto M, 2002, MICROSC RES TECHNIQ, V59, P58, DOI 10.1002/jemt.10177; Nikolov DB, 2005, BIOCHEMISTRY-US, V44, P10947, DOI 10.1021/bi050789w; Nikolova Z, 1998, J CELL SCI, V111, P2741; Noren NK, 2004, P NATL ACAD SCI USA, V101, P5583, DOI 10.1073/pnas.0401381101; Ohtaka H, 2004, INT J BIOCHEM CELL B, V36, P1787, DOI 10.1016/j.biocel.2004.02.021; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Schmucker D, 2001, CELL, V105, P701, DOI 10.1016/S0092-8674(01)00391-9; Smith FM, 2004, J BIOL CHEM, V279, P9522, DOI 10.1074/jbc.M309326200; Takemoto M, 2002, EUR J NEUROSCI, V16, P1168, DOI 10.1046/j.1460-9568.2002.02166.x; Toth J, 2001, DEV CELL, V1, P83, DOI 10.1016/S1534-5807(01)00002-8; Turnbull WB, 2003, J AM CHEM SOC, V125, P14859, DOI 10.1021/ja036166s; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wilkinson DG, 2000, INT REV CYTOL, V196, P177; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515	37	73	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28185	28192		10.1074/jbc.M605766200	http://dx.doi.org/10.1074/jbc.M605766200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16867992	hybrid			2022-12-25	WOS:000240534400056
J	Conway, JP; Kinter, M				Conway, James P.; Kinter, Michael			Dual role of peroxiredoxin I in macrophage-derived foam cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; THIOL-SPECIFIC ANTIOXIDANT; CYSTEINE-SULFINIC ACID; NECROSIS-FACTOR-ALPHA; SMOOTH-MUSCLE-CELLS; PROTEIN-KINASE-C; MOUSE PERITONEAL-MACROPHAGES; PEROXIDE-INDUCED APOPTOSIS; ACTIVATED RECEPTOR-GAMMA; OXIDATIVELY MODIFIED LDL	We and others have shown that foam cell formation initiated by exposing macrophages to oxidized low density lipoprotein (oxLDL) triggers the differential expression of a number of proteins. Specifically, our experiments have identified peroxiredoxin I (Prx I) as one of these up-regulated proteins. The peroxiredoxins, a family of peroxidases initially described for their antioxidant capability, have generated recent interest for their potential to regulate signaling pathways. Those studies, however, have not examined peroxiredoxin for a potential dual functionality as both cytoprotective antioxidant and signal modulator in a single, oxidant-stressed system. In this report, we examine the up-regulation of Prx I in macrophages in response to oxLDL exposure and its ability to function as both antioxidant enzyme and regulator of p38 MAPK activation. As an antioxidant, induction of Prx I expression led to improved cell survival following treatment with oxLDL or tert-butyl hydroperoxide. The improved survival coincided with a decrease in measurable reactive oxygen species (ROS), and both the increased survival and reduced ROS were reversed by Prx I small interfering RNA transfection. Additionally, our data show that activation of p38 MAPK in oxLDL-treated macrophages was dependent on the up-regulation of Prx I. Reduction of Prx I expression by small interfering RNA transfection resulted in a significant decrease in p38 MAPK activation, whereas the up-regulation of Prx I expression with either oxLDL or ethoxyquin led to increased p38 MAPK activation. These results are consistent with multiple roles for Prx I in macrophage-derived foam cells that include functionality as both an antioxidant and a regulator of oxidant-sensitive signal transduction.	Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University	Kinter, M (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, NC 10,9500 Euclid Ave, Cleveland, OH 44195 USA.	kinterm@ccf.org		Conway, James/0000-0002-1725-8193; Kinter, Michael/0000-0001-7409-8918				Arstall MA, 1998, J MOL CELL CARDIOL, V30, P1019, DOI 10.1006/jmcc.1998.0666; Bea F, 2003, CIRC RES, V92, P386, DOI 10.1161/01.RES.0000059561.65545.16; Bilski P, 2002, FREE RADICAL BIO MED, V33, P938, DOI 10.1016/S0891-5849(02)00982-6; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; BUETLER TM, 1995, TOXICOL APPL PHARM, V135, P45, DOI 10.1006/taap.1995.1207; Chang JW, 2001, BIOCHEM BIOPH RES CO, V289, P507, DOI 10.1006/bbrc.2001.5989; Chang TS, 2004, J BIOL CHEM, V279, P50994, DOI 10.1074/jbc.M409482200; Chen WC, 2002, J NEUROSCI RES, V70, P794, DOI 10.1002/jnr.10435; Chevallet M, 2003, J BIOL CHEM, V278, P37146, DOI 10.1074/jbc.M305161200; Choi MH, 2005, NATURE, V435, P347, DOI 10.1038/nature03587; Chung YM, 2001, ANTICANCER RES, V21, P1129; Conway JP, 2005, MOL CELL PROTEOMICS, V4, P1522, DOI 10.1074/mcp.M500111-MCP200; Diepeveen SHA, 2005, J INTERN MED, V257, P438, DOI 10.1111/j.1365-2796.2005.01484.x; Feng JW, 2000, J LIPID RES, V41, P688; Fischer B, 2002, J IMMUNOL, V168, P2828, DOI 10.4049/jimmunol.168.6.2828; Gelissen IC, 1996, J BIOL CHEM, V271, P17852, DOI 10.1074/jbc.271.30.17852; GERRITY RG, 1980, ARTERY, V8, P208; Guo ZH, 2000, EXP NEUROL, V166, P173, DOI 10.1006/exnr.2000.7497; Han JH, 1998, AM J PATHOL, V152, P1647; Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654; Han JH, 2001, J BIOL CHEM, V276, P16567, DOI 10.1074/jbc.M011302200; Han KH, 2000, J CLIN INVEST, V106, P793, DOI 10.1172/JCI10052; Hattori F, 2003, J NEUROCHEM, V86, P860, DOI 10.1046/j.1471-4159.2003.01918.x; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Heinloth A, 2000, J AM SOC NEPHROL, V11, P1819, DOI 10.1681/ASN.V11101819; Hess A, 2003, J BIOL CHEM, V278, P45419, DOI 10.1074/jbc.M307871200; Hsu HY, 2000, J BIOL CHEM, V275, P41035, DOI 10.1074/jbc.M003464200; ISHII T, 1995, BIOCHEM BIOPH RES CO, V216, P970, DOI 10.1006/bbrc.1995.2715; Ishii T, 2004, CIRC RES, V94, P609, DOI 10.1161/01.RES.0000119171.44657.45; ISHII T, 1993, J BIOL CHEM, V268, P18633; Jing Q, 2000, CIRC RES, V87, P52, DOI 10.1161/01.RES.87.1.52; Jing Q, 1999, CIRC RES, V84, P831; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kang SW, 2004, J BIOL CHEM, V279, P2535, DOI 10.1074/jbc.M307698200; Kim H, 2000, J BIOL CHEM, V275, P18266, DOI 10.1074/jbc.275.24.18266; Kim HJ, 2003, CELL BIOL TOXICOL, V19, P285, DOI 10.1023/B:CBTO.0000004952.07979.3d; Kim HS, 2001, AM J PHYSIOL-LUNG C, V280, pL1212, DOI 10.1152/ajplung.2001.280.6.L1212; Konig J, 2003, J BIOL CHEM, V278, P24409, DOI 10.1074/jbc.M301145200; Kwon J, 2004, P NATL ACAD SCI USA, V101, P16419, DOI 10.1073/pnas.0407396101; Lee K, 2002, BIOCHEM BIOPH RES CO, V296, P337, DOI 10.1016/S0006-291X(02)00801-X; Li BJ, 2002, J BIOL CHEM, V277, P12418, DOI 10.1074/jbc.M111443200; LIPTON BA, 1995, J LIPID RES, V36, P2232; Lupo G, 2001, BBA-MOL CELL BIOL L, V1531, P143, DOI 10.1016/S1388-1981(01)00102-0; Mu ZM, 2002, J BIOL CHEM, V277, P43175, DOI 10.1074/jbc.M206066200; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Noh DY, 2001, ANTICANCER RES, V21, P2085; Ogawa Y, 2004, INT J MOL MED, V14, P1007; Paromov VM, 2003, J BIOL CHEM, V278, P40859, DOI 10.1074/jbc.M306580200; Peshenko IV, 1998, FREE RADICAL BIO MED, V25, P654, DOI 10.1016/S0891-5849(98)00111-7; Plaisant F, 2003, FREE RADICAL BIO MED, V34, P862, DOI 10.1016/S0891-5849(02)01440-5; QUINN MT, 1985, P NATL ACAD SCI USA, V82, P5949, DOI 10.1073/pnas.82.17.5949; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; Rabilloud T, 2002, J BIOL CHEM, V277, P19396, DOI 10.1074/jbc.M106585200; SCHAFFNER T, 1980, AM J PATHOL, V100, P57; SCHMITT A, 1995, BBA-LIPID LIPID MET, V1256, P284, DOI 10.1016/0005-2760(95)00032-8; Shatrov VA, 2003, BIOCHEM J, V374, P505, DOI 10.1042/BJ20030420; Shau HY, 2000, ANTIOXID REDOX SIGN, V2, P347, DOI 10.1089/ars.2000.2.2-347; Shen JJ, 2004, CANCER RES, V64, P9018, DOI 10.1158/0008-5472.CAN-04-3262; SIOW RCM, 1995, FEBS LETT, V368, P239, DOI 10.1016/0014-5793(95)00650-X; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; Tokay T, 2005, J NEUROCHEM, V94, P607, DOI 10.1111/j.1471-4159.2005.03102.x; Tsukamoto Kayo, 2002, J Atheroscler Thromb, V9, P57; Veal EA, 2004, MOL CELL, V15, P129, DOI 10.1016/j.molcel.2004.06.021; Vivancos AP, 2005, P NATL ACAD SCI USA, V102, P8875, DOI 10.1073/pnas.0503251102; Vogel Christoph F A, 2004, Cardiovasc Toxicol, V4, P363, DOI 10.1385/CT:4:4:363; Wagner E, 2002, BIOCHEM J, V366, P777, DOI 10.1042/BJ20020525; Wagsater D, 2004, BIOCHEM BIOPH RES CO, V325, P1187, DOI 10.1016/j.bbrc.2004.10.160; Wang N, 1996, J BIOL CHEM, V271, P8837, DOI 10.1074/jbc.271.15.8837; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Wiegant FAC, 1999, HUM EXP TOXICOL, V18, P460, DOI 10.1191/096032799678840273; Woo HA, 2005, J BIOL CHEM, V280, P3125, DOI 10.1074/jbc.C400496200; Woo HA, 2003, J BIOL CHEM, V278, P47361, DOI 10.1074/jbc.C300428200; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200; Yoshida H, 1998, ARTERIOSCL THROM VAS, V18, P794, DOI 10.1161/01.ATV.18.5.794; Zeng Y, 2001, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V23, P328; ZHANG HF, 1990, J LIPID RES, V31, P1361; Zmijewski JW, 2005, AM J PHYSIOL-HEART C, V289, pH852, DOI 10.1152/ajpheart.00015.2005	78	50	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27991	28001		10.1074/jbc.M605026200	http://dx.doi.org/10.1074/jbc.M605026200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16880205	hybrid			2022-12-25	WOS:000240534400036
J	Tate, JJ; Rai, R; Cooper, TG				Tate, Jennifer J.; Rai, Rajendra; Cooper, Terrance G.			Ammonia-specific regulation of Gln3 localization in Saccharomyces cerevisiae by protein kinase Npr1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN CATABOLITE REPRESSION; RETROGRADE GENE-EXPRESSION; AMINO-ACID PERMEASES; METHIONINE SULFOXIMINE TREATMENT; TOR SIGNALING PATHWAY; UBIQUITIN LIGASE; NUCLEAR-LOCALIZATION; CARBON STARVATION; 2A PHOSPHATASES; UPTAKE SYSTEMS	Events directly regulating Gln3 intracellular localization and nitrogen catabolite repression (NCR)-sensitive transcription in Saccharomyces cerevisiae are interconnected with many cellular processes that influence the utilization of environmental metabolites. Among them are intracellular trafficking of the permeases that transport nitrogenous compounds and their control by the Tor1,2 signal transduction pathway. Npr1 is a kinase that phosphorylates and thereby stabilizes NCR-sensitive permeases, e. g. Gap1 and Mep2. It is also a phosphoprotein for which phosphorylation and kinase activity are regulated by Tor1,2 via Tap42 and Sit4. Npr1 has been reported to negatively regulate nuclear localization of Gln3 in SD (ammonia)-grown cells. Thus we sought to distinguish whether Npr1: (i) functions directly as a component of NCR control; or (ii) influences Gln3 localization indirectly, possibly as a consequence of participating in protein trafficking. If Npr1 functions directly, then the ability of all good nitrogen sources to restrict Gln3 to the cytoplasm should be lost in an npr1 Delta just as occurs when URE2 ( encoding this well studied negative Gln3 regulator) is deleted. We show that nuclear localization of Gln3-Myc(13) in an npr1 Delta occurred only with ammonia as the nitrogen source. Other good nitrogen sources, e. g. glutamine, serine, or asparagine, restricted Gln3-Myc(13) to the cytoplasm of both wild type and npr1 Delta cells. In other words, the npr1 Delta did not possess the uniform phenotype for all repressive nitrogen sources characteristic of ure2 Delta. This suggests that the connection between Gln3 localization and Npr1 is indirect, arising from the influence of Npr1 on the ability of cells to utilize ammonia as a repressive nitrogen source.	Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Cooper, TG (corresponding author), Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA.	tcooper@utmem.edu		Cooper, Terrance G./0000-0002-7651-9963	NIGMS NIH HHS [R01 GM035642, R01 GM035642-18, GM-35642] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; Blinder D, 1996, J BACTERIOL, V178, P4734, DOI 10.1128/jb.178.15.4734-4736.1996; BORNAES C, 1993, MOL CELL BIOL, V13, P7604, DOI 10.1128/MCB.13.12.7604; Boulay A, 2005, CLIN CANCER RES, V11, P5319, DOI 10.1158/1078-0432.CCR-04-2402; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Cooper T., 1982, MOL BIOL YEAST SACCH, P39, DOI DOI 10.1101/087969180.11B.39; Cooper TG, 2004, TOP CURR GENET, V7, P225; Cooper TG, 2002, FEMS MICROBIOL REV, V26, P223, DOI 10.1111/j.1574-6976.2002.tb00612.x; Cox KH, 2004, J BIOL CHEM, V279, P19294, DOI 10.1074/jbc.M309240200; Cox KH, 2004, J BIOL CHEM, V279, P10270, DOI 10.1074/jbc.M312023200; Cox KH, 2002, J BIOL CHEM, V277, P37559, DOI 10.1074/jbc.M204879200; Cox KH, 2000, J BIOL CHEM, V275, P17611, DOI 10.1074/jbc.M001648200; Crespo JL, 2004, J BIOL CHEM, V279, P37512, DOI 10.1074/jbc.M407372200; Crespo JL, 2002, P NATL ACAD SCI USA, V99, P6784, DOI 10.1073/pnas.102687599; De Craene JO, 2001, J BIOL CHEM, V276, P43939, DOI 10.1074/jbc.M102944200; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; DRILLIEN R, 1972, J BACTERIOL, V109, P203, DOI 10.1128/JB.109.1.203-208.1972; DRILLIEN R, 1973, BIOCHEM BIOPH RES CO, V53, P367, DOI 10.1016/0006-291X(73)90671-2; DUBOIS E, 1979, MOL GEN GENET, V175, P67, DOI 10.1007/BF00267857; Duvel K, 2003, MOL CELL, V11, P1467, DOI 10.1016/S1097-2765(03)00228-4; Galan JM, 1996, J BIOL CHEM, V271, P10946, DOI 10.1074/jbc.271.18.10946; Giannattasio S, 2005, J BIOL CHEM, V280, P42528, DOI 10.1074/jbc.M509187200; GRENSON M, 1983, EUR J BIOCHEM, V133, P141, DOI 10.1111/j.1432-1033.1983.tb07439.x; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; Helliwell SB, 2001, J CELL BIOL, V153, P649, DOI 10.1083/jcb.153.4.649; Hofman-Bang J, 1999, MOL BIOTECHNOL, V12, P35, DOI 10.1385/MB:12:1:35; Inoki K, 2005, MICROBIOL MOL BIOL R, V69, P79, DOI 10.1128/MMBR.69.1.79-100.2005; Jacinto E, 2001, MOL CELL, V8, P1017, DOI 10.1016/S1097-2765(01)00386-0; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Kaouass M, 1998, J BIOL CHEM, V273, P2109, DOI 10.1074/jbc.273.4.2109; Kulkarni A, 2006, FEMS YEAST RES, V6, P218, DOI 10.1111/j.1567-1364.2006.00031.x; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Lorber MI, 2005, TRANSPLANTATION, V80, P244, DOI 10.1097/01.TP.0000164352.65613.24; Lorenz MC, 1998, EMBO J, V17, P1236, DOI 10.1093/emboj/17.5.1236; Magasanik B, 2005, P NATL ACAD SCI USA, V102, P16537, DOI 10.1073/pnas.0507116102; Marini AM, 1997, MOL CELL BIOL, V17, P4282, DOI 10.1128/MCB.17.8.4282; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; Morgensztern D, 2005, ANTI-CANCER DRUG, V16, P797, DOI 10.1097/01.cad.0000173476.67239.3b; Omura F, 2004, FEMS MICROBIOL LETT, V230, P227, DOI 10.1016/S0378-1097(03)00918-2; Regenberg B, 1999, CURR GENET, V36, P317, DOI 10.1007/s002940050506; Schluter Michael, 2005, Am Heart Hosp J, V3, P182, DOI 10.1111/j.1541-9215.2005.04407.x; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; Smart WC, 1996, MOL CELL BIOL, V16, P5876; Springael JY, 1999, BIOCHEM BIOPH RES CO, V257, P561, DOI 10.1006/bbrc.1999.0505; Springael JY, 1998, MOL BIOL CELL, V9, P1253, DOI 10.1091/mbc.9.6.1253; Springael JY, 1999, J CELL SCI, V112, P1375; Tate JJ, 2002, J BIOL CHEM, V277, P20477, DOI 10.1074/jbc.M200962200; Tate JJ, 2003, J BIOL CHEM, V278, P36924, DOI 10.1074/jbc.M301829200; Tate JJ, 2005, J BIOL CHEM, V280, P27195, DOI 10.1074/jbc.M504052200; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3; THOMAS G, 2004, CURRENT TOPICS MICRO, V279; VANDENBOL M, 1990, MOL GEN GENET, V222, P393, DOI 10.1007/BF00633845; VANDENBOL M, 1987, EUR J BIOCHEM, V164, P607, DOI 10.1111/j.1432-1033.1987.tb11170.x; Wang HM, 2003, MOL BIOL CELL, V14, P4342, DOI 10.1091/mbc.E03-02-0072; Yashiroda H, 1996, MOL CELL BIOL, V16, P3255; Zhu X, 1996, CURR GENET, V30, P107, DOI 10.1007/s002940050108	58	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28460	28469		10.1074/jbc.M604171200	http://dx.doi.org/10.1074/jbc.M604171200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16864577	Green Accepted, hybrid			2022-12-25	WOS:000240534400083
J	Poggio, S; Osorio, A; Dreyfus, G; Camarena, L				Poggio, Sebastian; Osorio, Aurora; Dreyfus, Georges; Camarena, Laura			Transcriptional specificity of RpoN1 and RpoN2 involves differential recognition of the promoter sequences and specific interaction with the cognate activator proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; ENHANCER-BINDING PROTEINS; COLI RNA-POLYMERASE; FORK JUNCTION DNA; TURN-HELIX MOTIF; ESCHERICHIA-COLI; RHODOBACTER-SPHAEROIDES; SIGMA-FACTOR; KLEBSIELLA-PNEUMONIAE; TERMINAL REGION	The four RpoN factors of Rhodobacter sphaeroides are functionally specialized. In this bacterium, RpoN1 and RpoN2 are specifically required for the transcription of the nitrogen fixation and flagellar genes, respectively. Analysis of the promoter sequences recognized by each of these RpoN proteins revealed some significant differences. To investigate the functional relevance of these differences, the flagellar promoter fliOp was sequentially mutagenized to resemble the nitrogen fixation promoter nifUp. Our results indicate that the promoter sequences recognized by these sigma factors have diverged enough so that particular positions of the promoter sequence are differentially recognized. In this regard, we demonstrate that the identity of the -11-position is critical for promoter discrimination by RpoN1 and RpoN2. Accordingly, purified RpoN proteins with a deletion of Region I, which has been involved in the recognition of the -11-position, did not show differential binding of fliOp and nifUp promoters. Substitution of the flagellar enhancer region located upstream fliOp by the enhancer region of nifUp allowed us to demonstrate that RpoN1 and RpoN2 interact specifically with their respective activator protein. In conclusion, two different molecular mechanisms underlie the transcriptional specialization of these sigma factors.	Natl Autonomous Univ Mexico, Inst Invest Biomed, Dept Biol Mol & Biotecnol, Mexico City 04510, DF, Mexico; Natl Autonomous Univ Mexico, Inst Fisiol Celular, Dept Mol Genet, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	Camarena, L (corresponding author), Natl Autonomous Univ Mexico, Inst Invest Biomed, Dept Biol Mol & Biotecnol, Mexico City 04510, DF, Mexico.	rosal@servidor.unam.mx		Dreyfus, Georges/0000-0001-9502-5072; Poggio, Sebastian/0000-0001-9494-3365; Camarena, Rosa Laura/0000-0003-0344-6000				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Barrios H, 1999, NUCLEIC ACIDS RES, V27, P4305, DOI 10.1093/nar/27.22.4305; BEYNON J, 1983, CELL, V34, P665, DOI 10.1016/0092-8674(83)90399-9; Bordes P, 2003, P NATL ACAD SCI USA, V100, P2278, DOI 10.1073/pnas.0537525100; Brahmachary P, 2004, J BACTERIOL, V186, P4535, DOI 10.1128/JB.186.14.4535-4542.2004; Buck M, 2000, J BACTERIOL, V182, P4129, DOI 10.1128/JB.182.15.4129-4136.2000; BUCK M, 1992, NATURE, V358, P422, DOI 10.1038/358422a0; BUCK M, 1992, MOL MICROBIOL, V6, P1625, DOI 10.1111/j.1365-2958.1992.tb00887.x; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; BURGESS RR, 1970, FED PROC, V29, P1164; Burrows PC, 2003, J BIOL CHEM, V278, P29728, DOI 10.1074/jbc.M303596200; CANNON W, 1993, MOL MICROBIOL, V8, P287, DOI 10.1111/j.1365-2958.1993.tb01573.x; Cannon W, 2003, J BIOL CHEM, V278, P19815, DOI 10.1074/jbc.M301296200; CANNON W, 1995, J MOL BIOL, V248, P781, DOI 10.1006/jmbi.1995.0260; Cannon W, 1999, GENE DEV, V13, P357, DOI 10.1101/gad.13.3.357; Cannon W, 1999, NUCLEIC ACIDS RES, V27, P2478, DOI 10.1093/nar/27.12.2478; Cannon WV, 2000, NAT STRUCT BIOL, V7, P594; CASTANO I, 1984, MOL GEN GENET, V195, P228, DOI 10.1007/BF00332751; Chaney M, 1999, MOL MICROBIOL, V33, P1200, DOI 10.1046/j.1365-2958.1999.01566.x; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; DAVIS J, 1988, J BACTERIOL, V170, P320, DOI 10.1128/jb.170.1.320-329.1988; Doucleff M, 2005, J BIOL CHEM, V280, P41530, DOI 10.1074/jbc.M509010200; Girard L, 2000, MOL PLANT MICROBE IN, V13, P1283, DOI 10.1094/MPMI.2000.13.12.1283; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; Guo YL, 2000, GENE DEV, V14, P2242, DOI 10.1101/gad.794800; Guo YL, 1999, EMBO J, V18, P3736, DOI 10.1093/emboj/18.13.3736; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Hengge-Aronis R, 2002, CURR OPIN MICROBIOL, V5, P591, DOI 10.1016/S1369-5274(02)00372-7; HUALA E, 1989, J BACTERIOL, V171, P3354, DOI 10.1128/jb.171.6.3354-3365.1989; HUALA E, 1992, J BACTERIOL, V174, P1428, DOI 10.1128/jb.174.4.1428-1431.1992; Ishihama A, 2000, ANNU REV MICROBIOL, V54, P499, DOI 10.1146/annurev.micro.54.1.499; JEFFERSON RA, 1986, P NATL ACAD SCI USA, V83, P8447, DOI 10.1073/pnas.83.22.8447; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; Kelly MT, 2000, J BACTERIOL, V182, P513, DOI 10.1128/JB.182.2.513-517.2000; KULLIK I, 1991, J BACTERIOL, V173, P1125, DOI 10.1128/jb.173.3.1125-1138.1991; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lee SY, 2003, GENE DEV, V17, P2552, DOI 10.1101/gad.1125603; Mackenzie C, 2001, PHOTOSYNTH RES, V70, P19, DOI 10.1023/A:1013831823701; MEIJER WG, 1992, J BACTERIOL, V174, P3855, DOI 10.1128/jb.174.12.3855-3866.1992; MERRICK M, 1992, J BACTERIOL, V174, P7221, DOI 10.1128/jb.174.22.7221-7226.1992; MERRICK MJ, 1993, MOL MICROBIOL, V10, P903, DOI 10.1111/j.1365-2958.1993.tb00961.x; Michiels J, 1998, J BACTERIOL, V180, P3620, DOI 10.1128/JB.180.14.3620-3628.1998; Mittenhuber G, 2002, J MOL MICROB BIOTECH, V4, P77; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; North AK, 1997, J MOL BIOL, V267, P17, DOI 10.1006/jmbi.1996.0838; Poggio S, 2000, J BACTERIOL, V182, P5787, DOI 10.1128/JB.182.20.5787-5792.2000; Poggio S, 2005, MOL MICROBIOL, V58, P969, DOI 10.1111/j.1365-2958.2005.04900.x; Poggio S, 2002, MOL MICROBIOL, V46, P75, DOI 10.1046/j.1365-2958.2002.03158.x; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; QUANDT J, 1993, GENE, V127, P15, DOI 10.1016/0378-1119(93)90611-6; Rappas M, 2005, SCIENCE, V307, P1972, DOI 10.1126/science.1105932; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SISTROM WR, 1962, J GEN MICROBIOL, V28, P607, DOI 10.1099/00221287-28-4-607; Sockett R, 1990, FEMS S, V53, P473; Southern E, 2000, NUCLEIC ACIDS RES, V28, P2563, DOI 10.1093/nar/28.13.2563; Studholme DJ, 2000, J BACTERIOL, V182, P1616, DOI 10.1128/JB.182.6.1616-1623.2000; Syed A, 1998, J BACTERIOL, V180, P5619, DOI 10.1128/JB.180.21.5619-5625.1998; Wang L, 1998, J BACTERIOL, V180, P5626, DOI 10.1128/JB.180.21.5626-5631.1998; Wang L, 2001, J BIOL CHEM, V276, P8979, DOI 10.1074/jbc.M009587200; Wang YK, 1997, MOL MICROBIOL, V26, P373, DOI 10.1046/j.1365-2958.1997.5851955.x; Wigneshweraraj SR, 2001, J MOL BIOL, V306, P681, DOI 10.1006/jmbi.2000.4393; Wosten MMSM, 1998, FEMS MICROBIOL REV, V22, P127, DOI 10.1016/S0168-6445(98)00011-4; Xu H, 2001, CURR OPIN MICROBIOL, V4, P138, DOI 10.1016/S1369-5274(00)00179-X; Zhang X, 2002, MOL MICROBIOL, V45, P895, DOI 10.1046/j.1365-2958.2002.03065.x	66	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27205	27215		10.1074/jbc.M601735200	http://dx.doi.org/10.1074/jbc.M601735200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16854992	hybrid			2022-12-25	WOS:000240397700048
J	Rahier, A; Darnet, S; Bouvier, F; Camara, B; Bard, M				Rahier, Alain; Darnet, Sylvain; Bouvier, Florence; Camara, Bilal; Bard, Martin			Molecular and enzymatic characterizations of novel bifunctional 3 beta-hydroxysteroid dehydrogenases/C-4 decarboxylases from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT STEROL BIOSYNTHESIS; PROTEIN-PROTEIN INTERACTIONS; SITE-DIRECTED MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; MALIC ENZYME; BRASSINOSTEROID BIOSYNTHESIS; OXIDATIVE DECARBOXYLATION; PARTIAL-PURIFICATION; CHEMICAL MECHANISM; REDUCTASE	We have isolated two cDNAs from Arabidopsis thaliana encoding bifunctional 3 beta-hydroxysteroid dehydrogenase/C-4 decarboxylases (3 beta HSD/D) involved in sterol synthesis, termed At3 beta HSD/D1 and At3 beta HSD/D2. Transformation of the yeast ergosterol auxotroph erg26 mutant, which lacks 3 beta HSD/D activity, with the At3 beta HSD/D1 isoform or with At3 beta HSD/D2 isoform containing a C-terminal At3 beta HSD/D1 endoplasmic reticulum-retrieval sequence restored growth and ergosterol synthesis in erg26. An in vitro enzymatic assay revealed high 3 beta HSD/D activity for both isoenzymes in the corresponding microsomal extracts. The two At3 beta HSD/D isoenzymes showed similar substrate specificities that required free 3 beta-hydroxyl and C-4-carboxyl groups but were quite tolerant in terms of variations of the sterol nucleus and side chain structures. Data obtained with 4 alpha-carboxy-cholest-7-en-3 beta-ol and its 3 alpha-deuterated analog revealed that 3 alpha-hydrogen-carbon bond cleavage is not the rate-limiting step of the reaction. In planta reduction on the expression of the 3 beta HSD/D gene as a consequence of VIGS-mediated gene silencing in Nicotiana benthamiana led to a substantial accumulation of 3 beta-hydroxy-4 beta,14-dimethyl-5 alpha-ergosta-9 beta,19-cyclo-24(24(1))-en-4 alpha-carboxylic acid, consistent with a decrease in 3 beta HSD/D activity. These two novel oxidative decarboxylases constitute the first molecularly and functionally characterized HSDs from a short chain dehydrogenase/reductase family in plants.	CNRS, Inst Biol Mol Plantes, UPR2357, F-67083 Strasbourg, France; Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN 46202 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Indiana University System; Indiana University-Purdue University Indianapolis	Rahier, A (corresponding author), CNRS, Inst Biol Mol Plantes, UPR2357, 28 Rue Goethe, F-67083 Strasbourg, France.	enzymo@bota-ulp.u-strasbg.fr	DARNET, Sylvain Henri/G-4912-2012	DARNET, Sylvain Henri/0000-0001-6351-0903	NIGMS NIH HHS [GM62104] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062104] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bach TJ, 1997, PROG LIPID RES, V36, P197, DOI 10.1016/S0163-7827(97)00009-X; Bard M, 1996, P NATL ACAD SCI USA, V93, P186, DOI 10.1073/pnas.93.1.186; Baudry K, 2001, J BIOL CHEM, V276, P12702, DOI 10.1074/jbc.M100274200; Benveniste P, 2004, ANNU REV PLANT BIOL, V55, P429, DOI 10.1146/annurev.arplant.55.031903.141616; Bill RM, 2001, CURR GENET, V40, P157, DOI 10.1007/s002940100252; Bouvier F, 2005, PROG LIPID RES, V44, P357, DOI 10.1016/j.plipres.2005.09.003; Bouvier F, 2003, PLANT CELL, V15, P47, DOI 10.1105/tpc.006536; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Choe S, 1999, PLANT PHYSIOL, V119, P897, DOI 10.1104/pp.119.3.897; Choe SW, 1999, PLANT CELL, V11, P207, DOI 10.1105/tpc.11.2.207; CLELAND WW, 1982, CRC CR REV BIOCH MOL, V13, P385; Cleland WW, 2003, J BIOL CHEM, V278, P51975, DOI 10.1074/jbc.X300005200; COOK PF, 1981, BIOCHEMISTRY-US, V20, P1797, DOI 10.1021/bi00510a014; Darnet S, 2004, BIOCHEM J, V378, P889, DOI 10.1042/BJ20031572; Darnet S, 2003, BBA-MOL CELL BIOL L, V1633, P106, DOI 10.1016/S1388-1981(03)00093-3; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; Edens WA, 1997, BIOCHEMISTRY-US, V36, P1141, DOI 10.1021/bi962128s; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; Gachotte D, 1998, P NATL ACAD SCI USA, V95, P13794, DOI 10.1073/pnas.95.23.13794; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRISSOM CB, 1988, BIOCHEMISTRY-US, V27, P2934, DOI 10.1021/bi00408a040; HERMES JD, 1982, BIOCHEMISTRY-US, V21, P5106, DOI 10.1021/bi00263a040; HORINOUCHI S, 1991, APPL ENVIRON MICROB, V57, P1386, DOI 10.1128/AEM.57.5.1386-1393.1991; Hwang CC, 2005, J BIOL CHEM, V280, P3522, DOI 10.1074/jbc.M411751200; Hwang CC, 1998, BIOCHEMISTRY-US, V37, P12596, DOI 10.1021/bi980611s; Hyndman D, 2003, CHEM-BIOL INTERACT, V143, P621, DOI 10.1016/S0009-2797(02)00193-X; Jang JC, 2000, GENE DEV, V14, P1485; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kallberg Y, 2002, EUR J BIOCHEM, V269, P4409, DOI 10.1046/j.1432-1033.2002.03130.x; Kallberg Y, 2002, PROTEIN SCI, V11, P636, DOI 10.1110/ps.26902; KARSTEN WE, 1994, BIOCHEMISTRY-US, V33, P2096, DOI 10.1021/bi00174a016; Kumagai MH, 1998, PLANT J, V14, P305, DOI 10.1046/j.1365-313X.1998.00128.x; KUMAGAI MH, 1995, P NATL ACAD SCI USA, V92, P1679, DOI 10.1073/pnas.92.5.1679; LACHANCE Y, 1990, J BIOL CHEM, V265, P20469; LEES ND, 1995, LIPIDS, V30, P221, DOI 10.1007/BF02537824; Liu XY, 1999, NAT GENET, V22, P182, DOI 10.1038/9700; Mo C, 2002, P NATL ACAD SCI USA, V99, P9739, DOI 10.1073/pnas.112202799; Mo CQ, 2005, BBA-MOL CELL BIOL L, V1737, P152, DOI 10.1016/j.bbalip.2005.11.002; MORRISON JF, 1988, BIOCHEMISTRY-US, V27, P5499, DOI 10.1021/bi00415a017; Northrop DB, 1999, ADV ENZYMOL RAMB, V73, P25, DOI 10.1002/9780470123195.ch2; NORTHROP DB, 1975, BIOCHEMISTRY-US, V14, P2644, DOI 10.1021/bi00683a013; NORTHROP DB, 1982, METHOD ENZYMOL, V87, P607; Northrop DB, 2001, METHODS, V24, P117, DOI 10.1006/meth.2001.1173; Oppermann U, 2003, CHEM-BIOL INTERACT, V143, P247, DOI 10.1016/S0009-2797(02)00164-3; Oppermann UCT, 2001, CHEM-BIOL INTERACT, V130, P699, DOI 10.1016/S0009-2797(00)00301-X; PASCAL S, 1993, J BIOL CHEM, V268, P11639; PASCAL S, 1994, ARCH BIOCHEM BIOPHYS, V312, P260, DOI 10.1006/abbi.1994.1308; Rahier A, 2001, BIOCHEMISTRY-US, V40, P256, DOI 10.1021/bi001696b; Rahier A., 1989, ANAL STEROLS OTHER B, P223, DOI [10.1016/B978-0-12-515445-1.50016-1, DOI 10.1016/B978-0-12-515445-1.50016-1]; RAHIMTULA AD, 1972, J BIOL CHEM, V247, P9; RHEAUME E, 1991, MOL ENDOCRINOL, V5, P1147, DOI 10.1210/mend-5-8-1147; Roebroek AJM, 1998, GENOMICS, V51, P98, DOI 10.1006/geno.1997.5175; Rondet S, 1999, ARCH BIOCHEM BIOPHYS, V366, P249, DOI 10.1006/abbi.1999.1218; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Schrick K, 2000, GENE DEV, V14, P1471; SHEN AL, 1995, J BIOL CHEM, V270, P27475, DOI 10.1074/jbc.270.46.27475; Shirabe K, 1998, BBA-PROTEIN STRUCT M, V1384, P16, DOI 10.1016/S0167-4838(97)00146-5; STRITTMATTER P, 1990, J BIOL CHEM, V265, P21709; Taton M, 2000, BIOCHEMISTRY-US, V39, P701, DOI 10.1021/bi991467t; VANDEVELDE HJK, 1994, J CELL SCI, V107, P2403; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7	62	30	33	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27264	27277		10.1074/jbc.M604431200	http://dx.doi.org/10.1074/jbc.M604431200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16835224	hybrid			2022-12-25	WOS:000240397700053
J	Yamaguchi, J; Conlon, DM; Liang, JJ; Fisher, EA; Ginsberg, HN				Yamaguchi, Junji; Conlon, Donna M.; Liang, John J.; Fisher, Edward A.; Ginsberg, Henry N.			Translocation efficiency of apolipoprotein B is determined by the presence of beta-sheet domains, not pause transfer sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; NASCENT SECRETORY PROTEINS; ENDOPLASMIC-RETICULUM; INTRACELLULAR DEGRADATION; APO-B; CONTAINING LIPOPROTEINS; MOLECULAR CHAPERONES; APOPROTEIN B100; BINDING	Cotranslational translocation of apoB100 across the endoplasmic reticulum (ER) membrane is inefficient, resulting in exposure of nascent apoB on the cytosolic surface of the ER. This predisposes apoB100 to ubiquitinylation and targeting for proteasomal degradation. It has been suggested that pause transfer sequences (PTS) present throughout apoB cause inefficient translocation. On the other hand, our previous study demonstrated that the translocation efficiency of apoB100 is dependent on the presence of a beta-sheet domain between 29 and 34% of full-length apoB100 (Liang, J.-S., Wu, X., Jiang, H., Zhou, M., Yang, H., Angkeow, P., Huang, L.-S., Sturley, S. L., and Ginsberg, H. N. ( 1998) J. Biol. Chem. 273, 35216-35221); this region of apoB has no PTS. However, the effects of the beta-sheet domain may require the presence of PTS elsewhere in the N-terminal region of apoB100. To further investigate the roles of PTS and beta-sheet domains in the translocation of apoB100 across the ER, we transfected McArdle RH7777, HepG2, or Chinese hamster ovary cells with human albumin (ALB)/human apoB chimeric cDNA constructs: ALB/B12-17 (two PTS but no beta-sheet), ALB/B29-34 (beta-sheet but no PTS), ALB/B36-41 (two PTS and a beta-sheet), and ALB/B49-54 (neither PTS nor a beta-sheet). ALB/ALB1-40 served as a control. Compared with ALB/ALB1-40, secretion rates of ALB/B12-17, ALB/B29-34, and ALB/B36-41 were reduced. Secretion of ALB/B49-54 was similar to that of ALB/ALB1-40. However, only ALB/B29-34 and ALB/B36-41 had increased proteinase K sensitivity, ubiquitinylation, and increased physical interaction with Sec61 alpha. These results indicate that the translocation efficiency of apoB100 is determined mainly by the presence of beta-sheet domains. PTS do not appear to affect translocation, but may affect secretion by other mechanisms.	Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA	Columbia University; New York University	Ginsberg, HN (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, PH 10-305,630 W 168th St, New York, NY 10032 USA.	hng1@columbia.edu	Fisher, Edward/ABE-7469-2020	Fisher, Edward/0000-0001-9802-143X; Conlon, Donna/0000-0002-9471-3081	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007343, R01HL055638] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL55638, T32 HL07343] Funding Source: Medline; PHS HHS [R01 58541] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; CHUCK SL, 1993, J BIOL CHEM, V268, P22794; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1991, J BIOL CHEM, V266, P5080; Du XB, 1998, J CELL BIOL, V141, P585, DOI 10.1083/jcb.141.3.585; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; Gusarova V, 2001, J BIOL CHEM, V276, P24891, DOI 10.1074/jbc.M100633200; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; Hegde RS, 1998, CELL, V92, P621, DOI 10.1016/S0092-8674(00)81130-7; Herscovitz H, 2001, J LIPID RES, V42, P51; Johnson AE, 2000, CELL, V102, P709, DOI 10.1016/S0092-8674(00)00059-3; Kalies KU, 1998, J CELL BIOL, V141, P887, DOI 10.1083/jcb.141.4.887; Kivlen MH, 1997, J LIPID RES, V38, P1149; Liang JS, 2003, J BIOL CHEM, V278, P23984, DOI 10.1074/jbc.M302683200; Liang JS, 2001, J BIOL CHEM, V276, P28606, DOI 10.1074/jbc.M100294200; Liang JS, 1998, J BIOL CHEM, V273, P35216, DOI 10.1074/jbc.273.52.35216; Liang JS, 2000, J BIOL CHEM, V275, P32003, DOI 10.1074/jbc.M004646200; Manchekar M, 2004, J BIOL CHEM, V279, P39757, DOI 10.1074/jbc.M406302200; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; MILNE R, 1989, J BIOL CHEM, V264, P19754; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Pariyarath R, 2001, J BIOL CHEM, V276, P541, DOI 10.1074/jbc.M007944200; PEASE RJ, 1995, J BIOL CHEM, V270, P7261, DOI 10.1074/jbc.270.13.7261; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; SAKATA N, 1993, J BIOL CHEM, V268, P22967; Segrest JP, 2001, J LIPID RES, V42, P1346; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; Shelness GS, 2003, J BIOL CHEM, V278, P44702, DOI 10.1074/jbc.M307562200; Shelness GS, 1999, J NUTR, V129, p456S, DOI 10.1093/jn/129.2.456S; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; Yao ZM, 1997, J LIPID RES, V38, P1937; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; ZHOU MY, 1995, J BIOL CHEM, V270, P25220, DOI 10.1074/jbc.270.42.25220; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	46	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27063	27071		10.1074/jbc.M606809200	http://dx.doi.org/10.1074/jbc.M606809200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16854991	hybrid			2022-12-25	WOS:000240397700033
J	Youngblood, B; Reich, NO				Youngblood, Ben; Reich, Norbert O.			Conformational transitions as determinants of specificity for the DNA methyltransferase EcoRI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE METHYLTRANSFERASE; HAEIII METHYLTRANSFERASE; SUBSTRATE-RECOGNITION; FACILITATED DIFFUSION; POLYMERASE FIDELITY; DIRECTED EVOLUTION; ENZYME; BASE; BINDING; PROTEIN	Changes in DNA bending and base flipping in a previously characterized specificity-enhanced M. EcoRI DNA adenine methyltransferase mutant suggest a close relationship between precatalytic conformational transitions and specificity (Allan, B. W., Garcia, R., Maegley, K., Mort, J., Wong, D., Lindstrom, W., Beechem, J. M., and Reich, N. O. (1999) J. Biol. Chem. 274, 19269-19275). The direct measurement of the kinetic rate constants for DNA bending, intercalation, and base flipping with cognate and noncognate substrates (GAATTT, GGATTC) of wild type M. EcoRI using fluorescence resonance energy transfer and 2-aminopurine fluorescence studies reveals that DNA bending precedes both intercalation and base flipping, and base flipping precedes intercalation. Destabilization of these intermediates provides a molecular basis for understanding how conformational transitions contribute to specificity. The 3500- and 23,000-fold decreases in sequence specificity for noncognate sites GAATTT and GGATTC are accounted for largely by an similar to 2500-fold increase in the reverse rate constants for intercalation and base flipping, respectively. Thus, a predominant contribution to specificity is a partitioning of enzyme intermediates away from the Michaelis complex prior to catalysis. Our results provide a basis for understanding enzyme specificity and, in particular, sequence-specific DNA modification. Because many DNA methyltransferases and DNA repair enzymes induce similar DNA distortions, these results are likely to be broadly relevant.	Univ Calif Santa Barbara, Program Biomol Sci & Engn, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Reich, NO (corresponding author), Univ Calif Santa Barbara, Program Biomol Sci & Engn, Santa Barbara, CA 93106 USA.	reich@chem.ucsb.edu	Youngblood, Benjamin/N-2508-2018	Youngblood, Benjamin/0000-0002-1261-9957				Allan BW, 1999, BIOCHEMISTRY-US, V38, P5308, DOI 10.1021/bi9900020; Allan BW, 1999, J BIOL CHEM, V274, P19269, DOI 10.1074/jbc.274.27.19269; Allan BW, 1998, J BIOL CHEM, V273, P2368, DOI 10.1074/jbc.273.4.2368; Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; BLACKLOW SC, 1991, BIOCHEMISTRY-US, V30, P8470, DOI 10.1021/bi00098a026; Bruice TC, 2005, J AM CHEM SOC, V127, P12478, DOI 10.1021/ja053714o; Cao CY, 2004, NAT STRUCT MOL BIOL, V11, P1230, DOI 10.1038/nsmb864; Cohen HM, 2004, PROTEIN ENG DES SEL, V17, P3, DOI 10.1093/protein/gzh001; Cohen HM, 2002, NUCLEIC ACIDS RES, V30, P3880, DOI 10.1093/nar/gkf507; Daujotyte D, 2004, STRUCTURE, V12, P1047, DOI 10.1016/j.str.2004.04.007; Dwyer MA, 2004, SCIENCE, V304, P1967, DOI 10.1126/science.1098432; Fersht A, 1999, STRUCTURE MECH PROTE, P132; Garcia RA, 1996, P NATL ACAD SCI USA, V93, P7618, DOI 10.1073/pnas.93.15.7618; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; Heithoff DM, 1999, SCIENCE, V284, P967, DOI 10.1126/science.284.5416.967; HERMES JD, 1987, COLD SPRING HARB SYM, V52, P597, DOI 10.1101/SQB.1987.052.01.068; Hiller DA, 2005, J MOL BIOL, V354, P121, DOI 10.1016/j.jmb.2005.09.046; Hiller DA, 2003, BIOCHEMISTRY-US, V42, P14375, DOI 10.1021/bi035520w; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; HOPFIELD JJ, 1980, P NATL ACAD SCI-BIOL, V77, P5248, DOI 10.1073/pnas.77.9.5248; Hopkins BB, 2004, J BIOL CHEM, V279, P37049, DOI 10.1074/jbc.M404573200; Horton JR, 2006, J MOL BIOL, V358, P559, DOI 10.1016/j.jmb.2006.02.028; Horton JR, 2005, CELL, V121, P349, DOI 10.1016/j.cell.2005.02.021; Huang N, 2005, J MOL BIOL, V345, P265, DOI 10.1016/j.jmb.2004.10.042; Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S; Johnson K. A., 1992, ENZYMES, V20, P1, DOI DOI 10.1016/S1874-6047(08)60019-0; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Jones PA, 2003, ANN NY ACAD SCI, V983, P213, DOI 10.1111/j.1749-6632.2003.tb05976.x; Joyce CM, 2004, BIOCHEMISTRY-US, V43, P14317, DOI 10.1021/bi048422z; Kobayashi I, 2001, NUCLEIC ACIDS RES, V29, P3742, DOI 10.1093/nar/29.18.3742; Krosky DJ, 2005, BIOCHEMISTRY-US, V44, P5949, DOI 10.1021/bi050084u; Lakowicz J.R, 1999, PRINCIPLES FLUORESCE, P368; MASHHOON N, 1994, BIOCHEMISTRY-US, V33, P7113, DOI 10.1021/bi00189a014; Mashhoon N, 2004, J BIOL CHEM, V279, P52075, DOI 10.1074/jbc.M408182200; Mathieu O, 2004, J CELL SCI, V117, P4881, DOI 10.1242/jcs.01479; Matzke M, 2004, BBA-GENE STRUCT EXPR, V1677, P129, DOI 10.1016/j.bbaexp.2003.10.015; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; Nixon AE, 1999, P NATL ACAD SCI USA, V96, P3568, DOI 10.1073/pnas.96.7.3568; Parkhurst KM, 1996, BIOCHEMISTRY-US, V35, P7459, DOI 10.1021/bi9530301; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; Quemeneur E, 1998, NATURE, V391, P301, DOI 10.1038/34687; Rachofsky EL, 2001, BIOCHEMISTRY-US, V40, P957, DOI 10.1021/bi001665g; REICH NO, 1992, J BIOL CHEM, V267, P15802; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Samuelson JC, 2002, J MOL BIOL, V319, P673, DOI 10.1016/S0022-2836(02)00343-1; Su TJ, 2005, NUCLEIC ACIDS RES, V33, P3235, DOI 10.1093/nar/gki618; Surby MA, 1996, BIOCHEMISTRY-US, V35, P2209, DOI 10.1021/bi951884f; Surby MA, 1996, BIOCHEMISTRY-US, V35, P2201, DOI 10.1021/bi951883n; Svedruzic ZM, 2005, BIOCHEMISTRY-US, V44, P14977, DOI 10.1021/bi050988f; Wolfenden R, 2001, ACCOUNTS CHEM RES, V34, P938, DOI 10.1021/ar000058i	50	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26821	26831		10.1074/jbc.M603388200	http://dx.doi.org/10.1074/jbc.M603388200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16845123	hybrid			2022-12-25	WOS:000240397700009
J	Valeva, A; Hellmann, N; Walev, I; Strand, D; Plate, M; Boukhallouk, F; Brack, A; Hanada, K; Decker, H; Bhakdi, S				Valeva, Angela; Hellmann, Nadja; Walev, Iwan; Strand, Dennis; Plate, Markus; Boukhallouk, Fatima; Brack, Antje; Hanada, Kentaro; Decker, Heinz; Bhakdi, Sucharit			Evidence that clustered phosphocholine head groups serve as sites for binding and assembly of an oligomeric protein pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCAL ALPHA-TOXIN; HAMSTER OVARY CELLS; TRANSMEMBRANE CHANNEL; CHOLESTEROL DEPLETION; HEPTAMERIC PORE; FORMING PROTEIN; PHASE-DIAGRAM; LIPID RAFTS; MEMBRANE; HEMOLYSIN	High susceptibility of rabbit erythrocytes toward the pore-forming action of staphylococcal alpha-toxin correlates with the presence of saturable, high affinity binding sites. All efforts to identify a protein or glycolipid receptor have failed, and the fact that liposomes composed solely of phosphatidylcholine are efficiently permeabilized adds to the enigma. A novel concept is advanced here to explain the puzzle. We propose that low affinity binding moieties can assume the role of high affinity binding sites due to their spatial arrangement in the membrane. Evidence is presented that phosphocholine head groups of sphingomyelin, clustered in sphingomyelin-cholesterol microdomains, serve this function for alpha-toxin. Clustering is required so that oligomerization, which is prerequisite for stable attachment of the toxin to the membrane, can efficiently occur. Outside these clusters, binding to phosphocholine is too transient for toxin monomers to find each other. The principle of membrane targeting in the absence of any genuine, high affinity receptor may also underlie the assembly of other lipid-inserted oligomers including cytotoxic peptides, protein toxins, and immune effector molecules.	Inst Med Microbiol & Hyg, D-55101 Mainz, Germany; Univ Mainz, Inst Mol Biophys, D-55099 Mainz, Germany; Univ Mainz, Med Clin 1, D-55101 Mainz, Germany; Natl Inst Infect Dis, Dept Biochem & Cell Biol, Tokyo 1628640, Japan	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; National Institute of Infectious Diseases (NIID)	Bhakdi, S (corresponding author), Inst Med Microbiol & Hyg, Hochhaus Augustuspl, D-55101 Mainz, Germany.	sbhakdi@uni-mainz.de		Hanada, Kentaro/0000-0003-1383-2781				Abrami L, 1998, J CELL BIOL, V140, P525, DOI 10.1083/jcb.140.3.525; BAYLEY H, 1994, J CELL BIOCHEM, V56, P177, DOI 10.1002/jcb.240560210; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; de Almeida RFM, 2003, BIOPHYS J, V85, P2406, DOI 10.1016/S0006-3495(03)74664-5; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; Diep DB, 1998, J BIOL CHEM, V273, P2355, DOI 10.1074/jbc.273.4.2355; EISINGER J, 1987, BIOPHYS CHEM, V28, P273, DOI 10.1016/0301-4622(87)80098-4; Feigenson GW, 2001, BIOPHYS J, V80, P2775, DOI 10.1016/S0006-3495(01)76245-5; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRENKEL EJ, 1986, BIOCHIM BIOPHYS ACTA, V855, P293, DOI 10.1016/0005-2736(86)90177-X; Fukasawa M, 2000, J BIOL CHEM, V275, P34028, DOI 10.1074/jbc.M005151200; GIRAUD F, 1984, BIOCHIM BIOPHYS ACTA, V778, P191, DOI 10.1016/0005-2736(84)90462-0; HANADA K, 1992, J BIOL CHEM, V267, P23527; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HILDEBRAND A, 1991, J BIOL CHEM, V266, P17195; IKIGAI H, 1987, J BIOL CHEM, V262, P2156; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; MOLLBY R, 1978, BACTERIAL TOXINS CEL, P477; Olson R, 1999, NAT STRUCT BIOL, V6, P134; PALMER M, 1993, J BIOL CHEM, V268, P11963; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; PORN MI, 1995, BIOCHEM J, V308, P269; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; TITBALL RW, 1993, MICROBIOL REV, V57, P347, DOI 10.1128/MMBR.57.2.347-366.1993; TSCHOPP J, 1989, NATURE, V337, P272, DOI 10.1038/337272a0; Valeva A, 1997, BBA-BIOMEMBRANES, V1325, P281, DOI 10.1016/S0005-2736(96)00266-0; Valeva A, 1996, EMBO J, V15, P1857, DOI 10.1002/j.1460-2075.1996.tb00536.x; Valeva A, 1997, BIOCHEMISTRY-US, V36, P13298, DOI 10.1021/bi971075r; VALEVA A, 1995, BBA-BIOMEMBRANES, V1236, P213, DOI 10.1016/0005-2736(95)00060-G; Waheed AA, 2001, P NATL ACAD SCI USA, V98, P4926, DOI 10.1073/pnas.091090798; WALKER B, 1993, J BIOL CHEM, V268, P5285; WALKER B, 1992, J BIOL CHEM, V267, P21782; WALKER B, 1995, CHEM BIOL, V2, P99, DOI 10.1016/1074-5521(95)90282-1; WALKER B, 1995, J BIOL CHEM, V270, P23065, DOI 10.1074/jbc.270.39.23065; WARD RJ, 1994, BIOCHEMISTRY-US, V33, P7477, DOI 10.1021/bi00189a056; WATANABE M, 1987, BIOCHIM BIOPHYS ACTA, V898, P257, DOI 10.1016/0005-2736(87)90065-4; Yamaji-Hasegawa A, 2003, J BIOL CHEM, V278, P22762, DOI 10.1074/jbc.M213209200; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; Zitzer A, 2000, BBA-BIOMEMBRANES, V1509, P264, DOI 10.1016/S0005-2736(00)00303-5	42	87	89	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26014	26021		10.1074/jbc.M601960200	http://dx.doi.org/10.1074/jbc.M601960200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829693	hybrid			2022-12-25	WOS:000240249500016
J	Kansaku, A; Hirabayashi, S; Mori, H; Fujiwara, N; Kawata, A; Ikeda, M; Rokukawa, C; Kurihara, H; Hata, Y				Kansaku, A.; Hirabayashi, S.; Mori, H.; Fujiwara, N.; Kawata, A.; Ikeda, M.; Rokukawa, C.; Kurihara, H.; Hata, Y.			Ligand-of-Numb protein X is an endocytic scaffold for junctional adhesion molecule 4	ONCOGENE			English	Article						endocytosis; scaffold; cell adhesion	HEPATOCYTE GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; PHOSPHOTYROSINE-BINDING DOMAIN; ASYMMETRIC CELL-DIVISION; FATE DETERMINANT NUMB; MAMMALIAN NUMB; TIGHT JUNCTION; FAMILY PROTEINS; MDCK CELLS; TGF-BETA	Junctional adhesion molecule 4 (JAM4) is a cell adhesion molecule that interacts with a tight junction protein, membrane-associated guanylate kinase inverted 1 (MAGI-1). Our previous studies suggest that JAM4 is implicated in the regulation of paracellular permeability and the signalings of hepatocyte growth factor. In this study, we performed yeast two-hybrid screening to search for an unidentified JAM4-binding protein and obtained one isoform of Ligand-of-Numb protein X1 (LNX1), LNXp70, that is an interactor of Numb. Ligand-of-Numb protein X1 is expressed in kidney glomeruli and intestinal epithelial cells, where JAM4 is also detected. Immunoprecipitation from kidney lysates supports the in vivo interaction of proteins. Biochemical studies reveal that JAM4 directly binds the second PDZ domain of LNX1 through its carboxyl terminus. Junctional adhesion molecule 4, LNX1 and Numb form a tripartite complex in vitro and are partially colocalized in heterologous cells. Ligand-of-Numb protein X1 facilitates endocytosis of JAM4 and is involved in transforming growth factor beta-induced redistribution of JAM4 in mammary epithelial cells. Experiments using dominant-negative constructs and RNA interference insure that Numb is necessary for the LNX1-mediated endocytosis of JAM4. All these findings indicate that LNX1 provides an endocytic scaffold for JAM4 that is implicated in the reorganization of cell junctions.	Tokyo Med & Dent Univ, Grad Sch Med, Dept Biochem Med, Bunkyo Ku, Tokyo, Japan; Juntendo Univ, Sch Med, Dept Anat, Tokyo 113, Japan	Tokyo Medical & Dental University (TMDU); Juntendo University	Hata, Y (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Biochem Med, Bunkyo Ku, 15-45 Yushima, Tokyo, Japan.	yuhammch@med.tmd.ac.jp						Beckers J, 1999, MECH DEVELOP, V84, P165, DOI 10.1016/S0925-4773(99)00065-9; Berdnik D, 2002, DEV CELL, V3, P221, DOI 10.1016/S1534-5807(02)00215-0; Cayouette M, 2001, J NEUROSCI, V21, P5643, DOI 10.1523/JNEUROSCI.21-15-05643.2001; Cereijido M, 2000, AM J PHYSIOL-GASTR L, V279, pG477, DOI 10.1152/ajpgi.2000.279.3.G477; Coyne CB, 2005, ADV DRUG DELIVER REV, V57, P869, DOI 10.1016/j.addr.2005.01.007; Dejana E, 2000, INT J DEV BIOL, V44, P743; Dho SE, 1999, J BIOL CHEM, V274, P33097, DOI 10.1074/jbc.274.46.33097; Dho SE, 1998, J BIOL CHEM, V273, P9179, DOI 10.1074/jbc.273.15.9179; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; Feldman GJ, 2005, ADV DRUG DELIVER REV, V57, P883, DOI 10.1016/j.addr.2005.01.009; Fre S, 2005, NATURE, V435, P964, DOI 10.1038/nature03589; Frise E, 1996, P NATL ACAD SCI USA, V93, P11925, DOI 10.1073/pnas.93.21.11925; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; Heiz M, 2004, J BIOL CHEM, V279, P31149, DOI 10.1074/jbc.M403587200; Hirabayashi S, 2003, MOL CELL BIOL, V23, P4267, DOI 10.1128/MCB.23.12.4267-4282.2003; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Mandell KJ, 2005, ADV DRUG DELIVER REV, V57, P857, DOI 10.1016/j.addr.2005.01.005; McCright B, 2001, DEVELOPMENT, V128, P491; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Mirza M, 2005, EXP CELL RES, V309, P110, DOI 10.1016/j.yexcr.2005.05.023; Mori H, 2004, GENES CELLS, V9, P811, DOI 10.1111/j.1365-2443.2004.00765.x; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nie J, 2004, J BIOL CHEM, V279, P20807, DOI 10.1074/jbc.M311396200; Nie J, 2002, EMBO J, V21, P93, DOI 10.1093/emboj/21.1.93; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Politi K, 2004, SEMIN CANCER BIOL, V14, P341, DOI 10.1016/j.semcancer.2004.04.013; Pollack AL, 2004, AM J PHYSIOL-CELL PH, V286, pC482, DOI 10.1152/ajpcell.00377.2003; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Rice DS, 2001, MOL CELL NEUROSCI, V18, P525, DOI 10.1006/mcne.2001.1024; Roegiers F, 2004, CURR OPIN CELL BIOL, V16, P195, DOI 10.1016/j.ceb.2004.02.010; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Santolini E, 2000, J CELL BIOL, V151, P1345, DOI 10.1083/jcb.151.6.1345; Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003; Smith CA, 2004, MOL BIOL CELL, V15, P3698, DOI 10.1091/mbc.E04-01-0026; Sollerbrant K, 2003, J BIOL CHEM, V278, P7439, DOI 10.1074/jbc.M205927200; Spana EP, 1996, NEURON, V17, P21, DOI 10.1016/S0896-6273(00)80277-9; STOKER M, 1985, J CELL SCI, V77, P209; Tajima M, 2003, GENES CELLS, V8, P759, DOI 10.1046/j.1365-2443.2003.00673.x; Tanaka Y, 2002, BIOCHEM BIOPH RES CO, V299, P472, DOI 10.1016/S0006-291X(02)02681-5; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VANITALLIE CM, 2005, ANN REV PHYSL; Verdi J, 1996, CURR BIOL, V6, P1134, DOI 10.1016/S0960-9822(02)70680-5; Wakamatsu Y, 1999, NEURON, V23, P71, DOI 10.1016/S0896-6273(00)80754-0; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2	57	35	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2006	25	37					5071	5084		10.1038/sj.onc.1209468	http://dx.doi.org/10.1038/sj.onc.1209468			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16832352	Bronze			2022-12-25	WOS:000240063700001
J	Vegran, F; Boidot, R; Oudin, C; Defrain, C; Rebucci, M; Lizard-Nacol, S				Vegran, F.; Boidot, R.; Oudin, C.; Defrain, C.; Rebucci, M.; Lizard-Nacol, S.			Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer	ONCOGENE			English	Article						survivin expression; alternative splicing; p53 status; breast cancer	ANTI-APOPTOSIS GENE; WILD-TYPE P53; TRANSCRIPTIONAL REPRESSION; SURVIVIN-DELTA-EX3; INDUCTION; CELLS; INHIBITOR; MUTATIONS	Survivin, a member of the inhibitory apoptosis protein family, gives rise, by an alternative splicing, to four variants with different functions. Many experimental studies indicate that p53 can regulate the expression of survivin and some of its splice variants. Although both the expression of survivin splice variants and the p53 gene were frequently altered in human cancers, nothing is known about their interactions in in vivo tumour samples. Here, we report that, in 162 breast carcinomas, p53 mutations are significantly associated with an increased expression of survivin and, in particular, its antiapoptotic splice variants (survivin-Delta Ex3 and survivin-3B). The upregulation of these variant expressions is particularly related to p53 mutations occurring in the residues belonging to the tetramerization domain. The loss of heterozygosity in the p53 gene is also associated with an increased expression of the survivin-Delta Ex3 variant. The expression of the proapoptotic variants (survivin-2B and survivin-2 alpha) is not affected by any of these alterations. Our results provide for the first time in vivo evidence that, in human breast cancer, the survivin expression as well as its splicing depends on the p53 status. The results also suggest that the upregulation of antiapoptotic survivin variant expression by the mutant p53 may increase breast cancer cells survival and resistance to therapy.	Ctr Georges Francois Leclerc, INSERM, Mol Genet Lab, U 517, F-21034 Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Georges-Francois Leclerc	Lizard-Nacol, S (corresponding author), Ctr Georges Francois Leclerc, INSERM, Mol Genet Lab, U 517, 1 Rue Prof Marion, F-21034 Dijon, France.	slizard@dijon.fnclcc.fr	VEGRAN, Frédérique/H-4792-2017; VEGRAN, Frederique/O-9986-2018	VEGRAN, Frederique/0000-0002-4377-1441				Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Badran A, 2004, BIOCHEM BIOPH RES CO, V314, P902, DOI 10.1016/j.bbrc.2003.12.178; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Caldas H, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-11; CAWKWELL L, 1994, BRIT J CANCER, V70, P813, DOI 10.1038/bjc.1994.404; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Esteve PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102; Franco N, 2003, ARCH SURG-CHICAGO, V138, P291, DOI 10.1001/archsurg.138.3.291; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Mahotka C, 1999, CANCER RES, V59, P6097; Maxwell SA, 1999, APOPTOSIS, V4, P109, DOI 10.1023/A:1009618811038; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Moyret-Lalle C, 2001, CANCER RES, V61, P486; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; NASU S, 2002, ANTICANCER RES, V22, P2613; O'Driscoll L, 2003, CANCER LETT, V201, P225, DOI 10.1016/S0304-3835(03)00518-4; Punga T, 2003, FEBS LETT, V552, P214, DOI 10.1016/S0014-5793(03)00927-X; Ryan B, 2005, BRIT J CANCER, V92, P120, DOI 10.1038/sj.bjc.6602314; Sommer KW, 2003, ONCOGENE, V22, P4266, DOI 10.1038/sj.onc.1206509; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Tsuji N, 2004, BREAST CANCER RES TR, V87, P23, DOI 10.1023/B:BREA.0000041575.73262.aa; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; Vegran F, 2005, INT J ONCOL, V27, P1151; Xu H, 2003, ONCOL RES, V13, P429; Yoon H, 2002, P NATL ACAD SCI USA, V99, P15632, DOI 10.1073/pnas.242597299; Zhou XL, 1999, CANCER RES, V59, P843; Zhu NX, 2004, ONCOGENE, V23, P7545, DOI 10.1038/sj.onc.1208038	33	59	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					290	297		10.1038/sj.onc.1209784	http://dx.doi.org/10.1038/sj.onc.1209784			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16847456	Bronze			2022-12-25	WOS:000243398300013
J	Watanabe, S; Kodaki, T; Makino, K				Watanabe, Seiya; Kodaki, Tsutomu; Makino, Keisuke			A novel alpha-ketoglutaric semialdehyde dehydrogenase Evolutionary insight into an alternative pathway of bacterial L-arabinose metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-XYLULOSE REDUCTASE; ALDEHYDE DEHYDROGENASE; CATABOLIC PATHWAY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; PSEUDOMONAS SACCHAROPHILA; GENE; IDENTIFICATION; CLONING; EXPRESSION	Azospirillum brasilense possesses an alternative pathway of L-arabinose metabolism, which is different from the known bacterial and fungal pathways. In a previous paper (Watanabe, S., Kodaki, T., and Makino, K. (2006) J. Biol. Chem. 281, 2612-2623), we identified and characterized L-arabinose 1-dehydrogenase, which catalyzes the first reaction step in this pathway, and we cloned the corresponding gene. Here we focused on the fifth enzyme, alpha-ketoglutaric semialdehyde (alpha KGSA) dehydrogenase, catalyzing the conversion of alpha KGSA to alpha-ketoglutarate. alpha KGSA dehydrogenase was purified tentatively as a NAD(+)-preferring aldehyde dehydrogenase (ALDH) with high activity for glutaraldehyde. The gene encoding this enzyme was cloned and shown to be located on the genome of A. brasilense separately from a gene cluster containing the L-arabinose 1-dehydrogenase gene, in contrast with Burkholderia thailandensis in which both genes are located in the same gene cluster. Higher catalytic efficiency of ALDH was found with alpha KGSA and succinic semialdehyde among the tested aldehyde substrates. In zymogram staining analysis with the cell-free extract, a single active band was found at the same position as the purified enzyme. Furthermore, a disruptant of the gene did not grow on L-arabinose. These results indicated that this ALDH gene was the only gene of the NAD(+)-preferring alpha KGSA dehydrogenase in A. brasilense. In the phylogenetic tree of the ALDH family, alpha KGSA dehydrogenase from A. brasilense falls into the succinic semialdehyde dehydrogenase (SSALDH) subfamily. Several putative alpha KGSA dehydrogenases from other bacteria belong to a different ALDH subfamily from SSALDH, suggesting strongly that their substrate specificities for alpha KGSA are acquired independently during the evolutionary stage. This is the first evidence of unique "convergent evolution" in the ALDH family.	Kyoto Univ, Inst Adv Energy, Uji, Kyoto 6110011, Japan; Japan Sci & Technol Agcy, CREST, Uji, Kyoto 6110011, Japan; Kyoto Univ, Int Innovat Ctr, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Fac Engn, Saikyo Ku, Kyoto 6158530, Japan	Kyoto University; Japan Science & Technology Agency (JST); Kyoto University; Kyoto University	Makino, K (corresponding author), Kyoto Univ, Inst Adv Energy, Uji, Kyoto 6110011, Japan.	kmak@iae.kyoto-u.ac.jp						ADAMS E, 1967, J BIOL CHEM, V242, P1802; Ahvazi B, 2000, BIOCHEM J, V349, P853, DOI 10.1042/bj3490853; Barbosa JARG, 2000, J MOL BIOL, V303, P405, DOI 10.1006/jmbi.2000.4138; BARTSCH K, 1990, J BACTERIOL, V172, P7035, DOI 10.1128/jb.172.12.7035-7042.1990; Bateman OA, 2003, BIOCHEMISTRY-US, V42, P4349, DOI 10.1021/bi027367w; Busch KB, 1999, PLANT PHYSIOL, V121, P589, DOI 10.1104/pp.121.2.589; CHAMBLISS KL, 1995, J BIOL CHEM, V270, P461, DOI 10.1074/jbc.270.1.461; CHANG YF, 1977, J BIOL CHEM, V252, P7979; Cobessi D, 1999, J MOL BIOL, V290, P161, DOI 10.1006/jmbi.1999.2853; DAGLEY S, 1965, BIOCHEM J, V95, P48, DOI 10.1042/bj0950048; DAHMS AS, 1969, BIOCHEM BIOPH RES CO, V36, P809, DOI 10.1016/0006-291X(69)90681-0; DUNCAN MJ, 1979, J GEN MICROBIOL, V113, P177, DOI 10.1099/00221287-113-1-177; DUNCAN MJ, 1979, J BACTERIOL, V137, P415, DOI 10.1128/JB.137.1.415-419.1979; GENNADY PM, 2002, HDB DETECTION ENZYME, P27; Gros E., 1967, METHOD ENZYMOL, V11, P238; Gruez A, 2004, J MOL BIOL, V343, P29, DOI 10.1016/j.jmb.2004.08.030; HEMPEL J, 1993, PROTEIN SCI, V2, P1890, DOI 10.1002/pro.5560021111; Hosoya S, 2002, FEMS MICROBIOL LETT, V210, P193, DOI 10.1111/j.1574-6968.2002.tb11180.x; Iwaki H, 1999, APPL ENVIRON MICROB, V65, P5158; Junker F, 1997, J BACTERIOL, V179, P919, DOI 10.1128/jb.179.3.919-927.1997; KOO PH, 1974, J BIOL CHEM, V249, P1704; Kuznetsova E, 2005, FEMS MICROBIOL REV, V29, P263, DOI 10.1016/j.femsre.2004.12.006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL R, 1992, CRIT REV BIOCHEM MOL, V27, P283, DOI 10.3109/10409239209082565; Liu ZJ, 1997, NAT STRUCT BIOL, V4, P317, DOI 10.1038/nsb0497-317; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lutke-Eversloh T, 1999, FEMS MICROBIOL LETT, V181, P63; MATHIAS AL, 1989, J BACTERIOL, V171, P5206, DOI 10.1128/jb.171.9.5206-5209.1989; Moore RA, 2004, INFECT IMMUN, V72, P4172, DOI 10.1128/IAI.72.7.4172-4187.2004; Moore S, 1940, J BIOL CHEM, V133, P293; Moore SA, 1998, STRUCTURE, V6, P1541, DOI 10.1016/S0969-2126(98)00152-X; NOVICK NJ, 1982, J BACTERIOL, V149, P364, DOI 10.1128/JB.149.1.364-367.1982; Perozich J, 1999, PROTEIN SCI, V8, P137, DOI 10.1110/ps.8.1.137; Richard P, 2002, BIOCHEMISTRY-US, V41, P6432, DOI 10.1021/bi025529i; Richard P, 2001, J BIOL CHEM, V276, P40631, DOI 10.1074/jbc.M104022200; Schneider BL, 1998, J BACTERIOL, V180, P4278, DOI 10.1128/JB.180.16.4278-4286.1998; SIMON R, 1983, BIOTECHNOLOGY, V1, P789; SINGH RMM, 1964, SCIENCE, V144, P67, DOI 10.1126/science.144.3614.67; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; STOOLMILLER AC, 1966, J BIOL CHEM, V241, P5764; STRYER L, 1988, BIOCHEMISTRY-US, P805; Verho R, 2004, J BIOL CHEM, V279, P14746, DOI 10.1074/jbc.M312533200; Watanabe S, 2006, J BIOL CHEM, V281, P2612, DOI 10.1074/jbc.M506477200; WEIMBERG R, 1955, J BIOL CHEM, V217, P607; Zaldivar J, 2001, APPL MICROBIOL BIOT, V56, P17, DOI 10.1007/s002530100624	45	42	58	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28876	28888		10.1074/jbc.M602585200	http://dx.doi.org/10.1074/jbc.M602585200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16835232	Green Submitted, hybrid			2022-12-25	WOS:000240680500042
J	Cottrell, GS; Padilla, B; Pikios, S; Roosterman, D; Steinhoff, M; Gehringer, D; Grady, EF; Bunnett, NW				Cottrell, Graeme S.; Padilla, Benjamin; Pikios, Stella; Roosterman, Dirk; Steinhoff, Martin; Gehringer, Daphne; Grady, Eileen F.; Bunnett, Nigel W.			Ubiquitin-dependent down-regulation of the neurokinin-1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SUBSTANCE-P RECEPTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; BETA-ADRENERGIC-RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; ACTIVATED RECEPTOR-2; CARBOXYL-TAIL; KINASE-C; ARRESTIN; DESENSITIZATION	Transient stimulation with substance P (SP) induces endocytosis and recycling of the neurokinin-1 receptor (NK1R). The effects of sustained stimulation by high concentrations of SP on NK1R trafficking and Ca2+ signaling, as may occur during chronic inflammation and pain, are unknown. Chronic exposure to SP (100 nM, 3 h) completely desensitized Ca2+ signaling by wild-type NK1R (NK(1)Rwt). Resensitization occurred after 16 h, and cycloheximide prevented resensitization, implicating new receptor synthesis. Lysine ubiquitination of G-protein-coupled receptors is a signal for their trafficking and degradation. Lysine-deficient mutant receptors (NK1R Delta 5K/R, C-terminal tail lysines; and NK1R Delta 10K/R, all intracellular lysines) were expressed at the plasma membrane and were functional because they responded to SP by endocytosis and by mobilization of Ca2+ ions. SP desensitized NK(1)Rwt, NK1R Delta 5K/R, and NK1R Delta 10K/R. However, NK1R Delta 5K/R and NK1R Delta 10K/R resensitized 4 - 8-fold faster than NK1Rwt by cycloheximide-independent mechanisms. NK1R Delta 325 (a naturally occurring truncated variant) showed incomplete desensitization, followed by a marked sensitization of signaling. Upon labeling receptors in living cells using antibodies to extracellular epitopes, we observed that SP induced endocytosis of NK(1)Rwt, NK1R Delta 5K/R, and NK1R Delta 10K/R. After 4 h in SP-free medium, NK1R Delta 5K/R and NK1R Delta 10K/R recycled to the plasma membrane, whereas NK1Rwt remained internalized. SP induced ubiquitination of NK(1)Rwt and NK1R Delta 5K/R as determined by immunoprecipitation under nondenaturing and denaturing conditions and detected with antibodies for mono- and polyubiquitin. NK1R Delta 10K/R was not ubiquitinated. Whereas SP induced degradation of NK(1)Rwt, NK1R Delta 5K/R and NK1R Delta 10K/R showed similar to 50% diminished degradation. Thus, chronic stimulation with SP induces ubiquitination of the NK1R, which mediates its degradation and down-regulation.	Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Munster, Dept Dermatol, Interdisciplinary Ctr Clin Res, D-48149 Munster, Germany; Univ Munster, Ludwig Boltzmann Inst Cell Biol, D-48149 Munster, Germany	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Munster; University of Munster	Bunnett, NW (corresponding author), Univ Calif San Francisco, Dept Surg, 521 Parnassus Ave, San Francisco, CA 94143 USA.	nigel.bunnett@ucsf.edu	Steinhoff, Martin/F-6312-2013	Bunnett, Nigel W./0000-0003-3367-0644; Steinhoff, Martin/0000-0002-7090-2187; Cottrell, Graeme/0000-0001-9098-7627	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK043207, R01DK043207, R01DK057840, R01DK052388, R01DK039957, R37DK039957] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39957, DK43207, DK52388, DK57840] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bohm SK, 1997, J BIOL CHEM, V272, P2363; Bohm SK, 1996, J BIOL CHEM, V271, P22003; BOYD ND, 1991, BIOCHEMISTRY-US, V30, P336, DOI 10.1021/bi00216a005; Chaturvedi K, 2001, J BIOL CHEM, V276, P12345, DOI 10.1074/jbc.M008054200; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Dery O, 2001, AM J PHYSIOL-CELL PH, V280, pC1097, DOI 10.1152/ajpcell.2001.280.5.C1097; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FONG TM, 1992, MOL PHARMACOL, V41, P24; Garland AM, 1996, MOL PHARMACOL, V49, P438; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Grady EF, 1996, J NEUROSCI, V16, P6975, DOI 10.1523/jneurosci.16-21-06975.1996; Hammes SR, 1999, BIOCHEMISTRY-US, V38, P9308, DOI 10.1021/bi9902236; Hanyaloglu AC, 2005, EMBO J, V24, P2265, DOI 10.1038/sj.emboj.7600688; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hislop JN, 2004, J BIOL CHEM, V279, P22522, DOI 10.1074/jbc.M311062200; Jacob C, 2005, J BIOL CHEM, V280, P16076, DOI 10.1074/jbc.M500109200; Jensen LE, 2003, FEBS LETT, V553, P190, DOI 10.1016/S0014-5793(03)00998-0; KAGE R, 1993, J NEUROCHEM, V60, P347, DOI 10.1111/j.1471-4159.1993.tb05857.x; Kim YM, 2002, J BIOL CHEM, V277, P30760, DOI 10.1074/jbc.M204528200; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; Li HZ, 1997, P NATL ACAD SCI USA, V94, P9475, DOI 10.1073/pnas.94.17.9475; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Marchese A, 2003, DEV CELL, V5, P709, DOI 10.1016/S1534-5807(03)00321-6; McConalogue K, 1999, J BIOL CHEM, V274, P16257, DOI 10.1074/jbc.274.23.16257; McConalogue K, 1998, MOL BIOL CELL, V9, P2305, DOI 10.1091/mbc.9.8.2305; Milojevic T, 2006, MOL PHARMACOL, V69, P1083, DOI 10.1124/mol.105.015818; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; Roosterman D, 2004, J BIOL CHEM, V279, P30670, DOI 10.1074/jbc.M402479200; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Schmidlin F, 2002, P NATL ACAD SCI USA, V99, P3324, DOI 10.1073/pnas.052161299; Schmidlin F, 2003, AM J PHYSIOL-CELL PH, V285, pC945, DOI 10.1152/ajpcell.00541.2002; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Tanowitz M, 2002, J BIOL CHEM, V277, P50219, DOI 10.1074/jbc.C200536200; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; VIGNA SR, 1994, J NEUROSCI, V14, P834; Vigna SR, 1999, J NEUROCHEM, V73, P1925; Wojcikiewicz RJH, 2004, TRENDS PHARMACOL SCI, V25, P35, DOI 10.1016/j.tips.2003.11.008; Wojcikiewicz RJH, 2003, J BIOL CHEM, V278, P940, DOI 10.1074/jbc.M206607200; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	49	48	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27773	27783		10.1074/jbc.M603369200	http://dx.doi.org/10.1074/jbc.M603369200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16849335	hybrid			2022-12-25	WOS:000240534400013
J	Hati, S; Ziervogel, B; SternJohn, J; Wong, FC; Nagan, MC; Rosen, AE; Siliciano, PG; Chihade, JW; Musier-Forsyth, K				Hati, Sanchita; Ziervogel, Brigitte; SternJohn, Julius; Wong, Fai-Chu; Nagan, Maria C.; Rosen, Abbey E.; Siliciano, Paul G.; Chihade, Joseph W.; Musier-Forsyth, Karin			Pre-transfer editing by class II prolyl-tRNA synthetase - Role of aminoacylation active site in "selective release" of noncognate amino acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIES-SPECIFIC DIFFERENCES; STRUCTURAL BASIS; PROTEIN-SYNTHESIS; INSERTION DOMAIN; IN-VITRO; ADENYLATE; SIEVE; DISCRIMINATION; TRANSLOCATION; RECOGNITION	Aminoacyl-tRNA synthetases catalyze the attachment of cognate amino acids to specific tRNA molecules. To prevent potential errors in protein synthesis caused by misactivation of noncognate amino acids, some synthetases have evolved editing mechanisms to hydrolyze misactivated amino acids (pre-transfer editing) or misacylated tRNAs (post-transfer editing). In the case of post-transfer editing, synthetases employ a separate editing domain that is distinct from the site of amino acid activation, and the mechanism is believed to involve shuttling of the flexible CCA-3' end of the tRNA from the synthetic active site to the site of hydrolysis. The mechanism of pre-transfer editing is less well understood, and in most cases, the exact site of pre-transfer editing has not been conclusively identified. Here, we probe the pre-transfer editing activity of class II prolyl-tRNA synthetases from five species representing all three kingdoms of life. To locate the site of pre-transfer editing, truncation mutants were constructed by deleting the insertion domain characteristic of bacterial prolyl-tRNA synthetase species, which is the site of post-transfer editing, or the N- or C-terminal extension domains of eukaryotic and archaeal enzymes. In addition, the pre-transfer editing mechanism of Escherichia coli prolyl-tRNA synthetase was probed in detail. These studies show that a separate editing domain is not required for pre-transfer editing by prolyl-tRNA synthetase. The aminoacylation active site plays a significant role in preserving the fidelity of translation by acting as a filter that selectively releases non-cognate adenylates into solution, while protecting the cognate adenylate from hydrolysis.	Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Carleton Coll, Dept Chem, Northfield, MN 55057 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Carleton College	Musier-Forsyth, K (corresponding author), Univ Minnesota, Dept Chem, 207 Pleasant St SE, Minneapolis, MN 55455 USA.	musier@chem.umn.edu		Nagan, Maria/0000-0003-2678-6825	NIGMS NIH HHS [GM49928] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM049928, R01GM049928, R55GM049928] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahel I, 2003, P NATL ACAD SCI USA, V100, P15422, DOI 10.1073/pnas.2136934100; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; Beebe K, 2003, EMBO J, V22, P668, DOI 10.1093/emboj/cdg065; Beuning PJ, 2000, P NATL ACAD SCI USA, V97, P8916, DOI 10.1073/pnas.97.16.8916; Beuning PJ, 2001, J BIOL CHEM, V276, P30779, DOI 10.1074/jbc.M104761200; Bishop AC, 2003, P NATL ACAD SCI USA, V100, P490, DOI 10.1073/pnas.0237335100; Bullock TL, 2003, J MOL BIOL, V328, P395, DOI 10.1016/S0022-2836(03)00305-X; Burke B, 2001, J BIOL CHEM, V276, P20286, DOI 10.1074/jbc.M100456200; Chen JF, 2000, BIOCHEMISTRY-US, V39, P6726, DOI 10.1021/bi000108r; Cusack S, 1998, STRUCTURE, V6, P101, DOI 10.1016/S0969-2126(98)00011-2; DELARUE M, 1993, BIOESSAYS, V15, P675, DOI 10.1002/bies.950151007; Dock-Bregeon AC, 2000, CELL, V103, P877, DOI 10.1016/S0092-8674(00)00191-4; Dock-Bregeon AC, 2004, MOL CELL, V16, P375, DOI 10.1016/S1097-2765(04)00591-X; ELDRED EW, 1972, BIOCHEMISTRY-US, V11, P17, DOI 10.1021/bi00751a004; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; Farrow MA, 2001, BIOCHEMISTRY-US, V40, P4478, DOI 10.1021/bi0024052; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P1, DOI 10.1021/bi00672a001; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; FREIST W, 1989, BIOCHEMISTRY-US, V28, P6787, DOI 10.1021/bi00443a001; Freist W, 1998, J THEOR BIOL, V193, P19, DOI 10.1006/jtbi.1998.0672; Fukai S, 2000, CELL, V103, P793, DOI 10.1016/S0092-8674(00)00182-3; Fukunaga R, 2006, J MOL BIOL, V359, P901, DOI 10.1016/j.jmb.2006.04.025; Gruic-Sovulj I, 2005, J BIOL CHEM, V280, P23978, DOI 10.1074/jbc.M414260200; Heacock D, 1996, BIOORG CHEM, V24, P273, DOI 10.1006/bioo.1996.0025; Hendrickson TL, 2003, MOL B INT U, P34; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; ILLANGASEKARE M, 1995, SCIENCE, V267, P643, DOI 10.1126/science.7530860; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; Kamtekar S, 2003, P NATL ACAD SCI USA, V100, P1673, DOI 10.1073/pnas.0437911100; Larkin DC, 2002, NUCLEIC ACIDS RES, V30, P2103, DOI 10.1093/nar/30.10.2103; LAUGHREA M, 1982, EXP GERONTOL, V17, P305, DOI 10.1016/0531-5565(82)90020-1; LEWINSOHN R, 1967, BIOCHIM BIOPHYS ACTA, V140, P24, DOI 10.1016/0005-2795(67)90378-9; Lin L, 1996, BIOCHEMISTRY-US, V35, P5596, DOI 10.1021/bi960011y; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; Lincecum TL, 2003, MOL CELL, V11, P951, DOI 10.1016/S1097-2765(03)00098-4; LIU MS, 1993, BIOTECHNIQUES, V15, P264; Martinis S A, 1997, Nucleic Acids Symp Ser, V36, P125; Mursinna RS, 2004, BIOCHEMISTRY-US, V43, P155, DOI 10.1021/bi034919h; Mursinna RS, 2001, BIOCHEMISTRY-US, V40, P5376, DOI 10.1021/bi002915w; MUSIERFORSYTH K, 1991, P NATL ACAD SCI USA, V88, P209, DOI 10.1073/pnas.88.1.209; Nomanbhoy TK, 1999, MOL CELL, V4, P519, DOI 10.1016/S1097-2765(00)80203-8; Nomanbhoy TK, 2001, BIOORG MED CHEM LETT, V11, P1485, DOI 10.1016/S0960-894X(01)00127-5; Nomanbhoy TK, 2000, P NATL ACAD SCI USA, V97, P5119, DOI 10.1073/pnas.090102197; Nordin BE, 2003, BIOCHEMISTRY-US, V42, P12989, DOI 10.1021/bi035052q; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; ORGEL LE, 1963, P NATL ACAD SCI USA, V49, P517, DOI 10.1073/pnas.49.4.517; PAECHTHOROWITZ M, 1967, BIOCHIM BIOPHYS ACTA, V140, P14, DOI 10.1016/0005-2795(67)90377-7; Rho SB, 2002, EMBO J, V21, P6874, DOI 10.1093/emboj/cdf671; Roy H, 2004, EMBO J, V23, P4639, DOI 10.1038/sj.emboj.7600474; Sankaranarayanan R, 1999, CELL, V97, P371, DOI 10.1016/S0092-8674(00)80746-1; SCHMIDT E, 1994, SCIENCE, V264, P265, DOI 10.1126/science.8146659; SEGAL IH, 1975, ENZYME KINETICS, P100; Shiba K, 2002, J MOL BIOL, V320, P833, DOI 10.1016/S0022-2836(02)00567-3; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; Stehlin C, 1997, BIOCHEMISTRY-US, V36, P2932, DOI 10.1021/bi962295s; Stehlin C, 1998, BIOCHEMISTRY-US, V37, P8605, DOI 10.1021/bi980364s; TSUI WC, 1981, NUCLEIC ACIDS RES, V9, P4627, DOI 10.1093/nar/9.18.4627; Wong FC, 2003, J BIOL CHEM, V278, P52857, DOI 10.1074/jbc.M309627200; Wong FC, 2002, BIOCHEMISTRY-US, V41, P7108, DOI 10.1021/bi012178j; Yaremchuk A, 2001, J MOL BIOL, V309, P989, DOI 10.1006/jmbi.2001.4712	61	51	55	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27862	27872		10.1074/jbc.M605856200	http://dx.doi.org/10.1074/jbc.M605856200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16864571	hybrid			2022-12-25	WOS:000240534400022
J	Kelly, BL; Ferreira, A				Kelly, Brent L.; Ferreira, Adriana			beta-amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; ACTIVATED NEUTRAL PROTEINASE; SYNAPTIC VESICLE TRAFFICKING; ALZHEIMERS-DISEASE; A-BETA; CORTICAL-NEURONS; MEMORY DEFICITS; MOUSE MODEL; CALCIUM NEUROTOXICITY; PRECURSOR PROTEIN	Alzheimer disease (AD) is a progressive, neurodegenerative disorder that leads to debilitating cognitive deficits. Although little is known about the early functional or ultrastructural changes associated with AD, it has been proposed that a stage of synaptic dysfunction might precede neurodegeneration in the development of this disease. Unfortunately, the molecular mechanisms that underlie such synaptic dysfunction remain largely unknown. Recently we have shown that beta-amyloid (A beta), the main component of senile plaques, induced a significant decrease in dynamin 1, a protein that plays a critical role in synaptic vesicle recycling, and hence, in the signaling properties of the synapse. We report here that this dynamin 1 degradation was the result of calpain activation induced by the sustained calcium influx mediated by N-methyl-D-aspartate receptors in hippocampal neurons. In addition, our results showed that soluble oligomericA beta, and not fibrillar A beta, was responsible for this sustained calcium influx, calpain activation, and dynamin 1 degradation. Considering the importance of dynamin 1 to synaptic function, these data suggest that A beta soluble oligomers might catalyze a stage of synaptic dysfunction that precedes synapse loss and neurodegeneration. These data also highlight the calpain system as a novel therapeutic target for early stage AD intervention.	Northwestern Univ, Norwestern Inst Neurosci, Chicago, IL 60611 USA; Northwestern Univ, Dept Cell & Mol Biol, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Feinberg School of Medicine	Ferreira, A (corresponding author), Northwestern Univ, Norwestern Inst Neurosci, Chicago, IL 60611 USA.	a-ferreira@northwestern.edu		Ferreira, Adriana/0000-0003-3705-3918	NIA NIH HHS [AG20506] Funding Source: Medline; NINDS NIH HHS [NS39080] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG020506] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AbdelHamid KM, 1997, NEUROSCIENCE, V81, P673, DOI 10.1016/S0306-4522(97)00162-0; Battaglia F, 2003, J MOL NEUROSCI, V20, P357, DOI 10.1385/JMN:20:3:357; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Brewer GJ, 2006, NEUROBIOL AGING, V27, P306, DOI 10.1016/j.neurobiolaging.2005.01.019; BRORSON JR, 1994, J NEUROSCI, V14, P187; Bullock R, 2006, ALZ DIS ASSOC DIS, V20, P23, DOI 10.1097/01.wad.0000201847.29836.a5; Chen M, 2005, BIOCHEM BIOPH RES CO, V330, P714, DOI 10.1016/j.bbrc.2005.03.029; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; Clark SG, 1997, P NATL ACAD SCI USA, V94, P10438, DOI 10.1073/pnas.94.19.10438; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Czogalla A, 2005, CELL MOL LIFE SCI, V62, P1913, DOI 10.1007/s00018-005-5097-0; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; FANELLI RJ, 1994, ANN NY ACAD SCI, V747, P336; Fifre A, 2006, J BIOL CHEM, V281, P229, DOI 10.1074/jbc.M507378200; Fitzjohn SM, 2001, J NEUROSCI, V21, P4691, DOI 10.1523/JNEUROSCI.21-13-04691.2001; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Goslin K., 1991, CULTURING NERVE CELL, P251; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hernandez-Fonseca K, 2005, J NEUROSCI RES, V82, P196, DOI 10.1002/jnr.20631; Honer WG, 2003, NEUROBIOL AGING, V24, P1047, DOI 10.1016/j.neurobiolaging.2003.04.005; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; Kelly BL, 2005, J BIOL CHEM, V280, P31746, DOI 10.1074/jbc.M503259200; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; KOENIG JH, 1989, J NEUROSCI, V9, P3844; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EB, 2005, J BIOL CHEM, V16, P16; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; LEE SY, 2005, FASEB J, V25, P25; Leissring MA, 2001, NEUROBIOL DIS, V8, P469, DOI 10.1006/nbdi.2001.0382; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Liu F, 2005, J BIOL CHEM, V280, P37755, DOI 10.1074/jbc.M507475200; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MATTSON MP, 1993, BRAIN RES, V621, P35, DOI 10.1016/0006-8993(93)90295-X; MURPHY SN, 1989, MOL PHARMACOL, V35, P671; Nakayama K, 2005, J NEUROSCI, V25, P4040, DOI 10.1523/JNEUROSCI.4115-04.2005; ODDO S, 2005, J BIOL CHEM, V10, P10; Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9; Park SY, 2005, J NEUROSCI, V25, P5365, DOI 10.1523/JNEUROSCI.1125-05.2005; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; Qiu ZH, 2003, J NEUROIMMUNOL, V139, P51, DOI 10.1016/S0165-5728(03)00158-9; Rapoport M, 2002, P NATL ACAD SCI USA, V99, P6364, DOI 10.1073/pnas.092136199; Rovira C, 2002, BIOCHEM BIOPH RES CO, V296, P1317, DOI 10.1016/S0006-291X(02)02072-7; Rutten BR, 2003, NEUROBIOL DIS, V12, P110, DOI 10.1016/S0969-9961(02)00015-3; SAIDO TC, 1991, BIOMED BIOCHIM ACTA, V50, P485; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Sattler R, 1998, J NEUROCHEM, V71, P2349; SCHEFF SW, 2005, NEUROBIOL AGING, V7, P7; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Selkoe DJ, 2001, NEURON, V32, P177, DOI 10.1016/S0896-6273(01)00475-5; Selkoe DJ, 2001, P NATL ACAD SCI USA, V98, P11039, DOI 10.1073/pnas.211352598; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503; Stutzmann GE, 2005, NEUROSCIENTIST, V11, P110, DOI 10.1177/1073858404270899; Stutzmann GE, 2004, J NEUROSCI, V24, P508, DOI 10.1523/JNEUROSCI.4386-03.2004; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Tiraboschi P, 2000, NEUROLOGY, V55, P1278, DOI 10.1212/WNL.55.9.1278; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsuji T, 1998, NEUROSCI LETT, V248, P109, DOI 10.1016/S0304-3940(98)00348-6; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; Verkhratsky A, 2004, BIOL RES, V37, P693; Walsh DM, 2005, J NEUROSCI, V25, P2455, DOI 10.1523/JNEUROSCI.4391-04.2005; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Westerman MA, 2002, J NEUROSCI, V22, P1858, DOI 10.1523/JNEUROSCI.22-05-01858.2002; Yao PJ, 2004, TRENDS NEUROSCI, V27, P24, DOI 10.1016/j.tins.2003.10.012; Yao PJ, 2003, NEUROBIOL DIS, V12, P97, DOI 10.1016/S0969-9961(02)00009-8; Zhao FY, 2001, J BIOL CHEM, V276, P13810, DOI 10.1074/jbc.M006104200	74	200	211	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28079	28089		10.1074/jbc.M605081200	http://dx.doi.org/10.1074/jbc.M605081200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16864575	hybrid			2022-12-25	WOS:000240534400045
J	Sullivan, MM; Barker, TH; Funk, SE; Karchin, A; Seo, NS; Hook, M; Sanders, J; Starcher, B; Wight, TN; Puolakkainen, P; Sage, EH				Sullivan, Millicent M.; Barker, Thomas H.; Funk, Sarah E.; Karchin, Ari; Seo, Neung S.; Hook, Magnus; Sanders, Joan; Starcher, Barry; Wight, Thomas N.; Puolakkainen, Pauli; Sage, E. Helene			Matricellular hevin regulates decorin production and collagen assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL PROTEOGLYCAN DECORIN; SPARC-NULL MICE; TARGETED DISRUPTION; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; I COLLAGEN; MATRIX; FIBRILLOGENESIS; ADHESION; EXPRESSION	Matricellular proteins such as SPARC, thrombospondin 1 and 2, and tenascin C and X subserve important functions in extracellular matrix synthesis and cellular adhesion to extracellular matrix. By virtue of its reported interaction with collagen I and deadhesive activity on cells, we hypothesized that hevin, a member of the SPARC gene family, regulates dermal extracellular matrix and collagen fibril formation. We present evidence for an altered collagen matrix and levels of the proteoglycan decorin in the normal dermis and dermal wound bed of hevin-null mice. The dermal elastic modulus was also enhanced in hevin-null animals. The levels of decorin protein secreted by hevin-null dermal fibroblasts were increased by exogenous hevin in vitro, data indicating that hevin might regulate both decorin and collagen fibrillogenesis. We also report a decorin-independent function for hevin in collagen fibrillogenesis. In vitro fibrillogenesis assays indicated that hevin enhanced fibril formation kinetics. Furthermore, cell adhesion assays indicated that cells adhered differently to collagen fibrils formed in the presence of hevin. Our observations support the capacity of hevin to modulate the structure of dermal extracellular matrix, specifically by its regulation of decorin levels and collagen fibril assembly.	Benaroya Res Inst Virginia Mason, Hope Heart Program, Seattle, WA 98101 USA; Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30332 USA; Emory Univ, Atlanta, GA 30332 USA; Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; Texas A&M Univ Syst, Hlth Sci Ctr, Ctr Extracellular Matrix Biol, Inst Biosci & Technol, Houston, TX 77030 USA; Univ Texas Hlth Ctr, Dept Biochem, Tyler, TX 75708 USA; Helsinki Cent Univ, Dept Surg, Helsinki 00290, Finland	Benaroya Research Institute; Virginia Mason Medical Center; University System of Georgia; Georgia Institute of Technology; Emory University; University of Washington; University of Washington Seattle; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Sage, EH (corresponding author), Benaroya Res Inst Virginia Mason, Hope Heart Program, 1201 9th Ave, Seattle, WA 98101 USA.	hsage@benaroyaresearch.org	Sullivan, Millicent/D-1568-2012	Sullivan, Millicent/0000-0002-4787-7534	NCI NIH HHS [CA109559] Funding Source: Medline; NIGMS NIH HHS [GM40711, 5F32 GM073363] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA109559] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM073363, R01GM040711] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barker TH, 2005, AM J PATHOL, V166, P923, DOI 10.1016/S0002-9440(10)62312-7; BIDANSET DJ, 1992, J CELL BIOL, V118, P1523, DOI 10.1083/jcb.118.6.1523; Bradshaw AD, 2003, J INVEST DERMATOL, V120, P949, DOI 10.1046/j.1523-1747.2003.12241.x; Brekken RA, 2004, J HISTOCHEM CYTOCHEM, V52, P735, DOI 10.1369/jhc.3A6245.2004; Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI200316804; Clark RAF, 1996, BRIT J DERMATOL, V135, P46; Corbett SA, 1997, J BIOL CHEM, V272, P24999, DOI 10.1074/jbc.272.40.24999; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DAYAN D, 1989, HISTOCHEMISTRY, V93, P27, DOI 10.1007/BF00266843; Eming SA, 2004, EXPERT OPIN BIOL TH, V4, P1373, DOI 10.1517/14712598.4.9.1373; Evanko SP, 1999, ARTERIOSCL THROM VAS, V19, P1004, DOI 10.1161/01.ATV.19.4.1004; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Girard JP, 1996, J BIOL CHEM, V271, P4511; GIRARD JP, 1995, IMMUNITY, V2, P113, DOI 10.1016/1074-7613(95)90083-7; Graham HK, 2000, J MOL BIOL, V295, P891, DOI 10.1006/jmbi.1999.3384; GRINNELL F, 1989, EXP CELL RES, V181, P483, DOI 10.1016/0014-4827(89)90105-5; Gu JG, 1996, J BIOCHEM-TOKYO, V119, P743; Guidetti G, 2002, BLOOD, V100, P1707, DOI 10.1182/blood.V100.5.1707.h81702001707_1707_1714; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hambrock HO, 2003, J BIOL CHEM, V278, P11351, DOI 10.1074/jbc.M212291200; JOHNSTON IG, 1990, NEURON, V4, P165, DOI 10.1016/0896-6273(90)90452-L; KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137; Keene DR, 1998, J HISTOCHEM CYTOCHEM, V46, P215, DOI 10.1177/002215549804600210; KING GS, 1980, CONNECT TISSUE RES, V7, P263, DOI 10.3109/03008208009152362; Kinsella MG, 2004, CRIT REV EUKAR GENE, V14, P203, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i3.40; Kinsella MG, 2000, J BIOL CHEM, V275, P13924, DOI 10.1074/jbc.275.18.13924; Merle B, 1997, J CELL BIOCHEM, V67, P75; Minamitani T, 2004, EXP CELL RES, V298, P305, DOI 10.1016/j.yexcr.2004.04.030; Mothe AJ, 2001, HEARING RES, V155, P161, DOI 10.1016/S0378-5955(01)00246-5; Neame PJ, 2000, CELL MOL LIFE SCI, V57, P859, DOI 10.1007/s000180050048; Puolakkainen PA, 2005, J HISTOCHEM CYTOCHEM, V53, P571, DOI 10.1369/jhc.4A6425.2005; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; Reed CC, 2002, GLYCOCONJUGATE J, V19, P249, DOI 10.1023/A:1025383913444; RIDGE MICHAEL, 1964, BIORHEOLOGY, V2, P67; Sanders JE, 1997, IEEE T BIO-MED ENG, V44, P290, DOI 10.1109/10.563298; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; Schonherr E, 1999, EUR J CELL BIOL, V78, P44, DOI 10.1016/S0171-9335(99)80006-5; Sini P, 1997, GLYCOCONJUGATE J, V14, P871, DOI 10.1023/A:1018550307649; St Croix B, 2000, SCIENCE, V289, P1197; STARCHER B, 1995, CONNECT TISSUE RES, V31, P133, DOI 10.3109/03008209509028401; Sullivan MM, 2004, INT J BIOCHEM CELL B, V36, P991, DOI 10.1016/j.biocel.2004.01.017; Takeda U, 2002, J INVEST DERMATOL, V119, P678, DOI 10.1046/j.1523-1747.2002.01863.x; TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8; Timpl R., 1987, STRUCTURE FUNCTION C, P105, DOI [10.1016/B978--0--12--481280-2.50008---8, DOI 10.1016/B978--0--12--481280-2.50008---8]; WINNEMOLLER M, 1992, EUR J CELL BIOL, V59, P47; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10	48	53	56	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27621	27632		10.1074/jbc.M510507200	http://dx.doi.org/10.1074/jbc.M510507200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16844696	hybrid			2022-12-25	WOS:000240397700087
J	Tso, SC; Kato, M; Chuang, JL; Chuang, DT				Tso, Shih-Chia; Kato, Masato; Chuang, Jacinta L.; Chuang, David T.			Structural determinants for cross-talk between pyruvate dehydrogenase kinase 3 and lipoyl domain 2 of the human pyruvate dehydrogenase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROLIPOYL ACETYLTRANSFERASE; PHOSPHORYLATION SITES; MAMMALIAN PYRUVATE; PROTEIN-KINASE; ISOENZYMES; COMPONENT; BINDING; ROLES; HEART; ACID	Pyruvate dehydrogenase kinase isoforms (PDK1-4) are the molecular switch that down-regulates activity of the human pyruvate dehydrogenase complex through reversible phosphorylation. We showed previously that binding of the lipoyl domain 2 (L2) of the pyruvate dehydrogenase complex to PDK3 induces a "cross-tail" conformation in PDK3, resulting in an opening of the active site cleft and the stimulation of kinase activity. In the present study, we report that alanine substitutions of Leu-140, Glu-170, and Glu-179 in L2 markedly reduce binding affinities of these L2 mutants for PDK3. Unlike wildtype L2, binding of these L2 mutants to PDK3 does not preferentially reduce the affinity of PDK3 for ADP over ATP. The inefficient removal of product inhibition associated with ADP accounts for the decreased stimulation of PDK3 activity by these L2 variants. Serial truncations of the PDK3 C-terminal tail region either impede or abolish the binding of wild-type L2 to the PDK3 mutants, resulting in the reduction or absence of L2-enhanced kinase activity. Alanine substitutions of residues Leu-27, Phe-32, Phe-35, and Phe-48 in the lipoyl-binding pocket of PDK3 similarly nullify L2 binding and L2-stimulated PDK3 activity. Our results indicate that the above residues in L2 and residues in the C-terminal region and the lipoyl-binding pocket of PDK3 are critical determinants for the cross-talk between L2 and PDK3, which up-regulates PDK3 activity.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chuang, DT (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	david.chuang@utsouthwestern.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062306, R56DK062306] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK62306] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baker JC, 2000, J BIOL CHEM, V275, P15773, DOI 10.1074/jbc.M909488199; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; Harris RA, 2001, ADV ENZYME REGUL, V41, P269, DOI 10.1016/S0065-2571(00)00020-0; Hiromasa Y, 2006, J BIOL CHEM, V281, P12568, DOI 10.1074/jbc.M513514200; Holness MJ, 2003, BIOCHEM SOC T, V31, P1143; Kato M, 2005, EMBO J, V24, P1763, DOI 10.1038/sj.emboj.7600663; Klyuyeva A, 2005, BIOCHEMISTRY-US, V44, P13573, DOI 10.1021/bi0505868; Knoechel TR, 2006, BIOCHEMISTRY-US, V45, P402, DOI 10.1021/bi051402s; Kolobova E, 2001, BIOCHEM J, V358, P69, DOI 10.1042/0264-6021:3580069; Korotchkina LG, 2001, J BIOL CHEM, V276, P37223, DOI 10.1074/jbc.M103069200; LIU SJ, 1995, J BIOL CHEM, V270, P793, DOI 10.1074/jbc.270.2.793; Machius M, 2001, P NATL ACAD SCI USA, V98, P11218, DOI 10.1073/pnas.201220098; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; Popov KM, 1997, ADV SEC MESS PHOSPH, V31, P105; RADKE GA, 1993, BIOCHEM BIOPH RES CO, V190, P982, DOI 10.1006/bbrc.1993.1146; Reed LJ, 2001, J BIOL CHEM, V276, P38329, DOI 10.1074/jbc.R100026200; REED LJ, 1985, CURR TOP CELL REGUL, V27, P41; Roche TE, 2003, EUR J BIOCHEM, V270, P1050, DOI 10.1046/j.1432-1033.2003.03468.x; SALE GJ, 1981, EUR J BIOCHEM, V120, P535, DOI 10.1111/j.1432-1033.1981.tb05733.x; Steussy CN, 2001, J BIOL CHEM, V276, P37443, DOI 10.1074/jbc.M104285200; TEAGUE WM, 1979, BIOCHEM BIOPH RES CO, V87, P244, DOI 10.1016/0006-291X(79)91672-3; Tuganova A, 2005, BIOCHEM J, V387, P147, DOI 10.1042/BJ20040805; Tuganova A, 2002, BIOCHEM J, V366, P129, DOI 10.1042/BJ20020301; Wu PF, 1998, BIOCHEM J, V329, P197, DOI 10.1042/bj3290197; YEAMAN SJ, 1978, BIOCHEMISTRY-US, V17, P2364, DOI 10.1021/bi00605a017	25	11	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27197	27204		10.1074/jbc.M604339200	http://dx.doi.org/10.1074/jbc.M604339200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16849321	hybrid			2022-12-25	WOS:000240397700047
J	Cintron, NS; Toft, D				Cintron, Nela S.; Toft, David			Defining the requirements for Hsp40 and Hsp70 in the Hsp90 chaperone pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; STEROID-RECEPTOR COMPLEXES; PROGESTERONE-RECEPTOR; MOLECULAR CHAPERONE; SACCHAROMYCES-CEREVISIAE; COCHAPERONE DNAJ; BINDING; HOMOLOG; YDJ1; SIS1	The Hsp90 chaperoning pathway and its model client substrate, the progesterone receptor ( PR), have been used extensively to study chaperone complex formation and maturation of a client substrate in a near native state. This chaperoning pathway can be reconstituted in vitro with the addition of five proteins plus ATP: Hsp40, Hsp70, Hop, Hsp90, and p23. The addition of these proteins is necessary to reconstitute hormone-binding capacity to the immuno-isolated PR. It was recently shown that the first step for the recognition of PR by this system is binding by Hsp40. We compared type I and type II Hsp40 proteins and created point mutations in Hsp40 and Hsp70 to understand the requirements for this first step. The type I proteins, Ydj1 and DjA1 ( HDJ2), and a type II, DjB1 (HDJ1), act similarly in promoting hormone binding and Hsp70 association to PR, while having different binding characteristics to PR. Ydj1 and DjA1 bind tightly to PR whereas the binding of DjB1 apparently has rapid on and off rates and its binding cannot be observed by antibody pull-down methods using either purified proteins or cell lysates. Mutation studies indicate that client binding, interactions between Hsp40 and Hsp70, plus ATP hydrolysis by Hsp70 are all required to promote conformational maturation of PR via the Hsp90 pathway.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Mayo Grad Sch, Rochester, MN 55905 USA	Mayo Clinic	Toft, D (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Mayo Grad Sch, 200 1st St,SW, Rochester, MN 55905 USA.	toft.david@mayo.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059284] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK59284] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andres DA, 1997, ARCH BIOCHEM BIOPHYS, V346, P113, DOI 10.1006/abbi.1997.0296; Borges JC, 2005, J BIOL CHEM, V280, P13671, DOI 10.1074/jbc.M408349200; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; Chadli A, 2006, MOL CELL BIOL, V26, P1722, DOI 10.1128/MCB.26.5.1722-1730.2006; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Chiosis G, 2004, DRUG DISCOV TODAY, V9, P881, DOI 10.1016/S1359-6446(04)03245-3; CONNEELY OM, 1987, BIOCHEM BIOPH RES CO, V149, P493, DOI 10.1016/0006-291X(87)90395-0; CYR DM, 1994, J BIOL CHEM, V269, P9798; Davis AR, 1998, INT J BIOCHEM CELL B, V30, P1203, DOI 10.1016/S1357-2725(98)00091-0; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Edwards MC, 1997, GENETICS, V147, P1063; Fan CY, 2005, J BIOL CHEM, V280, P695, DOI 10.1074/jbc.M410645200; Fan CY, 2004, MOL BIOL CELL, V15, P761, DOI 10.1091/mbc.E03-03-0146; Fan CY, 2003, CELL STRESS CHAPERON, V8, P309, DOI 10.1379/1466-1268(2003)008<0309:MFROHF>2.0.CO;2; Fliss AE, 1999, J BIOL CHEM, V274, P34045, DOI 10.1074/jbc.274.48.34045; Gee AC, 2001, MOL ENDOCRINOL, V15, P421, DOI 10.1210/me.15.3.421; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; Hennessy F, 2005, PROTEIN SCI, V14, P1697, DOI 10.1110/ps.051406805; Hernandez MP, 2002, J BIOL CHEM, V277, P38294, DOI 10.1074/jbc.M206566200; Hernandez MP, 2002, J BIOL CHEM, V277, P11873, DOI 10.1074/jbc.M111445200; Hu JM, 2004, J VIROL, V78, P13122, DOI 10.1128/JVI.78.23.13122-13131.2004; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; Kim SY, 2002, J BIOL CHEM, V277, P44778, DOI 10.1074/jbc.M206176200; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; Landry SJ, 2003, BIOCHEMISTRY-US, V42, P4926, DOI 10.1021/bi027070y; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; Lee S, 2002, J BIOL CHEM, V277, P21675, DOI 10.1074/jbc.M111075200; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; Morishima Y, 2003, J BIOL CHEM, V278, P48754, DOI 10.1074/jbc.M309814200; Murphy PJM, 2003, J BIOL CHEM, V278, P34764, DOI 10.1074/jbc.M304469200; OBrien MC, 1996, J BIOL CHEM, V271, P15874, DOI 10.1074/jbc.271.27.15874; Odunuga OO, 2004, BIOESSAYS, V26, P1058, DOI 10.1002/bies.20107; Ohtsuka K, 2000, CELL STRESS CHAPERON, V5, P98, DOI 10.1379/1466-1268(2000)005<0098:MHDHCO>2.0.CO;2; Prapapanich V, 1998, MOL CELL BIOL, V18, P944, DOI 10.1128/MCB.18.2.944; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; Pratt WB, 2004, ESSAYS BIOCHEM, V40, P41, DOI 10.1042/bse0400041; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; RAABE T, 1991, NUCLEIC ACIDS RES, V19, P6645, DOI 10.1093/nar/19.23.6645; SCHOWALTER DB, 1991, J BIOL CHEM, V266, P21165; SISSON TH, 1990, J IMMUNOL METHODS, V127, P215, DOI 10.1016/0022-1759(90)90071-3; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; Smith DF, 2004, CELL STRESS CHAPERON, V9, P109, DOI 10.1379/CSC-31.1; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Suh WC, 1999, J BIOL CHEM, V274, P30534, DOI 10.1074/jbc.274.43.30534; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549; Sullivan WP, 2002, J BIOL CHEM, V277, P45942, DOI 10.1074/jbc.M207754200; Terada K, 2000, J BIOL CHEM, V275, P24728, DOI 10.1074/jbc.M002021200; Terada K, 2005, EMBO J, V24, P611, DOI 10.1038/sj.emboj.7600549; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Workman P, 2004, CANCER LETT, V206, P149, DOI 10.1016/j.canlet.2003.08.032; Yan W, 1999, MOL CELL BIOL, V19, P7751; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492; Zhao RM, 2005, CELL, V120, P715, DOI 10.1016/j.cell.2004.12.024	62	52	53	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26235	26244		10.1074/jbc.M605417200	http://dx.doi.org/10.1074/jbc.M605417200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16854979	hybrid			2022-12-25	WOS:000240249500040
J	Gonzalez, RR; Cherfils, S; Escobar, M; Yoo, JH; Carino, C; Styer, AK; Sullivan, BT; Sakamoto, H; Olawaiye, A; Serikawa, T; Lynch, MP; Rueda, BR				Gonzalez, Ruben R.; Cherfils, Salandre; Escobar, Maria; Yoo, Jin H.; Carino, Cecilia; Styer, Aaron K.; Sullivan, Brian T.; Sakamoto, Hideo; Olawaiye, Alex; Serikawa, Takehiro; Lynch, Maureen P.; Rueda, Bo R.			Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; FEMALE MICE; UP-REGULATION; CYCLIN D1; PROLIFERATION; ACTIVATION; SEQUENCES; ISOFORMS; PEPTIDE; CASCADE	To gain insight into the mechanism(s) by which leptin contributes to mammary tumor (MT) development we investigated the effects of leptin, kinase inhibitors, and/or leptin receptor antagonists (LPrA2) on 4T1 mouse mammary cancer cells in vitro and LPrA2 on 4T1-MT development in vivo. Leptin increases the expression of vascular endothelial growth factor (VEGF), its receptor (VEGF-R2), and cyclin D1 through phosphoinositide 3-kinase, Janus kinase 2/signal transducer and activator of transcription 3, and/or extracellular signal-activated kinase 1/2 signaling pathways. In contrast to leptin-induced levels of cyclin D1 the changes in VEGF or VEGF-R2 were more dependent on specific signaling pathways. Incubation of 4T1 cells with anti-VEGF-R2 antibody increased leptin-mediated VEGF expression suggesting an autocrine/paracrine loop. Pretreatment of syngeneic mice with LPrA2 prior to inoculation with 4T1 cells delayed the development and slowed the growth of MT (up to 90%) compared with controls. Serum VEGF levels and VEGF/VEGF-R2 expression in MT were significantly lower in mice treated with LPrA2. Interestingly, LPrA2-induced effects were more pronounced in vivo than in vitro suggesting paracrine actions in stromal, endothelial, and/or inflammatory cells that may impact the growth of MT. Although all the mechanism(s) by which leptin contributes to tumor development are unknown, it appears leptin stimulates an increase in cell numbers, and the expression of VEGF/VEGF-R2. Together, these results provide further evidence suggesting leptin is a MT growth-promoting factor. The inhibition of leptin signaling could serve as a potential adjuvant therapy for treatment of breast cancer and/or provide a new target for the designing strategies to prevent MT development.	Boston Biomed Res Inst, Watertown, MA 02472 USA; Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Boston Biomedical Research Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Rueda, BR (corresponding author), Morehouse Sch Med, 720 Westview Dr, Atlanta, GA 30310 USA.	brueda@partners.org						Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 2000, J BIOL CHEM, V275, P40649, DOI 10.1074/jbc.M007577200; Bjorbaek C, 2001, J BIOL CHEM, V276, P4747, DOI 10.1074/jbc.M007439200; Carpenter LR, 1998, P NATL ACAD SCI USA, V95, P6061, DOI 10.1073/pnas.95.11.6061; Catalano S, 2004, J BIOL CHEM, V279, P19908, DOI 10.1074/jbc.M313191200; Catalano S, 2003, J BIOL CHEM, V278, P28668, DOI 10.1074/jbc.M301695200; Chen CC, 2006, BREAST CANCER RES TR, V98, P121, DOI 10.1007/s10549-005-9139-y; Cleary MP, 2004, NUTR CANCER, V50, P174, DOI 10.1207/s15327914nc5002_7; Cleary MP, 2004, EXP BIOL MED, V229, P182, DOI 10.1177/153537020422900207; Cleary MP, 2003, BREAST CANCER RES TR, V77, P205, DOI 10.1023/A:1021891825399; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; Dumitrescu RG, 2005, J CELL MOL MED, V9, P208, DOI 10.1111/j.1582-4934.2005.tb00350.x; Eisenberg A, 2004, FEBS LETT, V565, P139, DOI 10.1016/j.febslet.2004.03.089; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Gonzalez RR, 2004, ENDOCRINOLOGY, V145, P3850, DOI 10.1210/en.2004-0383; Gonzalez RR, 2003, ENDOCRINE, V21, P185, DOI 10.1385/ENDO:21:2:185; Gonzalez RR, 2001, ENDOCRINE, V16, P21, DOI 10.1385/ENDO:16:1:21; Hu X, 2002, J NATL CANCER I, V94, P1704, DOI 10.1093/jnci/94.22.1704; Ishikawa M, 2004, CLIN CANCER RES, V10, P4325, DOI 10.1158/1078-0432.CCR-03-0749; Kloek C, 2002, J BIOL CHEM, V277, P41547, DOI 10.1074/jbc.M205148200; KLURFELD DM, 1991, P SOC EXP BIOL MED, V196, P381; Miyoshi Y, 2006, INT J CANCER, V118, P1414, DOI 10.1002/ijc.21543; Okumura M, 2002, BBA-MOL CELL RES, V1592, P107, DOI 10.1016/S0167-4889(02)00276-8; Pecheur I, 2002, FASEB J, V16, P1266, DOI 10.1096/fj.01-0911fje; Ramos MP, 2005, ENDOCRINOLOGY, V146, P694, DOI 10.1210/en.2004-1186; Rosenau F, 2004, CHEMBIOCHEM, V5, P153, DOI 10.1002/cbic.200300761; Saitoh M, 2005, ENDOCRINOLOGY, V146, P4917, DOI 10.1210/en.2004-1535; SEILKOP SK, 1995, FUND APPL TOXICOL, V24, P247, DOI 10.1006/faat.1995.1028; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Somasundar P, 2004, J SURG RES, V118, P71, DOI 10.1016/j.jss.2004.01.017; Somasundar P, 2004, J SURG RES, V116, P337, DOI 10.1016/j.jss.2003.09.004; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Veronese FM, 2002, ADV DRUG DELIVER REV, V54, P453; Wang YP, 1997, J BIOL CHEM, V272, P16216, DOI 10.1074/jbc.272.26.16216; Yin N, 2004, CANCER RES, V64, P5870, DOI 10.1158/0008-5472.CAN-04-0655; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416	40	191	199	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26320	26328		10.1074/jbc.M601991200	http://dx.doi.org/10.1074/jbc.M601991200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16825198	hybrid			2022-12-25	WOS:000240249500049
J	Holinstat, M; Voss, B; Bilodeau, ML; McLaughlin, JN; Cleator, J; Hamm, HE				Holinstat, Michael; Voss, Bryan; Bilodeau, Matthew L.; McLaughlin, Joseph N.; Cleator, John; Hamm, Heidi E.			PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y(12) receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE CORONARY SYNDROMES; THROMBIN RECEPTOR; INTEGRIN ALPHA(IIB)BETA(3); CARDIOVASCULAR EVENTS; RAP1B; TRIAL; RISK; PROTEIN; CLONING; ADP	Regulation of platelet activation plays a central role in hemostasis and pathophysiological processes such as coronary artery disease. Thrombin is the most potent activator of platelets. Human platelets express two thrombin receptors, PAR1 and PAR4, both of which signal platelet activation. Evidence is lacking on the mechanism by which PAR1 and PAR4 may differentially signal platelet aggregation. Here we show that at the relatively high concentration of agonist most likely found at the site of a local thrombus, dual inhibition of the P2Y(12) receptor and calcium mobilization result in a complete inhibition of PAR4-induced aggregation, while having no effect on either thrombin or PAR1-mediated platelet aggregation. Both PAR1-and PAR4-mediated aggregation are independent of calcium mobilization. Furthermore, we show that P2Y(12) receptor activation is not required for protease-activated receptor-mediated aggregation at higher agonist concentrations and is only partially required for Rap1 as well as GPIIbIIIa activation. P2Y(12) receptor inhibitors clinically in use such as clopidogrel are postulated to decrease platelet aggregation through partial inhibition of PAR1 signaling. Our data, however, indicate that at high local concentrations of thrombin, it is the signaling through PAR4 rather than PAR1 that may be regulated through purinergic feedback. Thus, our data identify an intra-platelet mechanism that may function as a future site for therapeutic intervention.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Med, Div Cardiovasc Med, Nashville, TN 37232 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60608 USA	Vanderbilt University; Vanderbilt University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Hamm, HE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, 23rd Ave S & Pierce,442 Robinson Res Bldg, Nashville, TN 37232 USA.	heidi.hamm@vanderbilt.edu	Hamm, Heidi E/G-2374-2014		NATIONAL EYE INSTITUTE [R01EY010291] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL082068, T32HL076133, R01HL084388] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY010291, EY010291] Funding Source: Medline; NHLBI NIH HHS [HL-082068-01, T32 HL076133, HL-076133-02, HL084388, F32 HL082068-01, R01 HL084388, F32 HL082068] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adam F, 2003, J THROMB HAEMOST, V1, P798, DOI 10.1046/j.1538-7836.2003.00138.x; Ali A, 2004, J CLIN PHARMACOL, V44, P1328, DOI 10.1177/0091270004269559; Bernardi B, 2006, BLOOD, V107, P2728, DOI 10.1182/blood-2005-07-3023; Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; Boekholdt SM, 2004, AM HEART J, V147, P181, DOI 10.1016/j.ahj.2003.07.008; Brass LF, 2003, CHEST, V124, p18S, DOI 10.1378/chest.124.3_suppl.18S; Chrzanowska-Wodnicka M, 2005, J CLIN INVEST, V115, P680, DOI 10.1172/JCI200522973; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Covic L, 2000, BIOCHEMISTRY-US, V39, P5458, DOI 10.1021/bi9927078; Crittenden JR, 2004, NAT MED, V10, P982, DOI 10.1038/nm1098; DAVEY MG, 1967, NATURE, V216, P857, DOI 10.1038/216857a0; Dorsam RT, 2004, J THROMB HAEMOST, V2, P804, DOI 10.1111/j.1538-7836.2004.00692.x; Dorsam RT, 2004, J CLIN INVEST, V113, P340, DOI 10.1172/JCI200420986; Espana F., 2005, Current Medicinal Chemistry - Cardiovascular & Hematological Agents, V3, P119, DOI 10.2174/1568016053544336; Faruqi TR, 2000, J BIOL CHEM, V275, P19728, DOI 10.1074/jbc.M909960199; Franke B, 2000, MOL CELL BIOL, V20, P779, DOI 10.1128/MCB.20.3.779-785.2000; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; FUSTER V, 1992, NEW ENGL J MED, V326, P310; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Graff J, 2004, THROMB RES, V113, P295, DOI 10.1016/j.thromres.2004.03.014; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Jamieson GA, 1997, THROMB HAEMOSTASIS, V78, P242; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Kim S, 2002, BLOOD, V99, P3629, DOI 10.1182/blood.V99.10.3629; LAPOSATA M, 1983, BLOOD, V62, P549; Larson MK, 2003, BLOOD, V101, P1409, DOI 10.1182/blood-2002-05-1533; Leon MB, 1998, NEW ENGL J MED, V339, P1665, DOI 10.1056/NEJM199812033392303; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Maroo A, 2004, SEMIN THROMB HEMOST, V30, P329, DOI 10.1055/s-2004-831045; Mosesson MW, 2005, J THROMB HAEMOST, V3, P1894, DOI 10.1111/j.1538-7836.2005.01365.x; Murugappan S, 2005, BLOOD, V106, P550, DOI 10.1182/blood-2004-12-4866; Ossovskaya VS, 2004, PHYSIOL REV, V84, P579, DOI 10.1152/physrev.00028.2003; Reed GL, 2004, SEMIN THROMB HEMOST, V30, P441, DOI 10.1055/s-2004-833479; Rosenberg RD, 1999, NEW ENGL J MED, V340, P1555, DOI 10.1056/NEJM199905203402007; Scase TJ, 1997, BLOOD, V90, P2113, DOI 10.1182/blood.V90.5.2113; Schultess J, 2005, BLOOD, V105, P3185, DOI 10.1182/blood-2004-09-3605; SHATTIL SJ, 1987, BLOOD, V70, P307; Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411; Tendera M, 2003, THROMB RES, V110, P355, DOI 10.1016/j.thromres.2003.08.003; van der Meijden PEJ, 2005, THROMB HAEMOSTASIS, V93, P1128, DOI 10.1160/TH04-09-0597; Van Triest M, 2001, METHOD ENZYMOL, V333, P343; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Woulfe D, 2004, J CLIN INVEST, V113, P441, DOI 10.1172/JCI200420267; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; Yusuf S, 2001, NEW ENGL J MED, V345, P494	49	86	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26665	26674		10.1074/jbc.M602174200	http://dx.doi.org/10.1074/jbc.M602174200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16837456	Green Accepted, hybrid			2022-12-25	WOS:000240249500084
J	Ochotny, N; Van Vliet, A; Chan, N; Yao, YQ; Morel, M; Kartner, N; von Schroeder, HP; Heersche, JNM; Manolson, MF				Ochotny, Noelle; Van Vliet, Aaron; Chan, Nelson; Yao, Yeqi; Morel, Mario; Kartner, Norbert; von Schroeder, Herbert P.; Heersche, Johan N. M.; Manolson, Morris F.			Effects of human a3 and a4 mutations that result in osteopetrosis and distal renal tubular acidosis on yeast V-ATPase expression and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; INFANTILE MALIGNANT OSTEOPETROSIS; AUTOSOMAL RECESSIVE OSTEOPETROSIS; AMINO-TERMINAL DOMAIN; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; SUBUNIT VPH1P; GENE ENCODES; IN-VIVO	V-ATPases are multimeric proton pumps. The 100-kDa " a" subunit is encoded by four isoforms (a1-a4) in mammals and two (Vph1p and Stv1p) in yeast. a3 is enriched in osteoclasts and is essential for bone resorption, whereas a4 is expressed in the distal nephron and acidifies urine. Mutations in human a3 and a4 result in osteopetrosis and distal renal tubular acidosis, respectively. Human a3 (G405R and R444L) and a4 (P524L and G820R) mutations were recreated in the yeast ortholog Vph1p, a3 (G424R and R462L), and a4 (W520L and G812R). Mutations in a3 resulted in wild type vacuolar acidification and growth on media containing 4 mM ZnCl2, 200 mM CaCl2, or buffered to pH 7.5 with V-ATPase hydrolytic and pumping activity decreased by 30-35%. Immunoblots confirmed wild type levels for V-ATPase a, A, and B subunits on vacuolar membranes. a4 G812R resulted in defective growth on selective media with V-ATPase hydrolytic and pumping activity decreased by 83-85% yet with wild type levels of a, A, and B subunits on vacuolar membranes. The a4 W520L mutation had defective growth on selective media with no detectable V-ATPase activity and reduced expression of a, A, and B subunits. The a4 W520L mutation phenotypes were dominant negative, as overexpression of wild type yeast a isoforms, Vph1p, or Stv1p, did not restore growth. However, deletion of endoplasmic reticulum assembly factors (Vma12p, Vma21p, and Vma22p) partially restored a and B expression. That a4 W520L affects both V-o and V-1 subunits is a unique phenotype for any V-ATPase subunit mutation and supports the concerted pathway for V-ATPase assembly in vivo.	Univ Toronto, Fac Dent, Res Inst, Toronto, ON M5G 1G6, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5G 1G6, Canada; Univ Toronto, Dept Surg, Toronto, ON M5G 1G6, Canada	University of Toronto; University of Toronto; University of Toronto	Manolson, MF (corresponding author), Univ Toronto, Fac Dent, Res Inst, 124 Edward St, Toronto, ON M5G 1G6, Canada.	m.manolson@utoronto.ca	Ochotny, Noelle/M-6480-2019; von Schroeder, Herbert/AAA-3592-2020	Ochotny, Noelle/0000-0001-7697-4360; Manolson, Morris/0000-0001-8755-5460				BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; Brisseau GF, 1996, J BIOL CHEM, V271, P2005, DOI 10.1074/jbc.271.4.2005; Brown D, 2000, J EXP BIOL, V203, P137; Clarke M, 2002, J CELL SCI, V115, P2893; Del Fattore A, 2006, J MED GENET, V43, P315, DOI 10.1136/jmg.2005.036673; Fasth A, 1999, Pediatr Transplant, V3 Suppl 1, P102; FORGAC M, 1992, J EXP BIOL, V172, P155; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; Graham LA, 2003, J BIOENERG BIOMEMBR, V35, P301, DOI 10.1023/A:1025772730586; Graham LA, 1998, J CELL BIOL, V142, P39, DOI 10.1083/jcb.142.1.39; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Hill K, 2000, EMBO J, V19, P550, DOI 10.1093/emboj/19.4.550; HILL KJ, 1995, J BIOL CHEM, V270, P22329, DOI 10.1074/jbc.270.38.22329; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; HIRATA R, 1993, J BIOL CHEM, V268, P961; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; HO MN, 1993, J BIOL CHEM, V268, P18286; Holliday LS, 2000, J BIOL CHEM, V275, P32331, DOI 10.1074/jbc.M004795200; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Jackson DD, 1997, J BIOL CHEM, V272, P25928, DOI 10.1074/jbc.272.41.25928; Kane PM, 1999, J BIOL CHEM, V274, P17275, DOI 10.1074/jbc.274.24.17275; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P17941, DOI 10.1074/jbc.M010790200; Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Lu M, 2002, J BIOL CHEM, V277, P38409, DOI 10.1074/jbc.M203521200; Malkus P, 2004, MOL BIOL CELL, V15, P5075, DOI 10.1091/mbc.E04-06-0514; Manolson MF, 2003, J BIOL CHEM, V278, P49271, DOI 10.1074/jbc.M309914200; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Michigami T, 2002, BONE, V30, P436, DOI 10.1016/S8756-3282(01)00684-6; Nanda A, 1996, J BIOL CHEM, V271, P15963, DOI 10.1074/jbc.271.27.15963; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Oka T, 2001, J BIOL CHEM, V276, P40050, DOI 10.1074/jbc.M106488200; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Ruf R, 2003, PEDIATR NEPHROL, V18, P105, DOI 10.1007/s00467-002-1018-8; Sambade M, 2004, J BIOL CHEM, V279, P17361, DOI 10.1074/jbc.M314104200; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; Sobacchi C, 2001, HUM MOL GENET, V10, P1767, DOI 10.1093/hmg/10.17.1767; Stehberger PA, 2003, J AM SOC NEPHROL, V14, P3027, DOI 10.1097/01.ASN.0000099375.74789.AB; Stover EH, 2002, J MED GENET, V39, P796, DOI 10.1136/jmg.39.11.796; Sun-Wada GH, 2003, GENE, V302, P147, DOI 10.1016/S0378-1119(02)01099-5; Sun-Wada GH, 2002, J BIOL CHEM, V277, P18098, DOI 10.1074/jbc.M111567200; Susani L, 2004, HUM MUTAT, V24, P225, DOI 10.1002/humu.20076; Taranta A, 2003, AM J PATHOL, V162, P57, DOI 10.1016/S0002-9440(10)63798-4; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Whyteside G, 2005, FEBS LETT, V579, P2981, DOI 10.1016/j.febslet.2005.04.049; Wilhovsky S, 2000, MOL BIOL CELL, V11, P1697, DOI 10.1091/mbc.11.5.1697; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909	61	25	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26102	26111		10.1074/jbc.M601118200	http://dx.doi.org/10.1074/jbc.M601118200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16840787	hybrid			2022-12-25	WOS:000240249500025
J	Braun, RJ; Zischka, H; Madeo, F; Eisenberg, T; Wissing, S; Buttner, S; Engelhardt, SM; Buringer, D; Ueffing, M				Braun, Ralf J.; Zischka, Hans; Madeo, Frank; Eisenberg, Tobias; Wissing, Silke; Buettner, Sabrina; Engelhardt, Silvia M.; Bueringer, Dietmute; Ueffing, Marius			Crucial mitochondrial impairment upon CDC48 mutation in apoptotic yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VALOSIN-CONTAINING PROTEIN; PROGRAMMED CELL-DEATH; CYTOCHROME-C RELEASE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; FRONTOTEMPORAL DEMENTIA; POLYACRYLAMIDE-GELS; ACTIN CYTOSKELETON; OXIDATIVE STRESS; ER	Mutation in CDC48 (cdc48(S565G)), a gene essential in the endoplasmic reticulum (ER)-associated protein degradation (ERAD) pathway, led to the discovery of apoptosis as a mechanism of cell death in the unicellular organism Saccharomyces cerevisiae. Elucidating Cdc48p-mediated apoptosis in yeast is of particular interest, because Cdc48p is the highly conserved yeast orthologue of human valosin-containing protein (VCP), a pathological effector for polyglutamine disorders and myopathies. Here we show distinct proteomic alterations in mitochondria in the cdc48S565G yeast strain. These observed molecular alterations can be related to functional impairment of these organelles as suggested by respiratory deficiency of cdc48S565G cells. Mitochondrial dysfunction in the cdc48S565G strain is accompanied by structural damage of mitochondria indicated by the accumulation of cytochrome c in the cytosol and mitochondrial enlargement. We demonstrate accumulation of reactive oxygen species produced predominantly by the cytochrome bc(1) complex of the mitochondrial respiratory chain as suggested by the use of inhibitors of this complex. Concomitantly, emergence of caspase-like enzymatic activity occurs suggesting a role for caspases in the cell death process. These data strongly point for the first time to a mitochondrial involvement in Cdc48p/VCP-dependent apoptosis.	GSF, Natl Res Ctr Environm & Hlth, Inst Human Genet, D-85764 Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Toxicol, D-85764 Munich, Germany; Graz Univ, Inst Mol Biosci, A-8010 Graz, Austria; Univ Tubingen, Inst Physiol Chem, D-72076 Tubingen, Germany; Max Planck Inst Neurobiol, Dept Syst & Computat Neurobiol, D-82152 Martinsried, Germany; Tech Univ Munich, Inst Human Genet, Klinikum Rechts Isar, D-81675 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Graz; Eberhard Karls University of Tubingen; Max Planck Society; Technical University of Munich	Zischka, H (corresponding author), GSF, Natl Res Ctr Environm & Hlth, Inst Human Genet, Ingolstaedter Landstr 1, D-85764 Munich, Germany.	zischka@gsf.de	Eisenberg, Tobias/AAV-7806-2021; Braun, Ralf/B-9123-2008; Zischka, Hans/M-1490-2017	Braun, Ralf/0000-0003-4234-8163; Zischka, Hans/0000-0002-4047-1566; Madeo, Frank/0000-0002-5070-1329; Eisenberg, Tobias/0000-0003-3559-1130; Buttner, Sabrina/0000-0002-2786-8542				Arevalo-Rodriguez M, 2004, FRONT BIOSCI-LANDMRK, V9, P2420, DOI 10.2741/1405; Barros MH, 2003, FREE RADICAL BIO MED, V35, P179, DOI 10.1016/S0891-5849(03)00307-1; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Boldogh IR, 2001, P NATL ACAD SCI USA, V98, P3162, DOI 10.1073/pnas.051494698; Boya P, 2002, CELL DEATH DIFFER, V9, P465, DOI 10.1038/sj.cdd.4401006; Breitenbach M, 2005, TRENDS CELL BIOL, V15, P637, DOI 10.1016/j.tcb.2005.09.011; BYERS B, 1991, GUIDE YEAST GENETICS, P603; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15807, DOI 10.1021/bi990962m; Drakulic T, 2005, FEMS YEAST RES, V5, P1215, DOI 10.1016/j.femsyr.2005.06.001; Elkabetz Y, 2004, J BIOL CHEM, V279, P3980, DOI 10.1074/jbc.M309938200; Fang J, 2003, FREE RADICAL BIO MED, V34, P478, DOI 10.1016/S0891-5849(02)01328-X; FARBER JL, 1994, ENVIRON HEALTH PERSP, V102, P17, DOI 10.2307/3432207; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; Gourlay CW, 2004, J CELL BIOL, V164, P803, DOI 10.1083/jcb.200310148; Graack HR, 1998, BIOCHEM J, V329, P433, DOI 10.1042/bj3290433; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Haynes CM, 2004, MOL CELL, V15, P767, DOI 10.1016/j.molcel.2004.08.025; Higashiyama H, 2002, CELL DEATH DIFFER, V9, P264, DOI 10.1038/sj.cdd.4400955; Hirabayashi M, 2001, CELL DEATH DIFFER, V8, P977, DOI 10.1038/sj.cdd.4400907; Imamura S, 2003, FEBS LETT, V549, P14, DOI 10.1016/S0014-5793(03)00723-3; Jana NR, 2001, HUM MOL GENET, V10, P1049, DOI 10.1093/hmg/10.10.1049; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Kussmann M, 2000, METH MOL B, V146, P405, DOI 10.1385/1-59259-045-4:405; Lamb JR, 2001, J BIOL CHEM, V276, P21512, DOI 10.1074/jbc.M100235200; Laun P, 2005, FEMS YEAST RES, V5, P1261, DOI 10.1016/j.femsyr.2005.07.006; Ludovico P, 2005, IUBMB LIFE, V57, P129, DOI 10.1080/15216540500090553; Ludovico P, 2002, MOL BIOL CELL, V13, P2598, DOI 10.1091/mbc.E01-12-0161; Madeo F, 1997, GENE, V204, P145, DOI 10.1016/S0378-1119(97)00535-0; Madeo F, 2004, CURR OPIN MICROBIOL, V7, P655, DOI 10.1016/j.mib.2004.10.012; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Miyake T, 1999, YEAST, V15, P1449, DOI 10.1002/(SICI)1097-0061(199910)15:14<1449::AID-YEA469>3.0.CO;2-S; Mizuno Y, 2003, NEUROSCI LETT, V343, P77, DOI 10.1016/S0304-3940(03)00280-5; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Nicchitta CV, 2002, CURR OPIN CELL BIOL, V14, P412, DOI 10.1016/S0955-0674(02)00353-8; OGUR M, 1956, J BACTERIOL, V72, P500, DOI 10.1128/JB.72.4.500-504.1956; Oxelmark E, 2000, MOL CELL BIOL, V20, P7784, DOI 10.1128/MCB.20.20.7784-7797.2000; Pozniakovsky AI, 2005, J CELL BIOL, V168, P257, DOI 10.1083/jcb.200408145; Rabilloud T, 2001, PROTEOMICS, V1, P699, DOI 10.1002/1615-9861(200104)1:5<699::AID-PROT699>3.3.CO;2-3; Richly H, 2005, CELL, V120, P73, DOI 10.1016/j.cell.2004.11.013; Rinnerthaler M, 2006, BBA-BIOENERGETICS, V1757, P631, DOI 10.1016/j.bbabio.2006.05.022; RUOHOLA H, 1987, P NATL ACAD SCI USA, V84, P8468, DOI 10.1073/pnas.84.23.8468; Schroder R, 2005, ANN NEUROL, V57, P457, DOI 10.1002/ana.20407; Schubert A, 2004, CANCER RES, V64, P85, DOI 10.1158/0008-5472.CAN-03-0476; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Wakabayashi T, 1999, ACTA BIOCHIM POL, V46, P223, DOI 10.18388/abp.1999_4156; Watts GDJ, 2004, NAT GENET, V36, P377, DOI 10.1038/ng1332; Weinberger M, 2003, IUBMB LIFE, V55, P467, DOI 10.1080/15216540310001612336; Woodman PG, 2003, J CELL SCI, V116, P4283, DOI 10.1242/jcs.00817; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; ZELENAYATROITSKAYA O, 1995, EMBO J, V14, P3268, DOI 10.1002/j.1460-2075.1995.tb07330.x; Zischka H, 2003, PROTEOMICS, V3, P906, DOI 10.1002/pmic.200300376	57	72	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25757	25767		10.1074/jbc.M513699200	http://dx.doi.org/10.1074/jbc.M513699200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16822868	hybrid			2022-12-25	WOS:000240031300078
J	Lammerding, J; Fong, LG; Ji, JY; Reue, K; Stewart, CL; Young, SG; Lee, RT				Lammerding, Jan; Fong, Loren G.; Ji, Julie Y.; Reue, Karen; Stewart, Colin L.; Young, Stephen G.; Lee, Richard T.			Lamins A and C but not lamin B1 regulate nuclear mechanics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DREIFUSS MUSCULAR-DYSTROPHY; GILFORD-PROGERIA-SYNDROME; DILATED CARDIOMYOPATHY; BUILDING-BLOCKS; HUMAN-DISEASE; PRELAMIN-A; ENVELOPE; CELLS; LAMINOPATHIES; MUTATIONS	Mutations in the nuclear envelope proteins lamins A and C cause a broad variety of human diseases, including Emery-Dreifuss muscular dystrophy, dilated cardiomyopathy, and Hutchinson-Gilford progeria syndrome. Cells lacking lamins A and C have reduced nuclear stiffness and increased nuclear fragility, leading to increased cell death under mechanical strain and suggesting a potential mechanism for disease. Here, we investigated the contribution of major lamin subtypes (lamins A, C, and B1) to nuclear mechanics by analyzing nuclear shape, nuclear dynamics over time, nuclear deformations under strain, and cell viability under prolonged mechanical stimulation in cells lacking both lamins A and C, cells lacking only lamin A (i.e. "lamin C-only" cells), cells lacking wild-type lamin B1, and wild-type cells. Lamin A/C-deficient cells exhibited increased numbers of misshapen nuclei and had severely reduced nuclear stiffness and decreased cell viability under strain. Lamin C-only cells had slightly abnormal nuclear shape and mildly reduced nuclear stiffness but no decrease in cell viability under strain. Interestingly, lamin B1-deficient cells exhibited normal nuclear mechanics despite having a significantly increased frequency of nuclear blebs. Our study indicates that lamins A and C are important contributors to the mechanical stiffness of nuclei, whereas lamin B1 contributes to nuclear integrity but not stiffness.	Harvard Univ, Sch Med, Div Cardiovasc, Dept Med, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Cambridge, MA 02139 USA; Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90095 USA; Vet Affairs Greater Los Angelese Healthcare Syst, Los Angeles, CA 90073 USA; NCI, Canc & Dev Biol Lab, Frederick, MD 21702 USA	Harvard University; Harvard University; Brigham & Women's Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lammerding, J (corresponding author), Partners Res Facil, Rm 283,65 Landsdowne St, Cambridge, MA 02139 USA.	jlammerding@rics.bwh.harvard.edu	Lammerding, Jan/A-9498-2016	Lammerding, Jan/0000-0003-4335-8611; Young, Stephen/0000-0001-7270-3176	NCI NIH HHS [CA099506] Funding Source: Medline; NHLBI NIH HHS [HL073809, HL64858, R01 HL082792] Funding Source: Medline; NIAID NIH HHS [AI05438] Funding Source: Medline; NIAMS NIH HHS [AR050200] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010377, R01CA099506] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082792, P01HL064858, R01HL073809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arimura T, 2005, HUM MOL GENET, V14, P155, DOI 10.1093/hmg/ddi017; Broers JLV, 2005, EXP CELL RES, V304, P582, DOI 10.1016/j.yexcr.2004.11.020; Broers JLV, 2004, J PATHOL, V204, P478, DOI 10.1002/path.1655; Broers JLV, 2004, HUM MOL GENET, V13, P2567, DOI 10.1093/hmg/ddh295; Broers JLV, 1997, HISTOCHEM CELL BIOL, V107, P505, DOI 10.1007/s004180050138; Burke B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/nrm879; Delbarre E, 2006, HUM MOL GENET, V15, P1113, DOI 10.1093/hmg/ddl026; DIAZ G, 1989, COMPUT BIOMED RES, V22, P405, DOI 10.1016/0010-4809(89)90034-7; Fidzianska A, 2003, J NEUROL SCI, V210, P47, DOI 10.1016/S0022-510X(03)00012-1; Fidzianska A, 1998, J NEUROL SCI, V159, P88, DOI 10.1016/S0022-510X(98)00130-0; Fong LG, 2004, P NATL ACAD SCI USA, V101, P18111, DOI 10.1073/pnas.0408558102; Fong LG, 2006, J CLIN INVEST, V116, P743, DOI 10.1172/JCI27125; GEORGATOS SD, 1988, P NATL ACAD SCI USA, V85, P4325, DOI 10.1073/pnas.85.12.4325; Goldman RD, 2002, GENE DEV, V16, P533, DOI 10.1101/gad.960502; Goldman RD, 2004, P NATL ACAD SCI USA, V101, P8963, DOI 10.1073/pnas.0402943101; Gruenbaum Y, 2005, NAT REV MOL CELL BIO, V6, P21, DOI 10.1038/nrm1550; Harborth J, 2001, J CELL SCI, V114, P4557; Hutchison CJ, 2004, NAT CELL BIOL, V6, P1062, DOI 10.1038/ncb1104-1062; Hutchison CJ, 2002, NAT REV MOL CELL BIO, V3, P848, DOI 10.1038/nrm950; KROHNE G, 1987, EMBO J, V6, P3801, DOI 10.1002/j.1460-2075.1987.tb02716.x; Lammerding J, 2005, J CELL BIOL, V170, P781, DOI 10.1083/jcb.200502148; Lammerding J, 2004, J CLIN INVEST, V113, P370, DOI 10.1172/JCI200419670; Melcon G, 2006, HUM MOL GENET, V15, P637, DOI 10.1093/hmg/ddi479; Motsch I, 2005, EUR J CELL BIOL, V84, P765, DOI 10.1016/j.ejcb.2005.04.004; Muchir A, 2004, PHYSIOLOGY, V19, P309, DOI 10.1152/physiol.00022.2004; Niebroj-Dobosz I, 2003, Acta Myol, V22, P52; Nikolova V, 2004, J CLIN INVEST, V113, P357, DOI 10.1172/JCI200419448; Ostlund C, 2006, BIOCHEMISTRY-US, V45, P1374, DOI 10.1021/bi052156n; Pugh GE, 1997, J CELL SCI, V110, P2483; Raharjo WH, 2001, J CELL SCI, V114, P4447; Schirmer EC, 2004, J BIOL CHEM, V279, P42811, DOI 10.1074/jbc.M407705200; Schutz W, 2005, EUR J CELL BIOL, V84, P649, DOI 10.1016/j.ejcb.2005.03.001; STEWART C, 1987, CELL, V51, P383, DOI 10.1016/0092-8674(87)90634-9; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Tsai MY, 2006, SCIENCE, V311, P1887, DOI 10.1126/science.1122771; Vaughan OA, 2001, J CELL SCI, V114, P2577; Vergnes L, 2004, P NATL ACAD SCI USA, V101, P10428, DOI 10.1073/pnas.0401424101; Vigouroux C, 2001, J CELL SCI, V114, P4459; WALKER PR, 1993, EXP CELL RES, V207, P142, DOI 10.1006/excr.1993.1173; Worman HJ, 2002, TRENDS CELL BIOL, V12, P591, DOI 10.1016/S0962-8924(02)02401-7; YE QA, 1995, EXP CELL RES, V219, P292, DOI 10.1006/excr.1995.1230; Zastrow MS, 2004, J CELL SCI, V117, P979, DOI 10.1242/jcs.01102	42	446	452	2	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25768	25780		10.1074/jbc.M513511200	http://dx.doi.org/10.1074/jbc.M513511200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16825190	hybrid			2022-12-25	WOS:000240031300079
J	Vandebroek, T; Terwel, D; Vanhelmont, T; Gysemans, M; Van Haesendonck, C; Engelborghs, Y; Winderickx, J; Van Leuven, F				Vandebroek, Tom; Terwel, Dick; Vanhelmont, Thomas; Gysemans, Maarten; Van Haesendonck, Chris; Engelborghs, Yves; Winderickx, Joris; Van Leuven, Fred			Microtubule binding and clustering of human Tau-4R and Tau-P301L proteins isolated from yeast deficient in orthologues of glycogen synthase kinase-3 beta or cdk5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE KINASE 3-BETA; TRANSGENIC MICE; FTDP-17 MUTATIONS; ALZHEIMERS-DISEASE; PHOSPHORYLATION; ABILITY; HYPERPHOSPHORYLATION; AXONOPATHY; TRANSPORT; FILAMENTS	Phosphorylation of Tau protein and binding to microtubules is complex in neurons and was therefore studied in the less complicated model of humanized yeast. Human Tau was readily phosphorylated at pathological epitopes, but in opposite directions regulated by kinases Mds1 and Pho85, orthologues of glycogen synthase kinase-3 beta and cdk5, respectively (1). We isolated recombinant Tau-4R and mutant Tau-P301L from wild type, Delta mds1 and Delta pho85 yeast strains and measured binding to Taxol-stabilized mammalian microtubules in relation to their phosphorylation patterns. Tau-4R isolated from yeast lacking mds1 was less phosphorylated and bound more to microtubules than Tau-4R isolated from wild type yeast. Paradoxically, phosphorylation of Tau-4R isolated from kinase Pho85-deficient yeast was dramatically increased resulting in very poor binding to microtubules. Dephosphorylation promoted binding to microtubules to uniform high levels, excluding other modifications. Isolated hyperphosphorylated, conformationally altered Tau-4R completely failed to bind microtubules. In parallel to Tau-4R, we expressed, isolated, and analyzed mutant Tau-P301L. Total dephosphorylated Tau-4R and Tau-P301L bound to microtubules very similarly. Surprisingly, Tau-P301L isolated from all yeast strains bound to microtubules more extensively than Tau-4R. Atomic force microscopy demonstrated, however, that the high apparent binding of Tau-P301L was due to aggregation on the microtubules, causing their deformation and bundling. Our data explain the pathological presence of granular Tau aggregates in neuronal processes in tauopathies.	Katholieke Univ Leuven, Expt Genet Grp, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Lab Funct Biol, B-3001 Heverlee, Belgium; Katholieke Univ Leuven, Lab Solid State Phys & Magnetism, B-3001 Heverlee, Belgium; Katholieke Univ Leuven, Lab Biomol Dynam, B-3001 Heverlee, Belgium	KU Leuven; KU Leuven; KU Leuven; KU Leuven	Van Leuven, F (corresponding author), KULeuven Campus,Campus Gasthuisberg ON1-06-602, B-3000 Louvain, Belgium.	fredvl@med.kuleuven.be						Ackmann M, 2000, J BIOL CHEM, V275, P30335, DOI 10.1074/jbc.M002590200; Alonso AD, 2004, J BIOL CHEM, V279, P34873, DOI 10.1074/jbc.M405131200; Arrasate M, 1999, FEBS LETT, V446, P199, DOI 10.1016/S0014-5793(99)00210-0; Baas PW, 2005, TRENDS CELL BIOL, V15, P183, DOI 10.1016/j.tcb.2005.02.001; Barghorn S, 2000, BIOCHEMISTRY-US, V39, P11714, DOI 10.1021/bi000850r; Boekhoorn K, 2006, J NEUROSCI, V26, P3514, DOI 10.1523/JNEUROSCI.5425-05.2006; Bunker JM, 2006, J BIOL CHEM, V281, P11856, DOI 10.1074/jbc.M509420200; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; Carroll AS, 2002, TRENDS BIOCHEM SCI, V27, P87, DOI 10.1016/S0968-0004(01)02040-0; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; Cho JH, 2004, J NEUROCHEM, V88, P349, DOI 10.1046/j.1471-4159.2003.02155.x; D'Souza I, 2006, J BIOL CHEM, V281, P2460, DOI 10.1074/jbc.M505809200; Dehmelt L, 2005, GENOME BIOL, V6; Drewes G, 2004, TRENDS BIOCHEM SCI, V29, P548, DOI 10.1016/j.tibs.2004.08.001; Geschwind DH, 2003, NEURON, V40, P457, DOI 10.1016/S0896-6273(03)00681-0; Goedert M, 1999, FEBS LETT, V450, P306, DOI 10.1016/S0014-5793(99)00508-6; GUSTKE N, 1992, FEBS LETT, V307, P199, DOI 10.1016/0014-5793(92)80767-B; Hallows JL, 2003, J NEUROSCI, V23, P10633; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Heutink P, 2000, HUM MOL GENET, V9, P979, DOI 10.1093/hmg/9.6.979; Hirokawa N, 2005, NAT REV NEUROSCI, V6, P201, DOI 10.1038/nrn1624; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Ingram EM, 2002, TRENDS MOL MED, V8, P555, DOI 10.1016/S1471-4914(02)02440-1; Iqbal K, 2005, ACTA NEUROPATHOL, V109, P25, DOI 10.1007/s00401-004-0951-y; IQBAL K, 1994, FEBS LETT, V349, P104, DOI 10.1016/0014-5793(94)00650-4; Le Corre S, 2006, P NATL ACAD SCI USA, V103, P9673, DOI 10.1073/pnas.0602913103; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Lim F, 2001, MOL CELL NEUROSCI, V18, P702, DOI 10.1006/mcne.2001.1051; Maeda S, 2006, NEUROSCI RES, V54, P197, DOI 10.1016/j.neures.2005.11.009; Mandelkow EM, 1996, ANN NY ACAD SCI, V777, P96, DOI 10.1111/j.1749-6632.1996.tb34407.x; Mandelkow EM, 2004, J CELL BIOL, V167, P99, DOI 10.1083/jcb.200401085; Masliah E, 2001, J NEUROPATH EXP NEUR, V60, P357, DOI 10.1093/jnen/60.4.357; Mitchell TW, 2000, J HISTOCHEM CYTOCHEM, V48, P1627, DOI 10.1177/002215540004801206; Mukhopadhyay R, 2001, FEBS LETT, V505, P374, DOI 10.1016/S0014-5793(01)02844-7; Sang HC, 2001, NEUROSCI LETT, V312, P141, DOI 10.1016/S0304-3940(01)02206-6; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; Spittaels K, 1999, AM J PATHOL, V155, P2153, DOI 10.1016/S0002-9440(10)65533-2; Spittaels K, 2000, J BIOL CHEM, V275, P41340, DOI 10.1074/jbc.M006219200; Stoothoff WH, 2005, BBA-MOL BASIS DIS, V1739, P280, DOI 10.1016/j.bbadis.2004.06.017; Teng JL, 2001, J CELL BIOL, V155, P65, DOI 10.1083/jcb.200106025; Terwel D, 2005, J BIOL CHEM, V280, P3963, DOI 10.1074/jbc.M409876200; Terwel D, 2002, NEUROMOL MED, V2, P151, DOI 10.1385/NMM:2:2:151; Utton MA, 1997, BIOCHEM J, V323, P741, DOI 10.1042/bj3230741; Van den Haute C, 2001, NEUROBIOL DIS, V8, P32, DOI 10.1006/nbdi.2000.0333; Van Dorpe J, 2000, AM J PATHOL, V157, P1283, DOI 10.1016/S0002-9440(10)64644-5; Vandebroek T, 2005, BIOCHEMISTRY-US, V44, P11466, DOI 10.1021/bi0506775; Wilson WA, 2002, CELL, V111, P155, DOI 10.1016/S0092-8674(02)01043-7	48	45	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25388	25397		10.1074/jbc.M602792200	http://dx.doi.org/10.1074/jbc.M602792200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16818492	hybrid			2022-12-25	WOS:000240031300041
J	Russo, J; Fernandez, SV; Russo, PA; Fernbaugh, R; Sheriff, FS; Lareef, HM; Garber, J; Russo, IH				Russo, Jose; Fernandez, Sandra V.; Russo, Patricia A.; Fernbaugh, Rachael; Sheriff, Fathima S.; Lareef, Hasan M.; Garber, James; Russo, Irma H.			17-beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells	FASEB JOURNAL			English	Article						estrogen; invasiveness; CGH; breast cancer	COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; CHROMOSOMAL IMBALANCES; ENDOGENOUS HORMONES; CANCER; ESTROGEN; RECEPTOR; ESTRADIOL; DNA; REGIONS	Breast cancer is a malignancy whose dependence on estrogen exposure has long been recognized even though the mechanisms whereby estrogens cause cancer are not clearly understood. This work was performed to determine whether 17 beta-estradiol (E-2), the predominant circulating ovarian steroid, is carcinogenic in human breast epithelial cells and whether nonreceptor mechanisms are involved in the initiation of breast cancer. For this purpose, the effect of four 24 h alternate periods of 70 nM E-2 treatment of the estrogen receptor alpha (ER-alpha) negative MCF-10F cell line on the in vitro expression of neoplastic transformation was evaluated. E-2 treatment induced the expression of anchorage-independent growth, loss of ductulogenesis in collagen, invasiveness in Matrigel, and loss of 9p11-13. Only invasive cells that exhibited a 4p15.3-16 deletion were tumorigenic. Tumors were poorly differentiated ER-alpha and progesterone receptornegative adenocarcinomas that expressed keratins, EMA, and E-cadherin. Tumors and tumor-derived cell lines exhibited loss of chromosome 4, deletions in chromosomes 3p12.3-13, 8p11.1-21, 9p21-qter, and 18q, and gains in 1p, and 5q15-qter. The induction of complete transformation of MCF-10F cells in vitro confirms the carcinogenicity of E-2, supporting the concept that this hormone could act as an initiator of breast cancer in women. This model provides a unique system for understanding the genomic changes that intervene for leading normal cells to tumorigenesis and for testing the functional role of specific genomic events taking place during neoplastic transformation.	Fox Chase Canc Ctr, Breast Canc Res Lab, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Russo, J (corresponding author), Fox Chase Canc Ctr, Breast Canc Res Lab, 333 Cottman Ave, Philadelphia, PA 19111 USA.	j_russo@fccc.edu						Achuthan R, 2001, CANCER GENET CYTOGEN, V130, P166, DOI 10.1016/S0165-4608(01)00475-7; Adam Z, 2000, CLIN EXP METASTAS, V18, P295, DOI 10.1023/A:1011043412634; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; BERNSTEIN L, 1993, EPIDEMIOL REV, V15, P48, DOI 10.1093/oxfordjournals.epirev.a036116; Berrino F, 1996, JNCI-J NATL CANCER I, V88, P291, DOI 10.1093/jnci/88.5.291; Bieche I, 1999, GENE CHROMOSOME CANC, V24, P255, DOI 10.1002/(SICI)1098-2264(199903)24:3<255::AID-GCC11>3.0.CO;2-2; Bieche I, 1998, ONCOL REP, V5, P267; BLOCK GE, 1958, SURGERY, V43, P415; Bocchinfuso WP, 1997, J MAMMARY GLAND BIOL, V2, P323, DOI 10.1023/A:1026339111278; Bocchinfuso WP, 1999, CANCER RES, V59, P1869; Boyd S, 1900, BRIT MED J, V1900, P1161; CALAF G, 1993, CARCINOGENESIS, V14, P483, DOI 10.1093/carcin/14.3.483; CALAF G, 1995, INT J ONCOL, V6, P5; Cauley JA, 1999, ANN INTERN MED, V130, P270, DOI 10.7326/0003-4819-130-4_Part_1-199902160-00004; Cavalieri E, 2004, METHOD ENZYMOL, V382, P293; Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937; Cavalieri EL, 2001, CHEM RES TOXICOL, V14, P1041, DOI 10.1021/tx010042g; Chakravarti D, 2001, ONCOGENE, V20, P7945, DOI 10.1038/sj.onc.1204969; Cuendet M, 2004, MUTAT RES-FUND MOL M, V550, P109, DOI 10.1016/j.mrfmmm.2004.02.005; Dallol A, 2002, CANCER RES, V62, P5874; Dellas A, 2002, CLIN CANCER RES, V8, P1210; Dorgan JF, 1997, CANCER EPIDEM BIOMAR, V6, P177; Dorgan JF, 2002, JNCI-J NATL CANCER I, V94, P606; Dorgan JF, 1996, CANCER EPIDEM BIOMAR, V5, P533; Fernandez SV, 2006, INT J CANCER, V118, P1862, DOI 10.1002/ijc.21590; Fernandez SV, 2005, INT J ONCOL, V26, P691; Forozan F, 1999, BRIT J CANCER, V81, P1328, DOI 10.1038/sj.bjc.6695007; Forozan F, 2000, CANCER RES, V60, P4519; GARLAND CF, 1992, AM J EPIDEMIOL, V135, P1220, DOI 10.1093/oxfordjournals.aje.a116228; Gelsi-Boyer W, 2005, MOL CANCER RES, V3, P655, DOI 10.1158/1541-7786.MCR-05-0128; GREEN S, 1986, J STEROID BIOCHEM, V24, P77, DOI 10.1016/0022-4731(86)90035-X; Hankinson SE, 1998, JNCI-J NATL CANCER I, V90, P1292, DOI 10.1093/jnci/90.17.1292; HELZLSOUER KJ, 1994, CANCER DETECT PREV, V18, P79; HENDERSON BE, 1988, CANCER RES, V48, P246; Hopman AHN, 2002, AM J PATHOL, V161, P1119, DOI 10.1016/S0002-9440(10)64388-X; Jakob J, 2005, GENE CHROMOSOME CANC, V42, P372, DOI 10.1002/gcc.20142; Johannsdottir HK, 2004, ANTICANCER RES, V24, P2681; Kabuto M, 2000, CANCER EPIDEM BIOMAR, V9, P575; Kaneko Mayumi, 2002, J Exp Ther Oncol, V2, P9, DOI 10.1046/j.1359-4117.2002.01001.x; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; Lareef MH, 2005, INT J ONCOL, V26, P423; LI JJ, 1995, CANCER RES, V55, P4347; LI JJ, 1983, CANCER RES, V43, P5200; LI JJ, 1987, FED PROC, V46, P1858; LIEHR JG, 1986, J STEROID BIOCHEM, V24, P353, DOI 10.1016/0022-4731(86)90080-4; Liu Suling, 2004, Breast J, V10, P514, DOI 10.1111/j.1075-122X.2004.21410.x; Loveday RL, 2000, INT J CANCER, V86, P494, DOI 10.1002/(SICI)1097-0215(20000515)86:4<494::AID-IJC8>3.3.CO;2-F; Marsit CJ, 2005, MOL CARCINOGEN, V44, P146, DOI 10.1002/mc.20125; MEITES J, 1972, J NATL CANCER I, V48, P1217; Melcher R, 2000, CYTOGENET CELL GENET, V88, P145, DOI 10.1159/000015508; MILLER W R, 1987, Steroids, V50, P537, DOI 10.1016/0039-128X(87)90037-7; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; Nessling M, 2005, CANCER RES, V65, P439; Newbold RR, 2000, CANCER RES, V60, P235; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; Ragnarsson G, 1999, BRIT J CANCER, V79, P1468, DOI 10.1038/sj.bjc.6690234; Richard F, 2000, INT J CANCER, V89, P305; Rogan EG, 2003, CARCINOGENESIS, V24, P697, DOI 10.1093/carcin/bgg004; Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.2307/3433143; RUSSO IH, 2005, MOL BASIS BREAST CAN, P89; Russo J, 1999, BREAST CANCER RES TR, V53, P217, DOI 10.1023/A:1006186719322; Russo J, 2002, J STEROID BIOCHEM, V80, P149, DOI 10.1016/S0960-0760(01)00183-2; Russo J, 2001, APMIS, V109, P39, DOI 10.1111/j.1600-0463.2001.tb00013.x; Russo J, 2003, J STEROID BIOCHEM, V87, P1, DOI 10.1016/S0960-0760(03)00390-X; RUSSO J, 2000, ENDOCRINE DISRUPTERS, P1; Russo Jose, 2005, Proceedings of the American Association for Cancer Research Annual Meeting, V46, P1464; Sarkar S, 2002, J BIOL CHEM, V277, P36585, DOI 10.1074/jbc.M204244200; Shivapurkar N, 1999, CANCER RES, V59, P3576; Simons A, 2000, CANCER GENET CYTOGEN, V118, P89, DOI 10.1016/S0165-4608(99)00178-8; Tahara H, 1996, J CLIN ENDOCR METAB, V81, P3663, DOI 10.1210/jc.81.10.3663; Thomas HV, 1997, BRIT J CANCER, V76, P401, DOI 10.1038/bjc.1997.398; TOFT D, 1967, P NATL ACAD SCI USA, V57, P1740, DOI 10.1073/pnas.57.6.1740; TONIOLO PG, 1995, JNCI-J NATL CANCER I, V87, P190, DOI 10.1093/jnci/87.3.190; Tsao SW, 2001, CANCER GENET CYTOGEN, V130, P141, DOI 10.1016/S0165-4608(01)00473-3; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Verdorfer I, 1999, CANCER GENET CYTOGEN, V111, P61, DOI 10.1016/S0165-4608(98)00217-9; Weber-Mangal S, 2003, INT J CANCER, V107, P583, DOI 10.1002/ijc.11460; Yager J D, 2000, J Natl Cancer Inst Monogr, P67; Yokota T, 1997, JPN J CANCER RES, V88, P959, DOI 10.1111/j.1349-7006.1997.tb00315.x; Zettl A, 2004, AM J PATHOL, V164, P1837, DOI 10.1016/S0002-9440(10)63742-X; Zhang LH, 2003, J CANCER RES CLIN, V129, P279, DOI 10.1007/s00432-002-0407-5; Zinn-Justin A, 2001, GENET EPIDEMIOL, V21, P40, DOI 10.1002/gepi.1017	82	117	121	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1622	1634		10.1096/fj.05-5399com	http://dx.doi.org/10.1096/fj.05-5399com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16873885				2022-12-25	WOS:000240266600007
J	Kivela, R; Silvennoinen, M; Touvra, AM; Lehti, TM; Kainulainen, H; Vihko, V				Kivela, Riikka; Silvennoinen, Mika; Touvra, Anna-Maria; Lehti, T. Maarit; Kainulainen, Heikki; Vihko, Veikko			Effects of experimental type 1 diabetes and exercise training on angiogenic gene expression and capillarization in skeletal muscle	FASEB JOURNAL			English	Article						angiogenesis; hyperglycemia; growth factor; VEGF	ENDOTHELIAL GROWTH-FACTOR; ANIMAL-MODELS; TEACH US; INSULIN; IMPAIRMENT; METABOLISM; RESPONSES; THERAPY; DENSITY; DISEASE	Diabetes alters microvascular structure and function and is a major risk factor for cardiovascular diseases. In diabetic skeletal muscle, impaired angiogenesis and reduced VEGF-A expression have been observed, whereas in healthy muscle exercise is known to have opposite effects. We studied the effects of type 1 diabetes and combined exercise training on angiogenic mRNA expression and capillarization in mouse skeletal muscle. Microarray and real-time PCR analyses showed that diabetes altered the expression of several genes involved in angiogenesis. For example, levels of proangiogenic VEGF-A, VEGF-B, neuropilin-1, VEGFR-1, and VEGFR-2 were reduced and the levels of antiangiogenic thrombospondin-1 and retinoblastoma like-2 were increased. Exercise training alleviated some of these changes, but could not completely restore them. VEGF-A protein content was also reduced in diabetic muscles. In line with the reduced levels of VEGF-A and other angiogenic factors, and increased levels of angiogenesis inhibitors, capillary-to-muscle fiber ratio was lower in diabetic mice compared to healthy controls. Exercise training could not restore capillarization in diabetic mice. In conclusion, these data illustrate that type 1 diabetes is associated with reduced skeletal muscle capillarization and the dysregulation of complex angiogenesis pathways.	LIKES Res Ctr Sport & Hlth Sci, FIN-40740 Jyvaskyla, Finland; Univ Jyvaskyla, Dept Biol Phys Activ, Neuromuscular Res Ctr, SF-40351 Jyvaskyla, Finland	University of Jyvaskyla	Kivela, R (corresponding author), LIKES Res Ctr Sport & Hlth Sci, Rautpohjankatu 8A, FIN-40740 Jyvaskyla, Finland.	riikka.kivela@likes.fi	Kivelä, Riikka/I-2859-2016; Kivelä, Riikka/AAD-9636-2020; Lehti, Maarit/T-3824-2019	Kivelä, Riikka/0000-0002-2686-8890; Kivelä, Riikka/0000-0002-2686-8890; Lehti, Maarit/0000-0002-9063-6541; Silvennoinen, Mika/0000-0002-5389-8251; Kainulainen, Heikki/0000-0001-5102-4350				Abaci A, 1999, CIRCULATION, V99, P2239, DOI 10.1161/01.CIR.99.17.2239; Ameln H, 2005, FASEB J, V19, P1009, DOI 10.1096/fj.04-2304fje; Breen EC, 1996, J APPL PHYSIOL, V81, P355, DOI 10.1152/jappl.1996.81.1.355; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chou E, 2002, CIRCULATION, V105, P373, DOI 10.1161/hc0302.102143; Claudio PP, 2001, CANCER RES, V61, P462; Emanueli C, 2004, DIABETES, V53, P1096, DOI 10.2337/diabetes.53.4.1096; Gavin TP, 2001, J APPL PHYSIOL, V90, P1219, DOI 10.1152/jappl.2001.90.4.1219; Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772; Gonzalez C, 2003, DIABETOLOGIA, V46, P1291, DOI 10.1007/s00125-003-1168-7; Gustafsson T, 1999, AM J PHYSIOL-HEART C, V276, pH679, DOI 10.1152/ajpheart.1999.276.2.H679; Gustafsson T, 2002, PFLUG ARCH EUR J PHY, V444, P752, DOI 10.1007/s00424-002-0845-6; HENRIKSSON J, 1992, DIABETES CARE, V15, P1701, DOI 10.2337/diacare.15.11.1701; HOLLOSZY JO, 1976, ANNU REV PHYSIOL, V38, P273, DOI 10.1146/annurev.ph.38.030176.001421; Hubbell E, 2002, BIOINFORMATICS, V18, P1585, DOI 10.1093/bioinformatics/18.12.1585; HUDLICKA O, 1991, J PHYSIOL-LONDON, V444, P1; HUDLICKA O, 1992, PHYSIOL REV, V71, P541; Jemiolo B, 2004, BIOCHEM BIOPH RES CO, V320, P1043, DOI 10.1016/j.bbrc.2004.05.223; Jiang ZY, 2003, J BIOL CHEM, V278, P31964, DOI 10.1074/jbc.M303314200; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; KAINULAINEN H, 1984, BASIC RES CARDIOL, V79, P110, DOI 10.1007/BF01935813; Kindig CA, 1998, RESP PHYSIOL, V111, P163, DOI 10.1016/S0034-5687(97)00122-9; Laakso M, 1997, DIABETES REV, V5, P294; Larger E, 2004, DIABETES, V53, P752, DOI 10.2337/diabetes.53.3.752; LASH JM, 1989, DIABETES, V38, P854, DOI 10.2337/diabetes.38.7.854; LEINONEN H, 1982, DIABETOLOGIA, V22, P158; Leiter EH, 2004, DIABETOLOGIA, V47, P1657, DOI 10.1007/s00125-004-1518-0; Lerman OZ, 2003, AM J PATHOL, V162, P303, DOI 10.1016/S0002-9440(10)63821-7; Liu WM, 2002, BIOINFORMATICS, V18, P1593, DOI 10.1093/bioinformatics/18.12.1593; Magnusson C, 2005, EUR J NEUROSCI, V21, P577, DOI 10.1111/j.1460-9568.2005.03855.x; Mora S, 2002, CIRCULATION, V106, P601; Olefsky JM, 2001, JAMA-J AM MED ASSOC, V285, P628, DOI 10.1001/jama.285.5.628; Penkowa M, 2005, EXP PHYSIOL, V90, P477, DOI 10.1113/expphysiol.2004.029371; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Rees DA, 2005, DIABETIC MED, V22, P359, DOI 10.1111/j.1464-5491.2005.01499.x; Richardson RS, 2000, AM J PHYSIOL-HEART C, V279, pH772, DOI 10.1152/ajpheart.2000.279.2.H772; Rissanen TT, 2003, CIRC RES, V92, P1098, DOI 10.1161/01.RES.0000073584.46059.E3; Rissanen TT, 2002, AM J PATHOL, V160, P1393, DOI 10.1016/S0002-9440(10)62566-7; Rivard A, 1999, AM J PATHOL, V154, P355, DOI 10.1016/S0002-9440(10)65282-0; Roep BO, 2004, DIABETOLOGIA, V47, P1650, DOI 10.1007/s00125-004-1517-1; Sage EH, 2003, J BIOL CHEM, V278, P37849, DOI 10.1074/jbc.M302946200; Sasso FC, 2005, J AM COLL CARDIOL, V46, P827, DOI 10.1016/j.jacc.2005.06.007; Schiekofer S, 2005, ARTERIOSCL THROM VAS, V25, P1603, DOI 10.1161/01.ATV.0000171994.89106.ca; SEXTON WL, 1994, AM J PHYSIOL, V266, pH1502, DOI 10.1152/ajpheart.1994.266.4.H1502; Sreenivasulu K., 2002, Gene Expression Patterns, V2, P51, DOI 10.1016/S0925-4773(02)00357-X; Stenina OI, 2003, CIRCULATION, V107, P3209, DOI 10.1161/01.CIR.0000074223.56882.97; Tamarat R, 2003, P NATL ACAD SCI USA, V100, P8555, DOI 10.1073/pnas.1236929100; Tammela T, 2005, CARDIOVASC RES, V65, P550, DOI 10.1016/j.cardiores.2004.12.002; *TIAB CONTR COMPL, 1993, NEW ENGL J MED, V329, P977; van Weel V, 2004, CIRC RES, V95, P58, DOI 10.1161/01.RES.0000133247.69803.c3; WALLBERGHENRIKSSON H, 1984, DIABETES, V33, P851, DOI 10.2337/diabetes.33.9.851; Williams RS, 2004, CIRC RES, V95, P7, DOI 10.1161/01.RES.0000136345.81719.37; Yechoor VK, 2002, P NATL ACAD SCI USA, V99, P10587, DOI 10.1073/pnas.142301999	55	93	96	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1570	+		10.1096/fj.05-4780fje	http://dx.doi.org/10.1096/fj.05-4780fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816123				2022-12-25	WOS:000240266000054
J	Yoon, K; Zhu, S; Ewing, SJ; Smart, RC				Yoon, K.; Zhu, S.; Ewing, S. J.; Smart, R. C.			Decreased survival of C/EBP beta-deficient keratinocytes is due to aberrant regulation of p53 levels and function	ONCOGENE			English	Article						apoptosis; p53; C/EBP beta; keratinocytes	BINDING-PROTEIN-BETA; TRANSCRIPTION FACTORS; TUMOR-SUPPRESSOR; DEPENDENT PHOSPHORYLATION; EPITHELIAL-CELLS; GENE-EXPRESSION; STABILIZES P53; MDM2; DIFFERENTIATION; REPRESSION	Recent studies have identified roles for C/EBP beta in cellular survival and tumorigenesis, however, the mechanisms through which C/EBPb regulates these processes are not fully understood. Previously, we demonstrated that C/EBP beta(-/-) mice are resistant to carcinogen-induced skin tumorigenesis and in response to topical carcinogen treatment display a 17-fold increase in keratinocyte apoptosis compared to wild-type mice. Here, we have investigated the mechanisms through which C/EBPb regulates apoptosis in response to carcinogenic stress. Analysis of carcinogen-treated C/EBP beta(-/-) mouse skin revealed a striking increase in the number of p53 immunopositive keratinocytes in the epidermis of C/EBP beta(-/-) mice compared to wild-type mice and this increase was temporally associated with a concomitant anomalous increase in apoptosis. The increased levels of p53 were functional as Mdm2, Bcl-2, C/EBP alpha and p21 were differentially regulated in the epidermis of carcinogenic treated C/EBP beta(-/-) mice. The increase in p53 protein was not associated with an increase in p53 mRNA levels. To determine whether p53 is required for the increased apoptosis in C/EBPb-/- mice, C/EBP beta/p53 compound knockout mice were generated. Carcinogen-treated C/EBP beta/p53 compound knockout mice did not display increased apoptosis demonstrating p53 is required for the proapoptotic phenotype in C/EBP beta(-/-) mice. Our results demonstrate that altered keratinocyte survival in C/EBP beta(-/-) mice results from aberrant regulation of p53 protein and function and indicate C/EBP beta has a role in the negative regulation of p53 protein levels in response to carcinogen-induced stress.	N Carolina State Univ, Dept Environm & Mol Toxicol, Cell Signaling & Canc Grp, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Smart, RC (corresponding author), N Carolina State Univ, Dept Environm & Mol Toxicol, Cell Signaling & Canc Grp, Raleigh, NC 27695 USA.	rcsmart@unity.ncsu.edu		Smart, Robert/0000-0002-6767-6756	NATIONAL CANCER INSTITUTE [R29CA046637, R01CA046637] Funding Source: NIH RePORTER; NCI NIH HHS [CA46637] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; Burkart AD, 2005, ENDOCRINOLOGY, V146, P1909, DOI 10.1210/en.2004-0842; Corbi AL, 2000, FEBS LETT, V474, P201, DOI 10.1016/S0014-5793(00)01591-X; Di-Poi N, 2005, J BIOL CHEM, V280, P38700, DOI 10.1074/jbc.M507782200; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Li WL, 2005, CANCER RES, V65, P2592, DOI 10.1158/0008-5472.CAN-04-1532; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; Oh HS, 1998, J INVEST DERMATOL, V110, P939, DOI 10.1046/j.1523-1747.1998.00199.x; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Rask K, 2000, INT J CANCER, V86, P337, DOI 10.1002/(SICI)1097-0215(20000501)86:3<337::AID-IJC6>3.3.CO;2-V; Sankpal NV, 2005, BBA-GENE STRUCT EXPR, V1728, P1, DOI 10.1016/j.bbaexp.2004.12.014; Sebastian T, 2005, EMBO J, V24, P3301, DOI 10.1038/sj.emboj.7600789; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shuman JD, 2004, MOL CELL BIOL, V24, P7380, DOI 10.1128/MCB.24.17.7380-7391.2004; Sterneck E, 2006, ONCOGENE, V25, P1272, DOI 10.1038/sj.onc.1209144; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Sundfeldt K, 1999, BRIT J CANCER, V79, P1240, DOI 10.1038/sj.bjc.6690199; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wessells J, 2004, MOL CELL BIOL, V24, P3238, DOI 10.1128/MCB.24.8.3238-3250.2004; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	35	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					360	367		10.1038/sj.onc.1209797	http://dx.doi.org/10.1038/sj.onc.1209797			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832342				2022-12-25	WOS:000243544000005
J	Southall, SM; Doel, JJ; Richardson, DJ; Oubrie, A				Southall, Stacey M.; Doel, Justin J.; Richardson, David J.; Oubrie, Arthur			Soluble aldose sugar dehydrogenase from Escherichia coli - A highly exposed active site conferring broad substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOPROTEIN GLUCOSE-DEHYDROGENASE; L-ASCORBIC-ACID; ACINETOBACTER-CALCOACETICUS; PYRROLOQUINOLINE-QUINONE; CRYSTAL-STRUCTURE; L-SORBOSONE; MECHANISM; REDUCTASE; COFACTOR; PQQ	A water-soluble aldose sugar dehydrogenase (Asd) has been purified for the first time from Escherichia coli. The enzyme is able to act upon a broad range of aldose sugars, encompassing hexoses, pentoses, disaccharides, and trisaccharides, and is able to oxidize glucose to gluconolactone with subsequent hydrolysis to gluconic acid. The enzyme shows the ability to bind pyrroloquinoline quinone (PQQ) in the presence of Ca2+ in a manner that is proportional to its catalytic activity. The x-ray structure has been determined in the apo-form and as the PQQ-bound active holoenzyme. The beta-propeller fold of this protein is conserved between E. coli Asd and Acinetobacter calcoaceticus soluble glucose dehydrogenase (sGdh), with major structural differences lying in loop and surface-exposed regions. Many of the residues involved in binding the cofactor are conserved between the two enzymes, but significant differences exist in residues likely to contact substrates. PQQ is bound in a large cleft in the protein surface and is uniquely solvent-accessible compared with other PQQ enzymes. The exposed and charged nature of the active site and the activity profile of this enzyme indicate possible factors that underlie a low affinity for glucose but generic broad substrate specificity for aldose sugars. These structural and catalytic properties of the enzymes have led us to propose that E. coli Asd provides a prototype structure for a new subgroup of PQQ-dependent soluble dehydrogenases that is distinct from the A. calcoaceticus sGdh subgroup.	Univ E Anglia, Ctr Met Prot Spect & Biol, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Southall, SM (corresponding author), Univ E Anglia, Ctr Met Prot Spect & Biol, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	Stacey.Southall@icr.ac.uk	Richardson, David J/E-2275-2011	Oubrie, Arthur/0000-0001-6765-9246	Biotechnology and Biological Sciences Research Council [B18695] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Abramson J, 2000, NAT STRUCT BIOL, V7, P910; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bamford VA, 2002, BIOCHEMISTRY-US, V41, P2921, DOI 10.1021/bi015765d; Bertero MG, 2003, NAT STRUCT BIOL, V10, P681, DOI 10.1038/nsb969; Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Dewanti AR, 1998, BIOCHEMISTRY-US, V37, P6810, DOI 10.1021/bi9722610; DOKTER P, 1986, BIOCHEM J, V239, P163, DOI 10.1042/bj2390163; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Felton LM, 2005, NATURE, V433, pE10, DOI 10.1038/nature03322; Haltia T, 2003, BIOCHEM J, V369, P77, DOI 10.1042/BJ20020782; Igarashi S, 2004, BIOMOL ENG, V21, P81, DOI 10.1016/j.bioeng.2003.12.001; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; Jormakka M, 2002, SCIENCE, V295, P1863, DOI 10.1126/science.1068186; Jormakka M, 2004, STRUCTURE, V12, P95, DOI 10.1016/j.str.2003.11.020; Kasahara T, 2005, NATURE, V433, pE11, DOI 10.1038/nature03324; Kasahara T, 2003, NATURE, V422, P832, DOI 10.1038/422832a; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie A. G. W., 1992, CRYSTALLOGRAPHY, V26; Maniatis T., 1989, MOL CLONING LAB MAN; Miyazaki T, 2006, APPL ENVIRON MICROB, V72, P1487, DOI 10.1128/AEM.72.2.1487-1495.2006; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Olsthoorn AJJ, 1998, EUR J BIOCHEM, V255, P255, DOI 10.1046/j.1432-1327.1998.2550255.x; Olsthoorn AJJ, 1996, ARCH BIOCHEM BIOPHYS, V336, P42, DOI 10.1006/abbi.1996.0530; Olsthoorn AJJ, 1997, EUR J BIOCHEM, V247, P659, DOI 10.1111/j.1432-1033.1997.00659.x; Olsthoorn AJJ, 1998, BIOCHEMISTRY-US, V37, P13854, DOI 10.1021/bi9808868; Oubrie A, 1999, EMBO J, V18, P5187, DOI 10.1093/emboj/18.19.5187; Oubrie A, 1999, P NATL ACAD SCI USA, V96, P11787, DOI 10.1073/pnas.96.21.11787; Oubrie A, 2003, BBA-PROTEINS PROTEOM, V1647, P143, DOI 10.1016/S1570-9639(03)00087-6; Oubrie A, 1999, J MOL BIOL, V289, P319, DOI 10.1006/jmbi.1999.2766; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PAZUR JH, 1964, BIOCHEMISTRY-US, V3, P578, DOI 10.1021/bi00892a018; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Rucker R, 2005, NATURE, V433, pE10, DOI 10.1038/nature03323; Satoh A, 2002, J BIOL CHEM, V277, P2830, DOI 10.1074/jbc.M109090200; Solnica B, 2003, CLIN CHIM ACTA, V331, P29, DOI 10.1016/S0009-8981(03)00079-2; Sugisawa T, 2005, BIOSCI BIOTECH BIOCH, V69, P659, DOI 10.1271/bbb.69.659; Tang ZP, 2001, CRIT CARE MED, V29, P1062, DOI 10.1097/00003246-200105000-00038; Unkrig V., 1996, [No title captured], Patent No. [5,484,708, 5484708]; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605	43	37	39	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30650	30659		10.1074/jbc.M601783200	http://dx.doi.org/10.1074/jbc.M601783200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16864586	hybrid			2022-12-25	WOS:000241075900041
J	Castang, S; Reverchon, S; Gouet, P; Nasser, W				Castang, Sandra; Reverchon, Sylvie; Gouet, Patrice; Nasser, William			Direct evidence for the modulation of the activity of the Erwinia chrysanthemi quorum-sensing regulator ExpR by acylhomoserine lactone pheromone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAROTOVORA SUBSP CAROTOVORA; ACYL-HOMOSERINE LACTONES; VIBRIO-FISCHERI LUXR; PROMOTERS IN-VITRO; C-TERMINAL DOMAIN; RNA-POLYMERASE; TRANSCRIPTIONAL ACTIVATION; PSEUDOMONAS-AERUGINOSA; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI	In Erwinia chrysanthemi production of pectic enzymes is controlled by a complex network involving several regulators. Among them is ExpR, the quorum-sensing regulatory protein. ExpR is a member of the LuxR family of transcriptional regulators, the activity of which is modulated by the binding of diffusible N-acylhomoserine lactone pheromones to the N-terminal receptor site of the proteins. Previous in vitro DNA-ExpR binding studies suggested that ExpR might activate pectic enzyme production and repress its cognate gene expression. This report presents genetic evidence that ExpR represses its own gene expression in the absence of pheromone and that the addition of pheromone promotes concentration-dependent de-repression. In vitro experiments show that (i) ExpR binds target DNA in the absence of pheromone and that the pheromone dissociates ExpR-DNA complexes, (ii) ExpR binds target DNA in a noncooperative fashion, and (iii) two molecules of pheromone are bound per molecule of ExpR dimer. In the absence of N-(3-oxohexanoyl)homoserine lactone, ExpR prevents RNA polymerase access to the expR promoter, thereby directly repressing transcription initiation. The presence of pheromone renders the expR promoter accessible to RNA polymerase and results in the de-repression of transcription initiation. Overall we have established that there is a direct modulation of the repressive activity of a LuxR family regulator by a pheromone. Furthermore, site-directed mutagenesis experiments strongly suggest that the ExpR residues Leu-19, Tyr-31, and Ser-125 are involved in the transduction of conformational changes induced by ligand binding, and this provides new insights into the structure-function relationship of this bacterial regulator family.	Univ Lyon 1, CNRS, UMR, Unite Microbiol & Genet,Inst Natl Sci Appl Lyon 5, F-69365 Villeurbanne, France; UCBL, UMR 5086, CNRS, Lab BioCristallog,Inst Biochim & Chim Prot, F-69367 Lyon 07, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Nasser, W (corresponding author), Univ Lyon 1, CNRS, UMR, Unite Microbiol & Genet,Inst Natl Sci Appl Lyon 5, Domaine Sci Dpua,Batiment Andre Lwoff 10 Rue Dubo, F-69365 Villeurbanne, France.	william.nasser@insa-lyon.fr	NASSER, William/C-9611-2019; Sylvie, Reverchon/P-7932-2016	NASSER, William/0000-0001-9848-3597; Sylvie, Reverchon/0000-0002-0478-3474; gouet, patrice/0000-0001-9485-6157				Andersson RA, 2000, MOL PLANT MICROBE IN, V13, P384, DOI 10.1094/MPMI.2000.13.4.384; Bachhawat P, 2005, STRUCTURE, V13, P1353, DOI 10.1016/j.str.2005.06.006; BARRAS F, 1994, ANNU REV PHYTOPATHOL, V32, P201, DOI 10.1146/annurev.py.32.090194.001221; Birck C, 1999, STRUCTURE, V7, P1505, DOI 10.1016/S0969-2126(00)88341-0; Burr T, 2006, MOL MICROBIOL, V59, P113, DOI 10.1111/j.1365-2958.2005.04939.x; Chai YR, 2004, MOL MICROBIOL, V51, P765, DOI 10.1046/j.1365-2958.2003.03857.x; Collins CH, 2005, MOL MICROBIOL, V55, P712, DOI 10.1111/j.1365-2958.2004.04437.x; Coulombre B, 1999, MICROBIOL MOL BIOL R, V63, P457, DOI 10.1128/MMBR.63.2.457-478.1999; Cui YY, 2005, J BACTERIOL, V187, P4792, DOI 10.1128/JB.187.14.4792-4803.2005; Ducros VMA, 2001, J MOL BIOL, V306, P759, DOI 10.1006/jmbi.2001.4443; Egland KA, 2001, J BACTERIOL, V183, P382, DOI 10.1128/JB.183.1.382-386.2001; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Finney AH, 2002, J BACTERIOL, V184, P4520, DOI 10.1128/JB.184.16.4520-4528.2002; Frezza M, 2006, BIOORGAN MED CHEM, V14, P4781, DOI 10.1016/j.bmc.2006.03.017; Fuqua C, 1996, ANNU REV MICROBIOL, V50, P727, DOI 10.1146/annurev.micro.50.1.727; Fuqua C, 2002, NAT REV MOL CELL BIO, V3, P685, DOI 10.1038/nrm907; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Halkides CJ, 2000, BIOCHEMISTRY-US, V39, P5280, DOI 10.1021/bi9925524; Hastings CA, 2003, BIOCHEMISTRY-US, V42, P9081, DOI 10.1021/bi0273866; HugouvieuxCottePattat N, 1996, ANNU REV MICROBIOL, V50, P213, DOI 10.1146/annurev.micro.50.1.213; Johnson DC, 2003, FEMS MICROBIOL LETT, V228, P193, DOI 10.1016/S0378-1097(03)00750-X; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kern D, 1999, NATURE, V402, P894, DOI 10.1038/47273; Kiratisin P, 2002, J BACTERIOL, V184, P4912, DOI 10.1128/JB.184.17.4912-4919.2002; Koch B, 2005, MICROBIOL-SGM, V151, P3589, DOI 10.1099/mic.0.27954-0; KOOP AH, 1987, GENE, V52, P245, DOI 10.1016/0378-1119(87)90051-5; Lamb JR, 2003, J BACTERIOL, V185, P7129, DOI 10.1128/JB.185.24.7129-7139.2003; LAZARUS LR, 1993, EMBO J, V12, P2483, DOI 10.1002/j.1460-2075.1993.tb05903.x; Lewis RJ, 1999, J MOL BIOL, V294, P9, DOI 10.1006/jmbi.1999.3261; Luo ZQ, 2003, J BIOL CHEM, V278, P13173, DOI 10.1074/jbc.M210035200; Miller J. H., 1972, EXPT MOL GENETICS, P431; Minogue TD, 2002, MOL MICROBIOL, V44, P1625, DOI 10.1046/j.1365-2958.2002.02987.x; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nasser W, 1998, MOL MICROBIOL, V29, P1391, DOI 10.1046/j.1365-2958.1998.01022.x; Nasser W, 2002, MOL MICROBIOL, V43, P733, DOI 10.1046/j.1365-2958.2002.02782.x; Nasser W, 1997, MOL MICROBIOL, V26, P1071, DOI 10.1046/j.1365-2958.1997.6472020.x; Nomura K, 1998, P NATL ACAD SCI USA, V95, P14034, DOI 10.1073/pnas.95.24.14034; PAO GM, 1994, RES MICROBIOL, V145, P356, DOI 10.1016/0923-2508(94)90082-5; Pappas KM, 2004, MOL MICROBIOL, V53, P755, DOI 10.1111/j.1365-2958.2004.04212.x; Qin YP, 2004, J BIOL CHEM, V279, P40844, DOI 10.1074/jbc.M405299200; Reverchon S, 1998, MOL MICROBIOL, V29, P1407, DOI 10.1046/j.1365-2958.1998.01023.x; Reverchon S, 2002, BIOORG MED CHEM LETT, V12, P1153, DOI 10.1016/S0960-894X(02)00124-5; Roussel A., 1989, SILICON GRAPHICS GEO; Schuster M, 2004, P NATL ACAD SCI USA, V101, P15833, DOI 10.1073/pnas.0407229101; SHADEL GS, 1990, J BACTERIOL, V172, P3980, DOI 10.1128/jb.172.7.3980-3987.1990; SLOCK J, 1990, J BACTERIOL, V172, P3974, DOI 10.1128/jb.172.7.3974-3979.1990; Stevens AM, 1999, J BACTERIOL, V181, P4704, DOI 10.1128/JB.181.15.4704-4707.1999; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Surgey N, 1996, J BACTERIOL, V178, P1593, DOI 10.1128/jb.178.6.1593-1599.1996; Urbanowski AL, 2004, J BACTERIOL, V186, P631, DOI 10.1128/JB.186.3.631-637.2004; Vannini A, 2002, EMBO J, V21, P4393, DOI 10.1093/emboj/cdf459; von Bodman SB, 2003, J BACTERIOL, V185, P7001, DOI 10.1128/JB.185.23.7001-7007.2003; von Bodman SB, 1998, P NATL ACAD SCI USA, V95, P7687, DOI 10.1073/pnas.95.13.7687; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; Weingart CL, 2005, MOL MICROBIOL, V57, P452, DOI 10.1111/j.1365-2958.2005.04656.x; Welch M, 2000, EMBO J, V19, P631, DOI 10.1093/emboj/19.4.631; White CE, 2005, MOL MICROBIOL, V55, P1473, DOI 10.1111/j.1365-2958.2004.04482.x; Whitehead NA, 2001, FEMS MICROBIOL REV, V25, P365, DOI 10.1111/j.1574-6976.2001.tb00583.x; Zhang RG, 2002, NATURE, V417, P971, DOI 10.1038/nature00833; Zhu J, 1999, P NATL ACAD SCI USA, V96, P4832, DOI 10.1073/pnas.96.9.4832	62	40	43	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29972	29987		10.1074/jbc.M601666200	http://dx.doi.org/10.1074/jbc.M601666200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16831870	hybrid			2022-12-25	WOS:000240896300058
J	Banci, L; Bertini, I; Cantini, F; DellaMalva, N; Herrmann, T; Rosato, A; Wurthrich, K				Banci, Lucia; Bertini, Ivano; Cantini, Francesca; DellaMalva, Nunzia; Herrmann, Torsten; Rosato, Antonio; Wuerthrich, Kurt			Solution structure and intermolecular interactions of the third metal-binding domain of ATP7A, the Menkes disease protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR STRUCTURE DETERMINATION; TORSION ANGLE DYNAMICS; P-TYPE ATPASE; COPPER CHAPERONE; BACKBONE DYNAMICS; CATALYTIC-ACTIVITY; BACILLUS-SUBTILIS; TRANSPORT; IDENTIFICATION; TRAFFICKING	The third metal-binding domain of the human Menkes protein (MNK3), a copper(I)-transporting ATPase, has been expressed in Escherichia coli and characterized in solution. The solution structure of MNK3, its copper(I)-binding properties, and its interaction with the physiological partner, HAH1, have been studied. MNK3is the domain most dissimilar in structure from the other domains of the Menkes protein. This is reflected in a significant rearrangement of the last strand of the four-stranded beta-sheet when compared with the other known homologous proteins or protein domains. MNK3 is also peculiar with respect to its interaction with the copper(I) ion, as it was found to be a comparatively weak binder. Copper(I) transfer from metal-loaded HAH1 was observed experimentally, but the metal distribution was shifted toward binding by HAH1. This is at variance with what is observed for the other Menkes domains.	Univ Florence, Magnet Resonance Ctr, I-50019 Sesto Fiorentino, Italy; Univ Florence, Dept Chem, I-50019 Sesto Fiorentino, Italy; FiorGen Fdn, I-50019 Sesto Fiorentino, Italy; Eidgenossiche Tech Hochschule Zurich, Inst Molekularbiol & Biophys, CH-8093 Zurich, Switzerland; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	University of Florence; University of Florence; Scripps Research Institute	Bertini, I (corresponding author), Univ Florence, Magnet Resonance Ctr, Via L Sacconi 6, I-50019 Sesto Fiorentino, Italy.	ivanobertini@cerm.unifi.it	Rosato, Antonio/D-8548-2011; Rosato, Antonio/M-3250-2019; Cantini, Francesca/O-1220-2015; Herrmann, Torsten/B-9978-2008	Rosato, Antonio/0000-0001-6172-0368; Rosato, Antonio/0000-0001-6172-0368; Cantini, Francesca/0000-0003-0526-6732; Wuthrich, Kurt/0000-0001-8739-6965; Herrmann, Torsten/0000-0003-2115-4781; BANCI, LUCIA/0000-0003-0562-5774				Achila D, 2006, P NATL ACAD SCI USA, V103, P5729, DOI 10.1073/pnas.0504472103; Arnesano F, 2002, GENOME RES, V12, P255, DOI 10.1101/gr.196802; Arnesano F, 2001, J BIOL CHEM, V276, P41365, DOI 10.1074/jbc.M104807200; Banci L, 2005, J BIOL CHEM, V280, P38259, DOI 10.1074/jbc.M506219200; Banci L, 2005, J MOL BIOL, V352, P409, DOI 10.1016/j.jmb.2005.07.034; Banci L, 2005, FEBS J, V272, P865, DOI 10.1111/j.1742-4658.2004.04526.x; Banci L, 2004, BIOCHEMISTRY-US, V43, P3396, DOI 10.1021/bi036042s; Banci L, 2003, ACCOUNTS CHEM RES, V36, P215, DOI 10.1021/ar010120r; Banci L, 2003, J MOL BIOL, V331, P473, DOI 10.1016/S0022-2836(03)00769-1; Banci L, 2003, BIOCHEMISTRY-US, V42, P1939, DOI 10.1021/bi027096p; Banci L, 2006, NAT CHEM BIOL, V2, P367, DOI 10.1038/nchembio797; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; CASE DA, 2004, AMBER 8 0; DeSilva TM, 2005, PROTEINS, V61, P1038, DOI 10.1002/prot.20639; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Goodyer ID, 1999, HUM MOL GENET, V8, P1473, DOI 10.1093/hmg/8.8.1473; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Herrmann T, 2002, J BIOMOL NMR, V24, P171, DOI 10.1023/A:1021614115432; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Huster D, 2003, J BIOL CHEM, V278, P32212, DOI 10.1074/jbc.M305408200; Ishima R, 2000, NAT STRUCT BIOL, V7, P740, DOI 10.1038/78963; Jones CE, 2003, J STRUCT BIOL, V143, P209, DOI 10.1016/j.jsb.2003.08.008; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Linder M, 1991, BIOCH COPPER; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Strausak D, 2003, J BIOL CHEM, V278, P20821, DOI 10.1074/jbc.M212437200; van Dongen EMWM, 2004, BIOCHEM BIOPH RES CO, V323, P789, DOI 10.1016/j.bbrc.2004.08.160; Voskoboinik I, 2001, J BIOL CHEM, V276, P28620, DOI 10.1074/jbc.M103532200; Voskoboinik N, 1999, J BIOL CHEM, V274, P22008, DOI 10.1074/jbc.274.31.22008; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453; Walker JM, 2004, J BIOL CHEM, V279, P15376, DOI 10.1074/jbc.M400053200; Wimmer R, 1999, J BIOL CHEM, V274, P22597, DOI 10.1074/jbc.274.32.22597; WISHART DS, 1994, J BIOMOL NMR, V4, P171	46	33	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29141	29147		10.1074/jbc.M603176200	http://dx.doi.org/10.1074/jbc.M603176200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16873374	hybrid			2022-12-25	WOS:000240680500068
J	Chaar, Z; O'Reilly, P; Gelman, I; Sabourin, LA				Chaar, Ziad; O'Reilly, Paul; Gelman, Irwin; Sabourin, Luc A.			v-Src-dependent down-regulation of the Ste20-like kinase SLK by casein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN-KINASE; STE20-RELATED KINASE; CATALYTIC-ACTIVITY; CELL MOTILITY; CK2; CANCER; APOPTOSIS; FIBRONECTIN; INDUCTION	We have previously shown that the Ste20-like kinase SLK is a microtubule-associated protein inducing actin stress fiber disassembly. Here, we show that v-Src expression can down-regulate SLK activity. This down-regulation is independent of focal adhesion kinase but requires v-Src kinase activity and membrane translocation. SLK down-regulation by v-Src is indirect and is accompanied by SLK hyperphosphorylation on serine residues. Deletion analysis revealed that casein kinase II (CK2) sites at position 347/348 are critical for v-Src-dependent modulation of SLK activity. Further studies show that CK2 can directly phosphorylate SLK at these positions and that inhibition of CK2 in v-Src-transformed cells results in normal kinase activity. Finally, CK2 and SLK can be co-localized in fibroblasts spreading on fibronectin-coated substrates, suggesting a mechanism whereby SLK may be regulated at sites of actin remodeling, such as membrane lamellipodia and ruffles, through CK2.	Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8L6, Canada; Ottawa Hlth Res Inst, Canc Therapeut Program, Ottawa, ON K1H 8L6, Canada; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Roswell Park Cancer Institute	Sabourin, LA (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	lsab@uottawa.ca						Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Donella-Deana A, 2003, BIOCHEM J, V372, P841, DOI 10.1042/BJ20021905; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Guerra B, 1999, PHARMACOL THERAPEUT, V82, P303, DOI 10.1016/S0163-7258(98)00064-3; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hao W, 2006, J BIOL CHEM, V281, P3075, DOI 10.1074/jbc.M511744200; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Jones RJ, 2000, EUR J CANCER, V36, P1595, DOI 10.1016/S0959-8049(00)00153-2; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Ruoslahti E, 1997, KIDNEY INT, V51, P1413, DOI 10.1038/ki.1997.193; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sabourin LA, 1999, ONCOGENE, V18, P7566, DOI 10.1038/sj.onc.1203119; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Sieg DJ, 1999, J CELL SCI, V112, P2677; Tawfic S, 2001, HISTOL HISTOPATHOL, V16, P573, DOI 10.14670/HH-16.573; Timpson P, 2001, CURR BIOL, V11, P1836, DOI 10.1016/S0960-9822(01)00583-8; Wagner S, 2002, J BIOL CHEM, V277, P37685, DOI 10.1074/jbc.M205899200	29	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28193	28199		10.1074/jbc.M605665200	http://dx.doi.org/10.1074/jbc.M605665200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16837460	hybrid			2022-12-25	WOS:000240534400057
J	Rosengren, KJ; Daly, NL; Fornander, LM; Jonsson, LMH; Shirafuji, Y; Qu, XQ; Vogel, HJ; Ouellette, AJ; Craik, DJ				Rosengren, K. Johan; Daly, Norelle L.; Fornander, Liselotte M.; Jonsson, Linda M. H.; Shirafuji, Yoshinori; Qu, Xiaoqing; Vogel, Hans J.; Ouellette, Andre J.; Craik, David J.			Structural and functional characterization of the conserved salt bridge in mammalian Paneth cell alpha-defensins - Solution structures of mouse cryptdin-4 AND (E15D)-cryptdin-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR STRUCTURE CALCULATION; MEMBRANE PERMEABILIZATION; TEMPERATURE COEFFICIENTS; ANTIMICROBIAL PEPTIDES; DISULFIDE ARRAY; SMALL-INTESTINE; HOST-DEFENSE; AMINO-ACIDS; GERM-FREE; NEUTROPHILS	alpha-Defensins are mediators of mammalian innate immunity, and knowledge of their structure-function relationships is essential for understanding their mechanisms of action. We report here the NMR solution structures of the mouse Paneth cell alpha-defensin cryptdin-4 (Crp4) and a mutant (E15D)-Crp4 peptide, in which a conserved Glu(15) residue was replaced by Asp. Structural analysis of the two peptides confirms the involvement of this Glu in a conserved salt bridge that is removed in the mutant because of the shortened side chain. Despite disruption of this structural feature, the peptide variant retains a well defined native fold because of a rearrangement of side chains, which result in compensating favorable interactions. Furthermore, salt bridge-deficient Crp4 mutants were tested for bactericidal effects and resistance to proteolytic degradation, and all of the variants had similar bactericidal activities and stability to proteolysis. These findings support the conclusion that the function of the conserved salt bridge in Crp4 is not linked to bactericidal activity or proteolytic stability of the mature peptide.	Univ Kalmar, Dept Chem & Biomed Sci, SE-39182 Kalmar, Sweden; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Australian Res Council, Special Res Ctr Funct & Appl Genom, Brisbane, Qld 4072, Australia; Univ Calif Irvine, Sch Med, Dept Pathol & Lab Med, Irvine, CA 92697 USA; Univ Calif Irvine, Sch Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calgary, Dept Biol Sci, Struct Biol Res Grp, Calgary, AB T2N 1N4, Canada	Linnaeus University; University of Kalmar; University of Queensland; University of Queensland; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Calgary	Rosengren, KJ (corresponding author), Univ Kalmar, Dept Chem & Biomed Sci, SE-39182 Kalmar, Sweden.	johan.rosengren@hik.se	Daly, Norelle L/D-4302-2013; Haugaard-Kedstrom, Linda/F-3705-2011; Rosengren, K. Johan/P-4450-2016; Craik, David/B-1695-2010; Haugaard-Kedstrom, Linda/O-7121-2014	Daly, Norelle L/0000-0002-4697-6602; Haugaard-Kedstrom, Linda/0000-0003-0113-6535; Rosengren, K. Johan/0000-0002-5007-8434; Craik, David/0000-0003-0007-6796; Haugaard-Kedstrom, Linda/0000-0003-0113-6535	NIDDK NIH HHS [DK44632] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK044632, R01DK044632] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayabe T, 2002, J BIOL CHEM, V277, P5219, DOI 10.1074/jbc.M109410200; Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Bateman A, 1996, J BIOL CHEM, V271, P10654, DOI 10.1074/jbc.271.18.10654; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; Cierpicki T, 2001, J BIOMOL NMR, V21, P249, DOI 10.1023/A:1012911329730; Cierpicki T, 2002, J MAGN RESON, V157, P178, DOI 10.1006/jmre.2002.2597; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; Jing WG, 2004, BIOCHEMISTRY-US, V43, P15759, DOI 10.1021/bi048645p; JONES DE, 1992, J BIOL CHEM, V267, P23216; Joshi MD, 1997, PROTEIN SCI, V6, P2667; Keller R., 2004, COMPUTER AIDED RESON, V1; LEHRER RI, 1988, J IMMUNOL METHODS, V108, P153, DOI 10.1016/0022-1759(88)90414-0; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; Maemoto A, 2004, J BIOL CHEM, V279, P44188, DOI 10.1074/jbc.M406154200; MATTHEW JB, 1985, CRC CR REV BIOCH MOL, V18, P91, DOI 10.3109/10409238509085133; McManus AM, 2000, BIOCHEMISTRY-US, V39, P15757, DOI 10.1021/bi000457l; OUELLETTE AJ, 1992, FEBS LETT, V304, P146, DOI 10.1016/0014-5793(92)80606-H; OUELLETTE AJ, 1994, INFECT IMMUN, V62, P5040, DOI 10.1128/IAI.62.11.5040-5047.1994; PARDI A, 1988, J MOL BIOL, V201, P625, DOI 10.1016/0022-2836(88)90643-2; PARDI A, 1992, BIOCHEMISTRY-US, V31, P11357, DOI 10.1021/bi00161a013; Rosengren KJ, 2003, J BIOL CHEM, V278, P8606, DOI 10.1074/jbc.M211147200; Salzman NH, 2003, INFECT IMMUN, V71, P1109, DOI 10.1128/IAI.71.3.1109-1115.2003; Satchell DP, 2003, PEPTIDES, V24, P1795, DOI 10.1016/j.peptides.2003.08.020; Satchell DP, 2003, J BIOL CHEM, V278, P13838, DOI 10.1074/jbc.M212115200; SATOH Y, 1986, DIGESTION, V34, P115, DOI 10.1159/000199319; SATOH Y, 1988, CELL TISSUE RES, V251, P87, DOI 10.1007/BF00215451; Selsted M E, 1993, Genet Eng (N Y), V15, P131; Selsted ME, 2005, NAT IMMUNOL, V6, P551, DOI 10.1038/ni1206; SELSTED ME, 1989, J BIOL CHEM, V264, P4003; Shirafuji Y, 2003, J BIOL CHEM, V278, P7910, DOI 10.1074/jbc.M210600200; TANG YQ, 1993, J BIOL CHEM, V268, P6649; Tang YQ, 1999, SCIENCE, V286, P498, DOI 10.1126/science.286.5439.498; WAGNER G, 1990, PROG NUCL MAG RES SP, V22, P101, DOI 10.1016/0079-6565(90)80003-Z; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Wu ER, 1998, PEPTIDES, V19, P793, DOI 10.1016/S0196-9781(98)00016-3; Wu ZB, 2005, J BIOL CHEM, V280, P43039, DOI 10.1074/jbc.M510562200; Xie C, 2005, J BIOL CHEM, V280, P32921, DOI 10.1074/jbc.M503084200	42	37	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28068	28078		10.1074/jbc.M604992200	http://dx.doi.org/10.1074/jbc.M604992200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16857681	hybrid			2022-12-25	WOS:000240534400044
J	Berasi, SP; Huard, C; Li, DM; Shih, HH; Sun, Y; Zhong, WY; Paulsen, JE; Brown, EL; Gimeno, RE; Martinez, RV				Berasi, Stephen P.; Huard, Christine; Li, Dongmei; Shih, Heather H.; Sun, Ying; Zhong, Wenyan; Paulsen, Janet E.; Brown, Eugene L.; Gimeno, Ruth E.; Martinez, Robert V.			Inhibition of gluconeogenesis through transcriptional activation of EGR1 and DUSP4 by AMP-activated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; PROTEIN-KINASE; INSULIN-RESISTANCE; GENE-EXPRESSION; CELLULAR-ENERGY; GLUCOSE; PHOSPHORYLATION; LIVER; GROWTH; PEPCK	Increased hepatic gluconeogenesis is an important contributor to the fasting hyperglycemia found in Type 2 diabetic patients. Low energy states activate the intracellular energy sensor AMP-activated kinase (AMPK). AMPK activation by the AMP mimetic AICAR (5-aminoimidazole-4-carboxamide riboside) has been shown to inhibit hepatic gluconeogenesis. We used transcriptional profiling to search for AICAR-regulated genes in hepatocyte cell lines. We report that a dual specificity phosphatase, Dusp4, is induced by AMPK in AML12, H4IIE, and Fao cells at both mRNA and protein levels. AMPK also induces the immediate early transcription factor Egr1 (early growth response 1), a known transcriptional activator of Dusp4, and it directly binds the Dusp4 promoter at its known binding site. Both reporter gene assays and real time PCR demonstrate that exogenous DUSP4 inhibits the promoter activity and expression of both glucose-6-phosphatase (Glc-6-P) and phosphoenolpyruvate carboxykinase (Pepck) to an extent similar to both AICAR and constitutively active AMPK. Conversely, depletion of EGR1 or DUSP4 using siRNA not only partially abrogates the inhibition of Pepck expression by AICAR, but also importantly affects glucose production by Fao cells. In Fao cells, small interfering RNA targeted EGR1 also depletes DUSP4 expression following treatment with AICAR, further supporting a direct link between EGR1 and DUSP4 activation. Expression of a constitutively active form of p38, a known effector of cAMP-mediated gluconeogenesis, rescues the DUSP4-mediated repression of PEPCK. These results suggest that the inhibition of hepatic gluconeogenesis by AMPK may, in part, be mediated by an immediate early gene response involving EGR1 and its target, DUSP4.	Wyeth Ayerst Res, Dept Biol Technol, Cambridge, MA 02140 USA; Wyeth Ayerst Res, Dept Cardiovasc & Metab Dis, Cambridge, MA 02140 USA	Pfizer; Pfizer	Martinez, RV (corresponding author), Wyeth Ayerst Res, Dept Biol Technol, 87 Cambridgepk Dr, Cambridge, MA 02140 USA.	rxmartinez@wyeth.com						Andreelli F, 2006, ENDOCRINOLOGY, V147, P2432, DOI 10.1210/en.2005-0898; Banerjee RR, 2004, SCIENCE, V303, P1195, DOI 10.1126/science.1092341; Cao WH, 2005, J BIOL CHEM, V280, P42731, DOI 10.1074/jbc.M506223200; Chen PL, 2001, J BIOL CHEM, V276, P29440, DOI 10.1074/jbc.M103463200; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x; Foretz M, 2005, DIABETES, V54, P1331, DOI 10.2337/diabetes.54.5.1331; Foretz M, 1998, J BIOL CHEM, V273, P14767, DOI 10.1074/jbc.273.24.14767; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Hardie DG, 2003, FEBS LETT, V546, P113, DOI 10.1016/S0014-5793(03)00560-X; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hong YH, 2003, J BIOL CHEM, V278, P27495, DOI 10.1074/jbc.M304112200; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jakobsen SN, 2001, J BIOL CHEM, V276, P46912, DOI 10.1074/jbc.C100483200; Jorgensen SB, 2004, DIABETES, V53, P3074, DOI 10.2337/diabetes.53.12.3074; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kawaguchi T, 2001, P NATL ACAD SCI USA, V98, P13710, DOI 10.1073/pnas.231370798; Koo SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967; Kotlyarov A, 2002, MOL CELL BIOL, V22, P4827, DOI 10.1128/MCB.22.13.4827-4835.2002; Leff T, 2003, BIOCHEM SOC T, V31, P224; Levkovitz Y, 2002, J NEUROSCI, V22, P3845, DOI 10.1523/JNEUROSCI.22-10-03845.2002; Lochhead PA, 2000, DIABETES, V49, P896, DOI 10.2337/diabetes.49.6.896; Moller DE, 2001, NATURE, V414, P821, DOI 10.1038/414821a; MUNDAY MR, 1988, EUR J BIOCHEM, V175, P331, DOI 10.1111/j.1432-1033.1988.tb14201.x; Muse ED, 2004, J CLIN INVEST, V114, P232, DOI 10.1172/JCI200421270; Nakatani Y, 2004, J BIOL CHEM, V279, P45803, DOI 10.1074/jbc.M406963200; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Stein CJ, 2004, J CLIN ENDOCR METAB, V89, P2522, DOI 10.1210/jc.2004-0288; Sutherland C, 1996, PHILOS T ROY SOC B, V351, P191, DOI 10.1098/rstb.1996.0016; Vincent MF, 1996, DIABETOLOGIA, V39, P1148, DOI 10.1007/BF02658500; Winder WW, 1997, J APPL PHYSIOL, V82, P219, DOI 10.1152/jappl.1997.82.1.219; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Wu Chaodong, 2005, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V5, P51, DOI 10.2174/1568008053174769; Xu HY, 2005, J BIOL CHEM, V280, P36013, DOI 10.1074/jbc.M508027200; Xu HY, 2003, J BIOL CHEM, V278, P30187, DOI 10.1074/jbc.M302010200; Yang WB, 2001, J BIOL CHEM, V276, P38341, DOI 10.1074/jbc.C100316200; Yu JX, 2004, MOL CELL, V15, P83, DOI 10.1016/j.molcel.2004.06.030; Zhang T, 2001, J BIOL CHEM, V276, P45604, DOI 10.1074/jbc.M107075200	38	65	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27167	27177		10.1074/jbc.M602416200	http://dx.doi.org/10.1074/jbc.M602416200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16849326	hybrid			2022-12-25	WOS:000240397700044
J	Veit, G; Hansen, U; Keene, DR; Bruckner, P; Chiquet-Ehrismann, R; Chiquet, M; Koch, M				Veit, Guido; Hansen, Uwe; Keene, Douglas R.; Bruckner, Peter; Chiquet-Ehrismann, Ruth; Chiquet, Matthias; Koch, Manuel			Collagen XII interacts with Avian tenascin-X through its NC3 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; EHLERS-DANLOS-SYNDROME; CHICK MYOTENDINOUS ANTIGEN; OLIGOMERIC MATRIX PROTEIN; EXTRACELLULAR-MATRIX; EMBRYONIC-DEVELOPMENT; SPLICE VARIANTS; CELL-ADHESION; IX COLLAGEN; VI COLLAGEN	Large oligomeric proteins often contain several binding sites for different molecules and can therefore induce formation of larger protein complexes. Collagen XII, a multidomain protein with a small collagenous region, interacts with fibrillar collagens through its C-terminal region. However, no interactions to other extracellular proteins have been identified involving the non-collagenous N-terminal NC3 domain. To further elucidate the components of protein complexes present close to collagen fibrils, different extracellular matrix proteins were tested for interaction in a solid phase assay. Binding to the NC3 domain of collagen XII was found for the avian homologue of tenascin-X that in humans is linked to Ehlers-Danlos disease. The binding was further characterized by surface plasmon resonance spectroscopy and supported by immunohistochemical co-localization in chick and mouse tissue. On the ultrastructural level, detection of collagen XII and tenascin-X by immunogold labeling confirmed this finding.	Univ Cologne, Fac Med, Ctr Biochem, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Dept Dermatol, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Ctr Mol Med Cologne, D-50931 Cologne, Germany; Univ Klinikum Munster, Inst Physiol Chem & Pathobiochem, D-48129 Munster, Germany; Shriners Hosp Children, Res Ctr, Portland, OR 97239 USA; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	University of Cologne; University of Cologne; University of Cologne; University of Munster; Friedrich Miescher Institute for Biomedical Research	Koch, M (corresponding author), Univ Cologne, Fac Med, Ctr Biochem, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.	Manuel.Koch@uni-koeln.de	Bruckner, Peter/F-4817-2019; Veit, Guido/C-9596-2009; Koch, Manuel/AAG-9914-2021	Bruckner, Peter/0000-0002-5566-5611; Veit, Guido/0000-0002-6758-2696; Koch, Manuel/0000-0002-2962-7814; Chiquet, Matthias/0000-0001-7812-4853				Aubert-Foucher E, 2001, BIOCHEM BIOPH RES CO, V286, P1131, DOI 10.1006/bbrc.2001.5522; BOHME K, 1995, DEV DYNAM, V204, P432; Bristow J, 2005, AM J MED GENET C, V139C, P24, DOI 10.1002/ajmg.c.30071; Budde B, 2005, MOL CELL BIOL, V25, P10465, DOI 10.1128/MCB.25.23.10465-10478.2005; Burch GH, 1997, NAT GENET, V17, P104, DOI 10.1038/ng0997-104; CHIQUET M, 1984, J CELL BIOL, V98, P1937, DOI 10.1083/jcb.98.6.1937; CHIQUET M, 1984, J CELL BIOL, V98, P1926, DOI 10.1083/jcb.98.6.1926; Elefteriou F, 1999, EUR J BIOCHEM, V263, P840, DOI 10.1046/j.1432-1327.1999.00563.x; Elefteriou F, 2001, FEBS LETT, V495, P44, DOI 10.1016/S0014-5793(01)02361-4; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; Fluck M, 2000, J CELL SCI, V113, P3583; Font B, 1998, EUR J BIOCHEM, V254, P580, DOI 10.1046/j.1432-1327.1998.2540580.x; GORDON MK, 1987, P NATL ACAD SCI USA, V84, P6040, DOI 10.1073/pnas.84.17.6040; Groenen MAM, 2000, GENOME RES, V10, P137; Hagios C, 1999, EXP CELL RES, V253, P607, DOI 10.1006/excr.1999.4658; Hagios C, 1996, J CELL BIOL, V134, P1499, DOI 10.1083/jcb.134.6.1499; Holden P, 2001, J BIOL CHEM, V276, P6046, DOI 10.1074/jbc.M009507200; JONES FS, 1989, P NATL ACAD SCI USA, V86, P1905, DOI 10.1073/pnas.86.6.1905; Jones FS, 2000, DEV DYNAM, V218, P235, DOI 10.1002/(SICI)1097-0177(200006)218:2<235::AID-DVDY2>3.3.CO;2-7; Kania AM, 1999, J BIOL CHEM, V274, P22053, DOI 10.1074/jbc.274.31.22053; Kapyla J, 2004, J BIOL CHEM, V279, P51677, DOI 10.1074/jbc.M409412200; Kassner A, 2003, MATRIX BIOL, V22, P131, DOI 10.1016/S0945-053X(03)00008-8; KEENE DR, 1991, J CELL BIOL, V113, P971, DOI 10.1083/jcb.113.4.971; KOCH M, 1992, EUR J BIOCHEM, V207, P847, DOI 10.1111/j.1432-1033.1992.tb17116.x; KOCH M, 1995, J CELL BIOL, V130, P1005, DOI 10.1083/jcb.130.4.1005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lethias C, 1996, MATRIX BIOL, V15, P11, DOI 10.1016/S0945-053X(96)90122-5; Lethias C, 2001, J BIOL CHEM, V276, P16432, DOI 10.1074/jbc.M010210200; Mao JR, 2002, NAT GENET, V30, P421, DOI 10.1038/ng850; MATSUMOTO K, 1994, J CELL BIOL, V125, P483, DOI 10.1083/jcb.125.2.483; Minamitani T, 2004, EXP CELL RES, V298, P305, DOI 10.1016/j.yexcr.2004.04.030; Minamitani T, 2004, EXP CELL RES, V297, P49, DOI 10.1016/j.yexcr.2004.03.002; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; NISHIYAMA T, 1994, J BIOL CHEM, V269, P28193; Nolte M, 1999, FEBS LETT, V452, P379, DOI 10.1016/S0014-5793(99)00666-3; OH SP, 1993, DEV DYNAM, V196, P37, DOI 10.1002/aja.1001960105; Pihlajamaa T, 2004, J BIOL CHEM, V279, P24265, DOI 10.1074/jbc.M402865200; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; TRUEB J, 1992, BIOCHIM BIOPHYS ACTA, V1171, P97, DOI 10.1016/0167-4781(92)90145-P; Veit G, 2006, J BIOL CHEM, V281, P3494, DOI 10.1074/jbc.M509333200; WALCHLI C, 1994, J CELL SCI, V107, P669; YAMAGATA M, 1991, J CELL BIOL, V115, P209, DOI 10.1083/jcb.115.1.209	43	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27461	27470		10.1074/jbc.M603147200	http://dx.doi.org/10.1074/jbc.M603147200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16861231	hybrid			2022-12-25	WOS:000240397700073
J	Bhalla, V; Oyster, NM; Fitch, AC; Wijngaarden, MA; Neumann, D; Schlattner, U; Pearce, D; Hallows, KR				Bhalla, Vivek; Oyster, Nicholas M.; Fitch, Adam C.; Wijngaarden, Marjolein A.; Neumann, Dietbert; Schlattner, Uwe; Pearce, David; Hallows, Kenneth R.			AMP-activated kinase inhibits the epithelial Na+ channel through functional regulation of the ubiquitin ligase Nedd4-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; TOAD URINARY-BLADDER; PROTEIN-KINASE; SODIUM-CHANNEL; LIDDLES-SYNDROME; SUBUNIT STOICHIOMETRY; MEMBRANE-TRANSPORT; GLUCOSE-TRANSPORT; GAMMA-SUBUNIT; BETA-SUBUNIT	We recently found that the metabolic sensor AMP-activated kinase (AMPK) inhibits the epithelial Na+ channel (ENaC) through decreased plasma membrane ENaC expression, an effect requiring the presence of a binding motif in the cytoplasmic tail of the beta-ENaC subunit for the ubiquitin ligase Nedd4-2. To further examine the role of Nedd4-2 in the regulation of ENaC by AMPK, we studied the effects of AMPK activation on ENaC currents in Xenopus oocytes co-expressing ENaC and wild-type (WT) or mutant forms of Nedd4-2. ENaC inhibition by AMPK was preserved in oocytes expressing WT Nedd4-2 but blocked in oocytes expressing either a dominant-negative (DN) or constitutively active (CA) Nedd4-2 mutant, suggesting that AMPK-dependent modulation of Nedd4-2 function is involved. Similar experiments utilizing WT or mutant forms of the serum- and glucocorticoid-regulated kinase (SGK1), modulators of protein kinase A(PKA), or extracellular-regulated kinase (ERK) did not affect ENaC inhibition by AMPK, suggesting that these pathways known to modulate the Nedd4-2-ENaC interaction are not responsible. AMPK-dependent phosphorylation of Nedd4-2 expressed in HEK-293 cells occurred both in vitro and in vivo, suggesting a potential mechanism for modulation of Nedd4-2 and thus cellular ENaC activity. Moreover, cellular AMPK activation significantly enhanced the interaction of the beta-ENaC subunit with Nedd4-2, as measured by co-immunoprecipitation assays in HEK-293 cells. In summary, these results suggest a novel mechanism for ENaC regulation in which AMPK promotes ENaC-Nedd4-2 interaction, thereby inhibiting ENaC by increasing Nedd4-2-dependent ENaC retrieval from the plasma membrane. AMPK-dependent ENaC inhibition may limit cellular Na+ loading under conditions of metabolic stress when AMPK becomes activated.	Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA 94107 USA; ETH, Inst Cell Biol, CH-8093 Zurich, Switzerland	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Francisco; Swiss Federal Institutes of Technology Domain; ETH Zurich	Hallows, KR (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, 5976 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	hallows@pitt.edu	Schlattner, Uwe/D-1267-2009; Wijngaarden, Marjolein A/F-9438-2010	Schlattner, Uwe/0000-0003-1159-5911; Wijngaarden, Marjolein A/0000-0002-4697-0286; Hallows, Kenneth/0000-0002-2964-2440; Neumann, Dietbert/0000-0002-4316-684X; Bhalla, Vivek/0000-0002-5420-9657	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK059477, R01DK075048, K08DK071648, R01DK056695, R03DK068390] Funding Source: NIH RePORTER; NIDDK NIH HHS [R03 DK068390, R01 DK075048-01A1, R01 DK075048, R03 DK068390-01, R01 DK056695, K08 DK071648, R03 DK068390-02, K08 DK059477] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Bhalla V, 2005, MOL ENDOCRINOL, V19, P3073, DOI 10.1210/me.2005-0193; Blazer-Yost BL, 1999, AM J PHYSIOL-CELL PH, V277, pC531, DOI 10.1152/ajpcell.1999.277.3.C531; Boehmer C, 2003, J NEUROCHEM, V86, P1181, DOI 10.1046/j.1471-4159.2003.01937.x; Booth RE, 2003, AM J PHYSIOL-RENAL, V284, pF938, DOI 10.1152/ajprenal.00373.2002; Carattino MD, 2005, J BIOL CHEM, V280, P17608, DOI 10.1074/jbc.M501770200; Carattino MD, 2003, J BIOL CHEM, V278, P36202, DOI 10.1074/jbc.M300312200; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Chen HC, 2002, J BIOL CHEM, V277, P23554, DOI 10.1074/jbc.M201152200; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Dieter M, 2004, OBES RES, V12, P862, DOI 10.1038/oby.2004.104; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; FRINDT G, 1995, AM J PHYSIOL-RENAL, V268, pF480, DOI 10.1152/ajprenal.1995.268.3.F480; Gallagher E, 2006, P NATL ACAD SCI USA, V103, P1717, DOI 10.1073/pnas.0510664103; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GARTY H, 1983, J MEMBRANE BIOL, V74, P15, DOI 10.1007/BF01870591; GULLANS SR, 2000, KIDNEY PHYSL PATHOPH, P443; Hallows KR, 2005, CURR OPIN NEPHROL HY, V14, P464, DOI 10.1097/01.mnh.0000174145.14798.64; Hallows KR, 2003, J BIOL CHEM, V278, P998, DOI 10.1074/jbc.M210621200; Hamilton SR, 2001, FEBS LETT, V500, P163, DOI 10.1016/S0014-5793(01)02602-3; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Ichimura T, 2005, J BIOL CHEM, V280, P13187, DOI 10.1074/jbc.M412884200; Jiang QS, 1998, J CELL BIOL, V143, P645, DOI 10.1083/jcb.143.3.645; Kamynina E, 2002, AM J PHYSIOL-RENAL, V283, pF377, DOI 10.1152/ajprenal.00143.2002; Kamynina E, 2001, KIDNEY INT, V60, P466, DOI 10.1046/j.1523-1755.2001.060002466.x; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Kim J, 2001, J BIOL CHEM, V276, P19102, DOI 10.1074/jbc.M011579200; Knight KK, 2006, P NATL ACAD SCI USA, V103, P2805, DOI 10.1073/pnas.0511184103; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Lemieux K, 2003, FASEB J, V17, P1658, DOI 10.1096/fj.02-1125com; Liang XB, 2006, J BIOL CHEM, V281, P16323, DOI 10.1074/jbc.M601360200; Malik B, 2005, AM J PHYSIOL-RENAL, V289, pF107, DOI 10.1152/ajprenal.00179.2002; Michlig S, 2005, J BIOL CHEM, V280, P38264, DOI 10.1074/jbc.M506308200; Nagaki K, 2006, BIOCHEMISTRY-US, V45, P6733, DOI 10.1021/bi052640q; Neumann D, 2003, PROTEIN EXPRES PURIF, V30, P230, DOI 10.1016/S1046-5928(03)00126-8; Palmada M, 2004, AM J PHYSIOL-GASTR L, V287, pG143, DOI 10.1152/ajpgi.00121.2003; PALMER LG, 1980, J MEMBRANE BIOL, V57, P59, DOI 10.1007/BF01868986; Planes C, 2002, J BIOL CHEM, V277, P47318, DOI 10.1074/jbc.M209158200; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shearwin-Whyatt L, 2006, BIOESSAYS, V28, P617, DOI 10.1002/bies.20422; Sheng S, 2006, AM J PHYSIOL-RENAL, V290, pF1488, DOI 10.1152/ajprenal.00439.2005; Shi HK, 2002, J BIOL CHEM, V277, P13539, DOI 10.1074/jbc.M111717200; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Snyder PM, 2004, J BIOL CHEM, V279, P45753, DOI 10.1074/jbc.M407858200; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Snyder PM, 2000, J CLIN INVEST, V105, P45, DOI 10.1172/JCI7869; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Soundararajan R, 2005, J BIOL CHEM, V280, P39970, DOI 10.1074/jbc.M508658200; Staruschenko A, 2005, BIOPHYS J, V88, P3966, DOI 10.1529/biophysj.104.056804; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Staub O, 2000, KIDNEY INT, V57, P809, DOI 10.1046/j.1523-1755.2000.00919.x; Staub O, 2006, PHYSIOL REV, V86, P669, DOI 10.1152/physrev.00020.2005; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; Thome UH, 2003, AM J PHYSIOL-LUNG C, V284, pL376, DOI 10.1152/ajplung.00218.2002; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woollhead AM, 2005, J PHYSIOL-LONDON, V566, P781, DOI 10.1113/jphysiol.2005.088674; Xi X, 2001, J BIOL CHEM, V276, P41029, DOI 10.1074/jbc.M102824200; Yang LM, 2006, J BIOL CHEM, V281, P9859, DOI 10.1074/jbc.M512046200; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	65	128	129	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26159	26169		10.1074/jbc.M606045200	http://dx.doi.org/10.1074/jbc.M606045200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16844684	hybrid			2022-12-25	WOS:000240249500032
J	Croteau, DL; DellaVecchia, MJ; Wang, H; Bienstock, RJ; Melton, MA; Van Houten, B				Croteau, Deborah L.; DellaVecchia, Matthew J.; Wang, Hong; Bienstock, Rachelle J.; Melton, Mark A.; Van Houten, Bennett			The C-terminal zinc finger of UvrA does not bind DNA directly but regulates damage-specific DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI UVRA; NUCLEOTIDE EXCISION-REPAIR; SITE-SPECIFIC MUTAGENESIS; ATP-BINDING; CRYSTAL-STRUCTURE; ABC TRANSPORTER; (A)BC EXCINUCLEASE; CASSETTE DIMER; XPA PROTEIN; RECOGNITION	In prokaryotic nucleotide excision repair, UvrA recognizes DNA perturbations and recruits UvrB for the recognition and processing steps in the reaction. One of the most remarkable aspects of UvrA is that it can recognize a wide range of DNA lesions that differ in chemistry and structure. However, how UvrA interacts with DNA is unknown. To examine the role that the UvrA C-terminal zinc finger domain plays in DNA binding, an eleven amino acid deletion was constructed (ZnG UvrA). Biochemical characterization of the ZnG UvrA protein was carried out using UvrABC DNA incision, DNA binding and ATPase assays. Although ZnG UvrA was able to bind dsDNA slightly better than wild-type UvrA, the ZnG UvrA mutant only supported 50-75% of wild type incision. Surprisingly, the ZnG UvrA mutant, while retaining its ability to bind dsDNA, did not support damage-specific binding. Furthermore, this mutant protein only provided 10% of wild-type Bca UvrA complementation for UV survival of an uvrA deletion strain. In addition, ZnG UvrA failed to stimulate the UvrB DNA damage-associated ATPase activity. Electrophoretic mobility shift analysis was used to monitor UvrB loading onto damaged DNA with wildtype UvrA or ZnG UvrA. The ZnG UvrA protein showed a 30-60% reduction in UvrB loading as compared with the amount of UvrB loaded by wild-type UvrA. These data demonstrate that the C-terminal zinc finger of UvrA is required for regulation of damage-specific DNA binding.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Sci Comp Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Summers Discovery Program, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Van Houten, B (corresponding author), NIEHS, Mol Genet Lab, NIH, 111 TW Alexander Dr,POB 12233, Res Triangle Pk, NC 27709 USA.	vanhout1@niehs.nih.gov	Messier, Claude/A-2322-2008; Croteau, Deb/AAP-5933-2020; Wang, Hong/F-3164-2014; Van Houten, Bennett/K-2284-2019	Messier, Claude/0000-0002-4791-1763; Wang, Hong/0000-0003-0165-3559; Bienstock, Rachelle/0000-0001-5228-3610; Croteau, Deborah/0000-0002-6094-4084	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES061060] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 ES061060-09] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ASAHINA H, 1994, MUTAT RES-DNA REPAIR, V315, P229, DOI 10.1016/0921-8777(94)90034-5; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Batty DP, 2000, GENE, V241, P193, DOI 10.1016/S0378-1119(99)00489-8; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11388; CROTEAU DL, 2005, DNA DAMAGE RECOGNITI, P111; DellaVecchia MJ, 2004, J BIOL CHEM, V279, P45245, DOI 10.1074/jbc.M408659200; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; DOOLITTLE RF, 1986, NATURE, V323, P451, DOI 10.1038/323451a0; Gattiker A, 2003, COMPUT BIOL CHEM, V27, P49, DOI 10.1016/S1476-9271(02)00094-4; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; Kulkarni Amit S, 2006, Indian J Exp Biol, V44, P7; Kuraoka I, 1996, MUTAT RES-DNA REPAIR, V362, P87, DOI 10.1016/0921-8777(95)00038-0; Li JZ, 2003, STRUCTURE, V11, P1475, DOI 10.1016/j.str.2003.10.012; LIN JJ, 1992, J BIOL CHEM, V267, P17693; Lu G, 2005, P NATL ACAD SCI USA, V102, P17969, DOI 10.1073/pnas.0506039102; Matthews JM, 2002, IUBMB LIFE, V54, P351, DOI 10.1080/15216540216035; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; MIYAMOTO I, 1992, J BIOL CHEM, V267, P12182; Moolenaar GF, 2001, EMBO J, V20, P6140, DOI 10.1093/emboj/20.21.6140; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3824, DOI 10.1021/bi00230a004; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3834, DOI 10.1021/bi00230a005; NAVARATNAM S, 1989, J BIOL CHEM, V264, P16067; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; Park SM, 2002, BIOCHEMISTRY-US, V41, P4137, DOI 10.1021/bi015961k; Reardon JT, 2004, CELL CYCLE, V3, P141; REARDON JT, 1993, J BIOL CHEM, V268, P21301; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Schofield MJ, 1998, BIOCHEMISTRY-US, V37, P7733, DOI 10.1021/bi980399s; Skorvaga M, 2002, J BIOL CHEM, V277, P1553, DOI 10.1074/jbc.M108847200; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; THIAGALINGAM S, 1993, J BIOL CHEM, V268, P18382; Truglio JJ, 2006, CHEM REV, V106, P233, DOI 10.1021/cr040471u; Truglio JJ, 2004, EMBO J, V23, P2498, DOI 10.1038/sj.emboj.7600263; Van Houten B, 2005, MUTAT RES-FUND MOL M, V577, P92, DOI 10.1016/j.mrfmmm.2005.03.013; VISSE R, 1993, MUTAT RES, V294, P263, DOI 10.1016/0921-8777(93)90009-6; WANG JT, 1993, J BIOL CHEM, V268, P5323; WANG JT, 1994, J BIOL CHEM, V269, P10771; ZIEGELHOFFER T, 1995, J BIOL CHEM, V270, P10412, DOI 10.1074/jbc.270.18.10412	45	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26370	26381		10.1074/jbc.M603093200	http://dx.doi.org/10.1074/jbc.M603093200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829526	Green Accepted, hybrid			2022-12-25	WOS:000240249500054
J	Sherman, DH; Li, SY; Yermalitskaya, LV; Kim, YC; Smith, JA; Waterman, MR; Podust, LM				Sherman, David H.; Li, Shengying; Yermalitskaya, Liudmila V.; Kim, Youngchang; Smith, Jarrod A.; Waterman, Michael R.; Podust, Larissa M.			The structural basis for substrate anchoring, active site selectivity, and product formation by P450 PikC from Streptomyces venezuelae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMBINATORIAL BIOSYNTHESIS; MACROLIDE ANTIBIOTICS; THERMOPHILIC CYTOCHROME-P450; SULFOLOBUS-SOLFATARICUS; ABSOLUTE CONFIGURATION; POLYKETIDE SYNTHASES; CRYSTAL-STRUCTURE; DESOSAMINE; HYDROXYLATION; CONSTRUCTION	The pikromycin (Pik)/methymycin biosynthetic pathway of Streptomyces venezuelae represents a valuable system for dissecting the fundamental mechanisms of modular polyketide biosynthesis, aminodeoxysugar assembly, glycosyltransfer, and hydroxylation leading to the production of a series of macrolide antibiotics, including the natural ketolides narbomycin and pikromycin. In this study, we describe four x-ray crystal structures and allied functional studies for PikC, the remarkable P450 monooxygenase responsible for production of a number of related macrolide products from the Pik pathway. The results provide important new insights into the structural basis for the C10/C12 and C12/C14 hydroxylation patterns for the 12-(YC-17) and 14-membered ring (narbomycin) macrolides, respectively. This includes two different ligand-free structures in an asymmetric unit (resolution 2.1 angstrom) and two co-crystal structures with bound endogenous substrates YC-17 (resolution 2.35 angstrom) or narbomycin (resolution 1.7 angstrom). A central feature of the enzyme-substrate interaction involves anchoring of the desosamine residue in two alternative binding pockets based on a series of distinct amino acid residues that form a salt bridge and a hydrogen-bonding network with the deoxysugar C3' dimethylamino group. Functional significance of the salt bridge was corroborated by site-directed mutagenesis that revealed a key role for Glu-94 in YC-17 binding and Glu-85 for narbomycin binding. Taken together, the x-ray structure analysis, site-directed mutagenesis, and corresponding product distribution studies reveal that PikC substrate tolerance and product diversity result from a combination of alternative anchoring modes rather than an induced fit mechanism.	Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Struct Biol, Nashville, TN 37232 USA; Argonne Natl Lab, Struct Biol Ctr, Argonne, IL 60439 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Vanderbilt University; Vanderbilt University; United States Department of Energy (DOE); Argonne National Laboratory	Sherman, DH (corresponding author), Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.	davidhs@umich.edu; m.podust@vanderbilt.edu	Podust, Larissa/ABB-7940-2020	Podust, Larissa/0000-0002-8537-8760; Kim, Youngchang/0000-0002-1610-4889	NIEHS NIH HHS [ES00627] Funding Source: Medline; NIGMS NIH HHS [R37 GM037942, GM69970, GM37942, R01 GM078553, GM078553, R01 GM069970, R37 GM037942-14, R01 GM078553-01, R01 GM069970-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069970, R01GM037942, R01GM078553, R37GM037942] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackermann G, 2003, J ANTIMICROB CHEMOTH, V51, P497, DOI 10.1093/jac/dkg123; ANLIKER R, 1956, HELV CHIM ACTA, V39, P1785, DOI 10.1002/hlca.19560390637; Auerbach T, 2004, TRENDS BIOTECHNOL, V22, P570, DOI 10.1016/j.tibtech.2004.09.006; Baltz RH, 1998, TRENDS MICROBIOL, V6, P76, DOI 10.1016/S0966-842X(97)01161-X; Berisio R, 2003, NAT STRUCT BIOL, V10, P366, DOI 10.1038/nsb915; Borisova SA, 1999, ORG LETT, V1, P133, DOI 10.1021/ol9906007; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chandrasena REP, 2004, J AM CHEM SOC, V126, P115, DOI 10.1021/ja038237t; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; de Visser SP, 2002, J AM CHEM SOC, V124, P11809, DOI 10.1021/ja026872d; DJERASSI C, 1958, TETRAHEDRON, V4, P369, DOI 10.1016/0040-4020(58)80058-7; DJERASSI C, 1957, J AM CHEM SOC, V79, P3926, DOI 10.1021/ja01571a088; Furneri P M, 1991, J Chemother, V3 Suppl 1, P24; GOLDMAN RC, 1990, ANTIMICROB AGENTS CH, V34, P426, DOI 10.1128/AAC.34.3.426; Goldman Robert C., 2004, Current Drug Targets - Infectious Disorders, V4, P241, DOI 10.2174/1568005043340812; Hansen JL, 2002, MOL CELL, V10, P117, DOI 10.1016/S1097-2765(02)00570-1; Hilal SH, 1995, QUANT STRUCT-ACT REL, V14, P348, DOI 10.1002/qsar.19950140405; Hutchinson CR, 1998, CURR OPIN MICROBIOL, V1, P319, DOI 10.1016/S1369-5274(98)80036-2; Jin SX, 2003, J AM CHEM SOC, V125, P3406, DOI 10.1021/ja029272n; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Khosla C, 1999, ANNU REV BIOCHEM, V68, P219, DOI 10.1146/annurev.biochem.68.1.219; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee SK, 2006, J NAT PROD, V69, P847, DOI 10.1021/np060026p; Menzella HG, 2005, NAT BIOTECHNOL, V23, P1171, DOI 10.1038/nbt1128; Meunier B, 2004, CHEM REV, V104, P3947, DOI 10.1021/cr020443g; Modi S, 1996, NAT STRUCT BIOL, V3, P414, DOI 10.1038/nsb0596-414; Nagano S, 2003, J BIOL CHEM, V278, P44886, DOI 10.1074/jbc.M308115200; Nagano S, 2005, J BIOL CHEM, V280, P31659, DOI 10.1074/jbc.M505261200; OMURA T, 1964, J BIOL CHEM, V239, P2379; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park SY, 2002, J INORG BIOCHEM, V91, P491, DOI 10.1016/S0162-0134(02)00446-4; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; Reeves CD, 2003, CRIT REV BIOTECHNOL, V23, P95, DOI 10.1080/713609311; Retsema J, 2001, INT J ANTIMICROB AG, V18, pS3, DOI 10.1016/S0924-8579(01)00401-0; Rix U, 2002, NAT PROD REP, V19, P542, DOI 10.1039/b103920m; Schlunzen F, 2003, STRUCTURE, V11, P329, DOI 10.1016/S0969-2126(03)00022-4; Schlunzen F, 2001, NATURE, V413, P814, DOI 10.1038/35101544; Scott EE, 2003, P NATL ACAD SCI USA, V100, P13196, DOI 10.1073/pnas.2133986100; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Tang L, 2001, CHEM BIOL, V8, P547, DOI 10.1016/S1074-5521(01)00032-1; Vaz ADN, 1998, P NATL ACAD SCI USA, V95, P3555, DOI 10.1073/pnas.95.7.3555; Xue YQ, 1998, CHEM BIOL, V5, P661, DOI 10.1016/S1074-5521(98)90293-9; Yano JK, 2000, J BIOL CHEM, V275, P31086, DOI 10.1074/jbc.M004281200; Yonath A, 2005, MOL CELLS, V20, P1; Yoon YJ, 2002, CHEM BIOL, V9, P203, DOI 10.1016/S1074-5521(02)00095-9; Zhang QB, 2001, J NAT PROD, V64, P1447, DOI 10.1021/np010146r; ZHAO L, 1999, J AM CHEM SOC, V121; Zhao LS, 1998, J AM CHEM SOC, V120, P10256, DOI 10.1021/ja981782n; Zhao LS, 1998, J AM CHEM SOC, V120, P12159, DOI 10.1021/ja982942y	49	115	120	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26289	26297		10.1074/jbc.M605478200	http://dx.doi.org/10.1074/jbc.M605478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16825192	Green Accepted, hybrid			2022-12-25	WOS:000240249500046
J	Ahmed, Z; Mazibrada, G; Seabright, RJ; Dent, RG; Berry, M; Logan, A				Ahmed, Zubair; Mazibrada, Gordon; Seabright, Ruth J.; Dent, Russell G.; Berry, Martin; Logan, Ann			TACE-induced cleavage of NgR and p75(NTR) in dorsal root ganglion cultures disinhibits outgrowth and promotes branching of neurites in the presence of inhibitory CNS myelin	FASEB JOURNAL			English	Article						ectodomain shedding; disinhibited DRGN neurite outgrowth; RIP of p75(NTR)	P75 NEUROTROPHIN RECEPTOR; NECROSIS-FACTOR-ALPHA; REGULATED INTRAMEMBRANE PROTEOLYSIS; CHONDROITIN SULFATE PROTEOGLYCANS; OPTIC-NERVE REGENERATION; HUMAN NOGO-66 RECEPTOR; SPINAL-CORD-INJURY; AXONAL REGENERATION; TNF RECEPTOR; PROTEIN 1B	After binding, central nervous system (CNS) myelin-derived axon growth inhibitory ligands, the Nogo-66 receptor (NgR), complexes with LINGO-1 and either the low-affinity neurotrophin receptor (p75(NTR)) or TROY to initiate growth cone collapse via a Rho-A inhibitory signaling pathway and/or Ca2+-dependent activation of epidermal growth factor receptor (EGFR) through an unknown signaling pathway. We have shown that axon growth through CNS myelin is disinhibited after neurotrophic factor administration by 1) initiating intramembranous proteolysis (RIP) of p75NTR, leading to cleavage of the extracellular (p75(ECD)) and intracellular domains (p75(ICD)) by alpha- and gamma-secretase, respectively, thereby paralyzing inhibitory signaling; 2) shedding of soluble NgR(ECD), which acts as a competitive antagonist to NgR for binding of inhibitory ligands; and 3) antagonizing NgR/p75(NTR) clustering by competitive p75(ECD)/NgR interaction. Here, we report that TNF-alpha converting enzyme (TACE) (a disintegrin and metalloproteinase 17, ADAM17) induces disinhibition of FGF2-stimulated neurite outgrowth of dorsal root ganglion neurons (DRGN) cultured in the presence of a predetermined concentration of inhibitory CNS myelin-derived ligands. After addition of TACE (which has alpha-secretase activity) to mitotically arrested adult rat mixed DRG cultures, we demonstrate 1) NgRECD shedding; 2) release of p75ECD and p75ICD by RIP of p75NTR; 3) blockade of Rho-A activation; 4) reduced EGFR phosphorylation; and 5) increased FGF2-stimulated DRGN neurite outgrowth and branching in the presence of CNS myelin-derived inhibitory ligands. Thus, TACE-induced cleavage of NgR and RIP of p75NTR abrogates axon growth inhibitory signaling, thereby disinhibiting CNS axon/neurite growth.	Univ Birmingham, Div Med Sci, Mol Neurosci Grp, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Logan, A (corresponding author), Univ Birmingham, Div Med Sci, Mol Neurosci Grp, Birmingham B15 2TT, W Midlands, England.	a.logan@bham.ac.uk	Ahmed, Zubair/AAN-1869-2021	Logan, Ann/0000-0003-3215-5042	Wellcome Trust [065920] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahmed Z, 2005, MOL CELL NEUROSCI, V28, P509, DOI 10.1016/j.mcn.2004.11.002; Ahmed Z, 2005, MOL CELL NEUROSCI, V28, P64, DOI 10.1016/j.mcn.2004.08.013; Ahmed Z, 2006, BRAIN, V129, P1517, DOI 10.1093/brain/awl080; Barrett GL, 2000, PROG NEUROBIOL, V61, P205, DOI 10.1016/S0301-0082(99)00056-8; Berry M, 1996, J NEUROCYTOL, V25, P147, DOI 10.1007/BF02284793; Berry M, 1999, J NEUROCYTOL, V28, P721, DOI 10.1023/A:1007086004022; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 2004, NAT GENET, V36, P934, DOI 10.1038/ng0904-934; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Bouquet C, 2004, J NEUROSCI, V24, P7204, DOI 10.1523/JNEUROSCI.2254-04.2004; Chao MV, 2002, NEURON, V33, P9, DOI 10.1016/S0896-6273(01)00573-6; Dechant G, 1997, CURR OPIN NEUROBIOL, V7, P413, DOI 10.1016/S0959-4388(97)80071-2; Dergham P, 2002, J NEUROSCI, V22, P6570; Domeniconi M, 2005, NEURON, V46, P849, DOI 10.1016/j.neuron.2005.05.029; Fischer D, 2004, J NEUROSCI, V24, P1646, DOI 10.1523/JNEUROSCI.5119-03.2004; Fournier AE, 2002, PROG BRAIN RES, V137, P361; Fournier AE, 2003, J NEUROSCI, V23, P1416, DOI 10.1523/JNEUROSCI.23-04-01416.2003; Galko MJ, 2000, SCIENCE, V289, P1365, DOI 10.1126/science.289.5483.1365; Goddard DR, 2001, GLIA, V34, P267, DOI 10.1002/glia.1060; Gonzalez-Billault C, 2002, BRAIN RES, V943, P56, DOI 10.1016/S0006-8993(02)02534-9; Hunt D, 2002, J NEUROCYTOL, V31, P93, DOI 10.1023/A:1023941421781; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Jiang H, 1999, J BIOL CHEM, V274, P26209, DOI 10.1074/jbc.274.37.26209; Jung KM, 2003, J BIOL CHEM, V278, P42161, DOI 10.1074/jbc.M306028200; Kanning KC, 2003, J NEUROSCI, V23, P5425, DOI 10.1523/jneurosci.23-13-05425.2003; Karan D, 2003, INT J ONCOL, V23, P1365; Koprivica V, 2005, SCIENCE, V310, P106, DOI 10.1126/science.1115462; Landman N, 2004, CYTOKINE GROWTH F R, V15, P337, DOI 10.1016/j.cytogfr.2004.04.001; Lee MH, 2002, BIOCHEM J, V364, P227, DOI 10.1042/bj3640227; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Li SX, 2005, MOL CELL NEUROSCI, V29, P26, DOI 10.1016/j.mcn.2004.12.008; Logan A, 2006, BRAIN, V129, P490, DOI 10.1093/brain/awh706; Lu P, 2004, J NEUROSCI, V24, P6402, DOI 10.1523/JNEUROSCI.1492-04.2004; Ma D, 2000, NEUROSCIENCE, V99, P157, DOI 10.1016/S0306-4522(00)00141-X; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; McKerracher L, 2002, NEURON, V36, P345, DOI 10.1016/S0896-6273(02)01018-8; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Nothias F, 1997, EUR J NEUROSCI, V9, P1553, DOI 10.1111/j.1460-9568.1997.tb01513.x; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Park JB, 2005, NEURON, V45, P345, DOI 10.1016/j.neuron.2004.12.040; Park K, 2004, J NEUROSCI, V24, P10806, DOI 10.1523/JNEUROSCI.3532-04.2004; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301-0082(02)00016-3; Russell JW, 2002, FASEB J, V16, P1738, DOI 10.1096/fj.01-1027com; Sandvig A, 2004, GLIA, V46, P225, DOI 10.1002/glia.10315; Shao ZH, 2005, NEURON, V45, P353, DOI 10.1016/j.neuron.2004.12.050; Simonen M, 2003, NEURON, V38, P201, DOI 10.1016/S0896-6273(03)00226-5; Sivasankaran R, 2004, NAT NEUROSCI, V7, P261, DOI 10.1038/nn1193; Strittmatter SM, 2002, J MOL NEUROSCI, V19, P117, DOI 10.1007/s12031-002-0021-7; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Teng FYH, 2006, J NEUROCHEM, V96, P1501, DOI 10.1111/j.1471-4159.2006.03663.x; van Deventer SJH, 2002, GUT, V51, P5, DOI 10.1136/gut.51.1.5; Walmsley AR, 2005, BIOCHEM BIOPH RES CO, V327, P112, DOI 10.1016/j.bbrc.2004.12.001; Walmsley AR, 2004, J CELL SCI, V117, P4591, DOI 10.1242/jcs.01324; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Weskamp G, 2004, J BIOL CHEM, V279, P4241, DOI 10.1074/jbc.M307974200; Wong ST, 2002, NAT NEUROSCI, V5, P1302, DOI 10.1038/nn975; Zheng BH, 2003, NEURON, V38, P213, DOI 10.1016/S0896-6273(03)00225-3	61	70	72	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2006	20	11					1939	+		10.1096/fj.05-5339fje	http://dx.doi.org/10.1096/fj.05-5339fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16849393				2022-12-25	WOS:000240267000037
J	Craciunescu, CN; Wu, R; Zeisel, SH				Craciunescu, Corneliu N.; Wu, Renan; Zeisel, Steven H.			Diethanolamine alters neurogenesis and induces apoptosis in fetal mouse hippocampus	FASEB JOURNAL			English	Article						choline; pregnancy; brain development	CHOLINE AVAILABILITY ALTERS; EMBRYONIC-DEVELOPMENT ALTERS; METABOLISM; LOCALIZATION; MITOSIS; PHOSPHORYLATION; DEFICIENCY; INHIBITORS	Diethanolamine (DEA) is present in many consumer products such as shampoo. Dermal administration of DEA diminishes hepatic stores of the essential nutrient choline, and we previously reported that dietary choline deficiency during pregnancy reduces neurogenesis and increases apoptosis in the hippocampus of fetal rats and mice. Therefore, DEA could also alter brain development. Timed-pregnant C57BL/ 6 mice were dosed dermally from gestation day 7 through 17 with DEA at 0, 20, 80, 160, 320, and 640 mg/ kg body/ day. At doses of DEA > 80 mg/ kg body/ day, we observed decreased litter size. In fetuses (embryonic day 17) collected from dams treated dermally with 80 mg/ kg body/ day DEA, we observed decreased neural progenitor cell mitosis at the ventricular surface of the ventricular zone of the hippocampus [to 56 +/- 14% (SE) histone 3 (H3) phosphorylation as compared to controls; P < 0.01]. We also observed increased apoptosis in fetal hippocampus (to 170 +/- 10% of control measured using TUNEL and to 178 +/- 7% of control measured using activated caspase 3; P < 0.01). Thus, maternal exposure to DEA reduces the number of neural progenitor cells in hippocampus by two mechanisms, and this could permanently alter memory function in offspring of mothers exposed to this common ingredient of shampoos and soaps.	Univ N Carolina, Michael Hooker Res Ctr, Dept Nutr, Sch Publ Hlth & Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Zeisel, SH (corresponding author), Univ N Carolina, Michael Hooker Res Ctr, Dept Nutr, Sch Publ Hlth & Med, CB 7461,2115A, Chapel Hill, NC 27599 USA.	steven_zeisel@unc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126, R21ES012997] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER; NIA NIH HHS [AG09125, P01 AG009525] Funding Source: Medline; NIDDK NIH HHS [DK56350, P30 DK056350] Funding Source: Medline; NIEHS NIH HHS [ES012997, P30 ES010126, R21 ES012997, ES10126] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Albright CD, 1999, DEV BRAIN RES, V115, P123, DOI 10.1016/S0165-3806(99)00057-7; Albright CD, 2005, DEV BRAIN RES, V159, P149, DOI 10.1016/j.devbrainres.2005.07.002; Albright CD, 2003, NUTR NEUROSCI, V6, P129, DOI 10.1080/1028415031000084418; Albright CD, 2001, DEV NEUROSCI-BASEL, V23, P100, DOI 10.1159/000048701; Albright CD, 1999, DEV BRAIN RES, V113, P13, DOI 10.1016/S0165-3806(98)00183-7; ALTMAN J, 1990, J COMP NEUROL, V301, P325, DOI 10.1002/cne.903010302; ANGEVINE JB, 1970, ANAT REC, V166, P257, DOI 10.1002/ar.1091660214; [Anonymous], 1983, J AM COLL TOXICOL, V2, P183; BARBEE SJ, 1979, TOXICOL APPL PHARM, V47, P421, DOI 10.1016/0041-008X(79)90511-8; Baschong W, 2001, J HISTOCHEM CYTOCHEM, V49, P1565, DOI 10.1177/002215540104901210; BROWNING E, 1987, ETHEL BROWNINGS TOXI, V4; *CIR, 1986, J AM COLL TOXICOL, V5, P415; Craciunescu CN, 2003, J NUTR, V133, P3614, DOI 10.1093/jn/133.11.3614; Fisher MC, 2002, FASEB J, V16, P619, DOI 10.1096/fj.01-0564fje; Fisher MC, 2001, TERATOLOGY, V64, P114, DOI 10.1002/tera.1053; Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326; Hayashi SM, 2003, CHEM-BIOL INTERACT, V146, P251, DOI 10.1016/j.cbi.2003.07.001; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; IACONO JM, 2000, SOME IND CHEM, V77, P349; Institute of Medicine, 1998, DIET REF INT THIAM R, P390, DOI [DOI 10.17226/6015, 10.17226/6015]; JACOBOWITZ DM, 1998, CHEMOARCHITECTONIC A; Knaak J B, 1997, Rev Environ Contam Toxicol, V149, P1; Koc H, 2002, ANAL CHEM, V74, P4734, DOI 10.1021/ac025624x; Lehman-McKeeman LD, 2002, TOXICOL SCI, V67, P38, DOI 10.1093/toxsci/67.1.38; Leung HW, 2005, REGUL TOXICOL PHARM, V43, P260, DOI 10.1016/j.yrtph.2005.08.001; MATHEWS JM, 1995, CHEM RES TOXICOL, V8, P625, DOI 10.1021/tx00047a001; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; Meck WH, 2003, NEUROSCI BIOBEHAV R, V27, P385, DOI 10.1016/S0149-7634(03)00069-1; *NAT TOX PROGR, 1999, NATL TOXICOL PROG TE, V481; *NAT TOX PROGR, 1999, NATL TOXICOL PROG TE, V480, P1; National Toxicology Program, 1999, Natl Toxicol Program Tech Rep Ser, V478, P1; Niculescu MD, 2004, J NEUROCHEM, V89, P1252, DOI 10.1111/j.1471-4159.2004.02414.x; Romijn HJ, 1999, J HISTOCHEM CYTOCHEM, V47, P229, DOI 10.1177/002215549904700211; Stott WT, 2004, TOXICOL SCI, V79, P242, DOI 10.1093/toxsci/kfh115; Stott WT, 2000, TOXICOL LETT, V114, P67, DOI 10.1016/S0378-4274(99)00197-6; SUN JD, 1996, CUTANEOUS OCULAR TOX, V15, P131; *TECHN PLANN MAN C, 2002, N01ES85421 NAT TOX P, P229	37	12	13	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1635	1640		10.1096/fj.06-5978com	http://dx.doi.org/10.1096/fj.06-5978com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16873886	Green Accepted, Green Submitted			2022-12-25	WOS:000240266600008
J	Moon, SK; Kang, SK; Kim, CH				Moon, Sung-Kwon; Kang, Sung-Koo; Kim, Cheorl-Ho			Reactive oxygen species mediates disialoganglioside GD3-induced inhibition of ERK1/2 and matrix metalloproteinase-9 expression in vascular smooth muscle cells	FASEB JOURNAL			English	Article						atherosclerosis; GD3 synthase gene; PDTC; NAC; cell cycle	MITOCHONDRIAL PERMEABILITY TRANSITION; SIGNALING TRANSDUCTION PATHWAY; NECROSIS-FACTOR-ALPHA; GD3 GANGLIOSIDE; DNA DAMAGE; ATHEROSCLEROSIS; APOPTOSIS; GROWTH; GLYCOSPHINGOLIPIDS; PROLIFERATION	Sialic acid containing glycosphingolipids (gangliosides) are thought to play important roles in the function of various biological phenomena such as atherosclerosis. We have previously shown that the overexpression of the disialoganglioside (GD3) synthase gene effectively suppresses cell proliferation, cell cycle progression, and MMP-9 expression in vascular smooth muscle cells (VSMC). However, the issue of how the overexpression of GD3 synthase gene results in the inhibition of cellular responses in VSMC remains unclear. The findings herein demonstrate that overexpression of the GD3 synthase gene suppresses VSMC responses through the generation of reactive oxygen species (ROS). Superoxide and hydrogen peroxide were generated at increased levels in GD3 synthase gene transfectants in comparison with empty vector (EV) -transfected VSMC. This phenomenon was blocked by antioxidants such as N-acetyl-L-cysteine (NAC) and pyrrolidine dithiocarbamate (PDTC). Increased ROS generation was associated with a decreased endogenous antioxidant activity, increased lipid peroxidation, and mitochondrial DNA damage. Further studies revealed that the blockade of ROS function with antioxidants reversed the effect of GD3 synthase gene overexpression on VSMC proliferation and cell cycle regulation in response to platelet-derived growth factor (PDGF). In addition, we found that treatment with antioxidants reversed the decreased matrix metalloproteinase-9 (MMP-9) expression in response to TNF-alpha as determined by zymography and immunoblot in GD3 synthase gene transfectants. This recovery effect was characterized by the up-regulation of MMP-9 promoter activity, which was transcriptionally regulated at NF-kappa B and activation protein-1 (activating protein (AP) -1) sites in the MMP-9 promoter. These findings suggest that ROS may play a role in GD3 synthase gene-mediated VSMC phenotypic changes that may contribute to plaque instability in atherosclerosis.	Sungkyunkwan Univ, Dept Sci Biol, Mol & Cellular Glycobiol Unit, Suwon 440746, South Korea	Sungkyunkwan University (SKKU)	Kim, CH (corresponding author), Sungkyunkwan Univ, Dept Sci Biol, Mol & Cellular Glycobiol Unit, Chunchun Dong 300, Suwon 440746, South Korea.	chkimbio@daum.net	Kim, Cheorl-Ho/T-6753-2019	Kim, Cheorl-Ho/0000-0002-6323-0714				Ahn HY, 1999, MOL BIOL CELL, V10, P1093, DOI 10.1091/mbc.10.4.1093; Akishita M, 1999, J CLIN INVEST, V103, P63, DOI 10.1172/JCI5182; Ballinger SW, 2002, CIRCULATION, V106, P544, DOI 10.1161/01.CIR.0000023921.93743.89; Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960; Bhunia AK, 1997, J BIOL CHEM, V272, P15642, DOI 10.1074/jbc.272.25.15642; Bhunia AK, 2002, J BIOL CHEM, V277, P16396, DOI 10.1074/jbc.M200877200; Bhunia AK, 1998, J BIOL CHEM, V273, P34349, DOI 10.1074/jbc.273.51.34349; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; Chatterjee S, 1998, ARTERIOSCL THROM VAS, V18, P1523, DOI 10.1161/01.ATV.18.10.1523; Chatterjee SB, 1997, GLYCOBIOLOGY, V7, P57, DOI 10.1093/glycob/7.1.57; Cho A, 2000, ARTERIOSCL THROM VAS, V20, P2527, DOI 10.1161/01.ATV.20.12.2527; Colell A, 2003, J BIOL CHEM, V278, P33928, DOI 10.1074/jbc.M210943200; Colell Anna, 2001, FASEB Journal, V15, P1068; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Fernandez-Checa JC, 2003, BIOCHEM BIOPH RES CO, V304, P471, DOI 10.1016/S0006-291X(03)00619-3; GALIS ZS, 1994, CIRC RES, V75, P181, DOI 10.1161/01.RES.75.1.181; Galis ZS, 1998, CIRCULATION, V97, P2445, DOI 10.1161/01.CIR.97.24.2445; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; Garcia-Ruiz C, 2002, J BIOL CHEM, V277, P36443, DOI 10.1074/jbc.M206021200; GARCIARUIZ C, 1994, J CLIN INVEST, V94, P193, DOI 10.1172/JCI117306; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Gouni-Berthold L, 2001, HYPERTENSION, V38, P1030, DOI 10.1161/hy1101.093104; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; HAKOMORI SI, 1993, ADV LIPID RES, V25, P147; HOLVOET P, 1995, J CLIN INVEST, V95, P2611, DOI 10.1172/JCI117963; Kawakami S, 2001, ANTICANCER RES, V21, P213; MCCORD JM, 1993, CLIN BIOCHEM, V26, P351, DOI 10.1016/0009-9120(93)90111-I; Moon SK, 2004, J BIOL CHEM, V279, P33063, DOI 10.1074/jbc.M313462200; Moon SK, 2003, BIOCHEM BIOPH RES CO, V301, P1069, DOI 10.1016/S0006-291X(03)00091-3; Moon SK, 2004, J CELL PHYSIOL, V198, P417, DOI 10.1002/jcp.10435; Moon SK, 2001, AM J PHYSIOL-HEART C, V280, pH2779, DOI 10.1152/ajpheart.2001.280.6.H2779; MUKHIN DN, 1995, ARTERIOSCL THROM VAS, V15, P1607, DOI 10.1161/01.ATV.15.10.1607; MULVANY MJ, 1990, PHYSIOL REV, V70, P921, DOI 10.1152/physrev.1990.70.4.921; Newby AC, 2000, J PATHOL, V190, P300, DOI 10.1002/(SICI)1096-9896(200002)190:3<300::AID-PATH596>3.0.CO;2-I; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sachinidis A, 1996, EUR J CELL BIOL, V71, P79; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SHAN XQ, 1993, CHEM RES TOXICOL, V6, P75, DOI 10.1021/tx00031a012; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SIWIK DA, 2001, AM J PHYSIOL-CELL PH, V280, P53; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Wolin MS, 2000, ARTERIOSCL THROM VAS, V20, P1430, DOI 10.1161/01.ATV.20.6.1430; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514	50	22	24	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2006	20	9					1387	1395		10.1096/fj.05-4618com	http://dx.doi.org/10.1096/fj.05-4618com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816114				2022-12-25	WOS:000240266000016
J	Ivanov, SV; Salnikow, K; Ivanova, AV; Bai, L; Lerman, MI				Ivanov, S. V.; Salnikow, K.; Ivanova, A. V.; Bai, L.; Lerman, M. I.			Hypoxic repression of STAT1 and its downstream genes by a pVHL/HIF-1 target DEC1/STRA13	ONCOGENE			English	Article						VHL; HIF-1; hypoxia; STRA13; STAT1; CASP1	RENAL-CELL CARCINOMA; TUMOR-SUPPRESSOR PROTEIN; INTERFERON-GAMMA; DEACETYLASE ACTIVITY; DOWN-REGULATION; TRANSCRIPTIONAL REPRESSOR; INDEPENDENT MECHANISMS; STRA13 EXPRESSION; INDUCED APOPTOSIS; CLASS-I	DEC1/STRA13 is a bHLH type transcriptional regulator involved with immune regulation, hypoxia response and carcinogenesis. We recently demonstrated that STRA13 interacts with STAT3 in the transcriptional activation of STAT-dependent promoters. Here, we pursue STRA13 involvement in the JAK/STAT pathway by studying its role in STAT1 expression. First, we showed that VHL deficiency or HIF-1 activation resulted in the repression of endogenous STAT1 mediated by STRA13. We then characterized the STAT1 proximal promoter to assess its response to STRA13 by transient coexpression in a luciferase reporter assay. Using sequential truncation and site-directed mutagenesis of the STAT1 promoter with STRA13 deletion constructs, we showed that the STRA13 C-terminal trans-activation domain, which is known to bind HDAC1, mostly determines the repressive activity. Involvement of HDAC activity in STAT1 regulation was validated by TSA inhibition and chromatin immuno-precipitation (ChIP) assay. Thus, we demonstrate that STRA13-mediated repression of STAT1 transcription utilizes an HDAC1-dependent mechanism. Furthermore, we show that targets of unphosphorylated STAT1, such as antigen presenting genes and CASP1, are also repressed by hypoxia possibly through the same STRA13-mediated mechanism. Thus, the newly discovered link between HIF-1 and STAT1 reveals a previously unknown role of STRA13 in hypoxia and carcinogenesis.	SAIC Frederick, Basic Res Program, Ft Detrick, MD 21702 USA; NCI, NIH, Frederick, MD 21701 USA; NYU, Med Ctr, Dept Cardiothorac Surg, New York, NY 10016 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); New York University; University of Michigan System; University of Michigan	Ivanov, SV (corresponding author), SAIC Frederick, Basic Res Program, B 560,POB B, Ft Detrick, MD 21702 USA.	Sergey.Ivanov@med.nyu.edu		Ivanov, Sergey/0000-0001-9770-7237	NATIONAL CANCER INSTITUTE [Z01BC008579] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atkins D, 2004, J UROLOGY, V171, P885, DOI 10.1097/01.ju.0000094807.95420.fe; Azmi S, 2003, J BIOL CHEM, V278, P20098, DOI 10.1074/jbc.M210427200; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Bai LC, 2003, NUCLEIC ACIDS RES, V31, P7264, DOI 10.1093/nar/gkg929; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chang HM, 2004, P NATL ACAD SCI USA, V101, P9578, DOI 10.1073/pnas.0400567101; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Darnell JE, 1998, J INTERF CYTOK RES, V18, P549, DOI 10.1089/jir.1998.18.549; Dhar M, 2001, ONCOGENE, V20, P4750, DOI 10.1038/sj.onc.1204637; Dudley Andrew C, 2004, Cell Commun Signal, V2, P8, DOI 10.1186/1478-811X-2-8; Gastl G, 1996, J UROLOGY, V155, P361, DOI 10.1016/S0022-5347(01)66661-8; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; Ivanova AV, 2005, CELL MOL LIFE SCI, V62, P471, DOI 10.1007/s00018-004-4423-2; Ivanova AV, 2004, J MOL BIOL, V340, P641, DOI 10.1016/J.Jmb.2004.05.025; Ivanova AV, 2001, J BIOL CHEM, V276, P15306, DOI 10.1074/jbc.M010516200; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Li YX, 2002, BIOCHEM J, V367, P413, DOI 10.1042/BJ20020514; Martin-Puig S, 2004, J BIOL CHEM, V279, P9504, DOI 10.1074/jbc.M310658200; Maxwell PH, 2004, CELL CYCLE, V3, P156; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Miyazaki K, 2002, J BIOL CHEM, V277, P47014, DOI 10.1074/jbc.M204938200; Nusinzon I, 2003, P NATL ACAD SCI USA, V100, P14742, DOI 10.1073/pnas.2433987100; Osborne A, 1997, NUCLEIC ACIDS RES, V25, P5095, DOI 10.1093/nar/25.24.5095; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Sakamoto S, 2004, J BIOL CHEM, V279, P40362, DOI 10.1074/jbc.M406400200; Salnikow K, 2004, J BIOL CHEM, V279, P40337, DOI 10.1074/jbc.M403057200; Salnikow K, 2004, TOXICOL APPL PHARM, V196, P258, DOI 10.1016/j.taap.2004.01.003; Salnikow K, 2000, CANCER RES, V60, P38; Satoh A, 2004, ONCOGENE, V23, P8876, DOI 10.1038/sj.onc.1208144; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; Seimiya M, 2004, EUR J IMMUNOL, V34, P1322, DOI 10.1002/eji.200324700; Seliger B, 2000, IMMUNOL TODAY, V21, P455, DOI 10.1016/S0167-5699(00)01692-3; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; Shen M, 2001, EUR J CELL BIOL, V80, P329, DOI 10.1078/0171-9335-00167; Shuai K, 1996, MOL CELL BIOL, V16, P4932; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; St-Pierre B, 2002, J BIOL CHEM, V277, P46544, DOI 10.1074/jbc.M111652200; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Sun H, 2001, NAT IMMUNOL, V2, P1040, DOI 10.1038/ni721; van den Elsen PJ, 2004, CURR OPIN IMMUNOL, V16, P67, DOI 10.1016/j.coi.2003.11.015; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wong LH, 2002, J BIOL CHEM, V277, P19408, DOI 10.1074/jbc.M111302200; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Xi SC, 2006, JNCI-J NATL CANCER I, V98, P181, DOI 10.1093/jnci/djj020; Yamamoto K, 2003, AUTOIMMUN REV, V2, P13, DOI 10.1016/S1568-9972(02)00121-0; Zagzag D, 2005, LAB INVEST, V85, P328, DOI 10.1038/labinvest.3700233; Zawel L, 2002, P NATL ACAD SCI USA, V99, P2848, DOI 10.1073/pnas.261714999	55	57	58	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2007	26	6					802	812		10.1038/sj.onc.1209842	http://dx.doi.org/10.1038/sj.onc.1209842			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16878149				2022-12-25	WOS:000244063800002
J	Goldoni, S; Iozzo, RA; Kay, P; Campbell, S; McQuillan, A; Agnew, C; Zhu, JX; Keene, DR; Reed, CC; Iozzo, RV				Goldoni, S.; Iozzo, R. A.; Kay, P.; Campbell, S.; McQuillan, A.; Agnew, C.; Zhu, J-X; Keene, D. R.; Reed, C. C.; Iozzo, R. V.			A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity	ONCOGENE			English	Article						leucine-rich protein; decorin; kekkon1; epidermal growth factor receptor; tumor growth inhibition	LEUCINE-RICH PROTEOGLYCANS; FACTOR RECEPTOR; DECORIN BINDS; LUNG-CANCER; C-TERMINUS; GENE; PROTEIN; DROSOPHILA; GRB2; ENDOCYTOSIS	Leucine-rich repeats and immunoglobulin-like domains-1 (LRIG1) is a transmembrane protein with an ectodomain containing 15 leucine-rich repeats (LRRs) homologous to mammalian decorin and the Drosophila kekkon1 gene. In this study, we demonstrate that a soluble ectodomain of LRIG1, containing only the LRRs, inhibits ligand-independent epidermal growth factor receptor (EGFR) activation and causes growth inhibition of A431, HeLa and MDA-468 carcinoma cells. In contrast, cells that do not express detectable levels of EGFR fail to respond to soluble LRIG1. However, when a functional EGFR gene is introduced in these cells, they become growth-inhibited by soluble LRIG1 protein. Furthermore, we demonstrate the existence of high-affinity (K-d = 10 nM) binding sites on the A431 cells that can be competitively displaced (up to 75%) by molar excess of EGF. Even more powerful effects are obtained with a chimeric proteoglycan harboring the N-terminus of decorin, substituted with a single glycosaminoglycan chain, fused to the LRIG1 ectodomain. Both proteins also inhibit ligand-dependent activation of the EGFR and extracellular signal-regulated protein kinase 1/2 signaling in a rapid and dose-dependent manner. These results suggest a novel mechanism of action evoked by a soluble ectodomain of LRIG1 protein that could modulate EGFR signaling and its growth-promoting activity. Attenuation of EGFR activity without physical downregulation of the receptor could represent a novel therapeutic approach toward malignancies in which EGFR plays a primary role in tumor growth and survival.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Shriners Hosp Children, Portland, OR 97201 USA; Thomas Jefferson Univ, Cellular Biol & Signaling Program, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Room 249 Jefferson Alumni Hall,1020 Locus St, Philadelphia, PA 19107 USA.	iozzo@mail.jci.tju.edu	Pranić, Shelly Melissa/E-1974-2017; Iozzo, Renato/AAS-1980-2020	Pranić, Shelly Melissa/0000-0001-5524-1723; Iozzo, Renato/0000-0002-5908-5112	NATIONAL CANCER INSTITUTE [R01CA047282, R01CA039481] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA47282, R01 CA39481] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alvarado D, 2004, GENETICS, V167, P187, DOI 10.1534/genetics.167.1.187; Alvarado D, 2004, GENETICS, V166, P201, DOI 10.1534/genetics.166.1.201; Bailly M, 2000, MOL BIOL CELL, V11, P3873, DOI 10.1091/mbc.11.11.3873; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BERKERS JAM, 1991, J BIOL CHEM, V266, P922; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Carraway KL, 2001, CURR OPIN CELL BIOL, V13, P125, DOI 10.1016/S0955-0674(00)00188-5; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Cook PW, 1997, J CLIN INVEST, V100, P2286, DOI 10.1172/JCI119766; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Derheimer FA, 2004, GENETICS, V166, P213, DOI 10.1534/genetics.166.1.213; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; FILMUS J, 1987, MOL CELL BIOL, V7, P251, DOI 10.1128/MCB.7.1.251; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Ghiglione C, 2003, DEVELOPMENT, V130, P4483, DOI 10.1242/dev.00617; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; Goldoni S, 2004, J BIOL CHEM, V279, P6606, DOI 10.1074/jbc.M310342200; Gonzalez EM, 2005, J BIOL CHEM, V280, P7080, DOI 10.1074/jbc.M409841200; Grovdal LM, 2004, EXP CELL RES, V300, P388, DOI 10.1016/j.yexcr.2004.07.003; Guo DS, 2004, GENOMICS, V84, P157, DOI 10.1016/j.ygeno.2004.01.013; Gur G, 2004, EMBO J, V23, P3270, DOI 10.1038/sj.emboj.7600342; Hedman H, 2002, ACTA ONCOL, V41, P352, DOI 10.1080/028418602760169398; Holmlund C, 2004, GENE, V332, P35, DOI 10.1016/j.gene.2004.02.002; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Keene DR, 2000, J BIOL CHEM, V275, P21801, DOI 10.1074/jbc.C000278200; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Laederich MB, 2004, J BIOL CHEM, V279, P47050, DOI 10.1074/jbc.M409703200; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li SQ, 2005, CANCER CELL, V7, P301, DOI 10.1016/j.ccr.2005.03.003; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Mongiat M, 2003, J BIOL CHEM, V278, P4238, DOI 10.1074/jbc.M210445200; Mongiat M, 2001, J BIOL CHEM, V276, P10263, DOI 10.1074/jbc.M011493200; Musacchio M, 1996, DEV BIOL, V178, P63, DOI 10.1006/dbio.1996.0198; Nilsson J, 2003, CELL TISSUE RES, V312, P65, DOI 10.1007/s00441-003-0697-1; Nilsson J, 2001, BIOCHEM BIOPH RES CO, V284, P1155, DOI 10.1006/bbrc.2001.5092; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; Pao W, 2005, J CLIN ONCOL, V23, P2556, DOI 10.1200/JCO.2005.07.799; Reed CC, 2005, ONCOGENE, V24, P1104, DOI 10.1038/sj.onc.1208329; Reed CC, 2002, ONCOGENE, V21, P3688, DOI 10.1038/sj.onc.1205470; Rubin C, 2005, CELL RES, V15, P66, DOI 10.1038/sj.cr.7290268; Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200; Schlessinger J, 2003, SCIENCE, V300, P750, DOI 10.1126/science.1082024; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Suzuki Y, 1996, J BIOL CHEM, V271, P22522, DOI 10.1074/jbc.271.37.22522; Suzuki Y, 2002, FEBS LETT, V521, P67, DOI 10.1016/S0014-5793(02)02824-7; Thomasson M, 2003, BRIT J CANCER, V89, P1285, DOI 10.1038/sj.bjc.6601208; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; WEBER W, 1984, SCIENCE, V224, P294, DOI 10.1126/science.6324343; YARDEN Y, 1985, J BIOL CHEM, V260, P315; Zhu JX, 2005, J BIOL CHEM, V280, P32468, DOI 10.1074/jbc.M503833200	62	58	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					368	381		10.1038/sj.onc.1209803	http://dx.doi.org/10.1038/sj.onc.1209803			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16847455				2022-12-25	WOS:000243544000006
J	Graham, ES; Ball, N; Scotter, EL; Narayan, P; Dragunow, M; Glass, M				Graham, E. Scott; Ball, Nicola; Scotter, Emma L.; Narayan, Pritika; Dragunow, Mike; Glass, Michelle			Induction of Krox-24 by endogenous cannabinoid type 1 receptors in Neuro2a cells is mediated by the MEK-ERK MAPK pathway and is suppressed by the phosphatidylinositol 3-kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; TRANSCRIPTION FACTOR EGR-1; ACID AMIDE HYDROLASE; ENDOCANNABINOID SYSTEM; SYNAPTIC-TRANSMISSION; NEUROBLASTOMA-CELLS; CHOLINERGIC NEURONS; GENE-EXPRESSION; NERVOUS-SYSTEM; BASAL GANGLIA	Neuro2a cells endogenously express cannabinoid type 1 (CB1) receptors. CB1 stimulation with HU210 activated ERK and induced the transcription factor Krox-24. A functional MEK-ERK pathway is an important requirement for CB1-mediated Krox-24 induction as blockade of MEK signaling by UO126 reduces both basal and CB1-mediated activation of Krox-24. CB1 receptor stimulation did not activate either JNK or p38 MAPK pathways or the pro-proliferation phosphatidylinositol 3-kinase (PI3K)-Akt pathway. However, serum removal or blockade of PI3K signaling by LY294002 transiently stimulated basal Krox-24 expression and increased CB1-mediated induction of Krox-24. This was consistent with a transient increase in pMEK, pERK, and pCREB levels following PI3K blockade. These data demonstrate that CB1-mediated activation of the Krox-24 transcription factor is negatively regulated through the PI3K-Akt pathway and reveals several points of signaling cross-talk between these two important kinase pathways.	Univ Auckland, Dept Pharmacol, Auckland, New Zealand; Univ Auckland, Natl Res Ctr Growth & Dev, Auckland, New Zealand	University of Auckland; University of Auckland	Glass, M (corresponding author), Univ Auckland, Dept Pharmacol, Private Bag 92019, Auckland, New Zealand.	m.glass@auckland.ac.nz	Scotter, Emma/C-4833-2012; Glass, Michelle/AAE-7799-2019	Scotter, Emma/0000-0003-4064-3599; Glass, Michelle/0000-0002-5997-6898; Narayan, Pritika/0000-0002-8713-1470; Graham, Scott/0000-0002-2925-9126				Azad SC, 2003, LEARN MEMORY, V10, P116, DOI 10.1101/lm.53303; Bodor AL, 2005, J NEUROSCI, V25, P6845, DOI 10.1523/JNEUROSCI.0442-05.2005; BOUABOULA M, 1995, BIOCHEM J, V312, P637, DOI 10.1042/bj3120637; Chiu JJ, 1999, CIRC RES, V85, P238, DOI 10.1161/01.RES.85.3.238; Demuth DG, 2006, LIFE SCI, V78, P549, DOI 10.1016/j.lfs.2005.05.055; Derkinderen P, 2003, J NEUROSCI, V23, P2371; Dragunow M, 1996, BEHAV GENET, V26, P293, DOI 10.1007/BF02359385; Dumaz N, 2005, FEBS J, V272, P3491, DOI 10.1111/j.1742-4658.2005.04763.x; Ebihara S, 2003, MOL BRAIN RES, V110, P126, DOI 10.1016/S0169-328X(02)00648-4; Egertova M, 2000, J COMP NEUROL, V422, P159, DOI 10.1002/(SICI)1096-9861(20000626)422:2<159::AID-CNE1>3.0.CO;2-1; Egertova M, 2003, NEUROSCIENCE, V119, P481, DOI 10.1016/S0306-4522(03)00145-3; Egertova M, 1998, P ROY SOC B-BIOL SCI, V265, P2081, DOI 10.1098/rspb.1998.0543; Freund TF, 2003, PHYSIOL REV, V83, P1017, DOI 10.1152/physrev.00004.2003; Galve-Roperh I, 2002, MOL PHARMACOL, V62, P1385, DOI 10.1124/mol.62.6.1385; Glass M, 2000, NEUROSCIENCE, V97, P505, DOI 10.1016/S0306-4522(00)00008-7; GLASS M, 1995, NEUROREPORT, V6, P241, DOI 10.1097/00001756-199501000-00004; Graham ES, 1999, MOL CELL ENDOCRINOL, V156, P45, DOI 10.1016/S0303-7207(99)00146-X; Harkany T, 2003, EUR J NEUROSCI, V18, P1979, DOI 10.1046/j.1460-9568.2003.02898.x; Helliwell RJA, 2004, J CLIN ENDOCR METAB, V89, P5168, DOI 10.1210/jc.2004-0388; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Huang CC, 2001, J PHYSIOL-LONDON, V532, P731, DOI 10.1111/j.1469-7793.2001.0731e.x; Hughes PE, 1998, MOL BRAIN RES, V53, P138, DOI 10.1016/S0169-328X(97)00288-X; Jiang W, 2005, J CLIN INVEST, V115, P3104, DOI 10.1172/JCI25509; Jordan JD, 2005, J BIOL CHEM, V280, P11413, DOI 10.1074/jbc.M411521200; Jun T., 1999, SCI STKE, V1999, pPE1; Karanian DA, 2005, EUR J PHARMACOL, V508, P47, DOI 10.1016/j.ejphar.2004.12.009; Katona I, 2006, J NEUROSCI, V26, P5628, DOI 10.1523/JNEUROSCI.0309-06.2006; Kim SH, 2005, J PHARMACOL EXP THER, V313, P88, DOI 10.1124/jpet.104.079509; Kofalvi A, 2005, J NEUROSCI, V25, P2874, DOI 10.1523/JNEUROSCI.4232-04.2005; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; Leterrier C, 2004, J BIOL CHEM, V279, P36013, DOI 10.1074/jbc.M403990200; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; Matyas F, 2006, NEUROSCIENCE, V137, P337, DOI 10.1016/j.neuroscience.2005.09.005; McAllister SD, 2002, PROSTAG LEUKOTR ESS, V66, P161, DOI 10.1054/plef.2001.0344; Nyiri G, 2005, NEUROSCIENCE, V136, P811, DOI 10.1016/j.neuroscience.2005.01.026; Nyiri G, 2005, EUR J NEUROSCI, V21, P3034, DOI 10.1111/j.1460-9568.2005.04146.x; Pignatelli M, 2003, BIOCHEM J, V373, P739, DOI 10.1042/BJ20021918; Pignatelli M, 1999, FEBS LETT, V461, P37, DOI 10.1016/S0014-5793(99)01420-9; Riegel AC, 2004, J NEUROSCI, V24, P11070, DOI 10.1523/JNEUROSCI.3695-04.2004; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sanchez MG, 2003, CELL SIGNAL, V15, P851, DOI 10.1016/S0898-6568(03)00036-6; Straiker A, 2005, J PHYSIOL-LONDON, V569, P501, DOI 10.1113/jphysiol.2005.091918; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Szabo G, 1996, DNA CELL BIOL, V15, P1081, DOI 10.1089/dna.1996.15.1081; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Tsou K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3; Valjent E, 2001, EUR J NEUROSCI, V14, P342, DOI 10.1046/j.0953-816x.2001.01652.x; van der Heide LP, 2003, J NEUROCHEM, V86, P86, DOI 10.1046/j.1471-4159.2003.01828.x; van der Stelt M, 2002, MOL NEUROBIOL, V26, P317, DOI 10.1385/MN:26:2-3:317; Yanai R, 2006, EXP EYE RES, V83, P76, DOI 10.1016/j.exer.2005.10.033; Yoshida T, 2006, J NEUROSCI, V26, P4740, DOI 10.1523/JNEUROSCI.0054-06.2006; Zhao Q, 2005, J BIOL CHEM, V280, P26735, DOI 10.1074/jbc.M412828200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	53	45	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29085	29095		10.1074/jbc.M602516200	http://dx.doi.org/10.1074/jbc.M602516200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16864584	hybrid			2022-12-25	WOS:000240680500063
J	He, X; Fan, HY; Narlikar, GJ; Kingston, RE				He, Xi; Fan, Hua-Ying; Narlikar, Geeta J.; Kingston, Robert E.			Human ACF1 alters the remodeling strategy of SNF2h	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE-FOLD PROTEINS; HUMAN SWI/SNF; TRANSCRIPTIONAL ACTIVATION; NUCLEOSOME MOBILIZATION; CHROMATIN-STRUCTURE; IN-VITRO; COMPLEX; ISWI; DNA; SUBUNITS	The human ACF chromatin- remodeling complex (hACF) contains the ATPase motor protein SNF2h and the non-catalytic hACF1 subunit. Here, we have compared the ability of SNF2h and a reconstituted hACF complex containing both SNF2h and hACF1 to remodel a series of nucleosomes containing different lengths of DNA overhang. Both SNF2h and hACF functioned in a manner consistent with sliding a canonical nucleosome. However, the non-catalytic subunit, hACF1, altered the remodeling properties of SNF2h by changing the nature of the requirement for a DNA overhang in the nucleosomal substrate and altering the DNA accessibility profile of the remodeled products. Surprisingly, addition of hACF1 to SNF2h increased the amount of DNA overhang needed to observe measurable amounts of DNA accessibility, but decreased the amount of overhang needed for a measurable binding interaction. We propose that these hACF1 functions might contribute to making the hACF complex more efficient at nucleosome spacing compared with SNF2h. In contrast, the SWI/SNF complex and its ATPase subunit BRG1 generated DNA accessibility profiles that were similar to each other, but different significantly from those of hACF and SNF2h. Thus, we observed divergent remodeling behaviors in these two remodeling families and found that the manner in which hACF1 alters the remodeling behavior of the ATPase is not shared by SWI/SNF subunits.	Massachusetts Gen Hosp, Dept Biol Mol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Kingston, RE (corresponding author), Massachusetts Gen Hosp, Dept Biol Mol, Simches Res Bldg,CPZN7811B,185 Cambridge St, Boston, MA 02114 USA.	kingston@molbio.mgh.harvard.edu			NCI NIH HHS [K01 CA093660, CA-093660] Funding Source: Medline; NIGMS NIH HHS [GM48405] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA093660] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048405, R01GM048405] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aalfs JD, 2001, J BIOL CHEM, V276, P34270, DOI 10.1074/jbc.M104163200; Aoyagi S, 2002, MOL CELL BIOL, V22, P3653, DOI 10.1128/MCB.22.11.3653-3662.2002; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Bozhenok L, 2002, EMBO J, V21, P2231, DOI 10.1093/emboj/21.9.2231; Collins N, 2002, NAT GENET, V32, P627, DOI 10.1038/ng1046; Corona DFV, 2000, EMBO J, V19, P3049, DOI 10.1093/emboj/19.12.3049; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; Dorigo B, 2004, SCIENCE, V306, P1571, DOI 10.1126/science.1103124; Eberharter A, 2004, EMBO J, V23, P4029, DOI 10.1038/sj.emboj.7600382; Eberharter A, 2001, EMBO J, V20, P3781, DOI 10.1093/emboj/20.14.3781; Fan HY, 2005, MOL CELL, V17, P805, DOI 10.1016/j.molcel.2005.02.024; Fan HY, 2003, MOL CELL, V11, P1311, DOI 10.1016/S1097-2765(03)00192-8; Fyodorov DV, 2004, GENE DEV, V18, P170, DOI 10.1101/gad.1139604; Fyodorov DV, 2002, NATURE, V418, P897, DOI 10.1038/nature00929; Fyodorov DV, 2002, MOL CELL BIOL, V22, P6344, DOI 10.1128/MCB.22.18.6344-6353.2002; Goldmark JP, 2000, CELL, V103, P423, DOI 10.1016/S0092-8674(00)00134-3; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Havas K, 2001, CELL MOL LIFE SCI, V58, P673, DOI 10.1007/PL00000891; Hayes JJ, 1997, METHODS, V12, P2, DOI 10.1006/meth.1997.0441; Hsiao PW, 2003, MOL CELL BIOL, V23, P6210, DOI 10.1128/MCB.23.17.6210-6220.2003; Imbalzano AN, 1996, J BIOL CHEM, V271, P20726, DOI 10.1074/jbc.271.34.20726; Inoue H, 2002, J BIOL CHEM, V277, P41674, DOI 10.1074/jbc.M205961200; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kagalwala MN, 2004, EMBO J, V23, P2092, DOI 10.1038/sj.emboj.7600220; Kukimoto I, 2004, MOL CELL, V13, P265, DOI 10.1016/S1097-2765(03)00523-9; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; Langst G, 2001, J CELL SCI, V114, P2561; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Logie C, 1999, BIOCHEMISTRY-US, V38, P2514, DOI 10.1021/bi982109d; Lowary PT, 1998, J MOL BIOL, V276, P19, DOI 10.1006/jmbi.1997.1494; Loyola A, 2003, MOL CELL BIOL, V23, P6759, DOI 10.1128/MCB.23.19.6759-6768.2003; Mizuguchi G, 1997, MOL CELL, V1, P141, DOI 10.1016/S1097-2765(00)80015-5; Morillon A, 2003, CELL, V115, P425, DOI 10.1016/S0092-8674(03)00880-8; Narlikar GJ, 2001, MOL CELL, V8, P1219, DOI 10.1016/S1097-2765(01)00412-9; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Poot RA, 2000, EMBO J, V19, P3377, DOI 10.1093/emboj/19.13.3377; Santoro R, 2002, NAT GENET, V32, P393, DOI 10.1038/ng1010; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; Strohner R, 2001, EMBO J, V20, P4892, DOI 10.1093/emboj/20.17.4892; Strohner R, 2005, NAT STRUCT MOL BIOL, V12, P683, DOI 10.1038/nsmb966; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; Whitehouse I, 2003, MOL CELL BIOL, V23, P1935, DOI 10.1128/MCB.23.6.1935-1945.2003; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Xiao H, 2001, MOL CELL, V8, P531, DOI 10.1016/S1097-2765(01)00345-8; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zofall M, 2004, MOL CELL BIOL, V24, P10047, DOI 10.1128/MCB.24.22.10047-10057.2004	53	49	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28636	28647		10.1074/jbc.M603008200	http://dx.doi.org/10.1074/jbc.M603008200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16877760	hybrid			2022-12-25	WOS:000240680500017
J	Joly, D; Berissi, S; Bertrand, A; Strehl, L; Patey, N; Knebelmann, B				Joly, Dominique; Berissi, Sophie; Bertrand, Amelie; Strehl, Laetitia; Patey, Natacha; Knebelmann, Bertrand			Laminin 5 regulates polycystic kidney cell proliferation and cyst formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBULAR EPITHELIAL-CELLS; ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; ALPHA-2-BETA-1 INTEGRIN; MEMBRANE-PROTEIN; GAMMA-2 CHAIN; DISEASE; GROWTH; MIGRATION; ADHESION	Renal cyst formation is the hallmark of autosomal dominant polycystic kidney disease (ADPKD). ADPKD cyst-lining cells have an increased proliferation rate and are surrounded by an abnormal extracellular matrix (ECM). We have previously shown that Laminin 5 (Ln-5, a alpha(3)beta(3)gamma(2) trimer) is aberrantly expressed in the pericystic ECM of ADPKD kidneys. We report that ADPKD cells in primary cultures produce and secrete Ln-5 that is incorporated to the pericystic ECM in an in vitro model of cystogenesis. In monolayers, purified Ln-5 induces ERK activation and proliferation of ADPKD cells, whereas upon epidermal growth factor stimulation blocking endogenously produced Ln-5 with anti-gamma(2) chain antibody reduces the sustained ERK activation and inhibits proliferation. In three-dimensional gel culture, addition of purified Ln-5 stimulates cell proliferation and cyst formation, whereas blocking endogenous Ln-5 strongly inhibits cyst formation. Ligation of alpha(6)beta(4) integrin, a major Ln-5 receptor aberrantly expressed by ADPKD cells, induces beta(4) integrin phosphorylation, ERK activation, cell proliferation, and cyst formation. These findings indicate that Ln-5 is an important regulator of ADPKD cell proliferation and cystogenesis and suggest that Ln-5 gamma(2) chain and Ln-5-alpha(6)beta(4) integrin interaction both contribute to these phenotypic changes.	Univ Paris Descartes, Fac Med, INSERM, U813,Hop Necker Enfants Malades,AP HP,Serv Nephro, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Knebelmann, B (corresponding author), Univ Paris Descartes, Fac Med, INSERM, U813,Hop Necker Enfants Malades,AP HP,Serv Nephro, 149 Rue Sevres, F-75015 Paris, France.	knebelmann@necker.fr						Adachi T, 2002, J CELL PHYSIOL, V192, P151, DOI 10.1002/jcp.10124; BEAVAN LA, 1991, ARCH BIOCHEM BIOPHYS, V284, P392, DOI 10.1016/0003-9861(91)90314-9; Boletta A, 2003, TRENDS CELL BIOL, V13, P484, DOI 10.1016/S0962-8924(03)00169-7; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chiu SJ, 2002, J BIOMED SCI, V9, P261, DOI 10.1159/000059427; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; COWLEY BD, 1993, KIDNEY INT, V43, P522, DOI 10.1038/ki.1993.79; CUPPAGE FE, 1980, KIDNEY INT, V17, P372, DOI 10.1038/ki.1980.43; Daemi N, 2000, INT J CANCER, V85, P850, DOI 10.1002/(SICI)1097-0215(20000315)85:6<850::AID-IJC19>3.0.CO;2-B; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Decline F, 2001, J CELL SCI, V114, P811; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Ghosh S, 2000, MICROSC RES TECHNIQ, V51, P238, DOI 10.1002/1097-0029(20001101)51:3<238::AID-JEMT4>3.0.CO;2-3; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Gilles C, 2001, J CELL SCI, V114, P2967; Gonzales M, 1999, MOL BIOL CELL, V10, P259, DOI 10.1091/mbc.10.2.259; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hood JD, 2003, J CELL BIOL, V162, P933, DOI 10.1083/jcb.200304105; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Joly D, 2003, AM J PATHOL, V163, P1791, DOI 10.1016/S0002-9440(10)63539-0; Kingsley K, 2002, BIOCHEM BIOPH RES CO, V293, P1000, DOI 10.1016/S0006-291X(02)00331-5; Koshikawa N, 2005, J BIOL CHEM, V280, P88, DOI 10.1074/jbc.M411824200; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; NAULI SM, 2003, NAT GENET; Nievers MG, 1999, MATRIX BIOL, V18, P5, DOI 10.1016/S0945-053X(98)00003-1; O'Brien LE, 2001, NAT CELL BIOL, V3, P831, DOI 10.1038/ncb0901-831; Richards WG, 1998, J CLIN INVEST, V101, P935, DOI 10.1172/JCI2071; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; SAELMAN EUM, 1995, J CELL SCI, V108, P3531; Schenk S, 2003, J CELL BIOL, V161, P197, DOI 10.1083/jcb.200208145; Slade MJ, 1998, BBA-MOL CELL RES, V1401, P203, DOI 10.1016/S0167-4889(97)00125-0; Streets AJ, 2003, J AM SOC NEPHROL, V14, P1804, DOI 10.1097/01.ASN.0000076075.49819.9B; Sweeney WE, 1998, AM J PHYSIOL-RENAL, V275, pF387, DOI 10.1152/ajprenal.1998.275.3.F387; TAUB M, 1990, KIDNEY INT, V37, P1090, DOI 10.1038/ki.1990.90; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Wilson PD, 1999, LAB INVEST, V79, P1311; Wilson PD, 2004, NEW ENGL J MED, V350, P151, DOI 10.1056/NEJMra022161; WILSON PD, 1992, J CELL PHYSIOL, V150, P360, DOI 10.1002/jcp.1041500220; Yoder BK, 2002, J AM SOC NEPHROL, V13, P2508, DOI 10.1097/01.ASN.0000029587.47950.25; Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023	44	30	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29181	29189		10.1074/jbc.M606151200	http://dx.doi.org/10.1074/jbc.M606151200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16870608	hybrid			2022-12-25	WOS:000240680500073
J	Murakami, Y; Yamagoe, S; Noguchi, K; Takebe, Y; Takahashi, N; Uehara, Y; Fukazawa, H				Murakami, Yuko; Yamagoe, Satoshi; Noguchi, Kohji; Takebe, Yutaka; Takahashi, Naoko; Uehara, Yoshimasa; Fukazawa, Hidesuke			Ets-1-dependent expression of vascular endothelial growth factor receptors is activated by latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus through interaction with Daxx	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP RESPONSE ELEMENT; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; MOLECULAR-BIOLOGY; BINDING PROTEIN; CELLS; ETS-1; FLT-1; LANA; ANGIOGENESIS	Vascular endothelial growth factor ( VEGF) and its receptors are highly expressed in Kaposi's sarcoma(KS) lesion and play a key role in angiogenesis. Latency-associated nuclear antigen ( LANA) of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8) has multiple functions related to viral latency and KSHV-induced oncogenesis. In this report, we have identified Daxx as a LANA-binding protein by co-immunoprecipitation analysis of HeLa cells stably expressing LANA. LANA associated with Daxx in a PEL cell line infected with KSHV. LANA and Daxx also bound in vitro, suggesting direct interaction. From the results of binding assays, a region containing the Glu/Asp-rich domain within LANA, and a central region including the second paired amphipathic helix within Daxx contributed to the interaction. To address the physiological significance of this interaction, we focused on a Daxx-mediated VEGF receptor gene regulation. We found that Daxx repressed Ets-1-dependent Flt-1/VEGF receptor-1 gene expression, and that LANA inhibited the repression by Daxx in a reporter assay. Analyses of flow cytometry and real-time PCR revealed that expression of VEGF receptor-1 and -2 in LANA-expressing human umbilical vein endothelial cells(HUVECs) significantly increased. Co-immunoprecipitation and immunoblotting experiments suggested that LANA-bound Daxx to inhibit the interaction between Daxx and Ets-1. Chromatin immunoprecipitation assays showed that Daxx associated with VEGF receptor-1 promoter in HUVECs, and that LANA expression reduced this association. These results suggested that LANA contributes to a high expression of VEGF receptors in KS lesion by interfering with the interaction between Daxx and Ets-1.	Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, AIDS Res Ctr, Tokyo 1628640, Japan; Natl Inst Infect Dis, Lab Mol Virol & Epidemiol, Shinjuku Ku, AIDS Res Ctr, Tokyo 1628640, Japan	National Institute of Infectious Diseases (NIID); National Institute of Infectious Diseases (NIID)	Yamagoe, S (corresponding author), Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, AIDS Res Ctr, Toyama 1-23-1, Tokyo 1628640, Japan.	syamagoe@nih.go.jp						An JB, 2004, BLOOD, V103, P222, DOI 10.1182/blood-2003-05-1538; Bais C, 2003, CANCER CELL, V3, P131, DOI 10.1016/S1535-6108(03)00024-2; Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; Chen ZQ, 1997, CANCER RES, V57, P2013; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Emelyanov AV, 2002, J BIOL CHEM, V277, P11156, DOI 10.1074/jbc.M111763200; Everett RD, 2001, ONCOGENE, V20, P7266, DOI 10.1038/sj.onc.1204759; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Fujimuro M, 2003, NAT MED, V9, P300, DOI 10.1038/nm829; Garber AC, 2001, J VIROL, V75, P7882, DOI 10.1128/JVI.75.17.7882-7892.2001; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Jang MS, 2002, BIOCHEM BIOPH RES CO, V295, P495, DOI 10.1016/S0006-291X(02)00699-X; Kappel A, 2000, BLOOD, V96, P3078; Katano H, 1999, AM J PATHOL, V155, P47, DOI 10.1016/S0002-9440(10)65097-3; Kim EJ, 2003, NUCLEIC ACIDS RES, V31, P5356, DOI 10.1093/nar/gkg741; KOIZUMI S, 1990, ONCOGENE, V5, P675; Krithivas A, 2000, J VIROL, V74, P9637, DOI 10.1128/JVI.74.20.9637-9645.2000; Krithivas A, 2002, J VIROL, V76, P11596, DOI 10.1128/JVI.76.22.11596-11604.2002; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Lim C, 2000, J GEN VIROL, V81, P2645, DOI 10.1099/0022-1317-81-11-2645; Lim C, 2003, J BIOL CHEM, V278, P7397, DOI 10.1074/jbc.M211912200; Lim C, 2001, J BIOL CHEM, V276, P31016, DOI 10.1074/jbc.M102431200; Masood R, 2002, AM J PATHOL, V160, P23, DOI 10.1016/S0002-9440(10)64344-1; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; Moore PS, 1998, AM J EPIDEMIOL, V147, P217, DOI 10.1093/oxfordjournals.aje.a009440; MORISHITA K, 1995, J BIOL CHEM, V270, P27948, DOI 10.1074/jbc.270.46.27948; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Platt GM, 1999, J VIROL, V73, P9789, DOI 10.1128/JVI.73.12.9789-9795.1999; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; SACCHI N, 1988, LEUKEMIA, V2, P12; Sato Y, 2000, ANN NY ACAD SCI, V902, P201; Spronk CAEM, 2000, NAT STRUCT BIOL, V7, P1100; Tang DG, 2004, SEMIN THROMB HEMOST, V30, P109; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; Wasylyk C, 2002, MOL CELL BIOL, V22, P2687, DOI 10.1128/MCB.22.8.2687-2702.2002; WERNERT N, 1992, AM J PATHOL, V140, P119; Yamagoe S, 2003, MOL CELL BIOL, V23, P1025, DOI 10.1128/MCB.23.3.1025-1033.2003; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9	41	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28113	28121		10.1074/jbc.M602026200	http://dx.doi.org/10.1074/jbc.M602026200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16861237	hybrid			2022-12-25	WOS:000240534400049
J	Romanenko, V; Nakamoto, T; Srivastava, A; Melvin, JE; Begenisich, T				Romanenko, Victor; Nakamoto, Tetsuji; Srivastava, Alaka; Melvin, James E.; Begenisich, Ted			Molecular identification and physiological roles of parotid acinar cell maxi-K channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY VOLUME DECREASE; ACTIVATED POTASSIUM CHANNEL; INTERMEDIATE CONDUCTANCE; MOUSE HIPPOCAMPUS; SECRETORY-CELLS; GENE-EXPRESSION; CATION CHANNELS; MEMBRANE; MICE; PROTEINS	The physiological success of fluid-secreting tissues relies on a regulated interplay between Ca2+-activated Cl- and K+ channels. Parotid acinar cells express two types of Ca2+-activated K+ channels: intermediate conductance IK1 channels and maxi-K channels. The IK1 channel is encoded by the K(Ca)3.1 gene, and the K(Ca)1.1 gene is a likely candidate for the maxi-K channel. To confirm the genetic identity of the maxi-K channel and to probe its specific roles, we studied parotid glands in mice with the K(Ca)1.1 gene ablated. Parotid acinar cells from these animals lacked maxi-K channels, confirming their genetic identity. The stimulated parotid gland fluid secretion rate was normal, but the sodium and potassium content of the secreted fluid was altered. In addition, we found that the regulatory volume decrease in acinar cells was substantially impaired in K(Ca)1.1-null animals. We examined fluid secretion from animals with both K channel genes deleted. The secretion rate was severely reduced, and the ion content of the secreted fluid was significantly changed. We measured the membrane potentials of acinar cells from wild-type mice and from animals with either or both K+ channel genes ablated. They revealed that the observed functional effects on fluid secretion reflected alterations in cell membrane voltage. Our findings show that the maxi-K channels are critical for the regulatory volume decrease in these cells and that they play an important role in the sodium uptake and potassium secretion process in the ducts of these fluid-secreting salivary glands.	Univ Rochester, Med Ctr, Dept Pharmacol & Physiol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Oral Biol, Aab Inst Biomed Sci, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Begenisich, T (corresponding author), Univ Rochester, Med Ctr, Dept Pharmacol & Physiol, POB 711, Rochester, NY 14642 USA.	Ted_Begenisich@URMC.rochester.edu	Romanenko, Victor/A-1956-2009		NIDCR NIH HHS [DE016960, DE13539] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE016960, P01DE013539] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Begenisich T, 2004, J BIOL CHEM, V279, P47681, DOI 10.1074/jbc.M409627200; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Bruce JIE, 2002, J BIOL CHEM, V277, P1340, DOI 10.1074/jbc.M106609200; Evans RL, 2000, J BIOL CHEM, V275, P26720; Fernandes C, 2004, EUR J NEUROSCI, V19, P2576, DOI 10.1111/j.0953-816X.2004.03358.x; Fernandez-Fernandez JM, 2002, AM J PHYSIOL-CELL PH, V283, pC1705, DOI 10.1152/ajpcell.00245.2002; FOSKETT JK, 1994, J EXP ZOOL, V268, P104, DOI 10.1002/jez.1402680206; FOSKETT JK, 1989, SCIENCE, V244, P1582, DOI 10.1126/science.2500708; GRAY PTA, 1988, J PHYSIOL-LONDON, V406, P35, DOI 10.1113/jphysiol.1988.sp017367; Gribkoff V K, 1997, Adv Pharmacol, V37, P319; Harmer AR, 2005, AM J PHYSIOL-GASTR L, V288, pG118, DOI 10.1152/ajpgi.00096.2004; Hayashi T, 1996, J MEMBRANE BIOL, V151, P19, DOI 10.1007/s002329900054; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; ISHIKAWA T, 1994, PFLUG ARCH EUR J PHY, V428, P516, DOI 10.1007/BF00374573; Krane CM, 2001, J BIOL CHEM, V276, P23413, DOI 10.1074/jbc.M008760200; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; MANGOS JA, 1973, AM J PHYSIOL, V225, P18, DOI 10.1152/ajplegacy.1973.225.1.18; MARUYAMA Y, 1986, JPN J PHYSIOL, V36, P219, DOI 10.2170/jjphysiol.36.219; Meredith AL, 2004, J BIOL CHEM, V279, P36746, DOI 10.1074/jbc.M405621200; Nehrke K, 2003, AM J PHYSIOL-CELL PH, V284, pC535, DOI 10.1152/ajpcell.00044.2002; Park K, 2001, ARCH ORAL BIOL, V46, P801, DOI 10.1016/S0003-9969(01)00047-4; PARK KP, 1994, J MEMBRANE BIOL, V141, P193; PETERSEN OH, 1984, NATURE, V307, P693, DOI 10.1038/307693a0; Pollak DD, 2006, NEUROSCIENCE, V138, P149, DOI 10.1016/j.neuroscience.2005.11.004; Pollak DD, 2006, GENES BRAIN BEHAV, V5, P200, DOI 10.1111/j.1601-183X.2006.00207.x; Schreiber R, 1999, J BIOL CHEM, V274, P11811, DOI 10.1074/jbc.274.17.11811; Shusterman V, 2002, AM J PHYSIOL-HEART C, V282, pH2076, DOI 10.1152/ajpheart.00917.2001; Tabibiazar R, 2005, ARTERIOSCL THROM VAS, V25, P302, DOI 10.1161/01.ATV.0000151372.86863.a5; Takahata T, 2003, AM J PHYSIOL-CELL PH, V284, pC127, DOI 10.1152/ajpcell.00250.2002; Thompson J, 2006, J GEN PHYSIOL, V127, P159, DOI 10.1085/jgp.200509457; WEGMAN EA, 1992, AM J PHYSIOL, V263, pG786, DOI 10.1152/ajpgi.1992.263.5.G786; Wehner F, 2004, REV PHYSIOL BIOCH P, V148, P1, DOI 10.1007/s10254-003-0009-x; Weskamp M, 2000, J MEMBRANE BIOL, V178, P11, DOI 10.1007/s002320010010; YOUNG JA, 1966, PFLUG ARCH GES PHYS, V291, P85, DOI 10.1007/BF00362654	35	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27964	27972		10.1074/jbc.M603871200	http://dx.doi.org/10.1074/jbc.M603871200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16873365	hybrid			2022-12-25	WOS:000240534400033
J	Caruthers, JM; Feng, YN; McKay, DB; Cohen, SN				Caruthers, Jonathan M.; Feng, Yanan; McKay, David B.; Cohen, Stanley N.			Retention of core catalytic functions by a conserved minimal ribonuclease E peptide that lacks the domain required for tetramer formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; ESCHERICHIA-COLI-AMS; 16S RIBOSOMAL-RNA; C-TERMINAL HALF; CAFA PROTEIN; GENE; DEGRADOSOME; DEGRADATION; CLEAVAGE; DECAY	Ribonuclease E (RNase E) is a multifunctional endoribonuclease that has been evolutionarily conserved in both Gram-positive and Gram-negative bacteria. X-ray crystallography and biochemical studies have concluded that the Escherichia coli RNase E protein functions as a homotetramer formed by Zn linkage of dimers within a region extending from amino acid residues 416 through 529 of the 116-kDa protein. Using fragments of RNase E proteins from E. coli and Haemophilus influenzae, we show here that RNase E derivatives that are as short as 395 amino acid residues and that lack the Zn-link region shown previously to be essential for tetramer formation (i.e. amino acid residues 400 415) are catalytically active enzymes that retain the 5' to 3' scanning ability and cleavage site specificity characteristic of full-length RNase E and that also confer colony forming ability on rne null mutant bacteria. Further truncation leads to loss of these properties. Our results, which identify a minimal catalytically active RNase E sequence, indicate that contrary to current models, a tetrameric quaternary structure is not required for RNase E to carry out its core enzymatic functions.	Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	McKay, DB (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.	dave.mckay@stanford.edu; sncohen@stanford.edu			NIGMS NIH HHS [GM 71696, GM 54158] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071696, R01GM054158] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APIRION D, 1978, J BIOL CHEM, V253, P1738; BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; Baginsky S, 2001, METHOD ENZYMOL, V342, P408, DOI 10.1016/S0076-6879(01)42562-6; Bernstein JA, 2004, P NATL ACAD SCI USA, V101, P2758, DOI 10.1073/pnas.0308747101; Callaghan AJ, 2005, NATURE, V437, P1187, DOI 10.1038/nature04084; Callaghan AJ, 2005, BIOCHEMISTRY-US, V44, P4667, DOI 10.1021/bi0478244; Callaghan AJ, 2004, J MOL BIOL, V340, P965, DOI 10.1016/j.jmb.2004.05.046; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; CASAREGOLA S, 1992, J MOL BIOL, V228, P30, DOI 10.1016/0022-2836(92)90489-7; Coburn GA, 1999, PROG NUCLEIC ACID RE, V62, P55; Diwa AA, 2002, MOL MICROBIOL, V46, P959, DOI 10.1046/j.1365-2958.2002.03231.x; Feng YA, 2002, P NATL ACAD SCI USA, V99, P14746, DOI 10.1073/pnas.202590899; GEGENHEIMER P, 1977, J BIOL CHEM, V252, P3064; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; Grunberg-Manago M, 1999, ANNU REV GENET, V33, P193, DOI 10.1146/annurev.genet.33.1.193; Huang HJ, 1998, NATURE, V391, P99, DOI 10.1038/34219; Jiang XQ, 2004, P NATL ACAD SCI USA, V101, P9211, DOI 10.1073/pnas.0401382101; Kaberdin VR, 2005, BIOCHEM BIOPH RES CO, V327, P382, DOI 10.1016/j.bbrc.2004.12.017; Kaberdin VR, 1998, P NATL ACAD SCI USA, V95, P11637, DOI 10.1073/pnas.95.20.11637; KUWANO M, 1977, MOL GEN GENET, V154, P279, DOI 10.1007/BF00571283; Lee K, 2003, MOL MICROBIOL, V48, P349, DOI 10.1046/j.1365-2958.2003.03435.x; Lee K, 2002, MOL MICROBIOL, V43, P1445, DOI 10.1046/j.1365-2958.2002.02848.x; Lee KS, 2003, CELL, V114, P623, DOI 10.1016/j.cell.2003.08.003; Leroy A, 2002, MOL MICROBIOL, V45, P1231, DOI 10.1046/j.1365-2958.2002.03104.x; Li ZW, 1999, EMBO J, V18, P2878, DOI 10.1093/emboj/18.10.2878; Lin-Chao S, 1999, P NATL ACAD SCI USA, V96, P12406, DOI 10.1073/pnas.96.22.12406; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; Lopez PJ, 1999, MOL MICROBIOL, V33, P188, DOI 10.1046/j.1365-2958.1999.01465.x; Mackie GA, 1998, NATURE, V395, P720, DOI 10.1038/27246; MCDOWALL KJ, 1995, NATURE, V374, P287, DOI 10.1038/374287a0; McDowall KJ, 1996, J MOL BIOL, V255, P349, DOI 10.1006/jmbi.1996.0027; MCPHERSON A, 1989, SCI AM, V260, P62, DOI 10.1038/scientificamerican0389-62; MELEFORS O, 1991, MOL MICROBIOL, V5, P857, DOI 10.1111/j.1365-2958.1991.tb00759.x; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; Ow MC, 2000, MOL MICROBIOL, V38, P854, DOI 10.1046/j.1365-2958.2000.02186.x; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; Steege DA, 2000, RNA, V6, P1079, DOI 10.1017/S1355838200001023; TARASEVICIENE L, 1995, J BIOL CHEM, V270, P26391, DOI 10.1074/jbc.270.44.26391; TARASEVICIENE L, 1991, MOL MICROBIOL, V5, P851, DOI 10.1111/j.1365-2958.1991.tb00758.x; Tock MR, 2000, J BIOL CHEM, V275, P8726, DOI 10.1074/jbc.275.12.8726; Wachi M, 1999, BIOCHEM BIOPH RES CO, V259, P483, DOI 10.1006/bbrc.1999.0806; Walsh AP, 2001, NUCLEIC ACIDS RES, V29, P1864, DOI 10.1093/nar/29.9.1864	45	22	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27046	27051		10.1074/jbc.M602467200	http://dx.doi.org/10.1074/jbc.M602467200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16854990	hybrid			2022-12-25	WOS:000240397700031
J	Colton, SL; Xu, XXS; Wang, YA; Wang, G				Colton, Stephanie L.; Xu, Xiaoxin S.; Wang, Y. Alan; Wang, Gan			The involvement of ataxia-telangiectasia mutated protein activation in nucleotide excision repair-facilitated cell survival with cisplatin treatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERSTRAND CROSS-LINKS; GROUP-C PROTEIN; DNA-DAMAGE RECOGNITION; ATM ACTIVATION; XPC PROTEIN; PHOSPHORYLATION; COMPLEX; PSORALEN; CHK2; TRANSCRIPTION	DNA damage can lead to either DNA repair with cell survival or to apoptotic cell death. Although the biochemical processes underlying DNA repair and apoptosis have been extensively studied, the mechanisms by which cells determine whether the damage will be repaired or the apoptotic pathway will be activated is largely unknown. We have studied the role of nucleotide excision repair (NER) in cisplatin DNA damage-induced apoptotic cell death using both normal human fibroblasts and NER-defective xeroderma pigmentosum (XP) XPA and XPG cells. The caspase-3 activation experiment demonstrated a greatly increased casapse-3 activation in the NER-defective cells following cisplatin treatment. The flow cytometry experiment revealed an altered cell cycle arrest pattern of the NER-defective cells following cisplatin treatment. The results obtained from the Western blot experiment showed that NER defects resulted in enhanced CHK1 phosphorylation and p21 induction after cisplatin treatment. The cisplatin treatment-induced ATM phosphorylation, however, was attenuated in NER-defective cells. The results obtained from our immunoprecipitation experiment further demonstrated that the ATM protein interacted with the TFIIH basal transcription factor and the XPG protein of the NER pathway. It also showed that a functional XPC protein was required for the association of the ATM protein to genomic DNA. These results suggest that the NER process may prevent the cisplatin treatment-induced apoptosis by activating the ATM protein, and that the presence of the XPC protein is essential for recruiting the ATM protein to the DNA template.	Wayne State Univ, IEHS, Detroit, MI 48201 USA; Wayne State Univ, Karmanos Canc Res Inst, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Wang, G (corresponding author), Wayne State Univ, IEHS, 2727 2nd Ave,Rm 4000, Detroit, MI 48201 USA.	g.wang@wayne.edu			NIEHS NIH HHS [T32 ES01216, P30 ES06639, R01ES09699] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009699, P30ES006639] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barre FX, 1999, J MOL BIOL, V286, P1379, DOI 10.1006/jmbi.1999.2550; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Batty DP, 2000, GENE, V241, P193, DOI 10.1016/S0378-1119(99)00489-8; Berardi P, 2004, CELL MOL LIFE SCI, V61, P2173, DOI 10.1007/s00018-004-4179-8; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Capasso H, 2002, J CELL SCI, V115, P4555, DOI 10.1242/jcs.00133; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chen ZW, 2004, BIOCHEM J, V379, P71, DOI 10.1042/BJ20031143; Chen ZW, 2003, CARCINOGENESIS, V24, P1111, DOI 10.1093/carcin/bgg051; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; EASTMAN A, 1985, BIOCHEMISTRY-US, V24, P5027, DOI 10.1021/bi00340a011; EASTMAN A, 1987, PHARMACOL THERAPEUT, V34, P155, DOI 10.1016/0163-7258(87)90009-X; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Furuta T, 2002, CANCER RES, V62, P4899; HARPER JW, 1993, CELL, V75, P805; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Irvine Ryan A, 2004, Methods Mol Biol, V287, P45; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kastan MB, 2000, COLD SPRING HARB SYM, V65, P521, DOI 10.1101/sqb.2000.65.521; Kumagai A, 2004, J BIOL CHEM, V279, P49599, DOI 10.1074/jbc.M408353200; Kumaresan KR, 2002, BIOCHEMISTRY-US, V41, P890, DOI 10.1021/bi011614z; Kuraoka I, 2000, J BIOL CHEM, V275, P26632, DOI 10.1074/jbc.C000337200; Lakin ND, 1996, ONCOGENE, V13, P2707; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Li L, 1997, MUTAT RES-DNA REPAIR, V383, P197, DOI 10.1016/S0921-8777(97)00002-5; Li L, 2000, NUCLEIC ACIDS RES, V28, P1424, DOI 10.1093/nar/28.6.1424; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu QH, 2000, GENE DEV, V14, P1448; Masutani C, 1997, MOL CELL BIOL, V17, P6915, DOI 10.1128/MCB.17.12.6915; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; McGowan CH, 2004, CURR OPIN CELL BIOL, V16, P629, DOI 10.1016/j.ceb.2004.09.005; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; Mu D, 2000, MOL CELL BIOL, V20, P2446, DOI 10.1128/MCB.20.7.2446-2454.2000; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; Paull TT, 2005, CELL CYCLE, V4, P737, DOI 10.4161/cc.4.6.1715; Pichierri P, 2004, EMBO J, V23, P1178, DOI 10.1038/sj.emboj.7600113; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shechter D, 2004, DNA REPAIR, V3, P901, DOI 10.1016/j.dnarep.2004.03.020; SHEN K, 2006, IN PRESS J CELL BIOL; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Sugasawa K, 2002, DNA REPAIR, V1, P95, DOI 10.1016/S1568-7864(01)00008-8; Sugasawa K, 2001, GENE DEV, V15, P507, DOI 10.1101/gad.866301; Tapias A, 2004, J BIOL CHEM, V279, P19074, DOI 10.1074/jbc.M312611200; Uchida A, 2002, DNA REPAIR, V1, P449, DOI 10.1016/S1568-7864(02)00031-9; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; vanderSpek PJ, 1996, NUCLEIC ACIDS RES, V24, P2551, DOI 10.1093/nar/24.13.2551; Vermeulen K, 2005, ANN HEMATOL, V84, P627, DOI 10.1007/s00277-005-1065-x; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wang D, 2003, BIOCHEMISTRY-US, V42, P6747, DOI 10.1021/bi034264k; Wang G, 2004, NUCLEIC ACIDS RES, V32, P2231, DOI 10.1093/nar/gkh541; Wang X, 2001, MOL CELL BIOL, V21, P713, DOI 10.1128/MCB.21.3.713-720.2001; Wood RD, 1999, BIOCHIMIE, V81, P39, DOI 10.1016/S0300-9084(99)80036-4; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; You ZS, 2005, MOL CELL BIOL, V25, P5363, DOI 10.1128/MCB.25.13.5363-5379.2005; Zhang NX, 2000, NUCLEIC ACIDS RES, V28, P4800, DOI 10.1093/nar/28.23.4800; Zhang YW, 2006, CELL CYCLE, V5, P125, DOI 10.4161/cc.5.2.2308; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	73	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27117	27125		10.1074/jbc.M602826200	http://dx.doi.org/10.1074/jbc.M602826200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16849332	hybrid			2022-12-25	WOS:000240397700039
J	Dammeyer, T; Frankenberg-Dinkel, N				Dammeyer, Thorben; Frankenberg-Dinkel, Nicole			Insights into phycoerythrobilin biosynthesis point toward metabolic channeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA REDUCTASE; FERREDOXIN OXIDOREDUCTASE; ESCHERICHIA-COLI; SPECTROSCOPIC CHARACTERIZATION; MARINE SYNECHOCOCCUS; CHROMATIC ADAPTATION; BILIVERDIN-IX; PHYCOCYANOBILIN; PURIFICATION; CHROMOPHORE	Phycoerythrobilin is a linear tetrapyrrole molecule found in cyanobacteria, red algae, and cryptomonads. Together with other bilins such as phycocyanobilin it serves as a light-harvesting pigment in the photosynthetic light-harvesting structures of cyanobacteria called phycobilisomes. The biosynthesis of both pigments starts with the cleavage of heme by heme oxygenases to yield biliverdin IX alpha, which is further reduced at specific positions by ferredoxin-dependent bilin reductases (FDBRs), a new family of radical enzymes. The biosynthesis of phycoerythrobilin requires two subsequent two-electron reductions, each step being catalyzed by one FDBR. This is in contrast to the biosynthesis of phycocyanobilin, where the FDBR phycocyanobilin: ferredoxin oxidoreductase (PcyA) catalyzes a four-electron reduction. The first reaction in phycoerythrobilin biosynthesis is the reduction of the 15,16-double bond of biliverdin IX alpha by 15,16-dihydrobiliverdin: ferredoxin oxidoreductase (PebA). This reaction reduces the conjugated pi-electron system thereby blue-shifting the absorbance properties of the linear tetrapyrrole. The second FDBR, phycoerythrobilin: ferredoxin oxidoreductase (PebB), then reduces the A-ring 2,3,3(1),3(2)-diene structure of 15,16-dihydrobiliverdin to yield phycoerythrobilin. Both FDBRs from the limnic filamentous cyanobacterium Fremyella diplosiphon and the marine cyanobacterium Synechococcus sp. WH8020 were recombinantly produced in Escherichia coli and purified, and their enzymatic activities were determined. By using various natural bilins, the substrate specificity of each FDBR was established, revealing conformational preconditions for their unique specificity. Preparation of the semi-reduced intermediate, 15,16-dihydrobiliverdin, enabled us to perform steady state binding experiments indicating distinct spectroscopic and fluorescent properties of enzyme.bilin complexes. A combination of substrate/product binding analyses and gel permeation chromatography revealed evidence for metabolic channeling.	Tech Univ Carolo Wilhelmina Braunschweig, Inst Microbiol, D-38106 Braunschweig, Germany	Braunschweig University of Technology	Frankenberg-Dinkel, N (corresponding author), Ruhr Univ Bochum, D-44780 Bochum, Germany.	nicole.frankenberg@rub.de	Frankenberg-Dinkel, Nicole/C-1058-2011	Frankenberg-Dinkel, Nicole/0000-0002-7757-6839; Dammeyer, Thorben/0000-0002-3542-1273				Alvey RM, 2003, PLANT CELL, V15, P2448, DOI 10.1105/tpc.015016; BEALE SI, 1984, PLANT PHYSIOL, V76, P7, DOI 10.1104/pp.76.1.7; Beutler M, 2002, PHOTOSYNTH RES, V72, P39, DOI 10.1023/A:1016026607048; CHAPMAN DJ, 1967, J AM CHEM SOC, V89, P5976, DOI 10.1021/ja00999a058; CLARKE AR, 1995, ENZYMOLOGY LABFAX, P191; COBLEY JG, 1993, PLASMID, V30, P90, DOI 10.1006/plas.1993.1037; Everroad C, 2006, J BACTERIOL, V188, P3345, DOI 10.1128/JB.188.9.3345-3356.2006; Falk H., 1989, CHEM LINEAR OLIGOPYR; Fischer AJ, 2004, P NATL ACAD SCI USA, V101, P17334, DOI 10.1073/pnas.0407645101; Frankenberg N, 2003, J BIOL CHEM, V278, P9219, DOI 10.1074/jbc.M211643200; Frankenberg N, 2001, PLANT CELL, V13, P965, DOI 10.1105/tpc.13.4.965; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLAZER AN, 1994, J APPL PHYCOL, V6, P105, DOI 10.1007/BF02186064; Goller AH, 2005, CHEMPHYSCHEM, V6, P1259, DOI 10.1002/cphc.200400667; Hagiwara Y, 2006, P NATL ACAD SCI USA, V103, P27, DOI 10.1073/pnas.0507266103; HEIRWEGH KPM, 1991, ANAL BIOCHEM, V195, P273, DOI 10.1016/0003-2697(91)90329-R; Lamparter T, 2003, J BIOL CHEM, V278, P33786, DOI 10.1074/jbc.M305563200; Luer C, 2005, J BIOL CHEM, V280, P18568, DOI 10.1074/jbc.M500440200; McDowell MT, 2001, PLANT PHYSIOL, V126, P1546, DOI 10.1104/pp.126.4.1546; Moser J, 2001, EMBO J, V20, P6583, DOI 10.1093/emboj/20.23.6583; Mukougawa K, 2006, FEBS LETT, V580, P1333, DOI 10.1016/j.febslet.2006.01.051; Murphy JT, 1997, CURR BIOL, V7, P870, DOI 10.1016/S0960-9822(06)00375-7; OI VT, 1982, J CELL BIOL, V93, P981, DOI 10.1083/jcb.93.3.981; Palenik B, 2001, APPL ENVIRON MICROB, V67, P991, DOI 10.1128/AEM.67.2.991-994.2001; Rufer AC, 2005, ACTA CRYSTALLOGR F, V61, P263, DOI 10.1107/S1744309105004823; SCHLUCHTER WM, 1994, THESIS PENNSYLVANIA; SHIN M, 1978, J BIOCHEM-TOKYO, V83, P357, DOI 10.1093/oxfordjournals.jbchem.a131921; STOCKER R, 1987, P NATL ACAD SCI USA, V84, P5918, DOI 10.1073/pnas.84.16.5918; Storf M, 2001, BIOCHEMISTRY-US, V40, P12444, DOI 10.1021/bi010776s; Tasler R, 2005, FEBS J, V272, P1927, DOI 10.1111/j.1742-4658.2005.04623.x; Tu SL, 2004, J AM CHEM SOC, V126, P8682, DOI 10.1021/ja049280z; Waterbury JB, 1986, CAN B FISH AQUAT SCI, V214, P71	32	44	47	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27081	27089		10.1074/jbc.M605154200	http://dx.doi.org/10.1074/jbc.M605154200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16857683	hybrid			2022-12-25	WOS:000240397700035
J	Fukui, N; Ikeda, Y; Ohnuki, T; Hikita, A; Tanaka, S; Yamane, S; Suzuki, R; Sandell, LJ; Ochi, T				Fukui, Naoshi; Ikeda, Yasuko; Ohnuki, Toshiyuki; Hikita, Atsuhiko; Tanaka, Sakae; Yamane, Shoji; Suzuki, Ryuji; Sandell, Linda J.; Ochi, Takahiro			Pro-inflammatory cytokine tumor necrosis factor-alpha induces bone morphogenetic protein-2 in chondrocytes via mRNA stabilization and transcriptional up-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENT; 3' UNTRANSLATED REGION; GENE-EXPRESSION; IN-VITRO; 3'-UNTRANSLATED REGION; OSTEOPHYTE FORMATION; KINASE; CELLS; GROWTH; CARTILAGE	In articular chondrocytes, the inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) induces the expression of bone morphogenetic protein-2 (BMP-2), a growth factor known to be involved in the induction of cartilage and bone. A study was performed to clarify the mechanism(s) underlying the induction of BMP-2 in chondrogenic ATDC5 cells and primary cultured adult human articular chondrocytes. In ATDC5 cells, the endogenous BMP-2 expression was consistently low throughout the process of chondrogenic differentiation, and TNF-alpha induced BMP-2 expression only after the cells acquired the chondrogenic phenotype. The results of nuclear run-off assay and cycloheximide treatment consistently indicated that ATDC5 cells acquire the capacity to synthesize BMP-2 mRNA in the nuclei during the differentiation process. In an attempt to explain the discrepancy between the active nuclear mRNA synthesis and the observed low expression level in differentiated ATDC5 cells, the stability of BMP-2 mRNA was evaluated, and the cells were found to regulate the expression of BMP-2 at the post-transcriptional level. Human chondrocytes were confirmed to have a similar post-transcriptional regulation. The result of 3'-rapid amplification of cDNA end revealed that both human and mouse BMP-2 mRNAs contain multiple pentameric AUUUA motifs in a conserved manner in the 3'-untranslated regions, and transient transfection experiments demonstrated that TNF-alpha increases the stability of BMP-2 mRNA through the pentameric motifs. Further experiments revealed that TNF-alpha modulates mRNA stability via p38 signal transduction pathway, whereas the cytokine also augmented the expression of BMP-2 through transcriptional up-regulation via the transcriptional factor NF-kappa B.	Sagamihara Hosp, Natl Hosp Org, Clin Res Ctr, Dept Pathomech, Sagamihara, Kanagawa 2288522, Japan; Univ Tokyo, Fac Med, Dept Orthopaed Surg, Bunkyo Ku, Tokyo 1130033, Japan; Washington Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO 63110 USA	University of Tokyo; Washington University (WUSTL)	Fukui, N (corresponding author), Sagamihara Hosp, Natl Hosp Org, Clin Res Ctr, Dept Pathomech, Sagamihara, Kanagawa 2288522, Japan.	n-fukui@sagamihara-hosp.gr.jp	Tanaka, Sakae/Y-3061-2019	Tanaka, Sakae/0000-0001-9210-9414				Abrams KL, 2004, J BIOL CHEM, V279, P15916, DOI 10.1074/jbc.M313531200; ASSONBATRES MA, 1994, P NATL ACAD SCI USA, V91, P1318, DOI 10.1073/pnas.91.4.1318; ATSUMI T, 1990, CELL DIFFER DEV, V30, P109, DOI 10.1016/0922-3371(90)90079-C; Bashirullah A, 2001, P NATL ACAD SCI USA, V98, P7025, DOI 10.1073/pnas.111145698; BEELMAN CA, 1994, J BIOL CHEM, V269, P9687; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; BOSTROM MPG, 1995, J ORTHOPAED RES, V13, P357, DOI 10.1002/jor.1100130309; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Carballo E, 2001, J BIOL CHEM, V276, P42580, DOI 10.1074/jbc.M104953200; Chen CY, 2000, GENE DEV, V14, P1236; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; DORSSERS L, 1987, GENE, V55, P115, DOI 10.1016/0378-1119(87)90254-X; Esnault S, 2002, BLOOD, V99, P4048, DOI 10.1182/blood.V99.11.4048; Feng JQ, 2003, J BIOL CHEM, V278, P29130, DOI 10.1074/jbc.M212296200; Fowler MJ, 1998, BIOCHEM BIOPH RES CO, V248, P450, DOI 10.1006/bbrc.1998.8988; Fritz DT, 2004, J BIOL CHEM, V279, P48950, DOI 10.1074/jbc.M409620200; Fukuda H, 2003, J BONE JOINT SURG BR, V85B, P3, DOI 10.1302/0301-620X.85B1.13846; Ghosh-Choudhury N, 2001, BIOCHEM BIOPH RES CO, V286, P101, DOI 10.1006/bbrc.2001.5351; Grunder T, 2004, OSTEOARTHR CARTILAGE, V12, P559, DOI 10.1016/j.joca.2004.04.001; Hallahan AR, 2003, NAT MED, V9, P1033, DOI 10.1038/nm904; Helvering LM, 2000, GENE, V256, P123, DOI 10.1016/S0378-1119(00)00364-4; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Kleeff J, 1999, GASTROENTEROLOGY, V116, P1202, DOI 10.1016/S0016-5085(99)70024-7; KUETTNER KE, 1982, J CELL BIOL, V93, P743, DOI 10.1083/jcb.93.3.743; Langenfeld EM, 2003, CARCINOGENESIS, V24, P1445, DOI 10.1093/carcin/bgg100; Lories RJU, 2003, ARTHRITIS RHEUM, V48, P2807, DOI 10.1002/art.11389; LYONS KM, 1990, DEVELOPMENT, V109, P833; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; Macias D, 1997, DEVELOPMENT, V124, P1109; Mignone F, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-3-reviews0004; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; Nakase T, 2003, OSTEOARTHR CARTILAGE, V11, P278, DOI 10.1016/S1063-4584(03)00004-9; Peng SSY, 1996, MOL CELL BIOL, V16, P1490; Pizette S, 2000, DEV BIOL, V219, P237, DOI 10.1006/dbio.2000.9610; Rountree RB, 2004, PLOS BIOL, V2, P1815, DOI 10.1371/journal.pbio.0020355; Saklatvala J, 2003, BIOCHEM SOC SYMP, V70, P95, DOI 10.1042/bss0700095; SAMPATH TK, 1993, P NATL ACAD SCI USA, V90, P6004, DOI 10.1073/pnas.90.13.6004; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; Schiavone N, 2000, FASEB J, V14, P174, DOI 10.1096/fasebj.14.1.174; Seto H, 2004, J CLIN INVEST, V113, P718, DOI 10.1172/JCI200419899; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shi J, 2004, INFLAMM RES, V53, P377, DOI 10.1007/s00011-004-1271-3; Short S, 2000, J BIOL CHEM, V275, P12963, DOI 10.1074/jbc.275.17.12963; Si SH, 1997, EUR J ORAL SCI, V105, P325, DOI 10.1111/j.1600-0722.1997.tb00248.x; Stewart MC, 2000, J BONE MINER RES, V15, P166, DOI 10.1359/jbmr.2000.15.1.166; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; van Lent PLEM, 2004, ARTHRITIS RHEUM, V50, P103, DOI 10.1002/art.11422; Vasudevan S, 2001, MOL CELL, V7, P1191, DOI 10.1016/S1097-2765(01)00279-9; Wilson GM, 2003, J BIOL CHEM, V278, P33029, DOI 10.1074/jbc.M305772200; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zhang DH, 2002, J BONE MINER RES, V17, P293, DOI 10.1359/jbmr.2002.17.2.293; Zhang HB, 1996, DEVELOPMENT, V122, P2977; Zhou SH, 2003, MOL ENDOCRINOL, V17, P56, DOI 10.1210/me.2002-0210; Zoricic S, 2003, J ANAT, V202, P269, DOI 10.1046/j.1469-7580.2003.00158.x	64	74	75	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27229	27241		10.1074/jbc.M603385200	http://dx.doi.org/10.1074/jbc.M603385200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16835229	hybrid			2022-12-25	WOS:000240397700050
J	Harikumar, KG; Pinon, DI; Miller, LJ				Harikumar, Kaleeckal G.; Pinon, Delia I.; Miller, Laurence J.			Fluorescent indicators distributed throughout the pharmacophore of cholecystokinin provide insights into distinct modes of binding and activation of type A and B cholecystokinin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECT IDENTIFICATION; PEPTIDE AGONIST; TRYPTOPHAN RESIDUES; ERYTHROID SPECTRIN; LIGAND; SITE; ORGANIZATION; DYNAMICS; AFFINITY; GASTRIN	Ligand probes with fluorescent indicators positioned throughout the pharmacophoric domain can provide important insights into the molecular basis of receptor binding and activation as reflected in the microenvironment of each indicator while docked at a receptor. We developed three cholecystokinin-like probes with Aladan situated at the N terminus, in the mid-region, and at the C terminus (positions 24, 29, and 33, respectively). These were studied in solution and docked at type A and B cholecystokinin receptors. This study demonstrated clear differences in mechanisms of cholecystokinin binding and activation of these structurally related receptors with distinct agonist structure-activity relationships. The fluorescence characteristics of Aladan are highly sensitive to the polarity of its microenvironment. The mid-region probe was least accessible to the aqueous milieu as determined by fluorescence emission spectra and iodide quenching, which was not altered by changes in conformation from active to inactive. Accessibility of the Nand C-terminal probes was affected by receptor conformation. The position 24 probe was more easily quenched in the active than in the G protein-uncoupled conformation for both receptors. However, the position 33 probe docked at the type A cholecystokinin receptor was more easily quenched in the active conformation, whereas the same probe docked at the type B cholecystokinin receptor was more easily quenched in the inactive conformation. Fluorescence anisotropy and red edge excitation shift determinations confirmed these observations and supported the proposed movements. Although both type A and B cholecystokinin receptors bind cholecystokinin with high affinity, resulting in fully efficacious biological responses, these receptors utilize distinct molecular modes of binding.	Mayo Clin, Ctr Canc, Scottsdale, AZ 85259 USA; Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Miller, LJ (corresponding author), Mayo Clin, Ctr Canc, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	miller@mayo.edu			NIDDK NIH HHS [DK32878] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032878, R37DK032878] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anders J, 1999, BIOCHEMISTRY-US, V38, P6043, DOI 10.1021/bi990269z; Arlander SJH, 2004, MOL PHARMACOL, V66, P545, DOI 10.1124/mol.104.001396; Chattopadhyay A, 2003, PROTEIN SCI, V12, P2389, DOI 10.1110/ps.03302003; Chattopadhyay A, 2003, CHEM PHYS LIPIDS, V122, P3, DOI 10.1016/S0009-3084(02)00174-3; Cheng ZJ, 2003, J BIOL CHEM, V278, P52972, DOI 10.1074/jbc.M310090200; Cohen BE, 2002, SCIENCE, V296, P1700, DOI 10.1126/science.1069346; Ding XQ, 2002, MOL PHARMACOL, V61, P1041, DOI 10.1124/mol.61.5.1041; Ding XQ, 2001, J BIOL CHEM, V276, P4236, DOI 10.1074/jbc.M003798200; Dong MQ, 2005, MOL PHARMACOL, V67, P1892, DOI 10.1124/mol.105.012179; Dong MQ, 2005, BIOCHEMISTRY-US, V44, P6693, DOI 10.1021/bi050130q; Dong MQ, 1999, J BIOL CHEM, V274, P4778, DOI 10.1074/jbc.274.8.4778; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hadac EM, 1998, J BIOL CHEM, V273, P12988, DOI 10.1074/jbc.273.21.12988; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; Harikumar KG, 2005, J BIOL CHEM, V280, P1044, DOI 10.1074/jbc.M409480200; Harikumar KG, 2002, J BIOL CHEM, V277, P18552, DOI 10.1074/jbc.M201164200; Ji ZS, 1997, J BIOL CHEM, V272, P24393, DOI 10.1074/jbc.272.39.24393; Kelkar DA, 2005, BIOPOLYMERS, V77, P325, DOI 10.1002/bip.20233; Kennedy K, 1997, J BIOL CHEM, V272, P2920, DOI 10.1074/jbc.272.5.2920; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; KOPIN AS, 1995, J BIOL CHEM, V270, P5019, DOI 10.1074/jbc.270.10.5019; MILLER LJ, 1981, J BIOL CHEM, V256, P2417; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUTT V, 1981, PEPTIDES, V2, P209, DOI 10.1016/0196-9781(81)90033-4; Noble F, 1999, PHARMACOL REV, V51, P745; Noble F, 1999, THERAPIE, V54, P121; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; Rehfeld JF, 2000, REGUL PEPTIDES, V93, P79, DOI 10.1016/S0167-0115(00)00179-8; Schmitz F, 1996, MOL PHARMACOL, V50, P436; Silvente-Poirot S, 1996, J BIOL CHEM, V271, P14698, DOI 10.1074/jbc.271.25.14698; Sundd M, 2002, NAT STRUCT BIOL, V9, P500, DOI 10.1038/nsb0702-500; vanKesteren RE, 1996, J BIOL CHEM, V271, P3619; WEBER G, 1979, BIOCHEMISTRY-US, V18, P3075, DOI 10.1021/bi00581a025	34	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27072	27080		10.1074/jbc.M605098200	http://dx.doi.org/10.1074/jbc.M605098200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16857665	hybrid			2022-12-25	WOS:000240397700034
J	Schieke, SM; Phillips, D; Mccoy, JP; Aponte, AM; Shen, RF; Balaban, RS; Finkel, T				Schieke, Stefan M.; Phillips, Darci; McCoy, J. Philip, Jr.; Aponte, Angel M.; Shen, Rong-Fong; Balaban, Robert S.; Finkel, Toren			The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMATIC RNAI SCREEN; LIFE-SPAN; CALORIE RESTRICTION; C-ELEGANS; SACCHAROMYCES-CEREVISIAE; BINDING PARTNER; CELL-GROWTH; TOR; PROTEIN; RAPTOR	Metabolic rate and the subsequent production of reactive oxygen species are thought to contribute to the rate of aging in a wide range of species. The target of rapamycin (TOR) is a well conserved serine/threonine kinase that regulates cell growth in response to nutrient status. Here we demonstrate that in mammalian cells the mammalian TOR (mTOR) pathway plays a significant role in determining both resting oxygen consumption and oxidative capacity. In particular, we demonstrate that the level of complex formation between mTOR and one of its known protein partners, raptor, correlated with overall mitochondrial activity. Disruption of this complex following treatment with the mTOR pharmacological inhibitor rapamycin lowered mitochondrial membrane potential, oxygen consumption, and ATP synthetic capacity. Subcellular fractionation revealed that mTOR as well as mTOR-raptor complexes can be purified in the mitochondrial fraction. Using two-dimensional difference gel electrophoresis, we further demonstrated that inhibiting mTOR with rapamycin resulted in a dramatic alteration in the mitochondrial phosphoproteome. RNA interference-mediated knockdown of TSC2, p70 S6 kinase (S6K1), raptor, or rictor demonstrates that mTOR regulates mitochondrial activity independently of its previously identified cellular targets. Finally we demonstrate that mTOR activity may play an important role in determining the relative balance between mitochondrial and non-mitochondrial sources of ATP generation. These results may provide insight into recent observations linking the TOR pathway to life span regulation of lower organisms.	NHLBI, Cardiol Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Lab Cardiac Energet, NIH, Bethesda, MD 20892 USA; NHLBI, Flow Cytometry Core Facil, NIH, Bethesda, MD 20892 USA; NHLBI, Proteom Core Facil, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Finkel, T (corresponding author), NHLBI, Cardiol Branch, NIH, Bldg 10CR-5-3330,10 Ctr Dr, Bethesda, MD 20892 USA.	finkelt@nih.gov	mccoy, john philip/ABD-9348-2021; Balaban, Robert S/A-7459-2009	Balaban, Robert S/0000-0003-4086-0948; Phillips, Darci/0000-0002-0804-3342	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005012, ZIAHL005012, Z01HL004601, ZIAHL004601] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Desai BN, 2002, P NATL ACAD SCI USA, V99, P4319, DOI 10.1073/pnas.261702698; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Hamilton B, 2005, GENE DEV, V19, P1544, DOI 10.1101/gad.1308205; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Hoffert JD, 2004, AM J PHYSIOL-RENAL, V286, pF170, DOI 10.1152/ajprenal.00223.2003; Hopper RK, 2006, BIOCHEMISTRY-US, V45, P2524, DOI 10.1021/bi052475e; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Martin K, 2003, PROTEOMICS, V3, P1244, DOI 10.1002/pmic.200300445; Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; Powers RW, 2006, GENE DEV, V20, P174, DOI 10.1101/gad.1381406; Rea S, 2003, DEV CELL, V5, P197, DOI 10.1016/S1534-5807(03)00242-9; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; SARIBANSOHRABY S, 1983, CANCER RES, V43, P4662; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Unwin RD, 2005, J BIOL CHEM, V280, P6316, DOI 10.1074/jbc.M410598200; Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wilson-Fritch L, 2004, J CLIN INVEST, V114, P1281, DOI 10.1172/JCI200421752; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016	33	467	483	0	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27643	27652		10.1074/jbc.M603536200	http://dx.doi.org/10.1074/jbc.M603536200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16847060	hybrid			2022-12-25	WOS:000240397700089
J	Thangaraju, M; Ananth, S; Martin, PM; Roon, P; Smith, SB; Sterneck, E; Prasad, PD; Ganapathy, V				Thangaraju, Muthusamy; Ananth, Sudha; Martin, Pamela M.; Roon, Penny; Smith, Sylvia B.; Sterneck, Esta; Prasad, Puttur D.; Ganapathy, Vadivel			c/ebp delta null mouse as a model for the double knock-out of slc5a8 and slc5a12 in kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN-DELTA; NA+-COUPLED TRANSPORTER; FUNCTIONAL IDENTIFICATION; TUMOR-SUPPRESSOR; MICE LACKING; LACTATE; EXPRESSION; PHYSIOLOGY; FAMILY; ACID	slc5a8 and slc5a12 represent the high affinity and low affinity Na+/lactate co-transporters, respectively, in the kidney. Here we show that these transporters are expressed in the apical membrane of the proximal tubular cells in mouse kidney, indicating that these transporters are likely to mediate the first step in the renal reabsorption of lactate. Interestingly, the renal expression of both transporters is almost completely ablated in mice homozygous for the deletion of the transcription factor c/ebp delta. This effect is tissue-specific since the expression of the transporters is not affected in non-renal tissues. The functional role of C/EBP delta in the expression of SLC5A8 and SLC5A12 is demonstrable in HEK293 cells in reporter assays using gene-specific promoters. The ablation of the transporters in the kidney is accompanied by a marked increase in urinary excretion of lactate as well as a decrease in blood levels of lactate in c/ebp delta(-/-). These data provide evidence for an obligatory role for slc5a8 and slc5a12 in the renal absorption of lactate. In addition, we show that urinary excretion of urate is significantly elevated in c/ebp delta(-/-) mice even though the expression of URAT1, the transporter responsible for the apical membrane uptake of urate in renal proximal tubule, is not altered. These data provide in vivo evidence for the functional coupling between lactate reabsorption and urate reabsorption in the kidney. Thus, the fortuitous double knock-out of slc5a8 and slc5a12 in kidney in c/ebp delta(-/-) mice reveals the physiologic role of these transporters in the renal handling of lactate and urate.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA; NCI, Lab Prot Dynam & Signaling, Canc Res Ctr, NIH, Frederick, MD 21702 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ganapathy, V (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.	vganapat@mail.mcg.edu		Sterneck, Esta/0000-0001-7716-8766				Brooks GA, 2002, BIOCHEM SOC T, V30, P258, DOI 10.1042/bst0300258; Dun Y, 2006, CELL TISSUE RES, V324, P189, DOI 10.1007/s00441-005-0116-x; Ganapathy V, 2005, BIOCHEM SOC T, V33, P237, DOI 10.1042/BST0330237; Gigliotti AP, 2003, EXP BIOL MED, V228, P278, DOI 10.1177/153537020322800306; Gopal E, 2005, BIOCHEM J, V388, P309, DOI 10.1042/BJ20041916; Gopal E, 2004, J BIOL CHEM, V279, P44522, DOI 10.1074/jbc.M405365200; Gupta N, 2006, LIFE SCI, V78, P2419, DOI 10.1016/j.lfs.2005.10.028; Hediger MA, 2005, PHYSIOLOGY, V20, P125, DOI 10.1152/physiol.00039.2004; Huang AM, 2004, ONCOGENE, V23, P1549, DOI 10.1038/sj.onc.1207285; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Martin PM, 2006, J NEUROCHEM, V98, P279, DOI 10.1111/j.1471-4159.2006.03878.x; Miyauchi S, 2004, J BIOL CHEM, V279, P13293, DOI 10.1074/jbc.C400059200; Palacin M, 2004, PFLUG ARCH EUR J PHY, V447, P490, DOI 10.1007/s00424-003-1062-7; Pellerin L, 2005, MOL NEUROBIOL, V32, P59, DOI 10.1385/MN:32:1:059; Srinivas SR, 2005, BIOCHEM J, V392, P655, DOI 10.1042/BJ20050927; Sterneck E, 1998, P NATL ACAD SCI USA, V95, P10908, DOI 10.1073/pnas.95.18.10908; Takeji M, 2004, J AM SOC NEPHROL, V15, P2383, DOI 10.1097/01.ASN.0000136426.01160.2F; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; ULLRICH KJ, 1993, CLIN INVESTIGATOR, V71, P843; Wright SH, 2004, PHYSIOL REV, V84, P987, DOI 10.1152/physrev.00040.2003	20	69	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26769	26773		10.1074/jbc.C600189200	http://dx.doi.org/10.1074/jbc.C600189200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16873376	hybrid			2022-12-25	WOS:000240397700002
J	Winn, RA; Van Scoyk, M; Hammond, M; Rodriguez, K; Crossno, JT; Heasley, LE; Nemenoff, RA				Winn, Robert A.; Van Scoyk, Michelle; Hammond, Mandy; Rodriguez, Karen; Crossno, Joseph T., Jr.; Heasley, Lynn E.; Nemenoff, Raphael A.			Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; EPITHELIAL-MESENCHYMAL TRANSITIONS; PPAR-GAMMA; NUCLEAR RECEPTORS; TRANSCRIPTIONAL ACTIVATION; SIGNALING PATHWAY; INHIBITION; EXPRESSION; GROWTH; DIFFERENTIATION	The Wnt pathway is critical for normal development, and mutation of specific components is seen in carcinomas of diverse orgins. The role of this pathway in lung tumorigenesis has not been clearly established. Recent studies from our laboratory indicate that combined expression of the combination of Wnt 7a and Frizzled 9 (Fzd 9) in Non-small Cell Lung Cancer (NSCLC) cell lines inhibits transformed growth. We have also shown that increased expression of peroxisome proliferator-activated receptor gamma(PPAR gamma) inhibits transformed growth of NSCLC and promotes epithelial differentiation of these cells. The goal of this study was to determine whether the effects of Wnt 7a/Fzd 9 were mediated through PPAR gamma. We found that Wnt 7a and Fzd 9 expression led to increased PPAR gamma activity. This effect was not mediated by altered expression of the protein. Wnt 7a and Fzd 9 expression resulted in activation of ERK5, which was required for PPAR gamma activation in NSCLC. SR 202, a known PPAR gamma inhibitor, blocked the increase in PPAR gamma activity and restored anchorage-independent growth in NSCLC expressing Wnt 7a and Fzd 9. SR 202 also reversed the increase in E-cadherin expression mediated by Wnt 7a and Fzd 9. These data suggest that ERK5-dependent activation of PPAR gamma represents a major effector pathway mediating the anti-tumorigenic effects of Wnt 7a and Fzd 9 in NSCLC.	Univ Colorado, Hlth Sci Ctr, Div Pulm & Crit Care Med, Dept Med, Denver, CO 80262 USA; Vet Adm Med Ctr, Denver, CO 80220 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Winn, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Pulm & Crit Care Med, Dept Med, 4200 E 9th Ave, Denver, CO 80262 USA.	robert.winn@uchsc.edu			NATIONAL CANCER INSTITUTE [R01CA103618, R01CA108610, R01CA116527, P50CA058187] Funding Source: NIH RePORTER; NCI NIH HHS [CA103618, CA58187, CA108610, R01 CA116527] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akaike M, 2004, MOL CELL BIOL, V24, P8691, DOI 10.1128/MCB.24.19.8691-8704.2004; Bren-Mattison Y, 2005, ONCOGENE, V24, P1412, DOI 10.1038/sj.onc.1208333; Calvo R, 2000, P NATL ACAD SCI USA, V97, P12776, DOI 10.1073/pnas.97.23.12776; Cameron SJ, 2003, J BIOL CHEM, V278, P18682, DOI 10.1074/jbc.M213283200; Chang TH, 2000, CANCER RES, V60, P1129; Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951; Feige JN, 2006, PROG LIPID RES, V45, P120, DOI 10.1016/j.plipres.2005.12.002; Fukuhara S, 2000, J BIOL CHEM, V275, P21730, DOI 10.1074/jbc.M002410200; Gelman L, 2005, CURR OPIN CELL BIOL, V17, P216, DOI 10.1016/j.ceb.2005.02.002; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; Hajra KM, 2002, CANCER RES, V62, P1613; Hayashi M, 2004, J MOL MED, V82, P800, DOI 10.1007/s00109-004-0602-8; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; JANSSON EA, 2005, P NATL ACAD SCI US; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Karim RZ, 2004, PATHOLOGY, V36, P120, DOI 10.1080/00313020410001671957; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kirikoshi H, 2002, INT J ONCOL, V21, P895; Mazieres J, 2005, CANCER LETT, V222, P1, DOI 10.1016/j.canlet.2004.08.040; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; Nemenoff RA, 2005, EUR J CANCER, V41, P2561, DOI 10.1016/j.ejca.2005.08.015; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Polakis P, 2000, GENE DEV, V14, P1837; Rieusset J, 2002, MOL ENDOCRINOL, V16, P2628, DOI 10.1210/me.2002-0036; Santini E, 2004, DIABETES, V53, pS79, DOI 10.2337/diabetes.53.suppl_3.S79; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Sasaki H, 2002, LUNG CANCER-J IASLC, V36, P71, DOI 10.1016/S0169-5002(01)00449-4; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Wick M, 2002, MOL PHARMACOL, V62, P1207, DOI 10.1124/mol.62.5.1207; Winn RA, 2002, ONCOGENE, V21, P7497, DOI 10.1038/sj.onc.1205963; Winn RA, 2005, J BIOL CHEM, V280, P19625, DOI 10.1074/jbc.M409392200; Yu C, 2005, J BIOL CHEM, V280, P13600, DOI 10.1074/jbc.M409468200	38	98	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26943	26950		10.1074/jbc.M604145200	http://dx.doi.org/10.1074/jbc.M604145200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16835228	hybrid			2022-12-25	WOS:000240397700021
J	Chhabra, ES; Higgs, HN				Chhabra, Ekta Seth; Higgs, Henry N.			INF2 is a WASP homology 2 motif-containing formin that severs actin filaments and accelerates both polymerization and depolymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPPING PROTEIN; ATP-ACTIN; ADP-ACTIN; INDUCED NUCLEATION; BUNDLING ACTIVITY; STRUCTURAL BASIS; MOUSE FORMIN; DOMAIN; MECHANISM; PROFILIN	Formin proteins modulate both nucleation and elongation of actin filaments through processive movement of their dimeric formin homology 2 (FH2) domains with filament barbed ends. Mammals possess at least 15 formin genes. A subset of formins termed "diaphanous formins" are regulated by autoinhibition through interaction between an N-terminal diaphanous inhibitory domain (DID) and a C-terminal diaphanous autoregulatory domain (DAD). Here, we found several striking features for the mouse formin, INF2. First, INF2 interacted directly with actin through a region C-terminal to the FH2. This second interacting region sequesters actin monomers, an activity that is dependent on a WASP homology 2 (WH2) motif. Second, the combination of the FH2 and C-terminal regions of INF2 resulted in its curious ability to accelerate both polymerization and depolymerization of actin filaments. The mechanism of the depolymerization activity, which is novel for formin proteins, involves both the monomer binding ability of the WH2 and a potent severing activity that is dependent on covalent attachment of the FH2 to the C terminus. Phosphate inhibits both the depolymerization and severing activities of INF2, suggesting that phosphate release from actin subunits in the filament is a trigger for depolymerization. Third, INF2 contains an N-terminal DID, and the WH2 motif likely doubles as a DAD in an autoinhibitory interaction.	Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Higgs, HN (corresponding author), Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA.	henry.higgs@dartmouth.edu		Higgs, Henry/0000-0002-2917-9644	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069818] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-069818] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; Belmont LD, 1999, P NATL ACAD SCI USA, V96, P29, DOI 10.1073/pnas.96.1.29; Bindschadler M, 2004, BIOPHYS J, V86, P2720, DOI 10.1016/S0006-3495(04)74326-X; Blanchoin L, 1999, J BIOL CHEM, V274, P15538, DOI 10.1074/jbc.274.22.15538; Bugyi B, 2006, J BIOL CHEM, V281, P10727, DOI 10.1074/jbc.M510252200; CARLIER MF, 1988, J BIOL CHEM, V263, P817; Chereau D, 2005, P NATL ACAD SCI USA, V102, P16644, DOI 10.1073/pnas.0507021102; Domanski M, 2004, J BIOL CHEM, V279, P23637, DOI 10.1074/jbc.M311413200; ESTES JE, 1981, BIOCHEMISTRY-US, V20, P708, DOI 10.1021/bi00507a006; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; Harris ES, 2006, J BIOL CHEM, V281, P14383, DOI 10.1074/jbc.M510923200; Harris ES, 2004, J BIOL CHEM, V279, P20076, DOI 10.1074/jbc.M312718200; Harris ES, 2006, METHOD ENZYMOL, V406, P190, DOI 10.1016/S0076-6879(06)06015-0; Hertzog M, 2004, CELL, V117, P611, DOI 10.1016/S0092-8674(04)00403-9; Higgs HN, 2005, MOL BIOL CELL, V16, P1, DOI 10.1091/mbc.E04-07-0565; Higgs HN, 2005, TRENDS BIOCHEM SCI, V30, P342, DOI 10.1016/j.tibs.2005.04.014; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; Hotulainen P, 2006, J CELL BIOL, V173, P383, DOI 10.1083/jcb.200511093; Kovar DR, 2003, J CELL BIOL, V161, P875, DOI 10.1083/jcb.200211078; Kovar DR, 2006, CURR OPIN CELL BIOL, V18, P11, DOI 10.1016/J.CEB.2005.12.011; Kovar DR, 2006, CELL, V124, P423, DOI 10.1016/j.cell.2005.11.038; Kovar DR, 2005, MOL BIOL CELL, V16, P2313, DOI 10.1091/mbc.E04-09-0781; Lammers M, 2005, EMBO J, V24, P4176, DOI 10.1038/sj.emboj.7600879; Li F, 2005, J BIOL CHEM, V280, P6986, DOI 10.1074/jbc.M411605200; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; Michelot A, 2005, PLANT CELL, V17, P2296, DOI 10.1105/tpc.105.030908; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; Moseley JB, 2005, J BIOL CHEM, V280, P28023, DOI 10.1074/jbc.M503094200; MOSELEY JB, 2004, MOL BIOL CELL, V116, P711; Nezami AG, 2006, STRUCTURE, V14, P257, DOI 10.1016/j.str.2005.12.003; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; Otomo T, 2005, MOL CELL, V18, P273, DOI 10.1016/j.molcel.2005.04.002; Paunola E, 2002, FEBS LETT, V513, P92, DOI 10.1016/S0014-5793(01)03242-2; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Pring M, 2003, BIOCHEMISTRY-US, V42, P486, DOI 10.1021/bi026520j; Quinlan ME, 2005, NATURE, V433, P382, DOI 10.1038/nature03241; Romero S, 2004, CELL, V119, P419, DOI 10.1016/j.cell.2004.09.039; Rose R, 2005, NATURE, V435, P513, DOI 10.1038/nature03604; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Vavylonis D, 2006, MOL CELL, V21, P455, DOI 10.1016/j.molcel.2006.01.016; Vavylonis D, 2005, P NATL ACAD SCI USA, V102, P8543, DOI 10.1073/pnas.0501435102; Wallar BJ, 2006, J BIOL CHEM, V281, P4300, DOI 10.1074/jbc.M510277200; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; WANGER M, 1987, BIOCHIM BIOPHYS ACTA, V914, P105, DOI 10.1016/0167-4838(87)90052-5; Zigmond SH, 2003, CURR BIOL, V13, P1820, DOI 10.1016/j.cub.2003.09.057; Zigmond SH, 2004, CURR OPIN CELL BIOL, V16, P99, DOI 10.1016/j.ceb.2003.10.019	50	142	148	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26754	26767		10.1074/jbc.M604666200	http://dx.doi.org/10.1074/jbc.M604666200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16818491	hybrid			2022-12-25	WOS:000240249500093
J	Fernandez, E; Jimenez-Vidal, M; Calvo, M; Zorzano, A; Tebar, F; Palacin, M; Chillaron, J				Fernandez, Esperanza; Jimenez-Vidal, Maite; Calvo, Maria; Zorzano, Antonio; Tebar, Francesc; Palacin, Manuel; Chillaron, Josep			The structural and functional units of heteromeric amino acid transporters - The heavy subunit rBAT dictates oligomerization of the heteromeric amino acid transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; GENOTYPE-PHENOTYPE CORRELATION; MEMBRANE-PROTEIN COMPLEXES; PLASMA-MEMBRANE; LIGHT SUBUNIT; LIVING CELLS; L-CYSTINE; SYSTEM; MUTATIONS; EXCHANGE	Heteromeric amino acid transporters are composed of a catalytic light subunit and a heavy subunit linked by a disulfide bridge. We analyzed the structural and functional units of systems b(0,+) and x(C)(-), formed by the heterodimers b(0,+) AT-rBAT and xCT-4F2hc, respectively. Blue Native gel electrophoresis, cross-linking, and fluorescence resonance energy transfer in vivo indicate that system b(0,+) is a heterotetramer [b(0,+) AT-rBAT](2), whereas xCT-4F2hc seems not to stably or efficiently oligomerize. However, substitution of the heavy subunit 4F2hc for rBAT was sufficient to form a heterotetrameric [xCT-\rBAT](2) structure. The functional expression of concatamers of two light subunits ( which differ only in their sensitivity to inactivation by a sulfhydryl reagent) suggests that a single heterodimer is the functional unit of systems b(0,+) and x(C)(-).	IRB, PCB, Barcelona 08028, Spain; Univ Barcelona, Dept Biochem & Mol Biol, Fac Biol, E-08028 Barcelona, Spain; Univ Barcelona, Fac Med, Dept Biol Cellular, Inst Invest Biomed August Pi Suyer, Barcelona 08036, Spain	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; University of Barcelona; University of Barcelona	Palacin, M (corresponding author), IRB, PCB, Barcelona Sci Pk,Josep Samitier 1-5, Barcelona 08028, Spain.	mpalacin@pcb.ub.es	Chillaron, Josep/ABF-7663-2021; Calvo, Maria/I-1872-2015; Zorzano, Antonio/R-5479-2018; Tebar, Francesc/H-1498-2015	Chillaron, Josep/0000-0003-3068-7598; Calvo, Maria/0000-0002-7473-0474; Tebar, Francesc/0000-0002-9522-9726; Palacin, Manuel/0000-0002-8670-293X				Baker DA, 2003, NAT NEUROSCI, V6, P743, DOI 10.1038/nn1069; BANNAI S, 1986, J BIOL CHEM, V261, P2256; Bassi MT, 2001, PFLUG ARCH EUR J PHY, V442, P286, DOI 10.1007/s004240100537; Bauch C, 2003, J BIOL CHEM, V278, P1316, DOI 10.1074/jbc.M210449200; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; Borsani G, 1999, NAT GENET, V21, P297, DOI 10.1038/6815; CALONGE MT, 1994, NAT GENET, V6, P420, DOI 10.1038/ng0494-420; Chillaron J, 2001, AM J PHYSIOL-RENAL, V281, pF995, DOI 10.1152/ajprenal.2001.281.6.F995; Estevez R, 1998, FASEB J, V12, P1319, DOI 10.1096/fasebj.12.13.1319; Feliubadalo L, 1999, NAT GENET, V23, P52, DOI 10.1038/12652; Feliubadalo L, 2003, HUM MOL GENET, V12, P2097, DOI 10.1093/hmg/ddg228; Feral CC, 2005, P NATL ACAD SCI USA, V102, P355, DOI 10.1073/pnas.0404852102; Fernandez E, 2003, J AM SOC NEPHROL, V14, P837, DOI 10.1097/01.ASN.0000057852.35075.AC; Fernandez E, 2002, AM J PHYSIOL-RENAL, V283, pF540, DOI 10.1152/ajprenal.00071.2002; Font M, 2001, HUM MOL GENET, V10, P305, DOI 10.1093/hmg/10.4.305; Font-Llitjos M, 2005, J MED GENET, V42, P58, DOI 10.1136/jmg.2004.022244; FRANCOIS V, 2004, PFLUEGERS ARCH EUR J, V447, P532; Fuchs BC, 2005, SEMIN CANCER BIOL, V15, P254, DOI 10.1016/j.semcancer.2005.04.005; FURRIOLS M, 1993, J BIOL CHEM, V268, P27060; Gasol E, 2004, J BIOL CHEM, V279, P31228, DOI 10.1074/jbc.M402428200; Gendreau S, 2004, J BIOL CHEM, V279, P39505, DOI 10.1074/jbc.M408038200; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Herrick-Davis K, 2004, BIOCHEMISTRY-US, V43, P13963, DOI 10.1021/bi048398p; Heuberger EHML, 2002, J MOL BIOL, V317, P591, DOI 10.1006/jmbi.2002.5416; Jimenez-Vidal M, 2004, J BIOL CHEM, V279, P11214, DOI 10.1074/jbc.M309866200; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; Kohler K, 2000, J BIOL CHEM, V275, P26113, DOI 10.1074/jbc.M003564200; Kunji ERS, 2004, FEBS LETT, V564, P239, DOI 10.1016/S0014-5793(04)00242-X; Lin CW, 2000, J GEN PHYSIOL, V116, P535, DOI 10.1085/jgp.116.4.535; Meisinger C, 2001, MOL CELL BIOL, V21, P2337, DOI 10.1128/MCB.21.7.2337-2348.2001; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; Palacin M, 2004, PFLUG ARCH EUR J PHY, V447, P490, DOI 10.1007/s00424-003-1062-7; Pfeiffer R, 1999, MOL BIOL CELL, V10, P4135, DOI 10.1091/mbc.10.12.4135; Pineda M, 2004, BIOCHEM J, V377, P665, DOI 10.1042/BJ20030956; PRAS E, 1994, NAT GENET, V6, P415, DOI 10.1038/ng0494-415; Reig N, 2002, EMBO J, V21, P4906, DOI 10.1093/emboj/cdf500; Rintoul RC, 2002, MOL BIOL CELL, V13, P2841, DOI 10.1091/mbc.01-11-0530; Rossier G, 1999, J BIOL CHEM, V274, P34948, DOI 10.1074/jbc.274.49.34948; Sato H, 2005, J BIOL CHEM, V280, P37423, DOI 10.1074/jbc.M506439200; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; Schroers A, 1998, J BIOL CHEM, V273, P14269, DOI 10.1074/jbc.273.23.14269; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Sorkina T, 2003, J BIOL CHEM, V278, P28274, DOI 10.1074/jbc.M210652200; Torras-Llort M, 2001, J MEMBRANE BIOL, V180, P213, DOI 10.1007/s002320010072; Torrents D, 1999, NAT GENET, V21, P293, DOI 10.1038/6809	48	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26552	26561		10.1074/jbc.M604049200	http://dx.doi.org/10.1074/jbc.M604049200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16825196	hybrid			2022-12-25	WOS:000240249500073
J	Thomas, DD; Ridnour, LA; Espey, MG; Donzelli, S; Ambs, S; Hussain, SP; Harris, CC; DeGraff, W; Roberts, DD; Mitchell, JB; Wink, DA				Thomas, Douglas D.; Ridnour, Lisa A.; Espey, Michael Graham; Donzelli, Sonia; Ambs, Stefan; Hussain, S. Perwez; Harris, Curtis C.; DeGraff, William; Roberts, David D.; Mitchell, James B.; Wink, David A.			Superoxide fluxes limit nitric oxide-induced signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE NITRATION; PEROXYNITRITE-MEDIATED OXIDATION; ENDOTHELIAL GROWTH-FACTOR; HUMAN BREAST-CANCER; INDUCIBLE FACTOR-1-ALPHA; XANTHINE-OXIDASE; REGULATED KINASE; CARCINOMA-CELLS; SYNTHASE GENE; TUMOR-GROWTH	Independently, superoxide (O-2(-)) and nitric oxide (NO) are biologically important signaling molecules. When co-generated, these radicals react rapidly to form powerful oxidizing and nitrating intermediates. Although this reaction was once thought to be solely cytotoxic, herein we demonstrate using MCF7, macrophage, and endothelial cells that when nanomolar levels of NO and O-2(-) were produced concomitantly, the effective NO concentration was established by the relative fluxes of these two radicals. Differential regulation of sGC, pERK, HIF-1 alpha, and p53 were used as biological dosimeters for NO concentration. Introduction of intracellular-or extracellular-generated O-2-during NO generation resulted in a concomitant increase in oxidative intermediates with a decrease in steady-state NO concentrations and a proportional reduction in the levels of sGC, ERK, HIF-1 alpha, and p53 regulation. NO responses were restored by addition of SOD. The intermediates formed from the reactions of NO with O-2(-) were non-toxic, did not form 3-nitrotyrosine, nor did they elicit any signal transduction responses. H2O2 in bolus or generated from the dismutation of O-2-by SOD, was cytotoxic at high concentrations and activated p53 independent of NO. This effect was completely inhibited by catalase, suppressed by NO, and exacerbated by intracellular catalase inhibition. We conclude that the reaction of O-2(-) with NO is an important regulatory mechanism, which modulates signaling pathways by limiting steady-state levels of NO and preventing H2O2 formation from O-2(-).	NCI, Radiat Biol Branch, Tumor Biol Sect, NIH, Bethesda, MD 20892 USA; NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Thomas, DD (corresponding author), NCI, Radiat Biol Branch, Tumor Biol Sect, NIH, Bldg 10,Rm B3-B69, Bethesda, MD 20892 USA.	thomasdo@mail.nih.gov	Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981; Ridnour, Lisa A./0000-0001-9446-8349; Wink, David/0000-0002-5652-7480; Thomas, Douglas/0000-0003-1252-0786; Azad, Mahan/0000-0002-8633-3513; Ambs, Stefan/0000-0001-7651-9309; Hussain, S. Perwez/0000-0002-2294-522X	NATIONAL CANCER INSTITUTE [ZIABC010033, Z01BC010033, ZIASC006387, Z01SC006387, Z01SC009172, ZIASC009172] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Alvarez B, 1999, J BIOL CHEM, V274, P842, DOI 10.1074/jbc.274.2.842; Alvarez B, 2003, AMINO ACIDS, V25, P295, DOI 10.1007/s00726-003-0018-8; Ambs S, 1998, NAT MED, V4, P1371, DOI 10.1038/3957; Andreadis AA, 2003, FREE RADICAL BIO MED, V35, P213, DOI 10.1016/S0891-5849(03)00278-8; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Branco MR, 2004, J BIOL CHEM, V279, P6501, DOI 10.1074/jbc.M311818200; Brune B, 2005, ANTIOXID REDOX SIGN, V7, P497, DOI 10.1089/ars.2005.7.497; Ekmekcioglu S, 2000, CLIN CANCER RES, V6, P4768; Erker L, 2005, HUM MOL GENET, V14, P1699, DOI 10.1093/hmg/ddi181; Espey MG, 2001, J BIOL CHEM, V276, P30085, DOI 10.1074/jbc.M101723200; Feng CW, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-8; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; Hirota K, 2005, BIOCHEM BIOPH RES CO, V338, P610, DOI 10.1016/j.bbrc.2005.08.193; Houston M, 1999, J BIOL CHEM, V274, P4985, DOI 10.1074/jbc.274.8.4985; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Hussain SP, 2004, CANCER RES, V64, P6849, DOI 10.1158/0008-5472.CAN-04-2201; Ischiropoulos H, 2003, BIOCHEM BIOPH RES CO, V305, P776, DOI 10.1016/S0006-291X(03)00814-3; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; Jourd'heuil D, 1999, ARCH BIOCHEM BIOPHYS, V365, P92, DOI 10.1006/abbi.1999.1143; Jourd'heuil D, 2001, J BIOL CHEM, V276, P28799, DOI 10.1074/jbc.M102341200; Juang SH, 1998, HUM GENE THER, V9, P845, DOI 10.1089/hum.1998.9.6-845; Kohl R, 2006, FREE RADICAL BIO MED, V40, P1430, DOI 10.1016/j.freeradbiomed.2005.12.012; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; Le XD, 2005, P NATL ACAD SCI USA, V102, P8758, DOI 10.1073/pnas.0409581102; Liu PT, 1998, AM J PHYSIOL-HEART C, V275, pH2191, DOI 10.1152/ajpheart.1998.275.6.H2191; Makino N, 2004, BBA-GEN SUBJECTS, V1673, P149, DOI 10.1016/j.bbagen.2004.04.011; Metzen E, 2003, MOL BIOL CELL, V14, P3470, DOI 10.1091/mbc.e02-12-0791; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; MITCHELL JB, 1991, ARCH BIOCHEM BIOPHYS, V289, P62, DOI 10.1016/0003-9861(91)90442-L; Morandini R, 1999, CELL MOL BIOL, V45, P1053; Nourooz-Zadeh J, 1999, METHOD ENZYMOL, V300, P58; Pervin S, 2003, CANCER RES, V63, P8853; Pervin S, 2001, P NATL ACAD SCI USA, V98, P3583, DOI 10.1073/pnas.041603998; Pfeiffer S, 2001, FASEB J, V15, P2355, DOI 10.1096/fj.01-0295com; Pfeiffer S, 2001, J BIOL CHEM, V276, P34051, DOI 10.1074/jbc.M100585200; Reiter CD, 2000, J BIOL CHEM, V275, P32460, DOI 10.1074/jbc.M910433199; Ridnour LA, 2005, P NATL ACAD SCI USA, V102, P13147, DOI 10.1073/pnas.0502979102; Sawa T, 2000, J BIOL CHEM, V275, P32467, DOI 10.1074/jbc.M910169199; Schmid T, 2004, J CELL MOL MED, V8, P423, DOI 10.1111/j.1582-4934.2004.tb00467.x; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; Thomas DD, 2004, P NATL ACAD SCI USA, V101, P8894, DOI 10.1073/pnas.0400453101; Thomas DD, 2002, P NATL ACAD SCI USA, V99, P12691, DOI 10.1073/pnas.202312699; Thomas DD, 2001, P NATL ACAD SCI USA, V98, P355, DOI 10.1073/pnas.98.1.355; Wang C, 2003, CHEM RES TOXICOL, V16, P1004, DOI 10.1021/tx0340448; Wang Liwei, 2005, Gastric Cancer, V8, P18, DOI 10.1007/s10120-004-0310-7; Watanabe N, 2003, ARCH BIOCHEM BIOPHYS, V411, P145, DOI 10.1016/S0003-9861(02)00716-6; Wink DA, 1995, TOXICOL LETT, V82-3, P221, DOI 10.1016/0378-4274(95)03557-5; WINK DA, 1995, ARCH BIOCHEM BIOPHYS, V319, P402, DOI 10.1006/abbi.1995.1310; Wink DA, 2001, ANTIOXID REDOX SIGN, V3, P203, DOI 10.1089/152308601300185179; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333; Zhou H, 2005, TOXICOLOGY, V208, P223, DOI 10.1016/j.tox.2004.11.021; Zhou J, 2003, AM J PHYSIOL-CELL PH, V284, pC439, DOI 10.1152/ajpcell.00294.2002	56	89	89	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25984	25993		10.1074/jbc.M602242200	http://dx.doi.org/10.1074/jbc.M602242200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829532	hybrid			2022-12-25	WOS:000240249500013
J	Waters, EK; Yegneswaran, S; Morrissey, JH				Waters, Emily K.; Yegneswaran, Subramanian; Morrissey, James H.			Raising the active site of factor VIIa above the membrane surface reduces its procoagulant activity but not factor VII autoactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; BLOOD-COAGULATION FACTOR; SOLUBLE TISSUE FACTOR; CRYSTAL-STRUCTURE; FACTOR-X; COFACTOR FUNCTION; GLA DOMAIN; PROTEIN-C; ACTIVATION; CALCIUM	Tissue factor, the physiologic trigger of blood clotting, is the membrane-anchored protein cofactor for the plasma serine protease, factor VIIa. Tissue factor is hypothesized to position and align the active site of factor VIIa relative to the membrane surface for optimum proteolytic attack on the scissile bonds of membrane-bound protein substrates such as factor X. We tested this hypothesis by raising the factor VIIa binding site above the membrane surface by creating chimeras containing the tissue factor ectodomain linked to varying portions of the membrane-anchored protein, P-selectin. The tissue factor/P-selectin chimeras bound factor VIIa with high affinity and supported full allosteric activation of factor VIIa toward tripeptidyl-amide substrates. That the active site of factor VIIa was raised above the membrane surface when bound to tissue factor/P-selectin chimeras was confirmed using resonance energy transfer techniques in which appropriate fluorescent dyes were placed in the active site of factor VIIa and at the membrane surface. The chimeras were deficient in supporting factor X activation by factor VIIa due to decreased k(cat). The chimeras were also markedly deficient in clotting plasma, although incubating factor VII or VIIa with the chimeras prior to the addition of plasma restored much of their procoagulant activity. Interestingly, all chimeras fully supported tissue factor-dependent factor VII autoactivation. These studies indicate that proper positioning of the factor VII/VIIa binding site on tissue factor above the membrane surface is important for efficient rates of activation of factor X by this membrane-bound enzyme/cofactor complex.	Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	University of Illinois System; University of Illinois Urbana-Champaign; Scripps Research Institute	Morrissey, JH (corresponding author), Univ Illinois, Coll Med, Dept Biochem, 417 Med Sci Bldg,MC-714,506 S Mathews, Urbana, IL 61801 USA.	jhmorris@uiuc.edu	Morrissey, James H/H-4933-2011; Morrissey, James H./GLR-5645-2022	Morrissey, James H/0000-0002-1570-1569; 	NHLBI NIH HHS [R01 HL047014-14A1, R01 HL47014, R01 HL047014] Funding Source: Medline; NIGMS NIH HHS [T32 GM007283] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007283] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; FIORE MM, 1994, J BIOL CHEM, V269, P143; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; Hathcock JJ, 2006, BLOOD CELL MOL DIS, V36, P194, DOI 10.1016/j.bcmd.2005.12.032; Hu PS, 2003, CANCER RES, V63, P5046; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; McCallum CD, 1996, J BIOL CHEM, V271, P28168, DOI 10.1074/jbc.271.45.28168; McCallum CD, 1997, J BIOL CHEM, V272, P30160, DOI 10.1074/jbc.272.48.30160; Moons AHM, 2002, CARDIOVASC RES, V53, P313, DOI 10.1016/S0008-6363(01)00452-7; Morrissey J. H., 2006, HEMOSTASIS THROMBOSI, P91; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; NEUENSCHWANDER PF, 1993, J BIOL CHEM, V268, P21489; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P13988, DOI 10.1021/bi00043a004; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; Rippmann JF, 2000, BIOCHEM J, V349, P805, DOI 10.1042/bj3490805; RUF W, 1991, J BIOL CHEM, V266, P2158; Schwarzenbacher R, 1999, EMBO J, V18, P6228, DOI 10.1093/emboj/18.22.6228; Smith SA, 2004, J THROMB HAEMOST, V2, P1155, DOI 10.1111/j.1538-7836.2004.00772.x; THORPE PE, 2000, CANC J SCI AM S3, V6, P237; Waters EK, 2006, BIOCHEMISTRY-US, V45, P3769, DOI 10.1021/bi052600m; Yegneswaran S, 1999, J BIOL CHEM, V274, P5462, DOI 10.1074/jbc.274.9.5462; Yegneswaran S, 1997, J BIOL CHEM, V272, P25013, DOI 10.1074/jbc.272.40.25013; Zwaal RFA, 1998, BBA-REV BIOMEMBRANES, V1376, P433, DOI 10.1016/S0304-4157(98)00018-5	32	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26062	26068		10.1074/jbc.M604915200	http://dx.doi.org/10.1074/jbc.M604915200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16835245	hybrid			2022-12-25	WOS:000240249500021
J	Cohen, L; Lipstein, N; Gordon, D				Cohen, Lior; Lipstein, Noa; Gordon, Dalia			Allosteric interactions between scorpion toxin receptor sites on voltage-gated Na channels imply a novel role for weakly active components in arthropod venom	FASEB JOURNAL			English	Article						ligand binding; toxicity to insects; gating modifiers; scorpion alpha toxin; beta-toxin	INSECT SODIUM-CHANNELS; LEIURUS-QUINQUESTRIATUS-HEBRAEUS; ALPHA-LIKE TOXINS; RAT-BRAIN; CURRENT INACTIVATION; DIFFERENTIALLY INTERACT; SELECTIVE NEUROTOXINS; MOLECULAR-MECHANISMS; DEPRESSANT TOXIN; DOMAIN-II	Scorpion beta and alpha-toxins modify the activation and inactivation of voltage-gated sodium channels. Although the two types of toxin bind at two distinct receptor sites on the same sodium channel, they exhibit synergic effects when coinjected into insects. To clarify the basis of this synergism we examined the mutual effects of alpha and beta toxin representatives in radio-ligand binding assays. We found positive allosteric interactions between receptor site-4 of the excitatory Bj-xtrIT and the depressant LqhIT2 beta toxins and receptor site-3 of the alpha toxin Lqh alpha IT, on locust neuronal membranes. Unexpectedly, a nontoxic mutant Bj-xtrIT-E15R, which binds with high affinity to receptor site-4, was able to enhance Lqh alpha IT binding and toxicity similarly to the unmodified Bj-xtrIT. This result indicates that mere binding of a nontoxic ligand to receptor site-4 ("silent binding") induces a conformational change that does not alter channel gating, but influences toxin binding at receptor site-3 leading to enhanced toxicity. This finding suggests a new functional role for weakly toxic polypeptides in that they enhance the effect of other active neurotoxins in the arthropod venom. Such silent binding may have also valuable implications in attempts to improve drug efficacy by combining potent drugs with nonactive allosteric enhancers.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, IL-69978 Tel Aviv, Israel	Tel Aviv University	Gordon, D (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, IL-69978 Tel Aviv, Israel.	dgordon@post.tau.ac.il		Lipstein, Noa/0000-0002-0755-5899				BABIN DR, 1974, ARCH BIOCHEM BIOPHYS, V164, P694, DOI 10.1016/0003-9861(74)90082-4; Benkhalifa R, 1997, LIFE SCI, V61, P819, DOI 10.1016/S0024-3205(97)00564-X; Benoit E, 2001, NEUROSCIENCE, V104, P551, DOI 10.1016/S0306-4522(01)00073-2; BLANC E, 1997, EUR J BIOCHEM, V247, P1181; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; Cestele S, 1998, J NEUROCHEM, V70, P1217; Cestele S, 1999, EUR J NEUROSCI, V11, P975, DOI 10.1046/j.1460-9568.1999.00505.x; Cestele S, 2001, J GEN PHYSIOL, V118, P291, DOI 10.1085/jgp.118.3.291; CESTELE S, 1995, J BIOL CHEM, V270, P15153, DOI 10.1074/jbc.270.25.15153; Cestele S, 2000, BIOCHIMIE, V82, P883, DOI 10.1016/S0300-9084(00)01174-3; Chanda B, 2004, J GEN PHYSIOL, V123, P217, DOI 10.1085/jgp.200308971; Coronas FV, 2003, TOXICON, V41, P989, DOI 10.1016/S0041-0101(03)00071-0; Corzo G, 2001, PROTEIN PEPTIDE LETT, V8, P385, DOI 10.2174/0929866013409256; EITAN M, 1990, BIOCHEMISTRY-US, V29, P5941, DOI 10.1021/bi00477a009; FAINZILBER M, 1994, J BIOL CHEM, V269, P2574; FAINZILBER M, 1995, J BIOL CHEM, V270, P1123, DOI 10.1074/jbc.270.3.1123; FONTECILLACAMPS JC, 1980, P NATL ACAD SCI-BIOL, V77, P6496, DOI 10.1073/pnas.77.11.6496; Froy O, 1999, J BIOL CHEM, V274, P5769, DOI 10.1074/jbc.274.9.5769; Gilles N, 2003, FEBS LETT, V540, P81, DOI 10.1016/S0014-5793(03)00226-6; Gilles N, 2000, J NEUROCHEM, V75, P1735, DOI 10.1046/j.1471-4159.2000.0751735.x; Gilles N, 2000, EUR J NEUROSCI, V12, P2823, DOI 10.1046/j.1460-9568.2000.00168.x; Gilles N, 1999, J NEUROSCI, V19, P8730, DOI 10.1523/JNEUROSCI.19-20-08730.1999; GORDON D, 1992, BIOCHEMISTRY-US, V31, P7622, DOI 10.1021/bi00148a025; Gordon D, 2003, EUR J BIOCHEM, V270, P2663, DOI 10.1046/j.1432-1033.2003.03643.x; Gordon D, 2002, PERSPECTIVES IN MOLECULAR TOXINOLOGY, P215; Gordon D, 1996, J BIOL CHEM, V271, P8034, DOI 10.1074/jbc.271.14.8034; Gordon D, 1998, J TOXICOL-TOXIN REV, V17, P131, DOI 10.3109/15569549809009247; GORDON D, 1984, BIOCHIM BIOPHYS ACTA, V778, P349, DOI 10.1016/0005-2736(84)90379-1; GORDON D, 1994, TOXINS SIGNAL TRANSD, P119; Gordon Dalia, 1997, Invertebrate Neuroscience, V3, P103, DOI 10.1007/BF02480365; Gurevitz M, 2002, PERSPECTIVES IN MOLECULAR TOXINOLOGY, P239; Gurevitz M, 2001, FASEB J, V15, P1201, DOI 10.1096/fj.00-0571hyp; Hamon A, 2002, EUR J BIOCHEM, V269, P3920, DOI 10.1046/j.1432-1033.2002.03065.x; HERRMANN R, 1995, TOXICON, V33, P1099, DOI 10.1016/0041-0101(95)98053-X; Karbat I, 2004, FASEB J, V18, P683, DOI 10.1096/fj.03-0733com; Lee D, 2000, J NEUROPHYSIOL, V83, P1181, DOI 10.1152/jn.2000.83.3.1181; LEIPOLD E, 2004, MOL PHARM, V65, P865; Mansuelle Pascal, 1992, Natural Toxins, V1, P61, DOI 10.1002/nt.2620010112; Marcotte P, 1997, CIRC RES, V80, P363, DOI 10.1161/01.RES.80.3.363; Martin-Eauclaire M. F., 1995, Handbook of neurotoxicology., P683; Moskowitz H, 1998, EUR J BIOCHEM, V254, P44, DOI 10.1046/j.1432-1327.1998.2540044.x; MOSKOWITZ H, 1994, INSECT BIOCHEM MOLEC, V24, P13, DOI 10.1016/0965-1748(94)90118-X; Oren DA, 1998, STRUCTURE, V6, P1095, DOI 10.1016/S0969-2126(98)00111-7; PELHATE M, 1982, J EXP BIOL, V97, P67; Pimenta AMC, 2001, RAPID COMMUN MASS SP, V15, P1562, DOI 10.1002/rcm.415; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; Prikhod'ko GG, 1998, BIOL CONTROL, V12, P66, DOI 10.1006/bcon.1997.0605; ROCHAT H, 1977, ANAL BIOCHEM, V82, P532, DOI 10.1016/0003-2697(77)90192-0; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; Sautiere P, 1998, TOXICON, V36, P1141, DOI 10.1016/S0041-0101(98)00080-4; SHARKEY RG, 1987, MOL PHARMACOL, V31, P273; Shichor I, 1996, J NEUROCHEM, V67, P2451; Shichor I, 2002, J NEUROSCI, V22, P4364, DOI 10.1523/JNEUROSCI.22-11-04364.2002; STANKIEWICZ M, 1996, PHYSL ECOTOXICOLOGY, V4, P93; Strugatsky D, 2005, BIOCHEMISTRY-US, V44, P9179, DOI 10.1021/bi050235t; Szeto TH, 2000, TOXICON, V38, P429, DOI 10.1016/S0041-0101(99)00174-9; Tedford HW, 2004, TOXICON, V43, P601, DOI 10.1016/j.toxicon.2004.02.010; Turkov M, 1997, PROTEIN EXPRES PURIF, V10, P123, DOI 10.1006/prep.1997.0724; ZLOTKIN E, 1991, BIOCHEMISTRY-US, V30, P4814, DOI 10.1021/bi00233a025; Zlotkin E., 1978, ARTHROPOD VENOMS, P317	62	28	29	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2006	20	11					1933	+		10.1096/fj.05-5545fje	http://dx.doi.org/10.1096/fj.05-5545fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16877526				2022-12-25	WOS:000240267000035
J	Lieskovska, J; Ling, Y; Badley-Clarke, J; Clemmons, DR				Lieskovska, Jaroslava; Ling, Yan; Badley-Clarke, Jane; Clemmons, David R.			The role of Src kinase in insulin-like growth factor-dependent mitogenic signaling in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; ACTIVATED PROTEIN-KINASE; TYROSINE PHOSPHATASE SHP-2; C-SRC; IGF-I; PHOSPHATIDYLINOSITOL 3-KINASE; ALPHA-V-BETA-3 INTEGRIN; SHC PHOSPHORYLATION; EPIDERMAL-GROWTH; BINDING-PROTEINS	Activation of the MAPK pathway mediates insulin-like growth factor-I (IGF-I)-dependent proliferation in vascular smooth muscle cells (SMC). Our previous studies have shown that IGF-I-induced Shc phosphorylation is necessary for sustained activation of MAPK and increased cell proliferation of SMCs, and both Shc and the tyrosine phosphatase SHP-2 must be recruited to the membrane protein SHPS-1 in order for Shc to be phosphorylated. These studies were undertaken to determine whether Src kinase activity is required to phosphorylate Shc in response to IGF-I in SMC and because SHP-2 binds to Src whether their interaction was also required for IGF-I-stimulated mitogenesis. Our results show that IGF-I induces activation of Src kinase and that is required for Shc phosphorylation and for optimal MAPK activation. We tested whether Shc is a substrate of c-Src in SMC by disrupting Src/Shc association using a peptide containing a YXXL (Tyr328) motif sequence derived from Src. The peptide blocked the binding of Src and Shc in vitro and in vivo. Cells expressing a mutant Src (Src-FF) that had Tyr328/Tyr358 substituted with phenylalanines (Src-FF) showed defective Src/Shc binding, impaired IGF-I-dependent Shc phosphorylation, and impaired mitogenesis. This supports the conclusion that Src phosphorylates Shc. IGF-I induced both Src/SHP-2 and Src/SHPS-1 association. SMCs expressing an SHP-2 mutant that had the polyproline-rich region of SH2 deleted (SHP-2 Delta 10) had disrupted SHP-2/Src association, impaired IGF-I-dependent Shc phosphorylation, and an attenuated mitogenic response. IGF-I-induced association of Src and SHPS-1 was also impaired in SHP-2 Delta 10-expressing cells, although SHP-2/SHPS-1 association was unaffected. Upon IGF-I stimulation, a complex assembles on SHPS-1 that contains SHP-2, c-Src, and Shc wherein Src phosphorylates Shc, a signaling step that is necessary for an optimal mitogenic response.	Univ N Carolina, Sch Med, Dept Med, Div Endocrinol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Clemmons, DR (corresponding author), Univ N Carolina, Sch Med, Dept Med, Div Endocrinol, CB 7170,5030 Burnett Womack, Chapel Hill, NC 27599 USA.	endo@med.unc.edu	Lieskovska, Jaroslava/G-9309-2014	Lieskovska, Jaroslava/0000-0001-6626-4912	NIA NIH HHS [AG-02331] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG002331, R37AG002331] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Biedi C, 2003, ENDOCRINOLOGY, V144, P5497, DOI 10.1210/en.2003-0417; Bjorndahl M, 2005, P NATL ACAD SCI USA, V102, P15593, DOI 10.1073/pnas.0507865102; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Boney CM, 2001, CELL GROWTH DIFFER, V12, P379; Boney CM, 2000, MOL ENDOCRINOL, V14, P805, DOI 10.1210/me.14.6.805; Cai T, 2002, J CELL BIOL, V159, P103, DOI 10.1083/jcb.200205017; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; Cho HM, 2005, MOL CELLS, V19, P60; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Corjay MH, 1999, J CELL BIOCHEM, V75, P492, DOI 10.1002/(SICI)1097-4644(19991201)75:3<492::AID-JCB13>3.3.CO;2-Q; Courter DL, 2005, J BIOL CHEM, V280, P12145, DOI 10.1074/jbc.M412555200; Cui QL, 2005, J BIOL CHEM, V280, P8918, DOI 10.1074/jbc.M414267200; De S, 2005, P NATL ACAD SCI USA, V102, P7589, DOI 10.1073/pnas.0502935102; Flossmann-Kast BBM, 1998, CANCER RES, V58, P3551; Harrington LS, 2005, TRENDS BIOCHEM SCI, V30, P35, DOI 10.1016/j.tibs.2004.11.003; Ho A, 2001, CANCER RES, V61, P474; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; Kim BS, 1998, J BIOL CHEM, V273, P34543, DOI 10.1074/jbc.273.51.34543; Knowlden JM, 2005, ENDOCRINOLOGY, V146, P4609, DOI 10.1210/en.2005-0247; Kuemmerle JF, 2006, AM J PHYSIOL-GASTR L, V290, pG1194, DOI 10.1152/ajpgi.00345.2005; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Ling Y, 2005, MOL BIOL CELL, V16, P3353, DOI 10.1091/mbc.E04-10-0918; Ling Y, 2003, MOL ENDOCRINOL, V17, P1824, DOI 10.1210/me.2003-0143; Maile LA, 2002, J BIOL CHEM, V277, P8955, DOI 10.1074/jbc.M109258200; Maile LA, 2002, ENDOCRINOLOGY, V143, P4259, DOI 10.1210/en.2002-220395; Morita N, 2004, MOL CELL BIOCHEM, V262, P71, DOI 10.1023/B:MCBI.0000038218.09259.1c; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nam TJ, 2000, ENDOCRINOLOGY, V141, P1100, DOI 10.1210/en.141.3.1100; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PARKER A, 1995, ENDOCRINOLOGY, V136, P2470, DOI 10.1210/en.136.6.2470; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Pereira JJ, 2004, CANCER RES, V64, P977, DOI 10.1158/0008-5472.CAN-03-3056; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Sakata T, 2004, J BONE MINER RES, V19, P436, DOI 10.1359/JBMR.0301241; Sasaoka T, 2001, ENDOCRINOLOGY, V142, P5226, DOI 10.1210/en.142.12.5226; Sato H, 2005, CARDIOVASC RES, V67, P714, DOI 10.1016/j.cardiores.2005.04.017; Sato K, 2005, J BIOCHEM, V137, P61, DOI 10.1093/jb/mvi011; Sato K, 1997, BIOCHEM BIOPH RES CO, V240, P399, DOI 10.1006/bbrc.1997.7667; Sato K, 2002, J BIOL CHEM, V277, P29568, DOI 10.1074/jbc.M203179200; Sayeski PP, 2003, EXP CELL RES, V287, P339, DOI 10.1016/S0014-4827(03)00154-X; Sekimoto H, 2005, MOL ENDOCRINOL, V19, P1859, DOI 10.1210/me.2004-0481; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Soon L, 1999, MOL CELL BIOL, V19, P3816; Summy JM, 2005, PANCREAS, V31, P263, DOI 10.1097/01.mpa.0000178280.50534.0c; Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006; Walter AO, 1999, ONCOGENE, V18, P1911, DOI 10.1038/sj.onc.1202513; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Yang K, 2005, J BIOL CHEM, V280, P39058, DOI 10.1074/jbc.M506921200; Zahradka P, 2004, ENDOCRINOLOGY, V145, P2978, DOI 10.1210/en.2004-0029; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	53	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25041	25053		10.1074/jbc.M602866200	http://dx.doi.org/10.1074/jbc.M602866200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16825188	hybrid, Green Published			2022-12-25	WOS:000240031300006
J	Faraco, JH; Appelbaum, L; Marin, W; Gaus, SE; Mourrain, P; Mignot, E				Faraco, Juliette H.; Appelbaum, Lior; Marin, Wilfredo; Gaus, Stephanie E.; Mourrain, Philippe; Mignot, Emmanuel			Regulation of hypocretin (orexin) expression in embryonic zebrafish	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLEEP-LIKE STATE; NERVOUS-SYSTEM; NEURONS; NARCOLEPSY; RECEPTOR; REGION; GENE; CONSERVATION; MODULATION; DROSOPHILA	Hypocretins/ orexins are neuropeptides involved in the regulation of sleep and energy balance in mammals. Conservation of gene sequence, hypothalamic localization of cell bodies, and projection patterns in adult zebrafish suggest that the architecture and function of the hypocretin system are conserved in fish. We report on the complete genomic structure of the zebrafish and Tetraodon hypocretin genes and the complete predicted hypocretin protein sequences from five teleosts. Using whole mount in situ hybridization, we have traced the development of hypocretin cells in zebrafish from onset of expression at 22 h post- fertilization through the first week of development. Promoter elements of similar size from zebrafish and Tetraodon were capable of driving efficient and specific expression of enhanced green fluorescent protein in developing zebrafish embryos, thus defining a minimal promoter region able to accurately mimic the native hypocretin pattern. This enhanced green fluorescent protein expression also revealed a complex pattern of projections within the hypothalamus, to the midbrain, and to the spinal cord. To further analyze the promoter, a series of deletion and substitution constructs were injected into embryos, and resulting promoter activity was monitored in the first week of development. Acritical region of 250 base pairs was identified containing a core 13- base pair element essential for hypocretin expression.	Stanford Univ, Ctr Narcolepsy Res, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA; Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA; INSERM, U784, F-75230 Paris, France	Stanford University; Howard Hughes Medical Institute; Stanford University; Institut National de la Sante et de la Recherche Medicale (Inserm)	Mignot, E (corresponding author), Stanford Univ, Ctr Narcolepsy Res, Dept Psychiat & Behav Sci, 701B Welch Rd, Palo Alto, CA 94304 USA.	mignot@stanford.edu	Mourrain, Philippe/N-4671-2017					Amiot C, 2005, EUR J NEUROSCI, V22, P531, DOI 10.1111/j.1460-9568.2005.04224.x; Amsterdam A, 2005, DEV DYNAM, V234, P255, DOI 10.1002/dvdy.20541; Arenzana FJ, 2005, BRAIN RES BULL, V66, P421, DOI 10.1016/j.brainresbull.2005.03.006; ASAHI S, 2000, P 36 S JAP PEPT S JA, P37; Bellipanni Gianfranco, 2002, Gene Expression Patterns, V2, P251, DOI 10.1016/S1567-133X(02)00056-X; Bernard R, 2006, J PHARMACOL EXP THER, V317, P163, DOI 10.1124/jpet.105.097071; Beuckmann CT, 2002, J MOL MED, V80, P329, DOI 10.1007/s00109-002-0322-x; Blanchette M, 2003, NUCLEIC ACIDS RES, V31, P3840, DOI 10.1093/nar/gkg606; Blouin AM, 2005, NEUROLOGY, V65, P1189, DOI 10.1212/01.wnl.0000175219.01544.c8; Chabas D, 2003, ANNU REV GENOM HUM G, V4, P459, DOI 10.1146/annurev.genom.4.070802.110432; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Crocker A, 2005, NEUROLOGY, V65, P1184, DOI 10.1212/01.WNL.0000168173.71940.ab; Dickmeis T, 2004, GENOME RES, V14, P228, DOI 10.1101/gr.1819204; Ellingsen S, 2005, DEVELOPMENT, V132, P3799, DOI 10.1242/dev.01951; Eriksson KS, 1998, EUR J NEUROSCI, V10, P3799, DOI 10.1046/j.1460-9568.1998.00394.x; Fisher S, 2006, SCIENCE, V312, P276, DOI 10.1126/science.1124070; Galas L, 2001, J COMP NEUROL, V429, P242, DOI 10.1002/1096-9861(20000108)429:2<242::AID-CNE5>3.0.CO;2-Z; Gomez-Skarmeta JL, 2006, DEV DYNAM, V235, P870, DOI 10.1002/dvdy.20659; Goode DK, 2005, GENOMICS, V86, P172, DOI 10.1016/j.ygeno.2005.04.006; HAUPTMANN G, 1994, TRENDS GENET, V10, P266, DOI 10.1016/0168-9525(90)90008-T; Holzschuh J, 2001, MECH DEVELOP, V101, P237, DOI 10.1016/S0925-4773(01)00287-8; Huang ZL, 2001, P NATL ACAD SCI USA, V98, P9965, DOI 10.1073/pnas.181330998; Huesa G, 2005, J COMP NEUROL, V488, P476, DOI 10.1002/cne.20610; JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8; JUJI T, 1984, TISSUE ANTIGENS, V24, P316, DOI 10.1111/j.1399-0039.1984.tb02144.x; Kaslin J, 2004, J NEUROSCI, V24, P2678, DOI 10.1523/JNEUROSCI.4908-03.2004; Kaslin J, 2001, J COMP NEUROL, V440, P342, DOI 10.1002/cne.1390; Kel AE, 2003, NUCLEIC ACIDS RES, V31, P3576, DOI 10.1093/nar/gkg585; Kumazawa Y, 1999, BIOL BIODIVERSITY, P35; Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0; Mignot E, 2002, ARCH NEUROL-CHICAGO, V59, P1553, DOI 10.1001/archneur.59.10.1553; Mignot E, 2001, AM J HUM GENET, V68, P686, DOI 10.1086/318799; Miyoshi K, 2001, GENOMICS, V71, P150, DOI 10.1006/geno.2000.6433; Moriguchi T, 2002, J BIOL CHEM, V277, P16985, DOI 10.1074/jbc.M107962200; Nambu T, 1999, BRAIN RES, V827, P243, DOI 10.1016/S0006-8993(99)01336-0; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Nishino S, 2000, LANCET, V355, P39, DOI 10.1016/S0140-6736(99)05582-8; OGAWA YKT, 2003, SLEEP BIOL RHYTHMS, V1, P143; Peitsaro N, 2000, J NEUROCHEM, V75, P718, DOI 10.1046/j.1471-4159.2000.0750718.x; Peyron C, 1998, J NEUROSCI, V18, P9996; Peyron C, 2000, NAT MED, V6, P991, DOI 10.1038/79690; Plessy C, 2005, TRENDS GENET, V21, P207, DOI 10.1016/j.tig.2005.02.006; Renier C, 2006, SLEEP, V29, pA360; Sakurai T, 1999, J BIOL CHEM, V274, P17771, DOI 10.1074/jbc.274.25.17771; Shibahara M, 1999, PEPTIDES, V20, P1169, DOI 10.1016/S0196-9781(99)00120-5; Shigemoto Y, 2004, BRAIN RES, V1023, P121, DOI 10.1016/j.brainres.2004.07.031; Singletary KG, 2005, BRAIN RES, V1041, P231, DOI 10.1016/j.brainres.2005.01.095; STUART GW, 1988, DEVELOPMENT, V103, P403; Taheri S, 2002, ANNU REV NEUROSCI, V25, P283, DOI 10.1146/annurev.neuro.25.112701.142826; Thannickal TC, 2000, NEURON, V27, P469, DOI 10.1016/S0896-6273(00)00058-1; van den Pol AN, 1998, J NEUROSCI, V18, P7962; van den Pol AN, 1999, J NEUROSCI, V19, P3171; Waleh NS, 2001, GENE, V262, P123, DOI 10.1016/S0378-1119(00)00544-8; Westerfield M., 1993, ZEBRAFISH BOOK GUIDE; Woolfe A, 2005, PLOS BIOL, V3, P116, DOI 10.1371/journal.pbio.0030007; Yokogawa T, 2006, SLEEP, V29, pA36; Zhdanova IV, 2006, ZEBRAFISH, V3, P215, DOI 10.1089/zeb.2006.3.215; Zhdanova IV, 2001, BRAIN RES, V903, P263, DOI 10.1016/S0006-8993(01)02444-1	58	92	96	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29753	29761		10.1074/jbc.M605811200	http://dx.doi.org/10.1074/jbc.M605811200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16867991	hybrid			2022-12-25	WOS:000240896300037
J	Mahmood, NABN; Biemans-Oldehinkel, E; Patzlaff, JS; Schuurman-Wolters, GK; Poolman, B				Mahmood, N. A. B. Nik; Biemans-Oldehinkel, Esther; Patzlaff, Jason S.; Schuurman-Wolters, Gea K.; Poolman, Bert			Ion specificity and ionic strength dependence of the osmoregulatory ABC transporter OpuA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETAINE CARRIER BETP; CORYNEBACTERIUM-GLUTAMICUM; ESCHERICHIA-COLI; OSMOTIC ACTIVATION; CRYSTAL-STRUCTURE; MEMBRANE; BINDING; SYSTEM; PROP; PROTEIN	The ATPase subunit of the osmoregulatory ATP- binding cassette transporterOpuAfrom Lactococcus lactis has a C- terminal extension, the tandem cystathionine beta- synthase ( CBS) domain, which constitutes the sensor that allows the transporter to sense and respond to osmotic stress ( Biemans- Oldehinkel, E., Mahmood, N. A. B. N., and Poolman, B. ( 2006) Proc. Natl. Acad. Sci. U. S. A. 103, 10624 - 10629). C- terminal of the tandem CBS domain is an 18- residue anionic tail ( DIPDEDEVEEIEKEEENK). To investigate the ion specificity of the full transporter, we probed the activity of inside- out reconstituted wild- type OpuA and the anionic tail deletion mutant OpuA Delta 12; these molecules have the tandem CBS domains facing the external medium. At a mole fraction of 40% of anionic lipids in the membrane, the threshold ionic strength for activation of OpuA was similar to 0.15, irrespective of the electrolyte composition of the medium. At equivalent concentrations, bivalent cations (Mg2+ and Ba2+) were more effective in activating OpuA than NH4+, K+, Na+, or Li+, consistent with an ionic strength-based sensing mechanism. Surprisingly, Rb+ and Cs+ were potent inhibitors of wild- type OpuA, and 0.1 mM RbCl was sufficient to completely inhibit the transporter even in the presence of 0.2 M KCl. Rb+ and Cs+ were no longer inhibitory in OpuA Delta 12, indicating that the anionic C- terminal tail participates in the formation of a binding site for large alkali metal ions. Compared with OpuA Delta 12, wild- type OpuA required substantially less potassium ions ( the dominant ion under physiological conditions) for activation. Our data lend new support for the contention that the CBS module in OpuA constitutes the ionic strength sensor whose activity is modulated by the C- terminal anionic tail.	Univ Groningen, Membrane Enzymol Grp, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands; Univ Groningen, Ctr Mat Sci, NL-9747 AG Groningen, Netherlands	University of Groningen; University of Groningen	Poolman, B (corresponding author), Univ Groningen, Membrane Enzymol Grp, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	b.poolman@rug.nl	Poolman, Bert/D-1882-2012					Avdeef A, 1998, PHARMACEUT RES, V15, P209, DOI 10.1023/A:1011954332221; Bennetts B, 2005, J BIOL CHEM, V280, P32452, DOI 10.1074/jbc.M502890200; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; BENTAL N, 1997, BIOPHYS J, V73, P17117; Biemans-Oldehinkel E, 2003, EMBO J, V22, P5983, DOI 10.1093/emboj/cdg581; Biemans-Oldehinkel E, 2006, P NATL ACAD SCI USA, V103, P10624, DOI 10.1073/pnas.0603871103; Bockris J.OM., 1970, MODERN ELECTROCHEMIS, P1, DOI DOI 10.1007/B114168; Cotton F.A., 1988, ADV INORGANIC CHEM, V5th, P1385; Culham DE, 2003, BIOCHEMISTRY-US, V42, P11815, DOI 10.1021/bi034939j; Culham DE, 2003, BIOCHEMISTRY-US, V42, P410, DOI 10.1021/bi0264364; DRIESSEN AJM, 1988, BIOCHEMISTRY-US, V27, P865, DOI 10.1021/bi00403a005; Horn C, 2003, J MOL BIOL, V334, P403, DOI 10.1016/j.jmb.2003.09.079; Knol J, 1998, BIOCHEMISTRY-US, V37, P16410, DOI 10.1021/bi981596u; Knol J, 1996, J BIOL CHEM, V271, P15358, DOI 10.1074/jbc.271.26.15358; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; Miller MD, 2004, PROTEINS, V57, P213, DOI 10.1002/prot.20024; Patzlaff JS, 2003, J BIOL CHEM, V278, P29546, DOI 10.1074/jbc.M304796200; Poolman B, 2005, METHOD ENZYMOL, V400, P429, DOI 10.1016/S0076-6879(05)00025-X; Poolman B, 2004, BBA-BIOMEMBRANES, V1666, P88, DOI 10.1016/j.bbamem.2004.06.013; Racher KI, 2001, BIOCHEMISTRY-US, V40, P7324, DOI 10.1021/bi002331u; Rubenhagen R, 2001, EMBO J, V20, P5412, DOI 10.1093/emboj/20.19.5412; Schiller D, 2006, J BIOL CHEM, V281, P7737, DOI 10.1074/jbc.M513052200; Schiller D, 2004, BIOCHEMISTRY-US, V43, P5583, DOI 10.1021/bi0359628; Schiller D, 2004, FEBS LETT, V563, P108, DOI 10.1016/S0014-5793(04)00279-0; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; SIKKEMA J, 1995, MICROBIOL REV, V59, P201, DOI 10.1128/MMBR.59.2.201-222.1995; Spitzer JJ, 2005, TRENDS BIOCHEM SCI, V30, P536, DOI 10.1016/j.tibs.2005.08.002; Tsatskis Y, 2005, J BIOL CHEM, V280, P41387, DOI 10.1074/jbc.M508362200; van der Heide T, 2000, P NATL ACAD SCI USA, V97, P7102, DOI 10.1073/pnas.97.13.7102; van der Heide T, 2002, EMBO REP, V3, P938, DOI 10.1093/embo-reports/kvf201; van der Heide T, 2001, EMBO J, V20, P7022, DOI 10.1093/emboj/20.24.7022; Wood JM, 1999, MICROBIOL MOL BIOL R, V63, P230, DOI 10.1128/MMBR.63.1.230-262.1999; Zhang RG, 1999, BIOCHEMISTRY-US, V38, P4691, DOI 10.1021/bi982858v	33	30	31	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29830	29839		10.1074/jbc.M604907200	http://dx.doi.org/10.1074/jbc.M604907200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16844687	hybrid, Green Published			2022-12-25	WOS:000240896300045
J	Hemmati, PG; Guner, D; Gillissen, B; Wendt, J; von Haefen, C; Chinnadurai, G; Dorken, B; Daniel, PT				Hemmati, P. G.; Guener, D.; Gillissen, B.; Wendt, J.; von Haefen, C.; Chinnadurai, G.; Doerken, B.; Daniel, P. T.			Bak functionally complements for loss of Bax during p14(ARF)-induced mitochondrial apoptosis in human cancer cells	ONCOGENE			English	Article						p14(ARF); Bax; Bak; p53; apoptosis; mitochondria	NF-KAPPA-B; REGULATED FORM; CYCLE ARREST; P53; ARF; DEATH; BCL-2; P19(ARF); ACTIVATION; INDUCTION	In contrast to the initial notion that the biological activity of p14(ARF) strictly depends on a functional mdm-2/p53 signaling axis, we recently demonstrated that p14ARF mediates apoptosis in a p53/Bax-independent manner. Here, we show that p14ARF induces breakdown of the mitochondrial membrane potential and cytochrome c release before triggering caspase-9- and caspase-3/7-like activities in p53/Bax-deficient DU145 prostate cancer cells expressing wild-type Bak. Re-expression of Bax in these cells failed to further enhance p14(ARF)-induced apoptosis, suggesting that p14(ARF)-induced apoptosis primarily depends on Bak but not Bax in these cells. To further de. ne the role of Bak and Bax in p14(ARF)-induced mitochondrial apoptosis, we employed short interference RNA for the knockdown of bak in isogeneic, p53 wildtype HCT116 colon cancer cells either proefficient or deficient for Bax. There, combined loss of Bax and Bak attenuated p14(ARF)-induced apoptosis whereas single loss of Bax or Bak was only marginally effective, as in the case of DU145. Notably, HCT116 cells deficient for Bax and Bak failed to release cytochrome c and showed attenuated activation of caspase-9 (LEHDase) and caspase-3/caspase-7 (DEVDase) upon p14ARF expression. These data indicate that p14ARF triggers apoptosis via a Bax/Bak-dependent pathway in p53-proficient HCT116, whereas Bax is dispensable in p53-deficient DU145 cells. Nevertheless, a substantial proportion of p14(ARF)-induced cell death proceeds in a Bax/Bak-independent manner. This is also the case for inhibition of clonogenic growth that occurs, at least in part, through an entirely Bax/Bak-independent mechanism.	Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; St Louis Univ, Sch Med, Inst Mol Virol, St Louis, MO 63103 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Saint Louis University	Daniel, PT (corresponding author), Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de		Gillissen, Bernhard/0000-0002-1815-2091	NCI NIH HHS [R01 CA033616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Chandra D, 2005, J BIOL CHEM, V280, P19051, DOI 10.1074/jbc.M501391200; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Fatyol K, 2001, J BIOL CHEM, V276, P28421, DOI 10.1074/jbc.M102847200; Gelinas W, 2005, GENE DEV, V19, P1263, DOI 10.1101/gad.1326205; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Groth A, 2000, J BIOL CHEM, V275, P27473; Hemmati PG, 2005, ONCOGENE, V24, P4114, DOI 10.1038/sj.onc.1208579; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; MAO L, 1995, CANCER RES, V55, P2995; Normand G, 2005, J BIOL CHEM, V280, P7118, DOI 10.1074/jbc.M412330200; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; QUELLE DE, 1995, CELL, V83, P993; Rocha S, 2005, CELL CYCLE, V4, P756, DOI 10.4161/cc.4.6.1739; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Scholz C, 2005, ONCOGENE, V24, P7031, DOI 10.1038/sj.onc.1208868; Scholz C, 2005, ONCOGENE, V24, P1904, DOI 10.1038/sj.onc.1208233; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shmueli A, 2005, CELL, V121, P963, DOI 10.1016/j.cell.2005.06.018; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Suzuki H, 2003, BIOCHEM BIOPH RES CO, V312, P1273, DOI 10.1016/j.bbrc.2003.11.071; Theodorakis P, 2002, CANCER RES, V62, P3373; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wendt J, 2005, ONCOGENE, V24, P4052, DOI 10.1038/sj.onc.1208580; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Yakovlev AG, 2004, J BIOL CHEM, V279, P28367, DOI 10.1074/jbc.M313526200; Yarbrough WG, 2002, CANCER RES, V62, P1171; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	48	34	35	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6582	6594		10.1038/sj.onc.1209668	http://dx.doi.org/10.1038/sj.onc.1209668			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16847458				2022-12-25	WOS:000241569700003
J	Drenan, RM; Doupnik, CA; Jayaraman, M; Buchwalter, AL; Kaltenbronn, KM; Huettner, JE; Linder, ME; Blumer, KJ				Drenan, Ryan M.; Doupnik, Craig A.; Jayaraman, Muralidharan; Buchwalter, Abigail L.; Kaltenbronn, Kevin M.; Huettner, James E.; Linder, Maurine E.; Blumer, Kendall J.			R7BP augments the function of RGS7(center dot)G beta 5 complexes by a plasma membrane-targeting mechanis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN BETA-SUBUNIT; GTPASE ACCELERATING PROTEIN; NUCLEAR EXPORT SIGNAL; RGS PROTEINS; PHOSPHOLIPID SCRAMBLASE-1; ACTIVATING PROTEINS; ALPHA-SUBUNITS; MICE LACKING; K+ CHANNELS; IN-VIVO	The RGS7 (R7) family of G protein regulators, G beta 5, and R7BP form heterotrimeric complexes that potently regulate the kinetics of G protein-coupled receptor signaling. Reversible palmitoylation of R7BP regulates plasma membrane/ nuclear shuttling of R7 center dot G beta 5 center dot R7BP heterotrimers. Here we have investigated mechanisms whereby R7BP controls the function of the R7 family. We show that unpalmitoylated R7BP undergoes nuclear/ cytoplasmic shuttling and that a C-terminal polybasic motif proximal to the palmitoylation acceptor sites of R7BP mediates nuclear localization, palmitoylation, and plasma membrane targeting. These results suggest a novel mechanism whereby palmitoyltransferases and nuclear import receptors both utilize the C-terminal domain of R7BP to determine the trafficking fate of R7 center dot G beta 5 center dot R7BP heterotrimers. Analogous mechanisms may regulate other signaling proteins whose distribution between the plasma membrane and nucleus is controlled by palmitoylation. Lastly, we show that cytoplasmic RGS7 center dot G beta 5 center dot R7BP heterotrimers and RGS7 center dot G beta 5 heterodimers are equivalently inefficient regulators of G proteincoupled receptor signaling relative to plasma membrane-bound heterotrimers bearing palmitoylated R7BP. Therefore, R7BP augments the function of the complex by a palmitoylation-regulated plasma membrane- targeting mechanism.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Univ S Florida, Coll Med, Dept Physiol & Biophys, Tampa, FL 33612 USA	Washington University (WUSTL); State University System of Florida; University of South Florida	Blumer, KJ (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	kblumer@cellbiology.wustl.edu	Linder, Maurine/AAU-9999-2021; Doupnik, Craig A/I-3617-2012; Jayaraman, Muralidharan/H-8563-2019; Huettner, James E/C-5219-2012; Blumer, Kendall J/C-5268-2012	Linder, Maurine/0000-0003-2202-9712; Doupnik, Craig A/0000-0002-7314-0747; Jayaraman, Muralidharan/0000-0003-3274-877X; 	NHLBI NIH HHS [HL075632] Funding Source: Medline; NIGMS NIH HHS [GM51466, GM44592] Funding Source: Medline; NINDS NIH HHS [NS30888, R01 NS030888] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051466, R01GM044592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030888] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Acconcia F, 2005, MOL BIOL CELL, V16, P231, DOI 10.1091/mbc.e04-07-0547; Basse F, 1996, J BIOL CHEM, V271, P17205, DOI 10.1074/jbc.271.29.17205; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berzat AC, 2005, J BIOL CHEM, V280, P33055, DOI 10.1074/jbc.M507362200; BYRAPPA S, 1995, GENOME RES, V5, P404, DOI 10.1101/gr.5.4.404; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Cabrera-Vera TM, 2004, P NATL ACAD SCI USA, V101, P16339, DOI 10.1073/pnas.0407416101; Carvalho J, 2003, J BIOL CHEM, V278, P16878, DOI 10.1074/jbc.M300429200; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Chen CK, 2003, P NATL ACAD SCI USA, V100, P6604, DOI 10.1073/pnas.0631825100; Chuang HH, 1998, P NATL ACAD SCI USA, V95, P11727, DOI 10.1073/pnas.95.20.11727; Donati RJ, 2003, LIFE SCI, V73, P1, DOI 10.1016/S0024-3205(03)00249-2; Dong BH, 2004, J VIROL, V78, P8983, DOI 10.1128/JVI.78.17.8983-8993.2004; Doupnik CA, 2004, METHOD ENZYMOL, V389, P131; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Drenan RM, 2005, J CELL BIOL, V169, P623, DOI 10.1083/jcb.200502007; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Goel R, 2002, J BIOL CHEM, V277, P18640, DOI 10.1074/jbc.M108995200; Gold SJ, 1997, J NEUROSCI, V17, P8024; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; HEPLER JR, 2005, SCI STKE, pPE38; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Hooks SB, 2003, J BIOL CHEM, V278, P10087, DOI 10.1074/jbc.M211382200; Hu G, 2003, J BIOL CHEM, V278, P14550, DOI 10.1074/jbc.M212046200; Hu G, 2002, P NATL ACAD SCI USA, V99, P9755, DOI 10.1073/pnas.152094799; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Jakacka M, 2002, MOL ENDOCRINOL, V16, P2188, DOI 10.1210/me.2001-0174; Jones TLZ, 2004, METHOD ENZYMOL, V389, P33; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; Koster M, 2005, CURR OPIN BIOTECH, V16, P28, DOI 10.1016/j.copbio.2004.11.002; Kovoor A, 2005, J NEUROSCI, V25, P2157, DOI 10.1523/JNEUROSCI.2840-04.2005; Krispel CM, 2003, J NEUROSCI, V23, P6965, DOI 10.1523/JNEUROSCI.23-18-06965.2003; Larminie C, 2004, MOL BRAIN RES, V122, P24, DOI 10.1016/j.molbrainres.2003.11.014; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Li L, 2003, P NATL ACAD SCI USA, V100, P4807, DOI 10.1073/PNAS.0831079100; Lishko PV, 2002, J BIOL CHEM, V277, P24376, DOI 10.1074/jbc.M203237200; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Martemyanov KA, 2005, J BIOL CHEM, V280, P5133, DOI 10.1074/jbc.C400596200; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Nishiguchi KM, 2004, NATURE, V427, P75, DOI 10.1038/nature02170; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; Povsic TJ, 2003, J BIOL CHEM, V278, P51334, DOI 10.1074/jbc.M309968200; Rahman Z, 1999, J NEUROSCI, V19, P2016; Rahman Z, 2003, NEURON, V38, P941, DOI 10.1016/S0896-6273(03)00321-0; Rai D, 2005, MOL ENDOCRINOL, V19, P1606, DOI 10.1210/me.2004-0468; Rose JJ, 2000, J NEUROCHEM, V75, P2103, DOI 10.1046/j.1471-4159.2000.0752103.x; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; Silverman RH, 2002, CANCER RES, V62, P397; Song JH, 2006, J BIOL CHEM, V281, P15361, DOI 10.1074/jbc.M600749200; Tao WK, 2001, GENE DEV, V15, P1796, DOI 10.1101/gad.894301; Wang P, 2003, J BIOL CHEM, V278, P11648, DOI 10.1074/jbc.M208109200; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wiedmer T, 2003, BIOCHEMISTRY-US, V42, P1227, DOI 10.1021/bi026679w; Williams CL, 2003, CELL SIGNAL, V15, P1071, DOI 10.1016/S0898-6568(03)00098-6; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Zachariou V, 2003, P NATL ACAD SCI USA, V100, P13656, DOI 10.1073/pnas.2232594100; Zhang D., 2000, J DESERT RES, V20, P59; Zhou QS, 2005, J BIOL CHEM, V280, P35062, DOI 10.1074/jbc.M504821200	63	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28222	28231		10.1074/jbc.M604428200	http://dx.doi.org/10.1074/jbc.M604428200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16867977	hybrid			2022-12-25	WOS:000240534400060
J	Hsiao, YS; Jogl, G; Tong, L				Hsiao, Yu-Shan; Jogl, Gerwald; Tong, Liang			Crystal structures of murine carnitine acetyltransferase in ternary complexes with its substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTONIN N-ACETYLTRANSFERASE; CHOLINE-ACETYLTRANSFERASE; PALMITOYLTRANSFERASE; RESOLUTION; BINDING; SYSTEM; ACYLTRANSFERASES; MACROMOLECULES; SELECTIVITY; METABOLISM	Carnitine acyltransferases catalyze the reversible exchange of acyl groups between coenzyme A (CoA) and carnitine. They have important roles in many cellular processes, especially the oxidation of long-chain fatty acids in the mitochondria for energy production, and are attractive targets for drug discovery against diabetes and obesity. To help define in molecular detail the catalytic mechanism of these enzymes, we report here the high resolution crystal structure of wild-type murine carnitine acetyltransferase (CrAT) in a ternary complex with its substrates acetyl-CoA and carnitine, and the structure of the S554A/M564G double mutant in a ternary complex with the substrates CoA and hexanoylcarnitine. Detailed analyses suggest that these structures may be good mimics for the Michaelis complexes for the forward and reverse reactions of the enzyme, representing the first time that such complexes of CrAT have been studied in molecular detail. The structural information provides significant new insights into the catalytic mechanism of CrAT and possibly carnitine acyltransferases in general.	Columbia Univ, Dept Sci Biol, New York, NY 10027 USA	Columbia University	Tong, L (corresponding author), Columbia Univ, Dept Sci Biol, New York, NY 10027 USA.	tong@como.bio.columbia.edu	Jogl, Gerwald/AAJ-5783-2021	Jogl, Gerwald/0000-0002-5465-5315; Tong, Liang/0000-0002-0563-6468	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067238] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK067238-05A2, R01 DK067238, DK67238] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RC, 1998, CURR PHARM DESIGN, V4, P1; BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; Bonnefont Jean-Paul, 2004, Molecular Aspects of Medicine, V25, P495, DOI 10.1016/j.mam.2004.06.004; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cai YY, 2004, EMBO J, V23, P2047, DOI 10.1038/sj.emboj.7600221; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; COLUCCI WJ, 1988, BIOORG CHEM, V16, P307, DOI 10.1016/0045-2068(88)90018-1; Cordente AG, 2004, J BIOL CHEM, V279, P33899, DOI 10.1074/jbc.M402685200; Cronin CN, 1997, BIOCHEM BIOPH RES CO, V238, P784, DOI 10.1006/bbrc.1997.7390; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Foster DW, 2004, ANN NY ACAD SCI, V1033, P1, DOI 10.1196/annals.1320.001; Govindasamy L, 2004, J STRUCT BIOL, V148, P226, DOI 10.1016/j.jsb.2004.06.005; Govindasamy L, 2004, J STRUCT BIOL, V146, P416, DOI 10.1016/j.jsb.2004.01.011; Hassett RP, 2000, ANAL BIOCHEM, V287, P176, DOI 10.1006/abio.2000.4799; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; Hsiao YS, 2004, J BIOL CHEM, V279, P31584, DOI 10.1074/jbc.M403484200; Hsiao YS, 2006, BIOCHEM BIOPH RES CO, V346, P974, DOI 10.1016/j.bbrc.2006.06.006; Jogl G, 2004, ANN NY ACAD SCI, V1033, P17, DOI 10.1196/annals.1320.002; Jogl G, 2005, J BIOL CHEM, V280, P738, DOI 10.1074/jbc.M409894200; Jogl G, 2003, CELL, V112, P113, DOI 10.1016/S0092-8674(02)01228-X; Jogl G, 2001, ACTA CRYSTALLOGR D, V57, P1127, DOI 10.1107/S0907444901006783; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kerner J, 2000, BBA-MOL CELL BIOL L, V1486, P1, DOI 10.1016/S1388-1981(00)00044-5; Lenhard JM, 2002, ADV DRUG DELIVER REV, V54, P1199, DOI 10.1016/S0169-409X(02)00092-3; LESLIE AGW, 1988, P NATL ACAD SCI USA, V85, P4133, DOI 10.1073/pnas.85.12.4133; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Mengi Sushma A, 2004, Am J Cardiovasc Drugs, V4, P201, DOI 10.2165/00129784-200404040-00001; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nyman LR, 2005, MOL GENET METAB, V86, P179, DOI 10.1016/j.ymgme.2005.07.021; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ramsay Rona R., 2004, Molecular Aspects of Medicine, V25, P475, DOI 10.1016/j.mam.2004.06.002; Ramsay RR, 2003, TRENDS BIOCHEM SCI, V28, P343, DOI 10.1016/S0968-0004(03)00137-3; Ramsay RR, 2001, BBA-PROTEIN STRUCT M, V1546, P21, DOI 10.1016/S0167-4838(01)00147-9; Ronnett GV, 2005, PHYSIOL BEHAV, V85, P25, DOI 10.1016/j.physbeh.2005.04.014; Rufer AC, 2006, STRUCTURE, V14, P713, DOI 10.1016/j.str.2006.01.008; Scheibner KA, 2002, J BIOL CHEM, V277, P18118, DOI 10.1074/jbc.M200595200; Steiber Alison, 2004, Molecular Aspects of Medicine, V25, P455, DOI 10.1016/j.mam.2004.06.006; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; Watt W, 1999, STRUCTURE, V7, P1135, DOI 10.1016/S0969-2126(99)80180-4	41	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28480	28487		10.1074/jbc.M602622200	http://dx.doi.org/10.1074/jbc.M602622200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16870616	Green Accepted, hybrid			2022-12-25	WOS:000240534400085
J	Weiske, J; Huber, O				Weiske, Joerg; Huber, Otmar			The histidine triad protein Hint1 triggers apoptosis independent of its enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN REMODELING COMPLEX; C-INTERACTING PROTEIN-1; BETA-CATENIN; CANCER-CELLS; SUPPRESSOR GENE; FHIT GENE; KINASE; EXPRESSION; SUBSTRATE; TARGET	Hint1 is a member of the evolutionarily conserved family of histidine triad proteins that acts as a haplo-insufficient tumor suppressor inducing spontaneous tumor formation in Hint(+/-) and Hint(-/-) mouse models. However, the molecular mechanisms for the tumor-suppressing activity are poorly defined. In this respect, we have recently shown that Hint1, by interaction with Pontin and Reptin, inhibits T-cell factor/beta-catenin-mediated transcription of Wnt target genes. In this study, we have found that, after transient transfection with Hint1, SW480 and MCF-7 cells undergo apoptosis as analyzed by pro-caspase-3 and poly(ADP-ribose) polymerase cleavage, M30 CytoDEATH staining, cytochrome c release, and DNA fragmentation enzyme-linked immunosorbent assay. Hint1 is involved in the regulation of apoptotic pathways by inducing an up-regulation of p53 expression coinciding with an up-regulation of the proapoptotic factor Bax and a concomitant down-regulation of the apoptosis inhibitor Bcl-2. Bad and Puma levels remained unchanged. Further analyses revealed that Hint1 is associated with the Bax promoter and is a component of the Tip60 histone acetyltransferase complex and, in this context, appears to be involved in the regulation of Bax expression. Knockdown of Hint1 by short hairpin RNA resulted in down-regulation of p53 and Bax but had no effect on Bcl-2 expression. A mutant Hint1 (H112N) protein defective in enzymatic activity as anAMP-NH2 hydrolase was not impaired in induction of apoptosis, suggesting that the Hint1 pro-apoptotic activity is independent of the Hint1 enzymatic activity.	Dept Lab Med & Pathobiochem, D-12200 Berlin, Germany		Huber, O (corresponding author), Univ Med Berlin, Inst Klin Chem & Pathobiochem, Charite, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.	otmar.huber@charite.de	Huber, Otmar/AAA-4548-2021	Huber, Otmar/0000-0003-4359-1747				Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; Bieganowski P, 2002, J BIOL CHEM, V277, P10852, DOI 10.1074/jbc.M111480200; Bojarski C, 2004, J CELL SCI, V117, P2097, DOI 10.1242/jcs.01071; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; Brenner C, 1999, J CELL PHYSIOL, V181, P179, DOI 10.1002/(SICI)1097-4652(199911)181:2<179::AID-JCP1>3.0.CO;2-8; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; BRZOSKA PM, 1995, P NATL ACAD SCI USA, V92, P7824, DOI 10.1073/pnas.92.17.7824; Choi EK, 2001, INT J RADIAT ONCOL, V49, P397, DOI 10.1016/S0360-3016(00)01485-1; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; Dugan KA, 2002, ONCOGENE, V21, P5835, DOI 10.1038/sj.onc.1205763; Dumon KR, 2001, CANCER RES, V61, P4827; Feng Y, 2003, CANCER RES, V63, P8726; Gilmour J, 1997, BIOCHEM J, V326, P471, DOI 10.1042/bj3260471; Huebner K, 2003, BRIT J CANCER, V88, P1501, DOI 10.1038/sj.bjc.6600937; Huebner K, 2001, NAT REV CANCER, V1, P214, DOI 10.1038/35106058; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Ishii H, 2001, CANCER RES, V61, P1578; Ji L, 1999, CANCER RES, V59, P3333; Jin JY, 2005, J BIOL CHEM, V280, P41207, DOI 10.1074/jbc.M509128200; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; Klein MG, 1998, EXP CELL RES, V244, P26, DOI 10.1006/excr.1998.4153; Korsisaari N, 2000, J BIOL CHEM, V275, P34837, DOI 10.1074/jbc.C000505200; Korsisaari N, 2003, MOL CELL BIOL, V23, P3929, DOI 10.1128/MCB.23.11.3929-3935.2003; Krakowiak A, 2004, J BIOL CHEM, V279, P18711, DOI 10.1074/jbc.M314271200; Kwasnicka DA, 2003, J BIOL CHEM, V278, P39051, DOI 10.1074/jbc.M306355200; Lee YN, 2004, IMMUNITY, V20, P145, DOI 10.1016/S1074-7613(04)00020-2; Li H, 2006, ONCOGENE, V25, P713, DOI 10.1038/sj.onc.1209111; Lima CD, 1996, P NATL ACAD SCI USA, V93, P5357, DOI 10.1073/pnas.93.11.5357; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; Lolli G, 2005, CELL CYCLE, V4, P572, DOI 10.4161/cc.4.4.1607; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nowak DE, 2005, BIOTECHNIQUES, V39, P715, DOI 10.2144/000112014; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Pace HC, 1998, P NATL ACAD SCI USA, V95, P5484, DOI 10.1073/pnas.95.10.5484; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Parks KP, 2004, PHYSIOL GENOMICS, V20, P12, DOI 10.1152/physiolgenomics.00204.2004; PEARSON JD, 1990, J BIOL CHEM, V265, P4583; Razin E, 1999, J BIOL CHEM, V274, P34272, DOI 10.1074/jbc.274.48.34272; Rottbauer W, 2002, CELL, V111, P661, DOI 10.1016/S0092-8674(02)01112-1; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; Schneider E, 1998, ONCOGENE, V17, P2733, DOI 10.1038/sj.onc.1202504; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Semba S, 2006, ONCOGENE, V25, P2860, DOI 10.1038/sj.onc.1209323; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Su T, 2003, P NATL ACAD SCI USA, V100, P7824, DOI 10.1073/pnas.1332160100; Trapasso F, 2003, P NATL ACAD SCI USA, V100, P1592, DOI 10.1073/pnas.0437915100; Tyteca S, 2006, EMBO J, V25, P1680, DOI 10.1038/sj.emboj.7601066; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Weiske J, 2005, J CELL SCI, V118, P3117, DOI 10.1242/jcs.02437; Weiske J, 2001, J BIOL CHEM, V276, P41175, DOI 10.1074/jbc.M105769200; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Yu J, 2003, CANCER CELL, V4, P248, DOI 10.1016/S1535-6108(03)00249-6; Yuan BZ, 2004, NEOPLASIA, V6, P412, DOI 10.1593/neo.03490	56	109	123	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27356	27366		10.1074/jbc.M513452200	http://dx.doi.org/10.1074/jbc.M513452200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16835243	hybrid			2022-12-25	WOS:000240397700062
J	Chi, P; Kwon, Y; Seong, C; Epshtein, A; Lam, I; Sung, P; Klein, HL				Chi, Peter; Kwon, Youngho; Seong, Changhyun; Epshtein, Anastasiya; Lam, Isabel; Sung, Patrick; Klein, Hannah L.			Yeast recombination factor Rdh54 functionally interacts with the Rad51 recombinase and catalyzes Rad51 removal from DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; STRAND EXCHANGE; HOMOLOGOUS RECOMBINATION; CHROMATIN; PROTEIN; REPAIR; DMC1; HELICASE; COMPLEX; BRCA2	The Saccharomyces cerevisiae RDH54-encoded product, a member of the Swi2/Snf2 protein family, is needed for mitotic and meiotic interhomologue recombination and DNA repair. Previous biochemical studies employing Rdh54 purified from yeast cells have shown DNA-dependent ATP hydrolysis and DNA supercoiling by this protein, indicative of a DNA translocase function. Importantly, Rdh54 physically interacts with the Rad51 recombinase and promotes D-loop formation by the latter. Unfortunately, the low yield of Rdh54 from the yeast expression system has greatly hampered the progress on defining the functional interactions of this Swi2/Snf2-like factor with Rad51. Here we describe an E. coli expression system and purification scheme that together provide milligram quantities of nearly homogeneous Rdh54. Using this material, we demonstrate that Rdh54-mediated DNA supercoiling leads to transient DNA strand opening. Furthermore, at the expense of ATP hydrolysis, Rdh54 removes Rad51 from DNA. We furnish evidence that the Rad51 binding domain resides within the N terminus of Rdh54. Accordingly, N-terminal truncation mutants of Rdh54 that fail to bind Rad51 are also impaired for functional interactions with the latter. Interestingly, the rdh54 K352R mutation that ablates ATPase activity engenders a DNA repair defect even more severe than that seen in the rdh54 Delta mutant. These results provide molecular information concerning the role of Rdh54 in homologous recombination and DNA repair, and they also demonstrate the functional significance of Rdh54 (.) Rad51 complex formation. The Rdh54 expression and purification procedures described here should facilitate the functional dissection of this DNA recombination/repair factor.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA	Yale University; New York University; New York University	Sung, P (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA.	Patrick.Sung@yale.edu; hannah.klein@med.nyu.edu	Chi, Peter/AAI-1580-2019; Huang, Wenchi/F-3981-2010	Chi, Peter/0000-0001-9229-8729; Huang, Wenchi/0000-0001-5556-1460; Klein, Hannah/0000-0003-4228-8535; Lam, Isabel/0000-0002-6247-8080	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057814, R01GM053738] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01ES07061] Funding Source: Medline; NIGMS NIH HHS [R01GM57814, GM053738] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUILERA A, 1988, GENETICS, V119, P779; Alexeev A, 2003, NAT STRUCT BIOL, V10, P182, DOI 10.1038/nsb901; Alexiadis V, 2004, J BIOL CHEM, V279, P27824, DOI 10.1074/jbc.M402648200; Alexiadis V, 2002, GENE DEV, V16, P2767, DOI 10.1101/gad.1032102; Arbel A, 1999, EMBO J, V18, P2648, DOI 10.1093/emboj/18.9.2648; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Catlett MG, 2003, MOL BIOL CELL, V14, P4707, DOI 10.1091/mbc.E03-05-0288; Cheok CF, 2005, BIOCHEM SOC T, V33, P1456, DOI 10.1042/BST0331456; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Dresser ME, 1997, GENETICS, V147, P533; Durr H, 2005, CELL, V121, P363, DOI 10.1016/j.cell.2005.03.026; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Jaskelioff M, 2003, J BIOL CHEM, V278, P9212, DOI 10.1074/jbc.M211545200; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Klein HL, 1997, GENETICS, V147, P1533; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; Krogh BO, 2004, ANNU REV GENET, V38, P233, DOI 10.1146/annurev.genet.38.072902.091500; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Lia G, 2006, MOL CELL, V21, P417, DOI 10.1016/j.molcel.2005.12.013; LYNN RM, 1989, PROTEINS, V6, P231, DOI 10.1002/prot.340060305; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Peterson CL, 2004, GENE DEV, V18, P602, DOI 10.1101/gad.1182704; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Petukhova G, 2000, GENE DEV, V14, P2206, DOI 10.1101/gad.826100; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Raschle M, 2004, J BIOL CHEM, V279, P51973, DOI 10.1074/jbc.M410101200; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; Saha A, 2002, GENE DEV, V16, P2120, DOI 10.1101/gad.995002; Sehorn MG, 2004, NATURE, V429, P433, DOI 10.1038/nature02563; Shinohara M, 2000, P NATL ACAD SCI USA, V97, P10814, DOI 10.1073/pnas.97.20.10814; Shinohara M, 1997, GENETICS, V147, P1545; Solinger JA, 2002, MOL CELL, V10, P1175, DOI 10.1016/S1097-2765(02)00743-8; Solinger JA, 2001, J MOL BIOL, V307, P1207, DOI 10.1006/jmbi.2001.4555; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Thoma NH, 2005, NAT STRUCT MOL BIOL, V12, P350, DOI 10.1038/nsmb919; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498	47	53	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26268	26279		10.1074/jbc.M602983200	http://dx.doi.org/10.1074/jbc.M602983200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16831867	hybrid			2022-12-25	WOS:000240249500044
J	Kim, JH; Johnston, M				Kim, Jeong-Ho; Johnston, Mark			Two glucose-sensing pathways converge on Rgt1 to regulate expression of glucose transporter genes in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; GTPASE-ACTIVATING PROTEIN; TRANSCRIPTION FACTOR; COUPLED RECEPTOR; S-CEREVISIAE; CAMP PATHWAY; YEAST; REPRESSOR; RAS; SPECIFICITY	The yeast Saccharomyces cerevisiae deploys two different types of glucose sensors on its cell surface that operate in distinct glucose signaling pathways: the glucose transporter-like Snf3 and Rgt2 proteins and the Gpr1 receptor that is coupled to Gpa2, a G-protein alpha subunit. The ultimate target of the Snf3/Rgt2 pathway is Rgt1, a transcription factor that regulates expression of HXT genes encoding glucose transporters. We have found that the cAMP-dependent protein kinase A (PKA), which is activated by the Gpr1/Gpa2 glucose-sensing pathway and by a glucose-sensing pathway that works through Ras1 and Ras2, catalyzes phosphorylation of Rgt1 and regulates its function. Rgt1 is phosphorylated in vitro by all three isoforms of PKA, and this requires several serine residues located in PKA consensus sequences within Rgt1. PKA and the consensus serine residues of Rgt1 are required for glucose-induced removal of Rgt1 from the HXT promoters and for induction of HXT expression. Conversely, overexpression of the TPK genes led to constitutive expression of the HXT genes. The PKA consensus phosphorylation sites of Rgt1 are required for an intramolecular interaction that is thought to regulate its DNA binding activity. Thus, two different glucose signal transduction pathways converge on Rgt1 to regulate expression of glucose transporters.	Univ So Mississippi, Dept Biol Sci, MFGN, Hattiesburg, MS 39406 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	University of Southern Mississippi; Washington University (WUSTL)	Kim, JH (corresponding author), Univ So Mississippi, Dept Biol Sci, MFGN, 118 Coll Dr 5018, Hattiesburg, MS 39406 USA.	jeongho.kim@mfgn.usm.edu	Johnston, Mark/K-3543-2019; Johnston, Mark/R-6156-2019	Johnston, Mark/0000-0002-4932-7229; 	NCRR NIH HHS [RR016476-04] Funding Source: Medline; NIGMS NIH HHS [GM32540] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032540] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; Broach JR, 1991, CURR OPIN GENET DEV, V1, P370, DOI 10.1016/S0959-437X(05)80302-8; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; Colombo S, 1998, EMBO J, V17, P3326, DOI 10.1093/emboj/17.12.3326; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; Flick KM, 2003, MOL BIOL CELL, V14, P3230, DOI 10.1091/mbc.E03-03-0135; Forsberg H, 2001, CURR GENET, V40, P91, DOI 10.1007/s002940100244; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; James P, 1996, GENETICS, V144, P1425; Johnston M, 2005, BIOCHEM SOC T, V33, P247, DOI 10.1042/BST0330247; Kaniak A, 2004, EUKARYOT CELL, V3, P221, DOI 10.1128/EC.3.1.221-231.2004; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kim JH, 2006, EUKARYOT CELL, V5, P167, DOI 10.1128/EC.5.1.167-173.2006; Kim JH, 2003, MOL CELL BIOL, V23, P5208, DOI 10.1128/MCB.23.15.5208-5216.2003; Kraakman L, 1999, MOL MICROBIOL, V32, P1002, DOI 10.1046/j.1365-2958.1999.01413.x; LAGUNAS R, 1979, MOL CELL BIOCHEM, V27, P139, DOI 10.1007/BF00215362; LAGUNAS R, 1986, YEAST, V2, P221, DOI 10.1002/yea.320020403; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; Moriya H, 2004, P NATL ACAD SCI USA, V101, P1572, DOI 10.1073/pnas.0305901101; Mosley AL, 2003, J BIOL CHEM, V278, P10322, DOI 10.1074/jbc.M212802200; Ozcan S, 1996, MOL CELL BIOL, V16, P5536; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; Ozcan S, 1996, MOL CELL BIOL, V16, P6419; Palomino A, 2006, NUCLEIC ACIDS RES, V34, P1427, DOI 10.1093/nar/gkl028; Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079; Polish JA, 2005, GENETICS, V169, P583, DOI 10.1534/genetics.104.034512; Rolland F, 2000, MOL MICROBIOL, V38, P348, DOI 10.1046/j.1365-2958.2000.02125.x; Rolland F, 2002, FEMS YEAST RES, V2, P183, DOI 10.1111/j.1567-1364.2002.tb00084.x; Santangelo GM, 2006, MICROBIOL MOL BIOL R, V70, P253, DOI 10.1128/MMBR.70.1.253-282.2006; Schmelzle T, 2004, MOL CELL BIOL, V24, P338, DOI 10.1128/MCB.24.1.338-351.2004; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; Thevelein JM, 2005, BIOCHEM SOC T, V33, P253, DOI 10.1042/BST0330253; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; Versele M, 1999, EMBO J, V18, P5577, DOI 10.1093/emboj/18.20.5577; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Zhu H, 2000, NAT GENET, V26, P283, DOI 10.1038/81576	42	126	131	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26144	26149		10.1074/jbc.M603636200	http://dx.doi.org/10.1074/jbc.M603636200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16844691	hybrid, Green Published			2022-12-25	WOS:000240249500030
J	Musson, JA; Morton, M; Walker, N; Harper, HM; McNeill, HV; Williamson, ED; Robinson, JH				Musson, Julie A.; Morton, Margaret; Walker, Nicola; Harper, Helen M.; McNeill, Hesta V.; Williamson, E. Diane; Robinson, John H.			Sequential proteolytic processing of the capsular Caf1 antigen of Yersinia pestis for major histocompatibility complex class II-restricted presentation to T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1 ANTIGEN; SUBUNIT VACCINE; SALMONELLA-TYPHIMURIUM; MONOCLONAL-ANTIBODIES; PNEUMONIC PLAGUE; IMMUNE-RESPONSE; CELL EPITOPES; PROTECTION; PROTEIN; MICE	We studied the mechanisms of antigen presentation of CD4 T cell epitopes of the capsular Caf1 antigen of Yersinia pestis using murine bone marrow macrophages as antigen presenting cells and T cell hybridomas specific for major histocompatibility complex (MHC) class II-restricted epitopes distributed throughout the Caf1 sequence. The data revealed diversity in the pathways used and the degrees of antigen processing required depending on the structural context of epitopes within the Caf1 molecule. Two epitopes in the carboxyl-terminal globular domain were presented by newly synthesized MHC class II after low pH-dependent lysosomal processing, whereas an epitope located in a flexible amino-terminal strand was presented by mature MHC class II independent of low pH and with no detectable requirement for proteolytic processing. A fourth epitope located between the two regions of Caf1 showed intermediate behavior. The data are consistent with progressive unfolding and cleavage of rCaf1 from the amino terminus as it traverses the endosomal pathway, the availability of epitopes determining which pool of MHC class II is preferentially loaded. The Caf1 capsular protein is a component of second generation plague vaccines and an understanding of the mechanisms and pathways of MHC class II-restricted presentation of multiple epitopes from this candidate vaccine antigen should inform the choice of delivery systems and adjuvants that target vaccines successfully to appropriate intracellular locations to induce protective immune responses against as wide a T cell repertoire as possible.	Univ Newcastle, Inst Cellular Med, Musculoskeletal Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Def Sci & Technol Lab, Salisbury SP4 0JQ, Wilts, England	Newcastle University - UK; Defence Science & Technology Laboratory	Robinson, JH (corresponding author), Univ Newcastle, Inst Cellular Med, Musculoskeletal Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	j.h.robinson@ncl.ac.uk	Williamson, Ethel Diane/AAQ-8878-2020					Anderson GW, 1998, AM J TROP MED HYG, V58, P793, DOI 10.4269/ajtmh.1998.58.793; Anderson GW, 1997, AM J TROP MED HYG, V56, P471, DOI 10.4269/ajtmh.1997.56.471; Andrews GP, 1996, INFECT IMMUN, V64, P2180, DOI 10.1128/IAI.64.6.2180-2187.1996; Chianese-Bullock KA, 1998, J IMMUNOL, V161, P1599; Conte MP, 1996, J MED MICROBIOL, V44, P418, DOI 10.1099/00222615-44-6-418; Cornelis GR, 2002, NAT REV MOL CELL BIO, V3, P742, DOI 10.1038/nrm932; Elvin SJ, 2004, MICROB PATHOGENESIS, V37, P177, DOI 10.1016/j.micpath.2004.06.009; Elvin SJ, 2000, MICROB PATHOGENESIS, V29, P223, DOI 10.1006/mpat.2000.0385; Eyles JE, 1998, VACCINE, V16, P2000, DOI 10.1016/S0264-410X(98)00089-9; Eyles JE, 1998, VACCINE, V16, P698, DOI 10.1016/S0264-410X(97)00249-1; FernandezBorja M, 1996, INT IMMUNOL, V8, P625, DOI 10.1093/intimm/8.5.625; FISCHER HG, 1988, EUR J IMMUNOL, V18, P1151, DOI 10.1002/eji.1830180802; GAGE K. L., 1998, TOPLEY WILSONS MICRO, V3, P885; Goddard J, 1999, INFECT MED, V16, P21; Grosfeld H, 2003, INFECT IMMUN, V71, P374, DOI 10.1128/IAI.71.1.374-383.2003; Hill J, 2003, INFECT IMMUN, V71, P2234, DOI 10.1128/IAI.71.4.2234-2238.2003; KARLYSHEV AV, 1992, FEBS LETT, V305, P37, DOI 10.1016/0014-5793(92)80650-6; Leary SEC, 1997, MICROB PATHOGENESIS, V23, P167, DOI 10.1006/mpat.1997.0141; Lennon-Dumenil AM, 2002, CURR OPIN IMMUNOL, V14, P15, DOI 10.1016/S0952-7915(01)00293-X; Levy CE, 1999, INFECT MED, V16, P54; Miller J, 1998, FEMS IMMUNOL MED MIC, V21, P213, DOI 10.1111/j.1574-695X.1998.tb01168.x; Musson JA, 2003, J BIOL CHEM, V278, P52425, DOI 10.1074/jbc.M309034200; ORCI L, 1991, CELL, V64, P1183; OYSTON PCF, 1995, INFECT IMMUN, V63, P563, DOI 10.1128/IAI.63.2.563-568.1995; Panda SK, 1996, CURR SCI INDIA, V71, P794; PERROW C, 1997, ORG ENV, V10, P66, DOI DOI 10.1177/0921810697101009; PURI J, 1988, J IMMUNOL, V141, P3313; Reddin KM, 1998, VACCINE, V16, P761, DOI 10.1016/S0264-410X(97)00305-8; Robinson JH, 2002, IMMUNOLOGY, V105, P252, DOI 10.1046/j.0019-2805.2001.01358.x; Sabhnani L, 2003, FEMS IMMUNOL MED MIC, V38, P215, DOI 10.1016/S0928-8244(03)00170-6; SHIM HK, 2006, IN PRESS IMMUNOLOGY, V119; SIMPSON WJ, 1990, AM J TROP MED HYG, V43, P389, DOI 10.4269/ajtmh.1990.43.389; Smego RA, 1999, EUR J CLIN MICROBIOL, V18, P1, DOI 10.1007/s100960050219; STPIERRE Y, 1990, J IMMUNOL, V145, P812; Titball RW, 1997, INFECT IMMUN, V65, P1926, DOI 10.1128/IAI.65.5.1926-1930.1997; Titball RW, 2003, ADV EXP MED BIOL, V529, P397; Unanue ER, 2002, IMMUNOL REV, V185, P86, DOI 10.1034/j.1600-065X.2002.18510.x; von Delwig A, 2003, EUR J IMMUNOL, V33, P3359, DOI 10.1002/eji.200324461; Watts C, 2004, NAT IMMUNOL, V5, P685, DOI 10.1038/ni1088; WILCOX D, 1992, BIOCHEM J, V285, P495, DOI 10.1042/bj2850495; Williamson ED, 2005, INFECT IMMUN, V73, P3598, DOI 10.1128/IAI.73.6.3598-3608.2005; Williamson ED, 2002, BRIT MED BULL, V62, P163, DOI 10.1093/bmb/62.1.163; WILLIAMSON ED, 1995, FEMS IMMUNOL MED MIC, V12, P223, DOI 10.1111/j.1574-695X.1995.tb00196.x; Williamson ED, 1997, VACCINE, V15, P1079, DOI 10.1016/S0264-410X(96)00303-9; Williamson ED, 1996, VACCINE, V14, P1613, DOI 10.1016/S0264-410X(96)00151-X; Zavialov AV, 2003, CELL, V113, P587, DOI 10.1016/S0092-8674(03)00351-9	46	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26129	26135		10.1074/jbc.M605482200	http://dx.doi.org/10.1074/jbc.M605482200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16840777	hybrid			2022-12-25	WOS:000240249500028
J	Baert, JL; Beaudoin, C; Monte, D; Degerny, C; Mauen, S; de Launoit, Y				Baert, J-L; Beaudoin, C.; Monte, D.; Degerny, C.; Mauen, S.; de Launoit, Y.			The 26S proteasome system degrades the ERM transcription factor and regulates its transcription-enhancing activity	ONCOGENE			English	Article						ETS; ERM; transcription factor; 26S proteasome; degradation; ubiquitin; regulation of transcription	UBIQUITIN-MEDIATED PROTEOLYSIS; FAMILY MEMBER ERM; ACTIVATION DOMAIN; TARGET GENES; ETS-DOMAIN; PEA3 GROUP; ORNITHINE-DECARBOXYLASE; EXPRESSION PATTERNS; DNA-BINDING; DEGRADATION	ERM is a member of the ETS transcription factor family. High levels of the corresponding mRNA are detected in a variety of human breast cancer cell lines, as well as in aggressive human breast tumors. As ERM protein is almost undetectable in these cells, high degradation of this transcription factor has been postulated. Here we have investigated whether ERM degradation might depend on the proteasome pathway. We show that endogenous and ectopically expressed ERM protein is short-lived protein and undergoes proteasome- dependent degradation. Deletion mutagenesis studies indicate that the 61 C-terminal amino acids of ERM are critical for its proteolysis and serve as a degradation signal. Although ERM conjugates with ubiquitin, this post-translational modi. cation does not depend on the C-terminaldomain. We have used an Ets-responsive ICAM-1 reporter plasmid to show that the ubiquitin - proteasome pathway can affect transcriptional function of ERM. Thus, ERM is subject to degradation via the 26S proteasome pathway, and this pathway probably plays an important	Univ Lille 1, Inst Pasteur Lille, CNRS, Inst Biol Lille,UMR 8161,Univ Lille 2,IFR 142, F-59021 Lille, France; Univ Libre Bruxelles, Fac Med, Mol Virol Lab, Brussels, Belgium	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite Libre de Bruxelles	de Launoit, Y (corresponding author), Univ Lille 1, Inst Pasteur Lille, CNRS, Inst Biol Lille,UMR 8161,Univ Lille 2,IFR 142, 1 Rue Prof Calmette, F-59021 Lille, France.	yvan.delaunoit@ibl.fr		monte, didier/0000-0002-0613-6203				Alvarez-Castelao B, 2005, FEBS LETT, V579, P4797, DOI 10.1016/j.febslet.2005.07.060; Baert JL, 2002, J BIOL CHEM, V277, P1002, DOI 10.1074/jbc.M107139200; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Blanquart C, 2002, J BIOL CHEM, V277, P37254, DOI 10.1074/jbc.M110598200; Bres V, 2003, NAT CELL BIOL, V5, P754, DOI 10.1038/ncb1023; Chotteau-Lelievre A, 2001, MECH DEVELOP, V108, P191, DOI 10.1016/S0925-4773(01)00480-4; Chotteau-Lelievre A, 2003, DEV BIOL, V259, P241, DOI 10.1016/S0012-1606(03)00182-9; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Dalton WS, 2004, SEMIN ONCOL, V31, P3, DOI 10.1053/j.seminoncol.2004.10.012; de Launoit Y, 1998, ONCOGENE, V16, P2065, DOI 10.1038/sj.onc.1201726; Defossez PA, 1997, NUCLEIC ACIDS RES, V25, P4455, DOI 10.1093/nar/25.22.4455; Degerny C, 2005, J BIOL CHEM, V280, P24330, DOI 10.1074/jbc.M411250200; Deroo BJ, 2002, MOL CELL BIOL, V22, P4113, DOI 10.1128/MCB.22.12.4113-4123.2002; Galang CK, 2004, J BIOL CHEM, V279, P11281, DOI 10.1074/jbc.M311887200; Goel A, 2003, MOL CELL BIOL, V23, P6243, DOI 10.1128/MCB.23.17.6243-6254.2003; Greer SF, 2003, NAT IMMUNOL, V4, P1074, DOI 10.1038/ni985; Janknecht R, 1996, ONCOGENE, V13, P1745; Kurosu T, 2004, CURR BIOL, V14, P1112, DOI 10.1016/j.cub.2004.06.020; Laget MP, 1996, ONCOGENE, V12, P1325; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; LELIEVRE AC, 2004, CLIN CANCER RES, V19, P7297; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; Maurer P, 2003, ONCOGENE, V22, P3319, DOI 10.1038/sj.onc.1206572; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Murakami Y, 1999, MOL CELL BIOL, V19, P7216; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Muratani M, 2005, CELL, V120, P887, DOI 10.1016/j.cell.2004.12.025; Peloponese JM, 2004, J VIROL, V78, P11686, DOI 10.1128/JVI.78.21.11686-11695.2004; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Pollenz RS, 2002, CHEM-BIOL INTERACT, V141, P41, DOI 10.1016/S0009-2797(02)00065-0; Prakash S, 2004, NAT STRUCT MOL BIOL, V11, P830, DOI 10.1038/nsmb814; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; Takahashi A, 2005, BIOCHEM BIOPH RES CO, V327, P575, DOI 10.1016/j.bbrc.2004.12.045; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Tworkowski KA, 2002, ONCOGENE, V21, P8515, DOI 10.1038/sj.onc.1205976; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158	42	16	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					415	424		10.1038/sj.onc.1209801	http://dx.doi.org/10.1038/sj.onc.1209801			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832340				2022-12-25	WOS:000243544000010
J	Huang, H; Wang, H; Sinz, M; Zoeckler, M; Staudinger, J; Redinbo, MR; Teotico, DG; Locker, J; Kalpana, GV; Mani, S				Huang, H.; Wang, H.; Sinz, M.; Zoeckler, M.; Staudinger, J.; Redinbo, M. R.; Teotico, D. G.; Locker, J.; Kalpana, G. V.; Mani, S.			Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole	ONCOGENE			English	Article						drug metabolism; transcriptional regulation; orphan nuclear receptors	PREGNANE-X-RECEPTOR; CYP3A4 GENE-EXPRESSION; XENOBIOTIC RECEPTOR; TRANSCRIPTIONAL REGULATION; COACTIVATOR PGC-1-ALPHA; CLINICAL-RELEVANCE; ACID SENSOR; BINDING; AGENTS; LIGAND	Individual variation in drug metabolism is a major cause of unpredictable side effects during therapy. Drug metabolism is controlled by a class of orphan nuclear receptors (NRs), which regulate expression of genes such as CYP (cytochrome) 3A4 and MDR-1 (multi-drug resistance-1), that are involved in this process. We have found that xenobiotic-mediated induction of CYP3A4 and MDR-1 gene transcription was inhibited by ketoconazole, a commonly used antifungal drug. Ketoconazole mediated its effect by inhibiting the activation of NRs, human pregnenolone X receptor and constitutive androstene receptor, involved in regulation of CYP3A4 and MDR-1. The effect of ketoconazole was specific to the group of NRs that control xenobiotic metabolism. Ketoconazole disrupted the interaction of the xenobiotic receptor PXR with the co-activator steroid receptor co-activator-1. Ketoconazole treatment resulted in delayed metabolism of tribromoethanol anesthetic in mice, which was correlated to the inhibition of PXR activation and downmodulation of cyp3a11 and mdr-1 genes and proteins. These studies demonstrate for the first time that ketoconazole represses the coordinated activation of genes involved in drug metabolism, by blocking activation of a specific subset of NRs. Our results suggest that ketoconazole can be used as a pan-antagonist of NRs involved in xenobiotic metabolism in vivo, which may lead to novel strategies that improve drug effect and tolerance.	Yeshiva Univ Albert Einstein Coll Med, Dept Oncol, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Bristol Myers Squibb Co, Wallingford, CT 06492 USA; Univ Kansas, Dept Toxicol, Lawrence, KS 66045 USA; Univ N Carolina, Dept Chem, Chapel Hill, NC USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Bristol-Myers Squibb; University of Kansas; University of North Carolina; University of North Carolina Chapel Hill; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Mani, S (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Oncol, Albert Einstein Canc Ctr, 1300 Morris Pk Ave,Chanin 302D-1, Bronx, NY 10461 USA.	smani@montefiore.org		Kalpana, Ganjam/0000-0003-4111-0604				Albers M, 2005, MOL CELL PROTEOMICS, V4, P205, DOI 10.1074/mcp.M400169-MCP200; BEETENS JR, 1986, BIOCHEM PHARMACOL, V35, P883, DOI 10.1016/0006-2952(86)90072-9; Berthold DR, 2005, J CLIN ONCOL, V23, P8247, DOI 10.1200/JCO.2005.03.1435; Bhalla S, 2004, J BIOL CHEM, V279, P45139, DOI 10.1074/jbc.M405423200; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Bourdoncle A, 2005, J MOL BIOL, V347, P921, DOI 10.1016/j.jmb.2005.01.048; Ding XS, 2005, J PHARMACOL EXP THER, V312, P849, DOI 10.1124/jpet.104.076331; Dresser GK, 2000, CLIN PHARMACOKINET, V38, P41, DOI 10.2165/00003088-200038010-00003; Dussault I, 2003, P NATL ACAD SCI USA, V100, P833, DOI 10.1073/pnas.0336235100; ELLSWORTH JL, 1994, BBA-LIPID LIPID MET, V1210, P321, DOI 10.1016/0005-2760(94)90236-4; Eloranta JJ, 2005, METHOD ENZYMOL, V400, P511, DOI 10.1016/S0076-6879(05)00028-5; Evans RM, 2005, MOL ENDOCRINOL, V19, P1429, DOI 10.1210/me.2005-0046; Fujino T, 2003, J STEROID BIOCHEM, V87, P247, DOI 10.1016/j.jsbmb.2003.09.008; Gnerre C, 2004, PHARMACOGENETICS, V14, P635, DOI 10.1097/00008571-200410000-00001; Hamaguchi Taizo, 2002, Nihon Ishinkin Gakkai Zasshi, V43, P95, DOI 10.3314/jjmm.43.95; Handschin C, 2005, ARCH BIOCHEM BIOPHYS, V433, P387, DOI 10.1016/j.abb.2004.08.030; Johnson DR, 2006, MOL PHARMACOL, V69, P99, DOI 10.1124/mol.105.013375; Kanda N, 2002, J INVEST DERMATOL, V119, P590, DOI 10.1046/j.1523-1747.2002.01864.x; Kanda N, 2002, J INVEST DERMATOL, V119, P174, DOI 10.1046/j.1523-1747.2002.01804.x; KIM SG, 1992, MOL PHARMACOL, V42, P273; Kliewer SA, 2002, ENDOCR REV, V23, P687, DOI 10.1210/er.2001-0038; Lee HS, 2002, J BIOCHEM, V131, P399, DOI 10.1093/oxfordjournals.jbchem.a003115; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Li TG, 2005, AM J PHYSIOL-GASTR L, V288, pG74, DOI 10.1152/ajpgi.00258.2004; LOOSE DS, 1983, J CLIN INVEST, V71, P1495, DOI 10.1172/JCI110903; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Mani S, 2005, CLIN CANCER RES, V11, P6359, DOI 10.1158/1078-0432.CCR-05-0252; Matheny CJ, 2004, DRUG METAB DISPOS, V32, P1008; Miquel M, 1999, PHARMACOL BIOCHEM BE, V64, P89, DOI 10.1016/S0091-3057(99)00070-2; Pascussi JM, 2001, EUR J BIOCHEM, V268, P6346, DOI 10.1046/j.0014-2956.2001.02540.x; SELYE H, 1971, J PHARM SCI, V60, P1, DOI 10.1002/jps.2600600102; Sohn YC, 2003, MOL ENDOCRINOL, V17, P366, DOI 10.1210/me.2002-0150; Sonoda J, 2003, CURR DRUG METAB, V4, P59, DOI 10.2174/1389200033336739; STALLA GK, 1988, ENDOCRINOLOGY, V122, P618; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912; Tabb MM, 2004, ENVIRON HEALTH PERSP, V112, P163, DOI 10.1289/ehp.6560; TAKAGI K, 1989, J BIOL CHEM, V264, P12352; Takeshita A, 2002, J BIOL CHEM, V277, P32453, DOI 10.1074/jbc.M111245200; Tzanakakis GN, 2002, J GASTROINTEST CANC, V32, P23, DOI 10.1385/IJGC:32:1:23; Undevia SD, 2005, NAT REV CANCER, V5, P447, DOI 10.1038/nrc1629; Venkatakrishnan K, 2000, CLIN PHARMACOKINET, V38, P111, DOI 10.2165/00003088-200038020-00002; Wei P., 2002, Pharmacogenomics Journal, V2, P117, DOI 10.1038/sj.tpj.6500087; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Xie W, 2003, P NATL ACAD SCI USA, V100, P4150, DOI 10.1073/pnas.0438010100; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Yamamoto A, 2000, J Dermatol, V27, P598; Yong WP, 2005, CLIN CANCER RES, V11, P6699, DOI 10.1158/1078-0432.CCR-05-0703; Zhu ZR, 2004, J BIOMOL SCREEN, V9, P533, DOI 10.1177/1087057104264902	50	168	180	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	2					258	268		10.1038/sj.onc.1209788	http://dx.doi.org/10.1038/sj.onc.1209788			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819505				2022-12-25	WOS:000243398300009
J	Durand, A; Merrick, M				Durand, Anne; Merrick, Mike			In vitro analysis of the Escherichia coli AmtB-GlnK complex reveals a stoichiometric interaction and sensitivity to ATP and 2-oxoglutarate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PROTEIN; AMMONIUM TRANSPORTER AMTB; P-II; GLUTAMINE-SYNTHETASE; MEMBRANE SEQUESTRATION; CRYSTAL-STRUCTURE; T-LOOP; PII; BINDING; KINASE	In Escherichia coli, the ammonia channel AmtB and the PII signal transduction protein GlnK constitute an ammonium sensory system that effectively couples the intracellular nitrogen regulation system to external changes in ammonium availability. Binding of GlnK toAmtBapparently inactivates the channel, thereby controlling ammonium influx in response to the intracellular nitrogen status. Wedesigned an N- terminally histidinetagged version of AmtB with a native C- terminal region in order to purify the AmtB- GlnK complex. Purification revealed a stable and direct interaction between AmtB and GlnK, thereby showing for the first time that stability of the complex does not require other proteins. The stoichiometry of the complex was determined by two independent approaches, both of which indicated a 1: 1 ratio of AmtB to GlnK. We also showed by mass spectrometry that only the fully deuridylylated form of GlnK co- purifies with AmtB. The purified complex allowed in vitro studies of dissociation and association of AmtB and GlnK. The interaction of GlnK with AmtB is dependent on ATP and is also sensitive to 2- oxoglutarate. Our in vitro data suggest that in vivo association and dissociation of the complex might not only be dependent on the uridylylation status of GlnK but may also be influenced by intracellular pools of ATP and 2- oxoglutarate.	John Innes Ctr, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Merrick, M (corresponding author), John Innes Ctr, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England.	mike.merrick@bbsrc.ac.uk						Andrade SLA, 2005, P NATL ACAD SCI USA, V102, P14994, DOI 10.1073/pnas.0506254102; Arcondeguy T, 2001, MICROBIOL MOL BIOL R, V65, P80, DOI 10.1128/MMBR.65.1.80-105.2001; Atkinson MR, 1999, MOL MICROBIOL, V32, P301, DOI 10.1046/j.1365-2958.1999.01349.x; Benelli EM, 2002, EUR J BIOCHEM, V269, P3296, DOI 10.1046/j.1432-1033.2002.03011.x; Blakey D, 2002, BIOCHEM J, V364, P527, DOI 10.1042/BJ20011761; Carr PD, 1996, ACTA CRYSTALLOGR D, V52, P93, DOI 10.1107/S0907444995007293; CHEAH E, 1994, STRUCTURE, V2, P981, DOI 10.1016/S0969-2126(94)00100-6; Chen YM, 2006, J BIOL CHEM, V281, P5726, DOI 10.1074/jbc.M510945200; Conroy MJ, 2004, EMBO REP, V5, P1153, DOI 10.1038/sj.embor.7400296; Coutts G, 2002, EMBO J, V21, P536, DOI 10.1093/emboj/21.4.536; Detsch C, 2003, MICROBIOL-SGM, V149, P3289, DOI 10.1099/mic.0.26512-0; Ehlers C, 2005, MOL MICROBIOL, V55, P1841, DOI 10.1111/j.1365-2958.2005.04511.x; Forchhammer K, 2004, FEMS MICROBIOL REV, V28, P319, DOI 10.1016/j.femsre.2003.11.001; Heinrich A, 2004, MOL MICROBIOL, V52, P1303, DOI 10.1111/j.1365-2958.2004.04058.x; Huergo LF, 2006, MOL MICROBIOL, V59, P326, DOI 10.1111/j.1365-2958.2005.04944.x; Jaggi R, 1996, FEBS LETT, V391, P223, DOI 10.1016/0014-5793(96)00737-5; Javelle A, 2005, BIOCHEM SOC T, V33, P170, DOI 10.1042/BST0330170; Javelle A, 2005, BIOCHEM J, V390, P215, DOI 10.1042/BJ20042094; Javelle A, 2004, J BIOL CHEM, V279, P8530, DOI 10.1074/jbc.M312399200; Jiang P, 1997, J BACTERIOL, V179, P4342, DOI 10.1128/jb.179.13.4342-4353.1997; Jiang P, 1998, BIOCHEMISTRY-US, V37, P12802, DOI 10.1021/bi980666u; Jiang P, 1998, BIOCHEMISTRY-US, V37, P12795, DOI 10.1021/bi9802420; Jiang P, 1999, J BACTERIOL, V181, P1906, DOI 10.1128/JB.181.6.1906-1911.1999; Jiang P, 1998, BIOCHEMISTRY-US, V37, P12782, DOI 10.1021/bi980667m; KAMBEROV ES, 1995, J BIOL CHEM, V270, P17797, DOI 10.1074/jbc.270.30.17797; Khademi S, 2004, SCIENCE, V305, P1587, DOI 10.1126/science.1101952; Little R, 2002, J BIOL CHEM, V277, P15472, DOI 10.1074/jbc.M112262200; Liu YM, 2006, J PHYS CHEM A, V110, P1375, DOI 10.1021/jp054261c; LODATO DT, 1987, BIOCHEMISTRY-US, V26, P2243, DOI 10.1021/bi00382a026; Maheswaran M, 2004, J BIOL CHEM, V279, P55202, DOI 10.1074/jbc.M410971200; Martinez-Argudo I, 2002, J BACTERIOL, V184, P3746, DOI 10.1128/JB.184.13.3746-3748.2002; Ninfa AJ, 2005, CURR OPIN MICROBIOL, V8, P168, DOI 10.1016/j.mib.2005.02.011; Pioszak AA, 2000, BIOCHEMISTRY-US, V39, P13450, DOI 10.1021/bi000795m; Ruppert U, 2002, MOL MICROBIOL, V44, P855, DOI 10.1046/j.1365-2958.2002.02927.x; SENIOR PJ, 1975, J BACTERIOL, V123, P407, DOI 10.1128/JB.123.2.407-418.1975; SON HS, 1987, J BIOL CHEM, V262, P8690; Soupene E, 1998, P NATL ACAD SCI USA, V95, P7030, DOI 10.1073/pnas.95.12.7030; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; Stips J, 2004, EUR J BIOCHEM, V271, P3379, DOI 10.1111/j.1432-1033.2004.04272.x; Strosser J, 2004, MOL MICROBIOL, V54, P132, DOI 10.1111/j.1365-2958.2004.04247.x; Thomas G, 2000, TRENDS GENET, V16, P11, DOI 10.1016/S0168-9525(99)01887-9; Thornton J, 2006, FEMS MICROBIOL LETT, V258, P114, DOI 10.1111/j.1574-6968.2006.00202.x; vanHeeswijk WC, 1996, MOL MICROBIOL, V21, P133, DOI 10.1046/j.1365-2958.1996.6281349.x; von Wiren N, 2004, TOP CURR GENET, V9, P95; Winkler F, 2006, PFLUG ARCH EUR J PHY, V451, P701, DOI 10.1007/s00424-005-1511-6; Xu YB, 1998, J MOL BIOL, V282, P149, DOI 10.1006/jmbi.1998.1979; Xu YB, 2001, EUR J BIOCHEM, V268, P2028, DOI 10.1046/j.1432-1327.2001.02074.x; Zheng L, 2004, P NATL ACAD SCI USA, V101, P17090, DOI 10.1073/pnas.0406475101	48	42	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29558	29567		10.1074/jbc.M602477200	http://dx.doi.org/10.1074/jbc.M602477200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16864585	hybrid			2022-12-25	WOS:000240896300017
J	Gory-Faure, S; Windscheid, V; Bosc, C; Peris, L; Proietto, D; Franck, R; Denarier, E; Job, D; Andrieux, A				Gory-Faure, Sylvie; Windscheid, Vanessa; Bosc, Christophe; Peris, Leticia; Proietto, Dominique; Franck, Ronald; Denarier, Eric; Job, Didier; Andrieux, Annie			STOP-like protein 21 is a novel member of the STOP family, revealing a Golgi localization of STOP proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD-STABLE MICROTUBULES; SECRETORY TRAFFICKING; DENDRITIC SPINES; SPOT-SYNTHESIS; PALMITOYLATION; MEMBRANE; CELLS; IDENTIFICATION; CALMODULIN; STABILITY	Neuronal microtubules are stabilized by two calmodulin-regulated microtubule-associated proteins, E-STOP and N-STOP, which when suppressed in mice induce severe synaptic and behavioral deficits. Here we show that mature neurons also contain a 21-kDa STOP-like protein, SL21, which shares calmodulin-binding and microtubule-stabilizing homology domains with STOP proteins. Accordingly, in different biochemical or cellular assays, SL21 has calmodulin binding and microtubule stabilizing activity. However, in cultured hippocampal neurons, SL21 antibodies principally stain the somatic Golgi and punctate Golgi material in neurites. In cycling cells, transfected SL21 decorates microtubules when expressed at high levels but is otherwise principally visible at the Golgi. The Golgi targeting of SL21 depends on the presence of cysteine residues located within the SL21 N-terminal domain, suggesting that Golgi targeting may require SL21 palmitoylation. Accordingly we find that SL21 is palmitoylated in vivo. N-STOP and E-STOP, which contain the Golgi targeting sequences present in SL21, also display distinct Golgi staining when expressed at low level in cycling cells. Thus neuronal proteins of the STOP family have the capacity to associate with Golgi material, which could be important for STOP synaptic functions.	CEA, INSERM, U366, DRDC CS,Commissariat Energie Atom, F-38054 Grenoble 9, France; Gessell Biotechnol Forschung, AG Mol Recognit, D-38124 Braunschweig, Germany	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Andrieux, A (corresponding author), CEA, INSERM, U366, DRDC CS,Commissariat Energie Atom, 17 Rue Martyrs, F-38054 Grenoble 9, France.	annie.andrieux@cea.fr	peris, leticia/P-9249-2017; ANDRIEUX, ANNIE/B-2134-2017; Bosc, Christophe/Q-8877-2019; Denarier, Eric/X-6137-2019; Denarier, Eric/H-3555-2017; Bosc, Christophe/P-3401-2017	peris, leticia/0000-0002-0668-1252; ANDRIEUX, ANNIE/0000-0002-4022-6405; Bosc, Christophe/0000-0002-3195-6692; Denarier, Eric/0000-0002-4169-397X; Denarier, Eric/0000-0002-4169-397X; Bosc, Christophe/0000-0002-3195-6692; Gory, Sylvie/0000-0001-5743-8079				Andrieux A, 2002, GENE DEV, V16, P2350, DOI 10.1101/gad.223302; Baratier J, 2006, J BIOL CHEM, V281, P19561, DOI 10.1074/jbc.M509602200; Bosc C, 2003, BIOCHEMISTRY-US, V42, P12125, DOI 10.1021/bi0352163; Bosc C, 1996, P NATL ACAD SCI USA, V93, P2125, DOI 10.1073/pnas.93.5.2125; Bosc C, 2001, J BIOL CHEM, V276, P30904, DOI 10.1074/jbc.M011614200; Brun P, 2005, J NEUROCHEM, V94, P63, DOI 10.1111/j.1471-4159.2005.03166.x; Denarier E, 1998, BIOCHEM BIOPH RES CO, V243, P791, DOI 10.1006/bbrc.1998.8179; DiPaolo G, 1997, J BIOL CHEM, V272, P5175, DOI 10.1074/jbc.272.8.5175; DOTTI CG, 1988, J NEUROSCI, V8, P1454; El-Husseini AED, 2002, NAT REV NEUROSCI, V3, P791, DOI 10.1038/nrn940; Frank R, 1996, Methods Mol Biol, V66, P149; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Galiano MR, 2004, J NEUROSCI RES, V78, P329, DOI 10.1002/jnr.20260; Guillaud L, 1998, J CELL BIOL, V142, P167, DOI 10.1083/jcb.142.1.167; Horton AC, 2005, NEURON, V48, P757, DOI 10.1016/j.neuron.2005.11.005; Horton AC, 2004, NAT CELL BIOL, V6, P585, DOI 10.1038/ncb0704-585; Horton AC, 2003, J NEUROSCI, V23, P6188; Huang K, 2005, CURR OPIN NEUROBIOL, V15, P527, DOI 10.1016/j.conb.2005.08.001; JOB D, 1981, P NATL ACAD SCI-BIOL, V78, P4679, DOI 10.1073/pnas.78.8.4679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEUVIN A, 1994, J CELL BIOL, V124, P985, DOI 10.1083/jcb.124.6.985; MASSON D, 1993, J CELL BIOL, V123, P357, DOI 10.1083/jcb.123.2.357; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; Pierce JP, 2000, NAT NEUROSCI, V3, P311, DOI 10.1038/73868; Pierce JP, 2001, CURR BIOL, V11, P351, DOI 10.1016/S0960-9822(01)00077-X; PIROLLET F, 1992, BIOCHEMISTRY-US, V31, P8849, DOI 10.1021/bi00152a022; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WEHLAND J, 1983, J CELL BIOL, V97, P1476, DOI 10.1083/jcb.97.5.1476	30	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28387	28396		10.1074/jbc.M603380200	http://dx.doi.org/10.1074/jbc.M603380200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16837464	Green Submitted, hybrid			2022-12-25	WOS:000240534400076
J	Griffin, SV; Olivier, JP; Pippin, JW; Roberts, JM; Shankland, SJ				Griffin, Sian V.; Olivier, J. Paul; Pippin, Jeffrey W.; Roberts, James M.; Shankland, Stuart J.			Cyclin I protects podocytes from apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR EPITHELIAL-CELLS; FAS-MEDIATED APOPTOSIS; PUROMYCIN AMINONUCLEOSIDE; DEPENDENT KINASES; GROWTH-FACTOR; RENAL-CELLS; CASPASE 3; INHIBITOR; PROLIFERATION; P21	The limited regenerative capacity of the glomerular podocyte following injury underlies the development of glomerulosclerosis and progressive renal failure in a diverse range of kidney diseases. We discovered that, in the kidney, cyclin I is uniquely expressed in the glomerular podocyte, and have constructed cyclin I knock-out mice to explore the biological function of cyclin I in these cells. Cyclin I knock-out (-/-) podocytes showed an increased susceptibility to apoptosis both in vitro and in vivo. Following induction of experimental glomerulonephritis, podocyte apoptosis was increased 4-fold in the cyclin I -/- mice, which was associated with dramatically decreased renal function. Our previous data showed that the Cdk inhibitor p21(Cip1/Waf1) protects podocytes from certain apoptotic stimuli. In cultured cyclin I -/- podocytes, the level of p21(Cip1/Waf1) was lower at base line, had a shorter half-life, and declined more rapidly in response to apoptotic stimuli than in wild- type cells. Enforced expression of p21(Cip1/Waf1) reversed the susceptibility of cyclin I -/- podocytes to apoptosis. Cyclin I protects podocytes from apoptosis, and we provide preliminary data to suggest that this is mediated by stabilization of p21(Cip1/Waf1).	Univ Washington, Sch Med, Dept Med, Div Nephrol, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Shankland, SJ (corresponding author), Univ Washington, Sch Med, Dept Med, Div Nephrol, Seattle, WA 98195 USA.	stuartjs@u.washington.edu	Roberts, James/AAI-3283-2020	Roberts, James/0000-0002-2671-3207	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051096, R01DK060525, R01DK056799] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56799, DK51096, DK60525] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER AJ, 1994, J CLIN INVEST, V94, P2105, DOI 10.1172/JCI117565; Barisoni L, 2003, CURR OPIN NEPHROL HY, V12, P251, DOI 10.1097/00041552-200305000-00005; Bates S, 1996, ONCOGENE, V13, P1103; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Ding GH, 2002, AM J PHYSIOL-RENAL, V283, pF173, DOI 10.1152/ajprenal.00240.2001; Durvasula RV, 2004, KIDNEY INT, V65, P30, DOI 10.1111/j.1523-1755.2004.00362.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Fornoni A, 2001, AM J PATHOL, V158, P275, DOI 10.1016/S0002-9440(10)63966-1; HARPER JW, 1993, CELL, V75, P805; Hughes J, 1999, AM J PHYSIOL-RENAL, V277, pF948, DOI 10.1152/ajprenal.1999.277.6.F948; Jascur T, 2005, MOL CELL, V17, P237, DOI 10.1016/j.molcel.2004.11.049; Jensen MR, 2000, GENE, V256, P59, DOI 10.1016/S0378-1119(00)00361-9; Kim YG, 1999, KIDNEY INT, V55, P2349, DOI 10.1046/j.1523-1755.1999.00504.x; Kim YH, 2001, KIDNEY INT, V60, P957, DOI 10.1046/j.1523-1755.2001.060003957.x; Kriz W, 1998, KIDNEY INT, V54, P687, DOI 10.1046/j.1523-1755.1998.00044.x; Kriz W, 1996, NEPHROL DIAL TRANSPL, V11, P1738, DOI 10.1093/oxfordjournals.ndt.a027660; Kriz W, 2002, MICROSC RES TECHNIQ, V57, P189, DOI 10.1002/jemt.10072; Kriz W, 1999, CURR OPIN NEPHROL HY, V8, P489, DOI 10.1097/00041552-199907000-00014; Lawson BR, 2004, J EXP MED, V199, P547, DOI 10.1084/jem.20031685; Lemley KV, 2002, KIDNEY INT, V61, P1475, DOI 10.1046/j.1523-1755.2002.00269.x; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Mundel P, 2002, J AM SOC NEPHROL, V13, P3005, DOI 10.1097/01.ASN.0000039661.06947.FD; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; MUNDLOS S, 1993, DEVELOPMENT, V119, P1329; NAKAMURA T, 1995, EXP CELL RES, V221, P534, DOI 10.1006/excr.1995.1406; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Nowak G, 2003, AM J PHYSIOL-RENAL, V285, pF440, DOI 10.1152/ajprenal.00233.2002; Ophascharoensuk V, 1998, KIDNEY INT, V54, P416, DOI 10.1046/j.1523-1755.1998.00003.x; Ophascharoensuk V, 1998, NAT MED, V4, P575, DOI 10.1038/nm0598-575; Pavenstadt H, 2003, PHYSIOL REV, V83, P253, DOI 10.1152/physrev.00020.2002; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; RENNKE HG, 1994, KIDNEY INT, V45, pS58; Sanwal V, 2001, EXP MOL PATHOL, V70, P54, DOI 10.1006/exmp.2000.2345; Schiffer M, 2004, J BIOL CHEM, V279, P37004, DOI 10.1074/jbc.M403534200; Schiffer M, 2001, J CLIN INVEST, V108, P807, DOI 10.1172/JCI12367; Scoltock AB, 2004, EXP CELL RES, V297, P212, DOI 10.1016/j.yexcr.2004.03.025; Shiiki H, 1998, PATHOBIOLOGY, V66, P221, DOI 10.1159/000028027; Susztak K, 2006, DIABETES, V55, P225, DOI 10.2337/diabetes.55.01.06.db05-0894; Suzuki A, 2000, CELL DEATH DIFFER, V7, P721, DOI 10.1038/sj.cdd.4400706; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; Suzuki T, 2001, FREE RADICAL BIO MED, V31, P615, DOI 10.1016/S0891-5849(01)00641-4; Truong LD, 1996, KIDNEY INT, V50, P200, DOI 10.1038/ki.1996.303; Wada T, 2005, J AM SOC NEPHROL, V16, P2615, DOI 10.1681/ASN.2005020142; White KE, 2002, DIABETES, V51, P3083, DOI 10.2337/diabetes.51.10.3083; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang DH, 1996, LAB INVEST, V74, P571	48	46	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28048	28057		10.1074/jbc.M513336200	http://dx.doi.org/10.1074/jbc.M513336200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16847066	hybrid			2022-12-25	WOS:000240534400042
J	Liu, XF; Kim, K; Leighton, T; Theil, EC				Liu, Xiaofeng; Kim, Kijeong; Leighton, Terrance; Theil, Elizabeth C.			Paired Bacillus anthracis Dps (mini-ferritin) have different reactivities with peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-CHAIN FERRITIN; DNA-BINDING PROTEIN; OXIDATIVE STRESS-RESPONSE; HYDROGEN-PEROXIDE; ESCHERICHIA-COLI; IRON STORAGE; DEINOCOCCUS-RADIODURANS; HALOBACTERIUM-SALINARUM; FERROXIDASE REACTION; CRYSTAL-STRUCTURES	Dps (DNA protection during starvation) proteins, mini-ferritins in the ferritin superfamily, catalyze Fe2+/H2O2/O-2 reactions and make minerals inside protein nanocages to minimize radical oxygen-chemistry (metal/osmotic/temperature/nutrient/oxidant) and sometimes to confer virulence. Paired Dps proteins in Bacillus, rare in other bacteria, have 60% sequence identity. To explore functional differences in paired Bacilli Dps protein, we measured ferroxidase activity and DNA protection (hydroxyl radical) for Dps protein dodecamers from Bacillus anthracis (Ba) since crystal structures and iron mineralization (iron-stain) were known. The self-assembled (200 kDa) Ba Dps1 (Dlp-1) and Ba Dps2 (Dlp-2) proteins had similar Fe2+/O-2 kinetics, with space for minerals of 500 iron atoms/protein, and protected DNA. The reactions with Fe2+ were novel in several ways: 1) Ba Dps2 reactions (Fe2+/H2O2) proceeded via an A(650) nm intermediate, with similar rates to maxi-ferritins (Fe2+/O-2), indicating a new Dps protein reaction pathway, 2) Ba Dps2 reactions (Fe2+/O-2 versus Fe2+/O-2 + H2O2) differed 3-fold contrasting with Escherichia coli Dps reactions, with 100-fold differences, and 3) Ba Dps1, inert in Fe2+/H2O2 catalysis, inhibited protein-independent Fe2+/H2O2 reactions. Sequence similarities between Ba Dps1 and Bacillus subtilis DpsA(Dps1), which is regulated by general stress factor (SigmaB) and Fur, and between Ba Dps2 and B. subtilis MrgA, which is regulated by H2O2 (PerR), suggest the function of Ba Dps1 is iron sequestration and the function of Ba Dps2 is H2O2 destruction, important in host/pathogen interactions. Destruction of H2O2 by Ba Dps2 proceeds via an unknown mechanism with an intermediate similar spectrally (A(650) nm) and kinetically to the maxi-ferritin diferric peroxo complex.	Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA; Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA; Chung Ang Univ, Coll Med, Dept Microbiol, Seoul 156756, South Korea	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; University of California System; University of California Berkeley; Chung Ang University; Chung Ang University Hospital	Liu, XF (corresponding author), Childrens Hosp, Oakland Res Inst, 5700 Martin Luther King,Jr Way, Oakland, CA 94609 USA.	etheil@chori.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK020251, R37DK020251, R01DK020251] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-20251] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; ALTUVIA S, 1994, MOL MICROBIOL, V13, P265, DOI 10.1111/j.1365-2958.1994.tb00421.x; Antelmann H, 1997, J BACTERIOL, V179, P7251, DOI 10.1128/jb.179.23.7251-7256.1997; Bou-Abdallah F, 2005, J AM CHEM SOC, V127, P3885, DOI 10.1021/ja044355k; Bou-Abdallah F, 2005, J MOL BIOL, V347, P543, DOI 10.1016/j.jmb.2005.01.007; Bou-Abdallah F, 2002, BIOCHEM J, V364, P57, DOI 10.1042/bj3640057; Boylan JA, 2003, P NATL ACAD SCI USA, V100, P11684, DOI 10.1073/pnas.2032956100; Carrondo MA, 2003, EMBO J, V22, P1959, DOI 10.1093/emboj/cdg215; Ceci P, 2004, NUCLEIC ACIDS RES, V32, P5935, DOI 10.1093/nar/gkh915; Ceci P, 2003, J BIOL CHEM, V278, P20319, DOI 10.1074/jbc.M302114200; Chasteen ND, 1999, J STRUCT BIOL, V126, P182, DOI 10.1006/jsbi.1999.4118; CHEN L, 1995, P NATL ACAD SCI USA, V92, P8190, DOI 10.1073/pnas.92.18.8190; Chiancone E, 2004, BIOMETALS, V17, P197, DOI 10.1023/B:BIOM.0000027692.24395.76; Cozzi A, 2004, BLOOD, V103, P2377, DOI 10.1182/blood-2003-06-1842; DOWDS BCA, 1994, FEMS MICROBIOL LETT, V124, P255; Fetter J, 1997, J BIOL INORG CHEM, V2, P652, DOI 10.1007/s007750050180; Gohar M, 2005, PROTEOMICS, V5, P3696, DOI 10.1002/pmic.200401225; Grant RA, 1998, NAT STRUCT BIOL, V5, P294, DOI 10.1038/nsb0498-294; Grove A, 2005, J MOL BIOL, V347, P495, DOI 10.1016/j.jmb.2005.01.055; Hintze KJ, 2005, P NATL ACAD SCI USA, V102, P15048, DOI 10.1073/pnas.0505148102; Horsburgh MJ, 2001, INFECT IMMUN, V69, P3744, DOI 10.1128/IAI.69.6.3744-3754.2001; Hwang J, 2000, SCIENCE, V287, P122, DOI 10.1126/science.287.5450.122; Ilari A, 2005, BIOCHEMISTRY-US, V44, P5579, DOI 10.1021/bi050005e; Jameson GNL, 2002, BIOCHEMISTRY-US, V41, P13435, DOI 10.1021/bi026478s; JENKINS DE, 1988, J BACTERIOL, V170, P3910, DOI 10.1128/jb.170.9.3910-3914.1988; Jin WL, 2001, BIOCHEMISTRY-US, V40, P7525, DOI 10.1021/bi002509c; JONES MM, 1967, NATURE, V216, P509, DOI 10.1038/216509a0; Katona LI, 2004, J BACTERIOL, V186, P6443, DOI 10.1128/JB.186.19.6443-6456.2004; Kauko A, 2004, J MOL BIOL, V338, P547, DOI 10.1016/j.jmb.2004.03.009; Liu XF, 2004, P NATL ACAD SCI USA, V101, P8557, DOI 10.1073/pnas.0401146101; Liu XF, 2003, P NATL ACAD SCI USA, V100, P3653, DOI 10.1073/pnas.0636928100; Liu XF, 2005, ACCOUNTS CHEM RES, V38, P167, DOI 10.1021/ar0302336; MABROUK PA, 1991, J AM CHEM SOC, V113, P4053, DOI 10.1021/ja00011a001; Martinez A, 1997, J BACTERIOL, V179, P5188, DOI 10.1128/jb.179.16.5188-5194.1997; Michan C, 1999, J BACTERIOL, V181, P2759; Minsky A, 2002, NAT REV MOL CELL BIO, V3, P50, DOI 10.1038/nrm700; Moenne-Loccoz P, 1999, BIOCHEMISTRY-US, V38, P5290, DOI 10.1021/bi990095l; Moore CM, 2005, MOL MICROBIOL, V57, P27, DOI 10.1111/j.1365-2958.2005.04642.x; Nair S, 2004, J BACTERIOL, V186, P4192, DOI 10.1128/JB.186.13.4192-4198.2004; O'Rourke EJ, 2003, P NATL ACAD SCI USA, V100, P2789, DOI 10.1073/pnas.0337641100; Olsen KN, 2005, MICROBIOL-SGM, V151, P925, DOI 10.1099/mic.0.27552-0; Papinutto E, 2002, J BIOL CHEM, V277, P15093, DOI 10.1074/jbc.M112378200; Pereira AS, 1998, BIOCHEMISTRY-US, V37, P9871, DOI 10.1021/bi980847w; Reindel S, 2002, BBA-PROTEINS PROTEOM, V1598, P140, DOI 10.1016/S0167-4838(02)00361-8; Ren B, 2003, J MOL BIOL, V329, P467, DOI 10.1016/S0022-2836(03)00466-2; Roy S, 2004, J MOL BIOL, V339, P1103, DOI 10.1016/j.jmb.2004.04.042; Stillman TJ, 2005, MOL MICROBIOL, V57, P1101, DOI 10.1111/j.1365-2958.2005.04757.x; Stillman TJ, 2003, J BIOL CHEM, V278, P26275, DOI 10.1074/jbc.M207354200; Su MH, 2005, BIOCHEMISTRY-US, V44, P5572, DOI 10.1021/bi0472705; SUN SJ, 1993, BIOCHEMISTRY-US, V32, P9362, DOI 10.1021/bi00087a015; Surguladze N, 2005, BIOCHEM J, V388, P731, DOI 10.1042/BJ20041853; Takagi H, 1998, J BIOL CHEM, V273, P18685, DOI 10.1074/jbc.273.30.18685; Theil E. C., 2001, HDB METALLOPROTEINS, P771; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; Torti FM, 2002, BLOOD, V99, P3505, DOI 10.1182/blood.V99.10.3505; TREFFRY A, 1995, BIOCHEMISTRY-US, V34, P15204, DOI 10.1021/bi00046a028; TRIKHA J, 1995, J MOL BIOL, V248, P949, DOI 10.1006/jmbi.1995.0274; WALDO GS, 1993, BIOCHEMISTRY-US, V32, P13262, DOI 10.1021/bi00211a039; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; Wiedenheft B, 2005, P NATL ACAD SCI USA, V102, P10551, DOI 10.1073/pnas.0501497102; Wolf SG, 1999, NATURE, V400, P83, DOI 10.1038/21918; Zeth K, 2004, P NATL ACAD SCI USA, V101, P13780, DOI 10.1073/pnas.0401821101; Zhao GH, 2002, J BIOL CHEM, V277, P27689, DOI 10.1074/jbc.M202094200; Zhao GH, 2006, BIOCHEMISTRY-US, V45, P3429, DOI 10.1021/bi052443r; Zhao GH, 2001, BIOCHEMISTRY-US, V40, P10832, DOI 10.1021/bi011052j	65	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27827	27835		10.1074/jbc.M601398200	http://dx.doi.org/10.1074/jbc.M601398200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16861227	hybrid			2022-12-25	WOS:000240534400018
J	Yang, JJ; Bitoun, JP; Ding, HG				Yang, Juanjuan; Bitoun, Jacob P.; Ding, Huangen			Interplay of IscA and IscU in biogenesis of iron-sulfur clusters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-S CLUSTER; CYSTEINE DESULFURASE ACTIVITY; ESCHERICHIA-COLI; ASSEMBLY PROTEIN; THIOREDOXIN REDUCTASE; CRYSTAL-STRUCTURE; AZOTOBACTER-VINELANDII; SCAFFOLD PROTEIN; 4FE-4S CLUSTERS; MARITIMA ISCU	Increasing evidence suggests that sulfur in ubiquitous iron-sulfur clusters is derived from L-cysteine via cysteine desulfurases. In Escherichia coli, the major cysteine desulfurase activity for biogenesis of iron-sulfur clusters has been attributed to IscS. The gene that encodes IscS is a member of an operon iscSUA, which also encodes two highly conserved proteins: IscU and IscA. Previous studies suggested that both IscU and IscA may act as the iron-sulfur cluster assembly scaffold proteins. However, recent evidence indicated that IscA is an iron-binding protein that can provide iron for the iron-sulfur cluster assembly in IscU ( Ding, H., Harrison, K., and Lu, J. (2005) J. Biol. Chem. 280, 30432 - 30437). To further elucidate the function of IscA in biogenesis of iron-sulfur clusters, we evaluate the iron-sulfur cluster binding activity of IscA and IscU under physiologically relevant conditions. When equal amounts of IscA and IscU are incubated with an equivalent amount of ferrous iron in the presence of IscS, L-cysteine and dithiothreitol, iron-sulfur clusters are assembled in IscU, but not in IscA, suggesting that IscU is a preferred iron-sulfur cluster assembly scaffold protein. In contrast, when equal amounts of IscA and IscU are incubated with an equivalent amount of ferrous iron in the presence of IscS and dithiothreitol but without L-cysteine, nearly all iron is bound to IscA. The iron binding in IscA appears to prevent the formation of the biologically inaccessible ferric hydroxide under aerobic conditions. Subsequent addition of L-cysteine efficiently mobilizes the iron center in IscA and transfers the iron for the iron-sulfur cluster assembly in IscU. The results suggest an intriguing interplay between IscA and IscU in which IscA acts as an iron chaperon that recruits "free" iron and delivers the iron for biogenesis of iron-sulfur clusters in IscU under aerobic conditions.	Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Ding, HG (corresponding author), Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA.	hding@lsu.edu	Ding, Huangen/AAJ-8550-2020	Ding, Huangen/0000-0002-4815-7336				Abdel-Ghany SE, 2005, PLANT PHYSIOL, V138, P161, DOI 10.1104/pp.104.058602; Adinolfi S, 2002, HUM MOL GENET, V11, P1865, DOI 10.1093/hmg/11.16.1865; Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; ARAKAWA S, 1979, BIOCHIM BIOPHYS ACTA, V580, P382, DOI 10.1016/0005-2795(79)90150-8; Bilder PW, 2004, BIOCHEMISTRY-US, V43, P133, DOI 10.1021/bi035440s; Bonomi F, 2005, J BIOL CHEM, V280, P29513, DOI 10.1074/jbc.M504344200; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; COWART RE, 1993, ANAL BIOCHEM, V211, P151, DOI 10.1006/abio.1993.1246; Crichton R R, 1990, Adv Protein Chem, V40, P281, DOI 10.1016/S0065-3233(08)60288-0; Cupp-Vickery JR, 2004, J MOL BIOL, V338, P127, DOI 10.1016/j.jmb.2004.02.027; Cupp-Vickery JR, 2003, J MOL BIOL, V330, P1049, DOI 10.1016/S0022-2836(03)00690-9; Ding BJ, 2005, BIOCHEM J, V389, P797, DOI 10.1042/BJ20050405; Ding H, 2004, J BIOL CHEM, V279, P37499, DOI 10.1074/jbc.M404533200; Ding HG, 2005, J BIOL CHEM, V280, P30432, DOI 10.1074/jbc.M504638200; Ding HG, 2004, BIOCHEM J, V379, P433, DOI 10.1042/BJ20031702; Duby G, 2002, HUM MOL GENET, V11, P2635, DOI 10.1093/hmg/11.21.2635; Flint DH, 1996, J BIOL CHEM, V271, P16068; Imlay JA, 2006, MOL MICROBIOL, V59, P1073, DOI 10.1111/j.1365-2958.2006.05028.x; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Kato S, 2002, P NATL ACAD SCI USA, V99, P5948, DOI 10.1073/pnas.082123599; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; KREDICH NM, 1996, ESCHERICHIA COLI SAL, P514; Kurihara T, 2003, BBA-PROTEINS PROTEOM, V1647, P303, DOI 10.1016/S1570-9639(03)00078-5; Li DS, 1999, FEBS LETT, V456, P13, DOI 10.1016/S0014-5793(99)00896-0; Mansy SS, 2004, J BIOL CHEM, V279, P10469, DOI 10.1074/jbc.M312051200; Mansy SS, 2002, J BIOL CHEM, V277, P21397, DOI 10.1074/jbc.M201439200; Mihara H, 2000, J BIOCHEM-TOKYO, V127, P559, DOI 10.1093/oxfordjournals.jbchem.a022641; Morimoto K, 2002, FEBS LETT, V519, P123, DOI 10.1016/S0014-5793(02)02736-9; MOURA I, 1980, J BIOL CHEM, V255, P2493; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; Mulrooney SB, 1997, PROTEIN EXPRES PURIF, V9, P372, DOI 10.1006/prep.1996.0698; Nuth M, 2002, J AM CHEM SOC, V124, P8774, DOI 10.1021/ja0264596; Ollagnier-de-Choudens S, 2004, J BIOL INORG CHEM, V9, P828, DOI 10.1007/s00775-004-0581-9; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; ONATE YA, 1993, BIOCHIM BIOPHYS ACTA, V1164, P113, DOI 10.1016/0167-4838(93)90237-L; Outten FW, 2003, J BIOL CHEM, V278, P45713, DOI 10.1074/jbc.M308004200; Park S, 2003, J BACTERIOL, V185, P1942, DOI 10.1128/JB.185.6.1942-1950.2003; Ramelot TA, 2004, J MOL BIOL, V344, P567, DOI 10.1016/j.jmb.2004.08.038; Rogers PA, 2001, J BIOL CHEM, V276, P30980, DOI 10.1074/jbc.M101037200; Rouault TA, 2005, NAT REV MOL CELL BIO, V6, P345, DOI 10.1038/nrm1620; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; Schwartz CJ, 2001, P NATL ACAD SCI USA, V98, P14895, DOI 10.1073/pnas.251550898; SIEGEL LM, 1965, ANAL BIOCHEM, V11, P126, DOI 10.1016/0003-2697(65)90051-5; Silberg JJ, 2004, J BIOL CHEM, V279, P53924, DOI 10.1074/jbc.M410117200; Smith AD, 2005, BIOCHEMISTRY-US, V44, P12955, DOI 10.1021/bi051257i; Smith AD, 2001, J AM CHEM SOC, V123, P11103, DOI 10.1021/ja016757n; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Tapley TL, 2004, J BIOL CHEM, V279, P28435, DOI 10.1074/jbc.M400803200; Tong WH, 2000, EMBO J, V19, P5692, DOI 10.1093/emboj/19.21.5692; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Veine DM, 1998, PROTEIN SCI, V7, P1441, DOI 10.1002/pro.5560070621; Wollenberg M, 2003, EUR J BIOCHEM, V270, P1662, DOI 10.1046/j.1432-1033.2003.03522.x; Wu G, 2002, J BIOL INORG CHEM, V7, P526, DOI 10.1007/s00775-001-0330-2; Wu SP, 2003, BIOCHEMISTRY-US, V42, P5784, DOI 10.1021/bi026939+; Yang WY, 2002, J BIOL CHEM, V277, P12868, DOI 10.1074/jbc.M109485200; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	57	61	66	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27956	27963		10.1074/jbc.M601356200	http://dx.doi.org/10.1074/jbc.M601356200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16877383	hybrid, Green Published			2022-12-25	WOS:000240534400032
J	Zhang, J; Smith, KM; Tackaberry, T; Sun, XJ; Carpenter, P; Slugoski, MD; Robins, MJ; Nielsen, LPC; Nowak, I; Baldwin, SA; Young, JD; Cass, CE				Zhang, Jing; Smith, Kyla M.; Tackaberry, Tracey; Sun, Xuejun; Carpenter, Pat; Slugoski, Melissa D.; Robins, Morris J.; Nielsen, Lars P. C.; Nowak, Ireneusz; Baldwin, Stephen A.; Young, James D.; Cass, Carol E.			Characterization of the transport mechanism and permeant binding profile of the uridine permease Fui1p of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EQUILIBRATIVE NUCLEOSIDE TRANSPORTER-2; IN-VIVO PHOSPHORYLATION; PLASMA-MEMBRANE ATPASE; YEAST URACIL PERMEASE; NUCLEOBASE TRANSPORTERS; RECOGNITION MOTIFS; HIGH-AFFINITY; PROTEINS; RESIDUES; SYSTEM	The uptake of Urd into the yeast Saccharomyces cerevisiae is mediated by Fui1p, a Urd-specific nucleoside transporter encoded by the FUI1 gene and a member of the yeast Fur permease family, which also includes the uracil, allantoin, and thiamine permeases. When Fui1p was produced in a double-permease knockout strain (fur4 Delta fui1 Delta) of yeast, Urd uptake was stimulated at acidic pH and sensitive to the protonophore carbonyl cyanide m-chlorophenylhydrazone. Electrophysiological analysis of recombinant Fui1p produced in Xenopus oocytes demonstrated that Fui1p- mediated Urd uptake was dependent on proton cotransport with a 1:1 stoichiometry. Mutagenesis analysis of three charged amino acids (Glu(259), Lys(288), and Asp(474) in putative transmembrane segments 3, 4, and 7, respectively) revealed that only Lys288 was required for maintaining high Urd transport efficiency. Analysis of binding energies between Fui1p and different Urd analogs indicated that Fuip1 interacted with C( 3')-OH, C(2')-OH, C(5)-H, and N(3)-H of Urd. Fui1p- mediated transport of Urd was inhibited by analogs with modifications at C-5', but was not inhibited significantly by analogs with modifications at C-3', C-5, and N-3orinversionsofconfigurationatC-2' andC-3'. This characterization of Fui1p contributes to the emerging knowledge of the structure and function of the Fur family of permeases, including the Fui1p orthologs of pathogenic fungi.	Cross Canc Inst, Dept Oncol, Edmonton, AB T6H 1Z2, Canada; Univ Alberta, Membrane Prot Res Grp, Edmonton, AB T6G 2M7, Canada; Univ Alberta, Dept Oncol, Edmonton, AB T6G 2M7, Canada; Univ Alberta, Dept Physiol, Edmonton, AB T6G 2M7, Canada; Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA; Univ Leeds, Inst Membrane & Syst Biol, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Alberta; University of Alberta; University of Alberta; University of Alberta; Brigham Young University; University of Leeds	Cass, CE (corresponding author), Cross Canc Inst, Dept Oncol, 11540 Univ Ave, Edmonton, AB T6H 1Z2, Canada.	carol.cass@cancerboard.ab.ca						ACTON EM, 1979, J MED CHEM, V22, P518, DOI 10.1021/jm00191a012; Arastu-Kapur S, 2003, J BIOL CHEM, V278, P33327, DOI 10.1074/jbc.M305141200; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; Blondel MO, 2004, MOL BIOL CELL, V15, P883, DOI 10.1091/mbc.E03-04-0202; BRUNELLI JP, 1993, YEAST, V9, P1309, DOI 10.1002/yea.320091204; CASS CE, 1999, MEMBRANE TRANSPORTER; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; de Koning HP, 2001, ACTA TROP, V80, P245, DOI 10.1016/S0001-706X(01)00177-2; De Montigny J, 1998, YEAST, V14, P1051, DOI 10.1002/(SICI)1097-0061(199808)14:11<1051::AID-YEA287>3.0.CO;2-1; Dujon B, 2004, NATURE, V430, P35, DOI 10.1038/nature02579; Eddy AA, 1998, BIOCHEM J, V336, P125, DOI 10.1042/bj3360125; Garnier C, 1996, MOL MICROBIOL, V21, P1061, DOI 10.1046/j.1365-2958.1996.621430.x; Grewer C, 2003, J BIOL CHEM, V278, P2585, DOI 10.1074/jbc.M207956200; HOPKINS P, 1988, FEMS MICROBIOL LETT, V49, P173; HUANG QQ, 1993, J BIOL CHEM, V268, P20613; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kaback HR, 1997, P NATL ACAD SCI USA, V94, P5539, DOI 10.1073/pnas.94.11.5539; Kimura K, 2003, NAT PROD REP, V20, P252, DOI 10.1039/b202149h; Landfear SM, 2004, EUKARYOT CELL, V3, P245, DOI 10.1128/EC.3.2.245-254.2004; Marchal C, 2000, J BIOL CHEM, V275, P23608, DOI 10.1074/jbc.M001735200; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; Pastor-Anglada M, 2004, LEUKEMIA, V18, P385, DOI 10.1038/sj.leu.2403271; Patil SD, 2000, CANCER CHEMOTH PHARM, V46, P394, DOI 10.1007/s002800000171; Pinson B, 1996, EUR J BIOCHEM, V239, P439, DOI 10.1111/j.1432-1033.1996.0439u.x; Pinson B, 1997, J BIOL CHEM, V272, P28918, DOI 10.1074/jbc.272.46.28918; Pinsoni B, 1999, BIOCHEM J, V339, P37, DOI 10.1042/0264-6021:3390037; Rapp RP, 2004, PHARMACOTHERAPY, V24, p4S, DOI 10.1592/phco.24.3.4S.33151; Ritzel MWL, 2001, MOL MEMBR BIOL, V18, P65, DOI 10.1080/09687680010026313; Seron K, 1999, J BACTERIOL, V181, P1793; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1984, CURR TOP CELL REGUL, V23, P87; Slugoski MD, 2004, YEAST, V21, P1269, DOI 10.1002/yea.1178; Smith KM, 2004, J PHYSIOL-LONDON, V558, P807, DOI 10.1113/jphysiol.2004.068189; Unkles SE, 2004, P NATL ACAD SCI USA, V101, P17549, DOI 10.1073/pnas.0405054101; Vernis L, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng121; Vickers MF, 2000, J BIOL CHEM, V275, P25931, DOI 10.1074/jbc.M000239200; Vickers MF, 2004, NUCLEOS NUCLEOT NUCL, V23, P361, DOI 10.1081/NCN-120028333; Vickers MF, 2002, BIOCHEM CELL BIOL, V80, P639, DOI 10.1139/O02-148; VICKERS MF, 2000, EMERGING THERAPEUTIC, V4, P515; Visser F, 2005, J BIOL CHEM, V280, P11025, DOI 10.1074/jbc.M410348200; Visser F, 2005, MOL PHARMACOL, V67, P1291, DOI 10.1124/mol.104.005884; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; VOLLAND C, 1992, J BIOL CHEM, V267, P23767; Wagner R, 1998, FEMS MICROBIOL LETT, V159, P69, DOI 10.1111/j.1574-6968.1998.tb12843.x; Wallace LJM, 2002, J BIOL CHEM, V277, P26149, DOI 10.1074/jbc.M202835200; Xiao GQ, 2001, MOL PHARMACOL, V59, P339, DOI 10.1124/mol.59.2.339; Zhang J, 2005, MOL PHARMACOL, V68, P830, DOI 10.1124/mol.105.012187; Zhang J, 2003, MOL PHARMACOL, V64, P1512, DOI 10.1124/mol.64.6.1512	49	10	10	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28210	28221		10.1074/jbc.M605129200	http://dx.doi.org/10.1074/jbc.M605129200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16854981	hybrid			2022-12-25	WOS:000240534400059
J	Brouns, SJJ; Walther, J; Snijders, APL; de Werken, HJGV; Willemen, HLDM; Worm, P; de Vos, MGJ; Andersson, A; Lundgren, M; Mazon, HFM; van den Heuvel, RHH; Nilsson, P; Salmon, L; de Vos, WM; Wright, PC; Bernander, R; van der Oost, J				Brouns, Stan J. J.; Walther, Jasper; Snijders, Ambrosius P. L.; de Werken, Harmen J. G. van; Willemen, Hanneke L. D. M.; Worm, Petra; de Vos, Marjon G. J.; Andersson, Anders; Lundgren, Magnus; Mazon, Hortense F. M.; van den Heuvel, Robert H. H.; Nilsson, Peter; Salmon, Laurent; de Vos, Willem M.; Wright, Phillip C.; Bernander, Rolf; van der Oost, John			Identification of the missing links in prokaryotic pentose oxidation pathways - Evidence for enzyme recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARABINOSE METABOLISM; ARCHAEON SULFOLOBUS-SOLFATARICUS; ENTNER-DOUDOROFF PATHWAY; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; THERMOACIDOPHILIC CRENARCHAEON; FUMARYLACETOACETATE HYDROLASE; PSEUDOMONAS-SACCHAROPHILA; GLUTAMATE-DEHYDROGENASE; CAULOBACTER-CRESCENTUS	The pentose metabolism of Archaea is largely unknown. Here, we have employed an integrated genomics approach including DNA microarray and proteomics analyses to elucidate the catabolic pathway for D-arabinose in Sulfolobus solfataricus. During growth on this sugar, a small set of genes appeared to be differentially expressed compared with growth on D-glucose. These genes were heterologously overexpressed in Escherichia coli, and the recombinant proteins were purified and biochemically studied. This showed that D-arabinose is oxidized to 2-oxoglutarate by the consecutive action of a number of previously uncharacterized enzymes, including a D-arabinose dehydrogenase, a D-arabinonate dehydratase, a novel 2-keto-3-deoxy-D-arabinonate dehydratase, and a 2,5-dioxopentanoate dehydrogenase. Promoter analysis of these genes revealed a palindromic sequence upstream of the TATA box, which is likely to be involved in their concerted transcriptional control. Integration of the obtained biochemical data with genomic context analysis strongly suggests the occurrence of pentose oxidation pathways in both Archaea and Bacteria, and predicts the involvement of additional enzyme components. Moreover, it revealed striking genetic similarities between the catabolic pathways for pentoses, hexaric acids, and hydroxyproline degradation, which support the theory of metabolic pathway genesis by enzyme recruitment.	Wageningen Univ, Microbiol Lab, Dept Agrotechnol & Food Sci, NL-6703 CT Wageningen, Netherlands; Univ Sheffield, Biol & Environm Syst Grp, Dept Chem & Proc Engn, Sheffield S1 3JD, S Yorkshire, England; Royal Inst Technol, Dept Biotechnol, SE-10691 Stockholm, Sweden; Uppsala Univ, Dept Mol Evolut, Evolutionary Biol Ctr, SE-75236 Uppsala, Sweden; Univ Utrecht, Dept Biomol Mass Spectrometry, Bijvoet Ctr Biomol Res, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Utrecht Inst Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands; Univ Paris 11, Lab Chim Bioorgan & Bioinorgan, CNRS,UMR 8142, ICMMO, F-91405 Orsay, France	Wageningen University & Research; University of Sheffield; Royal Institute of Technology; Uppsala University; Utrecht University; Utrecht University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Brouns, SJJ (corresponding author), Wageningen Univ, Microbiol Lab, Dept Agrotechnol & Food Sci, Hesselink Van Suchtelenweg 4, NL-6703 CT Wageningen, Netherlands.	stan.brouns@wur.nl	Andersson, Anders/J-9310-2019; Salmon, Laurent/T-5179-2018; van+der+Oost, John/Y-2548-2019; Nilsson, Peter/E-4547-2010; Werken, Harmen van de/G-8979-2013	Andersson, Anders/0000-0002-3627-6899; Salmon, Laurent/0000-0003-1946-8458; Nilsson, Peter/0000-0002-4657-8532; Werken, Harmen van de/0000-0002-9794-1477; de Vos, Marjon GJ/0000-0003-0601-908X; Snijders, Bram/0000-0002-5416-8592; Brouns, Stan/0000-0002-9573-1724; Wright, Phillip/0000-0002-8834-0426; Venkatasubramanian, Siddharth/0000-0002-5860-0768				Albers SV, 2006, APPL ENVIRON MICROB, V72, P102, DOI 10.1128/AEM.72.1.102-111.2006; Andersson A, 2005, BIOINFORMATICS, V21, P325, DOI 10.1093/bioinformatics/bti001; BABBITT PC, 1995, SCIENCE, V267, P1159, DOI 10.1126/science.7855594; BARTOLUCCI S, 1987, J BIOL CHEM, V262, P7725; Bateman RL, 2001, J BIOL CHEM, V276, P15284, DOI 10.1074/jbc.M007621200; Brouns SJJ, 2006, J BACTERIOL, V188, P2392, DOI 10.1128/JB.188.7.2392-2399.2006; Chen LM, 2005, J BACTERIOL, V187, P4992, DOI 10.1128/JB.187.14.4992-4999.2005; CHIANG C, 1960, NATURE, V188, P79, DOI 10.1038/188079a0; CLINE AL, 1965, J BIOL CHEM, V240, P4493; CONSALVI V, 1991, EUR J BIOCHEM, V196, P459, DOI 10.1111/j.1432-1033.1991.tb15837.x; Crestia D, 2001, J MOL CATAL B-ENZYM, V11, P207, DOI 10.1016/S1381-1177(00)00074-6; DAGLEY S, 1965, BIOCHEM J, V95, P48, DOI 10.1042/bj0950048; DAHMS AS, 1969, BIOCHEM BIOPH RES CO, V36, P809, DOI 10.1016/0006-291X(69)90681-0; Deshpande AD, 2004, CURR SCI INDIA, V87, P1684; DUNCAN MJ, 1979, J GEN MICROBIOL, V113, P177, DOI 10.1099/00221287-113-1-177; DUNCAN MJ, 1979, J BACTERIOL, V137, P415, DOI 10.1128/JB.137.1.415-419.1979; EGAN SE, 1992, J BACTERIOL, V174, P4638, DOI 10.1128/JB.174.14.4638-4646.1992; Elferink MGL, 2001, MOL MICROBIOL, V39, P1494, DOI 10.1046/j.1365-2958.2001.02336.x; ELSINGHORST EA, 1994, J BACTERIOL, V176, P7223, DOI 10.1128/JB.176.23.7223-7232.1994; Esposito L, 2003, BIOCHEMISTRY-US, V42, P14397, DOI 10.1021/bi035271b; FOSSITT D, 1964, J BIOL CHEM, V239, P2110; Gleissner M, 1997, J BIOL CHEM, V272, P8417, DOI 10.1074/jbc.272.13.8417; GROGAN DW, 1989, J BACTERIOL, V171, P6710, DOI 10.1128/jb.171.12.6710-6719.1989; HESS D, 1995, EUR J BIOCHEM, V233, P227, DOI 10.1111/j.1432-1033.1995.227_1.x; Hosoya S, 2002, FEMS MICROBIOL LETT, V210, P193, DOI 10.1111/j.1574-6968.2002.tb11180.x; Hottes AK, 2004, J BACTERIOL, V186, P1448, DOI 10.1128/JB.186.5.1448-1461.2004; IMANAKA T, 1993, J FERMENT BIOENG, V76, P161, DOI 10.1016/0922-338X(93)90001-O; JEFFCOAT R, 1969, BIOCHEM J, V115, P977, DOI 10.1042/bj1150977; JENSEN RA, 1976, ANNU REV MICROBIOL, V30, P409, DOI 10.1146/annurev.mi.30.100176.002205; Johnsen U, 2004, J BACTERIOL, V186, P6198, DOI 10.1128/JB.186.18.6198-6207.2004; Kappler U, 2005, MICROBIOL-SGM, V151, P35, DOI 10.1099/mic.0.27515-0; Kawarabayasi Y, 2001, DNA RES, V8, P123, DOI 10.1093/dnares/8.4.123; Kim S, 2006, J BIOCHEM, V139, P591, DOI 10.1093/jb/mvj057; Kim SH, 2005, BIOCHEM J, V387, P271, DOI 10.1042/BJ20041053; Komorowski L, 2002, BIOL CHEM, V383, P1791, DOI 10.1515/BC.2002.200; KRAUS GA, 1984, SYNTHESIS-STUTTGART, P885; Lebbink JHG, 1995, PROTEIN ENG, V8, P1287, DOI 10.1093/protein/8.12.1287; LEE N, 1986, GENE, V47, P231, DOI 10.1016/0378-1119(86)90067-3; Londei P, 2005, FEMS MICROBIOL REV, V29, P185, DOI 10.1016/j.femsre.2004.10.002; LUBELSKA JM, 2006, IN PRESS EXTREMOPHIL; Lundgren M, 2005, CURR OPIN MICROBIOL, V8, P662, DOI 10.1016/j.mib.2005.10.008; Lundgren M, 2004, P NATL ACAD SCI USA, V101, P7046, DOI 10.1073/pnas.0400656101; Macritchie JA, 1997, TETRAHEDRON-ASYMMETR, V8, P3895, DOI 10.1016/S0957-4166(97)00571-5; MATHIAS AL, 1989, J BACTERIOL, V171, P5206, DOI 10.1128/jb.171.9.5206-5209.1989; Meisenzahl AC, 1997, J BACTERIOL, V179, P592, DOI 10.1128/jb.179.3.592-600.1997; Mobley P W, 1975, Methods Enzymol, V41, P173; Moore RA, 2004, INFECT IMMUN, V72, P4172, DOI 10.1128/IAI.72.7.4172-4187.2004; NOVICK NJ, 1982, J BACTERIOL, V149, P364, DOI 10.1128/JB.149.1.364-367.1982; Osterman A, 2003, CURR OPIN CHEM BIOL, V7, P238, DOI 10.1016/S1367-5931(03)00027-9; PALLERONI NJ, 1956, J BIOL CHEM, V223, P499; PALLERONI NJ, 1957, J BACTERIOL, V74, P180, DOI 10.1128/JB.74.2.180-185.1957; PEDROSA FO, 1974, J BACTERIOL, V119, P336, DOI 10.1128/JB.119.1.336-338.1974; PORTSMOUTH D, 1967, J BIOL CHEM, V242, P2751; RAMASWAMY SG, 1984, J BIOL CHEM, V259, P249; ROSENFELD SA, 1984, MOL GEN GENET, V194, P410, DOI 10.1007/BF00425552; Schmidt A, 2001, ANAL CHEM, V73, P6040, DOI 10.1021/ac010451h; Schmidt S, 2003, TRENDS BIOCHEM SCI, V28, P336, DOI 10.1016/S0968-0004(03)00114-2; SHARMA BS, 1973, J BACTERIOL, V116, P1346, DOI 10.1128/JB.116.3.1346-1354.1973; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Siebers B, 2005, CURR OPIN MICROBIOL, V8, P695, DOI 10.1016/j.mib.2005.10.014; SINGH RMM, 1965, J BIOL CHEM, V240, P4344; Snijders APL, 2006, PROTEOMICS, V6, P1518, DOI 10.1002/pmic.200402070; Snijders APL, 2005, ELECTROPHORESIS, V26, P3191, DOI 10.1002/elps.200500218; Snijders APL, 2005, J PROTEOME RES, V4, P578, DOI 10.1021/pr0497733; SPERBER N, 1947, J AM CHEM SOC, V69, P915, DOI 10.1021/ja01196a053; StLouis M, 1997, HUM MUTAT, V9, P291, DOI 10.1002/(SICI)1098-1004(1997)9:4<291::AID-HUMU1>3.0.CO;2-9; Tahallah N, 2001, RAPID COMMUN MASS SP, V15, P596, DOI 10.1002/rcm.275; Tame JRH, 2002, BIOCHEMISTRY-US, V41, P2982, DOI 10.1021/bi015717t; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Thompson W, 2003, NUCLEIC ACIDS RES, V31, P3580, DOI 10.1093/nar/gkg608; Uhrigshardt H, 2002, FEBS LETT, V513, P223, DOI 10.1016/S0014-5793(02)02317-7; WARREN L, 1960, NATURE, V186, P237, DOI 10.1038/186237a0; Watanabe S, 2006, J BIOL CHEM, V281, P2612, DOI 10.1074/jbc.M506477200; WEIMBERG R, 1961, J BIOL CHEM, V236, P629; WEIMBERG R, 1955, J BIOL CHEM, V217, P607; WOJTKIEWICZ B, 1988, EUR J BIOCHEM, V172, P197, DOI 10.1111/j.1432-1033.1988.tb13873.x; YONEYA T, 1961, J BIOL CHEM, V236, P3272	77	88	93	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27378	27388		10.1074/jbc.M605549200	http://dx.doi.org/10.1074/jbc.M605549200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16849334	hybrid			2022-12-25	WOS:000240397700064
J	Cheng, VWT; Ma, E; Zhao, Z; Rothery, RA; Weiner, JH				Cheng, Victor W. T.; Ma, Elysia; Zhao, Zhongwei; Rothery, Richard A.; Weiner, Joel H.			The iron-sulfur clusters in Escherichia coli succinate dehydrogenase direct electron flow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTOCOCCUS-AEROGENES FERREDOXIN; FUMARATE REDUCTASE; REDOX POTENTIALS; DIMETHYLSULFOXIDE REDUCTASE; UBIQUINONE OXIDOREDUCTASE; CATALYTIC-ACTIVITY; PROTEIN CONTROL; 4FE-4S CLUSTER; HYDROGEN-BONDS; SITE	Succinate dehydrogenase is an indispensable enzyme involved in the Krebs cycle as well as energy coupling in the mitochondria and certain prokaryotes. During catalysis, succinate oxidation is coupled to ubiquinone reduction by an electron transfer relay comprising a flavin adenine dinucleotide cofactor, three iron-sulfur clusters, and possibly a heme b(556). At the heart of the electron transport chain is a [4Fe-4S] cluster with a low midpoint potential that acts as an energy barrier against electron transfer. Hydrophobic residues around the [4Fe-4S] cluster were mutated to determine their effects on the midpoint potential of the cluster as well as electron transfer rates. SdhB-I150E and SdhB-I150H mutants lowered the midpoint potential of this cluster; surprisingly, the His variant had a lower midpoint potential than the Glu mutant. Mutation of SdhB-Leu-220 to Ser did not alter the redox behavior of the cluster but instead lowered the midpoint potential of the [3Fe-4S] cluster. To correlate the midpoint potential changes in these mutants to enzyme function, we monitored aerobic growth in succinate minimal medium, anaerobic growth in glycerol-fumarate minimal medium, non-physiological and physiological enzyme activities, and heme reduction. It was discovered that a decrease in midpoint potential of either the [4Fe-4S] cluster or the [3Fe-4S] cluster is accompanied by a decrease in the rate of enzyme turnover. We hypothesize that this occurs because the midpoint potentials of the [Fe-S] clusters in the native enzyme are poised such that direction of electron transfer from succinate to ubiquinone is favored.	Univ Alberta, Dept Biochem, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada	University of Alberta	Weiner, JH (corresponding author), Univ Alberta, Dept Biochem, Membrane Prot Res Grp, 473 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	joel.weiner@ualberta.ca		Rothery, Richard/0000-0003-3265-1783; Zhao, Zhongwei/0000-0003-4081-7077				ADMAN E, 1975, P NATL ACAD SCI USA, V72, P4854, DOI 10.1073/pnas.72.12.4854; AGARWAL A, 1995, P NATL ACAD SCI USA, V92, P9440, DOI 10.1073/pnas.92.21.9440; Alric J, 2006, J AM CHEM SOC, V128, P4136, DOI 10.1021/ja058131t; Bertero MG, 2003, NAT STRUCT BIOL, V10, P681, DOI 10.1038/nsb969; CAMMACK R, 1986, BIOCHIM BIOPHYS ACTA, V870, P545, DOI 10.1016/0167-4838(86)90264-5; Cecchini G, 2003, FEBS LETT, V545, P31, DOI 10.1016/S0014-5793(03)00390-9; Cecchini G, 2002, BBA-BIOENERGETICS, V1553, P140, DOI 10.1016/S0005-2728(01)00238-9; Chen KS, 2002, NAT STRUCT BIOL, V9, P188, DOI 10.1038/nsb751; Cheng VWT, 2005, BIOCHEMISTRY-US, V44, P8068, DOI 10.1021/bi050362p; CONDON C, 1985, J BIOL CHEM, V260, P9427; Denke E, 1998, J BIOL CHEM, V273, P9085, DOI 10.1074/jbc.273.15.9085; GRAY KA, 1992, BIOCHEMISTRY-US, V31, P11864, DOI 10.1021/bi00162a027; Guigliarelli B, 1996, BIOCHEMISTRY-US, V35, P4828, DOI 10.1021/bi952459p; Guo J, 2003, J BIOL CHEM, V278, P47629, DOI 10.1074/jbc.M306312200; Hudson JM, 2005, J AM CHEM SOC, V127, P6977, DOI 10.1021/ja043404q; Jang SB, 2000, BIOCHEMISTRY-US, V39, P641, DOI 10.1021/bi991694v; JENSEN GM, 1994, BIOCHEMISTRY-US, V33, P10911, DOI 10.1021/bi00202a010; Jeuken LJC, 2002, J AM CHEM SOC, V124, P5702, DOI 10.1021/ja012638w; KITA K, 1989, J BIOL CHEM, V264, P2672; KOWAL AT, 1995, BIOCHEMISTRY-US, V34, P12284, DOI 10.1021/bi00038a024; LANGEN R, 1992, J BIOL CHEM, V267, P25625; Leggate EJ, 2005, BIOCHEMISTRY-US, V44, P7048, DOI 10.1021/bi050189x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maklashina E, 1998, J BACTERIOL, V180, P5989, DOI 10.1128/JB.180.22.5989-5996.1998; MAKLASHINA E, 2006, J BIOL CHEM; MANODORI A, 1992, BIOCHEMISTRY-US, V31, P2703, DOI 10.1021/bi00125a010; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Messner KR, 2002, METHOD ENZYMOL, V349, P354, DOI 10.1016/S0076-6879(02)49351-2; Messner KR, 2002, J BIOL CHEM, V277, P42563, DOI 10.1074/jbc.M204958200; NICHOLLS DG, 2002, BIOENERGETICS, V3, P89; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; RAYMENT I, 1992, J MOL BIOL, V228, P672, DOI 10.1016/0022-2836(92)90849-F; Rothery RA, 2005, FEBS J, V272, P313, DOI 10.1111/j.1742-4658.2004.04469.x; ROTHERY RA, 1991, BIOCHEMISTRY-US, V30, P8296, DOI 10.1021/bi00098a003; Rothery RA, 1998, BIOCHEM J, V332, P35, DOI 10.1042/bj3320035; SAMBASIVARAO D, 1991, J BACTERIOL, V173, P5935, DOI 10.1128/jb.173.19.5935-5943.1991; Sambrook J, 2001, MOL CLONING LAB MANU; Singer T P, 1980, Methods Enzymol, V66, P253; Stephens PJ, 1996, CHEM REV, V96, P2491, DOI 10.1021/cr950045w; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605	41	39	39	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27662	27668		10.1074/jbc.M604900200	http://dx.doi.org/10.1074/jbc.M604900200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16864590	hybrid			2022-12-25	WOS:000240397700091
J	Wang, SZ; Chen, Y; Sun, ZH; Zhou, Q; Sui, SF				Wang, Shi-Zhen; Chen, Yong; Sun, Zhan-Hua; Zhou, Qiang; Sui, Sen-Fang			Escherichia coli CorA periplasmic domain functions as a homotetramer to bind substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNESIUM TRANSPORT-SYSTEMS; SALMONELLA-TYPHIMURIUM; MG2+ TRANSPORTER; CONSERVED RESIDUES; PROTEIN; CRYSTALLIZATION; CLONING; MGTB; MUTAGENESIS; TOPOLOGY	CorA is a primary Mg2+ transporter in bacteria, which also mediates influx of Ni2+ and Co2+. Topological studies suggested that it could be divided into a large soluble periplasmic domain (PPD) and three membrane-spanning alpha-helixes. In the present study, glutathione S-transferase (GST) fusion Escherichia coli CorA PPD was purified by GST affinity chromatography, and PPD was obtained by on-column thrombin digestion. Size-exclusion chromatography indicated that purified PPD exists as a homotetramer. Single particle electron microscopy analysis of PPD and two-dimensional crystals of GST-PPD indicated that E. coli CorA PPD is a pyramid-like homotetramer with a central cavity. Comparison of the CD spectra of full-length CorA and PPD also suggested that PPD has similar secondary structure to the full- length CorA. Dissociation constants for CorA and PPD with their substrates, determined by dose-dependent fluorescence quench of ligands, suggested that purified PPD retains its substrate binding ability as native CorA. The CorA PPD structure described here may provide structural information for the E. coli CorA functional oligomeric state.	Tsinghua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembranes & Membrane Biotechnol, Beijing 100084, Peoples R China	Tsinghua University	Sui, SF (corresponding author), Tsinghua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembranes & Membrane Biotechnol, Beijing 100084, Peoples R China.	suisf@mail.tsinghua.edu.cn	chen, Yong/F-3938-2010; Wang, Shizhen/N-6577-2017; Chen, Yong/AAF-9915-2020	Wang, Shizhen/0000-0003-1065-4756; Chen, Yong/0000-0001-5857-6086				Chen Y, 2003, PROTEIN EXPRES PURIF, V32, P221, DOI 10.1016/S1046-5928(03)00233-X; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Daley DO, 2005, SCIENCE, V308, P1321, DOI 10.1126/science.1109730; Gardner RC, 2003, CURR OPIN PLANT BIOL, V6, P263, DOI 10.1016/S1369-5266(03)00032-3; GRUBBS RD, 1987, MAGNESIUM, V6, P113; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Hartwig A, 2001, MUTAT RES-FUND MOL M, V475, P113, DOI 10.1016/S0027-5107(01)00074-4; HMIEL SP, 1986, J BACTERIOL, V168, P1444, DOI 10.1128/jb.168.3.1444-1450.1986; Kehres D G, 1998, Microb Comp Genomics, V3, P151, DOI 10.1089/omi.1.1998.3.151; Kucharski LM, 2000, J BIOL CHEM, V275, P16767, DOI 10.1074/jbc.M001507200; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Lunin VV, 2006, NATURE, V440, P833, DOI 10.1038/nature04642; MAGUIRE ME, 1992, J BIOENERG BIOMEMBR, V24, P319; Moncrief MBC, 1998, INFECT IMMUN, V66, P3802, DOI 10.1128/IAI.66.8.3802-3809.1998; NELSON DL, 1971, J BIOL CHEM, V246, P3042; Payandeh J, 2006, ACTA CRYSTALLOGR F, V62, P148, DOI 10.1107/S1744309106000996; ROMANI A, 1993, MINER ELECTROL METAB, V19, P282; Romani AMP, 2000, FRONT BIOSCI, V5, pD720, DOI 10.2741/Romani; ROOF SK, 1994, J AM COLL NUTR, V13, P424; Saris NEL, 2000, CLIN CHIM ACTA, V294, P1, DOI 10.1016/S0009-8981(99)00258-2; SMITH DL, 1993, MINER ELECTROL METAB, V19, P266; SMITH RL, 1993, J BIOL CHEM, V268, P14071; Smith RL, 1998, J BIOL CHEM, V273, P28663, DOI 10.1074/jbc.273.44.28663; Smith RL, 1998, MOL MICROBIOL, V28, P217, DOI 10.1046/j.1365-2958.1998.00810.x; SMITH RL, 1995, J BACTERIOL, V177, P1638, DOI 10.1128/jb.177.6.1638-1640.1995; SMITH RL, 1995, J BACTERIOL, V177, P1233, DOI 10.1128/jb.177.5.1233-1238.1995; Smyth DR, 2003, PROTEIN SCI, V12, P1313, DOI 10.1110/ps.0243403; SNAVELY MD, 1989, J BACTERIOL, V171, P4761, DOI 10.1128/jb.171.9.4761-4766.1989; Szegedy MA, 1999, J BIOL CHEM, V274, P36973, DOI 10.1074/jbc.274.52.36973; TAO T, 1995, J BACTERIOL, V177, P2654, DOI 10.1128/jb.177.10.2654-2662.1995; TOWNSEND DE, 1995, J BACTERIOL, V177, P5350, DOI 10.1128/jb.177.18.5350-5354.1995; UZGIRIS EE, 1983, NATURE, V301, P125, DOI 10.1038/301125a0; VALPUESTA JM, 1994, J MOL BIOL, V240, P281, DOI 10.1006/jmbi.1994.1445; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; WALKER GM, 1986, MAGNESIUM, V5, P9; Walmsley AR, 2000, PRACT APPROACH SER, P167; Wang HW, 2001, J STRUCT BIOL, V134, P46, DOI 10.1006/jsbi.2001.4364; Wang HW, 1999, J STRUCT BIOL, V127, P283, DOI 10.1006/jsbi.1999.4161; Warren MA, 2004, J BACTERIOL, V186, P4605, DOI 10.1128/JB.186.14.4605-4612.2004; WHITE RE, 1989, BIOCHEM PHARMACOL, V38, P859, DOI 10.1016/0006-2952(89)90272-4	40	11	12	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26813	26820		10.1074/jbc.M602342200	http://dx.doi.org/10.1074/jbc.M602342200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16835234	hybrid			2022-12-25	WOS:000240397700008
J	Head, BP; Patel, HH; Roth, DM; Murray, F; Swaney, JS; Niesman, IR; Farquhar, MG; Insel, PA				Head, Brian P.; Patel, Hemal H.; Roth, David M.; Murray, Fiona; Swaney, James S.; Niesman, Ingrid R.; Farquhar, Marilyn G.; Insel, Paul A.			Microtubules and actin microfilaments regulate lipid raft/caveolae localization of adenylyl cyclase signaling components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; GTPASE-ACTIVATING PROTEIN; CYCLIC-AMP ACCUMULATION; SMOOTH-MUSCLE CELLS; S49 LYMPHOMA-CELLS; PLASMA-MEMBRANE; FOCAL ADHESIONS; PHOSPHORYLATED CAVEOLIN; CYTOSKELETAL ROLE; CARDIAC MYOCYTES	Microtubules and actin filaments regulate plasma membrane topography, but their role in compartmentation of caveolae-resident signaling components, in particular G protein-coupled receptors (GPCR) and their stimulation of cAMP production, has not been defined. We hypothesized that the microtubular and actin cytoskeletons influence the expression and function of lipid rafts/caveolae, thereby regulating the distribution of GPCR signaling components that promote cAMP formation. Depolymerization of microtubules with colchicine (Colch) or actin microfilaments with cytochalasin D (CD) dramatically reduced the amount of caveolin-3 in buoyant (sucrose density) fractions of adult rat cardiac myocytes. Colch or CD treatment led to the exclusion of caveolin-1, caveolin-2, beta 1-adrenergic receptors (beta(1)-AR), beta(2)-AR, G alpha(s), and adenylyl cyclase (AC)(5/6) from buoyant fractions, decreasing AC(5/6) and tyrosine-phosphorylated caveolin-1 in caveolin-1 immunoprecipitates but in parallel increased isoproterenol (beta-AR agonist)-stimulated cAMP production. Incubation with Colch decreased co-localization (by immunofluorescence microscopy) of caveolin-3 and alpha-tubulin; both Colch and CD decreased co-localization of caveolin-3 and filamin (an F-actin cross-linking protein), decreased phosphorylation of caveolin-1, Src, and p38 MAPK, and reduced the number of caveolae/mu m of sarcolemma (determined by electron microscopy). Treatment of S49 T-lymphoma cells (which possess lipid rafts but lack caveolae) with CD or Colch redistributed a lipid raft marker (linker for activation of T cells (LAT)) and G alpha s from lipid raft domains. We conclude that microtubules and actin filaments restrict cAMP formation by regulating the localization and interaction of GPCR-Gs-AC in lipid rafts/caveolae.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Vet Affairs San Diego Healthcare Syst, San Diego, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Insel, PA (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr,BSB 3076, La Jolla, CA 92093 USA.	pinsel@ucsd.edu	; Patel, Hemal/C-7325-2019	Niesman, Ingrid/0000-0001-9767-6629; Patel, Hemal/0000-0001-6722-9625	NHLBI NIH HHS [HL66941] Funding Source: Medline; NIGMS NIH HHS [GM66232] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066941] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066232] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Birukova AA, 2005, J CELL PHYSIOL, V204, P934, DOI 10.1002/jcp.20359; Cao HM, 2004, EXP CELL RES, V294, P159, DOI 10.1016/j.yexcr.2003.11.010; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; Capozza F, 2005, AM J PHYSIOL-CELL PH, V288, pC677, DOI 10.1152/ajpcell.00232.2004; Caselli A, 2001, J BIOL CHEM, V276, P18849, DOI 10.1074/jbc.M100705200; CHALDAKOV GN, 1989, CELL TISSUE RES, V255, P435; Chang L, 2004, NAT REV MOL CELL BIO, V5, P601, DOI 10.1038/nrm1438; De Vries L, 1998, MOL BIOL CELL, V9, P1123, DOI 10.1091/mbc.9.5.1123; del Pozo MA, 2005, NAT CELL BIOL, V7, P901, DOI 10.1038/ncb1293; Deng LH, 2005, J APPL PHYSIOL, V99, P634, DOI 10.1152/japplphysiol.00025.2005; Donati RJ, 2005, NEUROPSYCHOPHARMACOL, V30, P1238, DOI 10.1038/sj.npp.1300697; FOX JEB, 1993, J BIOL CHEM, V268, P25973; GALLI A, 1994, BIOPHYS J, V67, P2296, DOI 10.1016/S0006-3495(94)80715-5; GOLDMAN RD, 1971, J CELL BIOL, V51, P752, DOI 10.1083/jcb.51.3.752; GOTO Y, 1990, J SUBMICR CYTOL PATH, V22, P535; Gundersen GG, 2002, NAT REV MOL CELL BIO, V3, P296, DOI 10.1038/nrm777; Halayko AJ, 2005, CAN J PHYSIOL PHARM, V83, P877, DOI 10.1139/Y05-107; Head BP, 2005, J BIOL CHEM, V280, P31036, DOI 10.1074/jbc.M502540200; Howarth FC, 1999, J PHYSIOL-LONDON, V516, P409, DOI 10.1111/j.1469-7793.1999.0409v.x; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; INSEL PA, 1978, NATURE, V273, P471, DOI 10.1038/273471a0; Isshiki M, 2003, TRAFFIC, V4, P717, DOI 10.1034/j.1600-0854.2003.00130.x; JASPER JR, 1995, J PHARMACOL EXP THER, V274, P937; KENNEDY MS, 1979, MOL PHARMACOL, V16, P215; KOLODNEY MS, 1995, P NATL ACAD SCI USA, V92, P10252, DOI 10.1073/pnas.92.22.10252; Kuppuswamy D, 1997, J BIOL CHEM, V272, P4500, DOI 10.1074/jbc.272.7.4500; Lee H, 2006, BIOCHEMISTRY-US, V45, P234, DOI 10.1021/bi051560j; Lee H, 2002, J BIOL CHEM, V277, P34556, DOI 10.1074/jbc.M204367200; LEIBER D, 1993, J BIOL CHEM, V268, P3833; Mons S, 2000, BBA-BIOMEMBRANES, V1468, P381, DOI 10.1016/S0005-2736(00)00279-0; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; NAITO M, 1989, ARTERY, V17, P21; Ostrom RS, 2002, MOL PHARMACOL, V62, P983, DOI 10.1124/mol.62.5.983; PALADE GE, 1953, J APPL PHYS, V24, P1424; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; RASENICK MM, 1981, NATURE, V294, P560, DOI 10.1038/294560a0; Ratajczak P, 2003, CARDIOVASC RES, V57, P358, DOI 10.1016/S0008-6363(02)00660-0; Revenu C, 2004, NAT REV MOL CELL BIO, V5, P635, DOI 10.1038/nrm1437; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Steinberg SF, 2001, ANNU REV PHARMACOL, V41, P751, DOI 10.1146/annurev.pharmtox.41.1.751; Swaney JS, 2006, J BIOL CHEM, V281, P17173, DOI 10.1074/jbc.M513097200; Tagawa H, 1998, CIRC RES, V82, P751, DOI 10.1161/01.RES.82.7.751; Thomas S, 2004, MOL IMMUNOL, V41, P399, DOI 10.1016/j.molimm.2004.03.022; Thomsen P, 2002, MOL BIOL CELL, V13, P238, DOI 10.1091/mbc.01-06-0317; TSUTSUI H, 1993, SCIENCE, V260, P682, DOI 10.1126/science.8097594; van der Heyden MAG, 2005, CARDIOVASC RES, V65, P28, DOI 10.1016/j.cardiores.2004.09.028; vanDeurs B, 1996, J CELL SCI, V109, P1655; Volonte D, 2003, MOL BIOL CELL, V14, P4075, DOI 10.1091/mbc.E03-03-0161; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Webster DR, 2000, AM J PHYSIOL-HEART C, V278, pH1653, DOI 10.1152/ajpheart.2000.278.5.H1653; Zile MR, 2001, J AM COLL CARDIOL, V37, P1080, DOI 10.1016/S0735-1097(00)01207-9; Zinchuk O, 2004, CELL TISSUE RES, V317, P265, DOI 10.1007/s00441-004-0919-1; ZOR U, 1983, ENDOCR REV, V4, P1	57	221	225	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26391	26399		10.1074/jbc.M602577200	http://dx.doi.org/10.1074/jbc.M602577200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16818493	hybrid, Green Submitted			2022-12-25	WOS:000240249500056
J	Morrison, CJ; Overall, CM				Morrison, Charlotte J.; Overall, Christopher M.			TIMP independence of matrix metalloproteinase (MMP)-2 activation by membrane type 2 (MT2)-MMP is determined by contributions of both the MT2-MMP catalytic and hemopexin C domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GELATINASE-A; II-LIKE MODULES; CELL-SURFACE; TISSUE INHIBITOR; 1-MATRIX METALLOPROTEINASE; EXTRACELLULAR-MATRIX; BINDING-PROPERTIES; EFFICIENT ACTIVATION; ENDOTHELIAL-CELLS; COLLAGEN-BINDING	The important and distinct contribution that membrane type 2 (MT2)-matrix metalloproteinase (MMP) makes to physiological and pathological processes is now being recognized. This contribution may be mediated in part through MMP-2 activation by MT2-MMP. Using Timp2(-/-) cells, we previously demonstrated that MT2-MMP activates MMP-2 to the fully active form in a pathway that is TIMP-2-independent but MMP-2 hemopexin carboxyl (C) domain-dependent. In this study cells expressing MT2-MMP as well as chimera proteins in which the C-terminal half of MT2-MMP and MT1-MMP were exchanged showed that the MT2-MMP catalytic domain has a higher propensity than that of MT1-MMP to initiate cleavage of the MMP-2 prodomain in the absence of TIMP-2. Although we demonstrate that MT2-MMP is a weak collagenase, this first activation cleavage was enhanced by growing the cells in type I collagen gels. The second activation cleavage to generate fully active MMP-2 was specifically enhanced by a soluble factor expressed by Timp2(-/-) cells and was MT2-MMP hemopexin C domain-dependent; however, the RGD sequence within this domain was not involved. Interestingly, in the presence of TIMP-2, a MT2-MMP.MMP-2 trimolecular complex formed, but activation was not enhanced. Similarly, TIMP-3 did not promote MT2-MMP-mediated MMP-2 activation but inhibited activation at higher concentrations. This study demonstrates the influence that both the catalytic and hemopexin C domains of MT2-MMP exert in determining TIMP independence in MMP-2 activation. In tissues or pathologies characterized by low TIMP-2 expression, this pathway may represent an alternative means of rapidly generating low levels of active MMP-2.	Univ British Columbia, Ctr Blood Res, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Oral Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Med Sci, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Overall, CM (corresponding author), Univ British Columbia, Ctr Blood Res, Life Sci Bldg,2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	chris.overall@ubc.ca						Abraham R, 2005, J BIOL CHEM, V280, P34123, DOI 10.1074/jbc.M508155200; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; Bigg HF, 2001, CANCER RES, V61, P3610; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Davidson B, 2001, AM J CLIN PATHOL, V115, P517; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ellerbroek SM, 2001, J BIOL CHEM, V276, P24833, DOI 10.1074/jbc.M005631200; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; English WR, 2001, J BIOL CHEM, V276, P42018, DOI 10.1074/jbc.M107783200; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Gomis-Ruth FX, 2003, MOL BIOTECHNOL, V24, P157, DOI 10.1385/MB:24:2:157; Haas TL, 1999, TRENDS CARDIOVAS MED, V9, P70, DOI 10.1016/S1050-1738(99)00014-6; Holmbeck K, 2004, J CELL PHYSIOL, V200, P11, DOI 10.1002/jcp.20065; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Itoh Y, 2006, J CELL PHYSIOL, V206, P1, DOI 10.1002/jcp.20431; Jiang AX, 2003, J BIOL CHEM, V278, P38765, DOI 10.1074/jbc.M306618200; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kai HST, 2002, J BIOL CHEM, V277, P48696, DOI 10.1074/jbc.M209177200; Kinoshita T, 1996, CANCER RES, V56, P2535; Kitagawa Y, 1998, J UROLOGY, V160, P1540, DOI 10.1016/S0022-5347(01)62609-0; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Kolkenbrock H, 1997, BIOL CHEM, V378, P71, DOI 10.1515/bchm.1997.378.2.71; Lafleur MA, 2006, J BIOL CHEM, V281, P6826, DOI 10.1074/jbc.M513084200; Lafleur MA, 2002, J CELL SCI, V115, P3427; Lafleur MA, 2001, BIOCHEM J, V357, P107, DOI 10.1042/0264-6021:3570107; Lampert K, 1998, AM J PATHOL, V153, P429, DOI 10.1016/S0002-9440(10)65586-1; Mahloogi H, 2002, CARCINOGENESIS, V23, P565, DOI 10.1093/carcin/23.4.565; Miyamori H, 2000, BIOCHEM BIOPH RES CO, V267, P796, DOI 10.1006/bbrc.1999.2050; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Monea S, 2002, J CELL PHYSIOL, V192, P160, DOI 10.1002/jcp.10126; Morrison CJ, 2001, J BIOL CHEM, V276, P47402, DOI 10.1074/jbc.M108643200; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; Nisato RE, 2005, CANCER RES, V65, P9377, DOI 10.1158/0008-5472.CAN-05-1512; Ogiwara K, 2005, P NATL ACAD SCI USA, V102, P8442, DOI 10.1073/pnas.0502423102; Osenkowski P, 2005, J BIOL CHEM, V280, P26160, DOI 10.1074/jbc.M414379200; Osenkowski P, 2004, J CELL PHYSIOL, V200, P2, DOI 10.1002/jcp.20064; Overall CM, 1999, J BIOL CHEM, V274, P4421, DOI 10.1074/jbc.274.7.4421; Overall CM, 2000, J BIOL CHEM, V275, P39497, DOI 10.1074/jbc.M005932200; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Pelman GR, 2005, J BIOL CHEM, V280, P2370, DOI 10.1074/jbc.M409603200; Puente XS, 1996, CANCER RES, V56, P944; Sato H, 2005, CANCER SCI, V96, P212, DOI 10.1111/j.1349-7006.2005.00039.x; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; Shamamian P, 2001, J CELL PHYSIOL, V189, P197, DOI 10.1002/jcp.10014; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; Shimokawa K, 2001, Methods Mol Biol, V151, P275; Sounni NE, 2005, BIOCHIMIE, V87, P329, DOI 10.1016/j.biochi.2004.07.012; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; Steffensen B, 1998, J BIOL CHEM, V273, P20622, DOI 10.1074/jbc.273.32.20622; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Szabova L, 2005, J CELL PHYSIOL, V205, P123, DOI 10.1002/jcp.20385; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Tam EM, 2004, J BIOL CHEM, V279, P43336, DOI 10.1074/jbc.M407186200; Tam EM, 2004, P NATL ACAD SCI USA, V101, P6917, DOI 10.1073/pnas.0305862101; Tam EM, 2002, J BIOL CHEM, V277, P39005, DOI 10.1074/jbc.M206874200; Tanaka M, 1997, FEBS LETT, V402, P219, DOI 10.1016/S0014-5793(96)01537-2; Ueno H, 1997, CANCER RES, V57, P2055; Velasco G, 2000, CANCER RES, V60, P877; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; Wang P, 2004, J BIOL CHEM, V279, P51148, DOI 10.1074/jbc.M409074200; Wang YH, 1999, J BIOL CHEM, V274, P33043, DOI 10.1074/jbc.274.46.33043; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Wong H, 2000, METH MOL B, V151, P305, DOI 10.1385/1-59259-046-2:305; Wu YI, 2004, J BIOL CHEM, V279, P8278, DOI 10.1074/jbc.M311870200; Zhang J, 2005, CARCINOGENESIS, V26, P2069, DOI 10.1093/carcin/bgi183; Zhao HR, 2004, J BIOL CHEM, V279, P8592, DOI 10.1074/jbc.M308708200; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	79	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26528	26539		10.1074/jbc.M603331200	http://dx.doi.org/10.1074/jbc.M603331200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16825197	hybrid			2022-12-25	WOS:000240249500071
J	Winer, IS; Bommer, GT; Gonik, N; Fearon, ER				Winer, Ira S.; Bommer, Guido T.; Gonik, Nathan; Fearon, Eric R.			Lysine residues Lys-19 and Lys-49 of beta-catenin regulate its levels and function in T cell factor transcriptional activation and neoplastic transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN LIGASE; CANCER; COMPLEX; PHOSPHORYLATION; PATHWAY; BINDING; TARGET; AXIN; DEGRADATION; DISTINCT	Wnt signaling regulates cell fate determination, proliferation, and survival, among other processes. Certain Wnt ligands stabilize the beta-catenin protein, leading to the ability of beta-catenin to activate T cell factor-regulated genes. In the absence of Wnts, beta-catenin is phosphorylated at defined serine and threonine residues in its amino (N) terminus. The phosphorylated beta-catenin is recognized by a beta-transducin repeat-containing protein (beta TrCP) and associated ubiquitin ligase components. The serine/threonine residues and beta TrCP-binding site in the N-terminal region of beta-catenin constitute a key regulatory motif targeted by somatic mutations in human cancers, resulting in constitutive stabilization of the mutant beta-catenin proteins. Structural studies have implicated beta-catenin lysine 19 as the major target for beta TrCP-dependent ubiquitination, but Lys-19 mutations in cancer have not been reported. We studied the consequences of single amino acid substitutions of the only 2 lysine residues in the N-terminal 130 amino acids of beta-catenin. Mutation of Lys-19 minimally affected beta-catenin levels and functional activity, and mutation of Lys-49 led to reduced beta-catenin levels and function. In contrast, beta-catenin proteins with substitutions at both Lys-19 and Lys-49 positions were present at elevated levels and had the ability to potently activate T cell factor-dependent transcription and promote neoplastic transformation. We further more demonstrate that the K19/K49 double mutant forms of beta-catenin are stabilized as a result of reduced beta TrCP-dependent ubiquitination. Our findings suggest that Lys-19 is a primary in vivo site of beta TrCP-dependent ubiquitination and Lys-49 may be a secondary or cryptic site. Moreover, our results inform understanding of why single amino acid substitutions at lysine 19 or 49 have not been reported in human cancer.	Univ Michigan, Sch Med, Div Mol Med & Genet, Cell & Mol Biol Grad Program,Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Div Mol Med & Genet, Cell & Mol Biol Grad Program,Dept Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Div Mol Med & Genet, Cell & Mol Biol Grad Program,Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Div Mol Med & Genet, Cell & Mol Biol Grad Program,Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Fearon, ER (corresponding author), Univ Michigan, Sch Med, Div Mol Med & Genet, Cell & Mol Biol Grad Program,Dept Internal Med, 109 Zina Pitcher,1504 BSRB, Ann Arbor, MI 48109 USA.	fearon@umich.edu	Winer, Ira/M-4973-2019; Bommer, Guido/A-8425-2011	Winer, Ira/0000-0001-6056-8296; Bommer, Guido/0000-0001-6898-4884	NATIONAL CANCER INSTITUTE [P30CA046592, R01CA085463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007863] Funding Source: NIH RePORTER; NCI NIH HHS [CA46592, CA85463] Funding Source: Medline; NIGMS NIH HHS [T32GM07863] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cliffe A, 2003, CURR BIOL, V13, P960, DOI 10.1016/S0960-9822(03)00370-1; Feng Y, 2003, CANCER RES, V63, P8726; Fraser E, 2002, J BIOL CHEM, V277, P2176, DOI 10.1074/jbc.M109462200; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; Kolligs FT, 2000, GENE DEV, V14, P1319; Kolligs FT, 2002, CANCER CELL, V1, P145, DOI 10.1016/S1535-6108(02)00035-1; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; PEIFER M, 1993, SCIENCE, V262, P1667, DOI 10.1126/science.8259511; Sadot E, 2002, J CELL SCI, V115, P2771; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wolf D, 2002, J BIOL CHEM, V277, P25562, DOI 10.1074/jbc.M201196200; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X	27	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26181	26187		10.1074/jbc.M604217200	http://dx.doi.org/10.1074/jbc.M604217200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16849322	hybrid			2022-12-25	WOS:000240249500034
J	Rosner, M; Freilinger, A; Hengstschlager, M				Rosner, M.; Freilinger, A.; Hengstschlaeger, M.			Akt regulates nuclear/cytoplasmic localization of tuberin	ONCOGENE			English	Article						TSC2; tuberin; Akt; S6K; cell cycle	SCLEROSIS GENE-2 PRODUCT; TUMOR-SUPPRESSOR COMPLEX; MAMMALIAN TARGET; PHOSPHORYLATION; TSC2; RAPAMYCIN; PROTEIN; GROWTH; P27(KIP1); HAMARTIN	The autosomal dominantly inherited disease tuberous sclerosis (TSC) affects similar to 1 in 6000 individuals and is characterized by the development of tumors, named hamartomas, in different organs. TSC1, encoding hamartin, and TSC2, encoding tuberin are tumor suppressor genes responsible for TSC. Hamartin and tuberin form a complex, of which tuberin is assumed to be the functional component. The TSC proteins have been implicated in the control of cell cycle by activating the cyclin-dependent kinase inhibitor p27 and in cell size regulation by inhibiting the mammalian target of rapamycin (mTOR)/p70S6K cascade. Phosphorylation of S939 and T1462 by Akt downregulates tuberin's potential to inhibit mTOR/ p70S6K. Here, we show that this tuberin phosphorylation by Akt does not affect tuberin-mediated control of p27 protein amounts. This demonstrates that regulating p27 protein amounts and mTOR/p7OS6K are separable functions of tuberin. Furthermore, we found that phosphorylation by Akt triggers upregulation of cytoplasmic and downregulation of nuclear tuberin. In cycling cells with high Akt activity, tuberin is predominantly localized to the cytoplasm. In arrested GO cells with downregulated Akt activity, a significant proportion of tuberin is localized to the nucleus. Upon re-entry into the normal ongoing cell cycle, nuclear localization of tuberin is downregulated parallel to the activation of Akt. Recently, the mTOR/p7OS6K cascade has been demonstrated to exist in both the cytoplasm and nucleus. We here also found that tuberin harbors the potential to regulate p70S6K activity in both the cytoplasm and nucleus. This description of functional tuberin in the cytoplasm and the nucleus together with our observation of Akt-controlled and cell cycle-regulated tuberin localization are of particular interest for a further understanding of tuberin's function as a gate keeper of the GO cell status as well as of Akt's activity to control cell proliferation.	Med Univ Vienna, A-1090 Vienna, Austria	Medical University of Vienna	Hengstschlager, M (corresponding author), Med Univ Vienna, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	markus.hengstschlaeger@meduniwien.ac.at						Astrinidis A, 2005, ONCOGENE, V24, P7475, DOI 10.1038/sj.onc.1209090; Astrinidis A, 2006, HUM MOL GENET, V15, P287, DOI 10.1093/hmg/ddi444; Bachmann RA, 2006, J BIOL CHEM, V281, P7357, DOI 10.1074/jbc.M512218200; Chong-Kopera H, 2006, J BIOL CHEM, V281, P8313, DOI 10.1074/jbc.C500451200; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Dostie J, 2000, J CELL BIOL, V148, P239, DOI 10.1083/jcb.148.2.239; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Furuya F, 2006, P NATL ACAD SCI USA, V103, P1780, DOI 10.1073/pnas.0510849103; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liu H, 2006, P NATL ACAD SCI USA, V103, P4134, DOI 10.1073/pnas.0511342103; Lou Dingyuan, 2001, Molecular Cell Biology Research Communications, V4, P374, DOI 10.1006/mcbr.2001.0307; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; Pan DJ, 2004, TRENDS CELL BIOL, V14, P78, DOI 10.1016/j.tcb.2003.12.006; Pasumarthi KBS, 2000, CIRC RES, V86, P1069, DOI 10.1161/01.RES.86.10.1069; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Rosner M, 2004, J BIOL CHEM, V279, P48707, DOI 10.1074/jbc.M405528200; Rosner M, 2004, AMINO ACIDS, V27, P119, DOI 10.1007/s00726-004-0119-z; Rosner M, 2003, ONCOGENE, V22, P4786, DOI 10.1038/sj.onc.1206776; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Soucek T, 1998, ONCOGENE, V16, P2197, DOI 10.1038/sj.onc.1201743; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wienecke R, 1996, ONCOGENE, V13, P913; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Zhang XW, 2002, J BIOL CHEM, V277, P28127, DOI 10.1074/jbc.M202625200	43	48	48	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					521	531		10.1038/sj.onc.1209812	http://dx.doi.org/10.1038/sj.onc.1209812			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16862180				2022-12-25	WOS:000243731600005
J	Zhang, P; Castedo, M; Tao, Y; Violot, D; Metivier, D; Deutsch, E; Kroemer, G; Bourhis, J				Zhang, P.; Castedo, M.; Tao, Y.; Violot, D.; Metivier, D.; Deutsch, E.; Kroemer, G.; Bourhis, Jean			Caspase independence of radio-induced cell death	ONCOGENE			English	Article						apoptosis; delayed cell death; mitotic catastrophe; micronucleation; polyploidization	RADIATION-INDUCED APOPTOSIS; MITOTIC CATASTROPHE; CLONOGENIC SURVIVAL; MITOCHONDRIAL; CANCER; P53; SENESCENCE; EXPRESSION; CHK2	Colon carcinoma cells subjected to gamma-irradiation (4 Gy) manifest signs of apoptosis (caspase activation, chromatin condensation, phosphatidylserine (PS) exposure on the cell surface, sub-diploid DNA content), correlating with their radiosensitivity, which is increased in cells lacking the 14-3-3 sigma protein as compared to wild-type controls. Inhibition of caspases byaddition of Z-Val-Ala-DLAsp (OMe)-fluoromethylketone, by stable transfection with the Baculovirus gene coding for p35, or by Bax knockout reduced all signs of apoptosis, yet failed to suppress radio-induced micro- and multinucleation. Moreover, pharmacological caspase inhibition, p35 expression or Bax knockout had no effect on the clonogenic survival that was reduced by gamma-irradiation and caspase inhibition failed to abolish the increased radiosensitivity of 14-3-3 sigma-deficient cells. Micro- and multinucleation was detectable among non-apoptotic cells lacking PS exposure, as well as among cells undergoing apoptosis. Moreover, a fraction of micro- or multinucleated cells manifested caspase activation, and videomicroscopic analyses revealed that such cells could succumb to caspase-dependent apoptosis. Altogether, these results suggest that genomic instability induced by gamma-irradiation can trigger apoptosis, although apoptosis is dispensable for radio-induced clonogenic death.	Inst Gustave Roussy, Ctr Natl Rech Sci, UMR 8125, F-94805 Villejuif, France; Inst Gustave Roussy, UPRES EA 2710, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Kroemer, G (corresponding author), Inst Gustave Roussy, Ctr Natl Rech Sci, UMR 8125, Pavillon Rech 1,38 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; tao, yungan/0000-0002-6916-5263; Bourhis, Jean/0000-0001-5162-1171; deutsch, eric/0000-0002-8223-3697; Zhang, Ping/0000-0002-3043-8738				Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Albertini RJ, 2000, MUTAT RES-REV MUTAT, V463, P111, DOI 10.1016/S1383-5742(00)00049-1; Andreau K, 2004, J BIOL CHEM, V279, P55937, DOI 10.1074/jbc.M406411200; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Bulavin DV, 1999, ONCOGENE, V18, P5611, DOI 10.1038/sj.onc.1202945; BUSH C, 1993, BRIT J CANCER, V67, P102, DOI 10.1038/bjc.1993.17; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573; Castedo M, 1996, J IMMUNOL, V157, P512; Castedo M, 2006, EMBO J, V25, P2584, DOI 10.1038/sj.emboj.7601127; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Cohen-Jonathan E, 1999, CURR OPIN CHEM BIOL, V3, P77, DOI 10.1016/S1367-5931(99)80014-3; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Date T, 2003, HUM GENE THER, V14, P947, DOI 10.1089/104303403766682214; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Golstein P, 2005, CELL DEATH DIFFER, V12, P1490, DOI 10.1038/sj.cdd.4401607; Gourdier I, 2004, ONCOGENE, V23, P7449, DOI 10.1038/sj.onc.1208047; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Guo GZ, 1998, INT J RADIAT BIOL, V73, P297, DOI 10.1080/095530098142392; Held KD, 1997, APOPTOSIS, V2, P265, DOI 10.1023/A:1026485003280; Hendry JH, 1997, INT J RADIAT BIOL, V71, P709, DOI 10.1080/095530097143716; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724; Kyprianou N, 1997, INT J CANCER, V70, P341, DOI 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Mariya Y, 1997, RADIAT RES, V147, P29, DOI 10.2307/3579439; Methot N, 2004, J EXP MED, V199, P199, DOI 10.1084/jem.20031791; MULLER WU, 1995, STEM CELLS, V13, P199; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Olive PL, 1997, INT J RADIAT BIOL, V71, P695, DOI 10.1080/095530097143707; Perfettini JL, 2005, J EXP MED, V201, P279, DOI 10.1084/jem.20041502; Prise KM, 2005, LANCET ONCOL, V6, P520, DOI 10.1016/S1470-2045(05)70246-1; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Schulze-Bergkamen H, 2004, SEMIN ONCOL, V31, P90, DOI 10.1053/j.seminoncol.2003.11.006; Stennicke HR, 2002, TRENDS BIOCHEM SCI, V27, P94, DOI 10.1016/S0968-0004(01)02045-X; Vidair CA, 1996, CANCER RES, V56, P4116; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; ZHIVOTOVSKY B, 2004, NAT REV MOL CELL BIO, V117, P4461	46	24	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2006	25	59					7758	7770		10.1038/sj.onc.1209744	http://dx.doi.org/10.1038/sj.onc.1209744			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16862186				2022-12-25	WOS:000242830800010
J	Lopez, D; Calero, O; Jimenez, M; Garcia-Calvo, M; Del Val, M				Lopez, Daniel; Calero, Olga; Jimenez, Mercedes; Garcia-Calvo, Margarita; Del Val, Margarita			Antigen processing of a short viral antigen by proteasomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDES; SITES; 20S	Mass spectrometry (MS)-based methods coupled to reverse phase chromatography separation are a useful technology to analyze complex peptide pools that are comprised of different peptides with unrelated sequences. In antigen presentation, proteasomes generate a set of short peptides that are closely related and overlapping and in some instances may even have identical retention times and identical masses. In these situations, micro-liquid chromatography-MS/MS focused on each theoretical parent ion followed by manual interpretation optimizes the identification of generated peptides. The results suggest that the degradation of short antigens by the proteasome occurs by sequential cleavage.	Inst Salud Carlos III, Unidad Proteom, Madrid 28220, Spain; Inst Salud Carlos III, Unidad Inmunol Viral, Ctr Nacl Microbiol, Madrid 28220, Spain; Merck Res Labs, Dept Enzymol, Rahway, NJ 07065 USA	Instituto de Salud Carlos III; Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM); Merck & Company	Lopez, D (corresponding author), Inst Salud Carlos III, Unidad Proteom, Madrid 28220, Spain.	dlopez@isciii.es	López, Daniel/I-2632-2014; Del Val, Margarita/E-4769-2010	López, Daniel/0000-0003-0268-5878; Del Val, Margarita/0000-0001-6769-4279				Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DELVAL M, 1988, J VIROL, V62, P3965, DOI 10.1128/JVI.62.11.3965-3972.1988; EGGERS M, 1995, J EXP MED, V182, P1865, DOI 10.1084/jem.182.6.1865; Kisselev AF, 2002, J BIOL CHEM, V277, P22260, DOI 10.1074/jbc.M112360200; Kisselev AF, 2003, J BIOL CHEM, V278, P35869, DOI 10.1074/jbc.M303725200; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; Kloetzel PM, 2004, BBA-MOL CELL RES, V1695, P225, DOI 10.1016/j.bbamcr.2004.10.004; Lopez D, 1997, J IMMUNOL, V159, P5769; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Purcell AW, 2004, MOL CELL PROTEOMICS, V3, P193, DOI 10.1074/mcp.R300013-MCP200; Saveanu L, 2002, MOL IMMUNOL, V39, P203, DOI 10.1016/S0161-5890(02)00102-5; Skribanek Z, 2002, J PEPT SCI, V8, P398, DOI 10.1002/psc.395; York IA, 1999, IMMUNOL REV, V172, P49, DOI 10.1111/j.1600-065X.1999.tb01355.x	13	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30315	30318		10.1074/jbc.M605973200	http://dx.doi.org/10.1074/jbc.M605973200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16861221	Green Published, hybrid			2022-12-25	WOS:000241075900004
J	Yu, M; Luo, JC; Yang, WT; Wang, YP; Mizuki, M; Kanakura, Y; Besmer, P; Neel, BG; Gu, HH				Yu, Min; Luo, Jincai; Yang, Wentian; Wang, Yongping; Mizuki, Masao; Kanakura, Yuzuru; Besmer, Peter; Neel, Benjamin G.; Gu, Haihua			The scaffolding adapter Gab2, via Shp-2, regulates kit-evoked mast cell proliferation by activating the Rac/JNK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC FAMILY KINASE; C-KIT; EPIDERMAL-GROWTH; SIGNALING PATHWAY; PROTEIN GAB2; RECEPTOR; RHO; PHOSPHORYLATION; IDENTIFICATION; ASSOCIATION	The scaffolding adapter Gab2 mediates cell signaling and responses evoked by various extracellular stimuli including several growth factors. Kit, the receptor for stem cell factor (SCF), plays a critical role in the proliferation and differentiation of a variety of cell types, including mast cells. Kit, via Tyr(567) and Tyr(719), activates Src family kinases (SFK) and PI3K respectively, which converge on the activation of a Rac/JNK pathway required for mast cell proliferation. However, how Kit Tyr(567) signals to Rac/JNK is not well understood. By analyzing Gab2(-/-) mast cells, we find that Gab2 is required for SCF-evoked proliferation, activation of Rac/JNK, and Ras. Upon Kit activation in wild-type mast cells, Gab2 becomes tyrosyl-phosphorylated and associates with Kit and Shp-2. Tyr(567), an SFK binding site in Kit, and SFK activity were required for Gab2 tyrosyl phosphorylation and association with Shp-2. By re-expressing Gab2 or a Gab2 mutant that cannot bind Shp-2 in Gab2(-/-) mast cells or acutely by deleting Shp-2 in mast cells, we found that Gab2 requires Shp-2 for SCF-evoked Rac/JNK, Ras activation, and mast cell proliferation. Lastly, by analyzing mast cells from mice with compound Gab2 and Kit Y719F mutations (i.e., Gab2(-/-): KitY719F/Y719F mice), we find that Gab2, acting in a parallel pathway to PI3K from Kit Tyr(719), regulates mast cell proliferation and development in specific tissues. Our data show that Gab2 via Shp-2 is critical for transmitting signals from Kit Tyr(567) to activate the Rac/JNK pathway controlling mast cell proliferation, which likely contributes to mast cell development in specific tissues.	Beth Israel Deaconess Med Ctr, Canc Biol Program, Div Hematol Oncol, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Suita, Osaka 5650871, Japan; Sloan Kettering Inst, Dev Biol Program, New York, NY 10021 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Osaka University; Memorial Sloan Kettering Cancer Center	Gu, HH (corresponding author), NRB 1030N,77 Ave Louis Pasteur, Boston, MA 02115 USA.	hgu@bidmc.harvard.edu	Jin Cai, Luo/A-7900-2011		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050693, R01DK055748] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI51612] Funding Source: Medline; NIDDK NIH HHS [DK50693, HL/DK55748] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agosti V, 2004, J EXP MED, V199, P867, DOI 10.1084/jem.20031983; Ashman LK, 1999, INT J BIOCHEM CELL B, V31, P1037, DOI 10.1016/S1357-2725(99)00076-X; Barnard D, 1998, ONCOGENE, V17, P1539, DOI 10.1038/sj.onc.1202061; Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Blume-Jensen P, 2000, NAT GENET, V24, P157, DOI 10.1038/72814; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cai T, 2002, J CELL BIOL, V159, P103, DOI 10.1083/jcb.200205017; Chen CC, 2005, P NATL ACAD SCI USA, V102, P11408, DOI 10.1073/pnas.0504197102; Fukao T, 2002, NAT IMMUNOL, V3, P295, DOI 10.1038/ni768; Galli SJ, 2000, CURR OPIN HEMATOL, V7, P32, DOI 10.1097/00062752-200001000-00007; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Gurish MF, 2001, J EXP MED, V194, P1243, DOI 10.1084/jem.194.9.1243; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Hong L, 2004, MOL CELL BIOL, V24, P1401, DOI 10.1128/MCB.24.3.1401-1410.2004; Kimura Y, 2004, P NATL ACAD SCI USA, V101, P6015, DOI 10.1073/pnas.0305363101; Kissel H, 2000, EMBO J, V19, P1312, DOI 10.1093/emboj/19.6.1312; Kong M, 2003, J BIOL CHEM, V278, P5837, DOI 10.1074/jbc.M208286200; Kontaridis MI, 2004, MOL CELL BIOL, V24, P5340, DOI 10.1128/MCB.24.12.5340-5352.2004; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Lennartsson J, 2005, STEM CELLS, V23, P16, DOI 10.1634/stemcells.2004-0117; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; Linnekin D, 1997, J BIOL CHEM, V272, P27450, DOI 10.1074/jbc.272.43.27450; Liu Y, 2001, MOL CELL BIOL, V21, P3047, DOI 10.1128/MCB.21.9.3047-3056.2001; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Mao YW, 2005, J CELL BIOL, V170, P305, DOI 10.1083/jcb.200505061; Meng SS, 2005, BIOCHEM J, V391, P143, DOI 10.1042/BJ20050229; Mitin N, 2005, CURR BIOL, V15, pR563, DOI 10.1016/j.cub.2005.07.010; Montagner A, 2005, J BIOL CHEM, V280, P5350, DOI 10.1074/jbc.M410012200; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Nishida K, 2002, BLOOD, V99, P1866, DOI 10.1182/blood.V99.5.1866; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Price DJ, 1997, J BIOL CHEM, V272, P5915, DOI 10.1074/jbc.272.9.5915; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ronnstrand L, 2004, CELL MOL LIFE SCI, V61, P2535, DOI 10.1007/s00018-004-4189-6; Rosenkranz AR, 1998, J IMMUNOL, V161, P6463; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Saitoh S, 2000, IMMUNITY, V12, P525, DOI 10.1016/S1074-7613(00)80204-6; Shifrin VI, 1997, J BIOL CHEM, V272, P2957, DOI 10.1074/jbc.272.5.2957; Tan BL, 2003, BLOOD, V101, P4725, DOI 10.1182/blood-2002-08-2521; Thommes K, 1999, BIOCHEM J, V341, P211, DOI 10.1042/0264-6021:3410211; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Ueda S, 2002, BLOOD, V99, P3342, DOI 10.1182/blood.V99.9.3342; Wada T, 2005, NAT MED, V11, P394, DOI 10.1038/nm1203; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; Yang WT, 2006, DEV CELL, V10, P317, DOI 10.1016/j.devcel.2006.01.002; Yu M, 2006, J IMMUNOL, V176, P2421, DOI 10.4049/jimmunol.176.4.2421; Yu WM, 2002, BLOOD, V99, P2351, DOI 10.1182/blood.V99.7.2351; Zhao CM, 2003, J BIOL CHEM, V278, P34641, DOI 10.1074/jbc.M304594200	57	65	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28615	28626		10.1074/jbc.M603742200	http://dx.doi.org/10.1074/jbc.M603742200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16873377	hybrid			2022-12-25	WOS:000240680500015
J	Joy, S; Siow, RCM; Rowlands, DJ; Becker, M; Wyatt, AW; Aaronson, PI; Coen, CW; Kallo, I; Jacob, R; Mann, GE				Joy, Sheeja; Siow, Richard C. M.; Rowlands, David J.; Becker, Marko; Wyatt, Amanda W.; Aaronson, Philip I.; Coen, Clive W.; Kallo, Imre; Jacob, Ron; Mann, Giovanni E.			The isoflavone equol mediates rapid vascular relaxation - Ca2+-independent activation of endothelial nitric-oxide synthase/Hsp90 involving ERK1/2 and Akt phosphorylation in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR-ALPHA; DEPENDENT PROTEIN-KINASE; HUMAN UMBILICAL VEIN; POSTMENOPAUSAL WOMEN; NONGENOMIC ACTIVATION; PHYTO-ESTROGENS; SOY ISOFLAVONES; PLASMA-MEMBRANE; IN-VITRO; BETA	We recently reported that soy isoflavones increase gene expression of endothelial nitric-oxide synthase (eNOS) and antioxidant defense enzymes, resulting in improved endothelial function and lower blood pressure in vivo. In this study, we establish that equol (1-100 nM) causes acute endothelium- and nitric oxide (NO)-dependent relaxation of aortic rings and rapidly (2 min) activates eNOS in human aortic and umbilical vein endothelial cells. Intracellular Ca2+ and cyclic AMP levels were unaffected by treatment (100 nM, 2 min) with equol, daidzein, or genistein. Rapid phosphorylation of ERK1/2, protein kinase B/Akt, and eNOS serine 1177 by equol was paralleled by association of eNOS with heat shock protein 90 (Hsp90) and NO synthesis in human umbilical vein endothelial cells, expressing estrogen receptors (ER)alpha and ER beta. Inhibition of phosphatidylinositol 3-kinase and ERK1/2 inhibited eNOS activity, whereas pertussis toxin and the ER antagonists ICI 182,750 and tamoxifen had negligible effects. Our findings provide the first evidence that nutritionally relevant plasma concentrations of equol (and other soy protein isoflavones) rapidly stimulate phosphorylation of ERK1/2 and phosphatidylinositol 3-kinase/Akt, leading to the activation of NOS and increased NO production at resting cytosolic Ca2+ levels. Identification of the nongenomic mechanisms by which equol mediates vascular relaxation provides a basis for evaluating potential benefits of equol in the treatment of postmenopausal women and patients at risk of cardiovascular disease.	Kings Coll London, Div Cardiovasc, London SE1 1UL, England; Kings Coll London, Reprod & Endocrinol Div, London SE1 1UL, England; Kings Coll London, Asthma Allergy & Lung Biol Div, Sch Biomed & Hlth Sci, London SE1 1UL, England; Kings Coll London, Asthma Allergy & Lung Biol Div, Sch Med, London SE1 1UL, England; Inst Expt Med, Lab Endocrinol & Behav Neurobiol, H-1083 Budapest, Hungary	University of London; King's College London; University of London; King's College London; University of London; King's College London; University of London; King's College London; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine	Mann, GE (corresponding author), Kings Coll London, Div Cardiovasc, Guys Campus, London SE1 1UL, England.	giovanni.mann@kcl.ac.uk	Kalló, Imre/C-6262-2016	Kalló, Imre/0000-0003-3412-4100; Aaronson, Philip Irving/0000-0003-1086-1202; Coen, Clive/0000-0003-1303-216X; Mann, Giovanni/0000-0001-7311-2044	Wellcome Trust [060202] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADLERCREUTZ H, 1993, LANCET, V342, P1209, DOI 10.1016/0140-6736(93)92188-Y; Anselm E, 2005, FASEB J, V19, pA1230; Anter E, 2004, J BIOL CHEM, V279, P46637, DOI 10.1074/jbc.M405547200; Bachetti T, 2004, J MOL CELL CARDIOL, V37, P939, DOI 10.1016/j.yjmcc.2004.07.006; Borras C, 2005, AGING CELL, V4, P113, DOI 10.1111/j.1474-9726.2005.00151.x; Cassidy A, 2006, P NUTR SOC, V65, P76, DOI 10.1079/PNS2005476; Cassidy A, 2006, J NUTR, V136, P45, DOI 10.1093/jn/136.1.45; CaulinGlaser T, 1997, CIRC RES, V81, P885; Chambliss KL, 2000, CIRC RES, V87, pE44, DOI 10.1161/01.RES.87.11.e44; Chambliss KL, 2005, MOL ENDOCRINOL, V19, P277, DOI 10.1210/me.2004-0008; Chambliss KL, 2002, MOL ENDOCRINOL, V16, P938, DOI 10.1210/me.16.5.938; Chen DB, 2004, ENDOCRINOLOGY, V145, P113, DOI 10.1210/en.2003-0547; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Chin-Dusting JPF, 2004, ATHEROSCLEROSIS, V176, P45, DOI 10.1016/j.atherosclerosis.2004.03.025; Chin-Dusting JPF, 2001, BRIT J PHARMACOL, V133, P595, DOI 10.1038/sj.bjp.0704088; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Cuevas AM, 2003, EUR J CLIN NUTR, V57, P889, DOI 10.1038/sj.ejcn.1601622; Dan P, 2003, AM J PHYSIOL-HEART C, V284, pH1295, DOI 10.1152/ajpheart.00781.2002; de Kleijn MJJ, 2002, AM J EPIDEMIOL, V155, P339, DOI 10.1093/aje/155.4.339; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Evinger AJ, 2005, STEROIDS, V70, P361, DOI 10.1016/j.steroids.2005.02.015; Figtree GA, 2000, J AM COLL CARDIOL, V35, P1977, DOI 10.1016/S0735-1097(00)00645-8; Figtree GA, 2003, CIRCULATION, V107, P120, DOI 10.1161/01.CIR.0000043805.11780.F5; Fleming I, 1998, CIRC RES, V82, P686, DOI 10.1161/01.RES.82.6.686; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Goetz RM, 1999, P NATL ACAD SCI USA, V96, P2788, DOI 10.1073/pnas.96.6.2788; Haynes MP, 2003, J BIOL CHEM, V278, P2118, DOI 10.1074/jbc.M210828200; Hisamoto K, 2005, STEROIDS, V70, P382, DOI 10.1016/j.steroids.2005.02.011; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Hrabovszky E, 2004, J COMP NEUROL, V473, P315, DOI 10.1002/cne.20127; Hwang J, 2003, FREE RADICAL BIO MED, V34, P1271, DOI 10.1016/S0891-5849(03)00104-7; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; Kim-Schulze S, 1998, CIRCULATION, V98, P413, DOI 10.1161/01.CIR.98.5.413; Klinge CM, 2005, J BIOL CHEM, V280, P7460, DOI 10.1074/jbc.M411565200; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; KUPPUSAMY UR, 1992, BIOCHEM PHARMACOL, V44, P1307, DOI 10.1016/0006-2952(92)90531-M; Lissin LW, 2000, J AM COLL CARDIOL, V35, P1403; Liu DM, 2004, ENDOCRINOLOGY, V145, P5532, DOI 10.1210/en.2004-0102; Lorenz M, 2004, J BIOL CHEM, V279, P6190, DOI 10.1074/jbc.M309114200; Mahn K, 2005, FASEB J, V19, P1755, DOI 10.1096/fj.05-4008fje; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Mishra SK, 2000, CARDIOVASC RES, V46, P539, DOI 10.1016/S0008-6363(00)00049-3; NAKASHIMA S, 1991, MOL PHARMACOL, V39, P475; Ou JS, 2004, AM J PHYSIOL-HEART C, V286, pH561, DOI 10.1152/ajpheart.00736.2003; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; Quattrone S, 2004, MOL HUM REPROD, V10, P325, DOI 10.1093/molehr/gah040; Razandi M, 2003, MOL CELL BIOL, V23, P1633, DOI 10.1128/MCB.23.5.1633-1646.2003; Rivas M, 2002, J NUTR, V132, P1900, DOI 10.1093/jn/132.7.1900; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; Schulz E, 2005, CIRCULATION, V111, P3473, DOI 10.1161/CIRCULATIONAHA.105.546812; Setchell KDR, 2005, AM J CLIN NUTR, V81, P1072; Setchell KDR, 1999, J NUTR, V129, p758S, DOI 10.1093/jn/129.3.758S; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Squadrito F, 2003, AM J MED, V114, P470, DOI 10.1016/S0002-9343(03)00059-7; Squadrito F, 2000, CARDIOVASC RES, V45, P454, DOI 10.1016/S0008-6363(99)00359-4; Stefano GB, 2000, CIRCULATION, V101, P1594, DOI 10.1161/01.CIR.101.13.1594; Sumi D, 2003, P NATL ACAD SCI USA, V100, P14451, DOI 10.1073/pnas.2235590100; Teede HJ, 2003, ARTERIOSCL THROM VAS, V23, P1066, DOI 10.1161/01.ATV.0000072967.97296.4A; Valverde Miguel A., 2002, Trends in Biochemical Sciences, V27, P172, DOI 10.1016/S0968-0004(02)02075-3; Venkov CD, 1996, CIRCULATION, V94, P727, DOI 10.1161/01.CIR.94.4.727; Vera R, 2005, J PHARMACOL EXP THER, V314, P1300, DOI 10.1124/jpet.105.085530; Walker HA, 2001, CIRCULATION, V103, P258, DOI 10.1161/01.CIR.103.2.258; Wyatt AW, 2002, FASEB J, V16, P1584, DOI 10.1096/fasebj.16.12.1584; Wyckoff MH, 2001, J BIOL CHEM, V276, P27071, DOI 10.1074/jbc.M100312200	68	117	123	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27335	27345		10.1074/jbc.M602803200	http://dx.doi.org/10.1074/jbc.M602803200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16840783	hybrid			2022-12-25	WOS:000240397700060
J	Elbing, K; Rubenstein, EM; McCartney, RR; Schmidt, MC				Elbing, Karin; Rubenstein, Eric M.; McCartney, Rhonda R.; Schmidt, Martin C.			Subunits of the Snf1 kinase heterotrimer show interdependence for association and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; 3 SNF1-ACTIVATING KINASES; SACCHAROMYCES-CEREVISIAE; YEAST SNF1; GAMMA-SUBUNITS; CATALYTIC DOMAIN; UPSTREAM KINASES; BETA-SUBUNITS; COMPLEX; PURIFICATION	The Snf1 kinase and its mammalian orthologue, the AMP-activated protein kinase ( AMPK), function as heterotrimers composed of a catalytic alpha-subunit and two non-catalytic subunits, beta and gamma. The beta-subunit is thought to hold the complex together and control subcellular localization whereas the gamma-subunit plays a regulatory role by binding to and blocking the function of an auto-inhibitory domain (AID) present in the alpha-subunit. In addition, catalytic activity requires phosphorylation by a distinct upstream kinase. In yeast, any one of three Snf1-activating kinases, Sak1, Tos3, or Elm1, can fulfill this role. We have previously shown that Sak1 is the only Snf1-activating kinase that forms a stable complex with Snf1. Here we show that the formation of the Sak1 (.) Snf1 complex requires the beta- and gamma-subunits in vivo. However, formation of the Sak1 (.) Snf1 complex is not necessary for glucose-regulated phosphorylation of the Snf1 activation loop. Snf1 kinase purified from cells lacking the beta-subunits do not contain any gamma-subunit, indicating that the Snf1 kinase does not form a stable alpha gamma dimer in vivo. In vitro kinase assays using purified full-length and truncated Snf1 proteins demonstrate that the kinase domain, which lacks the AID, is significantly more active than the full-length Snf1 protein. Addition of purified beta- and gamma-subunits could stimulate the kinase activity of the full-length alpha-subunit but only when all three subunits were present, suggesting an interdependence of all three subunits for assembly of a functional complex.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Schmidt, MC (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA.	mcs2@pitt.edu		Rubenstein, Eric/0000-0003-4983-1430	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046443, R29GM046443] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46443] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; Caspary F, 1999, EMBO J, V18, P3463, DOI 10.1093/emboj/18.12.3463; Crute BE, 1998, J BIOL CHEM, V273, P35347, DOI 10.1074/jbc.273.52.35347; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; Elbing K, 2006, BIOCHEM J, V393, P797, DOI 10.1042/BJ20051213; ERICKSON JR, 1993, GENETICS, V135, P655; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hedbacker K, 2004, MOL CELL BIOL, V24, P8255, DOI 10.1128/MCB.24.18.8255-8263.2004; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Iseli TJ, 2005, J BIOL CHEM, V280, P13395, DOI 10.1074/jbc.M412993200; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; Jiang R, 1997, MOL CELL BIOL, V17, P2099, DOI 10.1128/MCB.17.4.2099; Leech A, 2003, EUKARYOT CELL, V2, P265, DOI 10.1128/EC.2.2.265-273.2003; Ludin K, 1998, P NATL ACAD SCI USA, V95, P6245, DOI 10.1073/pnas.95.11.6245; McCartney R, 2005, CURR GENET, V47, P335, DOI 10.1007/s00294-005-0576-2; McCartney RR, 2001, J BIOL CHEM, V276, P36460, DOI 10.1074/jbc.M104418200; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; Nath N, 2003, MOL CELL BIOL, V23, P3909, DOI 10.1128/MCB.23.11.3909-3917.2003; Nath N, 2002, J BIOL CHEM, V277, P50403, DOI 10.1074/jbc.M207058200; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rubenstein EM, 2006, EUKARYOT CELL, V5, P620, DOI 10.1128/EC.5.4.620-627.2006; Schmidt MC, 2000, EMBO J, V19, P4936, DOI 10.1093/emboj/19.18.4936; Scott JW, 2004, J CLIN INVEST, V113, P274, DOI 10.1172/JCI200419874; SIKORSKI RS, 1989, GENETICS, V122, P19; Sutherland CM, 2003, CURR BIOL, V13, P1299, DOI 10.1016/S0960-9822(03)00459-7; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; YANG XL, 1994, EMBO J, V13, P5878, DOI 10.1002/j.1460-2075.1994.tb06933.x	32	29	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26170	26180		10.1074/jbc.M603811200	http://dx.doi.org/10.1074/jbc.M603811200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16847059	hybrid			2022-12-25	WOS:000240249500033
J	Rossi, ML; Bambara, RA				Rossi, Marie L.; Bambara, Robert A.			Reconstituted Okazaki fragment processing indicates two pathways of primer removal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-DELTA; CELL NUCLEAR ANTIGEN; ESSENTIAL IN-VIVO; FLAP ENDONUCLEASE-1; DEOXYRIBONUCLEIC ACID; LIGATABLE NICK; YEAST; REPLICATION; CLEAVAGE; BINDING	Eukaryotic Okazaki fragments are initiated by an RNA/DNA primer and extended by DNA polymerase delta(pol delta) and the replication clamp proliferating cell nuclear antigen (PCNA). Joining of the fragments by DNA ligase I to generate the continuous double- stranded DNA requires complete removal of the RNA/DNA primer. Pol delta extends the upstream Okazaki fragment and displaces the downstream RNA/DNA primer into a flap removed by nuclease cleavage. One proposed pathway for flap removal involves pol delta displacement of long flaps, coating of those flaps by replication protein A(RPA), and sequential cleavage of the flap by Dna2 nuclease followed by flap endonuclease 1 (FEN1). A second pathway involves reiterative single nucleotide or short oligonucleotide displacement by pol delta and cleavage by FEN1. We measured the length of FEN1 cleavage products on flaps strand- displaced by pol delta in an oligonucleotide system reconstituted with Saccharomyces cerevisiae proteins. Results showed that in the presence of PCNA and FEN1, pol delta displacement synthesis favors formation and cleavage of primarily short flaps, up to eight nucleotides in length; still, a portion of flaps grows to 20 - 30 nucleotides. The proportion of long flaps can be altered by mutations in the relevant proteins, sequence changes in the DNA, and reaction conditions. These results suggest that FEN1 is sufficient to remove a majority of Okazaki fragment primers. However, some flaps become long and require the two-nuclease pathway. It appears that both pathways, operating in parallel, are required for processing of all flaps.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.	Robert_Bambara@urmc.rochester.edu			NIGMS NIH HHS [GM024441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayyagari R, 2003, J BIOL CHEM, V278, P1618, DOI 10.1074/jbc.M209801200; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bae SH, 2000, J BIOL CHEM, V275, P38022, DOI 10.1074/jbc.M006513200; Budd ME, 2006, MOL CELL BIOL, V26, P2490, DOI 10.1128/MCB.26.7.2490-2500.2006; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642; Budd ME, 2000, J BIOL CHEM, V275, P16518, DOI 10.1074/jbc.M909511199; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Budd ME, 2000, MUTAT RES-DNA REPAIR, V459, P173, DOI 10.1016/S0921-8777(99)00072-5; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; Garg P, 2004, GENE DEV, V18, P2764, DOI 10.1101/gad.1252304; Gary R, 1999, MOL CELL BIOL, V19, P5373; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Jin YH, 2003, J BIOL CHEM, V278, P1626, DOI 10.1074/jbc.M209803200; Jin YH, 2001, P NATL ACAD SCI USA, V98, P5122, DOI 10.1073/pnas.091095198; Kaiser MW, 1999, J BIOL CHEM, V274, P21387, DOI 10.1074/jbc.274.30.21387; Kao HI, 2004, J BIOL CHEM, V279, P50840, DOI 10.1074/jbc.M409231200; Kao HI, 2004, J BIOL CHEM, V279, P15014, DOI 10.1074/jbc.M313216200; Kao KI, 2002, J BIOL CHEM, V277, P14379, DOI 10.1074/jbc.M110662200; KELLY RB, 1970, J BIOL CHEM, V245, P39; Kokoska RJ, 1998, MOL CELL BIOL, V18, P2779, DOI 10.1128/MCB.18.5.2779; Kornberg A., 1992, DNA REPLICATION, VSecond, P113; Lee KH, 2000, NUCLEIC ACIDS RES, V28, P2873, DOI 10.1093/nar/28.15.2873; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Liu Y, 2004, ANNU REV BIOCHEM, V73, P589, DOI 10.1146/annurev.biochem.73.012803.092453; Liu Y, 2003, J BIOL CHEM, V278, P13728, DOI 10.1074/jbc.M212061200; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Rossi ML, 2006, CHEM REV, V106, P453, DOI 10.1021/cr040497l; SETLOW P, 1972, J BIOL CHEM, V247, P232; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Xie YL, 2001, MOL CELL BIOL, V21, P4889, DOI 10.1128/MCB.21.15.4889-4899.2001; Xu Y, 2000, J BIOL CHEM, V275, P20949, DOI 10.1074/jbc.M909135199	35	70	71	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26051	26061		10.1074/jbc.M604805200	http://dx.doi.org/10.1074/jbc.M604805200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16837458	hybrid			2022-12-25	WOS:000240249500020
J	Chatterjee, S; Home, P; Mukherjee, S; Mahata, B; Goswami, S; Dhar, G; Adhya, S				Chatterjee, Saibal; Home, Pratik; Mukherjee, Saikat; Mahata, Bidesh; Goswami, Srikanta; Dhar, Gunjan; Adhya, Samit			An RNA-binding respiratory component mediates import of type II tRNAs into Leishmania mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC TRANSFER-RNA; CYTOCHROME-C-OXIDASE; CRITHIDIA-FASCICULATA; DISTINCT MECHANISMS; INNER MEMBRANE; MESSENGER-RNA; COMPLEX; RECEPTORS; PROTEIN; YEAST	Transport of tRNAs across the inner mitochondrial membrane of the kinetoplastid protozoon Leishmania requires interactions with specific binding proteins (receptors) in a multi-subunit complex. The allosteric model of import regulation proposes cooperative and antagonistic interactions between two or more receptors with binding specificities for distinct tRNA families (types I and II, respectively). To identify the type II receptor, the gene encoding RIC8A, a subunit of the complex, was cloned. The C-terminal region of RIC8A is homologous to subunit 6b of ubiquinol cytochrome c reductase (respiratory complex III), while the N-terminal region has intrinsic affinity for type II, but not for type I, tRNAs. RIC8A is shared by the import complex and complex III, indicating its bi-functionality, but is assembled differently in the two complexes. Knockdown of RIC8A in Leishmania lowered the mitochondrial content of type II tRNAs but raised that of type I tRNAs, with downstream effects on mitochondrial translation and respiration, and cell death. In RIC8A knockdown cells, a subcomplex was formed that interacted with type I tRNA, but the negative regulation by type II tRNA was lost. Mitochondrial extracts from these cells were defective for type II, but not type I, import; import and regulation were restored by purified RIC8A. These results provide evidence for the relevance of allosteric regulation in vivo and indicate that acquisition of new tRNA-binding domains by ancient respiratory components have played a key role in the evolution of mitochondrial tRNA import.	Indian Inst Chem Biol, Genet Engn Lab, Kolkata 700032, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Adhya, S (corresponding author), Indian Inst Chem Biol, Genet Engn Lab, 4 Raja Sc Mullick Rd, Kolkata 700032, W Bengal, India.	sadhya@iicb.res.in	Home, Pratik/D-5061-2014; MUKHERJEE, SAIKAT/ABF-1050-2021	Mahata, Bidesh/0000-0002-4506-0184; Dhar, Gunjan/0000-0003-2754-4254				Bhattacharyya SN, 2004, J BIOL CHEM, V279, P11259, DOI 10.1074/jbc.C300540200; Bhattacharyya SN, 2003, MOL CELL BIOL, V23, P5217, DOI 10.1128/MCB.23.15.5217-5224.2003; Bhattacharyya SN, 2002, MOL CELL BIOL, V22, P4372, DOI 10.1128/MCB.22.12.4372-4382.2002; Bhattacharyya SN, 2000, MOL CELL BIOL, V20, P7410, DOI 10.1128/MCB.20.19.7410-7417.2000; Bhattacharyya Suvendra Nath, 2004, RNA Biol, V1, P84, DOI 10.4161/rna.1.2.1180; BRINGAUD F, 1995, MOL BIOCHEM PARASIT, V71, P65, DOI 10.1016/0166-6851(95)00023-T; Esseiva AC, 2004, MOL BIOL CELL, V15, P2750, DOI 10.1091/mbc.E03-11-0821; Gao XG, 2003, BIOCHEMISTRY-US, V42, P9067, DOI 10.1021/bi0341814; GHOSH A, 1994, NUCLEIC ACIDS RES, V22, P1663, DOI 10.1093/nar/22.9.1663; Goswami S, 2003, NUCLEIC ACIDS RES, V31, P5552, DOI 10.1093/nar/gkg773; Goswami S, 2006, P NATL ACAD SCI USA, V103, P8354, DOI 10.1073/pnas.0510869103; HANCOCK K, 1990, J BIOL CHEM, V265, P19203; Horvath A, 2000, J BIOL CHEM, V275, P17160, DOI 10.1074/jbc.M907246199; Horvath A, 2000, SCIENCE, V287, P1639, DOI 10.1126/science.287.5458.1639; Ivens AC, 2005, SCIENCE, V309, P436, DOI 10.1126/science.1112680; Mahapatra S, 1996, J BIOL CHEM, V271, P20432, DOI 10.1074/jbc.271.34.20432; Mahata B, 2005, J BIOL CHEM, V280, P5141, DOI 10.1074/jbc.C400572200; Maslov DA, 1999, MOL BIOCHEM PARASIT, V99, P207, DOI 10.1016/S0166-6851(99)00028-6; Nabholz CE, 1999, MOL BIOL CELL, V10, P2547, DOI 10.1091/mbc.10.8.2547; Schagger H, 1996, Methods Enzymol, V264, P555, DOI 10.1016/S0076-6879(96)64048-8; Schneider A, 2000, TRENDS CELL BIOL, V10, P509, DOI 10.1016/S0962-8924(00)01854-7; SCHOPPINK PJ, 1989, EUR J BIOCHEM, V181, P475, DOI 10.1111/j.1432-1033.1989.tb14749.x; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; Speijer D, 1997, MOL BIOCHEM PARASIT, V85, P171, DOI 10.1016/S0166-6851(96)02823-X; Speijer D, 1996, MOL BIOCHEM PARASIT, V79, P47, DOI 10.1016/0166-6851(96)02648-5; TARASSOV I, 1995, EMBO J, V14, P3461, DOI 10.1002/j.1460-2075.1995.tb07352.x; TARASSOV I, 1995, J MOL BIOL, V245, P315, DOI 10.1006/jmbi.1994.0026	27	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25270	25277		10.1074/jbc.M604126200	http://dx.doi.org/10.1074/jbc.M604126200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16825195	hybrid			2022-12-25	WOS:000240031300028
J	Irvine, KM; Burns, CJ; Wilks, AF; Su, S; Hume, DA; Sweet, MJ				Irvine, Katharine M.; Burns, Christopher J.; Wilks, Andrew F.; Su, Stephen; Hume, David A.; Sweet, Matthew J.			A CSF-1 receptor kinase inhibitor targets effector functions and inhibits pro-inflammatory cytokine production from murine macrophage populations	FASEB JOURNAL			English	Article						fms; imatinib mesylate; inflammation; BMM; TEPM	COLONY-STIMULATING FACTOR; FACTOR-I RECEPTOR; OF-FUNCTION MUTATIONS; T-CELL PROLIFERATION; GROWTH-FACTOR; C-FMS; TYROSINE KINASE; BACTERIAL LIPOPOLYSACCHARIDE; MONONUCLEAR PHAGOCYTES; SIGNAL-TRANSDUCTION	CSF-1 regulates macrophage differentiation, survival, and function, and is an attractive therapeutic target for chronic inflammation and malignant diseases. Here we describe the effects of a potent and selective inhibitor of CSF-1R -CYC10268 -on CSF1R-dependent signaling. In in vitro kinase assays, CYC10268 was active in the low nanomolar range and showed selectivity over other kinases such as Ab1 and Kit. CYC10268 blocked survival mediated by CSF-1R in primary murine bone marrow-derived macrophages (BMM) and in the factor-dependent cell line Ba/ F3, in which the CSF-1R was ectopically expressed. CYC10268 also inhibited CSF-1 regulated signaling (Akt, ERK-1/ 2), gene expression (urokinase plasminogen activator, toll-like receptor 9, and apolipoprotein E), and priming of LPS-inducible cytokine production in BMM. In thioglycollate-elicited peritoneal macrophages (TEPM), which survive in the absence of exogenous CSF-1, CYC10268 impaired LPS-induced cytokine production and regulated expression of known CSF-1 target genes. These observations support the conclusion that TEPM are CSF-1 autocrine and that CSF-1 plays a central role in macrophage effector functions during inflammation. CSF-1R inhibitors such as CYC10268 provide a powerful tool to dissect the role of the CSF-1/ CSF-1R signaling system in a range of biological systems and have potential for a number of therapeutic applications.	Univ Queensland, Cooperat Res Ctr Chron Inflammatory Dis, Brisbane, Qld, Australia; Univ Queensland, Special Res Ctr Funct & Appl Genom, Inst Mol Biosci, Brisbane, Qld, Australia; Univ Queensland, Sch Mol & Microbial Sci, Brisbane, Qld, Australia	University of Queensland; University of Queensland; University of Queensland	Sweet, MJ (corresponding author), Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.	m.sweet@imb.uq.edu.au	Hume, David A/C-7695-2013; Sweet, Matthew J/F-2229-2011; Wilks, Andrew F/R-5542-2019; Irvine, Katharine M/A-5559-2011	Sweet, Matthew J/0000-0002-0406-8139; Irvine, Katharine M/0000-0002-6716-1605; Hume, David/0000-0002-2615-1478; Burns, Christopher/0000-0002-4463-4916; Wilks, Andrew F/0000-0002-8554-2399				Agrawal S, 2002, TRENDS MOL MED, V8, P114, DOI 10.1016/S1471-4914(01)02264-X; Aharinejad S, 2004, CANCER RES, V64, P5378, DOI 10.1158/0008-5472.CAN-04-0961; Aharinejad S, 2002, CANCER RES, V62, P5317; Arora A, 2005, J PHARMACOL EXP THER, V315, P971, DOI 10.1124/jpet.105.084145; BACCARINI M, 1992, J IMMUNOL, V149, P2656; Balabanov S, 2005, ANN NY ACAD SCI, V1044, P168, DOI 10.1196/annals.1349.022; Bischof RJ, 2000, CLIN EXP IMMUNOL, V119, P361; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; BURNS CJ, 2003, Patent No. 03099796; Campbell IK, 2000, J LEUKOCYTE BIOL, V68, P144; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; Carter TA, 2005, P NATL ACAD SCI USA, V102, P11011, DOI 10.1073/pnas.0504952102; CECCHINI MG, 1994, DEVELOPMENT, V120, P1357; CHAMBERS SK, 1995, CANCER RES, V55, P1578; Chan J, 1998, BLOOD, V92, P1423, DOI 10.1182/blood.V92.4.1423.416k31_1423_1431; Chapoval AI, 1998, J LEUKOCYTE BIOL, V63, P245, DOI 10.1002/jlb.63.2.245; CHEN BDM, 1986, J IMMUNOL, V137, P563; CHODAKEWITZ JA, 1990, J IMMUNOL, V144, P2190; Conway JG, 2005, P NATL ACAD SCI USA, V102, P16078, DOI 10.1073/pnas.0502000102; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; Dewar AL, 2005, BLOOD, V105, P3127, DOI 10.1182/blood-2004-10-3967; Dey A, 2000, MOL BIOL CELL, V11, P3835, DOI 10.1091/mbc.11.11.3835; Dietz AB, 2004, BLOOD, V104, P1094, DOI 10.1182/blood-2003-12-4266; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; DOYLE AG, 1992, INFECT IMMUN, V60, P1465, DOI 10.1128/IAI.60.4.1465-1472.1992; EVANS R, 1992, J LEUKOCYTE BIOL, V51, P93, DOI 10.1002/jlb.51.1.93; Fabbro D, 2002, PHARMACOL THERAPEUT, V93, P79, DOI 10.1016/S0163-7258(02)00179-1; Fixe P, 1997, EUR CYTOKINE NETW, V8, P91; Goyal A, 2002, AM J RESP CELL MOL, V26, P224, DOI 10.1165/ajrcmb.26.2.4640; Guidez F, 1998, MOL CELL BIOL, V18, P3851, DOI 10.1128/MCB.18.7.3851; GUILBERT LJ, 1984, J IMMUNOL METHODS, V73, P17, DOI 10.1016/0022-1759(84)90027-9; Hamilton JA, 2003, J LEUKOCYTE BIOL, V73, P702, DOI 10.1189/jlb.0103037; Hamilton JA, 1997, IMMUNOL TODAY, V18, P313, DOI 10.1016/S0167-5699(97)01084-0; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hirota S, 2003, GASTROENTEROLOGY, V125, P660, DOI 10.1016/S0016-5085(03)01046-1; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; HUME DA, 1988, J IMMUNOL, V141, P3405; Isbel NM, 2001, NEPHROL DIAL TRANSPL, V16, P1638, DOI 10.1093/ndt/16.8.1638; KACINSKI BM, 1991, ONCOGENE, V6, P941; Kacinski BM, 1997, MOL REPROD DEV, V46, P71, DOI 10.1002/(SICI)1098-2795(199701)46:1<71::AID-MRD11>3.0.CO;2-6; Kamdar SJ, 1996, CELL IMMUNOL, V174, P165, DOI 10.1006/cimm.1996.0306; Klebl FH, 2001, J PATHOL, V195, P609, DOI 10.1002/path.991; Krieg AM, 2001, CURR OPIN MOL THER, V3, P15; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Lenda DM, 2003, J IMMUNOL, V170, P3254, DOI 10.4049/jimmunol.170.6.3254; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lin EY, 2002, J MAMMARY GLAND BIOL, V7, P147, DOI 10.1023/A:1020399802795; Moss ST, 2000, IMMUNOBIOLOGY, V202, P18, DOI 10.1016/S0171-2985(00)80048-0; Murray LJ, 2003, CLIN EXP METASTAS, V20, P757, DOI 10.1023/B:CLIN.0000006873.65590.68; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; Okada S, 1998, J IMMUNOL, V160, P2590; Okazaki T, 2005, J IMMUNOL, V174, P7531, DOI 10.4049/jimmunol.174.12.7531; Paul S, 2003, CURR OPIN MOL THER, V5, P553; Roth P, 1997, J IMMUNOL, V158, P3874; Sapi E, 1999, P SOC EXP BIOL MED, V220, P1, DOI 10.1046/j.1525-1373.1999.d01-1.x; Seggewiss R, 2005, BLOOD, V105, P2473, DOI 10.1182/blood-2004-07-2527; Sester DP, 1999, J IMMUNOL, V163, P6541; Sevilla L, 2001, J BIOL CHEM, V276, P17800, DOI 10.1074/jbc.M008270200; SHERR CJ, 1992, CIBA F SYMP, V170, P209; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; Smith JL, 2000, MOL CELL BIOL, V20, P8026, DOI 10.1128/MCB.20.21.8026-8034.2000; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V; Stewart C C, 1994, Immunol Ser, V60, P3; STEWART CC, 1975, J EXP MED, V141, P1114, DOI 10.1084/jem.141.5.1114; Sudo T, 1995, ONCOGENE, V11, P2469; Sweeney KJ, 2003, SURG J R COLL SURG E, V1, P177, DOI 10.1016/S1479-666X(03)80100-2; Sweet MJ, 2002, J IMMUNOL, V168, P392, DOI 10.4049/jimmunol.168.1.392; Taylor JR, 2006, ONCOGENE, V25, P147, DOI 10.1038/sj.onc.1209007; Toy EP, 2001, GYNECOL ONCOL, V80, P194, DOI 10.1006/gyno.2000.6070; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; Uden M, 1999, ONCOGENE, V18, P3846, DOI 10.1038/sj.onc.1202743; Utsunomiya Y, 1996, CLIN EXP IMMUNOL, V106, P286, DOI 10.1046/j.1365-2249.1996.d01-831.x; Wang HW, 2005, BLOOD, V105, P1135, DOI 10.1182/blood-2004-01-0027; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; WiktorJedrzejczak W, 1996, PHYSIOL REV, V76, P927, DOI 10.1152/physrev.1996.76.4.927; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WING EJ, 1986, J IMMUNOL, V137, P2768; Yee LD, 2000, ANTICANCER RES, V20, P4379	82	68	70	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1921	+		10.1096/fj.06-5848fje	http://dx.doi.org/10.1096/fj.06-5848fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16877523				2022-12-25	WOS:000240267000031
J	Levin, MH; Sullivan, S; Nielson, D; Yang, BX; Finkbeiner, WE; Verkman, AS				Levin, Marc H.; Sullivan, Shannon; Nielson, Dennis; Yang, Baoxue; Finkbeiner, Walter E.; Verkman, A. S.			Hypertonic saline therapy in cystic fibrosis - Evidence against the proposed mechanism involving aquaporins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG FLUID TRANSPORT; MUCOCILIARY CLEARANCE; WATER PERMEABILITY; INHALED MANNITOL; MUCUS CLEARANCE; SURFACE LIQUID; AMILORIDE; INHALATION; CHANNELS; SPUTUM	Recent data indicate the clinical benefit of nebulized hypertonic saline in cystic fibrosis lung disease, with a proposed mechanism involving sustained increase in airway surface liquid volume. To account for the paradoxical observation that amiloride suppresses the beneficial effect of hypertonic saline, it has been previously concluded (Donaldson, S. H., Bennett, W. D., Zeman, K. L., Knowles, M. R., Tarran, R., and Boucher, R. C. (2006) N. Engl. J. Med. 354, 241 - 250) that amiloride-inhibitable aquaporin (AQP) water channels in airway epithelia modulate airway surface liquid volume. Here, we have characterized water permeability and amiloride effects in well differentiated, primary cultures of human airway epithelial cells, stably transfected Fisher rat thyroid epithelial cells expressing individual airway/lung AQPs, and perfused mouse lung. We found high transepithelial water permeability (P-f, 54 +/- 5 mu m/s) in airway epithelial cells that was weakly temperature-dependent and inhibited by > 90% by reduced pH in the basal membrane-facing solution. Reverse transcription-PCR and immunofluorescence suggested the involvement of AQPs 3, 4, and 5 in high airway water permeability. Experiments using several sensitive measurement methods indicated that amiloride does not inhibit water permeability in non-cystic fibrosis (non-CF) or CF airway epithelia, AQP-transfected Fisher rat thyroid cells, or intact lung. Our data provide evidence against the mechanism proposed by Donaldson et al. to account for the effects of amiloride and hypertonic saline in CF lung disease, indicating the need to identify alternate mechanisms.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu			NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL73856] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124, DK72517] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574, P30EY002162] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073856, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072517, R37DK035124, R01DK035124] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APP EM, 1990, AM REV RESPIR DIS, V141, P605, DOI 10.1164/ajrccm/141.3.605; Bai CX, 1999, J CLIN INVEST, V103, P555, DOI 10.1172/JCI4138; Borok Z, 2002, J APPL PHYSIOL, V93, P2199, DOI 10.1152/japplphysiol.01171.2001; Carter EP, 1996, J GEN PHYSIOL, V108, P133, DOI 10.1085/jgp.108.3.133; Daviskas E, 1997, EUR RESPIR J, V10, P2449, DOI 10.1183/09031936.97.10112449; Daviskas E, 2005, RESPIROLOGY, V10, P46, DOI 10.1111/j.1440-1843.2005.00659.x; Daviskas E, 1996, EUR RESPIR J, V9, P725, DOI 10.1183/09031936.96.09040725; Donaldson SH, 2006, NEW ENGL J MED, V354, P241, DOI 10.1056/NEJMoa043891; Durairaj L, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-13; Elkins MR, 2006, NEW ENGL J MED, V354, P229, DOI 10.1056/NEJMoa043900; Eng PA, 1996, PEDIATR PULM, V21, P77, DOI 10.1002/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.0.CO;2-M; Fang X, 2002, J GEN PHYSIOL, V119, P199, DOI 10.1085/jgp.119.2.199; Feng W, 1998, AM J RESP CRIT CARE, V157, P710, DOI 10.1164/ajrccm.157.3.9703059; FOLKESSON HG, 1994, P NATL ACAD SCI USA, V91, P4970, DOI 10.1073/pnas.91.11.4970; Folkesson HG, 1996, J CLIN INVEST, V97, P664, DOI 10.1172/JCI118463; Fulcher M Leslie, 2005, Methods Mol Med, V107, P183; HASEGAWA H, 1994, AM J PHYSIOL, V266, pC893, DOI 10.1152/ajpcell.1994.266.4.C893; Hirsh AJ, 2004, J PHARMACOL EXP THER, V311, P929, DOI 10.1124/jpet.104.071886; King LS, 1997, AM J PHYSIOL-CELL PH, V273, pC1541, DOI 10.1152/ajpcell.1997.273.5.C1541; King M, 1997, AM J RESP CRIT CARE, V156, P173, DOI 10.1164/ajrccm.156.1.9512074; Kreda SM, 2001, AM J RESP CELL MOL, V24, P224, DOI 10.1165/ajrcmb.24.3.4367; Levin MH, 2004, INVEST OPHTH VIS SCI, V45, P4423, DOI 10.1167/iovs.04-0816; Ma TH, 1999, J BIOL CHEM, V274, P20071, DOI 10.1074/jbc.274.29.20071; Ma TH, 2000, J CLIN INVEST, V105, P93, DOI 10.1172/JCI8258; Matsui H, 2000, J CLIN INVEST, V105, P1419, DOI 10.1172/JCI4546; Matthay MA, 1996, AM J PHYSIOL-LUNG C, V270, pL487, DOI 10.1152/ajplung.1996.270.4.L487; PAVIA D, 1978, AM REV RESPIR DIS, V117, P199; Pedemonte N, 2005, J CLIN INVEST, V115, P2564, DOI 10.1172/JCI24898; Pedersen PS, 2005, PFLUG ARCH EUR J PHY, V451, P464, DOI 10.1007/s00424-005-1484-5; Robinson M, 1996, AM J RESP CRIT CARE, V153, P1503, DOI 10.1164/ajrccm.153.5.8630593; Robinson M, 1999, EUR RESPIR J, V14, P678, DOI 10.1034/j.1399-3003.1999.14c30.x; Robinson M, 1997, THORAX, V52, P900, DOI 10.1136/thx.52.10.900; Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460; Sajjan U, 2004, J HEART LUNG TRANSPL, V23, P1382, DOI 10.1016/j.healun.2003.09.023; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; Song YL, 2001, J GEN PHYSIOL, V117, P573, DOI 10.1085/jgp.117.6.573; Sood N, 2003, AM J RESP CRIT CARE, V167, P158, DOI 10.1164/rccm.200204-293OC; Verkman AS, 2005, J CELL SCI, V118, P3225, DOI 10.1242/jcs.02519; Wills PJ, 1997, J CLIN INVEST, V99, P9, DOI 10.1172/JCI119138; YAMAYA M, 1992, AM J PHYSIOL, V262, pL713, DOI 10.1152/ajplung.1992.262.6.L713; Zabner J, 2000, P NATL ACAD SCI USA, V97, P11614, DOI 10.1073/pnas.97.21.11614; Zeuthen T, 1999, J BIOL CHEM, V274, P21631, DOI 10.1074/jbc.274.31.21631	42	43	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25803	25812		10.1074/jbc.M604332200	http://dx.doi.org/10.1074/jbc.M604332200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16829520	hybrid			2022-12-25	WOS:000240031300082
J	Sun, XL; He, GQ; Song, WH				Sun, Xiulian; He, Guiqiong; Song, Weihong			BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome	FASEB JOURNAL			English	Article						BACE2; theta-secretase; Alzheimer; Down syndrome; Trisomy 21	AMYLOID PRECURSOR PROTEIN; BETA-SECRETASE; TRANSCRIPTIONAL REGULATION; ENZYMATIC-ACTIVITY; ASPARTYL PROTEASE; CRYSTAL-STRUCTURE; CLEAVING ENZYME; GENE-EXPRESSION; GENOME SCREEN; KNOCKOUT MICE	Amyloid beta protein (A beta), the major component of neuritic plaques in Alzheimer's disease (AD), is derived from APP by sequential cleavages of beta- and gamma-secretases. Beta-site APP cleaving enzyme 1 (BACE1) is the major beta-secretase in vivo. Beta-site APP cleaving enzyme 2 (BACE2) is the homologue of BACE1. The majority of people with Down syndrome (DS), also called Trisomy 21 syndrome, will develop AD neuropathology after middle age. We and others have shown that APP C99, the major beta-secretase product, and A beta are markedly increased in DS. Since BACE2 is located on chromosome 21, it is speculated that BACE2 may play a role in AD pathogenesis in DS. In this report we found that BACE2 cleaves APP at a novel theta site downstream of the alpha site, abolishing A beta production. Overexpression of BACE2 by lentivirus markedly reduced A beta production in primary neurons derived from Swedish mutant APP transgenic mice. Despite an extra copy of the BACE2 gene in DS and the increase of its transcription, BACE2 protein levels are unchanged. Our data clearly demonstrate that BACE2, as a novel theta-secretase to cleave APP within the A beta domain, is not involved in the AD pathogenesis of DS patients; instead, therapeutic interventions that potentiate BACE2 may prevent AD pathogenesis.	Univ British Columbia, Dept Psychiat, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Grad Program Neurosci, Vancouver, BC V6T 1Z3, Canada; Chongqing Univ Med Sci, Dept Human Anat, Chongqing, Peoples R China	University of British Columbia; University of British Columbia; Chongqing Medical University	Song, WH (corresponding author), Univ British Columbia, Dept Psychiat, Brain Res Ctr, 2255 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	weihong@interchange.ubc.ca	Song, Weihong/O-7623-2017	Song, Weihong/0000-0001-9928-889X				Acquati F, 2000, FEBS LETT, V468, P59, DOI 10.1016/S0014-5793(00)01192-3; Basi G, 2003, J BIOL CHEM, V278, P31512, DOI 10.1074/jbc.M300169200; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Blacker D, 2003, HUM MOL GENET, V12, P23, DOI 10.1093/hmg/ddg007; Busciglio J, 2002, NEURON, V33, P677, DOI 10.1016/S0896-6273(02)00604-9; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Charlwood J, 2001, J BIOL CHEM, V276, P16739, DOI 10.1074/jbc.M009361200; Christensen MA, 2004, MOL CELL BIOL, V24, P865, DOI 10.1128/MCB.24.2.865-874.2004; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Cruts M, 2001, NEUROSCI LETT, V313, P105, DOI 10.1016/S0304-3940(01)02234-0; DE SB, 1999, NATURE, V398, P518; Dittgen T, 2004, P NATL ACAD SCI USA, V101, P18206, DOI 10.1073/pnas.0407976101; Dominguez D, 2005, J BIOL CHEM, V280, P30797, DOI 10.1074/jbc.M505249200; Down J.L., 1866, OBSERVATION ETHNIC C, DOI DOI 10.1038/HDY.1966.69; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Fukumoto H, 2004, AM J PATHOL, V164, P719, DOI 10.1016/S0002-9440(10)63159-8; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOLDIN LR, 1993, GENET EPIDEMIOL, V10, P449, DOI 10.1002/gepi.1370100620; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HESTON LL, 1991, AM J MED GENET, V40, P449, DOI 10.1002/ajmg.1320400415; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; Hong L, 2002, BIOCHEMISTRY-US, V41, P10963, DOI 10.1021/bi026232n; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 2000, MOL CELL NEUROSCI, V16, P609, DOI 10.1006/mcne.2000.0884; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Hussain I, 2001, J BIOL CHEM, V276, P23322, DOI 10.1074/jbc.M101069200; JACOBS PA, 1959, LANCET, V1, P710; Kehoe P, 1999, HUM MOL GENET, V8, P237, DOI 10.1093/hmg/8.2.237; LEJEUNE J., 1959, BULL ACAD NATL MED [PARIS], V143, P256; Li Y, 2006, FASEB J, V20, P285, DOI 10.1096/fj.05-4986com; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Luo Y, 2003, NEUROBIOL DIS, V14, P81, DOI 10.1016/S0969-9961(03)00104-9; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Myers A, 2002, AM J MED GENET, V114, P235, DOI 10.1002/ajmg.10183; Myllykangas L, 2005, J NEUROL SCI, V236, P17, DOI 10.1016/j.jns.2005.04.008; Nicolaou M, 2001, NEUROGENETICS, V3, P203; Ostermann N, 2006, J MOL BIOL, V355, P249, DOI 10.1016/j.jmb.2005.10.027; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PODLISNY MB, 1987, SCIENCE, V238, P669, DOI 10.1126/science.2960019; Qing H, 2004, FASEB J, V18, P1571, DOI 10.1096/fj.04-1994fje; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Russo C, 2000, NATURE, V405, P531, DOI 10.1038/35014735; Shi XP, 2001, J BIOL CHEM, V276, P10366, DOI 10.1074/jbc.M009200200; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Solans A, 2000, CYTOGENET CELL GENET, V89, P177, DOI 10.1159/000015608; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Sun XL, 2006, FASEB J, V20, P1361, DOI 10.1096/fj.05-5628com; Sun XL, 2005, FASEB J, V19, P739, DOI 10.1096/fj.04-3426com; Van Dam D, 2003, EUR J NEUROSCI, V17, P388, DOI 10.1046/j.1460-9568.2003.02444.x; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108; Zhou WH, 2006, MOL CELL BIOL, V26, P3353, DOI 10.1128/MCB.26.9.3353-3364.2006	66	122	130	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2006	20	9					1369	1376		10.1096/FJ.05-5632COM	http://dx.doi.org/10.1096/FJ.05-5632COM			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816112				2022-12-25	WOS:000240266000014
J	Tancevski, I; Wehinger, A; Schgoer, W; Eller, P; Cuzzocrea, S; Foeger, B; Patsch, JR; Ritsch, A				Tancevski, Ivan; Wehinger, Andreas; Schgoer, Wilfried; Eller, Philipp; Cuzzocrea, Salvatore; Foeger, Bernhard; Patsch, Josef R.; Ritsch, Andreas			Aspirin regulates expression and function of scavenger receptor-BI in macrophages: studies in primary human macrophages and in mice	FASEB JOURNAL			English	Article						SR-BI; PPAR; KO mice; NF-kappa B	FACTOR-KAPPA-B; SR-BI; CELL-PROLIFERATION; CHOLESTEROL; INHIBITION; PROTEIN; IDENTIFICATION; SALICYLATES; ACTIVATION; PLASMA	Scavenger receptor class B type I (SR-BI) has been shown to be expressed in human atherosclerotic plaque macrophages, where it is believed to reduce atherosclerosis by promoting cholesterol efflux. In this study we investigated the influence of aspirin and other NSAIDs on SR-BI expression and function in cultured human macrophages as well as in different mouse strains. Incubation of human macrophages with 0.5 mmol/l aspirin resulted in increased SR-BI protein expression and increased uptake of HDL-associated [H-3]cholesteryl oleate without changes of SR-BI mRNA levels. In contrast, using 5 mmol/l of aspirin, SR-BI expression and function were significantly decreased. Sodium salicylate exerted similar effects on SR-BI expression, whereas no effects were observed using known COX1/2 inhibitors ibuprofen and naproxen, respectively. In in vivo studies low-dose aspirin treatment (6 mg/kg(.)day) induced SR-BI expression in wildtype and PPAR-alpha knockout mice, respectively, whereas the opposite effect was observed upon high-dose aspirin treatment (60 mg/kg(.)day) in these animals. We could show that COX-independent effects of aspirin were able to enhance expression of SR-BI in macrophages in a post-transcriptional, PPAR-alpha independent	Innsbruck Med Univ, Dept Internal Med, A-6020 Innsbruck, Austria; Univ Messina, Dipartimento Clin & Sperimentale Med & Farmacol, Ctr Studio & Trattamento Neurol Lungodegenti, Fac Med & Chirurg, Messina, Italy	Medical University of Innsbruck; University of Messina	Ritsch, A (corresponding author), Innsbruck Med Univ, Dept Internal Med, Anichstr 35, A-6020 Innsbruck, Austria.	andreas.ritsch@uibk.ac.at	Tancevski, Ivan/AID-5169-2022	Tancevski, Ivan/0000-0001-5116-8960; Ritsch, Andreas/0000-0002-0417-5161				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Awtry EH, 2000, CIRCULATION, V101, P1206, DOI 10.1161/01.CIR.101.10.1206; Bell E, 2003, DIABETES, V52, P2731, DOI 10.2337/diabetes.52.11.2731; CALVO D, 1993, J BIOL CHEM, V268, P18929; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; Chinetti G, 2000, CIRCULATION, V101, P2411, DOI 10.1161/01.CIR.101.20.2411; Connelly MA, 2004, CURR OPIN LIPIDOL, V15, P287, DOI 10.1097/00041433-200406000-00008; CRONSTEIN BN, 1995, ANNU REV PHARMACOL, V35, P449, DOI 10.1146/annurev.pa.35.040195.002313; Cronstein BN, 1999, P NATL ACAD SCI USA, V96, P6377, DOI 10.1073/pnas.96.11.6377; Cuzzocrea S, 2004, LAB INVEST, V84, P1643, DOI 10.1038/labinvest.3700185; Cyrus T, 2002, CIRCULATION, V106, P1282, DOI 10.1161/01.CIR.0000027816.54430.96; de la Llera-Moya M, 2001, J LIPID RES, V42, P1969; de Winther MPJ, 2005, ARTERIOSCL THROM VAS, V25, P904, DOI 10.1161/01.ATV.0000160340.72641.87; Dichtl W, 1999, CIRC RES, V84, P1085, DOI 10.1161/01.RES.84.9.1085; Garcia-Martinez JM, 2003, BIOCHEM PHARMACOL, V65, P209, DOI 10.1016/S0006-2952(02)01511-3; Hirano K, 1999, CIRC RES, V85, P108; Jans DM, 2004, J CARDIOVASC PHARM, V43, P462, DOI 10.1097/00005344-200403000-00019; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; Kagawa A, 1999, J BIOL CHEM, V274, P34111, DOI 10.1074/jbc.274.48.34111; Kaser S, 2001, METABOLISM, V50, P723, DOI 10.1053/meta.2001.23307; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Martel-Pelletier J, 2004, ARTHRITIS RHEUM-US, V50, P3925, DOI 10.1002/art.20632; Matasic R, 2000, IMMUNOLOGY, V101, P53, DOI 10.1046/j.1365-2567.2000.00065.x; Mouithys-Mickalad A, 2004, BIOCHEM BIOPH RES CO, V325, P1122, DOI 10.1016/j.bbrc.2004.10.155; PATSCH JR, 1974, J LIPID RES, V15, P356; Pillinger MH, 1998, P NATL ACAD SCI USA, V95, P14540, DOI 10.1073/pnas.95.24.14540; Planaguma A, 2002, FASEB J, V16, P1937, DOI 10.1096/fj.02-0224fje; Ranganathan S, 2003, BIOCHEM BIOPH RES CO, V301, P143, DOI 10.1016/S0006-291X(02)02987-X; RECALDE HR, 1984, J IMMUNOL METHODS, V69, P71, DOI 10.1016/0022-1759(84)90278-3; Ritsch A, 2004, J LIPID RES, V45, P214, DOI 10.1194/jlr.M300353-JLR200; Silver DL, 2004, REV ENDOCR METAB DIS, V5, P327, DOI 10.1023/B:REMD.0000045104.38104.8e; Tancevski I, 2005, J MOL MED, V83, P927, DOI 10.1007/s00109-005-0695-8; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Van Eck M, 2004, AM J PATHOL, V165, P785, DOI 10.1016/S0002-9440(10)63341-X; Vinals M, 2005, CARDIOVASC RES, V66, P141, DOI 10.1016/j.cardiores.2004.12.024; Voisard R, 2001, CIRCULATION, V103, P1688, DOI 10.1161/01.CIR.103.12.1688; Yesilaltay A, 2005, CURR OPIN LIPIDOL, V16, P147, DOI 10.1097/01.mol.0000162319.54795.e5	40	16	17	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1328	1335		10.1096/fj.05-5368com	http://dx.doi.org/10.1096/fj.05-5368com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16816107				2022-12-25	WOS:000240266000009
J	Borczuk, AC; Cappellini, GCA; Kim, HK; Hesdorffer, M; Taub, RN; Powell, CA				Borczuk, A. C.; Cappellini, G. C. A.; Kim, H. K.; Hesdorffer, M.; Taub, R. N.; Powell, C. A.			Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors	ONCOGENE			English	Article						mesothelioma; microarray analysis; bortezomib; drug therapy combination	PLEURAL MESOTHELIOMA; PHASE-II; EXPRESSION; GEMCITABINE; CANCER; CELL; COMBINATION; DOCETAXEL; OVEREXPRESSION; CISPLATIN	Malignant mesothelioma is an aggressive neoplastic proliferation derived from cells lining serosal membranes. The biological and clinical characteristics of epithelial type malignant mesothelioma are distinct from those of biphasic and sarcomatous type tumors. The goal of our study was to examine the molecular basis for this distinction. Microarray analysis confirmed that the molecular signatures of epithelial and biphasic histologic subtypes were distinct. Among the differentially expressed functional gene categories was the ubiquitin-proteasome pathway, which was upregulated in biphasic tumors. Cytotoxicity experiments indicated that 211H cells derived from biphasic tumors were synergistically sensitive to sequential combination regimens containing the proteasome inhibitor bortezomib and oxaliplatin. The mechanism of this synergistic response, which was not detected in cells of epithelial tumor origin, was apoptosis. Together, our results identify the ubiquitin-proteasome pathway as a biomarker of poor prognosis biphasic peritoneal mesothelioma tumors and suggest that proteasome inhibitors could increase the effectiveness of cytotoxic chemotherapy in this subset of patients.	Columbia Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Coll Phys & Surg,Dept Med, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Columbia University; Columbia University	Powell, CA (corresponding author), Columbia Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Coll Phys & Surg,Dept Med, 630 W 168th St,Box 91, New York, NY 10032 USA.	cap6@columbia.edu	Borczuk, Alain/AAI-8226-2021; Powell, Charles A/C-8663-2011; BORCZUK, alain/AHA-5172-2022; Borczuk, Alain/AFU-5278-2022	Borczuk, Alain/0000-0001-6807-8064; Powell, Charles A/0000-0003-3509-891X; Borczuk, Alain/0000-0001-6807-8064				Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Borczuk AC, 2005, AM J RESP CRIT CARE, V172, P729, DOI 10.1164/rccm.200504-615OC; Borczuk AC, 2005, CLIN CANCER RES, V11, P3303, DOI 10.1158/1078-0432.CCR-04-1884; Borczuk AC, 2003, AM J PATHOL, V163, P1949, DOI 10.1016/S0002-9440(10)63553-5; Fally BN, 2003, J SURG RES, V113, P88, DOI 10.1016/S0022-4804(03)00201-4; Fizazi K, 2003, J CLIN ONCOL, V21, P349, DOI 10.1200/JCO.2003.05.123; Gentiloni N, 1997, J CLIN GASTROENTEROL, V24, P276, DOI 10.1097/00004836-199706000-00023; GOLDBLUM J, 1995, AM J SURG PATHOL, V19, P1124, DOI 10.1097/00000478-199510000-00003; Gordon GJ, 2005, AM J PATHOL, V166, P1827, DOI 10.1016/S0002-9440(10)62492-3; Gordon GJ, 2003, J NATL CANCER I, V95, P598, DOI 10.1093/jnci/95.8.598; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Khalil N, 2001, THORAX, V56, P907, DOI 10.1136/thorax.56.12.907; Kim H, 2003, AM J RESP CELL MOL, V29, P694, DOI 10.1165/rcmb.2003-0061OC; Kitagawa Y, 1996, AM J RESP CELL MOL, V15, P45, DOI 10.1165/ajrcmb.15.1.8679221; Lee JJ, 1996, CANCER EPIDEM BIOMAR, V5, P191; Leu KM, 2004, J CLIN ONCOL, V22, P1706, DOI 10.1200/JCO.2004.08.043; Lopez-Rios F, 2006, CANCER RES, V66, P2970, DOI 10.1158/0008-5472.CAN-05-3907; McShane LM, 2002, BIOINFORMATICS, V18, P1462, DOI 10.1093/bioinformatics/18.11.1462; Mohamed Faheez, 2002, Curr Treat Options Oncol, V3, P375, DOI 10.1007/s11864-002-0003-6; Nawrocki ST, 2004, MOL CANCER THER, V3, P59; Nowak AK, 2002, BRIT J CANCER, V87, P491, DOI 10.1038/sj.bjc.6600505; Pass HI, 2004, CLIN CANCER RES, V10, P849, DOI 10.1158/1078-0432.CCR-0607-3; Rajkumar SV, 2005, J CLIN ONCOL, V23, P630, DOI 10.1200/JCO.2005.11.030; REILE H, 1990, ANAL BIOCHEM, V187, P262, DOI 10.1016/0003-2697(90)90454-H; Ricotti L, 2003, CLIN CANCER RES, V9, P900; Robinson BW, 2004, SEMIN ONCOL, V31, P2, DOI 10.1053/j.seminoncol.2004.03.021; Schenkein David P, 2005, Clin Lung Cancer, V7 Suppl 2, pS49, DOI 10.3816/CLC.2005.s.008; Schutte Wolfgang, 2003, Clin Lung Cancer, V4, P294, DOI 10.3816/CLC.2003.n.009; Sebbag G, 2000, BRIT J SURG, V87, P1587, DOI 10.1046/j.1365-2168.2000.01571.x; Singhal S, 2003, CLIN CANCER RES, V9, P3080; Sugarbaker Paul H, 2003, Surg Oncol Clin N Am, V12, P605, DOI 10.1016/S1055-3207(03)00045-0; Tallarida RJ, 2001, J PHARMACOL EXP THER, V298, P865; Taub R N, 2000, Curr Treat Options Oncol, V1, P303, DOI 10.1007/s11864-000-0046-5; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Voorhees PM, 2003, CLIN CANCER RES, V9, P6316	37	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					610	617		10.1038/sj.onc.1209809	http://dx.doi.org/10.1038/sj.onc.1209809			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16862182				2022-12-25	WOS:000243731600013
J	Duensing, A; Liu, Y; Spardy, N; Bartoli, K; Tseng, M; Kwon, JA; Teng, X; Duensing, S				Duensing, A.; Liu, Y.; Spardy, N.; Bartoli, K.; Tseng, M.; Kwon, J-A; Teng, X.; Duensing, S.			RNA polymerase II transcription is required for human papillomavirus type 16 E7-and hydroxyurea-induced centriole overduplication	ONCOGENE			English	Article						HPV-16 E7; hydroxyurea; centrioles; RNA polymerase II; cyclin A	CENTROSOME DUPLICATION; GENOMIC INSTABILITY; CELLS; CYCLE; AMPLIFICATION; TRANSFORMATION; DISSOCIATION; REPRODUCTION; REPLICATION; PROTEINS	Aberrant centrosome numbers are detected in virtually all human cancers where they can contribute to chromosomal instability by promoting mitotic spindle abnormalities. Despite their widespread occurrence, the molecular mechanisms that underlie centrosome amplification are only beginning to emerge. Here, we present evidence for a novel regulatory circuit involved in centrosome overduplication that centers on RNA polymerase II (pol II). We found that human papillomavirus type 16 E7(HPV-16 E7)- and hydroxyurea (HU)-induced centriole overduplication are abrogated by alpha-amanitin, a potent and specific RNA pol II inhibitor. In contrast, normal centriole duplication proceeded undisturbed in alpha-amanitin-treated cells. Centriole overduplication was significantly reduced by siRNA-mediated knock down of CREB-binding protein (CBP), a transcriptional co-activator. We identifi ed cyclin A2 as a key transcriptional target of RNA pol II during HU-induced centriole overduplication. Collectively, our results show that ongoing RNA pol II transcription is required for centriole overduplication whereas it may be dispensable for normal centriole duplication. Given that many chemotherapeutic agents function through inhibition of transcription, our results may help to develop strategies to target centrosome-mediated chromosomal instability for cancer therapy and prevention.	Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Mol Virol Program, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Biochem & Mol Genet Grad Program, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Duensing, S (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Mol Virol Program, Res Pavil Suite 1-8,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	duensing@pitt.edu		Duensing, Anette/0000-0002-0168-4067	NATIONAL CANCER INSTITUTE [R01CA112598] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA112598-03, R01 CA112598] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai VU, 2005, J CELL PHYSIOL, V204, P381, DOI 10.1002/jcp.20422; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; BRAUDE PR, 1979, DEV BIOL, V68, P440, DOI 10.1016/0012-1606(79)90216-1; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bushnell DA, 2002, P NATL ACAD SCI USA, V99, P1218, DOI 10.1073/pnas.251664698; Caldeira S, 2000, ONCOGENE, V19, P821, DOI 10.1038/sj.onc.1203375; D'Assoro AB, 2004, ONCOGENE, V23, P4068, DOI 10.1038/sj.onc.1207568; Derheimer FA, 2005, EUR J CANCER, V41, P2569, DOI 10.1016/j.ejca.2005.08.012; Dodson H, 2004, EMBO J, V23, P3864, DOI 10.1038/sj.emboj.7600393; Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8; Duensing A, 2006, ONCOGENE, V25, P2943, DOI 10.1038/sj.onc.1209310; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2005, CELL BIOL INT, V29, P352, DOI 10.1016/j.cellbi.2005.03.005; Duensing S, 2004, ONCOGENE, V23, P8206, DOI 10.1038/sj.onc.1208012; Duensing S, 2001, BBA-REV CANCER, V1471, pM81, DOI 10.1016/S0304-419X(00)00025-1; Duensing S, 2001, CANCER RES, V61, P2356; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Faivre J, 2002, ONCOGENE, V21, P1493, DOI 10.1038/sj.onc.1205215; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; GIRDHAM CH, 1991, GENE DEV, V5, P1786, DOI 10.1101/gad.5.10.1786; Gong XQ, 2004, J BIOL CHEM, V279, P27422, DOI 10.1074/jbc.M402163200; Guarguaglini G, 2005, MOL BIOL CELL, V16, P1095, DOI 10.1091/mbc.E04-10-0939; Hahn S, 2004, NAT STRUCT MOL BIOL, V11, P394, DOI 10.1038/nsmb763; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hoffelder DR, 2004, CHROMOSOMA, V112, P389, DOI 10.1007/s00412-004-0284-6; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Jiang Y, 2004, MOL CELL, V14, P375, DOI 10.1016/S1097-2765(04)00234-5; KURIYAMA R, 1981, J CELL BIOL, V91, P814, DOI 10.1083/jcb.91.3.814; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; McDermott KM, 2006, PLOS BIOL, V4, P350, DOI 10.1371/journal.pbio.0040051; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Parvin JD, 1998, CURR OPIN GENET DEV, V8, P565, DOI 10.1016/S0959-437X(98)80012-9; PHILLIPS SG, 1976, J CELL BIOL, V70, P9, DOI 10.1083/jcb.70.1.9; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; SLUDER G, 1986, J CELL BIOL, V103, P1873, DOI 10.1083/jcb.103.5.1873; TOMMASINO M, 1993, ONCOGENE, V8, P195; Urbani L, 1999, CURR BIOL, V9, pR315, DOI 10.1016/S0960-9822(99)80201-2; UZAWA M, 1995, DEV BIOL, V171, P51, DOI 10.1006/dbio.1995.1259; Wong C, 2003, NAT CELL BIOL, V5, P539, DOI 10.1038/ncb993; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y	50	17	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					215	223		10.1038/sj.onc.1209782	http://dx.doi.org/10.1038/sj.onc.1209782			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819507	Green Accepted			2022-12-25	WOS:000243398300005
J	Vidal, GA; Clark, DE; Marrero, L; Jones, FE				Vidal, G. A.; Clark, D. E.; Marrero, L.; Jones, F. E.			A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities	ONCOGENE			English	Article						EGFR-family; STAT5A; apoptosis; nuclear translocation; transactivation	TYROSINE KINASE-ACTIVITY; GROWTH-FACTOR RECEPTOR; BREAST-CANCER; NEU ONCOGENE; TRANSMEMBRANE DOMAIN; POINT MUTATION; MAMMARY-GLAND; EXPRESSION; PROTEIN; ACTIVATION	In the normal breast, ERBB4 regulates epithelial differentiation and functions as a nuclear chaperone for signal transducer and activator of transcription (STAT) 5A, thereby stimulating milk-gene expression. In addition, ERBB4 functions as a proapoptotic protein, suppressing the growth of malignant cells. We hypothesize that these ERBB4 activities can be marshaled to suppress the growth of breast tumors. To this end, we have created an ERBB4 allele harboring an activating transmembrane mutation (ERBB4-CA) by substituting isoleucine 658 for glutamic acid. This base substitution forms a valine-glutamic acidglycine activation domain first identified in oncogenic ERBB2/HER2/Neu. Ectopic expression of ERBB4-CA in HEK293T cells resulted in a fivefold increase in receptor tyrosine phosphorylation. Functionally, ERBB4-CA exhibited higher levels of nuclear translocation than wild-type ERBB4, leading to significantly enhanced ERBB4-induced STAT5A simulation of the beta-casein promoter. Activated ERBB4 has been demonstrated to induce cell killing of breast tumor cells. Significantly, ERBB4-CA potentiated the proapoptotic function of ERBB4 in each breast, prostate and ovarian cancer cell line tested. Untransformed cell lines were resistant to both ERBB4 and ERBB4-CA-mediated apoptosis underscoring the potential utility of active ERBB4 signaling for the therapeutic intervention of human cancer.	Tulane Univ, Hlth Sci Ctr, Tulane Canc Ctr, Dept Biochem, New Orleans, LA 70112 USA; Tulane Univ, Hlth Sci Ctr, Dept Struct & Cellular Biol, Tulane Canc Ctr, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Gene Therapy Program, Morphol & Imaging Core Lab, New Orleans, LA 70112 USA	Tulane University; Tulane University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Jones, FE (corresponding author), Tulane Univ, Hlth Sci Ctr, Tulane Canc Ctr, Dept Biochem, 1430 Tulane Ave, New Orleans, LA 70112 USA.	fjones@tulane.edu		Vidal, Gregory/0000-0003-3325-6224	NATIONAL CANCER INSTITUTE [R01CA096717, R01CA095783] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA95783, R01 CA96717] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; Barnes NLP, 2005, CLIN CANCER RES, V11, P2163, DOI 10.1158/1078-0432.CCR-04-1633; Burke CL, 1997, ONCOGENE, V14, P687, DOI 10.1038/sj.onc.1200873; Clark DE, 2005, J BIOL CHEM, V280, P24175, DOI 10.1074/jbc.M414044200; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Jones FE, 2003, CELL CYCLE, V2, P555, DOI 10.4161/cc.2.6.598; Kew TY, 2000, BRIT J CANCER, V82, P1163, DOI 10.1054/bjoc.1999.1057; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; MILOSO M, 1995, J BIOL CHEM, V270, P19557, DOI 10.1074/jbc.270.33.19557; Naresh A, 2006, CANCER RES, V66, P6412, DOI 10.1158/0008-5472.CAN-05-2368; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; Srinivasan R, 1998, J PATHOL, V185, P236, DOI 10.1002/(SICI)1096-9896(199807)185:3<236::AID-PATH118>3.0.CO;2-7; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Vidal GA, 2005, J BIOL CHEM, V280, P19777, DOI 10.1074/jbc.M412457200; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	21	31	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					462	466		10.1038/sj.onc.1209794	http://dx.doi.org/10.1038/sj.onc.1209794			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832345				2022-12-25	WOS:000243544000015
J	Fischer, K; Llamas, A; Tejada-Jimenez, M; Schrader, N; Kuper, J; Ataya, FS; Galvan, A; Mendel, RR; Fernandez, E; Schwarz, G				Fischer, Katrin; Llamas, Angel; Tejada-Jimenez, Manuel; Schrader, Nils; Kuper, Jochen; Ataya, Farid S.; Galvan, Aurora; Mendel, Ralf R.; Fernandez, Emilio; Schwarz, Guenter			Function and structure of the molybdenum cofactor carrier protein from Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFITE OXIDASE; NITRATE REDUCTASE; CRYSTALLOGRAPHIC STRUCTURE; XANTHINE DEHYDROGENASE; MOLYBDOPTERIN COFACTOR; CRYSTAL-STRUCTURES; BIOSYNTHESIS; IDENTIFICATION; INSIGHTS; BINDING	The molybdenum cofactor (Moco) forms the catalytic site in all eukaryotic molybdenum enzymes and is synthesized by a multistep biosynthetic pathway. The mechanism of transfer, storage, and insertion of Moco into the appropriate apo-enzyme is poorly understood. In Chlamydomonas reinhardtii, a Moco carrier protein (MCP) has been identified and characterized recently. Here we show biochemical evidence that MCP binds Moco as well as the tungstate-substituted form of the cofactor (Wco) with high affinity, whereas molybdopterin, the ultimate cofactor precursor, is not bound. This binding selectivity points to a specific metal-mediated interaction with MCP, which protects Moco and Wco from oxidation with t1/2 of 24 and 96 h, respectively. UV-visible spectroscopy showed defined absorption bands at 393, 470, and 570 nm pointing to ene-diothiolate and protein side-chain charge transfer bonds with molybdenum. We have determined the crystal structure of MCP at 1.6 angstrom resolution using seleno-methionated and native protein. The monomer constitutes a Rossmann fold with two homodimers forming a symmetrical tetramer in solution. Based on conserved surface residues, charge distribution, shape, in silico docking studies, structural comparisons, and identification of an anion-binding site, a prominent surface depression was proposed as a Moco-binding site, which was confirmed by structure-guided mutagenesis coupled to substrate binding studies.	Univ Cologne, Inst Biochem, D-50674 Cologne, Germany; Tech Univ Carolo Wilhelmina Braunschweig, Inst Plant Biol, D-38106 Braunschweig, Germany; Univ Cordoba, Dept Bioquim & Biol Mol, Cordoba 14071, Spain; Max Planck Inst Mol Physiol, Dept Biol Struct, D-44247 Dortmund, Germany; European Mol Biol Lab, Outstn, D-22603 Hamburg, Germany	University of Cologne; Braunschweig University of Technology; Universidad de Cordoba; Max Planck Society; European Molecular Biology Laboratory (EMBL)	Schwarz, G (corresponding author), Univ Cologne, Inst Biochem, Otto Fischer Str 12-14, D-50674 Cologne, Germany.	gschwarz@uni-koeln.de	Schrader, Katrin/GWM-7389-2022; Schwarz, Guenter/ABE-9643-2021; Llamas, Angel/B-7104-2015; Tejada-Jimenez, Manuel/A-9727-2017; Fernandez, Emilio/H-2892-2015; Llamas, Angel/L-1638-2014; Ataya, Farid Shokry/O-6570-2019; Galvan Cejudo, Aurora/A-9483-2010	Schrader, Katrin/0000-0003-4532-8918; Schwarz, Guenter/0000-0002-2118-9338; Llamas, Angel/0000-0001-6042-9472; Tejada-Jimenez, Manuel/0000-0003-1702-6015; Llamas, Angel/0000-0001-6042-9472; Ataya, Farid Shokry/0000-0002-0981-7805; Fernandez Reyes, Emilio/0000-0001-5957-5392; Galvan Cejudo, Aurora/0000-0002-7564-2281; Ataya, Farid/0000-0002-0247-5742				Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; AGUILAR M, 1992, FEBS LETT, V307, P162, DOI 10.1016/0014-5793(92)80758-9; AMY NK, 1979, J BACTERIOL, V140, P114, DOI 10.1128/JB.140.1.114-124.1979; Ataya FS, 2003, J BIOL CHEM, V278, P10885, DOI 10.1074/jbc.M211320200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bertero MG, 2003, NAT STRUCT BIOL, V10, P681, DOI 10.1038/nsb969; Bittner F, 2001, J BIOL CHEM, V276, P40381, DOI 10.1074/jbc.C100472200; Eilers T, 2001, J BIOL CHEM, V276, P46989, DOI 10.1074/jbc.M108078200; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Enemark JH, 2002, MET IONS BIOL SYST, V39, P621; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fischer K, 2005, PLANT CELL, V17, P1167, DOI 10.1105/tpc.104.029694; Garrett RM, 1996, J BIOL CHEM, V271, P7387, DOI 10.1074/jbc.271.13.7387; HAWKES TR, 1984, BIOCHEM J, V219, P481, DOI 10.1042/bj2190481; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; JOHNSON JL, 1980, P NATL ACAD SCI-BIOL, V77, P3715, DOI 10.1073/pnas.77.6.3715; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joshi MS, 1996, J BACTERIOL, V178, P4310, DOI 10.1128/jb.178.14.4310-4312.1996; Kalakoutskii KL, 1997, PLANTA, V201, P64, DOI 10.1007/s004250050230; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Kukimoto-Niino M, 2004, PROTEIN SCI, V13, P3038, DOI 10.1110/ps.041012404; Kuper J, 2000, P NATL ACAD SCI USA, V97, P6475, DOI 10.1073/pnas.110568497; Kuper J, 2004, NATURE, V430, P803, DOI 10.1038/nature02681; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Leimkuhler S, 2001, J BIOL CHEM, V276, P1837, DOI 10.1074/jbc.M007304200; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Llamas A, 2000, PLANT CELL ENVIRON, V23, P1247, DOI 10.1046/j.1365-3040.2000.00631.x; LLAMAS A, 2006, J BIOL MED; Magalon A., 2002, J BIOL CHEM, V7, P7; Mendel RR, 1999, CRIT REV PLANT SCI, V18, P33, DOI 10.1016/S0735-2689(99)00386-X; Mendel RR, 2002, MET IONS BIOL SYST, V39, P317; MOMANY C, 1995, J MOL BIOL, V252, P643, DOI 10.1006/jmbi.1995.0526; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NASON A, 1971, P NATL ACAD SCI USA, V68, P3242, DOI 10.1073/pnas.68.12.3242; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Santamaria-Araujo JA, 2004, J BIOL CHEM, V279, P15994, DOI 10.1074/jbc.M311815200; Schwarz G, 2005, CELL MOL LIFE SCI, V62, P2792, DOI 10.1007/s00018-005-5269-y; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; Temple CA, 2000, ARCH BIOCHEM BIOPHYS, V383, P281, DOI 10.1006/abbi.2000.2089; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Verdonk ML, 2003, PROTEINS, V52, P609, DOI 10.1002/prot.10465; Vergnes A, 2004, J BIOL CHEM, V279, P41398, DOI 10.1074/jbc.M407087200; WAHL RC, 1982, J BIOL CHEM, V257, P3958; Witte CP, 1998, FEBS LETT, V431, P205, DOI 10.1016/S0014-5793(98)00756-X	53	54	56	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					30186	30194		10.1074/jbc.M603919200	http://dx.doi.org/10.1074/jbc.M603919200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16873364	hybrid			2022-12-25	WOS:000240896300079
J	Bourne, Y; Radic, Z; Sulzenbacher, G; Kim, E; Taylor, P; Marchot, P				Bourne, Yves; Radic, Zoran; Sulzenbacher, Gerlind; Kim, Esther; Taylor, Palmer; Marchot, Pascale			Substrate and product trafficking through the active center gorge of acetylcholinesterase analyzed by crystallography and equilibrium binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS SIMULATION; CRYSTAL-STRUCTURE; STRUCTURAL INSIGHTS; PERIPHERAL SITE; MOUSE ACETYLCHOLINESTERASE; TORPEDO-CALIFORNICA; NANOSECOND DYNAMICS; LIGAND-BINDING; OMEGA-LOOP; BACK DOOR	Hydrolysis of acetylcholine catalyzed by acetylcholinesterase (AChE), one of the most efficient enzymes in nature, occurs at the base of a deep and narrow active center gorge. At the entrance of the gorge, the peripheral anionic site provides a binding locus for allosteric ligands, including substrates. To date, no structural information on substrate entry to the active center from the peripheral site of AChE or its subsequent egress has been reported. Complementary crystal structures of mouse AChE and an inactive mouse AChE mutant with a substituted catalytic serine (S203A), in various complexes with four substrates (acetylcholine, acetylthiocholine, succinyldicholine, and butyrylthiocholine), two non-hydrolyzable substrate analogues (m-(N, N, N-trimethylammonio)trifluoroacetophenone and 4-ketoamyltrimethylammonium), and one reaction product (choline) were solved in the 2.05-2.65-angstrom resolution range. These structures, supported by binding and inhibition data obtained on the same complexes, reveal the successive positions and orientations of the substrates bound to the peripheral site and proceeding within the gorge toward the active site, the conformations of the presumed transition state for acylation and the acyl-enzyme intermediate, and the positions and orientations of the dissociating and egressing products. Moreover, the structures of the AChE mutant in complexes with acetylthiocholine and succinyldicholine reveal additional substrate binding sites on the enzyme surface, distal to the gorge entry. Hence, we provide a comprehensive set of structural snapshots of the steps leading to the intermediates of catalysis and the potential regulation by substrate binding to various allosteric sites at the enzyme surface.	CNRS, Architecture & Fonct Macromol Biol, UMR 6098, F-13288 Marseille 09, France; Univ Mediterranee, Fac Med Secteur Nord, Inst Federat Rech Jean Roche, CNRS FRE2738, F-13916 Marseille 20, France; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; University of California System; University of California San Diego	Bourne, Y (corresponding author), CNRS, Architecture & Fonct Macromol Biol, UMR 6098, Campus Luminy,Case 932, F-13288 Marseille 09, France.	Yves.Bourne@afmb.univ-mrs.fr; marchot.p@jean-roche.univ-mrs.fr	Sulzenbacher, Gerlind/A-6801-2018; MARCHOT, Pascale/AAC-4752-2022; Bourne, Yves/AAC-4635-2022	Sulzenbacher, Gerlind/0000-0003-4844-2820; MARCHOT, Pascale/0000-0003-0630-0541; Bourne, Yves/0000-0003-3850-0548	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37GM18360] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDRIDGE WN, 1969, BIOCHEM J, V115, P147, DOI 10.1042/bj1150147; AXELSEN PH, 1994, PROTEIN SCI, V3, P188; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bar-On P, 2002, BIOCHEMISTRY-US, V41, P3555, DOI 10.1021/bi020016x; BARAK D, 1994, J BIOL CHEM, V269, P6296; BAROLUCCI C, 2001, PROTEINS, V42, P182; Bartolucci C, 1999, BIOCHEMISTRY-US, V38, P5714, DOI 10.1021/bi982723p; Bencharit S, 2002, NAT STRUCT BIOL, V9, P337, DOI 10.1038/nsb790; BERMAN HA, 1986, BIOCHIM BIOPHYS ACTA, V872, P125, DOI 10.1016/0167-4838(86)90155-X; Bourne Y, 2003, EMBO J, V22, P1, DOI 10.1093/emboj/cdg005; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; Bourne Y, 2004, P NATL ACAD SCI USA, V101, P1449, DOI 10.1073/pnas.0308206100; Boyd AE, 2004, J BIOL CHEM, V279, P26612, DOI 10.1074/jbc.M401482200; Bui JM, 2005, CHEM-BIOL INTERACT, V157, P357, DOI 10.1016/j.cbi.2005.10.049; CANEPA FG, 1966, NATURE, V210, P907, DOI 10.1038/210907a0; CHANGEUX JP, 1966, MOL PHARMACOL, V2, P369; Colletier JP, 2006, EMBO J, V25, P2746, DOI 10.1038/sj.emboj.7601175; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; EASTMAN J, 1995, J BIOL CHEM, V270, P19694, DOI 10.1074/jbc.270.34.19694; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Felder CE, 2002, ACTA CRYSTALLOGR D, V58, P1765, DOI 10.1107/S0907444902011642; FROEDE HC, 1984, J BIOL CHEM, V259, P1010; GILSON MK, 1994, SCIENCE, V263, P1276, DOI 10.1126/science.8122110; Harel M, 1996, J AM CHEM SOC, V118, P2340, DOI 10.1021/ja952232h; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; HODGE AS, 1992, MOL PHARMACOL, V41, P937; HOSEA NA, 1995, BIOCHEMISTRY-US, V34, P11528, DOI 10.1021/bi00036a028; Johnson JL, 2003, J BIOL CHEM, V278, P38948, DOI 10.1074/jbc.M304797200; Johnson JL, 2003, BIOCHEMISTRY-US, V42, P5438, DOI 10.1021/bi027065u; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; Kryger G, 1998, J PHYSIOLOGY-PARIS, V92, P191, DOI 10.1016/S0928-4257(98)80008-9; Kryger G, 1999, STRUCTURE, V7, P297, DOI 10.1016/S0969-2126(99)80040-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mallender WD, 2000, BIOCHEMISTRY-US, V39, P7753, DOI 10.1021/bi000210o; Marcel V, 1998, BIOCHEM J, V329, P329, DOI 10.1042/bj3290329; Marchot P, 1996, PROTEIN SCI, V5, P672; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; MASSOULIE J, 1993, PROG BRAIN RES, V98, P139; Millard CB, 1999, BIOCHEMISTRY-US, V38, P7032, DOI 10.1021/bi982678l; MOOSER G, 1974, BIOCHEMISTRY-US, V13, P2299, DOI 10.1021/bi00708a010; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NACHMANSOHN D, 1951, ADV ENZYMOL REL S BI, V12, P259; Nicolet Y, 2003, J BIOL CHEM, V278, P41141, DOI 10.1074/jbc.M210241200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARTINGTON P, 1972, MOL PHARMACOL, V8, P269; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; RADIC Z, 1994, J BIOL CHEM, V269, P11233; RADIC Z, 1995, J BIOL CHEM, V270, P20391, DOI 10.1074/jbc.270.35.20391; Radic Z, 2001, J BIOL CHEM, V276, P4622, DOI 10.1074/jbc.M006855200; RADIC Z, 1991, MOL PHARMACOL, V39, P98; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; Ravelli RBG, 1998, ACTA CRYSTALLOGR D, V54, P1359, DOI 10.1107/S0907444998005277; Raves ML, 1997, NAT STRUCT BIOL, V4, P57, DOI 10.1038/nsb0197-57; SHAFFERMAN A, 1992, J BIOL CHEM, V267, P17640; Shi JX, 2001, J BIOL CHEM, V276, P42196, DOI 10.1074/jbc.M106896200; Shi JX, 2003, J BIOL CHEM, V278, P30905, DOI 10.1074/jbc.M303730200; Simon S, 1999, J BIOL CHEM, V274, P27740, DOI 10.1074/jbc.274.39.27740; Stojan J, 1998, FEBS LETT, V440, P85, DOI 10.1016/S0014-5793(98)01434-3; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Szegletes T, 1999, BIOCHEMISTRY-US, V38, P122, DOI 10.1021/bi9813577; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029	65	109	109	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29256	29267		10.1074/jbc.M603018200	http://dx.doi.org/10.1074/jbc.M603018200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16837465	hybrid			2022-12-25	WOS:000240680500081
J	De Rivoyre, M; Ruel, L; Varjosalo, M; Loubat, A; Bidet, M; Therond, P; Mus-Veteau, I				De Rivoyre, Matthieu; Ruel, Laurent; Varjosalo, Markku; Loubat, Agnes; Bidet, Michel; Therond, Pascal; Mus-Veteau, Isabelle			Human receptors patched and smoothened partially transduce hedgehog signal when expressed in Drosophila cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SONIC HEDGEHOG; CUBITUS INTERRUPTUS; SCHNEIDER-2 CELLS; PROTEIN COSTAL2; PHOSPHORYLATION; MUTATIONS; KINASE; CANCER; INTERNALIZATION; IDENTIFICATION	In humans, dysfunctions of the Hedgehog receptors Patched and Smoothened are responsible for numerous pathologies. However, signaling mechanisms involving these receptors are less well characterized in mammals than in Drosophila. To obtain structure-function relationship information on human Patched and Smoothened, we expressed these human receptors in Drosophila Schneider 2 cells. We show here that, as its Drosophila counterpart, human Patched is able to repress the signaling pathway in the absence of Hedgehog ligand. In response to Hedgehog, human Patched is able to release Drosophila Smoothened inhibition, suggesting that human Patched is expressed in a functional state in Drosophila cells. We also provide experiments showing that human Smo, when expressed in Schneider cells, is able to bind the alkaloid cyclopamine, suggesting that it is expressed in a native conformational state. Furthermore, contrary to Drosophila Smoothened, human Smoothened does not interact with the kinesin Costal 2 and thus is unable to transduce the Hedgehog signal. Moreover, cell surface fluorescent labeling suggest that human Smoothened is enriched at the Schneider 2 plasma membrane in response to Hedgehog. These results suggest that human Smoothened is expressed in a functional state in Drosophila cells, where it undergoes a regulation of its localization comparable with its Drosophila homologue. Thus, we propose that the upstream part of the Hedgehog pathway involving Hedgehog interaction with Patched, regulation of Smoothened by Patched, and Smoothened enrichment at the plasma membrane is highly conserved between Drosophila and humans; in contrast, signaling downstream of Smoothened is different.	CNRS, UMR 6543, Ctr Biochim, Inst Signaling Dev Biol & Canc Res, F-06108 Nice 02, France; Univ Nice, UMR 6548, CNRS, Lab Physiol Cellulaire & Mol, F-06108 Nice 2, France; Univ Helsinki, Dept Virol, Biomedicum, Haartman Inst, FIN-00014 Helsinki, Finland; Fac Med, INSERM U364, F-06107 Nice 02, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Helsinki; Institut National de la Sante et de la Recherche Medicale (Inserm)	Therond, P (corresponding author), CNRS, UMR 6543, Ctr Biochim, Inst Signaling Dev Biol & Canc Res, Parv Valrose, F-06108 Nice 02, France.	Pascal.THEROND@unice.fr; Isabelle.Mus-Veteau@unice.fr	Michel, BIDET/B-6966-2009; Therond, pascal/AAE-4811-2019; Varjosalo, Markku/K-6424-2015; Mus-veteau, Isabelle/M-8875-2016	Varjosalo, Markku/0000-0002-1340-9732; Mus-veteau, Isabelle/0000-0001-5739-7684				Avidor-Reiss T, 2004, CELL, V117, P527, DOI 10.1016/S0092-8674(04)00412-X; Benting J, 2000, ANAL BIOCHEM, V278, P59, DOI 10.1006/abio.1999.4409; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Briscoe J, 2005, DEV CELL, V8, P143, DOI 10.1016/j.devcel.2005.01.008; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chen MH, 2005, MOL CELL BIOL, V25, P7042, DOI 10.1128/MCB.25.16.7042-7053.2005; Chen W, 2004, SCIENCE, V306, P2257, DOI 10.1126/science.1104135; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; Corcoran RB, 2006, P NATL ACAD SCI USA, V103, P8408, DOI 10.1073/pnas.0602852103; De Rivoyre M, 2005, FEBS LETT, V579, P1529, DOI 10.1016/j.febslet.2005.01.054; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; Huangfu D, 2005, P NATL ACAD SCI USA, V102, P11325, DOI 10.1073/pnas.0505328102; IALTABA AR, 2002, NAT REV CANCER, V2, P361; Incardona JP, 2002, CURR BIOL, V12, P983, DOI 10.1016/S0960-9822(02)00895-3; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jia JH, 2004, NATURE, V432, P1045, DOI 10.1038/nature03179; Kalderon D, 2004, CURR BIOL, V14, pR67, DOI 10.1016/j.cub.2003.12.047; Kurihara R, 2006, J BIOL CHEM, V281, P12908, DOI 10.1074/jbc.M510871200; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Merchant M, 2005, MOL CELL BIOL, V25, P7054, DOI 10.1128/MCB.25.16.7054-7068.2005; Murone M, 1999, EXP CELL RES, V253, P25, DOI 10.1006/excr.1999.4676; Ogden SK, 2003, CURR BIOL, V13, P1998, DOI 10.1016/j.cub.2003.10.004; Perret BG, 2003, PROTEIN EXPRES PURIF, V31, P123, DOI 10.1016/S1046-5928(03)00140-2; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Ruel L, 2003, NAT CELL BIOL, V5, P907, DOI 10.1038/ncb1052; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Strutt H, 2001, CURR BIOL, V11, P608, DOI 10.1016/S0960-9822(01)00179-8; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Taipale J, 2002, NATURE, V418, P892, DOI 10.1038/nature00989; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; Torroja C, 2005, J NEUROBIOL, V64, P334, DOI 10.1002/neu.20168; Torroja C, 2004, DEVELOPMENT, V131, P2395, DOI 10.1242/dev.01102; TOTA MR, 1995, J BIOL CHEM, V270, P26466, DOI 10.1074/jbc.270.44.26466; Varjosalo M, 2006, DEV CELL, V10, P177, DOI 10.1016/j.devcel.2005.12.014; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Zhang C, 2004, P NATL ACAD SCI USA, V101, P17900, DOI 10.1073/pnas.0408093101	47	16	16	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28584	28595		10.1074/jbc.M512986200	http://dx.doi.org/10.1074/jbc.M512986200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16867986	hybrid			2022-12-25	WOS:000240680500012
J	Fan, HP; Fan, FJ; Bao, L; Pei, G				Fan, Hua-Ping; Fan, Feng-Juan; Bao, Lan; Pei, Gang			SNAP-25/syntaxin 1A complex functionally modulates neurotransmitter gamma-aminobutyric acid reuptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; CFTR CHLORIDE CHANNELS; SYNTAXIN 1A; GABA TRANSPORTER; SEROTONIN TRANSPORTER; H3 DOMAIN; EXPRESSION; TRAFFICKING; KV2.1; ACTIVATION	Neurotransmitter gamma-aminobutyric acid (GABA) release to the synaptic clefts is mediated by the formation of a soluble N-ethylmaleimidesensitive factor attachment protein receptor (SNARE) complex, which includes two target SNAREs syntaxin 1A and SNAP-25 and one vesicle SNARE VAMP-2. The target SNAREs syntaxin 1A and SNAP-25 form a heterodimer, the putative intermediate of the SNARE complex. Neurotransmitter GABA clearance from synaptic clefts is carried out by the reuptake function of its transporters to terminate the postsynaptic signaling. Syntaxin 1A directly binds to the neuronal GABA transporter GAT-1 and inhibits its reuptake function. However, whether other SNARE proteins or SNARE complex regulates GABA reuptake remains unknown. Here we demonstrate that SNAP-25 efficiently inhibits GAT-1 reuptake function in the presence of syntaxin 1A. This inhibition depends on SNAP-25/syntaxin 1A complex formation. The H3 domain of syntaxin 1A is identified as the binding sites for both SNAP-25 and GAT-1. SNAP-25 binding to syntaxin 1A greatly potentiates the physical interaction of syntaxin 1A with GAT-1 and significantly enhances the syntaxin 1A-mediated inhibition of GAT-1 reuptake function. Furthermore, nitric oxide, which promotes SNAP-25 binding to syntaxin 1A to form the SNARE complex, also potentiates the interaction of syntaxin 1A with GAT-1 and suppresses GABA reuptake by GAT-1. Thus our findings delineate a further molecular mechanism for the regulation of GABA reuptake by a target SNARE complex and suggest a direct coordination between GABA release and reuptake.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China; Chinese Acad Sci, Grad Sch, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences	Bao, L (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	baolan@sibs.ac.cn; gpei@sibs.ac.cn	Fan, Huaping/B-8762-2012	Fan, Fengjuan/0000-0001-8727-5258				An SJ, 2004, SCIENCE, V306, P1042, DOI 10.1126/science.1102559; Bao L, 2003, NEURON, V37, P121, DOI 10.1016/S0896-6273(02)01103-0; Beckman ML, 1998, J NEUROSCI, V18, P6103; Beckman ML, 1999, J NEUROSCI, V19; Bernstein EM, 1999, J BIOL CHEM, V274, P889, DOI 10.1074/jbc.274.2.889; Borden LA, 1996, NEUROCHEM INT, V29, P335, DOI 10.1016/0197-0186(95)00158-1; Cai GQ, 2005, FEBS J, V272, P1625, DOI 10.1111/j.1742-4658.2005.04595.x; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Cormet-Boyaka E, 2002, P NATL ACAD SCI USA, V99, P12477, DOI 10.1073/pnas.192203899; Cui NG, 2004, J BIOL CHEM, V279, P53259, DOI 10.1074/jbc.M410171200; Cupello A, 1997, NEUROCHEM RES, V22, P1517, DOI 10.1023/A:1021966814942; Deken SL, 2000, NAT NEUROSCI, V3, P998, DOI 10.1038/79939; DINGLEDINE R, 1985, J PHYSIOL-LONDON, V366, P387, DOI 10.1113/jphysiol.1985.sp015804; Fasshauer D, 2004, J BIOL CHEM, V279, P7613, DOI 10.1074/jbc.M312064200; Fergestad T, 2001, J NEUROSCI, V21, P9142, DOI 10.1523/JNEUROSCI.21-23-09142.2001; Gao H, 2004, MOL CELL, V14, P303, DOI 10.1016/S1097-2765(04)00216-3; Geerlings A, 2000, FEBS LETT, V470, P51, DOI 10.1016/S0014-5793(00)01297-7; Haase J, 2001, BIOCHEM SOC T, V29, P722, DOI 10.1042/BST0290722; Horton N, 2001, MOL MEMBR BIOL, V18, P39; Hua YY, 2001, P NATL ACAD SCI USA, V98, P8065, DOI 10.1073/pnas.131214798; ISAACSON JS, 1993, NEURON, V10, P165, DOI 10.1016/0896-6273(93)90308-E; JURSKY F, 1994, J EXP BIOL, V196, P283; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Leung YM, 2005, BIOCHEM J, V387, P195, DOI 10.1042/BJ20041625; Leung YM, 2003, J BIOL CHEM, V278, P17532, DOI 10.1074/jbc.M213088200; Lin YF, 2004, P NATL ACAD SCI USA, V101, P7799, DOI 10.1073/pnas.0402496101; Liu J, 2004, J BIOL CHEM, V279, P55924, DOI 10.1074/jbc.M410024200; Loranger SS, 2002, J BIOL CHEM, V277, P34303, DOI 10.1074/jbc.M202125200; Meffert MK, 1996, NEURON, V16, P1229, DOI 10.1016/S0896-6273(00)80149-X; MEFFERT MK, 1994, NEURON, V12, P1235, DOI 10.1016/0896-6273(94)90440-5; Michaelevski I, 2003, J BIOL CHEM, V278, P34320, DOI 10.1074/jbc.M304943200; Misura KMS, 2001, J BIOL CHEM, V276, P13273, DOI 10.1074/jbc.M009636200; Mochida S, 2000, NEUROSCI RES, V36, P175, DOI 10.1016/S0168-0102(99)00128-5; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Ohkuma S, 1996, MOL BRAIN RES, V36, P137, DOI 10.1016/0169-328X(95)00256-R; Quick MW, 2002, INT J DEV NEUROSCI, V20, P219, DOI 10.1016/S0736-5748(02)00021-7; Quick MW, 1997, J NEUROSCI, V17, P2967; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; Sipila S, 2004, J NEUROSCI, V24, P5877, DOI 10.1523/JNEUROSCI.1287-04.2004; SOLIS JM, 1992, J NEUROSCI, V12, P3466; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Soudijn W, 2000, CURR MED CHEM, V7, P1063, DOI 10.2174/0929867003374363; Sung U, 2003, J NEUROSCI, V23, P1697; Tran NNP, 1998, J PHYSIOL-LONDON, V507, P163, DOI 10.1111/j.1469-7793.1998.163bu.x; Wang P, 2003, J BIOL CHEM, V278, P6363, DOI 10.1074/jbc.M210350200; Whitworth TL, 2001, J BIOL CHEM, V276, P42932, DOI 10.1074/jbc.M107638200; Xiao JN, 2004, J NEUROSCI RES, V75, P143, DOI 10.1002/jnr.10840; Xu NJ, 2003, J NEUROSCI, V23, P4775; Zhu Y, 2005, J NEUROSCI RES, V79, P503, DOI 10.1002/jnr.20385	49	22	24	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28174	28184		10.1074/jbc.M601382200	http://dx.doi.org/10.1074/jbc.M601382200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16861228	hybrid			2022-12-25	WOS:000240534400055
J	Hatch, NE; Hudson, M; Seto, ML; Cunningham, ML; Bothwell, M				Hatch, Nan E.; Hudson, Mark; Seto, Marianne L.; Cunningham, Michael L.; Bothwell, Mark			Intracellular retention, degradation, and signaling of glycosylation-deficient FGFR2 and craniosynostosis syndrome- associated FGFR2(C278F)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SUBSTRATE-DEPENDENCE; SYNDROME MUTATIONS; LIGAND-BINDING; IN-VITRO; BONE; DIFFERENTIATION; ACTIVATION; APOPTOSIS; SITES	Fibroblast growth factors (FGFs) and their receptors (FGFRs) are known to play a critical role in a variety of fundamental processes, including wound healing, angiogenesis, and development of multiple organ systems. Mutations in the FGFR gene family have been linked to a series of syndromes (the craniosynostosis syndromes) whose primary phenotype involves aberrant development of the craniofacial skeleton. Craniosynostosis syndrome-linked FGFR mutations have been shown to be gain of function in terms of receptor activation and have been presumed to result in increased levels of FGF/FGFR signaling. Unfortunately, studies attempting to link expression of mutant FGFRs with changes in cellular phenotype have yielded conflicting results. In an effort to better understand the biochemical consequences of these mutations on receptor function, here we have investigated the effect of the FGFR2(C278F) mutation of Crouzon craniosynostosis syndrome on receptor trafficking, ubiquitination, degradation, and signaling. We find that FGFR2(C278F) exhibits diminished glycosylation, increased degradation, and limited cellular sublocalization in the osteoblastic cell line, MC3T3E1(C4). Additionally, we show that trafficking and autoactivation of wild type FGFR2 is glycosylation-dependent. Both FGFR2(C278F) and unglycosylated wild type FGFR2 signal through phospholipase C gamma in a ligand-independent manner as well as exhibit dramatically increased binding to the adaptor protein, Frs2. These findings suggest that autoactive FGFR2 can signal from intracellular compartments. Based upon our results, we propose that the functional signaling of craniosynostosis mutant, autoactive receptors is limited in some cell types by protective cellular responses, such as increased trafficking to lysosomes and proteasomes for degradation.	Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Hatch, NE (corresponding author), Univ Michigan, Dept Orthodont, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.	nhatch@umich.edu	Hatch, Nan/ABC-9177-2020; Hatch, Nan/AAQ-8465-2020	Hatch, Nan/0000-0002-2632-0841; Bothwell, Mark/0000-0001-5423-2702	NIDCR NIH HHS [DE00161] Funding Source: Medline; NINDS NIH HHS [NS33200] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033200] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson J, 1998, HUM MOL GENET, V7, P1475, DOI 10.1093/hmg/7.9.1475; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Burgar HR, 2002, J BIOL CHEM, V277, P4018, DOI 10.1074/jbc.M107785200; Ceridono M, 2005, BIOCHEM BIOPH RES CO, V327, P523, DOI 10.1016/j.bbrc.2004.12.031; DePollack C, 1996, J BONE MINER RES, V11, P401; Dry GM, 2001, PLAST RECONSTR SURG, V107, P425, DOI 10.1097/00006534-200102000-00019; Eswarakumar VP, 2002, DEVELOPMENT, V129, P3783; FEIGE JJ, 1988, J BIOL CHEM, V263, P14023; Fioretos T, 2001, GENE CHROMOSOME CANC, V32, P302, DOI 10.1002/gcc.1195; Fragale A, 1999, AM J PATHOL, V154, P1465, DOI 10.1016/S0002-9440(10)65401-6; Galvin BD, 1996, P NATL ACAD SCI USA, V93, P7894, DOI 10.1073/pnas.93.15.7894; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hattori Y, 1996, CLIN CANCER RES, V2, P1373; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; HUGHES FJ, 1995, ENDOCRINOLOGY, V136, P2671, DOI 10.1210/en.136.6.2671; HUSAM A, 2003, J BIOL CHEM, V278, P35781; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; Lemonnier J, 2001, AM J PATHOL, V158, P1833, DOI 10.1016/S0002-9440(10)64139-9; Lemonnier J, 2000, EXP CELL RES, V256, P158, DOI 10.1006/excr.2000.4820; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Lomri A, 1998, J CLIN INVEST, V101, P1310; Mangasarian K, 1997, J CELL PHYSIOL, V172, P117, DOI 10.1002/(SICI)1097-4652(199707)172:1<117::AID-JCP13>3.3.CO;2-S; Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; NEILSON KM, 1995, J BIOL CHEM, V270, P26037, DOI 10.1074/jbc.270.44.26037; Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; Partridge EA, 2004, SCIENCE, V306, P120, DOI 10.1126/science.1102109; Petrescu AJ, 2004, GLYCOBIOLOGY, V14, P103, DOI 10.1093/glycob/cwh008; Quirk PL, 2004, J NEUROSCI RES, V77, P498, DOI 10.1002/jnr.20185; Rice DPC, 1999, EUR J ORAL SCI, V107, P265, DOI 10.1046/j.0909-8836.1999.eos107406.x; Ridyard MS, 2003, J BIOL CHEM, V278, P13803, DOI 10.1074/jbc.M210245200; Robertson SC, 1998, P NATL ACAD SCI USA, V95, P4567, DOI 10.1073/pnas.95.8.4567; Sato M, 2003, NAT CELL BIOL, V5, P1016, DOI 10.1038/ncb1054; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Takahashi S, 2002, NEUROCHEM INT, V40, P441, DOI 10.1016/S0197-0186(01)00097-3; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; Watson FL, 1999, J NEUROBIOL, V39, P323, DOI 10.1002/(SICI)1097-4695(199905)39:2<323::AID-NEU15>3.0.CO;2-4; Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899; Yoshida Y, 2003, J BIOCHEM, V134, P183, DOI 10.1093/jb/mvg128; Yu K, 2003, DEVELOPMENT, V130, P3063, DOI 10.1242/dev.00491; Yu K, 2000, P NATL ACAD SCI USA, V97, P14536, DOI 10.1073/pnas.97.26.14536; Zhang Z, 2001, J BIOL CHEM, V276, P41921, DOI 10.1074/jbc.M106608200; 2004, J NAT CANC I, V96, P1805	48	52	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27292	27305		10.1074/jbc.M600448200	http://dx.doi.org/10.1074/jbc.M600448200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16844695	hybrid			2022-12-25	WOS:000240397700056
J	Wang, ZY; Sun, ZH; Li, AV; Yarema, KJ				Wang, Zhiyun; Sun, Zhonghui; Li, Adrienne V.; Yarema, Kevin J.			Roles for UDP-GlcNAc 2-epimerase/ManNAc 6-kinase outside of sialic acid biosynthesis - Modulation of sialyltransferase and BiP expression, GM3 and GD3 biosynthesis, proliferation, and apoptosis, and ERK1/2 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCLUSION-BODY MYOPATHY; DISTAL MYOPATHY; CELL-PROLIFERATION; ALPHA-DYSTROGLYCAN; RIMMED VACUOLES; GANGLIOSIDE GD3; O-ACETYLATION; STEM-CELLS; GENE; GNE	Roles for UDP-GlcNAc 2-epimerase/ManNAc 6-kinase (GNE) beyond controlling flux into the sialic acid biosynthetic pathway by converting UDP-GlcNAc to N-acetylmannosamine are described in this report. Overexpression of recombinant GNE in human embryonic kidney (HEK AD293) cells led to an increase in mRNA levels for ST3Gal5 (GM3 synthase) and ST8Sia1 (GD3 synthase) as well as the biosynthetic products of these sialyltransferases, the GM3 and GD3 gangliosides. Conversely, down-regulation of GNE by RNA interference methods had the opposite, but consistent, effect of lowering ST3Gal5 and ST8Sia1 mRNAs and reducing GM3 and GD3 levels. Control experiments ensured that GNE-mediated changes in sialyltransferase expression and ganglioside biosynthesis were not the result of altered flux through the sialic acid pathway. Interestingly, exogenous GM3 and GD3 also changed the expression of GNE and led to reduced ST3Gal5 and ST8Sia1 mRNA levels, demonstrating a reciprocating feedback mechanism where gangliosides regulate upstream biosynthetic enzymes. Cellular responses to the GNE-mediated changes in ST3Gal5 and ST8Sia1 expression and GM3 and GD3 levels were investigated next. Conditions that led to reduced ganglioside production (e.g. short hairpin RNA exposure) stimulated proliferation, whereas conditions that resulted in increased ganglioside levels (e.g. recombinant GNE and exogenous gangliosides) led to reduced proliferation with a concomitant increase in apoptosis. Finally, changes to BiP expression and ERK1/2 phosphorylation consistent with apoptosis and proliferation, respectively, were observed. These results provide examples of specific biochemical pathways, other than sialic acid metabolism, that are influenced by GNE.	Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA	Johns Hopkins University	Yarema, KJ (corresponding author), Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA.	kyarema1@jhu.edu			NATIONAL CANCER INSTITUTE [R01CA112314] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA112314-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aerts JL, 2004, BIOTECHNIQUES, V36, P84, DOI 10.2144/04361ST04; Angata K, 2003, BIOCHIMIE, V85, P195, DOI 10.1016/S0300-9084(03)00051-8; Aoki T, 1997, J BIOCHEM-TOKYO, V121, P122; Bhunia AK, 2002, J BIOL CHEM, V277, P16396, DOI 10.1074/jbc.M200877200; Broccolini A, 2005, NEUROMUSCULAR DISORD, V15, P177, DOI 10.1016/j.nmd.2004.10.001; CALLIES R, 1977, EUR J BIOCHEM, V80, P425, DOI 10.1111/j.1432-1033.1977.tb11897.x; Castro-Palomino JC, 2001, CHEM-EUR J, V7, P2178, DOI 10.1002/1521-3765(20010518)7:10<2178::AID-CHEM2178>3.3.CO;2-5; Cen S, 2004, J BIOL CHEM, V279, P33177, DOI 10.1074/jbc.M402062200; Chefalo P, 2006, BIOCHEMISTRY-US, V45, P3733, DOI 10.1021/bi052161r; Chen H, 2005, HANDBOOK OF CARBOHYDRATE ENGINEERING, P1; Chen HY, 2006, J BIOL CHEM, V281, P7825, DOI 10.1074/jbc.M512379200; Chen HY, 2002, J EXP MED, V196, P1529, DOI 10.1084/jem.20021915; Chung TW, 2005, GLYCOBIOLOGY, V15, P233, DOI 10.1093/glycob/cwh156; Copley SD, 2003, CURR OPIN CHEM BIOL, V7, P265, DOI 10.1016/S1367-5931(03)00032-2; Di Sano F, 2006, J BIOL CHEM, V281, P2693, DOI 10.1074/jbc.M509110200; Eisenberg I, 2001, NAT GENET, V29, P83, DOI 10.1038/ng718; Eisenberg I, 1999, GENOMICS, V55, P43, DOI 10.1006/geno.1998.5630; Fukumoto S, 2000, J BIOL CHEM, V275, P5832, DOI 10.1074/jbc.275.8.5832; FURUKAWA K, 1989, J IMMUNOL, V142, P848; Hakomori S, 2004, GLYCOCONJUGATE J, V21, P125, DOI 10.1023/B:GLYC.0000044844.95878.cf; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P225, DOI 10.1073/pnas.012540899; Hakomori S, 2004, AN ACAD BRAS CIENC, V76, P553, DOI 10.1590/S0001-37652004000300010; Hanover JA, 2001, FASEB J, V15, P1865, DOI 10.1096/fj.01-0094rev; Heffer-Lauc M, 2005, BBA-MOL CELL BIOL L, V1686, P200, DOI 10.1016/j.bbalip.2004.10.002; Hinderlich S, 1997, J BIOL CHEM, V272, P24313, DOI 10.1074/jbc.272.39.24313; Hinderlich S, 2004, FEBS LETT, V566, P105, DOI 10.1016/j.febslet.2004.04.013; Huizing M, 2004, MOL GENET METAB, V81, P196, DOI 10.1016/j.ymgme.2003.11.012; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jeffery CJ, 2003, TRENDS GENET, V19, P415, DOI 10.1016/S0168-9525(03)00167-7; Jones MB, 2004, BIOTECHNOL BIOENG, V85, P394, DOI 10.1002/bit.10901; JOURDIAN GW, 1971, J BIOL CHEM, V246, P430; Kamimura Y, 2005, INT J ONCOL, V26, P337; Keppler OT, 1999, SCIENCE, V284, P1372, DOI 10.1126/science.284.5418.1372; Kim EJ, 2004, BIOTECHNOL PROGR, V20, P1674, DOI 10.1021/bp049841q; Kim EK, 2004, J BIOL CHEM, V279, P19970, DOI 10.1074/jbc.M402165200; Krause S, 2005, EXP CELL RES, V304, P365, DOI 10.1016/j.yexcr.2004.11.010; Li A, 2004, GLYCOBIOLOGY, V14, P1150; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lovat PE, 2004, JNCI-J NATL CANCER I, V96, P1288, DOI 10.1093/jnci/djh254; Lu PY, 2005, ADV GENET, V54, P117, DOI 10.1016/S0065-2660(05)54006-9; Malisan F, 2005, IUBMB LIFE, V57, P477, DOI 10.1080/15216540500167179; Malisan F, 2002, EXP GERONTOL, V37, P1273, DOI 10.1016/S0531-5565(02)00138-9; Malisan F, 2002, J EXP MED, V196, P1535, DOI 10.1084/jem.20020960; Mitsuzuka K, 2005, J BIOL CHEM, V280, P35545, DOI 10.1074/jbc.M505630200; Moon SK, 2004, J BIOL CHEM, V279, P33063, DOI 10.1074/jbc.M313462200; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; Nakano J, 1996, J INVEST DERMATOL, V107, P543, DOI 10.1111/1523-1747.ep12582802; Nishino I, 2002, NEUROLOGY, V59, P1689, DOI 10.1212/01.WNL.0000041631.28557.C6; Noguchi S, 2004, J BIOL CHEM, V279, P11402, DOI 10.1074/jbc.M313171200; Oetke C, 2003, BIOCHEM BIOPH RES CO, V308, P892, DOI 10.1016/S0006-291X(03)01471-2; Pekarik V, 2005, BRAIN RES BULL, V68, P115, DOI 10.1016/j.brainresbull.2005.08.007; Penner J, 2006, BIOCHEMISTRY-US, V45, P2968, DOI 10.1021/bi0522504; Pilkington GJ, 2005, CELL PROLIFERAT, V38, P423, DOI 10.1111/j.1365-2184.2005.00358.x; Rozen S, 2000, Methods Mol Biol, V132, P365; Salama I, 2005, BIOCHEM BIOPH RES CO, V328, P221, DOI 10.1016/j.bbrc.2004.12.157; Saqr HE, 2006, J NEUROCHEM, V96, P1301, DOI 10.1111/j.1471-4159.2005.03640.x; Schauer R, 2004, ARCH BIOCHEM BIOPHYS, V426, P132, DOI 10.1016/j.abb.2004.03.008; Schuit F, 2002, DIABETES, V51, pS326, DOI 10.2337/diabetes.51.2007.S326; SCHWARZMANN G, 1983, BIOCHEMISTRY-US, V22, P5041, DOI 10.1021/bi00290a025; Seppala R, 1999, AM J HUM GENET, V64, P1563, DOI 10.1086/302411; SEPPALA R, 1991, J BIOL CHEM, V266, P7456; Shamblott MJ, 2001, P NATL ACAD SCI USA, V98, P113, DOI 10.1073/pnas.021537998; Siddiqui RA, 2003, BIOCHEM J, V371, P621, DOI 10.1042/BJ20021667; Tanner ME, 2005, BIOORG CHEM, V33, P216, DOI 10.1016/j.bioorg.2005.01.005; Tessitore A, 2004, MOL CELL, V15, P753, DOI 10.1016/j.molcel.2004.08.029; Toledo MS, 2004, J BIOL CHEM, V279, P34655, DOI 10.1074/jbc.M403857200; Tomimitsu H, 2004, NEUROLOGY, V62, P1607, DOI 10.1212/01.WNL.0000123115.23652.6C; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Villavicencio-Lorini P, 2002, J MOL MED-JMM, V80, P671, DOI 10.1007/s00109-002-0382-y; Watts GDJ, 2003, NEUROMUSCULAR DISORD, V13, P559, DOI 10.1016/S0960-8966(03)00070-1; WEISS P, 1989, J BIOL CHEM, V264, P17635; Yamada A, 2005, ARCH ORAL BIOL, V50, P393, DOI 10.1016/j.archoralbio.2004.09.014; Yarema KJ, 2001, NAT BIOTECHNOL, V19, P553, DOI 10.1038/89305; Zachara NE, 2002, CHEM REV, V102, P431, DOI 10.1021/cr000406u; Zou W, 2004, J BIOL CHEM, V279, P25390, DOI 10.1074/jbc.M402787200	75	71	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27016	27028		10.1074/jbc.M604903200	http://dx.doi.org/10.1074/jbc.M604903200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16847058	hybrid			2022-12-25	WOS:000240397700028
J	Xu, YR; Shao, Y; Voorhees, JJ; Fisher, GJ				Xu, Yiru; Shao, Yuan; Voorhees, John J.; Fisher, Gary J.			Oxidative inhibition of receptor-type protein-tyrosine phosphatase kappa by ultraviolet irradiation activates epidermal growth factor receptor in human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSORBING AMINO-ACIDS; INDUCED EGF-RECEPTOR; HYDROGEN-PEROXIDE; SIGNALING PATHWAY; C-FOS; SKIN; OXYGEN; PHOSPHORYLATION; RADIATION; KINASES	Ultraviolet (UV) irradiation rapidly increases tyrosine phosphorylation (i.e. activates) of epidermal growth factor receptors (EGFR) in human skin. EGFR-dependent signaling pathways drive increased expression of matrix metalloproteinases, whose actions fragment collagen and elastin fibers, the primary structural protein components in skin connective tissue. Connective tissue fragmentation, which results from chronic exposure to solar UV irradiation, is a major determinant of premature skin aging (photoaging). UV irradiation generates reactive oxygen species, which readily react with conserved cysteine residues in the active site of protein-tyrosine phosphatases (PTP). We report here that EGFR activation by UV irradiation results from oxidative inhibition of receptor type PTP-kappa (RPTP-kappa). RPTP-kappa directly counters intrinsic EGFR tyrosine kinase activity, thereby maintaining EGFR in an inactive state. Reversible, oxidative inactivation of RPTP-kappa activity by UV irradiation shifts the kinase-phosphatase balance in favor of EGFR activation. These data delineate a novel mechanism of EGFR regulation and identify RPTP-kappa as a key molecular target for antioxidant protection against skin aging.	Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Fisher, GJ (corresponding author), Med Sci 1, Rm 6447, 1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	dianemch@umich.edu	Voorhees, John/AAM-9966-2020	Voorhees, John/0000-0003-1856-785X	NIEHS NIH HHS [1R01ES012920, R01 ES012920, R01 ES012920-03] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012920] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Berneburg M, 2000, PHOTODERMATOL PHOTO, V16, P239, DOI 10.1034/j.1600-0781.2000.160601.x; Bertling CJ, 1996, PHOTOCHEM PHOTOBIOL, V64, P137, DOI 10.1111/j.1751-1097.1996.tb02433.x; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; CADET J, 1990, BIOORGANIC PHOTOCHEM, P184; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; CHUI T, 2005, AM J PHYSIOL, V288, pG182; CREED D, 1984, PHOTOCHEM PHOTOBIOL, V39, P563; CREED D, 1984, PHOTOCHEM PHOTOBIOL, V39, P537; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Evinger AJ, 2005, STEROIDS, V70, P361, DOI 10.1016/j.steroids.2005.02.015; Filardo EJ, 2002, J STEROID BIOCHEM, V80, P231, DOI 10.1016/S0960-0760(01)00190-X; Fisher GJ, 2000, J CLIN INVEST, V106, P663, DOI 10.1172/JCI9362; Fisher GJ, 1998, J CLIN INVEST, V101, P1432, DOI 10.1172/JCI2153; Fisher GJ, 2002, ARCH DERMATOL, V138, P1462, DOI 10.1001/archderm.138.11.1462; FOOTE CS, 1982, PATHOLOGY OXYGEN, P21; Gulati P, 2004, EMBO REP, V5, P812, DOI 10.1038/sj.embor.7400190; Halder RM, 2003, DERMATOL CLIN, V21, P725, DOI 10.1016/S0733-8635(03)00085-8; HALLIWELL B, 1990, FREE RADICAL BIO MED, P22; Herrlich P, 2000, BIOCHEM PHARMACOL, V59, P35, DOI 10.1016/S0006-2952(99)00298-1; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang Y, 2004, ENDOCRINOLOGY, V145, P3297, DOI 10.1210/en.2003-1658; Ichihashi M, 2003, TOXICOLOGY, V189, P21, DOI 10.1016/S0300-483X(03)00150-1; JURKIEWICZ BA, 1994, PHOTOCHEM PHOTOBIOL, V59, P1, DOI 10.1111/j.1751-1097.1994.tb04993.x; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kang S, 2003, J INVEST DERMATOL, V120, P835, DOI 10.1046/j.1523-1747.2003.12122.x; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Kulms D, 2000, PHOTODERMATOL PHOTO, V16, P195, DOI 10.1034/j.1600-0781.2000.160501.x; Kwon J, 2004, P NATL ACAD SCI USA, V101, P16419, DOI 10.1073/pnas.0407396101; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; NISHI J, 1991, J INVEST DERMATOL, V97, P115, DOI 10.1111/1523-1747.ep12478534; Persson C, 2005, METHODS, V35, P37, DOI 10.1016/j.ymeth.2004.07.006; Peus D, 1998, J INVEST DERMATOL, V110, P966, DOI 10.1046/j.1523-1747.1998.00210.x; Peus D, 1999, FREE RADICAL BIO MED, V27, P1197, DOI 10.1016/S0891-5849(99)00198-7; Peus D, 2000, PHOTOCHEM PHOTOBIOL, V72, P135, DOI 10.1562/0031-8655(2000)072<0135:UIEGFR>2.0.CO;2; RHEE S, 2000, SCI STEKE 2000; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Thomas SM, 2005, NEOPLASIA, V7, P426, DOI 10.1593/neo.04454; van Montfort RLM, 2003, NATURE, V423, P773, DOI 10.1038/nature01681; Wang HQ, 2003, J BIOL CHEM, V278, P45737, DOI 10.1074/jbc.M300574200; Xu YR, 2005, J BIOL CHEM, V280, P42694, DOI 10.1074/jbc.M507722200; XU YR, 2005, J DERMATOL SC S2 DEC, pS1, DOI DOI 10.1016/J.DESCS.2005.06.002; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Zhang Q, 2004, CANCER RES, V64, P6166, DOI 10.1158/0008-5472.CAN-04-0504; Zheng Z S, 1993, Exp Dermatol, V2, P257, DOI 10.1111/j.1600-0625.1993.tb00042.x; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	49	210	218	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27389	27397		10.1074/jbc.M602355200	http://dx.doi.org/10.1074/jbc.M602355200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16849327	Green Accepted, hybrid			2022-12-25	WOS:000240397700065
J	Dong, W; Liu, YL; Peng, JH; Chen, L; Zou, TT; Xiao, HZ; Liu, ZX; Li, W; Bu, YW; Qi, YP				Dong, Wei; Liu, Yingle; Peng, Jinhong; Chen, Lu; Zou, Tingting; Xiao, Huazhong; Liu, Zhengxue; Li, Wen; Bu, Yiwen; Qi, Yipeng			The IRAK-1-BCL10-MALT1-TRAF6-TAK1 cascade mediates signaling to NF-kappa B from toll-like Receptor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL; FACTOR-6 TRAF6; BCL10; ACTIVATION; KINASE; MALT1; TAK1; UBIQUITINATION; IDENTIFICATION; TRANSLOCATION	Our previous studies have revealed that the signaling protein BCL10 plays a major role in adaptive immunity by mediating NF-kappa B activation in the LPS/ TLR4 pathway. In this study, we show that IRAK-1 acts as the essential upstream adaptor that recruits BCL10 to the TLR4 signaling complex and mediates signaling to NF-kappa B through the BCL10-MALT1-TRAF6-TAK1 cascade. Following dissociation from IRAK-1, BCL10 is translocated into the cytosol along with TRAF6 and TAK1, in a process bridged by a direct BCL10-Pellino2 interaction. RNA interference against MALT1 markedly reduced the level of NF-kappa B activation stimulated by lipopolysaccharide (LPS) in macrophages, which suggests that MALT1 plays a major role in the LPS/ TLR4 pathway. MALT1 interacted with BCL10 and TRAF6 to facilitate TRAF6 self-ubiquitination in the cytosol, which was strictly dependent on the dissociation of BCL10 from IRAK-1. We show that BCL10 oligomerization is a prerequisite for BCL10 function in LPS signaling to NF-kappa B and that IRAK-1 dimerization is an important event in this process.	Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China	Wuhan University	Liu, YL (corresponding author), Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China.	mvlwu@whu.edu.cn; qiyipeng@whu.edu.cn	Dong, Wei/D-2399-2015					Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cavalli F, 2001, Hematology Am Soc Hematol Educ Program, P241; Che TJ, 2004, J BIOL CHEM, V279, P15870, DOI 10.1074/jbc.M310599200; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Deng C, 2003, J IMMUNOL, V170, P2833, DOI 10.4049/jimmunol.170.6.2833; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Ea CK, 2004, P NATL ACAD SCI USA, V101, P15318, DOI 10.1073/pnas.0404132101; Fischer KD, 2004, TRENDS IMMUNOL, V25, P113, DOI 10.1016/j.it.2003.12.007; Guiet C, 2000, J CELL BIOL, V148, P1131, DOI 10.1083/jcb.148.6.1131; Jensen LE, 2003, J IMMUNOL, V171, P1500, DOI 10.4049/jimmunol.171.3.1500; Jensen LE, 2001, J BIOL CHEM, V276, P29037, DOI 10.1074/jbc.M103815200; Jiang ZF, 2003, J BIOL CHEM, V278, P10952, DOI 10.1074/jbc.M212112200; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Liu YL, 2004, J BIOL CHEM, V279, P37436, DOI 10.1074/jbc.M400241200; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; Ross K, 2002, J BIOL CHEM, V277, P37414, DOI 10.1074/jbc.M205160200; Ruefli-Brasse AA, 2004, J BIOL CHEM, V279, P1570, DOI 10.1074/jbc.C300460200; Ruefli-Brasse AA, 2003, SCIENCE, V302, P1581, DOI 10.1126/science.1090769; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Strelow A, 2003, FEBS LETT, V547, P157, DOI 10.1016/S0014-5793(03)00697-5; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Takatsuna H, 2003, J BIOL CHEM, V278, P12144, DOI 10.1074/jbc.M300720200; Thome M, 2004, NAT REV IMMUNOL, V4, P348, DOI 10.1038/nri1352; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Xue LQ, 2003, NAT IMMUNOL, V4, P857, DOI 10.1038/ni963; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	34	76	82	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26029	26040		10.1074/jbc.M513057200	http://dx.doi.org/10.1074/jbc.M513057200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16831874	hybrid			2022-12-25	WOS:000240249500018
J	Yakovleva, L; Shuman, S				Yakovleva, Lyudmila; Shuman, Stewart			Nucleotide misincorporation, 3 '-mismatch extension, and responses to abasic sites and DNA adducts by the polymerase component of bacterial DNA ligase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRICK HYDROGEN-BONDS; END-JOINING FUNCTION; CRYSTAL-STRUCTURE; SULFOLOBUS-SOLFATARICUS; SOLUTION CONFORMATION; TRANSLESION SYNTHESIS; OPPOSITE DT; PRIMASE; COMPLEX; MECHANISM	DNA ligase D (LigD) participates in a mutagenic pathway of nonhomologous end joining in bacteria. LigD consists of an ATP-dependent ligase domain fused to a polymerase domain (POL) and a phosphoesterase module. The POL domain performs templated and nontemplated primer extension reactions with either dNTP or rNTP substrates. Here we report that Pseudomonas LigD POL is an unfaithful nucleic acid polymerase. Although the degree of infidelity in nucleotide incorporation varies according to the mispair produced, we find that a correctly paired ribonucleotide is added to the DNA primer terminus more rapidly than the corresponding correct deoxyribonucleotide and incorrect nucleotides are added much more rapidly with rNTP substrates than with dNTPs, no matter what the mispair configuration. We find that 3' mispairs are extended by LigDPOL, albeit more slowly than 3' paired primer-templates. The magnitude of the rate effect on mismatch extension varies with the identity of the 3' mispair, but it was generally the case that mispaired ends were extended more rapidly with rNTP substrates than with dNTPs. These results lend credence to the suggestion that LigD POL might fill in short 5'-overhangs with ribonucleotides when repairing double strand breaks in quiescent cells. We report that LigD POL can add a deoxynucleotide opposite an abasic lesion in the template strand, albeit slowly. Ribonucleotides are inserted more rapidly at an abasic lesion than are deoxys. LigD POL displays feeble activity in extending a preformed primer terminus opposing an abasic site, but can readily bypass the lesion by slippage of the primer 3' di- or trinucleotide and realignment to the template sequence distal to the abasic site. Covalent benzo[a] pyrene-dG and benzo[c] phenanthrene-dA adducts in the template strand are durable roadblocks to POL elongation. POL can slowly insert a dNMP opposite the adduct, but is impaired in the subsequent extension step.			Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063611] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63611] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akey D, 2006, J BIOL CHEM, V281, P13412, DOI 10.1074/jbc.M513550200; Augustin MA, 2001, NAT STRUCT BIOL, V8, P57, DOI 10.1038/83060; Bocquier AA, 2001, CURR BIOL, V11, P452, DOI 10.1016/S0960-9822(01)00119-1; Chiapperino D, 2005, J BIOL CHEM, V280, P39684, DOI 10.1074/jbc.M508008200; COSMAN M, 1993, BIOCHEMISTRY-US, V32, P12488, DOI 10.1021/bi00097a029; COSMAN M, 1995, BIOCHEMISTRY-US, V34, P1295, DOI 10.1021/bi00004a024; De Falco M, 2004, NUCLEIC ACIDS RES, V32, P5223, DOI 10.1093/nar/gkh865; Della M, 2004, SCIENCE, V306, P683, DOI 10.1126/science.1099824; Desogus G, 1999, NUCLEIC ACIDS RES, V27, P4444, DOI 10.1093/nar/27.22.4444; Geacintov NE, 1997, CHEM RES TOXICOL, V10, P111, DOI 10.1021/tx9601418; Gibbs PEM, 2005, GENETICS, V169, P575, DOI 10.1534/genetics.104.034611; Gon S, 2006, EMBO J, V25, P1137, DOI 10.1038/sj.emboj.7600990; Gong CL, 2005, NAT STRUCT MOL BIOL, V12, P304, DOI 10.1038/nsmb915; Gong CL, 2004, J BIOL CHEM, V279, P20594, DOI 10.1074/jbc.M401841200; Haracska L, 2001, GENE DEV, V15, P945, DOI 10.1101/gad.882301; Hsu GW, 2005, J BIOL CHEM, V280, P3764, DOI 10.1074/jbc.M411276200; Ito N, 2003, GENES CELLS, V8, P913, DOI 10.1111/j.1365-2443.2003.00693.x; Kirk BW, 1999, BIOCHEMISTRY-US, V38, P10126, DOI 10.1021/bi990351u; Kokoska RJ, 2003, J BIOL CHEM, V278, P50537, DOI 10.1074/jbc.M308515200; Kokoska RJ, 2002, J BIOL CHEM, V277, P19633, DOI 10.1074/jbc.M202021200; Kool ET, 2002, ANNU REV BIOCHEM, V71, P191, DOI 10.1146/annurev.biochem.71.110601.135453; Lao-Sirieix SH, 2005, NAT STRUCT MOL BIOL, V12, P1137, DOI 10.1038/nsmb1013; Lao-Sirieix SH, 2004, J MOL BIOL, V344, P1251, DOI 10.1016/j.jmb.2004.10.018; Ling H, 2004, MOL CELL, V13, P751, DOI 10.1016/S1097-2765(04)00101-7; Ling H, 2004, P NATL ACAD SCI USA, V101, P2265, DOI 10.1073/pnas.0308332100; Lipps G, 2004, NAT STRUCT MOL BIOL, V11, P157, DOI 10.1038/nsmb723; Liu LD, 2001, J BIOL CHEM, V276, P45484, DOI 10.1074/jbc.M106391200; Matsui E, 2003, BIOCHEMISTRY-US, V42, P14968, DOI 10.1021/bi035556o; Moore CL, 2004, BIOCHEMISTRY-US, V43, P12367, DOI 10.1021/bi0490791; Pitcher RS, 2005, J MOL BIOL, V351, P531, DOI 10.1016/j.jmb.2005.06.038; Potapova O, 2006, BIOCHEMISTRY-US, V45, P890, DOI 10.1021/bi051792i; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; SHEAFF RJ, 1994, J BIOL CHEM, V269, P19225; Tian LE, 2003, J BIOL CHEM, V278, P9905, DOI 10.1074/jbc.M212468200; Tian LG, 2004, J BIOL CHEM, V279, P39718, DOI 10.1074/jbc.M407376200; Washington MT, 2003, MOL CELL BIOL, V23, P5107, DOI 10.1128/MCB.23.14.5107-5112.2003; Weller GR, 2002, SCIENCE, V297, P1686, DOI 10.1126/science.1074584; Wolfle WT, 2005, MOL CELL BIOL, V25, P7137, DOI 10.1128/MCB.25.16.7137-7143.2005; Yakovleva L, 2004, J BIOL CHEM, V279, P23335, DOI 10.1074/jbc.M401203200; Zerbe LK, 1999, BIOCHEMISTRY-US, V38, P12908, DOI 10.1021/bi991075m; ZHANG SS, 1990, J MOL BIOL, V216, P475, DOI 10.1016/0022-2836(90)90370-2; Zhu H, 2006, P NATL ACAD SCI USA, V103, P1711, DOI 10.1073/pnas.0509083103; Zhu H, 2005, J BIOL CHEM, V280, P33707, DOI 10.1074/jbc.M506838200; Zhu H, 2005, J BIOL CHEM, V280, P25973, DOI 10.1074/jbc.M504002200; Zhu H, 2005, J BIOL CHEM, V280, P418, DOI 10.1074/jbc.M410110200	45	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25026	25040		10.1074/jbc.M603302200	http://dx.doi.org/10.1074/jbc.M603302200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16816388	hybrid			2022-12-25	WOS:000240031300005
